--
-- PostgreSQL database dump
--

-- Dumped from database version 10.10 (Ubuntu 10.10-0ubuntu0.18.04.1)
-- Dumped by pg_dump version 11.5 (Ubuntu 11.5-1)

-- Started on 2019-10-29 14:44:32 GMT

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

DROP DATABASE ihw_annotator;
--
-- TOC entry 2932 (class 1262 OID 24586)
-- Name: ihw_annotator; Type: DATABASE; Schema: -; Owner: postgres
--

CREATE DATABASE ihw_annotator WITH TEMPLATE = template0 ENCODING = 'UTF8' LC_COLLATE = 'en_GB.UTF-8' LC_CTYPE = 'en_GB.UTF-8';


ALTER DATABASE ihw_annotator OWNER TO postgres;

\connect ihw_annotator

SET statement_timeout = 0;
SET lock_timeout = 0;
SET idle_in_transaction_session_timeout = 0;
SET client_encoding = 'UTF8';
SET standard_conforming_strings = on;
SELECT pg_catalog.set_config('search_path', '', false);
SET check_function_bodies = false;
SET xmloption = content;
SET client_min_messages = warning;
SET row_security = off;

SET default_tablespace = '';

SET default_with_oids = false;

--
-- TOC entry 196 (class 1259 OID 24587)
-- Name: annotations; Type: TABLE; Schema: public; Owner: postgres
--

CREATE TABLE public.annotations (
    docid character varying NOT NULL,
    page integer NOT NULL,
    "user" character varying NOT NULL,
    annotation json,
    corrupted character varying,
    "tableType" character varying,
    corrupted_text character varying,
    "N" integer NOT NULL
);


ALTER TABLE public.annotations OWNER TO postgres;

--
-- TOC entry 197 (class 1259 OID 24593)
-- Name: annotations_N_seq; Type: SEQUENCE; Schema: public; Owner: postgres
--

CREATE SEQUENCE public."annotations_N_seq"
    START WITH 1
    INCREMENT BY 1
    NO MINVALUE
    NO MAXVALUE
    CACHE 1;


ALTER TABLE public."annotations_N_seq" OWNER TO postgres;

--
-- TOC entry 2933 (class 0 OID 0)
-- Dependencies: 197
-- Name: annotations_N_seq; Type: SEQUENCE OWNED BY; Schema: public; Owner: postgres
--

ALTER SEQUENCE public."annotations_N_seq" OWNED BY public.annotations."N";


--
-- TOC entry 198 (class 1259 OID 24603)
-- Name: clusterdata; Type: TABLE; Schema: public; Owner: postgres
--

CREATE TABLE public.clusterdata (
    cn integer NOT NULL,
    rep_cuis character varying,
    excluded_cuis character varying,
    status character varying,
    proposed_name character varying
);


ALTER TABLE public.clusterdata OWNER TO postgres;

--
-- TOC entry 199 (class 1259 OID 24609)
-- Name: clusters; Type: TABLE; Schema: public; Owner: postgres
--

CREATE TABLE public.clusters (
    cn integer,
    concept character varying NOT NULL,
    cuis character varying,
    isdefault boolean,
    cn_override integer
);


ALTER TABLE public.clusters OWNER TO postgres;

--
-- TOC entry 2795 (class 2604 OID 24615)
-- Name: annotations N; Type: DEFAULT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY public.annotations ALTER COLUMN "N" SET DEFAULT nextval('public."annotations_N_seq"'::regclass);


--
-- TOC entry 2923 (class 0 OID 24587)
-- Dependencies: 196
-- Data for Name: annotations; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY public.annotations (docid, page, "user", annotation, corrupted, "tableType", corrupted_text, "N") FROM stdin;
10438259	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"characteristic_name":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	191
11527638	1	David	{"annotations":[{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"3"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false		undefined	196
12899584	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	198
12899584	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":4}]}	false	result_table_subgroup	undefined	201
14661009	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	202
14996776	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	203
12479763	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	227
12243636	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table		221
15028365	1	David	{"annotations":[{"location":"Row","content":{"p-interaction":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	204
15028365	2	David	{"annotations":[]}	false	result_table_subgroup	Multiple tables in one table. Need to separate first.	209
15103313	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table		240
15049402	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	216
12466506	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table		225
15051694v2	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"characteristic_level":true},"qualifiers":{},"number":2}]}	false	other_table	Same as previous table.	231
15049402	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		210
15051694	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	other_table	This is not a treatment comparison table.	228
10789664	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	194
11937179	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	220
16053964	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	269
15851647	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup		257
15537681	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false		undefined	250
16116047	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	274
16139123	4	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_without_subgroup		284
15851647	1	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	253
15883637	2	David	{"annotations":[{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	268
15851647	3	David	{"annotations":[{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup		261
16116047	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	275
16139123	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_without_subgroup		283
16139123	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	281
16139123	2	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	282
16116047	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Auto add did nice job	276
16116047	4	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_without_subgroup	undefined	278
16116047	5	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_without_subgroup	undefined	280
15537681	2	David	{"annotations":[]}	false	result_table_subgroup	No data in tables.	251
15238590	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		245
15639688	2	David	{"annotations":[]}	false	result_table_subgroup	No data in tables	252
16271642	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table		291
16267322	2	David	{"annotations":[]}	false		No data in this table.	290
10438259	1	testing	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	308
16488800	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table		302
16271643	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table		294
16278257	1	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Some rows without labels as values are split across two rows. Would need to collapse rows to fix this. Can fix this in post processing by filling across the column.	298
24323795	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	311
16495392	2	David	{"annotations":[]}	false		Empty table	304
16214598	1	David	{"annotations":[{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table		287
12456232v2	2	David	{"annotations":[]}	false		Table already formatted. Not suitable for annotator. Do manually	323
12456232	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"3"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Table already in canonical format.	322
12601075v2	1	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Fails. reason not clear.	336
12601075	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	313
11419425	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false		undefined	340
12601075v3	1	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	341
17292766	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	343
17292766v2	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	344
17292766v3	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	345
10438259	2	testing	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false		undefined	312
16495392v2	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup		305
17292766	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":"1"}]}	false		undefined	346
24918789	2	David	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	347
12601075	2	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Still fails with empty row with P-value	369
16508926	4	David	{"annotations":[]}	false		No data only text	425
9892586	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	351
12601075v2	2	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Misses off characteristic name	373
10438259	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	380
11419426	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	195
12456232	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Jesus please take a look at this one.Characteristic name is not populating down. Also value and characteristic level are switched.	324
12456232v2	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Fails, dont know why	328
24942540	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	348
15337732	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	Jesus - This one misses out characteristic name on the columns below	364
16508926	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	other_table	Not a true subgroup effects table, but may be able to estimate subgroup effects from table which shows association between baseline characteristic and outcome stratified by treatment arm.	421
16508926	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	other_table	Not a true subgroup effects table, but may be able to estimate subgroup effects from table which shows association between baseline characteristic and outcome stratified by treatment arm.	423
16508926	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Should read "Normal CRP and ESR" but ESR is in its own row.	424
16508926	5	David	{"annotations":[]}	false		No data just text	426
16508926	6	David	{"annotations":[]}	false		No data just text	427
16537663	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	428
17980928	3	David	{"annotations":[{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	488
17988947	1	David	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	489
16537663	2	David	{"annotations":[{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"4"},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Contains two tables Panel A and Panel B. Needs split outside anntoator to work properly in it.	429
17190893	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	447
16651474	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	Annotator (not auto-add) beautifully captures this table format despite it being unusual)	433
16714187	2	David	{"annotations":[]}	false		No data here	437
16801465	1	David	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	438
16801465	2	David	{"annotations":[{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	440
17010793	1	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	441
17022864	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	442
16537665	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	444
17060377	2	David	{"annotations":[]}	false		No data here	445
17124018	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	446
17259484	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	450
17259484	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	451
17304660	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	452
17304660	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup		453
17384434	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	454
17384437	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Auto add's first choice was right in every case. Need to think about handling strings which include characteristic levels AND names if implement the mutually excluding approach	456
17244641	2	David	{"annotations":[]}	false	result_table_subgroup	No data here	449
17384437v2	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	Beautiful, completely right by auto-add	457
17392541	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	458
17456819	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	459
17560879	2	David	{"annotations":[]}	false		No data	461
17605774	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Only one with bug. italic is present in auto-add and makes table fail. Can't see italics in table. Table succeeds when dropped.	462
17605774	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	I think that this is a post-randomisation stratifying variable	465
17605774	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	This is a 4 row table which is really a two row table. Rows 1 and 2 are one thing. Rows 3 and 4 another	466
17634458	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	Lovely job from autoadd again. 3 differnet types of thing in column 1, all captured	468
17846352	3	David	{"annotations":[]}	false	result_table_subgroup	No data	480
17634458	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Produces table, but annotator cannot capture the fact that the outcome differs in the last 7 rows of this table. Maybe a split table here feature.	469
17634459	2	David	{"annotations":[]}	false		No data	472
17723125	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true,"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	473
17846352	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	Original table, age is given as mean, but is also a header for age levels. So table doesn't make sense when converted	477
17846352	2	David	{"annotations":[{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	479
17878242	1	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"2"},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	482
17980928	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	486
17969365	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	Table doesn't seem to match PMID	483
17980928	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	487
18000186	1	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	490
18000186	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"other":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":"3"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	492
18025537	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	493
18025537	2	David	{"annotations":[{"location":"Row","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	other_table	Associations adjusted for treatment group. Not a subgroup effect or interaction table	494
18032739	2	David	{"annotations":[]}	false	result_table_subgroup	No data	495
18032739v2	2	David	{"annotations":[]}	false	result_table_subgroup	No data	496
18227370	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"arms":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Unusual layout. Column 1 includes the hazard ratio for each outcome followed by the event rate for each arm. No formatting distinguishes these two different types of measure.	505
18227370	4	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"arms":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Unusual layout. Column 1 includes the hazard ratio for each outcome followed by the event rate for each arm. No formatting distinguishes these two different types of measure.	507
18227370	5	David	{"annotations":[]}	false	result_table_subgroup	No data	508
18259029	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	509
18227370	1	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Empty row wont work for this table because of extraneous letters. Means wont be able to know that "current" refers to smoking	497
18227370	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"arms":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Unusual layout. Column 1 includes the hazard ratio for each outcome followed by the event rate for each arm. No formatting distinguishes these two different types of measure.	503
18259029	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":4}]}	false	result_table_subgroup	undefined	510
18284434	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	511
18284434	2	David	{"annotations":[]}	false	result_table_subgroup	No data	512
18370800	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	513
18371559	1	David	{"annotations":[]}	false	other_table	Not a subgroup table. Examine association between a post-randomisation characteristic and death (by type of death) stratified by treatment arm. Very unusual layout cannot be converted.	515
18479744	2	David	{"annotations":[]}	false	result_table_subgroup	No data	517
18511702	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	518
18511702	2	David	{"annotations":[]}	false	other_table	Not a treatment effects table, is for associations with outcome. remove	519
18539917	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	521
18549913	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	522
18597830	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Last 5 rows are composed of the footnotes	524
18600389	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Empty cell in column 1 is BMI	526
18667204	2	David	{"annotations":[]}	false	result_table_without_subgroup	No labels, just a single value. Not suitable for annotator	527
18676075	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	Empty rows are mostly caused by rows erroneously split eg  Baseline systolic blood is separated from pressure. Where it is a true heading, it is not needed to interpret the table	528
18676075	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Column 1 includes the hazard ratio for each subgroup level followed by the event rate for each arm. No formatting distinguishes these two different types of measure.	529
18813219	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	Row 1 and row 2 should be a single row	530
19001024	1	David	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	547
18821708	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Rows wrongly split across rows, but can ignore these apart from last two rows, where (Interquartile range) (mm) should read "Median of JSW (Interquartile range) (mm)"	531
18821708	2	David	{"annotations":[]}	false	result_table_subgroup	No data	534
18821708	3	David	{"annotations":[]}	false	result_table_subgroup	No data	535
18852398	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Last row is footnotes	536
18926433	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	538
18926433v2	1	David	{"annotations":[]}	false		As previous. Delete as this one less well captured in pdf software.	539
18926433v3	1	David	{"annotations":[]}	false		As previous. Delete	541
18972097	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3},{"location":"Col","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	542
18975369	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	"Recent use of allopurinol (within 30 days of" should finish "randomisation"	545
19026303	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Last column and last row have footnotes	549
19052124	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	550
19097665	3	David	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"time/period":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup		551
19166691	2	David	{"annotations":[]}	false	result_table_subgroup	No data	553
19190658	2	David	{"annotations":[]}	false	result_table_subgroup	No data	554
19201775	2	David	{"annotations":[{"location":"Col","content":{"arms":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Column 1 is a combination of arms and subgroup level.	555
19210140	2	David	{"annotations":[]}	false	result_table_subgroup	No data	557
19210140v2	2	David	{"annotations":[]}	false		Same as last table	558
19210298	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	559
19213680	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	560
19508464	1	David	{"annotations":[]}	false		No data	573
19332455	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	Some extra headings here which also have empty rows. Table conversion fails	561
19332455	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	564
19332455	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	565
19336502	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	566
19336502v2	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	567
19409693	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	568
19409693	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	569
19470885	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	570
19470885	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1}]}	false	result_table_subgroup	Fails because header row missing	571
19508464	2	David	{"annotations":[]}	false	result_table_subgroup	No data	574
19560810	1	David	{"annotations":[]}	false	other_table	Baseline table and results table mashed (columnwise) together. Need to separate	579
19515181	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Insufficient formatting to identify characteristic name HbA1c as also gives mean and sd and so is not an empty row	575
19515181	2	David	{"annotations":[]}	false	result_table_subgroup	No data	578
19567517	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	584
19567517	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	I can't see the indentation. It appears in the auto-add and then the converted table works.	581
19704100	2	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	604
19717844	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	605
19596014	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table	Table struggles with empty row/empty row with P-value./ Need to add an "OR" feature for this.	585
19596014	2	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Poor pdf reading here. Rows incorrectly split, decimals missing. Better to redo.	590
19596014	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Table structure OK wiht this one, but lots of characters are misread by the OCR.	592
19614946	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	594
19614946v2	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	595
19614946	2	David	{"annotations":[]}	false	result_table_subgroup	No data	596
19614946v2	2	David	{"annotations":[]}	false		Duplicate table.	597
19614946	3	David	{"annotations":[]}	false	result_table_subgroup	No data	598
19650752	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	599
19650752	2	David	{"annotations":[]}	false	result_table_subgroup	No data	600
19674165	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	601
19683639	2	David	{"annotations":[]}	false	result_table_subgroup	No data	602
19704100	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	603
19717844	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Cannot separate characteristic names and levels in column because the rows are not "empty with P-value"because two arm comparisons are presented	607
19735233	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	609
19735233v2	1	David	{"annotations":[]}	false		No data. This is a bit of subgroup text.	610
19735233v3	1	David	{"annotations":[]}	false		Same as a previous table	611
19752419	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Eye disease trial. Drop	612
19847908	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	614
19847908v2	2	David	{"annotations":[]}	false	result_table_subgroup	No data	615
19850249	1	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	616
19850249	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	617
19915221	2	David	{"annotations":[]}	false	result_table_subgroup	No data	618
20136164	5	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	result_table_without_subgroup	undefined	633
19929994	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"arms":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	"Black/African" should read "Black/African descent". Rows wrongly separated	619
20163842	1	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Several rows where row has been split across two rows.	635
19933596	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	Some rows are wrongly separated eg "Patients with negative anti-dsDNA"	622
19966341	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	626
19966341	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	628
20136164	1	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	629
20136164	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	630
20136164	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	result_table_without_subgroup	undefined	631
20136164	4	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	632
20163842	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":3},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":4}]}	false	result_table_subgroup	undefined	636
20185012	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	638
20185426	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	640
20185426	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"time/period":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	result_table_without_subgroup	undefined	641
20194881	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"arms":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	columns seem to be displaced where is is a name and level separate one, eg blood pressure	642
20194881	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	643
20200926	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"outcomes":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	644
29790415	2	Lili	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1863
20200926	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	645
20228402	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	646
20228402	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	647
20228402	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	648
20228402	4	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	649
20228403	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	650
20228403	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	651
20228403	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	652
20228403	4	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	654
20228404	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	655
20370912	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	656
20370912	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	657
20385930	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	658
20385930v2	1	David	{"annotations":[]}	false		No baseline characteristics table	659
20385930v3	1	David	{"annotations":[]}	false		Duplicate table.	660
20393175	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	661
20393175	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":5},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Table fails. Don't know why.	663
20393175	4	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":4}]}	false	result_table_subgroup	Table succeeds, but shouldn't. Rows 3 and 5 from the auto-add are actually rows 2 and 3.	669
20393175	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":5}]}	false	result_table_subgroup	Table succeeds, but shouldn't. Rows 3 and 5 from the auto-add are actually rows 2 and 3.	667
20400762	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	675
20409909	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	676
20429821	2	David	{"annotations":[]}	false	result_table_subgroup	No data	677
20429821	3	David	{"annotations":[]}	false	result_table_subgroup	No data	678
20429821	4	David	{"annotations":[]}	false	result_table_subgroup	No data	679
20436046	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	680
20436046	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	681
20436046	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	682
20463178	2	David	{"annotations":[]}	false	result_table_subgroup	No data	683
20484828	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	684
20491747	2	David	{"annotations":[]}	false	result_table_subgroup	No data	685
20582993	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	686
20593911	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	687
20644019	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	other_table	Not a treatment effect table. Examines effect of VT within subgroups	689
20644019v2	1	David	{"annotations":[]}	false		Same as previous table.	690
20670726	2	David	{"annotations":[]}	false	other_table	Not a treatment effects table. No data.	691
20678674	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	692
20678674	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	693
20707767	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	694
20723849	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	695
21224838	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	721
21332630	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	726
20801495	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Table conversion fails. Only returns column 7	696
20801495	2	David	{"annotations":[{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	699
20801495	3	David	{"annotations":[]}	false	result_table_subgroup	No data	700
20805623	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	701
20925534	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	703
20925534v2	2	David	{"annotations":[]}	false	result_table_subgroup	No data. Same as previous.	704
20925534	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	705
20925534v2	3	David	{"annotations":[]}	false	result_table_subgroup	Same as previous.	706
20925544	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	707
20925544	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	708
20953684	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	709
20953684	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	Last 5 rows is footnotes. But these do not appear in the converted table.	710
21045096	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	712
21059484	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	713
21059484	2	David	{"annotations":[{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	714
21109344	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	715
21128814	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	716
21128814	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Poor quality OCR	717
21128814	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	718
21147728	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	719
21147728	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	720
21227674	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	723
21227674	2	David	{"annotations":[]}	false	result_table_subgroup	No data	724
21320109	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"measures":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	725
21332630	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	undefined	727
21362764	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	Table needs re-scanned. Rows 1 and 2 do not make sense.	728
21388309	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	729
21411557	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"3"}]}	false	baseline_table	undefined	730
21428765	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"arms":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	732
21576658	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	743
21428765	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Header row incorrectly lumps tiotropium and salmeterol into the same cell. Table has other problems. Probably need to re-read.	733
21491487	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	736
21545942	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	737
21545942	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"p-interaction":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	738
21545947	3	David	{"annotations":[]}	false	other_table	Not a treatment effects table	739
21576658	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Table%20incorrectly%20read,%20eg%20%22Hypertension,%20No./total%20No.%20(%)%20Medications%20in%20use%20at%20baseline,%20No./total%20No.%20(%)%22%20in%20a%20single%20cell.%20Will%20need%20to%20re-read.	740
21576658	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	742
21586508	2	David	{"annotations":[]}	false	result_table_subgroup	No data	744
21586508v2	2	David	{"annotations":[]}	false		Same as previous.	745
21627828	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	746
21645018	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	Need to fix error with "Remission by: baseline duration of steroid" cell to make the table work.	747
21723220	2	David	{"annotations":[]}	false	result_table_without_subgroup	Table is a mess. Need to revisit original. Not even clear what kind of table it is.	752
21723220	1	David	{"annotations":[]}	false	result_table_without_subgroup	Table is a mess. Need to revisit original. Not even clear what kind of table it is.	749
21723220	3	David	{"annotations":[]}	false	result_table_without_subgroup	Table is a mess. Need to revisit original. Not even clear what kind of table it is.	753
21732835	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	754
21816478	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	755
21871706	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Row labels are missing.	756
21871706	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	759
21875546	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	760
21875546	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	761
21925996	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	762
21925996	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	763
21925996	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	764
21925996	4	David	{"annotations":[]}	false	result_table_subgroup	No data.	765
22084332	2	David	{"annotations":[{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	First two outcomes in different format. Prevents converting these tables "CHADS2 Score per Outcome Stroke or systemic embolism" and  "Major bleeding 0 to 1"	778
21933100	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Table doesn't recognise indented.	766
21933100	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	769
21939839	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	Table fails. Columns 2 and 3 missing. "Metabolic syndrome" is in the wrong place.	770
21976367	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	772
22052584	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	773
22052584	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	774
22077816	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	776
22084332	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	777
22085343	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	780
22193143	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	783
15883637	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	First example of a very useful table format. Part of column alternates between empty rows and indentations where the characteristic name and level correspond to each. Other part of column is neither empty nor indented, but has a single characteristic name and level.	264
22193143	2	David	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	801
22354934	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	819
22378566	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	821
22235820	1	David	{"annotations":[{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	803
22235820	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	808
22235820	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	809
22305835	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Table layout means no formatting to know which parts of column 1 are the subgroups, eg "diabetic (no)".	810
22311004	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	811
22316106	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	812
22316106	2	David	{"annotations":[]}	false	result_table_subgroup	No Data	813
22378566	2	David	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"outcomes":true,"characteristic_level":true},"qualifiers":{"empty_row":true,"indented":true},"number":"1"},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Table fails. Multiple levels of indented nesting. Would be a good case study	822
22335737	1	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Table%20fails%20for%20%22Any%20VTE%20or%20VTE-related%20death%20%E2%80%94%20no.%20(%)%22%20because%20this%20is%20nota%20n%20empty%20row.%20As%20such,%20%22Upper%20limbs%22,%20lower%20limbs%20etc%20is%20uninterpretable	814
22337213	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	817
22337213	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	818
22396585	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	Table malformed eg "Cholesterol" should be in own cell but is in with BMI	824
22396585	2	David	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		826
22436129	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	827
22436129	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	828
22443427	1	David	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	829
22443427	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	831
22443427	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	832
22470539	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	833
22470539	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	834
22490878	1	David	{"annotations":[{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	undefined	835
22490878	2	David	{"annotations":[{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	result_table_subgroup	undefined	836
22490878	3	David	{"annotations":[{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	result_table_subgroup	undefined	837
22491018	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":4},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":5}]}	false	baseline_table	Confusing table with 5 row headers. Will need to review manually.	838
22503610	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	Last 4 rows are footnotes.	841
22504093	2	David	{"annotations":[]}	false	result_table_subgroup	No data	842
22509859	1	David	{"annotations":[{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Unusual complex structure. Baseline table with results table together	843
22700854	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	850
22672586	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Missing arm labels, using n row instead. Need to fix manually.	845
22672586	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	848
22700854	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	849
22704916	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	851
22709460	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	852
22709460	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	853
22740508	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"outcomes":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	854
22740508v2	1	David	{"annotations":[]}	false		Same as previous	855
22740508	2	David	{"annotations":[]}	false	baseline_table	No data.	856
22747613	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	858
22747613	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	859
22873530	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	860
22873530	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Note no actual effect estimates as these are still in plots, just shows the accompanying numbers.	861
22913890	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	862
22931315	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	863
22932716	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	865
22932716	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"characteristic_name":true,"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Row%20header%20error%20has%20%22Vorapaxar%20Placebo%203-yr.%20KM%%22%20when%20voraxapar%20and%20placebo%20shoudl%20be%20separate	866
22939358	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	868
23040786	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	869
23048052	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table	undefined	870
23110471	1	David	{"annotations":[{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"arms":true,"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Complex table where treatment arm is indistinguishable from measures using formatting	871
23116881	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	873
23129601	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	874
23129601	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	875
23134522	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Columns 3 and 4 should be merged	876
23219284	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	877
23238658	1	David	{"annotations":[]}	false	other_table	Eye disease. Exclude	878
23271794	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	879
23271794	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	880
23271794	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	881
23279632	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	882
23307827	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	884
23325525	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	885
23396280	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	886
23396280	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"}]}	false	result_table_without_subgroup	undefined	887
23451835	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	900
23425163	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	Standard baseline characteristic layout, except that age is not indented, so the labels mean and range are disconnected from their context.	889
23425163	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"arms":true,"characteristic_name":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Row labels are out of alignment. Creatinine clearance is atypical in not having an empty row. Need to fix both manually.	892
23500237	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	901
23425163	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Row headers out of alignment. Dabigatran in wrong cell and not featured. Some OCR definitely wrong.	894
23436336	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	898
23451835	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"3"}]}	false	baseline_table	First cell in hearder row out of alignment	899
23501976	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	902
23501976	2	David	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	903
23519546	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	905
23529173	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	Structure disrupted by the fact that age is given as both a continuous statistic and a categorical statistic, so no empty row.	906
23529173	3	David	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_without_subgroup	Men	909
23529173	2	David	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":"1"}]}	false	result_table_without_subgroup	Women	908
23564916	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Two table in one. Need to split	911
23564919	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	912
23564919	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	913
23613569	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	Some table malformation due to rows being split	914
23656980	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	"P-values (not adjusted for repeated measures) for interaction between subgroups and treatment allocation are shown"	915
23683134	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	916
23683134	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	917
23726159	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	918
23726159	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	919
23735746	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	920
23735746	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	921
23743487	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	922
23743976	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	Some%20confusion%20with%20cells%20in%20first%20column%20eg%20%22H2%20blocker%20(n,%20%)%20Long-term%20VKA%20therapy%22%20as%20a%20single%20cell.	923
23743976	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":4},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":5},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":6}]}	false	result_table_subgroup	Column 1 should have merged cells eg "Death from any cause" not "Death from" "any cause".	925
23765873	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	926
23770182	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	927
23770182	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	928
23770182	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	929
23812596	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"arms":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":2}]}	false	baseline_table	Rows 1 and 2 should be a single row.	930
23812596	2	David	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	931
23992601	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	941
23964932	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table		932
23964932	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Age <35 repeated, one should be >=	935
23991658	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	937
23991658	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true,"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	938
23991658	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Cell "Need for 30 ng Edoxaban Dose at" is cut off	939
23992601	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	940
23992601	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	942
23992602	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	943
23992602	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	undefined	944
24339179	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	975
24283598	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Not possible to identify which subgroup comparison each p for interaction goes with as all formatting is the same	969
24001888	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	945
24001888	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	949
24067881	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	950
24119319	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	951
24119319	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	952
24120253	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	953
24120253v2	2	David	{"annotations":[]}	false		Same as previous.	954
24120253v3	2	David	{"annotations":[{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Column 1 formatting needs cleaned up	955
24120253v4	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	956
24120253	4	David	{"annotations":[]}	false	result_table_subgroup	No data.	957
24141036	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	958
24251359	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	959
24251359	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	Rows 2 and 3 should be collapsed into a single row. Not possible to separate characteristic name and label using formatting.	960
24253831	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	961
24253831	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	962
24253831	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Algorithm fails for empty rows with p-values because only a 3 column table	963
24321804	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	971
24283598	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	Age does not have empty row" so age levels are disconnected.	965
24321804	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	972
24323795	2	David	{"annotations":[{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	"Net clinical benefit*" not detected as an outcome	974
24339179	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	976
24411003	1	David	{"annotations":[]}	false	result_table_subgroup	No data.	977
24504810	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	978
24727254	2	David	{"annotations":[]}	false	result_table_subgroup	Malformed table. Need to convert this table again.	991
24621834	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	979
24621834	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	982
24727254	3	David	{"annotations":[]}	false	result_table_subgroup	Malformed table. Need to convert this table again.	993
24727258	1	David	{"annotations":[{"location":"Row","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	994
24727258	2	David	{"annotations":[{"location":"Row","content":{"outcomes":true,"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	995
24716680	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"2"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"2"},{"location":"Row","content":{"arms":true,"characteristic_name":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Fails. First column is narrow and empty.	983
24716680v2	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	988
24727254	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	989
24742013	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	996
24780614	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	1002
24748630	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table		997
24780614	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1000
24780614	2	David	{"annotations":[{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1001
24839241	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1003
24839241	2	David	{"annotations":[{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1004
24842697	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1006
24842697	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1007
24966672	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	The baseline use of tiotropium is the subgroup	1037
24966672	3	David	{"annotations":[]}	false		Same as previous	1039
24842697	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	"Lisinopril vs Chlorthalidone Normal" should be row 1 col 2, not row 1 col 1. So normal weight is missing.	1008
24842985	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1012
24842985	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1013
24859203	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1014
24907147	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1015
24907147v2	2	David	{"annotations":[]}	false		Same as previous.	1016
24907147	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	1017
24907147v2	3	David	{"annotations":[]}	false		Same as previous	1018
24907147	4	David	{"annotations":[]}	false	result_table_subgroup	No data.	1019
24907147v2	4	David	{"annotations":[]}	false		Same as previous	1020
24907147	5	David	{"annotations":[]}	false	result_table_subgroup	No data.	1021
24907147v2	5	David	{"annotations":[]}	false		Same as previoud	1022
24918789	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1023
25002161	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1040
25046337	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1048
24966672	1	David	{"annotations":[{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	First row is not same as what appears to be first row in display. Table fails strangely with different combinations.	1024
25046337	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1049
25002161	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1041
25005327	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1045
25045258	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1046
25045258	2	David	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1047
25047021	1	David	{"annotations":[]}	false	result_table_subgroup	No data.	1050
25135178	2	David	{"annotations":[]}	false	other_table	Not a treatment comparison table. Not possible to estimate interaction or subgroup effects.	1051
25135178v2	2	David	{"annotations":[]}	false		Same as previous	1052
25175921	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	%22Other%20antithrombotic%20medication%20for%20index%20event%20%E2%80%94%20no.%20(%)%22%20is%20indented%20and%20so%20is%20not%20captured.	1053
25175921	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1055
25175921	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1056
25277614	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1070
25282519	2	David	{"annotations":[]}	false	result_table_subgroup	No data. Double checked. Is a treatment comparison figure.	1071
25182247	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	Table fails when correctly specified. Succeeds if drop first row.	1057
25329038	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1072
25182247	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":"1"}]}	false	result_table_subgroup	Table fails.	1061
25199059	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1064
25214069	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1065
25229335	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1066
25271206	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1067
25271206	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Not possible to separate contents of column 1 using formatting.	1068
25329038	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1073
25354738	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1074
25455006	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1079
25354738	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	Table fails.	1075
25414932	1	David	{"annotations":[]}	false	result_table_subgroup	No data.	1078
25743173	3	David	{"annotations":[]}	false	result_table_subgroup	No data. Has labels.	1102
25455006	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"time/period":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	If not men or women is "Men and women"	1081
25468945	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	baseline_table	Table fails.	1085
25468945	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1087
25619410	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1088
25765696	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1103
25629790	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Table fails	1089
25629790	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1093
25728587	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1094
25728587	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1095
25728587	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"measures":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Need to split table.	1096
25736990	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1097
25736990	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1098
25743173	2	David	{"annotations":[]}	false	result_table_subgroup	No data. Labels only	1099
25743173v2	2	David	{"annotations":[]}	false	result_table_subgroup	Delete this duplicate, other duplicate has labels.	1100
25765696	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Column 1 includes overall outcomes as well as outcome broken down by components (as event rates), hazard ratios and p for interaction. However, unlike last table no empty row and so cannot automatically convert table well.	1107
25765696	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Handles this unexpected structure well. Gives outcome broken down by components (as event rates) and gives hazard ratio and p for interaction	1104
25769357	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1109
25769357	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Copes well with spillover of "clinically relevant non". Automatic conversion	1110
25769357	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1112
26065986	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1143
25881510	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1131
25772548	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"3"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"4"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1113
25772548	2	David	{"annotations":[]}	false		No data. No figure title or text. "Figure must be in supplement is not in paper"	1116
25775052	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1117
25775052	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1118
25775052	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1120
25775052	4	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1121
25775052	5	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1122
25779603	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1123
25779603	2	David	{"annotations":[{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1124
25787199	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1125
25795432	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table		1126
25795432	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	Subgroup is BMI, as can be seen from next table	1128
25795432	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	Subgroup is whole table, BMI	1130
25881510	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1132
26054553	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1134
26065986	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1142
26059896	4	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1139
27335114v2	2	Lili	{"annotations":[]}	false	result_table_subgroup	No table	1373
26049552	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1133
26054553	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_without_subgroup	undefined	1135
26066644	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1144
26059896	3	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup		1136
26072109	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1146
26093161	1	Lili	{"annotations":[]}	false		should split into 2 tables	1147
26093161	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1148
26097039	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1149
26097039	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1150
26097039	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true,"time/period":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1151
26100349	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1152
26100349	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1153
26100349	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1155
26112656	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Error%20in%20table%20%22Current%20smoker,%20n%20(%)%20Post-bronchodilator%20screening%22%20should%20be%20split%20across%20two%20cells	1156
26112656	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Annotator not recognising indication. Error- post-bronchodilator screening should be on a new line.	1164
26179767	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Error- column 1 labels carry over onto next line in error. Need to read this one again.	1180
26113687	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1175
26112656	3	Elaine	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"arms":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	Impossible to separate subgroup level and arm comparison based on formatting in column 1.	1166
26228097	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1185
26179767	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1177
26233481	2	Elaine	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1188
26233481	3	Elaine	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1189
26374849	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1204
26238672	2	Lili	{"annotations":[]}	false	result_table_subgroup	could not be produced and same data should be in the same row	1192
26254019	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table		1196
26299520	1	Lili	{"annotations":[]}	false	baseline_table	should be split into 2 tables	1197
26304934	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	some data should be in the same row	1198
26304934	2	Lili	{"annotations":[]}	false	result_table_subgroup	no data	1199
26373629	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1200
26373629	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	some rows should be in the same row	1201
26373629	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	composite endpoint should be in the same row	1202
26112656	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Error- post-bronchodilator screening should be on a new line	1211
26446706	1	Lili	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1214
26459421	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table		1218
26374849	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	some should be in the same row	1207
26452447	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"other":true,"measures":true},"qualifiers":{"empty_row":true,"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"characteristic_name":true,"other":true},"qualifiers":{},"number":1}]}	false	baseline_table	the format is wrong	1215
26471380	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1219
26233481	4	Elaine	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	undefined	1191
27335114v3	2	Lili	{"annotations":[]}	false	result_table_subgroup	No table	1374
28395936	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1612
28405473	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1615
26475142	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	baseline_table		1220
26475142	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup		1221
26475142	3	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		1222
26486868v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1224
26486868	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table		1223
26486868	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	1226
26491109	2	Lili	{"annotations":[]}	false		no table	1227
26541915	3	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1228
26547918	2	Lili	{"annotations":[]}	false		no table	1236
26563670	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1237
26578849	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1242
26541915	4	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	could not be produced	1229
26563670	2	Lili	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	FEV1 response should be in the next row	1238
26112656	3	David	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"arms":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	Unable to get correct- subgroup category "GOLD" and "Tiotropium" part of arm both on empty rows.	1249
26579834	1	Lili	{"annotations":[]}	false	baseline_table	should be split into 2 tables	1243
26579834	5	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1246
26589819	1	Lili	{"annotations":[]}	false	baseline_table	should be split into 2 tables	1247
26620248	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	baseline_table	Women Ethnic origin should be in 2 rows	1248
26541915	5	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	undefined	1235
26179767	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1252
26233481	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1258
26754626	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1283
26754626	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1286
26754626	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Angioedema carried down as outcome for "any adverse event" at bottom, will need to remove.	1287
26233481	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	Annotator doesn't seem to recognise indentation in column 1	1186
26238672	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1275
26620248	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1279
26630143	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1281
26630143	2	Elaine	{"annotations":[]}	false		No data in table	1282
26786577	2	Elaine	{"annotations":[]}	false		No table. Figure legend	1292
26783237	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1289
26786577	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Issue with characteristic name imputing down as mixture of characteristics level then new characteristic name in regular line.	1290
26833744	2	Elaine	{"annotations":[]}	false		No table. Figure legend	1306
26792812	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	if add row 2 label for doses, won't pick up placebo column.	1293
26792812	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1302
26833744	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":2}]}	false	baseline_table	labels%20for%20measurement%20e.g.%20SD,%20range,%20%%20not%20on%20correct%20lines%20therefore%20makes%20some%20values%20difficult%20to%20interpret%20once%20through%20annotator.%20negative%20values%20should%20be%20in%20brackets%20and%20positive.	1303
26833744	3	Elaine	{"annotations":[]}	false		No table. Figure legend.	1307
27581531	2	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1418
27977392	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1532
27046159	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	1333
27046160	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1335
27039126	1	David	{"annotations":[{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	Lots%20of%20errors%20in%20tables.%20Strings%20from%20different%20cells%20in%20same%20cell.%20eg%20%22Current%20smoker%20%E2%80%94%20no.%20(%)%20Blood%20pressure%20%E2%80%94%20mm%20Hg%22	1324
27039126	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	other_table	Not a treatment effect table. Associations.	1328
26915374	1	Elaine	{"annotations":[{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	difficulty assigning empty row with p value then empty row both to character name.	1308
26915374	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	1316
26934128	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1317
26934128	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1318
26949137	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1319
26994121	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1320
27018175	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1321
27028914	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1322
27028914	2	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1323
27039236	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1329
27039236	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1331
27046159	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1332
27046162	2	David	{"annotations":[]}	false	result_table_without_subgroup	No data.	1336
27056586	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1337
27056586	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1338
27087007	1	David	{"annotations":[]}	false		Two tables need to be split.	1339
27098404	1	David	{"annotations":[]}	false		Two table need to be split	1340
27102506	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1341
27103795	1	David	{"annotations":[]}	false		Two tables need to split.	1342
27144849	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	Cannot separate characteristic names from levels as last two columns have data in them,	1343
27161178	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1344
27161178	2	David	{"annotations":[]}	false	result_table_without_subgroup	No data.	1346
27165179	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1347
27165179v2	1	David	{"annotations":[]}	false		Same as previous.	1348
27165179	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1349
27190009	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1350
27190009	2	David	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{},"number":"3"},{"location":"Col","content":{"other":true},"qualifiers":{},"number":"4"}]}	false	result_table_subgroup	undefined	1351
27207971	1	David	{"annotations":[]}	false		Two tables. Need to split.	1352
27215502	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1353
27215502	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1354
27215749	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1355
27215749	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	1357
27215749	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"}]}	false	baseline_table	Should merge header rows 1 and 2	1356
27252787	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	Multiple tables. Need to split.	1359
27252787	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"other":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1360
27267268	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"arms":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1361
27289121	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1362
27289121	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	P for interaction is not on last column, so cannot separate components of column1	1363
27299675	1	David	{"annotations":[]}	false	baseline_table	Malformed table need to re-read	1364
27299675	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Note HRs in form of figures. N and P-interaction only.	1366
27316465	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1367
27316465	3	Lili	{"annotations":[]}	false	result_table_subgroup	No table	1368
27316465	4	Lili	{"annotations":[]}	false	result_table_subgroup	No table	1369
27316465	5	Lili	{"annotations":[]}	false	result_table_subgroup	No table	1370
27322571	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		1371
27335114	2	Lili	{"annotations":[]}	false	result_table_subgroup	No table	1372
27493790	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1405
27406394	1	lili	{"annotations":[{"location":"Col","content":{"measures":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table		1388
27406394	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	undefined	1393
27496855	1	Lili	{"annotations":[]}	false	baseline_table	should be split into 2 tables	1406
27418597	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1394
27358434	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	confused and not sure	1375
27358434	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		1384
27387994	1	Lili	{"annotations":[]}	false	result_table_subgroup	should split 2 tables	1385
27395349	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1386
27395349v2	2	lili	{"annotations":[]}	false	result_table_subgroup	no table	1387
27406394	1	Lili	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table		1389
27502582	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1407
27502866	1	Lili	{"annotations":[]}	false	result_table_subgroup	should be split into 2 tables	1409
27418597	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1397
27492833	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1404
27576559	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1410
27502857	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1408
27576559	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1411
27576775	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1414
27576775	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1415
27579635	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1416
27581531	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1417
27609406	2	lili	{"annotations":[]}	false	result_table_subgroup	no table	1434
27585384	1	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	some words should be in the same row and failed	1419
27589414	1	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	some words should be in the same row	1422
27589414v2	1	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table		1423
27589414v3	1	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	some words should be in the same row	1424
27589414	2	lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		1425
27609406v2	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1435
27600862	1	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table		1426
27609406	1	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table		1429
27609408	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"other":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"other":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table		1436
27609406v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"other":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"other":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1430
27609408	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1437
27609678	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1438
27609678	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1439
27612281	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1440
27612281	3	Lili	{"annotations":[{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	the word "score" shouldn't appear in the 2nd row	1442
27612281	2	Lili	{"annotations":[{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1441
27639327	2	Lili	{"annotations":[{"location":"Col","content":{"time/period":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup		1464
27639753	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"}]}	false	baseline_table		1465
27612281	6	Lili	{"annotations":[{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1451
27612281	5	Lili	{"annotations":[{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1447
27639753	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"3"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"4"},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":"5"}]}	false	result_table_subgroup		1466
27612281	4	Lili	{"annotations":[{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"outcomes":true,"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	result_table_subgroup		1446
27616196	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1455
27616196	2	Lili	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	missing information of subgroup name as "LAVOLTA 1" and "LAVOLTA 2"	1456
27616196	3	Lili	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	missing information of subgroup names as "LAVOLTA 1" and "LAVOLTA 2"	1458
27616196	4	Lili	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	missing information of subgroup name as "LAVOLTA 1" and "LAVOLTA 2"	1459
27619750	3	Lili	{"annotations":[]}	false	result_table_subgroup	should be split into 2 tables	1460
27633186	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	baseline_table		1461
27639327	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table		1462
27616196	5	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"outcomes":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		1463
27639753	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":4},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":5},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup		1467
27767328	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	unable to get characteristic name to impute down for all levels.	1497
27639753	4	Lili	{"annotations":[{"location":"Row","content":{"other":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":4},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":5},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup		1469
27639753	4	lili	{"annotations":[{"location":"Row","content":{"other":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":4},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":5},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	cannot be produced	1473
27659566	3	lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	SA(stable angina) and ACS( acute coronary syndrome) should be in different rows	1474
27672117	1	Lili	{"annotations":[]}	false		undefined	1475
27672117	1	lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1477
27672117	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1478
27689735	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1479
27689735	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1480
27767328	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	unable to get characteristic name to impute down for all levels.	1493
27689735	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"p-interaction":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1487
27689735	4	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1489
27715335	2	Elaine	{"annotations":[]}	false		no table. figure legend.	1490
27744141	2	Elaine	{"annotations":[]}	false		no table, figure legend	1491
27765312	2	Elaine	{"annotations":[]}	false		no table, figure legend	1492
27767328	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	unable to get characteristic name to impute down for all levels	1500
27767328	4	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Rows 2 and 3 should be separate. As prev unable to impute down characteristic name to all levels.	1502
27977392	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1531
28213368	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1557
27912982	4	Elaine	{"annotations":[{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":2},{"location":"Col","content":{"time/period":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1520
27796912	1	Elaine	{"annotations":[{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1504
27796912	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	difficulty separating subgroups as column in same format but could be two tables- one per subgroup	1508
27807306	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":4}]}	false	baseline_table	undefined	1510
27935736	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":4},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"}]}	false	baseline_table	undefined	1521
27807306	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":3},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":"10"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"11"}]}	false	result_table_subgroup	should be 2 tables	1511
27893045	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1514
27893045	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1515
27912982	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1516
27912982	2	Elaine	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1517
27912982	3	Elaine	{"annotations":[{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":"1"}]}	false	result_table_subgroup	undefined	1519
27956003	2	Elaine	{"annotations":[]}	false		no table, figure legend	1526
27965257	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1529
27935736	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	outcome location not imputing down to all subgroup levels.	1522
27959607	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"3"}]}	false	baseline_table	undefined	1527
27959607	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	undefined	1528
27965257	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1530
27977392	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"4"}]}	false	result_table_subgroup	undefined	1533
27977392	3	Elain	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"4"}]}	false	result_table_subgroup	undefined	1534
27977934	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1535
27977934	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1536
27993292	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1537
27993292	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1538
27993292	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1539
28119763	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	Annotator did very well with this one!	1540
28153828	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3}]}	false	baseline_table	undefined	1541
28153828	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1542
28159511	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1544
28189475	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"11"}]}	false	result_table_subgroup	should be 2 tables, rows 1 and 2 need fixed as run into each other	1553
28189475	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":"1"}]}	false	baseline_table	names impute down inappropriately	1549
28159511	2	Elaine	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":5},{"location":"Row","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Unable to get correct- strange structure with arms in column 5	1545
28189475v2	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1552
28197834	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1555
28197834	2	Elaine	{"annotations":[{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1556
28213368	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1558
28215362	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1559
28215362	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1560
28246236	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table	undefined	1561
28246236	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1562
28279891	2	Elaine	{"annotations":[]}	false		no table, figure legend	1563
28302288	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	baseline_table	arm labels over 2 rows therefore edoxaban imputes incorrectly	1574
28279891v2	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	characteristic names and levels in incorrect position in row 1 and 2. p values unclear	1564
28279891v3	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	characteristic name and level incorrect position in first 2 rows. P values not correctly labelled.	1568
28300867	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	error as some characteristic names spill onto second row in column one into an empty row therefore becoming a new characteristic name incorrectly	1570
28300867	2	Elaine	{"annotations":[{"location":"Col","content":{"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1572
28302288	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":"1"}]}	false	result_table_subgroup	arms over 2 rows therefore edoxaban incorrectly imputes down	1576
28316279	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	arms over 2 rows therefore imputes incorrectly	1578
28316279v2	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	arms over 2 rows and imputes incorrectly	1580
28316279	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1582
28316279v2	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1583
28327140	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1584
28385353	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1599
28327140	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	error - needs to be 2 tables	1585
28332144	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":4}]}	false	baseline_table	undefined	1588
28359411	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1589
28359411	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1590
28382371	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	for age unable to get label of characteristic name to Mean (SD) to identify. Other levels are identifiable without name.	1592
28382371	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1594
28382371	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"characteristic_name":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	difficult to label levels of outcome e.g. major and minor TIMI bleeding unclear	1595
28385353	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1597
28385353v2	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1598
28385353v2	2	Elaine	{"annotations":[]}	false		no table, figure legend	1600
28385353	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1601
28385353v2	3	Elaine	{"annotations":[]}	false		no table figure legend	1602
28385353	4	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1603
28385353v2	4	Elaine	{"annotations":[]}	false		no table, figure legend	1604
28385353	5	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1605
28385353	6	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1606
28385353	7	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1607
28391886	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	some characteristic names go over onto next line in error	1608
28391886	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1609
28395936	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1611
28405473	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"time/period":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	cannot distinguish between empty row for time period and empty row for name	1616
28432746	1	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1617
28467869	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1618
28467869	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1619
28467869	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1620
28520924	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true,"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1621
28520924	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":2},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	column 1 outcome names go over onto second line in error	1622
28520924	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	outcome names go over onto 2 lines in error	1623
28531241	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1624
28531241	2	Elaine	{"annotations":[{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true,"outcomes":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	unable to distinguish between outcome name and age level in column 1	1625
28544533	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1626
28544533	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	whole table is one subgroup	1627
28544533	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	?table incorrectly read in. whole table one subgroup	1628
28558833	2	Elaine	{"annotations":[]}	false		no table, figure legend	1629
28558833	3	Elaine	{"annotations":[]}	false		no table, figure legend	1630
28573499	4	Elaine	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1631
28666993	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true,"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1632
29064626	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1705
29793629	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1864
27977392	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	3 rows need to collapse, ">1 drug-related" "AEs" and "Positive" "orthostatic test" and "events" "requiring assistance"	1634
27977934	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1636
27977934	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1637
28666993	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1638
28689179	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1639
28689179	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_without_subgroup	undefined	1640
28720132	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1642
28720132	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"2"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1643
28720132	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	name doesn't impute down to all levels	1645
28720336	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1647
28720336	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1648
28753486	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	should be 2 tables	1649
28753486	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":"2"}]}	false	result_table_subgroup	undefined	1650
28753486	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"measures":true},"qualifiers":{"indented":true},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1651
28801539	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1652
28801539	4	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1654
28801539	5	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1655
29073947	2	Elaine	{"annotations":[]}	false		no table, figure legend	1706
28818881	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1656
28818881	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"p-interaction":true,"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1657
28827011	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1659
28827011	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_without_subgroup	undefined	1660
28842165	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1661
28842165	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1662
28842165	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1663
28844508	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1664
28844508	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1665
28844508	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1666
28848879	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1667
28848879	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1668
28877027	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true,"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1669
28877027	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"time/period":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	undefined	1670
28882235	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1676
28882235	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	1677
28879052	1	Elaine	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":3}]}	false	baseline_table	unable to get working. ?error in reading in table.	1671
29266675	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1736
28882235	3	Elaine	{"annotations":[{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"p-interaction":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1678
28899222	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1680
28899222	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	1681
28902593	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1682
28902593	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1683
28903864	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1684
28903864	2	Elaine	{"annotations":[]}	false		no table, figure legend	1685
28921862	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	missing first row with arms	1686
28924103	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1689
28924103	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1690
28939567	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1692
28939567	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1693
28968735	2	Elaine	{"annotations":[]}	false		no table, figure legend	1694
28968735	3	Elaine	{"annotations":[]}	false		no table, figure legend	1695
29028981	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1696
29028981	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1697
29028981	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1700
29045207	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	characteristic name and level merged in error onto one row at some points.	1701
29045207	2	Elaine	{"annotations":[]}	false		no table, figure legend	1703
29064626	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1704
29128192	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1707
29128192	2	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1708
29128192	3	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":"3"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	1709
29132879	3	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1710
29132879	4	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1711
29144061	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1712
29146124	3	Elaine	{"annotations":[]}	false		data from figure, missing column with characteristic names and levels. unable to produce table	1714
29148144	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	some characteristic names from column one split over 2 rows.	1715
29148144	2	Elaine	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1717
29159457	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1718
29159457	2	Elaine	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	should be 2 tables, need to split	1719
29248859	2	Elaine	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1721
29248859	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1722
29248384	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table		1723
29263150	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true,"arms":true,"characteristic_name":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1735
29228101	2	Elaine	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":4}]}	false	result_table_subgroup	not working, ?error in table extraction	1729
29242349	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1728
29228101	1	Elaine	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":3},{"location":"Row","content":{"characteristic_level":true,"arms":true},"qualifiers":{},"number":4}]}	false	baseline_table	not working ?error in table extraction	1732
29429593v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		1758
29266675	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{},"number":2},{"location":"Col","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Row","content":{"other":true,"measures":true},"qualifiers":{},"number":1}]}	false	other_table	table failed	1737
29279300	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		1740
29279300	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	2 empty rows seem wired	1741
29299340	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1743
29338762	2	Lili	{"annotations":[]}	false	baseline_table	no table	1744
29406853	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1745
29409133	1	Lili	{"annotations":[]}	false	baseline_table	no table	1746
29447769	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1768
30290801	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":4}]}	false	result_table_without_subgroup	undefined	1771
29429593v2	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1763
29409951	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		1747
29409951	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		1753
29409951	3	Lili	{"annotations":[{"location":"Col","content":{"arms":true,"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		1754
29413502	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1755
29414542	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup		1756
29429593	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		1757
29430796	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table		1764
29430801	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"arms":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table		1765
29445520	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table		1766
29429593	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	Failed. Single column of data.	1760
29447769	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1769
30290801	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1770
30290801	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":5}]}	false	result_table_without_subgroup	undefined	1772
30291013	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1773
30291013v2	1	David	{"annotations":[]}	false		Same as previous. Remove.	1774
30291013	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1775
30292589	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1776
30302940	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1778
30302940	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1779
30302940	4	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"3"},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":"4"}]}	false	result_table_subgroup	undefined	1780
30336824	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table	undefined	1781
30336824	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"indented":true,"empty_row":true},"number":1},{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_without_subgroup	undefined	1782
30336824	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"time/period":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	1783
30341453	1	David	{"annotations":[]}	false	result_table_subgroup	No data.	1784
30341453	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1785
30352894	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1786
30352894	2	David	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":2},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1787
30354517	1	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Not possible to separate contents of column 1 using formatting.	1788
30354781	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1793
30354781	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	Indentation not recognised by software.	1790
30371334	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1795
29782217	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	1861
30371334	6	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"other":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"other":true},"qualifiers":{},"number":"3"},{"location":"Col","content":{"outcomes":true,"p-interaction":true},"qualifiers":{},"number":"4"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"5"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup		1796
30392095	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1797
30392095	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1798
30425095	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1812
30393950	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	baseline_table	Table malformed. Need to remove table title and footnote from first two rows.	1799
30393950	2	David	{"annotations":[]}	false	result_table_subgroup	No data,	1802
30396865	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1803
30396865	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":2}]}	false	other_table	Not a treatment effect comparison. Not possible to estimate interactions as no arm-level data or estimates.	1804
30403574	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1806
30415602	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1807
30415602	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1808
30415628	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1809
30418475	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1810
30418475	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1811
30465321	2	David	{"annotations":[]}	false	result_table_subgroup	No data.	1816
30465321	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1815
30465321	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	1817
30465321	4	David	{"annotations":[]}	false	result_table_subgroup	No data.	1818
30465321	5	David	{"annotations":[]}	false	result_table_subgroup	No data.	1819
30465321	6	David	{"annotations":[]}	false	result_table_subgroup	No data.	1820
29463520	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1821
29463520	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1823
29471381	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1825
29490509	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1826
29490509	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"time/period":true,"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	undefined	1827
29526832	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1828
29526832	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1829
29544534	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1830
29544870	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	baseline_table	undefined	1831
29544870	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1832
29544870	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1833
29544870	4	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"other":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1834
29556416	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"time/period":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1835
29556416	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"outcomes":true,"other":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	1836
29556416	3	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1837
29563108	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1838
29661699	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1839
29661699	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1840
30473179	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1841
29664406	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table	undefined	1842
29664406	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1844
29671280	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1845
29680881	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"other":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1846
29685860	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1847
29685860v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":4}]}	false	baseline_table	failed, title and notes should not appear in the 1st and 2nd row	1848
29685860	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1850
29687620	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"measures":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"3"}]}	false	baseline_table	undefined	1851
29713156	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1852
29743836	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1853
29748996	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1854
29766634	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1855
29766634	2	Lili	{"annotations":[{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1856
29777264	1	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1857
29777264v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1858
29782217	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1859
29782217	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	undefined	1860
29790415	1	Lili	{"annotations":[{"location":"Col","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	not sure	1862
29793629	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1865
29797519	1	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1866
29857145	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1867
29857145	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1868
29903515	4	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1888
29857145	6	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1871
29857145	5	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1870
29857145	4	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1869
29857145	7	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1876
29908670	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1889
29908670	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	not sure for indented rows	1890
29909019	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	some text should be in the same row, table failed	1892
29909019	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1894
29880010	1	Lili	{"annotations":[{"location":"Col","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true,"indented":true},"number":"1"}]}	false	result_table_subgroup	TNF could not appear as sub level	1877
29903515	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1885
29903515	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true,"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1886
29903515	3	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1887
29910024	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1895
29925383	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1896
29925383	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1897
29937267	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1898
29937267v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1899
29937267	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	blood pressure >90 mm Hg should be in the same row with Systolic blood pressure <140 mm Hg	1900
29937431	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1901
29937431	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1902
29941478	1	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	undefined	1903
29941478v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1904
29941478	2	Lili	{"annotations":[{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1905
30012318	3	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":3}]}	false	result_table_subgroup	undefined	1906
30012431	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1907
30012431v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1908
30026335	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1909
30026335	2	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1910
30026335	3	Lili	{"annotations":[{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1911
30053967	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true,"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1912
30053967v2	1	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1913
30121827	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1917
30053967	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"3"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"4"}]}	false	result_table_subgroup	table failed	1914
30121827	3	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1918
30139780	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1919
30139780	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1920
30146931	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	some text should be in the same row	1921
30146931	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1922
30146931	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1923
30146932	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1924
30146932	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1925
30165610	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	1926
30165610	3	Lili	{"annotations":[{"location":"Col","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1927
30166073	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1929
30166073v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1930
30166073	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":3},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1931
30166073	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1932
30175930	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1933
30175930	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1934
30183102	1	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1935
30183102v2	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"measures":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true,"measures":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	notes should not appear in the row and some	1936
30183102	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1937
30191421	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1938
30191421	2	Lili	{"annotations":[{"location":"Col","content":{"time/period":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true,"other":true},"qualifiers":{},"number":3},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1939
30203005	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1940
30203005	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1941
30203580	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true,"measures":true},"qualifiers":{},"number":1}]}	false	baseline_table	undefined	1942
30203580	2	Lili	{"annotations":[{"location":"Col","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true,"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1944
30218434	1	Lili	{"annotations":[{"location":"Col","content":{"measures":true,"time/period":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1945
30248105	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true,"time/period":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"},{"location":"Col","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1946
30248105	2	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true,"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1947
30248105	3	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true,"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1949
30248105	4	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"measures":true,"arms":true},"qualifiers":{},"number":2},{"location":"Row","content":{"time/period":true},"qualifiers":{},"number":2},{"location":"Row","content":{"other":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	1950
30287422	1	Lili	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1951
30287422	2	Lili	{"annotations":[]}	false	result_table_subgroup	no table	1952
30473179	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true,"outcomes":true},"qualifiers":{},"number":2},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":3}]}	false	other_table	This is not a treatment effect table. Reviewed paper. No placebo arm in study at all. Updated results accordingly. Dropped from harmonise spreadsheet	1953
30473179	3	David	{"annotations":[]}	false	other_table	This is not a treatment effect table. Reviewed paper. No placebo arm in study at all. Updated results accordingly. Dropped from harmonise spreadsheet	1955
30474818	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1956
30474818	2	David	{"annotations":[{"location":"Col","content":{"time/period":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_without_subgroup	undefined	1957
30522501	1	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"empty_row":true},"number":"1"}]}	false	result_table_subgroup	Table will fail. Needs either split into multiple tables, or move row 2 (with treatment arms) into its own row, and delete the multiple copies of row 2. Note table annotated as if was in this latter format	1958
30525116	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1960
30525116	2	David	{"annotations":[{"location":"Col","content":{"measures":true,"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1961
30525116	3	David	{"annotations":[]}	false	result_table_subgroup	No data.	1962
30525116	4	David	{"annotations":[]}	false	result_table_without_subgroup	No data.	1963
30547388	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	Row 1 is trial name. Is not recognising indentation	1964
30547388	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	No formatting to separate (a), (b) and (c) which are the three trials (column 1).	1966
30547388	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	No formatting to separate (a), (b) and (c) which are the three trials (column 1).	1968
30547388	4	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	No formatting to separate (a), (b) and (c) which are the three trials (column 1).	1969
30564451	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3}]}	false	baseline_table	undefined	1970
30566006	1	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"p-interaction":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Impossible to separate subgroup levels from outcome in column 1 using formatting. Has P-value on the end.	1976
30564451	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	I think that the analysis method may have broken the randomisation.	1971
30566004	1	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true,"p-interaction":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1974
30566004v2	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1975
30566006v2	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true,"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	Fails to recognise indentation	1978
30566006	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	undefined	1980
30571562	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"2"}]}	false	baseline_table	undefined	1981
30571562	2	David	{"annotations":[]}	false	other_table	Not a treatment effect table.	1982
30571562	3	David	{"annotations":[{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Rows 2 and 3 need to be collapsed	1983
30584583	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"other":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	undefined	1985
30584583	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1986
30584583	3	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"outcomes":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1987
30586723	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true,"indented":true},"number":1},{"location":"Row","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	baseline_table	Strangely requires characteristic name to be indented despite already having empty row.	1988
30586757	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	Age messes-up the nice 3-level structure of column 1 as it is not an empty row	1997
30586723	2	David	{"annotations":[{"location":"Col","content":{"outcomes":true,"characteristic_level":true},"qualifiers":{},"number":1}]}	false	result_table_subgroup	Doesnt work as no header row. Need to introduce a row 0 option where this is the case (for single data column tables)	1991
30586723	3	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"measures":true,"p-interaction":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	1995
30586757	1	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	baseline_table	undefined	1996
30586757	4	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	Results table with similar 4-part structure which completely describes column1; empty rows (outcomes). Unusual in that it uses empty row and empty row ithe p-value as separate concepts.	2006
30586757	5	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Results table with similar 4-part structure which completely describes column1; empty rows (outcomes). Unusual in that it uses empty row and empty row ithe p-value as separate concepts.	2007
30586757	6	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	Results table with similar 4-part structure which completely describes column1; empty rows (outcomes). Unusual in that it uses empty row and empty row ithe p-value as separate concepts.	2009
30586757	3	David	{"annotations":[{"location":"Row","content":{"arms":true,"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":2},{"location":"Col","content":{"outcomes":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"},{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	Results table with similar 4-part structure which completely describes column1; empty rows (outcomes). Unusual in that it uses empty row and empty row ithe p-value as separate concepts.	2003
30587959	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	undefined	2010
30587959	2	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":"1"},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":"1"}]}	false	baseline_table	Fails to recognise indented	2011
30587959	3	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	Table fails inexplicably	2014
30587959	4	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	Table fails. Don't know why.	2018
30587959	5	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"1"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"3"}]}	false	result_table_subgroup	undefined	2020
30587959	6	David	{"annotations":[{"location":"Col","content":{"outcomes":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":"2"}]}	false	result_table_subgroup	Table fails, don't know why	2022
30590387	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":2},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":"3"}]}	false	baseline_table	Rows 2 and 3 need collapsed	2024
30590387	2	David	{"annotations":[{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	2025
30590387	3	David	{"annotations":[{"location":"Row","content":{"arms":true},"qualifiers":{},"number":1},{"location":"Row","content":{"outcomes":true},"qualifiers":{},"number":2},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":"1"}]}	false	result_table_subgroup	undefined	2026
30591006	1	David	{"annotations":[{"location":"Col","content":{"characteristic_name":true,"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"characteristic_level":true},"qualifiers":{"indented":true},"number":1},{"location":"Row","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":3},{"location":"Col","content":{"characteristic_name":true},"qualifiers":{"empty_row_with_p_value":true},"number":"1"}]}	false	baseline_table	undefined	2027
30591006	2	David	{"annotations":[{"location":"Col","content":{"characteristic_level":true},"qualifiers":{},"number":1},{"location":"Col","content":{"other":true,"characteristic_name":true},"qualifiers":{"empty_row":true},"number":1},{"location":"Row","content":{"measures":true},"qualifiers":{},"number":1},{"location":"Row","content":{"arms":true},"qualifiers":{},"number":2}]}	false	result_table_subgroup	undefined	2028
\.


--
-- TOC entry 2925 (class 0 OID 24603)
-- Dependencies: 198
-- Data for Name: clusterdata; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY public.clusterdata (cn, rep_cuis, excluded_cuis, status, proposed_name) FROM stdin;
96	C0677453	;C3890423	completed	\N
65	C0002962	;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468	completed	\N
66	C0039771		completed	\N
3			unhelpful	\N
32	C4553966;C0020621	;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637	completed	\N
4	C1620287		completed	\N
101	C1292728	;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	completed	\N
79	C0812399	;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665	completed	\N
111	C0444956		completed	\N
67	C0166128	;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207	completed	\N
8	C0374711;C0184252	;C1704414;C3888056;C0035139;C0043240;C4553149;C1720467	completed	\N
112	C0445550		completed	\N
68	C0257190	;C0687744;C1257890;C1519504;C1705428;C1705429;C0441848	completed	\N
80	C0455271	;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049	completed	\N
10	C0015672	;C4050243;C3542016;C0424589;C0542479;C1442080;C4330907;C0444504;C4553152	completed	\N
81	C0009262		completed	\N
82	C0010294	;C0205173;C0549183	completed	\N
90	C0004238		completed	\N
27	C0332157	;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607	completed	\N
28	C0032042		inprogress	\N
69	C0907402	;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488	completed	\N
99	C0017168		completed	\N
103	C0018824		completed	\N
104	C0022658		completed	\N
72	C1257987	;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634	completed	\N
64	C0002965	;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468	completed	\N
107	C0021390		completed	\N
73	C1120149	;C0039798;C0087111;C1363945;C1709561;C1947944	completed	\N
74	C0015620		completed	\N
33	C0020616	;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257	completed	\N
75	C0064636	;C0524166;C0274281	completed	\N
77	C0000618		completed	\N
120	C0239126	;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944	completed	\N
123	C0035970;C0017452		completed	\N
124	C1998280	;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603	completed	\N
132			unhelpful	\N
134	C0086582;C0086287		inprogress	\N
30	C0020461;C4552983	;C0439375;C0700287;C0684224;C0035173	completed	\N
29	C0020473;C4555212	;C0439810;C1710701	completed	\N
31	C4553967		completed	\N
261	C0019994	;C4049621	completed	
224	C1261316		completed	\N
21	C0455280;C0015663	;C0168634	completed	\N
913	C3641272	;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466	completed	\N
914	C0042373		completed	\N
169	C1697238	;C3484372;C0442734	inprogress	\N
170			inprogress	\N
227	C2144990		completed	\N
1816	C0006644	;C1710701	completed	\N
910	C0362046	;C0168634;C1334085;C1708411	completed	\N
188	C0005680	;C1706779	completed	\N
228	C0205042		completed	\N
189	C0027978	;C0324547	completed	\N
190	C0205179		completed	\N
191	C0002422	;C4049621	completed	\N
193	C0006560		inprogress	\N
909	C0011849	;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224	completed	\N
216	C0070166		completed	\N
907	C0011849;C1320657		completed	\N
912	C0011849		completed	\N
231	C0242708	;C0026544	completed	\N
274	C0003864		completed	\N
217	C0070166	;C0369286;C0033727;C4049621	completed	\N
259	C3898876	;C0026544	completed	\N
260	C0701159		completed	\N
264	C1533591		completed	
226	C0010068;C1956346	;C0026410;C1710701	completed	\N
225	C0948089	;C0026544	completed	\N
263	C0021775		completed	\N
268	C0006277		completed	\N
269	C0038012		completed	\N
270	C0868908		completed	\N
271	C1282952		completed	\N
272	;C0035455		completed	\N
273	C0031350		completed	\N
279	C0085619		completed	\N
280	C0019932		completed	\N
281	C0019930		completed	\N
285	C0033687		completed	\N
286	C0006560		completed	\N
282	C0332271	;C1538440;C3273279;C1412502	completed	\N
284	C0078988		completed	\N
288	C0024119		completed	\N
298	C1619634		completed	\N
305	C0451306		completed	\N
342	C0035078		completed	\N
307	C3811844;C0017654		inprogress	\N
592	C3811844;C0017654		completed	\N
333	C0743195		completed	\N
332	C0205318		completed	\N
336	C4554100		completed	\N
337	C0015176		completed	\N
872	C0360714		completed	\N
886	C0965129		completed	\N
885	C0286651		completed	\N
1840	C0074554		completed	\N
1165	C1142985		completed	\N
1199	C0012155		completed	\N
1841	C0085542		completed	\N
223	C0877341	;C4049621;C1552607	completed	\N
198			inprogress	\N
578	C0429271		completed	\N
580	C0037713		completed	\N
589	C0032285		completed	\N
596	C0342245		completed	\N
599			completed	\N
5	;C1709380	C0242960	completed	p value
108	C0009782		completed	null
267	C0018795	;C4049621	completed	
1366	C0004057		completed	\N
959	C0001645		completed	\N
1323	C0043210	;C3541888;C1720467	completed	\N
975	C2985465		inprogress	\N
306			inprogress	\N
952	C0600061;C0010294		inprogress	\N
1532	C0232804		completed	\N
989	C0012265		completed	\N
338	C0027396		completed	\N
340	C0014939		completed	\N
341	C0450199		completed	\N
343			inprogress	\N
348	C2825200		completed	\N
353	C0027430		completed	\N
354	C0650607		completed	\N
450	C0003280		completed	\N
356	C0589360;C0442038		completed	\N
359	C0043318		completed	\N
360	C4318437		completed	\N
451	C0085826		completed	\N
363	C0086528;C0086409;C0015031		completed	\N
364	C0522776		completed	\N
365	C1322815		completed	\N
368	C0041004		completed	\N
369	C0017446		completed	\N
371	C1608841		completed	\N
372	C2718773		completed	\N
373	C2981360		completed	\N
374	C0288672		completed	\N
375	C0001925		completed	\N
1153	C0014361;C2987634	;C1422069;C1425391;C1539338	completed	\N
376	C0033687		completed	\N
1848	C0003873		completed	\N
453	C0018802;C1882083		completed	\N
903	C0449238;C0872146		completed	\N
361	C1321567		completed	\N
378	C0003862		completed	\N
379	C0003195		completed	\N
380	C0003811		completed	\N
381	C0080203		completed	\N
382	C3537168		completed	\N
383	C0442120		completed	\N
384	C0151699		completed	\N
385	C1305738		completed	\N
389	C0010055		completed	\N
392	C0002454		completed	\N
504	C0239307		completed	\N
779	C0521942		completed	\N
601	C0239309		completed	\N
399			inprogress	\N
398	C1299007		completed	\N
1508	C0060657;C0073992		inprogress	\N
403	C0205412		completed	\N
406	C0232306		completed	\N
414	C1320716		completed	\N
811	C0003015		completed	\N
413			completed	\N
417	C0872913		completed	\N
420	C0037369		completed	\N
426	C0003593		completed	\N
427	C0003592		completed	\N
1579	;C0003364		completed	\N
433	C3494202		completed	\N
858	C0043031		completed	\N
993			completed	\N
78			completed	\N
1191			completed	\N
1773	C0086440		completed	\N
1810	C4330837		completed	\N
1774	C0585943;C0086440		completed	\N
12	C0018801	;C0168634;C1524003	completed	\N
1105	C0018810		completed	\N
1862	C0360714;C1142985		completed	\N
1856	C0520887	;C0011570;C0011581;C0344315;C4049644;C0702240;C4085311;C4084909	completed	\N
1361	C0010054;C0151744		completed	\N
467	C0013395		completed	\N
1225	C1739768		completed	\N
483	C1828181		completed	\N
482	C0027362		completed	\N
481	C1510829		completed	\N
480	C0001779		completed	\N
304	C0209368		completed	\N
1843	C0010055		completed	\N
1845	C0448964		completed	\N
1857	C1548168		completed	\N
1846	C0017725;C0015663		completed	\N
1858	C0443252		completed	\N
1847	C0023779;C0015663		completed	\N
1850	C1268740		completed	\N
1852	C0085201		completed	\N
1806	C0014467;C0007584		completed	\N
1809	C0449279		completed	\N
1875	C1722260		completed	\N
1814			completed	\N
1815	C0022341		completed	\N
1836	C0024117;C0205082	;C4050419;C1412502;C3714496;C0018026;C1304897;C4050465;C4050466	completed	\N
1828	C0035078	;C1424601	completed	\N
1818	C1527249		completed	\N
1273	C0018801;C0428772		completed	\N
1819	C0006826		completed	\N
1509	C3814772;C1722260		completed	\N
1865	C0235974;C0346647		completed	\N
933	C0085096		completed	\N
1790	C0007222		completed	\N
1698	C0004153		completed	\N
837	C4319571		completed	\N
1788	C0017631		completed	\N
1789	C1678805		completed	\N
1791	C0004916		completed	\N
1792	C1739768;C0004057		completed	\N
887	C2700378		completed	\N
1882	C0242707		completed	\N
1536	C0242350	;C0221138;C0277785;C0542341;C0700205;C1705273;C3887505	completed	\N
1799	C4279947		completed	\N
1176			completed	\N
1009	;C0004238		completed	\N
1446	C0235480		completed	\N
1500	C0023824		completed	\N
15	C0005823		completed	\N
1469	C0005823		completed	\N
615	C0871470		completed	\N
842	C0428883		completed	\N
1118	C0949236		completed	\N
1770	C0242339		completed	\N
1769	C0065058		completed	\N
1772	C0023779		completed	\N
1747	C0354604		completed	\N
1748	C0038257;C1444754		completed	\N
1749	C0439092		completed	\N
1758	C0002007	;C0034678;C0525678;C1514727	completed	\N
1757			completed	\N
1756	C0016018		completed	\N
1734	C1305855		completed	\N
1844	C0020740		completed	ibuprofen
1250	C0005910		completed	\N
1891	C1305855		completed	\N
1912	C0005910		completed	\N
961	C0001641		completed	\N
817	C0042402		completed	\N
818	C0271650		completed	\N
821	C0023822		completed	\N
838	C0870649		completed	\N
843	C0332240		completed	\N
844	C0012000		completed	\N
846	C1881332		completed	\N
847	C0065374		completed	\N
1041	C0232970		completed	\N
1930	C0126174;C0065374		completed	\N
70	C0008294		completed	\N
1248	C0497406		completed	\N
848	C0750879		completed	\N
849	C0014467		completed	\N
1932	C0023823		completed	\N
1499	C0008731		completed	\N
855	C1176316		completed	\N
856	C2604745		completed	\N
857	C2930696		completed	\N
859	C1098510		completed	\N
860	C0206232		completed	\N
862	C0206460		completed	\N
863	C0019134		completed	\N
864	C0019134		completed	\N
865	C0086409		completed	\N
866	C0042866		completed	\N
867	C0042890		completed	\N
939	C0035078;C0011065		completed	\N
868	;C0043031		completed	\N
869	C0042874		completed	\N
870	C0019590		completed	\N
871	C0027996		completed	\N
873	C0074554		completed	\N
874	C0529793		completed	\N
875	C0001948		completed	\N
877	C0004147		completed	\N
881	C0154723		completed	\N
1942	C1704272		completed	\N
1575	C1441416		completed	\N
292	C0194804		completed	\N
1866	C0376358		completed	\N
890	C0349790		completed	\N
889	C4086268		completed	\N
891	C0740304		completed	\N
894	C3810814		completed	\N
895	C0002688		completed	\N
897	C0007220		completed	\N
898	C1319171		completed	\N
1631	C0205199		completed	\N
899	C0021308;C0475264		completed	\N
902	C0013658		completed	\N
911	C0598284		inprogress	\N
918	C0425687		completed	\N
1684	;C0005437		completed	\N
1611	C0023895		completed	\N
937	C1565489		completed	\N
967	C1561643		completed	\N
320	C0022658		completed	\N
173	C0035647		completed	\N
1951	C0022646		completed	\N
938	C2986535;C0022646		completed	\N
179	C0443211		completed	\N
1956	C4044947		completed	\N
1042	C0279752		completed	\N
1043	C0282402		completed	\N
1197	;C0037981		completed	\N
1390			completed	\N
1087	C0478157		completed	\N
1504	C0543421		completed	\N
1068	C0023824		completed	\N
1501	C0008377		completed	\N
209	C0041004		completed	\N
1959	C0302353		completed	\N
1371	C0032821		completed	\N
1403	C0020336		completed	\N
716	C0025677		completed	\N
1051	C0745133		completed	\N
1408	C0025677		completed	\N
1966	C0304490		completed	\N
1379	C0523891		completed	\N
1027	C3812270		completed	\N
1028	C0003591		completed	\N
1048	C0020649		completed	\N
1032	C0301532	;C1710701;C1705970	completed	\N
1053	;C0001962		completed	\N
1970	C0086287		completed	\N
1088	C2826244		completed	\N
1037	;C0150904		completed	\N
1038	C0080179		completed	\N
1039	C0442158		completed	\N
1054	C0020885;C0009368		completed	\N
1055	C0004147		completed	\N
1089	C3251812		completed	\N
1066	C0023824;C0023826		completed	\N
1070	C3641947		completed	\N
1071	C0001924		completed	\N
1075	C3539026		completed	\N
1078	C0028873		completed	\N
1080	C0022742		completed	\N
1091	C0520887		completed	\N
1082	C0449813;C0234234		completed	\N
1083	C0079399		completed	\N
1084	C0017337		completed	\N
1093	C3714514		completed	\N
1094	C1744706;C0666743		completed	\N
1095	C2930789		completed	\N
1994	C0018801;C0449238		completed	\N
1997	C0003873;C0449238		completed	\N
1096	C0205103	;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375	completed	\N
1996	C0033860;C2926735		completed	\N
1988	C2926735;C0011849		completed	\N
1998	C0021149		completed	\N
1992	C0102118;C0449238		completed	\N
1995	C0020443;C0449238		completed	\N
1993	C0014544;C0449238		completed	\N
1990	C0013658		completed	\N
1991	C4086268		completed	\N
1989	C0449238		completed	\N
1987	C0740304		completed	\N
1986	C1709380		completed	\N
1985	C3714445		completed	\N
1984	C1744706		completed	\N
1983	C0151735		completed	\N
1982	C0087130		completed	\N
1981	C0520888		completed	\N
1980	C0234234		completed	\N
1999	C1744706;C0360714		completed	\N
1979	C0442037		completed	\N
1976	C0001288		completed	\N
1971	C0009368		completed	\N
1972	C0054836		completed	\N
1973	C0002688		completed	\N
1144	C1705492		completed	\N
1968	C1445957		completed	\N
1974	C0877248		completed	\N
1967	C0023779		completed	\N
1142	C0016006		completed	\N
1964	C0023824;C1442488		completed	\N
1962	C0023822		completed	\N
1960	C0015663;C0202042		completed	\N
1958	C0202042		completed	\N
1961	C0015688		completed	\N
1963	C0023824		completed	\N
1937	C0649350		completed	\N
1939	C0126174		completed	\N
1940	C0014549		completed	\N
1941	C0338480		completed	\N
1943	C1700247		completed	\N
1944	C0520886		completed	\N
1946	C0806915		completed	\N
1143	C0016017		completed	\N
1948	C1515974;C0021308		completed	\N
1949	C0042485		completed	\N
1952	C3166866;C0035647		completed	\N
1722	C0162577		completed	\N
1721	C0002996		completed	\N
1953	C1801960;C0449820;C0035647		completed	\N
1938	C1099677		completed	\N
1936	;C2349136		completed	\N
1934	C2700104		completed	\N
1933	C0206461		completed	\N
1923	C0766326		completed	\N
219	C0010055		completed	\N
1921	C0304289;C0009905		completed	\N
1920	C0520887		completed	\N
1919	C4687747		completed	\N
1917	C0039155		completed	\N
1916	C0013227;C0521115		completed	\N
1915	C0043100		completed	\N
1097	C1272706		completed	\N
1102	C0231832		completed	\N
1104	C0034642		completed	\N
1106	C1708485		completed	\N
1107	;C0034510		completed	\N
1110	C1521970		completed	\N
1112	C1514984		completed	\N
1113	C0040185		completed	\N
1114	C0019557		completed	\N
1524	C2936173;C0010055		completed	\N
1115	;C0020162		completed	\N
1116	C0034380		completed	\N
1117	C0232117		completed	\N
1122	C1707887;C2349179		completed	\N
1496	C0149721		completed	\N
1495			completed	\N
1129	C1623258		completed	\N
1130	C0972314		completed	\N
1131	C0013384		completed	\N
2035	C3272317		completed	\N
492	C0239161		completed	\N
1136	C2349179		completed	\N
1137	C0022417		completed	\N
1145	C4684714		completed	\N
1138	C0152031		completed	\N
1139	C0451530		completed	\N
1146	C0080331		completed	\N
1140	;C0451521		completed	\N
1147	C1519384		completed	\N
1189	C0348016		completed	\N
1150	C0037763		completed	\N
1148	C0009967		completed	\N
1154	C0006558		completed	\N
1155	C0061323		completed	\N
1156	;C0065880		completed	\N
1157	C2266929		completed	\N
1159	C1276807		completed	\N
1160	C0054201		completed	\N
1161	C0017718		completed	\N
1162	C0016860		completed	\N
1164	C0332324		completed	\N
1167	C0205231		completed	\N
1364	C0020538		completed	\N
1168	C2712122		completed	\N
1190	C1619966		completed	\N
1169	C0747973		completed	\N
1171	C3653470		completed	\N
1172	C1120110		completed	\N
1177	C0019046		completed	\N
1180	C4079805		completed	\N
1181	C2974540		completed	\N
1182	C3490348		completed	\N
1183	C1958126		completed	\N
1184	C1565750		completed	\N
1185	C2746078		completed	\N
1186	C0549193		completed	\N
47	C0877248		completed	\N
1023	C0042963		completed	\N
820			completed	\N
1209	C0288171		completed	\N
1456	C0877248;C0016976		completed	\N
1192	C0456525		completed	\N
1194	C0242618		completed	\N
1210	C0005902;C1879646		completed	\N
1195	C4086268;C1521828;C0439793		completed	\N
1196	C0225860		completed	\N
1198	C0036043		completed	\N
1204	C0429029		completed	\N
1205	C0248719		completed	\N
1206	C0216784		completed	\N
1207	C0126174		completed	\N
1208			completed	\N
1211	C0016536		completed	\N
1217	C3827656		completed	\N
1212	C0877341;C3272275		completed	\N
1213	C0581603		completed	\N
1218	C0524425		completed	\N
1214	C0443258;C0009566		completed	\N
1219	C0114873		completed	\N
1216	C0333559;C0241970		completed	\N
1220	C2975435		completed	\N
1221	C0023820		completed	\N
1222	C0082608		completed	\N
1223	C1176308		completed	\N
1224	C1831808		completed	\N
1226	C1956415		completed	\N
1227	C0013404		completed	\N
1228	C0012582		completed	\N
1229			completed	\N
1232	C1273169		completed	\N
1233	C1328319		completed	\N
1236	C0015684		completed	\N
1241	C0005841		completed	\N
1246	C1999375;C1510665		completed	\N
1249	C0489786		completed	\N
1247	C1121991		completed	\N
1243	C0205094		completed	\N
2097	C1121991;C0070166;C1709380		completed	\N
2096	C0007131		completed	\N
2093			completed	\N
2092	C0257685		completed	\N
2091	C0445550;C2975435		completed	\N
2098	C0226032		completed	left anterior descending
2089	C0022771		completed	\N
2088	C0009368;C1879646		completed	\N
2087	C1098320		completed	\N
1276	C0086582		completed	male gender
2086	C0126174;C0004147		completed	\N
1277	C0086287		completed	
2085	C0216784;C0051696		completed	\N
2084	C4033631		completed	\N
2082	C4034225		completed	\N
2081			inprogress	\N
2080	C0814843		completed	\N
2078	C0019080;C0205082		inprogress	\N
1278	C0018799		completed	
2077	C1320716;C0205082		completed	\N
1281			completed	\N
2076	C0019080;C0205082		completed	\N
2075	C0745343		completed	\N
1282	C1519255		completed	
2072	C0348016;C0012963		completed	\N
1284	C4042342		completed	
1285	C3529352		completed	
2099			inprogress	atonic cluster
2071	;C1980011;C0683092		completed	\N
1288	C0021308		completed	
2070	C0003280;C0019993;C0348016		completed	\N
2069	C1611934		completed	\N
2068	C1570906		completed	\N
2067	C3896939		completed	\N
2066	C2353951		completed	\N
2065	C0038760		completed	\N
1	;C0444706;C3541902	;C2699239;C0439230	inprogress	weeks_measured
2064	C0581603;C0206058;C0205100		completed	\N
2063	C0205231;C0009319		completed	\N
1289	;C0041912		completed	
1346	C0257343		completed	
1251	;C0005890		completed	height
1290	;C0086543		completed	
1292	C0518014		completed	
1293	C2919686		completed	
2083	C0027567		completed	null
1295	C0455536		completed	
1297	C1277691		completed	
-10			inprogress	discard pile here
2128			inprogress	CHADS2 score
1345	C0025598		completed	
1301	C0006823;C0041703		completed	
1309	C1533021		completed	
1312	C0026565		completed	
1313	C0311277		completed	
1314	C0522055		completed	
1347	C0201838		completed	
1315	C0449261;C0231999		completed	
1317	C0013893;C0035648		completed	
1318	C0521143		completed	
1324	C0012091		completed	
1328	C0252643		completed	
1327	C4534306		completed	
35	C0020615		completed	
1329	C0043157		completed	
1348	C0017710		completed	
2051	;C0439178		inprogress	acpa positive
1331	C0337920;C0242191		completed	
1332	;C0039260		completed	
1334	C0025677		completed	
2050	;C0076840		inprogress	torsemide
1336	C4277735		completed	
1254	;C1800706		completed	Idiopathic something testing
1337	C0004604		completed	
1268	C0018099;C1517741;C1517205		completed	
1272	C0149721		completed	
1338	C0030193		completed	
1349	C0005802		completed	
1340	;C0030198		completed	
1341	C0020885		completed	
1342	C1261082		completed	
1343	C3536766		completed	
1350	C0017628		completed	
1351	C1136206		completed	
1354	C1998004		completed	
1355	C3871128		completed	
1356	C0029408		completed	
1357	C0747055		completed	
1358	C0033860		completed	
2172	C0232492		completed	
2171	C2363731		completed	
2181	C0033860;C0205156;C0332157;C0205373		completed	
2178	C0406326		completed	
2177	C0005902;C0033860		completed	
2176			completed	\N
2175	C0451528		completed	
2174	C1320980		completed	
2173	C0037011		completed	
2170	C0037747		completed	
2163	C0267465		completed	
2169	C0030193;C0449244;C0034656		completed	
2168	C0007859		completed	
2167	C0360714		completed	
2166	C0246904		completed	
2165			inprogress	
2182	C3540778		completed	
2164	C0332173;C0011135		completed	
2162	C1439367		inprogress	Hazard ratio (unadjusted)
2161	C0013893		completed	
2160	C0449261		completed	
2159	C0027473		completed	
1360	C0972395		completed	
1362	C0033774;C4050142		completed	
1365	C0020538		completed	
1369	C0078988		completed	
1370	C0078988		completed	
1372	C0213771		completed	
1373	C0006675		completed	
1884	C0006684		completed	
1262			completed	carotid intima medial thickness
1547	C0007272		completed	
2196	C0007282		completed	
2195	C0007273		completed	
2194	;C0014099		completed	
2197	C0007272;C0184661		completed	
2198	C0162859		completed	
2199	C0007276		completed	
1376	;C1524031;C0806909		completed	
1374	C1518422;C0679199;C0006684		completed	
1375	C0004950		completed	
1378	C0037473		completed	
1380	C0015259		completed	
1381	C0036243		completed	
1382	C0003980		completed	
1384	C0010594		completed	
2231	C1511726;C0002978		completed	
1385	C0005847;C1521802;C1276802		completed	
1691	C0368663		completed	
1388	C0010200		completed	
1391	C0342882		completed	
1394	C0036572		completed	
1393	C0162522		completed	
1397			completed	\N
2259	C0035647;C1549031		completed	
1401	C0034510;C1518422;C0043157		completed	
1402	C0043157		completed	
2258	C0002454		completed	
1404	;C0008466		completed	
1405	C0037982		completed	
1406	C1872109		completed	
1409	C0205682		completed	
1412	C0392707		completed	
1413	C0455829		completed	
1414	C0226037		completed	
1416	C0746467		completed	
1420	C3241966		completed	
1423	C0007465		completed	
1424	C0021081		completed	
1425	C1527392		completed	
1426	C0149793		completed	
1851	;C1519255		completed	
1435	C0035448		completed	
1438	;C0040223		completed	time to treatment
230	C2986535		completed	
2257	C0019576		completed	
1441	C0034896;C0227391		completed	
1445	C3272301		completed	
1447	C0205107		completed	
1448	C2974521		completed	
1449	C2713485		completed	
1450	C0042523		completed	
1451	C0041582		completed	
1452			completed	\N
1455	C0005516		completed	
1458	C0043031;C2975435		completed	
685	C0005382		completed	
2256	C0596070		completed	
2251	C1570906;C0025598		completed	
2252	C3264599		completed	
1761	C0289313		completed	
2213	C1282952;C0750480		completed	
2253	C0038766;C0025598		completed	
2232	C1511726;C0022877		completed	
1461	;C0023122		completed	
1462	C0025885		completed	
1463	C0028405		completed	
1465	C2364172		completed	
1467	C0021149		completed	
2261	C0009667		completed	
2260	C0009667		completed	
2255	C0596070;C0302891;C0238611		completed	
2254	C0282204		completed	
2249	C0026269		completed	
2248	C0024141;C0005516		completed	
2233	C0053396		completed	
2247	C0232326;C0005516;C3163633		completed	
2246	C0851444		completed	
2234	C0001779		completed	
2244	C0042523;C0012373		completed	
2243	C0015967		completed	
2235	C0005910		completed	
2242	C0205107;C0521362		completed	
2224	C0037369;C0521116		completed	
2237	C0034896		completed	
2225	C0232970;C0279025		completed	
2239	C0439475		completed	
2226	C0032950;C0205420		completed	
1744	C0359086		completed	
2240	;C0430022		completed	
2228	;C1273410;C0205217		completed	
2229	C0030274		completed	
2230	C0027497		completed	
2216	C0008454		completed	
2241	C3272300		completed	
2204	C0730345		completed	
2205	C0360714		completed	
2208	C0599755		completed	
2222			inprogress	
2217	C0025677;C1872109		completed	
2218	C1880089		completed	
2209	C0033144;C0599755		completed	
2210	C0599755;C0679699		completed	
2212	C1521802		completed	
2186	C2826257;C0360714		completed	
2219	C0001948;C0521116		completed	
2223	C1282952;C0521116		completed	
2220	C0002962;C0521116		completed	
2227	C0002594;C0205217		completed	
2221	C0521116;C0005940		completed	
2200	C0006685		completed	
2201	C0806909		completed	
2202	C1524031		completed	
2203	C0751495		completed	
2187	C0006675;C2348609		inprogress	
2191	C0011849;C1442488		completed	
803	C0033228		completed	
1566	C1456408		completed	
940	C0966225		completed	
752	C0038766		completed	
2271	C0005845		completed	
991	C0354100		completed	
780			completed	Faecal calprotectin (No CUI assigned)
2280	C0017725;C0015663		completed	
20	C1272092		inprogress	\N
206	;C1305855		completed	BMI
211	C1709595;C1524024		completed	
212	C0205170		completed	
213	C0024117;C0521117		completed	
218	C0920424		completed	
220	C0011065		completed	
234	C2700379		completed	
238	C1553379		completed	
239			inprogress	mra
241			inprogress	
243	C0242428		completed	
244	C0856742		completed	
247	C2700280		completed	
252	C0149871		completed	
1661	C1532338		completed	
154	C0666743		completed	
266	C0870128		completed	
277	C2607479		completed	
293	C1959609;C0150312		completed	
295	C3714541;C0439565		completed	
296	C3714541		completed	
1493	C0241889		completed	
2399	C1861172		completed	
2384	C0032952		completed	
2380	C0038454;C0332152		completed	
2389	C0205156;C0011849		completed	
318	C1861172		completed	
324	C1836407		completed	
326	C2960025		completed	
\.


--
-- TOC entry 2926 (class 0 OID 24609)
-- Dependencies: 199
-- Data for Name: clusters; Type: TABLE DATA; Schema: public; Owner: postgres
--

COPY public.clusters (cn, concept, cuis, isdefault, cn_override) FROM stdin;
-10	> $nmbr$  < = $nmbr$	\N	\N	\N
-10	< = $nmbr$ . $nmbr$ %	\N	\N	\N
-10	< = $nmbr$ %	\N	\N	\N
-10	< = $nmbr$	\N	\N	\N
-10	> - $nmbr$ . $nmbr$	\N	\N	\N
-10	< - $nmbr$ . $nmbr$	\N	\N	\N
-10	x $nmbr$ = $nmbr$  p = $nmbr$ - $nmbr$	\N	\N	\N
-10	x $nmbr$ = $nmbr$ - l  p = $nmbr$ - $nmbr$	\N	\N	\N
-10	x $nmbr$ = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$	\N	\N	\N
-10	x $nmbr$  n ( % )	\N	\N	\N
-10	x ? = l - $nmbr$  p = $nmbr$ - $nmbr$	\N	\N	\N
-10	x ? = $nmbr$ - l  p = $nmbr$ - $nmbr$	\N	\N	\N
-10	x ? = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$	\N	\N	\N
-10	v $nmbr$ ( n = $nmbr$	\N	\N	\N
-10	t ( n = $nmbr$  $nmbr$ )	C2986835	\N	\N
-10	q $nmbr$ w ( n = $nmbr$ )	\N	\N	\N
-10	q $nmbr$ w ( n $nmbr$ $nmbr$ )	\N	\N	\N
-10	q $nmbr$ ( n   = $nmbr$ )	\N	\N	\N
-10	q $nmbr$ - q $nmbr$	\N	\N	\N
-10	q ( q $nmbr$ \\	\N	\N	\N
-10	e $nmbr$ / s $nmbr$ ( n = $nmbr$ )	C3846405	\N	\N
-10	e $nmbr$ ( n = $nmbr$ )	\N	\N	\N
-10	e $nmbr$ + a $nmbr$	\N	\N	\N
-10	b + a ( n = $nmbr$ )	\N	\N	\N
-10	a $nmbr$ . $nmbr$ ± $nmbr$ a . $nmbr$	\N	\N	\N
-10	a $nmbr$ c > s . $nmbr$ - s . $nmbr$ %	\N	\N	\N
-10	a $nmbr$ c > $nmbr$ . $nmbr$ %	\N	\N	\N
-10	a $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %	\N	\N	\N
-10	a $nmbr$ c  %	\N	\N	\N
-10	a $nmbr$ c < $nmbr$ . $nmbr$ %	\N	\N	\N
-10	a / c	\N	\N	\N
-10	a	\N	\N	\N
-10	$nmbr$ ( $nmbr$ j ) z $nmbr$ ( $nmbr$ . e	\N	\N	\N
-10	$nmbr$ - $nmbr$ y  n ( % )	\N	\N	\N
-10	$nmbr$ . $nmbr$ ± b . b	\N	\N	\N
-10	$nmbr$ q $nmbr$ w ( n = $nmbr$ )	\N	\N	\N
-10	$nmbr$ c . t	\N	\N	\N
-10	$nmbr$ - $nmbr$ ( s $nmbr$ - $nmbr$ ) t	C0718146	\N	\N
-10	> $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % )	\N	\N	\N
-10	< $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % )	\N	\N	\N
-10	- $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$  - c ) . $nmbr$ r	C0722969	\N	\N
-10	< $nmbr$ . $nmbr$ ( % )	\N	\N	\N
-10	> $nmbr$ . $nmbr$ ( % )	\N	\N	\N
-10	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ )	\N	\N	\N
-10	( % ) ( $nmbr$ - $nmbr$ )	\N	\N	\N
-10	( % ) ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ %	\N	\N	\N
-10	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$  $nmbr$ - < $nmbr$ . $nmbr$	\N	\N	\N
-10	$nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ %	\N	\N	\N
-10	$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ . $nmbr$ + $nmbr$ . $nmbr$	\N	\N	\N
-10	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$	\N	\N	\N
-10	> $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$	\N	\N	\N
-10	$nmbr$ - $nmbr$ - $nmbr$ - $nmbr$	\N	\N	\N
-10	> $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$	\N	\N	\N
-10	$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$	\N	\N	\N
-10	> $nmbr$ y . n ( % )	\N	\N	\N
-10	> $nmbr$ y  n ( % )	\N	\N	\N
-10	> = $nmbr$ ( % )	\N	\N	\N
-10	> = $nmbr$ * ( % )	\N	\N	\N
-10	< $nmbr$ ( % )	\N	\N	\N
-10	^ $nmbr$ y  n ( % )	\N	\N	\N
-10	< $nmbr$ y  n ( % )	\N	\N	\N
-10	< $nmbr$ { % )	\N	\N	\N
-10	a $nmbr$ c ( % )	\N	\N	\N
-10	> $nmbr$ ( % )	\N	\N	\N
-10	$nmbr$ - < $nmbr$ . $nmbr$	\N	\N	\N
-10	$nmbr$ . $nmbr$ % ( $nmbr$ )	\N	\N	\N
-10	$nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ - $nmbr$ . $nmbr$	\N	\N	\N
-10	> $nmbr$ - $nmbr$ - $nmbr$	\N	\N	\N
-10	$nmbr$ ( $nmbr$ e < $nmbr$ % )	\N	\N	\N
-10	$nmbr$ ( $nmbr$ . $nmbr$ % )	\N	\N	\N
-10	$nmbr$ ( $nmbr$  $nmbr$ )	\N	\N	\N
-10	$nmbr$ / $nmbr$ ( $nmbr$ )	\N	\N	\N
-10	$nmbr$ e < $nmbr$ %	\N	\N	\N
-10	> $nmbr$  < $nmbr$	\N	\N	\N
-10	^ $nmbr$	\N	\N	\N
-10	£ $nmbr$	\N	\N	\N
-10	« = $nmbr$	\N	\N	\N
-10	> $nmbr$ - $nmbr$	\N	\N	\N
-10	y $nmbr$	\N	\N	\N
-10	> = $nmbr$	\N	\N	\N
-10	< $nmbr$ . $nmbr$	\N	\N	\N
-10	b	\N	\N	\N
-10	x / n *	\N	\N	\N
-10	> $nmbr$ . $nmbr$	\N	\N	\N
-10	$nmbr$ . $nmbr$ %	\N	\N	\N
-10	> $nmbr$ . $nmbr$ %	\N	\N	\N
-10	> = $nmbr$ y	\N	\N	\N
-10	> $nmbr$ - < $nmbr$	\N	\N	\N
-10	$nmbr$ - < $nmbr$ ( % )	\N	\N	\N
-10	£ $nmbr$ %	\N	\N	\N
-10	c	\N	\N	\N
-10	≥ $nmbr$	\N	\N	\N
-10	%	\N	\N	\N
-10	> $nmbr$ y ( n = $nmbr$ )	\N	\N	\N
-10	$nmbr$ — < $nmbr$	\N	\N	\N
-10	> = $nmbr$ . $nmbr$	\N	\N	\N
-10	$ $nmbr$ %	\N	\N	\N
-10	e	\N	\N	\N
-10	$nmbr$ y	\N	\N	\N
-10	< $nmbr$ y	\N	\N	\N
-10	m / f	C1306057	\N	\N
-10	$nmbr$ - $nmbr$	\N	\N	\N
-10	\\ $nmbr$	\N	\N	\N
-10	$nmbr$ e $nmbr$	\N	\N	\N
-10	> $nmbr$ < $nmbr$	\N	\N	\N
-10	» $nmbr$ y	\N	\N	\N
-10	$nmbr$ . $nmbr$	\N	\N	\N
-10	< $nmbr$ - $nmbr$	\N	\N	\N
-10	$nmbr$ - < $nmbr$ y	\N	\N	\N
-10	< $nmbr$ %	\N	\N	\N
-10	« $nmbr$ - $nmbr$	\N	\N	\N
-10	= $nmbr$	\N	\N	\N
-10	v ( n = $nmbr$ )	\N	\N	\N
-10	$nmbr$ ( $nmbr$ % )	\N	\N	\N
-10	< $nmbr$ y ( n = $nmbr$ )	\N	\N	\N
-10	$nmbr$ / $nmbr$	\N	\N	\N
-10	$nmbr$ ( < $nmbr$ % )	\N	\N	\N
-10	$nmbr$ §	\N	\N	\N
-10	$nmbr$ - < $nmbr$	\N	\N	\N
-10	> $nmbr$	\N	\N	\N
-10	w	\N	\N	\N
-10	. $nmbr$	\N	\N	\N
-10	a $nmbr$	\N	\N	\N
-10	$ $nmbr$	\N	\N	\N
-10	$nmbr$ - < $nmbr$ %	\N	\N	\N
-10	a $nmbr$ c	\N	\N	\N
-10	≤ $nmbr$ . $nmbr$ %	\N	\N	\N
-10	$nmbr$ < - $nmbr$	\N	\N	\N
-10	> $nmbr$ y	\N	\N	\N
-10	≥ $nmbr$ %	\N	\N	\N
-10	^ $nmbr$ - $nmbr$	\N	\N	\N
-10	$nmbr$ % - $nmbr$ %	\N	\N	\N
-10	< $nmbr$ . $nmbr$ %	\N	\N	\N
-10	\\ $nmbr$ %	\N	\N	\N
-10	≤ $nmbr$ %	\N	\N	\N
-10	$nmbr$	\N	\N	\N
-10	> $nmbr$ $nmbr$	\N	\N	\N
-10	x / n	\N	\N	\N
-10	$nmbr$ +	\N	\N	\N
-10	< $nmbr$ » < $nmbr$ y	\N	\N	\N
-10	$nmbr$ % $nmbr$	\N	\N	\N
-10	< $nmbr$	\N	\N	\N
-10	> $nmbr$ %	\N	\N	\N
-10	$nmbr$ $nmbr$	\N	\N	\N
-10	> $nmbr$ % $nmbr$	\N	\N	\N
-10	$nmbr$ ( > $nmbr$ % )	\N	\N	\N
-10	≤ $nmbr$	\N	\N	\N
-10	% $nmbr$ - $nmbr$	\N	\N	\N
-10	之 $nmbr$	\N	\N	\N
-10	$nmbr$ . $nmbr$ - < $nmbr$	\N	\N	\N
-10	$nmbr$ % c . i .	C1547546	\N	\N
-10	= $nmbr$ ’ )	\N	\N	\N
-10	£ $nmbr$ . $nmbr$ % * *	\N	\N	\N
-10	a a ( $nmbr$ ( % )	\N	\N	\N
-10	$nmbr$ e < $nmbr$ %  n ( % )	\N	\N	\N
-10	$nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	$nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ )	\N	\N	\N
-10	e $nmbr$ + a $nmbr$ -	\N	\N	\N
-10	$nmbr$  $nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
-10	( % ) $nmbr$ - $nmbr$	\N	\N	\N
1834	r $nmbr$ + ezio ( n = $nmbr$ )	C0687673	\N	\N
1834	r $nmbr$ ( n = $nmbr$ )	C0687673	\N	\N
1833	d / mi / idr / st	C0036056;C0073187;C0332173;C3272372;C3810814;C4484261	\N	\N
1833	d / mi / idfvst	C0073187;C0332173;C3810814;C4484261	\N	\N
1833	d $nmbr$ % ( n / n )	C0073187;C0332173;C4484261	\N	\N
1833	d	C0073187;C0332173;C4484261	\N	\N
1833	$nmbr$ or $nmbr$ d / wk	C0073187;C0332173;C0332174;C0439230;C4484261	\N	\N
1832	ze + statin	C0360714	\N	\N
1832	[ zi = $nmbr$ ] $nmbr$ ( $nmbr$ . $nmbr$ )	C0043476	\N	\N
1832	$nmbr$ ( $nmbr$ . $nmbr$ ) / $nmbr$ z ( $nmbr$ ze )	\N	\N	\N
1831	feno + eze	\N	\N	\N
1831	feno $nmbr$ mg / eze $nmbr$ mg ( n = $nmbr$ )	C1319635	\N	\N
1828	esrd or $nmbr$ % dedine in gfr	C0017654;C0022661;C0035078;C1424601;C2316810	\N	\N
1828	esrd or $nmbr$ % decline in gfr	C0017654;C0022661;C0035078;C1424601;C2316810	\N	\N
1826	l / c	C0439394;C1706495;C3642217	f	-10
1826	l	C0439394;C1706495;C3642217	f	-10
1826	l $nmbr$ - $nmbr$ vs l $nmbr$ - $nmbr$ - $nmbr$	C0439394;C1706495;C3642217	f	-10
1826	l $nmbr$ - $nmbr$ vs placebo	C0032042;C0439394;C1696465;C1706408;C1706495;C3642217	f	-10
1826	( l ) t	C0439394;C1706495;C3642217	f	-10
1826	l vs . c	C0439394;C1706495;C3642217	f	-10
1827	l ( < l )	C3539687	f	-10
1827	l . l ± $nmbr$ . $nmbr$	C3539687	f	-10
1827	$nmbr$ l ( l $nmbr$ )	C3539687	f	-10
1827	$nmbr$ . l ( $nmbr$ l . $nmbr$ )	C3539687	f	-10
1827	$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ )	C3539687	f	-10
1827	$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ l )	C3539687	f	-10
1827	< $nmbr$ . $nmbr$ l - g / l	C0439267;C3539687	f	-10
1827	$nmbr$ . $nmbr$ ± l . l	C3539687	f	-10
1827	$nmbr$ . $nmbr$ ( $nmbr$ l . l )	C3539687	f	-10
1827	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - l . l )	C3539687	f	-10
1828	gfr as assessed by mdrd	C0017654;C1424601;C1516048;C3839656	f	592
1828	gfr $nmbr$ $nmbr$	C0017654;C1424601	f	592
1828	gmr	C1522544;C1704695	f	592
1828	gfr > $nmbr$	C0017654;C1424601	f	592
1828	gfr < $nmbr$	C0017654;C1424601	f	592
1828	estimated gfr — no . ( % ) $nmbr$	C0017654;C0750572;C1424601	f	592
1828	estimated gfr — no . ( % ) ^ |	C0017654;C0750572;C1424601	f	592
1828	estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . ( % )	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
1828	estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  no . ( % )	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
1829	hazard ratio glp - $nmbr$ analogue vs placebo [ $nmbr$ % cl ]	C0018301;C0032042;C0243071;C0596019;C1422069;C1425391;C1539338;C1696465;C1706408;C2350813;C2985465	f	1861
1829	glp - $nmbr$ receptor agonist	C0018301;C1422069;C1425391;C1539338;C2350813;C4543206	f	1153
1829	glp - $nmbr$ analogue	C0018301;C0243071;C1422069;C1425391;C1539338;C2350813	f	1153
1829	glp - $nmbr$ receptor agonist ( other than study drug )	C0013175;C0018301;C1422069;C1425391;C1539338;C2350813;C4543206	f	1153
1829	glp - $nmbr$ receptor agonists	C0018301;C1422069;C1425391;C1539338;C2350813;C4543206	f	1153
1830	gly	C0017890;C0523677	f	-10
1831	eze / simva ( n = $nmbr$ )	\N	f	1862
1830	gly $nmbr$ μ g bid	C0017890;C0439267;C0523677	f	-10
1830	ind / glyb n = $nmbr$	C1415124;C4049864	f	1509
1830	ind / gly	C0017890;C0523677;C4049864	f	1509
1830	ind / gly $nmbr$ / $nmbr$ pg o . d . n = $nmbr$	C0017890;C0523677;C2827928;C4049864	f	1509
1831	eze / simva	\N	f	1862
1831	eze / simva  $nmbr$ / $nmbr$ mg dr = $nmbr$ )	C0013014;C0024671;C0026410;C0031831;C0439269;C1707664;C1960952;C2346927;C2348314;C3540849;C4321396;C4521761	f	1862
1831	eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ )	C1319635;C1333964;C1707618	f	1862
1831	eze / simva $nmbr$ / $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1862
1831	eze / simva $nmbr$ / $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1862
1830	ind / gly ( n = $nmbr$ )	C0017890;C0523677;C4049864	f	1509
1830	ind + gly ( n = $nmbr$ )	C0017890;C0523677;C4049864	f	1509
1830	ind / gly n = $nmbr$	C0017890;C0523677;C4049864	f	1509
1830	no . of patients ind / gly sfc	C0017890;C0030705;C0523677;C4049864;C4521536	f	1509
1825	positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f	C0016327;C0741132;C1320283	\N	\N
1825	natalizumab ( n = $nmbr$ ) f	C0016327;C1172734	\N	\N
1825	f emale	C0016327	\N	\N
1823	p blockersubgroup	C0369773;C2603361	\N	\N
1823	p blocker before admission	C0184666;C0369773;C0809949;C2603361	\N	\N
1823	p blocker	C0369773;C2603361	\N	\N
1823	p . o )	C0369773;C2603361	\N	\N
1823	p - blocking agents  selective	C0036576;C0233660;C0332206;C0369773;C0450442;C1254351;C1521826;C1707391;C2603361	\N	\N
1823	p - blocker intake at randomisation ( n = $nmbr$ o )	C0034656;C0369773;C1512806;C2603361	\N	\N
1823	p - blocker intake at randomisation ( n = $nmbr$ )	C0034656;C0369773;C1512806;C2603361	\N	\N
1823	p - blocker	C0369773;C2603361	\N	\N
1823	p +	C0369773;C2603361	\N	\N
1823	p *	C0369773;C2603361	\N	\N
1823	p $nmbr$ z $nmbr$ ( n = $nmbr$ )	C0369773;C2603361	\N	\N
1823	p $nmbr$ y $nmbr$ antagonists	C0243076;C0369773;C2603361	\N	\N
1823	p $nmbr$ y $nmbr$ antagonist	C0231491;C0369773;C2603361	\N	\N
1823	p  regional difference *	C0369773;C0682132;C2603361	\N	\N
1823	p  regional difference	C0369773;C0682132;C2603361	\N	\N
1823	p	C0369773;C2603361	\N	\N
1822	ppci ( n = $nmbr$ )	\N	\N	\N
1822	ppci	\N	\N	\N
1822	pnorpci	\N	\N	\N
1822	fpci vs . ppci in men	C0025266	\N	\N
1821	fpg	\N	\N	\N
1821	baseline fpg  mean ( s . e . )	C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
1821	baseline fpg	C0168634;C1442488	\N	\N
1820	ratio fp / sal : sal ( $nmbr$ % ci )	C0008107;C0016704;C0036140;C0037494;C0206136;C0456603;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412	\N	\N
1820	fp versus no ics	C0016704;C0815320;C1419068;C1419906;C3541238;C3541412;C4551720	\N	\N
1820	fp ( n   = $nmbr$  $nmbr$ )	C0016704;C1419068;C1419906;C3541238;C3541412	\N	\N
1820	fp ( n [ $nmbr$ )	C0016704;C1419068;C1419906;C3541238;C3541412	\N	\N
1820	fp ( n = $nmbr$ )	C0016704;C1419068;C1419906;C3541238;C3541412	\N	\N
1820	fp $nmbr$ mg	C0016704;C0024671;C0026410;C0439269;C1419068;C1419906;C1960952;C2346927;C3541238;C3541412;C4321396;C4521761	\N	\N
1820	fp	C0016704;C1419068;C1419906;C3541238;C3541412	\N	\N
1819	prior cancer	C0006826;C0332152;C0998265;C1306459;C2826257	\N	\N
1819	previous cancer — no . ( % )	C0006826;C0205156;C0998265;C1306459;C1552607	\N	\N
1819	previous cancer  n ( % )	C0006826;C0205156;C0998265;C1306459;C1552607	\N	\N
1819	previous cancer	C0006826;C0205156;C0998265;C1306459;C1552607	\N	\N
1819	no prior cancer	C0006826;C0332152;C0998265;C1306459;C2826257	\N	\N
1819	no adk / e cancer	C0006826;C0998265;C1306459;C1412243	\N	\N
1819	no active cancer	C0006826;C0205177;C0998265;C1306459;C3853793;C3888249	\N	\N
1819	medical history : cancer	C0006826;C0262926;C0998265;C1306459;C1704706	\N	\N
1819	cancer — no . ( % )	C0006826;C0998265;C1306459	\N	\N
1819	cancer §	C0006826;C0998265;C1306459	\N	\N
1819	cancer n ( % )	C0006826;C0998265;C1306459	\N	\N
1810	numbers of events ( % ) :	C4330837	\N	\N
1823	p vaiue	C0369773;C2603361	f	1872
1819	prostate cancer	C0376358;C0600139;C2984325;C3541264	f	1866
1823	p valuec	C0369773;C2603361	f	1872
1823	p - valuec	C0369773;C2603361	f	1872
1823	p valued	C0369773;C1522609;C2603361	f	1872
1823	p valuej '	C0369773;C2603361	f	1872
1823	p valuer	C0369773;C0401806;C2603361	f	1872
1823	p valuey	C0369773;C2603361	f	1872
1823	* p for heterogeneity of treatment effect between tertiles > $nmbr$ . $nmbr$ .	C0019409;C0242960;C0369773;C1518681;C2603361	f	1873
1823	p - heterogeneity	C0019409;C0242960;C0369773;C2603361	f	1873
1823	p - interactio n	C0369773;C2603361	f	1874
1823	p - inte faction	C0369773;C2603361	f	1874
1823	p - for interaetion	C0369773;C2603361	f	1874
1823	p for i	C0021966;C0221138;C0369773;C2603361	f	1874
1824	$nmbr$ . $nmbr$ ( $nmbr$ . o - $nmbr$ . o )	C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ - i - $nmbr$ )	C0021966;C0221138;C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ - i - o $nmbr$ )	C0021966;C0221138;C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o $nmbr$ o - i - i $nmbr$ )	C0021966;C0221138;C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ )	C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o $nmbr$ - o - $nmbr$ )	C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ o )	C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ o - o - $nmbr$ )	C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ s - i - $nmbr$ )	C0021966;C0221138;C0483204	f	-10
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ s - o - $nmbr$ )	C0483204	f	-10
1824	$nmbr$ ( o - $nmbr$ - o - $nmbr$ )	C0483204	f	-10
1824	$nmbr$ o / $nmbr$ o $nmbr$ ( $nmbr$ - $nmbr$ % )	C0483204	f	-10
1824	$nmbr$ ( o - o $nmbr$ - o - $nmbr$ )	C0483204	f	-10
1824	o $nmbr$	C0483204	f	-10
1824	o	C0483204	f	-10
1824	> o - $nmbr$ - i - i	C0021966;C0221138;C0483204	f	-10
1824	- o $nmbr$ o ( - $nmbr$ - loto - $nmbr$ - $nmbr$ )	C0483204	f	-10
1824	o - oi $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )	C0029118;C0029434;C0483204	f	-10
1825	f	C0016327	f	-10
1825	f * >	C0016327	f	-10
1825	$nmbr$ f $nmbr$ q % )	C0016327	f	-10
1825	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % f	C0016327	f	-10
1825	accp bleeding risk at inclusion  no . ( % ) f	C0007637;C0016327;C1512693;C3251812	f	-10
1825	ancestry ( % ) f	C0016327	f	-10
1825	$nmbr$ f $nmbr$ l % $nmbr$	C0016327	f	-10
1825	? f ? n	C0016327	f	-10
1825	la grade b  n ( % ) f	C0016327;C1881342	f	-10
1819	cancer medications	C0006826;C0013227;C0802604;C0998265;C1306459;C2598133;C4284232	\N	\N
1819	cancer * *	C0006826;C0998265;C1306459	\N	\N
1819	cancer *	C0006826;C0998265;C1306459	\N	\N
1819	cancer ( n = $nmbr$ )	C0006826;C0998265;C1306459	\N	\N
1819	cancer  fatal and nonfatal	C0006826;C0998265;C1302234;C1306459;C1705232	\N	\N
1819	cancer	C0006826;C0998265;C1306459	\N	\N
1819	all cancer	C0006826;C0998265;C1306459	\N	\N
1819	active or previous cancer	C0006826;C0205156;C0205177;C0998265;C1306459;C1552607;C3853793;C3888249	\N	\N
1819	active cancer — no . ( % )	C0006826;C0205177;C0998265;C1306459;C3853793;C3888249	\N	\N
1819	active cancer at randomization  n ( % )	C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249	\N	\N
1819	active cancer at randomization	C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249	\N	\N
1819	active cancer at randomisation	C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249	\N	\N
1819	active cancer at baseline	C0006826;C0168634;C0205177;C0998265;C1306459;C1442488;C3853793;C3888249	\N	\N
1819	active cancer at any timeb	C0006826;C0205177;C0998265;C1306459;C3853793;C3888249	\N	\N
1819	active cancer	C0006826;C0205177;C0998265;C1306459;C3853793;C3888249	\N	\N
1819	ac tve cancer	C0001246;C0003354;C0006826;C0998265;C1306459;C1412573;C2000891;C3539770	\N	\N
1818	non - colorectal cancer	C0009402;C0346629;C1518422;C1527249;C2984278;C3542412	\N	\N
1818	colorectal cancer	C0009402;C0346629;C1527249;C2984278;C3542412	\N	\N
-10	oxcarbazepine	C0069751	\N	\N
1816	caffeine users  n ( % )	C3532939	\N	\N
1816	caffeine user  n ( % )	C3532939	\N	\N
1816	caffeine user	C3532939	\N	\N
1816	caffeine consumption *	C0948365	\N	\N
1816	caffeine consumption ( yes ) ( n )	C0948365;C1549445;C1705108;C1710701	\N	\N
1816	caffeine	C0006644;C0236734	\N	\N
1815	not - japan n = $nmbr$  $nmbr$	C0022341;C1518422	\N	\N
1815	not - japan	C0022341;C1518422	\N	\N
1815	japan n = $nmbr$	C0022341	\N	\N
1815	japan and south korea	C0022341;C0022773	\N	\N
1815	japan	C0022341	\N	\N
1815	calima japan ( n = $nmbr$ )	C0022341	\N	\N
1813	overallb	\N	\N	\N
1813	overall quality of life	C3641830	\N	\N
1813	( ofl )	\N	\N	\N
1812	otherj ^ :	\N	\N	\N
1812	other forms of	C0348078;C0376315	\N	\N
1812	history of other medical conditions  n ( % )	C0012634;C0262926;C0348080;C1705253;C3864998	\N	\N
8	valve repair / replacement with or without cabg	C0010055;C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149	\N	\N
8	valve repair / replacement only	C0035139;C0043240;C0184252;C0205171;C0374711;C0559956;C1186983;C1555302;C1704414;C1720467;C3888056;C4319951;C4553149	\N	\N
8	cabg or valve	C0010055;C0184252;C1186983;C1704414;C3888056	\N	\N
7	use of cgm interaction test p - value ^ =	C0022885;C0039593;C0392366;C0456984;C1515976;C1524063;C1704675;C1709380;C3831328;C4318744	\N	\N
7	univariate p - value	C1709380	\N	\N
7	test for interaction ( p value )	C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C1709380;C3831328;C4318744	\N	\N
7	subgroup p value 本	C1079230;C1515021;C1709380	\N	\N
7	subgroup p value !	C1079230;C1515021;C1709380	\N	\N
7	subgroup p - value $nmbr$	C1079230;C1515021;C1709380	\N	\N
1811	† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least $nmbr$ . $nmbr$ % of the patients in the any secukinumab group during the $nmbr$ ‐ week placebo ‐ controlled period and events with an eair of at least $nmbr$ . $nmbr$ cases per $nmbr$ patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version $nmbr$ . $nmbr$ )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .	C0012113;C0021149;C0030705;C0032042;C0034656;C0035171;C0036043;C0038013;C0039798;C0041912;C0087111;C0168634;C0205386;C0220856;C0220905;C0274281;C0332157;C0332174;C0332257;C0333052;C0374505;C0439230;C0439234;C0439531;C0439751;C0441471;C0441655;C0441833;C0444667;C0456081;C0680240;C0687744;C0745732;C0868928;C0871208;C0877248;C0947630;C1140263;C1257890;C1412268;C1442488;C1511726;C1512346;C1519255;C1519504;C1521828;C1522326;C1533148;C1533734;C1547177;C1547401;C1552866;C1622657;C1696465;C1704735;C1705169;C1705187;C1705428;C1705429;C1706408;C1707719;C1709305;C1709637;C1948053;C2347664;C2360800;C2607870;C2699274;C2700399;C2983265;C2986888;C3179547;C3245479;C3272378;C3538994;C3541888;C3714741;C3815594;C3887670;C3887704;C4553214;C4684790	\N	\N
1811	“ off ”	\N	\N	\N
1811	previous number of ciu / csu medications	C0205156;C0578870;C1552607;C1718138	\N	\N
1811	off omt ( n = $nmbr$ )	\N	\N	\N
1811	off omt	\N	\N	\N
1811	number of “ off ” periods	C0237753;C0439531;C0449788;C1948053	\N	\N
1811	number of treated patients	C1522326;C2360800	\N	\N
1811	number of patients with fractures	C0016658;C2360800	\N	\N
1811	number of patients with events	C0441471;C2360800;C3541888	\N	\N
1811	number of patients with dose available	C0178602;C0470187;C0869039;C1114758;C2360800	\N	\N
1811	number of patients with	C2360800	\N	\N
1811	number of patients ( % ) or mean ± sd	C0444504;C2347634;C2348143;C2360800;C2699239	\N	\N
1811	number of patients	C2360800	\N	\N
1811	number of medications  n ( % )	C1718138	\N	\N
1811	number of individuals	C1549735	\N	\N
1811	number ( % ) of patients	C2360800	\N	\N
1814	japanese	C0376247;C1556094	f	1815
1818	concern	C2699424	f	-10
1818	golden - $nmbr$	\N	f	-10
1818	golden - $nmbr$ and - $nmbr$	\N	f	-10
1812	other forms of atherosclerosis ^	C0003850;C0004153;C0348078;C0376315	f	1698
1812	other forms of atherosclerosis ’	C0003850;C0004153;C0348078;C0376315	f	1698
1813	korea  republic of	C0022773	f	1871
1810	number of events ( annualised rate [ % ] )	C0871208;C1521828;C4330837	\N	\N
1810	number of events  event per $nmbr$ person - years	C0027361;C0439234;C2347489;C4330837	\N	\N
1810	number of events	C4330837	\N	\N
1809	extent of disease — no . / total no . ( % ) § ^ |	C0439175;C0439810;C0449279;C4553144	\N	\N
1809	extent of disease  n ( % )	C0449279;C4553144	\N	\N
1809	extent of disease  %	C0449279;C4553144	\N	\N
1809	extent of disease	C0449279;C4553144	\N	\N
1809	angiographic extent of disease	C0002978;C0449279;C4553144	\N	\N
1807	effect of covariates on slopes	C0807955;C1280500;C1518681;C2348382	\N	\N
1807	covariates	\N	\N	\N
1807	covariate	\N	\N	\N
1807	ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .	C0002680;C0023779;C0039798;C0087111;C0168634;C0441833;C0687744;C0814908;C1257890;C1280500;C1442488;C1518681;C1519504;C1522326;C1522609;C1533734;C1705169;C1705428;C1705429;C2348382;C3538994;C3887704;C3887950	\N	\N
1806	median blood eosinophil count ( cells per pl ) t	C0200638;C0549183;C0876920;C2347635;C2348144;C2939193;C3897966;C4049765	\N	\N
1806	local eosinophil count ( cells per pl ) t	C0007584;C0007634;C0200638;C0205276;C0750879;C3897966;C4049765	\N	\N
1806	eosinophil count ( cells per pl )	C0007584;C0007634;C0200638;C0750879;C3897966;C4049765	\N	\N
1806	eosinophil count ( cells / pl )  median ( range ) c	C0007584;C0007634;C0200638;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3897966;C4049765	\N	\N
1806	eosinophil counf cells pl '	C0682547;C3897966;C4049765	\N	\N
1806	eos count ( cells / pl )	C0007584;C0007634;C0750480;C1623465;C1705566;C1861303;C3897966;C4049765	\N	\N
1806	biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl ) t	C0005516;C0005773;C0007584;C0007634;C0014467;C0200638;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209	\N	\N
1806	baseline eosinophil < $nmbr$ cells / pl	C0168634;C0682547;C1442488;C3897966;C4049765	\N	\N
1806	baseline eosinophil $nmbr$ cells / pl	C0168634;C0682547;C1442488;C3897966;C4049765	\N	\N
1806	( cells per pl ) t	C0007584;C0007634;C3897966;C4049765	\N	\N
1805	neutrophils  $nmbr$ / nl	C0027778;C0027950;C0560008;C3892223	\N	\N
1805	monocytes  $nmbr$ / nl	C0026473;C0027778;C0560008;C3892223	\N	\N
1805	leukocytes  $nmbr$ / nl	C0023516;C0027778;C0560008;C3892223	\N	\N
1804	proximal gl tract  n ( % )	C0018229;C0205107;C1185740;C1423073;C1427674;C4489236	\N	\N
1804	involved gl areas	C0018229;C1423073;C1427674;C1879646	\N	\N
1804	hemoglobin ( gl ' )	C0018229;C0019046;C1423073;C1427674	\N	\N
1804	bsl hb  gl - $nmbr$	C0018229;C0019046;C1423073;C1427674;C1549954	\N	\N
1803	positive hla - b $nmbr$ status  n ( % )	C0439178;C0449438;C1426226;C1446409;C1514241;C2825490;C3812269	\N	\N
1803	positive for hla - b $nmbr$  n ( % )	C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269	\N	\N
1803	hla ‐ b $nmbr$ positive    n   ( % )	C0439178;C1426226;C1446409;C1514241;C2825490;C3812269	\N	\N
1803	hla - b $nmbr$  n ( % ) ⁎ ⁎	C1426226	\N	\N
1803	hla - b $nmbr$	C0019737;C0550853;C1415561	\N	\N
1802	mean platelet volume  fl	C0200665;C0344388;C1300812;C1708024	\N	\N
1800	pdqol scale	C0175659;C0349674;C1947916	\N	\N
1799	hrqol	C4279947;C4300252	\N	\N
1799	health - related quality of life	C4279947	\N	\N
1798	right	C0205090;C0444532	\N	\N
1797	hfpef ( ef n $nmbr$ )  ( % )	\N	\N	\N
1797	ef b $nmbr$ %	\N	\N	\N
1797	ef > $nmbr$ % hfpef ( n = $nmbr$  $nmbr$ % )	\N	\N	\N
1797	ef > $nmbr$ % ( n = $nmbr$  $nmbr$ )	\N	\N	\N
1797	ef > $nmbr$ %	\N	\N	\N
1797	ef < $nmbr$ % n = $nmbr$	\N	\N	\N
1797	ef < $nmbr$ % ( n = $nmbr$  $nmbr$ )	\N	\N	\N
1797	ef $nmbr$ - $nmbr$ . $nmbr$ % ( n $nmbr$ $nmbr$ )	\N	\N	\N
1797	ef $nmbr$ - $nmbr$ % hfmref ( n = $nmbr$  $nmbr$ % )	\N	\N	\N
1797	ef $nmbr$ - $nmbr$ %	\N	\N	\N
1809	dates of recruitment	C0011008;C2348077;C2949735	f	1863
1808	$nmbr$ . $nmbr$ ± l . ot	C0439394;C1318464;C1418208;C1705587;C1706495;C3642217	f	-10
1808	exlertl ot disease	C0012634;C1318464;C1418208;C1705587	f	-10
1810	number of treated lesions	C0449791;C1522326	f	1870
1810	number of treated lesions ( per patient )	C0030705;C0449791;C1522326	f	1870
1798	r ight coronary	C0018787;C0205090;C0684010;C2603358	f	224
1798	r ight coronar y artery	C0003842;C0205090;C0226004;C0684010;C2603358	f	224
1798	right ventriculardysfunction atinclusion	C0205090;C0444532	f	1882
1798	r $nmbr$	C0205090;C0684010;C2603358	f	-10
1798	canvas - r	C0205090;C0684010;C2603358;C3281223	f	-10
1798	r	C0205090;C0684010;C2603358	f	-10
1800	psaqol	\N	f	1883
1801	hbalc < medan	\N	f	1176
1801	hbalc  median ( ql  q $nmbr$ )  %	C0549183;C0876920;C2347635;C2348144;C2939193	f	1176
1801	hbalc  mmol / mol	C3829066	f	1176
1801	hbalc < $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	1176
1801	hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	1176
1801	hbalc £ $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	1176
1801	hbalc £ $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	1176
1801	hbalc < $nmbr$ % ( < $nmbr$ mmol / mol )  n ( % )	C3829066	f	1176
1801	hbalc > $nmbr$ - < $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	1176
1801	mean ( s . d . ) hbalc  mmol / mol	C0444504;C2347634;C2348143;C3829066	f	1176
1802	fl ( $nmbr$ b )	C1300812;C1708024	f	-10
1802	fl ( $nmbr$ . $nmbr$ )	C1300812;C1708024	f	-10
1802	history of atrial fibrillation or fl utter	C0729790;C1300812;C1708024	f	1009
1797	ef  %	\N	\N	\N
1795	previous cd related surgery ( ref ) a	C0007928;C0034283;C0038894;C0038895;C0205156;C0439849;C0445223;C0543467;C1274039;C1425988;C1552607;C4552032	\N	\N
1794	prior electrical cardioversion for af ( n = $nmbr$ $nmbr$ )	C0013778;C0332152;C0344434;C0542380;C2826257;C4049859	\N	\N
1794	prior af ablation  n ( % )	C0332152;C0344434;C0547070;C1261381;C2826257;C4049859	\N	\N
1794	previous af	C0205156;C0344434;C1552607;C4049859	\N	\N
1794	maf	\N	\N	\N
1794	black / af rican american	C0085756;C0344434;C4049859	\N	\N
1794	af pattern	C0344434;C0449774;C4049859	\N	\N
1794	af alone	C0205171;C0344434;C0439044;C0679994;C4049859	\N	\N
1794	af	C0344434;C4049859	\N	\N
-10	qids - sr $nmbr$	C4331197	\N	\N
1792	rivaroxaban $nmbr$ . $nmbr$ mg bid + aspirin $nmbr$ mg od	C0004057;C0229089;C0439164;C1319635;C1512019;C1739768;C3273373;C3665488	\N	\N
1791	> $nmbr$ beds	C0004916	\N	\N
1791	< $nmbr$ beds	C0004916	\N	\N
1790	prior cvd	C0007222;C0332152;C2826257	\N	\N
1790	prior cardiovascular disease	C0007222;C0332152;C2826257	\N	\N
1790	patients with no prior cvd ( primary	C0007222;C0030705;C0205225;C0332152;C0439612;C0439631;C2826257	\N	\N
1790	patients with established cv disease aged > $nmbr$ years .	C0007222;C0030705;C0443211;C1272684;C1510829	\N	\N
1790	no prior cvd	C0007222;C0332152;C2826257	\N	\N
1790	no cvd	C0007222	\N	\N
1790	no cardiovascular disorder $nmbr$ '	C0007222	\N	\N
1790	no cardiovascular disease ( n = $nmbr$ )	C0007222	\N	\N
1790	n ( % ) patients with risk faetors for cv disease aged > $nmbr$	C0001779;C0001792;C0007222;C0030705;C0035647;C0369718;C0441922;C1999167;C4552904	\N	\N
1790	lisinopril cvd total	C0007222;C0065374;C0439175;C0439810	\N	\N
1790	established cardiovascular disease	C0007222;C0443211;C1272684	\N	\N
1790	cvd without ml ^ troke	C0007222;C0439526;C1705224;C3887665	\N	\N
1790	cvd without ml / stroke	C0007222;C0038454;C0439526;C1705224;C3887665;C4554100	\N	\N
1790	cvd without miatroke	C0007222	\N	\N
1790	cvd  total	C0007222;C0439175;C0439810	\N	\N
1790	cvd	C0007222	\N	\N
1790	cv disease	C0007222	\N	\N
1790	cardiovascular disorder  n ( % )	C0007222	\N	\N
1790	cardiovascular disorder	C0007222	\N	\N
1790	cardiovascular disease n ( % )	C0007222	\N	\N
1790	cardiovascular disease history ‡	C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460	\N	\N
1790	cardiovascular disease history  n ( % ) *	C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460	\N	\N
1790	cardiovascular disease history	C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460	\N	\N
1790	cardiovascular disease *	C0007222	\N	\N
1790	cardiovascular disease ( n = $nmbr$ )	C0007222	\N	\N
1790	cardiovascular disease	C0007222	\N	\N
1790	baseline cardiovascular disease	C0007222;C0168634;C1442488	\N	\N
1790	any cardiovascular disease history  n ( % )	C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460	\N	\N
1790	any cardiovascular disease	C0007222	\N	\N
1790	$nmbr$ - $nmbr$ with cv disease ( n = $nmbr$ )	C0007222	\N	\N
1790	$nmbr$ - $nmbr$  cv disease ( n = $nmbr$  $nmbr$ )	C0007222	\N	\N
1789	apremilast	C1678805	\N	\N
1788	gliclazide ( modified release ) 一 no . ( % ) ^	C0017631;C1709058;C4544813	\N	\N
1787	history of elms  n ( % )	C0019664;C0019665;C0262512;C0262926;C0330531;C1705255;C2004062;C2980688	\N	\N
1787	elms  n ( % )	C0330531;C2980688	\N	\N
1786	> $nmbr$ cells / mm ^	C0007584;C0007634;C4330985;C4554674	f	-10
1786	> $nmbr$ to < $nmbr$ cells / mm ^	C0007584;C0007634;C4330985;C4554674	f	-10
1786	> $nmbr$ to < $nmbr$ cells / mm ’	C0007584;C0007634;C4330985;C4554674	f	-10
1787	$nmbr$ — $nmbr$ nlmw	\N	f	-10
1788	reteplase	C0256103	f	1876
1789	roflumilast ( n = $nmbr$  $nmbr$ )	C0965618	f	1877
1791	number of arterial beds involved	C0003842;C0004916;C0221464;C0237753;C0449788;C1314939	f	1878
1792	bid	\N	f	-10
1792	idegasp bid	\N	f	-10
1792	$nmbr$ μ g bid ( n = $nmbr$ )	C0439267	f	-10
1795	ef < $nmbr$ % hfref ( n = $nmbr$  $nmbr$ % )	\N	f	1879
1795	hfref	\N	f	1879
1795	nothfref	\N	f	1879
1795	hfref ( n = $nmbr$ )	\N	f	1879
1795	history of bowel resection ( ref )	C0019664;C0019665;C0262512;C0262926;C0741614;C1425988;C1705255;C2004062	f	1880
1795	no history of extra - intestinal manifestations of ibd ( ref )	C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1425988;C1705255;C1883702;C2004062	f	1880
1795	( d ) aza treatment ( ref )	C0004482;C0039798;C0073187;C0087111;C0332173;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704;C4484261	f	1881
1795	$nmbr$ . $nmbr$ ( ref . )	C1425988	f	-10
1795	$nmbr$ ( ref )	C1425988	f	-10
1795	( ref )	C1425988	f	-10
1795	ref .	C1425988	f	-10
1795	ref §	C1425988	f	-10
1796	ef < $nmbr$ % ( n $nmbr$ $nmbr$ )	\N	f	887
1796	ef > $nmbr$ % ( n $nmbr$ $nmbr$ )	\N	f	887
1797	dysfunction  ef = erectile function  iief = i	C0021966;C0030847;C0031843;C0031847;C0221138;C0277785;C0542341;C0700205;C1705273;C3641331;C3887504;C3887505	f	1536
1796	reduced ef	C0392756	f	887
1796	hf ' without known reduced ef	C0018488;C0205309;C0392756;C1313497;C1538440;C3273279	f	1273
1796	hf without known reduced ef	C0018488;C0205309;C0392756;C1313497;C1538440;C3273279	f	1273
1796	hf without known reduced ef ( n = $nmbr$ )	C0018488;C0205309;C0392756;C1313497;C1538440;C3273279	f	1273
1784	« s $nmbr$ - $nmbr$	C0565930;C2603362	\N	\N
1784	| : s blocker	C0565930;C2603362	\N	\N
1784	s £ $nmbr$	C0565930;C2603362	\N	\N
1784	s fs $nmbr$	C0565930;C1517317;C2603362;C3814419	\N	\N
1784	s . e .	C0565930;C2603362	\N	\N
1784	s ( s $nmbr$	C0565930;C2603362	\N	\N
1784	s $nmbr$ yrs	C0565930;C2603362	\N	\N
1784	s $nmbr$ - $nmbr$ - s $nmbr$ . $nmbr$ %	C0565930;C2603362	\N	\N
1784	s $nmbr$ ( $nmbr$ . s )	C0565930;C2603362	\N	\N
1784	s $nmbr$ %	C0565930;C2603362	\N	\N
1784	s $nmbr$	C0565930;C2603362	\N	\N
1784	s	C0565930;C2603362	\N	\N
1784	= s $nmbr$	C0565930;C2603362	\N	\N
1784	$nmbr$ s f $nmbr$ )	C0016327;C0565930;C2603362	\N	\N
1784	$nmbr$ s . $nmbr$ ± s . $nmbr$	C0565930;C2603362	\N	\N
1784	$nmbr$ ( $nmbr$ s . s )	C0565930;C2603362	\N	\N
1783	second year !	C0205436;C0439234;C0439508;C0457385;C0565930;C1561503;C1705190	\N	\N
1783	second mi	C0205436;C0457385;C0565930;C1561503;C1705190;C3810814	\N	\N
1783	second loading dose	C0205436;C0457385;C0565930;C1561503;C1705190;C3714444	\N	\N
1783	second - generation stent	C0038257;C0079411;C0205436;C0457385;C0565930;C1561503;C1705190;C3146294	\N	\N
1783	second ( n = $nmbr$ )	C0205436;C0457385;C0565930;C1561503;C1705190	\N	\N
1783	no second mi	C0205436;C0457385;C0565930;C1561503;C1705190;C3810814	\N	\N
1782	short form $nmbr$ ( sf - $nmbr$ )	C0037712;C2964478	\N	\N
1782	sf ‐ $nmbr$ pcs  ls mean change ± se	C0023668;C0036919;C0037712;C0392747;C0443172;C0444504;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952	\N	\N
1782	sf ‐ $nmbr$ health survey	C0018762;C0037712	\N	\N
1782	sf - $nmbr$ v $nmbr$ pcs  mean [ sd ]	C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239	\N	\N
1782	sf - $nmbr$ v $nmbr$ mcs  mean [ sd ]	C0037712;C0444504;C2347634;C2348143;C2699239	\N	\N
1782	sf - $nmbr$ summary scores	C0037712;C0449820;C1552616;C1706244;C4050231	\N	\N
1782	sf - $nmbr$ score	C0037712;C0449820;C4050231	\N	\N
1782	sf - $nmbr$ pcs score	C0037712;C0449820;C1864389;C1882368;C4050231	\N	\N
1782	sf - $nmbr$ pcs  mean ± sd	C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239	\N	\N
1782	sf - $nmbr$ pcs  ls mean change from baseline   ±   se	C0023668;C0036919;C0037712;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952	\N	\N
1782	sf - $nmbr$ pcs	C0037712;C1864389;C1882368	\N	\N
1782	sf - $nmbr$ mcs score	C0037712;C0449820;C4050231	\N	\N
1782	sf - $nmbr$ mcs  mean ± sd	C0037712;C0444504;C2347634;C2348143;C2699239	\N	\N
1782	sf - $nmbr$ mcs	C0037712	\N	\N
1782	sf - $nmbr$ ( health transition score )	C0037712;C0376627;C0449820;C4050231	\N	\N
1782	sf $nmbr$ - pcs	C0037712;C1864389;C1882368	\N	\N
1781	density lipoprotein  csf =	C0023820;C0178587;C3540512;C3889436	\N	\N
1781	csii	\N	\N	\N
1781	csf cholesterol	C0008377;C3540512;C3889436	\N	\N
1781	csf	C3540512;C3889436	\N	\N
-10	uvb	C0454530;C0564461	\N	\N
1779	tvr	\N	\N	\N
1779	ischemic tvr	C0475224	\N	\N
1779	avr	C0449217	\N	\N
1778	jvp > $nmbr$ cm	\N	\N	\N
1778	jvp ( 〉 $nmbr$ cm )	\N	\N	\N
1778	jvp $ $nmbr$ cm h $nmbr$ o	C0455483	\N	\N
1778	jvp  ( % )	\N	\N	\N
1778	jvd $ $nmbr$ cm h $nmbr$ o  %	C0425687;C0455483	\N	\N
1777	qualifying cv event  n ( % )	C0441471;C1514624;C3538987;C4019010;C4048877;C4318503	\N	\N
1777	prior cv history  n ( % )	C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503	\N	\N
1777	prior cv history	C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503	\N	\N
1777	prior cv event at randomization !	C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503	\N	\N
1777	prior cv event	C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503	\N	\N
1777	previous cv events	C0205156;C0441471;C1552607;C3538987;C3541888;C4048877;C4318503	\N	\N
1777	previous cv event	C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503	\N	\N
1777	non cv mortality	C0026565;C0026566;C1518422;C3538987;C4048877;C4318503	\N	\N
1777	non - cv mortality	C0026565;C0026566;C1518422;C3538987;C4048877;C4318503	\N	\N
1777	no prior cv event	C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503	\N	\N
1777	no previous cv event	C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503	\N	\N
1777	no cv event ( n = $nmbr$  $nmbr$ )	C0441471;C3538987;C4019010;C4048877;C4318503	\N	\N
1777	no ascvd + additional cv risk factors  n ( % )	C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503	\N	\N
1777	incidence rate of cv events  n ( % )	C0441471;C1708485;C3538987;C3541888;C4048877;C4318503	\N	\N
1777	hospitalization for heart failure or cv death	C0011065;C1306577;C3538987;C3898876;C4048877;C4082313;C4318503;C4552775	\N	\N
1777	hospitalization for heart failure or cv	C3538987;C3898876;C4048877;C4318503	\N	\N
1777	heart failure hospitalisation or cv death	C0011065;C1306577;C3538987;C3898876;C4048877;C4082313;C4318503;C4552775	\N	\N
1777	first cv hospitalization	C0019993;C0205435;C1279901;C3538987;C4048877;C4318503	\N	\N
1777	expanded cv endpoint	C0205229;C2349179;C2826544;C3538987;C4048877;C4318503	\N	\N
1777	estimated cv risk at baseline	C0168634;C1442488;C1519101;C3538987;C4048877;C4318503	\N	\N
1777	cv risk factors and history	C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503	\N	\N
1777	cv risk factors	C0035648;C1553898;C3538987;C4048877;C4318503	\N	\N
1777	cv risk factor - no . ( % )	C0035648;C3538987;C4048877;C4318503	\N	\N
1777	cv risk factor	C0035648;C3538987;C4048877;C4318503	\N	\N
1777	cv mortality	C0026565;C0026566;C3538987;C4048877;C4318503	\N	\N
1777	cv historya	C3538987;C4048877;C4318503	\N	\N
1777	cv endpoints n ( % )	C2349179;C3538987;C4048877;C4318503	\N	\N
1777	cv disease history  no . ( % ) §	C0007222;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C2004062;C3538987;C4048877;C4318503	\N	\N
1786	< $nmbr$ cells / mm ^	C0007584;C0007634;C4330985;C4554674	f	-10
1786	$nmbr$ to < $nmbr$ cells	C0007584;C0007634	f	-10
1777	cv	C3538987;C4048877;C4318503	\N	\N
1777	baseline cv medications  n ( % )	C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503	\N	\N
1777	baseline cv medications	C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503	\N	\N
1777	baseline ( geometric mean  cv )	C0168634;C1442488;C2986759;C3538987;C4048877;C4318503	\N	\N
1777	ascvdor > $nmbr$ cv risk factors	C0035648;C1553898;C3538987;C4048877;C4318503	\N	\N
1777	any cv history / risk factors  n ( % )	C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503	\N	\N
1777	> $nmbr$ additional cv risk factors $nmbr$	C0035648;C1524062;C1553898;C3538987;C4048877;C4318503	\N	\N
1776	sokolow – lyon voltage ( mv )	C0598352;C1454484;C1705503;C4281602	\N	\N
1776	sokoiow - lyon voitage  mv	C1454484;C1705503;C4281602	\N	\N
1776	cornell voltage duration ( mv × ms )	C0449238;C0598352;C1454484;C1705503;C2349943;C2926735;C3539704;C3713294;C4281602	\N	\N
1775	no mvd ( n - $nmbr$  $nmbr$ )	C1417507;C3272839	\N	\N
1775	mvd ( n - $nmbr$  $nmbr$ )	C1417507;C3272839	\N	\N
1774	use of concomitant lipid - lowering therapy - no . ( % )	C0521115;C0585943;C1524063	\N	\N
1774	statin and / or other lipid - lowering agent therapy	C0039798;C0086440;C0087111;C0360714;C0450442;C0585943;C1254351;C1363945;C1521826	\N	\N
1774	lipid ‐ lowering therapies  n ( % )	C0585943	\N	\N
1774	lipid lowering therapy	C0585943	\N	\N
1774	lipid - lowering therapy — no . ( % )	C0585943	\N	\N
1774	lipid - lowering therapy - no . ( % )	C0585943	\N	\N
1774	lipid - lowering therapy	C0585943	\N	\N
1774	lipc	C1416867	\N	\N
7	subgroup by treatment interaction p - value	C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704	\N	\N
1774	hyperlipidaemia therapy use  n ( % ) * no lipid - lowering agent therapy	C0020473;C0039798;C0042153;C0086440;C0087111;C0428465;C0450442;C0457083;C0585943;C1254351;C1363945;C1521826;C1947944;C4555212	\N	\N
1774	concomitant lipid - lowering therapy ( any )	C0521115;C0585943	\N	\N
1774	concomitant lipid - lowering therapy  n ( % )	C0521115;C0585943	\N	\N
1774	background lipid - lowering therapy	C0585943;C1706907	\N	\N
1774	any other lipid ‐ lowering therapy  n ( % )	C0585943	\N	\N
1773	without lipid - lowering agents	C0086440	\N	\N
1773	with lipid - lowering agents	C0086440	\N	\N
1773	revascularisation but no antiplatelets  lipid - lowering agents  or p blockers	C0086440;C0369773;C0581603;C2603361	\N	\N
1773	revascularisation + antiplatelets + lipid - lowering agents + p blockers	C0086440;C0581603	\N	\N
1773	other lipid lowering drugs	C0086440	\N	\N
1773	non - smokers receiving lipid lowering drugs  ( $nmbr$ blockers  and either an ace inhibitor or angiotension receptor blocker	C0003015;C0086440;C0337672;C0597357;C1514756;C3844638;C4541021;C4554605	\N	\N
1773	non - smokers receiving lipid - lowering drugs  p blockers  and either an ace inhibitor or angiotension receptor blocker	C0003015;C0086440;C0337672;C0597357;C1514756;C3844638;C4541021;C4554605	\N	\N
1773	non - smokers receiving lipid - lowering drugs  p blockers	C0086440;C0337672;C1514756;C4554605	\N	\N
1773	lipid lowering drugs	C0086440	\N	\N
1773	lipid lowering agents	C0086440	\N	\N
1773	lipid lowering agent n ( % )	C0086440	\N	\N
1773	lipid disorder	C0154251	\N	\N
1773	lipid - lowering drugs  n ( % )	C0086440	\N	\N
1773	lipid - lowering drugs	C0086440	\N	\N
1773	lipid - lowering drug * *	C0086440	\N	\N
1773	lipid - lowering drug	C0086440	\N	\N
1773	lipid - lowering agents ( % )	C0086440	\N	\N
1773	lipid - lowering agents	C0086440	\N	\N
1773	lipid - lowering agent §	C0086440	\N	\N
1773	lipid - lowering agent	C0086440	\N	\N
1773	fibrate or other lipid - lowering agent	C0086440	\N	\N
1773	any lipid - lowering agent use	C0042153;C0086440;C0457083;C1947944	\N	\N
1773	any lipid - lowering agent	C0086440	\N	\N
1772	select lipids and lipoproteins	C0023779;C0023820;C1707391	\N	\N
1772	other lipid - modifying drug use at study entry  n ( % )	C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343	\N	\N
1772	metabolic syndrome $nmbr$ baseline lipids  mg / dl	C0023779;C0168634;C0439269;C0524620;C1442488	\N	\N
1772	mean lipid values  mg / dl	C0023779;C0042295;C0439269;C0444504;C2347634;C2348143	\N	\N
1772	lipids — mg / dl	C0023779;C0439269	\N	\N
1772	lipids	C0023779	\N	\N
1772	lipid values  mmol / l	C0023779;C0042295;C1532563	\N	\N
1772	lipid values  mean ( sd )	C0023779;C0042295;C0444504;C2347634;C2348143;C2699239	\N	\N
1772	lipid values	C0023779;C0042295	\N	\N
1772	lipid profile	C0023779;C1979963;C2003903	\N	\N
1772	lipid modifiers	C0023779;C4284280	\N	\N
1772	lipid concentrations total cholesterol ( mmol / l )	C0023779;C0086045;C0201950;C0543421;C1532563	\N	\N
1772	lipid concentrations	C0023779;C0086045	\N	\N
1772	lipid - lowerinq druq	C0023779	\N	\N
1772	lipid	C0023779	\N	\N
1772	drinking  n ( % ) lipid values  mmol / l	C0001948;C0023779;C0042295;C0684271;C1532563	\N	\N
1772	baseline lipids  mg / dl	C0023779;C0168634;C0439269;C1442488	\N	\N
1772	baseline lipid profile  mg / dl  mean ( sd )	C0023779;C0168634;C0439269;C0444504;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239	\N	\N
1771	losmapimod ( n = $nmbr$ )	C3272847	\N	\N
1771	losmapimod	C3272847	\N	\N
1771	blisibimod ( n = $nmbr$ )	C3713826	\N	\N
1770	dyslipidemia — no . { % )	C0242339	\N	\N
1770	dyslipidemia — no . ( % ) |	C0242339	\N	\N
1770	dyslipidemia — no . ( % )	C0242339	\N	\N
1770	dyslipidemia $nmbr$	C0242339	\N	\N
1770	dyslipidemia  n ( % )	C0242339	\N	\N
1770	dyslipidemia	C0242339	\N	\N
1770	dyslipidaemiat	\N	\N	\N
1770	dyslipidaemiaj	\N	\N	\N
1773	blockers	\N	f	-10
1770	dyslipidaemia 本	C0242339	\N	\N
1770	dyslipidaemia — no . ( % )	C0242339	\N	\N
1770	dyslipidaemia including hypercholesterol — no . ( % )	C0242339;C0332257	\N	\N
1770	dyslipidaemia and hypertension  n ( % )	C0020538;C0242339;C1963138	\N	\N
1770	dyslipidaemia  n ( % )	C0242339	\N	\N
1770	dyslipidaemia	C0242339	\N	\N
1770	baseline dyslipidemia	C0168634;C0242339;C1442488	\N	\N
1769	lp ( a ) §	C0065058;C1439335;C4553379	\N	\N
1769	lp ( a ) ( μ mol / l )	C0065058;C0347982;C1439335;C4553379	\N	\N
1769	lp ( a ) ( week $nmbr$ )	C0065058;C0332174;C0439230;C1439335;C4553379	\N	\N
1769	lp ( a ) ( pmol / l )	C0065058;C0439284;C1439335;C4553379	\N	\N
1769	lipoprotein ( a ) ( nmol / l )	C0065058;C0125953;C0439282;C1096202;C1439335	\N	\N
1769	lipoprotein ( a ) ( mg / dl )	C0065058;C0125953;C0439269;C1096202;C1439335	\N	\N
1769	lipoprotein ( a )  median ( ql  q $nmbr$ )  nmol / l	C0065058;C0125953;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193	\N	\N
1769	lipoprotein ( a )  median ( qi  q $nmbr$ )  nmol / l	C0065058;C0125953;C0376586;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193	\N	\N
1769	change in lp ( a )	C0065058;C0392747;C0443172;C1439335;C1705241;C4319952;C4553379	\N	\N
1769	baseline lipoprotein ( a ) ( nmol / l )  median ( iqr )	C0065058;C0125953;C0168634;C0439282;C0549183;C0876920;C1096202;C1439335;C1442488;C2347635;C2348144;C2939193	\N	\N
1768	range iga modified $nmbr$ score  n ( % )	C0392747;C0449820;C1514721;C2348147;C2825347;C3542016;C3889737;C4050231	\N	\N
1768	iga mod $nmbr$ score  n ( % )	C0011860;C0449820;C2825347;C4050231	\N	\N
1768	iga $nmbr$ / $nmbr$	C2825347	\N	\N
1767	placebo → golimumab $nmbr$ mg / $nmbr$ mga  b	C0024671;C0026410;C0032042;C0065879;C0439269;C1696465;C1706408;C1960952;C2346927;C2353893;C4321396;C4521761	\N	\N
28	* plus – minus values are means ± sd . percentages may not total $nmbr$ because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ace denotes angiotensin - converting enzyme  cabg coronary - artery bypass grafting  nt - probnp n - terminal pro - b – type natriuretic peptide  nyha new york heart association  and pci percutaneous coro - nary intervention . † race was reported by the investigators . ‡ one patient in nyha class i was mistakenly included in the placebo group . § this category includes any angina - like symptoms at any time in the past  with no confirmation of diagnosis of coro - nary heart disease required . ¶ possible scores range from $nmbr$ to $nmbr$  with lower scores indicating a better quality of life . ∥ anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women . * * nt - probnp levels are influenced by a variety of factors  including age  sex  body - mass index  and renal function . no clinically useful normal range has been established . † † some patients were taking both loop and thiazide diuretics .	C0001779;C0002871;C0004083;C0005893;C0005910;C0009253;C0010055;C0010294;C0012802;C0018787;C0022709;C0025266;C0027976;C0030705;C0032042;C0034510;C0035173;C0036864;C0040223;C0040363;C0041260;C0042295;C0043100;C0043210;C0043237;C0079399;C0086715;C0184661;C0205088;C0205120;C0205447;C0232804;C0243161;C0332126;C0332149;C0332257;C0332272;C0332288;C0332306;C0332307;C0332490;C0332849;C0376558;C0439092;C0439165;C0439175;C0439194;C0439209;C0439241;C0439267;C0439810;C0439849;C0441074;C0441833;C0441889;C0441994;C0443211;C0445022;C0449820;C0475211;C0489786;C0521091;C0522523;C0578022;C0596306;C0596672;C0683312;C0687744;C0699792;C0804628;C0814287;C0858277;C0886296;C1000483;C1144709;C1257890;C1272684;C1273869;C1275491;C1281911;C1292769;C1305855;C1305866;C1314687;C1317554;C1444637;C1449832;C1452534;C1514721;C1514873;C1515187;C1518422;C1519504;C1522384;C1547052;C1548802;C1549488;C1552595;C1552866;C1561533;C1561535;C1696465;C1704788;C1704970;C1705104;C1705314;C1705315;C1705428;C1705429;C1705910;C1706408;C1706779;C1709908;C1719797;C1882084;C1883351;C1883525;C2003888;C2346866;C2348147;C2362652;C2699239;C2700399;C2709270;C2825907;C2911648;C3537020;C3539106;C3541383;C3542016;C3827682;C3853635;C3889152;C3889287;C4049621;C4050156;C4283901;C4284014;C4284038;C4284302;C4522046;C4554633	f	1835
1767	$nmbr$ / $nmbr$ mga ( n = $nmbr$ )	C0065879	\N	\N
1766	sua < $nmbr$ . $nmbr$	\N	\N	\N
1766	spga > $nmbr$	\N	\N	\N
1766	ptga ⁎ ⁎ ⁎	\N	\N	\N
1766	ptga  $nmbr$ - $nmbr$	\N	\N	\N
1766	mean ( sd ) ptga vas *	C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561	\N	\N
1766	baseline sua  mean ± sd mg / dl	C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1766	baseline spga  mean ( sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1764	symptomatic infarct swelling	C0013604;C0021308;C0038999;C0231220	\N	\N
1764	swollen	C0038999	\N	\N
1764	question $nmbr$ ( pain / swelling in joints other than neck / back / hips )	C0003862;C0004600;C0013604;C0019552;C0027530;C0038999;C0205095;C0460009;C1522634;C1995000;C3159206	\N	\N
1764	number of swollen joints ( $nmbr$ assessed )	C0038999;C0449813;C1516048	\N	\N
1764	number of swollen joints ( $nmbr$ - $nmbr$ )  mean ( sd )	C0038999;C0444504;C0449813;C2347634;C2348143;C2699239	\N	\N
1764	number of swollen joints ( $nmbr$ - $nmbr$ )	C0038999;C0449813	\N	\N
1763	other !	\N	\N	\N
1763	other	\N	\N	\N
1763	or	\N	\N	\N
1763	any other llts ( other than statin )	C0360714;C2347090	\N	\N
1762	• iii : death from cv causes  nonfatal mi  hospitalization for ua  all revascularization > $nmbr$ days  nonfatal stroke	C0011065;C0015127;C0019993;C0038454;C0041580;C0042014;C0439070;C0439228;C0581603;C1306577;C1314792;C1524003;C1705160;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
1762	• any stroke	C0038454;C4554100	\N	\N
1762	• $nmbr$ : death from any cause  major coronary event  or nonfatal stroke	C0011065;C0015127;C0038454;C0205082;C0205164;C0741923;C1306577;C1524003;C4082313;C4318856;C4521762;C4552775;C4554100	\N	\N
1762	toast classification of qualifying stroke ( % )	C0038454;C1514624;C1710306;C4521230;C4554100	\N	\N
1762	toast classification of qualifying stroke  no . ( % )	C0038454;C1514624;C1710306;C4521230;C4554100	\N	\N
1762	toast classification of qualifying stroke	C0038454;C1514624;C1710306;C4521230;C4554100	\N	\N
1762	time from qualifying stroke to randomization	C0034656;C0038454;C0040223;C1514624;C3541383;C4554100	\N	\N
1762	time from onset of qualifying stroke to randomization	C0034656;C0038454;C0449244;C1514624;C4554100	\N	\N
1762	stroke — no . / total no . ( % )	C0038454;C0439175;C0439810;C4554100	\N	\N
1762	stroke — no . ( % )	C0038454;C4554100	\N	\N
1762	stroke thought due to atherothrombotic disease	C0012634;C0038454;C0039869;C0678226;C4319827;C4554100	\N	\N
1762	stroke subtype  n ( % )	C0038454;C0449560;C4554100	\N	\N
1762	stroke subtype	C0038454;C0449560;C4554100	\N	\N
1762	stroke ortiab	C0038454;C4554100	\N	\N
1762	stroke ortia	C0038454;C4554100	\N	\N
1762	stroke or transient ischemic attack	C0007787;C0038454;C0917805;C4554100	\N	\N
1762	stroke or tia — no . ( % )	C0007787;C0038454;C0917805;C1054154;C4554100	\N	\N
1762	stroke or tia	C0007787;C0038454;C0917805;C1054154;C4554100	\N	\N
1765	bloodpressure  mean ( sd )  m m hg	C0025424;C0428257;C0428886;C1709500;C2347108;C2347109;C2348272;C2699239	f	615
1765	sbp > $nmbr$ mnn hg	C0025424;C0085805;C0428257;C2347108;C2347109;C2348272	f	615
1767	hscrp < $nmbr$ . $nmbr$ mga . $nmbr$ ( $nmbr$ . $nmbr$ x $nmbr$ ( $nmbr$ . $nmbr$ )	C0065879	f	286
1767	hscrp > $nmbr$ . $nmbr$ mga .	C0065879	f	286
1762	stroke or systemic embolism	C0013922;C0038454;C0205373;C1704212;C4554100	\N	\N
1762	stroke or systemic	C0038454;C0205373;C4554100	\N	\N
1762	stroke or se ( s / se )	C0036919;C0038454;C4554100	\N	\N
1762	stroke or	C0038454;C4554100	\N	\N
1762	stroke of any etiology	C0015127;C0038454;C1314792;C1524003;C4554100	\N	\N
1762	stroke n = $nmbr$	C0038454;C4554100	\N	\N
1762	stroke n ( % )	C0038454;C4554100	\N	\N
1762	stroke at entry ( vs transient ischemic attack )	C0007787;C0038454;C0917805;C1705654;C4554100	\N	\N
1762	stroke at entry	C0038454;C1705654;C4554100	\N	\N
1762	stroke any	C0038454;C4554100	\N	\N
1762	stroke and tia  n ( % )	C0007787;C0038454;C0917805;C1054154;C4554100	\N	\N
1762	stroke / transient ischemic attack	C0007787;C0038454;C0917805;C4554100	\N	\N
1762	stroke / se	C0036919;C0038454;C4554100	\N	\N
1762	stroke / non -	C0038454;C1518422;C4554100	\N	\N
1762	stroke / m $nmbr$	C0038454;C0369637;C0441923;C4554100	\N	\N
1762	stroke / embolism	C0013922;C0038454;C1704212;C4554100	\N	\N
1762	stroke  total	C0038454;C0439175;C0439810;C4554100	\N	\N
1762	stroke  n ( % )	C0038454;C4554100	\N	\N
1762	stroke	C0038454;C4554100	\N	\N
1762	sensorimotor stroke	C0038454;C4554100	\N	\N
1762	qualifying stroke	C0038454;C1514624;C4554100	\N	\N
1762	pure sensory stroke	C0038454;C0445254;C2247561;C4554100	\N	\N
1762	prior stroke or transient ischemic attack	C0007787;C0038454;C0332152;C0917805;C2826257;C4554100	\N	\N
1762	previous stroke 一 no . ( % )	C0038454;C0205156;C1552607;C4554100	\N	\N
7	strata modelb hr  $nmbr$ % ci  p value	C0008107;C1709380;C3259781	\N	\N
1762	previous stroke — no . ( % ) concomitant treatment — no . ( % )	C0038454;C0039798;C0087111;C0205156;C0521115;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704;C4554100	\N	\N
1762	previous stroke — no . ( % )	C0038454;C0205156;C1552607;C4554100	\N	\N
1762	previous stroke ortransient ischaemic attack ( % )	C0038454;C0205156;C0745413;C1552607;C4554100	\N	\N
1762	previous stroke ortia $nmbr$ - $nmbr$	C0038454;C0205156;C1552607;C4554100	\N	\N
1762	previous stroke ortia	C0038454;C0205156;C1552607;C4554100	\N	\N
1762	previous stroke or transient ischemic attack — no . / total	C0007787;C0038454;C0205156;C0439175;C0439810;C0917805;C1552607;C4554100	\N	\N
1762	previous stroke or transient ischemic attack  no . / total no . ( % )	C0007787;C0038454;C0205156;C0439175;C0439810;C0917805;C1552607;C4554100	\N	\N
1762	previous stroke or tl a $nmbr$ - $nmbr$	C0038454;C0205156;C0220928;C1552607;C4554100	\N	\N
1762	previous stroke or tl a	C0038454;C0205156;C0220928;C1552607;C4554100	\N	\N
1762	previous stroke or tia  n ( % )	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1762	previous stroke / tia	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1762	previous stroke *	C0038454;C0205156;C1552607;C4554100	\N	\N
1762	previous stroke  n ( % )	C0038454;C0205156;C1552607;C4554100	\N	\N
1762	previous stroke	C0038454;C0205156;C1552607;C4554100	\N	\N
1762	previous clinical stroke or transient ischemic attack ( % )	C0007787;C0038454;C0205156;C0205210;C0917805;C1552607;C4554100	\N	\N
1762	previous clinical stroke or tia	C0007787;C0038454;C0205156;C0205210;C0917805;C1054154;C1552607;C4554100	\N	\N
1762	no stroke n = $nmbr$ $nmbr$	C0038454;C4554100	\N	\N
1762	no stroke / tia	C0007787;C0038454;C0917805;C1054154;C4554100	\N	\N
1762	no stroke ( n = $nmbr$ )	C0038454;C4554100	\N	\N
1762	no previous stroke ortia	C0038454;C0205156;C1552607;C4554100	\N	\N
1762	no previous stroke / tia	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1762	no . of strokes / no . of patients in category ( and % )	C0030705;C0038454;C0683312;C3889287	\N	\N
1762	no . of strokes ( % )	C0038454	\N	\N
1762	no . ( % ) of patients with stroke	C0030705;C0038454;C4554100	\N	\N
1762	new stroke *	C0038454;C0205314;C4554100	\N	\N
1762	months from qualifying stroke *   ( % )	C0038454;C0439231;C1514624;C4554100	\N	\N
1762	hx mi or stroke	C0038454;C0262926;C3810814;C3814444;C4554100	\N	\N
1762	history of stroke or tia — no . ( % )	C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100	\N	\N
1762	hemispheric stroke n = $nmbr$	C0038454;C0205139;C4554100	\N	\N
1762	disabling stroke	C0038454;C4554100	\N	\N
1762	death or disabling stroke	C0011065;C0038454;C1306577;C4082313;C4552775;C4554100	\N	\N
1762	cvd without mi or stroke ( n = $nmbr$ )	C0007222;C0038454;C3810814;C4554100	\N	\N
1762	cvd / mi / stroke / urgent vascular hospitalization	C0005847;C0007222;C0019993;C0038454;C0439609;C1558950;C1801960;C3272275;C3810814;C4554100	\N	\N
1762	cvd / mi / stroke	C0007222;C0038454;C3810814;C4554100	\N	\N
1762	cerebrovascular accident / tia	C0007787;C0038454;C0917805;C1054154	\N	\N
1762	cerebrovascular accident	C0038454	\N	\N
1762	atherothrombotic stroke  n ( % )	C0038454;C4554100	\N	\N
1762	any stroke ( n = $nmbr$ )	C0038454;C4554100	\N	\N
1762	any stroke	C0038454;C4554100	\N	\N
1762	all strokes *	C0038454;C4554100	\N	\N
1762	all strokes  n ( % )	C0038454;C0369718;C0441922;C4554100	\N	\N
1762	all strokes	C0038454;C4554100	\N	\N
1762	all stroke	C0038454;C4554100	\N	\N
1762	a stroke	C0038454;C4554100	\N	\N
1762	$nmbr$ days stroke ( ischemic )	C0038454;C0439228;C0475224;C4554100	\N	\N
1761	rotigotine n = $nmbr$	C1700683;C4318637	\N	\N
1761	rotigotine ( n = $nmbr$ )	C1700683;C4318637	\N	\N
1761	rosiglitazone versus metformin	C0025598;C0289313	\N	\N
1761	rosiglitazone versus glyburide	C0017628;C0289313	\N	\N
1761	rosiglitazone ( n = $nmbr$ )	C0289313	\N	\N
1761	rosiglitazone	C0289313	\N	\N
1761	p value for heterogeneity （ rosiglitazone versus glyburide ）	C0017628;C0019409;C0242960;C0289313;C1709380	\N	\N
1760	pioglitazone pts / n ( % )	C0071097;C1419129;C2698747	\N	\N
1760	pioglitazone events / n ( % )	C0071097;C0441471;C3541888	\N	\N
1760	pioglitazone dose  mean ( sd )  mg	C0024671;C0026410;C0071097;C0178602;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761	\N	\N
1760	pioglitazone ( n = $nmbr$ )	C0071097	\N	\N
1760	pioglitazone ( n = $nmbr$  $nmbr$ )	C0071097	\N	\N
1760	pioglitazone	C0071097	\N	\N
1759	eplerenone ( n   = $nmbr$ )	C0961485	\N	\N
1759	canrenone ( n z $nmbr$ )	C0006882	\N	\N
1758	ras - aldosterone inhibitor ^	C0002006;C0002007;C0034678;C0525678;C1514727	\N	\N
1758	aldosterone inhibitor	C0002007	\N	\N
1758	aldosterone antagonists ( e . g . spironolactone )	C0002007;C0037982;C2757004	\N	\N
1758	aldosterone antagonists	C0002007;C2757004	\N	\N
1758	aldosterone antagonist	C0002007;C2757004;C3536833	\N	\N
1757	peri - op amiodarone : no ( n = $nmbr$ )	C0002598;C0347985;C0369718;C0441922	\N	\N
1757	no amiodarone	C0002598	\N	\N
1757	amiodarone vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl )	C0002598;C0032042;C0596019;C1696465;C1706408;C2985465	\N	\N
1757	amiodarone vs . placebo	C0002598;C0032042;C1696465;C1706408	\N	\N
1757	amiodarone use at baseline	C0002598;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
1757	amiodarone ote at baseline	C0002598;C0168634;C1442488	\N	\N
1757	amiodarone ( n = $nmbr$ )	C0002598	\N	\N
1757	amiodarone ( n  % )	C0002598	\N	\N
1757	amiodarone  n ( % )	C0002598	\N	\N
1757	amiodarone	C0002598	\N	\N
7	rr ( $nmbr$ aci ) [ p value ]	C0814206;C1510682;C1709380;C2346870;C4050575;C4554402	\N	\N
7	p — value for interaction	C1704675;C1709380	\N	\N
7	p ‐ value *	C1709380	\N	\N
1756	fibrinolytic agent — no . ( % ) : t	C0016018;C2603360	\N	\N
1755	ra	C3538806;C4048756	\N	\N
1755	patients without ra  as  or psa ( n = $nmbr$  $nmbr$ )	C0030705;C3538806;C3810537;C3813209;C4048756	\N	\N
1755	patients with ra  as  or psa ( n = $nmbr$ )	C0030705;C3538806;C3810537;C3813209;C4048756	\N	\N
1755	no . of patients with ra	C0030705;C3538806;C4048756	\N	\N
1755	months since ra was first diagnosed  mean ( sd )	C0011900;C0205435;C0439231;C0444504;C1279901;C2347634;C2348143;C2699239;C3538806;C4048756	\N	\N
1754	epa / aa ratio	C0282379;C0456603;C1235746;C1547037;C1882141;C4554792	\N	\N
1754	aa / g	C0282379;C0439267;C1235746;C1882141;C4554792	\N	\N
1754	aa  mol %	C0027960;C0282379;C0324740;C0439189;C1235746;C1456781;C1824986;C1882141;C3665593;C4554792	\N	\N
1754	aa	C0282379;C1235746;C1882141;C4554792	\N	\N
1753	numab	\N	\N	\N
1753	dmab ( n = $nmbr$ )	C0012411	\N	\N
1753	azl - ma	C0024443;C3887485	\N	\N
1752	symptomatic pad of lower extremities *	C0023216;C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	risk factors for pad	C0035648;C0182158;C0332568;C1553898;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	pad symptoms ( % )	C0182158;C0332568;C0683368;C1457887;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	pad lower extremities	C0023216;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	pad details  n ( % )	C0182158;C0332568;C0369718;C0441922;C1522508;C1561567;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	pad at baseline	C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	pad ( n - $nmbr$  $nmbr$ )	C0182158;C0332568;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	pad	C0182158;C0332568;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	no pad baseline	C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657	\N	\N
1752	no pad ( n - $nmbr$  $nmbr$ )	C0182158;C0332568;C3540603;C3669270;C3814046;C4319657	\N	\N
1751	vas ( $nmbr$ - $nmbr$ )	C0042815;C3536884;C3827561	\N	\N
1751	ptga ( $nmbr$ - $nmbr$ cm vas )	C0042815;C3536884;C3827561	\N	\N
1751	physician global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm )	C0042815;C3536884;C3827561;C4050369;C4330985;C4554674	\N	\N
1751	physician global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas )	C0042815;C3536884;C3827561;C4050369	\N	\N
1751	physician global assessment ( $nmbr$ - $nmbr$ mm vas )	C0042815;C3536884;C3827561;C4050369;C4330985;C4554674	\N	\N
1751	physician ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd )	C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4050369;C4330985;C4554674	\N	\N
1751	physician ' s global assessment ( vas )	C0042815;C3536884;C3827561;C4050369	\N	\N
1751	physician ' s assessment of disease activity ( vas )  mm	C0031831;C0042815;C0456681;C0804815;C1261322;C1292728;C1516048;C3536884;C3827561	\N	\N
1743	overall	C0282416;C1561607	\N	\N
1743	overaii ( n = $nmbr$ )	\N	\N	\N
1757	dronedarone	C0766326	f	1923
1757	dronedarone ( n = $nmbr$ )	C0766326	f	1923
1757	dronedarone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0766326	f	1923
1756	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % t	C2603360	f	-10
1756	$nmbr$ . ' ^ / $nmbr$ t $nmbr$ c } u	C0439148;C2603360	f	-10
1756	t	C2603360	f	-10
1756	t - jj ( $nmbr$ - $nmbr$ )	C2603360	f	-10
1756	t $nmbr$ d	C2603360	f	-10
1753	body mass index ( kg / ma )	C0005893;C0022718;C0024443;C0439209;C0578022;C1305855;C3887485;C4054209	f	1734
1753	< $nmbr$ kg / ma $nmbr$	C0022718;C0024443;C0439209;C3887485;C4054209	f	1734
1753	> = $nmbr$ kg / ma $nmbr$	C0022718;C0024443;C0439209;C3887485;C4054209	f	1734
1755	all - baricitinib ra ( n = $nmbr$ ) *	C3538806;C4044947;C4048756	f	1956
1751	patient global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm )	C0042815;C3536884;C3827561;C4054228;C4330985;C4554674	\N	\N
1751	patient global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas )	C0042815;C3536884;C3827561;C4054228	\N	\N
1751	patient global assessment ( $nmbr$ - $nmbr$ mm vas )	C0042815;C3536884;C3827561;C4054229;C4330985;C4554674	\N	\N
1751	patient ' s global assessment ( vas )	C0042815;C3536884;C3827561;C4054229	\N	\N
1751	pain ( vas )	C0042815	\N	\N
1751	mean ( sd ) pain vas *	C0042815;C0444504;C2347634;C2348143;C2699239	\N	\N
1751	general health vas  $nmbr$ - $nmbr$ mm	C0042815;C0424575;C3536884;C3827561;C4018875;C4330985;C4554674	\N	\N
1751	baseline skin pain vas  mean ( sd )	C0042815;C0168634;C0241136;C0444099;C0444504;C1123023;C1442488;C1963195;C2347634;C2348143;C2699239;C3536884;C3827561;C4520765	\N	\N
1751	activity ( $nmbr$ - $nmbr$ vas )	C0042815;C0205177;C0439167;C0441655;C1561536;C3536884;C3668946;C3827561;C4049938;C4049939	\N	\N
1751	( $nmbr$ - $nmbr$ - cm vas )	C0042815;C3536884;C3827561	\N	\N
1750	physician ' s ga  $nmbr$ - $nmbr$ mmvas	C0016993;C0031831;C0804815	\N	\N
1750	patient ' s ga  $nmbr$ - $nmbr$ mm vas	C0016993;C0030705;C0042815;C3536884;C3827561;C4330985;C4554674	\N	\N
1750	ga / a	C0016993	\N	\N
1750	ga	C0016993	\N	\N
1750	a / ga	C0016993	\N	\N
1749	less than $nmbr$ mm hg	C0439092;C0439475	\N	\N
1749	less than $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439092;C0439445;C0441923	\N	\N
1749	less than $nmbr$ kg / m $nmbr$	C0439092;C1532718	\N	\N
1749	less than $nmbr$ . $nmbr$ %	C0439092	\N	\N
1749	less than $nmbr$ %	C0439092	\N	\N
1749	less than $nmbr$	C0439092	\N	\N
1748	total stent length - mm	C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674	\N	\N
1748	total stent length ( mm )  mean ± sd	C0038257;C0439175;C0439810;C0444504;C1444754;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
1748	total stent length  mm	C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674	\N	\N
1748	total stent length	C0038257;C0439175;C0439810;C1444754;C1706316	\N	\N
1747	oral anticoagulants	C0354604	\N	\N
1747	oral anticoagulant — no . / total no . ( % )	C0354604;C0439175;C0439810	\N	\N
1747	oral anticoagulant n ( % )	C0354604	\N	\N
1747	oral anticoagulant drugs  n ( % )	C0354604	\N	\N
1747	oral anticoagulant drugs	C0354604	\N	\N
1747	oral anticoagulant agent	C0354604	\N	\N
1747	oral anticoagulant  n ( % )	C0354604	\N	\N
1747	oral anticoagulant	C0354604	\N	\N
1746	oral β - adrenergics  n ( % )	C0001637;C0442027;C4521986	\N	\N
1746	oral treprostinil ( n = $nmbr$ )	C0442027;C1145760;C4521986	\N	\N
1746	oral blood glucose - lowering drug $nmbr$ ( $nmbr$ . $nmbr$ )	C0005802;C0013227;C0017725;C0018938;C0441994;C0442027;C1254351;C2003888;C4521986	\N	\N
1746	oral blood glucose - lowering	C0005802;C0441994;C0442027;C2003888;C4521986	\N	\N
1746	oral antidiabetic drugs / insulin ( % / % )	C0021641;C0029167;C0175795;C0304289;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986	\N	\N
1746	oral antidiabetic drugs	C0029167;C0175795;C0304289;C0442027;C0935929;C4521986	\N	\N
1746	oral antidiabetes monotherapya  n ( % )	C0442027;C4521986	\N	\N
1746	oral ( % )	C0442027;C4521986	\N	\N
1746	oral	C0442027;C4521986	\N	\N
1746	concomitant oral glucose - lowering agents  zz ( % )	C0017725;C0441994;C0442027;C2003888;C2347310;C2347852;C4521986	\N	\N
1746	baseline prednisone or oral prednisone equivalent daily dose	C0032952;C0168634;C0205163;C0439185;C0442027;C1442488;C2348070;C4521986	\N	\N
1745	patent foramen ovale	C0016522;C0344724	\N	\N
1745	ovary	C0029939;C0227898	\N	\N
1744	other oral hypoglycemic drug ( s )	C0359086	\N	\N
1744	oral hypoglycemics hormone replacement	C0282402;C0359086	\N	\N
1744	oral hypoglycemics	C0359086	\N	\N
1744	oral hypoglycemic drug	C0359086	\N	\N
1744	oral hypoglycemic agentsj	C0359086	\N	\N
1744	oral hypoglycemic agents	C0359086	\N	\N
1744	oral hypoglycemic agent	C0359086	\N	\N
1744	oral hypoglycemic	C0359086	\N	\N
1744	oral antihyperglycaemic  n ( % )	C0359086	\N	\N
1743	teaes reported by ≥ $nmbr$ % patients in the overall brv group    n   ( % )	C0030705;C0155502;C0282416;C0441848;C1561607;C1709908	\N	\N
1743	qveral	\N	\N	\N
1743	overally	\N	\N	\N
1743	overall ® $nmbr$ . $nmbr$	C0282416;C1561607	\N	\N
1743	overall vero population	C0032659;C0282416;C1257890;C1561607	\N	\N
1743	overall treatment effect	C0282416;C1518681;C1561607	\N	\N
1743	overall population ( n = $nmbr$ )	C0032659;C0282416;C1257890;C1561607	\N	\N
1743	overall population ( n - $nmbr$ )	C0032659;C0282416;C1257890;C1561607	\N	\N
1743	overall population	C0032659;C0282416;C1257890;C1561607	\N	\N
1743	overall pad	C0182158;C0282416;C0332568;C1561607;C3540603;C3669270;C3814046;C4319657	\N	\N
1743	overall n = $nmbr$  $nmbr$	C0282416;C1561607	\N	\N
1743	overall effect	C0282416;C1280500;C1518681;C1561607;C2348382	\N	\N
1743	overall ctd	C0282416;C1335071;C1442905;C1561607	\N	\N
1743	overall a phase population	C0032659;C0205390;C0282416;C1257890;C1561607;C1710475	\N	\N
1743	overall ( w = $nmbr$ )  $nmbr$ / $nmbr$	C0282416;C1561607	\N	\N
1743	overall ( pp ) ( n = $nmbr$ )	C0030375;C0063017;C0282416;C1561607;C4319755	\N	\N
1743	overall ( per protocol ) ( n = $nmbr$ )	C0282416;C1561607;C1698058	\N	\N
1743	overall ( n = u $nmbr$ )	C0282416;C0439148;C1561607	\N	\N
1743	overall ( n = $nmbr$ vs $nmbr$ )	C0282416;C1561607	\N	\N
1743	overall ( n = $nmbr$ )	C0282416;C1561607	\N	\N
1743	overall ( n = $nmbr$  $nmbr$ )	C0282416;C1561607	\N	\N
1743	overall ( itt ) ( n = $nmbr$ )	C0282416;C1561607	\N	\N
1743	overall ( $nmbr$  $nmbr$ )	C0282416;C1561607	\N	\N
1743	overall $nmbr$	C0282416;C1561607	\N	\N
1743	overall  qvai $nmbr$ - sfc	C0282416;C1561607;C4521536	\N	\N
1743	overall  n = $nmbr$	C0282416;C1561607	\N	\N
1748	laa length	C1444754;C1706316	f	1922
1749	ta	C0039297;C1506978;C1705538;C3272501;C4553364	f	-10
1743	overaii	\N	\N	\N
1743	omeprazole	C0028978	\N	\N
1743	metrex overall modified intention - to - treat population ? :	C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737	\N	\N
1743	calima overall ( n = $nmbr$ )	C0282416;C1561607	\N	\N
1743	brv overalla ( n = $nmbr$ )	C0155502	\N	\N
1743	brv overall ( n = $nmbr$ )	C0155502;C0282416;C1561607	\N	\N
1743	brv overall	C0155502;C0282416;C1561607	\N	\N
1742	infarct on brain imaging 丰	C0011923;C0079595;C0751955	\N	\N
1742	infarct on brain imaging ^	C0011923;C0079595;C0751955	\N	\N
1742	brazil	C0006137	\N	\N
1741	non - frail	C0871754;C1518422	\N	\N
1741	frail	C0871754	\N	\N
1741	fragile	C0302113	\N	\N
1740	stratified log - rank   p   value	C0205363;C0667477;C0699794;C1708728;C1709380;C2986775	\N	\N
1740	stratified log - rank p value	C0205363;C0667477;C0699794;C1708728;C1709380;C2986775	\N	\N
1740	log rank p - value	C0667477;C0699794;C1708728;C1709380;C2986775	\N	\N
1740	log - rank p value	C0667477;C0699794;C1708728;C1709380;C2986775	\N	\N
1740	log - rank	C0667477;C0699794;C1708728;C2986775	\N	\N
7	p ‐ value	C1709380	\N	\N
1740	cmann whitney u test / wilcoxon sum rank test .	C0439148;C0667477;C0683443;C0699794;C1515051	\N	\N
1740	amann whitney u test / wilcoxon sum rank test .	C0439148;C0667477;C0683443;C0699794;C1515051	\N	\N
1739	strain ( % )	C0080194;C0456178;C1518614;C2987481	\N	\N
1739	brain volume  cm '	C1113695	\N	\N
1739	brain volume  cm $nmbr$	C1113695	\N	\N
1738	regular ppi use	C0042153;C0205272;C0358591;C0457083;C0871125;C1947944;C3811894	\N	\N
1738	ppi use ( p = $nmbr$ . $nmbr$ t )	C0042153;C0358591;C0369773;C0457083;C0871125;C1947944;C2603361;C3811894	\N	\N
1738	ppi use ( p = $nmbr$ - $nmbr$ t )	C0042153;C0358591;C0369773;C0457083;C0871125;C1947944;C2603361;C3811894	\N	\N
1738	ppi use	C0042153;C0358591;C0457083;C0871125;C1947944;C3811894	\N	\N
1738	ppi	C0358591;C0871125;C3811894	\N	\N
1738	pi	C0122626;C0429863;C3537219;C3539772	\N	\N
1738	phi ( n = $nmbr$ )	C1333690;C1704947;C1706536;C2975867;C4084801	\N	\N
1738	phi ( n - $nmbr$ )	C1333690;C1704947;C1706536;C2975867;C4084801	\N	\N
1738	pgi - s  n ( % ) y :	C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133	\N	\N
1738	noppi	\N	\N	\N
1738	nontrial ppi	C0358591;C0871125;C3811894	\N	\N
1738	non - study ppi use	C0042153;C0358591;C0457083;C0557651;C0871125;C1518422;C1947944;C2603343;C3811894	\N	\N
1738	no regular ppi use	C0042153;C0205272;C0358591;C0457083;C0871125;C1947944;C3811894	\N	\N
1738	combinations of aspirin and ppi use ( p = $nmbr$ . $nmbr$ t )	C0004057;C0042153;C0358591;C0453882;C0457083;C0871125;C1947944;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3811894;C3854036	\N	\N
1737	pb	C1415801;C3819255	\N	\N
1737	median feno ( ppb ) f	C0016327;C0549183;C0876920;C1415800;C2347635;C2348144;C2939193	\N	\N
1737	mean ( sd ) feno  ppb	C0444504;C1415800;C2347634;C2348143;C2699239	\N	\N
1737	high feno subgroup ( > $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ )	C0205250;C1079230;C1299351;C1415800;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
1737	feno — ppb	C1415800	\N	\N
1737	> $nmbr$ to < $nmbr$ ppb	C1415800	\N	\N
1737	> $nmbr$ ppb	C1415800	\N	\N
1737	< $nmbr$ ppb	C1415800	\N	\N
1736	tenecteplase and pci ( n = $nmbr$ )	C0872913;C4049621	\N	\N
1736	single vessel pci	C0005847;C0037179;C0087136;C0205171;C4049621	\N	\N
1736	ret / abx - facil . pci	C0389252;C4049621	\N	\N
1736	prerandomization pci	C4049621	\N	\N
1736	pre - randomization pci	C0034656;C0332152;C0740175;C2257086;C3669034;C4049621	\N	\N
1736	poci ( n = $nmbr$ )	\N	\N	\N
1736	poci	\N	\N	\N
1736	pci — no . { % )	C4049621	\N	\N
1736	pci — no . ( % )	C4049621	\N	\N
1736	pci revascularization	C0581603;C4049621	\N	\N
1736	pci orcabg	C4049621	\N	\N
1736	pci :	C4049621	\N	\N
1736	pci ( % )	C4049621	\N	\N
1736	pci  n ( % )	C4049621	\N	\N
1736	pci	C4049621	\N	\N
1736	no pci or cabg — no . ( % )	C0010055;C4049621	\N	\N
1736	no pci	C4049621	\N	\N
1736	multivessel pci	C4049621	\N	\N
1736	interval study drug to pci	C0013175;C1272706;C1552654;C1552713;C4049621	\N	\N
1736	history of pci — no . / total no . ( % ) : t	C0019664;C0019665;C0262512;C0262926;C0439175;C0439810;C1705255;C2004062;C2603360;C4049621	\N	\N
1736	glycoprotein ilb / iiia inhibitor before pci ]	C0017968;C1999216;C4049621;C4697913	\N	\N
1736	facilitated pci ( n = $nmbr$ )	C4049621	\N	\N
1736	combo - facilitated pci	C4049621	\N	\N
1736	clopidogrel dose on / before pci	C0070166;C0178602;C0869039;C1114758;C4049621	\N	\N
1736	before pci	C4049621	\N	\N
1736	and after pci  median ( iqr )  d	C0549183;C0876920;C2347635;C2348144;C2939193;C4049621	\N	\N
1736	after pci	C4049621	\N	\N
1736	abx - facil . pci	C4049621	\N	\N
1736	abciximab - facilitated pci ( n = $nmbr$ )	C0288672;C4049621	\N	\N
1736	$nmbr$ vessel pci	C0005847;C4049621	\N	\N
1735	subpopulation analyses according to bmi	C0578022;C0680240;C1514228	\N	\N
1735	screening bmi ( kg / m $nmbr$ )	C0220908;C0220909;C0578022;C1532718;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
1735	risk factors bmi ( kg / m $nmbr$ )  mean + sd	C0035648;C0444504;C0578022;C1532718;C1553898;C2347634;C2348143;C2699239	\N	\N
1735	obese ( bmi £ $nmbr$ )	C0028754;C0578022	\N	\N
1735	normal weight ( bmi < $nmbr$ )	C0005910;C0043100;C0578022;C1305866;C1705104;C2712185;C4229017	\N	\N
1735	normal ( bmi < $nmbr$ )	C4229017	\N	\N
1735	mean ± s . d . bmi  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143	\N	\N
1735	mean bmi ( kg / m $nmbr$ ) ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	mean bmi ( $nmbr$ % ci )	C0008107;C0444504;C0578022;C2347634;C2348143;C3259781	\N	\N
1735	mean bmi  kg / m $nmbr$ ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	mean bmi  kg / m $nmbr$ ( s . d . )	C0022718;C0439209;C0444504;C0578022;C1512018;C2347634;C2348143;C4054209	\N	\N
1735	mean bmi  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143	\N	\N
1735	mean bmi	C0444504;C0578022;C2347634;C2348143	\N	\N
1735	mean baseline bmi	C0168634;C0444504;C0578022;C1442488;C2347634;C2348143	\N	\N
1735	mean ( sd ) bmi ( kg / m $nmbr$ )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	mean ( s . d . ) bmi  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143	\N	\N
1735	bms	\N	\N	\N
1735	bmit	\N	\N	\N
1735	bmij	\N	\N	\N
1735	bmia	\N	\N	\N
1735	bmi — mean ( sd ) ( kg / m $nmbr$ )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi £ $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi   kg · m − $nmbr$	C0578022;C1532718	\N	\N
1735	bmi o $nmbr$ kg / m $nmbr$  n ( % )	C0578022;C1532718	\N	\N
1735	bmi kg · m − $nmbr$	C0578022;C1532718	\N	\N
1735	bmi category ( kg / m $nmbr$ )	C0578022;C0683312;C1532718;C3889287	\N	\N
1735	bmi category ( % )	C0578022;C0683312;C3889287	\N	\N
1735	bmi category  no . ( % )	C0578022;C0683312;C3889287	\N	\N
1735	bmi category	C0578022;C0683312;C3889287	\N	\N
1735	bmi categories  n ( % )	C0578022;C0683312	\N	\N
1735	bmi a $nmbr$	C0578022	\N	\N
1735	bmi ^	C0578022	\N	\N
1735	bmi [ kg / m $nmbr$ ]	C0578022;C1532718	\N	\N
1735	bmi > = $nmbr$ kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi > = $nmbr$	C0578022	\N	\N
1735	bmi > $nmbr$ — no . { % ) $	C0578022	\N	\N
1735	bmi > $nmbr$ — no . ( % ) f	C0016327;C0578022	\N	\N
1735	bmi > $nmbr$ obese	C0028754;C0578022	\N	\N
1735	bmi > $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi > $nmbr$ kg / m $nmbr$ *	C0578022;C1532718	\N	\N
1735	bmi > $nmbr$ kg / m $nmbr$  n ( % )	C0578022;C1532718	\N	\N
1735	bmi > $nmbr$ kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi > $nmbr$ ( % )	C0578022	\N	\N
1735	bmi > $nmbr$  n ( % )	C0578022	\N	\N
1735	bmi > $nmbr$	C0578022	\N	\N
1735	bmi < = $nmbr$	C0578022	\N	\N
1735	bmi < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi < $nmbr$ kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi < $nmbr$	C0578022	\N	\N
1735	bmi : > $nmbr$ . $nmbr$ kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi : < $nmbr$ . $nmbr$ kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi - kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi ( median  iqr )  kg / m $nmbr$	C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193	\N	\N
1735	bmi ( kg = m $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi ( kg / m ’ )	C0578022;C1532718	\N	\N
1735	bmi ( kg / m ^ )  mean ± s . d .	C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C0578022;C1275571;C1513009;C2347634;C2348143;C4054209	\N	\N
1735	bmi ( kg / m ^ )	C0578022;C1532718	\N	\N
1735	bmi ( kg / m )	C0578022;C1532718	\N	\N
1735	bmi ( kg / m $nmbr$ ) mean ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi ( kg / m $nmbr$ ) cardiovascular history	C0578022;C1532718;C1880008	\N	\N
1735	bmi ( kg / m $nmbr$ ) cardiac parameters	C0018787;C0449381;C0578022;C1522601;C1532718	\N	\N
1735	bmi ( kg / m $nmbr$ ) a	C0578022;C1532718	\N	\N
1735	bmi ( kg / m $nmbr$ ) [ mean - sd ]	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi ( kg / m $nmbr$ ) : mean ± sd	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi ( kg / m $nmbr$ ) *	C0578022;C1532718	\N	\N
1735	bmi ( kg / m $nmbr$ )  mean ± sd	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi ( kg / m $nmbr$ )  mean ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi ( kg / m $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi ( kg / ( m ) $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi ( . kg / m - ) *	C0578022;C1532718	\N	\N
1735	bmi $nmbr$ - < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi $nmbr$ - < $nmbr$ kg / m - ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi $nmbr$ - < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi $nmbr$ - < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
1735	bmi $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$	C0578022	\N	\N
1735	bmi $nmbr$ - $nmbr$ - $nmbr$ $nmbr$	C0578022	\N	\N
1735	bmi $nmbr$ $nmbr$ - $nmbr$ $nmbr$	C0578022	\N	\N
1735	bmi $nmbr$	C0578022	\N	\N
1735	bmi  x $nmbr$ kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi  no . ( % )	C0578022	\N	\N
1735	bmi  n ( % )	C0578022	\N	\N
1735	bmi  median ( iqr )	C0549183;C0578022;C0876920;C2347635;C2348144;C2939193	\N	\N
1735	bmi  mean  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143	\N	\N
1735	bmi  kg per m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi  kg / m ’	C0578022;C1532718	\N	\N
1735	bmi  kg / m ^  mean ( sd ) ’	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi  kg / m $nmbr$  n	C0578022;C1532718	\N	\N
1735	bmi  kg / m $nmbr$  median ( iqr )	C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193	\N	\N
1735	bmi  kg / m $nmbr$  mean ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
1735	bmi  kg / m $nmbr$	C0578022;C1532718	\N	\N
1735	bmi	C0578022	\N	\N
1735	bm i < $nmbr$	C0006416;C0021966;C0221138	\N	\N
1735	baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks	C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952	\N	\N
1735	baseline bmi ( kg / m ^ )	C0168634;C0578022;C1442488;C1532718	\N	\N
1735	baseline bmi ( kg / m $nmbr$ )	C0168634;C0578022;C1442488;C1532718	\N	\N
1735	baseline bmi	C0168634;C0578022;C1442488	\N	\N
1735	> $nmbr$ years bmi	C0439234;C0578022	\N	\N
1735	( a ) bmi subgroups	C0578022;C1079230	\N	\N
1735	$nmbr$ < bmi < $nmbr$	C0578022	\N	\N
1734	• j . the body - mass index is the weight in kilograms divided by the square of the	C0005893;C0005910;C0043100;C0205120;C0332849;C0439209;C0578022;C1305855;C1305866;C1552595;C1705104	\N	\N
1734	median body mass index  kg / m $nmbr$ ( range )	C0005893;C0549183;C0578022;C0876920;C1305855;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
1734	median body mass index  kg / m $nmbr$ ( iqr )	C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193	\N	\N
1734	mean body mass index ( sd )  kg / m $nmbr$	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	mean body mass index ( kg / m $nmbr$ ) *	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143	\N	\N
1734	mean body mass index ( kg / m $nmbr$ )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143	\N	\N
1734	mean body mass index  kg / m $nmbr$	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143	\N	\N
1734	mean body - mass index ( = sd )  kg / m $nmbr$	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	mean body - mass index  kg / m $nmbr$   ( sd ) *	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	mean body - mass index  kg / m $nmbr$ ( sd ) *	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	mean body - mass index  kg / m $nmbr$	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143	\N	\N
1734	mean ( sd ) body mass index  kg / m $nmbr$	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index subgroups	C0005893;C0578022;C1079230;C1305855	\N	\N
1734	body mass index mean kg / m $nmbr$ ( sd )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index group ( kg / m $nmbr$ ) ≥ $nmbr$ kg / m $nmbr$ — no . ( % )	C0005893;C0022718;C0439209;C0441833;C0578022;C0687744;C1257890;C1305855;C1519504;C1705428;C1705429;C1709500;C4054209	\N	\N
1734	body mass index category  no . ( % ) l	C0005893;C0439394;C0578022;C0683312;C1305855;C1706495;C3642217;C3889287	\N	\N
1734	body mass index blood pressure — mmhg	C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855	\N	\N
1734	body mass index ^	C0005893;C0578022;C1305855	\N	\N
1734	body mass index [ kg / m $nmbr$ ]  mean ± sd	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index > $nmbr$ — no . ( % ) f	C0005893;C0016327;C0578022;C1305855	\N	\N
1734	body mass index > $nmbr$ t	C0005893;C0578022;C1305855	\N	\N
1734	body mass index > $nmbr$ kg / m  n ( % )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index > $nmbr$  n ( % )	C0005893;C0578022;C1305855	\N	\N
1734	body mass index :	C0005893;C0578022;C1305855	\N	\N
1734	body mass index / mean ( sd )	C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239	\N	\N
1734	body mass index - mean ( sd )	C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239	\N	\N
1734	body mass index - kg / m $nmbr$ t	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index +	C0005893;C0578022;C1305855	\N	\N
1734	body mass index *	C0005893;C0578022;C1305855	\N	\N
1734	body mass index ( kgm _ $nmbr$ )	C0005893;C0578022;C1305855	\N	\N
1734	body mass index ( kg / m “ ) ^	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index ( kg / m ’ ) ^	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index ( kg / m ^ ) ^	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index ( kg / m )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index ( kg / m $nmbr$ ) baseline systolic blood	C0005767;C0005768;C0005893;C0039155;C0168634;C0229664;C0578022;C1305855;C1442488;C1532718	\N	\N
1734	body mass index ( kg / m $nmbr$ ) - mean ± sd	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index ( kg / m $nmbr$ ) * '	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index ( kg / m $nmbr$ )  mean ( sd ) c	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index ( kg / m $nmbr$ )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index ( bmi )  kg / m $nmbr$	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index $nmbr$	C0005893;C0578022;C1305855	\N	\N
1734	body mass index  median  ( $nmbr$ th — $nmbr$ th percentiles )  kg / m $nmbr$	C0005893;C0039725;C0039738;C0549183;C0578022;C0876920;C1264641;C1305855;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344	\N	\N
1734	body mass index  mean ± sd ( kg / m $nmbr$ )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean kg / m ^ ( sd )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean + sd ( kg / m )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean ( sd ) t	C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean ( sd ) kg / m $nmbr$	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean ( sd ) d	C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean ( sd ) [ range ] a	C0005893;C0444504;C0578022;C1305855;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016	\N	\N
1734	body mass index  mean ( sd ) ( kg m ) $nmbr$ )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean ( sd )  kg / m $nmbr$	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  mean ( sd )	C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  kg / rn \\ mean ( sd )	C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819	\N	\N
1323	womens	\N	\N	\N
1734	body mass index  kg / m ’	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index  kg / m ^ mean ( sd )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  kg / m ^ ( meanisd )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index  kg / m ^	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index  kg / m $nmbr$   ( sd )	C0005893;C0578022;C1305855;C1532718;C2699239	\N	\N
1734	body mass index  kg / m $nmbr$ ( sd )	C0005893;C0578022;C1305855;C1532718;C2699239	\N	\N
1734	body mass index  kg / m $nmbr$ ( mean ± sd )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
7	p   values of interaction	C1704675;C1709380	\N	\N
1734	body mass index  kg / m $nmbr$  median ( q $nmbr$  q $nmbr$ )	C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193	\N	\N
1734	body mass index  kg / m $nmbr$  mean ± sd	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  kg / m $nmbr$  mean + sd	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  kg / m $nmbr$  mean ( sd ) §	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  kg / m $nmbr$  mean ( sd )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body mass index  kg / m $nmbr$	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index  * kg / m $nmbr$	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body mass index  %	C0005893;C0578022;C1305855	\N	\N
1734	body mass index	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index ”	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index — no . ( % ) : i :	C0005893;C0021966;C0221138;C0578022;C1305855	\N	\N
1734	body - mass index — no . ( % ) $	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index §	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index categories — no . ( % ) : c	C0005893;C0578022;C0683312;C1305855	\N	\N
1734	body - mass index ^ :	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index ^	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index \\ kg / m $nmbr$	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body - mass index > $nmbr$  n ( % )	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index > $nmbr$	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index : ! :	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index - kg / m $nmbr$  median ( iqr )	C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193	\N	\N
1734	body - mass index - ! '	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index *	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index ) -	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index ) '	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index )	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index ( kg / m   $nmbr$ )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body - mass index ( kg / m - )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body - mass index ( kg / m ' )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body - mass index ( kg / m $nmbr$ ) t	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body - mass index ( kg / m $nmbr$ ) *	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body - mass index ( kg / m $nmbr$ ) ( mean  sd )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body - mass index ( kg / m $nmbr$ )  mean ( sd )	C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239	\N	\N
1734	body - mass index ( kg / m $nmbr$ )	C0005893;C0578022;C1305855;C1532718	\N	\N
1734	body - mass index ( kg / cm $nmbr$ )	C0005893;C0578022;C1305855;C4054689	\N	\N
1734	body - mass index $	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index  mean ( sd )	C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239	\N	\N
1734	body - mass index  kq / nrn	C0005893;C0578022;C1305855;C1425210	\N	\N
1734	body - mass index  !	C0005893;C0578022;C1305855	\N	\N
1734	body - mass index	C0005893;C0578022;C1305855	\N	\N
1734	bmi ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )	C0578022	\N	\N
1734	baseline body mass index	C0005893;C0168634;C0578022;C1305855;C1442488	\N	\N
1733	fibrous  mm ’	C0016059;C0439709;C4330985;C4554674	\N	\N
1733	fibrous	C0016059;C0439709	\N	\N
1733	fibrofatty  mm ^	C4330985;C4554674	\N	\N
1733	fibrofatty	\N	\N	\N
1733	fibrates	C1449704;C3540783	\N	\N
1732	study population	C2348561	\N	\N
1732	placebo - control study	C0683952	\N	\N
1732	overall study population	C0282416;C1561607;C2348561	\N	\N
1731	temporary discontinuation of study drug	C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847	\N	\N
1731	teaes leading to discontinuation of study drug	C0013175;C0332152;C0457454;C1444662;C1522538;C4552847	\N	\N
1731	study drug	C0013175	\N	\N
1731	median duration of study - drug administration	C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193	\N	\N
1731	leading to study drug discontinuation	C0013175;C0040363;C0041260;C0332152;C0457454;C1444662;C1522538;C1883351;C4552847	\N	\N
1731	duration of study - drug administration — hr	C0013175;C2348354	\N	\N
1730	this study	C0557651;C2603343	\N	\N
1730	study druga	C0557651;C2603343	\N	\N
1730	study $nmbr$ . $nmbr$	C0557651;C2603343	\N	\N
1730	study $nmbr$	C0557651;C2603343	\N	\N
1730	study	C0557651;C2603343	\N	\N
1730	six - study placebo - controlled set	C0036849;C0205452;C0557651;C1442518;C1705195;C1706408;C2603343	\N	\N
1730	related to study druga	C0040363;C0041260;C0439849;C0445223;C0557651;C1883351;C2603343	\N	\N
1730	pool of fh i and ii studies	C0337051;C0557651;C0947630;C1260386;C1509144;C2349200;C2603343	\N	\N
1730	permanently stopped study drug because of adverse events	C0041755;C0557651;C1272691;C2603343	\N	\N
1730	no inducer at core study entry	C0444669;C0557651;C1167518;C1705654;C1706352;C1882467;C2603343;C3274653;C3898767	\N	\N
1730	induction study treatment	C0205263;C0557651;C0857127;C1521826;C2603343;C4049995	\N	\N
1730	included in this study ( n = $nmbr$ )	C0332257;C0557651;C2603343	\N	\N
1730	in extension study	C0231448;C0557651;C1880641;C2603343	\N	\N
1708	medication prior to admission  ( % )	C0013227;C0184666;C0332152;C0809949;C3244316;C4284232	\N	\N
1730	enrolled from re - cover study — no . ( % )	C0180153;C0556581;C0557651;C1999244;C2603343;C2986904;C3888055;C4684790	\N	\N
1730	duration of treatment in the healing study  n	C0043240;C0205249;C0444921;C0557651;C2603343	\N	\N
1730	concurrent treatment at study entry — no . ( % ) * *	C0009247;C0039798;C0087111;C0205420;C0557651;C0679827;C1521826;C1522326;C1533734;C1705169;C1705654;C2603343;C3161471;C3538994;C3887704	\N	\N
1729	tzd	\N	\N	\N
1729	met / tzd	C0428210;C1550543;C4317104	\N	\N
1729	met / su / tzd	C0038642;C0428210;C1550543;C1705534;C4317104	\N	\N
1729	did not meet atopy and ige $nmbr$ - $nmbr$ ku / lcriteriaa ( n = $nmbr$  $nmbr$ )	C0022804;C0392707;C1337080;C1518422;C1532717;C1550543;C1881335;C3539705	\N	\N
1729	> $nmbr$ % and < $nmbr$ %	\N	\N	\N
1728	woscops	\N	\N	\N
1728	patients with evaluable endoscopy	C0014245;C2986511	\N	\N
1728	endoscopy subscore  n ( % )	C0014245	\N	\N
1728	endoscopy subscore	C0014245	\N	\N
1728	colonoscopy	C0009378;C1548837	\N	\N
1727	std n ( n / loopy )	C0181687;C0445022	\N	\N
1727	overall n ( n / loopy )	C0181687;C0282416;C0445022;C1561607	\N	\N
1727	glargine n ( n / loopy )	C0181687;C0445022;C0907402	\N	\N
1726	prior copd medicationa  n ( % )	C0024117;C0332152;C1412502;C2826257;C3714496	\N	\N
1726	prior copd medication	C0013227;C0024117;C0332152;C1412502;C2826257;C3244316;C3714496;C4284232	\N	\N
1726	previous respiratory disease other than copd — no . ( % )	C0024117;C0035204;C0035242;C0205156;C1412502;C1552607;C3714496	\N	\N
1726	previous copd treatment  n ( % ) *	C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704	\N	\N
1726	patients with prior copd - related	C0024117;C0030705;C0332152;C0439849;C0445223;C1412502;C2826257;C3714496	\N	\N
1726	overall night - time copd symptom severity scorec	C0024117;C0240526;C0282416;C1319166;C1412502;C1561607;C3714496	\N	\N
1726	no previous copd medication	C0013227;C0024117;C0205156;C1412502;C1552607;C3244316;C3714496;C4284232	\N	\N
1726	mean copd duration  y ( sd )	C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496	\N	\N
1726	mean ( sd ) duration of copd  years	C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496	\N	\N
1726	grade $nmbr$ ( moderate copd )  n ( % )	C0024117;C0205081;C0441800;C0919553;C1412502;C1881878;C3244287;C3714496;C4049705;C4049706;C4085643;C4321335	\N	\N
1726	duration of copd — yr	C0024117;C0439234;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd — days ^	C0024117;C0439228;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd ( yr ) f	C0016327;C0024117;C0439234;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd ( yr )	C0024117;C0439234;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd ( years )  mean ( sd )	C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496	\N	\N
1726	duration of copd ( years )	C0024117;C0439234;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd  yr	C0024117;C0439234;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd  years	C0024117;C0439234;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd  y	C0024117;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	duration of copd	C0024117;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	data are mean ( sd ) or number ( % ) . bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . lvef = left ventricular ejection fraction . hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .	C0010055;C0011198;C0014442;C0017480;C0018801;C0021122;C0024117;C0030705;C0032042;C0042508;C0085805;C0155626;C0162589;C0205091;C0237753;C0428772;C0428883;C0443246;C0444504;C0449788;C0470187;C0488055;C0488728;C0521942;C0815017;C0871470;C0965129;C1305855;C1306620;C1452534;C1511726;C1532338;C1552822;C1696465;C1706408;C2347634;C2348143;C2699239;C3245479;C3541240;C3714741;C3888198;C4284014;C4521602	\N	\N
1726	copd — no . ( % ) medication use	C0024117;C0240320;C1412502;C3714496	\N	\N
1726	copd type	C0024117;C0332307;C1412502;C1547052;C3714496	\N	\N
1726	copd population ( n = $nmbr$ )	C0024117;C0032659;C1257890;C1412502;C3714496	\N	\N
1726	copd or asthma  ( % )	C0004096;C0024117;C1412502;C2984299;C3714496	\N	\N
1726	copd or asthma	C0004096;C0024117;C1412502;C2984299;C3714496	\N	\N
1726	copd medication at study entry	C0013175;C0024117;C1412502;C1705654;C3714496	\N	\N
1726	copd duration  y	C0024117;C0449238;C1412502;C2926735;C3714496	\N	\N
1726	copd ( n = $nmbr$ )	C0024117;C1412502;C3714496	\N	\N
1726	copd ( % )	C0024117;C1412502;C3714496	\N	\N
1726	copd    n   ( % )	C0024117;C1412502;C3714496	\N	\N
1726	copd	C0024117;C1412502;C3714496	\N	\N
1726	clinical copd phenotype ^	C0024117;C0031437;C0205210;C1285572;C1412502;C3714496	\N	\N
1726	chronic obstructive pulmonary disease — no . ( % )	C0024117	\N	\N
1726	chronic obstructive pulmonary disease  n ( % )	C0024117	\N	\N
1726	chronic obstructive pulmonary disease	C0024117	\N	\N
1726	chronic obstructive lung disease	C0024117	\N	\N
1726	augment copd	C0024117;C0205217;C1412502;C3714496	\N	\N
1726	any copd medication	C0013227;C0024117;C1412502;C3244316;C3714496;C4284232	\N	\N
-10	computed tomographic angiography	C1536105	\N	\N
1724	time from randomization to coronary angiography — hr	C0034656;C0040223;C0085532;C1548829;C3541383	\N	\N
1724	normal coronary angiography	C0853522	\N	\N
1724	coronary angiography — no . ( % )	C0085532;C1548829	\N	\N
1724	coronary angiography during the index hospital stay	C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408	\N	\N
1724	coronary angiography	C0085532;C1548829	\N	\N
1723	randomization to angiography	C0002978;C0034656	\N	\N
1723	randomization - to - angiography distribution time	C0002978;C0034656;C0681683	\N	\N
1723	randomization - to - angiography	C0002978;C0034656	\N	\N
1727	loop	C0445022	f	991
1727	loop at last follow - up	C0445022;C0589120;C1522577;C1704685;C3274571	f	991
1723	intravenous anticoagulant prior to pre - pci angiography	C0002978;C0003280;C0332152;C0348016;C0740175;C0848112;C2257086;C3536711;C3669034;C4049621	\N	\N
1723	interval from randomization to angiography	C0002978;C0034656;C1272706;C1552654;C1552713	\N	\N
1723	glycoprotein iib / iiia inhibitor use before angiography	C0002978;C0016011;C0042153;C0457083;C1947944;C1999216	\N	\N
1723	diagnostic angiography	C0002978	\N	\N
1723	contrast angiography	C0002978;C0009924;C1979874	\N	\N
1723	angiography — no . ( % )	C0002978	\N	\N
1723	angiography and revascularization	C0002978;C0581603	\N	\N
1723	angiography	C0002978	\N	\N
1723	additional angiography	C0002978;C1524062	\N	\N
1723	> $nmbr$ ( ml ) additional angiography	C0002978;C0439526;C1524062;C1705224;C3887665	\N	\N
1722	prior angioplasty	C0162577;C0332152;C1548817;C2826257	\N	\N
1722	previous angioplasty  n ( % )	C0162577;C0205156;C1548817;C1552607	\N	\N
1722	peripheral angioplasty	C0162577;C0205100;C1548817	\N	\N
1722	cabg or angioplasty	C0010055;C0162577;C1548817	\N	\N
1722	angioplasty	C0162577;C1548817	\N	\N
1721	previous balloon angioplasty  n ( % )	C0002996;C0002997;C0205156;C1552607	\N	\N
1721	previous balloon angioplasty	C0002996;C0002997;C0205156;C1552607	\N	\N
1721	balloon angioplasty — no . ( % )	C0002996;C0002997	\N	\N
1721	balloon angioplasty plus abciximab	C0002996;C0002997;C0288672;C0332287	\N	\N
1721	balloon angioplasty	C0002996;C0002997	\N	\N
-10	lymphadenopathy	C0497156;C4282165	\N	\N
1719	retinopathy — no . ( % )	C0035309;C1962966	\N	\N
1719	retinopathy — %	C0035309;C1962966	\N	\N
1719	retinopathy	C0035309;C1962966	\N	\N
1719	micro - / macro - albuminuria  ckd and / or retinopathy	C0001925;C0035309;C0085672;C1553035;C1561643;C1962966;C2984010;C3811161;C4049106	\N	\N
1718	peripheral sensory neuropathy	C0151313;C4554142	\N	\N
1718	peripheral neuropathy	C0031117	\N	\N
1718	neuropathy — no . ( % )	C0442874	\N	\N
1718	neuropathy	C0442874	\N	\N
1718	myopathyt	\N	\N	\N
1718	myopathy	C0026848	\N	\N
1718	autonomic neuropathy	C0259749	\N	\N
-10	radionuclide ventriculography	C0017200;C0034610	\N	\N
1716	spiralcomputedtomographyangiography	\N	\N	\N
1716	duplex ultrasonography	C3825392	\N	\N
1715	nice secondary prevention onlyb	C0679699;C4087029	\N	\N
1715	nice primary prevention onlyb	C0033144;C4087029	\N	\N
1715	gissi prevention $nmbr$ / $nmbr$ - $nmbr$ / $nmbr$	C0199176;C1706420;C2700409	\N	\N
1714	interruption ( n = $nmbr$ )	C0332453;C1512900	\N	\N
1714	interruption	C0332453;C1512900	\N	\N
1714	history of percutaneous coronary intervention	C1320647;C4554713	\N	\N
1714	$nmbr$ early intervention ( n = $nmbr$ )	C0242687;C1964029	\N	\N
1713	vka  only reason	C0205171;C0392360;C1720467	\N	\N
1713	redon	\N	\N	\N
1713	pci indication	C0392360;C3146298;C4049621	\N	\N
1713	patient ' s preference not to take vka  only reason * *	C0040363;C0041260;C0205171;C0376409;C0392360;C1515187;C1518422;C1720467;C1883351	\N	\N
1713	indication for stent	C0038257;C0392360;C3146298	\N	\N
1713	indication for pci	C0392360;C3146298;C4049621	\N	\N
1713	indication for index pci	C0392360;C0600653;C0918012;C1552854;C1637833;C2986546;C3146298;C4049621	\N	\N
1713	indication	C0392360;C3146298	\N	\N
1712	steroid - sparing remission *	C0038317;C0544452;C0687702	\N	\N
1712	steroid - free remission	C0038317;C0332296;C0544452;C0687702;C1880497;C1996904	\N	\N
1712	remission in overall population	C0032659;C0282416;C0544452;C0687702;C1257890;C1561607	\N	\N
1712	remission component of variable	C0439828;C0449432;C0544452;C0687702;C1705248;C4553760	\N	\N
1712	remission by : baseline steroid doses	C0038317;C0168634;C0178602;C0544452;C0687702;C1442488	\N	\N
1712	remission  n ( % )	C0544452;C0687702	\N	\N
1712	remission	C0544452;C0687702	\N	\N
1712	asdas inactive disease  %	C0544452	\N	\N
1711	no regular consumption	C0009830;C0205272;C1947907	\N	\N
1711	constitutional	C1511487	\N	\N
1711	constipation	C0009806;C1963087;C3641755;C4084722;C4084723;C4084724	\N	\N
1710	priorother ( predefined ) medical conditions	C0012634;C0199168;C0205476;C0348080;C1705253;C3864998	\N	\N
1710	priorother ( not predefined ) medical conditions	C0012634;C0199168;C0205476;C0348080;C1518422;C1705253;C3864998	\N	\N
1710	prespecified medical conditions  n ( % ) f	C0012634;C0016327;C0199168;C0205476;C0348080;C1705253;C3864998	\N	\N
1710	presenting condition  n ( % )	C0012634;C0348080;C0449450;C1705253;C3864998	\N	\N
1710	medical conditions  no . ( % )	C0012634;C0199168;C0205476;C0348080;C1705253;C3864998	\N	\N
1710	known thrombophilic condition — no . ( % )	C0012634;C0205309;C0348080;C0398623;C1705253;C3864998	\N	\N
1710	currentother ( notpredefined ) medical conditions	C0012634;C0199168;C0205476;C0348080;C1705253;C3864998	\N	\N
1710	current other ( predefined ) medical conditions	C0012634;C0199168;C0205476;C0348080;C0521116;C1705253;C1705970;C3864998	\N	\N
1710	contusion	C0009938	\N	\N
1710	condition $nmbr$ ( $nmbr$ . $nmbr$ )	C0012634;C0348080;C1705253;C3864998	\N	\N
1710	coexisting conditions — no . ( % )	C0012634;C0348080;C1705253;C3864998	\N	\N
1710	coexisting conditions	C0679225	\N	\N
1710	any condition	C0012634;C0348080;C1705253;C3864998	\N	\N
1709	time from randomization to study - drug initiation — hr	C0013175;C0013227;C0034656;C0040223;C0040227;C0589507;C1158830;C1254351;C1704686;C2349982;C3541383	\N	\N
1709	time from randomization to study - drug administration — hr	C0013175;C0034656;C0040227;C0150270;C0206209;C2349982;C3469597	\N	\N
1709	time from acs to randomization ( median  iqr )	C0034656;C0040223;C0549183;C0742343;C0876920;C2347635;C2348144;C2939193;C3541383;C4318612	\N	\N
1709	time from acs to randomization	C0034656;C0040223;C0742343;C3541383;C4318612	\N	\N
1709	randomization to arterial sheath insertion	C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719	\N	\N
1709	randomization to	C0034656	\N	\N
1709	randomization - to -	C0034656	\N	\N
1709	history of diagnosed hypertension prior to randomization  n ( % )	C0011900;C0034656;C0455527	\N	\N
1709	days from acs to randomization	C0034656;C0439228;C0742343;C4318612	\N	\N
1709	$nmbr$ tol ( n = $nmbr$ )	\N	\N	\N
1708	interval pain onset to admission	C0184666;C0809949;C1272706;C1507009;C1552654;C1552713	\N	\N
1708	$nmbr$ b ( $nmbr$ b to > $nmbr$ a )	\N	\N	\N
1708	$nmbr$ b ( $nmbr$ b to $nmbr$ a )	\N	\N	\N
1707	immobilization — no . ( % )	C0020944;C4048292	\N	\N
1707	immobilization at randomization  n ( % )	C0020944;C0034656;C4048292	\N	\N
1707	immobilization	C0020944;C4048292	\N	\N
1707	immobazaton	\N	\N	\N
1706	tni ultrapositive ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$	C0077401;C0439294;C0456615	\N	\N
1706	tni ultrapositive  ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$	C0077401;C0439294;C0456615	\N	\N
1706	apolipoprotein b ( g / l )	C0003593;C0439294;C0456615	\N	\N
1706	apolipoprotein b  mean ( sd )  g / l	C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239	\N	\N
1706	> $nmbr$ . $nmbr$ - g / l	C0439294;C0456615	\N	\N
1706	$nmbr$ . $nmbr$ ( g . l )	C0439294;C0456615	\N	\N
1705	use of parenteral antithrombotic agents — no . ( % )	C0030547;C1524063;C1704311;C4522267	\N	\N
1705	antithrombotic agents  n ( % )	C1704311	\N	\N
1705	antithrombotic agents	C1704311	\N	\N
1705	antithrombotic / coagulant	C0009117	\N	\N
1705	antithrombotic	\N	\N	\N
1705	$nmbr$ prolonged antithrombotic pretreatment ( n = $nmbr$ )	C0439590;C1550147;C2709094;C3539075;C3539076	\N	\N
1704	short - acting anticholinergics	C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375	\N	\N
1704	baseline short - acting anticholinergics  n ( % )	C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375	\N	\N
1704	baseline short - acting anticholinergics	C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375	\N	\N
1704	anticholinergics	C0242896;C3537307;C3540711	\N	\N
1704	anticholinergic use  n ( % )	C0042153;C0242896;C0457083;C1947944;C3537004	\N	\N
1704	anticholinergic drug	C0242896	\N	\N
1704	anticholinergic	C0242896;C3537004	\N	\N
1703	time from symptom onset to start of fibrinolytic therapy — hr	C0040044;C0040223;C0040363;C0041260;C0439659;C0449244;C1457887;C1883351;C3541383;C3854129;C4086878	\N	\N
1703	time from onset of symptoms to start of fibrinolytic therapy — hr	C0040044;C0040363;C0041260;C0439659;C1320528;C1883351	\N	\N
1703	time from fibrinolytic therapy to study - drug administration — no . / total no . ( % )	C0013175;C0013216;C0040044;C0040223;C0040227;C0150270;C0206209;C0439175;C0439810;C0557651;C1611232;C2349982;C2603343;C3469597;C3541383;C3665478	\N	\N
1703	thrombolytic therapy	C0040044	\N	\N
1703	fibrinolytics	C0040044	\N	\N
1703	fibrinolytic therapy — no . ( % )	C0040044	\N	\N
1703	fibrinolytic	C0040044	\N	\N
1702	tonic – clonic	C3543842	\N	\N
1702	tonic	C3543842	\N	\N
1702	functional assessment of chronic illness	C0008679;C0278372	\N	\N
1702	clonic	\N	\N	\N
1701	patients without chronic	C0030705;C0205191	\N	\N
1701	patients with chronic	C0030705;C0205191	\N	\N
1701	in patients with a history of chronic angina who have presented with an acute	C0002962;C0205178;C0205191;C0449450;C0679831	\N	\N
1701	chronic cvd	C0007222;C0205191	\N	\N
1701	chronic cox $nmbr$ inhibitors	C0085387;C0205191	\N	\N
1701	chronic bronchitist	C0205191	\N	\N
1701	cholecystitis chronic	C0008325;C0205191;C1963083;C4553186	\N	\N
1700	nordic countries	C0036273	\N	\N
1700	nordic	C0331873	\N	\N
1700	hordic	\N	\N	\N
1700	aortic valve disease ( n = $nmbr$ $nmbr$ )	C1260873;C4553103	\N	\N
1700	aortic - valve replacement	C0003506	\N	\N
1700	aortic	C0003483	\N	\N
1699	abdominal aortic — no . ( % )	C0003484	\N	\N
1699	$nmbr$ mortis	\N	\N	\N
1698	risk factors for atherosclerosis	C0003850;C0004153;C0035648;C1553898	\N	\N
1698	qualifying type of atherosclerosis — no . ( % )	C0003850;C0004153;C0332307;C1514624;C1547052	\N	\N
1698	qualifying type of atherosclerosis  n ( % )	C0003850;C0004153;C0332307;C1514624;C1547052	\N	\N
1698	qualifying atherosclerosis	C0003850;C0004153;C1514624	\N	\N
1698	large - artery atherosclerosis	C0003850;C0004153;C0226003	\N	\N
1698	high risk with atherosclerotic vascular disease *	C0004153;C0332167;C3272283;C4050568;C4319571	\N	\N
1698	established atherosclerotic cardiovascular disease — no . { % )	C0004153;C0443211;C1272684	\N	\N
1698	established atherosclerotic cardiovascular disease	C0004153;C0443211;C1272684	\N	\N
1698	atherosclerotic vascular disease — no .	C0004153	\N	\N
1698	atherosclerotic vascular disease  n ( % ) §	C0004153	\N	\N
1698	atherosclerotic cardiovascular disease *	C0004153	\N	\N
1698	atherosclerotic cardiovascular disease	C0004153	\N	\N
1698	atherosclerosis ^  n ( % )	C0003850;C0004153	\N	\N
1698	atherosclerosis	C0003850;C0004153	\N	\N
1698	arteriosclerosis	C0003850	\N	\N
1696	rosuvastain + fenofibric acid   n   =   $nmbr$	C0060179	\N	\N
1696	rosuvastain + fenofibric acid $nmbr$ = $nmbr$	C0060179	\N	\N
1696	fenofibric acid   n   =   $nmbr$	C0060179	\N	\N
1696	fenofibric acid + moderate - dose statin	C0060179;C0360714;C1709056	\N	\N
1696	fenofibric acid $nmbr$ = $nmbr$	C0060179	\N	\N
1696	fenofibric acid	C0060179	\N	\N
1696	fenofibric	\N	\N	\N
1696	drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .	C0060179	\N	\N
1695	gemfibrozil ( n = $nmbr$	C0017245	\N	\N
1695	gemfibrozil	C0017245	\N	\N
1694	aerobic exercise	C0001701	\N	\N
1694	aerobic activity	C0001701	\N	\N
1693	notable abnormalities	C0000768;C0000769;C4288581	\N	\N
1697	other atherosclerotic cvdd  e	C0333482;C1859330	f	1698
1697	other atherosclerotic cvd st depression on	C0007222;C0333482;C0520887	f	1698
1697	other atherosclerotic event	C0333482;C0441471;C4019010	f	1698
1693	concordant stress test abnormalities	C0000768;C0000769;C0015260;C3494508;C4553529	\N	\N
1692	subscale  and $nmbr$ to $nmbr$ for the function subscale  normalized scores can range from $nmbr$ to $nmbr$ . scores for the health assessment question -	C0031843;C0040363;C0041260;C0175637;C0449820;C0459443;C0542341;C0700205;C1514721;C1522634;C1705273;C1882115;C1883351;C2348147;C3542016	\N	\N
1692	normalized	C1882115	\N	\N
1691	oral aminosalicylates	C0368663;C0442027;C4521986	\N	\N
1691	no aminosalicylates  n	C0368663	\N	\N
1691	concomitant aminosalicylates  n [ % ] concomitant corticosteroids  n [ % ] mayo score  mean [ sd ]	C0001617;C0368663;C0444504;C0449820;C0454788;C0521115;C1077578;C2347634;C2348143;C2699239;C3539185;C3540725;C3540726;C3540727;C4050231	\N	\N
1691	aminosalicylates * *	C0368663	\N	\N
1691	aminosalicylates  n	C0368663	\N	\N
1691	aminosalicylates	C0368663	\N	\N
1691	aminosalicylate	C0368663;C2825094	\N	\N
1691	$nmbr$ - aminosalicylates ’ i  i ‘	C0021966;C0221138;C0368663	\N	\N
1691	$nmbr$ - aminosalicylates | | | |	C0368663	\N	\N
1691	$nmbr$ - aminosalicylates {	C0368663	\N	\N
1690	poor compliance / noncompliance	C0032646;C0376405;C0457432	\N	\N
1690	noncompliant	C0457432	\N	\N
1690	non - compliance	C0376405;C0457432	\N	\N
1689	nonblack ( n = $nmbr$ )  adjusted hazard ratio *	C0456081;C2985465	\N	\N
1689	nonblack ( n = $nmbr$ )	\N	\N	\N
1689	nonblack	\N	\N	\N
1688	not at goal	C0018017;C1518422;C1571704	\N	\N
1688	goal	C0018017;C1571704	\N	\N
1688	distance to ldl - c goal	C0012751;C0018017;C1571704	\N	\N
1688	at ldl - c ( bq ) goal * at baseline - no . ( % )	C0018017;C0168634;C0560038;C1442488;C1571704;C3541236	\N	\N
1688	at goal	C0018017;C1571704	\N	\N
1688	% to goal	C0018017;C1571704	\N	\N
1687	ldl - c goal attainment	C0680230	\N	\N
1687	dual bp / ldl - c goal attainment	C0037623;C0205173;C0680230;C1415692;C1554184;C1708288;C4318478	\N	\N
1687	bp goal attainment	C0037623;C0680230;C1415692;C1708288;C4318478	\N	\N
1686	getgoal - s	\N	\N	\N
1686	getgoal - l - asia	C0003980	\N	\N
1685	total ldl - c *	C0439175;C0439810	\N	\N
1685	total body ( without head )	C0018670;C0229960;C1706305	\N	\N
1685	total body	C0229960	\N	\N
1685	total bleeds	C0232100	\N	\N
1685	total bleeding	C0232100	\N	\N
1685	ldl *	\N	\N	\N
1684	total bilirubin > $nmbr$ x uln $nmbr$	C0005437;C0368753;C1519815	\N	\N
1684	total bilirubin  mg / dl	C0005437;C0368753;C0439269	\N	\N
1683	mitral regurgitation  n ( % )	C0026266	\N	\N
1683	mitral regurgitation  ( % )	C0026266	\N	\N
1683	mitral insufficiency  n ( % )	C0026266	\N	\N
1683	mitral insufficiency	C0026266	\N	\N
1683	italy ( n = $nmbr$ )	C0022277	\N	\N
1683	italy	C0022277	\N	\N
1682	nonfatal mi + fatal chdt	C1302234;C1705232;C3810814	\N	\N
1682	non - fatal mi	C1302234;C1518422;C1705232;C3810814	\N	\N
1682	mi ( fatal / nonfatal )	C1302234;C1705232;C3810814	\N	\N
1682	fatal or nonfatal myocardial infarction	C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959	\N	\N
1682	fatal or non - fatal myocardial infarction	C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959	\N	\N
1682	fatal chd and nonfatal mia	C0280604;C1302234;C1417154;C1705232;C3542407	\N	\N
1682	fatal / nonfatal mi  n ( % )	C1302234;C1705232;C3810814	\N	\N
1682	fatal & nonfatal ccvd	C1302234;C1705232	\N	\N
1682	fatal	C1302234;C1705232	\N	\N
1682	disabling or fatal stroke	C0038454;C1302234;C1705232;C4554100	\N	\N
1682	disabling or fatal	C1302234;C1705232	\N	\N
1682	cv death  non - fatal mi or non - fatal stroke	C0011065;C0038454;C1302234;C1306577;C1518422;C1705232;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
1682	chd ( nonfatal mi + fatal chd )	C0280604;C1302234;C1705232;C3542407;C3810814	\N	\N
1681	oil	C0028908;C0032085;C1517288;C3541397	\N	\N
1681	fish oil ( n = $nmbr$ )	C0016157	\N	\N
1681	fish oil	C0016157	\N	\N
1681	- oil	C0028908;C0032085;C1517288;C3541397	\N	\N
1680	mean percentage change from baseline to final visit	C0168634;C0205088;C0392747;C0439165;C0443172;C0444504;C0545082;C1442488;C1512346;C1546485;C1549488;C1561533;C1705241;C2347634;C2348143;C2826704;C3853528;C4319952	\N	\N
1680	final mean  mg / dl	C0205088;C0439269;C0444504;C1546485;C2347634;C2348143;C3853528	\N	\N
1680	final mean	C0205088;C0444504;C1546485;C2347634;C2348143;C3853528	\N	\N
1680	final a $nmbr$ c ( % )	C0205088;C1546485;C3853528	\N	\N
1680	final ( mg / dl )	C0205088;C0439269;C1546485;C3853528	\N	\N
1680	final	C0205088;C1546485;C3853528	\N	\N
1680	change from baseline to final apbm	C0168634;C0205088;C0392747;C0443172;C1442488;C1546485;C1705241;C3853528;C4319952	\N	\N
1679	triglycerides  mmol / lf	C0041004;C0439190;C1416933;C2986618;C4554443	\N	\N
1679	serum creatinine  umol / lf	C0201976;C0439194;C0600061;C1416933;C2986618;C4554443	\N	\N
1679	$nmbr$ . $nmbr$ ± $nmbr$ . lf	C1416933;C2986618;C4554443	\N	\N
1679	$nmbr$ % clf	C3540486;C4553190	\N	\N
1678	ldl cholesterol  mmol / lt	C0023376;C0023824;C0202117;C0230426;C0439190;C3887647;C4521399	\N	\N
1678	hdl cholesterol  mmol / lt	C0023376;C0023822;C0230426;C0392885;C0439190;C3887647;C4521399	\N	\N
1678	fpg  mmol / lt	C0023376;C0230426;C0439190;C3887647;C4521399	\N	\N
1678	$nmbr$ . $nmbr$ ± o . lt	C0023376;C0230426;C0483204;C3887647;C4521399	\N	\N
1677	time from ld to pci  min  median ( q $nmbr$ – q $nmbr$ )	C0040223;C0549183;C0694649;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3541383;C3813700;C4049621	\N	\N
1677	ld	C0694649	\N	\N
1677	cg / ld	C0043444;C0694649;C1567075;C3540479	\N	\N
1677	< $nmbr$ . $nmbr$ ld	C0694649	\N	\N
1677	$nmbr$ mg ld	C0024671;C0026410;C0439269;C0694649;C1960952;C2346927;C4321396;C4521761	\N	\N
1676	normal ( ≤   uln ) n   =   $nmbr$	C0205307;C0231683;C0439166;C1519815;C2347086;C4553972	\N	\N
1676	cpk > $nmbr$ times uln	C0040223;C1519815;C1632851	\N	\N
1676	ast > $nmbr$ x uln on two consecutive visits	C0205448;C0545082;C1415181;C1512346;C1519815;C1707491;C3891303	\N	\N
1676	alt or ast > $nmbr$ x uln $nmbr$	C1266129;C1415181;C1519815;C3891303;C4553172	\N	\N
1676	alt and / or ast > $nmbr$ times uln consecutive #	C0040223;C1266129;C1415181;C1519815;C1632851;C1707491;C3891303;C4553172	\N	\N
1676	alt > $nmbr$ x uln on two consecutive visits	C0205448;C0545082;C1266129;C1512346;C1519815;C1707491;C4553172	\N	\N
1676	alt  ast  or both > $nmbr$ x uln	C1519815;C3831581	\N	\N
1676	> $nmbr$ uln	C1519815	\N	\N
1675	ck > $nmbr$ xuln	C0009212;C0010287;C1872855	\N	\N
1675	ck > $nmbr$ x uln $nmbr$	C0009212;C0010287;C1519815;C1872855	\N	\N
1675	< $nmbr$ xuln	\N	\N	\N
1674	cardiac rhythm disorders	C0264886	\N	\N
1674	cardiac rhythm disorder at baseline no	C0168634;C0264886;C1442488	\N	\N
1674	cardiac rhythm	C0232187	\N	\N
1673	sinus rhythm at baseline	C0168634;C0232201;C1442488	\N	\N
1673	sinus rhythm	C0232201	\N	\N
1672	mixed chronic bronchitis and emphysema	C0008677;C0013990;C0034067;C0205430;C3160715	\N	\N
1672	emphysema ( n = $nmbr$ )	C0013990;C0034067	\N	\N
1672	emphysema ( itt ) ( n = $nmbr$ )	C0013990;C0034067	\N	\N
1672	emphysema ( % )	C0013990;C0034067	\N	\N
1672	emphysema	C0013990;C0034067	\N	\N
1672	centrilobular emphysema	C0221227	\N	\N
1671	psycholeptics	C3653516	\N	\N
1671	psychogenic	C0458006	\N	\N
1671	psychoactivesd	\N	\N	\N
1670	non - ischemic	C0475224;C1518422	\N	\N
1670	non - ischaemic cause	C0015127;C0475224;C1518422;C1524003	\N	\N
1670	non - ischaemic ( n = $nmbr$ o $nmbr$ )	C0475224;C1518422	\N	\N
1670	non - ischaemic ( n = $nmbr$ )	C0475224;C1518422	\N	\N
1670	non - ischaemic	C0475224;C1518422	\N	\N
1670	ischemic outcomes	C0475224;C1274040	\N	\N
1670	ischemic cause	C0015127;C0475224;C1524003	\N	\N
1670	ischemic	C0475224	\N	\N
1670	ischaemic skin lesions	C0037284;C0475224	\N	\N
1670	ischaemic cause	C0015127;C0475224;C1524003	\N	\N
1670	ischaemic ( n = $nmbr$ l $nmbr$ )	C0475224	\N	\N
1670	ischaemic ( n = $nmbr$ )	C0475224	\N	\N
1670	ischaemic  n ( % )	C0475224	\N	\N
1670	ischaemic	C0475224	\N	\N
1669	• ischemic stroke	C0948008	\N	\N
1669	prior ischemic stroke	C0332152;C0948008;C2826257	\N	\N
1669	previous ischemic stroke ortia	C0205156;C0948008;C1552607	\N	\N
1669	previous ischemic stroke / tia ( n = $nmbr$  $nmbr$ . $nmbr$ % )	C0007787;C0205156;C0917805;C0948008;C1054154;C1552607	\N	\N
1669	previous ischemic stroke  n ( % )	C0205156;C0948008;C1552607	\N	\N
1669	post - acute ischemic stroke	C0205178;C0475224;C0687676;C0751956;C0948008;C1704687;C3469826	\N	\N
1669	nonfatal ischemic stroke	C0948008	\N	\N
1669	no previous ischemic stroke / tia ( n = $nmbr$ $nmbr$  $nmbr$ . $nmbr$ % )	C0007787;C0205156;C0917805;C0948008;C1054154;C1552607	\N	\N
1669	minor ischaemic stroke	C0026193;C0205165;C0948008	\N	\N
1669	ischemic stroke with hemnrrhnaic cnnversinn	C0948008	\N	\N
1669	ischemic stroke subtype	C0449560;C0948008	\N	\N
1669	ischemic stroke ( % )	C0948008	\N	\N
1669	ischemic stroke	C0948008	\N	\N
1669	ischaemic stroke  n ( % )	C0948008	\N	\N
1669	ischaemic stroke	C0948008	\N	\N
1669	cvdeath  ml  or ischemic stroke	C0439526;C0948008;C1705224;C3887665	\N	\N
1669	cv death  ml  ischemic stroke  hosp . for hf  cor . revasc .  ua	C0011065;C0018488;C0018787;C0041580;C0042014;C0056331;C0378365;C0439526;C0948008;C1306577;C1313497;C1538440;C1705224;C3273279;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775	\N	\N
1669	cv death  ml  ischemic stroke	C0011065;C0439526;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775	\N	\N
1669	all ischemic stroke	C0948008	\N	\N
1668	severe recurrent ischemia	C0022116;C0205082;C1455761;C2945760;C4050465;C4050466;C4321499	\N	\N
1668	recurrent ischemia - urgent revascularization	C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499	\N	\N
1668	recurrent ischemia	C0022116;C1455761;C2945760;C4321499	\N	\N
1668	rec . ischemia requiring revasc	C0022116;C0378365;C1424025;C2606415;C4321499	\N	\N
1668	rec . ischemia leading to hosp	C0022116;C0332152;C1424025;C1522538;C2606415;C4321499	\N	\N
1668	rec . ischemia leading to hasp	C0022116;C0332152;C1424025;C1522538;C2606415;C4321499	\N	\N
1668	rec . ischemia	C0022116;C1424025;C2606415;C4321499	\N	\N
1668	no p value for ischemia ischemia hr ( $nmbr$ % ci ) interaction	C0008107;C0022116;C1704675;C1709380;C3259781;C4321499	\N	\N
1668	no ischemia ( n = $nmbr$  $nmbr$ )	C0022116;C4321499	\N	\N
1668	ischemia on cecg ( n = $nmbr$  $nmbr$ )	C0022116;C4321499	\N	\N
1668	ischemia on cecg ( % )	C0022116;C4321499	\N	\N
1668	ischemia driven revascularization	C0022116;C0581603;C4321499;C4683688	\N	\N
1668	ischemia - driven revascularization	C0022116;C0581603;C4321499;C4683688	\N	\N
1668	ischemia	C0022116;C4321499	\N	\N
1668	global ischemia ( % ) * *	C0022116;C0205246;C2348867;C4321499	\N	\N
1668	global ischemia	C0022116;C0205246;C2348867;C4321499	\N	\N
1668	effect of ranolazine compared with placebo on angina and recurrent ischemia	C0002962;C0022116;C0032042;C0073633;C1280500;C1455761;C1518681;C1696465;C1706408;C1707455;C2348382;C2945760;C4321499	\N	\N
1668	anti - ischaemia agents *	C0022116;C0040616;C4321499	\N	\N
1667	haq score ( $nmbr$ – $nmbr$ scale )	C0102923;C0175659;C0349674;C0449820;C0451208;C1947916;C4050231	\N	\N
1667	haq score	C0102923;C0449820;C0451208;C4050231	\N	\N
1667	haq pain score	C0102923;C0451208;C0582148	\N	\N
1667	haq alternative disability score	C0102923;C0231170;C0449820;C0451208;C1523987;C4050231	\N	\N
1667	haq	C0102923;C0451208	\N	\N
1666	total hands score	C0018563;C0439175;C0439810;C0449820;C1552914;C4050231	\N	\N
1666	hands	C0018563;C1552914	\N	\N
1666	hand	C0018563;C1552914	\N	\N
1665	mean score on haq - di §	C3533236;C3826998;C4321476	\N	\N
1323	women — no . ( % )	C0043210	\N	\N
1665	health assessment questionnaire - disability index	C4321476	\N	\N
1665	haq di score ( range $nmbr$ - $nmbr$ )  mean ± sd	C0444504;C0449820;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4050231;C4321476	\N	\N
1665	haq di score ( $nmbr$ - $nmbr$ )	C0449820;C3826998;C4050231;C4321476	\N	\N
1665	haq di ( range $nmbr$ - $nmbr$ )	C1514721;C2348147;C3542016;C3826998;C4321476	\N	\N
1665	haq di	C3826998;C4321476	\N	\N
1665	haq - di scoreff	C3826998;C4321476	\N	\N
1665	haq - di scored	C0449820;C3826998;C4321476	\N	\N
1665	haq - di score ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C3826998;C4050231;C4321476	\N	\N
1665	haq - di score ( $nmbr$ - $nmbr$ )	C0449820;C3826998;C4050231;C4321476	\N	\N
1665	haq - di score	C0449820;C3826998;C4050231;C4321476	\N	\N
1665	haq - di mcide	C3826998;C4321476	\N	\N
1665	haq - di improvement from baseline to week $nmbr$	C0168634;C0332174;C0439230;C1442488;C2986411;C3826998;C4321476	\N	\N
1665	haq - di improvement > $nmbr$ . $nmbr$	C2986411;C3826998;C4321476	\N	\N
1665	haq - di * *	C3826998;C4321476	\N	\N
1665	haq - di *	C3826998;C4321476	\N	\N
1665	haq - di ( range $nmbr$ - $nmbr$ )	C1514721;C2348147;C3542016;C3826998;C4321476	\N	\N
1665	haq - di ( $nmbr$ - $nmbr$ )	C3826998;C4321476	\N	\N
1665	haq - di  range $nmbr$ - $nmbr$  mean ( sd )	C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4321476	\N	\N
1665	haq - di  number ( % )	C0237753;C0449788;C3826998;C4321476	\N	\N
1665	haq - di	C3826998;C4321476	\N	\N
1665	change in haq - di ( mean ) t	C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476	\N	\N
1665	assessment of physical function ( $nmbr$ - $nmbr$  haq - di )	C0031809;C0031843;C0516981;C0542341;C0700205;C1261322;C1516048;C1705273;C3826998;C4049916;C4321476	\N	\N
1665	( haq - di  $nmbr$ - $nmbr$ )	C3826998;C4321476	\N	\N
1665	% with haq - di decrease > $nmbr$ . $nmbr$	C0392756;C0547047;C3826998;C4321476	\N	\N
1664	ipah / hpah	C0152171;C0340543;C0637939;C1150929	\N	\N
1664	ipah  hpah  hiv  drug or toxin induced	C0013227;C0019682;C0019699;C0040549;C0152171;C0205263;C0340543;C0637939;C1150929;C1254351;C4522020	\N	\N
1664	hi ) ah ( % )	C0018619;C0239849;C1412082;C1412316;C1431594;C1836672;C4552857	\N	\N
1663	time from pah diagnosis months	C0011900;C0030123;C0556969;C1704338;C1704656;C3203102;C4284467	\N	\N
1663	pooled pah - mctd and pah	C0026272;C0030123;C1709595;C2349200;C3203102;C4284467;C4522255	\N	\N
1663	pah - ssc	C0030123;C3203102;C3897657;C4284467	\N	\N
1663	pah - sle	C0024141;C0030123;C3203102;C4284467	\N	\N
1663	pah - mctd / ctd - other	C0026272;C0030123;C1335071;C1442905;C3203102;C4284467	\N	\N
1663	pah - ctd	C0030123;C1335071;C1442905;C3203102;C4284467	\N	\N
1662	subcutaneous unfractionated heparin	C0353681	\N	\N
1662	subcutaneous injections	C0021499	\N	\N
1662	subcutaneous ( n = $nmbr$ )	C0443315	\N	\N
1662	mucocutaneous	\N	\N	\N
1661	prior percutaneous coronary intervention — no . / total no . ( % )	C0332152;C0439175;C0439810;C1532338;C2826257	\N	\N
1661	prior percutaneous coronary intervention — no . ( % )	C0332152;C1532338;C2826257	\N	\N
1661	prior percutaneous coronary intervention  n ( % )	C0332152;C1532338;C2826257	\N	\N
1661	prior percutaneous coronary intervention	C0332152;C1532338;C2826257	\N	\N
1661	previous percutaneous coronary intervention  %	C0205156;C1532338;C1552607	\N	\N
1661	previous percutaneous coronary intervention	C0205156;C1532338;C1552607	\N	\N
1661	percutaneous coronary revascularization	C1532338	\N	\N
1661	percutaneous coronary intervention §	C1532338	\N	\N
1661	percutaneous coronary intervention n ( % )	C1532338	\N	\N
1661	percutaneous coronary intervention done *	C1532338	\N	\N
1661	percutaneous coronary intervention  n ( % )	C1532338	\N	\N
1661	percutaneous coronary intervention	C1532338	\N	\N
1661	index percutaneous coronary intervention	C0600653;C0918012;C1532338;C1552854;C1637833;C2986546	\N	\N
1660	othert	\N	\N	\N
1660	other supraventricular tachycardia	C0039240;C1963244;C3815188	\N	\N
1660	nutraceuticals  n ( % )	C1518478	\N	\N
1660	any llt other than nutraceuticals  n ( % )	C1518478;C2347090	\N	\N
-10	cutoffs	C1442160	\N	\N
1658	other bph - luts therapy	C0005001;C0039798;C0087111;C0574785;C1363945;C1704272	\N	\N
1658	luts severity	C0439793;C0522510;C0574785	\N	\N
1658	luts = lower urinary tract symptoms  is =	C0574785	\N	\N
1658	luts / bph characteristics	C0005001;C0574785;C1521970;C1704272	\N	\N
1658	is domain luts severity ( % )	C0439793;C0522510;C0574785;C1880389;C1883221;C3541951	\N	\N
1658	bph - luts severity	C0005001;C0439793;C0522510;C0574785;C1704272	\N	\N
1658	baseline luts severity * :	C0168634;C0439793;C0522510;C0574785;C1442488	\N	\N
1658	baseline luts severity  n ( % ) :	C0168634;C0439793;C0522510;C0574785;C1442488	\N	\N
1657	subsets	C1515021	\N	\N
1657	subset of patients on metformin	C0025598;C0030705;C1515021	\N	\N
1657	subset of patients not on metformin	C0025598;C0030705;C1515021;C1518422	\N	\N
1657	other climate subset	C0008946;C1515021	\N	\N
1657	hot climate subset	C0178683;C1515021	\N	\N
1656	musculoskeletal stiffness	C0427008;C0497254;C2707260	\N	\N
1656	musculoskeletal	C0497254;C2707260	\N	\N
1655	total subjects	C0439175;C0439810;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	subjects with prevalent vertebral fracture  n ( % ) prevalent vertebral fracture	C0033105;C0080179;C0220900;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	subjects who did receive labd prior to the study	C0332152;C0396059;C0557651;C0681850;C1514756;C1550501;C1706203;C2349001;C2603343;C2697811	\N	\N
1655	subjects who did not receive labd prior to the study	C0332152;C0396059;C0557651;C0681850;C1514756;C1518422;C1550501;C1706203;C2349001;C2603343;C2697811	\N	\N
1655	subjects randomized	C0034656;C0681850;C1550501;C1706203;C2349001;C2697811;C3815594	\N	\N
1655	subjects n	C0369718;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	subjects ( n )	C0369718;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	subjects	C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	subject disposition  n ( % )	C0681850;C0743223;C1550501;C1705555;C1706203;C2349001;C2697811	\N	\N
1655	subject completion status  n ( % )	C0205197;C0449438;C0681850;C0805732;C1550501;C1554962;C1706203;C2348577;C2349001;C2697811;C3891295	\N	\N
1655	number of subjects in analysis	C0002778;C0237753;C0449788;C0681850;C0936012;C1524024;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	number of subjects	C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	no . of subjects	C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	n events / n subjects	C0369718;C0441471;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811;C3541888	\N	\N
1655	mrf subjects	C0312443;C0681850;C1412879;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	male subjects ( n = $nmbr$  $nmbr$ )	C0086582;C0369718;C0441922;C0681850;C1550501;C1706180;C1706203;C1706428;C1706429;C2349001;C2697811	\N	\N
1655	in therapeutic range for warfarin subjects	C0043031;C0460097;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	female subjects ( n = $nmbr$ )	C0043210;C0086287;C0369718;C0441922;C0681850;C1550501;C1705497;C1705498;C1706203;C2349001;C2697811	\N	\N
1655	diabetic subjects  n = $nmbr$	C0241863;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	cvd subjects	C0007222;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	concomitant medications in > $nmbr$ % of subjects  no . ( % )	C0013227;C0521115;C0681850;C0802604;C1550501;C1706203;C2349001;C2598133;C2697811;C4284232	\N	\N
1655	all subjects - n	C0369718;C0441922;C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	all subjects	C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1655	( $nmbr$ subjects )	C0681850;C1550501;C1706203;C2349001;C2697811	\N	\N
1654	exacerbations requiring oral steroids / antibiotics ( past year ) ( % )	C0003232;C0003237;C0038317;C0442027;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710;C4086268;C4086728;C4521986	\N	\N
1654	antibiotics * *	C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710	\N	\N
1653	daily activities / social functioning	C0037395;C0871707	\N	\N
1653	daily activities	C0871707	\N	\N
1652	table $nmbr$ . characteristics of the patients at baseline . *	C0039224;C0168634;C0815172;C1442488;C1706074	\N	\N
1652	subject characteristics	C0681884;C1519021;C1706465	\N	\N
1652	patients with specific disease characteristics  n ( % )	C0030705;C0205369;C0599878;C1552740	\N	\N
1652	patients with specific disease characteristics	C0030705;C0205369;C0599878;C1552740	\N	\N
1652	patients ' characteristics	C0815172	\N	\N
1652	patient characteristics at randomization	C0034656;C0815172	\N	\N
1652	patient characteristics	C0815172	\N	\N
1652	lesion characteristics	C1286326	\N	\N
1652	disease characteristics *	C0599878	\N	\N
1652	disease characteristics	C0599878	\N	\N
1652	demographic / disease characteristics at baseline	C0011298;C0012634;C0168634;C0599878;C0683970;C1442488;C4684572	\N	\N
1652	characteristicsa	\N	\N	\N
1652	characteristica	\N	\N	\N
1652	anatomic complexity characteristics	C0439855;C0502371;C1704241	\N	\N
1651	stricturing	C1261287	\N	\N
1651	stenosis > $nmbr$ %	C0678234;C1261287;C2632116	\N	\N
1651	prior known stenosis > $nmbr$ %	C0205309;C0332152;C0678234;C1261287;C2632116;C2826257	\N	\N
1651	prior angiography showing stenosis ≥ $nmbr$ %  n   =   $nmbr$   $nmbr$ a	C0002978;C0332152;C0678234;C1261287;C1547282;C2632116;C2826257	\N	\N
1651	prior angiography showing stenosis > $nmbr$ %  n = $nmbr$ °	C0002978;C0332152;C0678234;C1261287;C1547282;C2632116;C2826257	\N	\N
1651	percent stenosis [ investigator ]	C0035173;C0439165;C0678234;C1261287;C2632116	\N	\N
1651	percent stenosis [ core lab ]	C0439165;C0678234;C1261287;C2632116;C4684837	\N	\N
1651	no . of vessels with > $nmbr$ % stenosis	C0005847;C0678234;C1261287;C2632116	\N	\N
1651	no . of coronary vessels with > $nmbr$ % diameter stenosis	C0010075;C0678234;C1261287;C1301886;C2632116	\N	\N
1651	maximal diameter stenosis	C0205289;C0678234;C0806909;C1261287;C1301886;C2632116;C4049713	\N	\N
1651	ica stenosis $nmbr$ % - $nmbr$ % f	C0016327;C0201519;C0678234;C1261287;C2632116	\N	\N
1651	diameter stenosis  mean ( sd )  %	C0552409;C0678234;C1261287;C2632116;C2699239	\N	\N
1651	% stenosis ( investigator )	C0035173;C0678234;C1261287;C2632116	\N	\N
1651	% stenosis ( core lab )	C0678234;C1261287;C2632116;C4684837	\N	\N
1651	% stenosis  as assessed by investigator	C0035173;C0678234;C1261287;C1516048;C2632116	\N	\N
1650	time to first inhaled corticosteroid ( % )	C0001617;C0004048;C0040223;C0205435;C1279901;C3536709;C3541383	\N	\N
1650	required corticosteroid and / or antibiotic ( without hospitalization )	C0001617;C0003232;C0019993;C1514873;C3536709	\N	\N
1650	refractory to corticosteroids  n ( % )	C0001617;C0205269;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	receiving concomitant corticosteroids	C0001617;C0521115;C1514756;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	prior corticosteroid treatment	C0001617;C1514463;C3536709	\N	\N
1650	patients taking oral corticosteroids at baseline  n ( % )	C0001617;C0030705;C0168634;C0442027;C1442488;C1515187;C3539185;C3540725;C3540726;C3540727;C4521986	\N	\N
1650	patients receiving corticosteroids at baseline	C0001617;C0030705;C0168634;C1442488;C1514756;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	patients not receiving corticosteroids at baseline	C0001617;C0030705;C0168634;C1442488;C1514756;C1518422;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	oral corticosteroids	C0001617;C0442027;C3539185;C3540725;C3540726;C3540727;C4521986	\N	\N
1650	oral corticosteroid use at enrolmentt	C0001617;C0239126;C0442027;C1527415;C3536709;C4521986	\N	\N
1650	oral corticosteroid use at baseline	C0001617;C0168634;C0239126;C0442027;C1442488;C1527415;C3536709;C4521986	\N	\N
1650	oral corticosteroid use  n ( % )	C0001617;C0239126;C0442027;C1527415;C3536709;C4521986	\N	\N
1650	oral corticosteroid	C0001617;C0442027;C3536709;C4521986	\N	\N
1650	no corticosteroids or immunosuppressants	C0001617;C0021081;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	no corticosteroid + no imm  n	C0001617;C0205470;C3536709	\N	\N
1650	no corticosteroid  no imm	C0001617;C0205470;C3536709	\N	\N
1650	no corticosteroid	C0001617;C3536709	\N	\N
1650	no baseline corticosteroids	C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	neither corticosteroid nor immunosuppressant	C0001617;C0021081;C3536709	\N	\N
1650	inhaled corticosteroids	C0001617;C0004048;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	inhaled corticosteroid - yes  n ( % )	C0001617;C0004048;C1549445;C1705108;C1710701;C3536709	\N	\N
1650	inhaled corticosteroid	C0001617;C0004048;C3536709	\N	\N
1650	immy ( without corticosteroid )  n	C0001617;C3536709	\N	\N
1650	immunosuppressant ( with or without corticosteroid )	C0001617;C0021081;C3536709	\N	\N
1650	imm + corticosteroid  n	C0001617;C0205470;C3536709	\N	\N
1650	imm ( without corticosteroid )	C0001617;C0205470;C3536709	\N	\N
1650	dmard or corticosteroid	C0001617;C0242708;C3536709	\N	\N
1650	current oral corticosteroid use	C0001617;C0239126;C0442027;C0521116;C1527415;C1705970;C3536709;C4521986	\N	\N
1650	corticosteroidsa	\N	\N	\N
1650	corticosteroids only	C0001617;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	corticosteroids and immunosuppressants	C0001617;C0021081;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	corticosteroids and antimalarials only	C0001617;C0003374;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	corticosteroids . immunosuppressants . and antimalarials	C0001617;C0003374;C0021081;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	corticosteroids ( excluding budesonide )	C0001617;C0054201;C0332196;C2828389;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	corticosteroids ' $nmbr$	C0001617;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	corticosteroids	C0001617;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	corticosteroid or immunosuppressant	C0001617;C0021081;C3536709	\N	\N
1650	corticosteroid and immunosuppressant	C0001617;C0021081;C3536709	\N	\N
1650	corticosteroid + imm	C0001617;C0205470;C3536709	\N	\N
1650	corticosteroid ( without imm )  n	C0001617;C0205470;C3536709	\N	\N
1650	corticosteroid ( without imm )	C0001617;C0205470;C3536709	\N	\N
1650	corticosteroid ( with or without immunosuppressants )	C0001617;C0021081;C3536709	\N	\N
1650	corticosteroid	C0001617;C3536709	\N	\N
1650	concomitant use of corticosteroids	C0001617;C0521115;C1524063;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	concomitant oral corticosteroids  n ( % ) * *	C0001617;C0442027;C0521115;C3539185;C3540725;C3540726;C3540727;C4521986	\N	\N
1650	catecholamines or corticosteroids without hospitalization	C0001617;C0007412;C0019993;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	baseline corticosteroids *	C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727	\N	\N
1650	b ) those on inhaled corticosteroids and long - acting bronchodilators as previous treatment use .	C0001617;C0004048;C0006280;C0039798;C0042153;C0079613;C0087111;C0205156;C0205166;C0457083;C1522326;C1533734;C1552607;C1704930;C1705169;C1706317;C1869853;C1947944;C3538994;C3539185;C3540725;C3540726;C3540727;C3887704;C3890007;C4048375	\N	\N
1650	any ( including corticosteroid )	C0001617;C0332257;C3536709	\N	\N
1650	> $nmbr$ corticosteroids or immunosuppressants	C0001617;C0021081;C3539185;C3540725;C3540726;C3540727	\N	\N
1649	time to first oral or systemic corticosteroid ( % )	C0040223;C0205435;C0442027;C1279901;C3541383;C4053960;C4521986	\N	\N
1649	systemic corticosteroids — no . ( % )	C4053960	\N	\N
1649	systemic corticosteroids  n ( % ) a	C4053960	\N	\N
1649	systemic corticosteroids  n ( % )	C4053960	\N	\N
1649	rate of oral or systemic corticosteroid	C0442027;C0871208;C1521828;C4053960;C4521986	\N	\N
1649	oral or other systemic corticosteroid	C0442027;C4053960;C4521986	\N	\N
1648	steroids § §	C0038317	\N	\N
1648	steroids ( other )	C0038317	\N	\N
1648	steroids ( n = $nmbr$ vs $nmbr$ )	C0038317	\N	\N
1648	steroids ( inhaled ) a	C0004048;C0038317	\N	\N
1648	steroids  n ( % )	C0038317	\N	\N
1648	other steroids	C0038317	\N	\N
1648	no steroids ( n = $nmbr$ vs $nmbr$ )	C0038317	\N	\N
1647	dutasteride ( w = $nmbr$ )  $nmbr$ / $nmbr$	C0754659	\N	\N
1647	dutasteride ( n = $nmbr$ )	C0754659	\N	\N
1647	dutasteride	C0754659	\N	\N
1647	combined ( dutasteride / ta msu losi n )	C0024776;C0039297;C0205195;C0754659;C1412759;C1506978;C1705538;C3272501;C4553364	\N	\N
1646	statini	\N	\N	\N
1646	statin therapy	C1278454	\N	\N
1646	standard therapy ( n = $nmbr$ )	C2936643	\N	\N
1646	standard therapy	C2936643	\N	\N
1646	prerandomization statin therapy	C1278454	\N	\N
1646	combined therapy vsta msu iosin	C0024776;C0033972;C1412759	\N	\N
1646	combined therapy vsdutasteride	C0033972	\N	\N
1646	combined therapy ( / v = $nmbr$ )  $nmbr$ / $nmbr$	C0033972	\N	\N
1645	tertiary endpoints :	C0205372;C2349179	\N	\N
1645	tertiary end points	C0205372;C2349179	\N	\N
1645	tertiary amines	C3653356	\N	\N
1645	tertiary	C0205372	\N	\N
1644	toward	\N	\N	\N
1644	third yeart	C0205437	\N	\N
1644	third heart sound  n ( % )	C0232237;C0232278	\N	\N
1644	third heart sound	C0232237;C0232278	\N	\N
1644	slowest third	C0205437;C0439834	\N	\N
1644	one - third radius	C0034627;C0205437;C0205447;C1306504	\N	\N
1644	in thirds	C0205437	\N	\N
1644	distal one - third of radius	C0034627;C0205437;C0205447;C0450168;C0588207;C1306504	\N	\N
1643	residual deep - vein thrombosis  no . ( % )	C0149871;C1609982	\N	\N
1643	previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis	C0042487	\N	\N
1643	patients with deep - vein thrombosis only	C0030705;C0149871;C0205171;C1720467	\N	\N
1643	isolated deep - vein thrombosis	C0149871;C0205409;C1548221	\N	\N
1643	deep vein thrombosis only	C0149871;C0205171;C1720467	\N	\N
1643	deep - vein thrombosis only	C0149871;C0205171;C1720467	\N	\N
1643	deep - vein thrombosis ( % )	C0149871	\N	\N
1643	deep - vein thrombosis	C0149871	\N	\N
1642	direct thrombin inhibitors	C0003440;C3541936	\N	\N
1642	antithrombin	C0003438;C0003440;C4521254	\N	\N
1641	thrombus aspiration done per lesion †	C0087086;C0220787;C0221198;C0302148;C0349707;C0700198;C1272695;C1546698;C2712334;C2827071;C3146237	\N	\N
1641	thrombus aspiration	C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237	\N	\N
1641	thrombus - containing lesion	C0087086;C0221198;C0302148;C0332256;C1546698;C2700400;C3146237	\N	\N
1641	new or suspected thrombus	C0087086;C0205314;C0302148;C0332147;C0750491;C3146237	\N	\N
1641	increased - risk for thrombotic cardiovascular	C0007226;C0087086;C3887460;C4699158	\N	\N
1641	anti - thrombotics	C0087086	\N	\N
1640	low risk and more symptoms ( group b )	C0205172;C0683368;C1457887;C3272281;C3538919;C4522078	\N	\N
1640	high risk and more symptoms ( group d )	C0205172;C0332167;C0441838;C0683368;C1457887;C3272283;C4050568;C4319571	\N	\N
1640	group d	C0441838	\N	\N
1640	group c	C0441837	\N	\N
1640	group b	C4522078	\N	\N
1640	group a	C0441835;C4522145	\N	\N
1640	gold group c	C0018026;C0441837;C1304897	\N	\N
1640	gold group a	C0018026;C0441835;C1304897;C4522145	\N	\N
1639	glycaemic control group	C0005802;C0009932	\N	\N
1639	events / control group	C0009932;C0441471;C3541888	\N	\N
1639	control group	C0009932	\N	\N
1638	total group ( n = $nmbr$ )	C0439175;C0439810;C0441848	\N	\N
1638	rate - control group ( n = $nmbr$ )	C0441848;C0489879	\N	\N
1638	racial group  n ( % )	C0034510;C0441848;C1706779;C3669213;C3853635	\N	\N
1638	pioglitazone group ( n = $nmbr$ )	C0071097;C0441848	\N	\N
1638	no epa group n = $nmbr$	C0441848	\N	\N
1638	group c ( n = $nmbr$ )	C0441848	\N	\N
1638	group b ( n = $nmbr$ )	C0441848	\N	\N
1638	group a ( n = $nmbr$ )	C0441848	\N	\N
1638	epa group n = $nmbr$	C0441848	\N	\N
1638	diclofenac group ( n = $nmbr$ $nmbr$ )	C0012091;C0441848	\N	\N
1638	colesevelam hydrochloride group ( n = $nmbr$ )	C0441848;C0541154	\N	\N
1638	certolizumab group ( n = $nmbr$ )	C0441848;C1872109	\N	\N
1638	c group ( n = $nmbr$ )	C0441848	\N	\N
1638	benazepril - hydrochlorothiazide group ( n = $nmbr$ )	C0441848;C0717481	\N	\N
1638	benazepril - amlodipine group ( n = $nmbr$ )	C0051696;C0053091;C0441848	\N	\N
1637	tpm subgroup  n = $nmbr$	C0076829;C1079230;C1515021	\N	\N
1637	the plot shows hazard ratios and $nmbr$ % confidence intervals for the primary outcome  with patients stratified according to eight sub - groups prespecified in the statistical analysis plan . no heterogeneity was observed for these subgroups .	C0009667;C0019409;C0205225;C0205363;C0205454;C0242960;C0270724;C0439612;C0439631;C0441833;C0542339;C0599880;C0680240;C0687744;C0871424;C1079230;C1257890;C1264637;C1301732;C1441672;C1519504;C1547282;C1547647;C1552839;C1705428;C1705429;C2985465	\N	\N
1637	subgroupt	\N	\N	\N
1637	subgroups	C1079230	\N	\N
1637	subgroup_level	C0441889;C0456079;C1079230;C1515021;C1547707;C2946261	\N	\N
1637	subgroup p valuef	C1079230;C1515021	\N	\N
1637	subgroup overall	C0282416;C1079230;C1515021;C1561607	\N	\N
1637	subgroup no .	C1079230;C1515021	\N	\N
1637	subgroup name / level	C0027365;C0441889;C0456079;C1079230;C1515021;C1547383;C1547707;C2946261;C4522128	\N	\N
1637	subgroup levels	C0441889;C1079230;C1515021	\N	\N
1637	subgroup level	C0441889;C0456079;C1079230;C1515021;C1547707;C2946261	\N	\N
1637	subgroup based on :	C1079230;C1515021;C1527178;C1705938	\N	\N
1637	subgroup $nmbr$	C1079230;C1515021	\N	\N
1637	subgroup	C1079230;C1515021	\N	\N
1637	secondary prevention subgroup	C0679699;C1079230;C1515021	\N	\N
1637	renal subgroup	C0022646;C1079230;C1515021	\N	\N
1637	renal function subgroups	C0232804;C1079230	\N	\N
1637	primary prevention subgroup	C0033144;C1079230;C1515021	\N	\N
1637	prespecified subgroups	C1079230	\N	\N
1637	p  subgroup *	C0369773;C1079230;C1515021;C2603361	\N	\N
1637	outcome_subgroup	C1079230;C1274040;C1515021	\N	\N
1637	m $nmbr$ subgroup	C0369637;C0441923;C1079230;C1515021	\N	\N
1637	latin american subgroup	C1079230;C1515021;C1553378	\N	\N
1637	genetic subgroup	C0017296;C0314603;C1079230;C1515021	\N	\N
1637	female subgroup	C0043210;C0086287;C1079230;C1515021;C1705497;C1705498	\N	\N
1637	diuretic subgroup	C0012798;C1079230;C1515021	\N	\N
1637	baseline subgroup	C0168634;C1079230;C1442488;C1515021	\N	\N
1637	baseline mtss subgroup	C0168634;C1079230;C1442488;C1515021	\N	\N
1637	baseline hba $nmbr$ c subgroup	C0019016;C0168634;C1079230;C1442488;C1515021;C1825777;C3538758	\N	\N
1637	asubset of the ≥ $nmbr$ years subgroup .	C0439234;C1079230;C1515021	\N	\N
1637	( subgroup )	C1079230;C1515021	\N	\N
1636	subgroup analyses	C2986480	\N	\N
1636	prespecified subgroup analyses	C2986480	\N	\N
1636	additional subgroup analyses	C1524062;C2986480	\N	\N
1635	tamong those enrolling via bnp stratum . the study - qualifying bnp or	C0054015;C0557651;C1095989;C1417808;C1514624;C2603343;C2982014	\N	\N
1635	nptercile $nmbr$ ( bnp $nmbr$ - $nmbr$ pg / ml  nt - probnp $nmbr$ - $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ )	C0054015;C0439297;C1095989;C1317554;C1417808;C2825907;C2982014;C4284038	\N	\N
1635	np tercile $nmbr$ ( bnp > $nmbr$ pg / ml  nt - probnp > $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ )	C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038	\N	\N
1635	np tercile $nmbr$ ( bnp < $nmbr$ pg / ml  nt - probnp < $nmbr$ pg / ml ) ( n - $nmbr$ )	C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038	\N	\N
7	p   value for interaction	C1704675;C1709380	\N	\N
7	p   value	C1709380	\N	\N
1635	normal bnp  ^ $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ )	C0054015;C0205307;C0231683;C0439166;C0439297;C1095989;C1417808;C2347086;C2982014;C4553972	\N	\N
1635	nesiritide ( n = $nmbr$ )	C0054015	\N	\N
1635	nesiritide  % z	C0054015	\N	\N
1635	median bnp ( iqr ) – pg / ml	C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014	\N	\N
1635	mean ( $nmbr$ th to $nmbr$ thquartile ) bnp ( pg / ml )	C0039725;C0039738;C0054015;C0439297;C0444504;C1095989;C1417808;C1420718;C2347634;C2348143;C2982014;C4282123;C4285344	\N	\N
1635	elevated bnp ( $nmbr$ pg / ml )  %	C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633	\N	\N
1635	elevated bnp  > $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ )	C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633	\N	\N
1635	elevated bnp	C0054015;C0205250;C1095989;C1417808;C2982014;C3163633	\N	\N
1635	bnp — pg / ml  i	C0021966;C0023806;C0030827;C0054015;C0072225;C0221138;C0439297;C1095989;C1266240;C1417808;C2982014	\N	\N
1635	bnp — pg / ml	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1621	days with heartburna ( days )	C0439228	\N	\N
1323	women t	C0043210	\N	\N
1637	additional antihypertensive subgroup	C0003364;C1079230;C1515021;C1524062	f	1579
1638	etoricoxib group ( n = $nmbr$ $nmbr$ )	C0441848;C0972314	f	1130
1635	bnp o $nmbr$ pg / ml or nt pro - bnp o $nmbr$ pg / ml  n ( % )	C0033382;C0054015;C0439297;C0523852;C1095989;C1417808;C2982014;C2987124;C4284038	\N	\N
1635	bnp indicates brain natriuretic peptide  and nyha  new york heart association .	C0004083;C0018787;C0027976;C0054015;C0439849;C0596306;C0699792;C1095989;C1275491;C1417808;C2982014	\N	\N
1635	bnp > $nmbr$ pg / ml or nt pro - bnp > $nmbr$ pg / ml  n ( % )	C0033382;C0054015;C0439297;C0523852;C1095989;C1417808;C2982014;C2987124;C4284038	\N	\N
1635	bnp > $nmbr$ pg / ml n = $nmbr$	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1635	bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1635	bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1635	bnp > $nmbr$ pg / ml  n = $nmbr$	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1635	bnp < $nmbr$ pg / ml n = $nmbr$	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1635	bnp / nt - probnp	C0054015;C0669479;C0754710;C1095989;C1417808;C2982014	\N	\N
1635	bnp ( pg / ml ) h	C0030827;C0033727;C0054015;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C1095989;C1266240;C1417808;C1705224;C2827929;C2982014;C3887665;C4528284	\N	\N
1635	bnp ( pg / ml )	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1635	bnp ( n = $nmbr$ )	C0054015;C1095989;C1417808;C2982014	\N	\N
1635	bnp  pg / mlt	C0030827;C0054015;C0072225;C1095989;C1266240;C1417808;C2982014;C4553833	\N	\N
1635	bnp  pg / ml	C0054015;C0439297;C1095989;C1417808;C2982014	\N	\N
1635	bnp  median ( iqr )  pg / ml	C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014	\N	\N
1635	bnp  * median ( iqr )  pg / ml	C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014	\N	\N
1635	bnp	C0054015;C1095989;C1417808;C2982014	\N	\N
1634	tr jet velocity ( m / sec )	C0108801;C0336862;C0439493;C0439830;C1539482;C1547053;C1705610;C1872943;C3811249;C3811250;C3814152	\N	\N
1634	m $nmbr$ s	C0439493;C1513009	\N	\N
1633	treatment comparison ( mg / day ) t	C0039798;C0087111;C0439422;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704	\N	\N
1633	treatment comparison	C0039798;C0087111;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704	\N	\N
1633	pairwise comparison	C1707455	\N	\N
1633	l compared wi	C0043193;C0439394;C1520135;C1706495;C1707455;C3642217	\N	\N
1633	comparison with baseline ( mean	C0168634;C0444504;C1442488;C1707455;C2347634;C2348143	\N	\N
1633	comparison with baseline	C0168634;C1442488;C1707455	\N	\N
1633	comparison	C1707455	\N	\N
1633	ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the $nmbr$ genotype groups ) .	C0008107;C0009667;C0017431;C0017446;C0022661;C0030705;C0032042;C0037623;C0039798;C0087111;C0126174;C0205147;C0233324;C0332257;C0441471;C0441833;C0683454;C0687744;C1257890;C1280500;C1415692;C1515273;C1517526;C1518681;C1519504;C1522326;C1522609;C1533734;C1552839;C1696465;C1704675;C1705169;C1705313;C1705428;C1705429;C1706408;C1707455;C1708288;C2348382;C2360800;C2826302;C3259781;C3538994;C3887704;C4019010;C4288115;C4318478	\N	\N
1633	a compared wi	C0043193;C1520135;C1707455	\N	\N
1633	a compared w	C1707455	\N	\N
1632	total comparators ( n = $nmbr$ )	C0439175;C0439810;C1707454;C4553389;C4553390	\N	\N
1632	total comparators  patients with events / total patients	C0030705;C0439175;C0439810;C0441471;C1707454;C3541888;C4553389;C4553390	\N	\N
1632	favors comparator	C0309049;C1707454;C4553389;C4553390	\N	\N
1632	comparator	C1707454;C4553389;C4553390	\N	\N
1631	renal composite *	C0022646;C0205199;C1547335	\N	\N
1631	primary composite endpoint ‡	C0205199;C1547335;C2986535	\N	\N
1631	primary composite end point ‡	C0205199;C1547335;C2986535	\N	\N
1631	primary composite end point	C0205199;C1547335;C2986535	\N	\N
1631	disease - progression composite outcome !	C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808	\N	\N
1631	cromoglicate	C0010347	\N	\N
1631	composite vascular endpoint	C0005847;C0205199;C1547335;C1558950;C1801960;C2349179;C2826544	\N	\N
1631	composite of doubling of serum creatinine  end - stage kidney disease  or death from renal causes	C0007465;C0022646;C0022658;C0201976;C0205088;C0205173;C0205199;C0600061;C1547335;C1705764	\N	\N
1631	composite ocular end point ^	C0015392;C0042789;C0205199;C0700042;C1299003;C1547335;C2349179;C2826544;C4521296	\N	\N
1631	composite microvascular end point *	C0205199;C0443258;C1547335;C2349179;C2826544	\N	\N
1631	composite endpoint ( a $nmbr$ c < $nmbr$ . $nmbr$ %  bp	C0037623;C0205199;C1415692;C1547335;C1708288;C2349179;C2826544;C4318478	\N	\N
1631	composite endpoint	C0205199;C1547335;C2349179;C2826544	\N	\N
1631	composite	C0205199;C1547335	\N	\N
1631	components of primary composite end point — secondary end points	C0205199;C1547335;C1882460;C4528314	\N	\N
1631	( composite endpoint )	C0205199;C1547335;C2349179;C2826544	\N	\N
1630	hospitalized without airway compromise	C0701159;C4055482	\N	\N
1630	airway compromise	C4055482	\N	\N
1629	implanted pacemaker	C0848753	\N	\N
1629	impacts	C1825598;C4049986	\N	\N
1628	implanted cardioverter defibrillator	C0021102;C0810516;C2828363	\N	\N
1628	implanted cardioverter - defibrillator	C0021102;C0810516;C2828363	\N	\N
1628	implantable cardioverter - defibrillator n ( % )	C0162589;C2825184	\N	\N
1628	implantable cardioverter - defibrillator	C0162589;C2825184	\N	\N
1621	day $nmbr$ oral glucocorticoid use — no . { % )	C0017710;C0042153;C0332173;C0439228;C0439505;C0442027;C0457083;C1947944;C4521986	\N	\N
1621	conversion to sinus rhythm in < $nmbr$ days	C0439228;C1321500	\N	\N
1621	change from baseline in rescue medication use ( puffs per day )	C0168634;C0240320;C0332173;C0392747;C0439228;C0439505;C0443172;C1442488;C1533107;C1705241;C4319952	\N	\N
1621	baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$ - q $nmbr$ )	C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352	\N	\N
1621	baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$  q $nmbr$ )	C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352	\N	\N
1628	data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids  bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . nyha = newyork heart association . lvef = left ventricular ejection fraction . hf = heartfailure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter defibrillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .	C0004083;C0005823;C0010055;C0012000;C0018787;C0018801;C0021122;C0022709;C0024117;C0030705;C0032042;C0032615;C0085805;C0155626;C0162589;C0185098;C0205042;C0237753;C0428772;C0439849;C0444504;C0449788;C0470187;C0488055;C0488728;C0521942;C0536221;C0596306;C0699792;C0815017;C0871470;C1264633;C1271104;C1272641;C1275491;C1305855;C1306620;C1511726;C1532338;C1554103;C1696465;C1706408;C2347634;C2348143;C2699239;C2733342;C2825184;C3245479;C3714741;C3813197;C3888198;C4281799	\N	\N
1627	subjects with imputed value for end ‐ of ‐ treatment body weight	C0039798;C0087111;C0681850;C1522326;C1522609;C1533734;C1550501;C1705169;C1706203;C2349001;C2697811;C2699638;C2983672;C3538994;C3887704	\N	\N
1627	imputed	C2699638	\N	\N
1627	bocf - iike imputation ( random . ) ( n = $nmbr$ )	C0034656;C0439605;C2699638;C2984917	\N	\N
1626	eos serum k +  meq / l	C0302353;C0439375;C1623465;C1861303	\N	\N
1626	elevated bun ( > $nmbr$ . $nmbr$ meq / l )	C0151539;C0439375	\N	\N
1626	baseline : > $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ meq / l	C0168634;C0439375;C1442488;C1623465;C1861303	\N	\N
1626	baseline : > $nmbr$ . $nmbr$ meq / l eos : < $nmbr$ . $nmbr$ meq / l	C0168634;C0439375;C1442488;C1623465;C1861303	\N	\N
1626	baseline : < $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ or < $nmbr$ . $nmbr$ meq / l	C0168634;C0439375;C1442488;C1623465;C1861303	\N	\N
1626	$nmbr$ mq / kq *	C0024853	\N	\N
1625	ssomgdayp . eq .	C0205163;C0439185	\N	\N
1625	eq - $nmbr$ dprofile - mobility  n ( % )	C0080078;C0205163;C0425245;C0439185;C0449580;C4318935	\N	\N
1625	eq - $nmbr$ d mobility	C0080078;C0205163;C0425245;C0439185;C0449580;C4318935	\N	\N
1625	eq - $nmbr$ d ( visual analog score )	C0205163;C0234621;C0243071;C0439185;C0449820;C4050231	\N	\N
1625	eq $nmbr$ da health index status score	C0011318;C0018759;C0205163;C0439185;C0449820;C0600653;C0918012;C1552854;C1637833;C2986546;C3668815;C4050231	\N	\N
1625	< $nmbr$ mgday p . eq .	C0205163;C0439185	\N	\N
1623	plasma dha  mean ( sd ) weight  %	C0005910;C0032105;C0043100;C0142831;C0444504;C1305866;C1550098;C1705104;C2347634;C2348143;C2348308;C2699239;C4521445	\N	\N
1623	dha ( n = $nmbr$ )	C0142831;C2348308	\N	\N
1622	radiate	C0332301	\N	\N
1622	ohs graduate	C0268353;C0588053;C1547183;C1861455	\N	\N
1622	hs graduate / ged	C0588053;C1547183;C1880947	\N	\N
1621	vte at day $nmbr$ +	C0332173;C0439228;C0439505;C0630906	\N	\N
1621	use of rescue albuterol  puffs / day *	C0001927;C0332173;C0439228;C0439505;C1524063;C1533107	\N	\N
1621	treatment duration before randomization — days	C0034656;C0439228;C0444921;C3259042	\N	\N
1621	treatment duration  days	C0439228;C0444921;C3259042	\N	\N
1621	treatment before randomization — days	C0034656;C0039798;C0087111;C0439228;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1621	time from onset of symptoms to randomization — days	C0034656;C0439228;C1320528	\N	\N
1621	time from index acs event to randomisation ( days )	C0034656;C0040223;C0439228;C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4019010;C4318612	\N	\N
1621	time from event to randomization — days	C0034656;C0040223;C0439228;C0441471;C3541383;C4019010	\N	\N
1621	subacute ( $nmbr$ - $nmbr$ days )	C0205365;C0439228	\N	\N
1621	slo days	C0439228;C1416602;C3539661	\N	\N
1621	saba puffs per day at baseline	C0168634;C0332173;C0439228;C0439505;C1442488;C1533107	\N	\N
1621	recent use of allopurinol ( within $nmbr$ days of	C0002144;C0332185;C0439228;C1524063	\N	\N
1621	recent cardioversion ( within $nmbr$ days before randomization ) — no . ( % )	C0013778;C0034656;C0332185;C0439228	\N	\N
1621	recent cardioversion ( within $nmbr$ days before randomization ) —	C0013778;C0034656;C0332185;C0439228	\N	\N
1621	patient status after wake - up  % of days patient woke :	C0439228;C0442696;C0449437;C0585034;C1170730	\N	\N
1621	no . of days to randomization — median ( iqr )	C0034656;C0439228;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1621	medications at discharge or day $nmbr$  if earlier ( % )	C0332173;C0439228;C0439505;C0806915;C1279919	\N	\N
1621	medication within $nmbr$ days before enrolment	C0013227;C0439228;C1516879;C1696073;C3244316;C3888021;C4284232	\N	\N
1621	median duration of study - drug administration ( iqr ) — days	C0013175;C0439228;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193	\N	\N
1621	median ( days )	C0439228;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1621	mean ( sd ) extent of exposure  days	C0274281;C0332157;C0439228;C0439792;C0444504;C2347634;C2348143;C2699239	\N	\N
1621	insulin dose — lu / day	C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939	\N	\N
1621	insulin dose ( lu / day )	C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939	\N	\N
1621	infarction > $nmbr$ days previously	C0021308;C0439228	\N	\N
1621	infarction $nmbr$ - $nmbr$ days	C0021308;C0439228	\N	\N
1621	infarct ion w ithin previous $nmbr$ day s	C0021308;C0022023;C0205156;C0332173;C0439228;C0439505;C1552607;C1700702	\N	\N
1621	index stroke > $nmbr$ days before randomization — no . ( % )	C0034656;C0439228;C0456712	\N	\N
1621	hospital stay ( days )	C0439228;C3489408	\N	\N
1621	hospital stay  days	C0439228;C3489408	\N	\N
1621	exposure to study drug — days	C0013175;C0332157;C0439228	\N	\N
1621	every day	C0332173;C0439228;C0439505	\N	\N
1621	ended > $nmbr$ days before trial entry	C0008976;C0439228;C1272693;C1705654;C2746065	\N	\N
1621	elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) : ! :	C0205156;C0205250;C0439228;C1144709;C1552607;C3163633	\N	\N
1621	elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) $	C0205156;C0205250;C0439228;C1144709;C1552607;C3163633	\N	\N
1626	serum potassium level  mean ( sd )  meq / l	C0302353;C0439375;C0444504;C0543465;C2347634;C2348143;C2699239	f	1959
1626	serum potassium  meq / l	C0302353;C0439375;C0543465	f	1959
1621	aspirin < $nmbr$ day	C0004057;C0332173;C0439228;C0439505	\N	\N
1621	as - needed inhalations / day	C0004048;C0332173;C0354922;C0439228;C0439505;C1879745;C1883728	\N	\N
1621	absolute time spent “ on ”  h / day	C0033727;C0332173;C0369286;C0439228;C0439505;C0439546;C0441932;C0564385;C0680968;C4528284	\N	\N
1621	a ngina > $nmbr$ day s previously *	C0332173;C0439228;C0439505	\N	\N
1621	^ $nmbr$ days	C0439228	\N	\N
1621	> = medion ( $nmbr$ days )	C0439228	\N	\N
1621	> = median ( $nmbr$ days )	C0439228;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1621	> = $nmbr$ days	C0439228	\N	\N
1621	> $nmbr$ days warfarin	C0043031;C0439228	\N	\N
1621	> $nmbr$ days ( % )	C0439228	\N	\N
1621	> $nmbr$ days	C0439228	\N	\N
1621	> $nmbr$ / day	C0332173;C0439228;C0439505	\N	\N
1621	< median ( $nmbr$ days )	C0439228;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1621	< $nmbr$ days ( n = $nmbr$ )	C0439228	\N	\N
1621	< $nmbr$ days ( % )	C0439228	\N	\N
1621	< $nmbr$ days	C0439228	\N	\N
1621	( iqr ) — days	C0439228	\N	\N
1621	$nmbr$ — $nmbr$ days	C0439228	\N	\N
1621	$nmbr$ or $nmbr$ days	C0439228	\N	\N
1621	$nmbr$ days new mi or definite acute st	C0036056;C0205178;C0205314;C0439228;C0439544;C1704787;C3272372;C3810814	\N	\N
1621	$nmbr$ days new mi	C0205314;C0439228;C3810814	\N	\N
1621	$nmbr$ days	C0439228	\N	\N
1621	$nmbr$ day l	C0332173;C0439228;C0439505	\N	\N
1621	$nmbr$ / day	C0332173;C0439228;C0439505	\N	\N
1621	$nmbr$ - day mortality	C0026565;C0026566;C0332173;C0439228;C0439505	\N	\N
1621	$nmbr$ - day cce	C0332173;C0439228;C0439505	\N	\N
1621	$nmbr$ - $nmbr$ days ( % )	C0439228	\N	\N
1621	$nmbr$ - $nmbr$ days	C0439228	\N	\N
1621	$nmbr$ - $nmbr$ / day	C0332173;C0439228;C0439505	\N	\N
1620	treatment ( de vs warfarin ) by thrombophilia interaction	C0011198;C0017480;C0039798;C0043031;C0087111;C0398623;C1522326;C1533734;C1704675;C1705169;C3538994;C3541240;C3887704	\N	\N
1620	hemoglobin ( gm / dl )	C0017480;C0019046;C3642216;C3854019	\N	\N
1620	germany	C0017480	\N	\N
1620	de ( n = $nmbr$ )	C0011198;C0017480;C3541240	\N	\N
1620	de $nmbr$ n = $nmbr$	C0011198;C0017480;C3541240	\N	\N
1620	de $nmbr$ mg bid ( n - $nmbr$  $nmbr$ )	C0011198;C0017480;C0024671;C0026410;C0439269;C1960952;C2346927;C3541240;C4321396;C4521761	\N	\N
1620	de	C0011198;C0017480;C3541240	\N	\N
1619	treatment during or after catheterization	C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1619	or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) < $nmbr$ . $nmbr$	\N	\N	\N
1619	or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$	\N	\N	\N
1619	fibrinolytic agents before or after entry	C0016018;C1705654	\N	\N
1618	on or after e ^ andomization	\N	\N	\N
1618	after $nmbr$ h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
1618	$nmbr$ hr after glucose challenge	C3840385	\N	\N
1617	leader	\N	\N	\N
1617	laser or vitrectomy	C0023089;C0042903;C0458142;C1023865;C1706315	\N	\N
1617	greater than or equal to $nmbr$ mm hg	C0205163;C0439093;C0439475	\N	\N
1617	greater than or equal to $nmbr$ %	C0205163;C0439093	\N	\N
1617	$nmbr$ or greater	C1704243	\N	\N
1616	othera	\N	\N	\N
1616	other teaes	\N	\N	\N
1616	other ischaemic heart disease ( non - infarction )	C0010054;C0021308;C0151744;C1518422	\N	\N
1616	other antihyperglycemic agents  not listed	C0020616;C0745732;C1518422;C3272378	\N	\N
1616	other *	\N	\N	\N
1616	other ( $nmbr$ . $nmbr$ % ) t	C2603360	\N	\N
1616	other '	\N	\N	\N
1615	tnfi ( no other bdmard taken ) t  n ( % )	C1883727;C2986835	\N	\N
1615	other bdmards ( no tnfi taken ) t  n ( % )	C1883727;C2986835	\N	\N
1615	other bdmard §	\N	\N	\N
1614	testing order	C0039593;C0392366;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072	\N	\N
1614	hder *	C3898895	\N	\N
1613	nontraumatic leg or foot amputation	C0023216;C0188605;C1140621	\N	\N
1613	lower limbs	C0023216	\N	\N
1613	lower limb fractures	C0016658;C0023216	\N	\N
1613	lower limb fracture	C0016658;C0023216;C0441994;C0596838;C1548802;C2003888	\N	\N
1613	lower - limb arterial — no . ( % )	C0003842;C0023216;C0221464	\N	\N
1612	other blood glucose - lowering agents	C0005802;C0441994;C0450442;C1254351;C1521826;C2003888	\N	\N
1612	other : :	\N	\N	\N
1612	lower than normal range — % ^	C0086715;C0441994;C1548802;C2003888	\N	\N
1612	lower tertile : b $nmbr$ . $nmbr$	C0441994;C1548802;C2003888	\N	\N
1612	lower	C0441994;C1548802;C2003888	\N	\N
1612	distal lower	C0205108;C0441994;C1548802;C2003888;C4522154	\N	\N
1611	liver disorder	C0023895	\N	\N
1611	hepatic disorders	C0023895	\N	\N
1610	neurocognitive disorders	C0029227;C4041080	\N	\N
1610	gastrointestinal disorders	C0017178	\N	\N
1610	gastrointestinal ( gi ) disorders	C0017178;C1708130;C3539617;C4050121	\N	\N
1609	pacific islander	C0242191	\N	\N
1609	other pacific islander	C0242191	\N	\N
1609	islander	\N	\N	\N
1609	bladder	C0005682;C4319531	\N	\N
1609	asian or pacific islander	C0078988;C0242191	\N	\N
1609	asian / pacific islander  n ( % )	C0078988;C0242191	\N	\N
1608	mucolytics	C0026698	\N	\N
1608	mucolytic agent	C0026698	\N	\N
1607	myoclonic	\N	\N	\N
1607	juvenile myoclonic epilepsy	C0270853	\N	\N
1606	pathological q waves	C0429090	\N	\N
1606	pathologic q waves — no . ( % )	C0429090	\N	\N
1606	pathologic q waves  n ( % )	C0429090	\N	\N
1606	hematologic	C0018943;C0205488	\N	\N
1606	haematological	C0018943;C0200627	\N	\N
1605	troponin t	C0077404;C1420827	\N	\N
1605	troponin ( - )	C0041199	\N	\N
1605	elevated troponin — %	C0041199;C0205250;C3163633	\N	\N
1605	elevated troponin t ( > $nmbr$ . $nmbr$ / xg / l )	C0017209;C0077404;C0205250;C1292284;C1420827;C1421532;C3163633	\N	\N
1605	elevated troponin ( > $nmbr$ . $nmbr$ pg / l )	C0041199;C0205250;C0439278;C3163633	\N	\N
1592	previous tia	C0007787;C0205156;C0917805;C1054154;C1552607	\N	\N
1605	elevated troponin ( > $nmbr$ . $nmbr$ mg / l )  %	C0041199;C0205250;C0439268;C3163633	\N	\N
1605	elevated troponin	C0041199;C0205250;C3163633	\N	\N
1604	cryptogenic localization - related	C0332240;C0439849;C0445223;C0475264;C1744691	\N	\N
1604	cryptogenic	C0332240	\N	\N
1603	troponin ( + )	C0041199	\N	\N
1603	troponin $nmbr$ at baseline *	C0041199;C0168634;C1442488	\N	\N
1603	troponin $nmbr$ at baseline	C0041199;C0168634;C1442488	\N	\N
1603	troponin	C0041199	\N	\N
1603	positive troponin or ck - mb	C0010290;C0041199;C0439178;C1446409;C1514241;C2825490;C3812269	\N	\N
1602	result	C1274040;C1546471;C2825142	\N	\N
1602	outcomes during accord	C0680240;C1274040	\N	\N
1602	outcomes	C1274040	\N	\N
1602	outcome severity	C0439793;C0522510;C1274040	\N	\N
1602	outcome according to stage of cancer — no . / total no . ( % )	C0027646;C0439175;C0439810;C0680240;C1274040	\N	\N
1602	outcome according to primary cancer site — no . / total no . ( % )	C0439175;C0439810;C0680240;C0872338;C1274040	\N	\N
1602	outcome according to no . of risk factors for vte	C0035648;C0630906;C0680240;C1274040;C1553898	\N	\N
1602	outcome - variant	C0205419;C1274040	\N	\N
1602	outcome ( n  % }	C1274040	\N	\N
1602	outcome	C1274040	\N	\N
1602	other outcomes	C1274040	\N	\N
1602	microvascular outcome	C0443258;C1274040	\N	\N
1602	exploratory kidney and microvascular outcomes	C0022646;C0227665;C0443258;C1274040	\N	\N
1602	clinical outcome	C0205210;C1274040	\N	\N
1602	characteristic / outcome	C1274040;C1521970	\N	\N
1602	baseline outcomes	C0168634;C1274040;C1442488	\N	\N
1602	ancova result	C0814908;C1274040;C1546471;C2825142	\N	\N
1602	adverse outcome	C1274040	\N	\N
1601	trough fevi l	C0429706;C0444506;C0849974;C1561566;C4528367	\N	\N
1601	proportion of patients with trough fevi > $nmbr$ ml above baseline  n ( % )	C0030705;C0168634;C0429706;C0439526;C0444506;C0849974;C1442488;C1561566;C1705224;C1709707;C3887665;C4528367	\N	\N
1601	prebronchodilator fevi — liters	C0429706;C0475211;C0849974;C1561566;C2599602;C4528367	\N	\N
1601	prebronchodilator fevi ( % predicted )	C0681842;C0849974;C1561566;C1882327;C2599602;C4528367	\N	\N
1601	pre - bronchodilator fevi change	C0392747;C0443172;C0849974;C1561566;C1705241;C2599602;C4319952;C4528367	\N	\N
1601	post - bronchodilator fevi $nmbr$ % predicted	C0681842;C0849974;C1561566;C1882327;C2599594;C4528367	\N	\N
1601	post - bronchodilator fevi  n ( % )	C0429706;C0849974;C1561566;C2599594;C4528367	\N	\N
1601	mean ( sd ) fevi / evc  %	C0013903;C0429706;C0429711;C0444504;C0849974;C1414479;C1561566;C2347634;C2348143;C2699239;C4528367	\N	\N
1601	mean ( sd ) fevi  ml	C0429706;C0439526;C0444504;C0849974;C1561566;C1705224;C2347634;C2348143;C2699239;C3887665;C4528367	\N	\N
1601	fevi percent predicted ( % )	C0429706;C0439165;C0681842;C0849974;C1561566;C1882327;C4528367	\N	\N
1601	fevi auc $nmbr$ - $nmbr$ l	C0376690;C0429706;C0849974;C1561566;C4528367	\N	\N
1601	fevi $nmbr$ l	C0429706;C0849974;C1561566;C4528367	\N	\N
1601	fevi  l *	C0429706;C0849974;C1561566;C4528367	\N	\N
1601	fevi  l	C0429706;C0849974;C1561566;C4528367	\N	\N
1601	fevi  % predicted *	C0681842;C0849974;C1561566;C1882327;C4528367	\N	\N
1601	adjusted mean ( se ) trough fevi  ml	C0036919;C0429706;C0439526;C0444504;C0444506;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367	\N	\N
1601	$nmbr$ ( fevi ^ $nmbr$ % pred )	C0032952;C0044955;C0849974;C1561566;C4528367	\N	\N
1601	$nmbr$ ( fevi $nmbr$ - < $nmbr$ % pred )	C0032952;C0044955;C0849974;C1561566;C4528367	\N	\N
1600	pre - bronchodilator fevi / fvc  %	C0802741;C2599602;C3815113	\N	\N
1600	mean ( sd ) fevi / fvc  %	C0444504;C0802741;C2347634;C2348143;C2699239;C3815113	\N	\N
1600	fevi / fvc ( % )	C0802741;C3815113	\N	\N
1599	trough fev $nmbr$	C0444506;C3714541	\N	\N
1599	severe ( fev  < $nmbr$ % predicted )	C0205082;C0681842;C1882327;C3714541;C4050465;C4050466	\N	\N
1599	screening fev $nmbr$   % predicted	C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541	\N	\N
1599	screening % predicted fev $nmbr$	C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541	\N	\N
1599	ratio of fev $nmbr$ to fvc ( % )	C0456603;C1547037;C3714541	\N	\N
1599	ratio of fev $nmbr$ to fvc	C0456603;C1547037;C3714541	\N	\N
1599	prebronchodilator fev $nmbr$ / fvc	C2599602;C3714541	\N	\N
1599	prebronchodilator fev $nmbr$ ( l ) t	C2599602;C3714541	\N	\N
1599	prebronchodilator fev $nmbr$ ( l )	C2599602;C3714541	\N	\N
1599	prebronchodilator fev $nmbr$ ( %	C2599602;C3714541	\N	\N
1599	prebronchodilator fev $nmbr$  mean ( sd )  l	C0444504;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	prebronchodilator fev $nmbr$  l	C2599602;C3714541	\N	\N
1599	prebronchodilator fev $nmbr$  % predicted	C0681842;C1882327;C2599602;C3714541	\N	\N
1599	pre fev $nmbr$	C0332152;C0740175;C2257086;C3669034;C3714541	\N	\N
1599	pre - bronchodilator mean ( sd ) fev $nmbr$  . l	C0444504;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	pre - bronchodilator fev $nmbr$ / fvc ratio *	C0456603;C1547037;C2599602;C3714541	\N	\N
1599	pre - bronchodilator fev $nmbr$ / fvc ( % )	C2599602;C3714541	\N	\N
1599	pre - bronchodilator fev $nmbr$  l *	C2599602;C3714541	\N	\N
1599	pre - bronchodilator fev $nmbr$	C2599602;C3714541	\N	\N
1599	pre - bronchodilation fvc	C0439566;C3714541	\N	\N
1599	pre - bronchodilation fev $nmbr$	C0439566;C3714541	\N	\N
1599	postdose fev / fvc at screening	C0220908;C0220909;C0439568;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541	\N	\N
1599	postbronchodilator fev $nmbr$ / fvc  %	C2599594;C3714541	\N	\N
1599	postbronchodilator fev $nmbr$  l	C2599594;C3714541	\N	\N
1599	post fev $nmbr$	C0687676;C1704687;C3469826;C3714541	\N	\N
1599	post - bronchodilator percent of predicted fev $nmbr$  % ( sd )	C1882327;C2599594;C2699239;C3714541	\N	\N
1599	post - bronchodilator fev $nmbr$ / fvc ratio  mean ( sd )	C0444504;C0456603;C1547037;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1599	post - bronchodilator fev $nmbr$  % predicted  mean ( sd ) c	C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1599	post - bronchodilation fvc	C0439576;C3714541	\N	\N
1599	post - bronchodilation fev $nmbr$	C0439576;C3714541	\N	\N
1323	women / men [ % ]	C0025266;C0043210	\N	\N
1599	post - albuterol % predicted fev $nmbr$ mean ( sd ) e	C0001927;C0444504;C0681842;C0687676;C1704687;C1882327;C2347634;C2348143;C2699239;C3469826;C3714541	\N	\N
1599	percent of predicted fev $nmbr$	C1882327;C3714541	\N	\N
1599	mild ( fev  > $nmbr$ % predicted )	C0681842;C1882327;C2945599;C3714541	\N	\N
1599	mean prebronchodilator fev $nmbr$ ( sd )  % predicted	C0444504;C0681842;C1882327;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	mean postbronchodilatora fev $nmbr$  % predicted ( sd )	C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541	\N	\N
1599	mean fvc ± sd	C0444504;C2347634;C2348143;C2699239;C3714541	\N	\N
1599	mean ( sd ) postbronchodilator fev $nmbr$ / fvc  %	C0444504;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1599	mean ( sd ) postbronchodilator fev $nmbr$ % predicted	C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1599	mean ( sd ) post - bronchodilator fev $nmbr$ percentage predicted	C0439165;C0444504;C0681842;C1549488;C1561533;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1599	mean ( sd ) fev $nmbr$ postbronchodilator  l	C0444504;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1599	mean ( sd ) fev $nmbr$ ( l ) pre - bronchodilator	C0444504;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	mean ( sd ) fev $nmbr$ ( l ) post - bronchodilator	C0444504;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1599	mean ( sd ) % predicted normal fev $nmbr$	C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C3714541;C4553972	\N	\N
1599	mean % predicted fvc ( sd )	C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541	\N	\N
1599	iv : fev $nmbr$ < $nmbr$ % predicted	C0022326;C0681842;C1882327;C3714541;C4265176	\N	\N
1599	iii : fev $nmbr$ > $nmbr$ % - < $nmbr$ % predicted	C0439070;C0681842;C1705160;C1882327;C3714541	\N	\N
1599	gold grades $nmbr$ - $nmbr$ ( percent - predicted fev ( )  n	C0018026;C0439165;C0441800;C0681842;C0919553;C1304897;C1882327;C3244287;C3714541	\N	\N
1599	fvc ∗	C3714541	\N	\N
1599	fvc — liters	C0475211;C3714541	\N	\N
1599	fvc change	C0392747;C0443172;C1705241;C3714541;C4319952	\N	\N
1599	fvc > $nmbr$ % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fvc < $nmbr$ % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fvc ( liters )	C0475211;C3714541	\N	\N
1599	fvc ( l ) *	C3714541	\N	\N
1599	fvc ( l )	C3714541	\N	\N
1599	fvc ( % predicted )	C0681842;C1882327;C3714541	\N	\N
1599	fvc % predicted !  t	C0681842;C1882327;C2603360;C3714541	\N	\N
1599	fvc  l	C3714541	\N	\N
1599	fvc  % predicted  mean ( sd )	C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541	\N	\N
1599	fvc  % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fvc	C3714541	\N	\N
1599	fevt : fvc ratio — % |	C0016529;C0456603;C1547037;C3714541	\N	\N
1599	fev_ ( l ) :	C3714541	\N	\N
1599	fev $nmbr$ — liters	C0475211;C3714541	\N	\N
1599	fev $nmbr$   at baseline ( randomization ) ∗	C0034656;C0168634;C1442488;C3714541	\N	\N
1599	fev $nmbr$ reversibilityz ( pre / post salbutamol )  %	C0001927;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541	\N	\N
1599	fev $nmbr$ reversibilityz ( pre / post ipratropium )  %	C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541	\N	\N
1599	fev $nmbr$ reversibility  pre - / post - albuterol  %	C0001927;C0332152;C0449261;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541	\N	\N
1599	fev $nmbr$ prebronchodilator [ l ]  mean ± sd	C0444504;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	fev $nmbr$ prebronchodilator [ % pn ]  mean ± sd	C0219433;C0444504;C1549735;C2347634;C2348143;C2599602;C2699239;C3541307;C3714541;C4049640;C4049767	\N	\N
1599	fev $nmbr$ pre - bronchodilator ( l )  mean ( sd ) c	C0444504;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	fev $nmbr$ post - bronchodilator	C2599594;C3714541	\N	\N
1599	fev $nmbr$ percent predicted ( sd )	C0439165;C0681842;C1882327;C2699239;C3714541	\N	\N
1599	fev $nmbr$ at baseline	C0168634;C1442488;C3714541	\N	\N
1599	fev $nmbr$ : fvc ratio	C0456603;C1547037;C3714541	\N	\N
1599	fev $nmbr$ / fvc ratio *	C0456603;C1547037;C3714541	\N	\N
1599	fev $nmbr$ / fvc ratio  % ( sd )	C0456603;C1547037;C2699239;C3714541	\N	\N
1599	fev $nmbr$ / fvc ratio  %	C0456603;C1547037;C3714541	\N	\N
1599	fev $nmbr$ / fvc prebronchodilatort	C3714541	\N	\N
1599	fev $nmbr$ / fvc prebronchodilator  mean ± sd	C0444504;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	fev $nmbr$ / fvc at baseline ( randomization ) ( % ) ∗	C0034656;C0168634;C1442488;C3714541	\N	\N
1599	fev $nmbr$ / fvc ( post salbutamol )	C0001927;C0687676;C1704687;C3469826;C3714541	\N	\N
1599	fev $nmbr$ / fvc %	C3714541	\N	\N
1599	fev $nmbr$ / fvc  % a	C3714541	\N	\N
1599	fev $nmbr$ / fvc  % *	C3714541	\N	\N
1599	fev $nmbr$ / fvc	C3714541	\N	\N
1599	fev $nmbr$ ( pre - albuterol )  l	C0001927;C0332152;C0740175;C2257086;C3669034;C3714541	\N	\N
1599	fev $nmbr$ ( post - albuterol )  l	C0001927;C0687676;C1704687;C3469826;C3714541	\N	\N
1599	fev $nmbr$ ( liters )	C0475211;C3714541	\N	\N
1599	fev $nmbr$ ( l )	C3714541	\N	\N
1599	fev $nmbr$ ( % predicted )	C0681842;C1882327;C3714541	\N	\N
1599	fev $nmbr$ % predicted ≥ $nmbr$ %	C0681842;C1882327;C3714541	\N	\N
1599	fev $nmbr$ % predicted at baseline	C0168634;C0681842;C1442488;C1882327;C3714541	\N	\N
1599	fev $nmbr$ % predicted < $nmbr$ %	C0681842;C1882327;C3714541	\N	\N
1599	fev $nmbr$ % predicted ( sd )	C0681842;C1882327;C2699239;C3714541	\N	\N
1599	fev $nmbr$ % predicted ( post salbutamol )	C0001927;C0681842;C0687676;C1704687;C1882327;C3469826;C3714541	\N	\N
1599	fev $nmbr$ % predicted  post - albuterol  %	C0001927;C0681842;C0687676;C1704687;C1882327;C3469826;C3714541	\N	\N
1599	fev $nmbr$ % predicted  mean ( sd )	C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541	\N	\N
1599	fev $nmbr$ % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fev $nmbr$ % pred . ( post - albuterol )  %	C0001927;C0032952;C0044955;C0687676;C1704687;C3469826;C3714541	\N	\N
1599	fev $nmbr$  pre - albuterol  l	C0001927;C0332152;C0740175;C2257086;C3669034;C3714541	\N	\N
1599	fev $nmbr$  post - albuterol  l	C0001927;C0687676;C1704687;C3469826;C3714541	\N	\N
1599	fev $nmbr$  mean  l	C0444504;C2347634;C2348143;C3714541	\N	\N
1323	women / men  %	C0025266;C0043210	\N	\N
1599	fev $nmbr$  mean  % predicted	C0444504;C0681842;C1882327;C2347634;C2348143;C3714541	\N	\N
1599	fev $nmbr$  litres ( pre salbutamol )  mean ( sd )	C0001927;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541	\N	\N
1599	fev $nmbr$  litres ( pre ipratropium )  mean ( sd )	C0027235;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541	\N	\N
1599	fev $nmbr$  litres ( post ipratropium )  mean ( sd )	C0027235;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541	\N	\N
1599	fev $nmbr$  l prebronchodilator fev $nmbr$  % predicted	C0681842;C1882327;C2599602;C3714541	\N	\N
1599	fev $nmbr$  l *	C3714541	\N	\N
1599	fev $nmbr$  l	C3714541	\N	\N
1599	fev $nmbr$  % predicteda	C3714541	\N	\N
1599	fev $nmbr$  % predicted  mean ( sd )	C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541	\N	\N
1599	fev $nmbr$  % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fev $nmbr$	C3714541	\N	\N
1599	fev  at baseline	C0168634;C1442488;C3714541	\N	\N
1599	fev  > $nmbr$ % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fev  < $nmbr$ % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fev  % predicted	C0681842;C1882327;C3714541	\N	\N
1599	fev	C3714541	\N	\N
1599	change from baseline in % predicted fev $nmbr$	C0168634;C0392747;C0443172;C0681842;C1442488;C1705241;C1882327;C3714541;C4319952	\N	\N
1599	c $nmbr$ ml decrease in trough fev $nmbr$	C0392756;C0439526;C0444506;C0547047;C1705224;C3714541;C3887665	\N	\N
1599	baseline post - bronchodilator % predicted fev  > $nmbr$ % and no concurrent tiotropium	C0168634;C0205420;C0213771;C0681842;C1442488;C1882327;C2599594;C3714541	\N	\N
1599	baseline post - bronchodilator % predicted fev  > $nmbr$ % and concurrent tiotropium use	C0042153;C0168634;C0205420;C0213771;C0457083;C0681842;C1442488;C1882327;C1947944;C2599594;C3714541	\N	\N
1599	baseline fvc  l	C0168634;C1442488;C3714541	\N	\N
1599	baseline fev $nmbr$ % predicted	C0168634;C0681842;C1442488;C1882327;C3714541	\N	\N
1599	baseline fev $nmbr$ #	C0168634;C1442488;C3714541	\N	\N
1599	baseline fev $nmbr$  median ( range )  l	C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3714541	\N	\N
1599	baseline fev $nmbr$  l *	C0168634;C1442488;C3714541	\N	\N
1599	baseline fev $nmbr$	C0168634;C1442488;C3714541	\N	\N
1599	baseline fev  ( l )	C0168634;C1442488;C3714541	\N	\N
1599	baseline % predicted fev $nmbr$	C0168634;C0681842;C1442488;C1882327;C3714541	\N	\N
1599	absolute decline in fvc > $nmbr$ % predicted or death  n ( % )	C0011065;C0205344;C0681842;C1306577;C1882327;C3714541;C4082313;C4552775	\N	\N
1599	absolute decline in fvc > $nmbr$ % predicted	C0205344;C0681842;C1882327;C3714541	\N	\N
1599	% predicted ” fev  at baseline  % *	C0168634;C0681842;C1442488;C1882327;C3714541	\N	\N
1599	% predicted prebronchodilator fev $nmbr$  mean ( sd )  l	C0444504;C0681842;C1882327;C2347634;C2348143;C2599602;C2699239;C3714541	\N	\N
1599	% predicted post - bronchodilator fev  ( sd ) ml	C0439526;C0681842;C1705224;C1882327;C2599594;C2699239;C3714541;C3887665	\N	\N
1599	% predicted fev ^	C0681842;C1882327;C3714541	\N	\N
1599	% predicted fev $nmbr$	C0681842;C1882327;C3714541	\N	\N
1599	% predicted fev	C0681842;C1882327;C3714541	\N	\N
1598	oral fi - blockers	C0442027;C4050619;C4521986	\N	\N
1598	fh ii	C1854107	\N	\N
1598	fh $nmbr$	\N	\N	\N
1598	% fhg	\N	\N	\N
1598	$nmbr$ . $nmbr$ ( fi . $nmbr$ )	C4050619	\N	\N
1597	ff – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )	C0008107;C3259781;C4554348	\N	\N
1597	ff / vi $nmbr$ / $nmbr$ gg ( n = $nmbr$  $nmbr$ )	C0017454;C0018370;C0205999;C4554348	\N	\N
1597	ff / vi $nmbr$ % ( $nmbr$ %  $nmbr$ % )	C0205999;C4554348	\N	\N
1597	ff / vi	C0205999;C4554348	\N	\N
1597	ff - blocker	C4554348	\N	\N
1597	ff - $nmbr$ % ( - $nmbr$ %  $nmbr$ % )	C4554348	\N	\N
1597	ff $nmbr$   µ g	C0439267;C4554348	\N	\N
1597	ff $nmbr$ pgod	C4554348	\N	\N
1597	ff $nmbr$ gg ( n = $nmbr$  $nmbr$ )	C0017454;C0018370;C4554348	\N	\N
1597	ff $nmbr$ % ( - $nmbr$ %  $nmbr$ % )	C4554348	\N	\N
1597	ff $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )	C0008107;C3259781;C4554348	\N	\N
1597	difference ff / vi versus uc  %	C0205999;C1705241;C1705242;C4554348	\N	\N
1597	bdp / ff / g ( n = $nmbr$ )	C0004906;C0439267;C1422585;C1538710;C4554348	\N	\N
1596	sinus tracts / perforation  ' ^ n ( % )	C0544791;C0549099;C0854572;C1185740;C1881710	\N	\N
1596	patients without draining fistulae at baseline [ n = $nmbr$ ]	C0030705;C0168634;C0544791;C1442488	\N	\N
1596	patients with draining fistulae at baseline [ n = $nmbr$ ]	C0030705;C0168634;C0544791;C1442488	\N	\N
1596	number of draining fistulae per patient  n	C0030705;C0237753;C0449788;C0544791	\N	\N
1596	no draining fistulas *	C0544791	\N	\N
1596	draining fistulae  n ( % )	C0544791	\N	\N
1595	patients with fistulas at baseline	C0016169;C0030705;C0168634;C1442488	\N	\N
1595	fistula at baseline  n ( % )	C0016169;C0168634;C1442488	\N	\N
1595	fistula  ' n ( % )	C0016169	\N	\N
1594	r - tpa	C0032143	\N	\N
1594	alteplase group ( n = $nmbr$ )	C0032143;C0441848	\N	\N
1594	alteplase ( n = $nmbr$ )	C0032143	\N	\N
1594	alteplase	C0032143	\N	\N
1593	type ic	C0020750;C0332307;C1547052;C4554818	\N	\N
1593	partial evolving to secondarily generalized ( ic )	C0020750;C0205246;C0332253;C0728938;C1550516;C4554818	\N	\N
1593	early ichaem ic stroke	C0020750;C0038454;C1279919;C4554100;C4554818	\N	\N
1593	$nmbr$ to $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % )	\N	\N	\N
1592	transient ischemic attack ( % ) type of lacunar syndrome ( % )	C0007787;C0332307;C0917805;C1547052;C3178801	\N	\N
1592	transient ischemic attack	C0007787;C0917805	\N	\N
1592	transient ischaemic attack — no . ( % )	C0007787;C0917805	\N	\N
1592	transient ischaemic attack	C0007787;C0917805	\N	\N
1592	tia  n ( % )	C0007787;C0917805;C1054154	\N	\N
1592	tia	C0007787;C0917805;C1054154	\N	\N
1592	stroke / tia	C0007787;C0038454;C0917805;C1054154;C4554100	\N	\N
1592	stroke ( vs tia )	C0007787;C0038454;C0917805;C1054154;C4554100	\N	\N
1592	previous transient ischemic attack	C0007787;C0205156;C0917805;C1552607	\N	\N
1592	previous tia or stroke	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1592	previous stroke or tia ( n = $nmbr$ )	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1592	previous stroke or tia ( % )	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1592	previous stroke or tia	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1592	no previous stroke or tia ( n = $nmbr$ )	C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100	\N	\N
1592	no history of tia / stroke	C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100	\N	\N
1592	ischemic stroke ( vs . tia )	C0007787;C0917805;C0948008;C1054154	\N	\N
1592	hx stroke / tia	C0007787;C0038454;C0262926;C0917805;C1054154;C3814444;C4554100	\N	\N
1592	history of tia / stroke	C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100	\N	\N
1592	hemispheric tia n = $nmbr$	C0007787;C0205139;C0917805;C1054154	\N	\N
1591	nc group ( n = $nmbr$ )	C0027964;C0028407;C0067895;C0265987;C0441848	\N	\N
1591	nc	C0027964;C0028407;C0067895;C0265987	\N	\N
1590	uac =	\N	\N	\N
1590	bmi  kg / m $nmbr$ uac  no . ( % )	C0578022;C1532718	\N	\N
1589	uc duration  y  mean ( range )	C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2926735;C3542016	\N	\N
1589	uc ( n   =   $nmbr$ )	\N	\N	\N
1589	tjc ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1589	tjc  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1589	tjc  $nmbr$ - $nmbr$	\N	\N	\N
1589	tjc	\N	\N	\N
1589	sjc ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1589	sjc  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1589	sjc  $nmbr$ - $nmbr$	\N	\N	\N
1589	sjc	\N	\N	\N
1589	baseline tjc  mean ( s . e . )	C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
1589	baseline sjc  mean ( s . e . )	C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
1588	udy entry	C1705654	\N	\N
1588	statin use at study entry  n ( % )	C0360714;C0869040;C1705654	\N	\N
1588	remission at maintenance - trial entry — no . ( % )	C0008976;C0024501;C0544452;C0687702;C1705654	\N	\N
1588	entry hip fracture location  n ( % )	C1705654;C3260017	\N	\N
1588	controllertreatment before entry *	C1705654	\N	\N
1588	at entry	C1705654	\N	\N
1587	etn  no	C0014758;C0717758	\N	\N
1587	etanercept ( n = $nmbr$ )	C0717758	\N	\N
1587	etanercept	C0717758	\N	\N
1586	snp	C0752046;C1527094	\N	\N
1586	ntbnp ( n = $nmbr$ )	\N	\N	\N
1586	bnp / ntbnp ( n = $nmbr$ )	C0054015;C1095989;C1417808;C2982014	\N	\N
1585	— no . ( % )	\N	\N	\N
1585	thromboaspiration — no . ( % )	\N	\N	\N
1585	omega - $nmbr$ fa intake $nmbr$ nd third	C0205437;C1512806;C1719844	\N	\N
1585	no p - blocker intake at randomisation ( n = $nmbr$ )	C0034656;C0369773;C1512806;C2603361	\N	\N
1585	no . ( % )	\N	\N	\N
1585	nd	\N	\N	\N
1585	$nmbr$ nd > $nmbr$ . $nmbr$ / < $nmbr$ . $nmbr$	\N	\N	\N
1584	statins used during follow - up	C0360714;C0589120;C1273517;C1522577;C1704685;C3274571	\N	\N
1584	fracture during follow - up	C0016658;C0589120;C1522577;C1704685;C3274571	\N	\N
1584	follow - up	C0589120;C1522577;C1704685;C3274571	\N	\N
1584	end of follow - up	C0444930;C0589120;C1522577;C1704685;C2746065;C3274571	\N	\N
1584	at end of follow - up — no . / total no . ( % )	C0439175;C0439810;C0444930;C0589120;C1522577;C1704685;C2746065;C3274571	\N	\N
1584	at end of follow - up — no . ( % )	C0444930;C0589120;C1522577;C1704685;C2746065;C3274571	\N	\N
1584	at end of follow - up	C0444930;C0589120;C1522577;C1704685;C2746065;C3274571	\N	\N
1583	ufh only	C0205171;C1720467	\N	\N
1583	ufh	\N	\N	\N
1582	pump	C0182537	\N	\N
1582	proton pump inhibitors	C0358591;C1384478;C3540020	\N	\N
1582	proton pump inhibitor use	C0042153;C0358591;C0457083;C1947944;C3536754;C4521480	\N	\N
1582	proton pump inhibitor ( n  % )	C0358591;C3536754;C4521480	\N	\N
1582	proton pump inhibitor	C0358591;C3536754;C4521480	\N	\N
1582	proton - pump inhibitors	C0358591;C1384478;C3540020	\N	\N
1582	proton - pump inhibitor	C0358591;C3536754;C4521480	\N	\N
1582	on pump	C3842462	\N	\N
1582	on - pump	C3842462	\N	\N
1582	off pump	C0182537;C1518543	\N	\N
1582	off - pump	C0182537;C1518543	\N	\N
1581	unadjusted p value	C1439367;C1709380	\N	\N
1581	unadjusted p - value for interaction	C1439367;C1704675;C1709380	\N	\N
1581	unadjusted hr .	C1439367	\N	\N
1581	unadjusted hr ( $nmbr$ % ci ) for $nmbr$ standard deviation increment	C0008107;C0871420;C1439367;C1705117;C3259781	\N	\N
1581	unadjusted hr ( $nmbr$ % ci ) for $nmbr$ sd increment	C0008107;C1439367;C1705117;C2699239;C3259781	\N	\N
1581	unadjusted hr ( $nmbr$ % ci ) a	C0008107;C1439367;C3259781	\N	\N
1581	unadjusted hr	C1439367	\N	\N
1581	unadjusted	C1439367	\N	\N
1581	score ( > $nmbr$ ) at $nmbr$ monthsb unadjusted or	C0449820;C1439367;C4050231	\N	\N
1581	or ( unadjusted )	C1439367	\N	\N
1580	p value for adjusted hr	C0456081;C1709380	\N	\N
1580	black ( n = $nmbr$ )  adjusted hazard ratio *	C0005680;C0027567;C0085756;C0439541;C0456081;C2985465	\N	\N
1580	adjustedaor	\N	\N	\N
1580	adjustedahr	\N	\N	\N
1580	adjusted *   hr	C0456081	\N	\N
1580	adjusted	C0456081	\N	\N
1573	risedronate ( n   =   $nmbr$ )	C0246719	\N	\N
1573	risedronate ( n = $nmbr$ )	C0246719	\N	\N
1573	current alendronate use	C0042153;C0102118;C0457083;C0521116;C1705970;C1947944	\N	\N
1573	alendronate ( n = $nmbr$ )	C0102118	\N	\N
1573	alendronate	C0102118	\N	\N
1572	aspartate aminotransferase increased	C0004002;C0205217;C0442805	\N	\N
1572	aspartate aminotransferase  u / l	C0004002;C0439339	\N	\N
1572	alanine aminotransferase or aspartate aminotransferase > $nmbr$ x upper limit of normal ( n = $nmbr$ )	C0001899;C0004002;C0057041;C1415274;C1519815;C3887708	\N	\N
1572	alanine aminotransferase increased	C0001899;C0057041;C0205217;C0442805;C1415274;C3887708	\N	\N
1572	alanine aminotransferase  u / l	C0001899;C0057041;C0439339;C1415274;C3887708	\N	\N
1579	use of antihypertensive drugs	C0003364;C1524063	\N	\N
1579	types of antihypertensive medications at $nmbr$ year   †	C0003364;C0332307;C0439234;C0439508	\N	\N
1579	type of antihypertensive medication use among patients using antihypertensive medications  n ( % )	C0003364;C0030705;C0332307;C1524063;C1547052	\N	\N
1579	taking antihypertensive medication at baseline  no . ( % ) e	C0003364;C0168634;C1442488;C1515187	\N	\N
1579	prior antihypertensive medication  n ( % )	C0003364;C0332152;C2826257	\N	\N
1579	previous antihypertensive treatment — no . ( % )	C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
1579	previous antihypertensive treatment	C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
1579	patients on antihypertensive medications  n ( % ) | |	C0003364;C0030705	\N	\N
1579	other blood pressure - lowering drugs	C0003364	\N	\N
1579	other blood - pressure drug	C0003364	\N	\N
1579	other antihypertensive medications	C0003364	\N	\N
1579	other antihypertensive drug	C0003364	\N	\N
1579	other antihypertensive agents	C0003364	\N	\N
1579	other antihypertensive	C0003364	\N	\N
1579	other anti - hypertensives	C0003364	\N	\N
1579	other anti - hypertensive	C0003364	\N	\N
1579	or taking antihypertensive medication	C0003364;C1290952	\N	\N
1579	one antihypertensive medication	C0003364;C0205447	\N	\N
1579	on antihypertensive treatment  n ( % )	C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1579	on antihypertensive medication at baseline  n ( % ) ‡	C0003364;C0168634;C1442488	\N	\N
1579	number of antihypertensive medications at study entry	C0003364;C0557651;C1705654;C1718138;C2603343	\N	\N
1579	number of antihypertensive medications  n ( % )	C0003364;C1718138	\N	\N
1579	medications antihypertensive drugs	C0003364;C0013227;C0802604;C2598133;C4284232	\N	\N
1579	mean number of antihypertensive medications at $nmbr$ year   *	C0003364;C0439234;C0439508;C0444504;C1718138;C2347634;C2348143	\N	\N
1579	hypertension ( bp > $nmbr$ / $nmbr$ mmhg or using antihypertensive medication )	C0003364;C0020538;C0037623;C0439475;C1415692;C1524063;C1708288;C1963138;C4318478	\N	\N
1579	baseline anti - hypertensive usea	C0003364;C0168634;C1442488	\N	\N
1579	any antihypertensive drug	C0003364	\N	\N
1579	any antihypertensive agent	C0003364	\N	\N
1579	any anti - hypertensive agent	C0003364	\N	\N
1579	antihypertensives ' *	C0003364	\N	\N
1579	antihypertensives  n ( % )	C0003364	\N	\N
1579	antihypertensives	C0003364	\N	\N
1579	antihypertensive use	C0003364;C0042153;C0457083;C1947944	\N	\N
1579	antihypertensive treatments	C0003364;C0087111	\N	\N
1579	antihypertensive treatment  n ( % )	C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1579	antihypertensive treatment	C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1579	antihypertensive medication use  n ( % )	C0003364;C0042153;C0457083;C1947944	\N	\N
1579	antihypertensive medication or	C0003364	\N	\N
1579	antihypertensive medication )	C0003364	\N	\N
1579	antihypertensive medication $nmbr$ '	C0003364	\N	\N
1579	antihypertensive medication	C0003364	\N	\N
1579	antihypertensive drugs	C0003364	\N	\N
1579	antihypertensive drug  %	C0003364	\N	\N
1579	antihypertensive agents *	C0003364	\N	\N
1579	antihypertensive agents ( n per patient )	C0003364;C0030705	\N	\N
1579	antihypertensive agents  n ( % )	C0003364	\N	\N
1579	antihypertensive agents	C0003364	\N	\N
1579	antihypertensive agent use	C0003364;C0042153;C0457083;C1947944	\N	\N
1579	antihypertensive	C0003364	\N	\N
1579	anti - hypertensives	C0003364	\N	\N
1579	anti - hypertensive	C0003364	\N	\N
1579	> $nmbr$ antihypertensive medications	C0003364	\N	\N
1579	$nmbr$ antihypertensive medication	C0003364	\N	\N
1578	death or absolute fvc decrease > $nmbr$ %	C0011065;C0205344;C0392756;C0547047;C1306577;C3714541;C4082313;C4552775	\N	\N
1578	absolute fvc decrease > $nmbr$ %	C0205344;C0392756;C0547047;C3714541	\N	\N
1578	absolute decrease > $nmbr$ %	C0205344;C0392756;C0547047	\N	\N
1578	absolute change	C1549031	\N	\N
1578	absolute ( l )	C0205344	\N	\N
1578	absolute  litres	C0205344;C0475211	\N	\N
1577	hospitalization for acute limb ischemia	C0019993;C0205178;C2945695	\N	\N
1577	acute reaction	C0205178;C0443286	\N	\N
1577	acute and delayed reaction	C0205178;C0205421;C0443286;C1545665;C3272602	\N	\N
1577	acute ( < $nmbr$ hr )	C0205178	\N	\N
1576	prosper	\N	\N	\N
1576	hormone - refractory prostate carcinoma	C1328504	\N	\N
1575	prostate volume ( ml )	C0439526;C1441416;C1705224;C3887665	\N	\N
1575	prostate volume ( cm $nmbr$ )	C1441416	\N	\N
1574	valproate	C0080356	\N	\N
1574	inappropriate	C1548788;C3537135;C3542467	\N	\N
1573	time since prior alendronate use  n ( % )	C0040223;C0042153;C0102118;C0332152;C0457083;C1947944;C2826257;C3541383	\N	\N
1573	still taking alendronate at study entry  n ( % )	C0102118;C0557651;C1515187;C1705654;C2603343	\N	\N
1573	risedronate n / n ( % )	C0246719	\N	\N
1571	subgoup_name	C0027365;C1547383;C4522128	\N	\N
1571	characteristic_name	C0027365;C1521970;C1547383;C4522128	\N	\N
1570	physical and cognitive examination : ! :	C0031809;C0205485;C1509143;C1516691;C4321457	\N	\N
1570	impaired cognitive	C0338656	\N	\N
1570	cognitive functioning	C0392334;C0392335	\N	\N
1570	cognitive	C1516691	\N	\N
1569	unstable angina ( biomarker negative )	C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545	\N	\N
1569	troponin negative ( n = $nmbr$ )	C0041199;C0205160;C1513916;C2825415;C2825491;C3853545	\N	\N
1569	rf and acpa negative $nmbr$	C0035448;C0201660;C0205160;C0748398;C1513916;C1525410;C1547111;C1706063;C2825415;C2825491;C3853545	\N	\N
1569	rf and acpa negative  n ( % )	C0035448;C0201660;C0205160;C0748398;C1513916;C1525410;C1547111;C1706063;C2825415;C2825491;C3853545	\N	\N
1569	patients with negative anti - dsdna	C0030705;C0205160;C0741099;C1513916;C2825415;C2825491;C3853545	\N	\N
1569	negative ctnl ( n = $nmbr$  $nmbr$ )	C0205160;C1513916;C2825415;C2825491;C3853545	\N	\N
1569	negative ( < $nmbr$ . $nmbr$ )  n ( % )	C0205160;C1513916;C2825415;C2825491;C3853545	\N	\N
1569	negative	C0205160;C1513916;C2825415;C2825491;C3853545	\N	\N
1569	anti - gad negative ( n = $nmbr$ )	C0205160;C0270549;C0432633;C1414925;C1513916;C2825415;C2825491;C3853545	\N	\N
1569	anti - gad negative	C0205160;C0270549;C1414925;C1513916;C2825415;C2825491;C3853545	\N	\N
1568	ularitide n / n ( % )	C0077910	\N	\N
1568	ularitide ( n = $nmbr$ )	C0077910	\N	\N
1568	dulaglutide $nmbr$ . $nmbr$ mgf	C1366394;C3179549;C3712803;C3887684	\N	\N
1567	sustain $nmbr$ : semaglutide vs . sitagliptin $nmbr$ mg	C0024671;C0026410;C0439269;C0443318;C1565750;C1960952;C2346927;C2732140;C3885068;C4321396;C4521761	\N	\N
1567	semaglutide exposure  nmol / l	C0274281;C0332157;C0439282;C3885068	\N	\N
1567	semaglutide ( n = $nmbr$ )	C3885068	\N	\N
1567	semaglutide $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C3885068;C4321396;C4521761	\N	\N
1567	semaglutide	C3885068	\N	\N
1566	n ( % ) liraglutide $nmbr$ placebo	C0032042;C0369718;C0441922;C1456408;C1696465;C1706408	\N	\N
1566	liraglutide n ( % )	C1456408	\N	\N
1566	liraglutide ( « = $nmbr$ )	C1456408	\N	\N
1566	liraglutide ( n = $nmbr$ )	C1456408	\N	\N
1566	liraglutide ( n = $nmbr$  $nmbr$ )	C1456408	\N	\N
1566	liraglutide ( $nmbr$ . $nmbr$ mg ) ± oad	C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg mean ( n )	C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg ls means ( n )	C0023668;C0024671;C0026410;C0439269;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg / day ( n = $nmbr$ )	C0439422;C1456408	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$  $nmbr$	C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$	C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ - $nmbr$ mg mean ( n )	C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761	\N	\N
1566	liraglutide $nmbr$ - $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761	\N	\N
1566	liraglutide	C1456408	\N	\N
1565	progestins	C0033306	\N	\N
1565	country : argentina ( n = $nmbr$ )	C0003761;C0454664;C1504311;C1511538	\N	\N
1565	argentina	C0003761;C1504311	\N	\N
1564	congestion *	C0700148;C2826600	\N	\N
1563	univariate logistic modela	C0242415	\N	\N
1563	multivariate logistic modelb	C0242415	\N	\N
1563	logistic regression	C0206031	\N	\N
1563	bmultivariate logistic regression with variables forced in the modela	C0206031;C0439828;C0441722;C0443221	\N	\N
1563	aunivariate logistic regression .	C0206031	\N	\N
1562	premature treatment discontinuation	C0039798;C0087111;C0151526;C0205252;C0457454;C1444662;C1522326;C1533734;C1705169;C3538994;C3887704;C4018905;C4552847	\N	\N
1562	premature discontinuation	C0151526;C0205252;C0457454;C1444662;C4018905;C4552847	\N	\N
1562	discontinued	C1444662	\N	\N
1562	discontinuations teaes	C0457454	\N	\N
1562	discontinuations	C0457454	\N	\N
1562	discontinuation of lama prior to baseline  n ( % )	C0168634;C0457454;C0999593;C1416775;C1442488;C1444662;C4552847	\N	\N
1561	data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p	C0237753;C0439828;C0444504;C0449788;C0549178;C0683312;C0871420;C1442989;C1511726;C1828170;C2347634;C2348143;C2828392;C3245479;C3714741;C3889287	\N	\N
1561	continuous	C0549178	\N	\N
1561	continued thienopyridine n = $nmbr$ subjects	C0549178;C0681850;C1120149;C1550501;C1706203;C2349001;C2697811	\N	\N
1561	continued thienopyridine n ( % )	C0549178;C1120149	\N	\N
1561	continued thienopyridine ( n = $nmbr$ )	C0549178;C1120149	\N	\N
1561	continued thienopyridine ( n $nmbr$ $nmbr$ )	C0549178;C1120149	\N	\N
1561	continued thienopyridine %	C0549178;C1120149	\N	\N
1561	continue thienopyridine n = $nmbr$	C0549178;C1120149	\N	\N
1561	$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ) ( continued )	C0549178	\N	\N
1561	$nmbr$ ( $nmbr$ . $nmbr$ ) ( continued )	C0549178	\N	\N
1560	other †	\N	\N	\N
1560	other countries	C0454664	\N	\N
1560	country  n ( % )	C0454664;C1511538	\N	\N
1560	country	C0454664;C1511538	\N	\N
1560	black region or country ( % )	C0005680;C0017446;C0027567;C0085756;C0205147;C0439541;C0454664;C1511538	\N	\N
1559	southern hemisphere	C0205139;C1710133	\N	\N
1566	pramlintide	C0537551	f	2289
1559	south or central american	C0238914;C1710133	\N	\N
1559	south or central america	C0007674;C1710133	\N	\N
1559	south  n ( % )	C1710133	\N	\N
1559	central / south	C0205099;C1710133;C1879652	\N	\N
1558	sacral and / or lumbar	C0024090;C0036037	\N	\N
1558	lumbar epidural	C0581283	\N	\N
1558	lumbar	C0024090	\N	\N
1558	general and lumbar epidural	C0205246;C0581283;C3812897;C3891294;C4521767	\N	\N
1557	number of co - aeds  n ( % )	C0180309;C0237753;C0449788;C3245499	\N	\N
1557	colombia	C3245499	\N	\N
1556	numbera	\N	\N	\N
1556	number ste  t > $nmbr$	C0237753;C0449788;C1420459;C3811127	\N	\N
1556	number resulting in hospital admission	C0184666;C0237753;C0449788;C0678226	\N	\N
1556	number resulting in emergency department visit	C0237753;C0332294;C0449788;C0545082;C0553618;C0562508;C1512346;C1704729;C2826704	\N	\N
1556	number resulting in ed visit	C0237753;C0332294;C0449788;C0545082;C1512346;C2826704;C3538926	\N	\N
1556	number of vessels disease	C0042373;C0237753;C0449788	\N	\N
1556	number of prior csdmards  n ( % )	C0237753;C0332152;C0449788;C2826257	\N	\N
1556	number of prior aeds    n   ( % )	C0180309;C0237753;C0332152;C0449788;C2826257	\N	\N
1556	number of prior aeds  n ( % ) b	C0180309;C0237753;C0332152;C0449788;C2826257	\N	\N
1556	number of prior aeds  n ( % )	C0180309;C0237753;C0332152;C0449788;C2826257	\N	\N
1556	number of prior aeds	C0180309;C0237753;C0332152;C0449788;C2826257	\N	\N
1556	number of previous reported aeds	C0180309;C0205156;C0237753;C0449788;C0684224;C0700287;C1552607;C4319718	\N	\N
1556	number of previous dmards	C0205156;C0237753;C0242708;C0449788;C1552607	\N	\N
1556	number of previous anti - tnf treatments for psa  n ( % )	C0087111;C0205156;C0237753;C0449788;C1448177;C1552607;C3810537;C3813209	\N	\N
1556	number of people ( n )	C0027361;C0237753;C0449788	\N	\N
1556	number of participants with an event	C0237753;C0441471;C0449788;C0679646;C4019010	\N	\N
1556	number of participants	C0237753;C0449788;C0679646	\N	\N
1556	number of exacerbations in the $nmbr$ months before screening	C0220908;C0220909;C0237753;C0439231;C0449788;C1698960;C1710031;C1710032;C1710477;C2348164;C4086268	\N	\N
1556	number of e	C0237753;C0449788	\N	\N
1556	number of copd exacerbations within $nmbr$ months  mean ( sd )	C0237753;C0439231;C0444504;C0449788;C0740304;C2347634;C2348143;C2699239	\N	\N
1556	number of concomitant csdmards  n ( % )	C0237753;C0449788;C0521115	\N	\N
1556	number of concomitant aedsc	C0237753;C0449788;C0521115	\N	\N
1556	number of antihypertensive agent reported	C0003364;C0237753;C0449788;C0684224;C0700287;C4319718	\N	\N
1556	number of antidiabetes drugs at screening  n ( % )	C0013227;C0220908;C0220909;C0237753;C0449788;C1698960;C1710031;C1710032;C1710477;C2348164;C3687832	\N	\N
1556	number insulin glargine	C0237753;C0449788;C0907402	\N	\N
1556	number ( % ) reporting migraine on $nmbr$ - month questionnaire	C0034394;C0149931;C0237753;C0332177;C0439231;C0449788;C0700287	\N	\N
1556	number ( % )	C0237753;C0449788	\N	\N
1556	number	C0237753;C0449788	\N	\N
1556	missing — number / n ( % )	C0237753;C0449788;C1551393;C1705492;C3272743	\N	\N
1556	female sex — number ( % )	C0086287;C0237753;C0449788	\N	\N
1556	> q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )	C0237753;C0449788	\N	\N
1556	> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )	C0237753;C0449788	\N	\N
1556	> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ ) — number / n ( % )	C0237753;C0449788	\N	\N
1556	> q $nmbr$ ( $nmbr$ ) — number / n ( % )	C0237753;C0449788	\N	\N
1556	> q $nmbr$ ( $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )	C0237753;C0449788	\N	\N
1556	> $nmbr$ months — number / n ( % )	C0237753;C0439231;C0449788	\N	\N
1556	< q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % )	C0237753;C0449788	\N	\N
1556	< q $nmbr$ ( $nmbr$ ) — number / n ( % )	C0237753;C0449788	\N	\N
1556	< $nmbr$ months — number / n ( % )	C0237753;C0439231;C0449788	\N	\N
1555	limb amputation	C0002689	\N	\N
1555	limb ( sd )	C0015385;C2699239	\N	\N
1555	limb	C0015385	\N	\N
1554	upper limbs	C1140618	\N	\N
1554	upper limb fractures	C0016658;C1140618	\N	\N
1554	upper limb fracture	C0178316	\N	\N
1554	upper limb	C1140618	\N	\N
1553	≥ $nmbr$ a ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	us n = $nmbr$	C0369718;C0441922	\N	\N
1553	us ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	type b $nmbr$ / c lesions  n ( % )	C0221198;C0369718;C0441922;C1546698;C4264484	\N	\N
1553	total phase $nmbr$ pooled ( n = $nmbr$ )	C0205390;C0369718;C0439175;C0439810;C0441922;C1709595;C1710475;C2349200;C4522255	\N	\N
1553	tophi present  n ( % )	C0150312;C0221248;C0369718;C0441922;C0449450	\N	\N
1553	patients analyzed  n	C0030705;C0369718;C0441922;C0936012	\N	\N
1553	non - us ( n = $nmbr$ )	C0369718;C0441922;C1518422	\N	\N
1553	neither n = $nmbr$  $nmbr$	C0369718;C0441922	\N	\N
1553	n_	C0369718;C0441922	\N	\N
1553	n t % )	C0369718;C0441922	\N	\N
1553	n observed	C0369718;C0441922;C1441672	\N	\N
1553	n o	C0369718;C0441922	\N	\N
1553	n events / n at risk	C0369718;C0441471;C0441922;C1444641;C3541888	\N	\N
1553	n analysed	C0369718;C0441922	\N	\N
1553	n = $nmbr$ t	C0369718;C0441922	\N	\N
1553	n = $nmbr$ lesions	C0221198;C0369718;C0441922;C1546698	\N	\N
1553	n = $nmbr$	C0369718;C0441922	\N	\N
1553	n =	C0369718;C0441922	\N	\N
1553	n / r	C0205090;C0369718;C0441922;C0684010;C2603358	\N	\N
1553	n / n   ( % )	C0369718;C0441922	\N	\N
1553	n / n ( % )	C0369718;C0441922	\N	\N
1553	n / n $nmbr$ / $nmbr$	C0369718;C0441922	\N	\N
1553	n / n	C0369718;C0441922	\N	\N
1553	n .	C0369718;C0441922	\N	\N
1553	n - $nmbr$ pufa events / patients ( % )	C0030705;C0032615;C0369718;C0441471;C0441922;C3541888	\N	\N
1553	n - $nmbr$ pufa ( n = $nmbr$ )	C0032615;C0369718;C0441922	\N	\N
1553	n - $nmbr$ pufa	C0032615;C0369718;C0441922	\N	\N
1553	n - $nmbr$ fatty acit	C0369718;C0441922	\N	\N
1553	n - $nmbr$ fatty acids slope lsm ± se ( mm / year )	C0015684;C0036919;C0369718;C0439234;C0439508;C0441922;C0807955;C4330985;C4554674	\N	\N
1323	women - no . ( % )	C0043210	\N	\N
1553	n - $nmbr$ fatty acids - placebo lsm ( $nmbr$ % cl )	C0015684;C0032042;C0369718;C0441922;C0596019;C1696465;C1706408	\N	\N
1553	n - $nmbr$ fatty acids ( n = $nmbr$ )	C0015684;C0369718;C0441922	\N	\N
1553	n - $nmbr$ fatty acids	C0015684;C0369718;C0441922	\N	\N
1553	n - $nmbr$ - pufa ( n = $nmbr$ )	C0032615;C0369718;C0441922	\N	\N
1553	n + v ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	n *	C0369718;C0441922	\N	\N
1553	n ( lesions )	C0221198;C0369718;C0441922;C1546698	\N	\N
1553	n ( iqr )	C0369718;C0441922	\N	\N
1553	n ( % ) unless otherwise specified	C0205369;C0369718;C0441922	\N	\N
1553	n ( % )	C0369718;C0441922	\N	\N
1553	n %	C0369718;C0441922	\N	\N
1553	n $nmbr$ yrs	C0369718;C0441922	\N	\N
1553	n $nmbr$ / n $nmbr$	C0369718;C0441922	\N	\N
1553	n $nmbr$	C0369718;C0441922	\N	\N
1553	n	C0369718;C0441922	\N	\N
1553	ll  n ( % )	C0369718;C0441922	\N	\N
1553	igehigh ( > i $nmbr$ ku / l  n = i  $nmbr$ )	C0021966;C0221138;C0369718;C0439340;C0441922	\N	\N
1553	duration of as  n ( % )	C0369718;C0441922;C0449238;C2926735	\N	\N
1553	diabetics • no ( n = $nmbr$  $nmbr$ )	C0241863;C0369718;C0441922	\N	\N
1553	diabetics - no ( n = $nmbr$  $nmbr$ )	C0241863;C0369718;C0441922	\N	\N
1553	clinical and patient reported outcomes  % ( observed n ) unless otherwise indicated	C0205210;C0369718;C0441922;C1441672;C1444656;C2987124	\N	\N
1553	a $nmbr$ n = $nmbr$	C0369718;C0441922	\N	\N
1553	a $nmbr$ / $nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	a $nmbr$ + ezio a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	> $nmbr$ . $nmbr$ ( n — $nmbr$ )	C0369718;C0441922	\N	\N
1553	> $nmbr$ . $nmbr$  n ( % )	C0369718;C0441922	\N	\N
1553	> $nmbr$ ( n — $nmbr$ )	C0369718;C0441922	\N	\N
1553	> $nmbr$ ( n = $nmbr$ l $nmbr$ )	C0369718;C0441922	\N	\N
1553	> $nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	> $nmbr$ % ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	> $nmbr$ %  n ( % )	C0369718;C0441922	\N	\N
1553	> $nmbr$  n ( % )	C0369718;C0441922	\N	\N
1553	< $nmbr$ . $nmbr$ ( n — $nmbr$ )	C0369718;C0441922	\N	\N
1553	< $nmbr$ ( n — $nmbr$ )	C0369718;C0441922	\N	\N
1553	< $nmbr$ ( n z $nmbr$ )	C0369718;C0441922	\N	\N
1553	< $nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	< $nmbr$ % ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	< $nmbr$ %  n ( % )	C0369718;C0441922	\N	\N
1553	< $nmbr$  n ( % )	C0369718;C0441922	\N	\N
1553	( n = l $nmbr$ )	C0369718;C0441922	\N	\N
1553	( n = $nmbr$ l $nmbr$ )	C0369718;C0441922	\N	\N
1553	( n = $nmbr$ ) ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	( n = $nmbr$ )  ' ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	( n = $nmbr$	C0369718;C0441922	\N	\N
1553	( n $nmbr$ $nmbr$ )	C0369718;C0441922	\N	\N
1553	$nmbr$ n qi	C0369718;C0376586;C0441922	\N	\N
1553	$nmbr$ n / n	C0369718;C0441922	\N	\N
1553	$nmbr$ - $nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	$nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )	C0369718;C0441922	\N	\N
1553	$nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	$nmbr$ ( n = $nmbr$  $nmbr$ )	C0369718;C0441922	\N	\N
1553	$nmbr$ ( n $nmbr$ $nmbr$ )	C0369718;C0441922	\N	\N
1553	$ $nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1553	$ $nmbr$ %  n ( % )	C0369718;C0441922	\N	\N
1552	uas $nmbr$	\N	\N	\N
1552	uae ( p  g / min )	C0560021;C1519789	\N	\N
1552	in - clinic uask	C0002424;C0150312;C0332285;C0442592;C1707101	\N	\N
1552	in - clinic uas $nmbr$	C0002424;C0150312;C0332285;C0442592;C1707101	\N	\N
1551	spinal	C0521329	\N	\N
1551	mean lumbar spine t score	C0024091;C3533236;C3887615	\N	\N
1551	lumbar spine bmd t - score	C0024091;C0449820;C3887615;C4050231	\N	\N
1551	lumbar spine bmd t -	C0024091;C3887615	\N	\N
1551	lumbar spine	C0024091;C3887615	\N	\N
7	p values	C1709380	\N	\N
1551	flex baseline bmd t - score at lumbar spine ( meanisd )	C0024091;C0168634;C0449820;C1442488;C3887615;C4050231	\N	\N
1550	usa and canada	C0006823;C0041703	\N	\N
1550	usa / canada	C0006823;C0041703	\N	\N
1550	usa ( n = $nmbr$ )	C0041703	\N	\N
1550	usa ( n = $nmbr$  $nmbr$ )	C0041703	\N	\N
1550	usa	C0041703	\N	\N
1550	united states or canada	C0006823;C0041703	\N	\N
1550	united states and canada	C0006823;C0041703	\N	\N
1550	united states ( n   = $nmbr$  $nmbr$ )	C0041703	\N	\N
1550	united states	C0041703	\N	\N
1550	umied	\N	\N	\N
1550	region united states	C0017446;C0041703;C0205147	\N	\N
1550	non usa	C0041703;C1518422	\N	\N
1549	necrosis  n ( % ) a	C0027540;C1334928	\N	\N
1549	cross - clamp	C0175721;C1883710;C2828360;C3810601	\N	\N
1548	necrotic core  mm ^	C0027540;C0444669;C1167518;C1706352;C1882467;C3274653;C4330985;C4554674	\N	\N
1548	necrotic core	C0027540;C0444669;C1167518;C1706352;C1882467;C3274653	\N	\N
1548	core laboratory percent stenosis	C0022877;C0439165;C0444669;C0678234;C1167518;C1261287;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904	\N	\N
1548	% stenosis  as assessed by core laboratory	C0022877;C0444669;C0678234;C1167518;C1261287;C1516048;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904	\N	\N
1547	ultrasound carotid arteries	C0948945	\N	\N
1547	carotid revascularization	C0581603;C0741968	\N	\N
1547	carotid infarct	C0021308;C0741968	\N	\N
1547	carotid artery — no . ( % )	C0007272;C0162859	\N	\N
1547	carotid artery diseaset	C0007272;C0162859	\N	\N
1547	carotid	C0741968	\N	\N
1547	> $nmbr$ % stenosis of coronary  carotid  or lower extremity arteries	C0007282;C0018787;C0226415;C0242231;C0741968	\N	\N
1546	severitya	\N	\N	\N
1546	severity of copda  combined assessment of copd  n ( % )	C0024117;C0205195;C0439793;C0522510;C1261322;C1412502;C1516048;C3714496	\N	\N
1546	severity of copd — no . ( % ) f	C0016327;C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	severity of copd *  n ( % )	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1517	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$	\N	\N	\N
1546	severity of copd  n ( % ) *	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	severity of copd  combined assessment  n ( % )	C0024117;C0205195;C0439793;C0522510;C1261322;C1412502;C1516048;C3714496	\N	\N
1546	severity of copd  ( gold $nmbr$ )  %	C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496	\N	\N
1546	severity of copd	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	nice classification of copd severity of obstruction  n ( % ) [ $nmbr$ ]	C0008902;C0008903;C0024117;C0028778;C0439793;C0522510;C0678229;C1412502;C1882136;C3714496;C4087029	\N	\N
1546	copd severityy	C0024117;C1412502;C3714496	\N	\N
1546	copd severitya    n   ( % )	C0024117;C1412502;C3714496	\N	\N
1546	copd severity : severe / very severe	C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496	\N	\N
1546	copd severity : mild / moderate	C0024117;C0439793;C0522510;C1299392;C1412502;C3714496	\N	\N
1546	copd severity ( gold $nmbr$ )	C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496	\N	\N
1546	copd severity  n ( % ) a	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	copd severity  n ( % ) *	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	copd severity  n ( % )	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	copd severity  %	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	copd severity	C0024117;C0439793;C0522510;C1412502;C3714496	\N	\N
1546	copd disease severity	C0024117;C0521117;C1412502;C3714496	\N	\N
1545	patients with baseline crp concentration £ $nmbr$ mg / l	C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285	\N	\N
1545	patients with baseline crp concentration < $nmbr$ mg / l	C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285	\N	\N
1545	hs - crp mg / l	C0439268;C3890735;C4048285	\N	\N
1545	hs - crp j $nmbr$ . $nmbr$ mg / l	C0439268;C3890735;C4048285	\N	\N
1545	hs - crp _ = $nmbr$ . $nmbr$ mg / l	C0439268;C3890735;C4048285	\N	\N
1545	hs - crp > $nmbr$ . $nmbr$ mg / l	C0439268;C3890735;C4048285	\N	\N
1545	hs - crp < $nmbr$ . $nmbr$ nlg l	C3890735;C4048285	\N	\N
1545	hs - crp < $nmbr$ . $nmbr$ mg / l	C0439268;C3890735;C4048285	\N	\N
1545	hs - crp < $nmbr$ . $nmbr$ g / l	C0439294;C0456615;C3890735;C4048285	\N	\N
1545	hs - crp ( mg / l )	C0439268;C3890735;C4048285	\N	\N
1545	hs - crp ( mg / l  median )	C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285	\N	\N
1545	hs - crp ( median  iqr )  mg / l	C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285	\N	\N
1545	hs - crp  mg / l	C0439268;C3890735;C4048285	\N	\N
1545	hs - crp	C3890735;C4048285	\N	\N
1545	crp   ≤   uln	C1519815;C3890735;C4048285	\N	\N
1545	crp   >   uln	C1519815;C3890735;C4048285	\N	\N
1545	crp concentration > $nmbr$ mg / l  n ( % ) \\	C0086045;C0439268;C1446561;C3827302;C3890735;C4048285	\N	\N
1545	crp ( mg / l ) ( cv )	C0439268;C3538987;C3890735;C4048285;C4048877;C4318503	\N	\N
1545	crp ( mg / l )	C0439268;C3890735;C4048285	\N	\N
1545	crp	C3890735;C4048285	\N	\N
1545	crj	\N	\N	\N
1545	baseline hs - crp tertiles ( mg / i ]	C0021966;C0024671;C0026410;C0168634;C0221138;C0439269;C1442488;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761	\N	\N
1545	baseline high - sensitivity crp	C0168634;C1441604;C1442488;C3890735;C4048285	\N	\N
1545	baseline crp < $nmbr$ mg / l	C0168634;C0439268;C1442488;C3890735;C4048285	\N	\N
1545	baseline crp	C0168634;C1442488;C3890735;C4048285	\N	\N
1545	baseline asdas - crp	C0168634;C1442488;C3890735;C4048285	\N	\N
1545	asdas - crp   <   $nmbr$ . $nmbr$	C3890735;C4048285	\N	\N
1545	asdas - crp δ   ≥   $nmbr$ . $nmbr$	C3890735;C4048285	\N	\N
1545	asdas - crp *	C3890735;C4048285	\N	\N
1545	> $nmbr$ mg / dl baseline high - sensitivity crp	C0168634;C0439269;C1441604;C1442488;C3890735;C4048285	\N	\N
1544	ticagrelor $nmbr$ mg vs . placebo hr ( $nmbr$ % ci )	C0008107;C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C1999375;C2346927;C3259781;C4321396;C4521761	\N	\N
1544	rr ^ ( $nmbr$ % ci )	C0008107;C3259781;C4554402	\N	\N
1544	rr ( $nmbr$ % ci ) c	C0008107;C3259781;C4554402	\N	\N
1544	rr ( $nmbr$ % ci ) *	C0008107;C3259781;C4554402	\N	\N
1544	rr ( $nmbr$ % ci )	C0008107;C3259781;C4554402	\N	\N
1544	rr $nmbr$ - $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$  $nmbr$ ) ’	\N	\N	\N
1544	rr	\N	\N	\N
1544	hr ‡	\N	\N	\N
1544	hr vs placebo ( $nmbr$ % ci )	C0008107;C0032042;C1696465;C1706408;C3259781	\N	\N
1544	hr and $nmbr$ % ci *	C0008107;C3259781	\N	\N
1544	hr * or rr † ( $nmbr$ % ci )	C0008107;C3259781;C4554402	\N	\N
1544	hr ( $nmbr$ % ci ) “	C0008107;C3259781	\N	\N
1544	hr ( $nmbr$ % ci ) *	C0008107;C3259781	\N	\N
1544	hr ( $nmbr$ % ci )  univariate cox proportional - hazard regression	C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781	\N	\N
1544	hr ( $nmbr$ % ci )  multivariate cox proportional - hazard regression	C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781	\N	\N
1544	hr ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
1544	hr $nmbr$ % ci	C0008107;C3259781	\N	\N
1544	esrd only rr ( ci ) “	C0008107;C0022661;C0035078;C0205171;C1720467;C2316810;C3259781;C4554402	\N	\N
1544	doubling of baseline serum creatinine or esrd rr ( ci ) “	C0008107;C0022661;C0035078;C0168634;C0201976;C0205173;C0600061;C1442488;C1705764;C2316810;C3259781;C4554402	\N	\N
1544	cox hr ( $nmbr$ % ci )	C0008107;C1565830;C3259781	\N	\N
1544	cmh rr ( $nmbr$ % ci )	C0008107;C3259781;C4554402	\N	\N
1543	patients with only mrf hr ( $nmbr$ % cl )	C0030705;C0205171;C0312443;C0596019;C1412879;C1720467	\N	\N
1543	mrf	C0312443;C1412879	\N	\N
1542	western europe hr ( $nmbr$ % cl )	C0043129;C0596019	\N	\N
1542	rrr ( $nmbr$ % cl )	C0596019	\N	\N
1542	rrr	\N	\N	\N
1542	rr reduction  $nmbr$ / $nmbr$ ( $nmbr$ / $nmbr$ cl )	C0301630;C0392756;C0596019;C1293152;C4551656;C4554402	\N	\N
1542	rr ( cl )	C0596019;C4554402	\N	\N
1542	rr ( $nmbr$ % cl ) p value	C0596019;C1709380;C4554402	\N	\N
1542	rr ( $nmbr$ % cl ) [ / ’ value ]	C0596019;C1522609;C4554402	\N	\N
1542	rr ( $nmbr$ % cl )	C0596019;C4554402	\N	\N
1542	patients with prior ml hr ( $nmbr$ % cl )	C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3887665	\N	\N
1516	symptomatic pe	C0070939;C0231220;C1880476;C4284304	\N	\N
1542	patients with ascvd but no prior ml hr ( $nmbr$ % cl )	C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3665365;C3887665	\N	\N
1542	hr vs control ( $nmbr$ % cl ) *	C0243148;C0596019;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
1542	hr ( enl vs lcz ) ( $nmbr$ % cl )	C0596019	\N	\N
1542	hr ( $nmbr$ s % a )	\N	\N	\N
1542	hr ( $nmbr$ % cl ) *	C0596019	\N	\N
1542	hr ( $nmbr$ % c ! )	\N	\N	\N
1542	hr  ( $nmbr$ % cl )	C0596019	\N	\N
1541	soe or sue	\N	\N	\N
1541	or : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )  p = $nmbr$ . $nmbr$	C0369773;C2603361	\N	\N
1541	intravenous inotropes or vasopressors ( % )	C0042397;C0348016;C1258199	\N	\N
1541	barc types $nmbr$  $nmbr$  or $nmbr$	C0332307	\N	\N
1541	barc $nmbr$ - $nmbr$	\N	\N	\N
1540	laba or lamab n = $nmbr$	\N	\N	\N
1540	conieosieroids and / or $nmbr$ - mp	C0024944	\N	\N
1540	$nmbr$ or $nmbr$  n ( % )	C0369718;C0441922	\N	\N
1539	three or more drugs	C0013227;C0205172;C0205449;C3687832	\N	\N
1539	one or more medications	C0013227;C0205172;C0205447;C0802604;C2598133;C4284232	\N	\N
1539	one or more exacerbations	C0205172;C0205447;C4086268	\N	\N
1539	one or more blood pressure medications  n ( % )	C0005823;C0013227;C0033095;C0205172;C0205447;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232	\N	\N
1539	no new a or and no more than $nmbr$ new bilag b domain score  %	C0205172;C0205314;C0449820;C1880389;C1883221;C3541951;C4050231	\N	\N
1539	college graduate or more	C0205172;C0682187	\N	\N
1539	$nmbr$ yrs or more	C0205172	\N	\N
1539	$nmbr$ years or more	C0205172;C0439234	\N	\N
1539	$nmbr$ or more	C0205172	\N	\N
1539	$nmbr$ . $nmbr$ or more	C0205172	\N	\N
1539	$nmbr$ . $nmbr$ % or more	C0205172	\N	\N
1538	using hrt or raloxifene at baseline ( % )	C0168634;C0244404;C0282402;C1442488;C1524063	\N	\N
1538	or raloxifene	C0244404	\N	\N
1538	benzodiazepine or bzra ‡	C0005064;C3536850;C4048284	\N	\N
1537	ors ( $nmbr$ % cis ) :	C0069590;C1504308;C1742862;C1963718	\N	\N
1537	$nmbr$ or $nmbr$	\N	\N	\N
1537	$nmbr$ ( or $nmbr$  if female only )	C0043210;C0086287;C0205171;C1705497;C1705498;C1720467	\N	\N
1536	erectile dysfunction	C0242350;C1961100	\N	\N
1535	severe dysfunction	C3274777	\N	\N
1535	moderate dysfunction ( crcl $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] )	C0439445;C1846718;C3274776	\N	\N
1535	moderate dysfunction	C3274776	\N	\N
1534	utis	C0042029	\N	\N
1534	uti	C0042029;C0077906;C1412376	\N	\N
1534	urinary tract infection	C0042029;C0262655;C4554638	\N	\N
1534	events consistent with uti	C0042029;C0077906;C0332290;C0441471;C1412376;C3541888	\N	\N
1533	social functioning	C0037395	\N	\N
1533	social function	C0037395	\N	\N
1533	physical functioning	C0516981;C4049916	\N	\N
1533	physical function	C0516981;C4049916	\N	\N
1533	opaqb physical function score	C0031843;C0449820;C0516981;C0542341;C0700205;C1705273;C4049916;C4050231;C4483112	\N	\N
1532	renal function : creatinine clearance	C0232804;C0812399	\N	\N
1532	renal function : ! : n ( % )	C0232804	\N	\N
1532	renal function *	C0232804	\N	\N
1532	renal function ( egfr ) according to mdrd  n ( % )	C0232804;C0680240;C1739039;C3811844;C3812682;C3839656	\N	\N
1532	renal function  bn ( % )	C0005005;C0034700;C0232804;C1706574;C4551963	\N	\N
1532	renal function	C0232804	\N	\N
1532	deterioration in renal function ( investigator reported )	C0035173;C0232804;C0684224;C0700287;C0868945;C4319718	\N	\N
1532	baseline renal function ( eclcr )	C0168634;C0232804;C1442488	\N	\N
7	p value 十	C1709380	\N	\N
7	p value ∥	C1709380	\N	\N
7	p value § ® ( w	C1709380	\N	\N
1531	physical function ( $nmbr$ - $nmbr$  short form - $nmbr$ subscale )	C0031843;C0348078;C0376315;C0516981;C0542341;C0597240;C0700205;C0700329;C1282927;C1522492;C1705273;C1806781;C2350002;C2964478;C4049916;C4255237	\N	\N
1531	nyha functional classification — no . ( % ) i	C0021966;C0205245;C0221138;C0542341;C1275491;C2700217	\N	\N
1531	nyha functional classification — no . ( % )	C0205245;C0542341;C1275491;C2700217	\N	\N
1531	nyha functional class i	C0205245;C0542341;C1882084;C2700217	\N	\N
1531	nyha functional class at screening	C0205245;C0220908;C0220909;C0542341;C1698960;C1710031;C1710032;C1710477;C1882083;C2348164;C2700217	\N	\N
1531	nyha functional class at randomization	C0034656;C0205245;C0542341;C1882083;C2700217	\N	\N
1531	nyha functional class ( % )	C0205245;C0542341;C1882083;C2700217	\N	\N
1531	nyha functional class $nmbr$	C0205245;C0542341;C1882083;C2700217	\N	\N
1531	nyha functional class  n ( % )	C0205245;C0542341;C1882083;C2700217	\N	\N
1531	nyha functional class	C0205245;C0542341;C1882083;C2700217	\N	\N
1531	lv function > $nmbr$ . $nmbr$ and < $nmbr$ . $nmbr$  n ( % ) medications  n ( % of patients )	C0013227;C0023128;C0030705;C0031843;C0369718;C0441922;C0542341;C0700205;C0731033;C0802604;C1705273;C1881413;C2598133;C4284232	\N	\N
1531	lv function	C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413	\N	\N
1531	inhibitors — no . { % ) se - $nmbr$ physical functioning score ^ ^	C0036919;C0205245;C0243077;C0542341;C4483112;C4552744	\N	\N
1531	haemodynamics and lv function	C0019010;C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413;C4281788	\N	\N
1531	functional outcome ( mrs $nmbr$ - $nmbr$ )	C0205245;C0542341;C1274040;C1522706;C2349188;C2700217;C3714939;C3854213	\N	\N
1531	function subscale	C0031843;C0542341;C0700205;C1705273	\N	\N
1531	emotional function	C0013987;C0031843;C0542341;C0700205;C0849912;C1705273	\N	\N
1530	significant worsening in kccq clinical score ( > $nmbr$ ) at $nmbr$ months $nmbr$	C0332271;C0439231;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231	\N	\N
1530	s $nmbr$ months	C0439231;C0565930;C2603362	\N	\N
1507	oxypurinol ( n = $nmbr$ )	C0030086	\N	\N
1530	symptoms of atrial fibrillation in the $nmbr$ months before randomiza -	C0004238;C0344434;C0439231;C0683368;C1457887;C1963067	f	90
1530	ppi use within $nmbr$ months of randomization	C0034656;C0358591;C0439231;C0871125;C1524063;C3811894	\N	\N
1530	poor outcome at $nmbr$ months	C0439231;C3806166	\N	\N
1530	months ( log - transformed )	C0439231;C1510411;C1708728;C2986775	\N	\N
1530	mi > $nmbr$ months *	C0439231;C3810814	\N	\N
1530	mi < $nmbr$ months *	C0439231;C3810814	\N	\N
1530	kccq ( $nmbr$ months )	C0439231;C3476798	\N	\N
1530	fall in last $nmbr$ months ( % )	C0085639;C0238715;C0439231;C4553726	\N	\N
1530	duration of prior alendronate use  months	C0102118;C0332152;C0439231;C1881378;C2826257;C2826775	\N	\N
1530	duration of previous use of vka  months	C0205156;C0439231;C1552607;C1881378;C2826775	\N	\N
1530	duration of metformin therapy ( months )	C0025598;C0439231;C0444917	\N	\N
1530	duration of dementia symptoms  months	C0011265;C0436359;C0439231;C0497327	\N	\N
1530	copd medication taken for at least $nmbr$ months before study entry	C0013227;C0024117;C0439231;C0557651;C1412502;C1705654;C1883727;C2603343;C3244316;C3714496;C4284232	\N	\N
1530	change in sbp ( $nmbr$ months )	C0085805;C0392747;C0439231;C0443172;C1705241;C4319952	\N	\N
1530	change in nt - probnp at $nmbr$ months ( log - transformed )	C0392747;C0439231;C0443172;C0669479;C0754710;C1510411;C1705241;C1708728;C2986775;C4319952	\N	\N
1530	blood eosinophil count > $nmbr$ / mm $nmbr$ in $nmbr$ months before screening — no . ( % )	C0005767;C0005768;C0014467;C0200638;C0220908;C0220909;C0229664;C0439231;C0750480;C0750879;C1698960;C1705566;C1710031;C1710032;C1710477;C2348164;C4330985;C4554674	\N	\N
1530	^ $nmbr$ months	C0439231	\N	\N
1530	> $nmbr$ months ( n = $nmbr$  $nmbr$ )	C0439231	\N	\N
1530	> $nmbr$ months  n ( % )	C0439231	\N	\N
1530	> $nmbr$ months	C0439231	\N	\N
1530	< $nmbr$ months in - $nmbr$ kill	C0162388;C0439231;C0681205;C1550555	\N	\N
1530	< $nmbr$ months  n ( % )	C0439231	\N	\N
1530	< $nmbr$ months	C0439231	\N	\N
1530	$nmbr$ – $nmbr$ months	C0439231	\N	\N
1530	$nmbr$ tob $nmbr$ months  n ( % )	C0439231;C1420851	\N	\N
1530	$nmbr$ tob $nmbr$ months	C0439231;C1420851	\N	\N
1530	$nmbr$ montlts	\N	\N	\N
1530	$nmbr$ months	C0439231	\N	\N
1530	$nmbr$ - < $nmbr$ months  n ( % )	C0439231	\N	\N
1530	$nmbr$ - $nmbr$ months fn = $nmbr$ . $nmbr$ )	C0439231;C1570610	\N	\N
1530	$nmbr$ - $nmbr$ months ( n = $nmbr$ )	C0439231	\N	\N
1530	$nmbr$ - $nmbr$ months  n ( % )	C0439231	\N	\N
1530	$nmbr$ - $nmbr$ months	C0439231	\N	\N
1529	intensified ( n 二 $nmbr$ )	\N	\N	\N
1529	intensified $nmbr$ months ( n - $nmbr$ )	C0439231	\N	\N
1528	montelukast ( n = $nmbr$ )	C0298130	\N	\N
1528	monteiukast vs placebo	C0032042;C1696465;C1706408	\N	\N
1528	monteiukast ( n = $nmbr$ )	\N	\N	\N
1528	monteiukast	\N	\N	\N
1527	panel b	C0441833;C1706365;C1999270	\N	\N
1527	panel a	C0441833;C1706365;C1999270	\N	\N
1527	device group	C1706365	\N	\N
1526	vascular disease ( % of group )	C0042373;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	treatment group  on - treatment il - $nmbr$ threshold	C0020898;C0021764;C0022271;C0039798;C0087111;C0441833;C0449864;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704	\N	\N
7	p value § ( < $nmbr$ vs . > = $nmbr$ years )	C0439234;C1709380	\N	\N
1526	total group	C0439175;C0439810;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	table_group	C0039224;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1706074	\N	\N
1526	subject group	C0441833;C0681850;C0687744;C1257890;C1519504;C1550501;C1705428;C1705429;C1706203;C2349001;C2697811	\N	\N
1526	statin group	C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	salmeterol - fluticasone group	C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	risk factors ( % of group )	C0035648;C0441833;C0687744;C1257890;C1519504;C1553898;C1705428;C1705429	\N	\N
1526	randomized group by subgroup interaction	C0034656;C0441833;C0687744;C1079230;C1257890;C1515021;C1519504;C1704675;C1705428;C1705429;C3815594	\N	\N
1526	randomization groups $nmbr$ and $nmbr$	C0034656;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429	\N	\N
1526	randomization group	C0034656;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	previous coronary procedure ( % of group )	C0018787;C0018821;C0205156;C0441833;C0687744;C1257890;C1279986;C1519504;C1552607;C1705428;C1705429;C2986530	\N	\N
1526	p value between groups	C0441833;C0441849;C0687744;C1257890;C1519504;C1522609;C1552839;C1705428;C1705429;C1709380	\N	\N
1526	no statin group	C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	no . of diseased vessels ( % of group )	C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	indacaterol - glycopyrronium group	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1722260;C3814772	\N	\N
1526	hbaic group ( % )	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	groups	C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429	\N	\N
1526	group — no . ( % )	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	group dif . ( $nmbr$ )	C0441833;C0687744;C0812246;C1257890;C1519504;C1705428;C1705429;C1710304	\N	\N
1526	group	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	for combined hemoglobin groups	C0019046;C0205195;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429	\N	\N
1526	ezetimibe / simvastatin group	C0441833;C0687744;C1257890;C1519504;C1532737;C1705428;C1705429	\N	\N
1526	experimental treatment group	C0441833;C0687744;C0949266;C1257890;C1519504;C1705428;C1705429;C2585119	\N	\N
1526	dabigatran group	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2348066	\N	\N
1526	coronary procedure ( % of group )	C0018787;C0018821;C0441833;C0687744;C1257890;C1279986;C1519504;C1705428;C1705429;C2986530	\N	\N
1526	certolizumab group	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1872109	\N	\N
1526	bmi group — no . ( % )	C0441833;C0578022;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	aga group	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1526	( % of group )	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1525	the square of the height in meters . patient ' s and physician ' s global assessment scores can range from $nmbr$ to $nmbr$ . scores for the western	C0030705;C0205120;C0441074;C0449820;C0489786;C1514721;C1552595;C1705493;C2348147;C3542016;C4050369	\N	\N
1525	physician global assessment of disease activity  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C4050369	\N	\N
1525	physician global assessment of disease	C0012634;C4050369	\N	\N
1525	physician ' s global assessment of dis -	C0451119;C1444662;C1970187;C4050369	\N	\N
1525	physician ' s global assessment . mean $nmbr$ sd	C0444504;C2347634;C2348143;C2699239;C4050369	\N	\N
1525	physician ' s global assessment !	C4050369	\N	\N
1525	physician ' s global assessment	C4050369	\N	\N
1525	pga subscore	C0016410;C3541266;C4050369	\N	\N
1525	pga score ( range )	C0016410;C0449820;C1514721;C2348147;C3541266;C3542016;C4050231;C4050369	\N	\N
1525	pga score  mean ( sd )	C0016410;C0444504;C0449820;C2347634;C2348143;C2699239;C3541266;C4050231;C4050369	\N	\N
1525	pga  $nmbr$ - $nmbr$	C0016410;C3541266;C4050369	\N	\N
1525	no worsening in pga  %	C0016410;C0332271;C1457868;C1546960;C3541266;C4050369	\N	\N
1525	mean pga score ± sd	C0016410;C2699239;C3533236;C3541266;C4050369	\N	\N
1525	mean ( sd ) pga vas *	C0016410;C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3541266;C3827561;C4050369	\N	\N
1524	ptca or pci	C2936173;C4049621	\N	\N
1524	ptca / cabg	C0010055;C2936173	\N	\N
1524	prior ptca or cabg	C0010055;C0332152;C2826257;C2936173	\N	\N
1524	cabg or ptca / pci	C0010055;C2936173;C4049621	\N	\N
1524	cabg or ptca ( % )	C0010055;C2936173	\N	\N
1524	both ptca and cabg	C0010055;C2936173	\N	\N
1523	phakic	\N	\N	\N
1523	participation in phase a	C0205390;C0679823;C1710475	\N	\N
1523	double - dummy phase * *	C0205390;C1710475;C4684647	\N	\N
1523	aphasia	C0003537	\N	\N
1522	ulpasi $nmbr$	\N	\N	\N
1522	tpasi $nmbr$	\N	\N	\N
1522	pasia	\N	\N	\N
1522	pasi score > $nmbr$ *	C0449820;C4050231;C4528685	\N	\N
1522	pasi score ( $nmbr$ – $nmbr$ scale )	C0175659;C0349674;C0449820;C1947916;C4050231;C4528685	\N	\N
1522	pasi score ( $nmbr$ - $nmbr$ ) d	C0449820;C4050231;C4528685	\N	\N
1522	pasi score ( $nmbr$ - $nmbr$ )	C0449820;C4050231;C4528685	\N	\N
1522	pasi score $nmbr$	C0449820;C4050231;C4528685	\N	\N
1522	pasi score ! * *	C0449820;C4050231;C4528685	\N	\N
1522	pasi score  $nmbr$ - $nmbr$ *	C0449820;C4050231;C4528685	\N	\N
1522	pasi score	C0449820;C4050231;C4528685	\N	\N
1522	pasi response by baseline mtx use  no . / total no . ( % ) * pasi $nmbr$	C0025677;C0042153;C0168634;C0439175;C0439810;C0457083;C0871261;C1417487;C1442488;C1704632;C1706817;C1947944;C2911692;C4528685	\N	\N
1522	pasi ^ i	C0021966;C0221138;C4528685	\N	\N
1522	pasi < $nmbr$ *	C4528685	\N	\N
1522	pasi *	C4528685	\N	\N
1522	pasi $nmbr$ a	C4528685	\N	\N
1522	pasi $nmbr$  no . / total no . ( % ) $nmbr$	C0439175;C0439810;C4528685	\N	\N
1522	pasi $nmbr$	C4528685	\N	\N
1522	pasi	C4528685	\N	\N
1522	median pasi score { range ) ' i  i '	C0021966;C0221138;C0449820;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231;C4528685	\N	\N
1522	llpasi $nmbr$	\N	\N	\N
1522	baseline pasi score	C0168634;C0449820;C1442488;C4050231;C4528685	\N	\N
-10	erysipelas	C0014733	\N	\N
1520	physician ' s judgment that vka inappropriate ]	C0022423;C0031831;C0804815;C1548788;C3537135;C3542467	\N	\N
1520	physician ' s judgment that vka inappropriate	C0022423;C0031831;C0804815;C1548788;C3537135;C3542467	\N	\N
1520	physician ' s judgment that vka	C0022423;C0031831;C0804815	\N	\N
1520	physician	C0031831;C0804815	\N	\N
1520	bone erosion ( judged by physician )  n ( % )	C0031831;C0221191;C0587240;C0804815	\N	\N
1519	study $nmbr$ - item short - form general health survey ( sf - $nmbr$ ) can range from $nmbr$ to $nmbr$ for the physical component and from $nmbr$ to $nmbr$ for the mental	C0031809;C0037712;C0040363;C0041260;C0205485;C0229992;C0348078;C0376315;C0449432;C0557651;C1282927;C1509143;C1514721;C1522492;C1551338;C1705248;C1806781;C1883351;C2348147;C2350002;C2603343;C3481509;C3542016;C4255237;C4554251	\N	\N
1519	sf - $nmbr$ physical component summaryjj	C0031809;C0037712;C0205485;C0449432;C1509143;C1705248	\N	\N
1519	physical examinations	C0031809	\N	\N
1519	physical examination	C0031809;C1744699	\N	\N
1519	physical component summary	C0031809;C0205485;C0449432;C1509143;C1552616;C1705248;C1706244	\N	\N
1519	physical component	C0031809;C0205485;C0449432;C1509143;C1705248	\N	\N
1519	physical characteristics	C0031809;C0205485;C1509143;C1521970	\N	\N
1519	and physical examination	C0031809;C1744699	\N	\N
1518	pr / virgin islands  n ( % )	C0042752;C0279759;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914	\N	\N
1518	n / pyr	C0369718;C0441922	\N	\N
1518	$nmbr$ . $nmbr$ per $nmbr$ pyr	\N	\N	\N
1518	$nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per $nmbr$ pyr pyr	\N	\N	\N
1518	$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ pyr	\N	\N	\N
1518	$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ . $nmbr$ per $nmbr$ pyr $nmbr$ pyr	\N	\N	\N
1518	$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per pyr $nmbr$ pyr	\N	\N	\N
1517	standard care n ( % ) / $nmbr$ py	C0030428;C1442989;C1947933;C2828392;C3538810	\N	\N
1517	py = $nmbr$ . $nmbr$ )	C0030428;C3538810	\N	\N
1517	py = $nmbr$ )	C0030428;C3538810	\N	\N
1517	py *	C0030428;C3538810	\N	\N
1517	pa	C0030428;C3541314	\N	\N
1517	no pa	C0030428;C3541314	\N	\N
1517	insulin glargine n ( % ) / $nmbr$ py	C0030428;C0907402;C3538810	\N	\N
1517	$nmbr$ events  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )	C0030428;C0441471;C3538810;C3541888	\N	\N
1517	$nmbr$ event  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )	C0030428;C0441471;C3538810;C4019010	\N	\N
1517	$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ } pty = $nmbr$	\N	\N	\N
1517	$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$	\N	\N	\N
1517	$nmbr$ . $nmbr$ per $nmbr$ py	C0030428;C3538810	\N	\N
1507	allopurinolt	\N	\N	\N
1516	sco . ’ ita ' rojs dvt . ' pe	C0022277;C0070939;C0149871;C1880476;C2926618;C2986561;C3899446;C4284304	\N	\N
1516	ruled out non - fatal pe with or	C0070939;C0439787;C0849355;C1302234;C1446409;C1518422;C1705232;C1880476;C4284304	\N	\N
1516	pre ' rtous eptscde ( s } d dvt / pe	C0070939;C0149871;C0332152;C0740175;C1880476;C2257086;C2926618;C3669034;C3899446;C4284304	\N	\N
1516	pe ± dvt	C0070939;C0149871;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	pe with / without dvt	C0070939;C0149871;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	pe only	C0070939;C0205171;C1720467;C1880476;C4284304	\N	\N
1516	pe associated with dvt at diagnosis	C0011900;C0070939;C0149871;C0332281;C1704338;C1704656;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	pe and dvt	C0070939;C0149871;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	pe ( with or without dvt )	C0070939;C0149871;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	pe	C0070939;C1880476;C4284304	\N	\N
1516	neither pe nor dvt	C0070939;C0149871;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	initial symptomatic pe	C0070939;C0205265;C0231220;C1279901;C1555582;C1705685;C1880476;C4284304	\N	\N
1516	index events : pe ± dvt n ( % )	C0070939;C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2926618;C2986546;C3541888;C3899446;C4284304	\N	\N
1516	extent of index pe ' ( n  % of pe patients )	C0030705;C0070939;C0439792;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4284304	\N	\N
1516	death  with pe not	C0011065;C0070939;C1306577;C1518422;C1880476;C4082313;C4284304;C4552775	\N	\N
1516	causes of dvt or pe — no . ( % ) ^ |	C0015127;C0070939;C0149871;C1314792;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	causes of dvt or pe  n ( % )	C0015127;C0070939;C0149871;C1314792;C1880476;C2926618;C3899446;C4284304	\N	\N
1516	cause of dvt or pe — no . ( % )	C0015127;C0070939;C0149871;C1524003;C1880476;C2926618;C3899446;C4284304	\N	\N
1515	stroke or pvd  ( % )	C0038454;C0085096;C4521226;C4554100	\N	\N
1515	pvd	C0085096;C4521226	\N	\N
1515	puva	C0853073;C1704892	\N	\N
1514	vdz / pla n = $nmbr$	C0456170	\N	\N
1514	pla « = $nmbr$	C0456170	\N	\N
1514	pla n = $nmbr$	C0456170	\N	\N
1514	pla	C0456170	\N	\N
1514	atio - pla	C0456170	\N	\N
1513	pt . years = $nmbr$	C0032743;C0439234;C0699718	\N	\N
1513	pt	C0032743;C0699718	\N	\N
1513	patients entering pt period n = $nmbr$	C0030705;C0032743;C0439531;C0699718;C1522196;C1948053	\N	\N
1513	event / patients ( $nmbr$ / pt - y )	C0030705;C0032743;C0441471;C0699718;C4019010	\N	\N
1513	diet diet + pravastatin event / patients ( $nmbr$ ooo / pt - y )	C0012155;C0012159;C0030705;C0032743;C0085542;C0441471;C0699718;C1519433;C2983588;C3668949;C4019010	\N	\N
1512	pts	C1419129;C2698747	\N	\N
1512	placebo pts / n ( % )	C0032042;C1419129;C1696465;C1706408;C2698747	\N	\N
1512	no . pts	C1419129;C2698747	\N	\N
1512	# pts	C1419129;C2698747	\N	\N
1511	ntprobnp ( pg / ml )	C0439297;C0669479;C0754710	\N	\N
1511	nt - probnp ， pmol / h	C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284	\N	\N
1511	nt - probnp — pg / ml * *	C0439297;C0669479;C0754710	\N	\N
1511	nt - probnp — pg / ml	C0439297;C0669479;C0754710	\N	\N
1511	nt - probnp ( pg / ml ) h	C0030827;C0033727;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C0669479;C0754710;C1266240;C1705224;C2827929;C3887665;C4528284	\N	\N
1511	nt - probnp ( pg / ml ) ( q $nmbr$ - q $nmbr$ )	C0439297;C0669479;C0754710	\N	\N
1511	nt - probnp ( pg / ml )	C0439297;C0669479;C0754710	\N	\N
1511	nt - probnp $nmbr$ pmol - l - $nmbr$	C0439284;C0669479;C0754710	\N	\N
1511	nt - probnp  pmol / l ^	C0439284;C0669479;C0754710	\N	\N
1511	nt - probnp  pmol / l	C0439284;C0669479;C0754710	\N	\N
1511	nt - probnp  pmol / h	C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284	\N	\N
1511	nt - probnp  pg / ml	C0439297;C0669479;C0754710	\N	\N
1511	nt - pro bnp	C0669479;C0754710	\N	\N
1511	nt - pro - bnp — pmol / literf	C0439192;C0669479;C0754710	\N	\N
1511	nt - pro - bnp — pmol / liter - j -	C0439192;C0475211;C0669479;C0754710	\N	\N
1511	nt - pro - bnp	C0669479;C0754710	\N	\N
1511	n - terminal pro - bnp — pg / ml §	C0439297;C0669479	\N	\N
1510	versus tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg	C0030827;C0072225;C1266240;C4032878	\N	\N
1510	versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg	C0030827;C0072225;C1266240;C4032878	\N	\N
1510	versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ - $nmbr$ / $nmbr$ pg	C0030827;C0072225;C1266240;C4032878	\N	\N
1510	versus olodaterol $nmbr$ pg	C0030827;C0072225;C1266240;C2934193	\N	\N
1510	tiotropium + olodaterol $nmbr$ / $nmbr$ pg	C0030827;C0072225;C1266240;C4032878	\N	\N
1510	tiotropium + olodaterol $nmbr$ / $nmbr$	C4032878	\N	\N
1510	tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg	C0030827;C0072225;C1266240;C4032878	\N	\N
1510	olodaterol sgg	C2934193	\N	\N
1510	olodaterol $nmbr$ pg	C0030827;C0072225;C1266240;C2934193	\N	\N
1510	olodaterol $nmbr$ m g	C0456715;C2934193	\N	\N
1510	olodaterol $nmbr$ jig	C2934193	\N	\N
1510	olodaterol $nmbr$ gg ( n = $nmbr$ )	C0017454;C0018370;C2934193	\N	\N
1510	olodaterol	C2934193	\N	\N
1509	indacaterol / glycopyrronium $nmbr$ / $nmbr$   μ g o . d .	C0439417;C1722260;C3814772	\N	\N
1509	indacaterol - glycopyrronium group ( n = $nmbr$ )	C0441848;C1722260;C3814772	\N	\N
1508	salmeterol ( n [ $nmbr$ )	C0073992	\N	\N
1508	salmeterol ( n = $nmbr$ )	C0073992	\N	\N
1508	salmeterol $nmbr$ gg bid	C0017454;C0018370;C0073992	\N	\N
1508	salmeterol	C0073992	\N	\N
1508	formoterol $nmbr$   μ g ( n   =   $nmbr$ )	C0060657;C0439267	\N	\N
1508	formoterol $nmbr$ gg bid	C0017454;C0018370;C0060657	\N	\N
1508	formoterol $nmbr$ gg ( n = $nmbr$ )	C0017454;C0018370;C0060657	\N	\N
1507	allopurinol $nmbr$ mg ( n = $nmbr$ ) +	C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1507	allopurinol $nmbr$ / $nmbr$ mg n = $nmbr$	C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1507	allopurinol $nmbr$ / $nmbr$ mg daily n = $nmbr$	C0002144;C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1507	allopurinol	C0002144	\N	\N
1506	lansoprazole ( n = $nmbr$ )	C0050940	\N	\N
1506	dexlansoprazole mr ( n = $nmbr$ )	C0024485;C1417249;C2347167;C2348248;C3254418;C4050513	\N	\N
1506	dexlansoprazole mr $nmbr$ mg qd	C0024485;C0024671;C0026410;C0332173;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761	\N	\N
1506	dexlansoprazole mr $nmbr$ mg  n = $nmbr$	C0024485;C0024671;C0026410;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761	\N	\N
1506	dexlansoprazole mr	C0024485;C1417249;C2347167;C2348248;C3254418;C4050513	\N	\N
1504	total cholesterol — mg / dl	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol ^	C0201950;C0543421	\N	\N
1504	total cholesterol > $nmbr$ mg / dl	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol - mg / dl * *	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol *	C0201950;C0543421	\N	\N
1504	total cholesterol ( sd )  mg / dl	C0201950;C0439269;C0543421;C2699239	\N	\N
1504	total cholesterol ( mmol / l ) :	C0201950;C0543421;C1532563	\N	\N
1504	total cholesterol ( mmol / l )  mean ( sd )	C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239	\N	\N
1504	total cholesterol ( mmol / l )	C0201950;C0543421;C1532563	\N	\N
1504	total cholesterol ( mmo $nmbr$ / $nmbr$ )	C0201950;C0543421	\N	\N
1504	total cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients	C0030705;C0201950;C0439269;C0444504;C0470187;C0543421;C2347634;C2348143;C2699239	\N	\N
1504	total cholesterol ( mg / dl )	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol $nmbr$ > $nmbr$ mg / dl	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol $nmbr$ < $nmbr$ mg / dl	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol  mmol / l 本	C0201950;C0543421;C1532563	\N	\N
1504	total cholesterol  mmol / l ( sd )	C0201950;C0543421;C1532563;C2699239	\N	\N
1504	total cholesterol  mmol / l  mean ( sd )	C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239	\N	\N
1504	total cholesterol  mmol / l	C0201950;C0543421;C1532563	\N	\N
1504	total cholesterol  mg / dl ^	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol  mg / dl  mean ( sd )	C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239	\N	\N
1504	total cholesterol  mg / dl  ^	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol  mg / dl	C0201950;C0439269;C0543421	\N	\N
1504	total cholesterol  mean ( sd )  mg / dl	C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239	\N	\N
1504	total cholesterol  mean ( sd )	C0201950;C0444504;C0543421;C2347634;C2348143;C2699239	\N	\N
1504	total cholesterol  %	C0201950;C0543421	\N	\N
1504	total cholesterol	C0201950;C0543421	\N	\N
1504	total cholesterohhdl cholesterol ratio	C0201950;C0456603;C0543421;C1547037	\N	\N
1504	median total cholesterol  mmol / l	C0201950;C0543421;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	\N	\N
1504	cholesterol  mg / dl total	C0201950;C0439269;C0543421	\N	\N
1504	baseline total cholesterol	C0168634;C0201950;C0543421;C1442488	\N	\N
1503	p - sitosterol / total c ( | imol / mmol )	C0037215;C0220914;C0369773;C0439175;C0439190;C0439810;C2603361	\N	\N
1503	p - sitosterol / lathosterol	C0037215;C0064673;C0220914;C0369773;C2603361	\N	\N
1503	cilostazol	C0055729	\N	\N
1503	( $nmbr$ - sitosterol ( p . mol / l )	C0037215;C0220914;C0347982	\N	\N
1502	lathosterol / total c ( | imol / mmol )	C0064673;C0439175;C0439190;C0439810	\N	\N
1502	lathosterol ( jimol / l )	C0064673	\N	\N
1502	csf lathosterol ( | jlg / cll )	C0023434;C0064673;C3540512;C3889436	\N	\N
1502	alathosterol ( % )	\N	\N	\N
1501	high - density lipoprotein cholesterol — mg / dl	C0023822;C0439269	f	821
1501	kdl cholesterol ( mmol / )	C0008377;C0439190	f	821
1501	high - density lipoprotein cholesterol mean ( mg / dl ± sd )	C0023822;C0439269;C0444504;C2347634;C2348143;C2699239	f	821
1501	hdl cholesterol ( sd )  mg / dl	C0023822;C0392885;C0439269;C2699239	f	821
1501	hdl cholesterol ( mmol / l ) ( median  iqr )	C0023822;C0392885;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	f	821
1501	hdl cholesterol  mmol / 冲	C0023822;C0392885;C0439190	f	821
1501	totalhdl cholesterol ratio	C0008377;C0456603;C1547037	f	821
1501	hdl cholesterol ( mmol / l )	C0023822;C0392885;C1532563	f	821
1501	hdl cholesterol < $nmbr$ mg / dl *	C0023822;C0392885;C0439269	f	821
1501	hdl cholesterol level	C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113	f	821
1501	high density lipoprotein cholesterol  mg / dl ^	C0023822;C0439269	f	821
1501	hdl cholesterol ( mmol / l ) :	C0023822;C0392885;C1532563	f	821
1501	hdl cholesterol < $nmbr$ - $nmbr$ mmol / l	C0023822;C0392885;C1532563	f	821
1501	high density lipoprotein cholesterol - mg / dl * *	C0023822;C0439269	f	821
1501	hdl cholesterol ( mg / dl )	C0023822;C0392885;C0439269	f	821
1501	hdl cholesterol > $nmbr$ - $nmbr$ mmol / l	C0023822;C0392885;C1532563	f	821
1505	hdlcholesterol	\N	f	821
1501	hdl cholesterol — mg / dl	C0023822;C0392885;C0439269	f	821
1501	high - density lipoprotein cholesterol  mg / dl	C0023822;C0439269	f	821
1501	terol  hdl - c  high - density lipoprotein cholesterol	C0023822	f	821
1505	tolal choleslerol	\N	f	1504
1505	tolal choleslerol - lo - hdl choleslerol ralio	C0206579;C1232424;C3715113	f	1504
1505	total cholesterol - to - hdl cholesterol ratio	C0428619	f	1504
1505	total cholesterol : hdl - c ratio	C0439175;C0439810;C0523558	f	1504
1501	hba $nmbr$ c — % cholesterol — mmol / l	C0008377;C0019016;C1532563;C1825777;C3538758	\N	\N
1501	cholesterol — mmol / liter	C0008377;C0439190;C0475211	\N	\N
1501	cholesterol ( mmol / l )	C0008377;C1532563	\N	\N
1501	cholesterol ( % )	C0008377	\N	\N
1501	cholesterol  mmol / l	C0008377;C1532563	\N	\N
1501	cholesterol  ( . $nmbr$ . $nmbr$ mmol / l )  n ( % )	C0008377;C1532563	\N	\N
1501	cholesterol	C0008377	\N	\N
7	p value interaction	C1704675;C1709380	\N	\N
7	p value heart failure vs no heart failure	C0018801;C0018802;C1709380;C4554158	\N	\N
7	p value for trend across tertiles	C1521798;C1709380;C4554533	\N	\N
7	p value for trend *	C1521798;C1709380;C4554533	\N	\N
7	p value for trend	C1521798;C1709380;C4554533	\N	\N
7	p value for mra vs no mra	C0243032;C1609165;C1709380;C3891069	\N	\N
7	p value for interactiont	C1709380	\N	\N
7	p value for interaction ® vertebral fracture at flex baseline :	C0080179;C0168634;C1442488;C1704675;C1709380	\N	\N
7	p value for interaction ®	C1704675;C1709380	\N	\N
7	p value for interaction by region	C0017446;C0205147;C1704675;C1709380	\N	\N
7	p value for interaction ^	C1704675;C1709380	\N	\N
7	p value for interaction ( age groups ) *	C0027362;C1704675;C1709380	\N	\N
7	p value for interaction	C1704675;C1709380	\N	\N
7	p value for	C1709380	\N	\N
7	p value fo interactio	C1709380	\N	\N
7	p value f	C0016327;C1709380	\N	\N
1493	family history of premature chd	C0151526;C0205252;C0241889;C0280604;C3542407;C4018905	\N	\N
1493	family history of premature	C0151526;C0205252;C0241889;C4018905	\N	\N
1123	mca	C0149566	\N	\N
1501	- hdl cholesterol	C0023822;C0392885	f	821
1501	hdl cholesterol	C0023822;C0392885	f	821
1501	hdl - cholesterol	C0023822;C0392885	f	821
1500	baseline ldl cholesterol	C0023824;C0168634;C0202117;C1442488	f	1068
1500	ldl cholesicrol ( minol / l )	\N	f	1068
1500	baseline ldl cholesterol ( derived )	C0023824;C0168634;C0202117;C1441547;C1442488;C3245521	f	1068
1500	ldl cholesterol	C0023824;C0202117	f	1068
1500	ldl - cholesterol	C0023824;C0202117	f	1068
1501	hdl - cholesterol  mmol / l	C0023822;C0392885;C1532563	f	821
1501	hdl - cholesterol ( mmol / l )	C0023822;C0392885;C1532563	f	821
1500	ldl - cholesterol (	C0023824;C0202117	f	1068
1500	- ldl cholesterol	C0023824;C0202117	f	1068
1500	ldl cholesterol ^ :	C0023824;C0202117	f	1068
1501	hdl cholesterol  mmol / l *	C0023822;C0392885;C1532563	f	821
1501	hdl cholesterol  mmol / l	C0023822;C0392885;C1532563	f	821
1500	ldl cholesterol level	C0023824;C0201950;C0202117;C0428466;C0441889;C0456079;C1547707;C2946261	f	1068
1500	ldl cholesterol mean	C0023824;C0202117;C0444504;C2347634;C2348143	f	1068
1500	ldl - cholesterol ( mmol / )	C0023824;C0202117;C0439190	f	1068
1500	ldl - cholesterol  mmol / lf	C0023824;C0202117;C0439190;C1416933;C2986618;C4554443	f	1068
1500	ldl $nmbr$ - c	\N	f	1068
1501	hdl - cholesterol  mmol / le	C0023190;C0023822;C0392885;C0439090;C0439190;C1423767;C2697858	f	821
1501	hdl cholesterol  ( mmol / l )	C0023822;C0392885;C1532563	f	821
1500	mean ( s . d . ) measured ldl cholesterol	C0023824;C0202117;C0444504;C0444706;C2347634;C2348143;C3541902	f	1068
1501	hdl cholesterol  mmol / l  men  mean ± sd	C0023822;C0025266;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239	f	821
1501	hdl - cholesterol ( mg / dl )	C0023822;C0392885;C0439269	f	821
1501	> $nmbr$ . $nmbr$ hdl cholesterol level	C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113	f	821
1501	hdl cholesterol  mg / dl	C0023822;C0392885;C0439269	f	821
1501	baseline high - density lipoprotein cholesterol ( mg / dl )	C0023822;C0168634;C0439269;C1442488	f	821
1501	aldl cholesterol	C0008377	f	1068
1500	atrial fibrillation ldl cholesterol level	C0004238;C0023824;C0202117;C0344434;C0441889;C0456079;C1547707;C1963067;C2946261	f	1068
1500	mean ( s . d . ) calculated ldl cholesterol	C0023824;C0202117;C0444504;C0444686;C1441506;C2347634;C2348143	f	1068
1500	low - density lipoprotein cholesterol  %	C0023824	f	1068
1500	visit $nmbr$ ldl cholesterol strata	C0023824;C0202117;C0545082;C1512346;C2826704	f	1068
1499	chylomicron triglycerides	C0008731;C0041004;C1325761	\N	\N
1499	chylomicron cholesterol	C0008377;C0008731;C1325761	\N	\N
1498	no history of hypertension ( n = $nmbr$ )	C0455527	\N	\N
1498	hyperlipidmemia	\N	\N	\N
1498	hypercholesterolemiat	\N	\N	\N
1498	history of systemic hypertension	C0205373;C0455527	\N	\N
1498	history of hypertension — no . ( % )	C0455527	\N	\N
1498	history of hypertension for $nmbr$ mo or more	C0026544;C0205172;C0332177;C0455527	\N	\N
1498	history of hypertension ^  %	C0455527	\N	\N
1498	history of hypertension . no . ( % )	C0455527	\N	\N
1498	history of hypertension - n ( % )	C0455527	\N	\N
1498	history of hypertension *	C0455527	\N	\N
1498	history of hypertension ( n = $nmbr$ )	C0455527	\N	\N
1498	history of hypertension ( a ) c	C0455527	\N	\N
1498	history of hypertension ( % )	C0455527	\N	\N
1498	history of hypertension  no . ( % )	C0455527	\N	\N
1498	history of hypertension  n ( % )	C0455527	\N	\N
1498	history of hypertension	C0455527	\N	\N
1498	history of hyperlipidemia ( % )	C4695788	\N	\N
1498	history of hypercholesterolemia  n ( % )	C1533076	\N	\N
1498	history of hypercholesterolemia	C1533076	\N	\N
1498	history of diagnosed hypertension n ( % )	C0011900;C0455527	\N	\N
1497	csf $nmbr$ s - hydroxy -	C0700307;C3540512;C3889436	\N	\N
1497	a $nmbr$ s - hydroxy -	C0700307	\N	\N
1496	lv hypertrophy  n ( % )	C0149721	\N	\N
1496	lelt ventricular hypertrophy *	C0340279	\N	\N
1496	left ventricular hypertrophy — no . ( % )	C0149721;C3484363	\N	\N
1496	left ventricular hypertrophy on echo	C0058928;C0149721;C1655045;C3484363	\N	\N
1496	left ventricular hypertrophy * *	C0149721;C3484363	\N	\N
1496	left ventricular hypertrophy ( % )	C0149721;C3484363	\N	\N
1496	left ventricular hypertrophy  n ( % )	C0149721;C3484363	\N	\N
1496	left ventricular hypertrophy	C0149721;C3484363	\N	\N
1496	hypertension and left ventricular hypertrophy	C0020538;C0149721;C1963138;C3484363	\N	\N
1495	hypertrophy  n ( % )	C0020564	\N	\N
1494	prior history of cardiovascular disease  n ( % )	C0332152;C0455539;C2826257	\N	\N
1494	history of postmenopausal fracture *	C0232970;C1272071	\N	\N
1494	history of osteoporotic fracture  n ( % ) a	C4075937	\N	\N
1494	history of falls	C1561668;C2919132	\N	\N
1494	history of clinical fracture ( > $nmbr$ years )	C0205210;C0439234;C1272071	\N	\N
1494	history of cerebrovascular disease — no . { % )	C0585890	\N	\N
1494	history of cerebrovascular disease	C0585890	\N	\N
1494	history of cardiovascular disease — no . { % )	C0455539	\N	\N
1494	history of cardiovascular disease — no . ( % ) ^ |	C0455539	\N	\N
1494	history of cardiovascular disease — no . ( % )	C0455539	\N	\N
1494	history of cardiovascular disease	C0455539	\N	\N
1494	family history of premature coronary heart disease	C0151526;C0205252;C0260520;C1313980;C2317524;C4018905	\N	\N
1494	family history of coronary artery disease	C2317524	\N	\N
1493	no history of migraine	C0455512	\N	\N
1493	no history of cancer	C0455471	\N	\N
1493	no family history of chd ( n = $nmbr$  $nmbr$ )	C0241889;C0280604;C3542407	\N	\N
1493	history of pvd  no . ( % )	C4534349	\N	\N
1493	history of pvd  n ( % )	C4534349	\N	\N
1493	history of pvd	C4534349	\N	\N
1493	history of cancer	C0455471	\N	\N
1493	family history of vte	C0241889;C0630906	\N	\N
1493	family history of venous thromboembolism ( % )	C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614	\N	\N
1493	family history of premature chdj	C0151526;C0205252;C0241889;C4018905	\N	\N
1493	family history of premature chd * *	C0151526;C0205252;C0241889;C0280604;C3542407;C4018905	\N	\N
1494	no history of heart failure at baseline	C0168634;C0455531;C1442488	f	12
1494	pinteraction for treatment and history of heart failure	C0039798;C0087111;C0455531;C1522326;C1533734;C1705169;C3538994;C3887704	f	12
1495	hypertrophy per ecg ( n = $nmbr$ $nmbr$ )	C0020564;C1623258	f	1496
1493	family history of chd ( n = $nmbr$  $nmbr$ )	C0241889;C0280604;C3542407	\N	\N
1493	family history of cancerf	C0241889	\N	\N
1493	family history of cancera	C0241889	\N	\N
1493	family history ^	C0241889	\N	\N
1493	family history  n ( % )	C0241889	\N	\N
1492	patient ' s history of :	C0679831;C1369882	\N	\N
1492	paternal history  n ( % )	C0424909	\N	\N
1492	medical history  n ( % of patients )	C0679831;C1369882;C1609576	\N	\N
1492	maternal history  n ( % )	C0559473	\N	\N
1492	history of intermittent claudication and abi < $nmbr$ - $nmbr$ or substantial peripheral arterial stenosis > $nmbr$ %	C0205267;C1328319;C2315493;C3888326;C4025272	\N	\N
1492	history of claudication	C2315493	\N	\N
1492	history of cardiac arrhythmia	C3494593	\N	\N
1491	positive family history of type $nmbr$ diabetes ( % )	C0332307;C0439178;C1313937;C1446409;C1514241;C1547052;C2825490;C3812269	\N	\N
1491	ol / l )	\N	\N	\N
1491	history of diabetes mellitus ( n = $nmbr$ )	C0455488	\N	\N
1491	history of diabetes mellitus  no . ( % )	C0455488	\N	\N
1491	history of diabetes mellitus  n ( % )	C0455488	\N	\N
1491	history of diabetes mellitus	C0455488	\N	\N
1491	family history ol diabetes ?	C1313937	\N	\N
1491	family history of diabetes — no . ( % )	C1313937	\N	\N
1491	family history of diabetes mellitus — no . { % )	C0260526;C1313937	\N	\N
1491	family history of diabetes mellitus — no . ( % )	C0260526;C1313937	\N	\N
1491	family history of diabetes ( - )	C1313937	\N	\N
1491	family history of diabetes ( + )	C1313937	\N	\N
1491	family history of diabetes ( % ) *	C1313937	\N	\N
1490	medical and lifestyle history	C0019664;C0019665;C0023676;C0199168;C0205476;C0262512;C0262926;C1705255;C2004062	\N	\N
1490	lifestyle modifications	C0870811;C2960841	\N	\N
1490	lifestyle behaviours	C0004927;C0023676;C0677505	\N	\N
1490	lifestyle behaviors	C0004927;C0023676;C0677505	\N	\N
1490	lifestyle	C0023676	\N	\N
1489	very elderly patients ( n - $nmbr$ )	C0442824;C0870602;C2984081	\N	\N
1489	non ‐ elderly	C0001792;C1518422;C1999167	\N	\N
1489	non - elderly ( < $nmbr$ years )	C0001792;C0439234;C1518422;C1999167	\N	\N
1489	elderly patients ( n — $nmbr$ )	C0870602	\N	\N
1489	elderly	C0001792;C1999167	\N	\N
1488	daily iglar dose at week $nmbr$ ( u )	C0560588;C2348070	\N	\N
1488	daily dose of study medication prescribed	C0013175;C0278329;C2348070	\N	\N
1488	daily	C0332173	\N	\N
1488	baseline insulin daily dose / kg	C0021641;C0022718;C0168634;C0332173;C0366513;C0439209;C1442488;C1533581;C1579433;C2348070;C3714501;C4054209	\N	\N
1488	average daily dose	C1510992;C2348070;C2825518	\N	\N
1487	patients with early cd ( n = $nmbr$ )	C0007928;C0030705;C0034283;C1279919;C4552032	\N	\N
1487	overall early - morning copd symptom severity scorec	C0024117;C0282416;C0332170;C1279919;C1319166;C1412502;C1561607;C3714496	\N	\N
1487	non - early crohn ' s disease	C0010346;C1279919;C1518422	\N	\N
1487	early use intended	C0042153;C0457083;C1279919;C1283828;C1551357;C1947944	\N	\N
1487	early routine	C0205547;C1279919	\N	\N
1487	early eptifibatide	C0253563;C1279919	\N	\N
1487	early crohn ' s disease *	C0010346;C1279919	\N	\N
1487	early clopidogrel intended	C0070166;C1279919;C1283828;C1551357	\N	\N
1487	early - start group ( n = $nmbr$ )	C0439659;C0441848;C1279919	\N	\N
1487	early - eptifibatide group ( n = $nmbr$ )	C0253563;C0441848;C1279919	\N	\N
1487	early ( n = $nmbr$ )	C1279919	\N	\N
1487	early  n ( % )	C1279919	\N	\N
1487	early	C1279919	\N	\N
1487	$nmbr$ mg / day early - start	C0439422;C0439659;C1279919	\N	\N
1486	hgb  g / dl < $nmbr$ men  < $nmbr$ women	C0019029;C0019046;C0025266;C0043210;C0439267;C0518015;C1424337	\N	\N
1486	hgb  g / dl	C0019029;C0019046;C0439267;C0518015;C1424337	\N	\N
1486	hemoglobin 一 g / dl	C0019046;C0439267;C1319312;C3642216	\N	\N
1486	hemoglobin — g / dl	C0019046;C0439267;C1319312;C3642216	\N	\N
1486	hemoglobin ( g / dl )	C0019046;C0439267;C1319312;C3642216	\N	\N
1486	hemoglobin  g / dl	C0019046;C0439267;C1319312;C3642216	\N	\N
1486	hb decrease ≥ $nmbr$ g / dl	C0019046;C0392756;C0439267;C0547047;C3642216;C3843510	\N	\N
1486	hb  g / dl	C0019046;C0439267;C3642216;C3843510	\N	\N
1486	haemoglobin ( g / dl )	C0019046;C0439267;C1319312;C3642216	\N	\N
1486	glu $nmbr$ asp g . t	C0125690;C0439267	\N	\N
1486	g - blockers	C0439267	\N	\N
1486	g + c	C0439267	\N	\N
1486	creatinine clearance by c - g ( ml / min )	C0151280;C0439267	\N	\N
1486	baseline trig > $nmbr$ millycerides g / dl	C0168634;C0202236;C0439267;C1442488;C1519533	\N	\N
1486	baseline hemoglobin  median ( iqr  g / dl )	C0019046;C0168634;C0439267;C0549183;C0876920;C1319312;C1442488;C2347635;C2348144;C2939193;C3642216	\N	\N
1486	$nmbr$ μ g ( n = $nmbr$ )	C0439267	\N	\N
1486	$nmbr$ a . g	C0439267	\N	\N
1485	very g ood / ex cellent	C0439267;C0442824;C2984081;C4267693	\N	\N
1485	g	C0439267	\N	\N
1485	aclidinium $nmbr$   μ g bid ( n   =   $nmbr$ )	C0439267;C2699757	\N	\N
1485	aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) b	C0439267;C2699757	\N	\N
1485	aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) a	C0439267;C2699757	\N	\N
1485	aclidinium $nmbr$   μ g ( n   =   $nmbr$ )	C0439267;C2699757	\N	\N
1484	sedentary	C0205254	\N	\N
1484	secondary pci	C0027627;C0175668;C0205436;C4049621	\N	\N
1484	secondary p	C0027627;C0175668;C0205436	\N	\N
1484	secondary outcomes	C0027627;C0175668;C0205436;C1274040	\N	\N
1484	secondary outcome	C0027627;C0175668;C0205436;C1274040	\N	\N
1469	> $nmbr$ . $nmbr$ mm hg	C0439475	f	1888
1484	secondary nonresponse	C0027627;C0175668;C0205436	\N	\N
1484	secondary kidney composite outcome	C0022646;C0027627;C0175668;C0205199;C0205436;C0227665;C1274040;C1547335	\N	\N
1484	secondary ip	C0027627;C0175668;C0205436;C1308226;C4049997	\N	\N
1484	secondary iii *	C0027627;C0175668;C0205436;C0439070;C1705160	\N	\N
1484	secondary end points iii	C0027627;C0175668;C0205436;C0439070;C1705160;C2349179	\N	\N
1484	secondary end points ii	C0027627;C0175668;C0205436;C1710602;C2349179;C4082587	\N	\N
1484	secondary end points $nmbr$	C0027627;C0175668;C0205436;C2349179	\N	\N
1484	secondary end points	C0027627;C0175668;C0205436;C2349179	\N	\N
1484	secondary dvt . ' fe	C0027627;C0149871;C0175668;C0205436;C2926618;C3848561;C3899446	\N	\N
1484	secondary *	C0027627;C0175668;C0205436	\N	\N
1484	secondary ( change in total updrs score from baseline to final visit in phase $nmbr$ )	C0027627;C0168634;C0175668;C0205088;C0205436;C0392747;C0439175;C0439810;C0443172;C0449820;C0545082;C1442488;C1512346;C1705241;C2826704;C3639721;C4050231;C4319952	\N	\N
1484	secondary ' outcomes	C0027627;C0175668;C0205436;C1274040	\N	\N
1484	secondary # $nmbr$	C0027627;C0175668;C0205436	\N	\N
1484	key secondary end points	C0027627;C0175668;C0205436;C2349179	\N	\N
1483	selected key secondary efficacy endpoints	C1280519;C1707391;C1707887;C4528314	\N	\N
1483	secondary endpoints :	C4528314	\N	\N
1482	standard therapyy ( n = $nmbr$ )	C1442989;C2828392	\N	\N
1482	standard control ( n = $nmbr$ ) no . of patients ( percent )	C0030705;C0243148;C0439165;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389	\N	\N
1482	standard control	C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389	\N	\N
1482	standard care n ( % )	C1442989;C1947933;C2828392	\N	\N
1482	standard care allocation	C1442989;C1706778;C1947933;C2828392	\N	\N
1482	standard care ( n = $nmbr$ )	C1442989;C1947933;C2828392	\N	\N
1482	standard care	C1442989;C1947933;C2828392	\N	\N
1482	standard bp lowering  < $nmbr$ mm hg ( n = $nmbr$ )	C0037623;C0439475;C0441994;C1415692;C1442989;C1708288;C2003888;C2828392;C4318478	\N	\N
7	p value c	C1709380	\N	\N
1482	standard allocation	C1442989;C1706778;C2828392	\N	\N
1482	standard ( n = $nmbr$ )	C1442989;C2828392	\N	\N
1482	standard ( $nmbr$ )	C1442989;C2828392	\N	\N
1482	standard	C1442989;C2828392	\N	\N
1482	size ( cm $nmbr$ ) ( mean ± standard deviation )	C0444504;C0456389;C0871420;C1442989;C1828170;C2347634;C2348143;C2828392	\N	\N
1482	sd  standard	C1442989;C2699239;C2828392	\N	\N
1482	number standard care	C0237753;C0449788;C1442989;C1947933;C2828392	\N	\N
1482	data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < $nmbr$ . $nmbr$ vs . ng . † p < $nmbr$ . $nmbr$ vs . ng .	C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0205251;C0221099;C0439165;C0444504;C0455280;C0549183;C0580545;C0596620;C0684224;C0700287;C0871420;C0876920;C1154908;C1442989;C1444656;C1511726;C1549488;C1550472;C1561533;C1706005;C1711350;C1828170;C2347634;C2347635;C2348143;C2348144;C2828392;C2939193;C3245479;C3714741;C3890211;C4048187;C4319718;C4321351;C4522223	\N	\N
1482	a mini - mental state examination  insulin glargine vs standard care	C0451306;C0907402;C1442989;C1947933;C2828392	\N	\N
1482	$nmbr$ standard ( n = $nmbr$ )	C1442989;C2828392	\N	\N
1481	urgent cor revasc	C0018787;C0056331;C0378365;C0439609;C3272275	\N	\N
1481	treated vessel - native coronary	C0005847;C0018787;C0302891;C1522326	\N	\N
1481	symptomatic heart fail	C0018787;C0231175;C0231220	\N	\N
1481	prior cardiac surgery  n ( % )	C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257	\N	\N
1481	pre - operative cardiac medications *	C0018787;C1522601;C1882154;C2347660	\N	\N
1481	native coronary	C0018787;C0302891	\N	\N
1481	major coronary	C0018787;C0205082;C0205164;C4318856;C4521762	\N	\N
1481	hospitaiization for heart faiiure	C0018787	\N	\N
1481	family history of premature heart disease	C0018787;C0151526;C0205252;C0850707;C4018905	\N	\N
1481	family history of coronary disease	C0018787;C0850707	\N	\N
1481	documented asymptomatic cardiac ischemiac	C0018787;C0231221;C1301725;C1522601;C1609436	\N	\N
1481	coronary	C0018787	\N	\N
1481	cor revasc	C0018787;C0056331;C0378365	\N	\N
1481	cardiac stretch	C0018787;C0600080;C1522601	\N	\N
1481	cardiac parameters	C0018787;C0449381;C1522601	\N	\N
1481	cardiac mediations	C0018787;C0680727;C1522601	\N	\N
1481	cardiac enzyates raised	C0018787;C0442818;C1522601	\N	\N
1481	cardiac diseasec	C0018787;C1522601	\N	\N
1481	cardiac and echocardiography parameters	C0013516;C0018787;C0449381;C1522601	\N	\N
1481	cardiac	C0018787;C1522601	\N	\N
-10	very good or excellent	C1548784;C1961136;C3641222	\N	\N
-10	large / very large	C0442824;C0549177;C2984081	\N	\N
1478	very high vs . normalb	C0442804;C4321397	\N	\N
1478	very high ( >   $nmbr$ xuln ) n   =   $nmbr$	C0442804;C4321397	\N	\N
1478	very high	C0442804;C4321397	\N	\N
1478	coronary heart disease  n ( % ) cardiovascular risk ( per protocol )  n ( % ) very high	C0007226;C0442711;C0442804;C1277690;C1507394;C1522729;C1698058;C2348563;C2599718;C3715209;C3887460;C4282383;C4321397	\N	\N
1477	nonobese ( < $nmbr$ kg / nr )	C0022718;C0027496;C0439209;C3844738;C4054209	\N	\N
1477	> $nmbr$ ky / nr	C0027496;C3844738	\N	\N
1477	< $nmbr$ ky / nr	C0027496;C3844738	\N	\N
1476	time since diagnosis — mo	C0011900;C0026544;C0040223;C0332177;C1704338;C1704656;C3541383	\N	\N
1476	smoking ( during the previous month )	C0332177;C0439231;C2114448	\N	\N
1476	placebo monthly ( n = $nmbr$ )	C0032042;C0332177;C1696465;C1706408	\N	\N
1476	pci > $nmbr$ month ago	C0332177;C0439231;C4049621	\N	\N
1476	one or more requiring hospitalization in $nmbr$ mo before screening — no . ( % ) $nmbr$	C0019993;C0026544;C0205172;C0205447;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
1476	no . in the $nmbr$ mo before screening	C0026544;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
1476	monthly	C0332177	\N	\N
1476	month $nmbr$	C0332177;C0439231	\N	\N
1476	median duration of chf — mo	C0018802;C0026544;C0332177;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	\N	\N
1476	lvef within $nmbr$ mo  %	C0026544;C0332177;C0428772;C0488728	\N	\N
1476	left ventricular ejection fraction within previous $nmbr$ mo — no . / total no . ( % ) $nmbr$	C0026544;C0205156;C0332177;C0428772;C0439175;C0439810;C0488728;C1552607	\N	\N
1476	left ventricular ejection fraction within previous $nmbr$ mo |	C0026544;C0205156;C0332177;C0428772;C0488728;C1552607	\N	\N
1476	hba $nmbr$ c month $nmbr$ ( % )	C0019016;C0332177;C0439231;C1825777;C3538758	\N	\N
1476	fall in last $nmbr$ mo	C0026544;C0085639;C0238715;C0332177;C4553726	\N	\N
1476	exacerbations in previous $nmbr$ mo ( n )  mean ( sd )	C0026544;C0205156;C0332177;C0444504;C1552607;C2347634;C2348143;C2699239;C4086268	\N	\N
1476	exacerbations in past $nmbr$ mo — no . ( % )	C0026544;C0332177;C1444637;C4086268;C4284302	\N	\N
1476	exacerbation within previous $nmbr$ mo  no . ( % )	C0026544;C0205156;C0332177;C1552607;C4086268	\N	\N
1476	exacerbation within $nmbr$ mo  %	C0026544;C0332177;C4086268	\N	\N
1476	duration of macular edema  mo	C0024440;C0026544;C0271051;C0332177;C0449238;C2926735	\N	\N
1476	duration of initial anticoagulation  mean ( sd )  mo	C0003281;C0026544;C0205265;C0332177;C0444504;C0449238;C1279901;C1555582;C1705685;C2347634;C2348143;C2699239;C2917212;C2919015;C2926735;C3537050	\N	\N
1476	duration of full - dose warfarin therapy before enrollment ( mo )	C0026544;C0332177;C0366686;C0443225;C0444917;C1516879;C1696073;C3888021	\N	\N
1476	duration of disease — mo	C0026544;C0332177;C0872146	\N	\N
1476	change in hba $nmbr$ c $nmbr$ to month $nmbr$ ( % )	C0019016;C0332177;C0392747;C0439231;C0443172;C1705241;C1825777;C3538758;C4319952	\N	\N
1476	ccsc at $nmbr$ month before enrollment	C0332177;C0439231;C1516705;C1516879;C1696073;C3888021	\N	\N
1476	atenolol use at $nmbr$ month	C0004147;C0042153;C0332177;C0439231;C0457083;C1947944	\N	\N
1476	at least $nmbr$ / mo	C0026544;C0332177	\N	\N
1476	> $nmbr$ month n = $nmbr$	C0332177;C0439231	\N	\N
1476	> $nmbr$ mo	C0026544;C0332177	\N	\N
1476	< $nmbr$ month n = $nmbr$	C0332177;C0439231	\N	\N
1476	< $nmbr$ mo  n ( % )	C0026544;C0332177	\N	\N
1476	< $nmbr$ mo	C0026544;C0332177	\N	\N
1476	$nmbr$ to < $nmbr$ mo	C0026544;C0332177	\N	\N
1476	$nmbr$ or $nmbr$ d / mo	C0026544;C0073187;C0332173;C0332177;C4484261	\N	\N
1476	$nmbr$ month l	C0332177;C0439231	\N	\N
1476	$nmbr$ mo - $nmbr$ y	C0026544;C0332177	\N	\N
1476	$nmbr$ mo  mean ( sd ) x	C0026544;C0332177;C0444504;C2347634;C2348143;C2699239	\N	\N
1476	$nmbr$ mo	C0026544;C0332177	\N	\N
1476	$nmbr$ - month follow - up median ( iq range )	C0332177;C0439231;C0549183;C0589120;C0876920;C1514721;C1522577;C1704685;C2347635;C2348144;C2348147;C2939193;C3274571;C3542016	\N	\N
1476	$nmbr$ - < $nmbr$ mo  n ( % )	C0026544;C0332177	\N	\N
1476	$nmbr$ - $nmbr$ mo	C0026544;C0332177	\N	\N
1476	$nmbr$ - $nmbr$ / month	C0332177;C0439231	\N	\N
1475	£ $nmbr$ ml / minute	C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665	\N	\N
1475	£ $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	£ $nmbr$ . $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	time to treatment initiation ( min )	C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700	\N	\N
1475	time to treatment initiation ( min	C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700	\N	\N
1475	time to treatment ( min ) t	C0702093;C1524029;C3494202;C3813700	\N	\N
1475	time to balloon / needle  min *	C0027551;C0040223;C0336867;C0441144;C0702093;C1524029;C1882041;C3541383;C3813700	\N	\N
1475	time to admission  min	C0702093;C1524029;C3813700;C3854258;C3854259	\N	\N
1475	time from sx onset to baseline ecg  min	C0168634;C0449244;C0702093;C1442488;C1519428;C1524029;C1623258;C3539997;C3813700;C3815196	\N	\N
1475	symptoms onset to first balloon inflation  min	C0021398;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700;C4086878	\N	\N
1475	stiffness ( min )	C0427008;C0702093;C1524029;C3813700	\N	\N
1475	range : min  max	C0702093;C1514721;C1524029;C2348147;C3542016;C3813700	\N	\N
1475	range ( min  max )	C0702093;C1514721;C1524029;C2348147;C3542016;C3813700	\N	\N
1475	range  ( min  max )	C0702093;C1514721;C1524029;C2348147;C3542016;C3813700	\N	\N
1475	randomization to first balloon inflation  min	C0021398;C0034656;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700	\N	\N
1475	qrs > $nmbr$ msec $nmbr$ - min walk test	C0439223;C0702093;C1524029;C3813700;C4277740	\N	\N
1475	pra  median ( min  max )  ng / ml / h	C0033727;C0369286;C0441932;C0549183;C0564385;C0633231;C0702093;C0876920;C1141951;C1419788;C1524029;C1533072;C2347635;C2348144;C2827900;C2939193;C3274822;C3669212;C3813700;C4050009;C4283900;C4528284	\N	\N
1475	pifr l / min	C0702093;C1524029;C3813700	\N	\N
1475	pefpm   ( l / min ) ∗	C0702093;C1524029;C3813700	\N	\N
1475	pefam   ( l / min ) ∗	C0702093;C1524029;C3813700	\N	\N
1475	pef at baseline  l_ / min	C0030771;C0168634;C0702093;C1442488;C1518922;C1524029;C1542834;C3813700	\N	\N
1475	pasi [ c ]  median ( min - max )	C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C4528685	\N	\N
1475	on - pump time : < l : $nmbr$ hrs : min ( n = $nmbr$ )	C0040223;C0702093;C1524029;C1568891;C3541383;C3813700;C3842462	\N	\N
1475	normal ( £ $nmbr$ ml / minute )	C0205307;C0231683;C0439166;C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347086;C2347166;C3887665;C4553972	\N	\N
1475	mtss  median ( min  max )	C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
1475	morning stiffness duration  min	C0449238;C0457086;C0702093;C1524029;C2926735;C3813700	\N	\N
1475	min – max	C0702093;C1524029;C3813700	\N	\N
1475	min per $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0441923;C0702093;C1524029;C3813700	\N	\N
1475	min - ’	C0702093;C1524029;C3813700	\N	\N
1475	min - max	C0702093;C1524029;C3813700	\N	\N
1475	min  max	C0702093;C1524029;C3813700	\N	\N
1475	median ( min  max )	C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
1476	heart failure $nmbr$ mo before admission	C0018801;C0018802;C0026544;C0184666;C0332177;C0809949;C4554158	f	12
1469	> $nmbr$ - < $nmbr$ mmhg	C0439475	f	1888
1475	mean score ( min  max range )	C0702093;C1514721;C1524029;C2348147;C3533236;C3542016;C3813700	\N	\N
1475	mean duration of surgery ± sd  min	C0038894;C0038895;C0444504;C0449238;C0543467;C0702093;C1274039;C1524029;C2347634;C2348143;C2699239;C2926735;C3813700	\N	\N
1475	jsn  median ( min  max )	C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
1475	iduration of symptoms > $nmbr$ min	C0683368;C0702093;C1457887;C1524029;C3813700	\N	\N
1475	esr ( mm / h )  median ( min - max )	C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284	\N	\N
1475	esr ( mm / h )  median ( min  max )	C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284	\N	\N
1475	erosion score  median ( min  max )	C0333307;C0449820;C0549183;C0702093;C0876920;C1524029;C1880549;C1959609;C2347635;C2348144;C2939193;C3813700;C3887524;C4050231	\N	\N
1475	egfr  ml / minute / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439232;C0439526;C0441923;C0700321;C0702093;C1282918;C1705224;C1739039;C2347166;C3811844;C3812682;C3887665	\N	\N
1475	duration of symptoms > $nmbr$ min	C0436359;C0702093;C1524029;C3813700	\N	\N
1475	crp ( mg / l )  median ( min  max )	C0439268;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C3890735;C4048285	\N	\N
1475	cross - damp time : < l : llhrs : min ( n = $nmbr$ )	C0040223;C0205381;C0702093;C1524029;C2828360;C3541383;C3813700;C3891560	\N	\N
1475	baseline pos frequency per $nmbr$ days  median ( min  max )	C0168634;C0549183;C0585290;C0702093;C0876920;C1262869;C1442488;C1524029;C2347635;C2348144;C2939193;C3496112;C3496399;C3813700	\N	\N
1475	baseline in - check * ’ pifr ( l / min )	C0168634;C0702093;C1283174;C1442488;C1524029;C1555524;C3813700;C4321547	\N	\N
1475	[ min  max ]	C0702093;C1524029;C3813700	\N	\N
1475	> $nmbr$ to < $nmbr$ ml / min / l $nmbr$ nr	C0027496;C0702093;C1524029;C1635169;C3813700;C3844738	\N	\N
1475	> $nmbr$ months  median ( min  max )	C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
1475	> $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	> $nmbr$ mi / min	C0702093;C1524029;C3810814;C3813700	\N	\N
1475	> $nmbr$ beats / min	C0702093;C1524029;C3813700	\N	\N
1475	> $nmbr$ : $nmbr$ hrs : min ( n = $nmbr$ )	C0702093;C1524029;C1568891;C3813700	\N	\N
1475	> $nmbr$ . $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	< $nmbr$ months  median ( min  max )	C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
1475	< $nmbr$ ml / minute )	C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665	\N	\N
1475	< $nmbr$ ml / minute	C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665	\N	\N
1475	< $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	< $nmbr$ mi / min	C0702093;C1524029;C3810814;C3813700	\N	\N
1475	< $nmbr$ beats / min	C0702093;C1524029;C3813700	\N	\N
1475	< $nmbr$ . $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	( min ) *	C0702093;C1524029;C3813700	\N	\N
1475	( < $nmbr$ ml / minute ) *	C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665	\N	\N
1475	$nmbr$ to < $nmbr$ ml / minute	C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665	\N	\N
1475	$nmbr$ min / time )	C0040223;C0702093;C1524029;C3541383;C3813700	\N	\N
1475	$nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	$nmbr$ . $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1475	$nmbr$ - min walk distance m	C0369637;C0429886;C0441923;C0702093;C1524029;C3813700	\N	\N
1475	$nmbr$ - min walk distance  ft	C0429886;C0702093;C1524029;C1881534;C3813700;C3890579	\N	\N
1475	$nmbr$ - lead ecg heart rate  beats / min	C0018810;C0179504;C0702093;C1524029;C3813700	\N	\N
1475	$nmbr$ - $nmbr$ min	C0702093;C1524029;C3813700	\N	\N
1474	timi minor bleeding	C0019080;C0026193;C0205165	\N	\N
1474	timi minor	C0026193;C0205165	\N	\N
1474	timi major or minor bleeding	C0019080;C0026193;C0205082;C0205164;C0205165;C4318856;C4521762	\N	\N
1474	minor bleeding	C0019080;C0026193;C0205165	\N	\N
1474	minor bleed	C0019080;C0026193;C0205165	\N	\N
1474	minor	C0026193;C0205165	\N	\N
1474	acuity minor	C0026193;C0205165;C0750509	\N	\N
1474	acuity - bleeding major / minor	C0019080;C0750509;C4441842	\N	\N
1474	> $nmbr$ mon ( n = $nmbr$ )	\N	\N	\N
1474	< $nmbr$ mon ( n = $nmbr$ )	\N	\N	\N
1474	$nmbr$ ( mono )	C1551432;C1551969	\N	\N
1473	updrs iii ( motor )	C0439070;C1513492;C1705160;C1705994;C3639721	\N	\N
1473	updrs  part iii ( motor )	C0439070;C0449719;C1513492;C1705160;C1705994;C1709471;C3639721	\N	\N
1473	pure motor hemiparesis	C0018989;C1513492;C1705994;C2247561	\N	\N
1473	motor weakness	C1513492;C1705994;C3714552	\N	\N
1473	motor updrs subscore ( baseline )  mean ( sd )	C0168634;C0444504;C1442488;C1513492;C1705994;C2347634;C2348143;C2699239;C3639721	\N	\N
1473	motor	C1513492;C1705994	\N	\N
1475	heart rate  / min	C0018810;C0702093;C1524029;C3813700	f	1105
1475	heart rate ( min − $nmbr$ )	C0018810;C0702093;C1524029;C3813700	f	1105
1475	heart rate  min_ $nmbr$ ( mean )	C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700	f	1105
1475	heart rates ( beats / minutes )	C0018810;C0439232;C0700321;C0702093;C1282918;C2347166	f	1105
1475	heart rate 一 beats / min	C0018810;C0702093;C1524029;C3813700	f	1105
1469	< $nmbr$ mmhg	C0439475	f	1888
1472	timi non - cabg major	C0010055;C0205082;C0205164;C1518422;C4318856;C4521762	f	2079
1472	timi major or	C0205082;C0205164;C4318856;C4521762	f	2079
1472	timi major bleeding	C0019080;C0205082;C0205164;C4318856;C4521762	f	2079
1472	timi major	C0205082;C0205164;C4318856;C4521762	f	2079
1472	previous major bleeding	C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762	f	2076
1472	net clinical benefit : on - treatment vte or major bleeding	C0019080;C0039798;C0087111;C0205082;C0205164;C0630906;C0814225;C1456447;C1516635;C1522326;C1533734;C1705169;C3538994;C3853572;C3887704;C3887809;C3890893;C4318856;C4521762;C4684590	\N	\N
1472	minor / major	C0026193;C0205082;C0205164;C0205165;C4318856;C4521762	\N	\N
1472	major secondary end pointf	C0027627;C0175668;C0205082;C0205164;C0205436;C0444930;C2746065;C4318856;C4521762	\N	\N
1472	major cvd /	C0007222;C0205082;C0205164;C4318856;C4521762	\N	\N
1472	major and crnm bleeds	C0019080;C0205082;C0205164;C4318856;C4521762	\N	\N
1472	major amputationsb	C0205082;C0205164;C4318856;C4521762	\N	\N
1472	major adverse cardiovascular events	C0007226;C0205082;C0205164;C0877248;C1705413;C3887460;C4318856;C4521762	\N	\N
1472	major / crnm bleed	C0019080;C0205082;C0205164;C4318856;C4521762	\N	\N
1472	major	C0205082;C0205164;C4318856;C4521762	\N	\N
1472	intracranial disease of major artery 寸	C0205082;C0205164;C0524466;C0852949;C4318856;C4521762	\N	\N
1472	intracranial disease of major artery disease t	C0012634;C0205082;C0205164;C0752138;C4318856;C4521762	\N	\N
1472	hospitalization in previous year with management of heart failure as major component — no . ( % )	C0001554;C0018801;C0018802;C0019993;C0205082;C0205156;C0205164;C0376636;C0439234;C0439508;C0449432;C1273870;C1552607;C1705248;C3273539;C4318856;C4521762;C4554158	\N	\N
1472	history of major cardiovascular disease  n ( % )	C0205082;C0205164;C0455539;C4318856;C4521762	\N	\N
1472	as major component — no . ( % )	C0205082;C0205164;C0449432;C1705248;C4318856;C4521762	\N	\N
1472	amputationsa	\N	\N	\N
1472	acuity major or	C0205082;C0205164;C0750509;C4318856;C4521762	\N	\N
1472	acuity major	C0205082;C0205164;C0750509;C4318856;C4521762	\N	\N
1472	> $nmbr$ % stenosis of major artery  n ( % )	C0038449;C0205082;C0205164;C4318856;C4521762	\N	\N
1471	mssbp ± sd  mmhg	C0439475;C2699239	\N	\N
1471	mssbp > $nmbr$ mmhg	C0439475	\N	\N
1471	mssbp / msdbp	\N	\N	\N
1471	mssbp  mmhg ( sd )	C0439475;C2699239	\N	\N
1471	mssbp	\N	\N	\N
1471	msdbp ± sd  mmhg	C0439475;C2699239	\N	\N
1471	msdbp  mmhg ( sd )	C0439475;C2699239	\N	\N
1471	msdbp	\N	\N	\N
1471	changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p $nmbr$ . $nmbr$ vs $nmbr$ y .	C0023189;C0168634;C0392747;C0443172;C0444504;C1442488;C1547282;C2347634;C2348143	\N	\N
1471	bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation	C0020261;C0277814;C0444504;C0488055;C0871420;C0871470;C1305855;C1306620;C1319894;C2347634;C2348143;C2584297;C2699239;C4050224	\N	\N
1471	baseline mssbp ( mmhg )  mean ± sd	C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1471	baseline msdbp ( mmhg )  mean ± sd	C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1470	mean blood pressure  mmhg ( s . d . j	C0428886;C0488053;C2347155	\N	\N
1470	> = $nmbr$ mmhq	\N	\N	\N
1469	visit $nmbr$ sbp  mm hg	C0085805;C0439475;C0545082;C1512346;C2826704	\N	\N
1469	untreated at baseline  mm hg : sbp  mean ( sd )	C0085805;C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1469	untreated at baseline  mean ( sd )  mm hg	C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1469	treated at baseline  mm hg : sbp  mean ( sd )	C0085805;C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239	\N	\N
1469	systolic — mm hg	C0039155;C0439475	\N	\N
1469	systolic — mean ( sd ) ( mm hg )	C0039155;C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1469	systolic pulmonary arterial pressure  mean ( sd )  mm hg	C0024109;C0039155;C0439475;C0444504;C0871470;C1168098;C2347634;C2348143;C2699239;C2707265;C2709248;C4522268	\N	\N
1469	systolic pressure — mm hg	C0439475;C0871470	\N	\N
1469	systolic pressure  mm hg	C0439475;C0871470	\N	\N
1469	systolic bp ( mmhg ) *	C0439475;C0871470	\N	\N
1469	systolic bp ( mmhg )	C0439475;C0871470	\N	\N
1469	systolic bp ( mm hg )	C0439475;C0871470	\N	\N
1469	systolic bp  mmhg ( sd )	C0439475;C0871470;C2699239	\N	\N
1408	other ^	\N	\N	\N
1472	major bleeding ( mb )	C0019080;C0024853;C0205082;C0205164;C4318856;C4521762	f	2076
1472	major bleeding $nmbr$ to $nmbr$	C0019080;C0205082;C0205164;C4318856;C4521762	f	2076
1472	major gastro - intestinal bleeding	C0017181;C0205082;C0205164;C4318856;C4521762	f	2076
1472	major gl bleeding	C0018229;C0019080;C0205082;C0205164;C1423073;C1427674;C4318856;C4521762	f	2076
1472	major cardiovascular	C0007226;C0205082;C0205164;C3887460;C4318856;C4521762	f	2077
1472	major cardiovascular event	C0205082;C0205164;C1320716;C4318856;C4521762	f	2077
1472	major cardiovascular event *	C0205082;C0205164;C1320716;C4318856;C4521762	f	2077
1472	major clinical response	C0205082;C0205164;C4055223;C4318856;C4521762	f	2077
1472	major cardiovascular events	C0205082;C0205164;C1320716;C4318856;C4521762	f	2077
1472	major coronary event	C0205082;C0205164;C0741923;C4318856;C4521762	f	2077
1472	major cv event	C0205082;C0205164;C0441471;C3538987;C4019010;C4048877;C4318503;C4318856;C4521762	f	2077
1472	major macrovascular events	C0205082;C0205164;C0441471;C3541888;C4318856;C4521762	f	2077
1472	all major cardiovascular events	C0205082;C0205164;C1320716;C4318856;C4521762	f	2077
1472	b major cardiovascular events	C0205082;C0205164;C1320716;C4318856;C4521762	f	2077
1472	combined major macrovascular events .	C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762	f	2077
1472	major st depression or	C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762	f	1091
1472	major st depression or t - wave	C0036056;C0041696;C0205082;C0205164;C0429103;C0520887;C1269683;C3272372;C4318856;C4521762	f	1091
1469	systolic bp  mmhg  mean ± sd	C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239	\N	\N
1469	systolic bp  mmhg  mean ( sd )	C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239	\N	\N
1469	systolic bp  mmhg	C0439475;C0871470	\N	\N
1469	systolic bp  mm   hg  mean ( sd )	C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239	\N	\N
1469	systolic bp  mm hg ( mean ) nyha class	C0039155;C0439475;C0444504;C0488053;C0871470;C1882083;C2347634;C2348143	\N	\N
1469	systolic bp  mm hg  mean ( sd )	C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239	\N	\N
1469	systolic bp  mm hg	C0439475;C0871470	\N	\N
1469	systolic blood pressurea  mm hg	C0005767;C0005768;C0039155;C0229664;C0439475	\N	\N
1469	systolic blood pressure — mmhg	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure — mm hg	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure mmhg  mean ( sd )	C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	systolic blood pressure [ mmhg ] ( interaction : p = $nmbr$ . $nmbr$ )	C0439475;C0488055;C0871470;C1306620;C1704675	\N	\N
1469	systolic blood pressure > $nmbr$ mm hg — no . ( % )	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure > $nmbr$ mm hg or diastolic blood pressure > $nmbr$ mm hg	C0428883;C0439475;C0488055;C0871470;C1305849;C1306620	\N	\N
1469	systolic blood pressure > $nmbr$ mm hg or diastolic	C0012000;C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure > $nmbr$ mm hg  n ( % )	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure > $nmbr$ mm hg	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure < $nmbr$ mm hg and diastolic blood pressure < $nmbr$ mm hg	C0428883;C0439475;C0488055;C0871470;C1305849;C1306620	\N	\N
1469	systolic blood pressure < $nmbr$ mm hg and diastolic	C0012000;C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure - mmhg	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure ( mmhg )  mean ± sd	C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	systolic blood pressure ( mm hg )  mean ( sd )	C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	systolic blood pressure ( mm hg )	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure  mmhg *	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure  mmhg  mean ( sd )	C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	systolic blood pressure  mm   hg	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure  mm hg ^	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure  mm hg < $nmbr$	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure  mm hg ( sd )	C0439475;C0488055;C0871470;C1306620;C2699239	\N	\N
1469	systolic blood pressure  mm hg  mean ± sd	C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	systolic blood pressure  mm hg  mean ( sd )	C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	systolic blood pressure  mm hg	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic blood pressure  mean ( sd )  mm hg	C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	systolic blood pressure  ( mm hg )	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	systolic ( mmhg )	C0039155;C0439475	\N	\N
1469	systolic ( mm hg )	C0039155;C0439475	\N	\N
1469	sl $nmbr$ mm hg	C0439475	\N	\N
1469	sitting systolic blood pressure ( mm hg )	C0277814;C0439475;C0488055;C0871470;C1306620;C2584297;C4050224	\N	\N
1469	sitting diastolic blood pressure ( mm hg )	C0439475;C1319894	\N	\N
1469	sitting blood pressure — mmhg	C0439475;C0580946	\N	\N
1469	sbp > $nmbr$ mm hg	C0085805;C0439475	\N	\N
1469	sbp < $nmbr$ mm hg	C0085805;C0439475	\N	\N
1469	sbp  mm   hg	C0085805;C0439475	\N	\N
1469	sbp  mm hg	C0085805;C0439475	\N	\N
1469	s $nmbr$ mmhg	C0439475;C0565930;C2603362	\N	\N
1469	receiving antihypertensive treatment  n ( % ) blood pressure  mm hg  mean ( sd )	C0003364;C0039798;C0087111;C0428886;C0439475;C1514756;C1522326;C1533734;C1705169;C2699239;C3538994;C3887704	\N	\N
1469	nob systolic blood pressure ( mm hg )	C0439475;C0488055;C0871470;C1306620	\N	\N
1469	nighttime mean dbp ( abpm ) at week $nmbr$  mmhg	C0240526;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799	\N	\N
1469	n ( % ) blood pressure - mean ( sd ) mm hg	C0369718;C0428886;C0439475;C0441922;C2699239	\N	\N
1469	mssbp < $nmbr$ mmhg	C0439475	\N	\N
1469	mssbp ( mm hg )	C0439475	\N	\N
1469	mssbp  mm hg	C0439475	\N	\N
1469	msdbp ( mm hg )	C0439475	\N	\N
1469	msdbp  mm hg	C0439475	\N	\N
1469	mm hg	C0439475	\N	\N
1469	mean — mm hg	C0439475;C0444504;C2347634;C2348143	\N	\N
1469	mean ± sd msdbp  mm hg	C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1469	mean systolic bp  mmhg  mean = sd	C0439475;C0444504;C0871470;C2347634;C2348143;C2699239	\N	\N
1469	mean systolic blood pressure ( sd )  mm hg	C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	mean systolic blood pressure  mm hg ( sd )	C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239	\N	\N
1469	mean systolic blood pressure  mm hg	C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143	\N	\N
1469	mean sd mssbp  mm hg	C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1469	mean pulmonary artery pressure  mm hg	C0439475;C3854605	\N	\N
1469	mean diastolic blood pressure ( sd )  mm hg	C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143;C2699239	\N	\N
1469	mean diastolic blood pressure  mm hg	C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143	\N	\N
1469	mean bp ( mmhg )	C0037623;C0439475;C0444504;C1415692;C1708288;C2347634;C2348143;C4318478	\N	\N
1469	mean blood pressure  mm hg	C0428886;C0439475;C0488053	\N	\N
1469	mean ( s . d . ) systolic blood pressure  mm hg	C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143	\N	\N
1099	< $nmbr$ yea ' s	\N	\N	\N
1469	mean ( s . d . ) diastolic blood pressure  mm hg	C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143	\N	\N
1469	map ( mmhg )	C0024779;C0439475;C1706473;C4050322	\N	\N
1469	diastolic — mm hg	C0012000;C0439475	\N	\N
1469	diastolic — mean ( sd ) ( mm hg )	C0012000;C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1469	diastolic pressure  mm hg	C0428883;C0439475	\N	\N
1469	diastolic blood pressurea  mmhg	C0005767;C0005768;C0012000;C0229664;C0439475	\N	\N
1469	diastolic blood pressure — mm hg	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure mmhg  mean ( sd )	C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239	\N	\N
1469	diastolic blood pressure > $nmbr$ mm hg	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure - mmhg	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure ( mmhg )	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure ( mm hg ) :	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure ( mm hg )  mean ( sd )	C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239	\N	\N
1469	diastolic blood pressure  mmhg  mean ( sd )	C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239	\N	\N
1469	diastolic blood pressure  mmhg	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure  mm   hg	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure  mm hg ^	C0428883;C0439475;C1305849	\N	\N
1469	diastolic blood pressure  mm hg ( sd )	C0428883;C0439475;C1305849;C2699239	\N	\N
1469	diastolic blood pressure  mm hg  mean ± sd	C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239	\N	\N
1469	diastolic blood pressure  mm hg  mean ( sd )	C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239	\N	\N
1469	diastolic blood pressure  ( mm hg )	C0428883;C0439475;C1305849	\N	\N
1469	diastolic ( mmhg )	C0012000;C0439475	\N	\N
1469	diastolic ( mm hg )	C0012000;C0439475	\N	\N
1469	diastolic  mean ( sd )  mm hg	C0012000;C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1469	daytime mean dbp ( abpm ) at week $nmbr$  mmhg	C0332169;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799	\N	\N
1469	change in bp  mm hg	C0439475;C1268766	\N	\N
1469	change from baseline  mmhg	C0168634;C0392747;C0439475;C0443172;C1442488;C1705241;C4319952	\N	\N
1469	blood pressure systolic  mm hg	C0005823;C0039155;C0439475;C1271104;C1272641	\N	\N
1469	blood pressure in mm hg  mean ( sd )	C0428886;C0439475;C0488053;C2699239	\N	\N
1469	blood pressure : systolic / diastolic ( mm hg ) ( mean  sd )	C0439475;C0444504;C2347634;C2348143;C2699239;C2704328	\N	\N
1469	blood pressure ( mm hg ) systolic	C0005823;C0039155;C0439475;C1271104;C1272641	\N	\N
1469	blood pressure  mmhg  mean ( sd )	C0428886;C0439475;C2699239	\N	\N
1469	blood pressure  mm hg  mean ( sd )	C0428886;C0439475;C2699239	\N	\N
1469	blood pressure  mean ± sd mm hg	C0428886;C0439475;C2699239	\N	\N
1469	blood pressure  mean ( sd ) [ range ]  mm hg	C0428886;C0439475;C1514721;C2348147;C2699239;C3542016	\N	\N
1469	blood pressure  mean ( sd )  mm hg systolic	C0039155;C0428886;C0439475;C2699239	\N	\N
1469	blood pressure  mean ( sd )  mm hg	C0428886;C0439475;C2699239	\N	\N
1469	bl mean ( mmhg )	C0005918;C0006413;C0439475;C0444504;C1552663;C2347634;C2348143;C2827109	\N	\N
1469	baseline systolic blood pressure ( mm hg )	C0439475;C4274438	\N	\N
1469	baseline systolic blood pressure  mean ( sd )  mm hg	C0439475;C0444504;C2347634;C2348143;C2699239;C4274438	\N	\N
1469	baseline sitting sbp  $nmbr$ mm hg	C0085805;C0168634;C0277814;C0439475;C1442488;C2584297;C4050224	\N	\N
1469	baseline sedbp  mean ( sd )  mm hg §	C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1469	baseline sbp ( mm hg )	C0085805;C0168634;C0439475;C1442488	\N	\N
1469	baseline mssbp / msdbp  mm hg	C0168634;C0439475;C1442488	\N	\N
1469	baseline diastolic blood pressure ( mm hg )	C0439475;C4274392	\N	\N
1469	baseline diastolic blood pressure  mean ( sd )  mm hg	C0439475;C0444504;C2347634;C2348143;C2699239;C4274392	\N	\N
1469	baseline  mm hg	C0168634;C0439475;C1442488	\N	\N
1469	at home systolic pressure > $nmbr$ mm hg	C0439475;C0871470;C4534363	\N	\N
1469	at home systolic pressure < $nmbr$ mm hg	C0439475;C0871470;C4534363	\N	\N
1469	at home diastolic pressure > $nmbr$ mm hg	C0428883;C0439475;C4534363	\N	\N
1469	at home diastolic pressure < $nmbr$ mm hg	C0428883;C0439475;C4534363	\N	\N
1469	at clinic systolic pressure > $nmbr$ mm hg	C0002424;C0439475;C0442592;C0871470	\N	\N
1469	at clinic systolic pressure < $nmbr$ mm hg	C0002424;C0439475;C0442592;C0871470	\N	\N
1469	at clinic diastolic pressure > $nmbr$ mm hg	C0002424;C0428883;C0439475;C0442592	\N	\N
1469	at clinic diastolic pressure < $nmbr$ mm hg	C0002424;C0428883;C0439475;C0442592	\N	\N
1469	^ numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^ hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . § hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . | | diabetes was defined by self - report .	C0005910;C0011847;C0011849;C0011900;C0020443;C0020473;C0020538;C0025424;C0031831;C0043100;C0201950;C0205120;C0237753;C0332849;C0428257;C0428465;C0428883;C0439175;C0439209;C0439269;C0439475;C0439810;C0439828;C0441074;C0441833;C0444686;C0449788;C0488055;C0489786;C0543421;C0577559;C0577573;C0600653;C0678226;C0681906;C0687744;C0804815;C0871470;C0918012;C1096155;C1257890;C1305849;C1305866;C1306372;C1306620;C1441506;C1515051;C1518422;C1519504;C1522133;C1532563;C1552595;C1552854;C1637833;C1704788;C1705104;C1705428;C1705429;C1963138;C2003902;C2347108;C2347109;C2348272;C2700446;C2986546;C3146286;C3152252;C3539106;C3539882;C3812891;C4283905;C4330985;C4524803;C4554674;C4555212	\N	\N
1469	^ $nmbr$ mm hg	C0439475	f	1888
1469	> $nmbr$ mm hg — no . ( % )	C0439475	f	1888
1469	> = $nmbr$ - < $nmbr$ mmhg	C0439475	f	1888
1469	> $nmbr$ / > $nmbr$ mm hg	C0439475	f	1888
1469	> $nmbr$ to < $nmbr$ mm hg	C0439475	f	1888
1469	apasp ( per mmhg )	C0439475	f	1889
1469	$nmbr$ l $nmbr$ mmhg	C0439394;C0439475;C1706495;C3642217	\N	\N
1468	somnolence	C0013144;C2830004;C4553740	\N	\N
7	p value * $nmbr$	C1709380	\N	\N
7	p value *	C1709380	\N	\N
1468	abbreviations : egfr = estimated glomerular filtration rate  imt = intimal medial thickness  lv = left ventricular . * two - sample comparison t - tests were calculated based on log - transformed variables . * * geometric mean with $nmbr$ % confidence interval in parenthesis .	C0000723;C0009667;C0023128;C0162864;C0205098;C0205448;C0225897;C0334121;C0370003;C0439828;C0444686;C0731033;C0871472;C1256463;C1280412;C1441506;C1510411;C1527178;C1704614;C1705938;C1707455;C1708728;C1739039;C1881413;C2347026;C2986759;C2986775;C3811844;C3812682;C4318736	\N	\N
1467	incidencea	\N	\N	\N
1467	incidence of each outcome	C0021149;C0220856;C1274040	\N	\N
1467	incidence ^	C0021149;C0220856	\N	\N
1467	incidence *	C0021149;C0220856	\N	\N
1467	incidence  ° / o ( $nmbr$ / $nmbr$ cl )	C0021149;C0220856;C0596019	\N	\N
1467	incidence  %	C0021149;C0220856	\N	\N
1467	event incidence / n	C0021149;C0220856;C0441471;C4019010	\N	\N
1467	event / patients in group ( incidence / $nmbr$ person - year )	C0021149;C0027361;C0030705;C0220856;C0439234;C0439508;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2347489;C4019010	\N	\N
1467	cumulative incidence lyear	C0021149;C0220856;C1511559	\N	\N
1467	cumulative incidence $nmbr$ years	C0021149;C0220856;C0439234;C1511559	\N	\N
1467	$nmbr$ - year cumulative incidence  % ( ci )	C0008107;C0021149;C0220856;C0439234;C0439508;C1511559;C3259781	\N	\N
1466	sbp  difference	C0085805;C1705241;C1705242	\N	\N
1466	risk difference	C0035647;C1705241;C1705242;C4552904	\N	\N
1466	percentage difference ( $nmbr$ % cl )	C0439165;C0596019;C1549488;C1561533;C1705241;C1705242	\N	\N
1466	mean arterial pressure  difference	C0428886;C1705241;C1705242	\N	\N
1466	lsm difference	C1705241;C1705242	\N	\N
1466	laba + ics versus indzgly lsm difference ( $nmbr$ % cl )	C0596019;C0815320;C1705241;C1705242;C4551720	\N	\N
1466	group difference	C0441833;C0687744;C1257890;C1519504;C1705241;C1705242;C1705428;C1705429	\N	\N
1466	estimated treatment difference ( % )	C0039798;C0087111;C0750572;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704	\N	\N
1466	estimated means and treatment differences ( % )	C0039798;C0087111;C0750572;C1522326;C1533734;C1704970;C1705169;C1705241;C1705242;C3538994;C3887704	\N	\N
1466	estimated means and difference	C0750572;C1704970;C1705241;C1705242	\N	\N
1466	estimated difference %	C0750572;C1705241;C1705242	\N	\N
1466	estimated difference	C0750572;C1705241;C1705242	\N	\N
1466	differencevs . pbof	\N	\N	\N
1466	difference vs pbo ( $nmbr$ % ci )	C0008107;C0031962;C1705241;C1705242;C3259781	\N	\N
1466	difference vs . pbof mean ( s . e . ) t	C0444504;C1705241;C1705242;C2347634;C2348143	\N	\N
1466	difference in sbp between treatment	C0039798;C0085805;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704	\N	\N
1466	difference in means ( $nmbr$ % cl )	C0596019;C1704970;C1705241;C1705242	\N	\N
1466	difference in means	C1704970;C1705241;C1705242	\N	\N
1466	difference in change	C0392747;C0443172;C1705241;C1705242;C4319952	\N	\N
1466	difference from baselinea	C1705241;C1705242	\N	\N
1466	difference ( tiotropium - placebo ) ml ( $nmbr$ % ci )	C0008107;C0032042;C0213771;C0439526;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665	\N	\N
1466	difference ( % )	C1705241;C1705242	\N	\N
1466	difference $nmbr$	C1705241;C1705242	\N	\N
1466	difference	C1705241;C1705242	\N	\N
1466	* plus - minus values are means ± sd . there were no significant differences ( at	C0042295;C0237881;C0332288;C0750502;C1546944;C1704970;C1705241;C1705242;C2699239	\N	\N
1466	% - point difference ( $nmbr$ % ci ) c	C0008107;C1552961;C1705241;C1705242;C2347617;C3259781;C3714763	\N	\N
1466	$nmbr$ % ci for difference	C0008107;C1705241;C1705242;C3259781	\N	\N
1465	medication adherence	C2364172	\N	\N
1465	adherence > $nmbr$ %	C1510802	\N	\N
1464	type of reference treatment strategy	C0455708;C0679199;C1514811;C1706462	\N	\N
1464	referent	C1706462	\N	\N
1464	reference	C1514811;C1706462	\N	\N
1464	no ( reference )	C1514811;C1706462	\N	\N
1464	< $nmbr$ mg dl ( reference )	C0439269;C1514811;C1706462	\N	\N
1464	< $nmbr$ kg  mj ( reference )	C0022718;C0439209;C0439254;C1514811;C1706462;C4054209;C4284025	\N	\N
1464	$nmbr$ . $nmbr$ ( referent )	C1706462	\N	\N
1464	$nmbr$ . $nmbr$ ( reference )	C1514811;C1706462	\N	\N
1463	sonti amenca	\N	\N	\N
1463	region north america	C0017446;C0028405;C0205147	\N	\N
1463	region - north america	C0017446;C0028405;C0205147	\N	\N
1463	region  north america	C0017446;C0028405;C0205147	\N	\N
1463	north america n z $nmbr$	C0028405	\N	\N
1463	north america / oceania	C0028405;C0282279;C4085681	\N	\N
1463	north america *	C0028405	\N	\N
1469	$nmbr$ mmhg	C0439475	f	1888
1469	$nmbr$ mm hg	C0439475	f	1888
1469	< $nmbr$ mm hg heart rate	C0018810;C0439475	f	1888
1469	< $nmbr$ / $nmbr$ mm hg	C0439475	f	1888
1469	< $nmbr$ / $nmbr$ mm hg +	C0439475	f	1888
1469	< $nmbr$ . $nmbr$ mm hg	C0439475	f	1888
1469	< $nmbr$ . $nmbr$ mm hg diastolic blood pressure	C0428883;C0439475;C1305849	f	1888
1469	$nmbr$ - $nmbr$ / $nmbr$ - $nmbr$ mm hg	C0439475	f	1888
1469	$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmhg	C0439475	f	1888
1469	$nmbr$ o - i $nmbr$ mm hg	C0021966;C0221138;C0439475;C0483204	f	1888
1469	$nmbr$ to < $nmbr$ mmhg	C0439475	f	1888
1469	$nmbr$ to < $nmbr$ mm hg	C0439475	f	1888
1469	$nmbr$ to $nmbr$ mm hg	C0439475	f	1888
1466	absolute risk difference ( ci )  % *	C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904	f	2259
1468	relative risk ( $nmbr$ % confidence interval )	C0009667;C0242492	f	2260
1468	$nmbr$ % confidence interval	C0009667	f	2261
1463	north america ( plus america and new zealand )	C0027978;C0028405;C0324547;C0332287	\N	\N
1463	north america ( n = $nmbr$ )	C0028405	\N	\N
1463	north america ( % )	C0028405	\N	\N
1463	north america	C0028405	\N	\N
1463	n america	C0002454;C0369718;C0441922	\N	\N
1463	latin and north america	C0028405	\N	\N
1463	geographic region - north america	C0017446;C0028405	\N	\N
1462	mexico  central / south america	C0007674;C0025885;C0037713;C0205099;C1710133;C1879652	\N	\N
1462	mexico	C0025885	\N	\N
1461	region latin american	C0017446;C0205147;C1553378	\N	\N
1461	latin ameriea	\N	\N	\N
1461	latin american	C1553378	\N	\N
1461	latin america hr ( $nmbr$ % cl )	C0023122;C0596019	\N	\N
1461	latin america ( n = $nmbr$ )	C0023122	\N	\N
1461	latin america	C0023122	\N	\N
1461	latin	\N	\N	\N
1460	vka experienced	C0237607;C0596545	\N	\N
1460	prior vka experience	C0237607;C0332152;C0596545;C2826257	\N	\N
1460	oac experienced  bn   ( % )	C0005005;C0034700;C0237607;C0596545;C1706574;C4551963	\N	\N
1460	experienced	C0237607;C0596545	\N	\N
1460	experience ( n  % )	C0237607;C0596545	\N	\N
1460	experience	C0237607;C0596545	\N	\N
1460	clinic research experience  n ( % )	C0008972;C0237607;C0596545	\N	\N
1460	cdmard experience  n ( % )	C0237607;C0596545	\N	\N
1459	vldm n = $nmbr$	\N	\N	\N
1459	hdm n = $nmbr$	\N	\N	\N
1458	hd edoxaban vs warfarin	C0043031;C2975435	\N	\N
1457	qd	C0332173	\N	\N
1457	indacaterol $nmbr$ gg qd	C0017454;C0018370;C0332173;C1722260	\N	\N
1456	gall bladder adverse event ( n = $nmbr$ )	C0016976;C0877248	\N	\N
1455	biomarker levels	C0005516;C0441889	\N	\N
1454	teaes ( > $nmbr$ % in any treatment group ) *	C0374505	\N	\N
1454	teaes ( > $nmbr$ % in any treatment group )	C0374505	\N	\N
1454	any teaes	\N	\N	\N
1454	any teae	\N	\N	\N
1454	all treatments	C0087111	\N	\N
1454	all	\N	\N	\N
1452	alleles	C0002085	\N	\N
1451	ulcers / gangrene	C0017086;C0041582	\N	\N
1451	ulcer  n ( % ) a	C0041582;C3887532	\N	\N
1451	ulcer	C0041582;C3887532	\N	\N
1451	or ulcerations  ® n ( % )	C0041582	\N	\N
1450	verapamil sr strategy ( n = $nmbr$  $nmbr$ )	C0679199;C1527129	\N	\N
1450	verapamil sr n = $nmbr$ no . ( % )	C1527129	\N	\N
1450	verapamil sr n = $nmbr$	C1527129	\N	\N
1450	verapamil sr ( no . = $nmbr$ )	C1527129	\N	\N
1450	verapamil sr	C1527129	\N	\N
1450	verapamil - sr strategy	C0679199;C1527129	\N	\N
1450	verapamil - sr ( « = $nmbr$ $nmbr$ )	C1527129	\N	\N
1450	verapamil ( n  % )	C0042523	\N	\N
1450	use of verapamil or quinidine	C0034414;C0042523;C1524063	\N	\N
1449	varespladib ( n = $nmbr$ )	C2713485	\N	\N
1449	varespladib	C2713485	\N	\N
1448	vorapaxar placebo	C0032042;C1696465;C1706408;C2974521	\N	\N
1448	vorapaxar no . ( $nmbr$ - y km % )	C2974521;C3887676	\N	\N
1448	vorapaxar n = $nmbr$	C2974521	\N	\N
1450	diltiazem or verapamil	C0012373;C0042523	f	2244
1451	irregular or ulcerated ica p ) laque : [ :	C0041582;C0201519;C0205271;C3887532	f	2245
1451	irregular or ulcerated ica plaquef	C0041582;C0201519;C0205271;C3887532	f	2245
1452	allergic disease by historyb  n ( % )	C0020517;C0851444	f	2246
1452	ongoing atopic or allergic condition — no . { % )	C0392707;C0549178;C0851444	f	2246
1453	aes *	C1412268;C2699274	f	47
1453	aes in ≥ $nmbr$ japanese patients in a study arm  n ( % ) §	C0030705;C0376247;C0446516;C0557651;C1412268;C1556094;C2603343;C2699274;C3715044;C4553528	f	47
1453	fatal aes	C1302234;C1412268;C1705232;C2699274	f	47
1453	gallbladder - related aes	C0016976;C0439849;C0445223;C1412268;C2699274	f	47
1453	investigator - reported aes	C0035173;C0684224;C0700287;C1412268;C2699274;C4319718	f	47
1453	most common aes ‡	C0205214;C0205393;C1412268;C1522138;C2699274;C3245511	f	47
1453	most common aes in any group	C0205214;C0205393;C0441833;C0687744;C1257890;C1412268;C1519504;C1522138;C1705428;C1705429;C2699274;C3245511	f	47
1453	> $nmbr$ aes	C1412268;C2699274	f	47
1453	osmotic diuresis - related aes	C0232823;C0439849;C0445223;C1412268;C2699274	f	47
1453	other selected aes	C1412268;C1707391;C2699274	f	47
1453	tier $nmbr$ aes	C1412268;C2699274	f	47
1453	volume depletion - related aes	C0439849;C0445223;C0546884;C1412268;C2699274	f	47
1455	elevated biomarkers and st - segment changes	C0005516;C0205250;C0232326;C3163633	f	2247
1455	sle markers  n ( % )	C0005516;C0024141	f	2248
1457	d  mitral stenosis vhd ( n = $nmbr$ )	C0026269;C0073187;C0264766;C0332173;C4484261	f	2249
1457	tiotropium $nmbr$ gg qd	C0017454;C0018370;C0213771;C0332173	f	1372
1457	a  no vhd ( n = $nmbr$ $nmbr$ )	\N	f	103
1457	b  vhd ( n = $nmbr$ )	\N	f	103
1457	no vhd	\N	f	103
1458	hd ( n = $nmbr$ )	\N	f	2250
1459	vildagliptin + metformin ( vldm )	C0025598;C1570906	f	2251
1459	metformin ( hdm )	C0025598	f	1345
1461	native american	C0282204;C1515945	f	2254
1461	native american or alaska native	C0282204;C0682125;C1515945	f	2254
1461	native american / alaskan	C0238611;C0282204;C0596070;C0682125;C1515945	f	2254
1461	native american or alaskan native	C0238611;C0282204;C0302891;C1515945	f	2254
1461	indian ( american ) or alaskan native	C0238611;C0302891;C0596070;C1524069	f	2255
1461	american	C0596070	f	2256
1461	hispanic american	C0019576	f	2257
1461	hispanic / latin american	C0019576	f	2257
1461	mexican	C0240339	f	1462
1463	america	C0002454	f	2258
1448	vorapaxar group ( n = $nmbr$ )	C0441848;C2974521	\N	\N
1448	vorapaxar event rate ( n = $nmbr$ )  %	C0441471;C0871208;C1521828;C2974521;C4019010	\N	\N
1448	vorapaxar ( n = $nmbr$ . $nmbr$ )	C2974521	\N	\N
1448	vorapaxar ( n = $nmbr$ )  n ( % )	C2974521	\N	\N
1448	vorapaxar ( n = $nmbr$ )	C2974521	\N	\N
1448	vorapaxar ( n = $nmbr$ $nmbr$ )	C2974521	\N	\N
1448	vorapaxar ( n = $nmbr$  $nmbr$ )	C2974521	\N	\N
1448	vorapaxar $nmbr$ - y	C2974521	\N	\N
1448	vorapaxar	C2974521	\N	\N
1447	proximal - mainleft	C0205107;C4489236	\N	\N
1447	proximal	C0205107;C4489236	\N	\N
1446	paroxysmal atrial fibrillation — no . ( % )	C0235480;C4050122	\N	\N
1446	paroxysmal af	C0235480	\N	\N
1446	history of paroxysmal atrial fibrillation  n ( % )	C0205311;C0729790	\N	\N
1446	history of paroxysmal af	C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062	\N	\N
1445	post - procedure	C3272301	\N	\N
1444	pressure	C0033095;C0460139;C1306345;C4284008	\N	\N
-10	czech repumc	C0337799	\N	\N
-10	puerperium	C0034042;C0086839;C1879329	\N	\N
1441	rectum and sigmoid colon only	C0034896;C0205171;C0227391;C1720467	\N	\N
1440	rib	C0035561	\N	\N
1440	( ri = $nmbr$ )	C0035487;C1826843	\N	\N
1439	subgroup w . r . t . re - cover	C0180153;C0232024;C0556581;C1079230;C1515021;C1999244;C2986904;C3888055	\N	\N
1439	re - medy	C0556581;C2986904	\N	\N
1438	time to rx	C0040223;C1425688;C1521941;C2709207;C3541383	\N	\N
-10	qmaxi rn l / s	C2827110;C3540639;C4281819	\N	\N
1436	> $nmbr$ rd quartile	C0694666;C2828255;C4553350	\N	\N
1436	> $nmbr$ nd and < $nmbr$ rd quartile	C0694666;C2828255;C4553350	\N	\N
1436	$nmbr$ rd tertile ( > $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) d	C0439190;C0439269;C0475219;C0567349;C0694666;C2348885;C3642216;C4553350	\N	\N
1436	$nmbr$ rd > $nmbr$ . $nmbr$	C0694666;C4553350	\N	\N
1435	seropositive ( rf + ve and / or acpa + ve ) subgroup	C0035448;C0042469;C0201660;C0521143;C0748398;C1079230;C1515021;C1525410;C1547111;C1706063;C3714652;C4321495	\N	\N
1435	rheumatoid factor - positive	C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269	\N	\N
1435	rheumatoid factor !	C0035448;C0201660	\N	\N
1435	rf positive — number ( % )	C0035448;C0201660;C0748398;C1547111;C3812269	\N	\N
1435	rf positive and acpa negative  n ( % )	C0035448;C0201660;C0205160;C0439178;C0748398;C1446409;C1513916;C1514241;C1525410;C1547111;C1706063;C2825415;C2825490;C2825491;C3812269;C3853545	\N	\N
1435	rf positive ( > $nmbr$ iu / ml )  n ( % )	C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269	\N	\N
1435	rf positive  no . ( % )	C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269	\N	\N
1435	rf positive  n ( % )	C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269	\N	\N
1435	rf positive  %	C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269	\N	\N
1435	rf positive	C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269	\N	\N
1435	rf negative and acpa positive  n ( % )	C0035448;C0201660;C0205160;C0439178;C0748398;C1446409;C1513916;C1514241;C1525410;C1547111;C1706063;C2825415;C2825490;C2825491;C3812269;C3853545	\N	\N
1435	rf and acpa positive  n ( % )	C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1525410;C1547111;C1706063;C2825490;C3812269	\N	\N
1435	rf - positive  > $nmbr$ iu / ml  %	C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269	\N	\N
1435	rf ( mg / dl )	C0035448;C0201660;C0439269;C0748398;C1547111	\N	\N
1435	rf ( mg / dl  per unit )	C0024671;C0026410;C0035448;C0201660;C0439148;C0439269;C0439453;C0748398;C1509845;C1519795;C1532632;C1547111;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C4321396;C4521761	\N	\N
1435	rf ( iu / ml )	C0035448;C0201660;C0439458;C0748398;C1547111	\N	\N
1435	rf  % positive	C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269	\N	\N
1435	positive for rheumatoid factor — no . ( % ) : t	C0035448;C0201660;C0439178;C1446409;C1514241;C2603360;C2825490;C3812269	\N	\N
1435	% rf +	C0035448;C0201660;C0748398;C1547111	\N	\N
1434	tk	C0041405;C0220928;C4050092	\N	\N
1444	systoiic biood pressure  mm hg	C0033095;C0439475;C0460139;C1306345;C4284008	f	1469
1444	diastoiic biood pressure  mm hg	C0033095;C0439475;C0460139;C1306345;C4284008	f	1469
1434	tc : hdlc	C0039411;C0040642;C0041405;C0041698;C1704429;C1824670;C3272447;C4522122	f	2236
1444	any blood pressure medications ( % )	C0005823;C0013227;C0033095;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232	f	1579
1434	tc ( mg / dl )	C0039411;C0040642;C0041405;C0041698;C0439269;C1824670;C3272447;C4522122	f	368
1434	tc ( mmol / l )	C0039411;C0040642;C0041405;C0041698;C1532563;C1824670;C3272447;C4522122	f	368
1434	tc  mmol / l ( mg / dl )	C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3642216;C3898312;C4522122	f	368
1434	waist circumference women : > $nmbr$ in ( $nmbr$ cm ) men : > $nmbr$ in ( $nmbr$ cm ) tc $nmbr$ c $nmbr$ mg / dl	C0025266;C0039411;C0040642;C0041405;C0041698;C0043210;C0439269;C0455829;C1824670;C3272447;C4522122	f	1413
1438	any new anti - hyperglycemic rx	C0205314;C1425688;C1521941;C2709207	f	33
1440	primary ep ( cvd / mi / ri )	C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526	f	230
1441	rectum	C0034896	f	2237
1444	question $nmbr$ ( discomfort from any areas tender to touch / pressure )	C0033095;C0152054;C0205146;C0234234;C0439815;C0460139;C0702221;C1306345;C1522634;C2364135;C4284008;C4319729	f	2238
1444	pressure ( mm hg )	C0033095;C0439475;C0460139;C1306345;C4284008	f	2239
1445	other diagnostic procedure *	C0430022;C1546908	f	2240
1445	pre - procedure	C3272300	f	2241
1447	proximal gastrointestinal tract	C0017189;C0205107;C0521362;C4489236	f	2242
1447	proximal gi tract	C0017189;C0205107;C4489236	f	2242
1447	proximal to the splenic flexure	C0205107;C0227387;C4489236	f	2242
1447	pyrexia	C0015967	f	2243
1433	uacr  mg / g  median ( $nmbr$ th − $nmbr$ th percentile )	C0039725;C0039738;C0549183;C0876920;C1264641;C1300563;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	\N	\N
1433	th c	C0039725;C0039738;C1420718;C4282123;C4285344	\N	\N
1433	th ( $nmbr$ % )	C0039725;C0039738;C1420718;C4282123;C4285344	\N	\N
1433	median ( $nmbr$ th  $nmbr$ th percentile )	C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	\N	\N
1433	euroscore logistic  median ( $nmbr$ th  $nmbr$ th % ) £	C0039725;C0039738;C0242415;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344	\N	\N
1433	euroscore additive  median ( $nmbr$ th  $nmbr$ th % ) §	C0039725;C0039738;C0442796;C0549183;C0876920;C1420718;C1550602;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344	\N	\N
1433	$nmbr$ th — $nmbr$ th percentiles	C0039725;C0039738;C1264641;C1420718;C4282123;C4285344	\N	\N
1433	$nmbr$ th : $nmbr$ . $nmbr$ - $nmbr$ pmol / l	C0039725;C0039738;C0439284;C1420718;C4282123;C4285344	\N	\N
1433	$nmbr$ th - $nmbr$ th percentiles	C0039725;C0039738;C1264641;C1420718;C4282123;C4285344	\N	\N
1432	any type  according to daily dose * *	C0332307;C0680240;C1547052;C2348070	\N	\N
1432	$nmbr$ % ( oto $nmbr$ )	\N	\N	\N
1432	$nmbr$ % ( ito $nmbr$ )	C0022283	\N	\N
1432	$nmbr$ % ( - ito $nmbr$ )	C0022283	\N	\N
1431	$nmbr$ to $nmbr$ y  n ( % )	\N	\N	\N
1430	tj ( $nmbr$ - $nmbr$ )	C0039247	\N	\N
1430	tj ( $nmbr$ % )	C0039247	\N	\N
1430	- $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ § ti	C0039247;C0040302;C1553045;C1704756	\N	\N
1429	unadjusteda beta ( se )	C0036919;C0330390;C0439096;C2004068	\N	\N
1429	beta $nmbr$ selective	C0036576;C0330390;C0439096;C1707391;C2004068	\N	\N
1429	adjustedb  c beta ( se )	C0036919;C0330390;C0439096;C2004068	\N	\N
1428	both adalimumab groups ( n = $nmbr$ ) baseline cd - related antibiotic use	C0003232;C0007928;C0034283;C0042153;C0168634;C0369718;C0439849;C0441833;C0441922;C0445223;C0457083;C0687744;C1122087;C1257890;C1442488;C1519504;C1552839;C1705428;C1705429;C1947944;C4552032	\N	\N
1428	both ( % )	\N	\N	\N
1428	both	\N	\N	\N
1428	> $nmbr$ and / or > $nmbr$ moderate or severe deformity  or both ( n = $nmbr$ )	C0000768;C0205081;C0205082;C0221430;C0302142;C0369718;C0441922;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
1427	pci data	C1511726;C3245479;C3714741;C4049621	\N	\N
1427	number of patients with available data	C0470187;C1511726;C2360800;C3245479;C3714741	\N	\N
1427	no ef data | |	C1511726;C3245479;C3714741	\N	\N
1427	fpg data '	C1511726;C3245479;C3714741	\N	\N
1427	ecg and imaging data	C0011923;C0079595;C1511726;C1623258;C3245479;C3714741	\N	\N
1427	data  ' ' n	C1511726;C3245479;C3714741	\N	\N
1427	baseline data	C0168634;C1442488;C1511726;C3245479;C3714741	\N	\N
1427	available data	C0470187;C1511726;C3245479;C3714741	\N	\N
1427	at c data	C1511726;C3245479;C3714741	\N	\N
1427	* data are expressed as median ± sd  except	C0549183;C0876920;C1511726;C2347635;C2348144;C2699239;C2939193;C3245479;C3714741	\N	\N
1427	* data are expr	C1511726;C3245479;C3714741	\N	\N
1426	transient monocular blindness	C0149793	\N	\N
1425	immunomodulatory agents	C0005525	\N	\N
1425	immunomodulators	C0001551;C0005525;C1527392	\N	\N
1424	no glucocorticoids or immunosuppressants	C0017710;C0021081;C3540777;C3540778	\N	\N
1099	< $nmbr$ . $nmbr$ years	C0439234	\N	\N
1427	laboratory data	C0022877;C1511726;C3244292;C3245479;C3714741;C4283904	f	2232
1427	laboratory data  mean ( sd )	C0022877;C0444504;C1511726;C2347634;C2348143;C2699239;C3244292;C3245479;C3714741;C4283904	f	2232
1429	beta receptor antagonist	C0330390;C0439096;C2004068;C4543207	f	959
1429	beta bloekers	C0330390;C0439096;C2004068	f	959
1430	sou ti africa	C0001737;C0039247;C0040302;C1553045;C1704756	f	48
1429	beta - carotene	C0053396;C0696105	f	2233
1429	beta - carotene ( n = $nmbr$  $nmbr$ )	C0053396;C0696105	f	2233
1433	age  median ( $nmbr$ th - $nmbr$ th percentiles )  y	C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	f	2234
1431	due to ae	C3887670	f	47
1431	due to drug - relateda ae	C0013227;C1254351;C3887670	f	47
1431	discontinuations due to ae	C0457454;C0678226;C3887670	f	1974
1433	age  y ( $nmbr$ th  $nmbr$ th percentiles )	C0001779;C0039725;C0039738;C1264641;C1420718;C4282123;C4285344	f	2234
1433	weight  kg  median ( $nmbr$ th  $nmbr$ th )	C0005910;C0022718;C0039725;C0039738;C0043100;C0439209;C0549183;C0876920;C1305866;C1420718;C1705104;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344	f	2235
1433	weight ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ]	C0039725;C0039738;C0549183;C0552346;C0876920;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344	f	2235
1433	weight  median ( $nmbr$ th — $nmbr$ th percentiles )  kg	C0022718;C0039725;C0039738;C0439209;C0549183;C0552346;C0876920;C1420718;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344	f	2235
1433	time from onset of pain to randomization  median ( $nmbr$ th — $nmbr$ th percentiles )  n	C0030193;C0034656;C0039725;C0039738;C0449244;C0518090;C0549183;C0876920;C1264641;C1420718;C1962977;C2347635;C2348144;C2939193;C2984058;C4085210;C4085211;C4085212;C4282123;C4285344;C4553004;C4554132	f	2169
1434	= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having	C0023128;C0039411;C0040363;C0040642;C0041260;C0041405;C0041698;C0062152;C0439190;C0694651;C1142985;C1824670;C1883351;C3272447;C3642216;C4522122	f	-10
1434	baseline tc  mg / dl	C0039411;C0040642;C0041405;C0041698;C0168634;C0439269;C1442488;C1824670;C3272447;C4522122	f	368
1434	tc	C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122	f	368
1424	no concomitant immunosuppressive and / or prior anti - tnf use	C0021081;C0042153;C0332152;C0457083;C0521115;C1448177;C1947944;C2826257	\N	\N
1424	no baseline immunosuppressant use	C0021081;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
1424	neither glucocorticoids nor immunosuppressive agents	C0017710;C0021081;C3540777;C3540778	\N	\N
1424	immunosuppressive use  n ( % )	C0021081;C0042153;C0457083;C1947944	\N	\N
1424	immunosuppressive agents only	C0021081;C0205171;C1720467	\N	\N
1424	immunosuppressants onlyff	C0021081	\N	\N
1424	immunosuppressants only	C0021081;C0205171;C1720467	\N	\N
1424	immunosuppressants	C0021081	\N	\N
1424	immunosuppressant use  %	C0021081;C0042153;C0457083;C1947944	\N	\N
1424	immunosuppressant ^ ^	C0021081	\N	\N
1424	immunosuppressant ^	C0021081	\N	\N
1424	glucocorticoids plus immunosuppressive agents	C0017710;C0021081;C3540777;C3540778	\N	\N
1424	glucocorticoids combined with immunosuppressive agents	C0017710;C0021081;C0205195;C3540777;C3540778	\N	\N
1424	glucocorticoids and immunosuppressants	C0017710;C0021081;C3540777;C3540778	\N	\N
1424	corticosteroids and immunosuppressants only	C0001617;C0021081;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727	\N	\N
1424	concomitant immunosuppressive and / or prior anti - tnf use	C0021081;C0042153;C0332152;C0457083;C0521115;C1448177;C1947944;C2826257	\N	\N
1424	both adalimumab groups ( n = $nmbr$ ) baseline immunosuppressant use	C0021081;C0042153;C0168634;C0369718;C0441833;C0441922;C0457083;C0687744;C1122087;C1257890;C1442488;C1519504;C1552839;C1705428;C1705429;C1947944	\N	\N
1424	any immunosuppressive agent	C0021081	\N	\N
1423	• death from any cause	C0007465	\N	\N
1423	death from any cause	C0007465	\N	\N
1423	cause of death unknown	C0007465;C0439673;C3541433;C4050014;C4050444	\N	\N
1423	by cause of death	C0007465;C4050444	\N	\N
1422	crude analysis  n ( % )	C0002778;C0936012;C1524024	\N	\N
1422	crude	\N	\N	\N
1421	ocs maintained / increased	C0205217;C0442805;C1314677	\N	\N
1420	smoking status current smoker ( n = $nmbr$ )	C1519386;C3173209;C3241966	\N	\N
1420	smoking history : current smoker	C1519384;C3173209;C3241966	\N	\N
1420	smoking : current smoker	C0037369;C0453996;C1881674;C3173209;C3241966	\N	\N
1420	former or current smokers ( % )	C0205156;C0750523;C3173209;C3241966	\N	\N
1420	ex - / current smoker	C0337671;C0521116;C1704625;C1705970;C3173209;C3241966;C4555205	\N	\N
1420	current tobacco smoker ( % ) qualifying event ( % )	C0040329;C0086707;C0441471;C0521116;C0740009;C1514624;C1705970;C3173209;C3241966;C4019010;C4505217	\N	\N
1420	current tobacco smoker	C0040329;C0086707;C0521116;C0740009;C1705970;C3173209;C3241966;C4505217	\N	\N
1420	current smokers *	C3173209;C3241966	\N	\N
1420	current smokers ( n = $nmbr$ )	C3173209;C3241966	\N	\N
1420	current smokers ( itt ) ( n = $nmbr$ )	C3173209;C3241966	\N	\N
1420	current smokers ( % )	C3173209;C3241966	\N	\N
1420	current smokers    n   ( % )	C3173209;C3241966	\N	\N
1420	current smokers  n ( % ) medicai history  n ( % )	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3173209;C3241966	\N	\N
1420	current smokers  n ( % )	C3173209;C3241966	\N	\N
1420	current smokers  %	C3173209;C3241966	\N	\N
1420	current smokers	C3173209;C3241966	\N	\N
1420	current smoker — no . { % )	C3173209;C3241966	\N	\N
1420	current smoker »	C3173209;C3241966	\N	\N
1420	current smoker at screeninga  n ( % )	C3173209;C3241966	\N	\N
1420	current smoker at screening  n ( % )	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3173209;C3241966	\N	\N
1420	current smoker at baseline    n   ( % )	C0168634;C1442488;C3173209;C3241966	\N	\N
1420	current smoker : ex - smoker ( % )	C3173209;C3241966	\N	\N
1420	current smoker ( n z $nmbr$ )	C3173209;C3241966	\N	\N
1420	current smoker ( n = $nmbr$ )	C3173209;C3241966	\N	\N
1420	current smoker ( n = $nmbr$  $nmbr$ ) former smoker ( n = $nmbr$  $nmbr$ )	C0205156;C0750523;C3173209;C3241966	\N	\N
1420	current smoker ( n = $nmbr$  $nmbr$ )	C3173209;C3241966	\N	\N
1420	current smoker ( > $nmbr$ cigarettes / day ) — no . ( % )	C0332173;C0439228;C0439505;C0677453;C3173209;C3241966	\N	\N
1420	current smoker ( % )	C3173209;C3241966	\N	\N
1420	current smoker  n [ % ]	C3173209;C3241966	\N	\N
1420	current smoker  n / n ( % )	C3173209;C3241966	\N	\N
1420	current smoker  n ( % }	C3173209;C3241966	\N	\N
1420	current smoker  n ( % of patients )	C0030705;C3173209;C3241966	\N	\N
1420	current smoker  n ( % )	C3173209;C3241966	\N	\N
1420	current smoker  %	C3173209;C3241966	\N	\N
1420	current smoker	C3173209;C3241966	\N	\N
1420	current cigarette smoker or within past year	C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423;C4086728	\N	\N
1420	current cigarette smoker  n ( % )	C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423	\N	\N
1420	current cigarette smoker	C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423	\N	\N
1420	current / past smoker	C1444637;C3173209;C3241966;C4284302	\N	\N
1420	> $nmbr$ . $nmbr$ bpm current smoker	C3173209;C3241966	\N	\N
1419	any recurrent stroke	C2242682	\N	\N
1419	all recurrent strokes	C1836785	\N	\N
1418	concurrent illness	C0205420;C0221423	\N	\N
1099	( years )	C0439234	\N	\N
1419	strokezsee	\N	f	1762
1418	concurrent prednisolone	C0032950;C0205420	f	2226
1420	current drinker	C0556297	f	875
1420	currentd	\N	f	-10
1421	alt increased	C0205217;C0442805;C1266129;C4553172	f	2227
1421	increased waist circumference	C0205217;C0442805;C0455829	f	1413
1421	increased risk for thrombotic cardiovascular event ^  n ( % )	C0087086;C0205217;C0442805;C1273410	f	2228
1421	pancreas	C0030274	f	2229
1423	nausea	C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767	f	2230
1421	ggt increased	C0205217;C0442805;C1415053	f	2262
1417	history of currently treated hypertension  n ( % )	C0455527;C0521116;C1522326	\N	\N
1417	currently	C0521116	\N	\N
1417	current use of hormone therapy	C0019932;C0279025;C0521116;C1524063;C1705970;C2827774;C4521914	\N	\N
7	p value ( nominal )	C1709380	\N	\N
1417	current prescribed medications	C0521116;C1705970;C3166216;C3202967	\N	\N
1417	current or previous atrial fibrillation	C0004238;C0205156;C0344434;C0521116;C1552607;C1705970;C1963067	\N	\N
1417	current n z $nmbr$	C0521116;C1705970	\N	\N
1417	current inhaler +	C0021461;C0521116;C1705970;C1881212;C4319647	\N	\N
1417	current corticosteroid use  n	C0239126;C0521116;C1705970	\N	\N
1417	current ( n   = $nmbr$  $nmbr$ )	C0521116;C1705970	\N	\N
1417	current ( % )	C0521116;C1705970	\N	\N
1417	current  n ( % )	C0521116;C1705970	\N	\N
1417	current	C0521116;C1705970	\N	\N
1416	current medication — no . ( % )	C0746467	\N	\N
1416	current medication  n ( % )	C0746467	\N	\N
-10	chest discomfort	C0235710	\N	\N
1414	left circumflex coronary artery	C0226037	\N	\N
1414	left circumflex artery  n ( % )	C0226037	\N	\N
1414	left circumflex artery	C0226037	\N	\N
1414	left circumflex  n ( % )	C0205091;C0443246;C1552822;C1880089	\N	\N
1414	left circumflex	C0205091;C0443246;C1552822;C1880089	\N	\N
1413	waist circumference — cmj	C0455829	\N	\N
1413	waist circumference — cm	C0455829	\N	\N
1413	waist circumference s $nmbr$ ( men ) or > $nmbr$ cm ( women )	C0025266;C0043210;C0455829	\N	\N
1413	waist circumference .	C0455829	\N	\N
1413	waist circumference ( cm ) : mean ± sd	C0444504;C0455829;C2347634;C2348143;C2699239	\N	\N
1413	waist circumference ( cm )	C0455829	\N	\N
1413	waist circumference  mean ( sd )  in	C0444504;C0455829;C2347634;C2348143;C2699239	\N	\N
1413	waist circumference  mean ( sd )  cm	C0444504;C0455829;C2347634;C2348143;C2699239	\N	\N
1413	waist circumference  cm mean ( sd )	C0444504;C0455829;C2347634;C2348143;C2699239	\N	\N
1413	waist circumference  cm ( sd )	C0455829;C2699239	\N	\N
1413	waist circumference  cm  mean ( sd )	C0444504;C0455829;C2347634;C2348143;C2699239	\N	\N
1413	waist circumference  cm	C0455829	\N	\N
1413	waist circumference  ( cm )	C0455829	\N	\N
1413	waist circumference	C0455829	\N	\N
1413	mean ± sd waist circumference  cm	C0444504;C0455829;C2347634;C2348143;C2699239	\N	\N
1412	no atopy ( n = $nmbr$ )	C0392707;C3539705	\N	\N
1412	met atopy and ige $nmbr$ - $nmbr$ ku / l criteria  ( n = $nmbr$ )	C0243161;C0392707;C0428210;C0439340;C1550543;C3539705;C4317104	\N	\N
1412	dermatitis atopic	C0011603;C0392707	\N	\N
1412	atopy ( specific ige ) c  n ( % )	C0205369;C0392707;C1552740;C3539705	\N	\N
1412	atopy ( n = $nmbr$  $nmbr$ )	C0392707;C3539705	\N	\N
1412	atopic at baseline : yes	C0168634;C0392707;C1442488;C1549445;C1705108;C1710701	\N	\N
1411	atv n ( % )	C0210243;C0674679;C1145759;C1334862	\N	\N
1411	atv $nmbr$ mg study protocol	C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761	\N	\N
1411	atv $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761	\N	\N
1411	atv $nmbr$ mg	C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761	\N	\N
1410	> lto £ $nmbr$ symptom days per week	C0677547;C1457887;C3854129	\N	\N
1410	> lto < $nmbr$ ( n = $nmbr$ )	\N	\N	\N
1410	> $nmbr$ days to $nmbr$ year ( n = $nmbr$ )	C0556972	\N	\N
1409	waist : hip ratio	C0205682	\N	\N
1409	waist - to - hip ratio	C0205682	\N	\N
1409	waist - to - hip  female	C0019552;C0022122;C0043210;C0086287;C0230097;C1505163;C1705497;C1705498;C3538851;C4284725	\N	\N
1409	waist - hip ratio	C0205682	\N	\N
1409	body - mass index  !  waist - to - hip ratio	C0005893;C0205682;C0578022;C1305855	\N	\N
1408	ssz + mtx ( n = $nmbr$ )	C0025677;C1417487	\N	\N
1408	pbo + mtx to mtx	C0025677;C0031962;C1417487	\N	\N
1408	pbo + mtx n = $nmbr$	C0025677;C0031962;C1417487	\N	\N
1408	pbo + mtx ^ mtx	C0025677;C0031962;C1417487	\N	\N
1408	pbo + mtx	C0025677;C0031962;C1417487	\N	\N
1412	atonic	C0541791	f	-10
1414	circumflex	C1880089	f	2218
1412	atopic	C0392707	f	1412
1417	current angina	C0002962;C0521116;C1705970	f	2220
1417	current angina ( % )	C0002962;C0521116;C1705970	f	2220
1417	current bone disease	C0005940;C0521116;C1705970	f	2221
1417	current enthesitis  n ( % ) ’	C0521116;C1282952;C1705970	f	2223
1417	current smoking	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	current smoking ( % )	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	current smoking  %	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	smoking  % current	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	smoking ( current )	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	current nonsmokers	C0337672;C0521116;C1705970;C4554605	f	2224
1417	current or prior smoking  %	C0037369;C0332152;C0453996;C0521116;C1705970;C1881674;C2826257	f	2224
1417	current (  $nmbr$ cigs / day )	C0332173;C0439228;C0439505;C0521116;C1570610;C1705970	f	2224
1417	current ( $nmbr$ + cigs / day )	C0332173;C0439228;C0439505;C0521116;C1570610;C1705970	f	2224
1417	postmenopausal  current hormone	C0019932;C0232970;C0521116;C1705970;C4521914	f	2225
1417	postmenopausal  current hormone therapy use	C0019932;C0042153;C0232970;C0279025;C0457083;C0521116;C1705970;C1947944;C2827774;C4521914	f	2225
1417	current inhaled corticosteroid use	C0004048;C0239126;C0521116;C1705970	f	2182
1417	current cigarette  n ( % )	C0521116;C0677453;C1704760;C1705970;C3890423	f	420
1408	no mtx use at baseline	C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944	\N	\N
1408	no mtx at baseline	C0025677;C0168634;C1417487;C1442488	\N	\N
1408	mtx use at randomization  n ( % )	C0025677;C0034656;C0042153;C0457083;C1417487;C1947944	\N	\N
1408	mtx use at baseline	C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944	\N	\N
1408	mtx plus infliximab	C0025677;C0332287;C0666743;C1417487	\N	\N
1408	mtx only	C0025677;C0205171;C1417487;C1720467	\N	\N
1408	mtx naive or free	C0025677;C0332296;C1417487;C1880497;C1996904	\N	\N
1408	mtx n = $nmbr$	C0025677;C1417487	\N	\N
1408	mtx at baseline  n ( % )	C0025677;C0168634;C1417487;C1442488	\N	\N
1408	mtx at baseline	C0025677;C0168634;C1417487;C1442488	\N	\N
1408	mtx + othetcsdmards	C0025677;C1417487	\N	\N
1408	mtx + other csomards	C0025677;C1417487	\N	\N
1408	mtx + other csdmards	C0025677;C1417487	\N	\N
1408	mtx + non - mtx	C0025677;C1417487;C1518422	\N	\N
1408	mtx ( n = $nmbr$ )	C0025677;C1417487	\N	\N
1408	mtx ( n )	C0025677;C1417487	\N	\N
1408	mtx	C0025677;C1417487	\N	\N
1408	methotrexate user	C0025677;C1548600;C1706077	\N	\N
1408	methotrexate plus other csdmardfl	C0025677	\N	\N
1408	methotrexate	C0025677	\N	\N
1408	lef + mtx ( n = $nmbr$ )	C0025677;C1417487	\N	\N
1408	hcq + mtx ( n = $nmbr$ )	C0020336;C0025677;C1417487	\N	\N
1408	etn + mtx ( n = $nmbr$ )	C0014758;C0025677;C0717758;C1417487	\N	\N
1408	etn $nmbr$ mg + mtx n = $nmbr$	C0014758;C0024671;C0025677;C0026410;C0439269;C0717758;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
1408	csdmards + mtx ( n = $nmbr$ )	C0025677;C1417487	\N	\N
1408	csdmard otherthan methotrexate	C0025677	\N	\N
1408	concomitant use of mtx to week $nmbr$	C0025677;C0332174;C0439230;C0521115;C1417487;C1524063	\N	\N
1408	concomitant mtx —	C0025677;C0521115;C1417487	\N	\N
1408	concomitant mtx use  n ( % )	C0025677;C0042153;C0457083;C0521115;C1417487;C1947944	\N	\N
1408	concomitant methotrexate  n ( % )	C0025677;C0521115	\N	\N
1408	$nmbr$ non - mtx	C0025677;C1417487;C1518422	\N	\N
1407	ldl - cz	C0206578	\N	\N
1407	czech republic	C0206578	\N	\N
1407	a $nmbr$ + ez n = $nmbr$ a $nmbr$ n = $nmbr$	C0206578	\N	\N
1407	a $nmbr$ + ez n = $nmbr$	C0206578	\N	\N
1407	a $nmbr$ + ez $nmbr$ a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ )	C0206578;C0369718;C0441922	\N	\N
1407	a $nmbr$ + ez $nmbr$	C0206578	\N	\N
1406	week $nmbr$ czp dose combined ( n   =   $nmbr$ )	C0054841;C0178602;C0205195;C0332174;C0369718;C0439230;C0441922;C0869039;C1114758;C1861828;C1872109	\N	\N
1406	week $nmbr$ czp dose combined	C0054841;C0178602;C0205195;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109	\N	\N
1406	czp combined arms ( n = $nmbr$ )	C0054841;C0205195;C0206655;C0446516;C1861828;C1872109;C2681631;C3715044;C4553528	\N	\N
1406	czp baseline	C0054841;C0168634;C1442488;C1861828;C1872109	\N	\N
1406	certolizumab pegol ( n = $nmbr$ )	C1872109	\N	\N
1405	values were reported for $nmbr$ patients in the spironolactone group and $nmbr$	C0037982;C0042295;C0441833;C0588446;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1405	spironolactone ( n = $nmbr$ )	C0037982	\N	\N
1405	spironolactone  n ( % )	C0037982	\N	\N
1405	spironolactone	C0037982	\N	\N
1405	outcomes by treatment ( spironolactone vs placebo )	C0032042;C0037982;C0085415;C1696465;C1706408	\N	\N
1405	mra ( spironolactone or eplerenone )	C0037982;C0243032;C0961485;C1609165;C3891069	\N	\N
1405	in the spironolactone group and $nmbr$ patients in the placebo group .	C0030705;C0032042;C0037982;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408	\N	\N
1404	glucosamine + chondroitin sulfate	C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965	\N	\N
1404	chondroitin sulfate ( n = $nmbr$ )	C0008466	\N	\N
1404	chondroitin sulfate	C0008466	\N	\N
1403	no methotrexate  hydroxychloroquine  or sulfasalazine treatment	C0020336;C0025677;C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1403	hydroxychloroquine treatment §	C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1403	hydroxychloroquine	C0020336	\N	\N
1402	whiteb	\N	\N	\N
1402	white race — no . { % ) - i -	C0007457;C0021966;C0034510;C0043157;C0220938;C0221138;C1706779;C3853635	\N	\N
1402	white race — no . { % ) ' i '	C0007457;C0021966;C0034510;C0043157;C0220938;C0221138;C1706779;C3853635	\N	\N
1402	white race — no . { % ) $	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1402	white race — no . / total no . ( % ) f	C0007457;C0016327;C0034510;C0043157;C0220938;C0439175;C0439810;C1706779;C3853635	\N	\N
1402	white race — no . / total no . ( % ) $	C0007457;C0034510;C0043157;C0220938;C0439175;C0439810;C1706779;C3853635	\N	\N
1402	white race — no . ( % ) f	C0007457;C0016327;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1402	white race — no . ( % ) : t	C0007457;C0034510;C0043157;C0220938;C1706779;C2603360;C3853635	\N	\N
1402	white race — no . ( % ) :	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1402	white race  n ( % )	C0007457;C0043157	\N	\N
1402	white race  %	C0007457;C0043157	\N	\N
1408	non - mtx csdmards	C0025677;C1417487;C1518422	f	231
1403	chloroquine	C0008269	f	1965
1408	non - mtx	C0025677;C1417487;C1518422	f	231
1404	chondroitin	C0008454	f	2216
1406	czp + mtx	C0025677;C0054841;C1417487;C1861828;C1872109	f	2217
1406	czp + mtx ^ mtx	C0025677;C0054841;C1417487;C1861828;C1872109	f	2217
1407	all ez / simva	C0206578	f	1862
1407	ez / simva	C0206578	f	1862
1407	ez / simva $nmbr$ mg	C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761	f	1862
1407	ez / simva < % >	C0206578	f	1862
1407	ez / simva n = $nmbr$ n ( % )	C0206578	f	1862
1402	white non - hispanic - n ( % )	C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021	\N	\N
1402	white non - hispanic	C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021	\N	\N
1402	white mtx ( n )	C0007457;C0025677;C0043157;C0220938;C1417487	\N	\N
1402	white : black : other	C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541	\N	\N
1402	white / other	C0007457;C0043157;C0220938	\N	\N
1402	white ( n — $nmbr$ )	C0007457;C0043157;C0220938	\N	\N
1402	white ( n   = $nmbr$  $nmbr$ )	C0007457;C0043157;C0220938	\N	\N
1402	white ( n = $nmbr$ )	C0007457;C0043157;C0220938	\N	\N
1402	white ( n = $nmbr$  $nmbr$ )	C0007457;C0043157;C0220938	\N	\N
1402	white ( $nmbr$ . $nmbr$ % )	C0007457;C0043157;C0220938	\N	\N
1402	white  non - hispanic	C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021	\N	\N
1402	white  no . ( % )	C0007457;C0043157;C0220938	\N	\N
1402	white  n / n ( % )	C0007457;C0043157;C0220938	\N	\N
1402	white  n ( % )	C0007457;C0043157;C0220938	\N	\N
1402	white  %	C0007457;C0043157;C0220938	\N	\N
1402	white	C0007457;C0043157;C0220938	\N	\N
1402	w hite	\N	\N	\N
1402	race_white  %	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1402	race  no . ( % ) white	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1402	non - hispanic white	C0007457;C0043157;C0220938;C1518424	\N	\N
1402	asian / black / white / hispanic / other ( % ) clinical parameters	C0005680;C0007457;C0027567;C0043157;C0078988;C0085756;C0205210;C0220938;C0439541;C0449381;C1533017;C1533018;C1533020;C1533021	\N	\N
1401	race - nonwhite	C0034510;C1706779;C3853635	\N	\N
1401	race  % nonwhite	C0034510;C1706779;C3853635	\N	\N
1401	nonwhite race — no . ( % ) ejection fraction	C0034510;C0489482;C1706779;C2700378;C3853635	\N	\N
1401	nonwhite race !	C0034510;C1706779;C3853635	\N	\N
1401	nonwhite race	C0034510;C1706779;C3853635	\N	\N
1401	nonwhite	\N	\N	\N
1400	sita / pio $nmbr$ / $nmbr$	C0030800;C2347712	\N	\N
1400	sita $nmbr$ + pio $nmbr$	C0030800;C2347712	\N	\N
1400	sita $nmbr$	\N	\N	\N
1400	= sia	C1225105;C1551538	\N	\N
1399	type ia	C0020980;C0332307;C0694634;C1547052;C1947960	\N	\N
1399	simple partial ( ia )	C0020980;C0205352;C0694634;C0728938;C1550516;C1947960	\N	\N
1398	type ib	C0332307;C1547052;C2744579;C3890035;C4283819	\N	\N
1398	ib ( $nmbr$ . $nmbr$ )	C2744579;C3890035;C4283819	\N	\N
1398	complex partial ( ib )	C0439855;C0728938;C1550516;C1704241;C2744579;C3890035;C4283819	\N	\N
1398	class ib	C0456387;C1518526;C1705943;C2744579;C3890035;C4283819	\N	\N
1397	tnfi - ir	C0022065;C0022071;C1448132	\N	\N
1397	tnf - ir	C0022065;C0022071;C1448132;C1448177	\N	\N
1397	mtx ir	C0022065;C0022071;C0025677;C1417487;C1448132	\N	\N
1397	mtx - ir	C0022065;C0022071;C0025677;C1417487;C1448132	\N	\N
1397	homa - ir score	C0022065;C0022071;C0449820;C1448132;C4050231	\N	\N
1397	homa - ir index — median ( iqr )	C0022065;C0022071;C0549183;C0600653;C0876920;C0918012;C1448132;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546	\N	\N
1397	homa - ir index	C0022065;C0022071;C0600653;C0918012;C1448132;C1552854;C1637833;C2986546	\N	\N
1397	homa - ir ( mu / l ^ mmol / l )	C0022065;C0022071;C0439190;C0439342;C1448132	\N	\N
1397	homa - ir ( % ) b	C0022065;C0022071;C1448132	\N	\N
1397	homa - ir  mean ( sd ) ( mu / l $ mmol / l ) b	C0022065;C0022071;C0439190;C0439342;C0444504;C1448132;C2347634;C2348143;C2699239	\N	\N
1397	homa - ir	C0022065;C0022071;C1448132	\N	\N
1397	dmard - ir / anti - tnf - ir	C0022065;C0022071;C0242708;C1448132;C1448177	\N	\N
1397	dmard - ir	C0022065;C0022071;C0242708;C1448132	\N	\N
1397	dmard - biologic ir	C0005515;C0022065;C0022071;C0205460;C0242708;C1448132	\N	\N
1397	bdmard - ir	C0022065;C0022071;C1448132	\N	\N
1397	anti - tnf ir	C0022065;C0022071;C1448132;C1448177	\N	\N
1397	anti - tnf - ir patients	C0022065;C0022071;C0030705;C1448132;C1448177	\N	\N
1395	coenzyme q $nmbr$ p  g / ml #	C0041536;C1300565	\N	\N
1395	coenzyme q $nmbr$  ^ g / ml #	C0041536;C1300565	\N	\N
1395	coenzyme q $nmbr$	C0041536	\N	\N
1395	all with coenzyme q $nmbr$ ( n = $nmbr$  $nmbr$ )	C0041536	\N	\N
1395	$nmbr$ coenzyme q $nmbr$ subgroups for time to first hospitalization ( number of patients variable ) .	C0019993;C0040223;C0041536;C0205435;C0439828;C1079230;C1279901;C2360800;C3541383;C4553760	\N	\N
1394	time from end of fit  years ( meanisd )	C0036572;C0439234;C1522314;C2349186;C4048158;C4553125	\N	\N
1394	seizure worry	C0036572;C0233481;C1959629;C4553401	\N	\N
1394	seizure types reported during baselinee	C0036572;C0332307;C0684224;C0700287;C1959629;C4319718;C4553401	\N	\N
1394	convulsion	C0036572;C4048158	\N	\N
1394	cluster seizures	C0036572;C1555715;C1704332	\N	\N
1393	laparoscopic cholecystectomy	C0162522	\N	\N
1393	cholecystectomy ( n = $nmbr$ )	C0008320	\N	\N
1392	cholesterol absorption inhibitor ( ezetimibe )	C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742	f	1165
1391	hvpercholesterolemia	\N	f	1390
1392	cabgorptca	\N	f	1524
1399	austral ia / new zealand	C0020980;C0027978;C0324547;C0694634;C1947960	f	189
1401	while	\N	f	2215
1401	race  while	C0034510;C1706779;C3853635	f	1402
1402	non white	C0007457;C0043157;C0220938;C1518422	f	1401
1402	non - white	C0007457;C0043157;C0220938;C1518422	f	1401
1402	non - white race	C0007457;C0043157;C1518422	f	1401
1402	non - white raceb	C0007457;C0043157;C0220938;C1518422	f	1401
1402	race  non - white	C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635	f	1401
1402	race - non - white	C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635	f	1401
1391	heterozygous familial hypercholesterolemia †	C0342882	\N	\N
1391	heterozygous familial hypercholesterolemia	C0342882	\N	\N
1390	reported high cholesterol ' !	C0020443;C0684224;C0700287;C1522133;C4319718	\N	\N
1390	hypertension — no . ( % ) hypercholesterolemia — no . ( % )	C0020443;C0020538;C1522133;C1963138	\N	\N
1390	hypercholesterolemia 一 no . ( % )	C0020443;C1522133	\N	\N
1390	hypercholesterolemia — no . ( % ) *	C0020443;C1522133	\N	\N
1390	hypercholesterolemia — no . ( % )	C0020443;C1522133	\N	\N
1390	hypercholesterolemia *	C0020443;C1522133	\N	\N
1390	hypercholesterolemia ( > $nmbr$ mg / dl )	C0020443;C0439269;C1522133	\N	\N
1390	hypercholesterolemia ( % )	C0020443;C1522133	\N	\N
1390	hypercholesterolemia  no . ( % )	C0020443;C1522133	\N	\N
1390	hypercholesterolemia  n ( % )	C0020443;C1522133	\N	\N
1390	hypercholesterolemia	C0020443;C1522133	\N	\N
1390	hypercholesterolaemia ( % )	C0020443;C1522133	\N	\N
1390	hypercholesterolaemia	C0020443;C1522133	\N	\N
1390	elevated cholesterol	C0020443	\N	\N
1390	duration of hypercholesterolaemia  mean ± sd ( year )	C0020443;C0439234;C0439508;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735	\N	\N
1389	< $nmbr$ with no historical count > $nmbr$	C0750480;C1552658;C1552723;C1705566;C2004062	\N	\N
1389	< $nmbr$ with historical count > $nmbr$	C0750480;C1552658;C1552723;C1705566;C2004062	\N	\N
1389	< $nmbr$ regardless of historical count	C0750480;C1552658;C1552723;C1705566;C2004062	\N	\N
1388	rs - cough & sputumc	C0010200;C0035970;C1961131;C3274924;C3714753;C3813325;C4084725;C4084726;C4084727	\N	\N
1388	cough ( investigator reported )	C0010200;C0035173;C0684224;C0700287;C1961131;C3274924;C4084725;C4084726;C4084727;C4319718	\N	\N
1388	cough  n ( % )	C0010200;C1961131;C3274924;C4084725;C4084726;C4084727	\N	\N
1388	cough	C0010200;C1961131;C3274924;C4084725;C4084726;C4084727	\N	\N
1388	any cough	C0010200;C1961131;C3274924;C4084725;C4084726;C4084727	\N	\N
1386	components	C0449432	\N	\N
1385	threatened abrupt vessel closure	C0005847;C0185003;C1276802;C1521802	\N	\N
1385	abrupt vessel closure	C0005847;C0185003;C1276802;C1521802	\N	\N
1384	cyclosporine ( n = $nmbr$ )	C0010592;C0010594	\N	\N
1384	cyclosporin	C0010592;C0010594	\N	\N
1383	itt cohort  overall study period	C0009247;C0282416;C0439531;C0557651;C0599755;C1561607;C1948053;C2603343	\N	\N
1382	residence in asia  n ( % )	C0003980;C0237096	\N	\N
1382	region  asia / paafic	C0003980;C0017446;C0205147	\N	\N
1382	geo graphic region : asia	C0003980;C0017446;C0017454;C0205147	\N	\N
1382	east asia	C0015631	\N	\N
1382	asia pacific or other	C0003980	\N	\N
1382	asia pacific and south africa	C0003980;C0037712	\N	\N
1382	asia pacific and other	C0003980	\N	\N
1382	asia pacific ( n = $nmbr$ )	C0003980	\N	\N
1382	asia pacific	C0003980	\N	\N
1382	asia and pacific islands	C0003980;C0030168	\N	\N
1382	asia / pacific / other	C0003980	\N	\N
1382	asia / pacific ( % )	C0003980	\N	\N
1382	asia / pacific	C0003980	\N	\N
1382	asia - pacific region and south africa	C0003980;C0017446;C0037712;C0205147	\N	\N
1382	asia - pacific hr ( $nmbr$ % cl )	C0003980;C0596019	\N	\N
1382	asia - pacific and south africa	C0003980;C0037712	\N	\N
1382	asia - pacific	C0003980	\N	\N
1382	asia ( n = $nmbr$ )	C0003980	\N	\N
1382	asia ( n = $nmbr$  $nmbr$ )	C0003980	\N	\N
1382	asia #	C0003980	\N	\N
1382	asia  pacific and other	C0003980	\N	\N
1382	asia	C0003980	\N	\N
1381	saudi arabia	C0036243	\N	\N
1380	with higher classes indicating greater limitations on physical activity owing to	C0015259;C0026606;C0205250;C0449295;C0456387;C1518526;C1704243;C1705943;C4019422	\N	\N
1380	walk for exercise ( % )	C0015259;C0080331;C1522704	\N	\N
1380	walk for exercise	C0015259;C0080331;C1522704	\N	\N
1380	some physical activity	C0015259;C0026606	\N	\N
1380	physical activity §	C0015259;C0026606	\N	\N
1380	physical activity  kcal / wk < $nmbr$	C0015259;C0026606;C0332174;C0439230;C0439259	\N	\N
1389	dactylitis count	C0239161;C0750480;C1705566	f	492
1386	chads $nmbr$ components  n ( % )	C0007928;C0449432;C1413373	f	2128
1381	sa	C0036243;C0038702;C1539696;C1825840;C3539736;C4521691	f	-10
1382	pacific	\N	f	2207
1383	total cohort	C0009247;C0439175;C0439810;C0599755	f	2208
1383	cohort	C0009247;C0599755	f	2208
1383	cohort $nmbr$ ( n = $nmbr$ )	C0009247;C0599755	f	2208
1383	entire cohort gender	C0009247;C0079399;C0439751;C0444667;C0599755;C1522384	f	2208
1383	entire evaluable cohort	C0009247;C0439751;C0444667;C0599755;C1516986	f	2208
1383	full cohort	C0009247;C0443225;C0599755	f	2208
1383	primary - prevention cohort	C0009247;C0033144;C0599755	f	2209
1383	secondary - prevention cohort	C0009247;C0599755;C0679699	f	2210
1385	pfo closure	C0185003;C1521802	f	2211
1385	pfo closure group ( n = $nmbr$ )	C0185003;C0441848;C1521802	f	2211
1385	closure	C0185003;C1521802	f	2212
1387	$nmbr$ - aminosalicylic compounds — no . ( % )	C0205198;C1706082	f	1691
1387	$nmbr$ - asa compounds  n ( % )	C0004057;C0205198;C1706082;C3853627	f	1691
1387	no use of $nmbr$ - asa compounds	C0004057;C0205198;C1524063;C1706082;C3853627	f	1691
1389	enthesitis count	C0750480;C1282952;C1705566	f	2213
1389	tender joint count ( $nmbr$ - $nmbr$ possible joints )	C0022417;C0240094;C0332149;C0392905;C0750480;C1705566;C1705910;C2362652;C4554549;C4696258	f	1139
1389	tender - or painful - joint count ( of $nmbr$ joints assessed ) — no .	C0003862;C0234234;C0750480;C1516048;C1705566	f	1139
1389	eosinoohil count	C0750480;C1705566	f	849
1380	physical activity  kcal / wk *	C0015259;C0026606;C0332174;C0439230;C0439259	\N	\N
1380	physical activity  kcal / wk	C0015259;C0026606;C0332174;C0439230;C0439259	\N	\N
7	p value ( interaction )	C1704675;C1709380	\N	\N
1380	exercise times per week  ( minimum	C0015259;C0456698;C1522704;C1524031;C1552614;C2826545	\N	\N
1380	exercise status	C0015259;C0449438;C1522704	\N	\N
1380	exercise at least weekly ( a )	C0015259;C0332174;C1522704	\N	\N
1380	exercise > once weekly ?	C0015259;C0558293;C1522704	\N	\N
1380	exercise > once weekly	C0015259;C0558293;C1522704	\N	\N
1380	exercise ( % )	C0015259;C1522704	\N	\N
1380	exercise  n ( % )	C0015259;C1522704	\N	\N
1380	exercise	C0015259;C1522704	\N	\N
1380	daily exercise ( % )	C0015259;C0332173;C1522704	\N	\N
1379	serum sodium — meq / liter	C0439152;C0475211;C0523891	\N	\N
1379	serum sodium . meq / l	C0439375;C0523891	\N	\N
1379	serum sodium  meq / l	C0439375;C0523891	\N	\N
1378	sodium  meq / l	C0037473;C0439375;C0597484;C3541959;C3714642	\N	\N
1378	sodium	C0037473;C0597484;C3541959;C3714642	\N	\N
1377	small / medium	C0009458;C0439536;C0700321;C1705217;C3244283;C4085196;C4522282;C4522283	\N	\N
1377	medium	C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283	\N	\N
1376	minimum — maximum	C0806909;C1524031;C1552614;C1552615;C2826545;C2826546	\N	\N
1376	minimum — maxim um	C0024968;C1524031;C1552614;C2826545	\N	\N
1376	minimum : maximum	C0806909;C1524031;C1552614;C1552615;C2826545;C2826546	\N	\N
1376	minimum / maximum	C0806909;C1524031;C1552614;C1552615;C2826545;C2826546	\N	\N
1376	minimum - maximum	C0806909;C1524031;C1552614;C1552615;C2826545;C2826546	\N	\N
1376	minimum  maximum	C0806909;C1524031;C1552614;C1552615;C2826545;C2826546	\N	\N
1376	median ( minimum – maximum ) focal seizure frequency / $nmbr$   days at baseline	C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0806909;C0871396;C0876920;C1442488;C1524031;C1552614;C1552615;C1561548;C1705502;C2347635;C2348144;C2826545;C2826546;C2939193;C3898838;C4321352	\N	\N
1375	belgium	C0004950	\N	\N
1374	non - calcium antagonist strategy ( ncas ) ( events / n )	C0006684;C0441471;C0679199;C1413309;C1518422;C3541888;C3813543	\N	\N
1374	non - calcium antagonist strategy ( n = $nmbr$ $nmbr$ )	C0006684;C0679199;C1518422	\N	\N
1373	serum albumin - adjusted calcium ( mg / dl )	C0006675;C0006726;C0036773;C0439269;C0456081;C0728877;C2936886;C3540037;C3714611	\N	\N
1373	dense calcium  mm ’	C0006675;C0006726;C0439794;C2936886;C3540037;C3714611;C4330985;C4554674	\N	\N
1373	dense calcium	C0006675;C0006726;C0439794;C2936886;C3540037;C3714611	\N	\N
1373	calcium ( mmol / l )	C0006675;C0006726;C1532563;C2936886;C3540037;C3714611	\N	\N
1373	calcium  mmol $nmbr$ $nmbr$	C0006675;C0006726;C0439190;C2936886;C3540037;C3714611	\N	\N
1372	with tiotropium	C0213771	\N	\N
1372	versus tiotropium $nmbr$ pg	C0030827;C0072225;C0213771;C1266240	\N	\N
1372	versus tiotropium $nmbr$ . $nmbr$ pg	C0030827;C0072225;C0213771;C1266240	\N	\N
1372	tiotropiumc	\N	\N	\N
1372	tiotropium vs . salmeterol	C0073992;C0213771	\N	\N
1372	tiotropium group ( n = $nmbr$ )	C0213771;C0441848	\N	\N
1372	tiotropium + placeb ( n [ $nmbr$ )	C0213771	\N	\N
1372	tiotropium ( nz $nmbr$ )	C0027978;C0213771	\N	\N
1372	tiotropium ( n z $nmbr$ )	C0213771	\N	\N
1372	tiotropium ( n = $nmbr$ )	C0213771	\N	\N
1372	tiotropium $nmbr$   μ g ( n   =   $nmbr$ )	C0213771;C0439267	\N	\N
1373	calcium supplements	C0006675;C0006726;C0242295;C1947943;C2348609;C2936886;C3540037;C3714611	f	2187
1374	calcium channel antagonists  n ( % )	C0006684;C2757014	f	1884
1374	calcium - channel antagonists	C0006684;C2757014	f	1884
1374	calcium antagonist strategy ( n = $nmbr$ $nmbr$ )	C0006684;C0679199	f	1884
1374	calcium antagonist — no . ( % )	C0006684	f	1884
1374	calcium antagonist	C0006684	f	1884
1374	calcium aniagonisi	C0006675;C0006726;C2936886;C3540037;C3714611	f	1884
1375	calcium - channel blockerf	C0006685	f	1884
1375	calcium - channel inhibitor	C0006685;C1999216	f	1884
1375	calcium - channel blockersubgroup	C0006685	f	1884
1376	average maximum cimt ( mm )	C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674	f	1262
1376	average of maximum far wall cimt ( mm )	C0205108;C0677535;C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674	f	1262
1376	average of maximum common carotid cimt ( mm )	C0205214;C0741968;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3245511;C4330985;C4554674	f	1262
1374	aniagonisi	\N	f	-10
1375	calcium channel	C0006685	f	2200
1376	maximum	C0806909;C1552615;C2826546	f	2201
1376	minimum	C1524031;C1552614;C2826545	f	2202
1376	( minimum - maximum ) focal seizure fre - quency / $nmbr$ days at baseline	C0168634;C0439228;C0751495;C0806909;C1414819;C1442488;C1524031;C1552614;C1552615;C2826545;C2826546	f	2203
1377	low - medium microalbuminuria ( n = $nmbr$ )	C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283	f	2204
1377	low to medium microalbuminuria ( n = $nmbr$ )	C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283	f	2204
1377	medium - or low - intensity statin	C0009458;C0360714;C0439536;C0596836;C1705217;C3244283;C4085196;C4522282;C4522283	f	2205
1377	statin potency medium ( n = $nmbr$ )	C0009458;C0360714;C0439536;C1705217;C3244283;C3245505;C4085196;C4522282;C4522283	f	2205
1378	sodium - glucose cotransporter $nmbr$ inhibitor	C0017725;C0037473;C0597484;C1999216;C3541959;C3714642	f	2206
1372	tiotropium $nmbr$ pg	C0030827;C0072225;C0213771;C1266240	\N	\N
7	p value $nmbr$ . $nmbr$	C1709380	\N	\N
1372	tiotropium $nmbr$ meg ( n = $nmbr$ )	C0024489;C0025175;C0072225;C0213771	\N	\N
1372	tiotropium $nmbr$ m g	C0213771;C0456715	\N	\N
1372	tiotropium $nmbr$ . $nmbr$ μ g ( n   = $nmbr$ )	C0213771;C0439267	\N	\N
1372	tiotropium $nmbr$ . $nmbr$   μ g ( n   =   $nmbr$ )	C0213771;C0439267	\N	\N
1372	tiotropium $nmbr$ . $nmbr$ pg	C0030827;C0072225;C0213771;C1266240	\N	\N
1372	tiotropium	C0213771	\N	\N
1372	patients using concurrent tiotropium	C0030705;C0205420;C0213771;C1524063	\N	\N
1372	non - tiotropium	C0213771;C1518422	\N	\N
1372	lama ( tiotropium )  b   n ( % )	C0213771;C0999593;C1416775	\N	\N
1372	formoterol tiotropium n = $nmbr$ non - tiotropium n = $nmbr$	C0060657;C0213771;C1518422	\N	\N
1372	( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ )	C0213771;C1518422	\N	\N
1372	( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ $nmbr$	C0213771;C1518422	\N	\N
1371	potassium — mmol / liter	C0032821;C0202194;C0304475;C0439190;C0475211;C0597277;C3714637	\N	\N
1371	potassium — mg / dl	C0032821;C0202194;C0304475;C0439269;C0597277;C3714637	\N	\N
1371	potassium supplement	C0304475	\N	\N
1371	potassium - sparing at enrollment	C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021	\N	\N
1371	potassium ( mmol / l )	C0032821;C0202194;C0304475;C0597277;C1532563;C3714637	\N	\N
1371	potassium ( mg / dl )	C0032821;C0202194;C0304475;C0439269;C0597277;C3714637	\N	\N
1371	potassium ( meql )  mean + sd  available for $nmbr$ patients	C0030705;C0032821;C0202194;C0304475;C0444504;C0470187;C0597277;C2347634;C2348143;C2699239;C3714637	\N	\N
1371	potassium ( meq / l )	C0032821;C0202194;C0304475;C0439375;C0597277;C3714637	\N	\N
1371	potassium  mmol / l	C0032821;C0202194;C0304475;C0597277;C1532563;C3714637	\N	\N
1371	potassium  meq / l	C0032821;C0202194;C0304475;C0439375;C0597277;C3714637	\N	\N
1371	potassium  meq / dl  mean	C0032821;C0202194;C0304475;C0444504;C0597277;C1532568;C2347634;C2348143;C3714637	\N	\N
1371	potassium  mean ( sd )  meq / l	C0032821;C0202194;C0304475;C0439375;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637	\N	\N
1371	potassium	C0032821;C0202194;C0304475;C0597277;C3714637	\N	\N
1371	hyperkalemia ‡   ( potassium ≥ $nmbr$ . $nmbr$ mmol / l )	C0020461;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4552983	\N	\N
1369	other asian	C0078988	\N	\N
1369	black or asian	C0005680;C0027567;C0078988;C0085756;C0439541	\N	\N
1369	asians ( n = $nmbr$ )	C0078988	\N	\N
1369	asian *	C0078988	\N	\N
1369	asian ( n — $nmbr$ )	C0078988	\N	\N
1369	asian ( n   = $nmbr$ )	C0078988	\N	\N
1369	asian ( n = $nmbr$ )	C0078988	\N	\N
1369	asian ( n = $nmbr$  $nmbr$ )	C0078988	\N	\N
1369	asian ( $nmbr$ . $nmbr$ % )	C0078988	\N	\N
1369	asian  n ( % )	C0078988	\N	\N
1369	asian	C0078988	\N	\N
1368	on $nmbr$	\N	\N	\N
1368	baseline use of adm  n ( % )	C0168634;C0215825;C1442488;C1524063;C4521767	\N	\N
1368	baseline numberf of adm classes  n ( % )	C0168634;C0215825;C0456387;C1442488;C1518526;C1705943;C4019422;C4521767	\N	\N
1366	without aspirin ( n = $nmbr$  $nmbr$ )	C0004057	\N	\N
1366	with aspirin ( n = $nmbr$  $nmbr$ )	C0004057	\N	\N
1366	spirono ( n = $nmbr$ )	\N	\N	\N
1366	no aspirin	C0004057	\N	\N
1366	long - term aspirin	C0004057;C0443252	\N	\N
1366	initial aspirin — no . ( % )	C0004057;C0205265;C1279901;C1555582;C1705685	\N	\N
1366	aspirin or thienopyridines ( % )	C0004057;C1120149;C2936588	\N	\N
1366	aspirin but no ppi	C0004057;C0358591;C0871125;C3811894	\N	\N
1366	aspirin and ppi	C0004057;C0358591;C0871125;C3811894	\N	\N
1366	aspirin and other antiplatelet	C0004057	\N	\N
1366	aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0004057;C0205171;C0439044;C0679994	\N	\N
1366	aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$	C0004057;C0205171;C0439044;C0679994	\N	\N
1366	aspirin alone ( n = $nmbr$ )	C0004057;C0205171;C0439044;C0679994	\N	\N
1366	aspirin alone ( n / n )	C0004057;C0205171;C0439044;C0679994	\N	\N
1366	aspirin alone	C0004057;C0205171;C0439044;C0679994	\N	\N
1366	aspirin / antiplatelet	C0004057	\N	\N
1366	aspirin - erdp clopidogrel no . of patients / total no .	C0004057;C0030705;C0070166;C0439175;C0439810	\N	\N
1366	aspirin - erdp ( n = $nmbr$  $nmbr$ )	C0004057	\N	\N
1366	aspirin ( n = $nmbr$ ) no . of participants with events ( % )	C0004057;C0441471;C0679646;C3541888	\N	\N
1366	aspirin ( n = $nmbr$ $nmbr$ )	C0004057	\N	\N
1366	aspirin ( n = $nmbr$  $nmbr$ )	C0004057	\N	\N
1366	aspirin ( n  % )	C0004057	\N	\N
1366	aspirin ( % )	C0004057	\N	\N
1366	aspirin  no . ( % )	C0004057	\N	\N
1366	aspirin  n ( % )	C0004057	\N	\N
1366	aspirin	C0004057	\N	\N
1366	$nmbr$ aspirin ( n = $nmbr$ $nmbr$ )	C0004057	\N	\N
1365	resistant htn n = $nmbr$	C0020538;C0332325;C1514892;C1550464;C2827757	\N	\N
1365	resistant htn : spiro n = $nmbr$	C0020538;C0332325;C1514892;C1550464;C2827757	\N	\N
1365	resistant htn : placebo n = $nmbr$	C0020538;C0032042;C0332325;C1514892;C1550464;C1696465;C1706408;C2827757	\N	\N
1365	prior hypertension yes	C0020538;C0332152;C1549445;C1705108;C1710701;C1963138;C2826257	\N	\N
1368	af on baseline ecg  n ( % )	C0168634;C0344434;C1442488;C1623258;C4049859	f	1009
1368	atrial fibrillation on baseline ecg  n ( % )	C0168634;C0344434;C1442488	f	1009
1368	on aspirin at baseline	C0004057;C0168634;C1442488	f	1366
1370	aslan	\N	f	1369
1370	non - asian	C0078988;C1518422	f	1369
1370	non - east asian §	C0078988;C1518422;C1707877	f	1369
1370	non - asian ( n = $nmbr$ $nmbr$ )	C0078988;C1518422	f	1369
1370	non - east asianf	C1518422;C1707877	f	1369
1370	p - value for east asian versus non - east asian *	C0078988;C1518422;C1707877;C1709380	f	1369
1365	prior hypertension	C0020538;C0332152;C1963138;C2826257	\N	\N
1365	prior htn ( n = $nmbr$  $nmbr$ )	C0020538;C0332152;C2826257	\N	\N
1365	no resistant htn n = $nmbr$  $nmbr$	C0020538;C0332325;C1514892;C1550464;C2827757	\N	\N
1365	no prior htn ( n = $nmbr$  $nmbr$ )	C0020538;C0332152;C2826257	\N	\N
1365	no htn	C0020538	\N	\N
1365	htn	C0020538	\N	\N
1365	high blood pressure	C0020538;C2926615	\N	\N
1365	elevated blood pressure	C0020538;C0497247	\N	\N
1364	treated hypertension :	C0020538;C1522326;C1963138	\N	\N
1364	treated for hypertension  %	C0020538;C1522326;C1963138	\N	\N
1364	systemic hypertension	C0020538	\N	\N
1364	systemic arterial hypertension  n ( % )	C0020538	\N	\N
1364	reported hypertension *	C0020538;C0684224;C0700287;C1963138;C4319718	\N	\N
1364	previous hypertension	C0020538;C0205156;C1552607;C1963138	\N	\N
1364	patient - reported hypertension — no . { % )	C0020538;C0030705;C0684224;C0700287;C1963138;C4319718	\N	\N
1364	participant - reported hypertension — no . { % )	C0020538;C0679646;C0684224;C0700287;C1963138;C2698741;C4319718;C4554048	\N	\N
1364	no hypertension ( n = $nmbr$ )	C0020538;C1963138	\N	\N
1364	no hypertension	C0020538;C1963138	\N	\N
1364	medical history of hypertension	C0020538;C0199168;C0205476;C0262926;C0455527;C1963138	\N	\N
1364	isoiated systoiic hypertension *	C0020538;C1963138	\N	\N
1364	hypertension 本	C0020538;C1963138	\N	\N
1364	hypertension 一 no . ( % )	C0020538;C1963138	\N	\N
1364	hypertension — no . / total no . ( % )	C0020538;C0439175;C0439810;C1963138	\N	\N
1364	hypertension — no . ( % ) |	C0020538;C1963138	\N	\N
1364	hypertension — no . ( % )	C0020538;C1963138	\N	\N
1364	hypertension § yes	C0020538;C1549445;C1705108;C1710701;C1963138	\N	\N
1364	hypertension §	C0020538;C1963138	\N	\N
1364	hypertension serum lipid values	C0020538;C0042295;C0428462;C1963138	\N	\N
1364	hypertension n ( % )	C0020538;C1963138	\N	\N
1364	hypertension history	C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C1963138;C2004062	\N	\N
1364	hypertension ^	C0020538;C1963138	\N	\N
1364	hypertension : no ( n = $nmbr$ )	C0020538;C0369718;C0441922;C1963138	\N	\N
1364	hypertension / yes	C0020538;C1549445;C1705108;C1710701;C1963138	\N	\N
1364	hypertension *	C0020538;C1963138	\N	\N
1364	hypertension ( n 二 $nmbr$ )	C0020538;C1963138	\N	\N
1364	hypertension ( > $nmbr$ / $nmbr$ mm hg or taking	C0020538;C0439475;C1515187;C1963138	\N	\N
1364	hypertension ( % ) : t	C0020538;C1963138	\N	\N
1364	hypertension ( % )	C0020538;C1963138	\N	\N
1364	hypertension $nmbr$ ( % )	C0020538;C1963138	\N	\N
1364	hypertension !	C0020538;C1963138	\N	\N
1364	hypertension    n   ( % )	C0020538;C1963138	\N	\N
1364	hypertension  treated	C0020538;C1522326;C1963138	\N	\N
1364	hypertension  no . / total no . ( % ) medications in use at baseline  no . / total no . ( % )	C0013227;C0020538;C0042153;C0150312;C0168634;C0332285;C0439175;C0439810;C0457083;C0802604;C1442488;C1707101;C1947944;C1963138;C2598133;C4284232	\N	\N
1364	hypertension  n / n ( % )	C0020538;C1963138	\N	\N
1364	hypertension  n ( % ) yes	C0020538;C1549445;C1705108;C1710701;C1963138	\N	\N
1364	hypertension  n ( % )	C0020538;C1963138	\N	\N
1364	hypertension  * n ( % )	C0020538;C1963138	\N	\N
1364	hypertension  ( % )	C0020538;C1963138	\N	\N
1364	hypertension  %	C0020538;C1963138	\N	\N
1364	hypertension	C0020538;C1963138	\N	\N
1364	hyperlension	\N	\N	\N
1364	hyper - tension	C0020538;C1963138	\N	\N
1364	hvpertension	\N	\N	\N
1364	grade of hypertension	C0020538;C0441800;C0919553;C1963138;C3244287	\N	\N
1364	duration of hypertension ( years )	C0020538;C0439234;C0449238;C1963138;C2926735	\N	\N
1364	duration of hypertension ( months )	C0020538;C0439231;C0449238;C1963138;C2926735	\N	\N
1364	duration of hypertension  y	C0020538;C0449238;C1963138;C2926735	\N	\N
1364	duration of hypertension  n ( % )	C0020538;C0449238;C1963138;C2926735	\N	\N
1364	arterial hypertension — no . ( % )	C0020538	\N	\N
1364	arterial hypertension *	C0020538	\N	\N
1364	arterial hypertension  no . ( % )	C0020538	\N	\N
1364	arterial hypertension  n ( % )	C0020538	\N	\N
1364	arterial hypertension	C0020538	\N	\N
1364	( including hypertension )	C0020538;C0332257;C1963138	\N	\N
1363	symptomatic ich	C0019191;C0231220;C3272597;C3281105	\N	\N
1363	nd not due to swelling or ich	C0013604;C0019191;C0038999;C0678226;C1518422;C3272597;C3281105	\N	\N
1363	ich	C0019191;C3272597;C3281105	\N	\N
1363	gusto moderate bleeding / ich	C0019080;C0019191;C0205081;C1881878;C3272597;C3281105;C4049705;C4049706;C4085643;C4321335	\N	\N
1362	itch nrs $nmbr$ - $nmbr$ ( v = $nmbr$ )	C0033774;C1422257;C2240043;C4050142	\N	\N
1362	itch nrs $nmbr$ - $nmbr$ ( at = $nmbr$ )	C0033774;C1422257;C2240043;C4050142	\N	\N
1362	itch nrs $nmbr$ - $nmbr$ ( a ' = $nmbr$ )	C0033774;C1422257;C2240043;C4050142	\N	\N
1362	itch nrs $nmbr$ - $nmbr$ ( . \\ ' = $nmbr$ )	C0033774;C1422257;C2240043;C4050142	\N	\N
1362	itch nrs $nmbr$ ( v = $nmbr$ )	C0033774;C1422257;C2240043;C4050142	\N	\N
1362	itch nrs	C0033774;C1422257;C2240043;C4050142	\N	\N
1361	previous ischemic heart disease — no . ( % )	C0010054;C0151744;C0205156;C1552607	\N	\N
1361	myocardial ischaemia	C0010054;C0151744	\N	\N
1361	ischemic heart disease indicator no ( n = $nmbr$ l )	C0010054;C0021212;C0151744;C0369718;C0441922;C1235732;C1522602	\N	\N
1361	ischemic heart disease *	C0010054;C0151744	\N	\N
1361	ischemic heart disease ( % )	C0010054;C0151744	\N	\N
1361	ischemic heart disease  no . ( % )	C0010054;C0151744	\N	\N
1361	ischemic heart disease  n ( % )	C0010054;C0151744	\N	\N
1361	ischemic heart disease  ( % )	C0010054;C0151744	\N	\N
1361	ischemic heart disease  %	C0010054;C0151744	\N	\N
1361	ischemic heart disease	C0010054;C0151744	\N	\N
1361	ischaemic heart disease or cerebrovascular disorder  n ( % )	C0007820;C0010054;C0151744	\N	\N
1361	ischaemic heart disease  n ( % )	C0010054;C0151744	\N	\N
1361	ischaemic heart disease	C0010054;C0151744	\N	\N
1361	ihd	C0151744	\N	\N
1099	% / yr	C0439234	\N	\N
1361	combined ischaemic heart disease and / or cerebrovascular disorder *	C0007820;C0010054;C0151744;C0205195	\N	\N
1360	relative risk comparing icd therapy and placebo	C0021122;C0032042;C0039798;C0087111;C0242492;C1363945;C1696465;C1706408;C1707455	\N	\N
1360	relative risk ( $nmbr$ % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *	C0021122;C0023732;C0032042;C0039798;C0087111;C0233324;C0242492;C0596019;C1363945;C1515273;C1524063;C1696465;C1704675;C1705313;C1706408;C1707455;C2826302	\N	\N
1360	pacemaker or icd	C0021122;C0030163;C0810633;C1546728;C3275122;C3853703	\N	\N
1360	icd vs . placebo	C0021122;C0032042;C1696465;C1706408	\N	\N
1360	icd  n ( % )	C0021122	\N	\N
1360	icd  %	C0021122	\N	\N
1360	icd	C0021122	\N	\N
1360	aicd  ( % )	C0972395;C2611803;C3537205;C3546309	\N	\N
1359	non - ics +	C0815320;C1518422;C4551720	\N	\N
1359	no laba  no ics  n ( % )	C0815320;C4551720	\N	\N
1359	laba  no ics  n ( % )	C0815320;C4551720	\N	\N
1359	ics subset	C0815320;C1515021;C4551720	\N	\N
1359	gold grade $nmbr$ and ics users at screening	C0018026;C0220908;C0220909;C0441800;C0815320;C0919553;C1304897;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C3244287;C4551720	\N	\N
1359	gold grade $nmbr$ and ics non - users at screening	C0018026;C0220908;C0220909;C0441800;C0815320;C0919553;C1304897;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C3244287;C4551720	\N	\N
1359	fp versus other ics	C0016704;C0815320;C1419068;C1419906;C3541238;C3541412;C4551720	\N	\N
1359	discontinuation of ics / laba prior to baseline  n ( % )	C0168634;C0457454;C0815320;C1442488;C1444662;C4551720;C4552847	\N	\N
1359	calima overalldhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ )	C0014467;C0168634;C0178602;C0815320;C1442488;C2699156;C2986497;C4551720	\N	\N
1359	baseline post - bronchodilator % predicted fev  > $nmbr$ % and no prior ics use	C0042153;C0168634;C0332152;C0457083;C0681842;C0815320;C1442488;C1882327;C1947944;C2599594;C2826257;C3714541;C4551720	\N	\N
1358	without psoriasis ( zi = $nmbr$ )	C0033860;C0043476	\N	\N
1358	without psoriasis ( zi = $nmbr$  $nmbr$ )	C0033860;C0043476	\N	\N
1358	without psoriasis ( n = $nmbr$ )	C0033860	\N	\N
1358	without psoriasis ( n = $nmbr$  $nmbr$ )	C0033860	\N	\N
1358	with psoriasis ( zi = $nmbr$ )	C0033860;C0043476	\N	\N
1358	with psoriasis ( n = $nmbr$ )	C0033860	\N	\N
1358	psoriasis covering > $nmbr$ % bsa  n ( % ) §	C0033860;C0180153;C0439844	\N	\N
1358	scalp psoriasis  n ( % )	C0406326	f	2178
1359	ics	C0815320;C4551720	f	2182
1359	ics # #	C0815320;C4551720	f	2182
1359	icsf	\N	f	2182
1359	ics  mg / day	C0439422;C0815320;C4551720	f	2182
1359	ics  n ( % )	C0815320;C4551720	f	2182
1359	ics non - users	C0815320;C1518422;C1706077;C4551720	f	2182
1359	ics : no	C0815320;C4551720	f	2182
1359	ics non - users at screening	C0220908;C0220909;C0815320;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720	f	2182
1359	ics nonusers  n ( % )	C0815320;C4551720	f	2182
1359	ics usage	C0457083;C0815320;C4551720	f	2182
1359	ics use	C0042153;C0457083;C0815320;C1947944;C4551720	f	2182
1359	ics use  %	C0042153;C0457083;C0815320;C1947944;C4551720	f	2182
1359	ics use at baseline : no	C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720	f	2182
1359	ics use at screening	C0042153;C0220908;C0220909;C0457083;C0815320;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164;C4551720	f	2182
1359	ics use at screeningg  n ( % )	C0042153;C0457083;C0815320;C1947944;C4551720	f	2182
1359	ics use at screening  n ( % )	C0042153;C0220908;C0220909;C0457083;C0815320;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164;C4551720	f	2182
1359	ics use no	C0042153;C0457083;C0815320;C1947944;C4551720	f	2182
1359	ics users	C0815320;C1706077;C4551720	f	2182
1359	ics users at baseline  %	C0168634;C0815320;C1442488;C1706077;C4551720	f	2182
1359	ics users at baseline  n ( % )	C0168634;C0815320;C1442488;C1706077;C4551720	f	2182
1359	ics users at screening	C0220908;C0220909;C0815320;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720	f	2182
1359	ics users  n ( % )	C0815320;C1706077;C4551720	f	2182
1359	no ics	C0815320;C4551720	f	2182
1359	ics no laba	C0815320;C4551720	f	2182
1359	ics  no laba  n ( % )	C0815320;C4551720	f	2182
1359	ics  no laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ )	C0032042;C0213771;C0815320;C1696465;C1706408;C4551720	f	2182
1359	other ics	C0815320;C4551720	f	2182
1359	other ics versus no ics	C0815320;C4551720	f	2182
1359	total ics dose at entry  / xg / d	C0017209;C0815320;C1292284;C1421532;C1705654;C2986497;C4551720	f	2182
1359	use of ics	C0815320;C1524063;C4551720	f	2182
1359	use of ics at baseline  %	C0168634;C0815320;C1442488;C1524063;C4551720	f	2182
1359	with concomitant ics	C0521115;C0815320;C4551720	f	2182
1359	with ics  n ( % )	C0815320;C4551720	f	2182
1359	without concomitant ics	C0521115;C0815320;C4551720	f	2182
1359	mean ics use at enrolment ( pg ) *	C0030827;C0042153;C0072225;C0444504;C0457083;C0815320;C1266240;C1516879;C1696073;C1947944;C2347634;C2348143;C3888021;C4551720	f	2182
1360	acd	C4554601	f	-10
1359	+ ics / + laba nz $nmbr$	C0027978;C0815320;C4551720	f	2193
1359	ics / laba subset	C0815320;C1515021;C4551720	f	2193
1359	ics plus laba	C0815320;C4551720	f	2193
1359	laba   +   ics	C0815320;C4551720	f	2193
1359	laba plus ics  n ( % )	C0332287;C0815320;C4551720	f	2193
1359	laba plus ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ )	C0032042;C0213771;C0332287;C0815320;C1696465;C1706408;C4551720	f	2193
1358	psoriasis characteristics	C0033860;C1521970	\N	\N
1358	psoriasis > $nmbr$ % of bsa	C0033860	\N	\N
1358	psoriasis ( n =	C0033860	\N	\N
1358	psoriasis	C0033860	\N	\N
1358	patients without psoriasis ( n = $nmbr$ )	C0030705;C0033860	\N	\N
1358	patients with psoriasis ( n = $nmbr$ )	C0030705;C0033860	\N	\N
1358	facial psoriasis  n ( % )	C1276112	\N	\N
1357	organic	C0747055	\N	\N
1356	severe oa symptoms at baselined	C0029408;C0436345;C3887876	\N	\N
1356	osteoarthritis	C0029408	\N	\N
1356	oa	C0029408;C3887876	\N	\N
1356	less severe oa symptoms at baseline	C0029408;C0168634;C0436345;C0439092;C0547044;C1442488;C3887876	\N	\N
1356	duration of osteoarthritis symptoms — yr	C0029408;C0436359;C0439234	\N	\N
1355	sdai < $nmbr$ t	C3871128	\N	\N
1355	sdai < $nmbr$ . $nmbr$ *	C3871128	\N	\N
1355	sdai ( $nmbr$ - $nmbr$ )	C3871128	\N	\N
1355	sdai  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3871128	\N	\N
1355	sdai	C3871128	\N	\N
1355	mean ( sd ) sdai *	C0444504;C2347634;C2348143;C2699239;C3871128	\N	\N
1354	total basdai score  mean ( sd )	C0439175;C0439810;C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231	\N	\N
1354	total basdai  mean ( sd )	C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239	\N	\N
1354	baseline basdai	C0168634;C1442488;C1998004	\N	\N
1354	basdai ⁎ ⁎	C1998004	\N	\N
1354	basdai responses at week $nmbr$	C0332174;C0439230;C0871261;C1998004	\N	\N
1354	basdai $nmbr$  n ( % )	C1998004	\N	\N
1354	basdai $nmbr$  %	C1998004	\N	\N
1352	vka at randomization	C0034656	\N	\N
1352	vka	\N	\N	\N
1352	no vka at randomization	C0034656	\N	\N
1351	glycemic indexes	C1136206	\N	\N
1350	glyburide dose duringthe study ( mg )	C0017628;C0024671;C0026410;C0178602;C0439269;C0557651;C0869039;C1114758;C1960952;C2346927;C2603343;C4321396;C4521761	\N	\N
1350	glyburide ( n = $nmbr$ )	C0017628	\N	\N
1350	glyburide	C0017628	\N	\N
1349	glycemic variability  mmol / lc	C0005802;C0439190;C2827666	\N	\N
1349	glycemic characteristics	C0005802;C1521970	\N	\N
1349	blood glucose lowering treatment	C0005802;C0017725;C0039798;C0087111;C0441994;C0596197;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704	\N	\N
1349	blood glucose - lowering treatments  n ( % )	C0005802;C0017725;C0087111;C0441994;C0596197;C2003888	\N	\N
1349	blood glucose	C0005802	\N	\N
1348	use of oral glucocorticoids	C0017710;C0442027;C1524063;C3540777;C3540778;C4521986	\N	\N
1348	systemic glucocorticoid use at randomization  n ( % )	C0017710;C0034656;C0042153;C0205373;C0457083;C1947944	\N	\N
1348	systemic glucocorticoid use at randomisation	C0017710;C0034656;C0042153;C0205373;C0457083;C1947944	\N	\N
1348	postoperative nsaid or glucocorticoid use post - randomisation characteristic * *	C0003211;C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826;C3536840	\N	\N
1348	postoperative nsaid or glucocorticoid use	C0003211;C0017710;C0032790;C0042153;C0457083;C1947944;C3536840	\N	\N
1348	postoperative glucocorticoid use post - randomisation characteristic * *	C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826	\N	\N
1348	postoperative glucocorticoid use	C0017710;C0032790;C0042153;C0457083;C1947944	\N	\N
1348	oral glucocorticoid use at baseline — no . ( % ) : t	C0017710;C0168634;C1442488;C1527415;C2603360	\N	\N
1348	oral glucocorticoid use	C0017710;C1527415	\N	\N
1348	no glucocorticoids at baseline	C0017710;C0168634;C1442488;C3540777;C3540778	\N	\N
1348	glucocorticoids only	C0017710;C0205171;C1720467;C3540777;C3540778	\N	\N
1348	glucocorticoids at baseline	C0017710;C0168634;C1442488;C3540777;C3540778	\N	\N
1348	glucocorticoids *	C0017710;C3540777;C3540778	\N	\N
1348	glucocorticoids	C0017710;C3540777;C3540778	\N	\N
1348	glucocorticoid ]	C0017710	\N	\N
1348	glucocorticoid	C0017710	\N	\N
1348	any glucocorticoid *	C0017710	\N	\N
1353	previous vka use	C0042153;C0205156;C0457083;C1552607;C1947944	f	1352
1353	vka ( n   = $nmbr$ )	\N	f	1352
1355	mean selena - sledai score ± sd	C0444504;C0449820;C0451528;C2347634;C2348143;C2699239;C4050231	f	2175
1355	selena - sledai mean score ( sd )	C0451528;C2699239;C3533236	f	2175
1357	psoriatic arthritis	C0003872	f	2176
1357	psoriatic arthritis  %	C0003872	f	2176
1357	psoriatic arthritis pain ]	C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132	f	2176
1357	number of previous anti - tnf treatments for psoriatic arthritis	C0003872;C0087111;C0205156;C0237753;C0449788;C1448177;C1552607	f	362
1358	patients with psoriasis > $nmbr$ % of body surface area	C0017446;C0030705;C0033860;C0205146;C0489451	f	2177
1358	patients with > $nmbr$ % bsa psoriasis skin involvement  n ( % )	C0030705;C0033860;C0444099;C1123023;C1314939;C4520765	f	2177
1358	psoriasis body surface area > $nmbr$ %	C0005902;C0033860	f	2177
1358	bsa > $nmbr$ %  n ( % ) t	\N	f	2177
1358	patients with psoriasis ( bsa ≥   $nmbr$ % )	C0030705;C0033860	f	2177
1348	use of inhaled glucocorticoids at baseline	C0004048;C0017710;C0168634;C1442488;C1524063;C3540777;C3540778	f	2182
1358	previous exposure to biologic systemic psoriasis therapyb ( yes )  n ( % )	C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1549445;C1552607;C1705108;C1710701	f	2181
1358	previous exposure to non - biologic systemic psoriasis therapyb ( yes )  n ( % )	C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1518422;C1549445;C1552607;C1705108;C1710701	f	2181
1358	dlqi ( patients with £ $nmbr$ % bsa psoriasis )	C0030705;C0033860;C3899393	f	2177
1358	psoriasis affecting > $nmbr$ % of body - surface	C0033860;C0392760;C0489451;C1314939	f	2177
1358	psoriasis bsa > $nmbr$ %  n ( % )	C0033860	f	2177
1347	baseline microalbumin : < $nmbr$	C0168634;C0201838;C1442488;C2362049	\N	\N
1347	albumin measurements ^ ^	C0201838	\N	\N
1346	without tamsulosin	C0257343	\N	\N
1346	with tamsulosin	C0257343	\N	\N
1346	tamsulosin ( w = $nmbr$ )  $nmbr$ / $nmbr$	C0257343	\N	\N
1346	tamsulosin ( n = $nmbr$ )	C0257343	\N	\N
1346	tamsulosin $nmbr$ . $nmbr$ mg vs . placebo	C0024671;C0026410;C0032042;C0257343;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761	\N	\N
1346	tamsulosin $nmbr$ . $nmbr$ mg vs . $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1346	tamsulosin $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1346	tamsulosin	C0257343	\N	\N
1345	previous metformin use  %	C0025598;C0042153;C0205156;C0457083;C1552607;C1947944	\N	\N
1345	plus metformin	C0025598;C0332287	\N	\N
1345	overall cohort ( post hoc analysis excluding metformin users )	C0025598;C0086027;C0282416;C0332196;C0687676;C1561607;C1704687;C1706077;C2828389;C3469826	\N	\N
1345	on metformin ir or metformin xr $nmbr$   mg / d	C0022065;C0022071;C0025598;C0038976;C0043309;C0439422;C1448132;C1707968;C1962945	\N	\N
1345	no metformin use	C0025598;C0042153;C0457083;C1947944	\N	\N
1345	no metformin	C0025598	\N	\N
1345	metformin 一 no . ( % )	C0025598	\N	\N
1345	metformin • pioglitazone	C1635037	\N	\N
1345	metformin — no . ( % )	C0025598	\N	\N
1345	metformin ± other oral anti - dm drugs	C0011816;C0025598;C0029167;C0175795;C0304289;C3250443	\N	\N
1345	metformin use  n ( % )	C0025598;C0042153;C0457083;C1947944	\N	\N
1345	metformin use	C0025598;C0042153;C0457083;C1947944	\N	\N
1345	metformin open - label *	C0025598;C1709323	\N	\N
1345	metformin monotherapy	C0025598	\N	\N
1345	metformin ? pioglitazone	C1635037	\N	\N
1345	metformin ( n = $nmbr$ )	C0025598	\N	\N
1345	metformin ( n $nmbr$ $nmbr$ )	C0025598	\N	\N
1345	metformin  n ( % )	C0025598	\N	\N
1345	metformin	C0025598	\N	\N
1345	merformin	\N	\N	\N
1345	baseline metformin	C0025598;C0168634;C1442488	\N	\N
1344	with lowest bwb	C1708760	\N	\N
1344	lowest activated clotting	C0005778;C1328723;C1708760;C1879547	\N	\N
1344	lowest	C1708760	\N	\N
1343	low molecular weight heparin	C0019139;C3536766	\N	\N
1343	low molecular weight ( lmw ) heparin before randomisation	C0019139;C0034656;C3536766	\N	\N
1343	low - molecular weight heparin or intravenous unfractionated heparin	C0019139;C0354566;C3536766	\N	\N
1343	low - molecular - weight heparin — no . ( % )	C0019139;C3536766	\N	\N
1343	low - molecular - weight heparin only	C0019139;C0205171;C1720467;C3536766	\N	\N
1343	low - molecular - weight heparin	C0019139;C3536766	\N	\N
1343	lmwh within $nmbr$ days before randomization — no . / total no . ( % )	C0019139;C0034656;C0439175;C0439228;C0439810;C3536766	\N	\N
1343	lmwh	C0019139;C3536766	\N	\N
1342	left main coronary artery  n ( % )	C1261082	\N	\N
1342	left main coronary artery	C1261082	\N	\N
1341	ileum only  n ( % )	C0020885;C0205171;C1720467	\N	\N
1341	ileum only	C0020885;C0205171;C1720467	\N	\N
1341	ileum	C0020885	\N	\N
1340	womac pain score	C0582148	\N	\N
1340	scores for global and pain assessments §	C0030198;C0205246;C0449820;C2348867	\N	\N
1340	$nmbr$ % decrease in womac pain score	C0392756;C0547047;C0582148	\N	\N
1338	patient assessment of pain ( $nmbr$ - $nmbr$ mm )  mean ( sd )	C0030193;C0030198;C0030705;C0444504;C0518090;C0679830;C1962977;C2347634;C2348143;C2699239;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674	\N	\N
1338	patient ' s assessment of pain !	C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
1338	patient ' s assessment of pain	C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
1338	pain subscale	C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
1338	pain	C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
1338	ontario and mcmaster universities osteoarthritis index ( womac ) can range from $nmbr$ to $nmbr$ for the pain subscale  $nmbr$ to $nmbr$ for the stiffness	C0029040;C0029408;C0030193;C0041740;C0427008;C0518090;C0600653;C0918012;C1514721;C1552854;C1637833;C1962977;C2348147;C2984058;C2986546;C3542016;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
7	p value $nmbr$	C1709380	\N	\N
1338	eq - $nmbr$ d - $nmbr$   l  no pain or discomfortf	C0030193;C0205163;C0439185;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
1338	eq - $nmbr$ d - $nmbr$   l  no pain or discomfortc	C0030193;C0205163;C0439185;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
1324	diclofenac $nmbr$ mg  n = $nmbr$  n ( % )	C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1324	diclofenac	C0012091	\N	\N
1339	bodily pain	C3890602	f	1338
1339	rest pain	C0234253	f	1338
1339	intensity of rest pain ( mmvas )  mean ± sd	C0035253;C0234253;C0444504;C0522510;C1320357;C1622890;C2347634;C2348143;C2699239;C4085211	f	1338
1339	sf - $nmbr$ bodily pain  mean change from baselinee	C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952	f	1338
1340	spain	C0037747	f	2170
1340	spain ( n = $nmbr$ )	C0037747	f	2170
1340	oropharyngeal pain	C2363731;C4554669	f	2171
1340	upper abdominal pain	C0232492	f	2172
1340	shoulder pain	C0037011	f	2173
1342	lm $nmbr$ bid ( n = $nmbr$ )	C1261082;C1551056	f	-10
1342	lm $nmbr$ $nmbr$	C1261082;C1551056	f	-10
1344	with lowest hba $nmbr$ cd	C0007928;C0019016;C0034283;C1708760;C1825777;C3538758;C4552032	f	820
1345	linagliptin / metformin	C3264599	f	2252
1337	total back pain score ( $nmbr$ – $nmbr$   mm scale )  mean   ±   sd	C0004604;C0175659;C0349674;C0444504;C1947916;C1963071;C2347634;C2348143;C2699239;C2964552;C4330985;C4553945;C4554674	\N	\N
1337	total back pain  mean ( sd )	C0004604;C0439175;C0439810;C0444504;C1963071;C2347634;C2348143;C2699239;C4553945	\N	\N
1337	question $nmbr$ ( neck / back / hip pain )	C0004600;C0004604;C0007859;C0019552;C0019559;C0022122;C0027530;C0205095;C0460009;C1505163;C1522634;C1963071;C1963180;C1995000;C3159206;C3538851;C4284725;C4551516;C4553909;C4553945	\N	\N
1337	back pain	C0004604;C1963071;C4553945	\N	\N
1336	patient - reported outcomes	C2987124	\N	\N
1336	patient - reported outcome measures	C4277735	\N	\N
1335	reported in ecrf	C0684224;C0700287;C4319718;C4551412	\N	\N
1335	not reported in ecrf	C0684224;C0700287;C1518422;C4319718;C4551412	\N	\N
1335	in	\N	\N	\N
1334	patients taking mtx  no . ( % )	C0025677;C0030705;C1417487;C1515187	\N	\N
1334	patients taking mtx  n ( % )	C0025677;C0030705;C1417487;C1515187	\N	\N
1333	patients with eot data  n	C2707520	\N	\N
1333	* patient characterization data are reproduced from morrow et al . ( $nmbr$ ) .	C0040028;C0202311;C1880022;C2707520	\N	\N
1332	taiwan	C0039260	\N	\N
1331	native hawaiian or other pacific islander	C0242191;C0337920	\N	\N
1331	native hawaiian or other pacific	C0337920	\N	\N
1331	native hawaiian or	C0337920	\N	\N
1331	native hawaiian / pacific islander	C0242191;C0337920	\N	\N
1331	native hawaiian / other	C0337920	\N	\N
1331	hawaiian pacific islander	C0242191;C0337920	\N	\N
1331	hawaiian / pacific islander	C0242191;C0337920	\N	\N
1331	hawaiian / pacific	C0337920	\N	\N
1330	watchman ( n = $nmbr$ )	C0335390	\N	\N
1330	device = watchman filter	C0180860;C0335390	\N	\N
1329	white or caucasian  n ( % )	C0007457;C0043157;C0220938	\N	\N
1329	white / caucasian	C0043157	\N	\N
1329	race  % caucasian	C0007457;C0034510;C0043157;C1706779;C3853635	\N	\N
1329	noncaucasian	\N	\N	\N
1329	non - caucasian simva ( „ = $nmbr$ }	C0007457;C0043157;C1518422	\N	\N
1329	non - caucasian simva ( n = $nmbr$ )	C0007457;C0043157;C1518422	\N	\N
1329	non - caucasian simva	C0007457;C0043157;C1518422	\N	\N
1329	non - caucasian eze / simva ( „ = $nmbr$ }	C0007457;C0043157;C1518422	\N	\N
1329	non - caucasian eze / simva ( n = $nmbr$ )	C0007457;C0043157;C1518422	\N	\N
1329	non - caucasian eze / simva	C0007457;C0043157;C1518422	\N	\N
1329	non - caucasian	C0007457;C0043157;C1518422	\N	\N
1329	causaslan	\N	\N	\N
1329	caucasians ( n = $nmbr$ )	C0007457;C0043157	\N	\N
1329	caucasians	C0007457;C0043157	\N	\N
1329	caucasiana ( % )	\N	\N	\N
1329	caucasian simva ( „ = $nmbr$ }	C0007457;C0043157	\N	\N
1329	caucasian simva ( n = $nmbr$ )	C0007457;C0043157	\N	\N
1329	caucasian race ( % )	C0007457	\N	\N
1329	caucasian race	C0007457	\N	\N
1329	caucasian n = $nmbr$  $nmbr$	C0007457;C0043157	\N	\N
1329	caucasian eze / simva ( „ = $nmbr$ }	C0007457;C0043157	\N	\N
1329	caucasian eze / simva ( n = $nmbr$ )	C0007457;C0043157	\N	\N
1329	caucasian eze / simva	C0007457;C0043157	\N	\N
1329	caucasian ethnicity	C0007457;C0015031;C0043157;C0243103	\N	\N
1329	caucasian ( % )	C0007457;C0043157	\N	\N
1329	caucasian $nmbr$	C0007457;C0043157	\N	\N
1329	caucasian  n ( % ) *	C0007457;C0043157	\N	\N
1329	caucasian  n ( % )	C0007457;C0043157	\N	\N
1329	caucasian  %	C0007457;C0043157	\N	\N
1329	caucasian	C0007457;C0043157	\N	\N
1328	concomitant use of bosentan  n ( % )	C0252643;C0521115;C1524063	\N	\N
1328	bosentan use :	C0042153;C0252643;C0457083;C1947944	\N	\N
1328	bosentan ( n = $nmbr$ )	C0252643	\N	\N
1328	bosentan	C0252643	\N	\N
1327	use of supplemental oxygen  n ( % )	C4067893;C4554557	\N	\N
1327	supplementary oxygen	C0030054	\N	\N
1327	supplemental oxygen	C4534306	\N	\N
1324	diclofenac ( n = $nmbr$ )	C0012091	\N	\N
1324	diclofenac ( n = $nmbr$ $nmbr$ )	C0012091	\N	\N
1324	diclofenac ( n = $nmbr$  $nmbr$ )	C0012091	\N	\N
1324	diclofenac $nmbr$ mg ( n = $nmbr$ ) n ( % )	C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1324	diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . n . . . ( . % . . ) . . . . . . . . . . .	C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1324	diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .	C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1324	diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . ( . % . . ) . . . . . . . . . . .	C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1324	diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .	C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1324	diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .	C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1323	£ $nmbr$ ( men ) / £ $nmbr$ ( women )	C0025266;C0043210	\N	\N
1332	previously taken dmards other than methotrexate  %	C0025677;C0242708;C1883727	f	231
1325	omega - $nmbr$ fa	C1719844	f	1236
1328	levosimendan ( n   = $nmbr$ )	C0246904	f	2166
1326	documented hypoglycaemiac	C1301725;C1609436	f	35
1326	hypoglycaemiad  %	\N	f	35
1326	angina with documented ischemia	C0002962;C0022116;C1301725;C1609436;C4321499	f	1361
1326	documented mi	C1301725;C1609436;C3810814	f	1361
1326	documented symptomatic chdb	C0231220;C1301725;C1609436	f	1361
1332	previously taken tnfi  %	C1883727	f	362
1334	taking statins  n ( % ) a	C0360714;C1515187	f	2167
1337	neck pain	C0007859;C1963180;C4553909	f	2168
1337	pin /	C0175718;C1168556;C1704584	f	-10
1323	women ( n = $nmbr$ ) events	C0043210;C0441471;C3541888	\N	\N
1323	women ( n = $nmbr$ )  n / n ( % )	C0043210	\N	\N
1323	women ( n = $nmbr$ )	C0043210	\N	\N
1323	women ( n ( % ) )	C0043210	\N	\N
1323	women ( % )	C0043210	\N	\N
1323	women  no . ( % )	C0043210	\N	\N
1323	women  n ( % ) *	C0043210	\N	\N
1323	women  n ( % )	C0043210	\N	\N
1323	women  %	C0043210	\N	\N
1323	women	C0043210	\N	\N
1323	woman	C0043210;C4281745	\N	\N
1323	no . women	C0043210	\N	\N
1323	gmi ( women )	C0043210	\N	\N
1323	gender  women n  % )	C0043210;C0079399;C1522384	\N	\N
1323	fpci vs . ppci in women	C0043210	\N	\N
1323	all women	C0043210	\N	\N
1323	< $nmbr$ ( men ) / < $nmbr$ ( women )	C0025266;C0043210	\N	\N
1323	( women only )	C0043210;C0205171;C1720467	\N	\N
1323	$nmbr$ - $nmbr$ ( women )	C0043210	\N	\N
1322	open — no . ( % )	C0175566	\N	\N
1322	open triple ( n = $nmbr$ )	C0175566;C0205174	\N	\N
1322	open	C0175566	\N	\N
1321	bowel function	C0011135	\N	\N
1320	risk model endpoint	C0035647;C2349179;C2826544;C3161035;C3274659;C3714583;C3853906;C4552904	\N	\N
1320	risk marker and model	C1519104;C3161035;C3274659;C3714583;C3853906	\N	\N
1320	model $nmbr$ §	C3161035;C3274659;C3714583;C3853906	\N	\N
1320	model $nmbr$ t	C3161035;C3274659;C3714583;C3853906	\N	\N
1320	model $nmbr$ +	C3161035;C3274659;C3714583;C3853906	\N	\N
1320	model $nmbr$	C3161035;C3274659;C3714583;C3853906	\N	\N
1320	model  n	C3161035;C3274659;C3714583;C3853906	\N	\N
-10	proctosigmoiditis	C0033252	\N	\N
1318	seropositivity status  n	C0449438;C0521143	\N	\N
1318	seropositivity	C0521143	\N	\N
1317	eligibility risk factorsa	C0013893;C0035647;C1548635;C4552904	\N	\N
1317	eligibility risk factors ’ )	C0013893;C0035648;C1548635;C1553898	\N	\N
1317	eligibility risk factors — n ( % ) :	C0013893;C0035648;C1548635;C1553898	\N	\N
1317	eligibility risk factors :	C0013893;C0035648;C1548635;C1553898	\N	\N
1317	eligibility risk factors /	C0013893;C0035648;C1548635;C1553898	\N	\N
1317	eligibility risk factors !	C0013893;C0035648;C1548635;C1553898	\N	\N
1317	eligibility risk factors  no . ( % ) t	C0013893;C0035648;C1548635;C1553898;C2603360	\N	\N
1317	eligibility risk factors  % t ascvo	C0013893;C0035648;C1548635;C1553898	\N	\N
1317	eligibility risk factors	C0013893;C0035648;C1548635;C1553898	\N	\N
1317	* eligibility risk factors  n ( % ) *	C0013893;C0035648;C1548635;C1553898	\N	\N
1315	screening absolute reversibility fev $nmbr$  ml	C0205344;C0220908;C0220909;C0439526;C0449261;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C3714541;C3887665	\N	\N
1315	screening % reversibility fev $nmbr$	C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541	\N	\N
1315	saba reversibility	C0449261	\N	\N
1315	reversibility to salbutamolc  d  mean ( sd )	C0444504;C0449261;C2347634;C2348143;C2699239	\N	\N
1315	reversibility of fev $nmbr$ ( % )	C0449261;C3714541	\N	\N
1315	reversibility ( b $nmbr$ - agonist )  %  mean ( sd ) $nmbr$	C0444504;C0449261;C2347634;C2348143;C2699239;C2987634	\N	\N
1315	reversibility ( anticholinergic )  %  mean ( sd ) $	C0242896;C0444504;C0449261;C2347634;C2348143;C2699239;C3537004	\N	\N
1315	reversibility ( % predicted fev $nmbr$ ) *	C0449261;C0681842;C1882327;C3714541	\N	\N
1315	postbronchodilator fev $nmbr$ reversibility  %	C0449261;C2599594;C3714541	\N	\N
1315	post - bronchodilator fev i reversibility  % b	C0021966;C0221138;C0449261;C2599594;C3714541	\N	\N
1315	post - bronchodilator fev $nmbr$ reversibility  % a	C0449261;C2599594;C3714541	\N	\N
1315	post - bronchodilator fev $nmbr$ reversibility  %	C0449261;C2599594;C3714541	\N	\N
1315	post - bronchodilator fev  reversibility	C0449261;C2599594;C3714541	\N	\N
1315	mean reversibility ( % )	C0444504;C0449261;C2347634;C2348143	\N	\N
1315	mean ( sd ) postbronchodilator fev $nmbr$ reversibility  %	C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
1315	mean ( sd ) % reversibility fev $nmbr$ at	C0444504;C0449261;C2347634;C2348143;C2699239;C3714541	\N	\N
1315	reversibility to	C0449261	f	2160
1315	reversibility ( % ) t	C0449261	f	2160
1315	reversibility stratum *	C0449261	f	2160
1315	reversibility < $nmbr$ % ( n = $nmbr$ )	C0449261	f	2160
1315	reversibility : > $nmbr$ - < $nmbr$ %	C0449261	f	2160
1315	reversibility > $nmbr$ % ( itt ) ( n = $nmbr$ )	C0449261	f	2160
1315	reversibility < $nmbr$ % ( itt ) ( n = $nmbr$ )	C0449261	f	2160
1315	reversibility : > $nmbr$ %	C0449261	f	2160
1315	reversibility : < $nmbr$ %	C0449261	f	2160
1315	reversibility ( % )  median ( range ) c	C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	f	2160
1315	reversibility [ % ]  median ( range )	C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	f	2160
1315	reversibility — %	C0449261	f	2160
1315	reversibility %	C0449261	f	2160
1315	reversibility *	C0449261	f	2160
1315	reversibility ( % )	C0449261	f	2160
1315	reversibility ’ ' %	C0449261	f	2160
1315	reversibility  %	C0449261	f	2160
1315	reversibility	C0449261	f	2160
1316	fevi reversibility — %	C3830088	f	1315
1316	reversibility to salbutamol  %	C1271924	f	1315
1317	eligibility strata	C0013893;C1548635	f	2161
1317	eligibility stratum	C0013893;C1548635	f	2161
1320	unadjusted model hr  $nmbr$ % ci  p value	C0008107;C1439367;C1709380;C3161035;C3259781;C3274659;C3714583;C3853906	f	2162
1320	crude model hr ( $nmbr$ % ci )	C0008107;C3161035;C3259781;C3274659;C3714583;C3853906	f	2162
1321	bowel stricturing  ' n ( % )	C0267465	f	2163
1321	daily bowel movements	C0011135;C0332173	f	2164
1322	statin ( open )	C0175566;C0360714	f	2167
1315	fev $nmbr$ reversibility  % b	C0449261;C3714541	\N	\N
1315	fev $nmbr$ reversibility  % *	C0449261;C3714541	\N	\N
1315	fev $nmbr$ % reversibility ( sd )	C0449261;C2699239;C3714541	\N	\N
1315	fev $nmbr$ % reversibility	C0449261;C3714541	\N	\N
1315	bronchial reversibility %	C0205039;C0449261;C1442216	\N	\N
1315	albuterol reversibility  %	C0001927;C0449261	\N	\N
1315	airway reversibility  mean  %	C0178987;C0444504;C0449261;C0458827;C2347634;C2348143	\N	\N
1315	airway reversibility  %	C0178987;C0449261;C0458827	\N	\N
1315	airflow reversibility — no . ( % ) |	C0231999;C0449261	\N	\N
1315	absolute reversibility in fev $nmbr$  ml *	C0205344;C0439526;C0449261;C1705224;C3714541;C3887665	\N	\N
1315	% reversibility in fev ^ at	C0449261;C3714541	\N	\N
1315	% bronchial reversibility ( sd )	C0205039;C0449261;C1442216;C2699239	\N	\N
1314	ecg abnormality at entry	C0522055;C1705654	\N	\N
1314	any electrocardiographic abnormality — no . ( % )	C0522055	\N	\N
1313	obesityj	\N	\N	\N
1313	abdominal obesity *	C0311277	\N	\N
1313	abdominal obesity	C0311277	\N	\N
1312	shfm annual mortality	C0026565;C0026566;C0332181	\N	\N
1312	overall mortality	C0026565;C0026566;C0282416;C1561607	\N	\N
1312	or morbidity and mortality	C0026538;C0026565;C0026566;C0220880	\N	\N
1312	non - cvd mortality	C0007222;C0026565;C0026566;C1518422	\N	\N
1312	non - cardiovascular mortality	C0007226;C0026565;C0026566;C1518422;C3887460	\N	\N
1312	mortality outcomes	C0026565;C0026566;C1274040	\N	\N
1312	mortality	C0026565;C0026566	\N	\N
1312	all - causa mortality	C0026565;C0026566;C3903827	\N	\N
1311	si . gni . fi . canr ecg changes  positive biomarkers  and age < $nmbr$ vrs	C0001779;C0005516;C0392747;C0439178;C0443172;C0458261;C1446409;C1514241;C1623258;C1705241;C2825490;C3273608;C3812269;C4050619;C4319952	\N	\N
1311	bi ( $nmbr$ . $nmbr$ )	\N	\N	\N
1311	age is > $nmbr$ vrs  significant ecg changes  and no positive bi . omark . ers	C0001779;C0237881;C0439178;C0458261;C0750502;C0855329;C1446409;C1514241;C1546944;C1704489;C2825490;C2931783;C3273608;C3812269	\N	\N
1311	age is > $nmbr$ vrs  positive biomarkers  and no si . gni . fi . canr ecg changes	C0001779;C0005516;C0392747;C0439178;C0443172;C0458261;C1446409;C1514241;C1623258;C1705241;C2825490;C3273608;C3812269;C4050619;C4319952	\N	\N
1311	- bi -	\N	\N	\N
1311	$nmbr$ ( $nmbr$ si	\N	\N	\N
1310	wrist	C0043262;C1322271	\N	\N
1310	hip  wrist  or spine *	C0019552;C0022122;C0037949;C0043262;C1322271;C1505163;C2752558;C3538851;C4284725	\N	\N
1309	white hispanic - n ( % )	C1533020;C1533021	\N	\N
1309	white hispanic	C1533020;C1533021	\N	\N
1308	patients with > $nmbr$ % bsa	C0030705	\N	\N
1308	patients with $ $nmbr$ % bsa at baseline  no .	C0030705;C0168634;C1442488	\N	\N
1308	bsa ( % )	\N	\N	\N
1308	bsa  % *	\N	\N	\N
1307	yaa	\N	\N	\N
1307	laa ostium	C0444567	\N	\N
1307	laa closure ( n = $nmbr$ )	C0185003;C1521802	\N	\N
1307	laa closure ( n - $nmbr$ )	C0185003;C1521802	\N	\N
1307	laa closure	C0185003;C1521802	\N	\N
1307	laa	\N	\N	\N
1305	sabaa	\N	\N	\N
1305	previous ics / labd	C0205156;C0396059;C0815320;C1552607;C4551720	\N	\N
1305	percentage of patients using ics or ics / laba on entry	C0030705;C0439165;C0815320;C1524063;C1549488;C1561533;C1705654;C4551720	\N	\N
1305	lamad	\N	\N	\N
1305	labaa	\N	\N	\N
1305	laba / lama / ics	C0815320;C0999593;C1416775;C4551720	\N	\N
1305	laba / ics #	C0815320;C4551720	\N	\N
1305	laba + ics n = $nmbr$	C0815320;C4551720	\N	\N
1305	laba + ics ( free or fixed - dose combination )	C0178602;C0205195;C0332296;C0443218;C0815320;C0869039;C1114758;C1880497;C1947911;C1996904;C2827483;C3714578;C3811910;C4551720	\N	\N
1305	laba + ics	C0815320;C4551720	\N	\N
1305	laba  n ( % )	\N	\N	\N
1305	laba	\N	\N	\N
1305	icsa	\N	\N	\N
1304	multivariable	\N	\N	\N
1303	lavolta ii	C1710602;C4082587	\N	\N
1303	lavolta $nmbr$	\N	\N	\N
1302	week $nmbr$  % ( n ) | | or for cana vs pbo ( $nmbr$ % ci ) §	C0008107;C0031962;C0332174;C0439230;C1418845;C3259781	\N	\N
1302	week $nmbr$  % ( n ) $nmbr$ or for cana vs pbo ( $nmbr$ % ci ) | |	C0008107;C0031962;C0332174;C0439230;C1418845;C3259781	\N	\N
1302	week $nmbr$  % ( n ) # or for cana vs pbo ( $nmbr$ % ci ) | |	C0008107;C0031962;C0332174;C0439230;C1418845;C3259781	\N	\N
1302	pooled non - canvas studies ( n = $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )	C0369718;C0441922;C0557651;C0947630;C1319635;C1418845;C1518422;C1709595;C2349200;C2603343;C3281223;C4522255	\N	\N
1304	univariable	\N	f	2154
1304	multivariable adjusted hr ( $nmbr$ % ci )	C0008107;C0456081;C3259781	f	975
1305	ics / lama	C0815320;C0999593;C1416775;C4551720	f	1650
1306	cardiovascu lar subg roup	C0276828;C1419115;C3814448	f	2155
1306	chajdsrvasc $nmbr$ - $nmbr$	\N	f	2128
1309	whitea	C1021495	f	-10
1312	cardiovascuiar mortaiity	\N	f	2157
1305	icsa plus laba  n ( % )	C0332287	f	1650
1305	ics / laba	C0815320;C4551720	f	1650
1305	ics + laba	C0815320;C4551720	f	1650
1305	- ics / + laba n z $nmbr$	C0815320;C4551720	f	1650
1312	cardiovascular mortality	C0007226;C0026565;C0026566;C3887460	f	2157
1312	cardiovascular mortality or mi	C0007226;C0026565;C0026566;C3810814;C3887460	f	2157
1312	cardiovascular mortality  mi  or revascularization	C0007226;C0026565;C0026566;C0581603;C3810814;C3887460	f	2157
1312	vitality	C0424589	f	2158
1314	nationality	C0027473	f	2159
1315	% reversibility	C0449261	f	2160
1302	overall population ( n = $nmbr$ $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )	C0032659;C0282416;C1257890;C1319635;C1418845;C1518422;C1561607	\N	\N
1302	or for cana vs pbo ( $nmbr$ % ci ) §	C0008107;C0031962;C1418845;C3259781	\N	\N
1302	or for cana vs pbo ( $nmbr$ % ci ) | |	C0008107;C0031962;C1418845;C3259781	\N	\N
1302	non - cana ( n = $nmbr$ )	C1418845;C1518422	\N	\N
1302	canvas ( n = $nmbr$ ) : placebo ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )	C0032042;C1319635;C1418845;C1696465;C1706408;C3281223	\N	\N
1302	canvas	C3281223	\N	\N
1302	cana $nmbr$ ( n = $nmbr$ )	C1418845	\N	\N
1302	cana	C1418845	\N	\N
1302	all cana	C1418845	\N	\N
1301	united states  canada	C0006823;C0041703	\N	\N
1301	canada or united states	C0006823;C0041703	\N	\N
1300	samac	\N	\N	\N
1300	sama $nmbr$	C1075468	\N	\N
1300	sama  b   n ( % )	C1075468	\N	\N
1300	sama	C1075468	\N	\N
1300	previous treatment with a laba and / or lama  n ( % ) c	C0039798;C0087111;C0205156;C0999593;C1416775;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
1300	lama use  n ( % )	C0042153;C0457083;C0999593;C1416775;C1947944	\N	\N
1300	lama +	C0999593;C1416775	\N	\N
1300	lama	C0999593;C1416775	\N	\N
1300	laba or lama ’	C0999593;C1416775	\N	\N
1300	laba or lama	C0999593;C1416775	\N	\N
1300	laba / lama	C0999593;C1416775	\N	\N
1300	current lama use	C0042153;C0457083;C0521116;C0999593;C1416775;C1705970;C1947944	\N	\N
1300	ama 士 s . e .	C0002461;C0279755;C2825862	\N	\N
1299	place of randomization	C0034656;C0442504;C1533810;C1704765;C1882509	\N	\N
1299	place !	C0442504;C1533810;C1704765;C1882509	\N	\N
1299	plac	C0048838	\N	\N
1298	peace ( n = $nmbr$ )	C0680443	\N	\N
1298	pace  no . ( $nmbr$ )	C0287990;C1552930;C4048252	\N	\N
1297	smoking history ( pack - years ) ∗	C1277691;C1519384	\N	\N
1297	smoking history ( pack - years )	C1277691;C1519384	\N	\N
1297	smoking history  pack - years	C1277691;C1519384	\N	\N
1297	smoking consumption pack - years	C0425291;C1277691	\N	\N
1297	pack years	C1277691	\N	\N
1297	pack - years smoked	C0037366;C0439994;C1277691;C1881674	\N	\N
1297	number of pack years	C0237753;C0449788;C1277691	\N	\N
1297	number of pack - years	C0237753;C0449788;C1277691	\N	\N
1297	nicotine pack - years	C0028040;C1277691	\N	\N
1297	estimated number of pack - years	C0237753;C0449788;C0750572;C1277691	\N	\N
1296	b lack	C0332268	\N	\N
1295	history of a transient ischaemic attack	C0455536	\N	\N
1294	pcr after acs	C0032520;C0742343;C3853643;C4050242;C4318612	\N	\N
1293	uncontrolled : acq - $nmbr$ > $nmbr$ . $nmbr$	C0205318;C2919686	\N	\N
1293	acq score  mean	C0444504;C0449820;C2347634;C2348143;C2919686;C4050231	\N	\N
1293	acq - $nmbr$ scoret	C2919686	\N	\N
1293	acq - $nmbr$ score 本	C0449820;C2919686;C4050231	\N	\N
1293	acq - $nmbr$ score *	C0449820;C2919686;C4050231	\N	\N
1293	acq - $nmbr$ score ' ! '	C0449820;C2919686;C4050231	\N	\N
1293	acq - $nmbr$ score  mean ( sd ) e	C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231	\N	\N
1293	acq - $nmbr$ score	C0449820;C2919686;C4050231	\N	\N
1293	acq $nmbr$ score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231	\N	\N
1293	acq $nmbr$ score	C0449820;C2919686;C4050231	\N	\N
1294	nste acs	C0742343;C4318612	f	2146
1294	nste - acs	C0742343;C4318612	f	2146
1294	acs	C0742343;C4318612	f	2147
1294	before index acs event	C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612	f	2147
1294	hospitalization for acs	C0019993;C0742343;C4318612	f	2147
1294	index acs ( % )	C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612	f	2147
1294	index acs event	C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612	f	2147
1294	no acs	C0742343;C4318612	f	2147
1294	qualifying acs event — no . ( % )	C0441471;C0742343;C1514624;C4019010;C4318612	f	2147
1294	days between acs and rand	C0439228;C0742343;C1555436;C4318612	f	2148
1294	time between index acs and randomization ( days )	C0034656;C0040223;C0439228;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612	f	2148
1294	time between index acs and randomization — days	C0034656;C0040223;C0439228;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612	f	2148
1294	previous cabg ( before index acs ) *	C0010055;C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4318612	f	2149
1294	myocardial infarction before index acs — no . ( % )	C0027051;C0428953;C0600653;C0742343;C0918012;C1552854;C1637833;C2926063;C2986546;C3810814;C4318612;C4552959	f	2150
1294	prior ml ( before index acs )	C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612	f	2150
1294	previous pci ( before index acs )	C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4049621;C4318612	f	1661
1295	attack ( % )	C0277793;C1261512;C1304680	f	-10
1295	attain	\N	f	-10
1296	lack of effectiveness	C0235828	f	2151
1296	lack of efficacy	C0235828	f	2151
1296	lack of efficacy with > $nmbr$ anti - interleukin $nmbr$	C0021764;C0235828;C1527200	f	2151
1296	lack of efficacy with > $nmbr$ bdmard	C0235828	f	2151
1296	laci	C1420705;C3273314;C4281721	f	2152
1296	laci ( n = $nmbr$ )	C1420705;C3273314;C4281721	f	2152
1297	sack	\N	f	-10
1297	yearl	\N	f	-10
1299	inhixanab $nmbr$ mgikg versus piacom	\N	f	154
1301	laaca	\N	f	2153
1301	saaca	\N	f	2153
1301	canada	C0006823	f	2156
1293	( sd ) l / min acq - $nmbr$ score  mean ( sd )	C0444504;C0449820;C0702093;C1524029;C2347634;C2348143;C2699239;C2919686;C3813700;C4050231	\N	\N
1292	hematocrit  %	C0018935;C0518014	\N	\N
1292	baseline hematocrit  median ( iqr )	C0018935;C0168634;C0518014;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
1291	exact - pro total score  mean ( sd )	C0033382;C0444504;C0523852;C2347634;C2348143;C2699239;C2828393;C2964552;C2987124;C4050514	\N	\N
1291	exact ( b )	C2828393;C4050514	\N	\N
1290	total cataract extraction	C0007389;C0185115;C0439175;C0439810;C0684295;C3665439	\N	\N
1290	total cataract	C3665439	\N	\N
1290	cataract removal	C0007389	\N	\N
1290	cataract	C0086543;C4555209	\N	\N
1289	upper respiratory tract inflammation	C0877266	\N	\N
1289	upper respiratory tract infection $nmbr$ ( $nmbr$ . $nmbr$ )	C0041912	\N	\N
1289	upper respiratory tract infection	C0041912	\N	\N
1288	vertebrobasilar infarct	C0021308;C0545733	\N	\N
1288	prior infarction	C0021308;C0332152;C2826257	\N	\N
1288	no infarct visible	C0021308;C0205379	\N	\N
1288	infarct territory ( % )	C0021308;C1301808;C2983136	\N	\N
1288	infarct size	C0021308;C0456389	\N	\N
1288	atherothrombotic infarction  n ( % )	C0021308	\N	\N
1288	any relevant infarct	C0021308;C2347946	\N	\N
1288	any infarct	C0021308	\N	\N
1287	± sd .	C2699239	\N	\N
1287	years ( sd )	C0439234;C2699239	\N	\N
1287	week o ( baseline ) mean 士 sd	C0168634;C0332174;C0439230;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	week $nmbr$ mean 士 sd	C0332174;C0439230;C0444504;C2347634;C2348143;C2699239	\N	\N
1287	week $nmbr$ mean ( sd )	C0332174;C0439230;C0444504;C2347634;C2348143;C2699239	\N	\N
1287	week $nmbr$ ( mean  sd )	C0332174;C0439230;C0444504;C2347634;C2348143;C2699239	\N	\N
1287	vital signs  mean ( sd )	C0150404;C0444504;C0518766;C2347634;C2348143;C2699239	\N	\N
1287	vessel size  mean ( sd )  mm	C0005847;C0444504;C0456389;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
1287	treated at baseline  mean ( sd )  mm hg	C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239	\N	\N
1287	total periventricular wml score  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C2964552	\N	\N
1287	total macular volume  mean ( sd )  mm $nmbr$	C0332574;C0444504;C0449468;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
1287	time from parkinson ’ s disease diagnosis in months  mean ( sd )	C0011900;C0030567;C0040223;C0439231;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383	\N	\N
1287	systolic pressure at ankle level ( mmhg )  mean ± sd	C0003086;C0003087;C0039155;C0439475;C0441889;C0444504;C0445074;C0456079;C0871470;C1547707;C2347634;C2348143;C2699239;C2946261	\N	\N
1287	symptom score ( sd )	C2699239;C3476546	\N	\N
1287	sf - $nmbr$ v $nmbr$ domain scores  mean [ sd ]	C0037712;C0444504;C0449820;C1880389;C1883221;C2347634;C2348143;C2699239;C3541951;C4050231	\N	\N
1287	sd or %	C2699239	\N	\N
1287	sd	C2699239	\N	\N
1287	ppbc score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
7	p value	C1709380	\N	\N
1287	oab - q score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C3641332;C4050231	\N	\N
1287	number of patients ( % ) or mean 士 sd	C0444504;C2347634;C2348143;C2360800;C2699239	\N	\N
1287	mean 土 sd ( n )	C0444504;C2347634;C2348143;C2699239	\N	\N
1277	female ( % )	C0043210;C0086287;C1705497;C1705498	\N	\N
1287	scdbp  mean ( sd )  mmhgf	C0444504;C2347634;C2348143;C2699239	f	2127
1287	scsbp  mean ( sd )  mmhge	C0444504;C2347634;C2348143;C2699239	f	2127
1287	sesbp ( mmhg ) [ mean - sd ] d	C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sesbp ( mmhg ) [ mean _sd ] a	C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sedbp ( mmhg ) [ mean _sd ] d	C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sedbp ( mmhg ) [ mean_ sd ] a	C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	seated sbp  mean ( sd )  mmhg	C0085805;C0277814;C0439475;C0444504;C1283233;C2347634;C2348143;C2699239	f	2127
1287	systolic blood pressure  mean ( sd )  mm hga	C0039155;C0428886;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239;C4330985;C4554674	f	2127
1287	systolic ( mean  sd )	C0039155;C0444504;C2347634;C2348143;C2699239	f	2127
1287	systolic  mean ( sd )  mm hg h	C0025424;C0039155;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239	f	2127
1287	post - bronchodilator fev $nmbr$  l  mean ( sd )	C0444504;C2347634;C2348143;C2599594;C2699239;C3714541	f	2142
1287	post - bronchodilator fev $nmbr$  l  mean ( sd ) c	C0444504;C2347634;C2348143;C2599594;C2699239;C3714541	f	2142
1287	post - bronchodilator fev $nmbr$  mean ( sd )  l	C0444504;C2347634;C2348143;C2599594;C2699239;C3714541	f	2142
1287	patient global assessment of disease activity  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C4054228	f	2143
1287	patient ' s global assessment of disease activity  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C4054228	f	2143
1287	patient ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd )	C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4054228;C4330985;C4554674	f	2143
1288	nonfatai myocardiai infarction	C0021308	f	2144
1288	nonfatal myocardiail infarction	C0021308	f	2144
1288	myocardiai infarction	C0021308	f	2144
1288	q wave in the infarct territory at baseline *  %	C0021308;C0168634;C0429089;C1301808;C1305738;C1442488;C2983136	f	2145
1288	q waves in the infarct territory at baseline *  %	C0021308;C0168634;C0429089;C1301808;C1305738;C1442488;C2983136	f	2145
1289	trait	C0599883	f	-10
1287	mean ± sd $nmbr$ - h adbp  mm hg	C0033727;C0168370;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284	\N	\N
1287	mean ± sd  n ( % )	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	mean   ±   sd	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	mean ucsd - sobq score * ( sd )	C2699239;C3533236	\N	\N
1287	mean total ipss ( sd )	C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063	\N	\N
1287	mean stent diameter per lesion  mm ( sd ) †	C0038257;C0221198;C0552409;C1546698;C2699239;C4330985;C4554674	\N	\N
1287	mean sd $nmbr$ - h asbp  mm hg	C0033727;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284	\N	\N
1287	mean fev $nmbr$  l ( sd )	C0444504;C2347634;C2348143;C2699239;C3714541	\N	\N
1287	mean diastolic bp  mmhg  mean = sd	C0428883;C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1287	mean bmi ( sd )	C0444504;C0578022;C2347634;C2348143;C2699239	\N	\N
1287	mean a ± sd ( mmhg )	C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1287	mean ( ± sd ) baseline score	C0168634;C1442488;C2699239;C3533236	\N	\N
1287	mean ( sd ) nonstudy eye e - etdrs visual acuity letter score	C0015392;C0042812;C0700042;C1096774;C2360551;C2699239;C3533236	\N	\N
1287	mean ( sd ) improvement from baseline to week $nmbr$ in basdai questions *	C0168634;C0332174;C0439230;C0444504;C1442488;C1522634;C1998004;C2347634;C2348143;C2699239;C2986411	\N	\N
1287	mean ( sd ) improvement from baseline to week $nmbr$ in basdai	C0168634;C0332174;C0439230;C0444504;C1442488;C1998004;C2347634;C2348143;C2699239;C2986411	\N	\N
1287	mean ( sd ) eevi  ml	C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665	\N	\N
1287	mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent )	C0042812;C0183370;C0205163;C0439185;C1096774;C2360551;C2699239;C3533236	\N	\N
1287	mean ( sd ) baseline scores	C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231	\N	\N
1287	mean ( sd ) baseline	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	mean ( sd ) aqlq	C0444504;C2347634;C2348143;C2699239;C4055434	\N	\N
1287	mean ( sd )  y	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	mean ( sd )  mmhg	C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
1287	mean ( sd )  kg / m $nmbr$	C0444504;C1532718;C2347634;C2348143;C2699239	\N	\N
1287	mean  sd	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	ldl - c in mmol / l ( mean ± sd for baseline [ n ]  mean ± se for week $nmbr$ [ n ] )	C0036919;C0168634;C0332174;C0439230;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239	\N	\N
1287	jsn  mean ± sd	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	iuss score  mean ( sd )	C0439453;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
1287	ipss ( mean ± sd )	C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063	\N	\N
1287	ibdq domain scores  mean [ sd ]	C0444504;C0449820;C1880389;C1883221;C2347634;C2348143;C2699239;C3541951;C4050231	\N	\N
1287	ibdq  mean ± sd	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	hrql mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	hours from clopidogrel loading  mean ( sd )	C0070166;C0439227;C0444504;C1708715;C2347634;C2348143;C2699239	\N	\N
1287	homa - ir  mean ( sd )	C0022065;C0022071;C0444504;C1448132;C2347634;C2348143;C2699239	\N	\N
7	p - value ‘ ’	C1709380	\N	\N
7	p - value ¶	C1709380	\N	\N
1287	heart rate  mean ( sd ) [ range ]  beats / min	C0018810;C0444504;C0702093;C1514721;C1524029;C2347634;C2348143;C2348147;C2699239;C3542016;C3813700	f	1105
1287	heart rate ( sd )	C0018810;C2699239	f	1105
1287	haq - di  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3826998;C4321476	f	2138
1287	haq - di  mean [ sd ]	C0444504;C2347634;C2348143;C2699239;C3826998;C4321476	f	2138
1287	haq - di total score  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C2964552;C3826998;C4321476	f	2138
1287	haq - di ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3826998;C4321476	f	2138
1287	hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo subtracted change ( se )	C0008107;C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0040363;C0041260;C0168634;C0230347;C0392747;C0443172;C0444504;C0456081;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C1883351;C2346906;C2347634;C2348143;C2348589;C2699239;C3259781;C3538758;C3829066;C4319952;C4553351	f	2139
1287	left ventricular ejection fraction  mean ( sd )  %	C0428772;C0444504;C0488728;C2347634;C2348143;C2699239	f	2140
1287	mean ( sd ) bmi	C0444504;C0578022;C2347634;C2348143;C2699239	f	2141
1287	mean ( sd ) change from pre - to post - bronchodilator fevi  nil	C0332152;C0442734;C0444504;C0687676;C0740175;C1704687;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034	f	2142
1287	mean ( sd ) fev $nmbr$ / fvc  %	C0444504;C2347634;C2348143;C2699239;C3714541	f	2142
1287	mean ( sd ) fev $nmbr$  l	C0444504;C2347634;C2348143;C2699239;C3714541	f	2142
1287	mean ( sd ) post - bronchodilator	C0444504;C2347634;C2348143;C2599594;C2699239	f	2142
1287	mean ( sd ) post - bronchodilator fev $nmbr$ reversibility  %	C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541	f	2142
1287	mean ( sd ) post - bronchodilator fev $nmbr$ / fvc  %	C0444504;C2347634;C2348143;C2599594;C2699239;C3714541	f	2142
1287	mean ( sd ) pre - bronchodilator	C0444504;C2347634;C2348143;C2599602;C2699239	f	2142
1287	fsn score  mean ± sd	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
1287	dha intake on food frequency questionnaire  mean ( sd )  mg / d	C0034394;C0142831;C0439422;C0444504;C1286336;C1512806;C2347634;C2348143;C2348308;C2699239;C2986698	\N	\N
1287	data are number of patients ( % ) or mean ( sd )  unless otherwise indicated . cabg = coronary - artery bypass grafting . ptca = percutaneous transluminal coronary angioplasty  ldl = low - density lipoprotein . hdl = high - density lipoprotein . iqr = i nterquarti le range  hmg coa ri = $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a reductase inhibitor . bmi = body - mass index  which is weight in kg divided by the square of height in metres  * median ( iqr ) .	C0005910;C0009235;C0010055;C0021966;C0022718;C0023190;C0023821;C0023823;C0035487;C0043100;C0047420;C0162577;C0189695;C0205120;C0221138;C0332849;C0439090;C0439209;C0444504;C0475209;C0489786;C0522520;C0522523;C0545743;C0549183;C0597153;C0700307;C0876920;C1305855;C1305866;C1423767;C1444656;C1511726;C1514721;C1522231;C1548817;C1552595;C1655741;C1705104;C1826843;C2347634;C2347635;C2348143;C2348144;C2348147;C2360800;C2697858;C2699239;C2936173;C2939193;C3245479;C3542016;C3714741;C4054209	\N	\N
1287	cumulative nsaid score  mean   ±   sd	C0003211;C0444504;C0449820;C1511559;C2347634;C2348143;C2699239;C3536840;C4050231	\N	\N
1287	comorbidity score  mean ( sd ) t	C0009488;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
1287	bw  mean ( sd )  kg	C0005910;C0006041;C0022718;C0439209;C0444504;C2347634;C2348143;C2699239;C2986891;C4054209	\N	\N
1287	bsa ( % )  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	bone erosion score  mean ( sd )	C0444504;C0449820;C0587240;C2347634;C2348143;C2699239;C4050231	\N	\N
1287	blood oxygenation  mean ± sd	C0005767;C0005768;C0229664;C0231940;C0282636;C0444504;C2347634;C2348143;C2699239	\N	\N
1287	bii ( mean ± sd )	C0444504;C1413059;C2347634;C2348143;C2699239	\N	\N
1287	basmi ( linear )  mean ( sd )	C0205132;C0444504;C2347634;C2348143;C2699239	\N	\N
7	p - value }	C1709380	\N	\N
1287	baseline pssi score  mean ( sd )	C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231	\N	\N
1287	baseline ppasi score  mean ( sd )	C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231	\N	\N
1287	baseline pasi  mean ( sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C4528685	\N	\N
1287	baseline mean fev $nmbr$ ( sd )  ml	C0168634;C0439526;C0444504;C1442488;C1705224;C2347634;C2348143;C2699239;C3714541;C3887665	\N	\N
1287	baseline mean ( sd )  % [ mmol / mol ]	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3829066	\N	\N
1287	baseline mean ( sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	baseline hbi  mean ( sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	baseline characteristics  mean ( sd ) a	C0444504;C2347634;C2348143;C2699239;C4684572	\N	\N
1287	baseline bsa  mean ( sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	baseline bii  mean ( sd )	C0168634;C0444504;C1413059;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	baseline . mean _ sd . mg / mg	C0168634;C0444504;C1319635;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	bmi ( kg / m $nmbr$ ) mean ± sd	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	bmi ( kg / m $nmbr$ )  mean ( sd ) a	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	bmi  mean ( sd )	C0444504;C0578022;C2347634;C2348143;C2699239	f	2125
1287	bmi  mean ± sd	C0444504;C0578022;C2347634;C2348143;C2699239	f	2125
1287	bmi  mean ( sd ) b	C0444504;C0578022;C2347634;C2348143;C2699239	f	2125
1287	bmi  mean ( sd )  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	fev $nmbr$ / fvc  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3714541	f	2126
1287	fev $nmbr$ / fvc  %  mean ( sd ) $nmbr$	C0444504;C2347634;C2348143;C2699239;C3714541	f	2126
1287	fev $nmbr$  l  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3714541	f	2126
1287	fev $nmbr$ ( l )  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3714541	f	2126
1287	fev $nmbr$  mean ( sd ) pre - bd fev $nmbr$ / fvc	C0005126;C0332152;C0444504;C0740175;C2257086;C2344255;C2347634;C2348143;C2699239;C3669034;C3714541;C4050145	f	2126
1287	baseline sesbp  mean ( sd )  mm hg §	C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239	f	2127
1287	chads $nmbr$ score  mean ( ± sd )	C0007928;C0444504;C0449820;C1413373;C2347634;C2348143;C2699239;C4050231	f	2128
1287	chads $nmbr$ score  mean ± sd	C0007928;C0444504;C0449820;C1413373;C2347634;C2348143;C2699239;C4050231	f	2128
1287	chads $nmbr$  mean ± sd	C0007928;C0444504;C1413373;C2347634;C2348143;C2699239	f	2128
1287	baseline total ipss  mean ( sd )	C0168634;C0439175;C0439810;C0444504;C1019118;C1442488;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063	f	2129
1287	diastolic ( mean  sd )	C0012000;C0444504;C2347634;C2348143;C2699239	f	2130
1287	diastolic bp  mmhg  mean ± sd	C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239	f	2130
1287	ejection fraction  mean ( sd )  %	C0444504;C0489482;C2347634;C2348143;C2699239;C2700378	f	2131
1287	ejection fraction — mean ± sd	C0444504;C0489482;C2347634;C2348143;C2699239;C2700378	f	2131
1287	femoral neck t - score ( mean = sd )	C0015815;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	f	2132
1287	erosion score  mean $nmbr$ sd	C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231	f	2133
1287	erosion score  mean ± sd	C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231	f	2133
1287	dietary calcium intake  mean ( sd )  mg / d	C0439422;C0444504;C0489458;C2347634;C2348143;C2699239	f	2134
1287	fpi  mean ( sd )  pu / mlt	C0018387;C0444504;C2347634;C2348143;C2699239;C4553833	f	2135
1287	fpi  mean ( sd )  pu / rnff	C0018387;C0444504;C2347634;C2348143;C2699239	f	2135
1287	fvc  l  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3714541	f	2136
1287	gout history  mean ± sd years	C0018099;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239	f	2137
1287	baseline ( mean  sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	baseline  mean ( sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
1287	aqlq score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434	\N	\N
1287	aqlq ( s ) + $nmbr$ score  mean ( sd ) c  f	C0016327;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434	\N	\N
1287	albuterol use ( sd )  puffs / day	C0001927;C0042153;C0332173;C0439228;C0439505;C0457083;C1533107;C1947944;C2699239	\N	\N
1287	[ sd ]	C2699239	\N	\N
1287	( sd )	C2699239	\N	\N
1287	( mean ± sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1287	( mean + . sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1286	sun - $nmbr$ ( $nmbr$ )	C0038817;C0376223	\N	\N
1286	su  n ( % )	C0038642;C1705534	\N	\N
1286	su	C0038642;C1705534	\N	\N
1285	evolocumab + soc ( n = $nmbr$ )	C3529352	\N	\N
1284	abl - sc n / n	C0023139;C0282380;C1704928;C3890208	\N	\N
1284	abl - sc mean	C0023139;C0282380;C0444504;C1704928;C2347634;C2348143;C3890208	\N	\N
1284	abaloparatide - sc  n ( % )	C0282380;C4042342	\N	\N
1283	women  qva $nmbr$ - sfc	C0043210;C4521536	\N	\N
1283	sfc ( n   = $nmbr$  $nmbr$ )	C4521536	\N	\N
1283	sfc ( n [ $nmbr$ )	C4521536	\N	\N
1283	sfc ( n = $nmbr$ )	C4521536	\N	\N
1283	sfc $nmbr$ mg / $nmbr$ mg	C1319635;C4521536	\N	\N
1283	sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$ )	C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761	\N	\N
1283	sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761	\N	\N
1283	sfc	C4521536	\N	\N
1283	severe cord * : qvai $nmbr$ - sfc	C0205082;C1550235;C1706500;C3489532;C4050465;C4050466;C4521536	\N	\N
1283	moderate cord * : qva $nmbr$ - sfc	C0205081;C1550235;C1706500;C1881878;C3489532;C4049705;C4049706;C4085643;C4321335;C4521536	\N	\N
1283	men : qvai $nmbr$ - sfc	C0025266;C4521536	\N	\N
1283	ics users : qvai $nmbr$ - sfc	C0815320;C1706077;C4521536;C4551720	\N	\N
1283	ics non - users : qvai $nmbr$ - sfc	C0815320;C1518422;C1706077;C4521536;C4551720	\N	\N
1283	annualized rate ind / gly sfc	C0017890;C0523677;C0871208;C1521828;C4049864;C4521536	\N	\N
1283	age > $nmbr$ : qvai $nmbr$ - sfc	C0001779;C4521536	\N	\N
1283	age < $nmbr$ : qvai $nmbr$ - sfc	C0001779;C4521536	\N	\N
1282	≥ $nmbr$ sae	C1519255;C1622657;C4553214	\N	\N
1282	saes	C1519255;C1622657;C4553214	\N	\N
1282	due to sae	C1519255;C1622657;C4553214	\N	\N
1282	due to drug - relateda sae	C0013227;C1254351;C1519255;C1622657;C4553214	\N	\N
1282	drug - related saes	C0013227;C0439849;C0445223;C1254351;C1519255;C1622657;C4553214	\N	\N
1282	because of sae	C1519255;C1622657;C4553214	\N	\N
1282	any sae	C1519255;C1622657;C4553214	\N	\N
1281	sabae	\N	\N	\N
1281	saba §	\N	\N	\N
1281	saba ( inhaled )  c   n ( % )	C0004048	\N	\N
1281	saba	\N	\N	\N
7	p - value vs . placebo	C0032042;C1696465;C1706408;C1709380	\N	\N
7	p - value n / n ( % )	C1709380	\N	\N
7	p - value interaction	C1704675;C1709380	\N	\N
7	p - value for variance	C1709380;C1711260;C2348152	\N	\N
1279	underlying disease	C0012634;C4067746	\N	\N
1279	uc disease durslion	C0012634	\N	\N
1279	site of disease — no . ( % )	C0012634;C2945843	\N	\N
1279	serious gi disorder	C0012634;C0205404;C1708130;C3539617;C4050121	\N	\N
1279	priorbone disease	C0012634	\N	\N
1277	female $nmbr$	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female  no . ( % )	C0043210;C0086287;C1705497;C1705498	\N	\N
1280	nsaid	C0003211;C3536840	f	2121
1280	other nsaids	C0003211	f	2121
1280	cox - $nmbr$ selective nsaid	C0003211;C0036576;C1565830;C1707391;C3536840	f	2123
1280	cox - $nmbr$ selective nsaid use	C0003211;C0036576;C0042153;C0457083;C1565830;C1707391;C1947944;C3536840	f	2123
1285	so	C0037640	f	-10
1280	chronic non - steroidal antiinflammatory drugs	C0003211;C0205191	f	2122
1280	never nsaid	C0003211;C2003901;C3536840	f	2122
1280	non - steroidal anti - inflammatory drugs	C0003211	f	2122
1285	soc	\N	f	-10
1285	so $nmbr$ %	C0037640	f	-10
1286	su monotherapy	C0038642;C1705534	f	752
1286	su / tzd	C0038642;C1705534	f	752
1286	baseline su dose > $nmbr$ / $nmbr$ maximal	C0038642;C0168634;C0178602;C0205289;C0806909;C0869039;C1114758;C1442488;C1705534;C4049713	f	752
1286	baseline su dose < $nmbr$ / $nmbr$ maximal	C0038642;C0168634;C0178602;C0205289;C0806909;C0869039;C1114758;C1442488;C1705534;C4049713	f	752
1286	su / met	C0038642;C0428210;C1550543;C1705534;C4317104	f	2253
1286	metformin + su	C0025598;C0038642;C1705534	f	2253
1286	metformin + su + tzd	C0025598;C0038642;C1705534	f	2253
1286	metformin ? su	C0025598;C0038642;C1705534	f	2253
1279	most frequent gi disorders	C0012634;C0205393;C0332183;C1708130;C3539617;C4050121	\N	\N
1279	mer ’ s disease assessment	C0012634;C0673013;C1261322;C1516048;C3810521;C4281714	\N	\N
1279	disorders ( soc )	C0012634	\N	\N
1279	disease hare . no . ( % ) i	C0012634;C0021966;C0221138;C0242372;C1425660	\N	\N
1279	disease extent  n ( % )	C0012634;C0439792	\N	\N
1279	disease	C0012634	\N	\N
1279	any disease	C0012634	\N	\N
1279	$nmbr$ - $nmbr$ with cv risk but not disease ( n = $nmbr$ )	C0012634;C0035647;C1518422;C3538987;C4048877;C4318503;C4552904	\N	\N
1279	$nmbr$ - $nmbr$  risk  not disease ( n = $nmbr$  $nmbr$ )	C0012634;C0035647;C1518422;C4552904	\N	\N
1278	patients with cardiac disorders  n ( % ) §	C0012634;C0018799;C0030705;C0741926	\N	\N
1278	patients with cardiac disorders  n ( % ) c	C0012634;C0018799;C0030705;C0741926	\N	\N
1278	no cardiac disease	C0018799	\N	\N
1278	no apparent heart disease	C0018799;C0750489	\N	\N
1278	cardiac disorders ( soc )	C0018799	\N	\N
1278	cardiac disorder  n ( % ) §	C0018799	\N	\N
1278	cardiac disorder	C0018799	\N	\N
1278	cardiac disease	C0018799	\N	\N
1277	sex : female	C0086287	\N	\N
1277	sex ( female )	C0086287	\N	\N
1277	sex  female    n   ( % )	C0086287	\N	\N
1277	sex  female  n ( % )	C0086287	\N	\N
1277	sex  female  %	C0086287	\N	\N
1277	sex  female	C0086287	\N	\N
1277	sex  % female	C0086287	\N	\N
1277	number of females n ( % )	C0086287;C0237753;C0449788	\N	\N
1277	number of ( % ) females	C0086287;C0237753;C0449788	\N	\N
1277	gender ( female : male  % )	C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1277	femalesex	\N	\N	\N
1277	females only	C0086287;C0205171;C1720467	\N	\N
1277	females ( n = $nmbr$ )	C0086287	\N	\N
1277	females ( itt ) ( n = $nmbr$ )	C0086287	\N	\N
1277	females  n ( % )	C0086287	\N	\N
1277	females  > $nmbr$ . $nmbr$	C0086287	\N	\N
1277	females  > $nmbr$	C0086287	\N	\N
1277	females  < $nmbr$ . $nmbr$	C0086287	\N	\N
1277	females  < $nmbr$	C0086287	\N	\N
1277	females  %	C0086287	\N	\N
1277	females	C0086287	\N	\N
1277	femaleb	\N	\N	\N
1277	female — no . ( % )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female sex — no . { % )	C0086287	\N	\N
1277	female sex — no . ( % )	C0086287	\N	\N
1277	female sex — %	C0086287	\N	\N
1277	female sex ( % )	C0086287	\N	\N
1277	female sex  no . / total ( % )	C0086287;C0439175;C0439810	\N	\N
1277	female sex  no . ( % )	C0086287	\N	\N
1277	female sex  n ( % )	C0086287	\N	\N
1277	female sex  %	C0086287	\N	\N
1277	female sex	C0086287	\N	\N
1277	female n ( % )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female gender n ( % )	C0086287	\N	\N
1277	female gender ( % )	C0086287	\N	\N
1277	female gender	C0086287	\N	\N
1277	female eze / simva ( „ = $nmbr$ }	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female eze / simva ( n = $nmbr$ )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female - n ( % )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female ( n — $nmbr$ )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female ( n   = $nmbr$  $nmbr$ )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female ( n z $nmbr$ )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female ( n = lll $nmbr$ )	C0043210;C0086287;C1261077;C1705497;C1705498	\N	\N
1277	female ( n = $nmbr$ )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female ( n = $nmbr$  $nmbr$ )	C0043210;C0086287;C1705497;C1705498	\N	\N
1279	multivessel disease	C0012634	f	1867
1279	multivessel disease  no . ( % )	C0012634	f	1867
1279	no polyvascular disease ( n = $nmbr$ $nmbr$ )	C0012634	f	1868
1279	no polyvascular disease * ( n = $nmbr$ $nmbr$ )	C0012634	f	1868
1279	polyvascular disease and no type $nmbr$ diabetes ( n = $nmbr$ )	C0012634;C1320657	f	1868
1279	microvascular disease *	C0012634;C0443258	f	1869
1279	microvascular disease  n ( % )	C0012634;C0443258	f	1869
1278	isehemie heart disease	C0018799	f	1361
1279	albuminuria and previous maerovaseular disease plus established renal disease ( egfr $nmbr$ - $nmbr$ ml / min / l $nmbr$ in - with an uacr > $nmbr$ mg / g or egfr $nmbr$ - < $nmbr$ ml / inin / l $nmbr$ in - with any uacr mg / g )	C0001925;C0012634;C0022658;C0205156;C0332287;C0443211;C0702093;C1272684;C1300563;C1524029;C1552607;C1635169;C1739039;C3811844;C3812682;C3813700	f	2112
1279	macrovascular disease  n ( % )	C0012634	f	2113
1279	established atherosclerotic disease	C0012634;C0333482;C0443211;C1272684	f	2113
1279	established atherosclerotic disease — no . { % )	C0012634;C0333482;C0443211;C1272684	f	2113
1279	peripherai arteriai disease	C0012634	f	2114
1279	cerebrovascuiar disease	C0012634	f	2115
1279	clinical atherosclerotic disease *	C0012634;C0205210;C0333482	f	2116
1279	coronarv arterv disease	C0012634	f	2117
1279	no multivessel disease	C0012634	f	2118
1279	disease localization  n ( % )	C0012634;C0475264;C1744691	f	2119
1279	disease localization ' ’  n ( % )	C0012634;C0475264;C1744691	f	2119
1279	prior disease	C0012634;C0332152;C2826257	f	2120
1279	prior disease - modifying drugs resulting in inadequate response — mean no . / patient	C0012634;C0013227;C0030705;C0205412;C0332152;C0332294;C0392747;C0439856;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2826257;C2911692;C3687832	f	2120
1279	previous disease :	C0012634;C0205156;C1552607	f	2120
1277	female  no ( % )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female  n ( % )	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female  %	C0043210;C0086287;C1705497;C1705498	\N	\N
1277	female	C0043210;C0086287;C1705497;C1705498	\N	\N
1276	years male gender  n ( % )	C0086582;C0439234;C1706180	\N	\N
1276	sexa male	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	sex : male ( n = $nmbr$ )	C0086582	\N	\N
1276	sex : male	C0086582	\N	\N
1276	sex ( male / female ) ( n )	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	sex ( male / female )	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	sex ( male ) - no . ( % )	C0086582	\N	\N
1276	sex ( male )  n ( % )	C0086582	\N	\N
1276	sex ( male )  %	C0086582	\N	\N
1276	sex ( male )	C0086582	\N	\N
1276	sex ( male  % )	C0086582	\N	\N
1276	sex  n ( % ) male	C0086582	\N	\N
1276	sex  male / female  %	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	sex  male  no . ( % )	C0086582	\N	\N
1276	sex  male  n ( % )	C0086582	\N	\N
1276	sex  male	C0086582	\N	\N
1276	sex  % male	C0086582	\N	\N
1276	overall  male : female	C0043210;C0086287;C0086582;C0282416;C1561607;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	males [ n ( % ) ]	C0086582	\N	\N
1276	males ( n = $nmbr$ )	C0086582	\N	\N
1276	males ( itt ) ( n = $nmbr$ )	C0086582	\N	\N
1276	males ( % )	C0086582	\N	\N
1276	males  n ( % )	C0086582	\N	\N
1276	males  > $nmbr$ . $nmbr$	C0086582	\N	\N
1276	males  > $nmbr$	C0086582	\N	\N
1276	males  < $nmbr$ . $nmbr$	C0086582	\N	\N
1276	males  < $nmbr$	C0086582	\N	\N
1276	males  %	C0086582	\N	\N
1276	males	C0086582	\N	\N
1276	male sex 一 no . ( % )	C0086582	\N	\N
1276	male sex — no . { % )	C0086582	\N	\N
1276	male sex — no . / total no . ( % )	C0086582;C0439175;C0439810	\N	\N
1276	male sex — no . ( % ) race — no . ( % ) ) :	C0034510;C0086582;C1706779;C3853635	\N	\N
1276	male sex — no . ( % ) medical history — no . / total no . ( % )	C0086582;C0262926;C0439175;C0439810;C1704706	\N	\N
1276	male sex — no . ( % ) f	C0016327;C0086582	\N	\N
1276	male sex — no . ( % )	C0086582	\N	\N
1276	male sex — %	C0086582	\N	\N
1276	male sex ^	C0086582	\N	\N
1276	male sex \\ no . ( % )	C0086582	\N	\N
1276	male sex ( % )	C0086582	\N	\N
1276	male sex  no . / total no . ( % )	C0086582;C0439175;C0439810	\N	\N
1276	male sex  no . ( % )	C0086582	\N	\N
1276	male sex  n [ % ]	C0086582	\N	\N
1276	male sex  n ( % )	C0086582	\N	\N
1276	male sex  ( % )	C0086582	\N	\N
1276	male sex  %	C0086582	\N	\N
1276	male sex	C0086582	\N	\N
1276	male nyha class	C0086582;C1706180;C1706428;C1706429;C1882083	\N	\N
1276	male gender ( % )	C0086582;C1706180	\N	\N
1276	male gender    n   ( % )	C0086582;C1706180	\N	\N
1276	male gender  n ( % )	C0086582;C1706180	\N	\N
1276	male gender	C0086582;C1706180	\N	\N
1276	male / female  %	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	male / female	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	male - no . ( % )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male *  n ( % )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male ( n   = $nmbr$  $nmbr$ )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male ( n z $nmbr$ )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male ( n = $nmbr$ )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male ( n = $nmbr$  $nmbr$ )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male ( n - $nmbr$ )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male ( % )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male    n   ( % )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male  no ( % )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male  n / n ( % )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male  n ( % )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male  n	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male  % ( n )	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male  %	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	male	C0086582;C1706180;C1706428;C1706429	\N	\N
1276	genital mycotic infections male $nmbr$	C0086582;C0740330;C1706180;C1706428;C1706429	\N	\N
1276	gender male	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender : male    n   ( % )	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender - male  n ( % )	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender ( male / female ) ( number )	C0043210;C0079399;C0086287;C0086582;C0237753;C0449788;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	gender ( male )  n ( % )	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender ( % ) male / female	C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	gender  n [ % ] male	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender  n ( % ) male	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender  male / female	C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1276	gender  male ( % )	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender  male  n ( % )	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	gender  male	C0079399;C0086582;C1522384;C1706180;C1706428;C1706429	\N	\N
1276	female / male ( % )	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
1266	lb	\N	\N	\N
1277	eze	\N	f	2110
1277	eze / simva ( „ = $nmbr$ }	\N	f	2110
1277	caleitonin  ng / l  females mean ± sd	C0086287;C0439297;C0444504;C2347634;C2348143;C2699239	f	2111
1275	never used lev	C0023556;C1273517;C2003901	\N	\N
1275	lev - naive	C0023556	\N	\N
1275	lev - exposed	C0023556;C0332157	\N	\N
1275	lev ( n   =   $nmbr$ )	C0023556	\N	\N
1274	triacylglycerol  mmol / le	C0023190;C0041004;C0439090;C0439190;C1423767;C2697858	\N	\N
1274	fema le	C0023190;C0439090;C1423767;C2697858	\N	\N
1273	white race — no . ( % ) y left ventricular ejection fraction — %	C0007457;C0034510;C0043157;C0220938;C0428772;C0488728;C1706779;C3853635	\N	\N
1273	nyha ll / lll patients with lvef < $nmbr$ . $nmbr$ at baseline	C0030705;C0168634;C0428772;C0488728;C1261077;C1275491;C1442488	\N	\N
1273	mean lvef	C0428772;C0444504;C0488728;C2347634;C2348143	\N	\N
1273	lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ a	C0428772;C0488728	\N	\N
1273	lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ ) a	C0428772;C0488728	\N	\N
1273	lvef within $nmbr$ months  %	C0428772;C0439231;C0488728	\N	\N
1273	lvef ^ $nmbr$ . $nmbr$ and nyha class ii  iii at baseline	C0168634;C0428772;C0439070;C0488728;C1442488;C1705160;C1710602;C1882085;C1882086;C4082587	\N	\N
1273	lvef > $nmbr$ %	C0428772;C0488728	\N	\N
1273	lvef < $nmbr$ . $nmbr$	C0428772;C0488728	\N	\N
1273	lvef < $nmbr$ %  n = $nmbr$ $nmbr$ ) “	C0428772;C0488728	\N	\N
1273	lvef < $nmbr$ %	C0428772;C0488728	\N	\N
1273	lvef ( u )	C0428772;C0439148;C0488728	\N	\N
1273	lvef ( mean ± sd )	C0428772;C0444504;C0488728;C2347634;C2348143;C2699239	\N	\N
1273	lvef ( % )  mean ± sd	C0428772;C0444504;C0488728;C2347634;C2348143;C2699239	\N	\N
1273	lvef ( % )	C0428772;C0488728	\N	\N
1273	lvef  %	C0428772;C0488728	\N	\N
1273	lvef	C0428772;C0488728	\N	\N
1273	left ventricular ejection fraction — no . / total no . ( % )	C0428772;C0439175;C0439810;C0488728	\N	\N
1273	left ventricular ejection fraction — % §	C0428772;C0488728	\N	\N
1273	left ventricular ejection fraction — %	C0428772;C0488728	\N	\N
1273	left ventricular ejection fraction < $nmbr$ %	C0428772;C0488728	\N	\N
1273	left ventricular ejection fraction ( % )	C0428772;C0488728	\N	\N
1273	left ventricular ejection fraction  median ( iqr )  %	C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1273	left ventricular ejection fraction  % af history	C0019664;C0019665;C0262512;C0262926;C0344434;C0428772;C0488728;C1705255;C2004062;C4049859	\N	\N
1273	left ventricular ejection fraction  % *	C0428772;C0488728	\N	\N
1273	left ventricular ejection fraction  %	C0428772;C0488728	\N	\N
1273	left ventricular ejection fraction	C0428772;C0488728	\N	\N
1273	history of hf or lvef b $nmbr$ % with index event  no . ( % )	C0018488;C0019664;C0019665;C0262512;C0262926;C0428772;C0441471;C0488728;C0600653;C0918012;C1313497;C1538440;C1552854;C1637833;C1705255;C2004062;C2986546;C3273279;C4019010	\N	\N
1273	hf or lvef < $nmbr$ % associated with index event	C0018488;C0332281;C0428772;C0441471;C0488728;C0600653;C0918012;C1313497;C1538440;C1552854;C1637833;C2986546;C3273279;C4019010	\N	\N
1273	heart failure or lvef < $nmbr$ % associated with index acs event	C0018801;C0018802;C0332281;C0428772;C0441471;C0488728;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612;C4554158	\N	\N
1273	heart failure  lvef < $nmbr$ %  or both	C0018801;C0018802;C0428772;C0488728;C4554158	\N	\N
1273	continuous lvef $nmbr$ treatment interaction	C0039798;C0087111;C0428772;C0488728;C0549178;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704	\N	\N
1273	baseline lvef  %	C0168634;C0428772;C0488728;C1442488	\N	\N
1273	baseline lvef	C0168634;C0428772;C0488728;C1442488	\N	\N
1272	lvh by minnesota code  no . ( % )	C0009219;C0026183;C0149721;C0805701;C3889831	\N	\N
1272	lvh by minnesota code	C0009219;C0026183;C0149721;C0805701;C3889831	\N	\N
1272	lvh by echocardiography	C0013516;C0149721	\N	\N
1272	lvh by echocardiogram	C0013516;C0149721;C2243117	\N	\N
1272	lvh - n = $nmbr$	C0149721	\N	\N
1272	lvh + n = $nmbr$	C0149721	\N	\N
1272	lvh ( from echocardiogram )	C0013516;C0149721;C2243117	\N	\N
1272	lvh	C0149721	\N	\N
1272	history of lvh on echocardiogram	C0013516;C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062;C2243117	\N	\N
1271	lv heart structure	C0018787;C0023128;C0731033;C1881413	\N	\N
1270	ultra	C0728475	\N	\N
1270	lira	C1555441	\N	\N
1269	la diameter	C0023031;C0023749;C0230347;C1301886;C2346906;C4553351	\N	\N
1268	years since last gout flare	C0018099;C0439234;C1517205;C1517741;C3540542	\N	\N
1267	$nmbr$ . $nmbr$ ( ll . $nmbr$ )	\N	\N	\N
1266	lda  %	C4553195	\N	\N
1273	alvef ( per $nmbr$ % )	\N	f	-10
1267	class l / ll heart failure	C0018801;C0018802;C0456387;C1518526;C1705943;C4554158	f	453
1269	fev $nmbr$  la	C0023031;C0023749;C0230347;C2346906;C3714541;C4553351	f	288
1268	at least $nmbr$ severe flare	C0205082;C1517205;C3540542;C4050465;C4050466	f	2101
1268	at least $nmbr$ flare	C1517205;C3540542	f	2101
1271	latvia	C0023128	f	2105
1271	lv ejection fraction	C0023128;C0489482;C0731033;C1881413;C2700378	f	2106
1271	lv ejection fraction ( % )	C0023128;C0489482;C0731033;C1881413;C2700378	f	2106
1271	lv ejection fractionb	C0023128;C0302131;C0336969;C0731033;C0812388;C1881413	f	2106
1271	lv ejection fraction  % ( n = $nmbr$ )	C0023128;C0489482;C0731033;C1881413;C2700378	f	2106
1271	lv ejection fraction > $nmbr$ % and < $nmbr$ %	C0023128;C0489482;C0731033;C1881413;C2700378	f	2106
1271	lv systolic dysfunction  n ( % )	C0023128;C0731033;C0749225;C1881413	f	2107
1271	lv diastolic dysfunction  n ( % )	C0023128;C0520863;C0731033;C1881413	f	2108
1274	total cholesterol  mmol / le	C0023190;C0201950;C0439090;C0439190;C0543421;C1423767;C2697858	f	1504
1276	[ cm ( female ) / cm ( male ) ]	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	f	2109
1266	ascot - lla	C0718674	\N	\N
1266	> $nmbr$ lb	\N	\N	\N
1266	< $nmbr$ lb	\N	\N	\N
1265	other llt use	C0042153;C0457083;C1947944;C2347090	\N	\N
1265	allhat - llt	C2347090	\N	\N
1264	p value ( int )	C1709380;C3272375	\N	\N
1264	p int . f	C0016327;C0369773;C2603361;C3272375	\N	\N
1264	p [ int ]	C0369773;C2603361;C3272375	\N	\N
1264	p . b “ int	C1539794;C3272375	\N	\N
1264	p . b * int	C1539794;C3272375	\N	\N
1264	p - value ( int )	C1709380;C3272375	\N	\N
1264	p - int .	C0369773;C2603361;C3272375	\N	\N
1264	p - int	C0369773;C2603361;C3272375	\N	\N
1264	int . p *	C3272375	\N	\N
1263	nt - probnp pg / mla ( iqr )	C0030827;C0072225;C0599973;C0669479;C0754710;C1266240	\N	\N
1263	iqr	\N	\N	\N
1262	imt ( mm )	C0334121;C1704614;C4318736;C4330985;C4554674	\N	\N
1262	carotid imt	C0334121;C0741968;C1704614;C4318736	\N	\N
1261	immunologic	C0152036;C0205470	\N	\N
1261	imm only	C0205171;C0205470;C1720467	\N	\N
1261	imm	C0205470	\N	\N
1260	umec $nmbr$ . $nmbr$ | ig ( n = $nmbr$ )	C0021027;C0305052;C0360506	\N	\N
1260	tio $nmbr$ | ig ( n = $nmbr$ )	C0021027;C0305052;C0360506	\N	\N
1260	sfc $nmbr$ / $nmbr$ | ig bid n = $nmbr$	C0021027;C0305052;C0360506;C4521536	\N	\N
1260	qva $nmbr$ $nmbr$ / $nmbr$ | ig od n = $nmbr$	C0021027;C0229089;C0305052;C0360506;C0439164;C1512019;C3273373;C3665488	\N	\N
1260	olodaterol $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$	C0021027;C0305052;C0360506;C1518422;C4032878	\N	\N
1260	olodaterol $nmbr$ $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$	C0021027;C0305052;C0360506;C1518422;C4032878	\N	\N
1260	igl ( n = $nmbr$ )	C0021037;C0314619;C2247518	\N	\N
1260	igg ( > $nmbr$ . $nmbr$ g / l )  %	C0439294;C0456615	\N	\N
1260	ig ( n = $nmbr$ )	C0021027;C0305052;C0360506	\N	\N
1260	ff / vi $nmbr$ / $nmbr$ | ig ( n = $nmbr$ )	C0021027;C0205999;C0305052;C0360506;C4554348	\N	\N
1260	ff $nmbr$ | ig ( n = $nmbr$ )	C0021027;C0305052;C0360506;C4554348	\N	\N
1260	air + ig ( n = $nmbr$ )	C0001861;C0021027;C0305052;C0360506;C3536832	\N	\N
1260	a . beuralizuinab $nmbr$ ing q $nmbr$ w	\N	\N	\N
1259	who / idf ifg	C1334085;C1708411	\N	\N
1259	igt or ifg	C1334085;C1708411	\N	\N
1259	igt / ifg	C1334085;C1708411	\N	\N
1259	ifg and igt	C1334085;C1708411	\N	\N
1259	ifg / igt	C1334085;C1708411	\N	\N
1259	ifg	C1334085;C1708411	\N	\N
1259	baseline ifg ( fpg $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l ) - n	C0168634;C1334085;C1442488;C1532563;C1708411	\N	\N
1259	ada ifg	C1060325;C1334085;C1708411;C3811629	\N	\N
1258	ivc ( n = $nmbr$ )	C4085887	\N	\N
1258	class iv only	C0205171;C0441888;C1720467;C2698970	\N	\N
1258	class iv	C0441888;C2698970	\N	\N
1257	lll / iv	C0022326;C1261077;C4265176	\N	\N
1257	lll - iv	C0022326;C1261077;C4265176	\N	\N
1257	iv ( n z $nmbr$ )	C0022326;C4265176	\N	\N
1257	iv ( $nmbr$ )	C0022326;C4265176	\N	\N
1257	iv	C0022326;C4265176	\N	\N
1257	iii or iv	C0022326;C0439070;C1705160;C4265176	\N	\N
1257	iii and iv	C0022326;C0439070;C1705160;C4265176	\N	\N
1257	iii / iv	C0022326;C0439070;C1705160;C4265176	\N	\N
1257	iii - iv	C0022326;C0439070;C1705160;C4265176	\N	\N
1257	iii & iv	C0022326;C0439070;C1705160;C4265176	\N	\N
1257	ii - iv ( % )	C0022326;C1710602;C4082587;C4265176	\N	\N
1257	ii - iv	C0022326;C1710602;C4082587;C4265176	\N	\N
1257	ii ( $nmbr$ )	\N	\N	\N
1257	dual iv	C0022326;C0205173;C1554184;C4265176	\N	\N
1257	class ll - iv	C0022326;C0456387;C1518526;C1705943;C4265176	\N	\N
1257	class iv / iv - v	C0022326;C0457166;C1880098;C4265176	\N	\N
1257	ciass ll - iv	C0022326;C4265176	\N	\N
1256	$nmbr$ ix	C0015491	\N	\N
1255	idm	C0270221	\N	\N
1255	id genotype	C0009450;C0017431;C0600091;C1441613	\N	\N
1255	id ( n = $nmbr$ )	C0009450;C0600091;C1441613	\N	\N
1255	id	C0009450;C0600091;C1441613	\N	\N
1255	( id	C0009450;C0600091;C1441613	\N	\N
1254	time since ipf diagnosisa  mean years ( sd )	C0034069;C0040223;C0439234;C0444504;C1800706;C2347634;C2348143;C2699239;C3541383	\N	\N
1253	of variation )  iu	C0049272;C0205419;C0439453;C0694756	\N	\N
1253	iu	C0049272;C0439453;C0694756	\N	\N
1253	dose ( iu )	C0049272;C0178602;C0439453;C0694756;C0869039;C1114758	\N	\N
1252	iee at baseline : < $nmbr$ iu / l	C0168634;C0439457;C1442488	\N	\N
1262	imt ( $nmbr$ )	C0334121;C1704614;C4318736	f	-10
1256	ifx ( n = $nmbr$ )	C0020823	f	154
1254	ipf	C0034069;C1800706	f	1254
1256	ifx treatment	C0020823;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	f	154
1257	nyha class iii or iv  n ( % )	C0022326;C1882086;C4265176	f	453
1257	nyha class iii or iv ( n = $nmbr$ )	C0022326;C1882086;C4265176	f	453
1257	nyha lll - iv	C0022326;C1261077;C1275491;C4265176	f	453
1257	killip class ii - iv  n ( % )	C0022326;C1710602;C2697845;C2697847;C4082587;C4265176	f	846
1257	angina class iii or iv — no . ( % )	C0022326;C0264677;C4265176	f	2102
1257	angina class iii or iv prior	C0022326;C0264677;C0332152;C2826257;C4265176	f	2102
1257	total diuretic dose ( iv + oral ) on day $nmbr$  mg	C0012798;C0022326;C0439422;C0442027;C2986497;C4265176;C4521986	f	992
1257	iii and iv ejection fraction	C0022326;C0439070;C0489482;C1705160;C2700378;C4265176	f	453
1257	gold iii - iv	C0018026;C0022326;C0439070;C1304897;C1705160;C4265176	f	1836
1258	class iv glomerulonephritis	C0017658;C0441888;C2698970	f	2103
1266	glycoprotein llb / illa inhibitor	C0017968;C1999216	f	2104
1266	glycoprotein llb / llla receptor inhibitor	C0017968;C0597357;C1999216	f	2104
1266	glycoprotein llb / llia inhibitor	C0017968;C1999216	f	2104
1252	> $nmbr$ to < $nmbr$ iu / l	C0439457	\N	\N
1252	> $nmbr$ iu / l	C0439457	\N	\N
1251	body height ( cm )	C0005890;C0487985	\N	\N
1250	yes ( % ) weight [ kg ] ( interaction : p = $nmbr$ . $nmbr$ )	C0005910;C0022718;C0043100;C0439209;C1305866;C1549445;C1704675;C1705104;C1705108;C1710701;C4054209	\N	\N
1250	weight — no . ( % )	C0005910;C0043100;C1305866;C1705104	\N	\N
1250	weight — kg cardiovascular history — no . ( % )	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C1880008;C4054209	\N	\N
1250	weight — kg ( median )	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209	\N	\N
1250	weight of < $nmbr$ kg  n ( % )	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight in kg  median ( iqr )	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209	\N	\N
1250	weight group  no . ( % )	C0005910;C0043100;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429	\N	\N
1250	weight category	C0005910;C0043100;C0683312;C1305866;C1705104;C3889287	\N	\N
1250	weight ab  %	C0005910;C0043100;C1305866;C1705104	\N	\N
1250	weight ^	C0005910;C0043100;C1305866;C1705104	\N	\N
1250	weight > $nmbr$ kg	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight < $nmbr$ kg	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight < $nmbr$ . $nmbr$ kg  n	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight < $nmbr$	C0005910;C0043100;C1305866;C1705104	\N	\N
1250	weight - kg  median ( iqr )	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209	\N	\N
1250	weight ( range ) ( kg )	C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209	\N	\N
1250	weight ( median [ iqr ] )  kg	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209	\N	\N
1250	weight ( kg }  median ( min  max }	C0005910;C0043100;C0549183;C0876920;C1305866;C1532757;C1705104;C2347635;C2348144;C2939193	\N	\N
1250	weight ( kg ) bmi ( kg / m $nmbr$ )	C0005910;C0043100;C0369637;C0441923;C0578022;C1305866;C1319635;C1705104	\N	\N
1250	weight ( kg ) *	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight ( kg )  median ( m / n  max )	C0005910;C0043100;C0549183;C0876920;C1305866;C1532718;C1705104;C2347635;C2348144;C2939193	\N	\N
1250	weight ( kg )  median ( iqr )	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209	\N	\N
1250	weight $nmbr$ - $nmbr$	C0005910;C0043100;C1305866;C1705104	\N	\N
1250	weight $nmbr$ +	C0005910;C0043100;C1305866;C1705104	\N	\N
1250	weight $ $nmbr$ . $nmbr$ kg  n	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight $ $nmbr$ . $nmbr$ kg  < $nmbr$ . $nmbr$ kg  n	C0005910;C0043100;C1305866;C1319635;C1705104	\N	\N
1250	weight # $nmbr$ kg	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight  median ( iqr )  kg	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209	\N	\N
1250	weight  median ( interquartile range )  kg	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C1711350;C2347635;C2348144;C2939193;C4054209	\N	\N
1250	weight  mean ( sd ) lbs .	C0005910;C0043100;C0439219;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C3161851	\N	\N
1250	weight  mean ( sd )  kgb	C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239	\N	\N
1250	weight  lbs	C0005910;C0043100;C0439219;C1305866;C1705104;C3161851	\N	\N
1250	weight  kg duration of pah  n ( % )	C0005910;C0022718;C0030123;C0043100;C0439209;C0449238;C1305866;C1705104;C2926735;C3203102;C4054209;C4284467	\N	\N
1250	weight  kg $nmbr$	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	\N	\N
1250	weight  kg  median ( range )	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1514721;C1705104;C2347635;C2348144;C2348147;C2939193;C3542016;C4054209	\N	\N
1250	weight	C0005910;C0043100;C1305866;C1705104	\N	\N
1250	per body weight  u / kg	C0005910;C1300561;C1305866	\N	\N
1250	male sex — no . ( % ) weight — no . ( % )	C0005910;C0043100;C0086582;C1305866;C1705104	\N	\N
1250	healthy weight	C0005910;C0043100;C1305866;C1705104;C3898900	\N	\N
1250	body weight reduction > $nmbr$ %	C0005910;C0242821;C0301630;C0392756;C0460148;C1262477;C1268086;C1293152;C1305866;C4082212;C4551656	\N	\N
1250	body weight index ( kg / m $nmbr$ )	C0005910;C0600653;C0918012;C1305866;C1532718;C1552854;C1637833;C2986546	\N	\N
1250	body weight at randonization { ixrs )	C0005910;C1305866	\N	\N
1250	body weight *	C0005910;C1305866	\N	\N
1250	body weight ( kg )  mean ( sd )	C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209	\N	\N
1250	body weight ( kg )  mean ( s . d . )	C0005910;C0444504;C1275571;C1305866;C2347634;C2348143	\N	\N
1250	dose / weight ( iu / kg )	C0005910;C0043100;C0178602;C0439463;C0869039;C1114758;C1305866;C1705104	f	1924
1250	electrophysiological study — no . ( % ) weight — ibj	C0005910;C0043100;C0850293;C1305866;C1705104	f	1925
1251	body weighta  kg	C0022718;C0242821;C0439209;C0460148;C1268086;C4054209;C4082212	f	1250
1251	body weiqht	C0242821;C0460148;C1268086;C4082212	f	1250
1251	body weight at randomization	C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212	f	1250
1251	> $nmbr$ kg body weight at randomization	C0005910;C0022718;C0034656;C0242821;C0439209;C0460148;C1268086;C1305866;C2985844;C4054209;C4082212	f	1250
1251	no body weight at randomization ( ixrs )	C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212	f	1250
1251	w eight ( k g )	C0205454;C0439267;C0597277;C1708601	f	1250
1237	fatty acid group ( n = $nmbr$ )	C0015684;C0441848	f	1236
1250	body weight  mean ± sd  kg	C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209	\N	\N
1250	body weight  %	C0005910;C1305866	\N	\N
1250	body weight	C0005910;C1305866	\N	\N
1250	> $nmbr$ ( n  % ) weight  kg	C0005910;C0022718;C0043100;C0369718;C0439209;C0441922;C1305866;C1705104;C4054209	\N	\N
1249	height — cm	C0489786	\N	\N
1249	height loss ( cm )	C0424641	\N	\N
1249	height loss	C0424641	\N	\N
1249	height ( cm ) ( mean ± sd )	C0444504;C0489786;C2347634;C2348143;C2699239	\N	\N
1249	height ( cm )  mean ( sd ) a	C0444504;C0489786;C2347634;C2348143;C2699239	\N	\N
1249	height ( cm )  mean ( s . e . )	C0439392;C0444504;C0489786;C2347634;C2348143	\N	\N
1249	height ( cm )	C0489786	\N	\N
1249	height '  cm	C0489786	\N	\N
1249	height  mean ( sd )  cm	C0444504;C0489786;C2347634;C2348143;C2699239	\N	\N
1249	height  inches	C0439204;C0489786	\N	\N
1249	height  cm *	C0489786	\N	\N
1249	height  cm ( mean ± s . d . )	C0439392;C0444504;C0489786;C2347634;C2348143	\N	\N
1249	height  cm  mean ( sd )	C0444504;C0489786;C2347634;C2348143;C2699239	\N	\N
1249	height  cm	C0489786	\N	\N
1249	baseline height ( cm )	C0168634;C0489786;C1442488	\N	\N
1248	overweight ( bmi £ $nmbr$ to < $nmbr$ )	C0497406;C0578022	\N	\N
1248	overweight ( bmi = $nmbr$ - $nmbr$ . $nmbr$ )	C0497406;C0578022	\N	\N
1248	overweight ( $nmbr$ to < $nmbr$ kg / m $nmbr$ )	C0497406;C1532718	\N	\N
1248	overweight	C0497406	\N	\N
1248	lisinopril vs chlorthalidone overweight	C0008294;C0065374;C0497406	\N	\N
1248	bmi $nmbr$ – $nmbr$ overweight	C0497406;C0578022	\N	\N
1248	$nmbr$ - $nmbr$ . $nmbr$ : overweight	C0497406	\N	\N
1248	$nmbr$ - $nmbr$ - $nmbr$  overweight	C0497406	\N	\N
1247	cangrelor n / n ( % )	C1121991	\N	\N
1247	cangrelor clopidogrel no . of events / total no . ( % )	C0070166;C0439175;C0439810;C0441471;C1121991;C3541888	\N	\N
1247	cangrelor ( n = $nmbr$ ) n / n ( % )	C1121991	\N	\N
1247	cangrelor ( n = $nmbr$ )	C1121991	\N	\N
1247	cangrelor  %	C1121991	\N	\N
1247	cangrelor	C1121991	\N	\N
1246	ticagrelor in ‐ hosp ( n = $nmbr$ )	C1999375	\N	\N
1246	prehospital ticagrelor ( n = $nmbr$ )	C1999375	\N	\N
1246	in hospital ticagrelor	C0019994;C1510665;C1999375	\N	\N
1246	in - hospital ticagrelor ( n = $nmbr$ )	C0019994;C1510665;C1999375	\N	\N
1245	posterior circulation	C0005775;C0205095;C1516559	\N	\N
1245	inferior or posterior	C0205095;C0542339;C0678975	\N	\N
1245	inferior / posterior	C0205095;C0542339;C0678975	\N	\N
1245	inferior ( n  % )	C0542339;C0678975	\N	\N
1245	inferior ( % )	C0542339;C0678975	\N	\N
1245	inferior	C0542339;C0678975	\N	\N
1245	anterior circulation	C0005775;C0205094;C1516559	\N	\N
1244	infarct location anterior	C0021308;C0205094;C0450429;C1515974;C4284930;C4284931	\N	\N
1244	anterior or non - anterior ml	C0205094;C0439526;C1518422;C1705224;C3887665	\N	\N
1243	nonanterior	\N	\N	\N
1243	anterior	C0205094	\N	\N
1242	time - to - first infusion	C0040223;C0205435;C0574032;C1279901;C1827465;C3541383	\N	\N
1242	time - to - first - infusion from hip surgery ( days )  n ( % )	C0040223;C0205435;C0439228;C0574032;C0596706;C1279901;C1827465;C3541383	\N	\N
1242	no . of infusions	C0574032	\N	\N
1242	median infusions — no . ( range )	C0549183;C0574032;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
1242	glyceryl trinitrate infusion	C0017887;C0574032;C1827465	\N	\N
1242	core study to first infusion	C0205435;C0444669;C0557651;C0574032;C1167518;C1279901;C1706352;C1827465;C1882467;C2603343;C3274653	\N	\N
1242	c $nmbr$ e $nmbr$ fab bolus and infusion ( n = $nmbr$ )	C0574032;C1186706;C1511237;C1705509;C1827465;C3812160	\N	\N
1242	bolus and infusion	C0574032;C1186706;C1511237;C1705509;C1827465;C3812160	\N	\N
1242	and infusion	C0574032;C1827465	\N	\N
1241	transfusions	C0005841;C0199960;C1879316	\N	\N
1241	transfusion ≥ $nmbr$ units rbcs or whole blood	C0005841;C0014792;C0199960;C0229664;C0370231;C0439148;C1519795;C1546552;C1608383;C1879316;C3853603	\N	\N
1241	transfusion	C0005841;C0199960;C1879316	\N	\N
1241	blood transfusion	C0005841;C0281867	\N	\N
1241	any blood transfusion	C0005841;C0281867	\N	\N
1241	any blood product transfusion	C0005841;C0199960;C0281867;C0456388;C1514468;C1547007;C1704444;C1879316	\N	\N
1239	non - carrier ( n = $nmbr$ )	C2986416	\N	\N
1239	cancert	\N	\N	\N
1238	no known frtrontxtfufoc cond aon	C0205309;C1856054;C2826243;C4597943	\N	\N
1238	known tiromtcch * c ccndifeon	C0205309	\N	\N
1238	known t ' rc - iitoji cccndilon	C0205309;C1167159;C1419366	\N	\N
1240	tnfi naive	\N	f	11
1240	tnfi - naive	\N	f	11
1240	# of prior tnfi among non - tnfi naive	C0332152;C1518422;C2826257	f	11
1240	acei	\N	f	44
1240	acei vs . non - acei	C1518422	f	44
1239	non – small - cell lung cancer	C0007131;C2984258;C3539721	f	2096
1247	p value ( cangrelor versus clopidogrel in men )	C0025266;C0070166;C1121991;C1709380	f	2097
1247	p value ( cangrelor versus clopidogrel in women )	C0043210;C0070166;C1121991;C1709380	f	2097
1243	left anterior descending	C0205386;C0441998;C1547177	f	2098
1243	l eft anterior descending	C0205094;C0205386;C0439394;C0451214;C1547177;C1706495;C3642217	f	2098
1243	left anterior descending artery	C0226032	f	2098
1243	left anterior descending  n ( % )	C0205386;C0441998;C1547177	f	2098
1244	anterior ( n  % )	C0205094	f	1243
1244	anterior { % )	C0205094	f	1243
1244	non - anterior	C0205094;C1518422	f	1243
1244	not anterior	C0205094;C1518422	f	1243
1236	fatty acid composition	C0015684;C0486616;C1555710	\N	\N
1235	therapy - fatigue ( facit - f  $nmbr$ - $nmbr$ )	C0015672;C0039798;C0087111;C1363945;C3272505;C3463815;C4050243;C4554645	\N	\N
1235	facit - f	C3272505	\N	\N
1234	bempedoic acid ( n = $nmbr$ )	C3659310	\N	\N
1234	bempedoic	\N	\N	\N
1233	cad and abi < $nmbr$ - $nmbr$ §	C1328319;C1504769;C2239547;C3813548;C3888326;C4284121	\N	\N
1233	baseline abi  affected limb	C0015385;C0168634;C0392760;C1314939;C1328319;C1442488;C3888326	\N	\N
1233	ankle / brachial index	C1328319;C3888326	\N	\N
1233	ankle - brachial index £ $nmbr$ . $nmbr$	C1328319;C3888326	\N	\N
1233	ankle - brachial index < $nmbr$ . $nmbr$ — no . ( % )	C1328319;C3888326	\N	\N
1233	ankle - brachial index < $nmbr$ . $nmbr$	C1328319;C3888326	\N	\N
1233	abi > $nmbr$ . $nmbr$	C1328319;C3888326	\N	\N
1233	abi < $nmbr$ . $nmbr$	C1328319;C3888326	\N	\N
1233	abi # $nmbr$ . $nmbr$	C1328319;C3888326	\N	\N
1233	abi	C1328319;C3888326	\N	\N
1232	perindopril - indapamide	C1273169	\N	\N
1232	pctindopnl - indapamide ( n = $nmbr$ )	C0021186	\N	\N
1231	lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - $nmbr$ — parkinson disease questionnaire .	C0001288;C0030567;C0034394;C0165921;C0353697;C0441655;C0681889;C1420005;C1423759;C1521736;C3273355;C3639721;C4552744	\N	\N
1231	l - dopa / carbidopa - l - dopa / carbidopa / entacapone	C0165921;C0353697	\N	\N
1231	entacapone	C0165921	\N	\N
1230	pdq - $nmbr$	\N	\N	\N
1230	paod	\N	\N	\N
1230	mean duration of pd  yr	C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C4553228;C4553229	\N	\N
1230	duration of procedure	C2346509	\N	\N
1230	duration of pd  y	C0449238;C2926735;C4553228;C4553229	\N	\N
1230	duration of paod ( years )  mean ± sd	C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
1229	dihydropyridine	C0012315;C0220821	\N	\N
1228	dipyridamole alone	C0012582;C0205171;C0439044;C0679994	\N	\N
1228	dipyridamole	C0012582	\N	\N
1227	without dyspnoea	C0013404;C1963100	\N	\N
1227	with dyspnoea	C0013404;C1963100	\N	\N
1227	no dyspnoea ( n = $nmbr$ )	C0013404;C1963100	\N	\N
1227	mmrc dyspnea scale score : t : t	C0013404;C1963100;C3826977;C4049715	\N	\N
1227	mmrc dyspnea scale  n ( % )	C0013404;C0175659;C0349674;C1947916;C1963100;C3826977	\N	\N
1227	dyspnoea ( n = $nmbr$ )	C0013404;C1963100	\N	\N
1227	dyspnea t	C0013404;C1963100	\N	\N
1227	dyspnea  frequent / continuous	C0013404;C0332183;C0549178;C1963100	\N	\N
1227	dyspnea  % ( frequent / continuous )	C0013404;C0332183;C0549178;C1963100	\N	\N
1227	dyspnea	C0013404;C1963100	\N	\N
1227	clopidogrel dyspnoea vs no dyspnoea *	C0013404;C0070166;C1963100	\N	\N
1227	cangrelor dyspnoea vs no dyspnoea *	C0013404;C1121991;C1963100	\N	\N
1226	pnd	C1417807;C1956415;C4552608	\N	\N
1226	paroxysmal nocturnal dyspnea	C1956415	\N	\N
1225	rivaroxaban plus aspirin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0004057;C0332287;C1739768	\N	\N
1225	rivaroxaban plus aspirin ( n = $nmbr$ )	C0004057;C0332287;C1739768	\N	\N
1225	rivaroxaban plus aspirin ( $nmbr$ % cl )	C0004057;C0332287;C0596019;C1739768	\N	\N
1225	rivaroxaban plus	C1739768	\N	\N
1225	rivaroxaban + aspirin	C0004057;C1739768	\N	\N
1225	rivaroxaban +	C1739768	\N	\N
1225	rivaroxaban ( n   = $nmbr$ )	C1739768	\N	\N
1225	rivaroxaban ( n = $nmbr$ )	C1739768	\N	\N
1225	rivaroxaban $nmbr$ mg	C0024671;C0026410;C0439269;C1739768;C1960952;C2346927;C4321396;C4521761	\N	\N
1225	rivaroxaban	C1739768	\N	\N
1225	low - dose rivaroxaban plus aspirin ( n = $nmbr$ )	C0332287;C1739768;C2608320	\N	\N
1225	low - dose rivaroxaban + aspirin group	C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320	\N	\N
1225	low - dose rivaroxaban + aspirin ( n / n )	C1739768;C2608320	\N	\N
1224	apixaban vs . placebo	C0032042;C1696465;C1706408;C1831808	\N	\N
1224	apixaban dose ( or matching placebo )	C0032042;C0150103;C0178602;C0869039;C1114758;C1696465;C1706408;C1708943;C1831808	\N	\N
1224	apixaban ( n = $nmbr$ )	C1831808	\N	\N
1224	apixaban	C1831808	\N	\N
1223	tolvaptan ( n = $nmbr$ )	C1176308	\N	\N
1223	tolvaptan	C1176308	\N	\N
1223	placebo tolvaptan ( $nmbr$ mg ) ( n $nmbr$ $nmbr$ ) ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0032042;C0439269;C1176308;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761	\N	\N
1222	fluvastatin ( n = $nmbr$ )	C0082608	\N	\N
1222	fluvastatin $nmbr$ mg	C0024671;C0026410;C0082608;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1221	plasma lipoproteins  mmol / l	C0023820;C0032105;C1532563;C1550098;C4521445	\N	\N
1220	hr with edoxaban ( $nmbr$ % ci )	C0008107;C2975435;C3259781	\N	\N
1220	higher dose edoxaban regimen	C0205250;C2348331;C2975435	\N	\N
1220	edoxaban n = $nmbr$ n / n ( % )	C2975435	\N	\N
1220	edoxaban n = $nmbr$	C2975435	\N	\N
1207	losartan	C0126174	\N	\N
1221	plasma creatine  mg / dl	C0010286;C0032105;C0439269;C1550098;C4521445	f	952
1221	plasma triglyceride — mg / dl	C0032105;C0041004;C0439269;C1550098;C4521445	f	368
1229	non - dihydropyridine ccbs	C0006684;C0012315;C0220821;C1518422	f	704
1234	zoledronic acid	C0257685	f	2092
1234	zoledronic acid arm	C0257685;C0446516;C3715044;C4553528	f	2092
1234	zoledronic acid ( n = $nmbr$ )	C0257685	f	2092
1234	baseline mean serum uric acid  pmol / l ( sd )	C0168634;C0439284;C0444504;C0455272;C0700634;C1442488;C2347634;C2348143;C2699239	f	2093
1234	serum uric acid  n	C0455272;C0700634	f	2093
1235	paci	C1165245	f	2094
1235	paci ( n = $nmbr$ )	C1165245	f	2094
1235	taci	C0666480;C1425349;C4284230	f	2094
1236	thromboaspiration	\N	f	2095
1237	a mini - mental state examination  omega - $nmbr$ fatty acids vs placebo	C0015684;C0032042;C0451306;C1696465;C1706408;C1719844	f	-10
1220	edoxaban n / n  rate ( % )	C0871208;C1521828;C2975435	\N	\N
1220	edoxaban ( n = $nmbr$ )	C2975435	\N	\N
1220	edoxaban	C2975435	\N	\N
1219	doxazosin group	C0114873;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
1219	doxazosin	C0114873	\N	\N
1218	endovascular — no . ( % )	C0524425	\N	\N
1218	endovascular	C0524425	\N	\N
1217	ventricular tachycardia or fibrillation	C0042514;C0232197;C0344428;C1963247;C4554446	\N	\N
1217	ventricular tachyarrhythmias	C3827656	\N	\N
1216	lacunar infarction  n ( % )	C0333559	\N	\N
1216	lacunar	C0241970;C1459585	\N	\N
1214	patients with microvascular complications  n ( % )	C0009566;C0030705;C0443258;C1171258	\N	\N
1214	microvascular complicationsb	C0443258	\N	\N
1214	microvascular complications  n ( % ) ’	C0009566;C0443258;C1171258	\N	\N
1213	revascularization in $nmbr$ days	C0439228;C0581603	\N	\N
1213	revascularization during index hospitalization  %	C0019993;C0581603;C0600653;C0918012;C1552854;C1637833;C2986546	\N	\N
1213	revascularization	C0581603	\N	\N
1213	revascularisation  n ( % )	C0581603	\N	\N
1213	prior revascularization ( n = $nmbr$  $nmbr$ )	C0332152;C0581603;C2826257	\N	\N
1213	prior revascularization ( % )	C0332152;C0581603;C2826257	\N	\N
1213	prior revascularization	C0332152;C0581603;C2826257	\N	\N
1213	peripheral arterial revascularization	C0003842;C0205100;C0221464;C0581603	\N	\N
1213	no revascularisation	C0581603	\N	\N
1213	no prior revascularization ( n = $nmbr$  $nmbr$ )	C0332152;C0581603;C2826257	\N	\N
1213	arterial revascularization	C0003842;C0221464;C0581603	\N	\N
1213	any revascularization	C0581603	\N	\N
1213	any peripheral revascularization	C0205100;C0581603	\N	\N
1213	$nmbr$ days urgent revascularization	C0439228;C0439609;C0581603;C3272275	\N	\N
1212	with rehospitalization  urgent coronary revascularization	C0439609;C0877341;C3272275	\N	\N
1212	urgent revascularizati on	C0439609;C3272275	\N	\N
1212	urgent coronary revascularization	C0439609;C0877341;C3272275	\N	\N
1212	cvd / mi / stroke / urgent coronary revascularization	C0007222;C0038454;C0439609;C0877341;C3272275;C3810814;C4554100	\N	\N
1211	forearm fracture	C1305215	\N	\N
1211	forearm	C0016536	\N	\N
1211	distal forearm	C0588203	\N	\N
7	p - value for trend across categories	C0683312;C1521798;C1709380;C4554533	\N	\N
1210	affected body - surface area > $nmbr$ % — no . { % )	C0005902;C0205148;C0392760;C1314939;C1879646	\N	\N
1209	irbesartan ( n = $nmbr$ )	C0288171	\N	\N
1209	irbesartan	C0288171	\N	\N
1208	other - candesartan	C0717550	\N	\N
1208	candesartan group ( n = $nmbr$ )	C0441848;C0717550	\N	\N
1208	candesartan $nmbr$ / $nmbr$	C0717550	\N	\N
1208	candesartan	C0717550	\N	\N
1207	p ( losartan versus placebo )	C0032042;C0126174;C0369773;C1696465;C1706408;C2603361	\N	\N
1207	losartan plus placebo ( n = $nmbr$ )	C0032042;C0126174;C0332287;C1696465;C1706408	\N	\N
1207	losartan n = $nmbr$	C0126174	\N	\N
1207	losartan + placebo	C0032042;C0126174;C1696465;C1706408	\N	\N
1207	losartan ( n = $nmbr$ )	C0126174	\N	\N
1207	losartan ( n = $nmbr$  $nmbr$ )	C0126174	\N	\N
1207	losartan  n / n ( % )	C0126174	\N	\N
1209	olmesartan along with diuretic ( n - $nmbr$ )	C0012798;C1098320	f	2087
1209	olmesartan ( n = $nmbr$ )	C1098320	f	2087
1210	colonic area involved	C0009368;C0017446;C0205146;C1314939	f	2088
1210	intestinal area involved  n ( % ) $	C0017446;C0021853;C0205146;C0369718;C0441922;C1314939	f	2088
1210	involved intestinal area  n ( % )	C0021853;C1879646	f	2088
1210	median fecal calprotectin — mg / kg gi areas involved — no . ( % )	C0015733;C0205146;C0439272;C0549183;C0876920;C0950624;C1314939;C1335798;C1366582;C1708130;C2347635;C2348144;C2939193;C3539617;C4050121;C4319729	f	780
1210	areas	C0205146;C4319729	f	-10
1211	korea	C0022771	f	2089
1211	korean	C1556095	f	2089
1211	vora	\N	f	-10
1213	urgent revascularisation due to unstable angina	C0002965;C0439609;C0581603;C0678226;C3272275	f	1212
1213	with revascularisation	C0581603	f	1212
1213	• urgent coronaiy revascularization > $nmbr$ days	C0439228;C0439609;C0581603;C3272275	f	1212
1215	glomerular	C0022663;C0268731	f	-10
1215	estimated glomerular filtration rate < $nmbr$	C3811844	f	592
1215	estimated glomerular filtration rate  n ( % )	C3811844	f	592
1215	estimated glomerular filtration rate - ml / min / $nmbr$ . $nmbr$ m $nmbr$ tt	C0369637;C0439445;C0441923;C1452561;C3811844;C4554543	f	592
1215	estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ) §	C0369637;C0439445;C0441923;C0444504;C2347634;C2348143;C2699239;C3811844	f	592
1215	estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C3811844	f	592
1215	estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C3811844	f	592
1215	estimated glomerular filtration rate - ml / min  median ( iqr ) '	C0439445;C0549183;C0876920;C2347635;C2348144;C2939193;C3811844	f	592
1215	estimated glomerular filtration rate §	C3811844	f	592
1215	estimated glomerular filtration rate | |	C3811844	f	592
1215	estimated glomerular filtration rate ^	C3811844	f	592
1218	rv and pulmonary vascular	C0035190;C0459963;C1508661;C3889272	f	2090
1210	agea	\N	f	-10
1207	adjusted $nmbr$ risk reduction losartan vs placebo ( $nmbr$ % cl )	C0032042;C0126174;C0456081;C0596019;C1137094;C1696465;C1706408	\N	\N
1206	valsartan n / n	C0216784	\N	\N
1206	valsartan / hctz ( n = $nmbr$ )	C0020261;C0216784	\N	\N
1206	valsartan / hctz  n / n ( % )	C0020261;C0216784	\N	\N
1206	valsartan / hctz	C0020261;C0216784	\N	\N
1206	valsartan ( n = $nmbr$ )	C0216784	\N	\N
1206	valsartan  n / n ( % )	C0216784	\N	\N
1206	valsartan  n ( % )	C0216784	\N	\N
1206	valsartan	C0216784	\N	\N
1206	hazard ratio ( $nmbr$ % cl ) valsartan vs . placebo	C0032042;C0216784;C0596019;C1696465;C1706408;C2985465	\N	\N
1205	telmisartan group ( n = $nmbr$ )	C0248719;C0441848	\N	\N
1205	telmisartan ( n = $nmbr$ )	C0248719	\N	\N
1205	telmisartan ( n = $nmbr$  $nmbr$ )	C0248719	\N	\N
1205	telmisartan	C0248719	\N	\N
1205	randomization to placebo or telmisartan	C0032042;C0034656;C0248719;C1696465;C1706408	\N	\N
1204	any dynamic st - segment shift	C0333051;C0429029;C0729333;C2347509	\N	\N
1203	self - reported descent  n ( % )	C0205386;C0369718;C0441922;C0680043;C0681906;C2700446	\N	\N
1203	descent	C0205386;C0680043	\N	\N
1202	requiring assistance	C0018896;C1269765	\N	\N
1202	events requiring assistance	C0018896;C0441471;C1269765;C3541888	\N	\N
1202	$nmbr$ = help needed  still independent	C0027552;C0085862;C0686904;C1269765;C1290940;C1299583;C1552861	\N	\N
1201	fixed triple ( n = $nmbr$ )	C0205174;C0443218;C2827483;C3714578	\N	\N
1201	adhere	C3714578	\N	\N
1200	verifynow pru - defined hpr ( % patients )	C0030705;C1337105;C1704788;C3539106	\N	\N
1200	vasp pri - defined hpr ( % patients )	C0030705;C0034044;C0255567;C1337105;C1421428;C1704788;C1826843;C3539106;C3539761;C3539762	\N	\N
1200	other defined	C1704788;C3539106	\N	\N
1200	lta ( max response to $nmbr$ pm adp ) defined hpr ( % patients )	C0030266;C0030705;C0523452;C1337105;C1704788;C2611142;C3539106;C4049155	\N	\N
1199	none or diet	C0012155;C0012159;C1519433;C2983588;C3668949	\N	\N
1199	hr is < $nmbr$ if pravastatin is better than diet alone	C0012155;C0012159;C0085542;C0205171;C0332272;C0439044;C0679994;C1519433;C2983588;C3668949;C4522046	\N	\N
1199	diet plus pravastatin group ( n = $nmbr$ )	C0012155;C0012159;C0085542;C0332287;C0441848;C1519433;C2983588;C3668949	\N	\N
1199	diet only	C0012155;C0012159;C0205171;C1519433;C1720467;C2983588;C3668949	\N	\N
1199	diet group ( n = $nmbr$ )	C0012155;C0012159;C0441848;C1519433;C2983588;C3668949	\N	\N
1199	diet group	C0012155;C0012159;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949	\N	\N
1199	diet diet + pravastatin	C0012155;C0012159;C0085542;C1519433;C2983588;C3668949	\N	\N
1199	diet and exercise	C0012155;C0012159;C0015259;C1519433;C1522704;C2983588;C3668949	\N	\N
1199	diet alone	C0012155;C0012159;C0205171;C0439044;C0679994;C1519433;C2983588;C3668949	\N	\N
1199	diet - i - pravastatin ( n = $nmbr$ )	C0012155;C0012159;C0021966;C0085542;C0221138;C1519433;C2983588;C3668949	\N	\N
1199	diet + pravastatin group	C0012155;C0012159;C0085542;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949	\N	\N
1199	diet + pravastatin ( n = $nmbr$ )	C0012155;C0012159;C0085542;C1519433;C2983588;C3668949	\N	\N
1199	diet + pravastatin $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )	C0012155;C0012159;C0085542;C1519433;C2983588;C3668949	\N	\N
1199	diet + pravastatin	C0012155;C0012159;C0085542;C1519433;C2983588;C3668949	\N	\N
1199	diet ( n 二 $nmbr$ )	C0012155;C0012159;C1519433;C2983588;C3668949	\N	\N
1199	diet ( n = $nmbr$ )	C0012155;C0012159;C1519433;C2983588;C3668949	\N	\N
1199	diet $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )	C0012155;C0012159;C1519433;C2983588;C3668949	\N	\N
1199	diet	C0012155;C0012159;C1519433;C2983588;C3668949	\N	\N
1198	safety variable	C0036043;C0439828;C1705187;C4553760	\N	\N
1198	safety : non - cabg - related bleeding	C0010055;C0019080;C0036043;C0439849;C0445223;C1518422;C1705187	\N	\N
1198	safety    n   ( % ) b	C0036043;C1705187	\N	\N
1198	safety  %	C0036043;C1705187	\N	\N
1198	primary safety outcome -	C0036043;C0205225;C0439612;C0439631;C1274040;C1705187	\N	\N
1197	spirometry	C0037981	\N	\N
1197	spirometric values at baseline	C0037981;C0042295;C0168634;C0183441;C1442488	\N	\N
1197	baseline spirometry	C0037981;C0168634;C1442488	\N	\N
1196	left atrial diameter : < $nmbr$ mm ( n = $nmbr$ )	C0225860;C0225861;C1301886;C4330985;C4554674	\N	\N
1196	left atrial diameter  mm ( sd )	C0225860;C0225861;C1301886;C2699239;C4330985;C4554674	\N	\N
1196	left atrial diameter	C0225860;C0225861;C1301886	\N	\N
1196	left atrial anteroposterior diameter — mm	C0225860;C0225861;C1301886;C4330985;C4554674	\N	\N
1195	mod / sev exacerbation rates	C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268	\N	\N
1195	mod / sev exacerbation rate	C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268	\N	\N
1194	sample size ( n )	C0242618	\N	\N
1194	sample size  n ( % ) by treatment	C0037793;C0039798;C0087111;C0242618;C0456389;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1194	sample size  n	C0242618	\N	\N
1194	sample size	C0242618	\N	\N
1193	us site	C0205145;C1515974;C2825164	\N	\N
1193	u . s . sites	C0041703;C0205145	\N	\N
1193	u . s . site	C0041703;C0205145;C1515974;C2825164	\N	\N
1193	sites	C0205145	\N	\N
1193	site	C0205145;C1515974;C2825164	\N	\N
1193	fractures ( site not specified )	C0016658;C0205145;C0205369;C1515974;C1518422;C2825164	\N	\N
1193	disease site — no . of patients ( % ) |	C0012634;C0030705;C0205145;C1515974;C2825164	\N	\N
1123	rca  n ( % )	\N	\N	\N
1195	diabetes type ii  n ( % )	C0011860	f	2081
1196	degree of stenosis  % of diameter	C1301886;C4034225	f	2082
1203	african descent	C0027567;C0205386;C0680043	f	2083
1204	legend	C2729544	f	-10
1206	sacubitril / valsartan	C4033631	f	2084
1206	amlodipine and valsartan	C0051696;C0216784	f	2085
1207	atenolol - losartan	C0004147;C0126174	f	2086
1207	adjusted hr losartan vs atenolol *	C0004147;C0126174;C0456081	f	2086
1193	internal carotid artery sites	C0007276;C0205145	f	2199
1193	disease site — no . ( % ) ^	C0012634;C0205145;C1515974;C2825164	\N	\N
1193	disease site  n [ % ]	C0012634;C0205145;C1515974;C2825164	\N	\N
1193	critical site	C0205145;C1511545;C1515974;C2825164	\N	\N
1193	any site	C0205145;C1515974;C2825164	\N	\N
1192	platelet  $nmbr$ / l	C0456525	\N	\N
1191	use of antiplatelet agents — no . / total no . ( % )	C0085826;C0439175;C0439810;C1524063	\N	\N
1191	use of antiplatelet agents ^	C0085826;C1524063	\N	\N
1191	use of antiplatelet agents  n ( % )	C0085826;C1524063	\N	\N
1191	previous use of antiplatelet drugs	C0085826;C0205156;C1524063;C1552607;C2963157	\N	\N
1191	previous chronic use of antiplatelet drugs	C0085826;C0205156;C0205191;C1524063;C1552607;C2963157	\N	\N
1191	other antiplatelet agent 一 no . ( % )	C0085826	\N	\N
1191	aspirin orother antiplatelet drug	C0004057;C0013227;C0085826;C1254351	\N	\N
1191	aspirin or other antiplatelet drug	C0004057;C0085826	\N	\N
1191	asa or antiplatelet agent	C0004057;C0085826;C3853627	\N	\N
1191	antiplateletsa	\N	\N	\N
1191	antiplatelets agents	C0085826	\N	\N
1191	antiplatelets  any	\N	\N	\N
1191	antiplatelet drugs	C0085826;C2963157	\N	\N
1191	antiplatelet drug	C0085826	\N	\N
1191	antiplatelet agents ( % )	C0085826	\N	\N
1191	antiplatelet agents	C0085826	\N	\N
1191	antiplatelet agent n ( % )	C0085826	\N	\N
1191	antiplatelet agent	C0085826	\N	\N
1191	> $nmbr$ . $nmbr$ mg / liter antiplatelet agents	C0024671;C0026410;C0085826;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	\N	\N
1190	placebo / open - label abatacept	C0032042;C1619966;C1696465;C1706408;C1709323	\N	\N
1190	placebo - abatacept $nmbr$ / $nmbr$ - abatacept $nmbr$ / $nmbr$	C0032042;C1619966;C1696465;C1706408	\N	\N
1190	abatacept ‡	C1619966	\N	\N
1190	abatacept ~ $nmbr$ mg / kg ( n = $nmbr$ )	C0439272;C1619966	\N	\N
1190	abatacept plus mtx ( n = $nmbr$ )	C0025677;C1417487;C1619966	\N	\N
1190	abatacept monotherapy ( n = $nmbr$ )	C1619966	\N	\N
1190	abatacept / open - label abatacept	C1619966;C1709323	\N	\N
1190	abatacept ( n = $nmbr$ * )	C1619966	\N	\N
1190	abatacept $nmbr$ mg / kg ( n = $nmbr$ )	C0439272;C1619966	\N	\N
1190	abatacept $nmbr$ / — $nmbr$ mg / kg ( n = $nmbr$ )	C0439272;C1619966	\N	\N
1190	abatacept $nmbr$ / $nmbr$ ( n = $nmbr$ )	C1619966	\N	\N
1190	abatacept	C1619966	\N	\N
1189	intravenous study drug administered — no . ( % )	C0013175;C0348016;C0557651;C0683092;C1521801;C2603343	\N	\N
1189	intravenous ( n = $nmbr$ )	C0348016	\N	\N
1187	parameters at baseline	C0168634;C0449381;C1442488	\N	\N
1187	parameters	C0449381	\N	\N
1187	other lipid parameters	C0023779;C0449381	\N	\N
1187	lipid parameters	C0023779;C0449381	\N	\N
1187	hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy	C0019010;C0030705;C0168634;C0449381;C1442488;C4281788;C4684790	\N	\N
1187	glycaemic parameters	C0005802;C0449381	\N	\N
1187	biometric parameters	C0005544;C0449381;C2718322	\N	\N
1186	parameter mean ± s . d .	C0444504;C0549193;C1704769;C2347634;C2348143;C2350001	\N	\N
1186	parameter at baseline	C0168634;C0549193;C1442488;C1704769;C2350001	\N	\N
1186	parameter / variable	C0439828;C0549193;C1704769;C2350001;C4553760	\N	\N
1186	parameter ( mg / dl )	C0439269;C0549193;C1704769;C2350001	\N	\N
1186	parameter  n ( % )	C0549193;C1704769;C2350001	\N	\N
1186	parameter  % ( $nmbr$ % ci )	C0008107;C0549193;C1704769;C2350001;C3259781	\N	\N
1186	parameter	C0549193;C1704769;C2350001	\N	\N
1186	efficacy parameter	C0549193;C1280519;C1704769;C1707887;C2350001	\N	\N
1186	baseline parameter	C0168634;C0549193;C1442488;C1704769;C2350001	\N	\N
1186	$nmbr$ parameter	C0549193;C1704769;C2350001	\N	\N
1185	placebo - linagliptin	C0032042;C1696465;C1706408;C2746078	\N	\N
1185	linagliptin ( n z $nmbr$ )	C2746078	\N	\N
1185	linagliptin ( n = $nmbr$ ) '	C2746078	\N	\N
1185	linagliptin ( n = $nmbr$ )	C2746078	\N	\N
1185	linagliptin  patients with events / total patients	C0030705;C0439175;C0439810;C0441471;C2746078;C3541888	\N	\N
1185	linagliptin	C2746078	\N	\N
1185	incidence rate difference  linagliptin - placebo ( $nmbr$ % cl )	C0032042;C0596019;C1696465;C1705241;C1705242;C1706408;C1708485;C2746078	\N	\N
1185	comparator - linagliptin	C1707454;C2746078;C4553389;C4553390	\N	\N
1184	sitagliptin ± oad	C1565750	\N	\N
1184	sitagliptin no . / total no .	C0439175;C0439810;C1565750	\N	\N
1184	sitagliptin n = $nmbr$	C1565750	\N	\N
1184	sitagliptin ( n = $nmbr$ )	C1565750	\N	\N
1184	sitagliptin $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761	\N	\N
1192	aspirin or other antiplatelet agent	C0004057;C0085826	f	1191
1189	intravenous anticoagulant during hospitalisation *	C0003280;C0019993;C0348016;C0848112;C3536711	f	2070
1189	intravenous anticoagulant during hospitalization	C0003280;C0019993;C0348016;C0848112;C3536711	f	2070
1189	intravenous vasoactive drugs  % y	C0683092;C1980011	f	2071
1189	intravenous vasodilators ( % )	C0443081	f	2071
1189	intravenous dobutamine	C0012963;C0348016	f	2072
1188	treatment with antiplatelet drugs	C3469597	f	2073
1188	with antiplatelets	\N	f	2073
1188	without antiplatelets	\N	f	2073
1188	antidiabetes drug usage [ % ( n ) ]	C0242510	f	995
1188	drug - related teaes	C0013227;C0439849;C0445223;C1254351	f	47
1188	drug - related teaes *	C0013227;C0439849;C0445223;C1254351	f	47
1188	drug - related teaes $nmbr$	C0013227;C0439849;C0445223;C1254351	f	47
1188	nsteacs	\N	f	47
1192	other $nmbr$	\N	f	-10
1193	carotid bulb sites	C0007281;C0205145	f	1547
1193	common carotid artery sites	C0007272;C0162859;C0205145	f	2198
1193	$nmbr$ carotid artery sites	C0007272;C0162859;C0205145	f	1547
1184	sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ $nmbr$ - h postprandial plasma glucose ( ppg ) ( mmol / l )	C0202042;C0376674;C0455280;C1418888;C1565750;C2827804	\N	\N
1184	sitagliptin $nmbr$	C1565750	\N	\N
1184	sitagliptin	C1565750	\N	\N
1184	canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg	C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C2974540;C4321396;C4521761	\N	\N
1183	with alogliptin $nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761	\N	\N
1183	with alogliptin $nmbr$ mg	C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761	\N	\N
1183	with alogliptin $nmbr$ . $nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761	\N	\N
1183	with alogliptin $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761	\N	\N
1183	alogliptin ( n = $nmbr$ )	C1958126	\N	\N
1183	alogliptin  n ( % )	C1958126	\N	\N
1183	alogliptin	C1958126	\N	\N
1183	allogliptin	\N	\N	\N
1182	empagllflozln	\N	\N	\N
1182	empagllflozin	\N	\N	\N
1182	empagliflozin n with event / n	C0441471;C3490348;C4019010	\N	\N
1182	empagliflozin ( n   =   $nmbr$ )	C3490348	\N	\N
1182	empagliflozin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C3490348	\N	\N
1182	empagliflozin ( n = $nmbr$ )	C3490348	\N	\N
1182	empagliflozin $nmbr$ mg / day ( n = $nmbr$ )	C0439422;C3490348	\N	\N
1182	empagliflozin $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761	\N	\N
1182	empagliflozin $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761	\N	\N
1182	empagliflozin	C3490348	\N	\N
1182	$nmbr$ mg empagliflozin	C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761	\N	\N
1181	canagliflozin dose	C0178602;C0869039;C1114758;C2974540	\N	\N
1181	canagliflozin ( n = $nmbr$ )	C2974540	\N	\N
1181	canagliflozin	C2974540	\N	\N
1181	canagiiflozin	\N	\N	\N
1180	ertugliflozin $nmbr$   mg ( n   =   $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$   mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg vs placebo / glirneplride	C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg vs placebo / glinepiride	C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg vs placebo / glimepiride	C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg vs placebo / giimepiride	C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg ( n   =   $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
1180	ertugliflozin	C4079805	\N	\N
1179	hemoglobin level  %	C0019029;C1314664	f	1177
1179	hemoglobin concentration — g / liter	C0019029;C0086045;C0439267;C0475211;C1314664;C1318517;C1319312;C1446561;C3827302	f	1177
1180	dapagliflozint	\N	f	2066
1180	dapagliflozin ( n = $nmbr$ )	C2353951	f	2066
1180	dapagliflozin  n *	C2353951	f	2066
1180	dapaglifloiin  n *	\N	f	2066
1180	sotagliflozin	C3896939	f	2067
1180	sotagliflozin $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3896939;C4321396;C4521761	f	2067
1180	sotagliflozin ( n = $nmbr$ )	C3896939	f	2067
1183	vildagliptin ( n = $nmbr$ )	C1570906	f	2068
1183	vildagliptin $nmbr$ mg qd	C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761	f	2068
1183	vildagliptin $nmbr$ mg qd n = $nmbr$	C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761	f	2068
1183	vildagliptin $nmbr$ mg daily	C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761	f	2068
1183	vildagliptin $nmbr$ mg bid	C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761	f	2068
1183	vildagliptin	C1570906	f	2068
1183	saxagiiptin	\N	f	2069
1183	saxagliptin ( % )	C1611934	f	2069
1183	saxagliptin	C1611934	f	2069
1183	saxagliptin $nmbr$ mg ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761	f	2069
1183	saxagliptin $nmbr$ mg	C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761	f	2069
1183	saxagliptin $nmbr$ mg ( n z $nmbr$ )	C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761	f	2069
1183	saxagliptin $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761	f	2069
1183	saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761	f	2069
1183	saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761	f	2069
1183	saxagliptin $nmbr$ . $nmbr$ mg ( n z $nmbr$ )	C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761	f	2069
1183	saxagliptin ( n = $nmbr$ )	C1611934	f	2069
1183	saxagliptin ( n = $nmbr$  $nmbr$ )	C1611934	f	2069
1179	ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  h $nmbr$  histamine $nmbr$  iqr  interquartile range  n  number of patients  sd  standard deviation .	C0006668;C0007226;C0017654;C0019588;C0033727;C0062408;C0369286;C0441932;C0564385;C0750572;C0871420;C1561549;C1711350;C1739039;C2360800;C2699239;C3538987;C3666909;C3811844;C3812682;C3887460;C4048877;C4318503;C4528284	\N	\N
1177	hemoglobin category	C0019046;C0683312;C3889287	\N	\N
1177	hemoglobin aj ^ ( % )	C0004486;C0019046;C0230613	\N	\N
1177	hemoglobin ( g / l )	C0019046;C0439267;C0439294;C0456615;C0635222	\N	\N
1177	hemoglobin  mg / dl	C0019046;C0439269	\N	\N
1177	hemoglobin  g / l	C0019046;C0439267;C0439294;C0456615;C0635222	\N	\N
1177	hemoglobin	C0019046	\N	\N
1177	haemoglobin ( mg / dl )	C0019046;C0439269	\N	\N
1177	haemoglobin ( g / l )	C0019046;C0439267;C0439294;C0456615;C0635222	\N	\N
1177	haemoglobin  mg / dl	C0019046;C0439269	\N	\N
1177	baseline hemoglobin aj ^ values	C0004486;C0019046;C0042295;C0168634;C0230613;C1442488	\N	\N
1176	patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode ofdiabetic ketoacidosis *	C0017853;C0030705;C1859860	\N	\N
1176	mean glycated hemoglobin reduction during characteristic follow - up ( $nmbr$ % ci ) percent	C0017853;C0439165;C0444504;C0520870;C0589120;C1521970;C1522577;C1704685;C2347634;C2348143;C3274571	\N	\N
1176	glycosylated hemoglobin  %	C0017853	\N	\N
1176	glycated hemoglobin — % -	C0017853	\N	\N
1176	glycated hemoglobin — %	C0017853	\N	\N
1176	glycated hemoglobin | |	C0017853	\N	\N
1176	glycated hemoglobin < median	C0017853;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1176	glycated hemoglobin - % ’	C0017853	\N	\N
1176	glycated hemoglobin ( % )	C0017853	\N	\N
1176	glycated hemoglobin  standardized level — %	C0017853;C0441889;C0456079;C1547707;C2946261	\N	\N
1176	glycated hemoglobin  median ( iqr )	C0017853;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1176	glycated hemoglobin  %  mean ( sd )	C0017853;C0444504;C2347634;C2348143;C2699239	\N	\N
1176	glycated hemoglobin  %	C0017853	\N	\N
1176	glycated hemoglobin	C0017853	\N	\N
1176	glycated haemoglobin ( % )	C0017853	\N	\N
1176	glycated haemoglobin  %	C0017853	\N	\N
1176	baseline glycated hemoglobin ( % )	C0017853;C0168634;C1442488	\N	\N
1174	modmy al randcnxzaton	C0202311	\N	\N
1174	iglar dose at randomization ( u / day )	C0034656;C0178602;C0456683;C0869039;C1114758	\N	\N
1174	iglar	\N	\N	\N
1174	ali	\N	\N	\N
1173	patients randomly assigned	C0030705;C1516050;C1552601	\N	\N
1173	indzgly	\N	\N	\N
1173	all randomly assigned	C1516050;C1552601	\N	\N
1172	enalapril + aliskiren dm = $nmbr$ non - dm = $nmbr$	C0011816;C0014025;C1120110;C1518422;C3250443	\N	\N
1172	aliskiren dm = $nmbr$ non - dm = $nmbr$	C0011816;C1120110;C1518422;C3250443	\N	\N
1172	aliskiren / valsartan ( n = $nmbr$ )	C2733073	\N	\N
1172	aliskiren ( n = $nmbr$ )	C1120110	\N	\N
1172	aliskiren ( dm - vs . dm + )	C0011816;C1120110;C3250443	\N	\N
1172	aliskiren	C1120110	\N	\N
1171	adamantane derivatives	C3653470	\N	\N
1170	dilatative  n ( % )	C0002940;C0012359;C0700124;C1322279	\N	\N
1170	dilatative	C0002940;C0012359;C0700124;C1322279	\N	\N
1169	elective surgery	C0206058	\N	\N
1169	elective procedure	C0747973	\N	\N
1168	normotensive ( n = $nmbr$ )	C2712122	\N	\N
1167	non - extensive	C0205231;C1518422	\N	\N
1167	extensive  n ( % )	C0205231	\N	\N
1167	extensive	C0205231	\N	\N
1167	extensive colitis	C0009319;C0205231;C1963084	f	2063
1167	extensive colitis  n	C0009319;C0205231;C1963084	f	2063
1167	extensive colitis or pancolitis	C0009319;C0205231;C0868908;C1963084	f	2063
1167	no extensive colitis  n	C0009319;C0205231;C1963084	f	2063
1167	extensive colitisy	C0205231	f	2063
1167	extenswe	\N	f	-10
1168	anti - hypertensive treatment history  n ( % )	C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0432633;C0857121;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704	f	1579
1168	use of anti - hypertensive agents  n ( % ) *	C0432633;C0450442;C0857121;C1254351;C1521826;C1524063	f	1579
1168	hypertensive	C0857121	f	1364
1168	hypertensive  n ( % )	C0857121	f	1364
1169	elective peripheral revascularization	C0205100;C0206058;C0439608;C0581603	f	2064
1170	mycophenolate ( any derivative )	C0883242;C1527240	f	304
1171	sulphonamides  urea derivatives	C0038760;C0041942;C0243072	f	2065
1175	glycated hemoglobin level	C0202054	f	1176
1175	glycated hemoglobin  nonstandardized level — %	C0202054	f	1176
1175	glycohemoglobin  %	C0202054;C0696092	f	1176
1175	glycohemoglobin  %  mean ( sd )	C0202054;C0444504;C0696092;C2347634;C2348143;C2699239	f	1176
1177	glyeated haemoglobin	C0019046	f	1176
1178	for baseline hemoglobin < $nmbr$ g $nmbr$ '	C0168634;C1319312;C1442488	f	1177
1178	hemoglobin  g $nmbr$ $nmbr$	C1319312	f	1177
1178	for baseline hemoglobin $nmbr$ g $nmbr$ ’	C0168634;C1319312;C1442488	f	1177
1178	hemoglobin  g / dlf	C1319312	f	1177
1178	hemoglobin ( g r $nmbr$ )	C0205090;C0684010;C1319312;C2603358	f	1177
1178	hemoglobin ( g $nmbr$ ! )	C1319312	f	1177
1179	glycated hemoglobin  n ( % )	C0062408;C3666909	f	1176
1179	hemoglobin a $nmbr$ c	C0019020;C3889898	f	1176
1179	hemoglobin - a $nmbr$ c ( % ) ' • ■ * *	C0019020;C3889898	f	1176
1179	hemoglobin a $nmbr$ c ( % )	C0019020;C3889898	f	1176
1179	hemoglobin a $nmbr$ c  %	C0019020;C3889898	f	1176
1165	ezetimibe  n ( % )	C1142985	\N	\N
1165	ezetimibe	C1142985	\N	\N
1164	sensitive responders ( n = $nmbr$ )	C0020517;C0332324;C1522640	\N	\N
1164	sensitive responder ( n = $nmbr$ )	C0020517;C0332324;C1522640	\N	\N
1164	sensitive	C0020517;C0332324;C1522640	\N	\N
1164	hypersensitivity  n ( % )	C0020517;C0520946	\N	\N
1164	highly sensitive responders ( n = $nmbr$ )	C0439822	\N	\N
1164	highly sensitive responder ( n = $nmbr$ )	C0439822	\N	\N
1164	highly sensitive	C0439822	\N	\N
1163	troponin positive ( n = $nmbr$ )	C0041199;C0439178;C1446409;C1514241;C2825490;C3812269	\N	\N
1163	shared epitope  a % positive	C0003316;C0237876;C0439178;C1446409;C1514241;C1522138;C2825490;C3812269	\N	\N
1163	positive vs . negative	C0205160;C0439178;C1446409;C1513916;C1514241;C2825415;C2825490;C2825491;C3812269;C3853545	\N	\N
1163	positive troponin i or t  no . ( % )	C0077401;C0439178;C1446409;C1514241;C2603360;C2825490;C3812269	\N	\N
1163	positive ctnl ( n = $nmbr$ )	C0439178;C1446409;C1514241;C2825490;C3812269	\N	\N
1163	positive atopic status	C0392707;C0439178;C0449438;C1446409;C1514241;C2825490;C3812269	\N	\N
1163	positive	C0439178;C1446409;C1514241;C2825490;C3812269	\N	\N
1163	low complement / anti - dsdna positive ( n = $nmbr$ )	C0012854;C0311474;C0432633;C0439178;C1446409;C1514241;C2825490;C3812269;C3897137	\N	\N
1163	hla - b $nmbr$ positive at baseline  n ( % )	C0019737;C0168634;C0439178;C0550853;C1415561;C1442488;C1446409;C1514241;C2825490;C3812269	\N	\N
1163	hla - b $nmbr$ positive  n ( % )	C0439178;C1426226;C1446409;C1514241;C2825490;C3812269	\N	\N
1163	anti - dsdna positive	C0439178;C0741099;C1446409;C1514241;C2825490;C3812269	\N	\N
1163	angina or positive stress test	C0002962;C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269	\N	\N
1163	age is > $nmbr$ vrs  significant ecg changes  and positive biomarkers	C0001779;C0005516;C0237881;C0439178;C0458261;C0750502;C0855329;C1446409;C1514241;C1546944;C2825490;C3273608;C3812269	\N	\N
1163	* * positive stress test	C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269	\N	\N
1162	furosemide equivalent  mg / kg	C0016860;C0205163;C0439185;C0439272	\N	\N
1162	furosemide	C0016860	\N	\N
1161	glucosamine + chondroitin sulfate ( n = $nmbr$ )	C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965	\N	\N
1161	glucosamine ( n = $nmbr$ )	C0017718	\N	\N
1161	glucosamine	C0017718	\N	\N
1160	bumetanide	C0006376	\N	\N
1160	budesonide — no . ( % )	C0054201	\N	\N
1160	budesonide { symptom days a week )	C0054201;C0332174;C0439228;C0439230;C1457887;C3854129	\N	\N
1160	budesonide mmx $nmbr$ mg  ( n = $nmbr$ )	C0024671;C0026410;C0054201;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1160	budesonide ( symptom days a week )	C0054201;C0332174;C0439228;C0439230;C1457887;C3854129	\N	\N
1160	budesonide ( n = $nmbr$ )	C0054201	\N	\N
1160	budesonide $nmbr$ ^ g ( n = $nmbr$ )	C0054201;C0439267	\N	\N
1160	budesonide  n ( % )	C0054201	\N	\N
1160	budesonide	C0054201	\N	\N
1159	budesonide - formoterol ( n = $nmbr$ )	C1276807	\N	\N
1159	budesonide - formoterol $nmbr$ ^ g + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ )	C1276807;C1319635	\N	\N
1159	budesonide - formoterol $nmbr$ + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ )	C0439267;C1276807	\N	\N
1159	budesonide - budesonide / formoterol	C1276807	\N	\N
-10	leflunomide	C0063041	\N	\N
1157	glinide 一 no . ( % )	C2266929	\N	\N
1157	glinide	C2266929	\N	\N
1123	rca	\N	\N	\N
1165	statin + ezetimibe { n = $nmbr$  $nmbr$ )	C0360714;C1142985	f	1862
1165	statin or ezetimibe	C0360714;C1142985	f	1862
1165	statins / ezetimibe	C0360714;C1142985	f	1862
1165	statin with ezetimibe	C0360714;C1142985	f	1862
1156	nateglinide and repaglinide	C0246689;C0903898	f	2047
1156	nateglinide n / n	C0903898	f	2047
1156	nateglinide ( n = $nmbr$ )	C0903898	f	2047
1157	flecainide	C0016229	f	2048
1161	lacosamide	C0893761	f	2049
1162	torsemide	C0076840	f	2050
1163	rheumatoid factor and acpa positive	C0035448;C0201660;C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269	f	2059
1163	rheumatoid factor or acpa positive  or both	C0035448;C0201660;C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269	f	2059
1163	acpa positive	C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269	f	2051
1163	acpa positive  %	C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269	f	2051
1163	acpa positive  n ( % )	C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269	f	2051
1163	anticyclic citrullinated peptide positive ^  n ( % )	C0439178;C1320283;C1446409;C1514241;C2825490;C3812269	f	360
1163	anti - ccp positive	C0439178;C1446409;C1514241;C2825490;C3812269;C4318437	f	360
1163	anti - ccp positive ( > $nmbr$ u / ml )  n ( % )	C0432633;C0439178;C0439340;C1446409;C1514241;C1525410;C1704514;C1880521;C2825490;C2945590;C3812269	f	360
1163	rf or acpa positive	C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1525410;C1547111;C1706063;C2825490;C3812269	f	2059
1163	rheumatoid factor positive	C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269	f	2060
1163	rheumatoid factor positive §  n ( % )	C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269	f	2060
1163	gad positive — no . ( % ) ^	C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269	f	2061
1163	anti - gad positive ( n = $nmbr$ )	C0270549;C0432633;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269	f	2061
1163	anti - gad positive	C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269	f	2061
1163	positive for rheumatoid factor  anti - cyclic citrullinated peptide antibodies  or both — % ff	C0003241;C0035448;C0201660;C0439178;C0439596;C0741132;C1320283;C1446409;C1511572;C1514241;C2825490;C3812269;C4505301;C4554348	f	2062
1156	meglitinides ( glinides )	C0065880;C1579432;C3537178	\N	\N
1156	meglitinide	C0065880	\N	\N
1155	placebo + glimepiride	C0032042;C0061323;C1696465;C1706408	\N	\N
1155	glimepiride	C0061323	\N	\N
1154	fasting c - peptide ( nmol / l ) c	C0006558;C0015663;C0439282	\N	\N
1154	c peptide  nmol / l * '	C0006558;C0439282	\N	\N
1154	c - peptide tx difference vs pbo  median change from baseline ( se ) $nmbr$	C0006558;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952	\N	\N
1154	c - peptide	C0006558	\N	\N
1153	glucagon - like peptide - $nmbr$ receptor agonist	C0014361;C4543206	\N	\N
1153	glucagon - like peptide - $nmbr$ agonist	C0014361;C2987634	\N	\N
1152	b - blockers at baseline	C0168634;C1442488	\N	\N
1152	( $nmbr$ - blockers	\N	\N	\N
1151	lc  n = $nmbr$	\N	\N	\N
1150	muscle twitching	C0015644;C0231530	\N	\N
1150	muscle spasms	C0037763	\N	\N
1149	val / hctz ( n = $nmbr$ )	C0020261;C0042285;C0523975	\N	\N
1149	v alsartan / hctz  n ( % )	C0020261	\N	\N
1149	v / hctz ( n = $nmbr$ )	C0020261	\N	\N
1149	v / hctz	C0020261	\N	\N
1149	telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide	C0020261;C0051696;C0939233;C2733369	\N	\N
1149	om $nmbr$ mg / hctz $nmbr$ mg ( n = $nmbr$ )	C0020261;C0028971;C1319635;C1705272	\N	\N
1149	om $nmbr$ mg / hctz $nmbr$ mg	C0020261;C0028971;C1319635;C1705272	\N	\N
1149	om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg	C0020261;C0023465;C0023467;C0028971;C1319635;C1705272	\N	\N
1149	om $nmbr$ / aml $nmbr$ / hctz $nmbr$ mg	C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761	\N	\N
1149	om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg *	C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761	\N	\N
1149	om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg	C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761	\N	\N
1149	olmesartan medoxomil $nmbr$ mg / hctz $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0020261;C0386393;C1319635	\N	\N
1149	olmesartan $nmbr$ - olmesartan $nmbr$ / hydrochlorothiazide $nmbr$ . $nmbr$	C0020261;C1098320	\N	\N
1149	hydrochlorothiazide	C0020261	\N	\N
1149	hydochlorothiazide ( n = $nmbr$ )	\N	\N	\N
1149	hctz = hydrochlorothiazide . * based on wilcoxon $nmbr$ - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / $nmbr$ tests for categorical variables . t data were missing for some patients .	C0001779;C0005767;C0005768;C0005893;C0012000;C0020261;C0022885;C0030705;C0039155;C0039593;C0229664;C0242931;C0370003;C0392366;C0439828;C0456984;C0578022;C0871472;C1305855;C1515051;C1515976;C1527178;C1551393;C1705492;C1705938;C2347026;C3272743;C3831328;C4318744;C4684582	\N	\N
7	p - value for trend *	C1521798;C1709380;C4554533	\N	\N
7	p - value for interaction *	C1704675;C1709380	\N	\N
7	p - value for interaction $nmbr$ :	C1704675;C1709380	\N	\N
1149	hctz = hydrochlorothiazide . * based on a ' / _ $nmbr$ test  t data were missing for some patients .	C0020261;C0022885;C0030705;C0039593;C0242356;C0392366;C0456984;C0993637;C1515976;C1551393;C1705492;C3272743;C3831328;C4318744	\N	\N
1149	hctz - hydrochlorothiazide . * data were missing for some patients .	C0020261;C0030705;C1511726;C1551393;C1705492;C3245479;C3272743;C3714741	\N	\N
1149	hctz * ( n = $nmbr$ )	C0020261	\N	\N
1149	hctz *	C0020261	\N	\N
1149	hctz	C0020261	\N	\N
1149	aml / hctz ( n = $nmbr$ )	C0020261;C0023465;C0023467	\N	\N
1149	aml $nmbr$ mg / hctz $nmbr$ mg	C0020261;C0023465;C0023467;C1319635	\N	\N
1149	aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ )	C0020261;C0023465;C0023467;C1319635	\N	\N
1149	aml $nmbr$ mg + hctz $nmbr$ mg	C0020261;C0023465;C0023467;C1319635	\N	\N
1148	coping	C0009967	\N	\N
1147	smoking history — no . ( % )	C1519384	\N	\N
1147	smoking history ( ever )	C1519384;C3887636	\N	\N
1147	smoking history    n   ( % )	C1519384	\N	\N
1147	smoking history  r ( % )	C0205090;C0684010;C1519384;C2603358	\N	\N
1147	smoking history  n ( % )	C1519384	\N	\N
1147	smoking history	C1519384	\N	\N
1147	history of smoking	C1519384	\N	\N
1146	walking	C0080331;C4283795;C4321241;C4321242	\N	\N
1146	some walking	C0080331;C4283795;C4321241;C4321242	\N	\N
1146	physical activity ( hours walking / wk )	C0015259;C0026606;C0080331;C0332174;C0439227;C0439230;C4283795;C4321241;C4321242	\N	\N
1145	other or missing data	C4684714	\N	\N
1145	missing data — no . / total no . ( % )	C0439175;C0439810;C4684714	\N	\N
1145	missing data	C4684714	\N	\N
1144	unknown or missing	C0439673;C1551393;C1705492;C3272743;C3541433;C4050014	\N	\N
1144	unknown / missing	C0439673;C1551393;C1705492;C3272743;C3541433;C4050014	\N	\N
1144	other / missing	C1551393;C1705492;C3272743	\N	\N
1144	missing hb at yr $nmbr$	C0019046;C0439234;C1551393;C1705492;C3272743	\N	\N
1144	missing *	C1551393;C1705492;C3272743	\N	\N
1144	missing  n ( % ) a	C1551393;C1705492;C3272743	\N	\N
1144	missing	C1551393;C1705492;C3272743	\N	\N
1148	morning	C0332170	f	2043
1150	nsclc	C0007131	f	2044
1151	baseline hbalc > $nmbr$ % to < $nmbr$ %	C0168634;C1442488	f	1176
1151	hbalc > $nmbr$ %	\N	f	1176
1151	baseline ldl - c > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc	C0168634;C0439190;C1442488	f	1068
1151	baseline ldl - c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc	C0168634;C0439190;C1442488	f	1068
1152	hscrp	\N	f	286
1152	hscrp at baseline	C0168634;C1442488	f	286
1155	eduglinozin $nmbr$ mg vs placebo / glimepiride	C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761	f	2045
1155	glipizide	C0017642	f	2046
1155	glipizide ( n = $nmbr$ )	C0017642	f	2046
1144	data missing or no drug given	C0013227;C1254351;C1442162;C1511726;C1550718;C1551393;C1705492;C1947971;C3244317;C3245479;C3272743;C3714741	\N	\N
1144	data missing	C1511726;C1551393;C1705492;C3245479;C3272743;C3714741	\N	\N
1143	fibrinolysist	\N	\N	\N
1143	fibrinolysis ( n = $nmbr$ )	C0016017;C1305868	\N	\N
1142	fibrinogen ( pmol / l ) c	C0016006;C0439284;C1167394;C2587184;C3540039	\N	\N
1142	fibrinogen  g / l	C0016006;C0439294;C0456615;C1167394;C2587184;C3540039	\N	\N
1142	fibrinogen	C0016006;C1167394;C2587184;C3540039	\N	\N
1141	inclusion findings ( % )	C0007637;C1512693;C2607943;C2926606;C3539655	\N	\N
1141	additional radiographic findings at week $nmbr$	C0332174;C0439230;C0444708;C1524062;C2607943;C2926606;C3539655	\N	\N
1140	swollen joints ( $nmbr$ - joint count )  mean ± sd	C0444504;C0451521;C2347634;C2348143;C2699239	\N	\N
1140	swollen joint count of $nmbr$ joints	C0451521	\N	\N
1140	swollen joint count ( range $nmbr$ - $nmbr$ joints )	C0451521;C1514721;C2348147;C3542016	\N	\N
1140	swollen joint count ( n / $nmbr$ )	C0451521	\N	\N
1140	swollen joint count ( $nmbr$ — $nmbr$  per swollen joint )	C0451521	\N	\N
1140	swollen joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd )	C0444504;C0451521;C2347634;C2348143;C2699239	\N	\N
1140	swollen joint count ( $nmbr$ joints )  mean ( sd ) ’	C0444504;C0451521;C2347634;C2348143;C2699239	\N	\N
1140	swollen joint count ( $nmbr$ joints )  mean ( sd )	C0444504;C0451521;C2347634;C2348143;C2699239	\N	\N
1140	swollen joint count ( $nmbr$ joints )	C0451521	\N	\N
1140	swollen joint count ( $nmbr$ - $nmbr$ possible joints )	C0332149;C0451521;C1705910;C2362652	\N	\N
1140	swollen joint count ( $nmbr$ - $nmbr$ joints )	C0451521	\N	\N
1140	swollen joint count ( $nmbr$ - $nmbr$ )	C0451521	\N	\N
1140	swollen joint count ( $nmbr$ )  mean ( sd )	C0444504;C0451521;C2347634;C2348143;C2699239	\N	\N
1140	swollen joint count  of $nmbr$	C0451521	\N	\N
1140	swollen joint count	C0451521	\N	\N
1140	swollen - joint count ( of $nmbr$ joints assessed ) — no .	C0451521;C1516048	\N	\N
1140	swollen - joint count ( of $nmbr$ joints )	C0451521	\N	\N
1140	swollen - joint count  of $nmbr$ joints examined	C0332128;C0451521	\N	\N
1140	mean ( sd ) swollen joint count *	C0444504;C0451521;C2347634;C2348143;C2699239	\N	\N
1139	tender joints ( $nmbr$ - joint count )  mean ± sd	C0444504;C0451530;C2347634;C2348143;C2699239	\N	\N
1139	tender joint count of $nmbr$ joints	C0451530	\N	\N
1139	tender joint count ( range $nmbr$ - $nmbr$ joints )	C0451530;C1514721;C2348147;C3542016	\N	\N
1139	tender joint count ( n / $nmbr$ )	C0451530	\N	\N
1139	tender joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd )	C0444504;C0451530;C2347634;C2348143;C2699239	\N	\N
1139	tender joint count ( $nmbr$ joints )  mean ( sd ) ’	C0444504;C0451530;C2347634;C2348143;C2699239	\N	\N
1139	tender joint count ( $nmbr$ joints )  mean ( sd )	C0444504;C0451530;C2347634;C2348143;C2699239	\N	\N
1139	tender joint count ( $nmbr$ joints )	C0451530	\N	\N
1139	tender joint count ( $nmbr$ - $nmbr$ joints )	C0451530	\N	\N
1139	tender joint count ( $nmbr$ - $nmbr$ )	C0451530	\N	\N
1139	tender joint count ( $nmbr$ - $nmbr$  per tender joint )	C0451530	\N	\N
1139	tender joint count ( $nmbr$ )  mean ( sd )	C0444504;C0451530;C2347634;C2348143;C2699239	\N	\N
1139	tender joint count  of $nmbr$	C0451530	\N	\N
1139	tender joint count	C0451530	\N	\N
1139	tender - joint count ( of $nmbr$ joints )	C0451530	\N	\N
1139	tender - joint count  of $nmbr$ joints examined	C0332128;C0451530	\N	\N
1139	mean ( sd ) tender joint count *	C0444504;C0451530;C2347634;C2348143;C2699239	\N	\N
1138	tender and swollen joints — mean no . : :	C0152031;C0234234;C0444504;C2347634;C2348143	\N	\N
1138	joint swelling  effusion  or both on clinical examination — no . ( % )	C0013604;C0013687;C0031809;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335	\N	\N
1138	joint swelling  effusion  or both on clinical examination	C0013604;C0013687;C0031809;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335	\N	\N
1138	joint swelling	C0152031	\N	\N
1143	post - fibrinolysis angioplasty ( n = $nmbr$ )	C0016017;C0162577;C0687676;C1305868;C1548817;C1704687;C3469826	f	1722
1137	tjc ( / $nmbr$ joints )	C0022417;C0392905	f	1139
1137	tjc ( $nmbr$ joints )	C0022417;C0392905	f	1139
1137	tjc ( $nmbr$ joints )  mean ( sd )	C0022417;C0392905;C0444504;C2347634;C2348143;C2699239	f	1139
1138	swollen joints > $nmbr$  n ( % )	C0152031	f	1140
1141	ecg findings	C0438154	f	1129
1141	ecg findings at baseline — no . ( % )	C0168634;C0438154;C1442488	f	1129
1141	electrocardiographic findings at randomization	C0034656;C0438154	f	1129
1141	electrocardiographic findings — no . ( % )	C0438154	f	1129
1141	angiographic findings | |	C0002978;C2607943;C2926606;C3539655	f	1723
1136	patients with end point	C0030705;C2349179;C2826544	\N	\N
1136	other prespecified end points	C2349179	\N	\N
1136	other end points	C2349179	\N	\N
1136	mean change in radiographic end points	C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952	\N	\N
1136	main accord endpoint	C0205225;C0680240;C1542147;C2349179;C2826544	\N	\N
1136	endpoints	C2349179	\N	\N
1136	endpointc	\N	\N	\N
1136	endpoint rate	C0871208;C1521828;C2349179;C2826544	\N	\N
1136	endpoint *	C2349179;C2826544	\N	\N
1136	endpoint	C2349179;C2826544	\N	\N
1136	end points	C2349179	\N	\N
1136	end point	C2349179;C2826544	\N	\N
1136	end - point ( sd )	C2349179;C2699239;C2826544	\N	\N
1136	combined end points	C0205195;C2349179	\N	\N
1136	combined end point	C0205195;C2349179;C2826544	\N	\N
1136	additional endpoints	C1524062;C2349179	\N	\N
1135	oct center point thickness  pm	C0030266;C0205099;C1280412;C1552961;C2347617;C3714763;C3810851;C3828732;C4049155	\N	\N
1135	mean change from baseline  % ‐ points	C0168634;C0392747;C0443172;C0444504;C1442488;C1552961;C1705241;C2347617;C2347634;C2348143;C3714763;C4319952	\N	\N
1135	( points )	C1552961;C2347617;C3714763	\N	\N
1134	time point	C2348792	\N	\N
1134	pint	C0560012;C3811619;C3890014;C3890556	\N	\N
1134	p value ( vs . previous time point )	C0205156;C1552607;C1709380;C2348792	\N	\N
1133	post erior - anterior spine	C0037949;C0205094;C0687676;C1704687;C2752558;C3469826	\N	\N
1132	£ $nmbr$ m b ' m in	C1709500	\N	\N
1132	ppci in - $nmbr$	\N	\N	\N
1132	pain in extremity	C0030196;C4553007	\N	\N
1132	in - h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
1131	“ on ” without troublesome dyskinesia	C0013384	\N	\N
1131	“ on ” with troublesome dyskinesia	C0013384	\N	\N
1131	absolute time spent “ on ” without troublesome dyskinesia  h / day	C0013384;C0033727;C0332173;C0369286;C0439228;C0439505;C0439546;C0441932;C0564385;C0680968;C4528284	\N	\N
1131	absolute time spent “ on ” with troublesome dyskinesia  h / day	C0013384;C0033727;C0332173;C0369286;C0439228;C0439505;C0439546;C0441932;C0564385;C0680968;C4528284	\N	\N
1130	etoricoxib dose	C0178602;C0869039;C0972314;C1114758	\N	\N
1130	etoricoxib ( n = $nmbr$ )	C0972314	\N	\N
1130	etoricoxib ( n = $nmbr$ $nmbr$ )	C0972314	\N	\N
1130	etoricoxib ( n = $nmbr$  $nmbr$ )	C0972314	\N	\N
1130	etoricoxib $nmbr$ mg n = $nmbr$ n ( % )	C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761	\N	\N
1130	etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . .	C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761	\N	\N
1130	etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . .	C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761	\N	\N
7	p - value for interaction $nmbr$ . $nmbr$	C1704675;C1709380	\N	\N
1130	etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . . ( . % . . ) . . . . . . . . . . .	C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761	\N	\N
1130	etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .	C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761	\N	\N
1130	etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .	C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761	\N	\N
1130	etoricoxib $nmbr$ mg  n = $nmbr$  n ( % )	C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761	\N	\N
1130	etoricoxib	C0972314	\N	\N
1129	electrocardiography	C0013798;C1623258	\N	\N
1129	electrocardiograph results  no . ( % )	C0013798;C0180600;C1274040;C1546471;C1623258;C2825142	\N	\N
1129	electrocardiogram	C0013798;C1547122;C1623258	\N	\N
1129	ecg abnormality ( resting )  %	C0035253;C1512899;C1623258;C1704258	\N	\N
1129	ecg	C1623258	\N	\N
1128	uc [ gemini $nmbr$ ] ‘	\N	\N	\N
1128	uc	\N	\N	\N
1128	surgical technique	C0683469	\N	\N
1128	other uc - related gi surgical procedure	C0439849;C0445223;C0543467;C1708130;C3539617;C4050121	\N	\N
1127	mean bdi focal score ( sd )	C0006448;C0205234;C0451022;C2699239;C3533236;C3714938;C3889415	\N	\N
1127	focal	C0205234	\N	\N
1127	bdi focal score $nmbr$	C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231	\N	\N
1127	bdi focal score	C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231	\N	\N
1127	> $nmbr$ % focal seizure frequency responders	C0149775;C0205234;C0376249;C0439603;C0751495;C0871396;C1561548;C1705502;C3898838;C4321352	\N	\N
-10	atypical absence	C0595948	\N	\N
1125	topical prescription	C0033080;C0332237;C1521941	\N	\N
1125	topical non - prescription	C0033080;C0332237;C1518422;C1521941	\N	\N
1125	topical	C0332237	\N	\N
-10	puerto rican	C0034043	\N	\N
1129	lvh by electrocardiogram	C0013798;C0149721;C1547122;C1623258	f	1496
1130	celecoxib	C0538927	f	2033
1130	celecoxib ( n = $nmbr$ )	C0538927	f	2033
1130	rofecoxib	C0762662	f	2034
1130	valdecoxib	C0913246	f	2034
1131	ocn	C1412791;C2347392	f	-10
1132	in - stent restenosis	C3272317	f	2035
1132	in - stent restenosis of des	C0011702;C3272317;C4551552	f	2035
1132	dactylitis in > $nmbr$ digit	C3863761	f	492
1132	dapaglifloz . in  n	\N	f	2036
1133	spine	C0037949;C2752558	f	2037
1133	spine *	C0037949;C2752558	f	2037
1136	bleeding end points	C0019080;C2349179	f	2038
1136	coronary endpoint	C0018787;C2349179;C2826544	f	2039
1136	coronary end point	C0018787;C2349179;C2826544	f	2039
1136	all randomized coronary end point	C0018787;C0034656;C2349179;C2826544;C3815594	f	2039
1137	sjc ( / $nmbr$ joints )	C0022417;C0392905	f	1140
1137	sjc ( $nmbr$ joints )	C0022417;C0392905	f	1140
1137	sjc ( $nmbr$ joints )  mean ( sd )	C0022417;C0392905;C0444504;C2347634;C2348143;C2699239	f	1140
1123	$nmbr$ degree of ica stenosis 丰	C0201519;C4034225	\N	\N
1122	primary / key efficacy endpoint	C1280519;C1707887;C1709665;C2349179;C2826544	\N	\N
1122	peripheral limb vascular efficacy	C0015385;C0150936;C0947487;C1280519;C1707887	\N	\N
1122	overall efficacy	C0282416;C1280519;C1561607;C1707887	\N	\N
1122	efficacy variable	C0439828;C1280519;C1707887;C4553760	\N	\N
1122	efficacy endpoints *	C1280519;C1707887;C2349179	\N	\N
1122	efficacy endpoint	C1280519;C1707887;C2349179;C2826544	\N	\N
1122	efficacy end points	C1280519;C1707887;C2349179	\N	\N
1122	efficacy and safety : net adverse clinical events *	C0036043;C0205210;C0877248;C1280519;C1456447;C1705187;C1705413;C1707887;C3853572;C3887809;C3890893	\N	\N
1122	efficacy    n   ( % ) a	C1280519;C1707887	\N	\N
1122	efficacy	C1280519;C1707887	\N	\N
1122	combined efficacy and safety endpoint	C0036043;C0205195;C1280519;C1705187;C1707887;C2349179;C2826544	\N	\N
-10	colesevelam ( n = $nmbr$ )	C0541155	\N	\N
1120	the american college of rheumatology ) .	C0035452;C0557806;C0596070	\N	\N
1120	some college / tech	C0557806;C1826596	\N	\N
1120	some college	C0557806	\N	\N
1119	volume change  mm ^	C0392747;C0443172;C0449468;C1690016;C1705102;C1705241;C2700258;C4319952;C4330985;C4554674	\N	\N
1119	voided volume  ml	C0042034;C0439526;C0449468;C1552835;C1690016;C1705102;C1705224;C2700258;C3887665	\N	\N
1119	normalized volume measures	C0079809;C0242485;C0449468;C1690016;C1705102;C1879489;C1882115;C2700258	\N	\N
1119	median change in atheroma volume  %	C0264956;C0392747;C0443172;C0449468;C0549183;C0876920;C1690016;C1705102;C1705241;C2347635;C2348144;C2700258;C2939193;C4319952	\N	\N
1118	pulse pressure ( mmhg )	C0439475;C0949236	\N	\N
1118	pulse pressure ( mm hg )	C0439475;C0949236	\N	\N
1118	pulse pressure	C0949236	\N	\N
1118	mean pulse pressure  mmhg ( s . d . ) “	C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347155;C2347634;C2348143	\N	\N
1117	sitting pulse  bpma	C0232117;C0277814;C0391850;C1947910;C2584297;C4050224	\N	\N
1117	pulse — beats / min	C0232117;C0391850;C0702093;C1524029;C1947910;C3813700	\N	\N
1117	pulse ( beats / min ) cholesterol ( mmol / l )	C0008377;C0232117;C0391850;C1947910;C2827896	\N	\N
1117	pulse  beats / min	C0232117;C0391850;C0702093;C1524029;C1947910;C3813700	\N	\N
1116	quality of life	C0034380;C0518214	\N	\N
1116	qol due to urinary symptoms	C0426359;C0518214;C0678226	\N	\N
1116	qol	C0518214	\N	\N
1116	mean ipss qol ( sd )	C0444504;C0518214;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063	\N	\N
1116	ipss qol ( ls	C0023668;C0518214;C1019118;C1998280;C2827405;C3811063	\N	\N
1116	ipss qol	C0518214;C1019118;C1998280;C2827405;C3811063	\N	\N
1116	disease and quality - of - life scores  mean ( sd )	C0012634;C0034380;C0444504;C0449820;C0518214;C2347634;C2348143;C2699239;C4050231	\N	\N
1116	disease and quality - of - life scores	C0012634;C0034380;C0449820;C0518214;C4050231	\N	\N
7	p - value for interaction	C1704675;C1709380	\N	\N
1116	baseline disease and quality - of - life scores	C0012634;C0034380;C0168634;C0449820;C0518214;C1442488;C4050231	\N	\N
1115	humerus fracture	C0020162	\N	\N
1114	pelvic fractures	C0149531	\N	\N
1114	hip fracture only	C0019557;C0149531;C0205171;C1720467;C4552776	\N	\N
1114	hip fracture + > $nmbr$	C0019557;C0149531;C4552776	\N	\N
1114	hip fracture	C0019557;C0149531;C4552776	\N	\N
1113	tibia fracture	C0040185	\N	\N
1107	race / ethnicity  %	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
1118	pollent < $nmbr$	\N	f	1906
1113	vertebral fracture and / or t score - $nmbr$ . $nmbr$	C0080179;C3854607	f	2023
1113	spinal fractures	C0080179;C0518450	f	1038
1115	fractures	C0016658	f	2026
1115	fracture history ( predefined )  n ( % )	C0016658;C0019664;C0019665;C0262512;C0262926;C0369718;C0441922;C1705255;C2004062	f	2026
1115	fracture	C0016658	f	2026
1115	bone fracture	C0016658	f	2026
1115	bone fracture due to fall	C0016658;C0085639;C0238715;C0678226;C4553726	f	2026
1115	nonvertebral fracture	C0016658	f	2026
1115	nonvertebral fractures	C0016658	f	2026
1115	prior clinical fracture ( since age $nmbr$ )	C0001779;C0016658;C0205210;C0332152;C2826257	f	2026
1115	prior nonvertebral fracture	C0016658;C0332152;C2826257	f	2026
1115	prior nonvertebral fracture at age > $nmbr$ years	C0016658;C0332152;C1510829;C2826257	f	2026
1115	d non - vertebral fragility fractures ( fas )	C0016658;C0073187;C0302113;C0332173;C0549207;C1518422;C4484261	f	2026
1115	c clinical fractures ( fas )	C0016658;C0205210	f	2026
1115	e major non - vertebral fragility fractures ( fas )	C0016658;C0205082;C0205164;C0302113;C0549207;C1518422;C4318856;C4521762	f	2026
1115	hip + other nonvertebral fractures	C0016658;C0019552;C0022122;C1505163;C3538851;C4284725	f	2026
1115	no fracture history	C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	2026
1115	femur fracture	C0015802	f	2027
1115	thoracic cage fractures	C0016658;C0222762	f	2028
1115	hand fracture	C0435632	f	2027
1115	foot fracture	C0272774	f	2027
1115	radius fracture	C0034628	f	2028
1115	skull  and facial bone fractures	C0015455;C0016658;C0037303;C2951888	f	2028
1115	wrist fracture	C0435630;C4553927	f	2029
1115	fas	\N	f	-10
1119	contrast volume > $nmbr$ ( ml )	C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665	f	2030
1119	contrast volume > $nmbr$ ml	C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665	f	2030
1112	stratification factors	C1514984	\N	\N
1111	temporary factors	C0205374;C1521761;C1548539;C2827422;C3245481	\N	\N
1111	risk factor for venous thromboembolism  no . ( % )	C1521761;C2827422;C3495424;C3496592	\N	\N
1111	hospital factor # $nmbr$	C0019994;C1510665;C1521761;C2827422	\N	\N
1111	factors that confer a	C1521761;C2827422	\N	\N
1111	factor at baseline	C0168634;C1442488;C1521761;C2827422	\N	\N
1111	factor *	C1521761;C2827422	\N	\N
1111	factor	C1521761;C2827422	\N	\N
1111	baseline factor	C0168634;C1442488;C1521761;C2827422	\N	\N
1110	patient characteristic	C0030705;C1521970	\N	\N
1110	medical characteristics	C0199168;C0205476;C1521970	\N	\N
1110	feature	C1521970;C1706388;C2346469;C2348519	\N	\N
1110	e ( characteristic n	C1521970	\N	\N
1110	demographic characteristic	C0011298;C1521970	\N	\N
1110	characteristics of pulmonary embolism at inclusion	C0007637;C0034065;C1512693;C1521970	\N	\N
1110	characteristics *	C1521970	\N	\N
1110	characteristics	C1521970	\N	\N
1110	characteristic †	C1521970	\N	\N
1110	characteristic at baseline	C0168634;C1442488;C1521970	\N	\N
1110	characteristic ^	C1521970	\N	\N
1110	characteristic *	C1521970	\N	\N
1110	characteristic ( a )	C1521970	\N	\N
1110	characteristic  no . ( % )	C1521970	\N	\N
1110	characteristic	C1521970	\N	\N
1110	baseline feature	C0168634;C1442488;C1521970;C1706388;C2346469;C2348519	\N	\N
1110	baseline characteristic	C0168634;C1442488;C1521970	\N	\N
1110	anthropometric characteristics	C0003188;C1521970	\N	\N
1108	macce ( % ) abciximab placebo	C0032042;C0288672;C1696465;C1706408	\N	\N
1108	macce ( % )	\N	\N	\N
1108	macce	\N	\N	\N
1107	white race — no . { % ) t	C0007457;C0034510;C0043157;C0220938;C1706779;C2603360;C3853635	\N	\N
1107	racec  n ( % )	C4287599	\N	\N
1107	race — no . { % ) - i -	C0021966;C0034510;C0221138;C1706779;C3853635	\N	\N
1107	race — no . { % ) ' i '	C0021966;C0034510;C0221138;C1706779;C3853635	\N	\N
1107	race — no . / total no . ( % ) f	C0016327;C0034510;C0439175;C0439810;C1706779;C3853635	\N	\N
1107	race — no . ( % ) 卞	C0034510;C1706779;C3853635	\N	\N
1107	race — no . ( % ) |	C0034510;C1706779;C3853635	\N	\N
1107	race — no . ( % ) f	C0016327;C0034510;C1706779;C3853635	\N	\N
1107	race — no . ( % ) : t	C0034510;C1706779;C2603360;C3853635	\N	\N
1107	race — no . ( % ) : c	C0034510;C1706779;C3853635	\N	\N
1107	race — no . ( % ) ' (	C0034510;C1706779;C3853635	\N	\N
1107	race — no . ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race §	C0034510;C1706779;C3853635	\N	\N
1107	race white	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race or ethnic group — no . ( % ) : t	C0015031;C0034510;C1706779;C1879937;C2603360;C3853635	\N	\N
1107	race or ethnic group  no . ( % )	C0015031;C0034510;C1706779;C1879937;C3853635	\N	\N
1107	race or ethnic background — no . ( % ) f	C0015031;C0016327;C0034510;C1706779;C3853635	\N	\N
1107	race nonwhitet	C0034510;C1706779;C3853635	\N	\N
1107	race n ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race : white	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race : non - white	C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635	\N	\N
1107	race :	C0034510;C1706779;C3853635	\N	\N
1107	race / ethnicity chinese	C0008120;C0015031;C0034510;C0152035;C0243103;C1706779;C3853635	\N	\N
1107	race / ethnicity  zz ( % )	C0015031;C0034510;C0243103;C1706779;C2347310;C3853635	\N	\N
1099	years with gout	C0018099;C0439234	\N	\N
1109	mace +	C0349381;C0949745;C1445339	f	414
1109	mae	C0286540;C4085238	f	414
1109	$nmbr$ - point mace	C0349381;C0949745;C1445339;C1552961;C2347617;C3714763	f	414
1109	mace category  n ( % ) [ ir ]	C0022065;C0022071;C0349381;C0683312;C0949745;C1445339;C1448132;C3889287	f	414
1109	$nmbr$ - polnt mace	C0349381;C0949745;C1445339	f	414
1109	primary mace endpoint	C0349381;C0949745;C1445339;C2986535	f	414
1109	primary outcome ( $nmbr$ - point mace )	C0205225;C0349381;C0439612;C0439631;C0949745;C1274040;C1445339;C1552961;C2347617;C3714763	f	414
1109	secondary mace endpoint	C0349381;C0949745;C1445339;C4528314	f	414
1109	three - point mace	C0205449;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763	f	414
1110	characteristic age	C0001779;C1521970	f	2015
1110	characteristic age — yr	C0001779;C0439234;C1521970	f	2015
1110	infarct characteristics	C0021308;C1521970	f	2016
1110	surgical technique post - randomisation characteristic * *	C0034656;C0683469;C0687676;C1521970;C1704687;C3469826	f	2017
1110	angiographic characteristics  no . ( % )	C0002978;C1521970	f	2018
1110	angiographic features	C0002978;C1521970;C1706388;C2346469;C2348519	f	2018
1112	factor v leiden ( % )	C0380964;C0584960;C1414509;C3542419	f	2019
1112	factor v leiden or prothrombin mutation	C0380964;C0584960;C1414509;C1610621;C3542419	f	2019
1112	stratification factor : menopausal status  n ( % )	C1513126;C1514984	f	2020
1112	factor xa inhibitor	C2825027;C4553708	f	2021
1112	predictive factor	C0683956	f	2022
1113	prevalent vertebral fracture	C0033105;C0080179;C0220900	f	2023
1113	prevalent vertebral fracture status	C0033105;C0080179;C0220900;C0449438	f	2023
1113	prevalent vertebral fracture  n ( % )	C0033105;C0080179;C0220900	f	2023
1113	number of prevalent vertebral fractures	C0033105;C0080179;C0220900;C0237753;C0449788	f	2023
1113	clinical vertebral fractures	C0080179;C0205210	f	2023
1113	ankle fracture	C0159877;C4552974	f	2024
1113	patella fracture	C0159849	f	2025
1113	clavicle fracture	C0159658	f	2024
1113	fibula fracture	C0149699	f	2024
1107	race / ethnicity	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
1107	race - white ( n = $nmbr$  $nmbr$ )	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race - non - white ( n = $nmbr$  $nmbr$ )	C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635	\N	\N
1107	race - no . ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race - n ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race *	C0034510;C1706779;C3853635	\N	\N
1107	race ( white  n [ % ] )	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race ( p = o - $nmbr$ )	C0034510;C1706779;C3853635	\N	\N
1107	race ( non - white ) ( % )	C0007457;C0034510;C0043157;C0220938;C1518422;C1706779;C3853635	\N	\N
1107	race ( % white )	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race ( % ) white	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race ( % ) *	C0034510;C1706779;C3853635	\N	\N
1107	race ( % ) ) '	C0034510;C1706779;C3853635	\N	\N
1107	race ( % ) $	C0034510;C1706779;C3853635	\N	\N
1107	race ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race $nmbr$	C0034510;C1706779;C3853635	\N	\N
1107	race    n   ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race  zz ( % )	C0034510;C1706779;C2347310;C3853635	\N	\N
1107	race  white ( % )	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race  white    n   ( % )	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race  white  n ( % )	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race  nonwhite	C0034510;C1706779;C3853635	\N	\N
1107	race  no . / total ( % )	C0034510;C0439175;C0439810;C1706779;C3853635	\N	\N
1107	race  no . ( % ) c	C0034510;C1706779;C3853635	\N	\N
1107	race  no . ( % ) b	C0034510;C1706779;C3853635	\N	\N
1107	race  no . ( % ) *	C0034510;C1706779;C3853635	\N	\N
1107	race  no . ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ]	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) ’	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) y	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) white	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race  n ( % ) t	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) b	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) a	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) :	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) +	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % ) *	C0034510;C1706779;C3853635	\N	\N
1107	race  n ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race  asian  n ( % )	C0034510;C0078988;C1706779;C3853635	\N	\N
1107	race  * ’ n ( % )	C0034510;C1706779;C3853635	\N	\N
1107	race  % white	C0007457;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1107	race  % of patients	C0030705;C0034510;C1706779;C3853635	\N	\N
1107	race  %	C0034510;C1706779;C3853635	\N	\N
1107	race	C0034510;C1706779;C3853635	\N	\N
1107	other race  n ( % )	C0034510;C1706779;C3853635	\N	\N
1107	other race	C0034510;C1706779;C3853635	\N	\N
1107	nonblack race — no . ( % ) f	C0016327;C0034510;C1706779;C3853635	\N	\N
1107	nonblack race — no . ( % ) - j -	C0034510;C1706779;C3853635	\N	\N
1107	$ race was determined by the investigator during the patient ' s interview .	C0034510;C0035173;C0521095;C0683518;C1706779;C3853635	\N	\N
1106	number and % of participants with events  and incidence rate per $nmbr$ person - year	C0027361;C0237753;C0439234;C0439508;C0441471;C0449788;C0679646;C1708485;C2347489;C3541888	\N	\N
1106	no . ( % ) with event [ incidence rate per $nmbr$ patient - y ]	C0030705;C0441471;C1708485;C4019010	\N	\N
1106	incidence rate *	C1708485	\N	\N
1106	incidence rate ( per $nmbr$ person - yr )	C0027361;C0439234;C1708485;C2347489	\N	\N
1106	incidence rate ( n ) a	C1708485	\N	\N
1106	incidence rate ( n )	C1708485	\N	\N
1106	incidence rate	C1708485	\N	\N
1106	$nmbr$ - y incidence rate ( se ) per $nmbr$ participants	C0036919;C0679646;C1708485	\N	\N
1105	preoperative heart rate ( beats per minute )	C0018810;C0439385;C0445204	\N	\N
1105	heart rate — bpm	C0018810	\N	\N
1105	heart rate ( bpm ) *	C0018810	\N	\N
1105	heart rate ( bpm )	C0018810	\N	\N
1105	heart rate ( bpm $nmbr$ ) *  * *	C0018810	\N	\N
1105	heart rate ( beats per minute )	C0018810;C0439385	\N	\N
1105	heart rate ( beats per min )	C0018810;C0439385	\N	\N
1105	heart rate ( b . p . m . )	C0018810;C0369637;C0441923	\N	\N
1105	heart rate  beats per minute	C0018810;C0439385	\N	\N
1105	heart rate  beats per min	C0018810;C0439385	\N	\N
1105	heart rate	C0018810	\N	\N
1105	baseline heart rate ( beats / min )	C0018810;C0168634;C0702093;C1442488;C1524029;C3813700	\N	\N
1105	baseline heart rate	C0018810;C0168634;C1442488	\N	\N
1104	rales  n ( % )	C0034642;C0240859	\N	\N
1104	rales  ( % )	C0034642;C0240859	\N	\N
1104	rales	C0034642;C0240859	\N	\N
1104	pulmonary rales  n ( % )	C0034642	\N	\N
1104	pulmonary rales	C0034642	\N	\N
1103	rate per $nmbr$ patient - years	C0030705;C0439234;C0871208;C1521828	f	2009
1103	rates	C0871208;C1521828	f	2009
1103	rates per $nmbr$ patient - years	C0030705;C0439234;C0871208;C1521828	f	2009
1103	vhd event rate / year ( n )	C0439234;C0439508;C0441471;C0871208;C1521828;C4019010	f	2011
1103	w event ( rate )	C0441471;C0871208;C1521828;C4019010	f	2011
1104	ramus	C3538818	f	2013
1107	female  n ( % ) race  n ( % )	C0034510;C0043210;C0086287;C1705497;C1705498;C1706779;C3853635	f	2014
1107	female race / ethnicity	C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635	f	2014
1103	rate of sares	C0871208;C1521828	\N	\N
1103	ranotazine vs . placebo km failure rate	C0032042;C0231174;C0680095;C0871208;C1521828;C1696465;C1706408;C3887676	\N	\N
1103	k ( rate )	C0597277;C0871208;C1521828;C1708601	\N	\N
1103	health - care use rate ( peryear )	C0814514;C0871208;C1521828	\N	\N
1103	> $nmbr$ % responder rate  n ( % )	C0871208;C1521828	\N	\N
1103	* rate is number of events per $nmbr$ patient - years of follow - up . fthe p value for number of patients from log - rank  for total number of hospitalizations from permutation test . ^ by treatment comparing the	C0022885;C0030705;C0039593;C0039798;C0087111;C0392366;C0439175;C0439234;C0439810;C0456984;C0589120;C0667477;C0699794;C0871208;C1515976;C1521828;C1522326;C1522577;C1533734;C1704685;C1705169;C1707455;C1708728;C1709380;C1882348;C2360800;C2986775;C3274571;C3538994;C3831328;C3887704;C4086639;C4318744;C4330837	\N	\N
1102	respiratory rate ( breaths / min )	C0231832;C0439386;C0489258	\N	\N
1102	respiratory rate  breaths / min	C0231832;C0439386;C0489258	\N	\N
1101	raee	\N	\N	\N
1100	racey  z	\N	\N	\N
1100	racea	\N	\N	\N
1099	赛 $nmbr$ years	C0439234	\N	\N
1099	〉 $nmbr$ years	C0439234	\N	\N
1099	■ $nmbr$ years	C0439234	\N	\N
1099	≥ $nmbr$ years	C0439234	\N	\N
1099	≥ $nmbr$ to < $nmbr$ years	C0439234	\N	\N
1099	≥ $nmbr$ . $nmbr$ years	C0439234	\N	\N
1099	≥ $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ years	C0439234	\N	\N
1099	≤ $nmbr$   year	C0439234;C0439508	\N	\N
1099	≤ $nmbr$ years	C0439234	\N	\N
1099	» $nmbr$ yr	C0439234	\N	\N
1099	» $nmbr$ years	C0439234	\N	\N
1099	£ $nmbr$ yr	C0439234	\N	\N
1099	£ $nmbr$ years	C0439234	\N	\N
1099	£ $nmbr$ to < $nmbr$ years	C0439234	\N	\N
1099	years with gouty arthritis	C0003868;C0439234	\N	\N
1099	years with gout  mean ± sd	C0018099;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
1100	racea white	C0007457;C0043157;C0220938	f	2004
1101	glomerular filtration rate §	C0017654;C1561549	f	592
1101	glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ ma	C0017654;C0024443;C0439445;C1561549;C3887485	f	592
1102	breakfastb	\N	f	-10
1103	adjusted exacerbation rate ( per patient peryear )	C0030705;C0456081;C0871208;C1521828;C4086268	f	2005
1103	exacerbation rate in the previous year ( range )	C0205156;C0439234;C0439508;C0871208;C1514721;C1521828;C1552607;C2348147;C3542016;C4086268	f	2006
1103	exacerbation rate per year	C0439234;C0439508;C0871208;C1521828;C4086268	f	2006
1103	event rate ( % / year )	C0439234;C0439508;C0441471;C0871208;C1521828;C4019010	f	2007
1103	event rate ( % / vr )	C0441471;C0871208;C1521828;C3476815;C4019010	f	2007
1103	event rates per $nmbr$ patient - years ( $nmbr$ % ci )	C0008107;C0030705;C0439234;C0441471;C0871208;C1521828;C3259781;C4019010	f	2007
1103	event rates  %	C0441471;C0871208;C1521828;C4019010	f	2007
1103	event rate ( per $nmbr$	C0441471;C0871208;C1521828;C4019010	f	2007
1103	event rate ( % ) of primary endpoints	C0441471;C0871208;C1521828;C2986535;C4019010	f	2007
1103	event rate	C0441471;C0871208;C1521828;C4019010	f	2007
1103	kaplan - meier rates  %	C0871208;C1521828	f	2008
1103	kaplan - meier rates  % i i	C0021966;C0221138;C0871208;C1521828	f	2008
1103	km event rate ( % )	C0441471;C0871208;C1521828;C3887676;C4019010	f	2008
1103	km rates { % ) p / s	C0234833;C0722388;C0871208;C1521828;C3887676	f	2008
1103	km rate ( % )	C0871208;C1521828;C3887676	f	2008
1103	km rates { % ) e / s	C0871208;C1521828;C3887676	f	2008
1103	n event ( rate )	C0369718;C0441471;C0441922;C0871208;C1521828;C4019010	f	2008
1103	$nmbr$ - y kaplan - meier rate ( $nmbr$ % ci )	C0008107;C0871208;C1521828;C3259781	f	2008
1103	$nmbr$ yr . km rate	C0439234;C0871208;C1521828;C3887676	f	2008
1103	$nmbr$ - yr rate / $nmbr$ participants	C0439234;C0679646;C0871208;C1521828	f	2008
1103	n ( $nmbr$ yr km event rate  % )	C0369718;C0439234;C0441471;C0441922;C0871208;C1521828;C3887676;C4019010	f	2008
1103	no . of events ( rate )	C0441471;C0871208;C1521828;C3541888	f	2008
1103	no vhd event rate / year ( n )	C0439234;C0439508;C0441471;C0871208;C1521828;C4019010	f	2008
1103	overal event rate	C0441471;C0871208;C1521828;C4019010	f	2008
1103	overall event rate	C0282416;C0441471;C0871208;C1521828;C1561607;C4019010	f	2008
1103	crude rate	C0871208;C1521828	f	2009
1103	rate *	C0871208;C1521828	f	2009
1103	rate	C0871208;C1521828	f	2009
1103	rate difference ( events / year )	C0439234;C0439508;C0441471;C0871208;C1521828;C1705241;C1705242;C3541888	f	2009
1103	rate in all participants  % / y	C0679646;C0871208;C1521828	f	2009
1103	rate * ( n )	C0871208;C1521828	f	2009
1103	rate / $nmbr$ patient - years	C0030705;C0439234;C0871208;C1521828	f	2009
1103	rate / $nmbr$ pyo	C0033809;C0871208;C1521828	f	2009
1103	rate ( % per year )	C0439234;C0439508;C0871208;C1521828	f	2009
1103	rate  % / y	C0871208;C1521828	f	2009
1103	rate ( % / year )	C0439234;C0439508;C0871208;C1521828	f	2009
1103	rate of non - progression ( defined as cfb in mtss £ $nmbr$ . $nmbr$ )  n / n ( % ) *	C0009002;C0871208;C1521828;C1704788;C1824728;C3539106;C3839460	f	2010
1103	rate of non - progression ( defined as cfb in mtss £ $nmbr$ )  n / n ( % ) *	C0009002;C0871208;C1521828;C1704788;C1824728;C3539106;C3839460	f	2010
1103	filtration rate $nmbr$ - $nmbr$	C0016107;C0871208;C1521828	f	592
1103	baseline monthly pos seizure rate	C0036572;C0168634;C0332177;C0871208;C1262869;C1442488;C1521828;C1959629;C3496112;C3496399;C4553401	f	2012
1099	years since symptom onset	C0439234;C4086878	\N	\N
1099	years since pd diagnosis  mean ± sd	C0011900;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C4553228;C4553229	\N	\N
1099	years since pah diagnosis	C0011900;C0030123;C0439234;C1704338;C1704656;C3203102;C4284467	\N	\N
1099	years since menopause	C0025320;C0439234;C0567312	\N	\N
1099	years since diagnosis  mean	C0011900;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143	\N	\N
1099	years since diagnosis	C0011900;C0439234;C1704338;C1704656	\N	\N
1099	years of follow - up  mean ( sd ) [ maximum ]	C0439234;C0444504;C0589120;C0806909;C1522577;C1552615;C1704685;C2347634;C2348143;C2699239;C2826546;C3274571	\N	\N
1099	years of education  mean ( sd )	C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
1099	years duration oa	C0029408;C0439234;C0449238;C2926735;C3887876	\N	\N
1099	years [ range ]	C0439234;C1514721;C2348147;C3542016	\N	\N
1099	years )	C0439234	\N	\N
1099	years  n ( % ) smoking  n ( % ) current	C0037369;C0439234;C0453996;C0521116;C1705970;C1881674	\N	\N
1099	years	C0439234	\N	\N
1099	year from randomization	C0034656;C0439234;C0439508	\N	\N
1099	year - $nmbr$	C0439234;C0439508	\N	\N
1099	year $nmbr$	C0439234;C0439508	\N	\N
1099	year  n ( % )	C0439234;C0439508	\N	\N
1099	x $nmbr$ years	C0439234	\N	\N
1099	women > $nmbr$ years	C0043210;C0439234	\N	\N
1099	women < $nmbr$ years	C0043210;C0439234	\N	\N
1099	vorapaxar placebo $nmbr$ - yr . km % rate	C0032042;C0439234;C0871208;C1521828;C1696465;C1706408;C2974521;C3887676	\N	\N
1099	vorapaxar placebo $nmbr$ - yr %	C0032042;C0439234;C1696465;C1706408;C2974521	\N	\N
1099	ukpds $nmbr$ - year risk score > $nmbr$ %	C0035647;C0439234;C0439508;C0449820;C4050231;C4552904	\N	\N
1099	ukpds $nmbr$ - year risk score < $nmbr$ %	C0035647;C0439234;C0439508;C0449820;C4050231;C4552904	\N	\N
1099	type $nmbr$ diabetes duration  years	C0439234;C0449238;C1320657;C2926735	\N	\N
1099	type $nmbr$ diabetes duration  mean ( sd )  years	C0439234;C0444504;C0449238;C1320657;C2347634;C2348143;C2699239;C2926735	\N	\N
1099	time since start of fit  years ( meanisd )	C0036572;C0040223;C0439234;C0439659;C1711239;C2349186;C3541383;C4048158;C4553125	\N	\N
1099	time since start insulin ( years )	C0021641;C0040223;C0439234;C0439659;C1533581;C1579433;C1711239;C3541383;C3714501	\N	\N
1099	time since rheumatoid arthritis diagnosis  years	C0003873;C0011900;C0040223;C0439234;C1704338;C1704656;C3541383	\N	\N
1099	time since psoriasis diagnosis  years $nmbr$	C0011900;C0033860;C0040223;C0439234;C1704338;C1704656;C3541383	\N	\N
1099	time since psa diagnosis ( years )  mean ( sd )	C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383;C3810537;C3813209	\N	\N
1099	time since pah diagnosisc ( years )	C0030123;C0040223;C0439234;C3203102;C3541383;C4284467	\N	\N
1099	time since first copd diagnosis ( years )	C0011900;C0024117;C0040223;C0205435;C0439234;C1279901;C1412502;C1704338;C1704656;C3541383;C3714496	\N	\N
1099	time since epilepsy diagnosis ( years )	C0011900;C0014544;C0040223;C0439234;C1704338;C1704656;C3541383	\N	\N
1099	time since diagnosis of sle  years	C0011900;C0024141;C0040223;C0439234;C1704338;C1704656;C3541383	\N	\N
1099	time since diagnosis of psa ( years )  mean ( sd )	C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383;C3810537;C3813209	\N	\N
1099	time since diagnosis of pah years #	C0011900;C0030123;C0040223;C0439234;C1704338;C1704656;C3203102;C3541383;C4284467	\N	\N
7	p - value for	C1709380	\N	\N
7	p - value * ' '	C1709380	\N	\N
1099	time since diagnosis of osteoarthritis — yr	C0011900;C0029408;C0040223;C0439234;C1704338;C1704656;C3541383	\N	\N
1099	time since diagnosis of ln  years	C0011900;C0040223;C0439234;C0861352;C1428884;C1704338;C1704656;C3541383;C3714709	\N	\N
1099	time since diagnosis of diabetes ( years ) ( median  iqr )	C0011847;C0011849;C0011900;C0040223;C0439234;C0549183;C0876920;C1704338;C1704656;C2347635;C2348144;C2939193;C3541383	\N	\N
1099	time since diagnosis of copd  years	C0011900;C0024117;C0040223;C0439234;C1412502;C1704338;C1704656;C3541383;C3714496	\N	\N
1099	time since diagnosis  years	C0011900;C0040223;C0439234;C1704338;C1704656;C3541383	\N	\N
1099	time since bph diagnosis ( years )	C0005001;C0011900;C0040223;C0439234;C1704272;C1704338;C1704656;C3541383	\N	\N
1099	time since as diagnosis ( years )  mean   ±   sd	C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383	\N	\N
1099	ticagrelor $nmbr$ mg $nmbr$ yr km %	C0024671;C0026410;C0439234;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761	\N	\N
1099	t $nmbr$ dm duration ( years )	C0011816;C0439234;C0449238;C2603360;C2926735;C3250443	\N	\N
1099	t $nmbr$ d duration  years	C0439234;C0449238;C2603360;C2926735	\N	\N
1099	surgical repair of vsd or pda > $nmbr$ - year duration	C0013274;C0018818;C0226047;C0374711;C0439234;C0439508;C0449238;C2926735;C4282128	\N	\N
1099	standard care slope lsm ± se ( mm / year )	C0036919;C0439234;C0439508;C0807955;C1442989;C1947933;C2828392;C4330985;C4554674	\N	\N
1099	ss years	C0439234;C2699257;C3891295;C4551874	\N	\N
1099	smoking index — pack - yr §	C0037369;C0439234;C0453996;C0600653;C0918012;C1552854;C1637833;C1881674;C1968515;C2825051;C2828395;C2986546	\N	\N
1099	smoking history ( pack - yr )	C0439234;C1519384;C1968515;C2825051;C2828395	\N	\N
1099	s $nmbr$ years ( n = $nmbr$ )	C0439234;C2986823	\N	\N
1099	s $nmbr$ years	C0439234;C0565930;C2603362	\N	\N
1099	recurrent infections ( > $nmbr$ per year )	C0239998;C0439234;C0439508	\N	\N
1099	ra duration ( years )  mean ( s . e . )	C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3538806;C4048756	\N	\N
1099	psoriasis duration ( years )  mean ( sd )	C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
1099	psoriasis duration  years	C0033860;C0439234;C0449238;C2926735	\N	\N
1099	psoriasis duration  mean ± sd  years	C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
1099	psa duration ( years )  mean ( sd )	C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3810537;C3813209	\N	\N
1099	psa duration ( years )	C0439234;C0449238;C2926735;C3810537;C3813209	\N	\N
1099	psa duration  years	C0439234;C0449238;C2926735;C3810537;C3813209	\N	\N
1099	prior years taking warfarin	C0043031;C0332152;C0439234;C1515187;C2826257	\N	\N
1099	person - years	C0027361;C0439234;C2347489	\N	\N
1099	< $nmbr$ years	C0439234	\N	\N
1099	persistent anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i $nmbr$	C0019046;C0021966;C0221138;C0439234;C0741008;C1319635;C1549954	\N	\N
1099	percentage with disease duration < $nmbr$ years	C0439165;C0439234;C0872146;C1549488;C1561533	\N	\N
1099	patients with an event per $nmbr$ patient - years	C0030705;C0439234;C0441471;C4019010	\N	\N
1099	patients per $nmbr$ patient - years	C0030705;C0439234	\N	\N
1099	patient years	C0030705;C0439234	\N	\N
1099	patient - years ) hr ( unadjusted )	C0030705;C0439234;C1439367	\N	\N
1099	participants with an event per $nmbr$ patient - years	C0030705;C0439234;C0441471;C0679646;C4019010	\N	\N
1099	p value ( aged > $nmbr$ vs . < $nmbr$ years )	C0001779;C0001792;C0439234;C1709380;C1999167	\N	\N
1099	older than $nmbr$ years	C0439234;C0580836	\N	\N
1099	of t $nmbr$ dm ( years )	C0011816;C0439234;C2603360;C3250443	\N	\N
1099	number ol ( % ) patients > $nmbr$ years	C0030705;C0237753;C0439234;C0449788	\N	\N
1099	number of patients > $nmbr$ years ( % )	C0439234;C2360800	\N	\N
1099	number of hospitalizations in last year prior to baseline	C0168634;C0332152;C0439234;C0439508;C1442488;C1517741;C4086639	\N	\N
1099	number of copd exacerbations in the previous year    n   ( % )	C0205156;C0237753;C0439234;C0439508;C0449788;C0740304;C1552607	\N	\N
1099	number of copd exacerbations in the previous year  n ( % )	C0205156;C0237753;C0439234;C0439508;C0449788;C0740304;C1552607	\N	\N
1099	number of clinically significant asthma exacerbations in last year prior to baseline	C0168634;C0237753;C0237881;C0332152;C0349790;C0439234;C0439508;C0449788;C0750502;C1442488;C1517741;C1546944	\N	\N
1099	number of ( % ) patients > $nmbr$ years	C0439234;C2360800	\N	\N
1099	no . of participants per $nmbr$ patient - yr	C0030705;C0439234;C0679646	\N	\N
1099	no . of pack - yr	C0439234;C1968515;C2825051;C2828395	\N	\N
1099	no . of events / patients % / yr	C0030705;C0439234;C0441471;C3541888	\N	\N
1099	no . of cardiovascular events ( cardiovascular events / $nmbr$ person - years )	C0027361;C0439234;C1320716;C2347489	\N	\N
1099	no . / $nmbr$ person - yr	C0027361;C0439234;C2347489	\N	\N
1099	necessitating hospitalization in previous year — no . ( % )	C0019993;C0205156;C0439234;C0439508;C1552607	\N	\N
1099	n / n ( % / yr )	C0369718;C0439234;C0441922	\N	\N
1099	myocardial infarction / cabg / pci < $nmbr$ years	C0010055;C0027051;C0428953;C0439234;C2926063;C3810814;C4049621;C4552959	\N	\N
1099	median duration of symptoms ( range )  yr	C0436359;C0439234;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
1099	median disease duration — yr	C0439234;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193	\N	\N
1099	median ( q $nmbr$ : q $nmbr$ ) duration of insulin use  years	C0021641;C0439234;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501	\N	\N
1099	median ( q $nmbr$ : q $nmbr$ ) duration of diabetes  years	C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	\N	\N
1099	median ( interquartile range ) — yr	C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193	\N	\N
1099	mean — yr age group — no . ( % )	C0027362;C0439234;C0444504;C2347634;C2348001;C2348143	\N	\N
1099	mean — yr	C0439234;C0444504;C2347634;C2348143	\N	\N
1099	mean ± sd ( yr )	C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
1099	mean ± s . d . duration of diabetes  years	C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735	\N	\N
1099	mean years since menopause	C0025320;C0439234;C0444504;C0567312;C2347634;C2348143	\N	\N
7	p - value *	C1709380	\N	\N
1099	mean time since diagnosis ( years )	C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C3541383	\N	\N
1099	mean duration offollow - up ( years ) *	C0439234;C0444504;C0449238;C2347634;C2348143;C2926735	\N	\N
1099	mean duration of disease  years	C0439234;C0444504;C0872146;C2347634;C2348143	\N	\N
1099	mean ( sd ) [ range ] duration of epilepsy  years	C0014544;C0439234;C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2699239;C2926735;C3542016	\N	\N
1099	mean $nmbr$ - year cvd risk *	C0007222;C0035647;C0439234;C0439508;C0444504;C2347634;C2348143;C4552904	\N	\N
1099	less than $nmbr$ year	C0439092;C0439234;C0439508	\N	\N
1099	interval of > $nmbr$ yr since diagnosis of type $nmbr$ diabetes — no . ( % )	C0011847;C0011849;C0011900;C0439234;C1272706;C1320657;C1550351;C1552654;C1552713;C1704338;C1704656	\N	\N
1099	interquartile range — yr	C0439234;C1711350	\N	\N
1099	insulin glargine slope lsm ± se ( mm / year )	C0036919;C0439234;C0439508;C0807955;C0907402;C4330985;C4554674	\N	\N
1099	history of falls in year before randomization	C0034656;C0439234;C0439508;C1561668;C2919132	\N	\N
1099	history of clinical fracture ( > $nmbr$ years old )	C0205210;C0439234;C0580836;C1272071	\N	\N
1099	heart failure $nmbr$ yr before admission	C0018801;C0018802;C0184666;C0439234;C0809949;C4554158	\N	\N
1099	framingham $nmbr$ - year cv risk score	C0035647;C0439234;C0439508;C0449820;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904	\N	\N
1099	formal education  years	C0439234;C0681344	\N	\N
1099	follow - up in - trial at $nmbr$ yr	C0008976;C0439234;C0589120;C1522577;C1704685;C3274571	\N	\N
1099	first year *	C0205435;C0439234;C0439508;C1279901	\N	\N
1099	eze / simva - $nmbr$ yr km rale ( % )	C0034642;C0439234;C3887676	\N	\N
1099	incidence [ n / n ( rate per $nmbr$ person - years ) ]	C0027361;C0439234;C1708485;C2347489	f	1998
1099	incidence  $nmbr$ person - year	C0021149;C0027361;C0220856;C0439234;C0439508;C2347489	f	1998
1099	incidence rate no . ( / $nmbr$ person - years )	C0027361;C0439234;C1708485;C2347489	f	1998
1099	incidence rate per $nmbr$ person - years	C0027361;C0439234;C1708485;C2347489	f	1998
1099	incidence rate per $nmbr$ person years	C0027361;C0439234;C1708485;C2347489	f	1998
1099	known duration of diabetes  yr	C0011847;C0011849;C0205309;C0439234;C0449238;C2926735	f	1988
1099	evenls per $nmbr$  $nmbr$ palienl - years	C0439234	\N	\N
1099	elderly ( > $nmbr$ years )	C0001792;C0439234;C1999167	\N	\N
1099	ed > $nmbr$ yr  no . ( % )	C0439234;C3538926	\N	\N
1099	duration — yr	C0439234;C0449238;C2926735	\N	\N
1099	duration since diagnosis ( years )	C0011900;C0439234;C0449238;C1704338;C1704656;C2926735	\N	\N
1099	duration of t $nmbr$ d ( years )	C0439234;C0449238;C2926735	\N	\N
1099	duration of rat  years	C0034693;C0034721;C0439234;C0449238;C2926735	\N	\N
1099	difference ( glargine - standard care ) lsm ± se ( mm / year )	C0036919;C0439234;C0439508;C0907402;C1442989;C1705241;C1705242;C1947933;C2828392;C4330985;C4554674	\N	\N
1099	diagnosis — yr	C0011900;C0439234;C1704338;C1704656	\N	\N
1099	diagnosis ( years )	C0011900;C0439234;C1704338;C1704656	\N	\N
1099	cv event  years	C0439234;C0441471;C3538987;C4019010;C4048877;C4318503	\N	\N
1099	copd duration  mean ( sd )  yr *	C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496	\N	\N
1099	characteristic age mean ± sd — yr	C0001779;C0439234;C0444504;C1521970;C2347634;C2348143;C2699239	\N	\N
1099	< $nmbr$ year	C0439234;C0439508	\N	\N
1099	copd exacerbations during the previous year	C0205156;C0439234;C0439508;C0740304;C1552607	f	1987
1099	diabetes duration  median ( iqr )  years	C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	f	1988
1099	diabetes duration  years ^	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration of diabetes < $nmbr$ years	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration of diabetes > $nmbr$ years	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration of diabetes  years	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration of diabetes ( years )	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration of diabetes  years  mean ( sd )	C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	f	1988
1099	duration of diabetes ( years )  mean ( sd )	C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	f	1988
1099	duration of diabetes  years  median ( iqr )	C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	f	1988
1099	duration of diabetes ( years ) t	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration of diabetes — yr	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration ofdiabetes — yr	C0439234;C0449238;C2926735	f	1988
1099	disease duration  median ( range ) years	C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	f	1989
1099	disease duration $nmbr$ to b $nmbr$ years ( n = $nmbr$ )	C0439234;C0872146	f	1989
1099	disease duration > $nmbr$ years ( n = $nmbr$ )	C0439234;C0872146	f	1989
1099	disease duration  years	C0439234;C0872146	f	1989
1099	disease duration ( years )	C0439234;C0872146	f	1989
1099	disease duration  years : median ( range )	C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	f	1989
1099	duration > $nmbr$ to < $nmbr$ years  n ( % )	C0439234;C0449238;C2926735	f	1989
1099	duration < $nmbr$ year  n ( % )	C0439234;C0439508;C0449238;C2926735	f	1989
1099	duration > $nmbr$ years  n ( % )	C0439234;C0449238;C2926735	f	1989
1099	duration of disease  years	C0439234;C0872146	f	1989
1099	duration of as  years	C0439234;C0449238;C2926735	f	1989
1099	duration of disease ( years )	C0439234;C0872146	f	1989
1099	education in years  mean	C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143	f	1990
1099	education in years  mean ( sd )	C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239	f	1990
1099	education  mean ( sd ) years	C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239	f	1990
1099	education $nmbr$ - $nmbr$ years	C0013621;C0013622;C0013658;C0039401;C0439234	f	1990
1099	education > $nmbr$ years	C0013621;C0013622;C0013658;C0039401;C0439234	f	1990
1099	education ( years )	C0013621;C0013622;C0013658;C0039401;C0439234	f	1990
1099	education  years  mean ( sd )	C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239	f	1990
1099	exacerbation in previous year	C0205156;C0439234;C0439508;C1552607;C4086268	f	1991
1099	duration alendronate use  years ( meanisd )	C0042153;C0102118;C0439234;C0449238;C0457083;C1947944;C2926735	f	1992
1099	duration of coronary artery disease — yr	C0018787;C0439234;C0449238;C0852949;C2926735	f	1992
1099	duration of epilepsy  mean ( sd )  years	C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	f	1993
1099	duration of epilepsy  years	C0014544;C0439234;C0449238;C2926735	f	1993
1099	duration of epilepsy  years  mean ( sd )	C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	f	1993
1099	duration of heart failure ( years )	C0018801;C0018802;C0439234;C0449238;C2926735;C4554158	f	1994
1099	duration of hypercholesterolemia  mean ± sd ( years )	C0020443;C0439234;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735	f	1995
1099	duration of hypercholesterolemia ( yr )	C0020443;C0439234;C0449238;C1522133;C2926735	f	1995
1099	duration of psoriasis  years	C0033860;C0439234;C0449238;C2926735	f	1996
1099	duration of psoriasis ( years )  mean ( sd )	C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	f	1996
1099	duration of ra  mean ± sd years	C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3538806;C4048756	f	1997
1099	duration of rheumatoid arthritis  year	C0003873;C0439234;C0439508;C0449238;C2926735	f	1997
1099	dm duration  years	C0011816;C0439234;C0449238;C2926735;C3250443	f	1988
1099	bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per $nmbr$ patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .	C0009667;C0019046;C0022661;C0030705;C0036773;C0042027;C0168634;C0201976;C0229671;C0439234;C0441471;C0456603;C0589120;C0596019;C0597277;C0600061;C0683312;C0728877;C0871208;C1442488;C1521828;C1522577;C1524119;C1546774;C1547037;C1549954;C1550100;C1565830;C1704685;C1708601;C2362049;C2985465;C3161035;C3274571;C3274659;C3541888;C3714583;C3853906;C3889287	\N	\N
1099	baseline to year $nmbr$	C0168634;C0439234;C0439508;C1442488	\N	\N
1099	baseline if have $nmbr$ yr follow - up *	C0168634;C0439234;C0589120;C1442488;C1522577;C1704685;C3274571	\N	\N
1099	at $nmbr$ years	C0439234	\N	\N
1099	asthma duration ( sd )  years	C0004096;C0439234;C0449238;C2699239;C2926735;C2984299	\N	\N
1099	aspirin group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years )	C0004057;C0027361;C0439234;C0441848;C2347489	\N	\N
1099	ard per $nmbr$ $nmbr$ patient - years ( $nmbr$ % ci )	C0008107;C0030705;C0439234;C1817569;C1826411;C3259781	\N	\N
1099	ard ( $nmbr$ % cl ) per $nmbr$ patient - years	C0030705;C0439234;C0596019;C1817569;C1826411	\N	\N
1099	all - cause mortality at $nmbr$ year	C0015127;C0026565;C0026566;C0439234;C0439508;C0444868;C1524003;C3539085	\N	\N
1099	all - cause mortality ( per $nmbr$ person - years )	C0015127;C0026565;C0026566;C0027361;C0439234;C0444868;C1524003;C2347489;C3539085	\N	\N
1099	age at menopause ( yr )	C0439234;C1625754;C1629609	\N	\N
1099	age at asthma diagnosis years	C0004096;C0439234;C1828181;C2984299;C3173302	\N	\N
1099	age  yr  mean ( sd )	C0001779;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
1099	a $nmbr$ years	C0439234	\N	\N
1099	> year $nmbr$	C0439234;C0439508	\N	\N
1099	> l $nmbr$ years	C0439234;C0439394;C1706495;C3642217	\N	\N
1099	> is years	C0439234	\N	\N
1099	> = medan ( $nmbr$ year - old )	C0439234;C0439508;C0580836	\N	\N
1099	> = $nmbr$ yr	C0439234	\N	\N
1099	> = $nmbr$ years and < $nmbr$ years	C0439234	\N	\N
1099	> = $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ )	C0032042;C0439234;C1611934;C1696465;C1706408	\N	\N
1099	> = $nmbr$ years ( n = $nmbr$ )	C0439234	\N	\N
1099	> = $nmbr$ years	C0439234	\N	\N
1099	> = $nmbr$ yea ' s	\N	\N	\N
1099	> $nmbr$   years	C0439234	\N	\N
1099	> $nmbr$ yr — no . { % )	C0439234	\N	\N
1099	> $nmbr$ yr — no . ( % )	C0439234	\N	\N
1099	> $nmbr$ yr — %	C0439234	\N	\N
1099	> $nmbr$ yr warfarin experience	C0043031;C0237607;C0439234;C0596545	\N	\N
1099	> $nmbr$ yr since menopause	C0025320;C0439234;C0567312	\N	\N
1099	> $nmbr$ yr from the united states	C0041703;C0439234	\N	\N
1099	> $nmbr$ yr ( n = $nmbr$ )	C0439234	\N	\N
1099	> $nmbr$ yr ( % )	C0439234	\N	\N
1099	> $nmbr$ yr  n ( % )	C0439234	\N	\N
1099	> $nmbr$ yr	C0439234	\N	\N
1099	> $nmbr$ yearstos is years	C0439234	\N	\N
1099	> $nmbr$ years vs .   ≤   $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ years to < $nmbr$ years ( n = $nmbr$ )	C0439234	\N	\N
1099	> $nmbr$ years to < $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ years simva ( „ = $nmbr$ }	C0439234	\N	\N
1099	> $nmbr$ years simva ( n = $nmbr$ )	C0439234	\N	\N
1099	> $nmbr$ years simva	C0439234	\N	\N
1099	> $nmbr$ years old	C0439234;C0580836	\N	\N
1099	> $nmbr$ years n z $nmbr$	C0439234	\N	\N
1099	> $nmbr$ years eze / simva baseline ldl - c	C0168634;C0439234;C1442488	\N	\N
1099	> $nmbr$ years eze / simva ( „ = $nmbr$ }	C0439234	\N	\N
1099	> $nmbr$ years eze / simva ( n = $nmbr$ )	C0439234	\N	\N
1099	> $nmbr$ years education	C0013621;C0013622;C0013658;C0039401;C0439234	\N	\N
1099	> $nmbr$ years ( n = $nmbr$ )	C0439234	\N	\N
1099	> $nmbr$ years ( % )	C0439234	\N	\N
1099	> $nmbr$ years $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )	C0439234	\N	\N
1099	> $nmbr$ years  n ( % )	C0439234	\N	\N
1099	> $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ year	C0439234;C0439508	\N	\N
1099	> $nmbr$ to   ≤   $nmbr$ years vs .   ≤   $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ to < = $nmbr$ years  n ( % )	C0439234	\N	\N
1099	> $nmbr$ to < $nmbr$ yr	C0439234	\N	\N
1099	> $nmbr$ to < $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ to $nmbr$   years	C0439234	\N	\N
1099	> $nmbr$ to $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ and < $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ - < $nmbr$ years	C0439234	\N	\N
1099	> $nmbr$ - $nmbr$ yr	C0439234	\N	\N
1099	> $nmbr$ - $nmbr$ years	C0439234	\N	\N
1099	< median ( $nmbr$ year - old )	C0439234;C0439508;C0549183;C0580836;C0876920;C2347635;C2348144;C2939193	\N	\N
1099	< l $nmbr$ years	C0439234;C0439394;C1706495;C3642217	\N	\N
1099	< = $nmbr$ yr	C0439234	\N	\N
1099	< = $nmbr$ year  n ( % )	C0439234;C0439508	\N	\N
1099	< $nmbr$ yr — no . ( % )	C0439234	\N	\N
1099	< $nmbr$ yr since menopause	C0025320;C0439234;C0567312	\N	\N
1099	< $nmbr$ yr of education — no . ( % )	C0013621;C0013622;C0013658;C0039401;C0439234	\N	\N
1099	< $nmbr$ yr ( n = $nmbr$ )	C0439234	\N	\N
1099	< $nmbr$ yr	C0439234	\N	\N
1099	< $nmbr$ years simva ( n = $nmbr$ }	C0439234	\N	\N
1099	< $nmbr$ years simva ( n = $nmbr$ )	C0439234	\N	\N
1099	< $nmbr$ years simva	C0439234	\N	\N
1099	< $nmbr$ years n z $nmbr$	C0439234	\N	\N
1099	< $nmbr$ years eze / simva ( n = $nmbr$ }	C0439234	\N	\N
1099	< $nmbr$ years eze / simva ( n = $nmbr$ )	C0439234	\N	\N
1099	< $nmbr$ years eze / simva	C0439234	\N	\N
1099	< $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ )	C0032042;C0439234;C1611934;C1696465;C1706408	\N	\N
1099	< $nmbr$ years ( n = $nmbr$ )	C0439234	\N	\N
1099	< $nmbr$ years ( % )	C0439234	\N	\N
1099	< $nmbr$ years  n ( % )	C0439234	\N	\N
1099	% / year	C0439234;C0439508	\N	\N
1099	$nmbr$ — < $nmbr$ years	C0439234	\N	\N
1099	$nmbr$ — $nmbr$ years	C0439234	\N	\N
1099	$nmbr$ yr km % ( n )	C0439234;C3887676	\N	\N
1099	$nmbr$ yr	C0439234	\N	\N
1099	$nmbr$ years or older	C0439234;C0580836	\N	\N
1099	$nmbr$ years ( n = $nmbr$ )	C0439234	\N	\N
1099	$nmbr$ years  n ( % )	C0439234	\N	\N
1099	$nmbr$ years	C0439234	\N	\N
1099	$nmbr$ year or more	C0205172;C0439234;C0439508	\N	\N
1099	$nmbr$ to < $nmbr$ yr — no . { % )	C0439234	\N	\N
1099	$nmbr$ to < $nmbr$ yr — no . ( % )	C0439234	\N	\N
1099	$nmbr$ to < $nmbr$ yr	C0439234	\N	\N
1099	$nmbr$ to < $nmbr$ years	C0439234	\N	\N
1099	$nmbr$ to $nmbr$ yr	C0439234	\N	\N
1099	$nmbr$ to $nmbr$ years	C0439234	\N	\N
1099	$nmbr$ moto < $nmbr$ yr  n ( % )	C0439234	\N	\N
1099	$nmbr$ mo to $nmbr$ yr	C0026544;C0332177;C0439234	\N	\N
1099	$nmbr$ e $nmbr$ years	C0439234	\N	\N
1099	$nmbr$ = $nmbr$ yr — no . ( % )	C0439234	\N	\N
1099	$nmbr$ - yr km mortality rate	C0026565;C0205848;C0439234;C3887676	\N	\N
1099	$nmbr$ - yr %	C0439234	\N	\N
1099	$nmbr$ - year risk of chd  % # < $nmbr$ . $nmbr$	C0439234;C0439508;C1282512	\N	\N
1099	$nmbr$ - year risk of chd  % #	C0439234;C0439508;C1282512	\N	\N
1099	$nmbr$ - year risk for chd	C0439234;C0439508;C1282512	\N	\N
1099	$nmbr$ - year predicted risk ( % ) of	C0035647;C0439234;C0439508;C0681842;C1882327;C4552904	\N	\N
1099	$nmbr$ - year mortality	C0026565;C0026566;C0439234;C0439508	\N	\N
1099	$nmbr$ - year km %	C0439234;C0439508;C3887676	\N	\N
1099	$nmbr$ - year framingham chd risk ( % ) $nmbr$ mean / sd )	C0439234;C0439508;C0444504;C1282512;C2347634;C2348143;C2699239;C3166866	\N	\N
1099	$nmbr$ - year framingham chd risk  %	C0439234;C0439508;C1282512;C3166866	\N	\N
1099	$nmbr$ - year framingham chd risk	C0439234;C0439508;C1282512;C3166866	\N	\N
1099	$nmbr$ - < $nmbr$ years	C0439234	\N	\N
1099	$nmbr$ - $nmbr$ yr — no . ( % )	C0439234	\N	\N
1099	$nmbr$ - $nmbr$ yr ( % )	C0439234	\N	\N
1099	$nmbr$ - $nmbr$ yr	C0439234	\N	\N
1099	$nmbr$ - $nmbr$ years	C0439234	\N	\N
1099	$nmbr$ $nmbr$ years  n ( % )	C0439234	\N	\N
1099	$ $nmbr$ years ( n = $nmbr$ )	C0439234	\N	\N
1099	$ $nmbr$ years	C0439234	\N	\N
1099	$ $nmbr$ and  $nmbr$ years	C0439234	\N	\N
1099	# $nmbr$ year	C0439234;C0439508	\N	\N
1098	teaes of special interest	C0205555;C0543488	\N	\N
1098	special interest categories	C0205555;C0543488;C0683312	\N	\N
1098	social interaction	C0037420	\N	\N
1098	interact !	\N	\N	\N
1097	interval from symptom onset to qualifying ecg obtained in the er — hr	C1272706;C1301820;C1514624;C1552654;C1552713;C1623258;C3810541;C3811131;C4086878	\N	\N
1097	interval from onset of symptoms	C1272706;C1552654;C1552713;C4086878	\N	\N
1097	interval between clinical evaluation and initiation oftreatment — no . ( % )	C0205210;C0589507;C1158830;C1261322;C1272706;C1552654;C1552713;C1704686;C2826267;C4084924	\N	\N
1097	interval between clinical evaluation and initiation of treatment — no . ( % )	C0039798;C0087111;C0205210;C0589507;C1158830;C1261322;C1272706;C1522326;C1533734;C1552654;C1552713;C1704686;C1705169;C2826267;C3538994;C3887704;C4084924	\N	\N
1096	long - acting  intermediate / long - acting + fast - acting	C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375	\N	\N
1096	intermediate / long - acting + fast - acting	C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375	\N	\N
1096	intermediate - acting	C0205103;C1550465;C2827755;C3889971	\N	\N
1096	intermediate ( $nmbr$ - $nmbr$ )	C0205103;C1550465;C2827755;C3889971	\N	\N
1096	intermediate ( $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % )	C0205103;C1550465;C2827755;C3889971	\N	\N
1096	intermediate ( $nmbr$ )  %	C0205103;C1550465;C2827755;C3889971	\N	\N
1096	intermediate	C0205103;C1550465;C2827755;C3889971	\N	\N
1095	nintedanib ( n   =   $nmbr$ )	C2930789	\N	\N
1095	nintedanib ( n = $nmbr$ )	C2930789	\N	\N
1094	previous intolerance of infliximab  n ( % ) *	C0205156;C0231199;C0666743;C1552607;C1744706;C2355652	\N	\N
1094	patients with previous loss of response to and intolerance of infliximab *	C0030705;C0205156;C0231199;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C1744706;C2355652;C2911692	\N	\N
1094	patients with previous intolerance of infliximab	C0030705;C0205156;C0231199;C0666743;C1552607;C1744706;C2355652	\N	\N
1094	inadequate response or intolerance to > $nmbr$ anti - tnfdrug	C0205412;C0231199;C0439856;C0871261;C1704632;C1706817;C1744706;C2355652;C2911692	\N	\N
1093	infections and infestations	C0851341;C3714514	\N	\N
1093	infections	C3714514	\N	\N
1093	infected  n ( % ) a	C0439663	\N	\N
1093	injection - site reaction  n ( % )	C0151735;C4551923	f	1983
1097	hazard ratio ( $nmbr$ % confi dence interval )	C1272706;C1552654;C1552713;C2985465	f	975
1094	intolerance	C0231199;C1744706;C2355652	f	1984
1095	maintenance dose	C3714445	f	1985
1095	ics dose of stable maintenance treatment ( μ g ) ∗  †	C0039798;C0087111;C0178602;C0205360;C0439267;C0814469;C0815320;C0869039;C1114758;C1522326;C1533734;C1547311;C1705169;C3538994;C3714445;C3887704;C4551720	f	1348
1096	p - inter	C0205103;C0369773;C1548610;C2603361	f	1986
1096	inter p - value	C0205103;C1548610;C1709380	f	1986
1096	inter .	C0205103;C1548610	f	-10
1094	statin intolerance $nmbr$  n ( % )	C0231199;C0360714;C1744706;C2355652	f	1999
1096	p value ( inter )	C0205103;C1548610;C1709380	f	1986
1096	p for inter - act	C0079613;C0205103;C0369773;C1548610;C1704930;C1869853;C2603361;C3890007;C4048375	f	1986
1096	p inter	C0205103;C0369773;C1548610;C2603361	f	1986
1093	acute infection without septic shock	C0036983;C0275518	\N	\N
1092	( incl . uncertain )	C0087130;C0268281;C1418854;C4085655	\N	\N
1091	st - segment depression or t - wave inversion on ecg	C0021943;C0021945;C0429104;C0520887;C0520888;C1623258;C1705687;C2349984	\N	\N
1091	st - depression and t - wave inversion	C0520887;C0520888	\N	\N
1091	major st depression or t - wave inversion	C0036056;C0041696;C0205082;C0205164;C0520887;C0520888;C1269683;C3272372;C4318856;C4521762	\N	\N
1090	patients with fingernail involvement	C0030705;C0222001;C1314939	\N	\N
1090	organ system involvement  no . ( % )	C0460002;C1314939	\N	\N
1090	no ststm	\N	\N	\N
1090	no . fingernails	C0222001	\N	\N
1090	no . ( % ) of patients with fingernail involvement	C0030705;C0222001;C1314939	\N	\N
1089	specific risk of bleeding ^	C0205369;C1552740;C3251812	\N	\N
1089	risk of bleeding	C3251812	\N	\N
1088	life - threatening bleeding  disabling stroke  and death	C0011065;C0019080;C0038454;C1306577;C1546953;C2826244;C3537125;C4082313;C4552775;C4554100	\N	\N
1088	life - threatening bleed	C0019080;C1546953;C2826244;C3537125	\N	\N
1088	life - threatening	C1546953;C2826244;C3537125	\N	\N
1087	undetermined etiology  n ( % )	C0478157	\N	\N
1087	undetermined etiology	C0478157	\N	\N
1086	undetermined	C0205258;C3536725;C4082977	\N	\N
1086	patients who received indeterminate results on test for antibodies to infliximabt	C0003241;C0030705;C0205258;C0456984;C1514756	\N	\N
1086	indeterminate nfs - $nmbr$ . $nmbr$ < nfs < $nmbr$ . $nmbr$ ! n = $nmbr$ )	C0205258;C1513839	\N	\N
1086	indeterminate ! !	C0205258	\N	\N
1085	generalized	C0205246	\N	\N
1085	general andthoracic epidural	C0205246;C0228134;C0812144;C3812897;C3891294;C4521767	\N	\N
1085	general alone	C0205171;C0205246;C0439044;C0679994;C3812897;C3891294;C4521767	\N	\N
1085	general allergic events	C0205246;C0441471;C0700624;C3541888;C3812897;C3891294;C4521767	\N	\N
1085	general	C0205246;C3812897;C3891294;C4521767	\N	\N
1084	gene / chr / snp	C0017337;C0043459;C0752046;C1527094;C1861559;C3890034;C4050175	\N	\N
1084	gene	C0017337	\N	\N
1083	gertder	\N	\N	\N
1083	gender n ( % )	C0079399;C1522384	\N	\N
1083	gender female	C0043210;C0079399;C0086287;C1522384;C1705497;C1705498	\N	\N
1083	gender [ n ( % ) ]	C0079399;C1522384	\N	\N
1083	gender :	C0079399;C1522384	\N	\N
1083	gender - n ( % )	C0079399;C1522384	\N	\N
1083	gender ( m / f )  ( % )	C0079399;C1306057;C1522384	\N	\N
1083	gender    n   ( % )	C0079399;C1522384	\N	\N
1083	gender  no . ( % )	C0079399;C1522384	\N	\N
1083	gender  n ( % ]	C0079399;C1522384	\N	\N
1083	gender  n ( % )	C0079399;C1522384	\N	\N
1083	gender  female  n ( % )	C0043210;C0079399;C0086287;C1522384;C1705497;C1705498	\N	\N
1083	gender  % of patients	C0030705;C0079399;C1522384	\N	\N
1083	gender  %	C0079399;C1522384	\N	\N
1083	gender	C0079399;C1522384	\N	\N
1083	gendar	\N	\N	\N
1083	eze / simva gender	C0079399;C1522384	\N	\N
1083	> $nmbr$  n ( % ) gender  n ( % )	C0079399;C0369718;C0441922;C1522384	\N	\N
1081	p  net difference	C0369773;C1456447;C1705241;C1705242;C2603361;C3853572;C3887809;C3890893	\N	\N
1081	net ep $nmbr$	C1456447;C1880476;C3853572;C3887809;C3890893;C4321526	\N	\N
1081	net composite	C0205199;C1456447;C1547335;C3853572;C3887809;C3890893	\N	\N
1081	net clinical benefit *	C1456447;C3853572;C3887809;C3890893;C4684590	\N	\N
1080	knees ( n )	C0022742	\N	\N
1080	knee	C0022742;C0022745;C1963703	\N	\N
1079	new des ( n = $nmbr$ )	C0011702;C0205314;C4551552	\N	\N
1078	odds ratio	C0028873	\N	\N
1078	estimated response rate and odds ratio	C0028873;C0237629;C0750572	\N	\N
1078	estimated odds ratio	C0028873;C0750572	\N	\N
1077	fdc $nmbr$ / $nmbr$   μ g ( n   =   $nmbr$ )	C0340427;C0439267;C1413520;C3539652	\N	\N
1076	ada impaired fasting glucose	C1060325;C1272092;C3811629	\N	\N
1076	ada $nmbr$ / $nmbr$ n [ $nmbr$	C1060325;C3811629	\N	\N
1076	ada $nmbr$ / $nmbr$ ( n [ $nmbr$ )	C1060325;C3811629	\N	\N
1076	ada  yes	C1060325;C1549445;C1705108;C1710701;C3811629	\N	\N
1076	ada  no	C1060325;C3811629	\N	\N
1075	adas — cog score	C0449820;C3539026;C4050231	\N	\N
1075	adas - cog score *	C0449820;C3539026;C4050231	\N	\N
1075	adas - cog	C3539026	\N	\N
1074	gaviscon da ( n = $nmbr$ )	C0011318;C0061146;C3668815	\N	\N
1063	> $nmbr$ aes leading to discontinuation	C0332152;C0457454;C1412268;C1444662;C1522538;C2699274;C4552847	\N	\N
1079	new or worsentna neohrodathv	C0205314	f	1718
1079	new or worsenina neohrodathv	C0205314	f	1718
1087	stroke of undetermined cause	C0015127;C0038454;C1524003	f	1762
1077	fluticasone propionate / salmeterol fdc	C0340427;C1413520;C1622832;C3539652	f	1978
1080	below - knee popliteal	C0022742;C0022745;C0442037;C0542339;C1552829;C1963703	f	1979
1082	tender	C0234234	f	1980
1091	symmetric t - wave inversions	C0332516;C0520888;C2699744	f	1981
1087	undeterminedc	\N	f	-10
1091	symmetric t wave inversions	C0332516;C0520888;C2699744	f	1981
1089	noirecerving	\N	f	-10
1089	noliecervrig	\N	f	-10
1091	t - wave inversion	C0520888	f	1981
1091	t wave inversion	C0520888	f	1981
1091	inversion	C0021943;C0021945;C1705687;C2349984	f	-10
1092	uncerlain	\N	f	1982
1092	uncertain	C0087130;C4085655	f	1982
1092	ischemic stroke ( incl . uncertain )	C0087130;C0948008;C4085655	f	1762
1081	net adverse clinical events at day $nmbr$	C0205210;C0332173;C0439228;C0439505;C0877248;C1456447;C1705413;C3853572;C3887809;C3890893	f	47
1082	number of tender joints ( $nmbr$ assessed )	C0234234;C0449813;C1516048	f	1139
1082	number of tender joints ( $nmbr$ - $nmbr$ )	C0234234;C0449813	f	1139
1074	abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .	C0000723;C0011318;C0011884;C0013850;C0017446;C0021888;C0180459;C0205146;C0920367;C1547561;C1556138;C1705370;C2348299;C3161471;C3668815;C4281784	\N	\N
1074	> $nmbr$ da of capillary nonperfusion in the eyec	C0006901;C0011318;C0935624;C3668815	\N	\N
1073	vdz n = \\ $nmbr$	\N	\N	\N
1073	vdz n = $nmbr$	\N	\N	\N
1073	vdz / vdz [ n = $nmbr$ ]	\N	\N	\N
1073	vdz / pbo [ n = $nmbr$ ]	C0031962	\N	\N
1071	albumin ( mg / dl )	C0001924;C0439269	\N	\N
1071	albumin  g / dl	C0001924;C0439267	\N	\N
1070	adcs - adl score *	C0449820;C3641947;C4050231	\N	\N
1070	adcs - adl	C3641947	\N	\N
1068	ldl : hdl ratio	C0428621	\N	\N
1068	ldl / hdl cholesterol ratio  mean ( sd ) §	C0008377;C0428621;C0444504;C2347634;C2348143;C2699239	\N	\N
1068	ldl - to - hdl cholesterol ratio  mean ( sd )	C0008377;C0428621;C0444504;C1171408;C2347634;C2348143;C2699239	\N	\N
1068	ldl - csmedian	\N	\N	\N
1068	ldl - c > median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1068	ldl - c : hdl - c ratio	C0428621	\N	\N
1068	ldl - c / hdl - c ratio  mean ( sd )	C0428621;C0444504;C2347634;C2348143;C2699239	\N	\N
1068	ldl - c / hdl - c ratio	C0428621	\N	\N
1068	ldl - c ( median  iqr )  mg / dl	C0439269;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
1068	ldl - c	\N	\N	\N
1068	lcl	C3658298	\N	\N
1066	vldl cholesterol	C0023826;C0523560	\N	\N
1066	vldl - c	C0523560	\N	\N
1066	vldl	C0523560	\N	\N
1065	inconsistent fao ( n [ $nmbr$ )	C0016457;C0442809	\N	\N
1065	$nmbr$ - $nmbr$ fo - $nmbr$ - o - q ^ i	C0021966;C0221138	\N	\N
1065	$nmbr$ - $nmbr$ fo - $nmbr$ $nmbr$ - $nmbr$ ^	\N	\N	\N
1065	$nmbr$ $nmbr$ fo $nmbr$ - $nmbr$ $nmbr$ )	\N	\N	\N
1064	metrex modified intention - to - treat population with an eosinophilic phenotypey	C0032659;C0087111;C0162425;C0333930;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737	\N	\N
1064	metreo modified intention - to - treat population §	C0032659;C0087111;C0162425;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737	\N	\N
1064	ization — no . ( % )	\N	\N	\N
1064	individual intended study duration — no . ( % )	C0027361;C0237401;C0489652;C1283828;C1551357	\N	\N
1063	no prior pci	C0332152;C2826257;C4049621	\N	\N
1063	no . of prior bdmards	C0332152;C2826257	\N	\N
1063	leading to discontinuation	C0332152;C0457454;C1444662;C1522538;C4552847	\N	\N
1063	> $nmbr$ b ( $nmbr$ b to $nmbr$ a )	\N	\N	\N
1066	serum ldl cholesterol	C0428474	f	1068
1064	intent - to - treatb	C0162425;C1283828;C1550453	f	1975
1066	ratio of ldl to hdl cholesterol	C0023822;C0392885;C0456603;C1547037	f	1068
1063	adverse events leading to premature treatment discontinuation	C0039798;C0087111;C0151526;C0205252;C0332152;C0457454;C0877248;C1444662;C1522326;C1522538;C1533734;C1705169;C1705413;C3538994;C3887704;C4018905;C4552847	f	1974
1064	intent - to - treat population	C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453	f	1975
1064	intention to treat	C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1883351	f	1975
1064	intent - to - treat population  n ( % )	C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453	f	1975
1067	ldu - c	\N	f	-10
1069	ldl - c ( calculated ) *	C0444686;C1441506	f	1068
1067	baseline fc - ldl - c	C0168634;C1442488;C2983605	f	1068
1067	ldlc	C1416822	f	1068
1067	baseline ldlc level ( n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mgzdl	C0168634;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261	f	1068
1069	fc - ldl - c  friedewald - calculated	C0444686;C1441506;C2983605	f	1068
1070	adl subscale ( range  $nmbr$ - $nmbr$ ) *	C0001288;C1420005;C1514721;C2348147;C3542016	f	1976
1070	adl	C0001288;C1420005	f	1976
1071	ldl - c  mmol / l ( mg / dl )	C3642216;C3898312	f	1068
1071	hdl - c  mmol / l ( mg / dl )	C3642216;C3715113;C3898312	f	1977
1071	tg  mmol / l [ mg / dl ]	C0337445;C3642216;C3898312	f	1977
1071	fpg  mmol / l ( mg / dl )	C3642216;C3898312	f	1977
1072	eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ) '	C1319635;C1333964;C1707618	f	803
1072	feno  $nmbr$ dn = $nmbr$ )	C1333964;C1707618	f	803
1063	< $nmbr$ — no . { % )	\N	\N	\N
1063	- $nmbr$ . $nmbr$ to - $nmbr$ cm	\N	\N	\N
1063	$nmbr$ to < $nmbr$ ( n z $nmbr$ )	C0369718;C0441922	\N	\N
1063	$nmbr$ to < $nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1063	$ $nmbr$ to  $nmbr$ ( n = $nmbr$ )	C0369718;C0441922	\N	\N
1062	some	\N	\N	\N
1062	geographic distribution - no . ( % )	C0681686	\N	\N
1062	edss stratification . no . ( % )	C0451246;C1514983;C3887783	\N	\N
1062	edss stratification  no . ( % )	C0451246;C1514983;C3887783	\N	\N
1062	$nmbr$ = some restrictions  no help needed	C0027552;C0443288;C0686904;C1269765;C1552861	\N	\N
1061	use of other medications — no . ( % )	C0240320	\N	\N
1061	other  no . ( % )	\N	\N	\N
1061	no immomtedion	\N	\N	\N
1061	no hemoconcentration hemoconcentration	C0549409;C0854379	\N	\N
1061	> $nmbr$ y  no . ( % )	\N	\N	\N
1060	region 一 no . ( % )	C0017446;C0205147	\N	\N
1060	region — no . { % )	C0017446;C0205147	\N	\N
1060	region — no . ( % )	C0017446;C0205147	\N	\N
1060	region - no . ( % )	C0017446;C0205147	\N	\N
1060	region  no . / total ( % )	C0017446;C0205147;C0439175;C0439810	\N	\N
1060	region  no . ( % ) c	C0017446;C0205147	\N	\N
1060	region  no . ( % )	C0017446;C0205147	\N	\N
1060	previous antiarrhythmic treatment — no . ( % )	C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704	\N	\N
1060	other ® region — no . ( % )	C0017446;C0205147	\N	\N
1060	no treatment or antihistamines only	C0019590;C0039798;C0087111;C0205171;C1522326;C1533734;C1705169;C1720467;C3538994;C3887704	\N	\N
1060	no ?	\N	\N	\N
1060	no .	\N	\N	\N
1060	geographic region — no . ( % )	C0017446	\N	\N
1060	enrollment by region  no . ( % )	C0017446;C0205147;C1516879;C1696073;C3888021	\N	\N
1059	primary end point  no . of events / total no . ( % )	C0439175;C0439810;C0441471;C2986535;C3541888	\N	\N
1059	no . of events / total no . ( % )	C0439175;C0439810;C0441471;C3541888	\N	\N
1059	no . of events / total no . $nmbr$ % )	C0439175;C0439810;C0441471;C3541888	\N	\N
1059	no . of events / total	C0439175;C0439810;C0441471;C3541888	\N	\N
1059	no . of events	C0441471;C3541888	\N	\N
1059	no . of	\N	\N	\N
1059	no . evenls	\N	\N	\N
1059	management of event — no . ( % )	C0001554;C0376636;C0441471;C1273870;C3273539;C4019010	\N	\N
1059	< $nmbr$ — no . ( % )	\N	\N	\N
1059	$nmbr$ no . of events	C0441471;C3541888	\N	\N
7	p - value ( vs placebo )	C0032042;C1696465;C1706408;C1709380	\N	\N
7	p - value ( trend )	C1521798;C1709380;C4554533	\N	\N
1058	eo severity by la classification at baseline ( baseline of the healing study )  n ( % )	C0043240;C0168634;C0205249;C0332120;C0439793;C0522510;C0557651;C1442488;C1881447;C2603343	\N	\N
1058	eo	C0332120	\N	\N
1057	low renin ( pra < $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ )	C0633231;C0855389;C1141951;C1419788;C1533072;C3274822;C3669212;C4050009;C4283900	\N	\N
1057	lo ( lo - lo )	C0206579;C1232424	\N	\N
1057	$nmbr$ . $nmbr$ ( lo . i )	C0021966;C0206579;C0221138;C1232424	\N	\N
1057	$nmbr$ . $nmbr$ ( lo - $nmbr$ . $nmbr$ )	C0206579;C1232424	\N	\N
1056	wml load at follow - up mri stratified by baseline severity of wml load	C0024485;C0168634;C0205363;C0439793;C0522510;C0589120;C1442488;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166	\N	\N
1056	wml load at follow - up mri	C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166	\N	\N
1056	wml load at baseline mri	C0024485;C0168634;C1442488;C1550025;C1704782;C1708715;C1824234;C3890166	\N	\N
1056	late load	C0205087;C1550025;C1704782;C1708715	\N	\N
1056	early load	C1279919;C1550025;C1704782;C1708715	\N	\N
1055	atenolol n = $nmbr$ no . ( % )	C0004147	\N	\N
1055	atenolol n = $nmbr$	C0004147	\N	\N
1055	atenolol *	C0004147	\N	\N
1055	atenolol ( « = $nmbr$ $nmbr$ )	C0004147	\N	\N
1055	atenolol ( no . = $nmbr$ )	C0004147	\N	\N
1055	atenolol ( n = $nmbr$ )	C0004147	\N	\N
1055	atenolol ( n = $nmbr$  $nmbr$ )	C0004147	\N	\N
1055	atenolol	C0004147	\N	\N
1055	atenoioi ( n = $nmbr$ )	\N	\N	\N
1054	lleocolon	\N	\N	\N
1054	ileum or colon	C0009368;C0020885;C3888384	\N	\N
1054	ileum and colon  n ( % )	C0009368;C0020885;C3888384	\N	\N
1054	ileum and colon  ' n ( % )	C0009368;C0020885;C3888384	\N	\N
1054	ileum and colon	C0009368;C0020885;C3888384	\N	\N
1054	ileocolonic ( both ileum and colon )	C0009368;C0020885;C3888384	\N	\N
1054	ileocolon	\N	\N	\N
1055	carvedilol	C0054836	f	1972
1055	carvedilol  % ( n )	C0054836	f	1972
1061	history of amputation — no . ( % )	C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062	f	1973
1061	amputation — no . ( % )	C0002688;C0332840;C1546539	f	1973
1061	history of amputation  no . ( % )	C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062	f	1973
1053	history of alcohol use	C0551571;C0552479	\N	\N
1053	current alcohol  n ( % )	C0001962;C0001975;C0521116;C1705970	\N	\N
1053	alcohol usef  n ( % )	C0001962;C0001975	\N	\N
1053	alcohol useb	C0001962;C0001975	\N	\N
1053	alcohol abuse	C0085762;C4050601	\N	\N
1053	alcohol ^	C0001962;C0001975	\N	\N
1053	alcohol > $nmbr$ / wk	C0001962;C0001975;C0332174;C0439230	\N	\N
1053	alcohol < = $nmbr$ / wk	C0001962;C0001975;C0332174;C0439230	\N	\N
1053	alcohol	C0001962;C0001975	\N	\N
1051	previously untreated isolated systolic hypertension	C0332155;C0745133	\N	\N
1051	isolated systolic hypertension ⁎	C0745133	\N	\N
1051	isolated systolic hypertension ^	C0745133	\N	\N
1051	isolated systolic hypertension  n ( ' % >	C0745133	\N	\N
1051	isolated systolic hypertension  n ( % ) “	C0745133	\N	\N
1051	isolated systolic hypertension	C0745133	\N	\N
1049	perfusion defectsatinclusion	C0031001;C4281794	\N	\N
1049	no reperfusion	C0035124;C0684253	\N	\N
1049	acute reperfusion	C0035124;C0205178;C0684253	\N	\N
1048	symptomatic hypotension with sbp < $nmbr$ mm   hg	C0020649;C0085805;C0231220;C0439475;C3163620	\N	\N
1048	symptomatic hypotension ( sbp < $nmbr$ mmhg )	C0020649;C0085805;C0231220;C0439475;C3163620	\N	\N
1048	symptomatic hypotension	C0020649;C0231220;C3163620	\N	\N
1048	orthostatic hypotension	C0020651	\N	\N
1048	hypotension  n ( % )	C0020649;C3163620	\N	\N
1048	hypotension	C0020649;C3163620	\N	\N
1047	proportions  n ( % )	C1709707	\N	\N
1047	proportion of responders n / n ( % )	C1709707	\N	\N
1047	proportion of > = $nmbr$ % responder rates	C0871208;C1521828;C1709707	\N	\N
1047	proportion	C1709707	\N	\N
1047	propafenone	C0033429	\N	\N
1047	mean proportion ( % )	C0444504;C1709707;C2347634;C2348143	\N	\N
1047	estimated proportions ( % ) and odds ratios	C0028873;C0750572;C1709707	\N	\N
1046	patients with radiographic erosion  n / n ( % )	C0030705;C0333307;C0444708;C1880549;C1959609;C3887524	\N	\N
1046	erosion score ( $nmbr$ – $nmbr$ scale )	C0175659;C0333307;C0349674;C0449820;C1880549;C1947916;C1959609;C3887524;C4050231	\N	\N
1046	erosion score ( $nmbr$ - $nmbr$ )	C0333307;C0449820;C1880549;C1959609;C3887524;C4050231	\N	\N
1046	erosion score	C0333307;C0449820;C1880549;C1959609;C3887524;C4050231	\N	\N
1046	erosion  mean ± sd	C0333307;C0444504;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524	\N	\N
1046	erosion	C0333307;C1880549;C1959609;C3887524	\N	\N
1046	change in erosion score ( mean )	C0333307;C0392747;C0443172;C1705241;C1880549;C1959609;C3533236;C3887524;C4319952	\N	\N
1046	baseline erosion	C0168634;C0333307;C1442488;C1880549;C1959609;C3887524	\N	\N
1046	> $nmbr$ erosion  n ( % )	C0333307;C1880549;C1959609;C3887524	\N	\N
1045	prior diagnosis - no . ( % )	C0332132	\N	\N
1045	previous hypersensitivity reaction — no . ( % )	C0020517;C0205156;C1552607	\N	\N
1045	previous events  no . ( % )	C0205156;C0441471;C1552607;C3541888	\N	\N
1045	previous diagnosis	C0332132	\N	\N
1045	previous antiparkinson medication  no . ( % )	C0003405;C0205156;C1552607	\N	\N
1045	no previous diagnosis of diabetes mellitus	C0011849;C0332132	\N	\N
1045	no . of previous csdmards  n ( % )	C0205156;C1552607	\N	\N
1045	no . of previous biologic dmards — no . ( % )	C0205156;C1552607;C4055380	\N	\N
1045	no . *	\N	\N	\N
1044	smoking status ( previous ) ( n )	C0205156;C1519386;C1552607	\N	\N
1044	previous vascular disease	C0042373;C0205156;C1552607	\N	\N
1044	previous use of niacin or niaspan §	C0027996;C0205156;C1142562;C1161310;C1524063;C1552607	\N	\N
1044	previous use of amiodarone	C0002598;C0205156;C1524063;C1552607	\N	\N
1044	previous treatment failure — no . ( % ) § * *	C0162643;C0205156;C0235828;C0521983;C1547544;C1552607	\N	\N
1044	previous therapy	C0039798;C0087111;C0205156;C1363945;C1552607	\N	\N
1044	previous therapies  n ( % )	C0087111;C0205156;C1552607	\N	\N
1044	previous systemic treatment  n ( % )	C0205156;C0678812;C1552607	\N	\N
1044	previous statin use	C0042153;C0205156;C0360714;C0457083;C1552607;C1947944	\N	\N
1044	previous segments resection ( s ) *	C0205156;C1552607;C2987624	\N	\N
1044	previous segmental resection — no . ( % )	C0205156;C1552607;C2987624	\N	\N
1044	previous revascularization	C0205156;C0581603;C1552607	\N	\N
1044	previous pde $nmbr$ inhibitors	C0031638;C0205156;C1552607	\N	\N
1050	hypertensiont	\N	f	1364
1054	all of the colon	C0009368;C3888384	f	1971
1052	alcohol > $nmbr$ drinks per week	C0332174;C0439230;C0556297	f	1053
1044	previous tnf - antagonist use  n ( % )	C0042153;C0205156;C0231491;C0457083;C1448177;C1552607;C1947944	f	2391
1044	reason for discontinuation of previous tnfa inhibitor	C0205156;C0392360;C0457454;C1444662;C1448177;C1552607;C1710304;C1999216;C4552847	f	2392
1044	severe episodes in previous year — no . / patient	C0030705;C0205082;C0205156;C0332189;C0439234;C0439508;C1552607;C4050465;C4050466	f	2393
1044	previous use of systemic steroids for ciu / csu	C0205156;C0205373;C0281991;C0578870;C1552607	f	2396
1044	previous use of systemic steroids  n ( % )	C0205156;C0205373;C0281991;C1552607	f	2396
1044	previous receipt of therapy against tnf - a — no . ( % )	C0039798;C0087111;C0205156;C1363945;C1448177;C1552607;C1710304	f	2398
1044	previous vte	C0205156;C0630906;C1552607	f	2399
1044	previous venous thromboembolism — no . ( % )	C0205156;C1552607;C1861172	f	2399
1044	previous vte n ( % )	C0205156;C0630906;C1552607	f	2399
1044	previous vte  n ( % )	C0205156;C0630906;C1552607	f	2399
1044	previous vte — no . ( % )	C0205156;C0630906;C1552607	f	2399
1044	previous pci or cabg	C0010055;C0205156;C1552607;C4049621	f	1661
1044	yes previous revascularization	C0205156;C0581603;C1549445;C1552607;C1705108;C1710701	f	1661
1044	previous htn  n ( % )	C0020538;C0205156;C1552607	\N	\N
1044	previous chronic kidney disease	C0205156;C1552607;C1561643;C4553188	\N	\N
1044	previous cancerc	C0205156;C1552607	\N	\N
1044	previous analgesic products n ( % )	C0002771;C0205156;C1552607	\N	\N
1044	previous ami  n ( % )	C0205156;C1552607;C4319936	\N	\N
1044	previous ami	C0205156;C1552607;C4319936	\N	\N
1044	previous $nmbr$ ari use	C0042153;C0205156;C0457083;C1412533;C1552607;C1947944;C4521376	\N	\N
1044	previous $nmbr$ - ari use ( % )	C0042153;C0205156;C0457083;C1412533;C1552607;C1947944;C4521376	\N	\N
1044	previous	C0205156;C1552607	\N	\N
1044	no previous dmard therapy	C0039798;C0087111;C0205156;C0242708;C1363945;C1552607	\N	\N
1044	> $nmbr$ in previous	C0205156;C1552607	\N	\N
1043	postmenopausal and no ht	C0018510;C0232970;C0677607	\N	\N
1043	postmenopausal and current ht	C0018510;C0232970;C0521116;C0677607;C1705970	\N	\N
1043	poslmenopausal  no ht	C0018510;C0677607	\N	\N
1043	poslmenopausal  ht	C0018510;C0677607	\N	\N
1043	menopause and ht	C0018510;C0025320;C0567312;C0677607	\N	\N
1043	menopause and hrt	C0025320;C0282402;C0567312	\N	\N
1042	premenopausal  %	C0279752	\N	\N
1042	premenopausal	C0279752	\N	\N
1042	menopausal status and hormone therapy use premenopausal	C0042153;C0279025;C0279752;C0457083;C1513126;C1947944	\N	\N
1042	female : premenopausal	C0043210;C0086287;C0279752;C1705497;C1705498	\N	\N
1041	postmenopausal hormone use	C0019932;C0042153;C0232970;C0457083;C1947944;C4521914	\N	\N
1041	postmenopausal ( % )	C0232970	\N	\N
1041	postmenopausal  never or past hormone therapy use	C0042153;C0232970;C0279025;C0457083;C1444637;C1947944;C2003901;C4284302	\N	\N
1041	postmenopausal	C0232970	\N	\N
1041	post - menopausal ( a )	C0232970	\N	\N
1041	peri - or postmenopausal	C0232970;C0347985	\N	\N
1041	female participants who are ≥ $nmbr$ years postmenopausal	C0043210;C0086287;C0232970;C0439234;C0679646;C1705497;C1705498	\N	\N
1041	female : ≥ $nmbr$ years postmenopausal	C0043210;C0086287;C0232970;C0439234;C1705497;C1705498	\N	\N
1041	female : perimenopausal or < $nmbr$ years postmenopausal	C0043210;C0086287;C0232970;C0439234;C0849668;C1705497;C1705498;C3839366	\N	\N
-10	personal relationships	C1552027	\N	\N
1039	perianal or anus	C0003461;C0442158	\N	\N
1039	perianal gi tract	C0017189;C0442158	\N	\N
1039	perianal  n ( % )	C0442158	\N	\N
1038	new vertebral fracture at $nmbr$ months	C0080179;C0205314;C0439231	\N	\N
1038	new or worsening vertebral fracture at $nmbr$ months	C0080179;C0205314;C0332271;C0439231;C1457868;C1546960	\N	\N
1038	b pooled new and worsened vertebral fractures ( mfas )	C0080179;C0205314;C1457868;C1549796;C1549980;C1709595;C2349200;C4084902;C4522255	\N	\N
1038	a new vertebral fractures ( mfas )	C0080179;C0205314;C1549796;C1549980	\N	\N
1037	male patients *	C0150904	\N	\N
1037	male patients  n ( % )	C0150904	\N	\N
1028	apolipoprotein b	C0003593	\N	\N
1044	previous heart failure — no . ( % )	C0018801;C0018802;C0205156;C1552607;C4554158	f	12
1044	previous heart failure	C0018801;C0018802;C0205156;C1552607;C4554158	f	12
1044	previous cabg surgery	C0010055;C0038894;C0038895;C0205156;C0543467;C1274039;C1552607	f	389
1038	mfns ( n = $nmbr$ )	\N	f	-10
1044	cardioversion in previous $nmbr$ wk	C0013778;C0205156;C0332174;C0439230;C1552607	f	2386
1037	femaie	\N	f	1970
1037	female patients ^	C0150905	f	1970
1037	female sex  n ( % of patients )	C0009253;C0030705;C0036864;C0043210;C0079399;C0086287;C0150831;C0150905;C0804628;C1314687;C1522384;C1705497;C1705498	f	1970
1044	previous anti - tnf therapy  n [ % ]	C0205156;C0279936;C0432633;C1552607	f	2387
1044	previous cabg	C0010055;C0205156;C1552607	f	389
1044	previous cabg  n ( % )	C0010055;C0205156;C1552607	f	389
1044	previous infliximab therapy | |	C0205156;C1552607;C4076075	f	2387
1044	previous chf	C0018802;C0205156;C1552607	f	2388
1044	previous chf — no . ( % )	C0018802;C0205156;C1552607	f	2388
1044	previous chf  n ( % )	C0018802;C0205156;C1552607	f	2388
1044	previous diabetes	C0011847;C0011849;C0205156;C1552607	f	2389
1044	previous diabetes mellitus	C0011849;C0205156;C1552607	f	2389
1044	previous myocardiaunfarction	C0205156;C1552607	f	2390
1044	previous cardiovascular disease !	C0007222;C0205156;C1552607	f	2390
1044	previous infarction ( % of group )	C0021308;C0205156;C0441833;C0687744;C1257890;C1519504;C1552607;C1705428;C1705429	f	2390
1044	previous dmards use  n ( % )	C0042153;C0205156;C0242708;C0369718;C0441922;C0457083;C1552607;C1947944	f	2391
1044	previous bdmard received	C0205156;C1514756;C1552607	f	2391
1044	exacerbations in the previous year	C0205156;C0439234;C0439508;C1552607;C4086268	f	2393
1044	moderate or severe exacerbations in the previous year ( range )	C0205081;C0205082;C0205156;C0439234;C0439508;C1514721;C1552607;C1881878;C2348147;C3542016;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335	f	2394
1044	hospitalization in previous year with management of heart failure	C0001554;C0018801;C0018802;C0019993;C0205156;C0376636;C0439234;C0439508;C1273870;C1552607;C3273539;C4554158	f	2395
1044	previous episode of heart failure	C0018801;C0018802;C0205156;C0332189;C1552607;C4554158	f	2395
1044	no . of previous venous thromboembolic events	C0205156;C1552607;C1861172;C1997614;C3160733	f	2399
1044	number of previous tnfa inhibitors	C0205156;C0237753;C0243077;C0449788;C1448177;C1552607;C1710304	f	2398
1044	> $nmbr$ previous venous thromboembolisms ( % )	C0205156;C1552607;C1997614	f	2399
1044	previous pci	C0205156;C1552607;C4049621	f	1661
1044	previous pci  n ( % )	C0205156;C1552607;C4049621	f	1661
1044	previous pci / cabg  n ( % )	C0010055;C0205156;C1552607;C4049621	f	1661
1035	worldwide black patients	C0005680;C0027567;C0030705;C0085756;C0439541	\N	\N
1035	vents / patients	C0030705	\N	\N
1035	u . s . black patients	C0005680;C0027567;C0030705;C0041703;C0085756;C0439541	\N	\N
1035	remaining patients	C0030705;C1527428	\N	\N
1035	randomised patients ( n )	C0030705	\N	\N
1035	race  white  n ( % of patients )	C0007457;C0030705;C0034510;C0043157;C0220938;C1706779;C3853635	\N	\N
1035	proportion of patients who achieved acr $nmbr$ n / n ( % )	C0030705;C1412134;C1515941;C1709707	\N	\N
1035	previous bowel resection performed — no . of patients ( % )	C0030705;C0205156;C0741614;C0884358;C1552607	\N	\N
1035	previous acute hypersensitivity reaction to infliximab — no . of patients ( % )	C0030705;C0205156;C0413234;C0666743;C1552607	\N	\N
1035	percentage patients reaching target	C0030705;C0439165;C1521840;C1549488;C1561533;C2584321;C2986546	\N	\N
1035	percent of patients	C0030705;C0439165	\N	\N
1035	patients without prevalent kidney disease at baseline	C0022646;C0030705;C0168634;C0227665;C0683921;C1442488	\N	\N
1035	patients without diabetesb	C0030705	\N	\N
1035	patients without	C0030705	\N	\N
1035	patients with uncomplicated events ( p = o - $nmbr$ 十 )	C0030705;C0441471;C0443334;C3541888	\N	\N
1035	patients with uncomplicated events	C0030705;C0441471;C0443334;C3541888	\N	\N
1035	patients with pulmonary embolism	C0030705;C0034065	\N	\N
1035	patients with prior dmard use  n ( % ) a	C0030705;C0042153;C0242708;C0332152;C0457083;C1947944;C2826257	\N	\N
1035	patients with prevalent kidney disease at baseline	C0022646;C0030705;C0168634;C0227665;C0683921;C1442488	\N	\N
1035	patients with pneumonia event  n ( % ) #	C0030705;C0032285;C0441471;C4019010	\N	\N
1035	patients with perianal fistulae  n [ % ]	C0030705;C0267561	\N	\N
1035	patients with nail psoriasis ( mnapsi > $nmbr$ )	C0030705;C0406322	\N	\N
1035	patients with level > $nmbr$ pg / ml	C0030705;C0439297;C0441889;C0456079;C1547707;C2946261	\N	\N
1035	patients with improvement $ $nmbr$ . $nmbr$	C0030705;C2986411	\N	\N
1035	patients with event / patients analyzed	C0030705;C0441471;C0936012;C4019010	\N	\N
1035	patients with event / patients analysed	C0030705;C0441471;C4019010	\N	\N
1035	patients with event / analyzed	C0030705;C0441471;C0936012;C4019010	\N	\N
1035	patients with event ( n  % )	C0030705;C0441471;C4019010	\N	\N
1035	patients with endpoin t  n ( % )	C0030705;C2986835	\N	\N
1035	patients with diabetic nephropathy	C0011881;C0030705;C1442864	\N	\N
1035	patients with diabetesb	C0030705	\N	\N
1035	patients with at least one concomitant disease | |	C0030705;C0205447;C0243087	\N	\N
1035	patients with at least one concomitant disease *	C0030705;C0205447;C0243087	\N	\N
1035	patients with any clinical event	C0030705;C0205210;C0441471;C4019010	\N	\N
1035	patients with any clinical	C0030705;C0205210	\N	\N
1035	patients with > $nmbr$ co - aeds	C0030705;C0180309;C3245499	\N	\N
1035	patients with $nmbr$ co - aeds	C0030705;C0180309;C3245499	\N	\N
1035	patients with $nmbr$ co - aed	C0030705;C0887457;C3245499	\N	\N
1035	patients who used insulin pump	C0030705;C1140609;C1273517	\N	\N
1035	patients who had ulcerations at	C0030705;C0041582	\N	\N
1035	patients who did not use insulin pump	C0030705;C0042153;C0457083;C1140609;C1518422;C1947944	\N	\N
1035	patients treated with statins ( n = $nmbr$ )	C0030705;C0332293;C0360714	\N	\N
1035	patients treated with atenoloi ( n = $nmbr$ )	C0030705;C0332293	\N	\N
1035	patients receiving immunotherapy  no . ( % )	C0005525;C0021083;C0030705;C1514756	\N	\N
1035	patients receiving immunosuppressive agents at baseline	C0021081;C0030705;C0168634;C1442488;C1514756	\N	\N
1035	patients receiving enl  no . ( % )	C0030705;C1514756	\N	\N
1035	patients randomised  n	C0030705;C0369718;C0441922	\N	\N
1035	patients not treated with statins ( n = $nmbr$ )	C0030705;C0332293;C0360714;C1518422	\N	\N
1035	patients not receiving immunosuppressive agents at baseline	C0021081;C0030705;C0168634;C1442488;C1514756;C1518422	\N	\N
1035	patients n	C0030705	\N	\N
1035	patients assessed	C0030705;C1516048	\N	\N
1035	patients > $nmbr$ y *	C0030705	\N	\N
1035	patients > $nmbr$ y	C0030705	\N	\N
1035	patients > $nmbr$ %	C0030705	\N	\N
1035	patients < $nmbr$ y *	C0030705	\N	\N
1035	patients < $nmbr$ y	C0030705	\N	\N
1035	patients < $nmbr$ %	C0030705	\N	\N
1035	patients / events n	C0030705;C0441471;C3541888	\N	\N
1035	patients ( n )	C0030705	\N	\N
1035	patients    n   ( % )	C0030705	\N	\N
1035	patients  no .	C0030705	\N	\N
1035	patients  n / n ( % ) a	C0030705	\N	\N
1035	patients  n ( % )	C0030705	\N	\N
1035	patients  n	C0030705	\N	\N
1035	patients	C0030705	\N	\N
1035	patient presentation	C0030705;C0449450	\N	\N
1035	patient	C0030705	\N	\N
1035	of patients	C0030705	\N	\N
1035	obese patients  ! n ( % )	C0028754;C0030705	\N	\N
1035	nyha class ( when patient was last in stable condition before admission )  %	C0030705;C0184666;C0677946;C0809949;C1517741;C1882083;C3538874	\N	\N
1035	nyha class ( when patient was last in stable condition	C0030705;C0677946;C1517741;C1882083;C3538874	\N	\N
1035	number of events / patients	C0030705;C0441471;C2360800;C3541888;C4330837	\N	\N
1035	no . patients with	C0030705	\N	\N
1035	no . patients ( % )	C0030705	\N	\N
1035	no . of patients with events ( % )	C0030705;C0441471;C3541888	\N	\N
1035	no . of patients with as	C0030705	\N	\N
1035	no . of patients ( % )	C0030705	\N	\N
1035	no . of patients	C0030705	\N	\N
1035	patients with dactylitisa	C0030705	f	492
1035	patients with digits with dactylitis  n ( % )	C0030705;C0239161;C0582802	f	492
1035	no . of hospitalised patients	C0030705	\N	\N
1035	n ( % of patients )	C0030705;C0369718;C0441922	\N	\N
1035	male sex — no . of patients ( % )	C0030705;C0086582	\N	\N
1035	laba use  % patients	C0030705;C0042153;C0457083;C1947944	\N	\N
1035	itt patients  n ( % )	C0030705	\N	\N
1035	intensive control ( n = $nmbr$ ) no . of patients ( percent )	C0030705;C0162425;C0243148;C0439165;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389	\N	\N
1035	for patients using personal cgm	C0030705;C1519021;C1524063	\N	\N
1035	for patients not using personal cgm	C0030705;C1518422;C1519021;C1524063	\N	\N
1035	all randomized patients ( range )	C0030705;C0034656;C1514721;C2348147;C3542016;C3815594	\N	\N
1035	all randomized patients	C0030705;C0034656;C3815594	\N	\N
1035	all patients with opg n - $nmbr$	C0030705;C1262886;C1336645;C1412836;C1710303	\N	\N
1035	all patients with fistulas ( n = $nmbr$ )	C0016169;C0030705	\N	\N
1035	all patients n = $nmbr$ $nmbr$	C0030705	\N	\N
1035	all patients n = $nmbr$	C0030705	\N	\N
1035	all patients ( « = $nmbr$ $nmbr$ )	C0030705	\N	\N
1035	all patients ( p = $nmbr$ . $nmbr$ )	C0030705	\N	\N
1035	all patients ( p < $nmbr$ . $nmbr$ )	C0030705	\N	\N
1035	all patients ( n   =   $nmbr$ ) b	C0030705	\N	\N
1035	all patients ( n = $nmbr$ )	C0030705	\N	\N
1035	all patients ( n = $nmbr$  $nmbr$ )	C0030705	\N	\N
1035	all patients ( n $nmbr$ $nmbr$ )	C0030705	\N	\N
1035	all patients  n =	C0030705	\N	\N
1035	all patients	C0030705	\N	\N
1035	all mn - na ï ve patients	C0026327;C0026405;C0030705;C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882	\N	\N
1035	> $nmbr$ %  n ( % of patients )	C0030705;C0369718;C0441922	\N	\N
1035	( $nmbr$ patients )	C0030705	\N	\N
1035	( $nmbr$ . $nmbr$ % )  values were not collected for $nmbr$ patients ( $nmbr$ . $nmbr$ % ) who were enrolled	C0030705;C0042295;C1516695;C1516698;C1518422;C4684790	\N	\N
1035	% patients with no progression	C0030705;C0242656;C0449258	\N	\N
1035	% patients	C0030705	\N	\N
1035	% of patients $nmbr$ . $nmbr$ $nmbr$ . $nmbr$	C0030705	\N	\N
1035	$nmbr$ %  n ( % of patients )	C0030705;C0369718;C0441922	\N	\N
-10	philippines	C0031529	\N	\N
1033	total no . of events / total no . of participants	C0439175;C0439810;C0441471;C0679646;C3541888	\N	\N
1033	total no . of events / participants	C0439175;C0439810;C0441471;C0679646;C3541888	\N	\N
1033	total no . of events ( % of participants ) / total no . of participants	C0439175;C0439810;C0441471;C0679646;C3541888	\N	\N
1033	peri - operative cabg participants :	C0010055;C0347985;C0679646;C1882154	\N	\N
1033	participants without hf at baseline	C0018488;C0168634;C0679646;C1313497;C1442488;C1538440;C3273279	\N	\N
1033	participants with hf at baseline	C0018488;C0168634;C0679646;C1313497;C1442488;C1538440;C3273279	\N	\N
1033	participants n	C0679646	\N	\N
1033	participants at baseline  n	C0168634;C0679646;C1442488	\N	\N
1033	participants  no . ( % )	C0679646	\N	\N
1033	participants  n	C0679646	\N	\N
1033	participants	C0679646	\N	\N
1033	normal cognitive function ( spmsq < $nmbr$ ) . n - $nmbr$ . $nmbr$ n ( % ) participants with the event of interest	C0009240;C0392335;C0441471;C0679646;C1276356;C4019010;C4050130	\N	\N
1033	nonblack participants	C0679646	\N	\N
1033	no . of participants with events ( % )	C0441471;C0679646;C3541888	\N	\N
1033	no . of participants ( % )	C0679646	\N	\N
1033	no . of participants	C0679646	\N	\N
1033	no . ( % ) of participants	C0679646	\N	\N
1033	n participants	C0369718;C0441922;C0679646	\N	\N
1033	impaired cognitive function ( spmsq > $nmbr$ ) . n - $nmbr$ n ( % ) participants with the event of interest	C0009240;C0221099;C0392335;C0441471;C0543488;C0679646;C4019010;C4050130	\N	\N
1033	characteristics no . of participants	C0679646;C1521970	\N	\N
1033	all participants ^ ^ ( n = $nmbr$ / $nmbr$ )	C0679646	\N	\N
1033	all participants * ( n = $nmbr$ / $nmbr$ )	C0679646	\N	\N
1033	all participants ( n = $nmbr$ )	C0679646	\N	\N
1033	all participants  mm hg : sbp  mean ( sd )	C0085805;C0439475;C0444504;C0679646;C2347634;C2348143;C2699239	\N	\N
1033	all participants	C0679646	\N	\N
1033	$nmbr$ % participants	C0679646	\N	\N
1032	multivitamins	C0301532;C3714835	\N	\N
1032	multivitamin use yes	C0042153;C0301532;C0457083;C1549445;C1705108;C1710701;C1947944	\N	\N
1032	multivitamin use ( current )	C0042153;C0301532;C0457083;C0521116;C1705970;C1947944	\N	\N
1032	multivitamin use	C0042153;C0301532;C0457083;C1947944	\N	\N
1031	sustain $nmbr$ : semaglutide vs . placebo	C0032042;C0443318;C1696465;C1706408;C2732140;C3885068	\N	\N
1031	sustain $nmbr$ : semaglutide vs . iglar	C0443318;C2732140;C3885068	\N	\N
1031	sustain $nmbr$	C0443318;C2732140	\N	\N
1031	sustain	C0443318;C2732140	\N	\N
1031	octave sustain	C0443318;C2732140	\N	\N
1030	mean lixi dose ± sd ( lg / day )	C0023128;C0178602;C0332173;C0439228;C0439505;C0444504;C0694651;C0869039;C1114758;C2347634;C2348143;C2699239	\N	\N
1030	mean ( s . d . ) ldl particle size  nm	C0203634;C0312860;C0444504;C2347634;C2348143;C3641256;C3890923	\N	\N
1030	lixi	\N	\N	\N
1030	ldi - b > $nmbr$ ( n = $nmbr$ )	\N	\N	\N
1030	ldi $nmbr$	\N	\N	\N
1030	ldi  mean [ sd ] b	C0444504;C2347634;C2348143;C2699239	\N	\N
1030	ldi  mean ( sd ) a	C0444504;C2347634;C2348143;C2699239	\N	\N
1029	napsit	\N	\N	\N
1029	mnapsi  mean [ sd ] d	C0444504;C2347634;C2348143;C2699239	\N	\N
1029	mnapsi  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1029	mnapsi	\N	\N	\N
1029	basfi *	\N	\N	\N
1029	basfi  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
1028	apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se )	C0003593;C0023668;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952	\N	\N
1028	apolipoprotein b ^	C0003593	\N	\N
1028	apolipoprotein a - i *	C0085201;C1677784	\N	\N
1028	apolipoprotein a - i	C0085201;C1677784	\N	\N
1028	apolipoprotein a $nmbr$ ( g / l )	C0003592;C0439294;C0456615;C0523508	\N	\N
1028	apolipoprotein a	C0003592;C0523508	\N	\N
1028	apolipoprotein	C0003591	\N	\N
1028	apolipoproiein b ( mij / $nmbr$ )	\N	\N	\N
1028	apolipoproiein a $nmbr$ ( tng / $nmbr$ )	\N	\N	\N
1027	periostin ( ng / ml )	C0219433;C0439275;C1424662;C3812270	\N	\N
1027	periostin	C0219433;C1424662;C3812270	\N	\N
1027	low periostin subgroup (  $nmbr$ ng / ml ) ( n = $nmbr$ )	C0205251;C0219433;C0439275;C1079230;C1424662;C1515021;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223	\N	\N
1026	ulcerative colitis	C0009324	\N	\N
1026	mouth ulceration	C0149745	\N	\N
1026	concomitant medications for ulcerative colitis — no . ( % )	C0009324;C0013227;C0521115;C0802604;C2598133;C4284232	\N	\N
1026	any ulcerative colitis medication	C0009324;C0013227;C3244316;C4284232	\N	\N
1025	penetrating no . of resections  n ( % )	C0015252;C0205321	\N	\N
1025	penetrating disease  %	C0012634;C0205321	\N	\N
1025	penetrating	C0205321	\N	\N
1024	monitoring treatment	C0039798;C0087111;C0150369;C1283169;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
1024	monitoring group ( n = $nmbr$ )	C0150369;C0441848;C1283169	\N	\N
1024	monitoring ( n = $nmbr$ )	C0150369;C1283169	\N	\N
1023	vomiting	C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769	\N	\N
1023	nausea and / or vomiting adverse events	C0027497;C0042963;C0877248;C1705413;C1963179;C1963281;C2984057;C3829611;C3898969;C4084766;C4084767;C4084768;C4084769;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767	\N	\N
1022	use of concomitant lipid - lowering treatment	C0023779;C0039798;C0087111;C0441994;C0521115;C1522326;C1524063;C1533734;C1705169;C2003888;C3538994;C3887704	\N	\N
1022	remodeling	\N	\N	\N
1022	prior urate lowering therapies  n ( % )	C0441994;C0729829;C0935936;C1514463;C2003888	\N	\N
1022	lipid lowering medication use	C0023779;C0240320;C0441994;C2003888	\N	\N
1022	lipid lowering	C0023779;C0441994;C2003888	\N	\N
1022	lipid - lowering	C0023779;C0441994;C2003888	\N	\N
1022	glucose - lowering drug	C0013227;C0017725;C0441994;C1254351;C2003888	\N	\N
1021	stratum i	C0021966;C0221138	\N	\N
1021	revive i	C0021966;C0221138	\N	\N
1021	previous pde $nmbr$ - i therapy  no . ( % )	C0021966;C0039798;C0087111;C0205156;C0221138;C1363945;C1552607	\N	\N
1021	pre - bronchodilator fev i ( l )	C0021966;C0221138;C2599602;C3714541	\N	\N
1021	pde - $nmbr$ i monotherapy	C0021966;C0221138	\N	\N
1021	pde - $nmbr$ i	C0021966;C0221138	\N	\N
1021	other ' i '	C0021966;C0221138	\N	\N
1021	lvef — no . ( % )  i	C0021966;C0221138;C0428772;C0488728	\N	\N
1021	infliiimab i	C0021966;C0221138	\N	\N
1021	i u - uj	C0021966;C0221138;C0439148	\N	\N
1021	i idl cholesterol ( mg / dl )	C0021966;C0123167;C0221138;C0439269;C0523559;C0619865	\N	\N
1021	i amiodarone	C0002598;C0021966;C0221138	\N	\N
1021	i . $nmbr$ i ( $nmbr$ . $nmbr$ - i . $nmbr$ )	C0021966;C0221138	\N	\N
1021	i . $nmbr$ ( $nmbr$ . $nmbr$ - i . $nmbr$ )	C0021966;C0221138	\N	\N
1021	i - ^ w « - i - $nmbr$	C0021966;C0221138	\N	\N
1021	i ( $nmbr$ . i )	C0021966;C0221138	\N	\N
1021	i % $nmbr$	C0021966;C0221138	\N	\N
1021	i $nmbr$ ± i $nmbr$	C0021966;C0221138	\N	\N
1021	i $nmbr$ ± $nmbr$ i	C0021966;C0221138	\N	\N
1021	i $nmbr$ i ± i $nmbr$	C0021966;C0221138	\N	\N
1021	i $nmbr$ i ( i $nmbr$ . $nmbr$ )	C0021966;C0221138	\N	\N
1021	i $nmbr$ i $nmbr$ ± $nmbr$	C0021966;C0221138	\N	\N
1021	i $nmbr$ i	C0021966;C0221138	\N	\N
1021	i $nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$	C0021966;C0221138	\N	\N
1021	i $nmbr$ ( i $nmbr$ . i )	C0021966;C0221138	\N	\N
1021	i $nmbr$ ( i $nmbr$ . $nmbr$ )	C0021966;C0221138	\N	\N
1021	i	C0021966;C0221138	\N	\N
1021	ffa / i	C0015688;C0021966;C0221138	\N	\N
1021	dual i extension - end of trial hba $nmbr$ c	C0008976;C0019016;C0021966;C0205173;C0221138;C0231448;C0444930;C1554184;C1825777;C1880641;C2746065;C3538758	\N	\N
1021	dual i extension	C0021966;C0205173;C0221138;C0231448;C1554184;C1880641	\N	\N
1021	antithrombotic ! i	C0021966;C0221138	\N	\N
1021	albumin - to - creatinine ratio ' i  /	C0021966;C0221138;C0486293;C1318293	\N	\N
1021	> i	C0021966;C0221138	\N	\N
1021	- f $nmbr$ . $nmbr$ ( - i - $nmbr$ . $nmbr$ )	C0016327;C0021966;C0221138	\N	\N
1021	- b - i —	C0021966;C0221138	\N	\N
1021	- b - i -	C0021966;C0221138	\N	\N
1021	$nmbr$ — — bh — i	C0004684;C0004952;C0021966;C0221138;C1412800;C2986890;C4284594;C4321407	\N	\N
1021	$nmbr$ tq - fi ' i	C0021966;C0221138;C3555502;C4050619	\N	\N
1021	$nmbr$ t i	C0021966;C0221138;C2603360	\N	\N
1021	$nmbr$ i $nmbr$ ( $nmbr$ i . $nmbr$ )	C0021966;C0221138	\N	\N
1021	$nmbr$ . i $nmbr$ ( $nmbr$ . $nmbr$ i - $nmbr$ . $nmbr$ )	C0021966;C0221138	\N	\N
1021	$nmbr$ . $nmbr$ to . $nmbr$ . i . iot	C0006196;C0021966;C0221138	\N	\N
1021	$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ) a	C0021966;C0221138	\N	\N
1021	$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ )	C0021966;C0221138	\N	\N
1021	$nmbr$ . $nmbr$ ( i $nmbr$ . s )	C0021966;C0221138	\N	\N
1021	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . i $nmbr$ i )	C0021966;C0221138	\N	\N
1021	$nmbr$ - i	C0021966;C0221138	\N	\N
1021	$nmbr$ ( $nmbr$ i . i )	C0021966;C0221138	\N	\N
1020	trial completers	C0008976	\N	\N
1020	trial $nmbr$	C0008976	\N	\N
1020	trial	C0008976	\N	\N
1020	time in trial	C0008976;C0040223;C0150312;C0332285;C1707101;C3541383	\N	\N
1020	pooled trials * n = $nmbr$	C0008976;C1709595;C2349200;C4522255	\N	\N
1020	non - trial treatment during hospital stay	C0008976;C0039798;C0087111;C1518422;C1522326;C1533734;C1705169;C3489408;C3538994;C3887704	\N	\N
1020	non - trial p blocker	C0008976;C1518422	\N	\N
1009	arial flutter or fibrillation	C0016385;C0232197;C2242390	\N	\N
1020	no in - trial stroke n = $nmbr$  $nmbr$	C0008976;C0038454;C0150312;C0332285;C1707101;C4554100	\N	\N
1020	lipid trial participantss	C0008976;C0023779	\N	\N
1020	lipid trial participantsk	C0008976;C0023779	\N	\N
1020	end of trial	C0008976;C0444930;C2746065	\N	\N
1020	enact - $nmbr$ trial rerandomization to natalizumab ( n = $nmbr$ )	C0008976;C1172734	\N	\N
1020	enact - $nmbr$ trial	C0008976	\N	\N
1020	dual iv - end of trial hba $nmbr$ c	C0008976;C0019016;C0205173;C0444930;C0444972;C1554184;C1825777;C2746065;C3538758	\N	\N
1020	dual ii - end of trial hba $nmbr$ c	C0008976;C0019016;C0205173;C0444930;C0444967;C1554184;C1825777;C2746065;C3538758	\N	\N
1020	completed trial	C0008976;C0205197;C3854010	\N	\N
1020	all trials	C0008976	\N	\N
1019	ure	\N	\N	\N
1019	pre - specified trial endpoints	C0008976;C2349179;C2826245	\N	\N
1019	cure trial	C0008976;C1880198	\N	\N
1018	variables .	C0439828	\N	\N
1018	variables *	C0439828	\N	\N
1018	variables $nmbr$	C0439828	\N	\N
1018	variables	C0439828	\N	\N
1018	variable ' ! '	C0439828;C4553760	\N	\N
1018	variable	C0439828;C4553760	\N	\N
1018	values were calculated using t tests for continuous variables and chi - square	C0042295;C0439828;C0444686;C0549178;C0871472;C1441506;C1524063;C1552646	\N	\N
1018	stratification variables	C0439828;C1514983	\N	\N
1018	diary variables  mean ( sd )	C0376660;C0439828;C0444504;C2347634;C2348143;C2699239	\N	\N
1018	continuous variables  mean ( sd ) ^	C0439828;C0444504;C0549178;C2347634;C2348143;C2699239	\N	\N
1018	continuous variables  mean ( sd )	C0439828;C0444504;C0549178;C2347634;C2348143;C2699239	\N	\N
1018	categorical variables . no . ( % ) * ’	C0439828;C0683312;C3889287	\N	\N
1018	categorical variables	C0439828;C0683312;C3889287	\N	\N
1018	baseline variable	C0168634;C0439828;C1442488;C4553760	\N	\N
1018	adjusted for all baseline variables and interaction between acei and baseline upb	C0168634;C0439828;C0456081;C1442488;C1704675	\N	\N
1018	adjusted for all baseline variables $nmbr$	C0168634;C0439828;C0456081;C1442488	\N	\N
1018	action tested is between the continuous variable and treatment .	C0039798;C0087111;C0392366;C0439828;C0441472;C0549178;C1522326;C1533734;C1705169;C3266814;C3538994;C3887704;C4553760	\N	\N
1017	quintile ( n )	C1508496	\N	\N
1017	quintile $nmbr$ ( $nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ % ) ( n = $nmbr$ )	C1508496	\N	\N
1017	quintile  range  mg / dl	C0439269;C1508496;C1514721;C2348147;C3542016	\N	\N
1017	quicki	\N	\N	\N
1016	suit quartile $nmbr$ ( b $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ )	C1532564;C1533073;C2828255	\N	\N
1016	suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ )	C1532564;C1533073;C2828255	\N	\N
1016	suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ )	C1532564;C1533073;C2828255	\N	\N
1016	estradiol quartiles	C0014912;C2828255	\N	\N
1015	teriparatide n / n ( % )	C0070093	\N	\N
1015	teriparatide ( n   =   $nmbr$ )	C0070093	\N	\N
1015	interquartile range height — cm	C0489786;C1711350	\N	\N
1015	interquartile range	C1711350	\N	\N
1015	bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure	C0004083;C0005767;C0005768;C0005823;C0012000;C0017654;C0018787;C0018810;C0027976;C0033095;C0039155;C0054015;C0085805;C0205088;C0229664;C0237753;C0332126;C0439849;C0449788;C0460139;C0536221;C0596306;C0699792;C1095989;C1271104;C1272641;C1275491;C1305855;C1306345;C1417808;C1424601;C1449832;C1561549;C1705314;C1705315;C1711350;C2982014;C3476086;C3476798;C3813197;C3889152;C4050156;C4281799;C4283901;C4284008;C4284038	\N	\N
1015	* interquartile range	C1711350	\N	\N
1015	( interquartile range ) ( mm )	C1711350;C4330985;C4554674	\N	\N
1014	sleeping problems in the past $nmbr$ weeks ( % )	C0700201;C2987125	\N	\N
1014	restriction in normal activities in the past $nmbr$ weeks	C0443288;C2987125;C4697852	\N	\N
1014	night - time awakenings in past $nmbr$ weeks prior to baseline	C0168634;C0860510;C1442488;C2987125	\N	\N
1014	night - time awakenings in past $nmbr$ weeks ( sd ) *	C0860510;C2699239;C2987125	\N	\N
1014	angina ( past $nmbr$ weeks )	C0002962;C2987125	\N	\N
1013	weekly iss {	C0332174;C1740819;C1845118	\N	\N
1013	weekly iss $nmbr$	C0332174;C1740819;C1845118	\N	\N
1013	weekly	C0332174	\N	\N
1013	patients with weekly iss mid response  n ( % ) v	C0030705;C0332174;C0871261;C1704632;C1706817;C1740819;C1845118;C2911692	\N	\N
1013	median ( $nmbr$ % ci ) time to weekly iss mid response up to week $nmbr$ ( wk ) f	C0008107;C0016327;C0034746;C0332174;C0439230;C0549183;C0876920;C1740819;C1845118;C2347635;C2348144;C2939193;C3259781	\N	\N
1013	change from baseline to week $nmbr$ in weekly iss	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C1740819;C1845118;C4319952	\N	\N
1013	baseline weekly iss	C0168634;C0332174;C1442488;C1740819;C1845118	\N	\N
1012	weeks	C0439230	\N	\N
1012	week   $nmbr$	C0332174;C0439230	\N	\N
1012	week and	C0332174;C0439230	\N	\N
1012	week - $nmbr$ changea	C0332174;C0439230;C4349366	\N	\N
1012	week $nmbr$ — mg / liter ^	C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	week $nmbr$ — mg / liter	C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	week $nmbr$ responders  ( n = $nmbr$ )	C0332174;C0439230	\N	\N
1012	week $nmbr$ overall population	C0032659;C0282416;C0332174;C0439230;C1257890;C1561607	\N	\N
1012	week $nmbr$ outcomes	C0332174;C0439230;C1274040	\N	\N
1012	week $nmbr$ outcome	C0332174;C0439230;C1274040	\N	\N
1012	week $nmbr$ crp	C0332174;C0439230;C3890735;C4048285	\N	\N
1012	week $nmbr$ a	C0332174;C0439230	\N	\N
1012	week $nmbr$ / et	C0040028;C0332174;C0439230	\N	\N
1012	week $nmbr$ - baseline	C0168634;C0332174;C0439230;C1442488	\N	\N
1012	week $nmbr$ * ’ ’	C0332174;C0439230	\N	\N
1012	week $nmbr$ *	C0332174;C0439230	\N	\N
1012	week $nmbr$ ( non - ee responders )	C0332174;C0439230;C1518422	\N	\N
1012	week $nmbr$ ( mmol / l )	C0332174;C0439230;C1532563	\N	\N
1012	week $nmbr$ ( itt population )	C0032659;C0332174;C0439230;C1257890	\N	\N
1012	week $nmbr$ ( geometric mean  cv )	C0332174;C0439230;C2986759;C3538987;C4048877;C4318503	\N	\N
1012	week $nmbr$ ( before ee )	C0332174;C0439230	\N	\N
1012	week $nmbr$ % of patients	C0030705;C0332174;C0439230	\N	\N
1012	week $nmbr$  % ( n ) §	C0332174;C0439230	\N	\N
1012	week $nmbr$  % ( n ) j	C0332174;C0439230	\N	\N
1012	week $nmbr$  % ( n ) ^	C0332174;C0439230	\N	\N
1012	week $nmbr$  % ( n ) * *	C0332174;C0439230	\N	\N
1012	week $nmbr$  % ( n ) $nmbr$	C0332174;C0439230	\N	\N
1012	week $nmbr$  % ( n ) #	C0332174;C0439230	\N	\N
1012	week $nmbr$  % ( n )	C0332174;C0439230	\N	\N
1012	week $nmbr$	C0332174;C0439230	\N	\N
1012	week	C0332174;C0439230	\N	\N
1012	treated patients with baseline and $nmbr$ post - baseline ef ﬁ cacy measurement  bp value for treatment group comparison ( proactive intervention vs usual care ) was calculated based on a $nmbr$ - sample t test for continuous variables and chi - square test for categorical variables  cbp values were measured at baseline ( week $nmbr$ )  whereas information on all of the other variables listed was collected during screening . abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .	C0000723;C0005823;C0008041;C0011849;C0012641;C0018787;C0023822;C0030705;C0034656;C0035647;C0037623;C0039411;C0039798;C0040642;C0041004;C0041405;C0041698;C0042295;C0065055;C0085805;C0087111;C0168634;C0184661;C0201950;C0205251;C0220825;C0220908;C0220909;C0237403;C0242485;C0280604;C0332174;C0332293;C0370003;C0374505;C0428883;C0439230;C0439828;C0441833;C0443252;C0444686;C0444706;C0488055;C0543421;C0549178;C0683312;C0687676;C0687744;C0745732;C0871420;C0871470;C0871472;C0886296;C1149372;C1257890;C1261322;C1273869;C1305855;C1306620;C1330119;C1415692;C1419788;C1441506;C1442488;C1516048;C1516695;C1516698;C1519504;C1522326;C1522609;C1527178;C1533716;C1533734;C1550472;C1552578;C1698960;C1704687;C1705169;C1705428;C1705429;C1705938;C1705981;C1707455;C1708288;C1710031;C1710032;C1710477;C1824670;C1947933;C2347026;C2348164;C2699239;C2986530;C3272378;C3272447;C3274822;C3469826;C3538928;C3538994;C3539643;C3541902;C3542407;C3815594;C3887704;C3887980;C3889287;C3890211;C4048187;C4318478;C4321351;C4522122;C4522223;C4552904	\N	\N
1012	total cholesterol ( week $nmbr$ )	C0201950;C0332174;C0439230;C0543421	\N	\N
1012	tdi total score ( week $nmbr$	C0205976;C0332174;C0439230;C2674784;C2964552;C3714807	\N	\N
1012	tcz - sc $nmbr$ mg every other week ( n = $nmbr$ )	C0024671;C0026410;C0282380;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	sgrq total score ( week	C0332174;C0439230;C2964552	\N	\N
1012	responders of three - item end point at $nmbr$ weeks *	C0205449;C0439230;C1551338;C2349179;C2826544;C4554251	\N	\N
7	p - value ( overall )	C0282416;C1561607;C1709380	\N	\N
7	p - value ( lnteraction )	C1709380	\N	\N
1012	received an oral aha within $nmbr$ weeks prior to screening	C0050451;C0220908;C0220909;C0439230;C0442027;C0772110;C1514756;C1698960;C1710031;C1710032;C1710477;C2348164;C4521986	\N	\N
1012	ratio to baseline in eosinophil count at week $nmbr$  geometric mean ( se on loge scale ) cells / ll	C0007584;C0007634;C0036919;C0168634;C0175659;C0200638;C0332174;C0349674;C0439230;C0456603;C0750879;C1442488;C1547037;C1947916;C2697934;C2986759	\N	\N
1012	randomized  double - blind reversal phase ( baseline = week $nmbr$ )	C0013072;C0034656;C0168634;C0205390;C0332174;C0439230;C0443290;C1442488;C1710475;C3815594	\N	\N
1012	randomised patients with basdai assessment at baseline and week $nmbr$  n	C0168634;C0332174;C0439230;C0679830;C1442488;C1998004	\N	\N
1012	pt baseline ( week $nmbr$ )	C0032743;C0168634;C0332174;C0439230;C0699718;C1442488	\N	\N
1012	proportion of patients in corticosteroid - free clinical remission at week $nmbr$	C0001617;C0030705;C0205210;C0332174;C0332296;C0439230;C0544452;C0687702;C1709707;C1880497;C1996904;C3536709	\N	\N
1012	percent change from baseline at week $nmbr$	C0332174;C0439230;C3272907	\N	\N
1012	patients with dactylitis at week $nmbr$  n ( % )	C0030705;C0239161;C0332174;C0439230	\N	\N
1012	pasi # $nmbr$ at week $nmbr$	C0332174;C0439230;C4528685	\N	\N
1012	p $nmbr$ min twice / week	C0332174;C0369773;C0439230;C0702093;C1524029;C1720725;C1948050;C2603361;C3813700	\N	\N
1012	open - label phase ( baseline = week $nmbr$ )	C0168634;C0205390;C0332174;C0439230;C1442488;C1709323;C1710475	\N	\N
1012	night - time awakenings / week	C0332174;C0439230;C0860510	\N	\N
1012	mtx ≥ $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	mtx £ $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	mtx sio mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1039355;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	mtx exposure ( mg / week )	C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	ixekizumab every $nmbr$ weeks ( n = $nmbr$ )	C0439230;C3489764	\N	\N
1012	habitual fish intake : < $nmbr$ servings / wk ( n = $nmbr$ )	C0205353;C0332174;C0439230;C0556216;C1519269	\N	\N
1012	evaluable for acr $nmbr$ at week $nmbr$  n	C0332174;C0439230;C1412134;C1515941;C1516986	\N	\N
1012	endpoint week $nmbr$	C0332174;C0439230;C2349179;C2826544	\N	\N
1012	dose ratio at week $nmbr$ ( $nmbr$ % cl )	C0178602;C0332174;C0439230;C0456603;C0596019;C0869039;C1114758;C1547037	\N	\N
1012	disease activity outcomes ( itt population ) week $nmbr$	C0032659;C0205177;C0332174;C0439167;C0439230;C0441655;C0679250;C1257890;C1274040;C1292728;C1561536;C3542417;C3668946;C4049938;C4049939	\N	\N
1012	db baseline ( week $nmbr$ )	C0168634;C0332174;C0439230;C1418892;C1442488	\N	\N
1012	daytime symptoms more than twice per week	C0332169;C0332174;C0439230;C0683368;C1457887;C1720725;C1948050	\N	\N
1012	concomitant use of nsaids to week $nmbr$	C0003211;C0332174;C0439230;C0521115;C1524063	\N	\N
1012	complete clinical response at week $nmbr$	C0205197;C0332174;C0439230;C3853530;C4055223;C4283785	\N	\N
1012	clinical efficacy at week $nmbr$	C0087113;C0332174;C0439230	\N	\N
1012	change to   week $nmbr$	C0332174;C0392747;C0439230;C0443172;C1705241;C4319952	\N	\N
996	diabetics ( n = $nmbr$ )	C0241863	\N	\N
1012	ldl particle size ( week $nmbr$ )	C0332174;C0439230;C3641256	f	1068
1012	change to week $nmbr$ *	C0332174;C0392747;C0439230;C0443172;C1705241;C4319952	\N	\N
1012	change to week $nmbr$	C0332174;C0392747;C0439230;C0443172;C1705241;C4319952	\N	\N
1012	change in fev $nmbr$ at week $nmbr$	C0332174;C0392747;C0439230;C0443172;C1705241;C3714541;C4319952	\N	\N
1012	change from baseline to week $nmbr$ in weekly size of largest hive score	C0042109;C0168634;C0221232;C0332174;C0392747;C0439230;C0443172;C0443228;C0449820;C0456389;C1442488;C1705241;C4050231;C4319952	\N	\N
1012	change from baseline to week $nmbr$ in dlqi scorez	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C3899393;C4319952	\N	\N
1012	change from baseline to week $nmbr$	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952	\N	\N
1012	cfb at week $nmbr$	C0009002;C0332174;C0439230;C1824728	\N	\N
1012	calculated ldl cholesterol ( week $nmbr$ )	C0023824;C0202117;C0332174;C0439230;C0444686;C1441506	\N	\N
1012	at weeks $nmbr$ and $nmbr$	C0439230	\N	\N
1012	at week $nmbr$	C0332174;C0439230	\N	\N
1012	at six weeks	C0205452;C0439230	\N	\N
1012	apob ( week $nmbr$ )	C0003593;C0332174;C0439230;C3252643	\N	\N
1012	acr $nmbr$ week $nmbr$ responders  ( n = $nmbr$ )	C0332174;C0439230;C1412134;C1515941	\N	\N
1012	> $nmbr$ weeks	C0439230	\N	\N
1012	> $nmbr$ servings / wk ( n = $nmbr$ )	C0332174;C0439230;C1519269	\N	\N
1012	> $nmbr$ / week	C0332174;C0439230	\N	\N
1012	> $nmbr$ - $nmbr$ mg / week	C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
1012	< $nmbr$ weeks	C0439230	\N	\N
1012	< $nmbr$ week	C0332174;C0439230	\N	\N
1012	- - week $nmbr$ - -	C0332174;C0439230	\N	\N
1012	( week )	C0332174;C0439230	\N	\N
1012	% change from baseline to week $nmbr$	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952	\N	\N
1012	$nmbr$ wk	C0332174;C0439230	\N	\N
1012	$nmbr$ week to $nmbr$ month	C0332174;C0332177;C0439230;C0439231	\N	\N
1012	$nmbr$ week	C0332174;C0439230	\N	\N
1012	$nmbr$ min twice / week	C0332174;C0439230;C0702093;C1524029;C1720725;C1948050;C3813700	\N	\N
1012	$nmbr$ / week ( n = $nmbr$ )	C0332174;C0439230	\N	\N
1012	$nmbr$ / week	C0332174;C0439230	\N	\N
1012	$nmbr$ - wk kaplan - meier rate  %	C0332174;C0439230;C0871208;C1521828	\N	\N
1012	$nmbr$ - $nmbr$ / week ( n = $nmbr$ ) $nmbr$ - $nmbr$ / week ( n = $nmbr$ )	C0332174;C0439230	\N	\N
1012	$nmbr$ - $nmbr$ / week ( n = $nmbr$ )	C0332174;C0439230	\N	\N
1012	$nmbr$ - $nmbr$ / week	C0332174;C0439230	\N	\N
1011	parenteral anticoagulation	C0003281;C0030547;C2917212;C2919015;C3537050;C4522267	\N	\N
1011	intended duration of anticoagulation	C0003281;C0449238;C1283828;C1551357;C2917212;C2919015;C2926735;C3537050	\N	\N
1011	antimalarial	C0003374;C3536844;C4552582	\N	\N
1010	rvalue for interaction	C1704675	\N	\N
1010	rvalue	\N	\N	\N
1010	pvaluefor interaction $nmbr$ - $nmbr$	C1704675	\N	\N
1010	interaction p - valuef	C1704675	\N	\N
1010	interaction j $nmbr$ - valuet	C1704675	\N	\N
1010	interaction : treatment by psoriasis p valueb	C1704675;C3258078	\N	\N
1009	type of atrial fibrillation — no . / total no . ( % )	C0004238;C0332307;C0344434;C0439175;C0439810;C1547052;C1963067	\N	\N
1009	type of atrial fibrillation - n ( % )	C0004238;C0332307;C0344434;C1547052;C1963067	\N	\N
1009	type of atrial fibrillation ( n = $nmbr$ $nmbr$ )	C0004238;C0332307;C0344434;C1547052;C1963067	\N	\N
1009	type of atrial fibrillation ( % )	C0004238;C0332307;C0344434;C1547052;C1963067	\N	\N
1009	type of atrial fibrillation  no . / total no . ( % )	C0004238;C0332307;C0344434;C0439175;C0439810;C1547052;C1963067	\N	\N
1009	type of atrial fibrillation  n ( % )	C0004238;C0332307;C0344434;C1547052;C1963067	\N	\N
1009	type of atrial fibrillation	C0004238;C0332307;C0344434;C1547052;C1963067	\N	\N
1009	rate of atrial fibrillation	C0004238;C0344434;C0871208;C1521828;C1963067	\N	\N
1009	no atrial fibrillation	C0004238;C0344434;C1963067	\N	\N
1009	history of atrial fibrillation / flutter  ( % )	C0016385;C0232197;C0729790;C1998417;C2242390	\N	\N
1009	history of atrial fibrillation / flutter	C0016385;C0232197;C0729790;C1998417;C2242390	\N	\N
1009	first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f	C0004238;C0016327;C0205435;C0332189;C0344434;C0443287;C1279901;C1963067	\N	\N
1009	fibrillation / flutter )	C0016385;C0232197;C2242390	\N	\N
1009	ecg atrial fibrillation  n ( % )	C0004238;C0344434;C1623258;C1963067	\N	\N
1009	duration of last qualifying episode of atrial fibrillation > $nmbr$ days	C0004238;C0332189;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735	\N	\N
1009	current atrial fibrillation or flutter on ecg	C0004238;C0016385;C0344434;C0521116;C1623258;C1705970;C1963067;C2242390	\N	\N
1009	atrial flutter / fibrillation	C0155709	\N	\N
1009	atrial flutter	C0004239;C0344423;C1963068	\N	\N
1009	atrial fibrillation — no . / total no . ( % )	C0004238;C0344434;C0439175;C0439810;C1963067	\N	\N
1009	atrial fibrillation — no . ( % )	C0004238;C0344434;C1963067	\N	\N
1009	atrial fibrillation type  n ( % )	C0004238;C0332307;C0344434;C1547052;C1963067	\N	\N
1009	atrial fibrillation pattern	C0004238;C0344434;C0449774;C1963067	\N	\N
1009	atrial fibrillation or flutter — no . ( % )	C0004238;C0016385;C0344434;C1963067;C2242390	\N	\N
1009	atrial fibrillation or flutter ( ecg ) §	C0004238;C0016385;C0344434;C1623258;C1963067;C2242390	\N	\N
1009	atrial fibrillation or flutter	C0004238;C0016385;C0344434;C1963067;C2242390	\N	\N
1009	atrial fibrillation onset	C0004238;C0206132;C0332162;C0344434;C1963067	\N	\N
1009	atrial fibrillation alone )	C0004238;C0205171;C0344434;C0439044;C0679994;C1963067	\N	\N
1009	atrial fibrillation / flutter  n ( % )	C0155709	\N	\N
1009	atrial fibrillation / flutter	C0155709	\N	\N
1009	atrial fibrillation / atrial flutter  %	C0155709	\N	\N
1009	atrial fibrillation . no . ( % )	C0004238;C0344434;C1963067	\N	\N
1009	atrial fibrillation ( % )	C0004238;C0344434;C1963067	\N	\N
1009	atrial fibrillation !	C0004238;C0344434;C1963067	\N	\N
1009	atrial fibrillation    n   ( % )	C0004238;C0344434;C1963067	\N	\N
1009	atrial fibrillation  n ( % )	C0004238;C0344434;C1963067	\N	\N
1009	atrial fibrillation  %	C0004238;C0344434;C1963067	\N	\N
1009	atrial fibrillation	C0004238;C0344434;C1963067	\N	\N
1009	af or atrial flutter 卞	C0004239;C0344423;C0344434;C1963068;C4049859	\N	\N
1009	af or atrial flutter !	C0004239;C0344423;C0344434;C1963068;C4049859	\N	\N
1009	> $nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo	C0004238;C0026544;C0205156;C0332177;C0332189;C0344434;C1552607;C1963067	\N	\N
1008	naive ( n = $nmbr$ )	\N	\N	\N
1008	iv inotropic drug	C1971835	\N	\N
1008	drug naive	C0013227;C1254351	\N	\N
1007	serum k + level and drug treatment	C0150270;C0302353;C0441889;C0456079;C1547707;C2946261;C3469597	\N	\N
1007	on drug treatment ( % )	C0150270;C3469597	\N	\N
1007	days of study - drug administration ( % ) * * $nmbr$ day	C0150270;C2826182;C3469597	\N	\N
1007	concomitant drug treatment	C0150270;C0521115;C3469597	\N	\N
1007	administration of study drug ( % )	C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1254351;C1533734;C2603343;C3161471;C3469597	\N	\N
1006	stool frequency subscore	C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352	\N	\N
1006	sotalol	C0037707	\N	\N
1006	socalone ( n = $nmbr$ )	\N	\N	\N
1005	symbol digit score	C0449820;C0582802;C0679214;C1698987;C3241971;C4050231	\N	\N
1005	digit symbol substitution	C0582802;C0679214;C1555721;C1698987;C1706204;C3241971	\N	\N
1005	b digit symbol substitution  insulin glargine vs standard care	C0291665;C0582802;C0679214;C0907402;C1442989;C1555721;C1698987;C1706204;C1947933;C2828392;C3241971	\N	\N
1004	total sample = $nmbr$ ( % )	C0370003;C0439175;C0439810;C2347026	\N	\N
1004	sample sizea	C0370003;C2347026	\N	\N
1004	no . of events / sample size i i	C0021966;C0221138;C0370003;C0441471;C0456389;C2347026;C3541888	\N	\N
1004	no . of events / sample size	C0370003;C0441471;C0456389;C2347026;C3541888	\N	\N
1004	atwo ‐ sample t ‐ test .	C0370003;C0871472;C2347026	\N	\N
1003	stable angina — no . ( % )	C0340288	\N	\N
1003	stable angina ( n = $nmbr$  $nmbr$ )	C0340288	\N	\N
1003	stable angina ( n - $nmbr$  $nmbr$ )	C0340288	\N	\N
1003	stable angina  n ( % )	C0340288	\N	\N
1003	stable angina	C0340288	\N	\N
1003	rankin scale ≥ $nmbr$	C0451405	\N	\N
1003	histor y of stable angina	C0340288	\N	\N
1003	chronic stable angina	C0340288	\N	\N
1002	• unstable angina	C0002965	\N	\N
1002	• hospitalization for unstable angina	C0002965;C0019993	\N	\N
1002	urgent revascularization because of unstable angina	C0002965;C0439609;C0581603;C3272275	\N	\N
1002	unstableangina	\N	\N	\N
1002	unstable anginat	C0443343;C1883468	\N	\N
1002	unstable anginad	C0443343;C1883468	\N	\N
1002	unstable angina §	C0002965	\N	\N
1002	unstable angina requiring hospitalization	C0002965;C0019993	\N	\N
1002	unstable angina > $nmbr$ mo ago	C0002965;C0026544;C0332177	\N	\N
1002	unstable angina *	C0002965	\N	\N
1002	unstable angina  n ( % )	C0002965	\N	\N
1002	unstable	C0443343;C1883468	\N	\N
1002	uncodable	\N	\N	\N
1002	hospitalization for unstable angina	C0002965;C0019993	\N	\N
1002	histor y of unstable angina	C0002965	\N	\N
1002	cvd  mi  stroke  or recurrent ischemia - urgent revascularization  or hospitalization for unstable angina	C0002965;C0007222;C0019993;C0022116;C0038454;C0439609;C0581603;C1455761;C2945760;C3272275;C3810814;C4321499;C4554100	\N	\N
1002	* * * unstable angina	C0002965	\N	\N
1001	probable stent thrombosis	C0033204;C0332148;C3897493	\N	\N
1001	probable	C0033204;C0332148	\N	\N
1001	heritable	C0439660	\N	\N
1000	octi & mate $nmbr$	C0682323;C1260875	\N	\N
1000	octi	\N	\N	\N
1000	mate !	C0682323;C1260875	\N	\N
1000	mate	C0682323;C1260875	\N	\N
1000	companion : wake - up stroke	C0031268;C0038454;C0335343;C0682323;C1170730;C4554100	\N	\N
1000	companion : $nmbr$ - $nmbr$ hours	C0031268;C0335343;C0439227;C0682323	\N	\N
999	empty	C1880497	\N	\N
999	corticosteroid - free remissioni	C0001617;C0332296;C1880497;C1996904;C3536709	\N	\N
998	romania	C0035826	\N	\N
998	iief - ef domain score  visit $nmbr$ y	C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231	\N	\N
998	iief - ef domain score  visit $nmbr$ * *	C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231	\N	\N
998	ef domain	C1880389;C1883221;C3541951	\N	\N
998	coumadin	C0699129	\N	\N
998	bilag a  b or c domain score  n ( % )	C0449820;C1440044;C1880389;C1883221;C3541951;C3845933;C4050231	\N	\N
997	other combination	C0205195;C1947911;C3811910	\N	\N
997	medication taken alone or in combination	C0013227;C0205171;C0205195;C0439044;C0679994;C1883727;C1947911;C3244316;C3811910;C4284232	\N	\N
997	continuation ( n = $nmbr$ )	\N	\N	\N
997	continuation	\N	\N	\N
997	combined trials	C0008976;C0205195	\N	\N
997	combined statin and other lipid - lowering agent use	C0042153;C0086440;C0205195;C0360714;C0457083;C1947944	\N	\N
997	combined n = $nmbr$	C0205195	\N	\N
997	combined macro + micro	C0085672;C0205195;C1553035;C2984010;C3811161;C4049106	\N	\N
997	combined insulin / oral hypoglycaemic agent use	C0205195;C0240016;C0359086	\N	\N
997	combined fatal / nonfatal outcomes	C0205195;C0206277	\N	\N
997	combined cvd	C0007222;C0205195	\N	\N
997	combined ( n = $nmbr$ )	C0205195	\N	\N
997	combined $nmbr$ - year cvd	C0007222;C0205195;C0439234;C0439508	\N	\N
997	combined	C0205195	\N	\N
997	combinationf	\N	\N	\N
997	combination - facilitated pci ( n = $nmbr$ )	C0205195;C1947911;C3811910;C4049621	\N	\N
997	combination - facilitated pci ( % )	C0205195;C1947911;C3811910;C4049621	\N	\N
997	combination ( n = $nmbr$ )	C0205195;C1947911;C3811910	\N	\N
997	combination	C0205195;C1947911;C3811910	\N	\N
996	total ! by baseline diabetic status	C0168634;C0241863;C0439175;C0439810;C0449438;C1442488	\N	\N
996	non - diabetics ( n = $nmbr$ )	C0241863;C1518422	\N	\N
996	non - diabetics	C0241863;C1518422	\N	\N
996	non - diabetic subjects  n = $nmbr$	C0241863;C0681850;C1518422;C1550501;C1706203;C2349001;C2697811	\N	\N
996	non - diabetic patients	C0241863;C1829939	\N	\N
996	non - diabetic ( n = $nmbr$ )	C0241863;C1518422	\N	\N
996	non - diabetic	C0241863;C1518422	\N	\N
996	diabetics	C0241863	\N	\N
996	diabeticb	\N	\N	\N
996	diabetic treatments !	C0087111;C0241863	\N	\N
996	diabetic therapy use  n ( % ) * no therapy	C0039798;C0042153;C0087111;C0241863;C0457083;C1363945;C1947944	\N	\N
996	diabetic status  n ( % )	C0241863;C0449438	\N	\N
996	diabetic status	C0241863;C0449438	\N	\N
996	diabetic patients	C0030705;C0241863	\N	\N
996	diabetic participants !	C0241863;C0679646	\N	\N
996	diabetic participants	C0241863;C0679646	\N	\N
996	diabetic no	C0241863	\N	\N
996	diabetic ( no )	C0241863	\N	\N
996	diabetic $nmbr$	C0241863	\N	\N
996	diabetic  n ( % )	C0241863	\N	\N
996	diabetic	C0241863	\N	\N
996	by gfr stratum tor diabetic participants  ml / min per $nmbr$ . $nmbr$ m ’ §	C0017654;C0076836;C0241863;C0369637;C0439445;C0441923;C0679646;C1199517;C1419603;C1424601;C3539732	\N	\N
996	by gfr stratum for diabetic participants  mt / min per $nmbr$ . $nmbr$ m ’ §	C0017654;C0241863;C0369637;C0441923;C0679646;C0702093;C1424601;C1524029;C3813700	\N	\N
996	by baseline diabetic status	C0168634;C0241863;C0449438;C1442488	\N	\N
996	brandomization was stratified by diabetic status .	C0205363;C0241863;C0449438	\N	\N
995	previous oral antidiabetic medication use  n ( % )	C0205156;C0935929;C1527415;C1552607	\N	\N
995	no oral antidiabetic medication	C0175795;C0442027;C0935929;C4521986	\N	\N
995	no antidiabetic drug	C0935929	\N	\N
995	insulin + oral antidiabetic medication ( s )	C0021641;C0175795;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986	\N	\N
995	duration of oral antidiabetic treatment  y  mean ( sd )	C0442027;C0444504;C0444921;C0935929;C2347634;C2348143;C2699239;C4521986	\N	\N
995	antidiabetic medications	C0935929	\N	\N
995	antidiabetic medication | |	C0935929	\N	\N
995	antidiabetic medication	C0935929	\N	\N
995	antidiabetic drug ‘ i “ j ‘	C0021966;C0221138;C0935929	\N	\N
995	antidiabetic drug	C0935929	\N	\N
995	antidiabetic agents	C0935929	\N	\N
995	antidiabetic agent	C0935929	\N	\N
995	antidiabetic	C0935929	\N	\N
995	> $nmbr$ oral antidiabetic medication	C0175795;C0442027;C0935929;C4521986	\N	\N
995	$nmbr$ oral antidiabetic medication	C0175795;C0442027;C0935929;C4521986	\N	\N
994	acitretin	C0050559	\N	\N
993	thiazide diuretics	C0012802	\N	\N
993	thiazide diuretic *	C0012802;C3536861	\N	\N
993	thiazide diuretic	C0012802;C3536861	\N	\N
993	loop or thiazide diuretic ^	C0012802;C0445022;C3536861	\N	\N
993	loop or thiazide diuretic : ! :	C0012802;C0445022;C3536861	\N	\N
993	loop or thiazide diuretic #	C0012802;C0445022;C3536861	\N	\N
993	loop or thiazide diuretic	C0012802;C0445022;C3536861	\N	\N
993	diuretic thiazide	C0012802	\N	\N
993	any thiazide diuretic	C0012802;C3536861	\N	\N
992	randomly assigned to diuretic	C0012798;C1516050;C1552601	\N	\N
992	other diuretic	C0012798	\N	\N
992	no - diuretics group ( n = $nmbr$ )	C0012798;C0441848	\N	\N
992	diuretics group ( n = $nmbr$ )	C0012798;C0441848	\N	\N
992	diuretics ^	C0012798	\N	\N
992	diuretics * *	C0012798	\N	\N
992	diuretics ( % )	C0012798	\N	\N
992	diuretics  n ( % )	C0012798	\N	\N
992	diuretics  %	C0012798	\N	\N
992	diuretics	C0012798	\N	\N
992	diureticff	\N	\N	\N
992	diuretic use at baseline	C0012798;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
992	diuretic use	C0012798;C0042153;C0457083;C1947944	\N	\N
992	diuretic n ( % )	C0012798	\N	\N
992	diuretic drugs ( excluding antialdosterone )	C0012798;C0013227;C0332196;C2828389;C3687832	\N	\N
992	diuretic drugs  n ( % )	C0012798;C0013227;C3687832	\N	\N
992	diuretic drugs	C0012798;C0013227;C3687832	\N	\N
992	diuretic agents ( excluding antialdosterone )	C0012798;C0332196;C0450442;C1254351;C1521826;C2828389	\N	\N
992	diuretic agents	C0012798;C0450442;C1254351;C1521826	\N	\N
992	diuretic agent	C0012798;C0450442;C1254351;C1521826	\N	\N
992	diuretic ( any )	C0012798	\N	\N
992	diuretic	C0012798	\N	\N
992	diurciic	\N	\N	\N
992	cluster $nmbr$ : reversible  no diuretic ( n = $nmbr$ )	C0012798;C0205343;C1555715;C1704332	\N	\N
992	cluster $nmbr$ : diuretic ( n = $nmbr$ )	C0012798;C1555715;C1704332	\N	\N
992	baseiine diuretic	C0012798	\N	\N
991	use of loop diuretics  n ( % )	C0354100;C1524063	\N	\N
991	use of loop diuretics	C0354100;C1524063	\N	\N
991	total intravenous loop diuretics  mg	C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C1960952;C2346927;C4321396;C4521761	\N	\N
991	loop diureties	C0445022	\N	\N
991	loop diuretics	C0354100	\N	\N
991	loop diuretic use	C0042153;C0354100;C0457083;C1947944;C3536704	\N	\N
991	loop diuretic	C0354100;C3536704	\N	\N
991	intravenous loop diuretics !	C0348016;C0354100	\N	\N
990	digital clubbing  n ( % )	C0009080;C0149651	\N	\N
989	previous use of digoxin	C0012265;C0205156;C1524063;C1552607	\N	\N
989	previous digoxin use ( % )	C0012265;C0042153;C0205156;C0457083;C1552607;C1947944	\N	\N
989	previous digoxin use	C0012265;C0042153;C0205156;C0457083;C1552607;C1947944	\N	\N
989	no digoxin scd  no . ( % / y )	C0012265	\N	\N
989	no digoxin n = $nmbr$ $nmbr$ ( $nmbr$ % )	C0012265	\N	\N
989	digoxin or digitalis preparations	C0012265;C0304520	\N	\N
989	digoxin or digitalis preparation	C0012265;C0304520	\N	\N
989	digoxin n = $nmbr$ ( $nmbr$ % )	C0012265	\N	\N
989	digoxin n ( % )	C0012265	\N	\N
989	digoxin at enrollment	C0012265;C1516879;C1696073;C3888021	\N	\N
989	digoxin  n ( % )	C0012265	\N	\N
989	digoxin  ( % )	C0012265	\N	\N
989	digoxin  % ( n )	C0012265	\N	\N
989	digoxin  %	C0012265	\N	\N
991	diureties	\N	f	2312
994	potassium - sparing diuretic	C0304490;C3536751	f	1966
989	digoxin	C0012265	\N	\N
988	item	C1551338;C4554251	\N	\N
988	fasting free fatty acids ( ^ mol / liter )	C0015663;C0015688;C0347982	\N	\N
988	> $nmbr$ ^ mol / liter — no . ( % )	C0347982	\N	\N
987	serum creatinine — pmol / liter	C0201976;C0439192;C0475211;C0600061	\N	\N
987	free fatty acids — mmol / liter	C0015688;C0439190;C0475211	\N	\N
987	> $nmbr$ / tmol / liter — no . ( % )	C0475211	\N	\N
987	> $nmbr$ . $nmbr$ pmol / liter hscrp level	C0439192;C0441889;C0456079;C0475211;C1547707;C2946261	\N	\N
987	> $nmbr$ . $nmbr$ pmol / liter	C0439192;C0475211	\N	\N
987	> $nmbr$ . $nmbr$ mmol / liter	C0439190;C0475211	\N	\N
987	< $nmbr$ . $nmbr$ pmol / liter	C0439192;C0475211	\N	\N
987	< $nmbr$ . $nmbr$ mmol / liter triglyceride level	C0428475;C0439190;C0475211	\N	\N
987	< $nmbr$ . $nmbr$ mmol / liter	C0439190;C0475211	\N	\N
986	d - dimer levelsatinclusion	C0060323	\N	\N
986	d - dimer ( ng / ml )	C0060323;C0439275	\N	\N
985	other / mixed ( n = $nmbr$ )	C0205430;C3160715	\N	\N
985	mixed hispanic	C0086409;C0205430;C3160715	\N	\N
985	mixed ( n = $nmbr$ )	C0205430;C3160715	\N	\N
985	mixed ( itt ) ( n = $nmbr$ )	C0205430;C3160715	\N	\N
985	mixed	C0205430;C3160715	\N	\N
985	lisrs	\N	\N	\N
985	ixeq $nmbr$ w  n = $nmbr$	\N	\N	\N
985	insulin lispro mix $nmbr$ / lispro mix $nmbr$ - insulin glargine / insulin lispro	C0205430;C0293359;C0907402;C1421951;C1720722;C4553942	\N	\N
985	insulin lispro mix $nmbr$	C0205430;C0293359;C1421951;C1720722;C4553942	\N	\N
984	planned conservative therapy subgroup	C0459914;C1079230;C1301732;C1515021	\N	\N
984	observation	C0302523;C0700325;C1964257;C3889687	\N	\N
984	conservative	\N	\N	\N
983	naire can range from $nmbr$ to $nmbr$ for the alternative disability portion and from $nmbr$ to $nmbr$ for the pain portion . scores for the medical outcomes	C0030193;C0040363;C0041260;C0199168;C0205476;C0231170;C0449719;C0449820;C0518090;C1274040;C1514721;C1523987;C1883351;C1962977;C2348147;C2984058;C3542016;C4050231;C4085210;C4085211;C4085212;C4553004;C4554132	\N	\N
983	alternative disability	C0231170;C1523987	\N	\N
982	obstructive subscore	C0549186	\N	\N
982	chronic obstructive pulmonary	C0024109;C0205191;C0549186;C2707265;C2709248;C4522268	\N	\N
981	strategy	C0679199	\N	\N
981	rerapamil - sr strategy ( n = $nmbr$ )	C0679199;C0753208;C1709991;C3813610;C3890900;C3891546	\N	\N
981	planned treatment strategy	C0599880;C0679199	\N	\N
981	intent of conservative strategy  %	C0162425;C0679199;C1283828;C1550453	\N	\N
981	conservative strategy ( n = $nmbr$  $nmbr$ )	C0679199	\N	\N
981	atenolol strategy ( n = $nmbr$ )	C0004147;C0679199	\N	\N
981	atenolol strategy ( n = $nmbr$  $nmbr$ )	C0004147;C0679199	\N	\N
981	atenolol strategy	C0004147;C0679199	\N	\N
980	stating	C1301808;C1442792;C3148680	\N	\N
980	state	C1301808;C1442792;C3148680	\N	\N
980	ipeated - measures state examinatioi	C0079809;C1301808;C1442792;C1879489;C3148680	\N	\N
980	disease characteristics  n ( % )  unless otherwise stated	C0599878;C1301808;C1442792	\N	\N
979	laboratory measurements	C0681902	\N	\N
979	laboratory examination	C0260877	\N	\N
979	clinical and laboratory measurements	C0205210;C0681902	\N	\N
979	catscorecategory  n ( % )	\N	\N	\N
978	symptom onset to arrival in catheterization laboratory	C0007430;C0022877;C1555577;C1706079;C3244292;C4086878;C4283904	\N	\N
978	randomization to arrival in catheterization laboratory	C0007430;C0022877;C0034656;C1555577;C1706079;C3244292;C4283904	\N	\N
978	laboratory variables at baseline	C0022877;C0168634;C0439828;C1442488;C3244292;C4283904	\N	\N
978	laboratory variables	C0022877;C0439828;C3244292;C4283904	\N	\N
978	laboratory values at admission ( median and iqr )	C0022877;C0042295;C0184666;C0549183;C0809949;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904	\N	\N
978	laboratory values	C0022877;C0042295;C3244292;C4283904	\N	\N
978	laboratory measures	C0022877;C0079809;C0242485;C1879489;C3244292;C4283904	\N	\N
978	laboratory evaluations	C0022877;C0220825;C3244292;C4283904	\N	\N
978	laboratory determinations	C0022877;C0680730;C3244292;C4283904	\N	\N
978	dbp > $nmbr$ or sbp > $nmbr$ mm hg laboratory determinations	C0022877;C0085805;C0439475;C0536221;C0680730;C3244292;C3813197;C4281799;C4283904	\N	\N
978	catheterization laboratory in center	C0007430;C0022877;C0205099;C3244292;C4283904;C4534362	\N	\N
978	catheterization laboratory in	C0007430;C0022877;C3244292;C4283904	\N	\N
978	baseline laboratory values  median ( iqr ) d	C0022877;C0042295;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C3244292;C4283904	\N	\N
977	inspiratory capacity ( l )	C0021610;C0802663	\N	\N
977	chronic respiratory failure	C0264492	\N	\N
977	acute respiratory insufficiency	C0865850	\N	\N
976	respiratory medication ( % )	C0418986	\N	\N
976	previous medication for respiratory disease — no . ( % )	C0012634;C0013227;C0035204;C0035242;C0205156;C0418986;C1552607;C3244316;C4284232	\N	\N
976	( b ) concomitant respiratory medications [ n ( % ) ]	C0418986;C0521115	\N	\N
975	unadjusted hazard ratio ( $nmbr$ % cl )	C0596019;C1439367;C2985465	\N	\N
975	unadjusted hazard ratio ( $nmbr$ % ci )	C0008107;C1439367;C2985465;C3259781	\N	\N
987	serum potassium — mmol / liter	C0302353;C0439190;C0475211;C0543465	f	1959
987	serum potassium 一 mmol / liter	C0302353;C0439190;C0475211;C0543465	f	1959
987	fasting blood glucose — mmol / liter	C0428568;C0439190;C0475211;C1261430	f	1960
987	serum cholesterol — mmol / liter	C0439190;C0475211;C0587184	f	1501
987	serum sodium — mmol / liter	C0439190;C0475211;C0523891	f	1379
987	fasting plasma glucose — mmol / liter	C0015663;C0202042;C0439190;C0455280;C0475211	f	1960
975	selexipag vs placebo hazard ratio ( $nmbr$ % cl )	C0032042;C0596019;C1696465;C1706408;C2000145;C2985465	\N	\N
975	hazard ratio with low ( $nmbr$ % cl )	C0205251;C0596019;C1550472;C2985465;C3890211;C4048187;C4321351;C4522223	\N	\N
975	hazard ratio with high ( $nmbr$ % cl )	C0205250;C0596019;C1299351;C2700149;C2985465;C3887512;C3889660;C4321237;C4522209	\N	\N
975	hazard ratio with	C2985465	\N	\N
975	hazard ratio vs . placebo	C0032042;C1696465;C1706408;C2985465	\N	\N
975	hazard ratio for event ( $nmbr$ % ci )	C0008107;C0441471;C2985465;C3259781;C4019010	\N	\N
975	hazard ratio and $nmbr$ % confidence interval	C0009667;C2985465	\N	\N
975	hazard ratio [ $nmbr$ % cl ]	C0596019;C2985465	\N	\N
975	hazard ratio [ $nmbr$ % ci ]	C0008107;C2985465;C3259781	\N	\N
975	hazard ratio * ( and $nmbr$ % ci )	C0008107;C2985465;C3259781	\N	\N
975	hazard ratio ( $nmbr$ % confidence interval ) *	C0009667;C2985465	\N	\N
975	hazard ratio ( $nmbr$ % confidence interval )	C0009667;C2985465	\N	\N
975	hazard ratio ( $nmbr$ % cl ]	C0596019;C2985465	\N	\N
975	hazard ratio ( $nmbr$ % cl ) nateglinide vs . placebo	C0032042;C0596019;C0903898;C1696465;C1706408;C2985465	\N	\N
975	hazard ratio ( $nmbr$ % cl ) *	C0596019;C2985465	\N	\N
975	hazard ratio ( $nmbr$ % cl ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )	C0596019;C2985465	\N	\N
975	hazard ratio ( $nmbr$ % cl )	C0596019;C2985465	\N	\N
975	hazard ratio ( $nmbr$ % ci ) vs . placebo	C0008107;C0032042;C1696465;C1706408;C2985465;C3259781	\N	\N
975	hazard ratio ( $nmbr$ % ci ) for adjudicated type $nmbr$ diabetes	C0008107;C1320657;C2985465;C3259781	\N	\N
975	hazard ratio ( $nmbr$ % ci ) - j -	C0008107;C2985465;C3259781	\N	\N
975	hazard ratio ( $nmbr$ % ci ) *	C0008107;C2985465;C3259781	\N	\N
975	hazard ratio ( $nmbr$ % c	C2985465	\N	\N
975	hazard ratio $nmbr$ )	C2985465	\N	\N
975	hazard ratio $nmbr$	C2985465	\N	\N
975	hazard ratio  umec / vi vs . tio ( $nmbr$ % ci )	C0008107;C0205999;C2985465;C3259781	\N	\N
975	hazard ratio	C2985465	\N	\N
975	hazard . ratio . ( $nmbr$ % ci ) . . . . . . . . . .	C0008107;C2985465;C3259781	\N	\N
975	genotype - specific treatment effect hazard ratio ( $nmbr$ % ci )	C0008107;C0017431;C0205369;C1518681;C1552740;C2985465;C3259781	\N	\N
975	adjusted ⁎ hazard ratio ( $nmbr$ % ci )	C0008107;C0456081;C2985465;C3259781	\N	\N
975	adjusted hazard ratio ≠ ( $nmbr$ % ci )	C0008107;C0456081;C2985465;C3259781	\N	\N
975	adjusted hazard ratio ‡ ( $nmbr$ % ci )	C0008107;C0456081;C2985465;C3259781	\N	\N
975	adjusted hazard ratio § ( $nmbr$ % ci )	C0008107;C0456081;C2985465;C3259781	\N	\N
975	adjusted hazard ratio *	C0456081;C2985465	\N	\N
975	adjusted hazard ratio ( $nmbr$ % cl ) *	C0456081;C0596019;C2985465	\N	\N
975	adjusted hazard ratio ( $nmbr$ % ci ) †	C0008107;C0456081;C2985465;C3259781	\N	\N
975	adiusted hazard ratio *	C2985465	\N	\N
974	ratet n ( % )	\N	\N	\N
974	ratet ( $nmbr$ % cl )	C0596019	\N	\N
974	ratet	\N	\N	\N
974	odds ratio and $nmbr$ % cl	C0028873;C0596019	\N	\N
974	odds ratio adj ( $nmbr$ % cl )	C0001552;C0028873;C0596019;C2826286	\N	\N
974	odds ratio ( $nmbr$ % cl )	C0028873;C0596019	\N	\N
973	waisthip ratio	C0205682;C0456603;C1547037	\N	\N
973	ratio	C0456603;C1547037	\N	\N
973	rate ratio { $nmbr$ % cl )	C0456603;C0596019;C0871208;C1521828;C1547037	\N	\N
973	rate ratio mepo / pbo ( $nmbr$ % ci )	C0008107;C0031962;C0456603;C0871208;C1521828;C1547037;C3259781	\N	\N
973	rate ratio ( $nmbr$ % cl )	C0456603;C0596019;C0871208;C1521828;C1547037	\N	\N
973	rate ratio ( $nmbr$ % ci )	C0008107;C0456603;C0871208;C1521828;C1547037;C3259781	\N	\N
973	rate ratio	C0456603;C0871208;C1521828;C1547037	\N	\N
973	pepsinogen i / ii ratio	C0030915;C0456603;C0523817;C1547037	\N	\N
973	iglarlixi ( n   =   $nmbr$ )	\N	\N	\N
973	iglarlixi ( fixed - ratio combination )	C0205195;C0443218;C0456603;C1547037;C1947911;C2827483;C3714578;C3811910	\N	\N
973	iglarlixi	\N	\N	\N
973	hzard ratio	C0456603;C1547037	\N	\N
973	hscrp ( post - baseline / baseline ratio )  ls mean   ±   se	C0023668;C0036919;C0168634;C0444504;C0456603;C0687676;C1442488;C1547037;C1704687;C2347634;C2348143;C3469826	\N	\N
973	e / a ratio	C0456603;C1547037	\N	\N
973	cardiothoracic ratio > $nmbr$ . $nmbr$	C0456603;C1547037;C4055270	\N	\N
973	cardiothoracic ratio	C0456603;C1547037;C4055270	\N	\N
972	multiple ( $nmbr$ + ) chd risk	C0439064;C1282512	\N	\N
972	chda	\N	\N	\N
972	chd risk equivalents  n ( % )	C0439185;C1282512;C4049980	\N	\N
970	repaired chd	C0205340;C0280604;C3542407	\N	\N
970	other chd	C0280604;C3542407	\N	\N
971	vhd	\N	f	-10
971	c  right - sided vhd ( n = $nmbr$ )	C0205090;C0444532	f	-10
970	no chd simva ( „ = $nmbr$ )	C0280604;C3542407	\N	\N
970	no chd simva ( n = $nmbr$ ]	C0280604;C3542407	\N	\N
970	no chd simva	C0280604;C3542407	\N	\N
970	no chd eze / simva ( n = $nmbr$ )	C0280604;C3542407	\N	\N
970	no chd eze / simva $nmbr$ = $nmbr$ }	C0280604;C3542407	\N	\N
970	no chd eze / simva	C0280604;C3542407	\N	\N
970	no chd at baseline	C0168634;C0280604;C1442488;C3542407	\N	\N
970	no chd	C0280604;C3542407	\N	\N
970	known chd	C0205309;C0280604;C3542407	\N	\N
970	history ot chd  n ( % )	C0019664;C0019665;C0262512;C0262926;C0280604;C1318464;C1418208;C1705255;C1705587;C2004062;C3542407	\N	\N
970	history ol chd at baselines	C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407	\N	\N
970	history of chd at baseline §	C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1442488;C1705255;C2004062;C3542407	\N	\N
970	history of chd at baseline d  g	C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C0439267;C1442488;C1705255;C2004062;C3542407	\N	\N
970	history of chd at baseline  no . ( % )	C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1442488;C1705255;C2004062;C3542407	\N	\N
970	history of chd at baseline	C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1442488;C1705255;C2004062;C3542407	\N	\N
970	history of chd  n ( % )	C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407	\N	\N
970	history of chd	C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407	\N	\N
970	history chd	C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407	\N	\N
970	family history ot chd  n ( % )	C0241889;C0280604;C1318464;C1418208;C1705587;C3542407	\N	\N
970	combined chd	C0205195;C0280604;C3542407	\N	\N
970	chd status §	C0280604;C0449438;C3542407	\N	\N
970	chd status	C0280604;C0449438;C3542407	\N	\N
970	chd simva ( „ = $nmbr$ )	C0280604;C3542407	\N	\N
970	chd simva $nmbr$ = $nmbr$ ]	C0280604;C3542407	\N	\N
970	chd simva	C0280604;C3542407	\N	\N
970	chd risk - no . ( % )	C0035647;C0280604;C3542407;C4552904	\N	\N
970	chd history  n ( % )	C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407	\N	\N
970	chd eze / simva ( „ = $nmbr$ )	C0280604;C3542407	\N	\N
970	chd eze / simva ( n = $nmbr$ ]	C0280604;C3542407	\N	\N
970	chd eze / simva	C0280604;C3542407	\N	\N
970	chd disease death	C0011065;C0012634;C0280604;C1306577;C3542407;C4082313;C4552775	\N	\N
970	chd deaths	C0011065;C0280604;C1306577;C3542407	\N	\N
970	chd death	C0011065;C0280604;C1306577;C3542407;C4082313;C4552775	\N	\N
970	chd at baseline	C0168634;C0280604;C1442488;C3542407	\N	\N
970	chd + cl all	C0280604;C0596019;C3542407	\N	\N
970	chd *  n ( % )	C0280604;C3542407	\N	\N
970	chd  total	C0280604;C0439175;C0439810;C3542407	\N	\N
970	chd  n ( % )	C0280604;C3542407	\N	\N
970	chd	C0280604;C3542407	\N	\N
970	> $nmbr$ mg / dl chd status	C0280604;C0439269;C0449438;C3542407	\N	\N
970	* p < $nmbr$ . $nmbr$ for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease	C0009247;C0012634;C0018787;C0023189;C0039798;C0074554;C0087111;C0178602;C0280604;C0369773;C0439751;C0444504;C0444667;C0445247;C0599755;C0869039;C1114758;C1142985;C1511726;C1522326;C1533734;C1705169;C1705241;C1705242;C1710181;C2347634;C2348143;C2603361;C3245479;C3538994;C3542407;C3714741;C3887704	\N	\N
969	chlor	C0308648	\N	\N
969	chl	C0019829	\N	\N
969	aml vs . chl	C0019829;C0023465;C0023467	\N	\N
968	charm	C0849759	\N	\N
968	chajdsj - vasc > $nmbr$	\N	\N	\N
968	chajdsj - vasc $nmbr$ - $nmbr$	\N	\N	\N
968	chajdsa - vasc $nmbr$ - $nmbr$	\N	\N	\N
968	cha $nmbr$ ds $nmbr$ vasc score ( % )	C0449820;C1420648;C3714751;C4050231	\N	\N
968	cha $nmbr$ ds $nmbr$ vasc score	C0449820;C1420648;C3714751;C4050231	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc score ( median  iqr )	C0449820;C0549183;C0876920;C1420648;C2347635;C2348144;C2939193;C3714751;C4050231	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc score    n   ( % )	C0449820;C1420648;C3714751;C4050231	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc score  mean ± sd	C0444504;C0449820;C1420648;C2347634;C2348143;C2699239;C3714751;C4050231	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc score	C0449820;C1420648;C3714751;C4050231	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc > $nmbr$	C1420648;C3714751	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc < $nmbr$	C1420648;C3714751	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc $nmbr$ - $nmbr$	C1420648;C3714751	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc $nmbr$ $nmbr$	C1420648;C3714751	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc $ $nmbr$	C1420648;C3714751	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc # $nmbr$	C1420648;C3714751	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc  mean ± sd	C0444504;C1420648;C2347634;C2348143;C2699239;C3714751	\N	\N
968	cha $nmbr$ ds $nmbr$ - vasc	C1420648;C3714751	\N	\N
968	baseline cha $nmbr$ ds $nmbr$ - vascb  c	C0168634;C1420648;C1442488;C3714751	\N	\N
967	without ckd ( $nmbr$ )	C1561643	\N	\N
967	with ckd standard ( n = $nmbr$ )	C1442989;C1561643;C2828392	\N	\N
967	with ckd intensive ( n = $nmbr$ )	C0162425;C0522510;C1283828;C1550453;C1561643	\N	\N
967	with ckd ( $nmbr$ )	C1561643	\N	\N
967	stage > $nmbr$ chronic kidney disease ( % )	C0205390;C1300072;C1306673;C1561643;C4553188	\N	\N
967	no moderate ckd	C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
967	no ckd rate ( # events )	C0441471;C0871208;C1521828;C1561643;C3541888	\N	\N
967	no ckd n	C1561643	\N	\N
967	no ckd ( % )	C1561643	\N	\N
967	no ckd	C1561643	\N	\N
967	no - ckd standard ( n = $nmbr$ )	C1442989;C1561643;C2828392	\N	\N
967	no - ckd intensive ( n = $nmbr$ )	C0162425;C0522510;C1283828;C1550453;C1561643	\N	\N
967	moderate ckd at randomization	C0034656;C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
967	moderate ckd	C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
967	gfr ( ckd - epi )	C0017654;C0162734;C1424601;C1561643;C4281721	\N	\N
967	cvd  ckd	C0007222;C1561643	\N	\N
967	ckdc  n ( % )	\N	\N	\N
960	p blockers	C0369773;C2603361	\N	\N
967	ckd rate ( # events )	C0441471;C0871208;C1521828;C1561643;C3541888	\N	\N
967	ckd prognosis by kdigo ' '	C0033325;C1561643;C3854082	\N	\N
967	ckd n	C1561643	\N	\N
967	ckd at baseline	C0168634;C1442488;C1561643	\N	\N
967	ckd *	C1561643	\N	\N
967	ckd  n ( % ) t	C1561643	\N	\N
967	ckd	C1561643	\N	\N
967	chronic renal insufficiency  %	C0403447;C1561643	\N	\N
967	chronic renal insufficiency	C0403447;C1561643	\N	\N
967	chronic renal failure  n ( % )	C0022661;C1561643;C2316810	\N	\N
967	chronic renal failure	C0022661;C1561643;C2316810	\N	\N
967	chronic renal disease — no . ( % )	C0022661;C1561643	\N	\N
967	chronic renal disease	C0022661;C1561643	\N	\N
967	chronic kidney disease †	C1561643;C4553188	\N	\N
967	chronic kidney disease ( % )	C1561643;C4553188	\N	\N
967	chronic kidney disease  no . ( % ) t	C1561643;C2603360;C4553188	\N	\N
967	chronic kidney disease  n ( % )	C1561643;C4553188	\N	\N
967	chronic kidney disease	C1561643;C4553188	\N	\N
967	change from baseline stage $nmbr$ ckd	C0168634;C0597205;C0679846;C1442488;C1561643	\N	\N
967	baseline - ckd - epi	C0162734;C0168634;C1442488;C1561643;C4281721	\N	\N
966	non - black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ )	C0005680;C1518422;C2699257;C3891295;C4551874	\N	\N
966	non - black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ )	C0005680;C1518422;C2699257;C3891295;C4551874	\N	\N
966	non - black race ( n = $nmbr$ vs $nmbr$ )	C0005680;C1518422	\N	\N
966	non - black	C0005680;C0027567;C0085756;C0439541;C1518422	\N	\N
966	blaic > $nmbr$ . $nmbr$ %	\N	\N	\N
966	blaic < $nmbr$ . $nmbr$ %	\N	\N	\N
966	blaek / afriean - ameriean	\N	\N	\N
966	blaek	\N	\N	\N
966	black race — no . / total no . ( % ) f	C0005680;C0016327;C0027567;C0034510;C0085756;C0439175;C0439541;C0439810;C1706779;C3853635	\N	\N
966	black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ )	C0005680;C2699257;C3891295;C4551874	\N	\N
966	black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ) ■ -	C0005680;C2699257;C3891295;C4551874	\N	\N
966	black race ( n = $nmbr$ vs $nmbr$ )	C0005680	\N	\N
966	black race  n ( % )	C0005680	\N	\N
966	black race	C0005680	\N	\N
966	black and other	C0005680;C0027567;C0085756;C0439541	\N	\N
966	black / african	C0337824	\N	\N
966	black /	C0005680;C0027567;C0085756;C0439541	\N	\N
966	black ( n = $nmbr$ )	C0005680;C0027567;C0085756;C0439541	\N	\N
966	$nmbr$ fe black *	C0005680;C0027567;C0085756;C0439541;C3848561	\N	\N
965	locf )	C2825507	\N	\N
965	left bundle - branch block	C0023211;C0344420;C2828132	\N	\N
965	bundle branch block	C0006384;C1879286	\N	\N
965	$nmbr$ locf )	C2825507	\N	\N
964	patients receiving lcz  no . ( % )	C0030705;C1514756	\N	\N
964	lcz $nmbr$ treatment  n ( % )	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
964	lcz $nmbr$ ( n = $nmbr$ )	\N	\N	\N
964	lcz $nmbr$	\N	\N	\N
964	lce  n = $nmbr$	C1423759;C3273355	\N	\N
963	β - blocker	\N	\N	\N
963	| ? > - blocker ( n  % )	\N	\N	\N
963	| ? ) - blocker  %	\N	\N	\N
963	renin - angiotensin - aldosterone system blocker	C0086907	\N	\N
963	b - blockers	\N	\N	\N
963	angiotensin receptor blocker yes	C0034787;C1549445;C1622222;C1705108;C1710701	\N	\N
963	angiotensin receptor blocker and / or ace	C0034787;C1452534;C1622222;C4284014	\N	\N
963	angiotensin receptor blocker	C0034787;C1622222	\N	\N
963	angiotensin - receptor blocker	C0034787;C1622222	\N	\N
963	angiotensin - converting enzyme or angiotensin receptor blocker	C0022709;C0034787;C1452534;C1622222	\N	\N
963	angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population )	C0003015;C0032659;C0034787;C0042153;C0457083;C1257890;C1622222;C1947944;C2757044;C3536837;C4541021	\N	\N
963	angiotensin - converting enzyme inhibitor or angiotensin receptor blocker	C0003015;C0034787;C1622222;C2757044;C3536837;C4541021	\N	\N
963	angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §	C0003015;C0034787;C1622222;C2757044;C3536837;C4541021	\N	\N
963	aldosterone blockers	C0002006	\N	\N
963	aldosterone blocker  %	C0002006	\N	\N
963	aldosterone blocker	C0002006	\N	\N
963	ace - i or angiotensin receptor blocker	C0021966;C0034787;C0221138;C1452534;C1622222;C4284014	\N	\N
963	/ $nmbr$ - blocker	\N	\N	\N
963	( i - blocker	C0021966;C0221138	\N	\N
963	( a blocker	\N	\N	\N
963	( $nmbr$ - blocker	\N	\N	\N
963	$nmbr$ blocker before admission	C0184666;C0809949	\N	\N
962	receptor blockers  n ( % ) baseline lipid and apolipoprotein levels	C0003591;C0023779;C0168634;C0441889;C0597357;C1442488	\N	\N
962	receptor blockers  n ( % )	C0597357	\N	\N
962	receptor blockers	C0597357	\N	\N
962	receptor blocker	C0597357	\N	\N
962	angiotensin - converting enzyme inhibitors / angiotensin receptor blockers	C0003015;C0597357;C2757044	\N	\N
962	and either an ace inhibitor or angiotension receptor blocker	C0003015;C0597357;C3844638;C4541021	\N	\N
962	$nmbr$ blockers	\N	\N	\N
962	$nmbr$ - blockers	\N	\N	\N
961	no . previous alpha - blocker use	C0001641;C0042153;C0205156;C0457083;C1552607;C1947944	\N	\N
961	alpha blockers	C0001641	\N	\N
961	alpha - blockers	C0001641	\N	\N
961	alpha - blocker	C0001641	\N	\N
961	alpha $nmbr$ blockers	C0001641	\N	\N
961	a - blockers	\N	\N	\N
960	β - blockers	\N	\N	\N
960	without p blockers	C0369773;C2603361	\N	\N
960	with p blockers	C0369773;C2603361	\N	\N
960	randomly assigned to calcium channel blocker	C0006684;C1516050;C1552601;C3536851;C4521885	\N	\N
960	p blockers ( % )	C0369773;C2603361	\N	\N
960	p blocker *	C0369773;C2603361	\N	\N
960	p - blockers ( % )	C0369773;C2603361	\N	\N
960	p - blockers  n ( % )	C0369773;C2603361	\N	\N
960	p - blockers	C0369773;C2603361	\N	\N
960	p - blocker yes	C0369773;C1549445;C1705108;C1710701;C2603361	\N	\N
960	p - blocker ( % )	C0369773;C2603361	\N	\N
960	j $nmbr$ - blocker  % ( n )	\N	\N	\N
960	apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [ standard deviation for medians calculated by ( q $nmbr$ q $nmbr$ ) / $nmbr$ . $nmbr$ ] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .	C0001645;C0003195;C0003591;C0003594;C0006684;C0008377;C0011849;C0012634;C0012798;C0017977;C0018787;C0023821;C0023824;C0035096;C0039411;C0040642;C0041004;C0041405;C0041698;C0042295;C0042402;C0079613;C0201950;C0202117;C0332257;C0428473;C0439070;C0439294;C0441885;C0444686;C0450442;C0456615;C0543421;C0549183;C0871420;C0876920;C1254351;C1273517;C1319793;C1441506;C1521826;C1521827;C1522601;C1552866;C1704930;C1705160;C1824670;C1869853;C2347635;C2348144;C2698967;C2700399;C2757014;C2939193;C2984247;C3272447;C3541930;C3715113;C3812761;C3890007;C4048375;C4522122	\N	\N
960	( e - blocker	\N	\N	\N
960	( : > blockers	\N	\N	\N
959	β ‐ blocker	\N	\N	\N
959	β blockers	\N	\N	\N
959	β blocker	\N	\N	\N
959	without beta blocker	C0001645	\N	\N
959	with beta blocker	C0001645	\N	\N
959	use of beta - blockers	C0001645;C1524063	\N	\N
959	use of beta - blocker	C0001645;C1524063	\N	\N
959	peri - op beta - blockers : no ( n = $nmbr$ )	C0001645;C0347985;C0369718;C0441922	\N	\N
959	no betablocker use	C0001645;C0042153;C0457083;C1947944	\N	\N
959	blocker	\N	\N	\N
959	betablocker use	C0001645;C0042153;C0457083;C1947944	\N	\N
959	betablocker	C0001645	\N	\N
959	beta blockers	C0001645	\N	\N
959	beta blocker users	C0001645;C1706077	\N	\N
959	beta blocker use ( % )	C0001645;C0042153;C0457083;C1947944	\N	\N
959	beta blocker use	C0001645;C0042153;C0457083;C1947944	\N	\N
959	beta blocker  n ( % )	C0001645	\N	\N
959	beta blocker  %	C0001645	\N	\N
959	beta blocker	C0001645	\N	\N
959	beta - blockers through hospital discharge or day $nmbr$ — %	C0001645;C0332173;C0439228;C0439505;C0586003	\N	\N
959	beta - blockers ( all )  n ( % )	C0001645;C0369718;C0441922	\N	\N
959	beta - blockers  n ( % )	C0001645	\N	\N
959	beta - blockers  ( % )	C0001645	\N	\N
959	beta - blockers	C0001645	\N	\N
959	beta - blocker — no . / total no . ( % )	C0001645;C0439175;C0439810	\N	\N
959	beta - blocker use at randomization	C0001645;C0034656;C0042153;C0457083;C1947944	\N	\N
959	beta - blocker use at baseline	C0001645;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
959	beta - blocker use	C0001645;C0042153;C0457083;C1947944	\N	\N
959	beta - blocker n ( % )	C0001645	\N	\N
959	beta - blocker at last follow - up |	C0001645;C0589120;C1522577;C1704685;C3274571	\N	\N
959	beta - blocker at enrollment	C0001645;C1516879;C1696073;C3888021	\N	\N
959	beta - blocker ( except sotalol )	C0001645;C0037707	\N	\N
959	beta - blocker % target dose	C0001645;C0178602;C0869039;C1114758;C1521840;C2986546	\N	\N
959	beta - blocker !	C0001645	\N	\N
959	beta - blocker  %	C0001645	\N	\N
959	beta - blocker	C0001645	\N	\N
959	beta - adrenergic blocker	C0001645;C2757061;C3536830	\N	\N
959	b - blockers  n ( % )	\N	\N	\N
958	tdi e ' ( septal ) ( cm / sec )	C0205976;C0439392;C0442004;C2674784;C3714807	\N	\N
958	ae ' ( per cm / s )	C0439392;C3887670	\N	\N
957	om $nmbr$ /	C0028971;C1705272	\N	\N
957	new om	C0028971;C0205314;C1705272	\N	\N
957	- ° - $nmbr$  wom -	\N	\N	\N
956	triglycerides  mmolt $nmbr$ ( gm * )	C0017480;C0041004;C3854019	\N	\N
956	lgm ( n = $nmbr$ )	\N	\N	\N
956	im on ] y	\N	\N	\N
956	igm ( n = $nmbr$ )	C1706005	\N	\N
956	igm	\N	\N	\N
956	gm	C0017480;C3854019	\N	\N
956	bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom $nmbr$ h urine was collected ( see materials and methods section ) .	C0002778;C0017480;C0025663;C0025664;C0030705;C0033727;C0039155;C0042036;C0042037;C0042295;C0042789;C0085805;C0152060;C0369286;C0428883;C0428886;C0441932;C0444504;C0449829;C0449851;C0488053;C0488055;C0520510;C0564385;C0700320;C0871470;C0936012;C1305855;C1306620;C1441672;C1511726;C1516695;C1516698;C1522472;C1524024;C1527178;C1551393;C1552923;C1705191;C1705492;C1705938;C1947903;C2347634;C2348143;C2699638;C2963137;C3245479;C3272743;C3714523;C3714741;C3854019;C4528284	\N	\N
956	( gm )	C0017480;C3854019	\N	\N
955	without t $nmbr$ dm n = $nmbr$	C0011816;C2986835;C3250443	\N	\N
955	without dm ( n = $nmbr$ i $nmbr$ * )	C0011816;C0021966;C0221138;C0369718;C0441922;C3250443	\N	\N
955	without dm	C0011816;C3250443	\N	\N
796	smoking status  n ( % )	C1519386	\N	\N
960	calcium - channel blocker	C0006684;C3536851;C4521885	f	1884
960	calcium - channel blocker *	C0006684;C3536851;C4521885	f	1884
960	calcium - channel blocker ( ratelowering )	C0006684;C3536851;C4521885	f	1884
960	calcium - channel blockers	C0006684;C2757014	f	1884
960	calcium - channel blockers ( % )	C0006684;C2757014	f	1884
960	calcium channel blockers	C0006684;C2757014	f	1884
960	calcium channel blockers  n ( % )	C0006684;C2757014	f	1884
960	caleium ehannel bloekers ( ccb )	C0006684	f	1884
960	dihydropyridine calcium - channel blocker	C2945601	f	1884
955	with t $nmbr$ dm n = $nmbr$	C0011816;C2986835;C3250443	\N	\N
955	with dm	C0011816;C3250443	\N	\N
955	t $nmbr$ dm	C0011816;C2603360;C3250443	\N	\N
955	prior dm	C0011816;C0332152;C2826257;C3250443	\N	\N
955	previous mi and t $nmbr$ dm	C0011816;C0205156;C1552607;C2603360;C3250443;C3810814	\N	\N
955	previous dm  n ( % )	C0011816;C0205156;C1552607;C3250443	\N	\N
955	previous dm	C0011816;C0205156;C1552607;C3250443	\N	\N
955	patients without dm ( n = $nmbr$ )	C0011816;C0030705;C3250443	\N	\N
955	patients without dm ( n = $nmbr$  $nmbr$ )	C0011816;C0030705;C3250443	\N	\N
955	patients with possible new dm at randomization ( fpg > $nmbr$ - $nmbr$ )	C0011816;C0030705;C0034656;C0205314;C0332149;C1705910;C2362652;C3250443	\N	\N
955	patients with dm vs . patients without dm	C0011816;C0030705;C3250443	\N	\N
955	patients with dm ( n = $nmbr$ )	C0011816;C0030705;C3250443	\N	\N
955	p value for dm vs . no dm	C0011816;C3250443;C4086240	\N	\N
955	oral anti - dm drug status  no . ( % )	C0011816;C0029167;C0175795;C0304289;C0449438;C3250443	\N	\N
955	non - insulin treated dm	C0011816;C0021641;C1518422;C1522326;C1533581;C1579433;C3250443;C3714501	\N	\N
955	non - dm	C0011816;C1518422;C3250443	\N	\N
955	no prior dm	C0011816;C0332152;C2826257;C3250443	\N	\N
955	no dm ( n = $nmbr$ )	C0011816;C3250443	\N	\N
955	no dm ( n = $nmbr$  $nmbr$ )	C0011816;C3250443	\N	\N
955	no dm	C0011816;C3250443	\N	\N
955	new dm	C0011816;C0205314;C3250443	\N	\N
955	neither t $nmbr$ dm nor mets	C0011816;C0812270;C1705694;C2603360;C2939420;C3250443	\N	\N
955	mets w / o t $nmbr$ dm	C0011816;C0812270;C1705694;C2939420;C3250443	\N	\N
955	dm or diabetic complications	C0011816;C0342257;C3250443	\N	\N
955	dm or ckd *	C0011816;C1561643;C3250443	\N	\N
955	dm medication  n ( % ) c	C0011816;C0013227;C3244316;C3250443;C4284232	\N	\N
955	dm ( n = $nmbr$ )	C0011816;C3250443	\N	\N
955	dm ( n = $nmbr$  $nmbr$ )	C0011816;C3250443	\N	\N
955	dm  n ( % )	C0011816;C3250443	\N	\N
955	dm	C0011816;C3250443	\N	\N
955	diff_measure ( dm added this as table had multiple headings )	C0011816;C0039224;C0079809;C0242485;C0439064;C1524062;C1706074;C3250443	\N	\N
955	concomitant oral anti - dm drugs  no . ( % ) a	C0011816;C0029167;C0175795;C0304289;C0521115;C3250443	\N	\N
954	pm  n ( % )	C0030266;C4049155	\N	\N
954	hr ( bpm )	\N	\N	\N
954	hr  bpm ( sd )	C2699239	\N	\N
954	hr  bpm	\N	\N	\N
954	csf a ( $nmbr$ ( pm )	C0030266;C3540512;C3889436;C4049155	\N	\N
954	> $nmbr$ bpm ( n = $nmbr$ l $nmbr$ )	\N	\N	\N
954	> $nmbr$ . $nmbr$ bpm	\N	\N	\N
953	serum albumin concentration  g / l	C0001924;C0036773;C0086045;C0229671;C0439294;C0456615;C0486291;C0683149;C0728877;C1446561;C1546774;C1550100;C3827302	\N	\N
953	serum albumin  g / l	C0036773;C0439294;C0456615;C0728877	\N	\N
953	serum albumin  g / dl	C0036773;C0439267;C0728877	\N	\N
953	serum albumin  g $nmbr$ $nmbr$	C0036773;C0439267;C0728877	\N	\N
953	serms	C0732611	\N	\N
952	serum creatinine — mg / dl §	C0201976;C0439269;C0600061	\N	\N
952	serum creatinine — mg / dl | |	C0201976;C0439269;C0600061	\N	\N
952	serum creatinine — mg / dl	C0201976;C0439269;C0600061	\N	\N
952	serum creatinine level	C0600061	\N	\N
952	serum creatinine > $nmbr$ pmol / l . n ( % ) |	C0201976;C0439284;C0600061	\N	\N
952	serum creatinine > $nmbr$ mmol / l  n ( % )	C0201976;C0600061;C1532563	\N	\N
952	serum creatinine > $nmbr$ / xmol / l  n ( % ) | |	C0201976;C0600061	\N	\N
952	serum creatinine . mg / dl	C0201976;C0439269;C0600061	\N	\N
952	serum creatinine - mean ( sd  n )	C0201976;C0444504;C0600061;C2347634;C2348143;C2699239	\N	\N
952	serum creatinine ( pmol / l )  mean ( sd )	C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239	\N	\N
952	serum creatinine ( mmol / l )	C0201976;C0600061;C1532563	\N	\N
952	serum creatinine ( mg / dl )	C0201976;C0439269;C0600061	\N	\N
952	serum creatinine ( gmol / )	C0201976;C0600061	\N	\N
952	serum creatinine  ≥ $nmbr$ . $nmbr$ mg / dl	C0201976;C0439269;C0600061	\N	\N
952	serum creatinine  μ mol / l	C0201976;C0347982;C0600061	\N	\N
952	serum creatinine  mg / dl  mean ( sd )	C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239	\N	\N
952	serum creatinine  mg / dl	C0201976;C0439269;C0600061	\N	\N
952	serum creatinine  mean ( sd ) mg / dl	C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239	\N	\N
952	serum creatinine  mean ( sd )  pmol / l	C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239	\N	\N
952	serum creatinine  mean ( sd )  mg / dl	C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239	\N	\N
952	serum creatinine  limo $nmbr$ $nmbr$	C0201976;C0600061	\N	\N
952	serum creatinine  gmol / l |	C0201976;C0600061	\N	\N
952	serum creatinine  gmol / ' l  mean ( sd )	C0201976;C0444504;C0600061;C2347634;C2348143;C2699239	\N	\N
952	serum creatinine  ^ mol / l	C0201976;C0347982;C0600061	\N	\N
952	serum creatinine  / xmol / l | |	C0201976;C0600061	\N	\N
952	serum creatinine	C0201976;C0600061	\N	\N
952	second serum creatinine	C0201976;C0205436;C0457385;C0565930;C0600061;C1561503;C1705190	\N	\N
952	preoperative serum creatinine > $nmbr$ pmol / l	C0201976;C0439284;C0445204;C0600061	\N	\N
952	mean serum creatinine  mg / dl	C0201976;C0439269;C0444504;C0600061;C2347634;C2348143	\N	\N
952	increase in serum creatinine	C0201976;C0442805;C0600061	\N	\N
952	first serum creatinine	C0201976;C0205435;C0600061;C1279901	\N	\N
952	doubling of serum creatinine	C0201976;C0205173;C0600061;C1705764	\N	\N
952	composite endpoint of doubling of serum creatinine  esrd	C0022661;C0035078;C0201976;C0205173;C0205199;C0600061;C1547335;C1705764;C2316810;C2349179;C2826544	\N	\N
952	acute increase in serum creatinine	C0010294;C0201976;C0205178;C0442805;C0600061;C1546542;C1561535	\N	\N
951	serum values ^	C0042295;C0229671;C1546774;C1550100	\N	\N
951	serum values	C0042295;C0229671;C1546774;C1550100	\N	\N
951	serum trap - $nmbr$ b ( u / liter )	C0184047;C0229671;C0439148;C0475211;C1336677;C1546774;C1550100;C1566918;C1706005;C1710330;C3887583	\N	\N
951	serum pepsinogen i / iit	C0077923;C0229671;C0523816;C1546774;C1550100	\N	\N
951	serum p $nmbr$ np ( ^ g / liter )	C0065827;C0229671;C0439267;C0475211;C1546774;C1550100;C1706141;C3887659	\N	\N
951	serum n - propeptide of type $nmbr$ collagen	C0009325;C0229671;C0332307;C1546774;C1547052;C1550100;C1709708;C1875696	\N	\N
951	serum gastrint  pg / ml	C0229671;C0439297;C1546774;C1550100	\N	\N
951	serum ctx i ( ng / ml )	C0229671;C0439275;C0631180;C1546774;C1550100	\N	\N
951	serum ctx - $nmbr$  ng / ml  median ( iqr )	C0010377;C0229671;C0439275;C0549183;C0631180;C0876920;C1546774;C1550100;C2347635;C2348144;C2939193;C3539598	\N	\N
951	serum ctx ( ng / ml )	C0010377;C0229671;C0439275;C0631180;C1546774;C1550100;C3539598	\N	\N
951	serum c - terminal telopeptide of	C0229671;C1546774;C1550100;C1707271	\N	\N
951	serum bone - specific alkaline	C0205369;C0229671;C0262950;C1546774;C1550100;C1552740;C1979842	\N	\N
951	serum $nmbr$ - hydroxyvitamin d  ng / ml	C0020337;C0229671;C0439275;C1546774;C1550100	\N	\N
951	serum	C0229671;C1546774;C1550100	\N	\N
951	patients with serum $nmbr$ ( oh ) d ≥   $nmbr$ . $nmbr$ and <   $nmbr$   ng / ml    n / n   ( % )	C0030705;C0220853;C0229671;C0439275;C1546774;C1550100	\N	\N
951	median serum periostin ( ng / ml ) t	C0219433;C0229671;C0439275;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270	\N	\N
951	mean total serum psa	C0229671;C0444504;C1546774;C1550100;C2347634;C2348143;C2986589	\N	\N
951	mean total serum ige ( sd )  iu / ml	C0229671;C0439175;C0439458;C0439810;C0444504;C1546774;C1550100;C2347634;C2348143;C2699239	\N	\N
950	two arm	C0205448;C0446516;C3715044;C4553528	\N	\N
950	treatment arm ( zoledronate ) ( % )	C0392938;C1522541	\N	\N
950	treatment arm	C1522541	\N	\N
950	three arm	C0205449;C0446516;C3715044;C4553528	\N	\N
950	s arm	C0446516;C0565930;C2603362;C3715044;C4553528	\N	\N
950	by treatment arm	C1522541	\N	\N
950	arm	C0446516;C3715044;C4553528	\N	\N
949	short term ^	C0443303	\N	\N
949	short term ( n = $nmbr$ ) +	C0443303	\N	\N
949	preferred term  %	C1709637;C2347664	\N	\N
948	evolocumab ( n = $nmbr$ )	C3529352	\N	\N
948	evolocumab ( $nmbr$ mg )	C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761	\N	\N
948	evolocumab $nmbr$ mg monthly ( n = $nmbr$ )	C0024671;C0026410;C0332177;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761	\N	\N
7	p - value ( interaction ) ≠	C1704675;C1709380	\N	\N
948	evolocumab $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ )	C0024671;C0026410;C0439230;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761	\N	\N
948	evolocumab	C3529352	\N	\N
948	alirocumab n = $nmbr$	C3491162	\N	\N
948	alirocumab ( n = $nmbr$ )	C3491162	\N	\N
948	alirocumab $nmbr$ mg q $nmbr$ w	C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761	\N	\N
948	alirocumab $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761	\N	\N
948	alirocumab	C3491162	\N	\N
948	aiirocumab ( n = $nmbr$ )	\N	\N	\N
948	aiirocumab	\N	\N	\N
947	veflonzumao	\N	\N	\N
947	resllzumab	\N	\N	\N
947	reslizumab ( n = $nmbr$ )	C1869620	\N	\N
947	reslizumab $nmbr$ . $nmbr$   mg / kg ( n   = $nmbr$ )	C0439272;C1869620	\N	\N
947	reslizumab $nmbr$ . $nmbr$ mg / kg ( n = $nmbr$ )	C0439272;C1869620	\N	\N
947	reslizumab	C1869620	\N	\N
947	benralizumab q $nmbr$ w ( n = $nmbr$ )	C2982078	\N	\N
947	benralizumab q $nmbr$ w ( n - $nmbr$ )	C2982078	\N	\N
947	benralizumab $nmbr$ mg q $nmbr$ w ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761	\N	\N
947	benralizumab $nmbr$ mg q $nmbr$ w	C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761	\N	\N
947	benralizumab	C2982078	\N	\N
947	b reslizumab $nmbr$ . $nmbr$ mg / kg n / n	C0439272;C1869620	\N	\N
947	b . benralizumab $nmbr$ mg q $nmbr$ w	C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761	\N	\N
947	a reslizumab $nmbr$ . $nmbr$ mg / kg n / n	C0439272;C1869620	\N	\N
946	rituximab ( $nmbr$ x $nmbr$ mg ) + mtx ( n = $nmbr$ )	C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
946	rituximab ( $nmbr$ x $nmbr$ mg ) + mtx	C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
946	rituximab  n = $nmbr$	C0393022	\N	\N
946	rituximab	C0393022	\N	\N
-10	jejunum	C0022378	\N	\N
944	secukinumab $nmbr$   mg ( n   =   $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761	\N	\N
944	secukinumab $nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761	\N	\N
944	secukinumab  $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761	\N	\N
944	secukinumab	C3179547	\N	\N
944	placebo secukinumab $nmbr$ mg	C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761	\N	\N
944	any secukinumab ( n   = $nmbr$ )	C3179547	\N	\N
943	vedolizumab n = $nmbr$	C2742797	\N	\N
943	vedolizumab cohort $nmbr$ ( n = $nmbr$ )	C0009247;C0599755;C2742797	\N	\N
943	vedolizumab	C2742797	\N	\N
943	mepolizumab group	C0441833;C0687744;C0969324;C1257890;C1519504;C1705428;C1705429	\N	\N
943	mepolizumab	C0969324	\N	\N
943	evomab + soc	\N	\N	\N
943	evomab ( n = $nmbr$ )	\N	\N	\N
943	evomab	\N	\N	\N
943	denosumab ( n = $nmbr$ ) n ( % )	C1690432	\N	\N
943	denosumab ( n = $nmbr$ )	C1690432	\N	\N
943	denosumab	C1690432	\N	\N
942	dupilumab $nmbr$	C3660996	\N	\N
942	both adalimumab groups ( n = $nmbr$ ) no baseline cd - related antibiotic use	C0003232;C0007928;C0034283;C0042153;C0168634;C0369718;C0439849;C0441833;C0441922;C0445223;C0457083;C0687744;C1122087;C1257890;C1442488;C1519504;C1552839;C1705428;C1705429;C1947944;C4552032	\N	\N
942	both adalimumab groups ( n = $nmbr$ )	C0369718;C0441833;C0441922;C0687744;C1122087;C1257890;C1519504;C1552839;C1705428;C1705429	\N	\N
942	adalimumab group ( n = $nmbr$ ) t	C0036669;C1122087	\N	\N
942	adalimumab croup  n / n ( % )	C0010380;C1122087	\N	\N
942	adalimumab ( n = $nmbr$ )	C1122087	\N	\N
942	adalimumab	C1122087	\N	\N
941	golimumab combined ( n = $nmbr$ )	C0205195;C2353893	\N	\N
796	smoking status	C1519386	\N	\N
941	golimumab $nmbr$ mg / $nmbr$ mgt	C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761	\N	\N
941	golimumab $nmbr$ mg ( n = $nmbr$ ) †	C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761	\N	\N
941	golimumab $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761	\N	\N
941	golimumab $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761	\N	\N
941	golimumab	C2353893	\N	\N
941	combined golimumab groups	C0205195;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C2353893	\N	\N
940	prior therapy with omalizumab : yes	C0966225;C1514463;C1549445;C1705108;C1710701	\N	\N
940	omalizumab ( lsm )	C0966225	\N	\N
940	omalizumab	C0966225	\N	\N
939	death due to renal failure ®	C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775	\N	\N
939	death due to renal failure or sustained esrd	C0011065;C0022661;C0035078;C0443318;C0678226;C1306577;C1963154;C2316810;C4082313;C4552775	\N	\N
938	primary renal endpoint or death	C0011065;C0022646;C1306577;C2986535;C4082313;C4552775	\N	\N
938	primary renal endpoint	C0022646;C2986535	\N	\N
937	severe renal impairment	C0205082;C1565489;C4050465;C4050466	\N	\N
937	renal impairment *	C1565489	\N	\N
937	renal impairment  n ( % )	C1565489	\N	\N
937	renal impairment	C1565489	\N	\N
937	renal dysfunction	C1565489;C3279454	\N	\N
937	non - endstage renal dysfunction *	C0205088;C1518422;C1565489;C3279454	\N	\N
937	non - end - stage renal dysfunction	C0205088;C1518422;C1565489;C3279454	\N	\N
937	no renal dysfunction	C1565489;C3279454	\N	\N
937	moderate renal impairment  n ( % ) *	C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
937	moderate renal impairment	C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
937	mild to moderate renal impairment *	C1299392;C1565489	\N	\N
937	level of renal impairment '	C0441889;C0456079;C1547707;C1565489;C2946261	\N	\N
937	level of renal impairment	C0441889;C0456079;C1547707;C1565489;C2946261	\N	\N
937	impaired renal function †	C1565489	\N	\N
937	impaired renal function §	C1565489	\N	\N
937	history of impaired renal function  no . ( % )	C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062	\N	\N
937	history of impaired renal function	C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062	\N	\N
936	medal	C0524670	\N	\N
936	beyond popliteal pedal	C0016504;C0442037;C0687080	\N	\N
935	wegu	\N	\N	\N
935	emotional well - being	C2984554;C3641833	\N	\N
934	peripheral artery revascularization without amputation	C0002688;C0332840;C0489868;C0581603;C1546539	\N	\N
934	peripheral artery diseasef	C0489868	\N	\N
934	peripheral artery diseaseb	C0489868	\N	\N
934	peripheral artery disease 一 no . ( % )	C1704436;C4025272	\N	\N
934	peripheral artery disease — no . ( % )	C1704436;C4025272	\N	\N
934	peripheral artery disease details	C1522508;C1561567;C1704436;C4025272	\N	\N
934	peripheral artery disease - -	C1704436;C4025272	\N	\N
934	peripheral artery disease *	C1704436;C4025272	\N	\N
934	peripheral artery disease	C1704436;C4025272	\N	\N
934	peripheral artery	C0489868	\N	\N
934	peripheral arterial stenosis	C4025272	\N	\N
934	peripheral - artery stenosis	C4025272	\N	\N
934	peripheral - artery disease — no . ( % )	C1704436;C4025272	\N	\N
934	peripheral - artery disease ( % )	C1704436;C4025272	\N	\N
934	peripheral - artery disease	C1704436;C4025272	\N	\N
934	only peripheral artery disease	C0205171;C1704436;C1720467;C4025272	\N	\N
934	history of peripheral artery disease — no . { % )	C0489868;C0683519;C0730226;C0850708;C0944983	\N	\N
934	history of peripheral artery disease	C0489868;C0683519;C0730226;C0850708;C0944983	\N	\N
934	baseline peripheral artery disease	C0168634;C1442488;C1704436;C4025272	\N	\N
933	qualifying peripheral arterial disease	C0085096;C1514624;C1704436	\N	\N
933	prior peripheral arterial disease	C0085096;C0332152;C1704436;C2826257	\N	\N
938	renal impairmentf	C0022646	f	937
938	renal impairmentt	C0022646	f	937
938	renal functiona	C0022646	f	1532
938	renal functionb	C0022646	f	1532
938	renal functionc  n ( % )	C0022646	f	1532
939	renal insufficiency	C0035078;C1565489	f	937
939	renal failure	C0035078;C1963154	f	937
939	renal insufficiency *	C0035078;C1565489	f	937
939	renal insufficiency / failure	C0035078;C0231174;C0231179;C0680095;C1565489;C1963154	f	937
939	renal insufficiency $nmbr$	C0035078;C1565489	f	937
939	renal insufficiency — no . ( % )	C0035078;C1565489	f	937
939	renal insufficiency or failure	C0035078;C0231174;C0680095;C1565489	f	937
938	renal	C0022646	f	1951
938	renal events	C0022646;C0441471;C3541888	f	1951
938	renal parameters	C0022646;C0449381	f	1951
940	tocilizumab	C1609165	f	2295
940	tocilizumab ( n = $nmbr$ )	C1609165	f	2295
933	peripheral vascular disease  n ( % )	C0085096	\N	\N
933	peripheral vascular disease	C0085096	\N	\N
933	peripheral artery occlusive disease ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ )	C0205390;C1300072;C1306673;C1306889	\N	\N
933	peripheral artery occlusive disease	C1306889	\N	\N
933	peripheral arterial disease — no . ( % ) §	C0085096;C1704436	\N	\N
933	peripheral arterial disease — no . ( % )	C0085096;C1704436	\N	\N
933	peripheral arterial disease §	C0085096;C1704436	\N	\N
933	peripheral arterial disease ( n = $nmbr$ $nmbr$ )	C0085096;C1704436	\N	\N
933	peripheral arterial disease  n ( % )	C0085096;C1704436	\N	\N
933	peripheral arterial disease	C0085096;C1704436	\N	\N
933	cerebrovascular or peripheral arterial disease    n   ( % )	C0085096;C1704436;C1880018	\N	\N
933	cerebrovascular or peripheral arterial disease  n ( % )	C0085096;C1704436;C1880018	\N	\N
933	cerebrovascular or peripheral arterial disease	C0085096;C1704436;C1880018	\N	\N
933	any peripheral arterial disease	C0085096;C1704436	\N	\N
933	any established peripheral arterial disease	C0085096;C0443211;C1272684;C1704436	\N	\N
932	urgent peripheral revascularization	C0205100;C0439609;C0581603;C3272275	\N	\N
932	peripheral vasodilators	C0724804	\N	\N
932	peripheral revascularization ( n = $nmbr$ )	C0205100;C0581603	\N	\N
932	peripheral revascularization	C0205100;C0581603	\N	\N
932	peripheral revascularisation	C0205100;C0581603	\N	\N
932	peripheral	C0205100	\N	\N
932	no peripheral revascularization ( n = $nmbr$  $nmbr$ )	C0205100;C0581603	\N	\N
932	history of peripheral vascular disease	C1881056	\N	\N
931	lateral	C0205093	\N	\N
931	bilateral disease ( % ) ' j ' ' j '	C1511113	\N	\N
930	vilanterol  n = $nmbr$	C2935023	\N	\N
930	fluticasone furoate and vilanterol ( n = $nmbr$ )	C1948374;C2935023	\N	\N
929	intracerebral	C0442111	\N	\N
929	chd plus cerebral infarction	C0007785;C0280604;C3542407	\N	\N
929	chd + cerebral infarction	C0007785;C0280604;C3542407	\N	\N
929	cerebral thrombosis	C0079102;C0151945;C0795687	\N	\N
929	cerebral ischemia	C0007785;C0917798	\N	\N
929	cerebral infarction	C0007785	\N	\N
929	cerebral hemorrhage	C2937358	\N	\N
929	cerebral embolism	C0007780	\N	\N
929	cerebral	\N	\N	\N
928	northamerica	\N	\N	\N
928	nonvertebral	\N	\N	\N
928	morphometric vertebral	C0200760;C0549207	\N	\N
928	hip + nonvertebral + vertebral	C0019552;C0022122;C0549207;C1505163;C3538851;C4284725	\N	\N
927	neuraxial anaesthesia	C0002903;C0002912;C0002930;C3714787;C4049933	\N	\N
927	neuraxial alonee	C3714787	\N	\N
927	central nervous system	C3540014;C3714787	\N	\N
926	treatment after randomization  in the single - dummy phase — days ]	C0034656;C0037179;C0039798;C0087111;C0087136;C0205171;C0205390;C0439228;C1522326;C1533734;C1705169;C1710475;C3538994;C3887704	\N	\N
926	thienopyridine alone	C0205171;C0439044;C0679994;C1120149	\N	\N
926	single	C0037179;C0087136;C0205171	\N	\N
926	rivaroxaban alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0205171;C0439044;C0679994;C1739768	\N	\N
926	rivaroxaban alone ( n = $nmbr$ )	C0205171;C0439044;C0679994;C1739768	\N	\N
926	previous ics alone	C0205156;C0205171;C0439044;C0679994;C0815320;C1552607;C4551720	\N	\N
926	pci alone ( n = $nmbr$ )	C0205171;C0439044;C0679994;C4049621	\N	\N
926	metformin alone	C0025598;C0205171;C0439044;C0679994	\N	\N
926	lived alone	C0205171;C0439044;C0679994;C1548795;C1634625;C2982691	\N	\N
926	ics alone	C0205171;C0439044;C0679994;C0815320;C4551720	\N	\N
926	heparin alone ( n = $nmbr$ )	C0019134;C0205171;C0439044;C0679994;C0770546	\N	\N
926	fluticasone alone ( n = $nmbr$ )	C0082607;C0205171;C0439044;C0679994	\N	\N
926	bivalirudin alone ( n = $nmbr$ )	C0168273;C0205171;C0439044;C0679994	\N	\N
926	basal alone	C0205112;C0205171;C0439044;C0679994	\N	\N
926	alone	C0205171;C0439044;C0679994	\N	\N
926	$nmbr$ ( except for female alone )	C0043210;C0086287;C0205171;C0439044;C0679994;C1705497;C1705498	\N	\N
925	unfractionated only	C0205171;C1720467	\N	\N
925	unfractionated heparin only	C0019134;C0205171;C1720467;C2825026	\N	\N
925	type of surgery cabg only	C0010055;C0038894;C0038895;C0205171;C0332307;C0543467;C1274039;C1547052;C1720467	\N	\N
925	t - wave inversion only	C0205171;C0520888;C1720467	\N	\N
925	statin only ( n = $nmbr$  $nmbr$ )	C0205171;C0360714;C1720467	\N	\N
925	statin only  n ( % )	C0205171;C0360714;C1720467	\N	\N
925	statin only	C0205171;C0360714;C1720467	\N	\N
925	st - depression only	C0205171;C0520887;C1720467	\N	\N
925	pulmonary embolism only	C0034065;C0205171;C1720467	\N	\N
925	ptca only	C0205171;C1720467;C2936173	\N	\N
925	previous lev only	C0023556;C0205156;C0205171;C1552607;C1720467	\N	\N
925	previous labd only	C0205156;C0205171;C0396059;C1552607;C1720467	\N	\N
925	pioglitazone only	C0071097;C0205171;C1720467	\N	\N
925	oral hypoglycemic drugs only	C0205171;C0359086;C1720467	\N	\N
925	oral hypoglycaemics only	C0205171;C0359086;C1720467	\N	\N
925	oad only	C0205171;C1720467	\N	\N
925	monotherapy $nmbr$	\N	\N	\N
925	metformin only	C0025598;C0205171;C1720467	\N	\N
925	medical management only — no . { % )	C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539	\N	\N
925	medical management only	C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539	\N	\N
925	lieum only  n ( % )	C0205171;C1720467	\N	\N
925	legs only	C0205171;C1140621;C1720467	\N	\N
925	lama ( only monotherapy )	C0205171;C0999593;C1416775;C1720467	\N	\N
925	laba ( only monotherapy )	C0205171;C1720467	\N	\N
925	jbs - $nmbr$ secondary prevention only $nmbr$	C0175692;C0205171;C0679699;C0795841;C1416527;C1720467	\N	\N
925	jbs - $nmbr$ primary prevention only $nmbr$	C0033144;C0175692;C0205171;C0795841;C1416527;C1720467	\N	\N
925	immunosuppressants and antimalarials only	C0003374;C0021081;C0205171;C1720467	\N	\N
925	sulphonylureas only	C0038766;C0205171;C1720467	f	752
925	image only	C0205171;C1704254;C1704922;C1720467;C3542466	\N	\N
925	handihaler only  n	C0205171;C1720467	\N	\N
925	enoxaparin only	C0205171;C0206460;C1720467	\N	\N
925	depressed only	C0205171;C0344315;C0549249;C1720467	\N	\N
925	class v only	C0205171;C0457166;C1720467;C1880098	\N	\N
925	cabg only	C0010055;C0205171;C1720467	\N	\N
925	basal only	C0205112;C0205171;C1720467	\N	\N
925	antimalarials only	C0003374;C0205171;C1720467	\N	\N
925	$nmbr$ ( only $nmbr$ distal )	C0205108;C0205171;C1720467;C4522154	\N	\N
924	range ed etiology ( n )	C0015127;C1314792;C1514721;C1524003;C2348147;C3538926;C3542016	\N	\N
924	pah origin / cause	C0015127;C1418251;C1524003	\N	\N
924	pah etiology :	C0015127;C0030123;C1314792;C1524003;C3203102;C4284467	\N	\N
924	pah etiology	C0015127;C0030123;C1314792;C1524003;C3203102;C4284467	\N	\N
924	other determined etiology	C0015127;C0521095;C1314792;C1524003	\N	\N
924	other cause  n ( % )	C0015127;C1524003	\N	\N
924	other cause	C0015127;C1524003	\N	\N
924	non - ischaemic aetiology	C0015127;C0475224;C1314792;C1518422;C1524003	\N	\N
924	neohrodathv . and all - cause mortalitv	C0015127;C1524003	\N	\N
924	main etiology of heart failure	C0015127;C0018801;C0018802;C0205225;C1314792;C1524003;C1542147;C4554158	\N	\N
924	ischemic heart failure etiology	C0015127;C0018801;C0018802;C0475224;C1314792;C1524003;C4554158	\N	\N
924	ischemic etiology ( % )	C0015127;C0475224;C1314792;C1524003	\N	\N
924	ischemic etiology  %	C0015127;C0475224;C1314792;C1524003	\N	\N
924	ischemic etiology	C0015127;C0475224;C1314792;C1524003	\N	\N
924	ischemic aetiology  n ( % )	C0015127;C0475224;C1314792;C1524003	\N	\N
924	ischemic aetiology	C0015127;C0475224;C1314792;C1524003	\N	\N
924	ischaemic etiology n ( % )	C0015127;C0475224;C1314792;C1524003	\N	\N
924	ischaemic aetiology	C0015127;C0475224;C1314792;C1524003	\N	\N
924	etiology ( % )	C0015127;C1314792;C1524003	\N	\N
924	etiology    n   ( % )	C0015127;C1314792;C1524003	\N	\N
924	etiology  n ( % )	C0015127;C1314792;C1524003	\N	\N
924	etiology	C0015127;C1314792;C1524003	\N	\N
924	ed etiology  no . ( % )	C0015127;C1314792;C1524003;C3538926	\N	\N
924	diabetes etiology	C0011847;C0011849;C0015127;C1314792;C1524003	\N	\N
924	combined major macrovascular events  neohrodathv . and all - cause mortalitv ■	C0015127;C0205082;C0205164;C0205195;C0441471;C1524003;C3541888;C4318856;C4521762	\N	\N
924	any cause	C0015127;C1524003	\N	\N
924	all randomized all - cause mortality or hospitalization for worsening hf ^	C0015127;C0018488;C0019993;C0026565;C0026566;C0034656;C0332271;C0444868;C1313497;C1457868;C1524003;C1538440;C1546960;C3273279;C3539085;C3815594	\N	\N
924	all randomized all - cause mortality	C0015127;C0026565;C0026566;C0034656;C0444868;C1524003;C3539085;C3815594	\N	\N
924	all cause mortality	C0015127;C0026565;C0026566;C0444868;C1524003;C3539085	\N	\N
924	all - cause mortality or hf hospitalization ^	C0015127;C0018488;C0019993;C0026565;C0026566;C0444868;C1313497;C1524003;C1538440;C3273279;C3539085	\N	\N
924	all - cause mortality or hf hospitalization	C0015127;C0018488;C0019993;C0026565;C0026566;C0444868;C1313497;C1524003;C1538440;C3273279;C3539085	\N	\N
924	all - cause mortality ( no . of events )	C0015127;C0026565;C0026566;C0441471;C0444868;C1524003;C3539085;C3541888	\N	\N
924	all - cause mortality ( n = $nmbr$ )	C0015127;C0026565;C0026566;C0444868;C1524003;C3539085	\N	\N
924	all - cause mortality	C0015127;C0026565;C0026566;C0444868;C1524003;C3539085	\N	\N
924	all - cause mortalitv	C0015127;C1524003	\N	\N
924	all - cause hospitalization	C0015127;C0019993;C1524003	\N	\N
924	all - cause	C0015127;C1524003	\N	\N
924	aetiology of pah	C0015127;C0030123;C1314792;C1524003;C3203102;C4284467	\N	\N
924	aetiology	C0015127;C1314792;C1524003	\N	\N
924	acute stroke of other determined cause	C0015127;C0521095;C0751956;C1524003	\N	\N
923	six - minute walk distance  m	C0012751;C0369637;C0441923;C3900196	\N	\N
923	rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C0871208;C1521828	\N	\N
923	mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ level — no . ( % )	C0369637;C0439445;C0441889;C0441923;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261	\N	\N
923	mab	C0003250;C0369637	\N	\N
923	m o nito ring treatment	C0039798;C0087111;C0369637;C0441923;C0521164;C1260969;C1522326;C1533734;C1705169;C1882954;C3538994;C3887704	\N	\N
923	m being	C0369637;C0441923	\N	\N
923	m	C0369637;C0441923	\N	\N
923	k - m % n	C0369637;C0441923;C0597277;C1708601	\N	\N
923	k - m %	C0369637;C0441923;C0597277;C1708601	\N	\N
923	glomerular filtration rate  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0017654;C0369637;C0439445;C0441923;C1561549	\N	\N
923	estimated glomerular filtration rate < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C3811844	\N	\N
923	estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . / total no . ( % ) §	C0369637;C0439175;C0439445;C0439810;C0441923;C3811844	\N	\N
923	estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ : i : §	C0021966;C0023806;C0221138;C0369637;C0439445;C0441923;C0702093;C1524029;C3811844;C3813700	\N	\N
923	estimated glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C3811844	\N	\N
923	estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$ *	C0369637;C0439445;C0441923;C3811844;C3839656	\N	\N
923	estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C3811844;C3839656	\N	\N
923	estimated glomerular filtration rate ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C3811844;C3839656	\N	\N
923	estimated glomerular filtration rate  ml / min per $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C3811844	\N	\N
923	death or $nmbr$ mwd decrease > $nmbr$ m	C0011065;C0369637;C0392756;C0441923;C0547047;C1306577;C4082313;C4552775	\N	\N
923	baseline mwd  m	C0168634;C0369637;C0441923;C1442488	\N	\N
923	baseline $nmbr$ - min walk distance m	C0168634;C0369637;C0429886;C0441923;C0702093;C1442488;C1524029;C3813700	\N	\N
923	azl - m / cld ( n = $nmbr$ )	C0369637;C0441923	\N	\N
923	azl - m + hctz ( n = $nmbr$ )	C0020261;C0369637;C0441923	\N	\N
923	azl - m + cldb	C0369637;C0441923	\N	\N
923	azl - m $nmbr$ mg + cld $nmbr$ mg	C0369637;C0441923;C1319635	\N	\N
923	azl - m $nmbr$ mg $nmbr$ - cld $nmbr$ mg ( n = l $nmbr$ )	C0369637;C0441923;C2827881	\N	\N
923	azl - m	C0369637;C0441923	\N	\N
923	> $nmbr$ to < $nmbr$ iiil / iiim / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0441923	\N	\N
923	> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % )	C0369637;C0439445;C0441923	\N	\N
923	> $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
923	< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . { % )	C0369637;C0439445;C0441923	\N	\N
923	< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % )	C0369637;C0439445;C0441923	\N	\N
923	< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ nt - pro - bnp	C0369637;C0439445;C0441923;C0669479;C0754710	\N	\N
923	< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0369637;C0439445;C0441923	\N	\N
923	. $nmbr$ . $nmbr$ ml / s / m $nmbr$ ( $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % )	C0369637;C0439445;C0441923	\N	\N
923	$nmbr$ to < $nmbr$ m um in	C0369637;C0441923	\N	\N
923	$nmbr$ mwt ( m )	C0369637;C0441923	\N	\N
923	$nmbr$ mwd decrease > $nmbr$ m	C0369637;C0392756;C0441923;C0547047	\N	\N
923	$nmbr$ mwd  m	C0369637;C0441923	\N	\N
923	$nmbr$ mw distance  m	C0012751;C0024548;C0026385;C0369637;C0441923;C0556966	\N	\N
923	$nmbr$ - minute walk distance — m	C0369637;C0429886;C0439232;C0441923;C0700321;C0702093;C1282918;C2347166	\N	\N
923	$nmbr$ - min walk distance ( m )	C0369637;C0429886;C0441923;C0702093;C1524029;C3813700	\N	\N
922	method of identification ofstenosis ( % )	C1301921	\N	\N
922	mestizos	C0682082	\N	\N
921	without mets	C0812270;C1705694;C2939420	\N	\N
921	with mets	C0812270;C1705694;C2939420	\N	\N
921	presence of mets ( % ) a	C0150312;C0392148;C0812270;C1705694;C2939420;C3854307	\N	\N
921	presence of mets	C0150312;C0392148;C0812270;C1705694;C2939420;C3854307	\N	\N
921	non - mets	C0812270;C1518422;C1705694;C2939420	\N	\N
921	no dysglycaemia or mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )	C0031962;C0812270;C1705694;C1960636;C2939420	\N	\N
921	no dysglycaemia or mets	C0812270;C1705694;C1960636;C2939420	\N	\N
921	mets  n ( % )	C0812270;C1705694;C2939420	\N	\N
921	mets	C0812270;C1705694;C2939420	\N	\N
921	i without mets ( n = $nmbr$ )	C0021966;C0221138;C0812270;C1705694;C2939420	\N	\N
921	i with mets ( n = $nmbr$ )	C0021966;C0221138;C0812270;C1705694;C2939420	\N	\N
921	dysglycaemia or mets	C0812270;C1705694;C1960636;C2939420	\N	\N
920	height in meters .	C0441074;C0489786	\N	\N
920	> = $nmbr$ meters	C0441074	\N	\N
920	< $nmbr$ meters	C0441074	\N	\N
919	neither ics nor laba	C0815320;C4551720	\N	\N
919	neither	\N	\N	\N
918	jugular venous distention > $nmbr$ cm	C0425687	\N	\N
918	jugular venous distension  n ( % )	C0425687	\N	\N
917	venous graft	C0042449;C0181074;C0332835;C0348013;C1961139	\N	\N
917	venous	C0042449;C0348013	\N	\N
916	sirius	\N	\N	\N
916	serious teaes	C0205404	\N	\N
916	serious infections	C0205404;C3714514	\N	\N
916	serious decline in kidney function *	C0205404;C0232804	\N	\N
916	serious decline in kidney function $nmbr$	C0205404;C0232804	\N	\N
916	serious aes	C0205404;C1412268;C2699274	\N	\N
916	serious ae	C0205404;C3887670	\N	\N
916	serious	C0205404	\N	\N
916	any serious teaes	C0205404	\N	\N
916	any serious ae  n ( % )	C0205404;C3887670	\N	\N
916	> $nmbr$ serious aes	C0205404;C1412268;C2699274	\N	\N
915	stent thrombosis arc definite / probable	C0033204;C0332148;C0439544;C1704787;C3897493	\N	\N
915	disseminated tuberculosis	C0152915	\N	\N
915	definite stent thrombosis	C0439544;C1704787;C3897493	\N	\N
915	definite / probable stent thrombosis	C0033204;C0332148;C0439544;C1704787;C3897493	\N	\N
915	definite	C0439544;C1704787	\N	\N
914	patients without clinically evident vascular disease	C0030705;C0042373;C3887511	\N	\N
914	patients with clinically evident vascular disease	C0030705;C0042373;C3887511	\N	\N
914	clinically evident vascular disease	C0042373;C3887511	\N	\N
913	very severe n z $nmbr$	C3641272;C4050419	\N	\N
913	very severe ( itt ) ( n = $nmbr$ )	C3641272;C4050419	\N	\N
913	very severe	C3641272;C4050419	\N	\N
913	severe or very severe smoking status	C0205082;C1519386;C3641272;C4050419;C4050465;C4050466	\N	\N
913	severe or very severe	C0205082;C3641272;C4050419;C4050465;C4050466	\N	\N
913	$nmbr$ - $nmbr$ ( very severe )	C3641272;C4050419	\N	\N
912	prior or new diabetes	C0011847;C0011849;C0205314;C0332152;C2826257	\N	\N
912	prior gestational diabetes	C0085207;C0332152;C2826257	\N	\N
912	prior diabetes	C0011847;C0011849;C0332152;C2826257	\N	\N
912	diabetese	\N	\N	\N
912	diabetesc	\N	\N	\N
912	comorbid diseasesa diabetesb	C0009488	\N	\N
910	prediabeticb	\N	\N	\N
910	prediabetese	\N	\N	\N
910	prediabetes — no . ( % ) $nmbr$	C0362046	\N	\N
910	prediabetes  n ( % )	C0362046	\N	\N
910	prediabetes  %	C0362046	\N	\N
910	pre – diabetes mellitus  n = $nmbr$	C0362046	\N	\N
910	pre – diabetes mellitus	C0362046	\N	\N
910	ifg / prediabetes ^	C0362046;C1334085;C1708411	\N	\N
913	very severe copd	C0024117;C1412502;C3641272;C3714496;C4050419	f	1836
914	evidence or thombus  n ( % )	C3887511	f	-10
918	venous insufficiency	C0042485	f	1949
911	progression to diabetes	C1735364	f	907
917	history of recurrent venous thromboembolism	C0042449;C0348013;C0455533;C1455761;C2945760	f	2399
911	amputation due to diabetes — no . ( % )	C0598284;C0678226	f	909
911	diabetesf	\N	f	909
910	baseline prediabetes	C0168634;C0362046;C1442488	\N	\N
909	without diabetes	C0011847;C0011849	\N	\N
909	with diabetes	C0011847;C0011849	\N	\N
909	undiagnosed diabetes mellitus  n = $nmbr$	C0011849;C1408353	\N	\N
909	undiagnosed diabetes mellitus	C0011849;C1408353	\N	\N
909	undiagnosed diabetes ( n = $nmbr$ )	C0011847;C0011849;C1408353	\N	\N
909	time since diagnosis of type $nmbr$ diabetes	C0011847;C0011849;C0011900;C0040223;C1320657;C1550351;C1704338;C1704656;C3541383	\N	\N
909	time since diagnosis of diabetes — no . ( % )	C0011847;C0011849;C0011900;C0040223;C1704338;C1704656;C3541383	\N	\N
909	time since diagnosis of diabetes  n ( % )	C0011847;C0011849;C0011900;C0040223;C1704338;C1704656;C3541383	\N	\N
909	time since diagnosis of diabetes	C0011847;C0011849;C0011900;C0040223;C1704338;C1704656;C3541383	\N	\N
909	short ( < $nmbr$ years ) duration of diabetes	C0011847;C0011849;C0439234;C0439593	\N	\N
909	reported diabetes mellitus	C0011849;C0684224;C0700287;C4319718	\N	\N
909	postbaseline new - onset diabetes - n ( % )	C0011847;C0011849;C0746890	\N	\N
909	people without diabetes n = $nmbr$	C0011847;C0011849;C0027361	\N	\N
909	people with diabetes n = $nmbr$	C0011847;C0011849;C0027361	\N	\N
909	patients without diabetes mellitus ( n = $nmbr$ )	C0011849;C0030705	\N	\N
909	patients without diabetes	C0011847;C0011849;C0030705	\N	\N
909	patients with diabetes mellitus ( n = $nmbr$ )	C0011849;C0030705	\N	\N
909	patients with diabetes mellitus	C0011849;C0030705	\N	\N
909	patients with diabetes	C0011847;C0011849;C0030705	\N	\N
909	other ( % ) diabetes ( interaction : p = $nmbr$ . $nmbr$ )	C0011847;C0011849;C1704675	\N	\N
909	non - diabetes	C0011847;C0011849;C1518422	\N	\N
909	no diabetes mellitus	C0011849	\N	\N
909	no diabetes ( p = . o $nmbr$ )	C0011847;C0011849	\N	\N
909	no diabetes ( p = . $nmbr$ )	C0011847;C0011849	\N	\N
909	no diabetes ( n = $nmbr$  $nmbr$ )	C0011847;C0011849	\N	\N
909	no diabetes ( n - $nmbr$  $nmbr$ )	C0011847;C0011849	\N	\N
909	no diabetes	C0011847;C0011849	\N	\N
909	new diabetes — no . ( % )	C0011847;C0011849;C0205314	\N	\N
909	new diabetes	C0011847;C0011849;C0205314	\N	\N
909	new - onset diabetes §	C0011847;C0011849;C0746890	\N	\N
909	new - onset diabetes	C0011847;C0011849;C0746890	\N	\N
909	n o diabetes	C0011847;C0011849;C0369718;C0441922	\N	\N
909	mellitus	\N	\N	\N
909	median duration of diabetes ( yr )	C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	\N	\N
909	long ( i $nmbr$ years ) duration of diabetes	C0011847;C0011849;C0021966;C0221138;C0439234;C0439591	\N	\N
909	long ( > $nmbr$ years ) duration of diabetes	C0011847;C0011849;C0439234;C0439591	\N	\N
909	laboratory values in patients with history of diabetes	C0011847;C0011849;C0019664;C0019665;C0022877;C0030705;C0042295;C0262512;C0262926;C1705255;C2004062;C3244292;C4283904	\N	\N
909	individuals without diabetes  n = $nmbr$  $nmbr$	C0011847;C0011849;C0027361;C0237401	\N	\N
909	individuals with t $nmbr$ dm ( scale diabetes )	C0011816;C0011847;C0011849;C0027361;C0175659;C0237401;C0349674;C1947916;C3250443	\N	\N
909	individuals with diabetes  n = $nmbr$	C0011847;C0011849;C0027361;C0237401	\N	\N
909	hx of diabetes  n ( % )	C0011847;C0011849;C0262926;C3814444	\N	\N
909	history of diabetes requiring drugs	C0011847;C0011849;C0019664;C0019665;C0020616;C0262512;C0262926;C1553893;C1705255;C2004062	\N	\N
909	history of diabetes :	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
909	history of diabetes - n ( % )	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
909	history of diabetes ( n = $nmbr$ )	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
909	history of diabetes ( a )	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
909	high risk of diabetes	C0011847;C0011849;C0332167	\N	\N
909	duration of diabetes — yr ^	C0011847;C0011849;C0439234;C0449238;C2926735	\N	\N
909	duration of diabetes microvascular disease — no . ( % )	C0011847;C0011849;C0443258;C0872146	\N	\N
909	duration of diabetes mellitus  y  mean ( sd ) §	C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
909	duration of diabetes mellitus  y	C0011849;C0449238;C2926735	\N	\N
909	duration of diabetes mellitus  median ( iqr )  y	C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	\N	\N
909	duration of diabetes mellitus	C0011849;C0449238;C2926735	\N	\N
909	duration of diabetes by tertiles	C0011847;C0011849;C0449238;C2926735	\N	\N
909	duration of diabetes < $nmbr$ yrs	C0011847;C0011849;C0449238;C2926735	\N	\N
909	duration of diabetes ( years )  mean  ( sd )	C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
909	duration of diabetes ( y )	C0011847;C0011849;C0449238;C2926735	\N	\N
909	duration of diabetes ( months )	C0011847;C0011849;C0439231;C0449238;C2926735	\N	\N
909	duration of diabetes  yrs	C0011847;C0011849;C0449238;C2926735	\N	\N
909	duration of diabetes  y  mean ( sd )	C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
909	duration of diabetes  y	C0011847;C0011849;C0449238;C2926735	\N	\N
909	duration of diabetes  median ( iqr )	C0011847;C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	\N	\N
909	duration of diabetes  mean ( sd )  y	C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
909	duration of diabetes	C0011847;C0011849;C0449238;C2926735	\N	\N
909	drugs used in diabetes  n ( % )	C0011847;C0011849;C0013227;C1273517;C3687832	\N	\N
909	drugs used in diabetes	C0011847;C0011849;C0013227;C1273517;C3687832	\N	\N
909	diagnosis of diabetes  n ( % )	C0011847;C0011849;C0011900;C1704338;C1704656	\N	\N
909	diagnosed diabetes ( n = $nmbr$ )	C0011847;C0011849;C0011900	\N	\N
909	diabetesz	\N	\N	\N
909	diabetes — no . ( % )	C0011847;C0011849	\N	\N
909	diabetes | |	C0011847;C0011849	\N	\N
909	diabetes with target organ disease *	C0011847;C0011849;C0012634;C0178784;C1521840;C2986546	\N	\N
909	diabetes treatment	C0011847;C0011849;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
909	diabetes t	C0011847;C0011849	\N	\N
707	all bleeding	C0019080	\N	\N
909	diabetes present $nmbr$ ( $nmbr$ . $nmbr$ )	C0011847;C0011849;C0150312;C0449450	\N	\N
909	diabetes n ( % )	C0011847;C0011849	\N	\N
909	diabetes mellitust	C0011847;C0011849	\N	\N
909	diabetes mellitus 一 no . ( % )	C0011849	\N	\N
909	diabetes mellitus — no . / total no . ( % )	C0011849;C0439175;C0439810	\N	\N
909	diabetes mellitus — no . ( % )	C0011849	\N	\N
909	diabetes mellitus n = $nmbr$  $nmbr$	C0011849	\N	\N
909	diabetes mellitus duration ( sd )  y	C0011849;C0449238;C2699239;C2926735	\N	\N
909	diabetes mellitus duration  y ( sd )	C0011849;C0449238;C2699239;C2926735	\N	\N
909	diabetes mellitus duration  y	C0011849;C0449238;C2926735	\N	\N
909	diabetes mellitus [ n ( % ) ]	C0011849	\N	\N
909	diabetes mellitus :	C0011849	\N	\N
909	diabetes mellitus ( % )	C0011849	\N	\N
909	diabetes mellitus !	C0011849	\N	\N
909	diabetes mellitus  § n ( % )	C0011849	\N	\N
909	diabetes mellitus  no . / total no . ( % )	C0011849;C0439175;C0439810	\N	\N
909	diabetes mellitus  no . ( % )	C0011849	\N	\N
909	diabetes mellitus  n = $nmbr$	C0011849	\N	\N
909	diabetes mellitus  n / n ( % )	C0011849	\N	\N
909	diabetes mellitus  n ( % )	C0011849	\N	\N
909	diabetes mellitus  ( % )	C0011849	\N	\N
909	diabetes mellitus  %	C0011849	\N	\N
909	diabetes mellitus	C0011849	\N	\N
909	diabetes melitus	C0011847;C0011849	\N	\N
909	diabetes history  mean ( sd )  years	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239	\N	\N
909	diabetes durationa < median	C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
909	diabetes duration subgroups	C0011847;C0011849;C0449238;C1079230;C2926735	\N	\N
909	diabetes duration mean ± sd	C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
909	diabetes duration ( years )	C0011847;C0011849;C0439234;C0449238;C2926735	\N	\N
909	diabetes duration ( y )	C0011847;C0011849;C0449238;C2926735	\N	\N
7	p - value ( anova )	C0753802;C1709380	\N	\N
909	diabetes duration ( known )  % of patients	C0011847;C0011849;C0030705;C0205309;C0449238;C2926735	\N	\N
909	diabetes duration  years ( mean ± sd )	C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
909	diabetes duration  years	C0011847;C0011849;C0439234;C0449238;C2926735	\N	\N
909	diabetes duration  ycars “	C0011847;C0011849;C0449238;C2926735	\N	\N
909	diabetes duration  y	C0011847;C0011849;C0449238;C2926735	\N	\N
909	diabetes duration  n ( % )	C0011847;C0011849;C0449238;C2926735	\N	\N
909	diabetes duration	C0011847;C0011849;C0449238;C2926735	\N	\N
909	diabetes classificationa	C0011847;C0011849	\N	\N
909	diabetes at randomization	C0011847;C0011849;C0034656	\N	\N
909	diabetes and untreated hypertension	C0011847;C0011849;C0745134	\N	\N
909	diabetes and currently on an oral hypoglycaemic agent orinsulin	C0011847;C0011849;C0359086;C0521116	\N	\N
909	diabetes absent $nmbr$ ( $nmbr$ . $nmbr$ )	C0011847;C0011849;C0332197;C4285062	\N	\N
909	diabetes ^	C0011847;C0011849	\N	\N
909	diabetes - related medication use    n   ( % )	C0011847;C0011849;C0240320;C0439849;C0445223	\N	\N
909	diabetes *	C0011847;C0011849	\N	\N
909	diabetes ( p = . oo $nmbr$ )	C0011847;C0011849	\N	\N
909	diabetes ( p = . o $nmbr$ )	C0011847;C0011849	\N	\N
909	diabetes ( p = . $nmbr$ )	C0011847;C0011849	\N	\N
909	diabetes ( n [ % ] ) *	C0011847;C0011849	\N	\N
909	diabetes ( n = $nmbr$ )	C0011847;C0011849	\N	\N
909	diabetes ( n - $nmbr$  $nmbr$ )	C0011847;C0011849	\N	\N
909	diabetes ( % )	C0011847;C0011849	\N	\N
909	diabetes $nmbr$ ( % )	C0011847;C0011849	\N	\N
909	diabetes $nmbr$	C0011847;C0011849	\N	\N
909	diabetes  no . ( % ) c	C0011847;C0011849	\N	\N
909	diabetes  no . ( % )	C0011847;C0011849	\N	\N
909	diabetes  n ( % )	C0011847;C0011849	\N	\N
909	diabetes  * n ( % )	C0011847;C0011849	\N	\N
909	diabetes  %	C0011847;C0011849	\N	\N
909	diabetes	C0011847;C0011849	\N	\N
909	dabetes	\N	\N	\N
909	current cvd / diabetes  n ( % )	C0007222;C0011847;C0011849;C0521116;C1705970	\N	\N
909	all without diabetes ( n = $nmbr$ )	C0011847;C0011849	\N	\N
909	all with diabetes ( n = $nmbr$ )	C0011847;C0011849	\N	\N
909	( scale diabetes )	C0011847;C0011849;C0175659;C0349674;C1947916	\N	\N
-10	dizziness	C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830	\N	\N
907	years since diagnosis of type $nmbr$ diabetes  n ( % )	C0011847;C0011849;C0011900;C0439234;C1320657;C1550351;C1704338;C1704656	\N	\N
907	type $nmbr$ diabetes 一 no . ( % )	C1320657	\N	\N
907	type $nmbr$ diabetes — no . { % ) §	C1320657	\N	\N
907	type $nmbr$ diabetes — no . ( % ) §	C1320657	\N	\N
907	type $nmbr$ diabetes — no . ( % )	C1320657	\N	\N
907	type $nmbr$ diabetes mellitusa	C1320657	\N	\N
907	type $nmbr$ diabetes mellitus ’	C1320657	\N	\N
907	type $nmbr$ diabetes mellitus ' $nmbr$ '	C1320657	\N	\N
907	type $nmbr$ diabetes mellitus  n ( % )	C1320657	\N	\N
907	type $nmbr$ diabetes mellitus	C1320657	\N	\N
907	type $nmbr$ diabetes meiiitus	C1320657	\N	\N
907	type $nmbr$ diabetes history  n ( % )	C0019664;C0019665;C0262512;C0262926;C1320657;C1705255;C2004062	\N	\N
907	type $nmbr$ diabetes . n ( % )	C1320657	\N	\N
907	type $nmbr$ diabetes *	C1320657	\N	\N
907	type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ )	C1320657	\N	\N
907	type $nmbr$ diabetes  no . ( % )	C1320657	\N	\N
907	type $nmbr$ diabetes  n ( % ) d	C1320657	\N	\N
907	type $nmbr$ diabetes  n ( % )	C1320657	\N	\N
907	type $nmbr$ diabetes	C1320657	\N	\N
907	time since diagnosis of type $nmbr$ diabetes mellitus	C0011900;C0040223;C1320657;C1704338;C1704656;C3541383	\N	\N
907	time since diagnosis of type $nmbr$ diabetes - no . ( % )	C0011847;C0011849;C0011900;C0040223;C1320657;C1550351;C1704338;C1704656;C3541383	\N	\N
907	no type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ )	C1320657	\N	\N
907	known duration of type $nmbr$ diabetes ( years )	C0205309;C0439234;C0449238;C1320657;C2926735	\N	\N
907	known duration of type $nmbr$ diabetes	C0205309;C0449238;C1320657;C2926735	\N	\N
907	duration of type $nmbr$ diabetes mellitus ( years )	C0439234;C0449238;C1320657;C2926735	\N	\N
907	duration of type $nmbr$ diabetes mellitus  years	C0439234;C0449238;C1320657;C2926735	\N	\N
907	duration of type $nmbr$ diabetes categories  n ( % )	C1320657;C1547660	\N	\N
907	duration of type $nmbr$ diabetes ( years )	C0439234;C0449238;C1320657;C2926735	\N	\N
907	duration of type $nmbr$ diabetes  years	C0439234;C0449238;C1320657;C2926735	\N	\N
907	duration of type $nmbr$ diabetes	C0449238;C1320657;C2926735	\N	\N
907	diabetes mellitus ( type $nmbr$ or $nmbr$ )	C1320657	\N	\N
907	diabetes mellitus ( type $nmbr$ )  n ( % )	C1320657	\N	\N
906	option	C1518601;C1550456	\N	\N
906	location of disease  n ( % )	C0012634;C0450429;C1515974;C4284930;C4284931	\N	\N
906	location of crohn ' s disease  %	C0010346;C0450429;C1515974;C4284930;C4284931	\N	\N
906	location  n ( % )	C0450429;C1515974;C4284930;C4284931	\N	\N
906	location	C0450429;C1515974;C4284930;C4284931	\N	\N
906	lesion location	C0221198;C0450429;C1515974;C1546698;C4284930;C4284931	\N	\N
906	geographical location  n ( % )	C4545686	\N	\N
906	ethnicity  location	C0015031;C0243103;C0450429;C1515974;C4284930;C4284931	\N	\N
906	disease location ( % ) *	C0012634;C0450429;C1515974;C4284930;C4284931	\N	\N
906	disease location  %	C0012634;C0450429;C1515974;C4284930;C4284931	\N	\N
906	discontinu - ation	\N	\N	\N
905	omega $nmbr$ allocation	C1706778;C1719844	\N	\N
905	n - $nmbr$ allocation	C0369718;C0441922;C1706778	\N	\N
904	uplift ® population	C0032659;C1257890	\N	\N
904	subpopulation	C1257890	\N	\N
904	safety population  n ( % )	C0032659;C0036043;C1257890;C1705187	\N	\N
904	safety population	C0032659;C0036043;C1257890;C1705187	\N	\N
904	populations :	C0032659;C1257890	\N	\N
904	population	C0032659;C1257890	\N	\N
904	patient population	C0030705;C0032659;C1257890	\N	\N
904	overall pea population	C0030738;C0032659;C0069964;C0070939;C0282416;C1257890;C1262903;C1561607;C3257529	\N	\N
904	overall freedom population ( n = $nmbr$ )	C0016694;C0032659;C0282416;C1257890;C1561607	\N	\N
904	open - label population	C0032659;C1257890;C1709323	\N	\N
904	indian subpopulation	C1257890;C1524069	\N	\N
904	global trial population	C0008976;C0032659;C0205246;C1257890;C2348867	\N	\N
904	full population	C0032659;C0443225;C1257890	\N	\N
904	d population	C0032659;C0073187;C0332173;C1257890;C4484261	\N	\N
904	ctd population subgroup	C0032659;C1079230;C1257890;C1335071;C1442905;C1515021	\N	\N
904	boost intensify premix i ( global patient population )	C0021966;C0030705;C0032659;C0205246;C0221138;C1257890;C1511253;C1874596;C2348867	\N	\N
904	boost intensify all ( pan - asian patient population )	C0030705;C0032659;C0078988;C0085999;C1257890;C1511253;C1874596;C3887654	\N	\N
904	^ ≥ $nmbr$ % incidence in any treatment group in the overall safety population .	C0021149;C0032659;C0036043;C0220856;C0282416;C0374505;C1257890;C1561607;C1705187	\N	\N
903	uc disease duration ( y )	C0872146	\N	\N
903	mean disease duration  years	C0439234;C0444504;C0872146;C2347634;C2348143	\N	\N
903	mean disease duration  y ( sd )	C0444504;C0872146;C2347634;C2348143;C2699239	\N	\N
903	mean ( sd ) disease duration  years	C0439234;C0444504;C0872146;C2347634;C2348143;C2699239	\N	\N
903	duration of disease — yr ^ mean	C0439234;C0444504;C0872146;C2347634;C2348143	\N	\N
903	duration of disease — yr : t	C0439234;C0872146	\N	\N
903	duration of disease — yr	C0439234;C0872146	\N	\N
903	duration of disease since	C0872146	\N	\N
903	duration of disease before baseline	C0168634;C0872146;C1442488	\N	\N
903	duration of disease ( yr )	C0439234;C0872146	\N	\N
903	duration of disease ( y )  median ( min  max }	C0549183;C0702093;C0872146;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
903	duration of disease  y	C0872146	\N	\N
903	duration of disease  n ( % )	C0872146	\N	\N
903	duration of disease  median	C0549183;C0872146;C0876920;C2347635;C2348144;C2939193	\N	\N
903	disease duration b $nmbr$ years ( n = $nmbr$ )	C0439234;C0872146	\N	\N
903	disease duration [ year ]  mean ± sda	C0276477;C0439234;C0439508;C0444504;C0872146;C1428349;C1553165;C2347634;C2348143	\N	\N
903	disease duration > $nmbr$ years  $nmbr$ [ % ] disease activity ‘ s	C0205177;C0439167;C0439234;C0441655;C0449238;C0872146;C1292728;C1561536;C2926735;C3668946;C4049938;C4049939	\N	\N
903	disease duration : < baseline mean	C0168634;C0444504;C0872146;C1442488;C2347634;C2348143	\N	\N
903	disease duration ( yr )  mean ± sd	C0439234;C0444504;C0872146;C2347634;C2348143;C2699239	\N	\N
903	disease duration ( yr )	C0439234;C0872146	\N	\N
903	disease duration ( y )  median ( m / n  max )	C0369637;C0441923;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193	\N	\N
903	disease duration  year ( median )	C0439234;C0439508;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193	\N	\N
903	disease duration  y  mean ± sd	C0444504;C0872146;C2347634;C2348143;C2699239	\N	\N
903	disease duration  y	C0872146	\N	\N
906	infarct location	C0021308;C0450429;C1515974;C4284930;C4284931	f	1948
906	location of infarction — no . ( % ) §	C0021308;C0450429;C1515974;C4284930;C4284931	f	1948
906	location of ml	C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931	f	1948
903	disease duration  mean yr ( sd )	C0439234;C0444504;C0872146;C2347634;C2348143;C2699239	\N	\N
903	disease duration  mean [ sd ] years	C0439234;C0444504;C0872146;C2347634;C2348143;C2699239	\N	\N
903	disease duration	C0872146	\N	\N
903	disease characteristics duration of psoriatic arthritis — yr	C0003872;C0439234;C0449238;C0599878;C0872146;C1521970;C2926735	\N	\N
902	years of education *	C0013621;C0013622;C0013658;C0039401;C0439234	\N	\N
902	education — no . ( % )	C0013621;C0013622;C0013658;C0039401	\N	\N
902	education level	C0013621;C0013658	\N	\N
902	education > $nmbr$ yr ( % )	C0013621;C0013622;C0013658;C0039401;C0439234	\N	\N
902	education > $nmbr$ y	C0013621;C0013622;C0013658;C0039401	\N	\N
902	education < $nmbr$ y	C0013621;C0013622;C0013658;C0039401	\N	\N
902	education *	C0013621;C0013622;C0013658;C0039401	\N	\N
902	education ( % )	C0013621;C0013622;C0013658;C0039401	\N	\N
902	education $nmbr$ to $nmbr$ y	C0013621;C0013622;C0013658;C0039401	\N	\N
902	education  yrs  mean ( sd )	C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239	\N	\N
902	education  y  mean ( sd )	C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239	\N	\N
902	education  y	C0013621;C0013622;C0013658;C0039401	\N	\N
902	education  mean ( sd )  ya	C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239	\N	\N
902	education  mean ( sd )  y	C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239	\N	\N
902	education	C0013621;C0013622;C0013658;C0039401	\N	\N
902	age of completion of highest education  years ( sd )	C0013621;C0013622;C0013658;C0039401;C0205197;C1510829;C1522410;C1554962;C2699239	\N	\N
901	t $nmbr$ dm duration  y	C0011816;C0449238;C2603360;C2926735;C3250443	\N	\N
901	symptom duration  months	C0439231;C0449238;C1457887;C2926735;C3854129	\N	\N
901	symptom duration	C0449238;C1457887;C2926735;C3854129	\N	\N
901	ra symptom duration — year	C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756	\N	\N
901	ra symptom duration < $nmbr$ months — number ( % )	C0237753;C0439231;C0449238;C0449788;C1457887;C2926735;C3538806;C3854129;C4048756	\N	\N
901	ra duration ( months ) *	C0439231;C0449238;C2926735;C3538806;C4048756	\N	\N
901	pci duration in min ( median  iqr )	C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621	\N	\N
901	pci duration	C0449238;C2926735;C4049621	\N	\N
901	median crohn ' s disease duration  y ( range )	C0010346;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016	\N	\N
901	mean ( sd ) duration of t $nmbr$ dm  y	C0011816;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3250443	\N	\N
901	mean ( s . d . ) duration of t $nmbr$ dm  years	C0011816;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3250443	\N	\N
901	known duration of t $nmbr$ dm  y	C0011816;C0205309;C0449238;C2926735;C3250443	\N	\N
901	known duration	C0205309;C0449238;C2926735	\N	\N
901	extended - duration enoxaparin ( n = $nmbr$ )	C0206460;C0231448;C0231449;C0439792;C0449238;C2926735	\N	\N
901	extended - duration enoxaparin  n / n ( % )	C0206460;C0231448;C0231449;C0439792;C0449238;C2926735	\N	\N
901	duration of ulcerative colitis	C0009324;C0449238;C2926735	\N	\N
901	duration of t $nmbr$ dm > $nmbr$ years	C0011816;C0439234;C0449238;C2926735;C3250443	\N	\N
901	duration of t $nmbr$ dm < $nmbr$ years	C0011816;C0439234;C0449238;C2926735;C3250443	\N	\N
901	duration of t $nmbr$ dm ( years )	C0011816;C0439234;C0449238;C2926735;C3250443	\N	\N
901	duration of t $nmbr$ dm ( % )	C0011816;C0449238;C2926735;C3250443	\N	\N
901	duration of t $nmbr$ dm  years	C0011816;C0439234;C0449238;C2926735;C3250443	\N	\N
901	duration of t $nmbr$ dm  y	C0011816;C0449238;C2926735;C3250443	\N	\N
901	duration of t $nmbr$ dm	C0011816;C0449238;C2926735;C3250443	\N	\N
901	duration of t $nmbr$ d  y	C0449238;C2926735	\N	\N
901	duration of study - drug infusion	C0392877;C0449238;C0557651;C2603343;C2926735	\N	\N
901	duration of ra ( years )	C0439234;C0449238;C2926735;C3538806;C4048756	\N	\N
901	duration of ra ( time from symptom onset )  years	C0040223;C0439234;C0449238;C2926735;C3538806;C3541383;C4048756;C4086878	\N	\N
901	duration of ra	C0449238;C2926735;C3538806;C4048756	\N	\N
901	duration of pci — min	C0449238;C0702093;C1524029;C2926735;C3813700;C4049621	\N	\N
901	duration of pci ( min )  median	C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621	\N	\N
901	duration of pci  min	C0449238;C0702093;C1524029;C2926735;C3813700;C4049621	\N	\N
901	duration of morning	C0332170;C0449238;C2926735	\N	\N
901	duration of dm - years	C0011816;C0439234;C0449238;C2926735;C3250443	\N	\N
901	duration of chf ( months )	C0018802;C0439231;C0449238;C2926735	\N	\N
901	duration of assigned regimen before surgery post - randomisation characteristic * *	C0034656;C0038894;C0038895;C0040808;C0449238;C0543467;C0687676;C1274039;C1516050;C1521970;C1552601;C1704687;C2926735;C2945654;C3469826	\N	\N
901	duration of assigned regimen before surgery post - randomisation characteristic *	C0034656;C0038894;C0038895;C0040808;C0449238;C0543467;C0687676;C1274039;C1516050;C1521970;C1552601;C1704687;C2926735;C2945654;C3469826	\N	\N
901	duration of assigned regimen before surgery	C0038894;C0038895;C0040808;C0449238;C0543467;C1274039;C1516050;C1552601;C2926735;C2945654	\N	\N
901	duration of	C0449238;C2926735	\N	\N
901	duration	C0449238;C2926735	\N	\N
901	dm duration	C0011816;C0449238;C2926735;C3250443	\N	\N
901	crohn ' s disease duration	C0010346;C0449238;C2926735	\N	\N
901	cornell voltage - duration product ( mmxmsec ) *	C0449238;C0598352;C1514468;C1704444;C2926735	\N	\N
901	af duration  n ( % )	C0344434;C0449238;C2926735;C4049859	\N	\N
900	severe exacerbations  itt population  n ( % )	C0032659;C0205082;C1257890;C4050465;C4050466;C4086268	\N	\N
900	moderate / severe exacerbations  itt population  n ( % )	C0032659;C0205081;C0205082;C1257890;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335	\N	\N
900	mitt population ( n = $nmbr$ )	C0032659;C1257890	\N	\N
900	mitt population	C0032659;C1257890	\N	\N
900	joint damage outcomes ( mitt population )	C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709	\N	\N
900	itt population  n	C0032659;C1257890	\N	\N
900	itt population	C0032659;C1257890	\N	\N
900	itt	\N	\N	\N
900	asian itt population total ( n = $nmbr$ )	C0032659;C0078988;C0439175;C0439810;C1257890	\N	\N
899	infarct localization  n ( % )	C0021308;C0475264;C1744691	\N	\N
899	infarct localization	C0021308;C0475264;C1744691	\N	\N
899	infarct localisation	C0021308;C0475264;C1744691	\N	\N
898	medication effects	C1319171	\N	\N
897	cardiovascular medications  %	C0007220	\N	\N
897	cardiovascular medications	C0007220	\N	\N
897	cardiovascular medication usage	C0007220;C0457083	\N	\N
897	baseline concomitant cardiovascular medications	C0007220;C0168634;C0521115;C1442488	\N	\N
897	baseline cardiovascular medications  n ( % )	C0007220;C0168634;C1442488	\N	\N
897	baseline cardiovascular medication  c n ( % )	C0007220;C0168634;C1442488	\N	\N
897	baseline cardiovascular medication	C0007220;C0168634;C1442488	\N	\N
897	antihypertensive  antianginal  and other cardiovascular medications	C0003364;C0007220;C1874267;C3537168	\N	\N
896	laboratory investigations	C0022877;C1261322;C3244292;C4283904	\N	\N
896	investigations	C1261322	\N	\N
896	additional investigations	C2359834	\N	\N
895	prior amputation	C0002688;C0332152;C0332840;C1546539;C2826257	\N	\N
895	major amputations at week $nmbr$	C0002688;C0205082;C0205164;C0332174;C0439230;C4318856;C4521762	\N	\N
895	amputations  n ( % )	C0002688	\N	\N
895	amputation	C0002688;C0332840;C1546539	\N	\N
894	• ml without st - segment elevation	C0439526;C0520886;C1705224;C3887665	\N	\N
894	• ml with st - segment elevation	C0439526;C0520886;C1705224;C3887665	\N	\N
894	st - segment elevation mi	C0520886;C3810814	\N	\N
894	non - st - segment elevation mi	C0520886;C1518422;C3810814	\N	\N
894	non - st - segment elevation acs	C0520886;C0742343;C1518422;C4318612	\N	\N
894	non - st - segment elevation	C0520886;C1518422	\N	\N
894	non - st - elevation ml	C0439526;C0520886;C1518422;C1705224;C3887665	\N	\N
894	ml without st - segment elevation !	C0439526;C0520886;C1705224;C3887665	\N	\N
894	ml with st - segment elevation	C0439526;C0520886;C1705224;C3887665	\N	\N
893	lm bifurcation treated	C0184906;C1261082;C1522326;C1551056;C3146289	\N	\N
893	lm bifurcation not treated	C0184906;C1261082;C1518422;C1522326;C1551056;C3146289	\N	\N
893	bifurcation per lesion ‡	C0184906;C0221198;C1546698;C3146289	\N	\N
893	bifurcation lesion with side branch ≥ $nmbr$ . $nmbr$ mm stented	C0038257;C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674	\N	\N
893	bifurcation lesion with side branch $ $nmbr$ . $nmbr$ mm stented	C0038257;C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674	\N	\N
893	bifurcation lesion	C0184906;C0221198;C1546698;C3146289	\N	\N
893	bifurcation  n ( % )	C0184906;C3146289	\N	\N
893	bifurcation	C0184906;C3146289	\N	\N
892	score distribution : < $nmbr$	C0449820;C0520511;C1704711;C4050231	\N	\N
892	score distribution :	C0449820;C0520511;C1704711;C4050231	\N	\N
892	distribution — no . { % )	C0520511;C1704711	\N	\N
892	distribution — no . ( % )	C0520511;C1704711	\N	\N
892	distribution time	C0040223;C0520511;C1704711;C3541383	\N	\N
892	distribution of metformin dose at randomization  n ( % )	C0025598;C0034656;C0178602;C0520511;C0869039;C1114758;C1704711	\N	\N
892	bmi distribution  n ( % )	C0520511;C0578022;C1704711	\N	\N
892	a $nmbr$ c distribution ( % )	C0520511;C1704711	\N	\N
891	one or more copd exacerbations ( n / n [ % ] )	C0205172;C0205447;C0740304	\N	\N
891	copd exacerbation : no	C0740304	\N	\N
890	mean number of clinically significant asthma exacerbations †	C0237753;C0237881;C0349790;C0444504;C0449788;C0750502;C1546944;C2347634;C2348143	\N	\N
890	asthma exacerbations	C0349790	\N	\N
889	s $nmbr$ exacerbations	C0565930;C2603362;C4086268	\N	\N
889	patients with > $nmbr$ exacerbations resulting in hospital admission	C0030705;C0184666;C0678226;C4086268	\N	\N
889	patients with > $nmbr$ exacerbations resulting in emergency department visit	C0030705;C0332294;C0545082;C0553618;C0562508;C1512346;C1704729;C2826704;C4086268	\N	\N
889	patients with > $nmbr$ exacerbations resulting in ed visit	C0030705;C0332294;C0545082;C1512346;C2826704;C3538926;C4086268	\N	\N
889	patients with > $nmbr$ exacerbation in previous $nmbr$ months	C0030705;C0205156;C0439231;C1552607;C4086268	\N	\N
889	patients having exacerbation	C0030705;C4086268	\N	\N
889	p ) atients with > $nmbr$ exacerbations resulting in emergency department visit	C0332294;C0369773;C0545082;C0553618;C0562508;C1512346;C1704729;C2603361;C2826704;C4086268	\N	\N
889	number of patients with exacerbations in the previous $nmbr$ months  n ( % )	C0205156;C0439231;C1552607;C2360800;C4086268	\N	\N
889	number of exacerbations in the past $nmbr$ months	C0237753;C0449788;C4086268;C4331910	\N	\N
889	number of exacerbations in the last $nmbr$ months  mean ± sd	C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268;C4331910	\N	\N
889	number of exacerbations in the last $nmbr$ months	C0237753;C0449788;C4086268;C4331910	\N	\N
889	number of exacerbations in previous $nmbr$   months	C0205156;C0237753;C0439231;C0449788;C1552607;C4086268	\N	\N
889	number of exacerbations in previous $nmbr$ months	C0205156;C0237753;C0439231;C0449788;C1552607;C4086268	\N	\N
889	number of exacerbations in last $nmbr$ months	C0237753;C0449788;C4086268;C4331910	\N	\N
889	number of exacerbations $nmbr$ months before randomisation	C0034656;C0237753;C0439231;C0449788;C4086268	\N	\N
889	number of exacerbations	C0237753;C0449788;C4086268	\N	\N
889	number of exacerbation in the previous $nmbr$ months  n ( % )	C0205156;C0237753;C0439231;C0449788;C1552607;C4086268	\N	\N
889	hospitalized for an exacerbation	C0701159;C4086268	\N	\N
707	all bleed	C0019080	\N	\N
894	time from randomization to pci ( st - elevation mi )  min	C0034656;C0040223;C0520886;C0702093;C1524029;C3541383;C3810814;C3813700;C4049621	f	1945
898	cardiac medications at discharge  %	C0018787;C0806915;C1522601	f	897
898	medications at discharge	C0806915	f	1946
899	symptomatic localization - related	C0231220;C0439849;C0445223;C0475264;C1744691	f	1947
889	hospitalized exacerbation rates	C0701159;C0871208;C1521828;C4086268	\N	\N
889	exacerbations in the past $nmbr$ months n	C4086268;C4331910	\N	\N
889	exacerbations	C4086268	\N	\N
889	exacerbation historyh  n ( % )	C4086268	\N	\N
889	> $nmbr$ exacerbations	C4086268	\N	\N
889	> $nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ )	C0369637;C0441923;C1552852;C4086268	\N	\N
889	$nmbr$ exacerbations	C4086268	\N	\N
889	$nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ )	C0369637;C0441923;C1552852;C4086268	\N	\N
889	$nmbr$ exacerbation	C4086268	\N	\N
889	$ $nmbr$ exacerbations	C4086268	\N	\N
888	| interactior $nmbr$ p	\N	\N	\N
888	time to randomisation [ hours ] ( interaction : p = $nmbr$ . $nmbr$ )	C0034656;C0040223;C0439227;C1704675;C3541383	\N	\N
888	pinteraction = $nmbr$ . $nmbr$	\N	\N	\N
888	pinteraction	\N	\N	\N
888	pfor interaction	C1151635;C1704675	\N	\N
888	p   values for interaction	C1704675;C1709380	\N	\N
888	p value for interaction - dosage with dabigatran  $nmbr$ mg	C0024671;C0026410;C0178602;C0439269;C1704675;C1709380;C1960952;C2346927;C2348066;C2986497;C4321396;C4521761	\N	\N
888	p value for interaction  dosage with dabigatran  $nmbr$ mg	C0024671;C0026410;C0178602;C0439269;C1704675;C1709380;C1960952;C2346927;C2348066;C2986497;C4321396;C4521761	\N	\N
888	p vaiue ( interaction )	C0369773;C1704675;C2603361	\N	\N
888	p lace of randomization ( interaction : p = $nmbr$ . $nmbr$ )	C0034656;C0280109;C0369773;C0453991;C1704675;C2603361	\N	\N
888	p interaction women vs men	C0025266;C0043210;C0369773;C1704675;C2603361	\N	\N
888	p interaction = $nmbr$ . $nmbr$	C0369773;C1704675;C2603361	\N	\N
888	p interaction	C0369773;C1704675;C2603361	\N	\N
888	p for interaction between rhtn and no rhtn and treatmenta	C0369773;C1704675;C2603361	\N	\N
888	p for interaction *	C0369773;C1704675;C2603361	\N	\N
888	p for interaction	C0369773;C1704675;C2603361	\N	\N
888	p : interaction	C0369773;C1704675;C2603361	\N	\N
888	p / interaction	C0369773;C1704675;C2603361	\N	\N
888	p . interaction	C0369773;C1704675;C2603361	\N	\N
888	p - interaction	C0369773;C1704675;C2603361	\N	\N
888	p $nmbr$ interaction	C0369773;C1704675;C2603361	\N	\N
888	p  interaction !	C0369773;C1704675;C2603361	\N	\N
888	lue for interaction	C1704675	\N	\N
888	interactior p - value	C1709380	\N	\N
888	interaction pf	C1704675;C3815179	\N	\N
888	interaction p vaiue	C1704675	\N	\N
888	interaction p = $nmbr$ . $nmbr$	C1704675	\N	\N
888	interaction p - vaiue	C1704675	\N	\N
888	interaction p	C1704675	\N	\N
888	interaction - p	C1704675	\N	\N
888	interaction $nmbr$	C1704675	\N	\N
888	interaction	C1704675	\N	\N
888	egfr_p_interaction	C1704675;C1739039;C3811844;C3812682	\N	\N
888	/ ’ interaction	C1704675	\N	\N
887	section $nmbr$ c	C0152060;C0700320;C1522472;C1552923;C1705191;C3714523	\N	\N
887	section $nmbr$ b	C0152060;C0700320;C1522472;C1552923;C1705191;C3714523	\N	\N
887	section $nmbr$ a	C0152060;C0700320;C1522472;C1552923;C1705191;C3714523	\N	\N
887	method of assessing ejection fraction	C0025663;C0302131;C0336969;C0449851;C0812388;C0871511;C1264633;C1516048	\N	\N
887	fraction ( % )	C1264633;C1554103	\N	\N
887	ejection fraction group	C0441833;C0489482;C0687744;C1257890;C1519504;C1705428;C1705429;C2700378	\N	\N
887	ejection fraction category	C0489482;C0683312;C2700378;C3889287	\N	\N
887	ejection fraction based on local reading	C0034754;C0205276;C0489482;C1527178;C1705179;C1705938;C2700378;C4284139	\N	\N
887	ejection fraction : < $nmbr$ % ( n = $nmbr$ )	C0489482;C2700378	\N	\N
887	ejection fraction *	C0489482;C2700378	\N	\N
887	ejection fraction ( % )	C0489482;C2700378	\N	\N
887	ejection fraction  percent ( sd )	C0439165;C0489482;C2699239;C2700378	\N	\N
887	ejection fraction  % nyha class  n ( % )	C0489482;C1882083;C2700378	\N	\N
887	ejection fraction  %	C0489482;C2700378	\N	\N
887	ejection fraction	C0489482;C2700378	\N	\N
886	rosuvastatin   n   =   $nmbr$	C0965129	\N	\N
886	rosuvastatin of patients ( rate )	C0030705;C0871208;C0965129;C1521828	\N	\N
886	rosuvastatin n = $nmbr$	C0965129	\N	\N
886	rosuvastatin n ( rate ) *	C0871208;C0965129;C1521828	\N	\N
886	rosuvastatin n ( rate ) $nmbr$	C0871208;C0965129;C1521828	\N	\N
886	rosuvastatin n ( rate )	C0871208;C0965129;C1521828	\N	\N
886	rosuvastatin events / patients ( % )	C0030705;C0441471;C0965129;C3541888	\N	\N
886	rosuvastatin + fenofibric acid	C0060179;C0965129	\N	\N
886	rosuvastatin +	C0965129	\N	\N
886	rosuvastatin ( n = $nmbr$ . $nmbr$ )	C0965129	\N	\N
886	rosuvastatin ( n = $nmbr$ )	C0965129	\N	\N
886	rosuvastatin ( n = $nmbr$  $nmbr$ )	C0965129	\N	\N
886	rosuvastatin $nmbr$ mg	C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761	\N	\N
886	rosuvastatin $nmbr$ - $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761	\N	\N
886	rosuvastatin  n ( rate )	C0871208;C0965129;C1521828	\N	\N
886	rosuvastatin  n ( % )	C0965129	\N	\N
886	rosuvastatin  events / patients ( % )	C0030705;C0441471;C0965129;C3541888	\N	\N
886	rosuvastatin	C0965129	\N	\N
886	rosuva  rosuvastatin  sd  standard deviation  t $nmbr$ dm  type $nmbr$ diabetes mellitus .	C0011816;C0011849;C0332307;C0871420;C0965129;C1320657;C1547052;C2699239;C3250443	\N	\N
886	i rosuvastatin ( n = $nmbr$ )	C0021966;C0221138;C0965129	\N	\N
886	dose of rosuvastatin	C0178602;C0869039;C0965129;C1114758	\N	\N
886	crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .	C0060179;C0965129	\N	\N
886	copd - rosuvastatin ( n = $nmbr$ )	C0024117;C0965129;C1412502;C3714496	\N	\N
886	copd - rosuvastatin ( $nmbr$ pt ) n . ( % )	C0024117;C0032743;C0699718;C0965129;C1412502;C3714496	\N	\N
886	$nmbr$ mg  rosuvastatin $nmbr$ mg .	C0965129;C1319635	\N	\N
885	z\\tonastaiin	\N	\N	\N
885	dose of atorvastatin	C0178602;C0286651;C0869039;C1114758	\N	\N
885	concomitant atorvastatin dose  mg	C0024671;C0026410;C0178602;C0286651;C0439269;C0521115;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761	\N	\N
885	atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment   [ expressed as number of patients reaching ldl - c goal at week $nmbr$ / number of patients above goal at baseline  ^ treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg .	C0018017;C0022885;C0023824;C0024671;C0026410;C0039593;C0039798;C0087111;C0168634;C0210243;C0237455;C0286651;C0332174;C0376209;C0392366;C0439230;C0439269;C0449822;C0456081;C0456984;C0674679;C0680230;C1079230;C1145759;C1334862;C1442488;C1512806;C1515021;C1515976;C1518422;C1522326;C1533734;C1571704;C1704675;C1704788;C1705169;C1709380;C1960952;C2346927;C2360800;C2584321;C2945673;C2986480;C3538994;C3539106;C3831328;C3887704;C4048755;C4318744;C4321396;C4521761	\N	\N
885	atorvastatinb	\N	\N	\N
885	atorvastatin { n = $nmbr$  $nmbr$ )	C0286651	\N	\N
885	atorvastatin monotherapy ( n = $nmbr$ * )	C0286651	\N	\N
885	atorvastatin factorial study	C0286651;C2826344	\N	\N
885	atorvastatin dose	C0178602;C0286651;C0869039;C1114758	\N	\N
885	atorvastatin ( n = $nmbr$  $nmbr$ )	C0286651	\N	\N
885	atorvastatin $nmbr$ mg + ezetimibe $nmbr$ mg ( n = $nmbr$ )	C0286651;C1142985;C1319635	\N	\N
885	atorvastatin $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
885	atorvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
885	atorvastatin $nmbr$ mg	C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
885	atorvastatin  n ( % )	C0286651	\N	\N
885	atorvastatin	C0286651	\N	\N
885	aiorvasiaiin	\N	\N	\N
884	metastatic disease	C0027627;C2939419;C2939420	\N	\N
884	metastatic	C0036525;C1522484;C4085632	\N	\N
884	epistaxis	C0014591;C4554627	\N	\N
883	prosthetic	\N	\N	\N
883	alprostadil n / n %	C0002335	\N	\N
883	alprostadil n / n	C0002335	\N	\N
883	alprostadil ( n = $nmbr$ )	C0002335	\N	\N
882	i moderate  $nmbr$ mg of pravastatin ( n = $nmbr$ )	C0021966;C0024671;C0026410;C0085542;C0205081;C0221138;C0439269;C1881878;C1960952;C2346927;C4049705;C4049706;C4085643;C4321335;C4321396;C4521761	\N	\N
882	clow - potency stratum : simvastatin $nmbr$ mg  pravastatin $nmbr$ mg  fluvastatin $nmbr$ mg  atorvastatin $nmbr$ mg  high - potency stratum : simvastatin $nmbr$ mg  atorvastatin	C0074554;C0082608;C0085542;C0205250;C0286651;C1299351;C1319635;C2700149;C2985073;C3245505;C3887512;C3889660;C4321237;C4522209	\N	\N
881	migraine with aura	C0154723	\N	\N
880	without revascularsation	\N	\N	\N
880	without ( n = $nmbr$ $nmbr$ )	C0369718;C0441922	\N	\N
879	withdrew consent	C1511481;C1554192;C2349954;C2923685	\N	\N
879	withdrawals  n / n ( % )	C1710677;C2349954;C2825032;C3812880;C4049634	\N	\N
878	with an sfua	\N	\N	\N
878	with ( n = $nmbr$ )	C0369718;C0441922	\N	\N
878	patients with specific disease characteris -	C0205369;C0683521;C1552740	\N	\N
878	patients with remission	C1277626	\N	\N
877	treated with atenolol ( n = $nmbr$ )	C0004147;C0332293	\N	\N
876	without an sfua	\N	\N	\N
876	or ( itt ) ( n = $nmbr$ )	\N	\N	\N
876	associated with hiv infection	C0019693;C0332281	\N	\N
876	associated with drug or toxin exposure	C0013227;C0040537;C0332281;C1254351	\N	\N
876	associated with drug / toxin	C0013221;C0332281	\N	\N
876	associated with ctd	C0332281;C1335071;C1442905	\N	\N
876	associated with corrected - congenital shunts	C0009678;C0205202;C0232180;C0332281;C0542331;C1442858;C1744681	\N	\N
876	associated with corrected	C0205202;C0332281	\N	\N
876	associated with an atrial septal defect	C0018817;C0332281	\N	\N
875	regular alcohol consumption per week  no . ( % )	C0001948;C0205272;C0332174;C0439230	\N	\N
875	no alcohol consumption  on average	C0001948;C1510992;C2825518	\N	\N
875	drinking  n ( % )	C0001948;C0684271	\N	\N
875	drinking	C0001948;C0684271	\N	\N
875	current weekly alcohol use ( % )	C0001948;C0332174;C0521116;C1705970	\N	\N
875	current alcohol use  n ( % )	C0001948;C0521116;C1705970	\N	\N
875	alcohol use ( > $nmbr$ drink / wk )	C0001948;C0042153;C0332174;C0439230;C0452428;C0457083;C0556297;C1947944	\N	\N
875	alcohol use ( % )	C0001948	\N	\N
875	alcohol use ( %  > $nmbr$ / day )	C0001948;C0332173;C0439228;C0439505	\N	\N
875	alcohol use  n ( % )	C0001948	\N	\N
875	alcohol use	C0001948	\N	\N
875	alcohol intake never / rarely	C0001948;C0522498;C2003901	\N	\N
875	alcohol intake ( a )	C0001948	\N	\N
875	alcohol intake ( + ) ( % )	C0001948	\N	\N
875	alcohol intake  drinks / week	C0001948;C0332174;C0439230;C0452428	\N	\N
875	alcohol intake	C0001948	\N	\N
875	alcohol consumption at baseline	C0001948;C0168634;C1442488	\N	\N
875	alcohol consumption > once weekly	C0001948;C0558293	\N	\N
875	alcohol consumption *	C0001948	\N	\N
875	alcohol consumption ( yes ) ( n )	C0001948;C1549445;C1705108;C1710701	\N	\N
875	alcohol consumption ( % ) < $nmbr$ drink / dav	C0001948;C0009830;C0452428;C0556297;C1947907	\N	\N
875	alcohol consumption ( % )	C0001948	\N	\N
875	alcohol consumption !	C0001948	\N	\N
625	baseline vfx	C0168634;C1442488	\N	\N
882	atorvastatin - pravastatin	C0085542;C0286651	f	885
877	patients treated with losartan ( n = $nmbr$ )	C0030705;C0126174;C0332293	f	1939
877	treated with losartan ( n = $nmbr$ )	C0126174;C0332293	f	1939
877	table $nmbr$ . characteristics of patients treated with losartan and atenolol *	C0004147;C0039224;C0126174;C0332293;C0815172;C1706074	f	1939
877	treated with laba  %	C0332293	f	1508
881	epilepsy with grand mal seizures on awakening	C0014549;C0494475;C1720052	f	1940
880	migraine without aura	C0338480	f	1941
883	benign prostatic hyperplasia	C1704272	f	1942
875	alcohol consumption  no . ( % )	C0001948	\N	\N
875	alcohol consumption  n ( % )	C0001948	\N	\N
875	alcohol consumption	C0001948	\N	\N
875	alcohol  % with > $nmbr$ drink / d	C0001948;C0556297	\N	\N
874	sildenafil ( n = $nmbr$ )	C0529793	\N	\N
873	pooled simvastatin factorial studies	C0074554;C1709595;C2349200;C2826344;C4522255	\N	\N
873	placebo / simvastatin	C0032042;C0074554;C1696465;C1706408	\N	\N
873	placebo + $nmbr$ mg / d of simvastatin	C0032042;C0074554;C0439422;C1696465;C1706408	\N	\N
872	use of statins	C0360714;C1524063	\N	\N
872	use of statin at any follow - up visit ( % )	C0360714;C0589121;C1524063	\N	\N
872	treatment with statins	C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
872	statins 一 no . ( % )	C0360714	\N	\N
872	statins  no . ( % )	C0360714	\N	\N
872	statins  n ( % )	C0360714	\N	\N
872	statins	C0360714	\N	\N
872	statin without other llt	C0360714;C2347090	\N	\N
872	statin with other llt	C0360714;C2347090	\N	\N
872	statin with niacin	C0027996;C0360714;C1142562	\N	\N
872	statin use at baseline	C0042153;C0168634;C0360714;C0457083;C1442488;C1947944	\N	\N
872	statin use  n ( % )	C0042153;C0360714;C0457083;C1947944	\N	\N
872	statin usage	C0360714;C0457083	\N	\N
872	statin treatment	C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
872	statin potency stratum  n ( % )	C0360714;C3245505	\N	\N
872	statin medication	C0013227;C0360714;C3244316;C4284232	\N	\N
872	statin intolerant *	C0231200;C0360714	\N	\N
872	statin during admission	C0184666;C0360714;C0809949	\N	\N
872	statin alone	C0205171;C0360714;C0439044;C0679994	\N	\N
872	statin + er niacin ( n = $nmbr$ )	C0027996;C0360714;C1142562;C3810541;C3811131	\N	\N
872	statin ( s )	C0360714	\N	\N
872	statin ( n = $nmbr$ )	C0360714	\N	\N
872	statin ( n - $nmbr$ )	C0360714	\N	\N
872	statin ( % )	C0360714	\N	\N
872	statin  n ( % )	C0360714	\N	\N
872	statin  % ( n )	C0360714	\N	\N
872	statin	C0360714	\N	\N
872	stalin	\N	\N	\N
872	prevention )  n ( % ) patients on llt ( other than statin )  n ( % )	C0030705;C0199176;C0360714;C1706420;C2347090;C2700409	\N	\N
872	peri - op statins : no ( n = $nmbr$ )	C0347985;C0360714;C0369718;C0441922	\N	\N
872	patients receiving statin	C0030705;C0360714;C1514756	\N	\N
872	patients not receiving statin	C0030705;C0360714;C1514756;C1518422	\N	\N
872	non high dose statin ( n = $nmbr$  $nmbr$ )	C0360714;C0444956;C1518422	\N	\N
872	non - statin ( n = $nmbr$ )	C0360714;C1518422	\N	\N
872	no statin during admission	C0184666;C0360714;C0809949	\N	\N
872	no statin ( + / - llt )	C0360714;C2347090	\N	\N
872	no statin	C0360714	\N	\N
872	moderate - intensity statin use	C0042153;C0360714;C0457083;C1947944;C4081855	\N	\N
872	moderate - intensity statin	C0360714;C4081855	\N	\N
872	ltt other than statin	C0360714	\N	\N
872	llv wlalil $nmbr$ statin	C0360714	\N	\N
872	history of statin use	C0019664;C0019665;C0262512;C0262926;C0360714;C1524063;C1705255;C2004062	\N	\N
872	high - dose statin pretreatment ( n = $nmbr$ )	C0360714;C0444956;C1550147;C2709094;C3539075;C3539076	\N	\N
872	eze + statin n = $nmbr$	C0360714	\N	\N
872	eze + statin	C0360714	\N	\N
872	baseline statin use	C0042153;C0168634;C0360714;C0457083;C1442488;C1947944	\N	\N
872	baseiine statin	C0360714	\N	\N
872	any statin versus no statin at randomization	C0034656;C0360714	\N	\N
872	any statin ( with / without llt )	C0360714;C2347090	\N	\N
872	any statin	C0360714	\N	\N
872	all patients on maximally tolerated statin ± other llt	C0030705;C0360714;C2347090	\N	\N
872	a . overall and subgroups bv statin potency - -	C0085166;C0282416;C0360714;C1079230;C1511278;C1561607;C3245505	\N	\N
871	niacini	\N	\N	\N
871	niacin + statin	C0027996;C0360714;C1142562	\N	\N
871	niacin ( n = $nmbr$ )	C0027996;C1142562	\N	\N
871	niacin  n ( % )	C0027996;C1142562	\N	\N
871	niacin	C0027996;C1142562	\N	\N
870	histamine - $nmbr$ - receptor antagonist	C0019590;C4521896	\N	\N
870	anti - histamines	C0019590	\N	\N
869	vitamin e	C0042874;C3714803	\N	\N
869	randomized to receive vitamin e	C0034656;C0040363;C0041260;C0042874;C1514756;C1883351;C3714803;C3815594	\N	\N
869	i vitamin e ( n = $nmbr$ )	C0021966;C0042874;C0042890;C0221138;C0683454;C3714803	\N	\N
869	i vitamin e	C0021966;C0042874;C0042890;C0221138;C0683454;C3714803	\N	\N
869	$nmbr$ vitamin e ( n = $nmbr$ $nmbr$ )	C0042874;C3714803	\N	\N
869	$nmbr$ vitamin e	C0042874;C3714803	\N	\N
868	vitamin k antagonists	C3653316	\N	\N
868	vitamin k antagonist naive	C1096489;C2267235	\N	\N
873	simvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761	f	1840
873	simvastatin ( n = $nmbr$ )	C0074554	f	1840
873	simvastatin ( n = $nmbr$  $nmbr$ )	C0074554	f	1840
873	simvastatin ( n = $nmbr$ . $nmbr$ )	C0074554	f	1840
873	atorvastatin $nmbr$ mg and simvastatin $nmbr$ - $nmbr$ mg ( zi = $nmbr$ )	C0024671;C0026410;C0043476;C0074554;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761	f	1840
873	exetimibe / simvastatin	C0074554	f	1840
873	patients on atorvastatin  rosuvastatin  or simvastatin at	C0030705;C0074554;C0286651;C0965129	f	1840
871	extended - release niacin plus statin ( n = $nmbr$ )	C0027996;C0332287;C0360714;C1142562;C1707968	f	872
870	rivastigmine	C0649350	f	1937
870	rivastigmine ( n = $nmbr$ )	C0649350	f	1937
874	solifenacin ( n = $nmbr$ )	C1099677	f	1938
868	vitamin k antagonist experiencedk ( n = $nmbr$ $nmbr$ )	C1096489;C2267235	\N	\N
868	vitamin k antagonist experienced  n ( % )	C0237607;C0369718;C0441922;C0596545;C1096489;C2267235	\N	\N
868	vitamin k antagonist ( e . g . warfarin / coumarol )	C0043031;C1096489;C2267235	\N	\N
868	vitamin k antagonist	C1096489;C2267235	\N	\N
868	previous use of vitamin k antagonist for > $nmbr$ days — no . ( % )	C0205156;C0439228;C1096489;C1524063;C1552607;C2267235	\N	\N
867	vitamins	C0042890;C3540032;C3714649	\N	\N
867	other plain vitamin preparations	C0042890	\N	\N
866	vitamin d §	C0014695;C0042866;C2936842;C3537249;C3714503	\N	\N
866	serum vitamin d ( nmol / l )	C0014695;C0042866;C0229671;C0439282;C1546774;C1550100;C2936842;C3537249;C3714503	\N	\N
866	daily dose of vitamin d ( iu / day )	C0014695;C0042866;C0439465;C2348070;C2936842;C3537249;C3714503	\N	\N
866	baseline vitamin - d	C0014695;C0042866;C0168634;C1442488;C2936842;C3537249;C3714503	\N	\N
866	$nmbr$ ( oh ) vitamin d ( ng / ml )	C0014695;C0042866;C0220853;C0439275;C2936842;C3537249;C3714503	\N	\N
865	white not of hispanic origin	C0007457;C0043157;C0079946;C0086409;C0220938;C0439659;C1518422;C1518424;C1550512	\N	\N
865	not hispanic or latino ( n — $nmbr$ )	C0086528;C1518424	\N	\N
865	not hispanic or latino ( n = $nmbr$ )	C0086528;C1518424	\N	\N
865	not hispanic or latino	C0086528;C1518424	\N	\N
865	not hispanic / latino ( n = $nmbr$  $nmbr$ )	C0086528;C1518424	\N	\N
865	not hispanic / latino	C0086528;C1518424	\N	\N
865	not hispanic	C1518424	\N	\N
865	non - hispanic or latino	C0086528;C1518424	\N	\N
865	non - hispanic and latino	C0086528;C1518424	\N	\N
865	non - hispanic / latino	C0086528;C1518424	\N	\N
865	non - hispanic  non - latino	C0086528;C1518424	\N	\N
865	non - hispanic	C1518424	\N	\N
865	hispanic — no . ( % )	C0086409	\N	\N
865	hispanic or non - hispanic ethnic group — no . ( % ) f	C0015031;C0016327;C0086409;C1518424;C1879937	\N	\N
865	hispanic ethnic group — no . { % ) ’ i '	C0015031;C0021966;C0086409;C0221138;C1879937	\N	\N
865	hispanic ethnic group — no . / total no . ( % ) ‘ j ‘	C0015031;C0086409;C0439175;C0439810;C1879937	\N	\N
865	hispanic ethnic group — no . ( % ) f	C0015031;C0016327;C0086409;C1879937	\N	\N
865	hispanic ethnic group — no . ( % ) : t	C0015031;C0086409;C1879937;C2603360	\N	\N
865	hispanic ethnic group  n ( % )	C0015031;C0086409;C0441848;C0680174	\N	\N
865	hispanic / non - hispanic	C0086409;C1518422	\N	\N
865	hispanic ( n = $nmbr$ l $nmbr$ )	C0086409	\N	\N
865	hispanic ( n = $nmbr$ )	C0086409	\N	\N
865	hispanic  n ( % )	C0086409	\N	\N
865	hispanic	C0086409	\N	\N
865	ethnicity  not hispanic / latino    n   ( % )	C0015031;C0086528;C0243103;C1518424	\N	\N
865	black hispanic - n ( % )	C1533017;C1533018	\N	\N
865	black hispanic	C1533017;C1533018	\N	\N
865	black  non - hispanic	C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018	\N	\N
865	biack non - hispanic	C1518424	\N	\N
865	biack hispanic	C0086409	\N	\N
865	biack	\N	\N	\N
865	american hispanic ( n   = $nmbr$ )	C0086409;C0596070	\N	\N
864	unfractionated heparin — no . ( % )	C0019134;C2825026	\N	\N
864	unfractionated heparin within $nmbr$ hr before randomization — no . / total no . ( % )	C0019134;C0034656;C0439175;C0439810;C2825026	\N	\N
864	unfractionated heparin before randomisation	C0019134;C0034656;C2825026	\N	\N
864	unfractionated heparin ( n = $nmbr$ )	C0019134;C2825026	\N	\N
864	unfractionated heparin ( n = $nmbr$  $nmbr$ )	C0019134;C2825026	\N	\N
864	unfractionated heparin	C0019134;C2825026	\N	\N
864	non - pci intravenous unfractionated heparin	C0354566;C1518422;C4049621	\N	\N
864	neither unfractionated heparin nor low - molecular - weight heparin	C0019134;C0019139;C2825026;C3536766	\N	\N
864	intravenous heparin	C0354566	\N	\N
864	both unfractionated heparin and low - molecular - weight heparin	C0019134;C0019139;C2825026;C3536766	\N	\N
863	neither uh or lmw heparin	C0019134;C0770546	\N	\N
863	initial heparin treatment duration on or after randomization	C0019134;C0034656;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042	\N	\N
863	initial heparin treatment duration	C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042	\N	\N
863	heparin plus gpi ( n = $nmbr$  $nmbr$ )	C0019134;C0332287;C0770546;C1415351	\N	\N
863	heparin plus a gpi ( n = $nmbr$ )	C0019134;C0770546;C1415351	\N	\N
863	heparin only	C0019134;C0205171;C0770546;C1720467	\N	\N
863	heparin dose regimen	C0019134;C0770546;C2348331	\N	\N
863	heparin	C0019134;C0770546	\N	\N
863	bivalirudin - heparin plus gpi	C0019134;C0168273;C0770546;C1415351	\N	\N
863	additional heparin	C0019134;C0770546;C1524062	\N	\N
863	> = $nmbr$ day s initial heparin treatment duration	C0019134;C0205265;C0332173;C0439228;C0439505;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042	\N	\N
863	> = $nmbr$ ^ initial heparin treatment duration	C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042	\N	\N
862	unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ )	C0016011;C0019134;C0206460;C0243077;C0332287;C2825026	\N	\N
862	enoxaparin / vka n / n ( % ) $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )	C0206460	\N	\N
862	enoxaparin / vka	C0206460	\N	\N
862	enoxaparin ( n = $nmbr$ )	C0206460	\N	\N
862	enoxaparin ( n = $nmbr$  $nmbr$ )	C0206460	\N	\N
862	enoxaparin $nmbr$ mg ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0206460;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
862	enoxaparin	C0206460	\N	\N
861	nyhaiiioriv	\N	\N	\N
860	no nadroparin ( n = $nmbr$ )	C0206232	\N	\N
860	nadroparin vs control	C0206232;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
860	nadroparin ( n = $nmbr$ )	C0206232	\N	\N
860	nadroparin	C0206232	\N	\N
623	thrombophilia	C0398623	\N	\N
860	dalteparin ( n = $nmbr$ )	C0206461	f	1933
862	semuloparin ( n = $nmbr$ )	C2700104	f	1934
864	unfractionated	\N	f	1935
868	vitamin c	C0003968;C2349136;C3714687;C4522080	f	1936
859	total time of fondaparinux treatment before	C0039798;C0040223;C0087111;C0439175;C0439810;C1098510;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704	\N	\N
859	heparins and fondaparinux	C0019134;C1098510	\N	\N
859	heparin  fondaparinux or brvalirudin use between - oex event	C0019134;C0042153;C0441471;C0457083;C0770546;C1098510;C1947944;C4019010	\N	\N
859	fondaparinux — no . ( % )	C1098510	\N	\N
859	fondaparinux ( n = $nmbr$ )	C1098510	\N	\N
859	fondaparinux ( n = $nmbr$  $nmbr$ )	C1098510	\N	\N
859	fondaparinux	C1098510	\N	\N
859	commercially available fondaparinux	C0470187;C1098510	\N	\N
858	warfarin naive	C0043031	\N	\N
858	warfarin n = $nmbr$ n / n ( % )	C0043031	\N	\N
858	warfarin n = $nmbr$	C0043031	\N	\N
858	warfarin n / n  rate ( % )	C0043031;C0871208;C1521828	\N	\N
858	warfarin group ( n = $nmbr$ )	C0043031;C0441848	\N	\N
858	warfarin group	C0043031;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
858	warfarin at enrollment	C0043031;C1516879;C1696073;C3888021	\N	\N
858	warfarin ( s $nmbr$ % cl )	C0043031;C0596019	\N	\N
858	warfarin ( n = $nmbr$ )  n ( % / y )	C0043031	\N	\N
858	warfarin ( n = $nmbr$ )	C0043031	\N	\N
858	warfarin ( n - $nmbr$  $nmbr$ )	C0043031	\N	\N
858	warfarin ( % )	C0043031	\N	\N
858	warfarin % ( n / n )	C0043031	\N	\N
858	warfarin  no . ( % )	C0043031	\N	\N
858	warfarin	C0043031	\N	\N
858	warf	C0043031	\N	\N
858	vs . warfarin	C0043031	\N	\N
858	ttr ( warfarin arm only )	C0032923;C0043031;C0205171;C0446516;C1421224;C1720467;C3715044;C4553528	\N	\N
858	re - cover $nmbr$ warfarin	C0043031;C0180153;C0556581;C1999244;C2986904;C3888055	\N	\N
858	previous warfarin use  no . ( % )	C0042153;C0043031;C0205156;C0457083;C1552607;C1947944	\N	\N
858	previous transient ischaemic attack / ischaemic stroke previous warfarin use	C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100	\N	\N
858	median time in therapeutic range for warfarin recipients  %	C0040223;C0043031;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C1709854;C2347635;C2348144;C2939193;C3541383	\N	\N
858	low - dose edoxaban vs warfarin	C0043031;C0445550;C1708745;C2975435	\N	\N
858	ld edoxaban vs warfarin	C0043031;C0694649;C2975435	\N	\N
858	hr vs . warfarin ( $nmbr$ % ci )	C0008107;C0043031;C3259781	\N	\N
858	edoxaban warfarin	C0043031;C2975435	\N	\N
858	edoxaban vs . warfarin	C0043031;C2975435	\N	\N
858	d $nmbr$ vs warfarin rr ( $nmbr$ % ci  p value )	C0008107;C0043031;C0073187;C0332173;C1709380;C3259781;C4484261;C4554402	\N	\N
858	d $nmbr$ vs warfarin	C0043031;C0073187;C0332173;C4484261	\N	\N
857	tofacitinib $nmbr$ mg two times a day	C0024671;C0026410;C0332173;C0439228;C0439269;C0439505;C1948050;C1960952;C2346927;C2930696;C4321396;C4521761	\N	\N
857	tofacitinib $nmbr$ mg bid [ n = $nmbr$ |	C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761	\N	\N
857	tofacitinib $nmbr$ mg bid ( n   = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761	\N	\N
857	tofacitinib $nmbr$ mg bid ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761	\N	\N
857	tofacitinib $nmbr$ mg bid	C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761	\N	\N
857	tofacitinib  $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761	\N	\N
857	tofacitinib	C2930696	\N	\N
856	anacetrapib ( n = $nmbr$ )	C2604745	\N	\N
856	anacetrapib ( n = $nmbr$  $nmbr$ )	C2604745	\N	\N
856	anacetrapib $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761	\N	\N
856	anacetrapib $nmbr$ mg ( n - $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761	\N	\N
856	anacetrapib $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761	\N	\N
855	tadalafil $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761	\N	\N
855	tadalafil $nmbr$ mg mean change ( sd )	C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1176316;C1705241;C1960952;C2346927;C2347634;C2348143;C2699239;C4319952;C4321396;C4521761	\N	\N
855	tadalafil $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761	\N	\N
855	tadalafil $nmbr$ mg	C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761	\N	\N
855	tadalafil $nmbr$ . $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761	\N	\N
855	tadalafil $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761	\N	\N
855	tadalafil $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761	\N	\N
855	tadalafil	C1176316	\N	\N
854	tnl ultrapositive > $nmbr$ . $nmbr$ pg / l  $nmbr$ = $nmbr$	C0439278;C1540071	\N	\N
854	ag + gg	C0002037;C0017454;C0018370;C0051080;C0152305;C3888235	\N	\N
854	ag	C0002037;C0051080;C0152305;C3888235	\N	\N
853	sal ( n   = $nmbr$  $nmbr$ )	C0036140;C0037494;C0206136	\N	\N
853	sal ( n = $nmbr$ )	C0036140;C0037494;C0206136	\N	\N
853	sal $nmbr$ pg ( n = $nmbr$ )	C0030827;C0036140;C0037494;C0072225;C0206136;C1266240	\N	\N
853	sal $nmbr$ mg	C0024671;C0026410;C0036140;C0037494;C0206136;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
853	fp / sal $nmbr$ / $nmbr$ pg ( n = $nmbr$ )	C0016704;C0030827;C0036140;C0037494;C0072225;C0206136;C1266240;C1419068;C1419906;C3541238;C3541412	\N	\N
852	rvw	\N	\N	\N
852	row §	C1552840;C1552846	\N	\N
852	row * n = $nmbr$	C1552840;C1552846	\N	\N
852	row	C1552840;C1552846	\N	\N
852	analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .	C0002778;C0007806;C0012634;C0023823;C0168634;C0348080;C0936012;C1442488;C1524024;C1550147;C1705253;C1707455;C2709094;C3539075;C3539076;C3864998	\N	\N
851	scale — cognitive portion  ldl — low -	C0175659;C0205251;C0349674;C0449719;C1516691;C1550472;C1947916;C3890211;C4048187;C4321351;C4522223	\N	\N
851	periostin low	C0205251;C0219433;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223	\N	\N
851	patients with low ( < $nmbr$ mg / dl ) c $nmbr$	C0030705;C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	nfs < - $nmbr$ . $nmbr$ ( low )	C0205251;C1550472;C1555018;C3890211;C4048187;C4321351;C4522223	\N	\N
851	moderate / low	C0205081;C0205251;C1550472;C1881878;C3890211;C4048187;C4049705;C4049706;C4085643;C4321335;C4321351;C4522223	\N	\N
851	low ’	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low { < $nmbr$ % )	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )	C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low subgroup	C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low potencyc	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low perceived social support only	C0030971;C0037438;C0205171;C0205251;C0748877;C1540833;C1550472;C1720467;C3669642;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low or moderate	C0205081;C0205251;C1550472;C1881878;C3890211;C4048187;C4049705;C4049706;C4085643;C4321335;C4321351;C4522223	\N	\N
851	low normal ( n = $nmbr$ )	C0205251;C0205307;C0231683;C0439166;C1550472;C2347086;C3890211;C4048187;C4321351;C4522223;C4553972	\N	\N
851	low nfs nfs < - $nmbr$ . $nmbr$ ( n = $nmbr$ )	C0205251;C1513839;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low nafld fibrosis score ( nfs < - $nmbr$ . $nmbr$ )	C0205251;C0400966;C1550472;C1555018;C1954436;C1954437;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low feno subgroup (  $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ )	C0205251;C1079230;C1415800;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low eosinophil subgroup (  $nmbr$ / ml ) ( n = $nmbr$ )	C0014467;C0205251;C0439526;C1079230;C1515021;C1550472;C1705224;C3887665;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low c $nmbr$ / c $nmbr$ and anti - dsdna	C0012854;C0205251;C0311474;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low c $nmbr$ ( < $nmbr$ mg / dl )  %	C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low c $nmbr$ ( < $nmbr$ . $nmbr$ g / l )	C0205251;C0439294;C0456615;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low - molecular - weight only	C0026385;C0041667;C0205171;C0205251;C1521991;C1550472;C1720467;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low - molecular - weight	C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low - ceiling diuretic	C0012798;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( no risk factor )	C0035648;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( n = $nmbr$ )	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( > $nmbr$ . $nmbr$ and < $nmbr$ )	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( < $nmbr$ % ) baseline hbalc	C0168634;C0205251;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( < $nmbr$ % ) baseline hba $nmbr$ c	C0019016;C0168634;C0205251;C1442488;C1550472;C1825777;C3538758;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( < $nmbr$ % )	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( $nmbr$ - $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % )	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( $nmbr$ - $nmbr$ )  %	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low ( $nmbr$ - $nmbr$ )	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low  %	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	low	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	fgf - $nmbr$ low / egfr > $nmbr$	C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223	\N	\N
851	fgf - $nmbr$ low / egfr < $nmbr$	C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223	\N	\N
851	fgf - $nmbr$ low / > $nmbr$ elevated biomarkers	C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223	\N	\N
851	fgf - $nmbr$ low / < $nmbr$ elevated biomarkers	C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223	\N	\N
851	eosinophil low	C0014467;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	depressed and low perceived social support	C0030971;C0037438;C0205251;C0344315;C0549249;C0748877;C1540833;C1550472;C3669642;C3890211;C4048187;C4321351;C4522223	\N	\N
851	bl updrs : low	C0005918;C0006413;C0205251;C1550472;C1552663;C2827109;C3639721;C3890211;C4048187;C4321351;C4522223	\N	\N
851	biomarker low	C0005516;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
851	$nmbr$ low ( n = $nmbr$ )	C0205251;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
850	igelow ( n = $nmbr$  $nmbr$ )	\N	\N	\N
850	igelow ( < i $nmbr$ ku / l  n = i  $nmbr$ )	C0021966;C0221138;C0369718;C0439340;C0441922	\N	\N
850	igelow ( < $nmbr$ ku / l  n = $nmbr$  $nmbr$ )	C0439340	\N	\N
849	eosinophils £ $nmbr$ % ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils £ $nmbr$ % ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ^ ^ ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils > $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ^ ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils > $nmbr$ % ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils > $nmbr$ % ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils > $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / $nmbr$ ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils < $nmbr$ % ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils < $nmbr$ % ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils < $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / l ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils $nmbr$ % ( n - $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils $nmbr$ % ( itt ) ( n = $nmbr$ )	C0014467;C0200638	\N	\N
849	eosinophils	C0014467;C0200638	\N	\N
849	calima japandhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ) y	C0014467;C0168634;C0178602;C0815320;C1442488;C2699156;C2986497;C4551720	\N	\N
849	blood eosinophils count	C0014467;C0750480;C1705566	\N	\N
849	blood eosinophils  mean ( range )  cells / mlb	C0005773;C0007584;C0007634;C0014467;C0200638;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
849	blood eosinophils  cells / ml	C0014467;C2699156	\N	\N
849	blood eosinophil proportion ( % )	C0014467;C1709707	\N	\N
849	blood eosinophil count  geometric mean ( sd loge scale ) cells / ll	C0007584;C0007634;C0014467;C0175659;C0349674;C0750480;C1705566;C1947916;C2697934;C2699239;C2986759	\N	\N
849	blood eosinophil	C0014467	\N	\N
848	median blood eosinophil count  cells per pla	C0200638;C0456170;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
848	local eosinophil count [ cells / µ l ]  median ( range )	C0200638;C0205276;C0347983;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
848	local eosinophil count [ cells / ml ]  median ( range )	C0200638;C0205276;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2699156;C2939193;C3542016	\N	\N
848	local eosinophil count	C0200638;C0205276;C0750879	\N	\N
848	eosinophil count	C0200638;C0750879	\N	\N
848	blood eosinophil count — cells / mm ’	C0005773;C0200638;C0750879;C4330985;C4554674	\N	\N
848	blood eosinophil count cells / mm $nmbr$ no .	C0005773;C0200638;C0750879;C4330985;C4554674	\N	\N
848	blood eosinophil count > $nmbr$ / mm $nmbr$ at screening — no . ( % )	C0200638;C0750879;C1511226;C4330985;C4554674	\N	\N
848	blood eosinophil count ( $nmbr$ cells per l )	C0200638	\N	\N
847	lisinopril ( n = $nmbr$ )	C0065374	\N	\N
847	lisinopril	C0065374	\N	\N
847	ii lisinopril i	C0021966;C0065374;C0221138;C1710602;C4082587	\N	\N
847	i lisinopril ( n = $nmbr$ )	C0021966;C0065374;C0221138	\N	\N
847	$nmbr$ lisinopril	C0065374	\N	\N
846	killip class — no . / total no . ( % ) i	C0021966;C0221138;C0439175;C0439810;C1881332	\N	\N
846	killip class — no . ( % ) i	C0021966;C0221138;C1881332	\N	\N
846	killip class lll - iv	C1261077;C2697847	\N	\N
846	killip class iv at randomization	C0034656;C2697847	\N	\N
846	killip class i — no . ( % )	C2697844	\N	\N
846	killip class at admission — no . / total no . ( % )	C0184666;C0439175;C0439810;C0809949;C1881332	\N	\N
846	killip class > ii ( % )	C2697845	\N	\N
846	killip class > i  %	C2697844	\N	\N
846	killip class > $nmbr$  no . ( % )	C1881332	\N	\N
846	killip class *	C1881332	\N	\N
846	killip class ( interaction : p = $nmbr$ . $nmbr$ )	C1704675;C1881332	\N	\N
846	killip class $nmbr$ / $nmbr$	C1881332	\N	\N
846	killip class $nmbr$	C1881332	\N	\N
846	killip class  n ( % ) i	C0021966;C0221138;C0369718;C0441922;C1881332	\N	\N
846	killip class  n ( % )	C1881332	\N	\N
846	killip class	C1881332	\N	\N
846	baseline killip class	C0168634;C1442488;C1881332	\N	\N
846	< $nmbr$ baseline killip class	C0168634;C1442488;C1881332	\N	\N
845	who functional class ii / iii	C0205245;C0439070;C0441886;C0441887;C0542341;C1705160;C1710602;C2698968;C2698969;C2700217;C4082587	\N	\N
845	iorii ( n z $nmbr$ )	\N	\N	\N
845	iiiv	\N	\N	\N
845	class iii	C0441887;C2698969	\N	\N
845	class ii ( b - blockers )	C0441886;C2698968	\N	\N
845	class ii	C0441886;C2698968	\N	\N
845	class > ii	C0441886;C2698968	\N	\N
845	> ii	\N	\N	\N
845	> $nmbr$ : obese class iii	C1319441	\N	\N
845	$nmbr$ - $nmbr$ . $nmbr$ : obese class ii	C3853263	\N	\N
844	diastolic fmmhff ' )	C0012000	\N	\N
844	diastolic  treated at baseline	C0012000;C0168634;C1442488;C1522326	\N	\N
844	diastolic  total	C0012000;C0439175;C0439810	\N	\N
844	diastolic	C0012000	\N	\N
843	idiopathica	\N	\N	\N
843	idiopathic / familial	C0015576;C0241888;C0332240	\N	\N
843	idiopathic	C0332240	\N	\N
842	diastolic bp ( mmhg ) *	C0428883;C0439475	\N	\N
842	diastolic bp ( mmhg )	C0428883;C0439475	\N	\N
842	diastolic bp ( mm hg )	C0428883;C0439475	\N	\N
842	diastolic bp  mmhg ( sd )	C0428883;C0439475;C2699239	\N	\N
842	diastolic bp  mmhg	C0428883;C0439475	\N	\N
842	diastolic bp  mm   hg  mean ( sd )	C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239	\N	\N
842	diastolic bp  mm hg  mean ( sd )	C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239	\N	\N
842	diastolic bp  mm hg	C0428883;C0439475	\N	\N
842	diastolic bp	C0428883	\N	\N
842	diastolic blood pressure subgroups	C0428883;C1079230;C1305849	\N	\N
842	diastolic blood pressure ( mm hg ) medications	C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232	\N	\N
842	diastolic blood pressure ( mm hg )	C0428883;C0439475;C1305849	\N	\N
842	diastolic blood pressure  mm hq	C0428883;C1305849;C4330985;C4554674	\N	\N
842	diastolic blood pressure  mm hg  median ( range )	C0428883;C0439475;C0549183;C0876920;C1305849;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
842	diastolic blood pressure  mm hg	C0428883;C0439475;C1305849	\N	\N
842	diastolic blood pressure  and lp ( a )	C0065058;C0428883;C1305849;C1439335;C4553379	\N	\N
842	diastolic blood pressure	C0428883;C1305849	\N	\N
841	time since diagnosis of t $nmbr$ dm  y  n ( % )	C0011816;C0011900;C0040223;C1704338;C1704656;C3250443;C3541383	\N	\N
841	time since diagnosis of t $nmbr$ dm	C0011816;C0011900;C0040223;C1704338;C1704656;C3250443;C3541383	\N	\N
841	time since diagnosis of pah — yrf	C0011900;C0030123;C0040223;C1704338;C1704656;C3203102;C3541383;C4284467	\N	\N
841	time since diagnosis of diabetesa  n ( % )	C0011900;C0040223;C1704338;C1704656;C3541383	\N	\N
841	time since diagnosis of ciu / csuf ( y )	C0011900;C0040223;C0578870;C1704338;C1704656;C3541383	\N	\N
824	recurrent hf	C0018488;C1313497;C1455761;C1538440;C2945760;C3273279	f	12
841	time since diagnosis of ciu / csu ( years ) $nmbr$	C0011900;C0040223;C0439234;C0578870;C1704338;C1704656;C3541383	\N	\N
841	since diagnosis	C0011900;C1704338;C1704656	\N	\N
841	qualifying diagnosis	C0011900;C1514624;C1704338;C1704656	\N	\N
841	presenting history or diagnosis — no . ( % )	C0011900;C0019664;C0019665;C0262512;C0262926;C0449450;C1704338;C1704656;C1705255;C2004062	\N	\N
841	presenting diagnosis	C0011900;C0449450;C1704338;C1704656	\N	\N
841	predominant cardiac diagnosis — no . ( % )	C0011900;C0018787;C1522601;C1542147;C1704338;C1704656	\N	\N
841	inclusion diagnosis	C0007637;C0011900;C1512693;C1704338;C1704656	\N	\N
841	first diagnosed	C0011900;C0205435;C1279901	\N	\N
841	diagnosis of hefh  n ( % )	C0011900;C1704338;C1704656	\N	\N
841	diagnosis of allergic rhinitis	C0011900;C1334103;C1704338;C1704656;C2607914;C4552864	\N	\N
841	diagnosis at presentation — no . ( % )	C0011900;C0449450;C1704338;C1704656	\N	\N
841	diagnosis at presentation	C0011900;C0449450;C1704338;C1704656	\N	\N
841	diagnosed  y	C0011900	\N	\N
841	age when diabetes first diagnosed — yr	C0001779;C0011847;C0011849;C0011900;C0205435;C0439234;C1279901	\N	\N
841	af first diagnosis > $nmbr$ years  n ( % )	C0011900;C0205435;C0344434;C0439234;C1279901;C1704338;C1704656;C4049859	\N	\N
840	with highest bwa	C0006041;C1522410	\N	\N
840	highest killip classiciation pre - pci	C0332152;C0740175;C1522410;C2257086;C3669034;C4049621	\N	\N
840	highest	C1522410	\N	\N
839	cv death or first hhf	C0011065;C0205435;C1279901;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
838	less than high school	C0439092;C0599395;C0683862;C0870649	\N	\N
838	high - school graduate or ged	C0870649;C1549971;C1880947	\N	\N
838	high - school graduate	C0870649;C1549971	\N	\N
837	very high risk	C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904	\N	\N
837	qualifying high - risk features — %	C0332167;C1514624;C1521970;C1706388;C2346469;C2348519;C3272283;C4050568;C4319571	\N	\N
837	moderately high risk without atherosclerotic vascular disease *	C0004153;C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491	\N	\N
837	moderately high risk	C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491	\N	\N
837	higher risk ( n = $nmbr$ )	C0332167;C3272283;C4050568;C4319571	\N	\N
837	high risk without atherosclerotic vascular disease +	C0004153;C0332167;C3272283;C4050568;C4319571	\N	\N
837	high risk for diabetes *	C0011847;C0011849;C0205250;C0332167;C1171304;C1299351;C2700149;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209	\N	\N
837	high risk and fewer symptoms ( group c )	C0205388;C0332167;C0441837;C0683368;C1457887;C3272283;C4050568;C4319571	\N	\N
837	high risk *  %	C0332167;C3272283;C4050568;C4319571	\N	\N
837	high risk ( ri ≥ $nmbr$ )	C0035487;C0332167;C1826843;C3272283;C4050568;C4319571	\N	\N
837	high risk ( receiving treatment for ) :	C0039798;C0087111;C0332167;C1514756;C1522326;C1533734;C1705169;C3272283;C3538994;C3887704;C4050568;C4319571	\N	\N
837	high risk ( n $nmbr$ $nmbr$ )	C0332167;C3272283;C4050568;C4319571	\N	\N
837	high risk ( ? ics )	C0332167;C0815320;C3272283;C4050568;C4319571;C4551720	\N	\N
837	high risk ( > $nmbr$ )	C0332167;C3272283;C4050568;C4319571	\N	\N
837	high risk ( - ics )	C0332167;C0815320;C3272283;C4050568;C4319571;C4551720	\N	\N
837	high risk ( $nmbr$ - $nmbr$ )	C0332167;C3272283;C4050568;C4319571	\N	\N
837	high risk	C0332167;C3272283;C4050568;C4319571	\N	\N
837	high fracture risk stratum	C0016658;C0332167;C3272283;C4050568;C4319571	\N	\N
837	high cv risk	C0332167;C3272283;C3538987;C4048877;C4050568;C4318503;C4319571	\N	\N
837	high cardiovascular risk  n ( % ) ^	C0007226;C0332167;C3272283;C3887460;C4050568;C4319571	\N	\N
837	high - risk cvd  n ( % )	C0007222;C0332167;C3272283;C4050568;C4319571	\N	\N
837	high - risk criterion	C0243161;C0332167;C3272283;C4050568;C4319571	\N	\N
837	high - risk clinical features	C0332167;C0683325;C3272283;C4050568;C4319571	\N	\N
837	high - risk	C0332167;C3272283;C4050568;C4319571	\N	\N
837	high ( > $nmbr$ risk factor )	C0035648;C0205250;C0332167;C1299351;C1521761;C2700149;C2827422;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209	\N	\N
837	group d ( high risk  more symptoms )  n ( % )	C0332167;C0441848;C0683368;C1457887;C3272283;C4050568;C4319571	\N	\N
837	> $nmbr$ ( high risk )	C0332167;C3272283;C4050568;C4319571	\N	\N
837	$nmbr$ or $nmbr$ high cardiovascular risk categories	C0007226;C0332167;C0683312;C3272283;C3887460;C4050568;C4319571	\N	\N
837	$nmbr$ or $nmbr$ high - risk categories	C0332167;C0683312;C3272283;C4050568;C4319571	\N	\N
836	high intensity	C4081854	\N	\N
835	high density lipoprotein ( mg / dl )	C0023821;C0439269	\N	\N
835	high - density lipoprotein ]	C0023821	\N	\N
835	high - density lipoprotein  mg / dl	C0023821;C0439269	\N	\N
835	high - density lipoprotein	C0023821	\N	\N
834	total aim ‐ high study	C0205250;C0439175;C0439810;C0557651;C1299351;C1947946;C2603343;C2700149;C2744535;C2948600;C3540471;C3540472;C3887512;C3889660;C3890193;C4321237;C4522209	\N	\N
834	periostin high	C0205250;C0219433;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209	\N	\N
834	p - value low vs . high nfs ^	C0205250;C0205251;C1299351;C1550472;C1555018;C1709380;C2700149;C3887512;C3889660;C3890211;C4048187;C4321237;C4321351;C4522209;C4522223	\N	\N
834	nfs > $nmbr$ . $nmbr$ ( high )	C0205250;C1299351;C1555018;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	ige high ( > $nmbr$ ku / l  n = $nmbr$  $nmbr$ )	C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	highjj	\N	\N	\N
834	high vs . normalc	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
821	hdl - c ( mmol / l )	C1532563;C3715113	\N	\N
839	first hhf	C0205435;C1279901	f	1929
839	hhf ( n = $nmbr$ )	\N	f	1929
834	high vs . normalb	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high tt > $nmbr$ . $nmbr$ ( n = $nmbr$ )	C0205250;C1299351;C1452561;C2700149;C3887512;C3889660;C4321237;C4522209;C4554543	\N	\N
834	high trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )	C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high titre ( > $nmbr$ times of uln )  n ( % )	C0040223;C0205250;C0475208;C1299351;C1519815;C1632851;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high subgroup	C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high potencyc	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high periostin subgroup ( > $nmbr$ ng / ml ) ( n = $nmbr$ )	C0205250;C0219433;C0439275;C1079230;C1299351;C1424662;C1515021;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high on - treatment platelet reactivity *	C0005821;C0039798;C0087111;C0205250;C0443286;C1299351;C1522326;C1533734;C1705169;C2700149;C3538994;C3887512;C3887704;C3889660;C4321237;C4522209	\N	\N
834	high nfs nfs > $nmbr$ . $nmbr$ ( n = $nmbr$ )	C0205250;C1299351;C1513839;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high nafld fibrosis score ( nfs > $nmbr$ . $nmbr$ )	C0205250;C0400966;C1299351;C1555018;C1954436;C1954437;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high microalbuminuria to macroalbuminuria ( n = $nmbr$ )	C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high crp or esr	C0205250;C1299351;C2700149;C3811131;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209	\N	\N
834	high crp and esr	C0205250;C1299351;C2700149;C3811131;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209	\N	\N
834	high - dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl ( n = $nmbr$ )	C0005773;C0007584;C0007634;C0014467;C0168634;C0178602;C0200638;C0205250;C0815320;C1299351;C1442488;C2700149;C2986497;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209;C4551720	\N	\N
834	high - dosage ics plus laba with baseline blood eosinophils > $nmbr$ cells per pl ( n = $nmbr$ )	C0005773;C0007584;C0007634;C0014467;C0168634;C0178602;C0200638;C0205250;C0815320;C1299351;C1442488;C2700149;C2986497;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209;C4551720	\N	\N
834	high - dosage ics plus laba with baseline blood eosinophils < $nmbr$ cells per pl ( n = $nmbr$ )	C0005773;C0007584;C0007634;C0014467;C0168634;C0178602;C0200638;C0205250;C0815320;C1299351;C1442488;C2700149;C2986497;C3887512;C3889660;C3897966;C4049765;C4321237;C4522209;C4551720	\N	\N
834	high *	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( n = $nmbr$ )	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( i $nmbr$ % ) baseline hba $nmbr$ c	C0019016;C0021966;C0168634;C0205250;C0221138;C1299351;C1442488;C1825777;C2700149;C3538758;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( >   uln and   ≤   $nmbr$ xuln ) ( n   =   $nmbr$ )	C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( > uln )	C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( > $nmbr$ . $nmbr$ u / ml )	C0205250;C0439340;C1299351;C1880521;C2700149;C2945590;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( > $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % )	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( > $nmbr$ )  %	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( > $nmbr$ )	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( > $nmbr$ % ) baseline hbalc	C0168634;C0205250;C1299351;C1442488;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( > $nmbr$ % )	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( $nmbr$ - $nmbr$ )	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high ( $nmbr$ % )	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high  %	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	high	C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	fgf - $nmbr$ high / egfr > $nmbr$	C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209	\N	\N
834	fgf - $nmbr$ high / egfr < $nmbr$	C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209	\N	\N
834	fgf - $nmbr$ high / > $nmbr$ elevated biomarkers	C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209	\N	\N
834	fgf - $nmbr$ high / < $nmbr$ elevated biomarkers	C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209	\N	\N
834	eosinophil high	C0014467;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
834	education  high school or higher	C0205250;C0683862	\N	\N
834	college degree or higher	C0205250;C0441889;C0449286;C0542560;C0557806;C2348088	\N	\N
834	bl updrs : high	C0005918;C0006413;C0205250;C1299351;C1552663;C2700149;C2827109;C3639721;C3887512;C3889660;C4321237;C4522209	\N	\N
834	biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl )  na	C0005516;C0005773;C0007584;C0007634;C0014467;C0200638;C0205250;C0219433;C0439275;C0597484;C1272460;C1299351;C1424662;C1546968;C1879645;C2700149;C3812270;C3887512;C3889660;C3897966;C4049765;C4049872;C4321237;C4522209;C4552882	\N	\N
834	biomarker high	C0005516;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
833	hscrp §	\N	\N	\N
833	hcru ( a )	\N	\N	\N
833	elevated hscrp > $nmbr$ mg / l  n ( % )	C0205250;C0439268;C3163633	\N	\N
833	elevated hscrp	C0205250;C3163633	\N	\N
832	white  n ( % ) medical history  n ( % )	C0007457;C0043157;C0220938;C0262926;C1704706	\N	\N
832	vascular history  %	C0005847;C0019664;C0019665;C0262512;C0262926;C1558950;C1705255;C1801960;C2004062	\N	\N
832	uc history	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	selective vascular history	C0005847;C0019664;C0019665;C0036576;C0262512;C0262926;C1558950;C1705255;C1707391;C1801960;C2004062	\N	\N
832	seizure history  n ( % )	C0019664;C0019665;C0036572;C0262512;C0262926;C1705255;C1959629;C2004062;C4553401	\N	\N
832	risk factors and medical history	C0035648;C0262926;C1553898;C1704706	\N	\N
832	revascularization history	C0019664;C0019665;C0262512;C0262926;C0581603;C1705255;C2004062	\N	\N
832	prior treatment history $nmbr$	C0019664;C0019665;C0262512;C0262926;C1514463;C1705255;C2004062	\N	\N
832	history of stroke *	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100	\N	\N
832	plus – minus values are means ± sd . cabg denotes coronary - artery by - pass graft  ptca percutaneous transluminal coronary angioplasty  and ace angiotensin - converting enzyme . hypertension and diabetes were de - fined by clinical history . a more complete list of base - line characteristics is given in rubins et al . $nmbr$ † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$ . to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ .	C0001645;C0005893;C0005910;C0006448;C0006539;C0006684;C0008377;C0010055;C0011198;C0011847;C0011849;C0013227;C0017480;C0017887;C0019664;C0019665;C0020538;C0022709;C0028125;C0030125;C0040028;C0040363;C0041004;C0041260;C0042295;C0043100;C0181074;C0202311;C0205042;C0205120;C0205172;C0205197;C0205210;C0205232;C0252873;C0262512;C0262926;C0332257;C0332288;C0332835;C0332849;C0439190;C0439209;C0441074;C0475211;C0489786;C0578022;C0687757;C0699857;C0745732;C0885378;C1254351;C1305855;C1305866;C1442162;C1452534;C1521827;C1532563;C1550718;C1552595;C1552866;C1704788;C1704970;C1705104;C1705255;C1719797;C1820373;C1874267;C1879745;C1883351;C1883728;C1947971;C1961139;C1963138;C2004062;C2699239;C2700399;C2828386;C2911648;C2936173;C3244317;C3272378;C3536851;C3537168;C3539106;C3541240;C3812761;C3848573;C3853530;C3854028;C4283785;C4284014;C4321248;C4521885;C4522126;C4684572	\N	\N
832	parental history of mii	C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062	\N	\N
832	parental history of mi before age $nmbr$ y	C0001779;C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062;C3810814	\N	\N
832	other medical history — no . / total no . ( % )	C0262926;C0439175;C0439810;C1704706	\N	\N
832	other medical history — no . ( % )	C0262926;C1704706	\N	\N
832	other medical history  no . ( % )	C0262926;C1704706	\N	\N
832	oad history  years	C0019664;C0019665;C0262512;C0262926;C0439234;C1705255;C2004062	\N	\N
832	no history of paroxysmal af	C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062	\N	\N
832	no history of mi ( n = $nmbr$  $nmbr$ )	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814	\N	\N
832	no history of hf	C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279	\N	\N
832	no history of diabetes ( n = $nmbr$ )	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	no history of chf	C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	no history of bowel resections	C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062	\N	\N
832	no history of af	C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859	\N	\N
832	medical history — no . / total no . ( % )	C0262926;C0439175;C0439810;C1704706	\N	\N
832	medical history — no . ( % )	C0262926;C1704706	\N	\N
832	medical history — %	C0262926;C1704706	\N	\N
832	medical history of diabetic retinopathy §	C0011884;C0262926	\N	\N
832	medical history before index acute coronary syndrome — no . { % )	C0262926;C0600653;C0918012;C0948089;C1552854;C1637833;C1704706;C2986546	\N	\N
832	medical history at randomization — no . ( % )	C0034656;C0262926;C1704706	\N	\N
832	medical history and risk factors — no . ( % )	C0035648;C0262926;C1553898;C1704706	\N	\N
832	medical history and risk factors ( % )	C0035648;C0262926;C1553898;C1704706	\N	\N
832	medical history and risk factors  no . / total ( % ) *	C0035648;C0262926;C0439175;C0439810;C1553898;C1704706	\N	\N
832	medical history and risk factors	C0035648;C0262926;C1553898;C1704706	\N	\N
832	medical history . no . ( % )	C0262926;C1704706	\N	\N
832	medical history ( % )	C0262926;C1704706	\N	\N
832	medical history    n   ( % )	C0262926;C1704706	\N	\N
832	medical history  no . ( % )	C0262926;C1704706	\N	\N
832	medical history  n ( % )	C0262926;C1704706	\N	\N
832	medical history	C0262926;C1704706	\N	\N
832	hx cabg	C0010055;C0262926;C3814444	\N	\N
832	htn hx	C0020538;C0262926;C3814444	\N	\N
832	history pci	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621	\N	\N
832	history ol mi or stroke	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100	\N	\N
832	history of vte * *	C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062	\N	\N
832	history of vte	C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062	\N	\N
832	history of venous	C0019664;C0019665;C0042449;C0262512;C0262926;C0348013;C1705255;C2004062	\N	\N
832	history of upper gi events ( perforations  ulcers and bleeding ) n ( % )	C0019080;C0019664;C0019665;C0041582;C0203057;C0262512;C0262926;C0441471;C0549099;C1705255;C2004062;C3541888	\N	\N
832	history of upper	C0019664;C0019665;C0262512;C0262926;C1282910;C1705255;C2004062	\N	\N
832	history of tia or stroke	C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100	\N	\N
832	history of tia  n ( % )	C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062	\N	\N
832	history of strokea	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of stroke †	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100	\N	\N
832	history of stroke or transient ischemic attack	C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1705255;C2004062;C4554100	\N	\N
832	history of stroke or tia - n ( % )	C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100	\N	\N
832	history of stroke or tia	C0007787;C0019664;C0019665;C0038454;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062;C4554100	\N	\N
832	history of stroke at baseline	C0019664;C0019665;C0038454;C0168634;C0262512;C0262926;C1442488;C1705255;C2004062;C4554100	\N	\N
832	history of stroke / see / tia  n ( % )	C0007787;C0019664;C0019665;C0038454;C0042789;C0262512;C0262926;C0917805;C1054154;C1705255;C1947903;C2004062;C4554100	\N	\N
832	history of stroke / see / tia	C0007787;C0019664;C0019665;C0038454;C0042789;C0262512;C0262926;C0917805;C1054154;C1705255;C1947903;C2004062;C4554100	\N	\N
832	history of stroke * *	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100	\N	\N
814	α - glucosidase inhibitor	C1512211	\N	\N
832	pci history	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621	f	1661
832	history of stroke ( % )	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100	\N	\N
832	history of stroke $nmbr$	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100	\N	\N
832	history of stroke  n ( % )	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100	\N	\N
832	history of stroke	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100	\N	\N
832	history of second prior mi  n ( % )	C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814	\N	\N
832	history of parental myocardial	C0019664;C0019665;C0027061;C0030551;C0262512;C0262926;C1522564;C1705255;C2004062	\N	\N
832	history of pad	C0019664;C0019665;C0182158;C0262512;C0262926;C0332568;C1705255;C2004062;C3540603;C3669270;C3814046;C4319657	\N	\N
832	history of oxygen use - yes  n ( % )	C0019664;C0019665;C0030054;C0262512;C0262926;C1524063;C1549445;C1705108;C1705255;C1710701;C2004062	\N	\N
832	history of or current cardiac disorders  %	C0018799;C0019664;C0019665;C0262512;C0262926;C0521116;C1705255;C1705970;C2004062	\N	\N
832	history of non - hemor - rhagic stroke	C0019664;C0019665;C0038454;C0262512;C0262926;C1518422;C1705255;C2004062;C4554100	\N	\N
832	history of nicotine use	C0019664;C0019665;C0028040;C0262512;C0262926;C1524063;C1705255;C2004062	\N	\N
832	history of more than $nmbr$ prior mi ( % )	C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3810814	\N	\N
832	history of ml or stroke	C0019664;C0019665;C0038454;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665;C4554100	\N	\N
832	history of ml or ischemic stroke	C0019664;C0019665;C0262512;C0262926;C0439526;C0948008;C1705224;C1705255;C2004062;C3887665	\N	\N
832	history of mi or stroke history of coronary	C0018787;C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100	\N	\N
832	history of mi or stroke d	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100	\N	\N
832	history of mi or stroke  no . ( % )	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100	\N	\N
832	history of mi or stroke  n ( % )	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100	\N	\N
832	history of mi or stroke	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100	\N	\N
832	history of mi ( n = $nmbr$  $nmbr$ )	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814	\N	\N
832	history of mi  n ( % )	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814	\N	\N
832	history of mi	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814	\N	\N
832	history of major bleeding	C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762	\N	\N
832	history of macroalbuminuriat  n ( % )	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of ischemic stroke	C0019664;C0019665;C0262512;C0262926;C0948008;C1705255;C2004062	\N	\N
832	history of htn  %	C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of high cholesterol ( a ) $nmbr$	C0019664;C0019665;C0020443;C0262512;C0262926;C1522133;C1705255;C2004062	\N	\N
832	history of hf	C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279	\N	\N
832	history of h pylori eradication *	C0019664;C0019665;C0079488;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of extra - intestinal manifestations of ibd	C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1705255;C1883702;C2004062	\N	\N
832	history of dyslipidemia	C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of dyslipidaemia	C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of diabetes { p = $nmbr$ * $nmbr$ )	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of diabetes nyha class	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C1882083;C2004062	\N	\N
832	history of diabetes ( % )	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of diabetes	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of cvd  n ( % )	C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of cvd	C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of coronary revascularization d	C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062	\N	\N
832	history of coronary revascularization	C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062	\N	\N
832	history of coronary	C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of copd	C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496	\N	\N
832	history of chronic hf	C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279	\N	\N
832	history of chf - n ( % )	C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of chf  nyha class ii or iii — no . ( % )	C0018802;C0019664;C0019665;C0262512;C0262926;C0439070;C1705160;C1705255;C1882085;C2004062	\N	\N
832	history of chf  n ( % )	C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of chf	C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of cardiovascular events	C0019664;C0019665;C0262512;C0262926;C0441471;C1320716;C1705255;C1880008;C2004062;C3541888	\N	\N
832	history of cad / mi	C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3810814;C3813548;C4284121	\N	\N
832	history of cad	C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121	\N	\N
814	pde $nmbr$ inhibitors	C0031638	\N	\N
832	history of omalizumab treatment	C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704	f	940
832	history of pci	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621	f	1661
832	history of pci  n ( % )	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621	f	1661
832	history of pci with stenting	C0019664;C0019665;C0038257;C0262512;C0262926;C1705255;C2004062;C2348535;C4049621	f	1661
832	history of bowel resections  n ( % )	C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062	\N	\N
832	history of atrial arrhythmia  n ( % )	C0019664;C0019665;C0085611;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history of amputation  n ( % )	C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062	\N	\N
832	history of amputation	C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062	\N	\N
832	history of af	C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859	\N	\N
832	history of > $nmbr$ previous vte ( excluding index event )	C0019664;C0019665;C0205156;C0262512;C0262926;C0332196;C0441471;C0600653;C0630906;C0918012;C1552607;C1552854;C1637833;C1705255;C2004062;C2828389;C2986546;C4019010	\N	\N
832	history of ( % )	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history mi or stroke	C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C3810814;C4554100	\N	\N
832	history coronary revascularization	C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062	\N	\N
832	history coronary	C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history congestive heart failure	C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	history ( pack - years )	C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062	\N	\N
832	history  pack - years	C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062	\N	\N
832	history	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	diabetic history ( years ) x	C0019664;C0019665;C0241863;C0262512;C0262926;C0439234;C1705255;C2004062	\N	\N
832	copd history yrs	C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496	\N	\N
832	copd exacerbation history  n ( % )	C0019664;C0019665;C0262512;C0262926;C0740304;C1705255;C2004062	\N	\N
832	clinical history — no . ( % )	C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062	\N	\N
832	clinical history  no . ( % )	C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062	\N	\N
832	clinical history  n ( % )	C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062	\N	\N
832	clinical history	C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062	\N	\N
832	chf history	C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
832	cardiovascular risk factors and medical history	C0262926;C0850624;C1704706	\N	\N
832	cardiac history  %	C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062	\N	\N
832	cardiac history	C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062	\N	\N
832	cad history and risk factors  n ( % )	C0019664;C0019665;C0035648;C0262512;C0262926;C1504769;C1553898;C1705255;C2004062;C2239547;C3813548;C4284121	\N	\N
832	baseline copd exacerbation history  * n ( % )	C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062	\N	\N
832	any cvd history ( % )	C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	\N	\N
831	hiv	C0019682;C0019699	\N	\N
831	hip circumference — cm	C0562350	\N	\N
830	waist - to - hip  male	C0019552;C0022122;C0086582;C0230097;C1505163;C1706180;C1706428;C1706429;C3538851;C4284725	\N	\N
830	total hip or knee replacement	C0019552;C0022122;C0086511;C0439175;C0439810;C1505163;C3538851;C4284725	\N	\N
830	total hip bmi ) t - score	C0019552;C0022122;C0578022;C1505163;C2964552;C3538851;C4284725	\N	\N
830	total hip bmd t - score	C0019552;C0022122;C1505163;C2964552;C3538851;C4284725	\N	\N
830	total - hip bmd t - score	C0019552;C0022122;C1505163;C2964552;C3538851;C4284725	\N	\N
830	hip + $nmbr$ vertebral fractures	C0019552;C0019557;C0022122;C0080179;C0549207;C1505163;C3538851;C4284725	\N	\N
830	hip  femur	C0015811;C0019552;C0022122;C1505163;C3538851;C4284725	\N	\N
830	hip	C0019552;C0022122;C1505163;C3538851;C4284725	\N	\N
-10	hub	C0063034;C1414372;C1708389	\N	\N
828	aspirin < $nmbr$ hours	C0004057;C0439227	\N	\N
828	$nmbr$ - hour postload glucose	C0017725;C0439227;C0564385	\N	\N
828	$nmbr$ - $nmbr$ hours	C0439227	\N	\N
827	use of medication from randomization through $nmbr$ hr — no . / total no . ( % )	C0013227;C0034656;C0439175;C0439810;C1524063;C3244316;C4284232	\N	\N
827	hr ( b . p . m . )	C0369637;C0441923	\N	\N
827	hr ( adjusteda )	\N	\N	\N
827	> $nmbr$ hr	\N	\N	\N
827	$nmbr$ hr prandial glucose ' * ’	C0017725;C1998602;C4553624	\N	\N
827	$nmbr$ - $nmbr$ hr	\N	\N	\N
825	hr $nmbr$ . $nmbr$	\N	\N	\N
825	hr	\N	\N	\N
825	hc	C0020268;C0262499;C1413512	\N	\N
825	duration of infusion — hr	C0449238;C0574032;C1827465;C2926735	\N	\N
825	duration of infusion during medical management — hr	C0001554;C0199168;C0205476;C0376636;C0449238;C0574032;C1273870;C1827465;C2926735;C3273539	\N	\N
825	duration of infusion before pci — hr	C0449238;C0574032;C1827465;C2926735;C4049621	\N	\N
825	duration of infusion before cabg — hr	C0010055;C0449238;C0574032;C1827465;C2926735	\N	\N
825	duration of infusion after pci — hr	C0449238;C0574032;C1827465;C2926735;C4049621	\N	\N
825	duration of clopidogrel pretreatment — hr median	C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076	\N	\N
825	direction of hr	C0449738	\N	\N
826	< $nmbr$ hr	\N	f	298
832	atherosclerotic vascular disease history †	C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	1698
832	atherosclerotic vascular disease history  n ( % ) t	C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	1698
828	$nmbr$ - hour madbp  mm hg	C0439227;C0439475;C0564385	f	15
828	$nmbr$ - hour masbp  mm hg	C0439227;C0439475;C0564385	f	15
824	recurrent hf hospitalization	C0018488;C0019993;C1313497;C1455761;C1538440;C2945760;C3273279	f	12
824	stroke / m l / hf hospitalization	C0018488;C0019993;C0038454;C0456616;C1313497;C1538440;C3273279;C4554100	f	12
824	without hx of hf	C0018488;C0262926;C1313497;C1538440;C3273279;C3814444	f	12
832	all participants history of cabg	C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062	f	389
823	hl 土 $nmbr$ . $nmbr$	C1453952;C4085347	\N	\N
821	total cholesterol / hdl - c	C0023822;C0201950;C0439175;C0439810;C0543421;C3715113	\N	\N
821	total c / hdl - c ratio * *	C0439175;C0439810;C0456603;C1547037;C3715113	\N	\N
821	total - c : hdl - c	C0439175;C0439810;C3715113	\N	\N
821	ratio of ldl to hdl	C0456603;C1547037;C3715113	\N	\N
821	non - hdl choleslerol	C1518422;C3715113	\N	\N
821	non - hdl - c in $nmbr$ classes	C0456387;C1518422;C1518526;C1705943;C3715113;C4019422	\N	\N
821	non - hdl - c / hdl - c	C1518422;C3715113	\N	\N
821	non - hdl - c *	C1518422;C3715113	\N	\N
821	non - hdl - c ( mmol / l )	C1518422;C1532563;C3715113	\N	\N
821	non - hdl - c ( mmol / l  mean )	C0444504;C1518422;C1532563;C2347634;C2348143;C3715113	\N	\N
821	non - hdl - c  mmol / l  mean ( sd )	C0444504;C1518422;C1532563;C2347634;C2348143;C2699239;C3715113	\N	\N
821	non - hdl - c  mmol / l	C1518422;C1532563;C3715113	\N	\N
821	non - hdl - c  mean ( sd )  rng / dl	C0444504;C1518422;C2347634;C2348143;C2699239;C3642216;C3715113	\N	\N
821	non - hdl - c  mean ( sd )	C0444504;C1518422;C2347634;C2348143;C2699239;C3715113	\N	\N
821	non - hdl - c	C1518422;C3715113	\N	\N
821	non - hdl	C1518422;C3715113	\N	\N
821	ldl - c : hdl - c	C3715113	\N	\N
821	ldl - c / hdl - cx	C3715113	\N	\N
821	ldl - c / hdl - c	C3715113	\N	\N
821	hdl — male	C0086582;C1706180;C1706428;C1706429;C3715113	\N	\N
821	hdl — female	C0043210;C0086287;C1705497;C1705498;C3715113	\N	\N
821	hdl choleslerol	C3715113	\N	\N
821	hdl - cy	C0010622;C0332298;C2239193;C3715113	\N	\N
821	hdl - cd	C0007928;C0034283;C3715113;C4552032	\N	\N
821	hdl - c at baseline .	C0168634;C1442488;C3715113	\N	\N
823	elevated non - hdl cholesterol	C0205250;C0729627;C1535899;C3163633	f	821
823	low hdl - c	C0151691	f	821
823	low hdl cholesterol * |	C0151691	f	821
823	non - hdl cholesterol / apob ( ratio )	C0003593;C0456603;C0729627;C1518422;C1535899;C1547037;C2938854;C3252643	f	821
823	non - hdl cholesterol j	C0729627;C1535899	f	821
823	non - hdl cholesterol ( mg / dl )	C0439269;C0729627;C1535899	f	821
823	non - hdl cholesterol ( mmol / l )	C0729627;C1532563;C1535899	f	821
823	non - hdl cholesterol ( week $nmbr$ )	C0332174;C0439230;C0729627;C1535899	f	821
823	reduced hdl cholesterol	C0151691	f	821
824	cardiovascular death or hospitalized hf	C0007226;C0011065;C0018488;C0701159;C1306577;C1313497;C1538440;C3273279;C3887460;C4082313;C4552775	f	12
824	clinical features of hf	C0018488;C0683325;C1313497;C1538440;C3273279	f	12
824	all ~ cause mort / hf hosp .	C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322	f	12
824	enrolment through hf	C0018488;C1313497;C1516879;C1538440;C1696073;C3273279;C3888021	f	12
824	duration of hf  y	C0018488;C0449238;C1313497;C1538440;C2926735;C3273279	f	12
824	heart failure ( hf )  ( % )	C0018488;C0018801;C0018802;C1313497;C1538440;C3273279;C4554158	f	12
824	hf	C0018488;C1313497;C1538440;C3273279	f	12
824	hf cause	C0015127;C0018488;C1313497;C1524003;C1538440;C3273279	f	12
824	hf duration  y  n ( % )	C0018488;C0449238;C1313497;C1538440;C2926735;C3273279	f	12
824	hf hosp .	C0018488;C1313497;C1538440;C3273279	f	12
824	hf hospitalisation	C0018488;C0019993;C1313497;C1538440;C3273279	f	12
824	hf hospitalization n	C0018488;C0019993;C1313497;C1538440;C3273279	f	12
824	hf  lvd  or both	C0018488;C1313497;C1538440;C3273279	f	12
824	hf signs and symptoms	C0018488;C0220912;C0220913;C0311392;C0683368;C1313497;C1457887;C1538440;C3273279	f	12
824	hf symptomatic improvement	C0018488;C0231220;C1313497;C1538440;C2986411;C3273279	f	12
824	hf symptom unchanged	C0018488;C0442739;C1313497;C1457887;C1538440;C2346711;C3273279;C3854129	f	12
824	hf symptoms and signs	C0018488;C0220912;C0220913;C0311392;C0683368;C1313497;C1457887;C1538440;C3273279	f	12
824	history of hf hospitalization	C0018488;C0551577;C1313497;C1538440;C3273279	f	12
824	hf  total	C0018488;C0439175;C0439810;C1313497;C1538440;C3273279	f	12
824	hosp . for hf	C0018488;C1313497;C1538440;C3273279	f	12
824	hospitalization for hf previous year  ( % )	C0018488;C0019993;C0205156;C0439234;C0439508;C1313497;C1538440;C1552607;C3273279	f	12
824	hospitalized hf	C0018488;C0701159;C1313497;C1538440;C3273279	f	12
824	hospitalized hf !	C0018488;C0701159;C1313497;C1538440;C3273279	f	12
824	hosp . worsening hf	C0018488;C0332271;C1313497;C1457868;C1538440;C1546960;C3273279	f	12
824	ischemic hf etiology	C0015127;C0018488;C0475224;C1313497;C1314792;C1524003;C1538440;C3273279	f	12
824	ischemic hf  % ( n )	C0018488;C0475224;C1313497;C1538440;C3273279	f	12
824	new hf medication	C0013227;C0018488;C0205314;C1313497;C1538440;C3244316;C3273279;C4284232	f	12
824	no hx of hf ( n = $nmbr$ )	C0018488;C0262926;C1313497;C1538440;C3273279;C3814444	f	12
824	no prior hf hospitalization ( n   = $nmbr$  $nmbr$ )	C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279	f	12
824	no prior hf n = $nmbr$	C0018488;C0332152;C1313497;C1538440;C2826257;C3273279	f	12
824	no prior hf ( n = $nmbr$  $nmbr$ )	C0018488;C0332152;C1313497;C1538440;C2826257;C3273279	f	12
824	pharmacological therapy for hf	C0013217;C0018488;C1313497;C1538440;C3273279	f	12
824	previous hf	C0018488;C0205156;C1313497;C1538440;C1552607;C3273279	f	12
824	previous hf hospitalization  n ( % )	C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279	f	12
824	prior hf n = $nmbr$	C0018488;C0332152;C1313497;C1538440;C2826257;C3273279	f	12
824	prior hf ( n = $nmbr$  $nmbr$ )	C0018488;C0332152;C1313497;C1538440;C2826257;C3273279	f	12
821	hdl - c  mmol / l  mean ( sd )	C0444504;C1532563;C2347634;C2348143;C2699239;C3715113	\N	\N
821	hdl - c  mmol / l	C1532563;C3715113	\N	\N
821	hdl - c	C3715113	\N	\N
821	hdl *	C3715113	\N	\N
821	hdl ( mmol / l )	C1532563;C3715113	\N	\N
821	hdl $nmbr$ - c	C3715113	\N	\N
821	hdl $nmbr$	C3715113	\N	\N
821	hdl	C3715113	\N	\N
821	baseline non - hdl - ca	C0168634;C1442488;C1518422;C3715113;C3887642	\N	\N
821	baseline hdl - c in $nmbr$ classes	C0168634;C0456387;C1442488;C1518526;C1705943;C3715113;C4019422	\N	\N
821	baseline hdl - c	C0168634;C1442488;C3715113	\N	\N
820	with highest hba $nmbr$ cc	C0008318;C0019016;C1522410;C1825777;C3538758;C3538933	\N	\N
820	week $nmbr$ hba $nmbr$ c  mean ( s . e . )	C0019016;C0332174;C0439230;C0444504;C1825777;C2347634;C2348143;C3538758	\N	\N
820	subpopulation analyses according to baseline hba $nmbr$ c	C0002778;C0019016;C0168634;C0441837;C0680240;C0936012;C1442488;C1524024;C1825777;C3538758	\N	\N
820	subgroup analysis : change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category	C0019016;C0168634;C0332174;C0392747;C0439230;C0443172;C0683312;C1442488;C1705241;C1825777;C2986480;C3538758;C3889287;C4319952	\N	\N
820	screening hba $nmbr$ c ( % )	C0019016;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C1825777;C2348164;C3538758	\N	\N
820	qualifying hba $nmbr$ c ( % )	C0019016;C1514624;C1825777;C3538758	\N	\N
820	proportion ( $nmbr$ % ci ) adjusted for baseline hba $nmbr$ c  %	C0008107;C0019016;C0168634;C0456081;C1442488;C1709707;C1825777;C3259781;C3538758	\N	\N
820	mean ± s . d . hba $nmbr$ c	C0019016;C0444504;C1825777;C2347634;C2348143;C3538758	\N	\N
820	mean hba $nmbr$ c ± s . d .  %	C0019016;C0444504;C1825777;C2347634;C2348143;C3538758	\N	\N
820	mean hba $nmbr$ c  %	C0019016;C0444504;C1825777;C2347634;C2348143;C3538758	\N	\N
820	mean ( sd ) hba $nmbr$ c level  %	C0019016;C0441889;C0444504;C0456079;C1547707;C1825777;C2347634;C2348143;C2699239;C2946261;C3538758	\N	\N
820	mean ( s . d . ) baseline hba $nmbr$ c  %	C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758	\N	\N
820	hba „ ( % )	C0019016;C1825777;C3538758	\N	\N
820	hba ] c ( mmol / mol )	C0019016;C1825777;C3538758;C3829066	\N	\N
820	hba $nmbr$ ca  % ( mmol / mol )	C0019016;C1825777;C3538758;C3829066;C3887642	\N	\N
820	hba $nmbr$ c ≤ $nmbr$ . $nmbr$ % without gi adverse reactions	C0019016;C0559546;C1708130;C1825777;C3538758;C3539617;C4050121	\N	\N
820	hba $nmbr$ c ≤ $nmbr$ . $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c   baseline ( % )	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	hba $nmbr$ c   at randomization	C0019016;C0034656;C1825777;C3538758	\N	\N
820	hba $nmbr$ c   ( mmol / mol )	C0019016;C1825777;C3538758;C3829066	\N	\N
820	hba $nmbr$ c   ( % )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c subgroups	C0019016;C1079230;C1825777;C3538758	\N	\N
820	hba $nmbr$ c strata	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c levels	C0019016;C0441889;C1825777;C3538758	\N	\N
820	hba $nmbr$ c in patients with baseline hba $nmbr$ c < $nmbr$ % ( < $nmbr$ mmol / l )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se )	C0008107;C0019016;C0023031;C0023749;C0027960;C0030705;C0032042;C0036919;C0168634;C0230347;C0324740;C0392747;C0439189;C0443172;C0444504;C0456081;C1442488;C1456781;C1696465;C1705241;C1706408;C1719767;C1824986;C1825777;C1960955;C2346906;C2347634;C2348143;C2348589;C2699239;C3259781;C3538758;C3665593;C4319952;C4553351	\N	\N
820	hba $nmbr$ c distribution at baseline  n ( % )	C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758	\N	\N
820	hba $nmbr$ c distribution at baseline	C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758	\N	\N
820	hba $nmbr$ c distribution	C0019016;C0520511;C1704711;C1825777;C3538758	\N	\N
820	hba $nmbr$ c category  n ( % )	C0019016;C0683312;C1825777;C3538758;C3889287	\N	\N
820	hba $nmbr$ c category	C0019016;C0683312;C1825777;C3538758;C3889287	\N	\N
820	hba $nmbr$ c categories  n ( % )	C0019016;C0683312;C1825777;C3538758	\N	\N
820	hba $nmbr$ c at week $nmbr$	C0019016;C0332174;C0439230;C1825777;C3538758	\N	\N
820	hba $nmbr$ c at baseline :	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	hba $nmbr$ c at baseline  %	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	hba $nmbr$ c at baseline	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	hba $nmbr$ c at $nmbr$ weeks *	C0019016;C0439230;C1825777;C3538758	\N	\N
820	hba $nmbr$ c \\n	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c > = $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c > $nmbr$ · $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c > $nmbr$ . $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c > $nmbr$ % level	C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758	\N	\N
820	hba $nmbr$ c > $nmbr$ % ( n $nmbr$ $nmbr$ )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c > $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c < = $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c < $nmbr$ . $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c < $nmbr$ % level	C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758	\N	\N
820	hba $nmbr$ c < $nmbr$ % ( n - $nmbr$ )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c < $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c ( sd )  %	C0019016;C1825777;C2699239;C3538758	\N	\N
820	hba $nmbr$ c ( n )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c ( mmol / mol )	C0019016;C1825777;C3538758;C3829066	\N	\N
820	hba $nmbr$ c ( change from baseline )	C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952	\N	\N
820	hba $nmbr$ c ( % patients < $nmbr$ . $nmbr$ % )	C0019016;C0030705;C1825777;C3538758	\N	\N
820	hemoglobin a    ( % )	C0019016	f	2074
820	hba $nmbr$ c ( % ) *	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c ( % )  mean ( sd )	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c ( % )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c % ( range )	C0019016;C1514721;C1825777;C2348147;C3538758;C3542016	\N	\N
820	hba $nmbr$ c $nmbr$ weeks	C0019016;C0439230;C1825777;C3538758	\N	\N
820	hba $nmbr$ c $nmbr$ - < = $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c $nmbr$ % - < $nmbr$ % ( n - $nmbr$ )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c $ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )	C0019016;C1825777;C3538758;C3829066	\N	\N
820	hba $nmbr$ c  n	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  mmol / mole	C0019016;C1825777;C3538758;C3829066	\N	\N
820	hba $nmbr$ c  mmol / mold	C0019016;C0369241;C0439190;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  mmol / mol	C0019016;C1825777;C3538758;C3829066	\N	\N
820	hba $nmbr$ c  median ( sd )  %	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2699239;C2939193;C3538758	\N	\N
820	hba $nmbr$ c  mean = sd  %	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  mean ( sd )  % [ mmol / mol ]	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066	\N	\N
820	hba $nmbr$ c  mean ( sd )  %	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  mean ( sd )	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  baseline mean hba $nmbr$ c  % ( sd )	C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  > $nmbr$ . $nmbr$	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  < $nmbr$ . $nmbr$	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  ( % )	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  % §	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  % d	C0012358;C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  % *	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  % ( sd )	C0019016;C1825777;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  % ( mean ± sd ) [ range ]	C0019016;C0444504;C1514721;C1825777;C2347634;C2348143;C2348147;C2699239;C3538758;C3542016	\N	\N
820	hba $nmbr$ c  % ( mean $nmbr$ sd )	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  %  n ( % ) b	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  %  mean ± sd	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  %  mean ( sd ) b	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  %  mean ( sd )	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
820	hba $nmbr$ c  %	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c  $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$	C0019016;C1825777;C3538758	\N	\N
820	hba $nmbr$ c	C0019016;C1825777;C3538758	\N	\N
820	hba  c ( % )	C0019016;C1825777;C3538758	\N	\N
820	hba  % $nmbr$ c	C0019016;C1825777;C3538758	\N	\N
820	hba   ( % )	C0019016;C1825777;C3538758	\N	\N
820	change from baseline in hba $nmbr$ c ( % )	C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952	\N	\N
820	baseline hba ^ c	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	baseline hba $nmbr$ c in $nmbr$ classes	C0019016;C0168634;C0456387;C1442488;C1518526;C1705943;C1825777;C3538758;C4019422	\N	\N
820	baseline hba $nmbr$ c concentration	C0019016;C0086045;C0168634;C1442488;C1446561;C1825777;C3538758;C3827302	\N	\N
820	baseline hba $nmbr$ c ^	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	baseline hba $nmbr$ c > $nmbr$ . $nmbr$ %	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	baseline hba $nmbr$ c < $nmbr$ . $nmbr$ %	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	baseline hba $nmbr$ c ( % )	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	baseline hba $nmbr$ c  n ( % )	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	baseline hba $nmbr$ c  mean ( s . e . )	C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758	\N	\N
820	baseline hba $nmbr$ c  %	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	baseline hba $nmbr$ c	C0019016;C0168634;C1442488;C1825777;C3538758	\N	\N
820	any hba $nmbr$ c	C0019016;C1825777;C3538758	\N	\N
820	% hba $nmbr$ c ( mmol / mol )	C0019016;C1825777;C3538758;C3829066	\N	\N
820	$nmbr$ % < hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ )	C0019016;C1825777;C3538758	\N	\N
820	$nmbr$ % < hba $nmbr$ c < = $nmbr$ %	C0019016;C1825777;C3538758	\N	\N
-10	bisphosphonates	C0012544;C3541401	\N	\N
818	isolated impaired glucose tolerance — no .	C0205409;C0271650;C1548221	\N	\N
818	isolated igt	C0205409;C1548221	\N	\N
817	vasodilator therapy	C0039798;C0042402;C0087111;C1363945;C3537240	\N	\N
817	vasodilator	C0042402;C3537240	\N	\N
817	other vasodilators §	C0042402	\N	\N
817	other vasodilator	C0042402;C3537240	\N	\N
817	iv vasodilator	C0022326;C0042402;C3537240;C4265176	\N	\N
817	both iv vasodilator and inotrope	C0022326;C0042402;C1258199;C3537240;C4265176	\N	\N
816	non - ischaemic dilated cardiomyopathy	C1518422;C1960867	\N	\N
816	ischaemic dilated cardiomyopathy	C1960867	\N	\N
816	hypertrophic cardiomyopathy	C0007194;C4551472	\N	\N
816	dilated cardiomyopathy	C0007193;C2984282	\N	\N
816	combined cardiac failure  cardiomyopathy or other cardiac disorders	C0018799;C0018801;C0018802;C0205195;C0878544	\N	\N
816	cardiomyopathy	C0878544	\N	\N
815	rhabdomyolysis or myopathy	C0026848;C0035410;C4552660	\N	\N
815	rhabdomyolysis ( n = $nmbr$ )	C0035410;C4552660	\N	\N
815	rhabdomyolysis  myopathy  or myalgia with ck elevation > $nmbr$ x uln	C0009212;C0010287;C0026848;C0035410;C0231528;C0439775;C0702240;C1519815;C1872855;C4552646;C4552660	\N	\N
815	rhabdomyolysis  myopathy  or elevated creatine phosphokinase > $nmbr$ x upper limit of normal ( n = $nmbr$ )	C0010286;C0026848;C0035410;C0205250;C1427255;C1519815;C3163633;C4552660	\N	\N
815	rhabdomyolysis	C0035410;C4552660	\N	\N
818	isolated upper gastrointestinal disease behavior  n ( % )	C0004927;C0205409;C0810300;C1548221;C2707008	f	1927
818	isolated pulmonary embolism	C0034065;C0205409;C1548221	f	630
814	pde $nmbr$ inhibitor monotherapy	C0031638	\N	\N
814	monoamine oxidase b inhibitors	C2917290;C3653412	\N	\N
814	era and pde $nmbr$ inhibitors	C0031638;C1521863;C3495919	\N	\N
814	a - glucosidase inhibitors ' $nmbr$	C1512211	\N	\N
814	a - glucosidase inhibitors	C1512211	\N	\N
814	a - glucosidase inhibitor	C1512211	\N	\N
813	sglt - $nmbr$ inhibitors ^	C3665045	\N	\N
813	renin inhibitors	C2917241;C3653375	\N	\N
813	renin inhibitor ( e . g . aliskerin )	C1960108;C3537174;C4521920	\N	\N
813	renin inhibitor	C1960108;C3537174;C4521920	\N	\N
813	renin - angiotensin inhibitors	C0003018;C2917241;C3653375;C4521302	\N	\N
813	platelet aggregation inhibitors excluding heparin	C0019134;C0032177;C0332196;C0770546;C2828389	\N	\N
813	platelet aggregation inhibitors  n ( % )	C0032177	\N	\N
812	renin – angiotensin system inhibitor	C0035096;C1999216;C2984247	\N	\N
812	renin - angiotensin system inhibitor use	C0035096;C0042153;C0457083;C1947944;C1999216;C2984247	\N	\N
812	raas inhibitor use	C0042153;C0457083;C1947944;C1999216	\N	\N
812	raas inhibitor	C1999216	\N	\N
812	p $nmbr$ y $nmbr$ inhibitor maintenance	C0024501;C0369773;C1999216;C2603361	\N	\N
812	p $nmbr$ y $nmbr$ inhibitor loading dos	C0369773;C1428722;C1708715;C1999216;C2603361	\N	\N
812	p $nmbr$ y $nmbr$ inhibitor	C0369773;C1999216;C2603361	\N	\N
812	other sglt - $nmbr$ inhibitor	C1999216	\N	\N
812	inhibitor	C1999216	\N	\N
812	gpifo ' llia inhibitor use before angography	C0042153;C0457083;C1947944;C1999216	\N	\N
812	gpifeellla inhibitor use before angography	C0042153;C0457083;C1947944;C1999216	\N	\N
811	use of ace inhibitor	C0003015;C1524063;C4541021	\N	\N
811	current use of an ace inhibitor	C0003015;C0521116;C1524063;C1705970;C4541021	\N	\N
811	angiotensin - converting enzyme inhibitors ^	C0003015;C2757044	\N	\N
811	angiotensin - converting enzyme inhibitors	C0003015;C2757044	\N	\N
811	angiotensin - converting enzyme inhibitor / angiotensin receptor blocker	C0003015;C0597357;C2757044;C3536837;C4541021	\N	\N
811	angiotensin - converting enzyme inhibitor	C0003015;C2757044;C3536837;C4541021	\N	\N
811	angiotensin - converting - enzyme inhibitor or angiotensin -	C0003015;C0003018;C2757044;C3536837;C4521302;C4541021	\N	\N
811	angiotensin - converting - enzyme inhibitor	C0003015;C2757044;C3536837;C4541021	\N	\N
811	ace inhibitors through hospital discharge or day $nmbr$ — %	C0003015;C0332173;C0439228;C0439505;C0586003	\N	\N
811	ace inhibitors / sartans	C0003015;C1563745	\N	\N
811	ace inhibitors	C0003015	\N	\N
811	ace inhibitor — no . ( % )	C0003015;C4541021	\N	\N
811	ace inhibitor use ( % )	C0003015;C0042153;C0457083;C1947944;C4541021	\N	\N
811	ace inhibitor or arb use	C0003015;C0042153;C0457083;C1947944;C3888198;C4541021	\N	\N
811	ace inhibitor or angiotensin ii receptor	C0003011;C0003015;C4541021	\N	\N
811	ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % )	C0003015;C0034787;C0439175;C0439810;C1622222;C4541021	\N	\N
811	ace inhibitor monotherapy	C0003015;C4541021	\N	\N
811	ace inhibitor  n ( % )	C0003015;C4541021	\N	\N
811	ace inhibitor  %	C0003015;C4541021	\N	\N
811	ace inhibitor	C0003015;C4541021	\N	\N
811	ace - inhibitors  n ( % )	C0003015	\N	\N
811	ace - inhibitors	C0003015	\N	\N
811	ace - inhibitor use	C0003015;C0042153;C0457083;C1947944;C4541021	\N	\N
810	p - gp inhibitor	C3898062	\N	\N
810	gp llb / llla inhibitors	C0243077;C1705010;C3811116	\N	\N
809	tnf inhibitors	C0243077;C1448177	\N	\N
809	raas inhibitors	C0243077	\N	\N
809	non - tnf inhibitors	C0243077;C1448177;C1518422	\N	\N
809	no . of previous tne inhibitors	C0205156;C0243077;C1552607;C3896585	\N	\N
808	no ilb / iiia inhibitors	C0243077;C4697913	\N	\N
808	ilb / iiia inhibitors	C0243077;C4697913	\N	\N
808	ijb ^	\N	\N	\N
808	gpiib / iiia receptor inhibitor	C0016011;C0597357;C1999216	\N	\N
808	gpiib - iiia inhibitors	C0016011;C0243077	\N	\N
808	gp iib / iiia inhibitors	C0016011;C0243077	\N	\N
808	gp iib / iiia inhibitor used	C0016011;C1273517;C1999216	\N	\N
808	gp iib / iiia inhibitor before pci — no . ( % )	C0016011;C1999216;C4049621	\N	\N
808	glycoprotein iib / iiia inhibitort	C0016011	\N	\N
808	glycoprotein iib / iiia inhibitors	C0016011;C0243077	\N	\N
808	glycoprotein iib / iiia inhibitor	C0016011;C1999216	\N	\N
808	bail ‐ out use of glycoprotein iib / iiia inhibitors	C0016011;C0175673;C0243077;C1524063	\N	\N
807	potent phosphorylated glycoprotein inhibitor use	C0017968;C0042153;C0457083;C1947944;C1999216;C3245505	\N	\N
807	glycoprotein iib / iiiareceptorinhibitor	C0017968	\N	\N
806	received first loading dose	C0205435;C1279901;C1514756;C3714444	\N	\N
806	no ipst ( n = $nmbr$  $nmbr$ )	\N	\N	\N
806	no ipst	\N	\N	\N
806	missing data initial diagnosis — no .	C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685;C4684714	\N	\N
806	ipst ( n = $nmbr$ )	\N	\N	\N
806	ipst	\N	\N	\N
806	initial timi flow grade $nmbr$	C0205265;C0441800;C0919553;C1279901;C1555582;C1705685;C3244287;C3272266	\N	\N
806	initial timi flow	C0205265;C1279901;C1555582;C1705685;C3272266	\N	\N
806	initial heparin — no . ( % ) §	C0019134;C0205265;C0770546;C1279901;C1555582;C1705685	\N	\N
806	initial diagnosis — no . ( % )	C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685	\N	\N
806	first loading dose	C0205435;C1279901;C3714444	\N	\N
806	first - recorded event  no . ( and % ) of patients	C0030705;C0034869;C0205435;C0441471;C1279901;C3853788;C4019010	\N	\N
806	first - generation stentt	C0079411;C0205435;C1279901;C3146294	\N	\N
806	first ( n = $nmbr$ )	C0205435;C1279901	\N	\N
806	criterion reached first  n ( % )	C0205435;C0243161;C1279901;C2584321;C4321250	\N	\N
806	components of the first cid	C0205435;C0449432;C1279901;C1707433	\N	\N
805	micral test result	C0456984;C0587081	\N	\N
805	labs at randomization	C0034656;C0587081	\N	\N
805	laboratory findings	C0587081	\N	\N
805	> $nmbr$ microg / l	\N	\N	\N
805	< $nmbr$ microg / l	\N	\N	\N
804	tirofiban ( n = $nmbr$ )	C0247025	\N	\N
804	irofiban	\N	\N	\N
804	heparin ± tirofiban ( n = $nmbr$ )	C0019134;C0247025;C0770546	\N	\N
804	heparin plus tirofiban ( n = $nmbr$ )	C0019134;C0247025;C0332287;C0770546	\N	\N
804	heparin + tirofiban ( n = $nmbr$ )	C0019134;C0247025;C0770546	\N	\N
803	simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg ( n = $nmbr$ /	C0033228;C0074554;C0332287;C1319635	\N	\N
803	fenofibrate ( n = $nmbr$ )	C0033228	\N	\N
802	non - fibrin - specific	C0015982;C0205370	\N	\N
802	fibrin - specilic	C0015982	\N	\N
802	fibrin - specific	C0015982;C0205369;C1552740	\N	\N
801	minority	C0026192	\N	\N
801	ethnic minority group — no . ( % )	C0015031;C0026192;C0680174;C1879937	\N	\N
800	evening mealb	C0587117	\N	\N
800	evening	C0587117	\N	\N
799	selexipag patients / events n	C0030705;C0441471;C2000145;C3541888	\N	\N
799	selexipag ( n = $nmbr$ )	C2000145	\N	\N
799	selexipag	C2000145	\N	\N
798	theophylline use at screening	C0220908;C0220909;C0241361;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
798	screening visit	C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704	\N	\N
798	screening and baseline lung function characteristics	C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C4684572	\N	\N
798	screening ( visit $nmbr$ )	C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704	\N	\N
798	screening  l	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
798	screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
798	risk factor ( predefined ) for falling at screening  n ( % )	C0000921;C0035648;C0085639;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
798	pre - bronchodilator screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602	\N	\N
798	post - bronchodilator screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594	\N	\N
798	post - bronchodilator fev $nmbr$ at screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541	\N	\N
798	patients with > $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening	C0184666;C0220908;C0220909;C0439231;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C3810541;C3811131;C4086268	\N	\N
798	patients with > $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening	C0019994;C0030673;C0220908;C0220909;C0439231;C1510665;C1698960;C1710031;C1710032;C1710477;C2348164;C4086268	\N	\N
798	oad at screening  n ( % )	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
798	modified rankin scale at screening  $nmbr$ - $nmbr$	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2984908;C3854213	\N	\N
798	mean blood pressure at screening visit ( mm hg )	C0220908;C0220909;C0428886;C0439475;C0488053;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704	\N	\N
798	lama use at screening  n ( % )	C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	\N	\N
798	lama use at screening	C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	\N	\N
798	laba use at screening  n ( % )	C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	\N	\N
798	laba use at screening	C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	\N	\N
798	fev $nmbr$   at screening ∗	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541	\N	\N
798	devices for heart failure at screening visit	C0018787;C0018801;C0018802;C0025078;C0025080;C0220819;C0220908;C0220909;C0231174;C0545082;C0680095;C0699733;C1512346;C1698960;C1710031;C1710032;C1710477;C2024216;C2348164;C2826704;C4554158	\N	\N
798	current smoker  n ( % ) post - bronchodilator screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3173209;C3241966	\N	\N
798	at screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
798	aspirin use before screening — no . { % )	C0004057;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	\N	\N
798	> $nmbr$ per pl in $nmbr$ months before screening	C0220908;C0220909;C0439231;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765	\N	\N
798	> $nmbr$ per pl at screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765	\N	\N
798	> $nmbr$ at screening	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
797	smokingb	\N	\N	\N
797	smoking habit  n ( % )	C4505437	\N	\N
797	current cigarette smoking  no . ( % )	C0239059;C0521116;C0700219;C1705970	\N	\N
797	current cigarette smoking	C0239059;C0521116;C0700219;C1705970	\N	\N
797	cigarette smoking in the past year	C0239059;C0700219;C4086728	\N	\N
797	cigarette smoking  n ( % )	C0239059;C0700219	\N	\N
797	cigarette smoking	C0239059;C0700219	\N	\N
796	smoking status — no . { % )	C1519386	\N	\N
796	smoking status — no . ( % )	C1519386	\N	\N
796	smoking status at screening  n ( % )	C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164	\N	\N
796	smoking status at screening	C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164	\N	\N
796	smoking status . no . ( % )	C1519386	\N	\N
796	smoking status *	C1519386	\N	\N
796	smoking status ( ongoing ) ( n )	C0549178;C1519386	\N	\N
796	smoking status ( % )	C1519386	\N	\N
796	smoking status  no . ( % )	C1519386	\N	\N
796	smoking status  n [ % ] ®	C1519386	\N	\N
796	smoking status  n ( % ) *	C1519386	\N	\N
798	laba - inhaled glucocorticoid use at screening	C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	f	2182
796	cigarette smoking status	C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423	\N	\N
796	cigarette - smoking status — no . ( % )	C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423	\N	\N
796	cigarette - smoking status ( % )	C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423	\N	\N
796	baseline smoking status	C0168634;C1442488;C1519386	\N	\N
-10	streptokinase	C0038418	\N	\N
794	use of compression stockings  no . ( % )	C0038348;C1524063	\N	\N
794	compression stockings	C0038348	\N	\N
793	no clinical or lesion rfs for st	C0036056;C0205210;C0221198;C0341703;C1546698;C3272372	\N	\N
793	durable clinical responseg	C0205210	\N	\N
793	durable clinical remissionh	C0205210	\N	\N
793	clinical responsed	C0205210	\N	\N
793	clinical remissione	C0205210	\N	\N
793	clinical or lesion rf for st	C0035448;C0036056;C0201660;C0205210;C0221198;C0748398;C1546698;C1547111;C3272372	\N	\N
793	clinical details	C0205210;C1522508	\N	\N
793	clinical criteria $nmbr$	C0205210;C0243161	\N	\N
793	clinical and patient - reported characteristics at baseline and randomization	C0034656;C0205210;C0588446;C4684572	\N	\N
793	clinical	C0205210	\N	\N
793	any clinical or lesion rf for st	C0035448;C0036056;C0201660;C0205210;C0221198;C0748398;C1546698;C1547111;C3272372	\N	\N
792	non - cortical	C0001613;C0007776;C0022655;C1518422	\N	\N
792	cortical only	C0001613;C0007776;C0022655;C0205171;C1720467	\N	\N
791	clinical endpoint	C2347784	\N	\N
791	clinical dementia rating score	C4304227	\N	\N
790	clinical presentation of vte at initial diagnosis — no . ( % )	C0011900;C0205265;C0630906;C1279901;C1555582;C1704338;C1704656;C1705685;C2708283	\N	\N
790	clinical presentation	C2708283	\N	\N
789	selected clinical characteristics — no . / total no . ( % )	C0439175;C0439810;C0683325;C1707391	\N	\N
789	selected clinical characteristics  n ( % )	C0683325;C1707391	\N	\N
789	selected clinical characteristics	C0683325;C1707391	\N	\N
789	other clinical characteristics	C0683325	\N	\N
789	demographics and clinical characteristics	C0011298;C0683325;C1704791	\N	\N
789	clinical characteristics ( % )	C0683325	\N	\N
789	clinical characteristics  n ( % )	C0683325	\N	\N
789	clinical characteristics	C0683325	\N	\N
788	timi clinically significant	C0237881;C0750502;C1546944	\N	\N
788	significant worsening in kccq clinical	C0205210;C0237881;C0332271;C0750502;C1457868;C1546944;C1546960;C3476798	\N	\N
787	women ethnic origin	C0015031;C0043210	\N	\N
787	white ethnicity	C0007457;C0015031;C0043157;C0220938;C0243103	\N	\N
787	white ethnic origin	C0007457;C0015031;C0043157;C0220938	\N	\N
787	while ethnic origin	C0015031	\N	\N
787	sex ( male ) ethnic origin	C0015031;C0086582	\N	\N
787	race or ethnicity  n ( % )	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
787	race or ethnicity	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
787	race or ethnic origin	C0015031;C0034510;C1706779;C3853635	\N	\N
787	race or ethnic group — no . { % ) ■ ' ( white	C0007457;C0015031;C0034510;C0043157;C0220938;C1706779;C1879937;C3853635	\N	\N
787	race or ethnic group — no . f	C0015031;C0016327;C0034510;C1706779;C1879937;C3853635	\N	\N
787	race or ethnic group — no . / total no . ( % ) f	C0015031;C0016327;C0034510;C0439175;C0439810;C1706779;C1879937;C3853635	\N	\N
787	race or ethnic group — no . ( % ) f	C0015031;C0016327;C0034510;C1706779;C1879937;C3853635	\N	\N
787	race or ethnic group ( % ) f	C0015031;C0016327;C0034510;C0441840;C0680174;C1706779;C1879937;C3853635	\N	\N
787	race or ethnic group ( % )	C0015031;C0034510;C1706779;C1879937;C3853635	\N	\N
787	race or ethnic group  n ( % ) *	C0015031;C0034510;C0441848;C0680174;C1706779;C3853635	\N	\N
787	race or ethnic group	C0015031;C0034510;C1706779;C1879937;C3853635	\N	\N
787	race / ethnicity white	C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1706779;C3853635	\N	\N
787	race / ethnicity n ( % )	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
787	race / ethnicity  no . ( % ) *	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
787	race / ethnicity  no . ( % )	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
787	race / ethnicity  n ( % )	C0015031;C0034510;C0243103;C1706779;C3853635	\N	\N
787	race / ethnicity  % white non - hispanic	C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1518422;C1518424;C1533020;C1533021;C1706779;C3853635	\N	\N
787	othery ethnicity  n ( % ) *	C0015031;C0243103	\N	\N
787	othery ethnicity  n ( % )	C0015031;C0243103	\N	\N
787	male sex ( % ) race or ethnic group ( % ) f	C0015031;C0016327;C0034510;C0086582;C0441840;C0680174;C1706779;C1879937;C3853635	\N	\N
787	hispanic ethnicity  n ( % )	C0015031;C0086409;C0243103	\N	\N
787	hispanic ethnicity	C0015031;C0086409;C0243103	\N	\N
787	hispanic / latino ethnicity  n ( % )	C0015031;C0086409;C0086528;C0243103	\N	\N
787	hispanic / latino ethnicity	C0015031;C0086409;C0086528;C0243103	\N	\N
787	ethnieity	\N	\N	\N
787	ethnicity t	C0015031;C0243103	\N	\N
787	ethnicity - no . ( % )	C0015031;C0243103	\N	\N
787	ethnicity - - hispanic or latino	C0015031;C0086409;C0086528;C0243103	\N	\N
787	ethnicity ( % )	C0015031;C0243103	\N	\N
787	ethnicity $nmbr$ '	C0015031;C0243103	\N	\N
787	ethnicity  no . ( % )	C0015031;C0243103	\N	\N
787	ethnicity  n ( % ) b	C0015031;C0243103	\N	\N
787	ethnicity  n ( % ) :	C0015031;C0243103	\N	\N
787	ethnicity  n ( % ) *	C0015031;C0243103	\N	\N
787	ethnicity  n ( % )	C0015031;C0243103	\N	\N
787	ethnicity  hispanic / latino  n ( % )	C0015031;C0086409;C0086528;C0243103	\N	\N
787	ethnicity  %	C0015031;C0243103	\N	\N
787	ethnicity	C0015031;C0243103	\N	\N
787	ethnic origin white	C0007457;C0015031;C0043157;C0220938	\N	\N
787	ethnic origin *	C0015031	\N	\N
787	ethnic origin  n ( % )	C0015031	\N	\N
787	ethnic origin	C0015031	\N	\N
787	ethnic group — no . ( % ) '	C0015031;C1879937	\N	\N
787	ethnic group ( % )	C0015031;C1879937	\N	\N
787	ethnic group	C0015031;C1879937	\N	\N
787	ethnic background	C0015031	\N	\N
787	age  mean ( sd )  y ethnicity  no . ( % )	C0001779;C0015031;C0243103;C0444504;C2347634;C2348143;C2699239	\N	\N
7	p - value ( ancova treatment difference ) a	C0039798;C0087111;C0814908;C1522326;C1533734;C1705169;C1705241;C1705242;C1709380;C3538994;C3887704	\N	\N
7	p - value $nmbr$	C1709380	\N	\N
7	p - value	C1709380	\N	\N
787	* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by	C0005893;C0005910;C0015031;C0034510;C0036595;C0042295;C0043100;C0332288;C0332849;C0439209;C0578022;C1305855;C1305866;C1704970;C1705104;C1706779;C1879937;C2699239;C3853635	\N	\N
786	urti	\N	\N	\N
786	single vessel coronary artery disease †	C0581374	\N	\N
786	single vessel coronary artery disease *	C0581374	\N	\N
786	single vessel coronary artery disease $nmbr$	C0581374	\N	\N
786	multi - vessel coronary artery disease	C1299432	\N	\N
786	ischemic coronary artery disease	C0852149	\N	\N
786	history of coronary artery disease — no . { % )	C1881055	\N	\N
786	history of coronary artery disease - n ( % )	C1881055	\N	\N
786	history of coronary artery disease	C1881055	\N	\N
786	coronar y artery disease	C0852949	\N	\N
786	coronaiy artery disease	C0852949	\N	\N
785	non - lad artery	C0003842;C0226004;C1518422	\N	\N
785	lad artery	C0003842;C0226004	\N	\N
785	imaged artery	C0003842;C0226004;C1704254;C1704922;C3542466	\N	\N
784	carrier ( n = $nmbr$ )	C0007294;C0560175;C1325398;C1706209;C3273162	\N	\N
784	apolipoprotein e carrier	C0003595;C0007294;C0560175;C1325398;C1706209;C3273162	\N	\N
784	apoe   ε $nmbr$ carrier	C0003595;C0007294;C0523511;C0560175;C1325398;C1412481;C1706209;C3273162	\N	\N
784	apoe e $nmbr$ carriers  no . ( % )	C0003595;C0007294;C0523511;C1412481	\N	\N
784	ala carriers	C0007294;C0523459;C3888236	\N	\N
783	prevalence of each metabolic syndrome criterion	C0033105;C0220900;C0243161;C0524620	\N	\N
783	entry criteria ( % )	C0243161;C1705654	\N	\N
783	entry criteria	C0243161;C1705654	\N	\N
783	cv entry criteria	C0243161;C1705654;C3538987;C4048877;C4318503	\N	\N
783	criterion	C0243161	\N	\N
783	by who / simon broome criteria	C0243161;C0443058	\N	\N
782	total  adjusted weight of $nmbr$ . $nmbr$ for gastrointestinal bleeding	C0005910;C0017181;C0043100;C0439175;C0439810;C0456081;C1305866;C1705104	\N	\N
782	gastrointestinal bleeding	C0017181	\N	\N
782	gastroenteritis	C0017160	\N	\N
781	upper gastrointestinal tract	C3203348	\N	\N
781	upper gastrointestinal	C3203348	\N	\N
781	history of upper gastrointestinal event	C0019664;C0019665;C0262512;C0262926;C0441471;C1705255;C2004062;C3203348;C4019010	\N	\N
780	fecal calprotectin — pg / g * *	C0015733;C0950624;C1335798;C1366582;C1638318	\N	\N
779	angiotensin receptor blockers	C0521942;C0815017	\N	\N
779	angiotensin receptor	C0034787;C1622222	\N	\N
779	angiotensin receptive blocker	C0003018;C0544683;C4521302	\N	\N
779	angiotensin ll - receptor blocker	C0003018;C0597357;C4521302	\N	\N
779	angiotensin ll - receptor antagonist — no . ( % )	C0003018;C4521302;C4543207	\N	\N
779	angiotensin il - receptor blocker	C0003018;C0020898;C0021764;C0022271;C0034787;C1149183;C1622222;C4521302	\N	\N
779	angiotensin ii receptor blockers	C0521942;C2757003	\N	\N
779	angiotensin ii receptor blocker	C0521942;C3536793	\N	\N
779	angiotensin - receptor	C0034787;C1622222	\N	\N
778	urticaria	C0042109;C1559188	\N	\N
778	other / multiracial	C1881928	\N	\N
778	multiracial or other	C1881928	\N	\N
778	multiracial  n ( % )	C1881928	\N	\N
778	multiracial	C1881928	\N	\N
777	prior exposure to levetiracetam	C0274281;C0332152;C0332157;C0377265;C2826257;C3693636	\N	\N
777	levetiracetam	C0377265;C3693636	\N	\N
776	bivalirudin used during pci	C0168273;C1273517;C4049621	\N	\N
776	bivalirudin used	C0168273;C1273517	\N	\N
776	bivalirudin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ )	C0016011;C0168273;C0243077	\N	\N
776	bivalirudin only	C0168273;C0205171;C1720467	\N	\N
776	bivalirudin ( n = $nmbr$ )	C0168273	\N	\N
776	bivalirudin ( n = $nmbr$  $nmbr$ )	C0168273	\N	\N
776	bivalirudin	C0168273	\N	\N
775	re - cover $nmbr$ dabigatran	C0180153;C0556581;C1999244;C2348066;C2986904;C3888055	\N	\N
775	hazard ratio with dabigatran  $nmbr$ mg ( $nmbr$ % cl )	C0024671;C0026410;C0439269;C0596019;C1960952;C2346927;C2348066;C2985465;C4321396;C4521761	\N	\N
775	favors dabigatran	C0309049;C2348066	\N	\N
775	factors dabigatran event incidence / n	C0021149;C0220856;C0441471;C1521761;C2348066;C2827422;C4019010	\N	\N
775	factors dabigatran	C1521761;C2348066;C2827422	\N	\N
775	dabigatran ( n = $nmbr$ )	C2348066	\N	\N
775	dabigatran  $nmbr$ mg twice daily	C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2348066;C4321396;C4521761	\N	\N
775	dabigatran	C2348066	\N	\N
775	$nmbr$ mg dabigatran ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	\N	\N
775	$nmbr$ mg dabigatran	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	\N	\N
774	placebo - ideglira	C0032042;C1696465;C1706408;C4308663	\N	\N
774	ideglira - ideg - lira	C1555441;C4308663	\N	\N
774	ideglira - ideg	C4308663	\N	\N
774	ideglira	C4308663	\N	\N
774	ideg	\N	\N	\N
773	cgi - s  n ( % ) z :	C4526016	\N	\N
773	bpearson ' s chi ‐ square test .	C0008041	\N	\N
772	china / tjapan	C0008115	\N	\N
772	china / japan	C0008115;C0022341	\N	\N
772	china	C0008115	\N	\N
780	vasoprotectives	C0304533	f	2316
779	angiogenesis	C0302600;C1519670	f	-10
779	angiotensin -	C0003018;C4521302	f	-10
779	ace inhibitors or angiotensin receptor blockers	C0003015;C0521942;C0815017	f	811
771	mean ( ± sd ) change from	C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2699239;C4319952	\N	\N
771	mean ( sd ) change from pre - to post - bronchodilator fevi  ml	C0332152;C0439526;C0444504;C0687676;C0740175;C1704687;C1705224;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034;C3887665	\N	\N
771	mean ( sd ) change from pre - to post - bronchodilator fev $nmbr$  l	C0332152;C0392747;C0443172;C0444504;C0687676;C0740175;C1704687;C1705241;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3669034;C3714541;C4319952	\N	\N
771	change from pre - to	C0332152;C0392747;C0443172;C0740175;C1705241;C2257086;C3669034;C4319952	\N	\N
770	chinese subgroup	C0008120;C0152035;C1079230;C1515021	\N	\N
770	chinese	C0008120;C0152035	\N	\N
769	prior congestive heart failure yes	C0018802;C0332152;C1549445;C1705108;C1710701;C2826257	\N	\N
769	prior congestive heart failure	C0018802;C0332152;C2826257	\N	\N
769	prior chf  %	C0018802;C0332152;C2826257	\N	\N
769	prior chf	C0018802;C0332152;C2826257	\N	\N
769	first hospitalization for chf or cv death	C0011065;C0018802;C0019993;C0205435;C1279901;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
769	chf on losartan ( % )	C0018802;C0126174	\N	\N
769	chf ( % )	C0018802	\N	\N
769	chf	C0018802	\N	\N
768	pulmonary congestion ( cxr )	C0006888;C0039985;C0242073	\N	\N
768	chest x - ray	C0039985	\N	\N
767	total psa ‐ modified shs	C0392747;C2986589;C3889737	\N	\N
767	second primary ( estimated change in total updrs score from baseline to wk $nmbr$ )	C0168634;C0205225;C0205436;C0332174;C0392747;C0439175;C0439230;C0439612;C0439631;C0439810;C0443172;C0449820;C0457385;C0565930;C0750572;C1442488;C1561503;C1705190;C1705241;C3639721;C4050231;C4319952	\N	\N
767	retinal severity change	C0035298;C0392747;C0439793;C0443172;C0522510;C1705241;C4319952	\N	\N
767	rec . ischemia due to ecg changes	C0022116;C0392747;C0443172;C0678226;C1424025;C1623258;C1705241;C2606415;C4319952;C4321499	\N	\N
767	percent change	C0392747;C0439165;C0443172;C1705241;C4319952	\N	\N
767	patients with enthesitis at week $nmbr$ radiographic progression § change from baseline to week $nmbr$ in psa - modified total shs score	C0030705;C0168634;C0242656;C0332174;C0392747;C0439175;C0439230;C0439810;C0443172;C0444708;C0449258;C0449820;C1282952;C1442488;C1705241;C3810537;C3813209;C3889737;C4050231;C4319952	\N	\N
767	patients with change from baseline in total psa ‐ modified shs ≤ $nmbr$	C0030705;C0168634;C0392747;C0443172;C1442488;C1705241;C2986589;C3889737;C4319952	\N	\N
767	pain vas  mean change from baselined	C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
767	pain vas  mean change from baselinea	C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
767	nominal change	C0392747;C0443172;C1705241;C4319952	\N	\N
767	no incident dm or change in fg > $nmbr$	C0011816;C0016703;C0392747;C0439214;C0443172;C1551358;C1705241;C2348814;C3250443;C4319952	\N	\N
767	no change	C0392747;C0443172;C1705241;C4319952	\N	\N
767	modified total sharp score * *	C0392747;C1444775;C1539835;C2964552;C3889737;C3890003	\N	\N
767	modified total sharp score	C0392747;C1444775;C1539835;C2964552;C3889737;C3890003	\N	\N
767	modified has - bled score  mean ± sd	C0019080;C0392747;C0444504;C0449820;C2347634;C2348143;C2699239;C3889737;C4050231	\N	\N
767	modified has - bled > $nmbr$	C0019080;C0392747;C3889737	\N	\N
767	modified has - bled < $nmbr$	C0019080;C0392747;C3889737	\N	\N
767	modified has - bled $ $nmbr$	C0019080;C0392747;C3889737	\N	\N
767	modified has - bled	C0019080;C0392747;C3889737	\N	\N
767	mean change in sgrq	C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
767	mean change in fev $nmbr$	C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3714541;C4319952	\N	\N
767	mean change in acq score	C0392747;C0443172;C1705241;C2919686;C3533236;C4319952	\N	\N
767	mean change from baseline in the number of	C0168634;C0237753;C0392747;C0443172;C0444504;C0449788;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
767	mean change from baseline in fev $nmbr$ % predicted  % ( sd ) *	C0168634;C0392747;C0443172;C0444504;C0681842;C1442488;C1705241;C1882327;C2347634;C2348143;C2699239;C3714541;C4319952	\N	\N
767	mean change from baseline bp at week $nmbr$	C0168634;C0332174;C0392747;C0439230;C0443172;C0444504;C0488053;C1268766;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
767	mean change at week $nmbr$	C0332174;C0392747;C0439230;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
767	mean change	C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
767	mean - sd change in pre - bronchodilator fev $nmbr$  l	C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2599602;C2699239;C3714541;C4319952	\N	\N
767	mean % change in fn bmd	C0392747;C0443172;C0444504;C1570610;C1705241;C2347634;C2348143;C4319952	\N	\N
767	lyear mean change from baseline	C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
767	ls mean change from baseline ( se )	C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
767	ls mean change from baseline $nmbr$	C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
767	ls mean change from baseline	C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
767	low - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se )	C0023668;C0023824;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952	\N	\N
767	lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se )	C0023668;C0031962;C0036919;C0041403;C0065058;C0125953;C0168634;C0392747;C0443172;C0444504;C1096202;C1439335;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952	\N	\N
767	incident dm or change in	C0011816;C0392747;C0443172;C1551358;C1705241;C3250443;C4319952	\N	\N
767	high - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se )	C0023668;C0023822;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952	\N	\N
767	fasting plasma glucose ( change from baseline )	C0168634;C0392747;C0443172;C0583513;C1442488;C1705241;C4319952	\N	\N
767	ecg changes ( % ) t	C0392747;C0443172;C1623258;C1705241;C2603360;C4319952	\N	\N
767	due to ecg changes	C0392747;C0443172;C1623258;C1705241;C4319952	\N	\N
767	changes in shs	C0392747;C0443172	\N	\N
767	changes in serum creatinine  pmol / l	C0201976;C0392747;C0439284;C0443172;C0600061	\N	\N
767	change to week $nmbr$ * ’ ’	C0332174;C0392747;C0439230;C0443172;C1705241;C4319952	\N	\N
767	change in tc	C0039411;C0040642;C0041405;C0041698;C0392747;C0443172;C1705241;C1824670;C3272447;C4319952;C4522122	\N	\N
767	change in retinal pathology	C0030664;C0035298;C0205469;C0392747;C0443172;C0677042;C1705241;C4319952	\N	\N
767	change in psa ‐ modified shs  baseline to week $nmbr$	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C3810537;C3813209;C3889737;C4319952	\N	\N
767	change in nt - probnp at $nmbr$	C0392747;C0443172;C0669479;C0754710;C1705241;C4319952	\N	\N
767	change in mtss ( mean )	C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
767	change in ldl ‐ c	C0392747;C0443172;C1705241;C4319952	\N	\N
767	change in hdl ‐ c	C0392747;C0443172;C1705241;C3715113;C4319952	\N	\N
767	change in hbalc after $nmbr$ weeks etd ( $nmbr$ % cl )	C0392747;C0439230;C0443172;C0596019;C1180255;C1705241;C4319952	\N	\N
767	change in das $nmbr$ > $nmbr$ . $nmbr$	C0051767;C0057671;C0392747;C0443172;C1705241;C4319952	\N	\N
767	change in das $nmbr$ - esr ( mean ) i physical function outcomes week $nmbr$	C0021966;C0051767;C0057671;C0221138;C0332174;C0392747;C0439230;C0443172;C0444504;C0516981;C1274040;C1705241;C2347634;C2348143;C3811131;C4049916;C4319952	\N	\N
767	change from baseline in sgrq	C0168634;C0392747;C0443172;C1442488;C1705241;C4319952	\N	\N
767	change from baseline in fevj ( mb )	C0024853;C0168634;C0392747;C0443172;C1442488;C1705241;C4319952	\N	\N
767	change from baseline in acq - $nmbr$ score	C0168634;C0392747;C0443172;C0449820;C1442488;C1705241;C2919686;C4050231;C4319952	\N	\N
767	change from baseline in acq - $nmbr$	C0168634;C0392747;C0443172;C1442488;C1705241;C2919686;C4319952	\N	\N
767	change from baseline in	C0168634;C0392747;C0443172;C1442488;C1705241;C4319952	\N	\N
767	change from baseline at week $nmbr$	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952	\N	\N
767	change from baseline	C0168634;C0392747;C0443172;C1442488;C1705241;C4319952	\N	\N
767	change from	C0392747;C0443172;C1705241;C4319952	\N	\N
767	change at week $nmbr$	C0332174;C0392747;C0439230;C0443172;C1705241;C4319952	\N	\N
767	change $nmbr$	C0392747;C0443172;C1705241;C4319952	\N	\N
767	change	C0392747;C0443172;C1705241;C4319952	\N	\N
767	body weight ( change from baseline )	C0005911;C0168634;C0392747;C0443172;C1303013;C1442488;C1705241;C4319952	\N	\N
767	before a change to the enrollment form was implemented in august $nmbr$ . bnp	C0054015;C0348078;C0376315;C0392747;C0443172;C1095989;C1417808;C1516879;C1522492;C1696073;C1705241;C2982014;C3831448;C3888021;C4255237;C4319952;C4520547	\N	\N
767	basdai  mean change from baseline	C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952	\N	\N
767	at c change ( % ) *	C0392747;C0443172;C1705241;C4319952	\N	\N
767	% change from baseline  mean ( s . e . )	C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
767	% change from baseline	C0168634;C0392747;C0443172;C1442488;C1705241;C4319952	\N	\N
767	% change ( meantse )	C0392747;C0443172;C1705241;C4319952	\N	\N
767	% change ( meanlse )	C0392747;C0443172;C1705241;C4319952	\N	\N
767	% change	C0392747;C0443172;C1705241;C4319952	\N	\N
767	$nmbr$ year mean change from baseline	C0168634;C0392747;C0439234;C0439508;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
766	charlson comorbidity index  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C4546361	\N	\N
766	charlson comorbidity index	C4546361	\N	\N
766	charlson comobility score  n ( % )	C0449820;C4050231	\N	\N
766	charlson	\N	\N	\N
765	comorbidity  no . ( % )	C0009488	\N	\N
765	comorbidities other than diabetes	C0009488;C0011847;C0011849	\N	\N
765	comorbidities ( % )	C0009488	\N	\N
765	comorbidities  no . ( % )	C0009488	\N	\N
765	comorbidities  n ( % ) a	C0009488	\N	\N
765	comorbidities  %	C0009488	\N	\N
765	comorbidities	C0009488	\N	\N
765	comorbidites  n ( % )	\N	\N	\N
765	comorbid illnesses	C0009488;C0221423	\N	\N
765	comorbid conditionsb	C0009488	\N	\N
765	co - morbidities  n ( % )	C0009488	\N	\N
765	co - morbidities  a n ( % )	C0009488;C0369718;C0441922	\N	\N
765	co - morbidities	C0009488	\N	\N
764	prior exposure to carbamazepine	C0006949;C0006950;C0274281;C0332152;C0332157;C0682993;C2826257	\N	\N
764	cbz - naive	C0006949	\N	\N
764	cbz - exposed	C0006949;C0332157	\N	\N
764	carbamazepine	C0006949;C0006950;C0682993	\N	\N
763	native latin	C0302891	\N	\N
763	american ‐ indian / alaska native	C0002460;C0682125	\N	\N
763	american indian or alaskan native	C0002460;C0238611;C0302891	\N	\N
763	american indian or alaska native  :	C0002460;C0682125	\N	\N
763	american indian or alaska native	C0002460;C0682125	\N	\N
763	american indian / alaskan native  n ( % )	C0002460;C0238611;C0302891;C0886378;C1524069	\N	\N
763	american indian / alaskan native	C0002460;C0238611;C0302891	\N	\N
763	american indian / alaska native	C0002460;C0682125	\N	\N
763	alaska native	C0682125	\N	\N
762	pharmaco - invasive n = $nmbr$	C0205281;C1334278	\N	\N
762	pharmaco - invasive ( n = $nmbr$ )	C0205281;C1334278	\N	\N
762	invasive	C0205281;C1334278	\N	\N
762	intent of early invasive strategy  %	C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453	\N	\N
762	early invasive strategy ( n = $nmbr$  $nmbr$ )	C0205281;C0679199;C1279919;C1334278	\N	\N
762	early invasive *	C0205281;C1279919;C1334278	\N	\N
762	early invasive $nmbr$	C0205281;C1279919;C1334278	\N	\N
-10	oxidative stress	C0242606	\N	\N
760	relative wall thickness	C0080103;C0205345;C0677535;C1280412;C1547039	\N	\N
760	relative decrease > $nmbr$ %	C0080103;C0205345;C0392756;C0547047;C1547039	\N	\N
759	sustain $nmbr$ : semaglutide vs . exenatide er $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0167117;C0439269;C0443318;C1960952;C2346927;C2732140;C3810541;C3811131;C3885068;C4321396;C4521761	\N	\N
759	lixisenatide ( n = $nmbr$ o )	C2973895	\N	\N
759	lixisenatide ( n = $nmbr$ )	C2973895	\N	\N
759	lixisenatide	C2973895	\N	\N
759	exenatide ± oad	C0167117	\N	\N
759	exenatide no . of events / total no . ( % )	C0167117;C0439175;C0439810;C0441471;C3541888	\N	\N
759	exenatide n = $nmbr$	C0167117	\N	\N
759	exenatide lar	C0167117;C1419115;C3814448	\N	\N
759	exenatide er	C0167117;C3810541;C3811131	\N	\N
759	exenatide	C0167117	\N	\N
757	timi ≥ $nmbr$ and spoke and time ≤ $nmbr$ h	C0033727;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284	\N	\N
757	timi ≥ $nmbr$ and spoke	\N	\N	\N
757	time to first sare * ( % )	C0040223;C0205435;C1279901;C3541383	\N	\N
757	time to first morbidity / mortality event up to the end of the treatment periodd	C0026538;C0026565;C0026566;C0039798;C0040223;C0087111;C0205435;C0220880;C0441471;C0444930;C0547043;C1279901;C1522326;C1533734;C1705169;C2746065;C3538994;C3541383;C3887704;C4019010	\N	\N
757	time to first exacerbation	C0040223;C0205435;C1279901;C3541383;C4086268	\N	\N
757	time since primary diagnosis	C0040223;C0332137;C0801658;C3541383	\N	\N
757	time since most recent myocardial	C0027061;C0040223;C0332185;C1522564;C3541383	\N	\N
757	time since first luts ( years )	C0040223;C0205435;C0439234;C0574785;C1279901;C3541383	\N	\N
757	time since cabg	C0010055;C0040223;C3541383	\N	\N
757	time since asthma diagnosis years	C0004096;C0011900;C0040223;C0439234;C1704338;C1704656;C2984299;C3541383	\N	\N
757	time since asthma diagnosis [ years ]  median ( range )	C0004096;C0011900;C0040223;C0439234;C0549183;C0876920;C1514721;C1704338;C1704656;C2347635;C2348144;C2348147;C2939193;C2984299;C3541383;C3542016	\N	\N
757	time since asthma diagnosis ( years )	C0004096;C0011900;C0040223;C0439234;C1704338;C1704656;C2984299;C3541383	\N	\N
757	time since asthma	C0004096;C0040223;C2984299;C3541383	\N	\N
757	time in therapeutic range before inclusion	C0007637;C0040223;C0087111;C0302350;C0460097;C1512693;C1554109;C3541383	\N	\N
757	time in therapeutic range  median ( iqr )  %	C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383	\N	\N
757	time in therapeutic range	C0040223;C0087111;C0302350;C0460097;C1554109;C3541383	\N	\N
757	time from randomization to cabg — hr	C0010055;C0034656;C0040223;C3541383	\N	\N
757	time from qualifying mi  yrs	C0040223;C1514624;C3541383;C3810814	\N	\N
757	time from qualifying mi  %	C0040223;C1514624;C3541383;C3810814	\N	\N
757	time from most recent qualifying	C0040223;C0332185;C1514624;C3541383	\N	\N
757	time from first eval	C0040223;C0205435;C1279901;C1707957;C2698624;C3541383	\N	\N
757	time ( sec ) *	C0040223;C0565930;C3541383	\N	\N
757	spoke	\N	\N	\N
757	percentage of time in therapeutic inr range  mean ( sd )	C0040223;C0439165;C0444504;C0460097;C0525032;C1549488;C1561533;C1704538;C2347634;C2348143;C2699239;C3541383	\N	\N
757	percent work time missed due to asthma	C0004096;C0040223;C0043227;C0439165;C0678226;C1705492;C2984299;C3541383	\N	\N
757	percent of the time that inr was in the therapeutic range	C0040223;C0439165;C0460097;C0525032;C1704538;C3541383	\N	\N
757	mean time to first oral dose postsurgeryh  hr	C0040223;C0178602;C0205435;C0442027;C0444504;C0869039;C1114758;C1279901;C2347634;C2348143;C3541383;C4521986	\N	\N
757	mean time since asthma	C0004096;C0040223;C0444504;C2347634;C2348143;C2984299;C3541383	\N	\N
757	ecg at time of qualifying symptoms	C0040223;C0683368;C1457887;C1514624;C1623258;C3541383	\N	\N
757	at any time	C0040223;C3541383	\N	\N
756	time since last dose of	C0946444	\N	\N
756	time intervals  h	C0033727;C0369286;C0441932;C0564385;C0872291;C4528284	\N	\N
756	time intervals	C0872291	\N	\N
756	time from last dose of p $nmbr$ y $nmbr$ inhibitor  days	C0439228;C0946444;C1999216	\N	\N
755	tpm - naive	C0076829	\N	\N
755	tpm - exposed	C0076829;C0332157	\N	\N
755	topiramate	C0076829	\N	\N
755	assigned to topiramate	C0040363;C0041260;C0076829;C1516050;C1552601;C1883351	\N	\N
754	womac stiffness score	C0427008;C0449820;C4050231	\N	\N
754	stiffness subscale	C0427008	\N	\N
754	question $nmbr$ ( morning stiffness since arising )	C0332284;C0457086;C1522634;C4019053;C4318616	\N	\N
754	question $nmbr$ ( length of morning stiffness since arising )	C0332284;C0457086;C1444754;C1522634;C1706316;C4019053;C4318616	\N	\N
753	voiding subscore	C0042034;C4067975	\N	\N
753	rectal bleeding subscore {	C0018932;C0267596	\N	\N
753	rectal bleeding subscore	C0018932;C0267596	\N	\N
753	mean ipss  voiding subscore ( sd )	C0042034;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063;C4067975	\N	\N
753	irritative subscore	C0441723;C1706307;C2700617	\N	\N
753	ipss voiding subscore	C0042034;C1019118;C1998280;C2827405;C3811063;C4067975	\N	\N
752	sulphonylureas	C0038766	\N	\N
752	sulphonylurea	C0038766;C3536898	\N	\N
752	sulfonylureasb	\N	\N	\N
752	sulfonylureas	C0038766;C3653359	\N	\N
752	sulfonylureaa	\N	\N	\N
752	sulfonylurea — no . ( % )	C0038766;C3536898	\N	\N
752	sulfonylurea use at baseline	C0038766;C0042153;C0168634;C0457083;C1442488;C1947944;C3536898	\N	\N
752	sulfonylurea derivatives	C0038766	\N	\N
752	sulfonylurea based	C0038766;C1527178;C1705938;C3536898	\N	\N
752	sulfonylurea	C0038766;C3536898	\N	\N
752	other sulfonylurea 一 no . ( % )	C0038766;C3536898	\N	\N
752	on sulfonylurea	C0038766;C3536898	\N	\N
752	non - sulfonylurea secretagogues	C0038766;C1518422;C3536898;C4704833	\N	\N
752	insulin + sulphonylureas	C0021641;C0038766;C1533581;C1579433;C3714501	\N	\N
752	insulin + metformin + sulphonylureas	C0021641;C0025598;C0038766;C1533581;C1579433;C3714501	\N	\N
752	duration of sulphonylurea use ( months )  mean ± s . d .	C0038766;C0439231;C0444504;C1881378;C2347634;C2348143;C2826775;C3536898	\N	\N
752	any sulfonylurea	C0038766;C3536898	\N	\N
751	st george ' s respiratory questionnaire total score !	C0439175;C0439810;C3472502	\N	\N
751	score on st . george ' s respiratory questionnaire ^ ^	C3472502	\N	\N
751	score on asthma control questionnaire * *	C4706265	\N	\N
750	mean aqlq total score t	C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236;C4055434	\N	\N
752	metformin + sulphonylureas	C0025598;C0038766	f	2253
750	aqlq ( s ) + $nmbr$ scorets	C4055434	\N	\N
749	physical component score ( pcs )	C0449432;C1705248;C1864389;C1882368;C4483112	\N	\N
749	pcs score ( $nmbr$ – $nmbr$ scale )	C0175659;C0349674;C0449820;C1864389;C1882368;C1947916;C4050231	\N	\N
749	pcs score	C0449820;C1864389;C1882368;C4050231	\N	\N
749	lithe	\N	\N	\N
749	iwqol - lite physical score ( arbitrary units )	C0439183;C4483112	\N	\N
748	— $nmbr$ . $nmbr$ < fn t - score < — $nmbr$ . $nmbr$	C0449820;C1570610;C4050231	\N	\N
748	— $nmbr$ . $nmbr$ < fn t - score	C0449820;C1570610;C4050231	\N	\N
748	womac score	C0449820;C4050231	\N	\N
748	womac function score	C0031843;C0449820;C0542341;C0700205;C1705273;C4050231	\N	\N
748	vadas score *	C0449820;C4050231	\N	\N
748	updrs score	C0449820;C3639721;C4050231	\N	\N
748	target nail napsi score ( $nmbr$ – $nmbr$ scale )	C0027342;C0175659;C0349674;C0449820;C1432728;C1521840;C1947916;C2986546;C3538766;C4050231	\N	\N
748	stroke risk score	C0449820;C1277291;C4050231	\N	\N
748	st - segment deviation timi risk score  %	C0012727;C0035647;C0036056;C0205419;C0429029;C0429066;C0441635;C0449820;C1114722;C1116089;C1705236;C3272372;C4050231;C4552904	\N	\N
748	sss score	C0037052;C0449820;C0723181;C4050231	\N	\N
748	significant worsening in kccq clinical score ( ≥ $nmbr$ ) at $nmbr$ mo †	C0026544;C0332177;C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231	\N	\N
748	shs ( $nmbr$ - $nmbr$  per $nmbr$ score )	C0449820;C4050231	\N	\N
748	score 一 no . ( % )	C0449820;C4050231	\N	\N
748	score of > $nmbr$ . $nmbr$ — %	C0449820;C4050231	\N	\N
748	score of $ $nmbr$  no . ( % )	C0449820;C4050231	\N	\N
748	score of # $nmbr$  no . ( % )	C0449820;C4050231	\N	\N
748	score > $nmbr$ . $nmbr$	C0449820;C4050231	\N	\N
748	score > $nmbr$ %  % of patients	C0030705;C0449820;C4050231	\N	\N
748	score $nmbr$ . $nmbr$	C0449820;C4050231	\N	\N
748	score $nmbr$ - $nmbr$	C0449820;C4050231	\N	\N
748	score  no . ( % )	C0449820;C4050231	\N	\N
748	score  %	C0449820;C4050231	\N	\N
748	score	C0449820;C4050231	\N	\N
748	schwab & england score	C0014282;C0449820;C4050231	\N	\N
748	rope score * *	C0449820;C1563164;C4050231	\N	\N
748	rope score	C0449820;C1563164;C4050231	\N	\N
748	rentrop score	C0449820;C4050231	\N	\N
748	patients with mild pain ( womac pain score  $nmbr$ - $nmbr$ )	C0030705;C0278138;C0449820;C0582148;C2945599;C4050231;C4522280	\N	\N
748	nvf at flex baseline - $nmbr$ < flex fn t - score	C0168634;C0449820;C1442488;C1570610;C4050231	\N	\N
748	npi - $nmbr$ score *	C0449820;C1412208;C1549728;C3539727;C4050231	\N	\N
748	normalized womac score	C0449820;C1882115;C4050231	\N	\N
748	nihss score	C0449820;C1697238;C4050231	\N	\N
748	napsi score ( $nmbr$ - $nmbr$ ) of target fingernail	C0222001;C0449820;C1521840;C2986546;C4050231	\N	\N
748	midas score	C0449820;C1309950;C1423498;C4049617;C4050231	\N	\N
748	mhis score	C0449820;C4050231	\N	\N
748	mcs score ( $nmbr$ – $nmbr$ scale )	C0175659;C0349674;C0449820;C1947916;C4050231	\N	\N
748	mcs score	C0449820;C4050231	\N	\N
748	ls t - score < — $nmbr$ . $nmbr$	C0023668;C0449820;C4050231	\N	\N
748	leeds enthesitis index ^ score > $nmbr$ — no . { % )	C0449820;C0451148;C4050231	\N	\N
748	kccq score	C0449820;C3476798;C4050231	\N	\N
748	karnofsky score 竺 $nmbr$	C0206065;C0449820;C4050231	\N	\N
748	karnofsky score < $nmbr$	C0206065;C0449820;C4050231	\N	\N
748	ibdq score |	C0449820;C4050231	\N	\N
748	ibdq score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
748	hit - $nmbr$ score	C0272285;C0332159;C0449820;C1708373;C4050231	\N	\N
748	gds score *	C0449820;C0451184;C1149049;C1418244;C4050231	\N	\N
748	fn t - score < — $nmbr$ . $nmbr$	C0449820;C1570610;C4050231	\N	\N
748	fn t - score < = - $nmbr$ . $nmbr$ ( % )	C0449820;C1570610;C4050231	\N	\N
748	flex fn f - score < - $nmbr$ . $nmbr$	C0016327;C0449820;C1570610;C4050231	\N	\N
748	flex baseline bmd t - score at femoral neck ( meanisd )	C0015815;C0168634;C0449820;C1442488;C4050231	\N	\N
7	p ' value	C1709380	\N	\N
7	nteraction p value	C1709380	\N	\N
748	timi risk score > $nmbr$  %	C0035647;C0449820;C4050231;C4552904	f	2052
748	timi risk score — no . ( % ) : t	C0035647;C0449820;C2603360;C4050231;C4552904	f	2052
748	timi risk score — no . / total no . ( % ) f	C0016327;C0035647;C0439175;C0439810;C0449820;C4050231;C4552904	f	2052
748	tim $nmbr$ nsk score	C0449820;C1313407;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633	f	2052
748	tlmi risk score	C0035647;C0449820;C4050231;C4552904	f	2052
748	timi score	C0449820;C4050231	f	2052
748	score on modified rankin scale ( ' % / '	C0449820;C2984908;C3854213;C4050231	f	2053
748	score on modified rankin scale — no . ( % ) §	C0449820;C2984908;C3854213;C4050231	f	2053
748	modified rankin scale score	C0449820;C2984908;C3854213;C4050231	f	2054
748	modified rankin score	C0392747;C0449820;C3889737;C4050231	f	2054
748	joint space narrowing score	C0449820;C1859695;C4050231	f	2055
748	joint space narrowing score  mean ( sd )	C0444504;C0449820;C1859695;C2347634;C2348143;C2699239;C4050231	f	2055
748	jsn score	C0449820;C4050231	f	2055
748	jsn score  mean $nmbr$ sd	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	f	2055
748	jsn score ( $nmbr$ – $nmbr$ scale )	C0175659;C0349674;C0449820;C1947916;C4050231	f	2055
748	weekly number of hives score {	C0042109;C0237753;C0332174;C0449788;C0449820;C4050231	f	2058
748	weekly number of hives score $nmbr$	C0042109;C0237753;C0332174;C0449788;C0449820;C4050231	f	2058
748	weekly size of largest hives score {	C0042109;C0332174;C0443228;C0449820;C0456389;C4050231	f	2058
748	first primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ )	C0205225;C0205435;C0332174;C0392747;C0439230;C0439612;C0439631;C0443172;C0449820;C1279901;C1705241;C3639721;C4050231;C4319952	\N	\N
748	femoral neck t - score	C0015815;C0449820;C4050231	\N	\N
748	femoral neck bmd t - score	C0015815;C0449820;C4050231	\N	\N
748	facit - f score	C0449820;C3272505;C4050231	\N	\N
748	edss score	C0449820;C0451246;C3887783;C4050231	\N	\N
748	crohn ' s disease activity index score ]	C0449820;C0451071;C4050231	\N	\N
748	chf score ( u )	C0018802;C0439148;C0449820;C4050231	\N	\N
748	change from baseline to week $nmbr$ in weekly no . of hives score	C0042109;C0168634;C0332174;C0392747;C0439230;C0443172;C0449820;C1442488;C1705241;C4050231;C4319952	\N	\N
748	change from baseline in aqlq { s ) score	C0168634;C0392747;C0443172;C0449820;C1442488;C1705241;C4050231;C4055434;C4319952	\N	\N
748	cha $nmbr$ s $nmbr$ score	C0449820;C1420648;C4050231	\N	\N
748	ccq score § §	C0449820;C4050231	\N	\N
748	cadillac score	C0449820;C4050231	\N	\N
748	bii score	C0449820;C1413059;C4050231	\N	\N
748	baseline nihss score ( % ) #	C0168634;C0449820;C1442488;C1697238;C4050231	\N	\N
748	baseline nihss score  median ( range )	C0168634;C0449820;C0549183;C0876920;C1442488;C1514721;C1697238;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231	\N	\N
748	baseline dyspnea index score	C0449820;C1511069;C4050231	\N	\N
748	baseline bmd t score at femoral neck	C0015815;C0168634;C0449820;C1442488;C4050231	\N	\N
748	admission grace score	C0184666;C0449820;C0809949;C4050231	\N	\N
748	accp score	C0449820;C4050231	\N	\N
748	abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( $nmbr$ - $nmbr$ )  intermediate ( $nmbr$ - $nmbr$ )  and high ( $nmbr$ - $nmbr$ ) risk . $nmbr$	C0000723;C0021308;C0022709;C0027061;C0030705;C0035647;C0040363;C0041260;C0205103;C0205250;C0205251;C0205369;C0439175;C0439390;C0439526;C0439810;C0439836;C0449820;C0552449;C0812399;C0871968;C1273517;C1299351;C1511726;C1514721;C1522564;C1524063;C1550465;C1550472;C1705224;C1719797;C1883351;C2348147;C2700149;C2827755;C2911648;C3245479;C3542016;C3714741;C3887512;C3887665;C3889660;C3889971;C3890211;C4048187;C4050231;C4321237;C4321351;C4522209;C4522223;C4552904	\N	\N
748	- $nmbr$ < flex fn f - score	C0016327;C0449820;C1570610;C4050231	\N	\N
748	- $nmbr$ . $nmbr$ < ls t - score < — $nmbr$ . $nmbr$	C0023668;C0449820;C4050231	\N	\N
748	- $nmbr$ . $nmbr$ < ls t - score	C0023668;C0449820;C4050231	\N	\N
748	- $nmbr$ . $nmbr$ < flex fn f - score < - $nmbr$	C0016327;C0449820;C1570610;C4050231	\N	\N
747	target vessel diameter	C0449618;C1301886	\N	\N
747	target vessel	C0449618	\N	\N
747	target - vessel revascularization	C0449618;C0581603	\N	\N
747	number of target vessels	C0237753;C0449618;C0449788	\N	\N
747	no . of target vessels	C0449618	\N	\N
747	large vessel	C0225990	\N	\N
746	two - vessel disease	C0581375	\N	\N
746	triple - vessel disease  n ( % )	C0856738	\N	\N
746	three - vessel disease	C3272265	\N	\N
746	small vessel	C0225988	\N	\N
745	vessels with stenosis > $nmbr$ %	C0679403	\N	\N
745	stented vessels	C0183521	\N	\N
745	stented vessel	C0183521	\N	\N
745	non - stenotic vessels  n ( % )	C0679403;C1518422	\N	\N
745	> $nmbr$ vessels with > $nmbr$ % stenosis	C0679403	\N	\N
744	variable_level	C0439828;C0441889;C0456079;C1547707;C2946261;C4553760	\N	\N
744	troponin level	C0041199;C0441889;C0456079;C1547707;C2946261	\N	\N
744	risk factors and immobility level  n ( % )	C0035648;C0231441;C0441889;C0456079;C1547707;C1553898;C2946261	\N	\N
744	no active cancer center - level inr percent time	C0040223;C0205177;C0439165;C0441889;C0456079;C0525032;C1513817;C1547707;C1704538;C2946261;C3541383;C3853793;C3888249	\N	\N
744	mean — mm hg level — no . ( % )	C0439475;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261	\N	\N
744	level — no . ( % )	C0441889;C0456079;C1547707;C2946261	\N	\N
744	level $nmbr$ immobility § | |	C0231441;C0441889;C0456079;C1547707;C2946261	\N	\N
744	level $nmbr$ immobility ^	C0231441;C0441889;C0456079;C1547707;C2946261	\N	\N
744	level $nmbr$	C0441889;C0456079;C1547707;C2946261	\N	\N
744	hscrp level	C0441889;C0456079;C1547707;C2946261	\N	\N
744	geometric anti - dsdna antibody binding level	C0441889;C0449829;C0456079;C1145667;C1167622;C1547707;C2355607;C2746079;C2946261	\N	\N
744	european quality of life - $nmbr$ dimensions - $nmbr$ level ( eq - $nmbr$ d )	C0034380;C0205163;C0239307;C0439185;C0439534;C0441889;C0456079;C0518214;C1535514;C1547707;C2946261	\N	\N
744	elevated natriuretic peptide level ( n = $nmbr$ )	C0205250;C0441889;C0456079;C1144709;C1547707;C2709270;C2946261;C3163633;C3537020	\N	\N
744	characteristic_level	C0441889;C0456079;C1521970;C1547707;C2946261	\N	\N
744	center level ttr	C0032923;C0205099;C0441889;C0456079;C1421224;C1547707;C2946261;C3810851	\N	\N
744	cardiac troponin t level > $nmbr$ . $nmbr$ pg / l	C0439278;C0441889;C0456079;C1547707;C2946261;C3538889	\N	\N
744	cardiac troponin t level  median ( iqr )  pg / l	C0439278;C0441889;C0456079;C0549183;C0876920;C1547707;C2347635;C2348144;C2939193;C2946261;C3538889	\N	\N
743	vessel treated  n	C0005847;C0369718;C0441922;C1522326	\N	\N
743	vascular territory # $nmbr$	C0005847;C1301808;C1558950;C1801960;C2983136	\N	\N
743	vascular intervention	C0005847;C0184661;C0886296;C1273869;C1558950;C1801960	\N	\N
743	vascular disordersb	C0005847;C1558950;C1801960	\N	\N
748	crusade bleeding score	C0019080;C0449820;C4050231	f	2056
748	aqlq score	C0449820;C4050231;C4055434	f	2057
748	aqlq score  mean	C0444504;C0449820;C2347634;C2348143;C4050231;C4055434	f	2057
748	aqlq ( si + $nmbr$ score ’	C0449820;C4050231;C4055434	f	2057
743	vascular accidents  n ( % )	C0000924;C0005847;C1558950;C1801960	\N	\N
743	vascular access site †	C0005847;C0205145;C0589360;C0750138;C1515974;C1558950;C1801960;C2825164	\N	\N
743	vascular	C0005847;C1558950;C1801960	\N	\N
743	urgent vascular hospitalization	C0005847;C0019993;C0439609;C1558950;C1801960;C3272275	\N	\N
743	treated vessel ( s )	C0005847;C1522326	\N	\N
743	treated vessel !	C0005847;C1522326	\N	\N
743	treated vessel	C0005847;C1522326	\N	\N
743	timi flow grade $nmbr$ of mi culprit vessel pre ‐ pci	C0005847;C0332152;C0441800;C0740175;C0919553;C2257086;C3244287;C3272266;C3669034;C3810814;C4049621	\N	\N
743	single vessel coronary artery diseasea	C0005847;C0265903	\N	\N
743	restenotic vessel	C0005847;C0333186	\N	\N
743	number of vessels treated  index pci	C0005847;C0237753;C0449788;C0600653;C0918012;C1522326;C1552854;C1637833;C2986546;C4049621	\N	\N
743	number of treated vessels ( per patient )	C0005847;C0030705;C0237753;C0449788;C1522326	\N	\N
743	number of treated vessels	C0005847;C0237753;C0449788;C1522326	\N	\N
743	number of diseased vessels  mean ( sd )	C0005847;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239	\N	\N
743	no culprit vessel identified	C0005847;C0205396;C1550043	\N	\N
743	no . of vessels treated	C0005847;C1522326	\N	\N
743	no . of vessels	C0005847	\N	\N
743	no . of treated vessels	C0005847;C1522326	\N	\N
743	multi vessel ( or left main )	C0005847;C0205091;C0205225;C0439064;C0443246;C1542147;C1552822;C3266262	\N	\N
743	more than $nmbr$ vessels stented	C0005847;C0038257;C0205172	\N	\N
743	cvd / mi / stroke / revascularization / urgent vascular hospitalization	C0005847;C0007222;C0019993;C0038454;C0439609;C0581603;C1558950;C1801960;C3272275;C3810814;C4554100	\N	\N
743	culprit vessel	C0005847	\N	\N
743	any vascular diasease	C0005847;C1558950;C1801960	\N	\N
743	any vascular *   efficacy	C0005847;C1280519;C1558950;C1707887;C1801960	\N	\N
743	> $nmbr$ vessels treated	C0005847;C1522326	\N	\N
743	> $nmbr$ diseased vessels	C0005847	\N	\N
743	$nmbr$ vessels or left main	C0005847;C0205091;C0205225;C0443246;C1542147;C1552822	\N	\N
743	$nmbr$ vessels	C0005847	\N	\N
743	$nmbr$ vessel	C0005847	\N	\N
742	tnfi and other bdmardst  n ( % )	\N	\N	\N
742	otherx	\N	\N	\N
742	otherd	\N	\N	\N
742	other { n = $nmbr$ )	C0369718;C0441922	\N	\N
742	other vasculars	\N	\N	\N
742	other vascular disease ( cvd or pad )  %	C0007222;C0042373;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657	\N	\N
742	other vascular disease	C0042373	\N	\N
742	other n ( % )	C0369718;C0441922	\N	\N
742	other * ( n = $nmbr$ )	C0369718;C0441922	\N	\N
742	other ( n — $nmbr$ )	C0369718;C0441922	\N	\N
742	other ( n   = $nmbr$ )	C0369718;C0441922	\N	\N
742	other ( n = $nmbr$ )	C0369718;C0441922	\N	\N
742	other ( n = $nmbr$  $nmbr$ ]	C0369718;C0441922	\N	\N
742	other ( n = $nmbr$  $nmbr$ )	C0369718;C0441922	\N	\N
742	other ( n  % )	C0369718;C0441922	\N	\N
742	other  n ( % )	C0369718;C0441922	\N	\N
742	extensive disease other	C0849867	\N	\N
742	dpi ( other than diskus )  n	C1553480	\N	\N
742	all other	\N	\N	\N
741	othersc	\N	\N	\N
741	others  n ( % )	C1955473;C3539125	\N	\N
741	others	C1955473;C3539125	\N	\N
741	otherc	\N	\N	\N
741	all others eteed for $nmbr$ mg edoxaban dose at	C1955473;C2975435;C3539125;C4086581	\N	\N
741	all others  n ( % )	C1955473;C3539125	\N	\N
741	all others	C1955473;C3539125	\N	\N
740	otherz	\N	\N	\N
740	otherf	\N	\N	\N
740	other osteoporosis medication	C0013227;C0029456;C3244316;C4284232;C4554622	\N	\N
740	other medication usage	C0013227;C0457083;C3244316;C4284232	\N	\N
740	other glucose - lowering drugs	C0013227;C0017725;C0441994;C2003888;C3687832	\N	\N
740	other drugs — no . ( % )	C0013227;C3687832	\N	\N
740	other drugs	C0013227;C3687832	\N	\N
740	other * ’	\N	\N	\N
740	any other antihyperglycaemic drugs	C0013227;C0020616;C3687832	\N	\N
739	upper tertile : > $nmbr$ . $nmbr$	C1282910	\N	\N
739	upper	C1282910	\N	\N
739	none of the above	C1282910;C1552828	\N	\N
739	history of upper gl events ( perforations  ulcers  bleeding )  n ( % )	C0018229;C0019080;C0019664;C0019665;C0041582;C0262512;C0262926;C0369718;C0441471;C0441922;C0549099;C1282910;C1423073;C1427674;C1705255;C2004062;C3541888	\N	\N
739	any of the above	C1282910;C1552828	\N	\N
739	all of the above	C1282910;C1552828	\N	\N
738	one - vessel disease	C3275121	\N	\N
738	noneh	\N	\N	\N
738	none 一 no . ( % )	\N	\N	\N
738	none ( n = $nmbr$ )	C0369718;C0441922	\N	\N
738	none	\N	\N	\N
737	one vessel	C0005847;C0205447	\N	\N
737	one tnfi and	C0205447	\N	\N
737	one tnfi *	C0205447	\N	\N
737	one of the above	C0205447	\N	\N
737	one lesion	C0205447;C0221198;C1546698	\N	\N
736	time since psa onset  mean years ( sd )	C0040223;C0206132;C0332162;C0439234;C0444504;C2347634;C2348143;C2699239;C3541383;C3810537;C3813209	\N	\N
736	time since onset ( h )	C0033727;C0040223;C0206132;C0332162;C0369286;C0441932;C0564385;C3541383;C4528284	\N	\N
736	since onset	C0206132;C0332162	\N	\N
736	onset of chest pain	C0024902;C0206132;C0332162	\N	\N
736	onset $nmbr$ [ $nmbr$ ]	C0206132;C0332162	\N	\N
736	age of onset < $nmbr$ years ( n = $nmbr$ )	C0206132;C0439234;C3175530	\N	\N
736	age of onset $nmbr$ years ( n = $nmbr$ )	C0206132;C0439234;C3175530	\N	\N
736	age of onset	C0206132;C3175530	\N	\N
736	age of asthma onset  years	C0004096;C0206132;C0439234;C2984299;C3175530	\N	\N
736	age at onset  y	C0206132;C3870509	\N	\N
736	age at disease onset  years *	C0012634;C0206132;C0439234;C3870509	\N	\N
736	age at disease onset  n ( % ) *	C0012634;C0206132;C3870509	\N	\N
735	lower - target group ( n = $nmbr$ )	C0441848;C0441994;C1521840;C1548802;C2003888;C2986546	\N	\N
7	multivariate p - value	C1709380	\N	\N
735	higher - target group ( n = $nmbr$ )	C0205250;C0441848;C1521840;C2986546	\N	\N
735	average daily dose ( % of target ) *	C1510992;C1521840;C2348070;C2825518;C2986546	\N	\N
735	( % of target ) ∗	C1521840;C2986546	\N	\N
734	suit index  nmol / mmol	C0600653;C0918012;C1532564;C1533073;C1552854;C1637833;C2986546	\N	\N
734	qualifying index event as pe	C0070939;C0441471;C0600653;C0918012;C1514624;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304	\N	\N
734	nternational index of	C0600653;C0918012;C1552854;C1637833;C2986546	\N	\N
734	mean slicc damage index score ± sd	C0010957;C0600653;C0918012;C1552854;C1637833;C1883709;C2699239;C2986546;C3533236	\N	\N
734	mean preoperative abpi of the index	C0444504;C0445204;C0600653;C0918012;C1552854;C1637833;C2347634;C2348143;C2986546	\N	\N
734	mass index	C0577559;C0577573;C0600653;C0918012;C1096155;C1306372;C1552854;C1637833;C2986546;C3152252;C3539882;C4283905	\N	\N
734	lv mass index ( g / m $nmbr$ - $nmbr$ )	C0455825;C0456715;C0600653;C0918012;C1552854;C1637833;C2986546	\N	\N
734	labs at the index acs event	C0441471;C0587081;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612	\N	\N
734	interval after index event	C0441471;C0600653;C0918012;C1272706;C1552654;C1552713;C1552854;C1637833;C2986546;C4019010	\N	\N
734	insulinogenic index ( dinsulino_ $nmbr$ o min / dglucoseo - $nmbr$ o min )	C0600653;C0702093;C0918012;C1524029;C1552854;C1637833;C2986546;C3813700	\N	\N
734	indication for index procedure	C0600653;C0918012;C1552854;C1637833;C2315323;C2986546	\N	\N
734	index pe : event during	C0070939;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304	\N	\N
734	index mi ( n - $nmbr$  $nmbr$ )	C0600653;C0918012;C1552854;C1637833;C2986546;C3810814	\N	\N
734	index inclusion acute coronary syndrome	C0007637;C0600653;C0918012;C0948089;C1512693;C1552854;C1637833;C2986546	\N	\N
734	index event subtype	C0441471;C0449560;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
734	index event  %	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
734	index diagnosis	C0011900;C0600653;C0918012;C1552854;C1637833;C1704338;C1704656;C2986546	\N	\N
734	index acute coronary syndrome — no . { % )	C0600653;C0918012;C0948089;C1552854;C1637833;C2986546	\N	\N
734	extent of index event	C0439792;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
734	extent of index dvt ' ( n  % of dvt patients ' )	C0030705;C0149871;C0439792;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446	\N	\N
734	disposition index	C0600653;C0743223;C0918012;C1552854;C1637833;C1705555;C2986546	\N	\N
734	des type at index procedure	C0011702;C0455713;C0600653;C0918012;C1552854;C1637833;C2986546;C4551552	\N	\N
734	coronary angiography during the index hospitalization	C0002978;C0019993;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546	\N	\N
734	cornell index  pv	C0030840;C0032463;C0600653;C0918012;C1552854;C1637833;C2986546	\N	\N
734	composite physiologic index §	C0205199;C0205463;C0600653;C0918012;C1547335;C1552854;C1637833;C2986546	\N	\N
734	clinical indication at the index procedure  n ( % )	C0205210;C0600653;C0918012;C1552854;C1637833;C2315323;C2347896;C2986546	\N	\N
734	classification of index venous thromboembolism — no . ( % )	C0008902;C0008903;C0600653;C0678229;C0918012;C1552854;C1637833;C1997614;C2986546	\N	\N
734	charlson index ( % )	C0600653;C0918012;C1552854;C1637833;C2986546	\N	\N
734	at index event	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
734	at index acs event	C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612	\N	\N
734	angiography during index hospitalization	C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546	\N	\N
733	reversible to bronchodilator  b %	C0006280;C0205343	\N	\N
733	reversible to albuterolc  d  n ( % )	C0205343	\N	\N
733	reversible ( % )	C0205343	\N	\N
733	reversible	C0205343	\N	\N
733	nonreversible	\N	\N	\N
733	non - reversible ( % )	C0205343;C1518422	\N	\N
733	cluster $nmbr$ : not reversible  no diuretic ( n = $nmbr$ )	C0012798;C0205343;C1518422;C1555715;C1704332	\N	\N
733	associated with transient or reversible risk factor	C0035648;C0040704;C0205343;C0205374;C0332281	\N	\N
732	measured at home with automated device	C0025080;C0205554;C0444706;C0699733;C3541902;C4534363	\N	\N
732	measured at clinic visit with usual device	C0008952;C0025080;C0444706;C0699733;C3538928;C3541902	\N	\N
732	measured at clinic visit with automated device §	C0008952;C0025080;C0205554;C0444706;C0699733;C3541902	\N	\N
732	devices	C0025080;C0220819;C0699733	\N	\N
732	device group ( n = $nmbr$ )	C0025080;C0441848;C0699733	\N	\N
731	recervng	\N	\N	\N
731	recervini }	\N	\N	\N
731	received pci	C1514756;C4049621	\N	\N
731	received $nmbr$ prior biologic therapy  n	C0278947;C1514756	\N	\N
731	received $nmbr$ prior biologic therapies  n	C0278947;C1514756	\N	\N
731	patients who received positive results on test for antibodies to infliximabt	C0003241;C0030705;C1335447;C1514756	\N	\N
731	patients who received negative results on test for antibodies to infliximabt	C0003241;C0030705;C1334932;C1514756	\N	\N
731	patients who received $nmbr$ or $nmbr$ drugs	C0013227;C0030705;C1514756;C3687832	\N	\N
731	patients who received $nmbr$ drug	C0013227;C0030705;C1254351;C1514756	\N	\N
731	patients receiving mtx  n =	C0025677;C0030705;C1417487;C1514756	\N	\N
731	patients receiving mtx	C0025677;C0030705;C1417487;C1514756	\N	\N
731	patients not receiving mtx  n =	C0025677;C0030705;C1417487;C1514756;C1518422	\N	\N
731	not receiving	C1514756;C1518422	\N	\N
730	seizure reduction from baseline	C0036572;C0168634;C0301630;C0392756;C1293152;C1442488;C1959629;C4551656;C4553401	\N	\N
730	reduction of hba $nmbr$ c from baseline ≥ $nmbr$ . $nmbr$ %	C0019016;C0168634;C0301630;C0392756;C1293152;C1442488;C1825777;C3538758;C4551656	\N	\N
730	reduction in odds %	C0301630;C0392756;C1293152;C4551656	\N	\N
734	pci for index mi ( % )	C0600653;C0918012;C1552854;C1637833;C2986546;C3810814;C4049621	f	1661
731	received antihypertensive within last $nmbr$ days  n ( % )	C0003364;C0439228;C1514756	f	1579
730	rate reduction ( % )	C0301630;C0392756;C0871208;C1293152;C1521828;C4551656	\N	\N
730	osteoprotegerin decreased	C0205216;C0392756;C0442797;C0538161;C1308614;C1336645	\N	\N
730	ocs reduced / stopped	C0392756;C1272691	\N	\N
730	% reduction	C0301630;C0392756;C1293152;C4551656	\N	\N
730	$nmbr$ ‐ point reduction in selena – sledai score  %	C0301630;C0392756;C0449820;C0451528;C1293152;C1552961;C2347617;C3714763;C4050231;C4551656	\N	\N
-10	= cerebrospinal fluid .	C0007806;C0007807	\N	\N
728	without cerebrovascular disease	C0007820	\N	\N
728	with cerebrovascular disease	C0007820	\N	\N
728	stroke or cerebrovascular disease	C0007820;C0038454;C4554100	\N	\N
728	prior cerebrovascular disease	C0007820;C0332152;C2826257	\N	\N
728	only cerebrovascular disease	C0007820;C0205171;C1720467	\N	\N
728	ischemic cerebrovascular disease  n ( % )	C0007820;C0475224	\N	\N
728	cerebrovascular disorders  n ( % )	C0007820	\N	\N
728	cerebrovascular disease n ( % )	C0007820	\N	\N
728	cerebrovascular disease  n ( % )	C0007820	\N	\N
728	cerebrovascular disease  %	C0007820	\N	\N
728	cerebrovascular disease	C0007820	\N	\N
728	cerebral vascular disease	C0007820	\N	\N
727	sri ‐ $nmbr$ response rate  %	C0237629;C1420401	\N	\N
727	n ( % ) responders	C0369718;C0441922	\N	\N
727	all responders  ( n = $nmbr$ )	\N	\N	\N
726	trough fvc response ( l ) !	C0444506;C0871261;C1704632;C1706817;C2911692;C3714541	\N	\N
726	trough fvc response ( l )	C0444506;C0871261;C1704632;C1706817;C2911692;C3714541	\N	\N
726	trough fev | response ( l )	C0444506;C0871261;C1704632;C1706817;C2911692;C3714541	\N	\N
726	trough fev $nmbr$   response	C0444506;C0871261;C1704632;C1706817;C2911692;C3714541	\N	\N
726	trough fev  response ( l ) i	C0021966;C0221138;C0444506;C0871261;C1704632;C1706817;C2911692;C3714541	\N	\N
726	stratum $nmbr$ : inadequate response or intolerance to > $nmbr$ bdmards of same moa or > $nmbr$ of multiple moa	C0205412;C0231199;C0439064;C0439856;C0445247;C0871261;C1704632;C1706817;C1744706;C2355652;C2911692;C4551881	\N	\N
726	stratum $nmbr$ : inadequate response or intolerance to $nmbr$ - $nmbr$ bdmards of same moa	C0205412;C0231199;C0439856;C0445247;C0871261;C1704632;C1706817;C1744706;C2355652;C2911692;C4551881	\N	\N
726	sri response  %	C0871261;C1420401;C1704632;C1706817;C2911692	\N	\N
726	previous loss of response to infliximab  n ( % ) *	C0205156;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692	\N	\N
726	previous loss of response to and intolerance of infliximab  n ( % ) *	C0205156;C0231199;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C1744706;C2355652;C2911692	\N	\N
726	peak fev $nmbr$ ( $nmbr$ - $nmbr$ h )   response	C0033727;C0369286;C0441932;C0444505;C0564385;C0871261;C1704632;C1706817;C2911692;C3714541;C4528284	\N	\N
726	patients with previous loss of response to infliximab	C0030705;C0205156;C0666743;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692	\N	\N
726	pasi response by baseline weight  no . / total no . ( % ) * pasi $nmbr$	C0439175;C0439810;C0871261;C1303013;C1704632;C1706817;C2911692;C4528685	\N	\N
726	pasi $nmbr$ response }	C0871261;C1704632;C1706817;C2911692;C4528685	\N	\N
726	omeract - oarsi response	C0871261;C1704632;C1706817;C2911692	\N	\N
726	loss of response ‘ s	C0871261;C1517945;C1704632;C1706817;C2911692	\N	\N
726	loss of response ®	C0871261;C1517945;C1704632;C1706817;C2911692	\N	\N
726	loss of response : ! : : ! :	C0871261;C1517945;C1704632;C1706817;C2911692	\N	\N
726	loss of response	C0871261;C1517945;C1704632;C1706817;C2911692	\N	\N
726	inadequate response / intolerance to prior therapy  %	C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692	\N	\N
726	inadequate response ' ’ '	C0205412;C0439856;C0871261;C1704632;C1706817;C2911692	\N	\N
726	inadequate response ' ^	C0205412;C0439856;C0871261;C1704632;C1706817;C2911692	\N	\N
726	inadequate response	C0205412;C0439856;C0871261;C1704632;C1706817;C2911692	\N	\N
726	eular good response	C0205170;C0871261;C1704632;C1706817;C2911692	\N	\N
726	bronchodilator response  ml	C0006280;C0439526;C0871261;C1704632;C1705224;C1706817;C2911692;C3887665	\N	\N
725	medical treatment  n ( % )	C0679624	\N	\N
725	medical treatment	C0679624	\N	\N
725	hypertension requiring treatment	C0578998	\N	\N
725	hypertension requiring medical treatment	C0020538;C0679624;C1963138	\N	\N
725	hypertension  receiving treatment  n ( % )	C0578998;C1514756	\N	\N
725	conventional treatment ( n = $nmbr$ )	C2945704	\N	\N
725	conventional treatment	C2945704	\N	\N
724	≥ $nmbr$ teae	\N	\N	\N
724	abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .	C0000723;C0017890;C0017970;C0523677;C0585361;C1154181;C4684800	\N	\N
723	naive : no	\N	\N	\N
723	naive ( no treatment for current flare )	C1517205;C2827774;C3540542	\N	\N
723	active treatment	C1704532	\N	\N
722	transient st elevation	C0040704;C0205374;C0520886	\N	\N
722	transient	C0040704;C0205374	\N	\N
722	prior transient ischaemic	C0040704;C0205374;C0332152;C0475224;C2826257	\N	\N
721	prevalent cvd	C0007222;C0033105;C0220900	\N	\N
721	fracture status prevalent vertebral fractured	C0016658;C0033105;C0220900;C0449438;C0549207;C4554413	\N	\N
720	sufficient	C0205410	\N	\N
720	j $nmbr$ coefficient	C1707429	\N	\N
720	coefficient	C1707429	\N	\N
719	persistent wrf ( n = $nmbr$ )	C0205322;C0332996	\N	\N
719	persistent or paroxysmal	C0205311;C0205322;C0332996	\N	\N
719	persistent faol ( n [ $nmbr$ )	C0205322;C0332996	\N	\N
719	persistent faod ( n [ $nmbr$ )	C0205322;C0332996	\N	\N
719	persistent af  n ( % )	C0205322;C0332996;C0344434;C4049859	\N	\N
719	persistent af	C0205322;C0332996;C0344434;C4049859	\N	\N
719	persistent *	C0205322;C0332996	\N	\N
719	persistent ( n  % )	C0205322;C0332996	\N	\N
719	persistent  n ( % )	C0205322;C0332996	\N	\N
719	persistent	C0205322;C0332996	\N	\N
719	persisent	\N	\N	\N
719	no persistent wrf ( n = $nmbr$  $nmbr$ )	C0205322;C0332996	\N	\N
719	long - standing persistent	C0205166;C0205322;C0231472;C0332996;C1706317	\N	\N
718	persistent or permanent immobilization	C0020944;C0205322;C0205355;C0332996;C4048292	\N	\N
718	persistent / permanent	C0205322;C0205355;C0332996	\N	\N
718	permanent users  n	C0205355;C1706077	\N	\N
718	permanent users	C0205355;C1706077	\N	\N
718	permanent af	C0205355;C0344434;C4049859	\N	\N
718	permanent ( n  % )	C0205355	\N	\N
718	permanent  n ( % )	C0205355	\N	\N
718	permanent	C0205355	\N	\N
717	treatment throughout study	C1521826;C3161471	\N	\N
717	study treatment — no . / total no . ( % )	C0439175;C0439810;C1521826	\N	\N
717	study treatment	C1521826	\N	\N
717	standard treatment ( n - $nmbr$ )	C4684780	\N	\N
717	prior treatment status	C0332152;C0449438;C0749659;C1514463;C2826257	\N	\N
717	previously failed anti - tnf treatment  no . ( % )	C0039798;C0087111;C0231175;C1448177;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
717	previously	\N	\N	\N
717	previous treatment in the healing study  n ( % )	C0043240;C0205156;C0205249;C1521826;C1552607;C3161471	\N	\N
717	prestudy treatment status	C0749659	\N	\N
717	continued treatment study	C0549178;C3161471	\N	\N
716	treatment satisfaction	C3476649	\N	\N
716	rank based on treatment   =   placebo	C0032042;C0667477;C0699794;C1527178;C1696465;C1705938;C1706408;C4684449	\N	\N
716	planned treatment duration  n ( % )	C4528394	\N	\N
716	past treatment for paod	C2945691	\N	\N
716	on - treatment	C4684449	\N	\N
716	methotrexate treatment !	C0746573	\N	\N
715	with laba  n ( % ) pretreatment	C1550147;C2709094;C3539075;C3539076	\N	\N
715	pretreatment hdl - c	C1550147;C2709094;C3539075;C3539076;C3715113	\N	\N
715	pre - treatment [ n ( % ) ] c	C1550147;C2709094;C3539075;C3539076	\N	\N
715	no pretreatment	C1550147;C2709094;C3539075;C3539076	\N	\N
714	bb after randomisation	C0004739;C0034656;C0332297	\N	\N
714	bb	C0004739;C0332297	\N	\N
714	acei / arb and bb after randomisation	C0004739;C0034656;C0332297;C3888198	\N	\N
714	- < — ■ bb — - ►	C0004739;C0332297	\N	\N
713	subjects stratified by baseline pra	C0168634;C0205363;C0633231;C0681850;C1141951;C1419788;C1442488;C1550501;C1706203;C2349001;C2697811;C3274822;C3669212;C4283900	\N	\N
713	stratified by	C0205363	\N	\N
711	trough seated hr ( bpm ) a	C0277814;C0444506;C1283233	\N	\N
711	seated sbp  n	C0085805;C0277814;C1283233	\N	\N
710	obesity t	C0028754;C1963185	\N	\N
710	obesity * ( bm $nmbr$ > $nmbr$ kg / m $nmbr$ )	C0006416;C0028754;C1532718;C1963185	\N	\N
710	obesity *	C0028754;C1963185	\N	\N
710	obesity ( % ) §	C0028754;C1963185	\N	\N
710	obesity  % *	C0028754;C1963185	\N	\N
710	obesity	C0028754;C1963185	\N	\N
710	obese ( > $nmbr$ kg / m $nmbr$ ) b	C0028754;C1532718	\N	\N
710	obese ( > $nmbr$ kg / m $nmbr$ )	C0028754;C1532718	\N	\N
710	obese	C0028754	\N	\N
710	> $nmbr$  obesity class $nmbr$	C0028754;C0456387;C1518526;C1705943;C1963185	\N	\N
710	( scale obesity and prediabetes )	C0028754;C0175659;C0349674;C0362046;C1947916;C1963185	\N	\N
710	$nmbr$ - $nmbr$ - $nmbr$  obesity class $nmbr$	C0028754;C0456387;C1518526;C1705943;C1963185	\N	\N
709	volumetric bmd by qct	C0412669;C0445383	\N	\N
709	lost bmd	C0745777;C3815882	\N	\N
709	gained bmd	C1517378	\N	\N
708	form / bud	C0348078;C0376315;C1522492;C2700462;C2945744;C4255237	\N	\N
708	bud / fm $nmbr$ / $nmbr$ atg n = ^ $nmbr$	C2700462;C2945744;C3540627;C3815109	\N	\N
708	bud $nmbr$ ptg n = $nmbr$	C0039512;C1418830;C2700462;C2945744	\N	\N
707	timi - defined bleeding	C0019080;C1704788;C3539106	\N	\N
707	primary + gusto severe bleeding	C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466	\N	\N
707	primary + gusto moderate or severe bleeding	C0019080;C0205081;C0205082;C0205225;C0439612;C0439631;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
707	has - bled score ’	C0019080;C0449820;C4050231	\N	\N
707	has - bled score > $nmbr$	C0019080;C0449820;C4050231	\N	\N
707	has - bled score	C0019080;C0449820;C4050231	\N	\N
707	has - bled > $nmbr$	C0019080	\N	\N
707	has - bled $nmbr$ - $nmbr$	C0019080	\N	\N
707	gusto severe bleed	C0019080;C0205082;C4050465;C4050466	\N	\N
707	gusto moderate / severe bleed	C0019080;C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
707	gusto - defined bleeding	C0019080;C1704788;C3539106	\N	\N
707	gusto - bleeding severe / moderate	C0019080;C1299393	\N	\N
707	fatal bleeding	C0019080;C1302234;C1705232	\N	\N
707	fatal bleed	C0019080;C1302234;C1705232	\N	\N
707	bleeding outcomes	C0019080;C1274040	\N	\N
707	bleeding events during the entire study	C0019080;C0439751;C0441471;C0444667;C0557651;C2603343;C3541888	\N	\N
707	bleeding events during first $nmbr$ days of treatmen	C0019080;C0205435;C0439228;C0441471;C1279901;C3541888	\N	\N
707	bleeding	C0019080	\N	\N
707	any timi bleeding	C0019080	\N	\N
707	any overt bleed	C0019080	\N	\N
707	any gusto bleeding	C0019080	\N	\N
707	any bleeding	C0019080	\N	\N
712	heart rate > $nmbr$ bpm	C0018810	f	1105
712	heart rate ( sd )  bpm	C0018810;C2699239	f	1105
712	heart rate ( sd )  bpm blood pressure  mm hg	C0005823;C0018810;C0439475;C1271104;C1272641;C2699239	f	1105
712	pulse rate ( bpm )	C0232117	f	1105
712	pulse rate  bpm ( mean $nmbr$ h )  mean ( sd ) *	C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284	f	1105
712	pulse rate ( mean $nmbr$ h )  bpm *	C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284	f	1105
712	< $nmbr$ bpm ( n = $nmbr$ )	\N	f	1105
712	≥ $nmbr$ bpm ( n = $nmbr$ )	\N	f	1105
712	> $nmbr$ bpm ( n = $nmbr$ )	\N	f	1105
712	< $nmbr$ . $nmbr$ bpm	\N	f	1105
707	acuity - defined bleeding	C0019080;C0750509;C1704788;C3539106	\N	\N
706	cyclo	C1172566	\N	\N
706	crcl < $nmbr$	C1846718	\N	\N
706	crcl $nmbr$ - $nmbr$	C1846718	\N	\N
706	crci > $nmbr$ - < $nmbr$	\N	\N	\N
706	crci > $nmbr$	\N	\N	\N
706	admission crcl	C0184666;C0809949;C1846718	\N	\N
706	> $nmbr$ years or < $nmbr$ crcl  n ( % )	C0439234;C1846718	\N	\N
706	> $nmbr$ crcl	C1846718	\N	\N
706	< $nmbr$ crcl  n ( % )	C1846718	\N	\N
706	< $nmbr$ crcl	C1846718	\N	\N
706	$nmbr$ - $nmbr$ crcl	C1846718	\N	\N
705	rs $nmbr$ ( cc ) & rs $nmbr$	C0008318;C0035970;C3538933;C3714753;C3813325	\N	\N
705	cc	C0008318;C3538933	\N	\N
704	olmesartan along with ccb ( n - $nmbr$ )	C0006684;C1098320	\N	\N
704	olmesartan / ccb - olmesartan / diuretic	C0006684;C0012798;C1098320	\N	\N
704	dihydropyridine ccbs	C0006684;C0012315;C0220821	\N	\N
704	ccbs  ( % )	C0006684	\N	\N
704	ccb	C0006684	\N	\N
704	baseiine ccb	C0006684	\N	\N
704	arb = angiotensin ii receptor blocker  ccb	C0006684;C0521942;C3536793;C3888198	\N	\N
704	arb - arb / ccb	C0006684;C3888198	\N	\N
704	arb + ccb ( n = $nmbr$ )	C0006684;C3888198	\N	\N
703	women  > $nmbr$ cm	C0043210	\N	\N
703	women  < $nmbr$ cm	C0043210	\N	\N
703	wc ( cm )	C0013123;C2825512	\N	\N
703	mean wall thickness ( cm )	C0677535;C4054557	\N	\N
703	< - $nmbr$ . $nmbr$ cm	\N	\N	\N
702	waist ( cm )	C0230097	\N	\N
702	pulmonary vascular resistance  dyne • s • cm $nmbr$	C0308914;C0456261;C0488644;C0600130	\N	\N
701	mean bmd ( = sd )  g / cm $nmbr$	C0439267;C0444504;C2347634;C2348143;C2699239	\N	\N
701	mean ( sd ) bmd in g / cm $nmbr$	C0439267;C0444504;C2347634;C2348143;C2699239	\N	\N
701	flex baseline bmd  mean ( sd )  g / cm $nmbr$	C0168634;C0439267;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
701	flex baseline bmd  g / cm ^ ( meanisd )	C0168634;C0439267;C1442488	\N	\N
701	femoral neck bmd ( g / cm $nmbr$ )	C0015815;C0439267	\N	\N
701	femoral neck ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd )	C0015815;C0439267;C2699239	\N	\N
701	cm	\N	\N	\N
701	bone mineral density ( g / cm $nmbr$ )  mean ( sd )	C0005938;C0177804;C0439267;C0444504;C2347634;C2348143;C2699239	\N	\N
701	> - $nmbr$ cm	\N	\N	\N
701	> $nmbr$ cm	\N	\N	\N
701	> $nmbr$ - $nmbr$ cm	\N	\N	\N
701	< $nmbr$ cm	\N	\N	\N
701	( cm )	\N	\N	\N
700	urine p / cr	C0042036;C0042037;C0201975;C2963137;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
700	steroid - free cr - $nmbr$	C0038317;C0201975;C0332296;C1880497;C1996904;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
700	crpnonr ?	\N	\N	\N
700	cr imputation ( random . ) ( n = $nmbr$ )	C0034656;C0201975;C0439605;C2699638;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
700	cr + mh + crpnorr	C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
700	cr + crpnorr	C0201975;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
700	albuminuria < $nmbr$ gram / gram cr	C0001925;C0201975;C1319635;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
699	prior surgery for cd  n [ % ]	C0007928;C0034283;C0455610;C4552032	\N	\N
699	prior surgery for cd  n ( % )	C0007928;C0034283;C0455610;C4552032	\N	\N
699	patients with eligible ses - cd score	C0007928;C0030705;C0034283;C0449820;C1548635;C4050231;C4552032	\N	\N
699	cd duration  y	C0007928;C0034283;C0449238;C2926735;C4552032	\N	\N
699	cd complications	C0007928;C0009566;C0034283;C1171258;C4552032	\N	\N
699	cd [ gemini $nmbr$ ] * ’	C0007928;C0034283;C4552032	\N	\N
698	prior cad	C0332152;C1504769;C2239547;C2826257;C3813548;C4284121	\N	\N
698	previous cad  n ( % )	C0205156;C1504769;C1552607;C2239547;C3813548;C4284121	\N	\N
698	previous cad	C0205156;C1504769;C1552607;C2239547;C3813548;C4284121	\N	\N
698	premature cad among family members	C0086282;C0151526;C0205252;C1504769;C2239547;C3813548;C4018905;C4284121	\N	\N
698	no cad / mi	C1504769;C2239547;C3810814;C3813548;C4284121	\N	\N
698	multivessel cad ( % )	C1504769;C2239547;C3813548;C4284121	\N	\N
698	multivessel cad  n ( % )	C1504769;C2239547;C3813548;C4284121	\N	\N
698	mi or cad	C1504769;C2239547;C3810814;C3813548;C4284121	\N	\N
698	family history of cad	C0241889;C1504769;C2239547;C3813548;C4284121	\N	\N
698	familv historv of cad	C1504769;C2239547;C3813548;C4284121	\N	\N
698	cad death	C0011065;C1306577;C1504769;C2239547;C3813548;C4082313;C4284121;C4552775	\N	\N
699	chads $nmbr$ < $nmbr$	C0007928;C1413373	f	2128
699	chads $nmbr$ risk factors  n ( % )	C0007928;C0035648;C1413373;C1553898	f	2128
699	chads - $nmbr$ score	C0007928;C0449820;C1413373;C4050231	f	2128
699	chads $nmbr$ score	C0007928;C0449820;C1413373;C4050231	f	2128
699	chads $nmbr$ score *	C0007928;C0449820;C1413373;C4050231	f	2128
699	chads $nmbr$ scoref	C0007928;C1413373	f	2128
699	chads $nmbr$ score  n ( % )	C0007928;C0369718;C0441922;C0449820;C1413373;C4050231	f	2128
699	chads $nmbr$ score > $nmbr$	C0007928;C0449820;C1413373;C4050231	f	2128
699	chads $nmbr$ score $nmbr$	C0007928;C0449820;C1413373;C4050231	f	2128
699	chads $nmbr$ score $nmbr$ - $nmbr$  n ( % )	C0007928;C0369718;C0441922;C0449820;C1413373;C4050231	f	2128
699	chads $nmbr$ scoret	C0007928;C1413373	f	2128
699	chads $nmbr$   score    n   ( % )	C0007928;C0369718;C0441922;C0449820;C1413373;C4050231	f	2128
699	chads score	C0007928;C0449820;C1413373;C4050231	f	2128
699	chads score  n ( % )	C0007928;C0369718;C0441922;C0449820;C1413373;C4050231	f	2128
699	baseline chads $nmbr$ a  c	C0007928;C0168634;C1413373;C1442488	f	2128
699	> $nmbr$ ( n  % ) chads $nmbr$ score	C0007928;C0369718;C0441922;C0449820;C1413373;C4050231	f	2128
698	cad and / or crvd ( % )	C1504769;C2239547;C3813548;C4284121	\N	\N
698	cad *	C1504769;C2239547;C3813548;C4284121	\N	\N
698	cad	C1504769;C2239547;C3813548;C4284121	\N	\N
697	mean cdai score ( sd )	C0444504;C0449820;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706;C4050231	\N	\N
697	mean cdai score	C0444504;C0449820;C0683448;C1413248;C2347634;C2348143;C3273706;C4050231	\N	\N
697	mean ( sd ) cdai *	C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706	\N	\N
697	cdai §	C0683448;C1413248;C3273706	\N	\N
697	cdai score §	C0449820;C0683448;C1413248;C3273706;C4050231	\N	\N
697	cdai score < $nmbr$	C0449820;C0683448;C1413248;C3273706;C4050231	\N	\N
697	cdai score  median ( min  max )	C0449820;C0549183;C0683448;C0702093;C0876920;C1413248;C1524029;C2347635;C2348144;C2939193;C3273706;C3813700;C4050231	\N	\N
697	cdai score  mean ± sda	C0276477;C0444504;C0449820;C0683448;C1413248;C1428349;C1553165;C2347634;C2348143;C3273706;C4050231	\N	\N
697	cdai score  mean ( s . d . )	C0444504;C0449820;C0683448;C1413248;C2347634;C2348143;C3273706;C4050231	\N	\N
697	cdai score	C0449820;C0683448;C1413248;C3273706;C4050231	\N	\N
697	cdai > $nmbr$  n [ % ]	C0683448;C1413248;C3273706	\N	\N
697	cdai < $nmbr$ t	C0683448;C1413248;C3273706	\N	\N
697	cdai < $nmbr$ . $nmbr$ *	C0683448;C1413248;C3273706	\N	\N
697	cdai ( $nmbr$ - $nmbr$ )	C0683448;C1413248;C3273706	\N	\N
697	cdai  mean [ sd ]	C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706	\N	\N
697	cdai  mean ( sd )	C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706	\N	\N
697	cdai	C0683448;C1413248;C3273706	\N	\N
697	baseline cdai score  mean ( sd )	C0168634;C0444504;C0449820;C0683448;C1413248;C1442488;C2347634;C2348143;C2699239;C3273706;C4050231	\N	\N
697	baseline cdai score  mean ( s . d . )	C0168634;C0444504;C0449820;C0683448;C1413248;C1442488;C2347634;C2348143;C3273706;C4050231	\N	\N
697	baseline cdai  mean ( sd )	C0168634;C0444504;C0683448;C1413248;C1442488;C2347634;C2348143;C2699239;C3273706	\N	\N
697	baseline cdai	C0168634;C0683448;C1413248;C1442488;C3273706	\N	\N
697	a decrease of > $nmbr$ points in the cdai score	C0392756;C0449820;C0547047;C0683448;C1413248;C2924612;C3273706;C4050231	\N	\N
696	cdr - sob	C0013404;C4521843	\N	\N
696	baseline cdr - sb ( n   = $nmbr$ + $nmbr$ )	C0038111;C0168634;C1442488;C3811240;C4521843	\N	\N
695	oam	\N	\N	\N
695	no oam	\N	\N	\N
695	atm - locus	C1708726;C3711796	\N	\N
695	atm - locm	C3711796	\N	\N
695	am △ 士 s . e .	C3813124;C3890196;C4520798	\N	\N
695	acm	C0001143;C1549040	\N	\N
694	total asthma symptom score :	C0004096;C2984299;C3533163	\N	\N
694	total asthma symptom score  mean ± sdz	C0004096;C0444504;C2347634;C2348143;C2984299;C3533163	\N	\N
694	total asthma symptom score  mean ± sd ‡	C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163	\N	\N
694	total asthma symptom score	C0004096;C2984299;C3533163	\N	\N
694	percent overall work impairment due to asthma	C0004096;C0043227;C0221099;C0282416;C0439165;C0678226;C0684336;C1561607;C2984299	\N	\N
694	percent impairment while working due to asthma	C0004096;C0043227;C0221099;C0439165;C0678226;C0684336;C2984299	\N	\N
694	percent activity impairment due to asthma	C0004096;C0221099;C0439167;C0678226;C0684336;C2984299	\N	\N
694	newly diagnosed asthma ( n )	C0004096;C0011900;C0750546;C2984299	\N	\N
694	median ( range ) duration of asthma ( years )	C0004096;C0439234;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016	\N	\N
694	median ( range ) duration of asthma ( y )	C0004096;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016	\N	\N
694	hospitalized for asthma  n ( % ) *	C0004096;C0701159;C2984299	\N	\N
694	duration of asthma — yr	C0004096;C0439234;C0449238;C2926735;C2984299	\N	\N
694	duration of asthma > $nmbr$ years	C0004096;C0439234;C0449238;C2926735;C2984299	\N	\N
694	duration of asthma ( years )	C0004096;C0439234;C0449238;C2926735;C2984299	\N	\N
694	duration of asthma  years	C0004096;C0439234;C0449238;C2926735;C2984299	\N	\N
694	duration of asthma  y	C0004096;C0449238;C2926735;C2984299	\N	\N
694	duration of asthma	C0004096;C0449238;C2926735;C2984299	\N	\N
694	asthma population ( n = $nmbr$ )	C0004096;C0032659;C1257890;C2984299	\N	\N
694	asthma	C0004096;C2984299	\N	\N
693	noncomplex anatomy ( n - $nmbr$  $nmbr$ )	C0002808;C0700276;C1384516	\N	\N
693	complex anatomy ( n - $nmbr$  $nmbr$ )	C0002808;C0439855;C0700276;C1384516;C1704241	\N	\N
693	anatomy	C0002808;C0700276;C1384516	\N	\N
692	treatments at randomisation	C0034656;C0087111	\N	\N
692	treatmentofpulmonary embolismpriorto randomization	C0034656	\N	\N
692	treatment randomization	C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
692	treatment at randomization — no . ( % )	C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
692	treatment at randomization	C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
692	treatment at randomisation	C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
692	to randomization	C0034656	\N	\N
692	time to randomization from symptom onset	C0034656;C0040223;C3541383;C4086878	\N	\N
692	time to randomization	C0034656;C0040223;C3541383	\N	\N
692	time to randomisation from symptom onset ( h )	C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4086878;C4528284	\N	\N
692	time since randomization	C0034656;C0040223;C3541383	\N	\N
692	time of randomization ( interaction : p = $nmbr$ . $nmbr$ )	C0034656;C0040223;C1704675;C3541383	\N	\N
692	time of randomization	C0034656;C0040223;C3541383	\N	\N
692	time from symptom onset to randomization	C0034656;C0040223;C0449244;C1457887;C3541383;C3854129;C4086878	\N	\N
692	time from randomization to pci — hr	C0034656;C0040223;C3541383;C4049621	\N	\N
692	time from qualifying event to randomization	C0034656;C0040223;C0441471;C1514624;C3541383;C4019010	\N	\N
692	time from presentation to randomization — hr	C0034656;C0040223;C0449450;C3541383	\N	\N
692	time from longest event to randomisation	C0034656;C0040223;C0441471;C1522425;C3541383;C4019010	\N	\N
692	time from hospitalization to randomization — hr	C0019993;C0034656;C0040223;C3541383	\N	\N
396	all patientsb	\N	\N	\N
692	thienopyridine at randomization	C0034656;C1120149	\N	\N
692	symptom onset to randomization	C0034656;C4086878	\N	\N
692	symptom onset - to - randomization	C0034656;C4086878	\N	\N
692	renal function at randomization	C0034656;C0232804	\N	\N
692	randomized treatments  n ( % )	C0034656;C0087111;C3815594	\N	\N
692	randomized to receiveaspirin	C0034656;C3815594	\N	\N
692	randomized to aspirin use	C0004057;C0034656;C0042153;C0457083;C1947944;C3815594	\N	\N
692	randomized patients	C0030705;C0034656;C3815594	\N	\N
692	randomized < $nmbr$ hr after presentation — %	C0034656;C0449450;C3815594	\N	\N
692	randomized	C0034656;C3815594	\N	\N
692	randomize	\N	\N	\N
692	randomization )	C0034656	\N	\N
692	randomization  n ( % )	C0034656	\N	\N
692	randomization	C0034656	\N	\N
692	randomisation scheme	C0034656;C1519193	\N	\N
692	randomisation	C0034656	\N	\N
692	radiographic characteristics at baseline and randomization	C0034656;C0444708;C4684572	\N	\N
692	patients randomized  no .	C0030705;C0034656;C3815594	\N	\N
692	patients randomized  n	C0030705;C0034656;C0369718;C0441922;C3815594	\N	\N
692	patients randomized	C0030705;C0034656;C3815594	\N	\N
692	participants randomized	C0034656;C0679646;C3815594	\N	\N
692	parenteral anticoagulalion before randomization	C0030547;C0034656;C4522267	\N	\N
692	other llt at randomization	C0034656;C2347090	\N	\N
692	on oac at time of randomisation  n ( % )	C0034656;C0040223;C3541383	\N	\N
692	number randomized	C0034656;C0237753;C0449788;C3815594	\N	\N
692	number of patients randomized	C0034656;C2360800;C3815594	\N	\N
692	no . randomized	C0034656;C3815594	\N	\N
692	nihss at randomization  $nmbr$ - $nmbr$	C0034656;C1697238	\N	\N
692	nihss at randomization	C0034656;C1697238	\N	\N
692	medications at timing of randomization  n ( % )	C0034656;C2359859	\N	\N
692	malignancy at randomization	C0006826;C0034656;C1306459;C4282132	\N	\N
692	mafcaiancy at randorrtzaton	\N	\N	\N
692	llt other than statin at randomization	C0034656;C0360714;C2347090	\N	\N
692	heparin at randomization	C0019134;C0034656;C0770546	\N	\N
692	edoxaban at randomization  n ( % )	C0034656;C2975435	\N	\N
692	coronary revascularization $nmbr$ days after randomization	C0034656;C0439228;C0877341	\N	\N
692	concomitant treatments at randomization	C0034656;C0087111;C0521115	\N	\N
692	at randomization	C0034656	\N	\N
692	asastoppedat randomization  n	C0034656	\N	\N
692	all randomized women	C0034656;C0043210;C3815594	\N	\N
692	all randomized	C0034656;C3815594	\N	\N
692	- [ the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -	C0001779;C0034656;C0040223;C0205103;C1079230;C1548610;C1705241;C1705242;C3541383;C4684719	\N	\N
691	peripheral edema	C0085649	\N	\N
691	eczema	C0013595;C4553957	\N	\N
691	ankle edema	C0235439	\N	\N
690	physical exam oedema	C0013604;C0031809;C1717255	\N	\N
690	edema peripheral	C0013604;C0205100;C1717255	\N	\N
690	edema  peripheral	C0013604;C0205100;C1717255	\N	\N
690	edema  n ( % )	C0013604;C1717255	\N	\N
690	edema  ( % )	C0013604;C1717255	\N	\N
690	edema  % z	C0013604;C1717255	\N	\N
689	proportion of angioedema - free days from week $nmbr$ to week $nmbr$ x	C0002994;C0332174;C0332296;C0439228;C0439230;C1709707;C1880497;C1996904	\N	\N
689	angioedema ( adjudicated )  n ( % )	C0002994	\N	\N
688	pnorcabg	\N	\N	\N
688	normal renal function	C0232805	\N	\N
688	normal cognitive	C2712133	\N	\N
687	very high vs . normal	C0205307;C0231683;C0439166;C0442804;C2347086;C4321397;C4553972	\N	\N
687	size of left atrium normal — no . ( % ) £	C0205307;C0225860;C0231683;C0439166;C0456389;C2347086;C4553972	\N	\N
687	serum mg > $nmbr$ . $nmbr$ mmol / l ( normal mg / hvpermagnesemia )	C0205307;C0229671;C0231683;C0439166;C0439190;C1546774;C1550100;C2347086;C2827881;C4553972	\N	\N
687	percent of predicted normal value	C0205307;C0231683;C0439166;C1882327;C2347086;C4553972	\N	\N
687	normal troponin	C0041199;C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal study termination	C0205307;C0231683;C0439166;C0557651;C1549081;C1692758;C2347086;C2603343;C4553972	\N	\N
687	normal responders ( n = $nmbr$ )	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal responder ( n = $nmbr$ )	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal responder	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal left ventricular ejection fraction — no . ( % ) j	C0205091;C0205307;C0231683;C0428772;C0439166;C0443246;C0488728;C1535947;C1552822;C2347086;C4553972	\N	\N
687	normal hscrp	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal hba $nmbr$ c  n = $nmbr$	C0019016;C0205307;C0231683;C0439166;C1825777;C2347086;C3538758;C4553972	\N	\N
687	normal fasting glucose level ( n = $nmbr$ )	C0015663;C0202045;C0205307;C0231683;C0439166;C0522082;C2347086;C4553972	\N	\N
687	normal crp and	C0205307;C0231683;C0439166;C2347086;C3890735;C4048285;C4553972	\N	\N
687	normal baseline crp	C0168634;C0205307;C0231683;C0439166;C1442488;C2347086;C3890735;C4048285;C4553972	\N	\N
687	normal albuminuria ( uacr < $nmbr$ )	C0001925;C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal > $nmbr$ - $nmbr$	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal - high renin ( pra > $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ )	C0205307;C0231683;C0439166;C0633231;C0855390;C1141951;C1419788;C1533072;C2347086;C3274822;C3669212;C4050009;C4283900;C4553972	\N	\N
687	normal ( ≥ $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )	C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C2347086;C4553972	\N	\N
687	normal ( > $nmbr$ mlvmin per $nmbr$ . $nmbr$ m $nmbr$ )	C0205307;C0231683;C0369637;C0439166;C0441923;C2347086;C4553972	\N	\N
687	normal ( > $nmbr$ ml / min )	C0205307;C0231683;C0439166;C0439445;C2347086;C4553972	\N	\N
687	normal ( > $nmbr$ )	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal ( < $nmbr$ . $nmbr$ u / ml )	C0205307;C0231683;C0439166;C0439340;C1880521;C2347086;C2945590;C4553972	\N	\N
692	aspirin dose at randomization	C0034656;C4696290	f	1366
687	normal  < $nmbr$	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	normal	C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
687	mild dysfunction or normal	C0205307;C0231683;C0439166;C2347086;C3274775;C4553972	\N	\N
687	medium normal ( n = $nmbr$ )	C0009458;C0205307;C0231683;C0439166;C0439536;C1705217;C2347086;C3244283;C4085196;C4522282;C4522283;C4553972	\N	\N
687	lowest normal ( n = $nmbr$ )	C0205307;C0231683;C0439166;C1708760;C2347086;C4553972	\N	\N
687	high normal ( n = $nmbr$ )	C0205250;C0205307;C0231683;C0439166;C1299351;C2347086;C2700149;C3887512;C3889660;C4321237;C4522209;C4553972	\N	\N
686	prior ml or abnormal angiogram	C0002978;C0205161;C0332152;C0439526;C1548816;C1705224;C2347472;C2699333;C2826257;C3887665;C3891555;C4255126	\N	\N
686	previous ml or abnormal angiogram	C0002978;C0205156;C0205161;C0439526;C1548816;C1552607;C1705224;C2347472;C2699333;C3887665;C3891555;C4255126	\N	\N
686	abnormal angiogram	C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126	\N	\N
686	abnormal	C0205161;C2347472;C2699333	\N	\N
685	biguanides ¶	C0005382;C0360396;C3540012	\N	\N
685	biguanides ( metformin )	C0005382;C0025598;C0360396;C3540012	\N	\N
685	biguanides	C0005382;C0360396;C3540012	\N	\N
685	biguanide use at baseline	C0005382;C0042153;C0168634;C0457083;C1442488;C1947944;C3537187;C4317165	\N	\N
685	biguanide ( metformin )	C0005382;C0025598;C3537187;C4317165	\N	\N
685	biguanide	C0005382;C3537187;C4317165	\N	\N
684	prior migraine *	C0149931;C0332152;C2826257	\N	\N
684	prior migraine	C0149931;C0332152;C2826257	\N	\N
684	migraine — no . ( % ) $	C0149931	\N	\N
684	migraine severity score	C0149931;C0457451	\N	\N
684	migraine occurrence ( days / month )	C0149931;C0243132;C0556971;C1554210;C2745955	\N	\N
683	≥ $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %	\N	\N	\N
683	rankin grade	C0441800;C0919553;C3244287	\N	\N
683	nerd grade	C0441800;C0919553;C3244287	\N	\N
683	nerd	\N	\N	\N
683	modi fied la grade *	C0023031;C0023749;C0230347;C0342276;C0441800;C0919553;C2346906;C3244287;C4553351	\N	\N
683	mmrc grade  n ( % )	C0441800;C0919553;C3244287;C3826977	\N	\N
683	mmrc grade	C0441800;C0919553;C3244287;C3826977	\N	\N
683	mean mmrc grade  units ( sd )	C0439148;C0441800;C0444504;C0919553;C1519795;C2347634;C2348143;C2699239;C3244287;C3826977;C3853603	\N	\N
683	la grade a  n ( % ) f	C0016327;C0023031;C0023749;C0230347;C0369718;C0441800;C0441922;C0919553;C2346906;C3244287;C4553351	\N	\N
683	kellgren and lawrence radiographic reading grade $nmbr$ — no . ( % )	C0034754;C0441800;C0444708;C0919553;C1705179;C3244287;C4284139	\N	\N
683	grade > $nmbr$	C0441800;C0919553;C3244287	\N	\N
683	grade $nmbr$	C0441800;C0919553;C3244287	\N	\N
683	gold grade $nmbr$	C0018026;C0441800;C0919553;C1304897;C3244287	\N	\N
683	dyspnoea - mmrc grade  n ( % )	C0013404;C0441800;C0919553;C1963100;C3244287;C3826977	\N	\N
683	dyspnea – mmrc grade  n ( % )	C0013404;C0441800;C0919553;C1963100;C3244287;C3826977	\N	\N
683	baseline los angeles grade of eo  n ( % )	C0024015;C0168634;C0332120;C0441800;C0919553;C1442488;C3244287	\N	\N
682	screening prebronchodilator fev $nmbr$  l	C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541	\N	\N
682	prebronchodilator fevj ( % predicted )	C0681842;C1882327;C2599602	\N	\N
682	prebronchodilator fev $nmbr$	C2599602;C3714541	\N	\N
682	prebronchodilator	C2599602	\N	\N
682	pre - bronchodilator screening fev $nmbr$ ml	C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541;C3887665	\N	\N
682	pre - bronchodilator fvc ’ % pred	C0032952;C0044955;C2599602;C3714541	\N	\N
682	pre - bronchodilator fvc ( l )	C2599602;C3714541	\N	\N
682	pre - bronchodilator fevr l	C1708033;C2599602	\N	\N
682	pre - bronchodilator fevr % pred	C0032952;C0044955;C1708033;C2599602	\N	\N
682	pre - bronchodilator fevj	C2599602	\N	\N
682	pre - bronchodilator fev ^ ( l )	C2599602;C3714541	\N	\N
682	pre - bronchodilator fev $nmbr$ ( l )	C2599602;C3714541	\N	\N
682	pre - bronchodilator fev $nmbr$ ( % predicted normal )	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599602;C3714541;C4553972	\N	\N
682	pre - bronchodilator fev  ( l )	C2599602;C3714541	\N	\N
682	pre - bronchodilator fev  % predicted	C0681842;C1882327;C2599602;C3714541	\N	\N
682	pre - bronchodilator fef $nmbr$ . $nmbr$ ( ml / s ) baseline blood eosinophil count	C0005767;C0005768;C0014467;C0168634;C0200638;C0229664;C0439390;C0750480;C0750879;C1442488;C1705566;C2599602	\N	\N
682	pre - bronchodilator	C2599602	\N	\N
682	percentage of predicted pre - bronchodilator fev ^	C0439165;C0681842;C1549488;C1561533;C1882327;C2599602;C3714541	\N	\N
682	fvc pre - bronchodilator	C2599602;C3714541	\N	\N
682	fev $nmbr$ pre - bronchodilator ( % predicted normal )  mean ( sd ) c  d	C0012358;C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2599602;C2699239;C3714541;C4553972	\N	\N
682	fev $nmbr$ pre - bronchodilator	C2599602;C3714541	\N	\N
682	fev $nmbr$ ( l ) pre - bronchodilator	C2599602;C3714541	\N	\N
682	baseline pre - bronchodilator fev $nmbr$  l	C0168634;C1442488;C2599602;C3714541	\N	\N
682	a prebronchodilator fevl ( % predicted )	C0681842;C1882327;C2599602	\N	\N
682	% predicted pre - bronchodilator fev $nmbr$  % *	C0681842;C1882327;C2599602;C3714541	\N	\N
681	before bronchodilation — liters §	C0475211;C1371299;C3537072	\N	\N
681	before bronchodilation	C1371299;C3537072	\N	\N
681	after bronchodilation	C1371299;C3537072	\N	\N
680	postbronchodilator lung function at screening	C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594	\N	\N
680	postbronchodilator fev $nmbr$  % predicted	C0681842;C1882327;C2599594;C3714541	\N	\N
680	postbronchodilator $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )	C2599594	\N	\N
680	postbronchodilator	C2599594	\N	\N
680	post - bronchodilator screening fev $nmbr$ ml	C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541;C3887665	\N	\N
680	post - bronchodilator ratio of fev $nmbr$ to fvc — %	C0456603;C1547037;C2599594;C3714541	\N	\N
680	post - bronchodilator fvc ( l ) a	C2599594;C3714541	\N	\N
683	adverse events ( any grade )	C0441800;C0877248;C0919553;C1705413;C3244287	f	47
680	post - bronchodilator fevx ( l )	C2599594	\N	\N
680	post - bronchodilator fev $nmbr$ — liters	C0475211;C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ — % of predicted value	C0681842;C1522609;C1882327;C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ ml	C0439526;C1705224;C2599594;C3714541;C3887665	\N	\N
680	post - bronchodilator fev $nmbr$ / fvc ( % ) a	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ / fvc  %	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ ( l ) a	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ ( l ) *	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ ( l )	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ ( % predicted normal ) a	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599594;C3714541;C4553972	\N	\N
680	post - bronchodilator fev $nmbr$ ( % predicted * )	C0681842;C1882327;C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$ % predictedb	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$  l *	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$  l	C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$  % predicted of normal value	C0086715;C0681842;C1882327;C2599594;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$  % predicted  mean ( sd )	C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
680	post - bronchodilator fev $nmbr$  % predicted	C0681842;C1882327;C2599594;C3714541	\N	\N
680	post - bronchodilator fev  / fvc	C2599594;C3714541	\N	\N
680	post - bronchodilator fev  ( l )	C2599594;C3714541	\N	\N
680	post - bronchodilator fev  % predicted	C0681842;C1882327;C2599594;C3714541	\N	\N
680	post - bronchodilator fev   % predicted	C0681842;C1882327;C2599594;C3714541	\N	\N
680	post - bronchodilator	C2599594	\N	\N
680	fvc post - bronchodilator	C2599594;C3714541	\N	\N
680	fev $nmbr$ post - bronchodilator  % predicted normal	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599594;C3714541;C4553972	\N	\N
680	baseline post - bronchodilator fev $nmbr$   ( sd )  ml	C0168634;C0439526;C1442488;C1705224;C2599594;C2699239;C3714541;C3887665	\N	\N
680	baseline post - bronchodilator % predicted fev  > $nmbr$ % and prior ics use	C0042153;C0168634;C0332152;C0457083;C0681842;C0815320;C1442488;C1882327;C1947944;C2599594;C2826257;C3714541;C4551720	\N	\N
680	baseline post - bronchodilator % predicted fev  < $nmbr$ %	C0168634;C0681842;C1442488;C1882327;C2599594;C3714541	\N	\N
680	% predicted post - bronchodilator fev $nmbr$  mean ( sd )  l	C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541	\N	\N
679	nebivolol ( n = $nmbr$ )	C0068475	\N	\N
679	metoprolol group ( n = $nmbr$ )	C0025859;C0441848	\N	\N
679	metoprolol ( n = $nmbr$ $nmbr$ )	C0025859	\N	\N
678	study protocol	C1507394;C2348563;C2599718	\N	\N
677	location of treatment center	C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
677	centre	C0205099;C3810851	\N	\N
677	central eosinophil count ( cells per pl ) t	C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765	\N	\N
677	central eosinophil count ( cells per pl )	C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765	\N	\N
677	central eosinophil count	C0200638;C0205099;C0750879;C1879652	\N	\N
677	central / eastern	C0205099;C1707877;C1879652	\N	\N
677	center location	C0205099	\N	\N
677	center - level ihr percent time in therapeutic range for warfarin subjects	C0040223;C0043031;C0087111;C0205099;C0302350;C0439165;C0441889;C0456079;C0460097;C0681850;C1547707;C1550501;C1554109;C1706203;C2349001;C2697811;C2946261;C3541383;C3810851	\N	\N
677	center	C0205099;C3810851	\N	\N
676	ldl - c concentration	C0086045;C1446561;C3827302	\N	\N
676	hdlc - concentration	C0086045;C1446561;C1704429;C3827302	\N	\N
676	geometric c $nmbr$ concentration  mg / dl	C0086045;C0439269;C0449829;C1446561;C3827302	\N	\N
676	crp concentration > $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mg / l )  n ( % )	C0086045;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285	\N	\N
676	blood leucocyte concentration ( $nmbr$ cells per l )	C0023516;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302	\N	\N
676	blood eosinophil concentration  $nmbr$ cells per l	C0014467;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302	\N	\N
675	rhythm - control group ( n = $nmbr$ )	C0243148;C0441848;C0871269;C1523018;C1550141;C1882979;C2587213;C3274648;C3828331;C4553389	\N	\N
675	proportion ( % ) of individuals • control alirocumab	C0027361;C0237401;C0243148;C1550141;C1709707;C1882979;C2587213;C3274648;C3491162;C4553389	\N	\N
675	good control ( < $nmbr$ )	C0205170;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	glycaemic control ( hba $nmbr$ c )  n ( % )	C0005802;C0019016;C0243148;C1550141;C1825777;C1882979;C2587213;C3274648;C3538758;C4553389	\N	\N
675	fair control ( $nmbr$ - $nmbr$ . $nmbr$ )	C0243148;C1550141;C1882979;C2587213;C2911689;C3274648;C4553389	\N	\N
675	controls ( n = $nmbr$ )	C0243148;C0369718;C0441922;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	controlled : acq - $nmbr$ < $nmbr$ . $nmbr$	C2587213;C2911690;C2919686	\N	\N
675	controlled $nmbr$ — no . ( % )	C2587213;C2911690	\N	\N
675	controlled	C2587213;C2911690	\N	\N
675	controlld	\N	\N	\N
675	control of sitting bp at week $nmbr$	C0037623;C0243148;C0277814;C0332174;C0439230;C1415692;C1550141;C1708288;C1882979;C2584297;C2587213;C3274648;C4050224;C4318478;C4553389	\N	\N
675	control n = $nmbr$	C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control group ( n = $nmbr$ )	C0243148;C0441848;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control baseline ( n - $nmbr$ )	C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control = warfarin	C0043031;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control ( nz $nmbr$ )	C0027978;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control ( n z $nmbr$ )	C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control ( n = $nmbr$ )	C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
359	xanthines	C0043318;C3541955	\N	\N
678	original dabigatran protocol	C0205313;C0442711;C1507394;C1522729;C2347409;C2348066;C2348563;C2599718;C3715209;C4282383	f	775
675	control ( n - $nmbr$ )	C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control $nmbr$ months ( n - $nmbr$ )	C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	control	C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	bp control	C0037623;C0243148;C1415692;C1550141;C1708288;C1882979;C2587213;C3274648;C4318478;C4553389	\N	\N
675	blood pressure control *	C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	blood pressure control	C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	baseline glycemic control	C0005802;C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	asthma control	C0004096;C0243148;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389	\N	\N
675	asthma - control status at randomization — no . ( % )	C0004096;C0034656;C0243148;C0449438;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389	\N	\N
675	active - control study	C0243148;C0557651;C1550141;C1706449;C1882979;C2347179;C2587213;C2603343;C3274648;C4553389	\N	\N
675	( % ) control ( $nmbr$ )	C0243148;C1550141;C1882979;C2587213;C3274648;C4553389	\N	\N
675	% asthma control days {  #	C0004096;C0243148;C0439228;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389	\N	\N
674	tertile $nmbr$ ( > $nmbr$ . $nmbr$ pg / ml ) n - $nmbr$	C0439297	\N	\N
674	tertile $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pg / ml ) n = $nmbr$	C0439297	\N	\N
674	tertile $nmbr$	\N	\N	\N
674	terrible	C3827840	\N	\N
674	terlile $nmbr$	\N	\N	\N
673	terminal ileum	C0227327	\N	\N
673	disease location / type : terminal ileum	C0227327;C0450429;C0457464;C1515974;C4284930;C4284931	\N	\N
673	$nmbr$ rrmnl )	\N	\N	\N
672	western europe and israel	C0022271;C0043129	\N	\N
672	lymphocytes  $nmbr$ / + il	C0020898;C0021764;C0022271;C0024264;C4018897	\N	\N
672	israel	C0022271	\N	\N
672	il - $nmbr$ ( pg / ml )	C0020898;C0021764;C0022271;C0439297	\N	\N
672	il - $nmbr$  ng / l	C0020898;C0021764;C0022271;C0439297	\N	\N
672	il - $nmbr$	C0020898;C0021764;C0022271	\N	\N
672	canakinumab  $nmbr$ month on - treatment il - $nmbr$ above the median value ( ≥ $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ )	C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704	\N	\N
671	ppg  mmol / l	C1418888;C1532563	\N	\N
671	phosphorus  mmol $nmbr$ $nmbr$	C0031705;C0080014;C0439190;C3714498	\N	\N
671	fpg ( mmol / $nmbr$ )	C0439190	\N	\N
671	fpg  mmol / la	C0023031;C0023749;C0230347;C0439190;C2346906;C4553351	\N	\N
671	> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l - mmol / l	C0439190;C0439342	\N	\N
671	> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l $ mmol / l	C0439190;C0439342	\N	\N
671	> $nmbr$ . $nmbr$ mu / l - mmol / l	C0439190;C0439342	\N	\N
671	> $nmbr$ . $nmbr$ mu / l $ mmol / l	C0439190;C0439342	\N	\N
671	< $nmbr$ . $nmbr$ mu / l - mmol / l	C0439190;C0439342	\N	\N
671	< $nmbr$ . $nmbr$ mu / l $ mmol / l	C0439190;C0439342	\N	\N
671	( mu / l $ mmol / l ) b	C0439190;C0439342	\N	\N
671	$nmbr$ - hour ppg  mmol / l	C0439227;C0564385;C1418888;C1532563	\N	\N
671	$nmbr$ - h ppg ( mmol / l ) *	C1418888;C2827804	\N	\N
671	$nmbr$ - h ppg ( mmol / l )	C1418888;C2827804	\N	\N
671	$nmbr$ - h pmg ( mmol / l )	C2827804	\N	\N
671	$nmbr$ - h pmg  mmol / l ( mean ± sd )	C0444504;C2347634;C2348143;C2699239;C2827804	\N	\N
670	£ $nmbr$ . $nmbr$ mmol / l	C1532563	\N	\N
670	women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l )	C0043210;C0439269;C1532563	\N	\N
670	triacylglycerol  mmol / l  mean ( sd )	C0041004;C0444504;C1532563;C2347634;C2348143;C2699239	\N	\N
670	tertile of total cholesterol at baseline  mean ( sd )  mmol / l	C0168634;C0201950;C0444504;C0543421;C1442488;C1532563;C2347634;C2348143;C2699239	\N	\N
670	sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ fasting plasma glucose ( fpg ) ( mmol / l )	C0015663;C0202042;C0455280;C1532563;C1565750	\N	\N
670	serum phosphate  mmol / l	C0036820;C1532563	\N	\N
670	serum mg < $nmbr$ . $nmbr$ mmol / l ( hypomagnesemia )	C0024671;C0026410;C0151723;C0229671;C0439190;C0439268;C0439269;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761;C4552839	\N	\N
670	serum hdl cholesterol ( mmol / l )  mean ( sd )	C0428472;C0444504;C1532563;C2347634;C2348143;C2699239	\N	\N
670	serum glucose ( mmol / l )	C0202041;C1532563;C3534430	\N	\N
670	serum calcium  mmol / l	C0036785;C0728876;C1532563	\N	\N
670	phosphate ( mmol / l )	C0031603;C0031701;C1532563;C1601799	\N	\N
670	mmol / l [ n ]	C1532563	\N	\N
670	mmol / l )	C1532563	\N	\N
670	mmol / l	C1532563	\N	\N
670	mg / dl fpg ( mmol / l )	C0439269;C1532563	\N	\N
670	mean fpg  mmol / l	C0444504;C1532563;C2347634;C2348143	\N	\N
670	mean change ‘ s in fasting blood glucose [ mg / dl ( mmol / l ) ]	C0392747;C0428568;C0443172;C0444504;C1261430;C1532563;C1705241;C2347634;C2348143;C2827883;C3642216;C4319952	\N	\N
670	mean ( s . d . ) baseline fpg  mmol / l	C0168634;C0444504;C1442488;C1532563;C2347634;C2348143	\N	\N
670	mdg ( mmol / l )	C0024443;C1417239;C1532563;C2986643	\N	\N
670	lipoprotein ( a ) ( mmol / l )	C0065058;C0125953;C1096202;C1439335;C1532563	\N	\N
359	xanthine	C0043314;C0043318	\N	\N
670	serum potassium : < $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ )	C0302353;C0543465;C1532563	f	1959
670	serum total cholesterol ( mmol / l )  mean ( sd )	C0444504;C0587184;C1287371;C1532563;C2347634;C2348143;C2699239	f	1504
670	serum potassium  mean ( sd ) mmol / l	C0302353;C0444504;C0543465;C1532563;C2347634;C2348143;C2699239	f	1959
670	serum potassium  > $nmbr$ . $nmbr$ mmol / l	C0302353;C0543465;C1532563	f	1959
670	potassium at admission  mmol / l - $nmbr$	C0032821;C0184666;C0202194;C0304475;C0597277;C0809949;C1532563;C3714637	f	1959
670	serum biochemistry potassium  mmol / l	C0005477;C0302353;C0543465;C1532563	f	1371
670	haemoglobin ( mmol / l )	C0019046;C0439190;C0635222;C1532563	\N	\N
670	glucose  mmol / l	C0017725;C1532563	\N	\N
670	fc > $nmbr$ mg / dl ( > _ $nmbr$ . $nmbr$ mmol / l ) or history of diabetes	C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C0439269;C1532563;C1705255;C2004062;C2983605	\N	\N
670	change  mg / dl ( mmol / l )	C0392747;C0439269;C0443172;C1532563;C1705241;C4319952	\N	\N
670	bun  mmol / l	C1532563	\N	\N
670	baseline normoglycaemia ( fpg < $nmbr$ . $nmbr$ mmol / l ) - n	C0168634;C0580545;C1442488;C1532563	\N	\N
670	baseline lipids  mean ± sd ( mmol / l )	C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239	\N	\N
670	baseline lipid parameters  mg / dl  mmol / l or g / l	C0023779;C0168634;C0439269;C0439294;C0449381;C0456615;C1442488;C1532563	\N	\N
670	baseline ( mmol / l )	C0168634;C1442488;C1532563	\N	\N
670	[ $nmbr$ . $nmbr$ mmol / l ] )	C1532563	\N	\N
670	> $nmbr$ mmol / l	C1532563	\N	\N
670	> $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ) + +	C0439269;C1532563	\N	\N
670	> $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ )	C1532563	\N	\N
670	> $nmbr$ . $nmbr$ mmol / l	C1532563	\N	\N
670	> $nmbr$ - $nmbr$ mmol / l	C1532563	\N	\N
670	> $nmbr$ + $nmbr$ mmol / l	C1532563	\N	\N
670	> $nmbr$ ' $nmbr$ mmol / l	C1532563	\N	\N
670	< $nmbr$ mmol / l	C1532563	\N	\N
670	< $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l )	C0439269;C1532563	\N	\N
670	< $nmbr$ . $nmbr$ mmol / l	C1532563	\N	\N
670	< $nmbr$ - $nmbr$ mmol / l	C1532563	\N	\N
670	( mmol / l ]	C1532563	\N	\N
670	( mmol / l )	C1532563	\N	\N
670	( < $nmbr$ . $nmbr$ mmol / l )	C1532563	\N	\N
670	( $ $nmbr$ mg / dl [ $nmbr$ . $nmbr$ mmol / l ] )	C0439269;C1532563	\N	\N
670	$nmbr$ st tertile ( < = $nmbr$ mg / dl [ < = $nmbr$ . $nmbr$ mmol / l ] ) b	C0036056;C0439269;C1532563;C3272372	\N	\N
670	$nmbr$ nd tertile ( > $nmbr$ to < = $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ to < = $nmbr$ . $nmbr$ mmol / l ] ) c	C0439269;C1532563	\N	\N
670	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l	C1532563	\N	\N
670	$nmbr$ - $nmbr$ mmol / l	C1532563	\N	\N
669	unbound pcsk $nmbr$ ( nmol / l )	C0439282	\N	\N
669	testosterone level ( nmol / l )	C0428412;C0439282;C0523912	\N	\N
359	methylxanthines	C0066447	\N	\N
670	ldl cholesterol  mmol / l  mean ( sd ) §	C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239	f	1068
670	ldl cholesterol  mmol / l  mean ± sd	C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239	f	1068
670	ldl cholesterol ( mmol / l )  mean ( sd )	C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239	f	1068
670	ldl cholesterol ( mmol / l ) ( median  iqr )	C0023824;C0202117;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	f	1068
670	ldl - c   *   ( mmol / l )	C1532563	f	1068
670	ldl ( mmol / l )	C1532563	f	1068
670	ldl - c < $nmbr$ . $nmbr$ mmol / l	C1532563	f	1068
670	ldl - c < $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l )	C0439269;C1532563	f	1068
670	ldl - c  mmol / l ( sd )	C1532563;C2699239	f	1068
670	ldl - c ( mmol / l  mean )	C0444504;C1532563;C2347634;C2348143	f	1068
670	ldl - c  mmol / l  mean ( sd )	C0444504;C1532563;C2347634;C2348143;C2699239	f	1068
670	ldl - c * ( mmol / l )	C1532563	f	1068
670	ldl - c ( mmol / l )	C1532563	f	1068
670	ldl - c  mmol / l	C1532563	f	1068
670	ldl cholesterol > $nmbr$ - $nmbr$ mmol / l	C0023824;C0202117;C1532563	f	1068
670	ldl cholesterol < $nmbr$ - $nmbr$ mmol / l	C0023824;C0202117;C1532563	f	1068
670	ldl cholesterol  mmol / l 丰	C0023824;C0202117;C1532563	f	1068
670	fasting plasma glucose ( mmol / l )	C0015663;C0202042;C0455280;C1532563	f	1960
670	fasting serum glucose  mmol / l  median ( q $nmbr$  q $nmbr$ )	C0015663;C0202041;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193;C3534430	f	1960
670	fbg  mmol / l	C1532563	f	1960
670	fpg  median ( q $nmbr$  q $nmbr$ )  mmol / l	C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	f	1960
670	fpg  mean ( sd )  mmol / l	C0444504;C1532563;C2347634;C2348143;C2699239	f	1960
670	fpg  median ( ql  q $nmbr$ )  mmol / l	C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	f	1960
670	fpg  mmol / l	C1532563	f	1960
670	fpg  ( mmol / l )	C1532563	f	1960
670	fpg  mg / dl ( mmol / l )	C0439269;C1532563	f	1960
670	fpg  mmol / l ( mean ± sd )	C0444504;C1532563;C2347634;C2348143;C2699239	f	1960
670	fpg ( mmol / l )	C1532563	f	1960
670	fpg  mmol / l  mean ( sd )	C0444504;C1532563;C2347634;C2348143;C2699239	f	1960
670	fpg ( mmol / l )  mean ( sd )	C0444504;C1532563;C2347634;C2348143;C2699239	f	1960
670	fpg ( mmol / l )  mean ( sd ) 、	C0444504;C1532563;C2347634;C2348143;C2699239	f	1960
670	fpg ( range ) ( mmol / l )	C1514721;C1532563;C2348147;C3542016	f	1960
670	f - plasma glucose  mmol / l	C0016327;C0202042;C0455280;C1532563	f	1960
670	free fatty acids ( mmol / l )	C0015688;C1532563	f	1961
670	ffa ( mmol / l )	C0015688;C1532563	f	1961
670	k  mmol / l	C0597277;C1532563;C1708601	f	1959
670	k ( mmol / l )	C0597277;C1532563;C1708601	f	1959
670	admission k  mmol / l	C0184666;C0597277;C0809949;C1532563;C1708601	f	1959
670	hdl - c ( mmol / l  mean )	C0444504;C1532563;C2347634;C2348143;C3715113	f	821
670	hdl - c > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l )	C0439269;C1532563;C3715113	f	821
670	high - density lipoprotein cholesterol  mean ( sd )  mmol / l	C0023822;C0444504;C1532563;C2347634;C2348143;C2699239	f	821
670	elevated serum potassium  > $nmbr$ . $nmbr$ mmol / l	C0553704;C1532563	f	1371
670	hyperkalaemia ( serum potassium > $nmbr$ . $nmbr$ mmol / l )	C0020461;C0302353;C0543465;C1532563;C4552983	f	1371
669	testosterone ( tt ) ( nmol / l )	C0039601;C0439282;C1452561;C4554543	\N	\N
669	testosterone ( nmol / l )	C0039601;C0439282	\N	\N
669	hscrp ( nmol / l )	C0439282	\N	\N
669	crp  nmol / l  median ( range )	C0439282;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285	\N	\N
669	cholesterol ( nmol / l )	C0008377;C0439282	\N	\N
668	≥   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % )	C3829066	\N	\N
668	≥ $nmbr$ . $nmbr$ % ( ≥ $nmbr$ mmol / mol )	C3829066	\N	\N
668	≤   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % )	C3829066	\N	\N
668	mmol / mol	C3829066	\N	\N
668	mean hba $nmbr$ c  mmol / mol †	C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066	\N	\N
668	ls mean ( $nmbr$ % ci )  mmol / mol	C0008107;C0023668;C0444504;C2347634;C2348143;C3259781;C3829066	\N	\N
668	alc ( mmol / mol )	C1424945;C3811058;C3829066	\N	\N
668	a $nmbr$ c ( mmol / mol )	C3829066	\N	\N
668	a $nmbr$ c  % ( mmol / mol )	C3829066	\N	\N
668	>   $nmbr$ – <   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ % )    n   ( % )	C3829066	\N	\N
668	> = $nmbr$ . $nmbr$ % ( > = $nmbr$ mmol / mol )	C3829066	\N	\N
668	> = $nmbr$ % and < $nmbr$ % ( > = $nmbr$ and < $nmbr$ mmol / mol )	C3829066	\N	\N
668	> = $nmbr$ % ( $nmbr$ mmol / mol )	C3829066	\N	\N
668	> $nmbr$ % ( > $nmbr$ mmol / mol )	C3829066	\N	\N
668	< $nmbr$ . $nmbr$ % ( < $nmbr$ mmol / mol )	C3829066	\N	\N
668	< $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )	C3829066	\N	\N
668	< $nmbr$ % ( < $nmbr$ mmol / mol )	C3829066	\N	\N
668	< $nmbr$ % ( $nmbr$ mmol / mol )	C3829066	\N	\N
667	trigl yeerides * ( m mol / l )	C0027960;C0324740;C0347982;C0369637;C0439189;C0441923;C0456616;C1456781;C1824986;C3665593	\N	\N
667	serum creatinine  弘 mol 儿 | |	C0027960;C0201976;C0324740;C0439189;C0600061;C1456781;C1824986;C3665593	\N	\N
667	epa ( mol % )	C0027960;C0324740;C0439189;C1456781;C1824986;C3665593	\N	\N
667	epa  mol %	C0027960;C0324740;C0439189;C1456781;C1824986;C3665593	\N	\N
666	fpi  m - u / ml ( pmol / l )	C0369637;C0439192;C0439284;C0439340;C0441923;C0456616;C1880521;C2945590	\N	\N
666	fpi  gu / ml ( pmol / l )	C0120446;C0439192;C0439284;C0439526;C1635169;C1705224;C3887515;C3887665	\N	\N
666	estradiol ( pmol / l )	C0014912;C0439284	\N	\N
666	estradiol ( e $nmbr$ ) ( pmol / l )	C0014912;C0439284	\N	\N
666	$nmbr$ rd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l	C0439284;C0694666;C4553350	\N	\N
666	$nmbr$ nd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l	C0439284	\N	\N
665	fasting proinsulin ( pmol / l )	C0015663;C0033362;C0439284;C3813208	\N	\N
665	$nmbr$ - h postprandial proinsulin ( pmol / l )	C0033362;C0376674;C2827799;C3813208	\N	\N
664	el  n ( % )	C1416870;C1447747;C1823249;C3811107;C3811848;C3815598	\N	\N
664	( $nmbr$ % ell ' ll  * non - hdl - c	C1427925;C1518422;C3273466;C3715113	\N	\N
664	( $nmbr$ % ell ' ll	C1427925;C3273466	\N	\N
664	$nmbr$ ± ll	\N	\N	\N
663	ll $nmbr$ ( $nmbr$ )	\N	\N	\N
663	l / ll	C0439394;C1706495;C3642217	\N	\N
663	insulin glargine ( n = $nmbr$ ll )	C0907402	\N	\N
663	- $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) * ll	\N	\N	\N
662	ll ( $nmbr$ )	\N	\N	\N
662	eosinophils ( cells / ll ) inclusion criteria  n ( % )	C0682547;C1512693	\N	\N
662	eosinophil count ( cells / microlitre )	C0200638;C0439378;C0750879	\N	\N
662	> $nmbr$ cells / ul	C0439378	\N	\N
662	< $nmbr$ cells / ul $nmbr$ $nmbr$	C0439378	\N	\N
661	squamous cell carcinoma	C0007137;C1302853	\N	\N
661	dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only	C0007613;C0079809;C0168634;C0205171;C0242485;C0392747;C0443172;C0729333;C1442488;C1515021;C1516048;C1705241;C1720467;C4319952	\N	\N
661	^ $nmbr$ - cell function — % §	C0007613	\N	\N
660	ill -	C0231218	\N	\N
660	all noncompleters	\N	\N	\N
660	all completers ( n $nmbr$ $nmbr$ )	\N	\N	\N
660	all completers	\N	\N	\N
660	< $nmbr$ . $nmbr$ tng > cll	C0023434	\N	\N
659	white blood cell count  cellsx $nmbr$	C0023508;C0427512	\N	\N
668	hbajc ( mmol / mol ) mean ± sd	C0444504;C2347634;C2348143;C2699239;C3829066	f	820
668	hbaj ( - ( %  mmol / mol )	C3829066	f	820
668	hbalc a $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	820
668	hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) at week $nmbr$	C0332174;C0439230;C3829066	f	820
668	hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	820
668	hba $nmbr$ c  ( mmol / mol )	C0019016;C1825777;C3538758;C3829066	f	820
668	hba $nmbr$ c  % [ mmol / mol ]	C0019016;C1825777;C3538758;C3829066	f	820
668	hba $nmbr$ c  mmol / mol ( mean )	C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066	f	820
668	hba $nmbr$ c  mmol / mol  mean ( sd )	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066	f	820
668	hba $nmbr$ c  mmol / mol  median ( q $nmbr$  q $nmbr$ )	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066	f	820
668	hba $nmbr$ c ( mmol / mol [ se ] )	C0019016;C0036919;C1825777;C3538758;C3829066	f	820
668	hba $nmbr$ c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ - $nmbr$ mmol / mol )	C0019016;C1825777;C3538758;C3829066	f	820
668	hba $nmbr$ c ( sd )  mmol / mol	C0019016;C1825777;C2699239;C3538758;C3829066	f	820
659	white - cell count — x $nmbr$ _ $nmbr$ / liter	C0023508;C0427512;C0475211	\N	\N
659	blood leukocyte count ( $nmbr$ cells per l )	C0023508;C0023516;C0347983;C0427512	\N	\N
658	ucl	\N	\N	\N
658	treatment difference ( $nmbr$ % cl )	C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704	\N	\N
658	treatment difference % ( $nmbr$ % cl )	C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704	\N	\N
658	risk reduction ( $nmbr$ % cl )	C0596019;C1137094	\N	\N
658	risk ratio [ $nmbr$ % cl ]	C0028873;C0242492;C0596019	\N	\N
658	relative risk ® ( $nmbr$ % cl )	C0242492;C0596019	\N	\N
658	relative risk ® ' ( $nmbr$ % cl )	C0242492;C0596019	\N	\N
658	relative risk vs . placebo ( $nmbr$ % cl )	C0032042;C0242492;C0596019;C1696465;C1706408	\N	\N
658	relative risk reduction ( $nmbr$ % cl ) percent	C0080103;C0205345;C0242492;C0301630;C0392756;C0439165;C0596019;C1137094;C1293152;C1547039;C4551656	\N	\N
658	relative risk reduction ( $nmbr$ % cl )	C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1547039;C4551656	\N	\N
658	relative risk * ( $nmbr$ % cl )	C0242492;C0596019	\N	\N
658	relative risk ( $nmbr$ % cl )	C0242492;C0596019	\N	\N
658	ratio of hrs ( $nmbr$ % cl )  p for sex interaction	C0009253;C0036864;C0079399;C0456603;C0596019;C0804628;C1314687;C1522384;C1547037;C1568891;C1704675	\N	\N
658	pre - specified hr ( $nmbr$ % cl )	C0596019;C2826245	\N	\N
658	p ( $nmbr$ % cl )	C0369773;C0596019;C2603361	\N	\N
658	overall hr ( $nmbr$ % cl )	C0282416;C0596019;C1561607	\N	\N
658	orc ( $nmbr$ % cl )	C0596019;C1167125	\N	\N
658	oradj ( $nmbr$ % cl )	C0596019	\N	\N
658	or [ $nmbr$ % cl ]	C0596019	\N	\N
658	or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )	C0596019	\N	\N
658	or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ . $nmbr$ )	C0596019	\N	\N
658	or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ $nmbr$ )	C0596019	\N	\N
658	or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ )	C0596019	\N	\N
658	or ( $nmbr$ % cl )	C0596019	\N	\N
658	or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ — $nmbr$  $nmbr$ )	C0596019	\N	\N
658	or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ )	C0596019	\N	\N
658	north america hr ( $nmbr$ % cl )	C0028405;C0596019	\N	\N
658	mean difference ( $nmbr$ % cl )	C0444504;C0596019;C1705241;C1705242;C2347634;C2348143	\N	\N
658	lsm difference ( $nmbr$ % cl )	C0596019;C1705241;C1705242	\N	\N
658	lsm ( $nmbr$ % cl )	C0596019	\N	\N
658	ls mean difference ( $nmbr$ % cl )	C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143	\N	\N
658	ls - mean difference ® ( $nmbr$ % cl )	C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143	\N	\N
658	least - squares mean difference ( $nmbr$ % cl )	C0023189;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143	\N	\N
658	laba or lama ’ versus ind / gly lsm difference ( $nmbr$ % cl )	C0017890;C0523677;C0596019;C0999593;C1416775;C1705241;C1705242;C4049864	\N	\N
658	hr : $nmbr$ . $nmbr$ ( $nmbr$ % cl : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$	C0596019	\N	\N
658	hr ( $nmbr$ % cl ) pvalue	C0596019	\N	\N
658	hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ b ( $nmbr$  $nmbr$ . $nmbr$ )	C0596019	\N	\N
658	hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ )	C0596019	\N	\N
658	hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$  $nmbr$ . $nmbr$ )	C0596019	\N	\N
658	hr ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$  $nmbr$ )	C0596019	\N	\N
658	hr ( $nmbr$ % cl )	C0596019	\N	\N
658	hr $nmbr$ and $nmbr$ % cl	C0596019	\N	\N
658	hr $nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$ *	C0596019	\N	\N
658	hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$ )	C0596019	\N	\N
658	hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ )	C0596019	\N	\N
658	hr $nmbr$ % cl	C0596019	\N	\N
658	hr  $nmbr$ % cl	C0596019	\N	\N
658	hazard ratio or difference $nmbr$ * ( $nmbr$ % cl ) p - value	C0596019;C1705241;C1705242;C1709380;C2985465	\N	\N
658	hazard ratio or difference $nmbr$ ( $nmbr$ % cl ) p - value	C0596019;C1705241;C1705242;C1709380;C2985465	\N	\N
658	estimated mean $nmbr$ % cl	C0444504;C0596019;C0750572;C2347634;C2348143	\N	\N
658	estimate ( $nmbr$ % cl )	C0596019;C0750572	\N	\N
658	difference in ls mean $nmbr$ ( $nmbr$ % cl )	C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143	\N	\N
658	difference ( $nmbr$ % cl )	C0596019;C1705241;C1705242	\N	\N
658	cl - $nmbr$ ]	C0596019	\N	\N
658	cl $nmbr$ %	C0596019	\N	\N
658	change in pav  mean ( $nmbr$ % cl )  %	C0058890;C0392747;C0443172;C0444504;C0596019;C1705241;C2347634;C2348143;C4319952	\N	\N
7	multivariable or ( $nmbr$ % ci )  p value *	C0008107;C1709380;C3259781	\N	\N
7	interaction p value 中	C1704675;C1709380	\N	\N
7	interaction p value ∗	C1704675;C1709380	\N	\N
7	interaction p value §	C1704675;C1709380	\N	\N
7	interaction p value *	C1704675;C1709380	\N	\N
658	bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per $nmbr$ patient - years of follow - up  rrr  relative risk reduction  yr  year . ^ treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < $nmbr$ or > $nmbr$ g i - $nmbr$ ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year $nmbr$ as covariates .	C0001924;C0009667;C0010294;C0019046;C0022661;C0022885;C0030705;C0032042;C0036773;C0039593;C0042027;C0080103;C0086706;C0126174;C0168634;C0201976;C0205345;C0229671;C0237455;C0242492;C0301630;C0374505;C0392366;C0392747;C0392756;C0439234;C0439508;C0441471;C0441833;C0443172;C0455271;C0456603;C0456984;C0486293;C0589120;C0596019;C0597277;C0600061;C0687744;C0728877;C0871208;C1137094;C1257890;C1293152;C1318330;C1442488;C1515976;C1518681;C1519504;C1521828;C1522577;C1524119;C1546774;C1547037;C1547039;C1549954;C1550100;C1561535;C1565830;C1626828;C1696465;C1704675;C1704685;C1705241;C1705428;C1705429;C1706408;C1708601;C1708728;C2986775;C3161035;C3274571;C3274659;C3541888;C3714583;C3831328;C3853906;C4281686;C4318744;C4319952;C4551656	\N	\N
658	adjusted or ( $nmbr$ % cl )	C0456081;C0596019	\N	\N
658	adjusted hr * ( $nmbr$ % cl ) pvalue	C0456081;C0596019	\N	\N
658	adjusted hr ( enl vs lcz ) ( $nmbr$ % cl )	C0456081;C0596019	\N	\N
658	adjusted hr ( $nmbr$ % cl )	C0456081;C0596019	\N	\N
658	adjusted $nmbr$ or ( $nmbr$ % cl )	C0456081;C0596019	\N	\N
658	adj . hr ( $nmbr$ % cl ) a	C0001552;C0596019;C2826286	\N	\N
658	[ $nmbr$ % cl ]	C0596019	\N	\N
658	( %  $nmbr$ % cl )	C0596019	\N	\N
658	( $nmbr$ % cl ) interaction	C0596019;C1704675	\N	\N
658	( $nmbr$ % cl )	C0596019	\N	\N
658	% risk reduction ( $nmbr$ % cl )	C0596019;C1137094	\N	\N
658	$nmbr$ cl )	C0596019	\N	\N
658	$nmbr$ ( $nmbr$ cl )	C0596019	\N	\N
658	$nmbr$ % cl	C0596019	\N	\N
657	kl $nmbr$ ( % )	C1366480;C1416656;C1704887	\N	\N
657	hmgcoa rl	C0047420;C1419337;C3539667	\N	\N
656	cox bsl onlyc	C1549954;C1565830	\N	\N
656	cox bsl + yr $nmbr$ hbd	C0439234;C1549954;C1565830	\N	\N
655	diabetes bl	C0005918;C0006413;C0011847;C0011849;C1552663;C2827109	\N	\N
655	bl mean ( cm )	C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109	\N	\N
655	bl h / y : unilateral	C0005918;C0006413;C0033727;C0205092;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284	\N	\N
655	bl h / y : bilateral	C0005918;C0006413;C0033727;C0238767;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284	\N	\N
655	bl bml > $nmbr$ kg / m ^	C0005918;C0006413;C1532718;C1552663;C2827109	\N	\N
655	bl bml > $nmbr$ ke / m ^	C0005918;C0006413;C0022558;C0369637;C0441923;C1552663;C2827109	\N	\N
655	bl bml < $nmbr$ kg / m ^	C0005918;C0006413;C1532718;C1552663;C2827109	\N	\N
655	bl bmioo kg / m ^	C0005918;C0006413;C1532718;C1552663;C2827109	\N	\N
655	bl alc < $nmbr$ . $nmbr$ %	C0005918;C0006413;C1424945;C1552663;C2827109;C3811058	\N	\N
655	bl	C0005918;C0006413;C1552663;C2827109	\N	\N
655	\\bl - sc n / n	C0005918;C0006413;C0282380;C1552663;C2827109	\N	\N
-10	caribbean	C0043122;C0206155;C1331005	\N	\N
653	cardiogenic shock during first $nmbr$ hr after randomization	C0034656;C0036980;C0205435;C1279901	\N	\N
653	cardiogenic shock	C0036980	\N	\N
652	nonischemic cardiomyopathy — no . ( % )	C0878544	\N	\N
652	nonischemic cardiomyopathy	C0878544	\N	\N
652	nonischemic	\N	\N	\N
652	non - ischaemic cardiomyopathy	C0349782;C1518422	\N	\N
652	ischemic cardiomyopathy	C0349782	\N	\N
652	ischaemic cardiomyopathy	C0349782	\N	\N
651	other cardiovascular risk factors	C0850624	\N	\N
651	nonglycemic cardiovascular risk factors	C0850624	\N	\N
651	major cerebrovascular	C0205082;C0205164;C1880018;C4318856;C4521762	\N	\N
651	cerebrovascular	C1880018	\N	\N
651	cardiovascular risk factors — no . { % )	C0850624	\N	\N
651	cardiovascular risk factors — no . / total no . ( % )	C0439175;C0439810;C0850624	\N	\N
651	cardiovascular risk factors and history — no . ( % )	C0019664;C0019665;C0262512;C0262926;C0850624;C1705255;C2004062	\N	\N
651	cardiovascular risk factors and history ( % )	C0019664;C0019665;C0262512;C0262926;C0850624;C1705255;C2004062	\N	\N
651	cardiovascular risk factors and history	C0019664;C0019665;C0262512;C0262926;C0850624;C1705255;C2004062	\N	\N
651	cardiovascular risk factors alone ( n = $nmbr$ )	C0205171;C0439044;C0679994;C0850624	\N	\N
651	cardiovascular risk factors  no . ( % )	C0850624	\N	\N
651	cardiovascular risk factors  n ( % )	C0850624	\N	\N
651	cardiovascular risk factors	C0850624	\N	\N
651	cardiovascular risk factor — no . { % )	C0850624	\N	\N
651	at least two cardiovascular risk factors	C0205448;C0850624	\N	\N
650	cardiovascular history 一 no . ( % )	C1880008	\N	\N
650	cardiovascular history — no . / total no . ( % )	C0439175;C0439810;C1880008	\N	\N
650	cardiovascular history — no . ( % )	C1880008	\N	\N
650	cardiovascular history	C1880008	\N	\N
649	secondary cardiovascular endpoint	C0007226;C3887460;C4528314	\N	\N
649	primary cardiovascular endpoint	C0007226;C2986535;C3887460	\N	\N
649	previous history of cardiovascular events	C0007226;C2004062;C3887460	\N	\N
649	no . of predictors of cardiovascular risk	C0007226;C0035647;C2698872;C3887460;C4552904	\N	\N
649	extended cardiovascular endpoint	C0007226;C0231448;C0231449;C0439792;C2349179;C2826544;C3887460	\N	\N
649	death from cardiovascular causes	C0007226;C0007465;C3887460	\N	\N
649	core cardiovascular endpoint	C0007226;C0444669;C1167518;C1706352;C1882467;C2349179;C2826544;C3274653;C3887460	\N	\N
649	cardiovascular status	C0007226;C0449438;C3887460	\N	\N
649	cardiovascular risk  n ( % )	C0007226;C0035647;C3887460;C4552904	\N	\N
649	cardiovascular risk	C0007226;C0035647;C3887460;C4552904	\N	\N
649	cardiovascular hospitalization	C0007226;C0019993;C3887460	\N	\N
649	cardiovascular hospitalisation §	C0007226;C0019993;C3887460	\N	\N
649	cardiovascular and respiratory	C0007226;C0521346;C1546767;C3887460	\N	\N
649	cardiovascular and oral hypoglycemic drugs - no . ( % )	C0007226;C0359086;C3887460	\N	\N
649	cardiovascular	C0007226;C3887460	\N	\N
649	any cardiovascular diseased	C0007226;C3887460	\N	\N
649	all cardiovascular	C0007226;C3887460	\N	\N
649	* per $nmbr$ participant years . composite of first occurrence death ( all cause )  nonfatal ml  or nonfatal stroke . cardiovascular death excluding those classified as “ unable to determine . ”	C0007226;C0008902;C0011065;C0015127;C0038454;C0040363;C0041260;C0205199;C0205435;C0243132;C0332196;C0439234;C0439526;C0566415;C0679646;C1279901;C1299582;C1306577;C1524003;C1547335;C1554210;C1705224;C1883351;C2698741;C2745955;C2828389;C3887460;C3887665;C4048706;C4082313;C4321405;C4552775;C4554048;C4554100	\N	\N
648	concomitant cardiovascular therapy — no . ( % )	C0007226;C0521115;C0587038;C1707479;C3887460	\N	\N
648	concomitant cardiovascular therapy ( taken > $nmbr$ days )	C0007226;C0439228;C0521115;C0587038;C1707479;C1883727;C3887460	\N	\N
648	concomitant cardiovascular therapy	C0007226;C0521115;C0587038;C1707479;C3887460	\N	\N
648	concomitant cardiovascular therapies — no . ( % )	C0007226;C0521115;C0587038;C1707479;C3887460	\N	\N
648	cardiovascular therapies — no . { % )	C0587038	\N	\N
647	prior myocardial infarction 一 no . ( % )	C0155668	\N	\N
647	prior myocardial infarction — no . { % )	C0155668	\N	\N
647	prior myocardial infarction — no . / total no . ( % )	C0155668;C0439175;C0439810	\N	\N
647	prior myocardial infarction — no . ( % )	C0155668	\N	\N
647	prior myocardial infarction yes	C0155668;C1549445;C1705108;C1710701	\N	\N
647	prior myocardial infarction ( % )	C0155668	\N	\N
647	prior myocardial infarction  no . / total no . ( % )	C0155668;C0439175;C0439810	\N	\N
647	prior myocardial infarction  n ( % )	C0155668	\N	\N
647	prior myocardial infarction  %	C0155668	\N	\N
647	prior myocardial infarction	C0155668	\N	\N
647	cardioembolic infarction  n ( % )	C0021308	\N	\N
647	cardioembolic	\N	\N	\N
647	anterior myocardial infarction — no . / total no . ( % )	C0340293;C0439175;C0439810	\N	\N
647	anterior myocardial infarction — no . ( % )	C0340293	\N	\N
647	angina class iii or iv prior myocardial infarction	C0022326;C0155668;C0264677;C4265176	\N	\N
647	> $nmbr$ prior myocardial infarction — no . ( % )	C0155668	\N	\N
646	years since myocardial infarction	C0027051;C0428953;C0439234;C2926063;C3810814;C4552959	\N	\N
646	type of myocardial infarction — no . ( % )	C0027051;C0332307;C0428953;C1547052;C2926063;C3810814;C4552959	\N	\N
646	time from qualifying myocardial infarction	C0027051;C0040223;C0428953;C1514624;C2926063;C3541383;C3810814;C4552959	\N	\N
646	suspected myocardial infarction	C0027051;C0332147;C0428953;C0750491;C2926063;C3810814;C4552959	\N	\N
646	qualifying myocardial infarction	C0027051;C0428953;C1514624;C2926063;C3810814;C4552959	\N	\N
646	previous stroke yes ( n  % ) previous myocardial infarction	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C3841753;C4552959	\N	\N
646	previous myocardial infarction — no . ( % )	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959	\N	\N
646	previous myocardial infarction ( % )	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959	\N	\N
646	previous myocardial infarction  no . ( % )	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959	\N	\N
646	previous myocardial infarction  n ( % )	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959	\N	\N
646	previous myocardial infarction	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959	\N	\N
646	nonfatal myocardial infarction ®	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	nonfatal myocardial infarction	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	non - fatal myocardial infarction	C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959	\N	\N
646	no previous myocardial infarction $nmbr$ / $nmbr$	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959	\N	\N
646	no previous myocardial infarction	C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959	\N	\N
646	no myocardial infarction at presentation ( n = $nmbr$ )	C0027051;C0428953;C0449450;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction — no . ( % )	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction §	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction within the previous $nmbr$ yr	C0027051;C0205156;C0428953;C0439234;C1552607;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction n ( % )	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction at presentation ( n = $nmbr$ )	C0027051;C0428953;C0449450;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction :	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction / cabg / pci	C0010055;C0027051;C0428953;C2926063;C3810814;C4049621;C4552959	\N	\N
646	myocardial infarction ( % )	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction  n ( % )	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction  ( % )	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	myocardial infarction	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	investigator - determined myocardial infarction	C0027051;C0035173;C0428953;C2926063;C3810814;C4552959	\N	\N
646	histor y of myocardial infarction	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
646	fatal myocardial infarction	C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959	\N	\N
646	cardiovasculardeath / myocardial infarction / stroke	C0027051;C0038454;C0428953;C2926063;C3810814;C4552959;C4554100	\N	\N
646	cardiovasculardeath	\N	\N	\N
646	cardiovascular death or nonfatal myocardial infarction	C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959	\N	\N
646	cardiovascular death  nonfatal myocardial infarction  nonfatal stroke	C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959	\N	\N
646	b . myocardial infarction	C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
645	sudden cardiac death §	C0085298	\N	\N
645	noncardiovascular death	C0011065;C1306577;C4082313;C4552775	\N	\N
645	noncardiovascular	\N	\N	\N
645	cardiac death	C0376297	\N	\N
7	interaction p value $nmbr$ . $nmbr$	C1704675;C1709380	\N	\N
644	cardiac therapy §	C3654025	\N	\N
644	cardiac therapy  n ( % ) d	C3654025	\N	\N
644	cardiac therapy	C3654025	\N	\N
643	rvfac ( % )	\N	\N	\N
643	elevation of cardiac biomarker levels — no . / total no . ( % )	C0439175;C0439775;C0439810;C0441889;C0702240;C1271630	\N	\N
643	cardiac procedure :	C1279986	\N	\N
643	cardiac biomarker status !	C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302	\N	\N
643	cardiac biomarker elevation	C0439775;C0702240;C1271630	\N	\N
643	cardiac biomarker  n ( % )	C1271630	\N	\N
643	arvfac ( per $nmbr$ % )	\N	\N	\N
643	aborted cardiac arrest	C0018790;C1550015;C1609614;C4085625;C4318470;C4553105	\N	\N
-10	phenobarbital	C0031412	\N	\N
641	reinfarction	\N	\N	\N
641	prior myocardial intarction	C0027061;C0332152;C1522564;C2826257	\N	\N
641	parental history of myocardial infarction before age $nmbr$ y yes	C0001779;C0030551;C1275835;C1549445;C1705108;C1710701	\N	\N
641	parental history of myocardial infarction before age $nmbr$ y	C0001779;C0030551;C1275835	\N	\N
641	parental history of myocardial infarction before $nmbr$ yr of age ( % )	C0001779;C0030551;C0439234;C1275835	\N	\N
641	history of myocardial infarction ( % )	C1275835	\N	\N
641	history of myocardial infarction  n ( % )	C1275835	\N	\N
641	history of myocardial infarction	C1275835	\N	\N
641	history myocardial infarction	C0155668;C1275835	\N	\N
641	fatal or nonlatal myocardial inlarctlon	C0027061;C1302234;C1522564;C1705232	\N	\N
640	useofmedical therapyathospitaldischarge	\N	\N	\N
640	stenting plus medical therapy ( n = $nmbr$ )	C0038257;C0418981;C2348535	\N	\N
640	stent plus medical therapy	C0038257;C0418981	\N	\N
640	medical therapy only ( n = $nmbr$ )	C0205171;C0418981;C1720467	\N	\N
640	medical therapy only	C0205171;C0418981;C1720467	\N	\N
640	medical therapy before admission	C0184666;C0418981;C0809949	\N	\N
640	medical therapy alone	C0205171;C0418981;C0439044;C0679994	\N	\N
640	medical therapy ( n = $nmbr$ )	C0418981	\N	\N
640	medical therapy	C0418981	\N	\N
640	medical therapies	C0418981	\N	\N
639	medical historv	C0199168;C0205476	\N	\N
639	first medical contact — no . ( % ) §	C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666	\N	\N
639	first medical contact	C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666	\N	\N
638	minimal important change threshold ( improvement ) a	C0449864;C2986411;C3845594;C3898777;C4084912	\N	\N
638	medically important infectionsa	C3898777;C4084912	\N	\N
637	indian ( indian subcontinent )	C0454693	\N	\N
637	indian ( american ) or alaska native	C0596070;C0682125;C1524069	\N	\N
637	indian	C1524069	\N	\N
637	american indian or native alaskan	C0002460;C0682125	\N	\N
637	american indian or alaskan	C0002460;C0238611	\N	\N
637	american indian or alaska	C0001905;C0002460	\N	\N
637	american indian or	C0002460	\N	\N
637	american indian / native alaskan	C0002460;C0682125	\N	\N
637	american indian /	C0002460	\N	\N
637	american indian  alaskan native  or aboriginal canadian	C0002460;C0238611;C0238884;C0302891;C0935542	\N	\N
637	american indian	C0002460	\N	\N
636	rarertd antocagibtcn before andorrtzafon	\N	\N	\N
636	indomethacin	C0021246	\N	\N
635	≤ median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	£ median ( $nmbr$ . $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	£ median ( $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	£ median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	years since mi ( median	C0439234;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814	\N	\N
635	wt  second  median	C0205436;C0457385;C0549183;C0565930;C0876920;C1561503;C1705190;C1883559;C2347635;C2348144;C2700323;C2939193	\N	\N
635	waisvhip > = median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	waist / hip < median	C0019552;C0022122;C0230097;C0549183;C0876920;C1505163;C2347635;C2348144;C2939193;C3538851;C4284725	\N	\N
635	urine acr > = median	C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137	\N	\N
635	urine acr < median	C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137	\N	\N
635	urinary albumin / creatinine ratio  median mg / g ( range )	C0455271;C0549183;C0876920;C1300563;C1318330;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	triglycerides  median ( range )	C0041004;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	triglycerides  median ( q $nmbr$ : q $nmbr$ )	C0041004;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	total ige levelx ( iu / ml )  median ( range )	C0439175;C0439458;C0439810;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	total cholesterol ( median  iqr )  mg / dl	C0201950;C0439269;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	tngtycerides a median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	tngtycerides < median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	tngtycendes a median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	tnglycendes < median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	time to end - of - study ivus  median ( iqr )  days	C0439548;C0444930;C0549183;C0557651;C0876920;C1456025;C2347635;C2348144;C2603343;C2746065;C2939193	\N	\N
635	time from symptom onset of ra  years  median	C0439234;C0549183;C0876920;C1320528;C2347635;C2348144;C2939193;C3538806;C4048756	\N	\N
635	time from study drug administration to coronary revascularization  median ( iqr )  h	C0013175;C0033727;C0040227;C0150270;C0206209;C0369286;C0441932;C0549183;C0564385;C0876920;C0877341;C2347635;C2348144;C2349982;C2939193;C3469597;C4528284	\N	\N
635	time from ra diagnosis  years  median	C0011900;C0549183;C0556970;C0876920;C1704338;C1704656;C2347635;C2348144;C2939193;C3538806;C4048756	\N	\N
635	time from hospital admission to pci  h  median ( q $nmbr$  q $nmbr$ )	C0019994;C0033727;C0040223;C0369286;C0441932;C0549183;C0564385;C0876920;C1510665;C1959907;C2347635;C2348144;C2939193;C3541383;C4049621;C4528284	\N	\N
635	time from  median ( iqr )  h	C0033727;C0040223;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C3541383;C4528284	\N	\N
635	tg ( mmol / l  median )	C0337445;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	\N	\N
635	tg  mmol / l ( mg / dl ) [ median ]	C0337445;C0549183;C0876920;C2347635;C2348144;C2939193;C3642216;C3898312	\N	\N
635	tg  median ( sdy rng / cjl	C0337445;C0549183;C0876920;C1424906;C2347635;C2348144;C2939193	\N	\N
635	tg  median ( interquartile range )	C0337445;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193	\N	\N
635	systolic blood pressure  mm hg  median ( range )	C0439475;C0488055;C0549183;C0871470;C0876920;C1306620;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	score on nih stroke scale — median ( iqr )	C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231	\N	\N
635	score on modified rankin scale — median ( iqr )	C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C2984908;C3854213;C4050231	\N	\N
635	score on modified mini - mental state examination — median ( iqr )	C0549183;C0876920;C2347635;C2348144;C2939193;C4304091	\N	\N
635	score improvement  baseline to week $nmbr$  median ( iqr )	C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411;C4050231	\N	\N
635	sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .	C0000545;C0003695;C0042295;C0085805;C0282379;C0428883;C0439175;C0439632;C0439810;C0441833;C0444504;C0456603;C0488055;C0536221;C0549183;C0578022;C0687744;C0871470;C0876920;C1235746;C1257890;C1306620;C1519504;C1547037;C1552839;C1705241;C1705242;C1705428;C1705429;C1709380;C1711350;C1882141;C1882932;C2316832;C2347634;C2347635;C2348143;C2348144;C2699193;C2939193;C3813197;C4281799;C4554792	\N	\N
635	sbp > median ( n = $nmbr$ )	C0085805;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	sbp < median ( n = $nmbr$ o $nmbr$ )	C0085805;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	sbp ( mm hg )  median ( iqr )	C0085805;C0439475;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	s median	C0549183;C0565930;C0876920;C2347635;C2348144;C2603362;C2939193	\N	\N
635	pulse pressure ( median $nmbr$ . $nmbr$ ]	C0549183;C0876920;C0949236;C2347635;C2348144;C2939193	\N	\N
635	percent improvement  baseline to week $nmbr$  median ( iqr )	C0168634;C0332174;C0439165;C0439230;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411	\N	\N
635	pasi  median ( range ) * *	C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4528685	\N	\N
635	number of visits  median	C0549183;C0876920;C1549755;C2347635;C2348144;C2939193	\N	\N
635	nt - probnp  median pg / ml	C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193	\N	\N
635	nt - probnp  median ( iqr )  pg / ml	C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193	\N	\N
635	non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = $nmbr$  $nmbr$ )	C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193	\N	\N
635	non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = $nmbr$  $nmbr$ )	C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193	\N	\N
635	msfc timed $nmbr$ - foot walk test  median seconds	C0016504;C0347981;C0392761;C0457385;C0549183;C0876920;C2346504;C2347635;C2348144;C2348613;C2348704;C2939193;C4277740	\N	\N
635	months from mi — median ( iqr )	C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814	\N	\N
635	minutes from symptom onset to prehospital ecg  median ( iqr )	C0439232;C0549183;C0700321;C0702093;C0876920;C1282918;C1623258;C2347166;C2347635;C2348144;C2939193;C4086878	\N	\N
635	minutes from prehospital ecg to pci  median ( iqr )	C0439232;C0549183;C0700321;C0702093;C0876920;C1282918;C1623258;C2347166;C2347635;C2348144;C2939193;C4049621	\N	\N
635	minutes from pre - pci angiography to post - pci angiography  median ( iqr )	C0002978;C0332152;C0439232;C0549183;C0687676;C0700321;C0702093;C0740175;C0876920;C1282918;C1704687;C2257086;C2347166;C2347635;C2348144;C2939193;C3469826;C3669034;C4049621	\N	\N
635	medians ( iqr )	C0549183	\N	\N
635	median — yr	C0439234;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median — vr	C0549183;C0876920;C2347635;C2348144;C2939193;C3476815	\N	\N
635	median §	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median time to event ( weeks )	C0040223;C0439230;C0441471;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383;C4019010	\N	\N
635	median time since diagnosis * ( range )  yr	C0011900;C0040223;C0439234;C0549183;C0876920;C1514721;C1704338;C1704656;C2347635;C2348144;C2348147;C2939193;C3541383;C3542016	\N	\N
635	median time delay ( interquartile range ) — min	C0522486;C0549183;C0702093;C0876920;C1524029;C1711350;C2347635;C2348144;C2939193;C3813700	\N	\N
635	median seconds	C0457385;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median of jsw	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median nt - probnp ( iqr ) – pg / ml	C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median n - terminal probnp ( iqr ) — pg / ml	C0439297;C0549183;C0669479;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median feno  ppba	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median egfr ( interquartile range )	C0549183;C0876920;C1711350;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682	\N	\N
635	median duration oftype $nmbr$ diabetes ( iqr ) — yr	C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	\N	\N
635	median delay ( h ) §	C0033727;C0205421;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284	\N	\N
635	median daily dose - iu ™	C0049272;C0439453;C0549183;C0694756;C0876920;C2347635;C2348070;C2348144;C2939193	\N	\N
635	median change  %	C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952	\N	\N
7	interaction p value !	C1704675;C1709380	\N	\N
635	median ( range ) total ige level ( iuml ~ ’ ) $nmbr$	C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1514721;C1547707;C2347635;C2348144;C2348147;C2939193;C2946261;C3542016	\N	\N
635	median ( range )	C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	median ( q $nmbr$ – q $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median ( q $nmbr$ : q $nmbr$ ) total daily insulin dose $nmbr$	C0021641;C0549183;C0876920;C1533581;C1579433;C2347635;C2348070;C2348144;C2939193;C3714501	\N	\N
635	median ( q $nmbr$ : q $nmbr$ ) tgs	C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193	\N	\N
635	median ( q $nmbr$ : q $nmbr$ ) lp ( a )  mg / dl	C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379	\N	\N
635	median ( q $nmbr$ : q $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
342	esrd	C0022661;C0035078;C2316810	\N	\N
635	median albumin / creatinine ratio ( g / mg )	C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761	f	1902
635	median cardiac troponin t ( iqr ) — pg / ml	C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889	f	1903
635	median c - reactive protein — mg / dl ^	C0006560;C0439269;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285	f	286
635	median ( q $nmbr$  q $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median ( iqr ) — yr	C0439234;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median ( iqr ) cholesterol	C0008377;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median ( iqr ) change from baseline to week $nmbr$ in psa - modified total shs score	C0168634;C0332174;C0392747;C0439175;C0439230;C0439810;C0443172;C0449820;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C3810537;C3813209;C3889737;C4050231;C4319952	\N	\N
635	median ( iqr ) age  years	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
635	median ( iqr ) admission data	C0184666;C0549183;C0809949;C0876920;C1511726;C2347635;C2348144;C2939193;C3245479;C3714741	\N	\N
635	median ( iqr )  h	C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284	\N	\N
635	median ( iqr )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median ( iq range )	C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	median ( interquartile range )	C0549183;C0876920;C1711350;C2347635;C2348144;C2939193	\N	\N
635	median  y ( range )	C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	median  range	C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	median  ml	C0439526;C0549183;C0876920;C1705224;C2347635;C2348144;C2939193;C3887665	\N	\N
635	median  mg / dl	C0439269;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median  iqr )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median  iqr	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	mean age  y  median ( range )	C0001779;C0444504;C0549183;C0876920;C1514721;C2347634;C2347635;C2348143;C2348144;C2348147;C2939193;C3542016	\N	\N
635	maximum cimt < median	C0549183;C0806909;C0876920;C1552615;C2347635;C2348144;C2826546;C2939193	\N	\N
635	lvef  %  median ( iqr )	C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	lp ( a )  mg / dl  median ( q $nmbr$ : q $nmbr$ )	C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379	\N	\N
635	lp ( a )  median ( q $nmbr$ : q $nmbr$ )	C0065058;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379	\N	\N
635	less than the median	C0439092;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	less than median	C0439092;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	laboratory values at randomization ( median and iqr )	C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904	\N	\N
635	laboratory parameters  median ( iqr )	C0022877;C0449381;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904	\N	\N
635	index event to randomization  median ( iqr )  h	C0033727;C0034656;C0369286;C0441471;C0441932;C0549183;C0564385;C0600653;C0876920;C0918012;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C4019010;C4528284	\N	\N
635	ige ( ku / l )  median ( range ) c	C0439340;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	hscrp ( mg / l )  median ( min – max )	C0439420;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	hscrp  mg / l  median ( min – max )	C0439420;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	hscrp  median ( min  max )  mg / l	C0549183;C0876920;C2347635;C2348144;C2827895;C2939193	\N	\N
635	homa_ir  median ( q $nmbr$  q $nmbr$ )  % / $nmbr$	C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193	\N	\N
635	homa_ % b tx difference vs pbo  median change from baseline ( se ) $nmbr$	C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952	\N	\N
635	homa_ % b  median ( q $nmbr$  q $nmbr$ )  %	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	hbak > median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	hbak < median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	hba < median	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758	\N	\N
635	fasting tgs  median ( q $nmbr$ : q $nmbr$ )	C0015663;C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193	\N	\N
342	erd *  n ( % )	\N	\N	\N
635	fasting plasma glucose in mmol / l ( median ( q $nmbr$  q $nmbr$ ) [ n ] )	C0549183;C0583513;C0876920;C1532563;C2347635;C2348144;C2939193	f	1896
635	hba $nmbr$ c in % ( median ( q $nmbr$  q $nmbr$ ) [ n ] )	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758	f	1897
635	hba $nmbr$ c ( % ) ( median ( iqr )	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758	f	1897
635	hbalca median	C0549183;C0876920;C2347635;C2348144;C2939193	f	1897
635	hbalc in %  median ( iqr )	C0549183;C0876920;C2347635;C2348144;C2939193	f	1897
635	hbalc < median	C0549183;C0876920;C2347635;C2348144;C2939193	f	1897
635	hbalc > median	C0549183;C0876920;C2347635;C2348144;C2939193	f	1897
635	heart rate ( median $nmbr$ . $nmbr$ }	C0018810;C0549183;C0876920;C2347635;C2348144;C2939193	f	1898
635	insulin dose ( iu / day )  median	C0366513;C0439465;C0549183;C0876920;C2347635;C2348144;C2939193	f	1899
635	insulin  median ( ql  q $nmbr$ )  pmol / l	C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501	f	1899
635	insulin  median ( q $nmbr$  q $nmbr$ )  pmol / l	C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501	f	1899
635	length of stent < median	C0449462;C0549183;C0876920;C2347635;C2348144;C2939193	f	1900
635	length of stent > median	C0449462;C0549183;C0876920;C2347635;C2348144;C2939193	f	1900
635	duration from hospital admission to pci  h ( median  iqr )	C0019994;C0033727;C0369286;C0441932;C0449238;C0549183;C0564385;C0876920;C1510665;C1959907;C2347635;C2348144;C2926735;C2939193;C4049621;C4528284	\N	\N
635	difference  % median	C0549183;C0876920;C1705241;C1705242;C2347635;C2348144;C2939193	\N	\N
635	data represent number of patients ( % ) or mean ( standard deviation )  unless otherwise indicated . a self - reported information . bc physician - diagnosed diabetes or fasting plasma glucose ≥ $nmbr$ mg / dl or hemoglobin a $nmbr$ c ≥ $nmbr$ . $nmbr$ % . d physician - diagnosed hypertension or systolic blood pressure ≥ $nmbr$ mmhg or diastolic blood pressure ≥ $nmbr$ mmhg . median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .	C0006041;C0011847;C0011849;C0011900;C0015663;C0019020;C0020538;C0023820;C0031831;C0062152;C0073187;C0178587;C0202042;C0205251;C0332173;C0337445;C0428883;C0439269;C0439475;C0444504;C0455280;C0488055;C0549183;C0681906;C0804815;C0871420;C0871470;C0876920;C1305849;C1306620;C1442989;C1444656;C1511726;C1533716;C1550472;C1711350;C1828170;C1882932;C1963138;C2347634;C2347635;C2348143;C2348144;C2360800;C2700446;C2828392;C2939193;C2984916;C3245479;C3714741;C3889898;C3890211;C4048187;C4321351;C4484261;C4522223	\N	\N
635	clinical variables  median ( iqr )	C0205210;C0439828;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	change from baseline  median ( iqr )	C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952	\N	\N
635	below median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	baseline total pcsk $nmbr$ level by median	C0168634;C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C2347635;C2348144;C2939193;C2946261	\N	\N
635	baseline tg  ( mg / dl )  median ( iqr )	C0168634;C0337445;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline tav - > = median ( n = $nmbr$  $nmbr$ )	C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline tav - < median ( n = $nmbr$  $nmbr$ )	C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline scales  median ( range )	C0168634;C0175659;C0222045;C0349674;C0549183;C0876920;C1442488;C1514721;C1947916;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	baseline pav - > = median ( n = $nmbr$  $nmbr$ )	C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline pav - < median ( n = $nmbr$  $nmbr$ )	C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline median [ mg / l ]	C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline median ( iq range )	C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
635	baseline median  mg / dl	C0168634;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline median	C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
635	baseline free pcsk $nmbr$ level by median	C0168634;C0332296;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C1880497;C1996904;C2347635;C2348144;C2939193;C2946261	\N	\N
635	at or above the median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	at or above median	C0549183;C0876920;C1282910;C1552828;C2347635;C2348144;C2939193	\N	\N
635	a median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	a $nmbr$ c > = median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	a $nmbr$ c < median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	a $nmbr$ c < $nmbr$ . $nmbr$ % ( median )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	a $nmbr$ = $nmbr$ . $nmbr$ % ( median )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	^ median > median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	^ median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
625	baseline vertebral fracture	C0080179;C0168634;C1442488	\N	\N
635	age ( median [ iqr ] )  y	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	f	1890
635	age  median ( iqr )  years	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	f	1890
635	age - years  median ( iqr )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	f	1890
635	bmi ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ]	C0039725;C0039738;C0549183;C0876920;C1420718;C1532718;C2347635;C2348144;C2923536;C2939193;C4282123;C4285344	f	1891
635	bmi * ( kg / m $nmbr$ )  median ( q $nmbr$  q $nmbr$ )	C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193	f	1891
635	bmi  median ( sd )  kg / m $nmbr$	C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2699239;C2939193	f	1891
635	c - peptide  median ( q $nmbr$  q $nmbr$ )  nmol / l	C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193	f	1892
635	c - peptide  median ( ql  q $nmbr$ )  nmol / l	C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193	f	1892
635	dactylitis score at baseline  median ( iqr ) week $nmbr$	C0168634;C0239161;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C4050231	f	492
635	c - reactive protein  median ( iqr )  mg / l	C0006560;C0439268;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285	f	286
635	c - reactive protein  median ( q $nmbr$  q $nmbr$ )	C0006560;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285	f	286
635	crp median ( se )  rng / l	C0036919;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285	f	286
635	crp ( mg / l ) [ b ]  median ( min - max )	C0439420;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285	f	286
635	crp [ mg / l ]  median	C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285	f	286
635	> median ( $nmbr$ mm )	C0549183;C0876920;C2347635;C2348144;C2939193;C4330985;C4554674	\N	\N
635	> median ( $nmbr$ kg )	C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209	\N	\N
635	> median ( $nmbr$ . $nmbr$ years ) — number / n ( % )	C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> median ( $nmbr$ . $nmbr$ ) — number / n ( % )	C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> median ( $nmbr$ . $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> median ( $nmbr$ ) — number / n ( % )	C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> median ( $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> median ( $nmbr$ % )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> median $nmbr$ . $nmbr$	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	> = median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	< median { $nmbr$ days )	C0439228;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	< median ( $nmbr$ kg )	C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209	\N	\N
635	< median ( $nmbr$ . $nmbr$ years ) — number / n ( % )	C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	< median ( $nmbr$ . $nmbr$ ) — number / n ( % )	C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	< median ( $nmbr$ . $nmbr$ )	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	< median ( $nmbr$ ) — number / n ( % )	C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	< median $nmbr$ . $nmbr$	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	< median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	- median tg ( iqr )	C0337445;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	- median pulse pressure ( mm hg ) ( iqr )	C0439475;C0549183;C0876920;C0949236;C2347635;C2348144;C2939193	\N	\N
635	* data reported as n ( % ) or median ( quartiles $nmbr$  $nmbr$ ) .	C0549183;C0684224;C0700287;C0876920;C1511726;C2347635;C2348144;C2828255;C2939193;C3245479;C3714741;C4319718	\N	\N
635	( median  h )	C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284	\N	\N
635	& median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
635	% change ( median  q $nmbr$  q $nmbr$ )	C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952	\N	\N
634	no . of days to homa - ir testing — median ( iqr )	C0022065;C0022071;C0039593;C0392366;C0439228;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193	\N	\N
634	homa > median	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
634	homa . ir  median ( ql  q $nmbr$ )  % / $nmbr$	C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193	\N	\N
634	homa . % b  median ( ql  q $nmbr$ )  %	C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
634	homa - p	\N	\N	\N
634	homa - ir  median ( q $nmbr$  q $nmbr$ )	C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193	\N	\N
634	homa - b	\N	\N	\N
634	homa	\N	\N	\N
633	zotarolimust	\N	\N	\N
633	zotarolimus - eluting	C1700035	\N	\N
633	zotarolimus	C1700035	\N	\N
633	sirolimus eluting stent	C0038257;C0072980	\N	\N
633	sirolimus - eluting stent use  n ( % )	C0038257;C0042153;C0072980;C0457083;C1947944	\N	\N
633	sirolimus - eluting	C0072980	\N	\N
633	sirolimus	C0072980	\N	\N
633	everolimus - eluting	C0541315	\N	\N
633	everolimus	C0541315	\N	\N
632	c $nmbr$ e $nmbr$ fab bolus ( n = $nmbr$ )	C1186706;C1511237;C1705509;C3812160	\N	\N
632	c $nmbr$ e $nmbr$ fab bolus	C1186706;C1511237;C1705509;C3812160	\N	\N
632	bolus of heparin given	C0019134;C0770546;C1186706;C1442162;C1511237;C1550718;C1705509;C1947971;C3244317;C3812160	\N	\N
632	bolus and corrections	C1186706;C1511237;C1705509;C1705565;C1947976;C3812160	\N	\N
632	bolus alone	C0205171;C0439044;C0679994;C1186706;C1511237;C1705509;C3812160	\N	\N
632	bolus administered — no . ( % )	C1186706;C1511237;C1521801;C1705509;C3812160	\N	\N
632	bolus	C1186706;C1511237;C1705509;C3812160	\N	\N
632	basal plus bolus	C0205112;C0332287;C1186706;C1511237;C1705509;C3812160	\N	\N
631	systemic embolism	C0013922;C0205373;C1704212	\N	\N
631	peripheral embolism	C0013922;C0205100;C1704212	\N	\N
631	non cns embolism	C0013922;C1518422;C1704212;C3714787	\N	\N
631	embolism	C0013922;C1704212	\N	\N
631	cns systemic embolism	C0013922;C0205373;C1704212;C3714787	\N	\N
630	pulmonary embolism ± deep vein thrombosis	C0034065;C0149871;C0226514;C0852030	\N	\N
630	pulmonary embolism	C0034065	\N	\N
630	previous deep - vein thrombosis or pulmonary embolism	C0034065;C0149871;C0205156;C1552607	\N	\N
630	neither deep - vein thrombosis nor pulmonary embolism §	C0034065;C0149871	\N	\N
630	neither deep - vein thrombosis nor pulmonary embolism ^	C0034065;C0149871	\N	\N
630	deep - vein thrombosis or pulmonary embolism — no . ( % )	C0034065;C0149871	\N	\N
630	both deep - vein thrombosis and pulmonary embolism	C0034065;C0149871	\N	\N
629	metabolism and nutrition	C0025519;C0025520;C0028707;C0392209;C0518896;C1442959	\N	\N
629	glucose metabolism	C0596620	\N	\N
629	data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < $nmbr$ . $nmbr$ vs . non - epa . § p < $nmbr$ . $nmbr$ vs . non - epa	C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0205251;C0221099;C0439165;C0444504;C0455280;C0549183;C0580545;C0596620;C0684224;C0700287;C0871420;C0876920;C1154908;C1442989;C1444656;C1511726;C1518422;C1549488;C1550472;C1561533;C1706005;C1711350;C1828170;C2347634;C2347635;C2348143;C2348144;C2828392;C2939193;C3245479;C3714741;C3890211;C4048187;C4319718;C4321351;C4522223	\N	\N
628	undetermined  other  or cardioembolism	C0205258;C3536725;C4082977	\N	\N
628	cardioembolism	\N	\N	\N
627	table $nmbr$ . selected baseline characteristics of the study patients . *	C0030705;C0039224;C0168634;C0557651;C1442488;C1568011;C1706074;C1707391;C2603343;C4684572	\N	\N
625	baseline uric acid	C0041980;C0168634;C1442488	\N	\N
627	p < $nmbr$ . $nmbr$ ) between the study groups in any of the baseline characteristics . ace	C0369773;C0441849;C0557651;C0681848;C1452534;C1959644;C2603343;C2603361;C4284014;C4684572	\N	\N
627	no baseline characteristics	C4684572	\N	\N
627	endpoint / baselinec	C2349179;C2826544	\N	\N
627	endpoint / baseline	C0168634;C1442488;C2349179;C2826544	\N	\N
627	baselinec	\N	\N	\N
627	baseline characteristics	C4684572	\N	\N
626	weight at baseline	C1303013	\N	\N
626	baseline body weight quartile	C1303013;C2828255	\N	\N
625	without hypertension at baseline to hypertension	C0020538;C0168634;C1442488;C1963138	\N	\N
625	without baseline vertebral fracture	C0080179;C0168634;C1442488	\N	\N
625	with baseline vertebral fracture	C0080179;C0168634;C1442488	\N	\N
625	vertebral fractures at baseline	C0080179;C0168634;C1442488	\N	\N
625	using alendronate at baseline ( % )	C0102118;C0168634;C1442488;C1524063	\N	\N
625	use at baseline  n	C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
625	use at baseline	C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
625	uas $nmbr$ {	\N	\N	\N
625	triglycerides at baseline	C0041004;C0168634;C1442488	\N	\N
625	treated at baseline	C0168634;C1442488;C1522326	\N	\N
625	thienopyridine at baseline	C0168634;C1120149;C1442488	\N	\N
625	systolic  treated at baseline	C0039155;C0168634;C1442488;C1522326	\N	\N
625	supine after $nmbr$ minutes change from baseline	C0038846;C0168634;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1442488;C1705241;C2347166;C4319952	\N	\N
625	standing after $nmbr$ minutes change from baseline	C0168634;C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1442488;C1705241;C2347166;C4319952	\N	\N
625	standing after $nmbr$ minute change from baseline	C0168634;C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1442488;C1705241;C2347166;C4319952	\N	\N
625	selected baseline medications	C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232	\N	\N
625	seizure types reported during baseline  n ( % ) a	C0036572;C0168634;C0332307;C0684224;C0700287;C1442488;C1959629;C4319718;C4553401	\N	\N
625	seizure types reported during baseline  b n ( % )	C0036572;C0168634;C0332307;C0684224;C0700287;C1442488;C1959629;C4319718;C4553401	\N	\N
625	respiratory medication taken at baseline  n ( % )	C0168634;C0418986;C1442488;C1883727	\N	\N
625	remission by : baseline duration of steroid	C0038317;C0168634;C0814126;C1442488	\N	\N
625	randomised patients with > $nmbr$ % bsa psoriasis skin involvement at baseline	C0030705;C0033860;C0168634;C0444099;C1123023;C1314939;C1442488;C4520765	\N	\N
625	radiographic progression based on change from baseline > sdc	C0168634;C0242656;C0392747;C0443172;C0444708;C0449258;C1419891;C1442488;C1527178;C1705241;C1705938;C3273112;C4319952	\N	\N
625	ppi use at baseline	C0042153;C0168634;C0358591;C0457083;C0871125;C1442488;C1947944;C3811894	\N	\N
625	planned thienopyridine at baseline	C0168634;C1120149;C1301732;C1442488	\N	\N
625	percent atheroma volume at baseline	C0168634;C0264956;C1442488;C1690016;C3887614	\N	\N
625	patients without syndesmophytes at baseline	C0030705;C0168634;C0221690;C1442488	\N	\N
625	patients with syndesmophytes at baseline	C0030705;C0168634;C0221690;C1442488	\N	\N
625	pah therapy at baseline	C0030123;C0039798;C0087111;C0168634;C1363945;C1442488;C3203102;C4284467	\N	\N
625	one at baseline	C0168634;C0205447;C1442488	\N	\N
625	on steroid at baseline	C0038317;C0168634;C1442488	\N	\N
625	on statins at baseline	C0168634;C0360714;C1442488	\N	\N
625	ocs at baseline	C0168634;C1442488	\N	\N
625	normonatremic ( > $nmbr$ meq / l ) at baseline	C0168634;C0439375;C1442488	\N	\N
625	none at baseline	C0168634;C1442488	\N	\N
625	non - smokers ( at baseline )	C0168634;C0337672;C1442488;C4554605	\N	\N
625	no new jsn among patients with ≥ $nmbr$ uninvolved joint at baseline ¶	C0022417;C0030705;C0168634;C0205314;C0205429;C0392905;C1442488;C1706309	\N	\N
625	no new erosions among patients with ≥ $nmbr$ uninvolved joint at baseline ¶	C0022417;C0030705;C0168634;C0205314;C0205429;C0333307;C0392905;C1442488;C1706309;C1959609	\N	\N
625	no immunosuppressive agents at baseline	C0021081;C0168634;C1442488	\N	\N
625	no hospitalization in the past $nmbr$ months prior to baseline ( ref )	C0019993;C0168634;C1425988;C1442488;C4331910	\N	\N
625	no aspirin at baseline	C0004057;C0168634;C1442488	\N	\N
625	nihss at baseline	C0168634;C1442488;C1697238	\N	\N
625	mmrc at baseline	C0168634;C1442488;C3826977	\N	\N
625	microalbuminuria at baseline ( $nmbr$ % of patients treated )	C0030705;C0168634;C0730345;C1442488;C1522326	\N	\N
625	methotrexate use at baseline	C0025677;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
625	methotrexate dose at baseline	C0025677;C0168634;C0178602;C0869039;C1114758;C1442488	\N	\N
625	mental activities updrs subscore ( baseline )  mean ( sd )	C0168634;C0229992;C0441655;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721	\N	\N
625	memantine use at baseline  no . ( % )	C0025242;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
625	medication use at baseline — no . ( % )	C0168634;C0240320;C1442488	\N	\N
625	medication use at baseline - n ( % )	C0168634;C0240320;C1442488	\N	\N
625	medication use at baseline  n ( % )	C0168634;C0240320;C1442488	\N	\N
625	medication in use at the baseline	C0013227;C0042153;C0150312;C0168634;C0332285;C0457083;C1442488;C1707101;C1947944;C3244316;C4284232	\N	\N
625	mean change from baseline in acq overall score ( sd ) *	C0168634;C0282416;C0392747;C0443172;C0444504;C0449820;C1442488;C1561607;C1705241;C2347634;C2348143;C2699239;C2919686;C4050231;C4319952	\N	\N
625	mean change from baseline  %	C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
625	mean baseline ucdai score	C0168634;C0444504;C0449820;C1442488;C2347634;C2348143;C4050231	\N	\N
625	mean baseline nasal congestion score	C0027424;C0168634;C1442488;C3533236;C4554631	\N	\N
625	mean baseline ldl - c ( mmol / l )	C0168634;C0444504;C1442488;C1532563;C2347634;C2348143	\N	\N
625	mean baseline ei score	C0022067;C0168634;C0444504;C0449820;C1414370;C1442488;C2347634;C2348143;C2348481;C4050231	\N	\N
625	mean baseline ( n )	C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
625	mean arterial pressure  baseline	C0168634;C0428886;C1442488	\N	\N
625	macroalbuminuria at baseline ( $nmbr$ % of patients treated )	C0030705;C0168634;C1442488;C1522326	\N	\N
625	low - dose aspirin use at baseline yes	C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320	\N	\N
625	level of thyroperoxidase antibody at baseline	C0021965;C0168634;C0428536;C0441889;C0456079;C0487652;C1318460;C1364508;C1429427;C1442488;C1547707;C2946261;C3272921	\N	\N
625	ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening	C0023824;C0168634;C0202117;C0220908;C0220909;C1442488;C1532563;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
625	ldl - c in mmol / l ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] )	C0036919;C0168634;C0332174;C0392747;C0439230;C0443172;C0444504;C1442488;C1532563;C1705241;C2347634;C2348143;C2699239;C4319952	\N	\N
625	ldl - c at baseline :	C0168634;C1442488	\N	\N
625	killip at baseline	C0168634;C1442488	\N	\N
625	intensified baseline ( n - $nmbr$ )	C0168634;C1442488	\N	\N
625	in remission at maintenance study baseline	C0024501;C0168634;C0544452;C0557651;C0687702;C1442488;C2603343	\N	\N
625	improvement from baseline ≥   $nmbr$	C0168634;C1442488;C2986411	\N	\N
625	immunosuppressive agents at baseline	C0021081;C0168634;C1442488	\N	\N
625	icsusers atbaseline  n ( % )	\N	\N	\N
625	ics use at baseline : yes	C0042153;C0168634;C0457083;C0815320;C1442488;C1549445;C1705108;C1710701;C1947944;C4551720	\N	\N
625	ics use at baseline  n ( % )	C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720	\N	\N
625	ics use at baseline	C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720	\N	\N
625	hyponatremic ( < $nmbr$ meq / l ) at baseline	C0168634;C0439375;C0857122;C1442488	\N	\N
625	hypertension severity at baseline  n ( % )	C0168634;C1442488;C4013784	\N	\N
625	hypertension at baseline	C0020538;C0168634;C1442488;C1963138	\N	\N
625	hospitalization in the past $nmbr$ months prior to baseline	C0019993;C0168634;C1442488;C4331910	\N	\N
625	heart - rate group at baseline	C0018810;C0168634;C0441833;C0687744;C1257890;C1442488;C1519504;C1705428;C1705429	\N	\N
625	flex baseline bmd t score	C0168634;C0449820;C1442488;C4050231	\N	\N
625	femoral neck f - score at flex baseline	C0015815;C0016327;C0168634;C0449820;C1442488;C4050231	\N	\N
625	fbg baseline	C0168634;C1442488	\N	\N
625	draining cutaneous fistula at baseline  n ( % )	C0013103;C0168634;C0180499;C0423772;C1442488;C4265177	\N	\N
625	dmard at baseline	C0168634;C0242708;C1442488	\N	\N
625	difference $nmbr$ years - baseline *	C0168634;C0439234;C1442488;C1705241;C1705242	\N	\N
625	difference $nmbr$ years - baseline	C0168634;C0439234;C1442488;C1705241;C1705242	\N	\N
625	diabetic retinopathy at baseline	C0011884;C0168634;C1442488	\N	\N
625	diabetes duration at baseline	C0011847;C0011849;C0168634;C0449238;C1442488;C2926735	\N	\N
625	diabetes at baseline	C0011847;C0011849;C0168634;C1442488	\N	\N
625	csdmard use at baseline ^	C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
625	crohn ' s disease - related medication at baseline  n ( % )	C0010346;C0013227;C0168634;C0439849;C0445223;C1442488;C3244316;C4284232	\N	\N
625	creatinine > $nmbr$ x baseline	C0010294;C0168634;C1442488;C1561535	\N	\N
625	creatinine > $nmbr$ . $nmbr$ x baseline and above uln	C0010294;C0168634;C1282910;C1442488;C1519815;C1552828;C1561535	\N	\N
625	conventional synthetic dmard use at baseline	C0042153;C0168634;C0242708;C0439858;C0457083;C1442488;C1883254;C1947944	\N	\N
625	concentrations at baseline	C0086045;C0168634;C1442488	\N	\N
625	common study baseline	C0168634;C0205214;C0557651;C1442488;C1522138;C2603343;C3245511	\N	\N
625	coiticosieroids at baseline	C0168634;C1442488	\N	\N
625	changes at baseline	C0168634;C0392747;C0443172;C1442488	\N	\N
625	change in psa ‐ modified shs  baseline to week $nmbr$ ‡	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C3810537;C3813209;C3889737;C4319952	\N	\N
625	change in femoral neck bmd from fit baseline to flex baseline	C0015815;C0036572;C0168634;C0392747;C0443172;C1442488;C1705241;C2349186;C4048158;C4319952;C4553125	\N	\N
625	change from baseline to week $nmbr$ in uas $nmbr$	C0168634;C0332174;C0392747;C0439230;C0443172;C1442488;C1705241;C4319952	\N	\N
625	change from baseline to eos  uu / ml	C0168634;C0392747;C0439342;C0443172;C1442488;C1623465;C1705241;C1861303;C4319952	\N	\N
625	change from baseline in pre - bd	C0005126;C0168634;C0332152;C0392747;C0443172;C0740175;C1442488;C1705241;C2257086;C2344255;C3669034;C4050145;C4319952	\N	\N
625	change from baseline in post - bd	C0005126;C0168634;C0392747;C0443172;C0687676;C1442488;C1704687;C1705241;C2344255;C3469826;C4050145;C4319952	\N	\N
625	change from baseline *	C0168634;C0392747;C0443172;C1442488;C1705241;C4319952	\N	\N
625	change from baseline ( % )	C0168634;C0392747;C0443172;C1442488;C1705241;C4319952	\N	\N
625	change from baseline  adjusted mean ( $nmbr$ % ci )  %	C0008107;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952	\N	\N
625	change from baseline  adjusted mean ( $nmbr$ % ci )	C0008107;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952	\N	\N
625	biomarkers at baseline	C0005516;C0168634;C1442488	\N	\N
625	baselineb	\N	\N	\N
625	baseline upgr > $nmbr$ gm / gm ( $nmbr$ mg / mmole )	C0017480;C0168634;C0567349;C1442488;C2348885;C3854019	\N	\N
625	baseline upgr  mg / mmole ( n = $nmbr$  $nmbr$  $nmbr$ )	C0168634;C0567349;C1442488;C2348885	\N	\N
625	baseline uas $nmbr$	C0168634;C1442488	\N	\N
625	baseline trl - c by quintiles	C0168634;C1442488;C1508496	\N	\N
625	baseline triglycerides by quintiles	C0041004;C0168634;C1442488;C1508496	\N	\N
625	baseline triglycerides	C0041004;C0168634;C1442488	\N	\N
625	baseline treatments  n ( % ) a	C0087111;C0168634;C1442488	\N	\N
625	baseline total pcsk $nmbr$ level	C0168634;C0439175;C0439810;C0441889;C0456079;C1442488;C1547707;C2946261	\N	\N
625	baseline tophusa	C0168634;C1442488	\N	\N
625	baseline therapy	C0039798;C0087111;C0168634;C1363945;C1442488	\N	\N
625	baseline tava	C0168634;C1442488	\N	\N
625	baseline t - score at femoral neck  n ( % )	C0015815;C0168634;C0449820;C1442488;C4050231	\N	\N
625	baseline steroids	C0038317;C0168634;C1442488	\N	\N
625	baseline sitosterol / lathosterol	C0037215;C0064673;C0168634;C0220914;C1442488	\N	\N
625	baseline sitosterol / cholesterol	C0008377;C0037215;C0168634;C0220914;C1442488	\N	\N
625	baseline sitosterol	C0037215;C0168634;C0220914;C1442488	\N	\N
625	baseline shs ( $nmbr$ - $nmbr$ )	C0168634;C1442488	\N	\N
625	baseline sgrq score	C0168634;C0449820;C1442488;C4050231	\N	\N
625	baseline serum k +  meq / l	C0168634;C0302353;C0439375;C1442488	\N	\N
625	baseline serum calcium level  n ( % )	C0036785;C0168634;C0728876;C1442488	\N	\N
625	baseline rst - segment elevation  mm	C0168634;C0439775;C0441635;C0702240;C1425219;C1442488;C4330985;C4554674	\N	\N
625	baseline rst - segment	C0168634;C0441635;C1425219;C1442488	\N	\N
625	baseline ptga	C0168634;C1442488	\N	\N
625	baseline pos frequency per $nmbr$ days	C0168634;C0585290;C1262869;C1442488;C3496112;C3496399	\N	\N
625	baseline pfd  m	C0016065;C0168634;C0369637;C0441923;C1442488;C1839454;C2827389;C3889643	\N	\N
625	baseline pcsi < $nmbr$ a	C0168634;C1442488	\N	\N
625	baseline pava	C0135567;C0168634;C1442488	\N	\N
625	baseline of induction )  n ( % )	C0168634;C0205263;C0857127;C1442488	\N	\N
625	baseline of induction	C0168634;C0205263;C0857127;C1442488	\N	\N
625	baseline nihss	C0168634;C1442488;C1697238	\N	\N
625	baseline nih stroke scale — no . ( % ) ^	C0168634;C1442488;C1697238;C3484372	\N	\N
625	baseline medications ( % )	C0013227;C0168634;C0802604;C1442488;C2598133;C4284232	\N	\N
625	baseline medications  n ( % )	C0013227;C0168634;C0802604;C1442488;C2598133;C4284232	\N	\N
625	baseline medication	C0013227;C0168634;C1442488;C3244316;C4284232	\N	\N
625	baseline medical therapy  n ( % )	C0168634;C0418981;C1442488	\N	\N
625	baseline medical therapy	C0168634;C0418981;C1442488	\N	\N
625	baseline measurements	C0168634;C0242485;C1442488	\N	\N
625	baseline mean 士 sd	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
625	baseline mean mtss	C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
625	baseline mean	C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
625	baseline mdrd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656	\N	\N
625	baseline mdrd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656	\N	\N
625	baseline hstni	C0168634;C1442488	\N	\N
625	baseline glycated	C0168634;C1442488;C3666909	\N	\N
625	baseline free pcsk $nmbr$ level	C0168634;C0332296;C0441889;C0456079;C1442488;C1547707;C1880497;C1996904;C2946261	\N	\N
625	baseline fecal caicrctectin	C0015733;C0168634;C1442488	\N	\N
625	baseline ezetimibe usec	C0168634;C0439224;C1142985;C1442488	\N	\N
625	baseline ecro < $nmbr$ mumin	C0168634;C1442488	\N	\N
625	baseline ecrcl k $nmbr$ to < $nmbr$ ml / min	C0168634;C0439445;C0597277;C1442488;C1708601	\N	\N
625	baseline ecrcl $nmbr$ $nmbr$ ml / min	C0168634;C0439445;C1442488	\N	\N
625	baseline ecrcl	C0168634;C1442488	\N	\N
625	baseline ecg with lvh  n ( % )	C0168634;C0232306;C1442488	\N	\N
625	baseline dmard use  n ( % )	C0042153;C0168634;C0242708;C0457083;C1442488;C1947944	\N	\N
625	baseline dlco . mmol kpa - ’ -	C0168634;C0263428;C0439190;C0439474;C1442488;C1516251	\N	\N
625	baseline dipeptidyl peptidase $nmbr$	C0022709;C0168634;C1442488	\N	\N
625	baseline demographics	C0011298;C0168634;C1442488;C1704791	\N	\N
625	baseline hbalc	C0168634;C1442488	f	2188
625	baseline hbalc ^	C0168634;C1442488	f	2188
625	baseline hbalc < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$	C0168634;C1442488;C3829066	f	2188
625	baseline hbalc > $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$	C0168634;C1442488;C3829066	f	2188
625	baseline hb $nmbr$ g i $nmbr$ n = $nmbr$	C0062408;C0086706;C0168634;C1442488	f	2188
625	baseline hb < $nmbr$ g $nmbr$ $nmbr$ n = $nmbr$	C0062408;C0168634;C0439267;C1442488	f	2188
625	baseline ldl - c	C0168634;C1442488	f	2189
625	baseline ldl - c :	C0168634;C1442488	f	2189
625	baseline ldl - c strata  n ( ° / o )	C0168634;C1442488	f	2189
625	baseline lipid and apolipoprotein levels	C0003591;C0023779;C0168634;C0441889;C1442488	f	2190
625	baseline lipid and lipoprotein values	C0023779;C0023820;C0042295;C0168634;C1442488	f	2190
625	baseline lipid / lipoprotein values	C0042295;C0168634;C0443602;C1442488	f	2190
625	baseline lipid therapy	C0023779;C0039798;C0087111;C0168634;C1363945;C1442488	f	2190
625	baseline diabetes mellitus therapy  n ( % )	C0168634;C0948092;C1442488	f	2191
625	baseline diabetes	C0011847;C0011849;C0168634;C1442488	f	2191
625	baseline das $nmbr$  mean ( s . e . )	C0051767;C0057671;C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
625	baseline dad ( n   = $nmbr$ + $nmbr$ )	C0168634;C1442488;C3641946	\N	\N
625	baseline cv treatment  n ( % ) y	C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503	\N	\N
625	baseline cv treatment	C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503	\N	\N
625	baseline crohn ' s disease medications	C0010346;C0013227;C0168634;C0802604;C1442488;C2598133;C4284232	\N	\N
625	baseline creatinine clearance	C0168634;C0812399;C1442488	\N	\N
625	baseline creatinine  median ( range ) mg / dl	C0010294;C0168634;C0439269;C0549183;C0876920;C1442488;C1514721;C1561535;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
625	baseline concentration	C0086045;C0168634;C1442488;C1446561;C3827302	\N	\N
625	baseline cardiovascular assessment	C0007226;C0168634;C0846600;C1442488;C3887460;C4684571	\N	\N
625	baseline cardiac biomarkers elevated	C0168634;C0205250;C1442488;C2735101;C2735102;C3163633	\N	\N
625	baseline cardiac biomarkers	C0168634;C1442488;C2735101;C2735102	\N	\N
625	baseline bp  mean ( sd ) *	C0168634;C0488053;C1442488;C2699239	\N	\N
625	baseline bnp concentration ( pg / ml )	C0054015;C0086045;C0168634;C0439297;C1095989;C1417808;C1442488;C1446561;C2982014;C3827302	\N	\N
625	baseline basfi	C0168634;C1442488	\N	\N
625	baseline albuminuria	C0001925;C0168634;C1442488	\N	\N
625	baseline albumin : < $nmbr$	C0001924;C0168634;C1442488	\N	\N
625	baseline adas - cog $nmbr$	C0168634;C1442488;C3539026	\N	\N
625	baseline acq - $nmbr$ score	C0168634;C0449820;C1442488;C2919686;C4050231	\N	\N
625	baseline a $nmbr$ c ( % )	C0168634;C1442488	\N	\N
625	baseline - adjusted hr	C0168634;C0456081;C1442488	\N	\N
625	baseline - - mdrd	C0168634;C1442488;C3839656	\N	\N
625	baseline ( sd )	C0168634;C1442488;C2699239	\N	\N
625	baseline ( n )	C0168634;C1442488	\N	\N
625	baseline % bsa involvement	C0168634;C1314939;C1442488	\N	\N
625	baseline $nmbr$ - mlnute walk distance :	C0168634;C0429886;C1442488	\N	\N
625	baseline $nmbr$ - h ppg	C0033727;C0168634;C0369286;C0441932;C0564385;C1418888;C1442488;C4528284	\N	\N
625	baseline  no . ( % )	C0168634;C1442488	\N	\N
625	baseline  % ( n )	C0168634;C1442488	\N	\N
625	baseline	C0168634;C1442488	\N	\N
625	available baseline blood specimen n	C0168634;C0178913;C0470187;C1442488	\N	\N
625	at baseline — no . ( % )	C0168634;C1442488	\N	\N
625	at baseline	C0168634;C1442488	\N	\N
625	asthma control test score at baseline	C0168634;C1442488;C2733224	\N	\N
625	antihyperglycaemic medication at baseline	C0013227;C0020616;C0168634;C1442488;C3244316;C4284232	\N	\N
625	antiepileptic drug type at baseline	C0003299;C0168634;C0332307;C0457591;C1442488;C1547052;C3537002	\N	\N
625	antibody binding level at baseline	C0168634;C0428536;C0441889;C0456079;C1145667;C1149306;C1167622;C1442488;C1547707;C2946261	\N	\N
625	adjusted mean change from baseline ( $nmbr$ % ci )  % [ mmol / mol ]	C0008107;C0168634;C0392747;C0439190;C0443172;C0444504;C0456081;C0948922;C1442488;C1705241;C2347634;C2348143;C3259781;C3829066;C4319952	\N	\N
625	adjusted mean change from baseline	C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
625	adjusted change from baseline mean ( s . e . )	C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
625	adjusted change from baseline	C0168634;C0392747;C0443172;C0456081;C1442488;C1705241;C4319952	\N	\N
7	interaction p value	C1704675;C1709380	\N	\N
625	activities of daily living updrs subscore ( baseline )  mean ( sd )	C0001288;C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721;C4050548	\N	\N
625	abdominal or perianal fistula at baseline  n ( % )	C0000726;C0168634;C0267561;C1442488	\N	\N
625	abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg  less severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .	C0000723;C0003015;C0005767;C0005768;C0005823;C0006684;C0014122;C0022067;C0025424;C0039798;C0040363;C0041260;C0042295;C0051696;C0087111;C0168634;C0205082;C0229664;C0277814;C0302595;C0332152;C0428257;C0439092;C0439385;C0439453;C0439475;C0443150;C0444504;C0488055;C0547044;C0597357;C0871470;C1271104;C1272641;C1306620;C1319894;C1363945;C1442488;C1444656;C1537110;C1705850;C1707719;C1881173;C1883351;C2347108;C2347109;C2347634;C2348143;C2348272;C2584297;C2699239;C2757044;C3275241;C3536837;C3536851;C3888198;C4050224;C4050465;C4050466;C4330985;C4521885;C4541021;C4554371;C4554674	\N	\N
625	a from baselineb	\N	\N	\N
625	a from baseline	C0168634;C1442488	\N	\N
625	a $nmbr$ c at baseline ≥ $nmbr$ . $nmbr$ %	C0168634;C1442488	\N	\N
625	a $nmbr$ c at baseline < $nmbr$ . $nmbr$ %	C0168634;C1442488	\N	\N
625	> $nmbr$ years baseline ldl - c	C0168634;C0439234;C1442488	\N	\N
625	> $nmbr$ med at baseline cardiac disorder *	C0018799;C0168634;C1442488;C4321267	\N	\N
625	> $nmbr$ % blood eosinophils at baseline	C0014467;C0168634;C1442488	\N	\N
625	< $nmbr$ % blood eosinophils at baseline	C0014467;C0168634;C1442488	\N	\N
625	( baseline )	C0168634;C1442488	\N	\N
625	$nmbr$ med at baseline	C0168634;C1442488;C4321267	\N	\N
625	$nmbr$ baseline mean	C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
624	thrombocytopenia	C0040034;C0392386	\N	\N
624	profound thrombocytopenia ( < $nmbr$ x $nmbr$ / l )	C0040034;C0392386;C0439808	\N	\N
624	moderate thrombocytopenia ( < $nmbr$ x $nmbr$ / l )	C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
624	mild thrombocytopenia ( < $nmbr$ x $nmbr$ / l )	C1856453	\N	\N
623	thrombophilia  no . ( % ) e	C0398623	\N	\N
625	baseline anti - hyperglycemic medications	C0013227;C0168634;C0802604;C1442488;C2598133;C4284232	f	33
623	known thrombophilia — no . ( % )	C0205309;C0398623	\N	\N
623	known thrombophilia	C0205309;C0398623	\N	\N
622	stent thrombosis or mi	C3810814;C3897493	\N	\N
622	stent thrombosis - related mi	C0439849;C0445223;C3810814;C3897493	\N	\N
622	stent thrombosis *	C3897493	\N	\N
622	stent thrombosis	C3897493	\N	\N
622	non stent thrombosis - related mi	C0439849;C0445223;C1518422;C3810814;C3897493	\N	\N
622	definite acute stent thrombosis	C0205178;C0439544;C1704787;C3897493	\N	\N
622	death or stent thrombosis	C0011065;C1306577;C3897493;C4082313;C4552775	\N	\N
622	death / q - ml / stent thrombosis	C0011065;C0439526;C1306577;C1705224;C3887665;C3897493;C4082313;C4552775	\N	\N
622	composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis	C0011065;C0022558;C0155626;C0205199;C0378365;C0439609;C1306577;C1547335;C3272275;C3897493;C4082313;C4552775	\N	\N
622	acute stent thrombosis ( definite or probable )	C0033204;C0205178;C0332148;C0439544;C1704787;C3897493	\N	\N
622	acute stent thrombosis	C0205178;C3897493	\N	\N
621	use of pci or thrombolysis within one day of randomization	C0034656;C0520997;C1524063;C3844320;C4049621	\N	\N
621	thrombolysis	C0520997	\N	\N
621	pci / thrombolysis at randomization	C0034656;C0520997;C4049621	\N	\N
620	treatment with open - label perindopril	C0136123;C3640652	\N	\N
620	trandolapril ( n = $nmbr$ )	C0076891	\N	\N
620	trandolapril	C0076891	\N	\N
620	perindopril	C0136123	\N	\N
619	phenytoin	C0031507;C0202454	\N	\N
619	outcome and metabolizer phenotype	C0031437;C1274040;C1285572	\N	\N
619	metabolizer phenotype ( % ) §	C0031437;C1285572	\N	\N
618	genotyping	C1285573	\N	\N
618	by genotyping	C1285573	\N	\N
617	without metabolic syndrome	C0524620	\N	\N
617	with metabolic syndrome	C0524620	\N	\N
617	the metabolic syndrome ^	C0524620	\N	\N
617	syndrome  n ( % )	C0039082	\N	\N
617	specific syndromes	C0039082;C0205369;C1552740;C1558916	\N	\N
617	participants without metabolic syndrome	C0524620;C0679646	\N	\N
617	participants with metabolic syndrome	C0524620;C0679646	\N	\N
617	nonmetabolic syndrome ( n = $nmbr$ )	C0039082	\N	\N
617	no metabolic syndrome	C0524620	\N	\N
617	ncep atp - iii metabolic syndrome features  n ( % )	C0369718;C0439070;C0441922;C0524620;C1521970;C1705160;C1706388;C2346469;C2348519;C2744579;C4552600	\N	\N
617	metabolic syndromeb	C0311400;C1524026;C2707259	\N	\N
617	metabolic syndrome — no . ( % ) ^	C0524620	\N	\N
617	metabolic syndrome — no . ( % ) $nmbr$	C0524620	\N	\N
617	metabolic syndrome — no . ( % ) !	C0524620	\N	\N
617	metabolic syndrome w / o t $nmbr$ dm	C0011816;C0524620;C3250443	\N	\N
617	metabolic syndrome visit $nmbr$ low - density lipoprotein cholesterol strata	C0023824;C0524620;C0545082;C1512346;C2826704	\N	\N
617	metabolic syndrome characteristics  n ( % )	C0524620;C1521970	\N	\N
617	metabolic syndrome * n = $nmbr$	C0524620	\N	\N
617	metabolic syndrome *	C0524620	\N	\N
617	metabolic syndrome ( n = $nmbr$ )	C0524620	\N	\N
617	metabolic syndrome ( > $nmbr$ of $nmbr$ characteristics )	C0524620;C1521970	\N	\N
617	metabolic syndrome ( % ) b	C0524620	\N	\N
617	metabolic syndrome ( % )	C0524620	\N	\N
617	metabolic syndrome $nmbr$ *	C0524620	\N	\N
617	metabolic syndrome  n / n ( % ) *	C0524620	\N	\N
617	metabolic syndrome  n ( % )	C0524620	\N	\N
617	metabolic syndrome  ! n ( % )	C0524620	\N	\N
617	metabolic syndrome	C0524620	\N	\N
617	high - density lipoprotein cholesterol metabolic syndrome  patients were to	C0023822;C0030705;C0040363;C0041260;C0524620;C1883351	\N	\N
7	interaction p - value *	C1704675;C1709380	\N	\N
7	interaction p - value $nmbr$	C1704675;C1709380	\N	\N
617	changes ( a ) in metabolic syndrome parameters hdl cholesterol	C0392747;C0443172;C0449381;C0524620;C1705241;C2357172;C4319952	\N	\N
617	cardiovascular metabolic syndrome risk lactors	C0007226;C0035647;C0524620;C3887460;C4552904	\N	\N
617	cardiometabolic syndrome  ^ n ( % )	C0039082	\N	\N
616	syncope — no . ( % )	C0039070;C3541349;C4554644	\N	\N
616	syncope	C0039070;C3541349;C4554644	\N	\N
615	systolic bp at baseline :	C0168634;C0871470;C1442488	\N	\N
615	systolic bp	C0871470	\N	\N
615	systolic blood pressure subgroups	C0488055;C0871470;C1079230;C1306620	\N	\N
615	systolic blood pressure ^	C0488055;C0871470;C1306620	\N	\N
615	systolic blood pressure ( mmhg )	C0439475;C0488055;C0871470;C1306620	\N	\N
615	systolic blood pressure ( median $nmbr$ . $nmbr$ )	C0488055;C0549183;C0871470;C0876920;C1306620;C2347635;C2348144;C2939193	\N	\N
615	systolic blood pressure  mmhg	C0439475;C0488055;C0871470;C1306620	\N	\N
615	systolic blood pressure  mm hq	C0488055;C0871470;C1306620;C4330985;C4554674	\N	\N
615	systolic blood pressure	C0488055;C0871470;C1306620	\N	\N
615	nonglycemic cardiovascular risk factors systolic blood pressure — mmhg	C0439475;C0488055;C0850624;C0871470;C1306620	\N	\N
615	baseline systolic bp	C0168634;C0871470;C1442488	\N	\N
614	mean systolic pressure gradient	C0039155;C4687744	\N	\N
613	systemic symptoms	C0205373;C0683368;C1457887	\N	\N
613	symptoms and feelings	C0683368;C1457887;C1527305	\N	\N
613	symptoms	C0683368;C1457887	\N	\N
613	symptom bother	C1457887;C3854129	\N	\N
613	symptom - free days in the past $nmbr$ weeks ( % )	C0332296;C0439228;C0677547;C1444637;C1457887;C1880497;C1996904;C2987125;C3854129;C4284302	\N	\N
613	presenting signs and symptoms	C0220912;C0220913;C0311392;C0449450;C0683368;C1457887	\N	\N
613	placebo ( symptom days a week )	C0032042;C0332174;C0439228;C0439230;C1457887;C1696465;C1706408;C3854129	\N	\N
613	number of symptom days per week	C0237753;C0332174;C0439228;C0439230;C0449788;C1457887;C3854129	\N	\N
613	nocturnal symptoms in past week	C0240526;C0683368;C1457887;C2987125	\N	\N
613	no symptoms	C0683368;C1457887	\N	\N
613	no . of ' signs or symptoms of chff	C0220912;C0220913;C0311392;C0683368;C1457887	\N	\N
614	peak systolic pressure gradient	C0039155;C4687747	f	1919
613	days with asthma symptoms / week	C0004096;C0677547;C0683368;C1457887;C2984299	\N	\N
613	class i or no symptoms	C0441885;C0683368;C1319793;C1457887;C2698967	\N	\N
613	class $nmbr$ or no symptoms	C0456387;C0683368;C1457887;C1518526;C1705943	\N	\N
613	baseline symptom days perweek	C0168634;C0439228;C1442488;C1457887;C3854129	\N	\N
613	asthma symptoms in the past $nmbr$ weeks	C0004096;C0683368;C1457887;C2984299;C2987125	\N	\N
613	> $nmbr$ symptom days per week	C0677547;C1457887;C3854129	\N	\N
613	$nmbr$ to $nmbr$ symptom days per week	C0677547;C1457887;C3854129	\N	\N
613	$nmbr$ = no symptoms	C0683368;C1457887	\N	\N
613	$nmbr$ = minor symptoms  no limitations	C0026193;C0205165;C0449295;C0683368;C1457887	\N	\N
612	symptom onset to hospitalization	C0019993;C4086878	\N	\N
612	symptom onset to hospital arrival  median ( iqr )  h	C0019994;C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C1510665;C1555577;C1706079;C2347635;C2348144;C2939193;C4086878;C4528284	\N	\N
612	symptom onset to hospital arrival  hours	C0019994;C0439227;C1510665;C1555577;C1706079;C4086878	\N	\N
612	symptom onset to hospital admission	C0184666;C4086878	\N	\N
612	symptom onset - to -	C4086878	\N	\N
612	symptom onset	C4086878	\N	\N
611	symptomaticb	\N	\N	\N
611	symptomatic remissionb n / n ( % )	C0231220	\N	\N
611	symptomatic padt	C0231220	\N	\N
611	symptomatic pad	C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657	\N	\N
611	symptomatic hypoglycaemia	C0020615;C0231220;C4553659	\N	\N
611	symptomatic deep - vein thrombosis	C0149871;C0231220	\N	\N
611	symptomatic	C0231220	\N	\N
611	history of symptomatic	C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062	\N	\N
610	dpp ‐ $nmbr$ inhibitors	C0243077;C1414174	\N	\N
610	dpp - $nmbr$ inhibitors	C0243077;C1414174	\N	\N
610	dpp - $nmbr$ inhibitor therapy	C0039798;C0087111;C1363945;C1414174;C1999216	\N	\N
610	dpp - $nmbr$ inhibitor	C1414174;C1999216	\N	\N
610	dpp - $nmbr$	C1414174	\N	\N
609	cyp $nmbr$ a $nmbr$ inhibitors	C0243077;C1418793;C2634343	\N	\N
609	cyp $nmbr$ a $nmbr$	C1418793;C2634343	\N	\N
608	treatment with any bp lowering drugs	C0037623;C0441994;C1415692;C1708288;C2003888;C3469597;C4318478	\N	\N
608	syst . bp ( mmhg )	C0037623;C0439475;C1415692;C1708288;C4318478	\N	\N
608	patientswith bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt	C0037623;C0168634;C0332126;C0439475;C1415692;C1442488;C1449832;C1708288;C3889152;C4050156;C4283901;C4284038;C4318478	\N	\N
608	patientswith bp  $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  n §	C0037623;C0168634;C0439475;C1415692;C1442488;C1708288;C4318478	\N	\N
608	patients with bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt	C0030705;C0037623;C0168634;C0332126;C0439475;C1415692;C1442488;C1449832;C1708288;C3889152;C4050156;C4283901;C4284038;C4318478	\N	\N
608	other bp drug	C0013227;C0037623;C1254351;C1415692;C1708288;C4318478	\N	\N
608	on bp medication  n ( % )	C0013227;C0037623;C1415692;C1708288;C3244316;C4284232;C4318478	\N	\N
608	intensive bp lowering  < $nmbr$ mm hg ( n = $nmbr$ )	C0037623;C0162425;C0439475;C0441994;C0522510;C1283828;C1415692;C1550453;C1708288;C2003888;C4318478	\N	\N
608	hba $nmbr$ c < $nmbr$ . $nmbr$ %  bp < $nmbr$ / $nmbr$ mm hg  ldl - c < $nmbr$ mg / dl	C0019016;C0037623;C0439269;C0439475;C1415692;C1708288;C1825777;C3538758;C4318478	\N	\N
608	bp variable  mm hg	C0037623;C0439475;C0439828;C1415692;C1708288;C4318478;C4553760	\N	\N
608	bp in pre - treated patients	C0030705;C0037623;C0332152;C0740175;C1415692;C1522326;C1708288;C2257086;C3669034;C4318478	\N	\N
608	bp goal at week $nmbr$	C0018017;C0037623;C0332174;C0439230;C1415692;C1571704;C1708288;C4318478	\N	\N
608	bp goal  no . ( % )	C0018017;C0037623;C1415692;C1571704;C1708288;C4318478	\N	\N
608	bp component ( mm hg )	C0037623;C0439475;C0449432;C1415692;C1705248;C1708288;C4318478	\N	\N
608	bp and fasting glucose results	C0015663;C0017725;C0037623;C1274040;C1415692;C1546471;C1708288;C2825142;C4318478	\N	\N
608	bp < $nmbr$ / $nmbr$  n ( % )	C0037623;C1415692;C1708288;C4318478	\N	\N
608	bp - lowering treatments  n ( % )	C0037623;C0087111;C0441994;C1415692;C1708288;C2003888;C4318478	\N	\N
608	bp - lowering treatment ( n = $nmbr$ )	C0037623;C0039798;C0087111;C0441994;C1415692;C1522326;C1533734;C1705169;C1708288;C2003888;C3538994;C3887704;C4318478	\N	\N
608	any bp - lowering agents ^	C0037623;C0441994;C0450442;C1254351;C1415692;C1521826;C1708288;C2003888;C4318478	\N	\N
607	trough seated sbp ( mmhg ) a	C0085805;C0277814;C0439475;C0444506;C1283233	\N	\N
607	seated sbp at $nmbr$ weeks  mmhg + * *	C0085805;C0277814;C0439230;C0439475;C1283233	\N	\N
607	seated sbp at $nmbr$ weeks  mmhg +	C0085805;C0277814;C0439230;C0439475;C1283233	\N	\N
607	sd of sbp	C0085805;C2699239	\N	\N
607	sbp ≥ $nmbr$ mmhg	C0085805;C0439475	\N	\N
607	sbp during the follow - up period ( mmhg )	C0085805;C0439475;C0439531;C0589120;C1522577;C1704685;C1948053;C3274571	\N	\N
607	sbp > $nmbr$ mmhg or dbp > $nmbr$ mmhg	C0085805;C0439475;C0536221;C3813197;C4281799	\N	\N
607	sbp > $nmbr$ mmhg n = $nmbr$	C0085805;C0439475	\N	\N
607	sbp > $nmbr$ mmhg and / or dbp > $nmbr$ mmhg	C0085805;C0439475;C0536221;C3813197;C4281799	\N	\N
607	sbp > $nmbr$ mmhg	C0085805;C0439475	\N	\N
607	sbp > $nmbr$ mm hg and / or dbp > $nmbr$ mm hg $nmbr$ / $nmbr$	C0085805;C0439475;C0536221;C3813197;C4281799	\N	\N
607	sbp < $nmbr$ mmhg n = $nmbr$	C0085805;C0439475	\N	\N
607	sbp < $nmbr$ mmhg and dbp < $nmbr$ mmhg	C0085805;C0439475;C0536221;C3813197;C4281799	\N	\N
607	sbp < $nmbr$ mmhg	C0085805;C0439475	\N	\N
607	sbp < $nmbr$ mm hg and dbp < $nmbr$ mm hg $nmbr$ / $nmbr$	C0085805;C0439475;C0536221;C3813197;C4281799	\N	\N
607	sbp / dbp ( mmhg )	C0085805;C0439475;C0536221;C3813197;C4281799	\N	\N
607	sbp / dbp $ $nmbr$ / $ $nmbr$ mmhg	C0085805;C0439475;C0536221;C3813197;C4281799	\N	\N
607	sbp . mean ( sd ) mm hg	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
607	sbp ( sd )  mm   hg	C0085805;C0439475;C2699239	\N	\N
607	sbp ( sd )	C0085805;C2699239	\N	\N
607	sbp ( office measurement )  mmhg	C0085805;C0242485;C0439475;C0442603	\N	\N
607	sbp ( mmhg ) < $nmbr$	C0085805;C0439475	\N	\N
607	sbp ( mmhg ) *	C0085805;C0439475	\N	\N
607	sbp ( mmhg )	C0085805;C0439475	\N	\N
607	sbp ( mm hg )	C0085805;C0439475	\N	\N
330	other / multiple	C0439064	\N	\N
607	sbp ( mean over $nmbr$ h )  mmhg	C0033727;C0085805;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284	\N	\N
607	sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .	C0007787;C0027051;C0085805;C0369637;C0428883;C0439385;C0441923;C0488055;C0871420;C0871470;C1306620;C2699239	\N	\N
607	sbp  mmhg	C0085805;C0439475	\N	\N
607	sbp  mm   hg ( sd )	C0085805;C0439475;C2699239	\N	\N
607	sbp  mm   hg	C0085805;C0439475	\N	\N
607	sbp  mm hg ( office measurement )  mean ( sd )	C0085805;C0242485;C0439475;C0442603;C0444504;C2347634;C2348143;C2699239	\N	\N
607	sbp  mean ( sd ) mm hg	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
607	sbp  mean ( sd )  mm hg	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	\N	\N
607	sbp  last	C0085805;C1517741	\N	\N
607	sbp	C0085805	\N	\N
607	nighttime mean sbp ( abpm ) at week $nmbr$  mmhg	C0085805;C0240526;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143	\N	\N
607	mean sitting sbp ( mmhg )	C0085805;C0277814;C0439475;C0444504;C2347634;C2348143;C2584297;C4050224	\N	\N
607	mean change in sbp from baseline  mmhg  mean ( sd )	C0085805;C0168634;C0392747;C0439475;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C4319952	\N	\N
607	daytime mean sbp ( abpm ) at week $nmbr$  mmhg	C0085805;C0332169;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143	\N	\N
607	change in sbp	C0085805;C0392747;C0443172;C1705241;C4319952	\N	\N
607	change from baseline in mean $nmbr$ - h sbp  mmhg	C0033727;C0085805;C0168634;C0369286;C0392747;C0439475;C0441932;C0443172;C0444504;C0564385;C1442488;C1705241;C2347634;C2348143;C4319952;C4528284	\N	\N
607	baseline sbp  mean ± sd  mm hg	C0085805;C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
607	baseline mean seated sbp  mm hg ( sd )	C0085805;C0168634;C0277814;C0439475;C0444504;C1283233;C1442488;C2347634;C2348143;C2699239	\N	\N
607	baseline mean ambulatory sbp  mm hg ( sd ) *	C0085805;C0168634;C0439475;C0439841;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
607	ambulatory sbp  n	C0085805;C0439841	\N	\N
607	$nmbr$ < sbp < $nmbr$ mmhg n = $nmbr$	C0085805;C0439475	\N	\N
606	tbp	\N	\N	\N
606	sbp at baseline	C0085805;C0168634;C1442488	\N	\N
606	sbp  baseline	C0085805;C0168634;C1442488	\N	\N
606	nbp	\N	\N	\N
606	baseline tbp	C0168634;C1442488	\N	\N
606	baseline sbp { p = o - $nmbr$ )	C0085805;C0168634;C1442488	\N	\N
606	baseline sbp	C0085805;C0168634;C1442488	\N	\N
606	baseline nbp	C0168634;C1442488	\N	\N
606	baseline $nmbr$ - hour mean sbp  mm hg	C0085805;C0168634;C0439227;C0439475;C0444504;C0564385;C1442488;C2347634;C2348143	\N	\N
606	adjusted for all baseline variables  interaction between acei and baseline up  and declines in sbp and up	C0085805;C0168634;C0439828;C0456081;C1442488;C1704675	\N	\N
605	visit $nmbr$ dbp  mm hg	C0439475;C0536221;C0545082;C1512346;C2826704;C3813197;C4281799	\N	\N
605	trough seated dbp ( mmhg ) a	C0277814;C0439475;C0444506;C0536221;C1283233;C3813197;C4281799	\N	\N
605	seated dbp  mean ( sd )  mmhg	C0277814;C0439475;C0444504;C0536221;C1283233;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	sbp / dbp mean	C0085805;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799	\N	\N
605	mean sitting dbp ( mmhg )	C0277814;C0439475;C0444504;C0536221;C2347634;C2348143;C2584297;C3813197;C4050224;C4281799	\N	\N
605	mean $nmbr$ - h dbp +	C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284	\N	\N
605	dbp ≥ $nmbr$ mmhg	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp mm hg	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp during the follow - up period ( mmhg )	C0439475;C0439531;C0536221;C0589120;C1522577;C1704685;C1948053;C3274571;C3813197;C4281799	\N	\N
605	dbp < $nmbr$ mmhg	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp . mean ( sd ) mm hg	C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp ( sd )  mm   hg	C0439475;C0536221;C2699239;C3813197;C4281799	\N	\N
605	dbp ( sd )	C0536221;C2699239;C3813197;C4281799	\N	\N
605	dbp ( office measurement )  mmhg	C0242485;C0439475;C0442603;C0536221;C3813197;C4281799	\N	\N
605	dbp ( mmhg )  mean ( sd )	C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp ( mmhg )	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp ( mmghg )  mean ( sd )	C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp ( mm hg )  median ( iqr )	C0439475;C0536221;C0549183;C0876920;C2347635;C2348144;C2939193;C3813197;C4281799	\N	\N
605	dbp ( mm hg )	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp ( mean over $nmbr$ h )  mmhg	C0033727;C0369286;C0439475;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284	\N	\N
605	dbp  mmhg	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp  mm   hg ( sd )	C0439475;C0536221;C2699239;C3813197;C4281799	\N	\N
605	dbp  mm   hg	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp  mm hg ( office measurement )  mean ( sd )	C0242485;C0439475;C0442603;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp  mm hg ( mean $nmbr$ h )  mean ( sd )	C0025424;C0428257;C0444504;C0456680;C0536221;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239;C3813197;C4281799	\N	\N
605	dbp  mm hg  mean ± sdc	C0439475;C0444504;C0536221;C1419891;C2347634;C2348143;C3273112;C3813197;C4281799	\N	\N
605	dbp  mm hg	C0439475;C0536221;C3813197;C4281799	\N	\N
605	dbp  mean ± sd ( mmhg )	C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp  mean ( sd ) mm hg	C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp  mean ( sd )  mmhg	C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp  mean ( sd )  mm hg glycaemic parameters	C0005802;C0439475;C0444504;C0449381;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp  mean ( sd )  mm hg	C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp  mean ( sd )	C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	dbp	C0536221;C3813197;C4281799	\N	\N
605	change from baseline in mean $nmbr$ - h dbp  mmhg	C0033727;C0168634;C0369286;C0392747;C0439475;C0441932;C0443172;C0444504;C0536221;C0564385;C1442488;C1705241;C2347634;C2348143;C3813197;C4281799;C4319952;C4528284	\N	\N
605	baseline sitting dbp  * mm hg	C0168634;C0277814;C0439475;C0536221;C1442488;C2584297;C3813197;C4050224;C4281799	\N	\N
605	baseline dbp ( mm hg )	C0168634;C0439475;C0536221;C1442488;C3813197;C4281799	\N	\N
605	baseline dbp  mean ± sd  mm hg	C0168634;C0439475;C0444504;C0536221;C1442488;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
605	baseline dbp	C0168634;C0536221;C1442488;C3813197;C4281799	\N	\N
604	type of treatment  n ( % )	C0455708	\N	\N
604	type of intervention	C3274412	\N	\N
604	type of index event — no . ( % )	C0600653;C0918012;C1552854;C1561488;C1637833;C2986546	\N	\N
604	type of hospitalization	C3177060	\N	\N
604	type of event — no . ( % )	C1561488	\N	\N
604	type of event :	C1561488	\N	\N
604	type of event	C1561488	\N	\N
604	initial type of heparin treatment received	C0019134;C0205265;C0455708;C0770546;C1279901;C1514756;C1555582;C1705685	\N	\N
604	hope ( n = $nmbr$ )	C0392347	\N	\N
603	type of stent at index procedure	C0038257;C0184661;C0332307;C0600653;C0918012;C1547052;C1552854;C1637833;C2700391;C2986546;C3274430;C3539779	\N	\N
603	type of lipid - lowering regimen	C0023779;C0040808;C0332307;C0441994;C1547052;C2003888;C2945654	\N	\N
603	type of hospital care	C0259945;C0332307;C1547052	\N	\N
603	type of end point	C0332307;C1547052;C2349179;C2826544	\N	\N
603	type of des at index procedure	C0011702;C0184661;C0332307;C0600653;C0918012;C1547052;C1552854;C1637833;C2700391;C2986546;C3274430;C3539779;C4551552	\N	\N
603	type of des	C0011702;C0332307;C1547052;C4551552	\N	\N
603	type of af  n ( % )	C0332307;C0344434;C1547052;C4049859	\N	\N
603	type of af	C0332307;C0344434;C1547052;C4049859	\N	\N
603	type / no . of valves repaired / replaced mitral	C0184252;C0205340;C0332307;C0559956;C0746591;C1186983;C1299987;C1547052	\N	\N
603	type $nmbr$  n ( % )	C0332307;C1547052	\N	\N
603	type	C0332307;C1547052	\N	\N
603	stent type implanted	C0021102;C0038257;C0332307;C1547052;C2828363	\N	\N
603	stent type	C0038257;C0332307;C1547052	\N	\N
603	predominant type of heparin	C0019134;C0332307;C0770546;C1542147;C1547052	\N	\N
603	phosphodiesterase type $nmbr$ inhibitors	C0031638;C0332307;C1547052;C1656262;C3539996	\N	\N
603	outcome type	C0332307;C1274040;C1547052	\N	\N
603	des type	C0011702;C0332307;C1547052;C4551552	\N	\N
603	cardiac surgery type	C0018821;C0332307;C0524727;C1547052	\N	\N
603	af type — no . ( % )	C0332307;C0344434;C1547052;C4049859	\N	\N
603	af type	C0332307;C0344434;C1547052;C4049859	\N	\N
603	acs type	C0332307;C0742343;C1547052;C4318612	\N	\N
603	> $nmbr$ type	C0332307;C1547052	\N	\N
603	> $nmbr$ des type	C0011702;C0332307;C1547052;C4551552	\N	\N
602	known prothrombotic genotype	C0017431;C0205309	\N	\N
602	haplotype	C0018591	\N	\N
602	gentype	\N	\N	\N
602	genotype	C0017431	\N	\N
601	eastern european	C0239309	\N	\N
601	eastern europe and africa	C0001737;C0015177	\N	\N
601	eastern europe ( n   = $nmbr$  $nmbr$ )	C0015177	\N	\N
601	eastern europe ( n = $nmbr$ )	C0015177	\N	\N
601	eastern europe ( % )	C0015177	\N	\N
601	eastern europe  africa	C0001737;C0001741;C0015176;C0015177	\N	\N
601	eastern europe	C0015177	\N	\N
601	central and eastern europe	C0015177;C0205099;C1879652	\N	\N
600	western friroce	C1705493	\N	\N
600	western	C1705493	\N	\N
600	west europe	C0015176;C1705493	\N	\N
599	western europe plus other	C0043129;C0332287	\N	\N
599	western europe and other	C0043129	\N	\N
599	western europe and lebanon	C0023190;C0043129	\N	\N
599	western europe ( n   = $nmbr$  $nmbr$ )	C0043129	\N	\N
599	western europe ( n = $nmbr$ )	C0043129	\N	\N
599	western europe ( including south africa )	C0037712;C0043129;C0332257	\N	\N
599	western europe ( % )	C0043129	\N	\N
599	western europe  australia  new zealand  middle east	C0026068;C0043129;C4289954	\N	\N
599	western europe  australia  new zealand  and middle east	C0026068;C0043129;C4289954	\N	\N
599	western europe  australia  new zealand	C0043129;C4289954	\N	\N
599	western europe	C0043129	\N	\N
598	without previous surgery	C0038894;C0038895;C0205156;C0543467;C1274039;C1552607	\N	\N
598	with previous surgery	C0038894;C0038895;C0205156;C0543467;C1274039;C1552607	\N	\N
598	valve surgery  n ( % )	C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1704414;C3888056	\N	\N
598	type of surgery cabg	C0010055;C0038894;C0038895;C0332307;C0543467;C1274039;C1547052	\N	\N
598	type of surgery	C0038894;C0038895;C0332307;C0543467;C1274039;C1547052	\N	\N
598	surgery	C0038894;C0038895;C0543467;C1274039	\N	\N
598	recent surgery or trauma	C0038894;C0038895;C0043251;C0332185;C0543467;C1274039;C1510467;C3263723;C3714660;C4049136	\N	\N
598	prior pci or cabg surgery	C0010055;C0038894;C0038895;C0332152;C0543467;C1274039;C2826257;C4049621	\N	\N
598	planned valve surgery  n ( % )	C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056	\N	\N
598	operative procedure	C0543467;C0677612	\N	\N
598	no previous cd related surgery $nmbr$	C0007928;C0034283;C0038894;C0038895;C0205156;C0439849;C0445223;C0543467;C1274039;C1552607;C4552032	\N	\N
598	interventional or surgical procedures	C0184661;C0543467;C3274035	\N	\N
598	diuretic — no . ( % ) surgery	C0012798;C0038894;C0038895;C0543467;C1274039	\N	\N
598	crohn ’ s disease related surgery	C0010346;C0038894;C0038895;C0439849;C0445223;C0543467;C1274039	\N	\N
598	cardiac valve surgery : no ( n = $nmbr$ )	C0018821;C0018826;C0038894;C0038895;C0184252;C0369718;C0441922;C0524727;C0543467;C1186983;C1274039;C1704414;C3888056	\N	\N
597	study eye characteristics	C0015392;C0700042;C1568011	\N	\N
597	microvascular eye diseased	C0015392;C0443258;C0700042	\N	\N
306	men  n ( % ) *	C0025266	f	1842
603	type of concomitant statin by daily dose - no . ( % )	C0332307;C0360714;C0521115;C1547052;C2348070	f	872
603	type of concomitant statin by daily dose	C0332307;C0360714;C0521115;C1547052;C2348070	f	872
598	cabg surgery	C0010055;C0038894;C0038895;C0543467;C1274039	f	389
596	major diabetic eye disease  n ( % )	C0205082;C0205164;C0342245;C4318856;C4521762	\N	\N
596	diabetic eye disease	C0342245	\N	\N
595	edge ii	C0205154;C1710602;C2697523;C4082587	\N	\N
595	edge	C0205154;C2697523	\N	\N
594	sertraline	C0074393;C0524265	\N	\N
594	postbaseline binding antibodies	C0003241;C1145667;C1167622	\N	\N
594	femoralneck t - scorebybaselinevfxstatus	\N	\N	\N
593	postprandial indices	C0376674;C4033634	\N	\N
593	$nmbr$ - h postprandial c - peptide ( ng / ml )	C0006558;C0376674;C2827809	\N	\N
592	treatment by egfr stage	C0815181;C1739039;C3811844;C3812682	\N	\N
592	sustained decrease of > $nmbr$ % in egfr ®	C0392756;C0443318;C0547047;C1739039;C3811844;C3812682	\N	\N
592	stage $nmbr$ ckd egfr > $nmbr$ ml / ( n = $nmbr$ )	C0205390;C0439526;C1300072;C1306673;C1561643;C1705224;C1739039;C3811844;C3812682;C3887665	\N	\N
592	normal or increased egfr	C0205217;C0205307;C0231683;C0439166;C0442805;C1739039;C2347086;C3811844;C3812682;C4553972	\N	\N
592	normal egfr ( $nmbr$ < egfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0168634;C0205250;C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1299351;C1442488;C1739039;C2347086;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209;C4553972	\N	\N
592	normal ( egfr ≥ $nmbr$ )  n ( % )	C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972	\N	\N
592	normal ( egfr > $nmbr$ )	C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972	\N	\N
592	moderate impairment ( egfr $nmbr$ – $nmbr$ )  n ( % )	C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335	\N	\N
592	moderate impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ )	C0205081;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335	\N	\N
592	moderate impairment ( egfr $nmbr$ - $nmbr$ )	C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335	\N	\N
592	moderate / severe reduction in egfr	C0205081;C0205082;C0301630;C0392756;C1293152;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335;C4551656	\N	\N
592	mild reduction in egfr	C0301630;C0392756;C1293152;C1739039;C2945599;C3811844;C3812682;C4551656	\N	\N
592	mdrd egfr geometric mean ( cv % )  a  b ml /	C0439526;C1705224;C1739039;C2986759;C3538987;C3811844;C3812682;C3839656;C3887665;C4048877;C4318503	\N	\N
592	estimated glomerular filtration rate — no . ( % )	C3811844	\N	\N
592	estimated glomerular filtration rate - no . ( % ) : :	C3811844	\N	\N
592	estimated glomerular filtration rate	C3811844	\N	\N
592	egfr ≥ $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ‡ ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr   ≥ $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr   < $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr using cg / mdrd formulae  % of patients	C0012164;C0030705;C0043444;C0489829;C1524063;C1567075;C1705501;C1739039;C3540479;C3811844;C3812682;C3839656	\N	\N
592	egfr s $nmbr$ o ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr s $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr category ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % )	C0369637;C0439445;C0441923;C0683312;C1739039;C3811844;C3812682;C3889287	\N	\N
592	egfr category  n ( % )	C0683312;C1739039;C3811844;C3812682;C3889287	\N	\N
592	egfr category	C0683312;C1739039;C3811844;C3812682;C3889287	\N	\N
592	egfr and albuminuria	C0001925;C1739039;C3811844;C3812682	\N	\N
28	abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hba $nmbr$ c  hemoglobin a $nmbr$ c  hmg - coa  $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a . asome subjects took more than $nmbr$ oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .	C0000723;C0005910;C0008287;C0009226;C0011816;C0011849;C0013227;C0017628;C0017642;C0019016;C0019046;C0022709;C0025598;C0029167;C0032042;C0040372;C0042295;C0043100;C0050393;C0061323;C0066535;C0073187;C0175795;C0205120;C0205172;C0289313;C0304289;C0332173;C0332257;C0332287;C0332849;C0369718;C0439209;C0441074;C0441833;C0441922;C0442027;C0444686;C0489786;C0521115;C0541154;C0681850;C0687744;C0700307;C0795660;C0872972;C1185738;C1254351;C1257890;C1305855;C1305866;C1441506;C1512211;C1515187;C1519504;C1550501;C1552595;C1552866;C1696465;C1705104;C1705428;C1705429;C1706132;C1706203;C1706408;C1825777;C2349001;C2697811;C2700399;C3250443;C3538758;C4288115;C4484261;C4521986;C4553328	f	-10
592	egfr > $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m '	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
64	no rest angina	C0002965;C0152172	f	65
592	egfr > $nmbr$  n ( % )	C1739039;C3811844;C3812682	\N	\N
592	egfr > $nmbr$	C1739039;C3811844;C3812682	\N	\N
64	rec . ischemia due worsening angina	C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499	f	65
7	interaction p - value	C1704675;C1709380	\N	\N
64	rest angina past $nmbr$ h	C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C4284302;C4528284	f	65
79	data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation	C0040363;C0041260;C0205369;C0439175;C0439390;C0439453;C0439810;C0439836;C0552449;C0750572;C0812399;C1511726;C1719797;C1883351;C2911648;C3245479;C3714741	f	-10
588	other individual and exploratory end points	C0027361;C0237401;C2349179	\N	\N
588	normoglycaemic individuals  n ( % )	C0027361;C0237401;C0580545	\N	\N
97	component . for all instruments  higher scores indicate more severe disease . ara denotes american rheumatism association ( now called	C0004083;C0009326;C0035435;C0205172;C0205250;C0325983;C0439849;C0449432;C0449820;C0596070;C0596306;C0679006;C0699792;C1705248;C1836348;C1947967;C1948052;C2316832;C3890184;C4282437;C4321455;C4551823	f	-10
134	$nmbr$ . $nmbr$ % vs . $nmbr$ . $nmbr$ %	\N	f	-10
134	> $nmbr$   vs .   ≤   $nmbr$	\N	f	-10
106	b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fev $nmbr$    forced expiratory volume in $nmbr$   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd	C0001617;C0004048;C0007450;C0016529;C0018026;C0024115;C0024117;C0034394;C0079816;C0152277;C0205191;C0205246;C0325090;C0332173;C0392747;C0424093;C0521346;C0524517;C0549186;C0585361;C0815320;C0871420;C1304897;C1306036;C1412502;C1443200;C1546767;C1551807;C1553316;C2348867;C2699239;C3536709;C3665481;C3714496;C3714541;C3826872;C3826977;C3889737;C4050461;C4277733;C4284282;C4551720	f	-10
123	rs $nmbr$	C0035970;C3714753;C3813325	f	-10
123	e - rs total scoreb	C0035970;C0439175;C0439810;C3714753;C3813325	f	-10
123	rs $nmbr$ ( aa ) & rs $nmbr$	C0035970;C0282379;C1235746;C1882141;C3714753;C3813325;C4554792	f	-10
123	rs $nmbr$ ( ac ) & rs $nmbr$	C0001246;C0003354;C0035970;C1412573;C2000891;C3539770;C3714753;C3813325	f	-10
123	rs $nmbr$ & rs $nmbr$	C0035970;C3714753;C3813325	f	-10
123	rs - breathlessnessb	C0035970;C3714753;C3813325	f	-10
31	p value *  placebo group p value *  hyponatremia normonatremic group  tolvaptan vs hyponatremic vs placebo	C0020625;C0032042;C0441833;C0687744;C0857122;C1176308;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408;C1709380;C4553967	f	-10
592	egfr < $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr < $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m '	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr < $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ )	C1739039;C3811844;C3812682	\N	\N
592	egfr < $nmbr$  n ( % )	C1739039;C3811844;C3812682	\N	\N
592	egfr < $nmbr$	C1739039;C3811844;C3812682	\N	\N
592	egfr -	C1739039;C3811844;C3812682	\N	\N
592	egfr ( mumin / $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( ml / min per $nmbr$ ^ $nmbr$ m ' )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( ml / min per $nmbr$ - $nmbr$ m ’ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( ml / min per $nmbr$ - $nmbr$ m ^ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( ml / min per $nmbr$ - $nmbr$ kg / m ^ )	C0369637;C0439402;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( ml / min per $nmbr$ + $nmbr$ m ”	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr ( mdrd )  n ( % )	C1739039;C3811844;C3812682;C3839656	\N	\N
592	egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ )	C1739039;C3811844;C3812682	\N	\N
592	egfr $nmbr$ - $nmbr$	C1739039;C3811844;C3812682	\N	\N
592	egfr  n ( % ) normal ( egfr > $nmbr$ ml / min / em ^ )	C0205307;C0231683;C0439166;C0439445;C1739039;C2347086;C3811844;C3812682;C4553972	\N	\N
592	egfr  ml • mn ' • $nmbr$ . $nmbr$ m $nmbr$	C0026327;C0026405;C0369637;C0439526;C0441923;C1705224;C1739039;C3811844;C3812682;C3887665;C4285072	\N	\N
592	egfr  ml / min per $nmbr$ · $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr  ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  ‡	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	\N	\N
592	egfr	C1739039;C3811844;C3812682	\N	\N
592	ckd ( egfr < $nmbr$ b )	C1561643;C1739039;C3811844;C3812682	\N	\N
592	ckd ( egfr < $nmbr$ )  n ( % )	C1561643;C1739039;C3811844;C3812682	\N	\N
592	bp = blood pressure  egfr = estimated glomerular filtration rate ( men : $nmbr$ en : $nmbr$ x cr $nmbr$ . $nmbr$ x age $nmbr$ . $nmbr$ x $nmbr$ . $nmbr$ )  hdl = high - density lipoprotein .	C0001779;C0005823;C0014908;C0017654;C0023821;C0025266;C0201975;C0750572;C1417861;C1561549;C1739039;C2987294;C3539604;C3711669;C3811844;C3812682;C3889152;C4084730;C4553336;C4553337	\N	\N
592	baseline egfr ≥ $nmbr$ to < $nmbr$	C0168634;C1442488;C1739039;C3811844;C3812682	\N	\N
592	baseline egfr < $nmbr$	C0168634;C1442488;C1739039;C3811844;C3812682	\N	\N
592	baseline egfr ( ml / min per $nmbr$ « $nmbr$ m ’ )	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	\N	\N
592	baseline egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	\N	\N
592	baseline egfr	C0168634;C1442488;C1739039;C3811844;C3812682	\N	\N
592	baseline ckd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682	\N	\N
592	$nmbr$ — em	\N	\N	\N
-10	inguinal hernia repair	C0021446	\N	\N
590	hiatus hernia	C3489393	\N	\N
590	hiatal hernia ( yes ) ( n )	C1549445;C1705108;C1710701;C3489393	\N	\N
590	esophageal hiatal hernia *	C3489393	\N	\N
589	previous pneumonia	C0032285;C0205156;C1552607	\N	\N
589	pneumonia	C0032285	\N	\N
589	bacterial pneumonia	C0004626	\N	\N
588	teaes in a $nmbr$ % of individuals	C0027361;C0237401	\N	\N
588	no . ( % ) of individuals *	C0027361;C0237401	\N	\N
588	individuals with type $nmbr$ diabetes  n ( % )	C0027361;C0237401;C1320657	\N	\N
588	individuals with prediabetes	C0027361;C0237401;C0362046	\N	\N
588	individuals with pre - diabetes  n ( % )	C0027361;C0237401;C0362046	\N	\N
588	individuals with normoglycaemia	C0027361;C0237401;C0580545	\N	\N
588	individual endpoints	C0027361;C0237401;C2349179	\N	\N
587	smi :	\N	\N	\N
587	meddra smq	C1140263	\N	\N
587	intended durat - sm of antccagubficn	C0036154;C1283828;C1551357;C4553627	\N	\N
586	simva n = $nmbr$ n ( % )	\N	\N	\N
586	simva ( „ = $nmbr$ }	\N	\N	\N
586	simva ( n = $nmbr$ )	\N	\N	\N
586	simva ( % )	\N	\N	\N
586	simva	\N	\N	\N
586	male simva ( „ = $nmbr$ }	C0086582;C1706180;C1706428;C1706429	\N	\N
586	male simva ( n = $nmbr$ )	C0086582;C1706180;C1706428;C1706429	\N	\N
586	male simva	C0086582;C1706180;C1706428;C1706429	\N	\N
586	male eze / simva ( „ = $nmbr$ }	C0086582;C1706180;C1706428;C1706429	\N	\N
586	male eze / simva ( n = $nmbr$ )	C0086582;C1706180;C1706428;C1706429	\N	\N
586	male eze / simva	C0086582;C1706180;C1706428;C1706429	\N	\N
586	female simva ( „ = $nmbr$ }	C0043210;C0086287;C1705497;C1705498	\N	\N
586	female simva ( n = $nmbr$ )	C0043210;C0086287;C1705497;C1705498	\N	\N
586	female simva	C0043210;C0086287;C1705497;C1705498	\N	\N
586	female eze / simva	C0043210;C0086287;C1705497;C1705498	\N	\N
586	caucasian simva	C0007457;C0043157	\N	\N
585	subdural / epidural	C0038541;C0228134;C0812144	\N	\N
585	structural heart disease — no . ( % ) f	C0016327;C1290384	\N	\N
585	structural heart disease §	C1290384	\N	\N
585	structural heart disease	C1290384	\N	\N
585	structural	C0678594	\N	\N
584	salbutamol  %	C0001927	\N	\N
584	post - salbutamol fev $nmbr$ / fvcb  mean ( sd )	C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541	\N	\N
584	post - salbutamol fev $nmbr$ ( l ) b  mean ( sd )	C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541	\N	\N
584	fev $nmbr$  litres ( post - salbutamol )  mean ( sd )	C0001927;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541	\N	\N
583	variable demographic characteristics	C0439828;C0683970;C4553760	\N	\N
583	demographic features	C0683970	\N	\N
583	demographic feature	C0683970	\N	\N
583	demographic data	C4684639	\N	\N
583	demographic characteristics  mean ± sd unless otherwise indicated	C0444504;C0683970;C1444656;C2347634;C2348143;C2699239	\N	\N
583	demographic characteristics  mean ( sd )  unless otherwise stated	C0444504;C0683970;C1301808;C1442792;C2347634;C2348143;C2699239	\N	\N
583	demographic characteristics	C0683970	\N	\N
582	patient demographics age — yr	C0011298;C0439234;C1704791;C4698447	\N	\N
582	demography	C0011298	\N	\N
582	demographics age ( years )	C0011298;C1510829;C1704791	\N	\N
582	demographics age  years  mean ( sd )	C0011298;C0444504;C1510829;C1704791;C2347634;C2348143;C2699239	\N	\N
582	demographics	C0011298;C1704791	\N	\N
582	demographic variable	C0011298;C0439828;C4553760	\N	\N
582	demographic factors	C0011292;C0011298	\N	\N
582	demographic and medical variables	C0011298;C0199168;C0205476;C0439828	\N	\N
582	demographic and clinical characteristics	C0011298;C0683325	\N	\N
582	demographic and clinical	C0011298;C0205210	\N	\N
582	demographic $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )	C0011298	\N	\N
582	demographic	C0011298	\N	\N
582	( a ) demographics	C0011298;C1704791	\N	\N
581	• hemorrhagic stroke	C0553692	\N	\N
581	subarachnoid hemorrhage	C0038525	\N	\N
581	prior non - haemorrhagic stroke	C0332152;C0553692;C1518422;C2826257	\N	\N
581	primary hemorrhagic stroke	C0205225;C0439612;C0439631;C0553692	\N	\N
581	non ‐ haemorrhagic stroke — no . ( % )	C0038454;C0333275;C1518422;C4554100	\N	\N
581	ischemic stroke without hemorrhagic conversior	C0333275;C0475224;C0553692;C0948008	\N	\N
581	hemorrhagic stroke ( n = $nmbr$ )	C0553692	\N	\N
581	hemorrhagic stroke	C0553692	\N	\N
581	hemorrhagic	C0333275	\N	\N
581	haemorrhagic stroke — no . ( % )	C0553692	\N	\N
581	haemorrhagic stroke	C0553692	\N	\N
581	haemorrhagic	C0333275	\N	\N
580	south asian	C1519427	\N	\N
580	south asia	C0037723;C1519427	\N	\N
580	south american	C0425359	\N	\N
580	south america ( n = $nmbr$ )	C0037713	\N	\N
580	south america ( % )	C0037713	\N	\N
580	south america	C0037713	\N	\N
580	south africa / south america	C0001737;C0002454;C0037712;C0037713	\N	\N
580	south africa	C0037712	\N	\N
580	south ! central america	C0007674;C0037713;C0205099;C1710133;C1879652	\N	\N
580	latin america or south africa	C0023122;C0037712	\N	\N
580	central or south america	C0037713;C0205099;C1879652	\N	\N
580	central and south america and mexico	C0025885;C0037713;C0205099;C1879652	\N	\N
580	central and south america	C0037713;C0205099;C1879652	\N	\N
580	central america and south america	C0007674;C0037713	\N	\N
580	central / south america and mexico	C0007674;C0025885;C0037713;C0205099;C1710133;C1879652	\N	\N
580	central / south america	C0007674;C0037713;C0205099;C1710133;C1879652	\N	\N
579	north ameriea	C1709269	\N	\N
579	north american	C0425358;C2700615	\N	\N
579	north	C1709269	\N	\N
579	< $nmbr$ nwrrtn	\N	\N	\N
578	grip strength > = median	C0429271;C0549183;C0876920;C2347635;C2348144;C2598165;C2939193	\N	\N
578	grip strength < meidan	C0429271;C2598165	\N	\N
577	health state index score  uk algorithm	C0002045;C0041700;C0449820;C0600653;C0683314;C0918012;C1552854;C1553907;C1637833;C2986546;C4050231	\N	\N
577	algorithm $nmbr$	C0002045;C1553907	\N	\N
576	tertile $nmbr$ index pci performed	C0600653;C0884358;C0918012;C1552854;C1637833;C2986546;C4049621	\N	\N
576	resection performed — no . { % )	C0015252;C0728940;C0884358	\N	\N
576	resection performed  %	C0015252;C0728940;C0884358	\N	\N
576	pci performed	C0884358;C4049621	\N	\N
576	index pci performed	C0600653;C0884358;C0918012;C1552854;C1637833;C2986546;C4049621	\N	\N
575	thienopyridine drug at start of open - label period	C0439531;C1120149;C1709323;C1948053;C2348346	\N	\N
575	study period fatal pe	C0070939;C0439531;C0557651;C1302234;C1705232;C1880476;C1948053;C2603343;C4284304	\N	\N
575	placebo ‐ controlled period	C0439531;C1706408;C1948053	\N	\N
575	period i	C0021966;C0221138;C0439531;C1948053	\N	\N
575	overall study period	C0282416;C0439531;C0557651;C1561607;C1948053;C2603343	\N	\N
575	during overall study period	C0282416;C0439531;C0557651;C1561607;C1948053;C2603343	\N	\N
575	- recurrent vte during overall study period	C0282416;C0439531;C0557651;C0630906;C1455761;C1561607;C1948053;C2603343;C2945760	\N	\N
574	prior treatment — no . ( % )	C1514463	\N	\N
574	prior treatment — %	C1514463	\N	\N
574	prior treatment	C1514463	\N	\N
574	prior tnfi treatment	C1514463	\N	\N
574	prior tnf antagonist treatment - no	C0231491;C1448177;C1514463	\N	\N
574	prior therapy  %	C1514463	\N	\N
574	prior ms treatment with ifn - beta or glatiramer acetate . no . ( % )	C0015980;C0289884;C1514463;C2349943;C3539704;C3713294	\N	\N
574	prior ms treatment with ifn - beta or	C0015980;C1514463;C2349943;C3539704;C3713294	\N	\N
574	prior lipid - modifying therapy	C0023779;C0392747;C1514463	\N	\N
574	prior lev treatment    n   ( % )	C0023556;C1514463	\N	\N
574	prior lev treatment	C0023556;C1514463	\N	\N
574	prior anti - tnf treatment	C1448177;C1514463	\N	\N
574	no prior ms therapies	C1514463;C2349943;C3539704;C3713294	\N	\N
573	negative for helicobacter pylori — no . / total no . ( % )	C0439175;C0439810;C4688581	\N	\N
573	helicobacter pylori infection ( + ) ( n )	C0850666	\N	\N
573	helicobacter pylori - negative  n ( % )	C4688581	\N	\N
573	h pylori serology *	C0036745;C0079488;C0220911;C0455278	\N	\N
573	h . pylori infection	C0850666	\N	\N
572	pulmonary medications ( % )	C0013227;C0024109;C0802604;C2598133;C2707265;C2709248;C4284232;C4522268	\N	\N
572	pulmonary medication during baseline ! '	C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268	\N	\N
572	pulmonary embolismb  n / n ( % )	C0024109;C2707265;C2709248;C4522268	\N	\N
572	pulmonary embolisma  n / n ( % )	C0024109;C2707265;C2709248;C4522268	\N	\N
572	proportion taking pulmonary medications ( % ) b	C0013227;C0024109;C0802604;C1515187;C1709707;C2598133;C2707265;C2709248;C4284232;C4522268	\N	\N
572	fvc ( l ) proportion taking pulmonary medications ( % ) b	C0013227;C0024109;C0802604;C1515187;C1709707;C2598133;C2707265;C2709248;C3714541;C4284232;C4522268	\N	\N
572	baseline pulmonary medications	C0013227;C0024109;C0168634;C0802604;C1442488;C2598133;C2707265;C2709248;C4284232;C4522268	\N	\N
572	baseline pulmonary medication  n ( % )	C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268	\N	\N
572	baseline pulmonary medication  b n ( % )	C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268	\N	\N
572	baseline pulmonary medication	C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268	\N	\N
572	any pulmonary medication  n ( % )	C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268	\N	\N
572	any pulmonary medication	C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268	\N	\N
571	sleep	C0037313	\N	\N
571	on step - $nmbr$ drug  %	C0013227;C1254351;C1261552;C1704379;C1705117;C2825408;C3814463	\N	\N
571	. $nmbr$ step or incident vitrectomy or photocoagulation	C0023694;C0042903;C1261552;C1328010;C1551358;C1704379;C1705117;C2825408;C3814463	\N	\N
571	$nmbr$ step	C1261552;C1704379;C1705117;C2825408;C3814463	\N	\N
571	$nmbr$ or $nmbr$ step	C1261552;C1704379;C1705117;C2825408;C3814463	\N	\N
570	stemi ( % )	C1536220;C3538872	\N	\N
570	stemi	C1536220;C3538872	\N	\N
570	st - segment — elevation myocardial infarction	C1536220	\N	\N
570	st - segment elevation myocardial infarction	C1536220	\N	\N
570	st - segment - elevation myocardial infarction — no . ( % )	C1536220	\N	\N
570	st - elevation myocardial infarction	C1536220;C3538872	\N	\N
570	qualifying mi : stemi	C1514624;C1536220;C3538872;C3810814	\N	\N
570	prior stemi	C0332152;C1536220;C2826257;C3538872	\N	\N
570	no prior stemi	C0332152;C1536220;C2826257;C3538872	\N	\N
570	myocardial infarction without st - segment elevation — no . ( % )	C1536220	\N	\N
569	without stent	C0038257	\N	\N
569	with stent ^ l	C0038257	\N	\N
569	with stent	C0038257	\N	\N
569	with any stent	C0038257	\N	\N
569	vein graft stented	C0038257;C0042449;C0181074;C0332835;C1961139	\N	\N
569	vein bypass stented	C0038257;C0042449;C0741847	\N	\N
569	vein bypass graft stented	C0038257;C0398147	\N	\N
569	stent plus placebo	C0032042;C0038257;C0332287;C1696465;C1706408	\N	\N
569	stent plus abciximab	C0038257;C0288672;C0332287	\N	\N
569	stent length per lesion  mm	C0038257;C0221198;C1444754;C1546698;C1706316;C4330985;C4554674	\N	\N
569	stent group ( n = $nmbr$ )	C0038257;C0441848	\N	\N
569	stent diameter < $nmbr$ mm	C0038257;C1301886;C4330985;C4554674	\N	\N
569	stent diameter $ $nmbr$ mm	C0038257;C1301886;C4330985;C4554674	\N	\N
569	stent / abciximab - stent / placebo	C0032042;C0038257;C0288672;C1696465;C1706408	\N	\N
569	stent ( n = $nmbr$ )	C0038257	\N	\N
569	stent	C0038257	\N	\N
569	prior stent	C0038257;C0332152;C2826257	\N	\N
569	previous stenting ( % previous pci )	C0038257;C0205156;C1552607;C2348535;C4049621	\N	\N
569	other stent	C0038257	\N	\N
569	number stent > $nmbr$	C0038257;C0237753;C0449788	\N	\N
569	number of stents implanted	C0021102;C0038257;C0237753;C0449788;C2828363	\N	\N
569	number of stents ( per patient )	C0030705;C0038257;C0237753;C0449788	\N	\N
569	number of stents	C0038257;C0237753;C0449788	\N	\N
569	number of stent = l or $nmbr$ or $nmbr$	C0038257;C0237753;C0449788	\N	\N
569	number of stent = $nmbr$	C0038257;C0237753;C0449788	\N	\N
569	no . of stents	C0038257	\N	\N
569	multivessel stenting	C0038257;C2348535	\N	\N
569	minimum stent diameter	C0038257;C4054490	\N	\N
549	pre - menopausal with hormone replacement	C0206158;C0282402	\N	\N
569	mean total stent length per lesion  mm ( sd ) ‡	C0038257;C0221198;C0439175;C0439810;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
569	coronary angioplasty or stenting	C0002997;C0038257;C0190211;C2348535	\N	\N
569	biolimus a $nmbr$ - eluting stent ¶	C0038257	\N	\N
568	subgroup sex	C0009253;C0036864;C0079399;C0804628;C1079230;C1314687;C1515021;C1522384	\N	\N
568	sexy	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex — no . / total no . ( % )	C0009253;C0036864;C0079399;C0439175;C0439810;C0804628;C1314687;C1522384	\N	\N
568	sex — no . ( % )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex m / f	C0009253;C0036864;C0079399;C0804628;C1306057;C1314687;C1522384	\N	\N
568	sex :	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex ( women  n [ % ] )	C0009253;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex ( p = $nmbr$ )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex ( no . )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex ( interaction : p = $nmbr$ . $nmbr$ )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C1704675	\N	\N
568	sex ( % )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex  no . ( % ) male	C0009253;C0036864;C0079399;C0086582;C0804628;C1314687;C1522384;C1706180;C1706428;C1706429	\N	\N
568	sex  no . ( % )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex  no  ( % )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex  n ( % ) b	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex  n ( % ) *	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex  n ( % )	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex  %	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	sex	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	p interaction ( rx arm * sex )	C0009253;C0036864;C0079399;C0369773;C0446516;C0804628;C1314687;C1425688;C1521941;C1522384;C1704675;C2603361;C2709207;C3715044;C4553528	\N	\N
568	intercourse satisfac -	C0009253	\N	\N
568	assigned treatment by sex interaction	C0009253;C0036864;C0039798;C0079399;C0087111;C0804628;C1314687;C1516050;C1522326;C1522384;C1533734;C1552601;C1704675;C1705169;C3538994;C3887704	\N	\N
568	> $nmbr$ yrs sex :	C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
568	> $nmbr$ yr sex	C0009253;C0036864;C0079399;C0439234;C0804628;C1314687;C1522384	\N	\N
567	week $nmbr$ mean ( se )	C0036919;C0332174;C0439230;C0444504;C2347634;C2348143	\N	\N
567	triglycerides tx difference vs pbo  ls mean % change from baseline ( se )	C0023668;C0031962;C0036919;C0041004;C0041403;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1705242;C2347634;C2348143;C4319952	\N	\N
567	sesbp	\N	\N	\N
567	sedbp	\N	\N	\N
567	se	C0036919	\N	\N
567	modified se - adl scale	C0001288;C0036919;C0175659;C0349674;C0392747;C1420005;C1947916;C3889737	\N	\N
567	mean ± se ) bii ( ls mean ± se )	C0023668;C0036919;C0444504;C1413059;C2347634;C2348143	\N	\N
567	mean ± se	C0036919;C0444504;C2347634;C2348143	\N	\N
567	mean change  % ( se )	C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
567	mean ( se ) trough l	C0036919;C0444504;C0444506;C2347634;C2348143	\N	\N
567	mean ( se ) trough  l	C0036919;C0444504;C0444506;C2347634;C2348143	\N	\N
567	mean ( se ) auc ^ p l	C0036919;C0376690;C0444504;C2347634;C2348143	\N	\N
567	mean ( se ) auc $nmbr$ - $nmbr$  l	C0036919;C0376690;C0444504;C2347634;C2348143	\N	\N
567	mean ( se ) $nmbr$ - year rates per $nmbr$ population	C0036919;C0439234;C0439508;C0871208;C1521828;C2347634	\N	\N
567	mean ( se )	C0036919;C0444504;C2347634;C2348143	\N	\N
567	ls mean ± se	C0023668;C0036919;C0444504;C2347634;C2348143	\N	\N
567	ls mean difference ( se )	C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143	\N	\N
567	ls mean change from baseline ( se )  %	C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
567	ls mean change from baseline  ml ( se ) a	C0023668;C0036919;C0168634;C0392747;C0439526;C0443172;C0444504;C1442488;C1705224;C1705241;C2347634;C2348143;C3887665;C4319952	\N	\N
567	ls mean change ( se )	C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
567	ls mean ( se )	C0023668;C0036919;C0444504;C2347634;C2348143	\N	\N
567	ls mean % change from baseline _ se	C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
567	ipss ( ls mean ± se )	C0023668;C0036919;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063	\N	\N
567	in ibdq total score at week $nmbr$  mean [ se ]	C0036919;C0332174;C0439175;C0439230;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236	\N	\N
567	in - trial and post - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk	C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0687676;C0871208;C1264674;C1444641;C1521828;C1704687;C1707101;C3469826;C3541888;C4288115	\N	\N
567	hscrp  exp ls mean change ± se ‡	C0023668;C0036919;C0392747;C0443172;C0444504;C1417055;C1705241;C2347634;C2348143;C4319952	\N	\N
567	homajr tx difference vs pbo  median change from baseline ( se ) $nmbr$ lipid parameters	C0031962;C0036919;C0041403;C0168634;C0449381;C0549183;C0876920;C1158406;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193	\N	\N
567	homa_ir tx difference vs pbo  median change from baseline ( se ) $nmbr$	C0022065;C0022071;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1448132;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952	\N	\N
567	fev $nmbr$ at week $nmbr$  mean ml ( se ) difference mepo - pbo ( $nmbr$ % ci )	C0031962;C0036919;C0332174;C0439230;C0444504;C1705241;C1705242;C2347634;C2348025;C2348143;C3714541	\N	\N
567	difference ( se )	C0036919;C1705241;C1705242	\N	\N
567	daytime nasal symptoms score change from baseline  mean ± se	C0036919;C0168634;C0231918;C0332169;C0392747;C0443172;C0444504;C0449820;C1442488;C1705241;C2347634;C2348143;C4050231;C4319952	\N	\N
567	das $nmbr$ - crp  ls mean change from baseline ( se ) §	C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952	\N	\N
567	cwt  mean ( se )  mm	C0036919;C0444504;C2347634;C2348143;C4330985;C4554674	\N	\N
567	change in sesbp  ls mean ( se )	C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
567	change in sedbp  ls mean ( se )	C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
567	change from baseline in morning pef during weeks $nmbr$ - $nmbr$  mean l / min ( se )	C0030771;C0036919;C0168634;C0332170;C0392747;C0439230;C0443172;C0444504;C0702093;C1442488;C1518922;C1524029;C1542834;C1705241;C2347634;C2348143;C3813700;C4319952	\N	\N
567	baseline mean ( se )	C0036919;C0168634;C0444504;C1442488;C2347634;C2348143	\N	\N
567	baseline insulin dose ( u = kg ) [ lsm ( se ) ]	C0036919;C0168634;C0366513;C1300561;C1442488	\N	\N
567	baseline a $nmbr$ c ( % ) [ lsm ( se ) ]	C0036919;C0168634;C1442488	\N	\N
567	basdai  ls mean change from baseline   ±   se	C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952	\N	\N
567	asqol  ls mean change ± se	C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
567	asqol  ls mean change from baseline   ±   se	C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
567	adjusted ∗   mean ( se ) ( ml )	C0036919;C0439526;C0444504;C0456081;C1705224;C2347634;C2348143;C3887665	\N	\N
567	adjusted mean change from baseline ( se )	C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
567	adjusted mean _ se change from baseline	C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
567	adjusted mean ( se ) fevi auco_ $nmbr$  ml	C0036919;C0429706;C0439526;C0444504;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367	\N	\N
567	( se ] tf total - c	C0036919;C0439175;C0439810;C4048299;C4048587	\N	\N
567	( se ] tf hdl - c	C0036919;C3715113;C4048299;C4048587	\N	\N
567	( se ] tf	C0036919;C4048299;C4048587	\N	\N
567	( se ] t *	C0036919	\N	\N
567	( se ] t	C0036919	\N	\N
567	( se ] +	C0036919	\N	\N
567	( se ) t *	C0036919	\N	\N
567	( se )	C0036919	\N	\N
567	% change from baseline ls means ( se )	C0023668;C0036919;C0168634;C0392747;C0443172;C1442488;C1704970;C1705241;C4319952	\N	\N
567	% change ( mean ± se )	C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
567	% ( se )	C0036919	\N	\N
567	$nmbr$ - y rate per $nmbr$ persons ( se )  n	C0027361;C0036919;C0871208;C1521828	\N	\N
566	screening  mean ( sd ) morning pef  mean	C0030771;C0220908;C0220909;C0332170;C0444504;C1518922;C1542834;C1698960;C1710031;C1710032;C1710477;C2347634;C2348143;C2348164;C2699239	\N	\N
566	pm pef ( sd )  l / min	C0030266;C0030771;C0702093;C1518922;C1524029;C1542834;C2699239;C3813700;C4049155	\N	\N
566	pef !	C0030771;C1518922;C1542834	\N	\N
566	am pef ( sd )  l / min	C0030771;C0702093;C1518922;C1524029;C1542834;C2699239;C3813700	\N	\N
565	aortic stenosis  n ( % )	C0003507	\N	\N
565	aortic stenosis	C0003507	\N	\N
565	> $nmbr$ y pathogenesis  n ( % )	C0543483;C0699748	\N	\N
564	osteoporosis drug	C0013227;C0029456;C1254351;C4554622	\N	\N
564	osteoporosis	C0029456;C4554622	\N	\N
-10	exercise category ( % )	C3669314	\N	\N
562	t - score categories lumbar spineb	C0024090;C0683312;C3854607	\N	\N
562	racial category *	C0034510;C0683312;C1706779;C3669213;C3853635;C3889287	\N	\N
562	racial category	C0034510;C0683312;C1706779;C3669213;C3853635;C3889287	\N	\N
562	qmax category  n ( % ) :	C0683312;C3889287	\N	\N
562	p value within category	C0683312;C1709380;C3889287	\N	\N
562	mean ± sd age ( y ) mean bmi category ( % )	C0001779;C0444504;C0578022;C0683312;C2347634;C2348143;C2699239;C3889287	\N	\N
562	key : fc = fasting glucose  bp = * this category did not include ar have $nmbr$ of the indicated charac	C0015663;C0017725;C0037623;C0332257;C0683312;C1415692;C1436327;C1444656;C1518422;C1552866;C1708288;C2700399;C2983605;C2986463;C3884535;C3889287;C4318478;C4521369	\N	\N
562	interaction between treatment and baseline bmi category	C0039798;C0087111;C0168634;C0578022;C0683312;C1442488;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704;C3889287	\N	\N
562	glycatedhemoglobin category  %	C0683312;C3889287	\N	\N
562	entry category	C0683312;C1705654;C3889287	\N	\N
562	dysglycemic categories  n ( % )	C0683312;C1960636	\N	\N
562	creatine clearance category $nmbr$ to < $nmbr$ ml / min $nmbr$ / $nmbr$	C0373595;C0439445;C0683312;C3889287	\N	\N
562	creatine clearance category	C0373595;C0683312;C3889287	\N	\N
562	category $nmbr$ and $nmbr$	C0683312;C3889287	\N	\N
562	category $nmbr$	C0683312;C3889287	\N	\N
562	category	C0683312;C3889287	\N	\N
562	cardiovascular disease risk category	C0683312;C1113685;C3889287	\N	\N
562	background csdmard category	C0683312;C1706907;C3889287	\N	\N
562	age category >	C0001779;C0683312;C3889287	\N	\N
562	age category ( years )  n ( % )	C0683312;C1510829;C3889287	\N	\N
562	age category ( % )	C0001779;C0683312;C3889287	\N	\N
562	age category  n ( % ) < $nmbr$ years	C0683312;C1510829;C3889287	\N	\N
562	age category  n ( % ) :	C0001779;C0683312;C3889287	\N	\N
562	age category  n ( % )	C0001779;C0683312;C3889287	\N	\N
562	age category	C0001779;C0683312;C3889287	\N	\N
562	/ \\ge category	C0683312;C1292300;C3538705;C3889287	\N	\N
561	severity ofhypertension [ n ( % ) ] b	C0439793;C0522510	\N	\N
561	severity of hypertensionb	C0439793;C0522510	\N	\N
561	severity of heartburnb	C0439793;C0522510	\N	\N
561	severity of copda  airflow limitation  n ( % )	C0231999;C0439793;C0443288;C0449295;C0522510	\N	\N
561	severity of copd  airflow limitation  n ( % )	C0024117;C0231999;C0439793;C0443288;C0449295;C0522510;C1412502;C3714496	\N	\N
561	severity of airflow obstruction	C0028778;C0231999;C0439793;C0522510;C1882136	\N	\N
561	severity of airflow limitation	C0231999;C0439793;C0443288;C0449295;C0522510	\N	\N
561	severity n ( % )	C0439793;C0522510	\N	\N
561	severity	C0439793;C0522510	\N	\N
561	nocturnal heartburn severity	C0018834;C0240526;C0439793;C0522510	\N	\N
565	carotid stenosis	C0007282	f	2196
565	carotid artery stenosis  n ( % )	C0007282	f	2196
565	extracranial carotid stenosis  n ( % )	C0007282;C0580586	f	2196
561	morning stiffness severity  $nmbr$ - $nmbr$ scale	C0175659;C0349674;C0439793;C0457086;C0522510;C1947916	\N	\N
561	lowzmedium intensity	C0522510	\N	\N
561	lntensityd	\N	\N	\N
561	intensive therapy ( n = $nmbr$ )	C0039798;C0087111;C0162425;C0522510;C1283828;C1363945;C1550453	\N	\N
561	intensive glycemia lowering	C0005802;C0162425;C0441994;C0522510;C1283828;C1550453;C2003888	\N	\N
561	intensive control	C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389	\N	\N
561	intensive blood glucose control	C0162425;C0522510;C1283828;C1550453;C3267174	\N	\N
561	intensive ( n = $nmbr$ )	C0162425;C0522510;C1283828;C1550453	\N	\N
561	intensity $nmbr$	C0522510	\N	\N
561	intense physical activity	C0015259;C0026606;C0522510	\N	\N
561	intense	C0522510	\N	\N
561	hypertension severity	C0020538;C0439793;C0522510;C1963138	\N	\N
561	heartburn severity during the run - in periodt	C0018834;C0439793;C0522510;C3274438	\N	\N
561	ed severity * *  n ( % ) :	C0439793;C0522510;C3538926	\N	\N
561	ed severity  no . ( % ) a	C0439793;C0522510;C3538926	\N	\N
561	data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ]  gold $nmbr$ [ $nmbr$ ]    bon a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status  the mcid is a change of $nmbr$   units  on a scale of $nmbr$ – $nmbr$  with higher scores indicating more severe dyspnea  on a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status	C0018026;C0018759;C0175659;C0205172;C0205250;C0205369;C0243161;C0332271;C0349674;C0392747;C0439148;C0439793;C0443172;C0444504;C0449450;C0449820;C0522510;C1279889;C1304897;C1457868;C1511726;C1519795;C1527178;C1552041;C1705241;C1705938;C1947916;C2080700;C2347634;C2348143;C2699239;C2986536;C3245479;C3714741;C3853603;C4319952	\N	\N
561	baseline statin intensity	C0168634;C0360714;C0522510;C1442488	\N	\N
561	baseline ed severity * * :	C0168634;C0439793;C0522510;C1442488;C3538926	\N	\N
561	any severity	C0439793;C0522510	\N	\N
560	hrg	C1437978;C1705020	\N	\N
560	hmg - coa reductase inhibitors	C0360714;C2756999;C3539119	\N	\N
559	ra - beam	C0338248;C2347880;C3538806;C4048756;C4521565	\N	\N
559	beam   <   $nmbr$   mg / dl at week $nmbr$  n ( % )	C0332174;C0338248;C0439230;C0439269;C2347880;C4521565	\N	\N
558	menopausal status and hormone therapy use	C0042153;C0279025;C0457083;C1513126;C1947944	\N	\N
558	hormone therapy use	C0042153;C0279025;C0457083;C1947944	\N	\N
558	hormone therapy	C0279025	\N	\N
558	hormonal therapy — no . ( % )	C0279025	\N	\N
558	baseline use of hormone therapy ( % )	C0168634;C0279025;C1442488;C1524063	\N	\N
556	no diuretic therapy	C0948575	\N	\N
556	diuretic therapy	C0948575	\N	\N
556	diabetes therapy at baseline ( alone or in combination )	C0168634;C0205171;C0205195;C0439044;C0679994;C1442488;C1947911;C3274787;C3539002;C3811910	\N	\N
556	diabetes therapy  n ( % )	C3274787;C3539002	\N	\N
556	diabetes therapy	C3274787;C3539002	\N	\N
555	estrogen therapy	C0279494	\N	\N
555	anticoagulant therapy	C0150457	\N	\N
554	pharmacotherapy	C0013216;C0013217	\N	\N
554	other drug therapy  n ( % )	C0013216;C0013217	\N	\N
554	macroalbuminuria — no . ( % ) drug therapy — no . ( % )	C0013216;C0013217	\N	\N
554	drug therapy  no . ( % )	C0013216;C0013217	\N	\N
554	drug therapy  n ( % )	C0013216;C0013217	\N	\N
554	drug therapy	C0013216;C0013217	\N	\N
553	statin monotherapy	C0360714	\N	\N
553	phototherapy previous systemic treatment  n ( % )	C0031765;C0205156;C0678812;C1552607	\N	\N
553	phototherapy	C0031765	\N	\N
553	monotherapy	\N	\N	\N
553	metforminmonotherapy	\N	\N	\N
553	glulisine monotherapy	\N	\N	\N
552	treatment stratum ^ :	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
552	treated lesions ‡	C0221198;C1522326	\N	\N
552	treated	C1522326	\N	\N
552	stratum	\N	\N	\N
552	patients treated for > $nmbr$ weeks ( % )	C0030705;C0439230;C1522326	\N	\N
552	patients treated and operated  n ( % )	C0030705;C1522326;C3242339	\N	\N
552	patients treated	C0030705;C1522326	\N	\N
552	patients ( treated set * )  n	C0030705;C0036849;C1442518;C1522326;C1705195	\N	\N
552	not treated	C1518422;C1522326	\N	\N
552	normoalbuminuria at baseline ( $nmbr$ % of patients treated )	C0030705;C0168634;C1442488;C1522326	\N	\N
552	no . of treated lesions	C0221198;C1522326	\N	\N
552	lesions treated per patient	C0030705;C0221198;C1522326	\N	\N
552	coronary artery treated  no . ( % )	C0205042;C1522326	\N	\N
551	untreated at baseline	C0168634;C0332155;C1442488	\N	\N
551	untreated	C0332155	\N	\N
550	pvaluefor trend	C1521798;C4554533	\N	\N
550	pfor trend	C1151635;C1521798;C4554533	\N	\N
550	p trend	C0369773;C1521798;C2603361;C4554533	\N	\N
550	p j $nmbr$ * trend	C1518835;C1521798;C4554533	\N	\N
550	p for trend -	C0369773;C1521798;C2603361;C4554533	\N	\N
550	p for trend	C0369773;C1521798;C2603361;C4554533	\N	\N
550	heterogeneity or trend p vaiue	C0019409;C0242960;C1521798;C4554533	\N	\N
549	use of hormone replacement therapy ( a )	C0282402;C1524063	\N	\N
549	pre - menopausal without hormone replacement	C0206158;C0282402	\N	\N
561	intensity of statin therapy	C0522510;C1278454	f	872
561	intensity of statin therapy at baseline — no . { % )	C0168634;C0522510;C1278454;C1442488	f	872
557	anti - hypertensive therapy	C0585941	f	1579
557	antihypertensive therapy	C0585941	f	1579
557	antihypertensive therapy  n ( % )	C0585941	f	1579
557	number of antihypertensive medications used  n ( % ) no antihypertensive therapy	C0003364;C0369718;C0441922;C0585941;C1273517;C1718138	f	1579
549	postmenopausal and no hrt	C0232970;C0282402	\N	\N
549	postmenopausal and current hrt	C0232970;C0282402;C0521116;C1705970	\N	\N
549	postmenopausal  no hrt	C0232970;C0282402	\N	\N
549	postmenopausal  current hrt	C0232970;C0282402;C0521116;C1705970	\N	\N
549	hrt use	C0042153;C0282402;C0457083;C1947944	\N	\N
549	hrt	C0282402	\N	\N
549	hormone replacement therapy use	C0042153;C0282402;C0457083;C1947944	\N	\N
549	hormone replacement therapy	C0282402	\N	\N
549	hormone replacement ! !	C0282402	\N	\N
549	hormone replacement	C0282402	\N	\N
548	itherchdt	\N	\N	\N
548	atherectomy	C0162513	\N	\N
548	> $nmbr$ or incident vitrectomy or photocoagulation	C0023694;C0042903;C1328010;C1551358	\N	\N
547	rarely	C0522498	\N	\N
547	none or seldom	C0522498	\N	\N
547	never / rarely	C0522498;C2003901	\N	\N
546	stratum ii	C1710602;C4082587	\N	\N
546	stratum *	\N	\N	\N
546	stratum  n ( % )	\N	\N	\N
546	randomization stratum	C0034656	\N	\N
545	moderatex	\N	\N	\N
545	fibrate	\N	\N	\N
544	risk factors and diabetes status ( % )	C0035648;C1317301;C1553898	\N	\N
544	polyvascular disease * and type $nmbr$ diabetes status	C0012634;C0332307;C0449438;C1317301;C1320657;C1547052	\N	\N
544	diabetes status  no . ( % )	C1317301	\N	\N
544	diabetes status  n ( % )	C1317301	\N	\N
544	diabetes status	C1317301	\N	\N
544	diabetes mellitus status	C1317301	\N	\N
544	biomarker status	C0449442	\N	\N
543	ugt induction status : per aeda  n ( % )	C0205263;C0449438;C0857127;C1420188;C4284131	\N	\N
543	status ( spmsq > $nmbr$	C0449438	\N	\N
543	status ( spmsq < $nmbr$	C0449438	\N	\N
543	smokinq status	C0449438	\N	\N
543	other glucose status	C0017725;C0449438	\N	\N
543	lev status  n ( % )	C0023556;C0449438	\N	\N
543	lev status	C0023556;C0449438	\N	\N
543	hormonal status	C0449438;C0458083	\N	\N
543	h . pylori status  n ( % )	C0079488;C0449438	\N	\N
543	frailty status	C0424594;C0449438	\N	\N
543	emotional status	C0013987;C0449438;C0849912	\N	\N
543	cortteosterom relrsclory status	C0449438	\N	\N
543	angina status — no . ( % )	C0002962;C0449438	\N	\N
543	aha status at screeningb  n ( % )	C0050451;C0449438;C0772110	\N	\N
543	aed inducer status	C0449438;C0887457;C3898767	\N	\N
542	stage iii	C0441771	\N	\N
542	stage ii	C0441767	\N	\N
542	stage $nmbr$ b : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441781;C0441923;C1739039;C3811844;C3812682	\N	\N
542	stage $nmbr$ b : > = $nmbr$ and < $nmbr$	C0441781	\N	\N
542	stage $nmbr$ b : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441781;C0441923	\N	\N
542	stage $nmbr$ b	C0441781	\N	\N
542	gold stage iii	C0018026;C0441771;C1304897	\N	\N
542	gold stage ii	C0018026;C0441767;C1304897	\N	\N
541	years modified hoehn and yahr stage  n ( % )	C0205390;C0392747;C0439234;C1300072;C1306673;C3889737	\N	\N
541	stage of pda	C0013274;C0205390;C0226047;C1300072;C1306673;C4282128	\N	\N
541	stage iv	C0022326;C0205390;C1300072;C1306673;C4265176	\N	\N
541	stage $nmbr$ a ckd cohort ( secondary analysis )	C0027627;C0086027;C0175668;C0205390;C0205436;C1300072;C1306673;C1561643	\N	\N
541	stage $nmbr$ a ckd cohort ( post hoc analysis excluding metformin users )	C0025598;C0086027;C0205390;C0332196;C0687676;C1300072;C1306673;C1561643;C1704687;C1706077;C2828389;C3469826	\N	\N
541	stage $nmbr$ a : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$	C0205390;C0369637;C0439445;C0441923;C1300072;C1306673;C1739039;C3811844;C3812682	\N	\N
541	stage $nmbr$ a : > = $nmbr$ and < $nmbr$	C0205390;C1300072;C1306673	\N	\N
541	stage $nmbr$ a : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0205390;C0369637;C0439445;C0441923;C1300072;C1306673	\N	\N
541	stage $nmbr$ a	C0205390;C1300072;C1306673	\N	\N
541	stage $nmbr$ : > = $nmbr$	C0205390;C1300072;C1306673	\N	\N
541	stage $nmbr$ : < $nmbr$	C0205390;C1300072;C1306673	\N	\N
541	stage $nmbr$ ( four - variable modification of diet in kidney disease )	C0022658;C0086153;C0205390;C0205450;C0439828;C1300072;C1306673;C3671772;C4553760	\N	\N
541	stage $nmbr$ ( cockcroft - gault )	C0205390;C1300072;C1306673	\N	\N
541	stage $nmbr$	C0205390;C1300072;C1306673	\N	\N
541	retinopathy ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ )	C0035309;C0205390;C1300072;C1306673;C1962966	\N	\N
541	nkf stage	C0205390;C1300072;C1306673	\N	\N
541	hoehn and yahr stage ( range  $nmbr$ - $nmbr$ )	C0205390;C1300072;C1306673;C1514721;C2348147;C3542016	\N	\N
541	hoehn and yahr stage ( baseline )  mean ( sd )	C0168634;C0205390;C0444504;C1300072;C1306673;C1442488;C2347634;C2348143;C2699239	\N	\N
541	hoehn and yahr stage	C0205390;C1300072;C1306673	\N	\N
541	hoehn & yahr stage ( “ on ” )  n ( % )	C0205390;C1300072;C1306673	\N	\N
541	hoehn & yahr stage ( “ off ” )  n ( % )	C0205390;C1300072;C1306673	\N	\N
541	hoehn & yahr stage	C0205390;C1300072;C1306673	\N	\N
541	gold stage — no . ( % ) * *	C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	gold stage iv	C0018026;C0022326;C0205390;C1300072;C1304897;C1306673;C4265176	\N	\N
541	gold stage [ n ( % ) ]	C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	gold stage ( % ) f	C0016327;C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	gold stage #	C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	gold stage  nf * ( % )	C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	gold stage  n ( % )	C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	gold stage  %	C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	gold stage	C0018026;C0205390;C1300072;C1304897;C1306673	\N	\N
541	estimated gfr renal function stage	C0017654;C0205390;C0232804;C0750572;C1300072;C1306673;C1424601	\N	\N
541	copd severity stage ( gold )	C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496	\N	\N
541	copd severity ( gold stage )	C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496	\N	\N
541	ckd stages	C1306673;C1561643	\N	\N
541	ckd stage $nmbr$ ( % )	C0205390;C1300072;C1306673;C1561643	\N	\N
541	ckd stage $nmbr$	C0205390;C1300072;C1306673;C1561643	\N	\N
540	total vdh - s score ( $nmbr$ - $nmbr$ ) ( n )	C2964552	\N	\N
540	total vdh - s score	C2964552	\N	\N
540	total sgrq mean total score ( sd )	C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236	\N	\N
540	total score §	C2964552	\N	\N
540	total score on the sgrq - c  i	C0021966;C0221138;C2964552;C3826872	\N	\N
540	total score > $nmbr$	C2964552	\N	\N
540	total score < $nmbr$	C2964552	\N	\N
540	total score ( $nmbr$ – $nmbr$ scale )	C0175659;C0349674;C1947916;C2964552	\N	\N
540	total score	C2964552	\N	\N
540	total feet score	C0016504;C0347981;C2964552	\N	\N
540	source	C0449416;C1705919;C4521696	\N	\N
540	sgrq total score * *	C2964552	\N	\N
540	sgrq total score * ( units )	C0439148;C1519795;C2964552;C3853603	\N	\N
540	sgrq total score ( units ) : ! :	C0439148;C1519795;C2964552;C3853603	\N	\N
540	sgrq total score ( units )	C0439148;C1519795;C2964552;C3853603	\N	\N
540	sgrq total score $nmbr$	C2964552	\N	\N
540	sgrq total score  units	C0439148;C1519795;C2964552;C3853603	\N	\N
540	sgrq total score	C2964552	\N	\N
540	sgrq responder ( % )	\N	\N	\N
540	selena - sledai total score	C0451528;C2964552	\N	\N
540	mean sgrq total score ( sd )	C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236	\N	\N
540	mean sgrq total score	C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236	\N	\N
540	iwqol - lite total score ( arbitrary units ) #	C0439183;C2964552	\N	\N
540	eacit - e total score ) |	C2964552	\N	\N
540	ccq total score	C2964552	\N	\N
540	c $nmbr$ - unit sgrq total score increase	C0439148;C0439453;C0442805;C1509845;C1519795;C1704753;C1880519;C2964552;C3853603	\N	\N
540	bdi total score ( baseline )	C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415	\N	\N
540	baseline sgrq total score	C0168634;C1442488;C2964552	\N	\N
540	acq - $nmbr$ total score ∗	C2919686;C2964552	\N	\N
540	( total ses - cd score at	C0007928;C0034283;C2964552;C4552032	\N	\N
539	storage subscore	C0337174;C1698986;C1753314	\N	\N
539	stomach	C0038351;C3714551	\N	\N
539	mean ipss  storage sub - score ( sd )	C0337174;C0542339;C1019118;C1264637;C1698986;C1753314;C1998280;C2699239;C2827405;C3533236;C3811063	\N	\N
539	ipss storage subscore	C0337174;C1019118;C1698986;C1753314;C1998280;C2827405;C3811063	\N	\N
538	trochanter	C0162370	\N	\N
538	subtrochanteric	\N	\N	\N
538	intertrochanteric	C0745355	\N	\N
537	nitratesf	\N	\N	\N
537	nitrates ( oral or topical )	C0028125;C0332237;C0442027;C0699857;C3848573;C4521986	\N	\N
537	nitrates ( % )	C0028125;C0699857;C3848573	\N	\N
537	nitrates  n ( % )	C0028125;C0369718;C0441922;C0699857;C3848573	\N	\N
537	nitrates  ( % )	C0028125;C0699857;C3848573	\N	\N
537	nitrates	C0028125;C0699857;C3848573	\N	\N
537	nitrate — no . ( % )	C0028125;C0699857;C3848573	\N	\N
537	nitrate use	C0028125;C0042153;C0457083;C0699857;C1947944;C3848573	\N	\N
537	nitrate ( oral or intravenous )	C0028125;C0348016;C0442027;C0699857;C3848573;C4521986	\N	\N
537	nitrate	C0028125;C0699857;C3848573	\N	\N
537	iv nitrates	C0022326;C0028125;C0699857;C3848573;C4265176	\N	\N
537	intravenous nitrates	C0028125;C0348016	\N	\N
536	no estimate	C0750572	\N	\N
536	estimated glomerular filtration	C0232809;C0750572	\N	\N
536	estimated gfr	C0017654;C0750572;C1424601	\N	\N
536	estimate	C0750572	\N	\N
536	combined estimated gfr and albuminuria status	C0001925;C0017654;C0205195;C0449438;C0750572;C1424601	\N	\N
536	baseline estimated gfr	C0017654;C0168634;C0750572;C1424601;C1442488	\N	\N
536	< $nmbr$ . $nmbr$ mmol / liter estimated gfr	C0017654;C0439190;C0475211;C0750572;C1424601	\N	\N
535	used	C1273517	\N	\N
535	spacer use during the study	C0221874;C0869040	\N	\N
535	gpi used during pci	C1273517;C1415351;C4049621	\N	\N
535	acei use	C0042153;C0457083;C1947944	\N	\N
535	acei  n ( % )	\N	\N	\N
534	user	C1548600;C1706077	\N	\N
534	nonuser	\N	\N	\N
534	non - user $nmbr$	C1518422;C1548600;C1706077	\N	\N
534	low - dose corticosteroid user	C0001617;C0445550;C1548600;C1706077;C1708745;C3536709	\N	\N
534	laba users	C1706077	\N	\N
534	laba non - users	C1518422;C1706077	\N	\N
534	dmard user	C0242708;C1548600;C1706077	\N	\N
534	bivariate frailty model ( statin users vs non - users )	C0360714;C0424594;C1518422;C1706077;C3161035;C3274659;C3714583;C3853906	\N	\N
534	biologics user	C0005515;C0005522;C1548600;C1706077;C4553887	\N	\N
533	western eu  australia  new zealand	C0015179;C0027978;C0043128;C0324547;C1705493;C3665627;C4289954	\N	\N
533	european union	C0015179	\N	\N
533	eu	C0015179;C3665627	\N	\N
533	eastern eu	C0015179;C1707877;C3665627	\N	\N
-10	environmental stimuli	C0450025	\N	\N
531	timi flow ‡	C3272266	\N	\N
531	final timi flow grade post - ppci	C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528	\N	\N
531	final timi flow grade < $nmbr$	C0205088;C0441800;C0919553;C1546485;C3244287;C3272266;C3853528	\N	\N
531	final timi flow	C0205088;C1546485;C3272266;C3853528	\N	\N
530	timi ≥ $nmbr$	\N	\N	\N
530	timi major / minor bleeding	C0019080;C4441842	\N	\N
530	timi major / minor	C4441842	\N	\N
530	timi - bleeding major / minor	C0019080;C4441842	\N	\N
540	baseline ibdq total score  mean	C0168634;C0444504;C1442488;C2347634;C2348143;C2964552	f	2313
540	ibdq total score	C2964552	f	2313
529	qualifying nstemi  n ( % )	C1514624;C3537184;C4255010	\N	\N
529	nstemi ( n = $nmbr$  $nmbr$ )	C3537184;C4255010	\N	\N
529	nstemi ( % )	C3537184;C4255010	\N	\N
529	nstemi	C3537184;C4255010	\N	\N
529	nste - mi	C3537184;C4255010	\N	\N
529	non — st - segment — elevation myocardial infarction	C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010	\N	\N
529	non - stemi	C3537184	\N	\N
529	non - st - segment elevation myocardial infarction	C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010	\N	\N
529	non - st - elevation myocardial infarction	C1536221;C1536222;C3537184;C4255010	\N	\N
528	moderate decrease ( $nmbr$ - < $nmbr$ mlymin per $nmbr$ . $nmbr$ m $nmbr$ )	C0205081;C0369637;C0392756;C0441923;C0547047;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
528	lvmi ( $nmbr$	\N	\N	\N
528	alvmi ( per g / m $nmbr$ )	C0456715	\N	\N
528	> $nmbr$ mlymin	\N	\N	\N
528	< $nmbr$ mlymin	\N	\N	\N
528	< $nmbr$ mlmin ) $nmbr$	\N	\N	\N
528	$nmbr$ - < $nmbr$ mvmin	\N	\N	\N
527	overall dlqi score $nmbr$	C0282416;C0449820;C1561607;C3899393;C4050231	\N	\N
527	overall dlqi score	C0282416;C0449820;C1561607;C3899393;C4050231	\N	\N
527	mean dlqi score ( $nmbr$ % ci )	C0008107;C0444504;C0449820;C2347634;C2348143;C3259781;C3899393;C4050231	\N	\N
527	dlqi §	C3899393	\N	\N
527	dlqi score	C0449820;C3899393;C4050231	\N	\N
527	dlqi improvement from baseline to week $nmbr$	C0168634;C0332174;C0439230;C1442488;C2986411;C3899393	\N	\N
527	dlqi ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3899393	\N	\N
527	dlqi  $nmbr$ - $nmbr$ *	C3899393	\N	\N
527	dlqi	C3899393	\N	\N
527	baseline dlqi  mean ( sd )	C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3899393	\N	\N
526	patients with enthesitis ( lei > $nmbr$ )	C0023401;C0030705;C0428209;C1282952	\N	\N
526	li $nmbr$ ( $nmbr$ . $nmbr$ )	C0023617;C3495095	\N	\N
526	lei > $nmbr$ ( n = $nmbr$ )	C0023401;C0428209	\N	\N
526	lei $nmbr$	C0023401;C0428209	\N	\N
526	lei  mean [ sd ] c	C0023401;C0428209;C0444504;C2347634;C2348143;C2699239	\N	\N
526	lei  mean ( sd )	C0023401;C0428209;C0444504;C2347634;C2348143;C2699239	\N	\N
525	no gi bleed	C0019080;C1708130;C3539617;C4050121	\N	\N
525	gi bleed	C0019080;C1708130;C3539617;C4050121	\N	\N
525	$nmbr$ - gi	C1708130;C3539617;C4050121	\N	\N
524	who fc iii symptoms at baseline	C0168634;C0439070;C0683368;C1442488;C1457887;C1705160;C2983605	\N	\N
524	updrs total ( ii + iii )	C0439070;C0439175;C0439810;C1705160;C1710602;C3639721;C4082587	\N	\N
524	ncep atp iii risk factors	C0035648;C0439070;C1553898;C1705160;C2744579;C4552600	\N	\N
524	killip class ii  iii  or iv — %	C0022326;C0439070;C1705160;C1710602;C2697845;C2697846;C4082587;C4265176	\N	\N
524	iii ( n z $nmbr$ )	C0439070;C1705160	\N	\N
524	iii ( $nmbr$ )	C0439070;C1705160	\N	\N
524	iii	C0439070;C1705160	\N	\N
524	ii or iii	C0439070;C1705160	\N	\N
524	ii / iii	C0439070;C1705160;C1710602;C4082587	\N	\N
524	ii - iii	C0439070;C1705160;C1710602;C4082587	\N	\N
524	class iii / iii - v	C0439070;C0457166;C1705160;C1880098	\N	\N
524	class i or iii aad use in $nmbr$ months before enrollment	C0042153;C0439070;C0439231;C0441885;C0457083;C1319793;C1516879;C1696073;C1705160;C1947944;C2698967;C3888021	\N	\N
524	$nmbr$ ii ( $nmbr$ . $nmbr$ )	\N	\N	\N
523	re - cover ii	C0180153;C0556581;C1999244;C2986904;C3888055	\N	\N
523	re - cover / re - cover ii	C0180153;C0556581;C1999244;C2986904;C3888055	\N	\N
523	ii = $nmbr$	\N	\N	\N
523	ii $nmbr$ ( i $nmbr$ . $nmbr$ )	C0021966;C0221138;C1710602;C4082587	\N	\N
523	i or ii	C0021966;C0221138	\N	\N
523	i & ii : fev $nmbr$ > $nmbr$ % predicted	C0021966;C0221138;C0681842;C1710602;C1882327;C3714541;C4082587	\N	\N
523	i $nmbr$ ± $nmbr$ ii	C0021966;C0221138;C1710602;C4082587	\N	\N
523	enrolled from re - cover ii study — no . ( % )	C0180153;C0556581;C0557651;C1999244;C2603343;C2986904;C3888055;C4684790	\N	\N
523	asteria i / ii	C0021966;C0221138;C1093020;C1710602;C4082587	\N	\N
523	$nmbr$ . i ± ii . $nmbr$	C0021966;C0221138;C1710602;C4082587	\N	\N
523	$nmbr$ . $nmbr$ ± ii . $nmbr$	\N	\N	\N
522	ii . $nmbr$ ( $nmbr$ . $nmbr$ ) $nmbr$	\N	\N	\N
522	ii $nmbr$ ± $nmbr$	\N	\N	\N
521	who fc ii symptoms at baselinef	C0683368;C1457887;C1710602;C2983605;C4082587	\N	\N
521	who fc ii symptoms at baseline $nmbr$	C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587	\N	\N
521	who fc ii symptoms at baseline	C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587	\N	\N
521	updrs  part ii ( adl )	C0001288;C0449719;C1420005;C1709471;C1710602;C3639721;C4082587	\N	\N
521	sr ii b $nmbr$ - cjl $nmbr$	C0753208;C1709991;C1710602;C3813610;C3890900;C3891546;C4082587	\N	\N
521	revive ii	\N	\N	\N
521	period ii	C0439531;C1710602;C1948053;C4082587	\N	\N
521	lor ii	C1416897;C1416899;C1710602;C2986770;C4082587	\N	\N
521	ii lisinopril	C0065374;C1710602;C4082587	\N	\N
521	ii chiorthaiidone amiodipine	C1710602;C4082587	\N	\N
521	ii ( n = $nmbr$ )	C1710602;C4082587	\N	\N
521	ii $nmbr$ amlodipine - lisinopril - chlorthalidone chlorthalidone	C0008294;C0051696;C0065374;C1710602;C4082587	\N	\N
521	ii $nmbr$ ( ii . $nmbr$ )	C1710602;C4082587	\N	\N
521	ii	\N	\N	\N
521	i / ii	C0021966;C0221138;C1710602;C4082587	\N	\N
521	europe ii	C0015176;C1710602;C4082587	\N	\N
521	dual ii	C0205173;C1554184;C1710602;C4082587	\N	\N
521	> o - $nmbr$ - ii	C0483204;C1710602;C4082587	\N	\N
520	xi = ° - ° $nmbr$	C1720296	\N	\N
520	xi = oo  p = o - $nmbr$	C1720296	\N	\N
520	xi = o - $nmbr$  p = o - $nmbr$	C1720296	\N	\N
520	xi = l ’ $nmbr$  p = $nmbr$ - $nmbr$	C1720296	\N	\N
520	xi = $nmbr$ . $nmbr$	C1720296	\N	\N
520	xi = $nmbr$ - l  p = $nmbr$ - $nmbr$	C1720296	\N	\N
520	xi = $nmbr$ - $nmbr$  p = o - l	C1720296	\N	\N
520	xi = $nmbr$ - $nmbr$  p = $nmbr$ - l	C1720296	\N	\N
520	xi = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$	C1720296	\N	\N
520	xi = $nmbr$ - $nmbr$  p = $nmbr$	C1720296	\N	\N
520	xi = $nmbr$ - $nmbr$	C1720296	\N	\N
520	xi = $nmbr$	C1720296	\N	\N
519	unadjusted or ( $nmbr$ % ci ) p value	C0008107;C1439367;C1709380;C3259781	\N	\N
519	treatment difference ( $nmbr$ % ci )	C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3259781;C3538994;C3887704	\N	\N
519	treatment diff . vs tio ( $nmbr$ % ci )	C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C3259781;C3538994;C3887704	\N	\N
519	stratified hazard ratio ( $nmbr$ % ci )	C0008107;C0205363;C2985465;C3259781	\N	\N
519	relative risk { $nmbr$ % ci )	C0008107;C0242492;C3259781	\N	\N
519	relative risk ( $nmbr$ % ci ) ofprimary end point	C0008107;C0242492;C2349179;C2826544;C3259781	\N	\N
519	relative risk ( $nmbr$ % ci )	C0008107;C0242492;C3259781	\N	\N
519	ratio of hrs ( $nmbr$ % ci )  p for sex interaction	C0008107;C0009253;C0036864;C0079399;C0456603;C0804628;C1314687;C1522384;C1547037;C1568891;C1704675;C3259781	\N	\N
519	ratio mepo / pbo ( $nmbr$ % ci )	C0008107;C0031962;C0456603;C1547037;C3259781	\N	\N
519	ratio ( $nmbr$ % ci ) *	C0008107;C0456603;C1547037;C3259781	\N	\N
519	rate estimate ( $nmbr$ % ci )	C0008107;C0750572;C0871208;C1521828;C3259781	\N	\N
519	r | r ' ' ' ( $nmbr$ % ci )	C0008107;C0205090;C0684010;C2603358;C3259781	\N	\N
519	r elative risk ( $nmbr$ % ci )	C0008107;C0035647;C0205090;C0233492;C0684010;C2603358;C3259781;C4552904	\N	\N
519	placebo - adjusted mean difference in % hba $nmbr$ c ( $nmbr$ % ci  [ p value ] )	C0008107;C0019016;C0032042;C0444504;C0456081;C1696465;C1705241;C1705242;C1706408;C1709380;C1825777;C2347634;C2348143;C3259781;C3538758	\N	\N
519	pav  mean ( $nmbr$ % ci )	C0008107;C0058890;C0444504;C2347634;C2348143;C3259781	\N	\N
519	oradj ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	or 、 ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	or [ $nmbr$ % ci ]	C0008107;C3259781	\N	\N
519	or ( $nmbr$ % ci ) a	C0008107;C3259781	\N	\N
519	or ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	or $nmbr$ % ci	C0008107;C3259781	\N	\N
519	odds ‐ ratio ( $nmbr$ % ci )	C0008107;C0028873;C3259781	\N	\N
519	odds ratios ( $nmbr$ % ci )	C0008107;C0028873;C3259781	\N	\N
519	odds ratio versus placebo ( $nmbr$ % ci )	C0008107;C0028873;C0032042;C1696465;C1706408;C3259781	\N	\N
519	odds ratio ( $nmbr$ % ci )	C0008107;C0028873;C3259781	\N	\N
519	mmrm estimates  ls mean ( se )  [ $nmbr$ % ci ]	C0008107;C0023668;C0036919;C0444504;C0750572;C2347634;C2348143;C3259781	\N	\N
519	median time to first exacerbation ( months [ $nmbr$ % ci ] )	C0008107;C0205435;C0549183;C0556969;C0876920;C1279901;C2347635;C2348144;C2939193;C3259781;C4086268	\N	\N
519	mean sf $nmbr$ score ( $nmbr$ % ci )	C0008107;C0037712;C3259781;C3533236	\N	\N
519	mean pasi score ( $nmbr$ % ci )	C0008107;C3259781;C3533236;C4528685	\N	\N
519	mean number of exacerbations ( per patient - year [ $nmbr$ % ci ] )	C0008107;C0030705;C0237753;C0439234;C0439508;C0444504;C0449788;C2347634;C2348143;C3259781;C4086268	\N	\N
519	mean ham - d score ( $nmbr$ % ci )	C0008107;C1570167;C3259781;C3533236;C3853311	\N	\N
519	mean eq - $nmbr$ d response ( $nmbr$ % ci )	C0008107;C0205163;C0439185;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2911692;C3259781	\N	\N
519	mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  % ‐ points	C0008107;C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1552961;C1705241;C1960952;C2346927;C2347617;C2347634;C2348143;C3259781;C3714763;C4319952;C4321396;C4521761	\N	\N
519	mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  %	C0008107;C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1705241;C1960952;C2346927;C2347634;C2348143;C3259781;C4319952;C4321396;C4521761	\N	\N
519	lsms difference ( $nmbr$ % ci ) $nmbr$	C0008107;C1705241;C1705242;C3259781	\N	\N
519	lsm ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	ls means difference ( $nmbr$ % ci ) a	C0008107;C0023668;C1704970;C1705241;C1705242;C3259781	\N	\N
519	ls means difference ( $nmbr$ % ci ) $nmbr$	C0008107;C0023668;C1704970;C1705241;C1705242;C3259781	\N	\N
519	ls mean treatment difference ( $nmbr$ % ci )	C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704	\N	\N
519	ls mean difference ( $nmbr$ % ci )	C0008107;C0023668;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781	\N	\N
519	ls mean ( $nmbr$ % ci ) a	C0008107;C0023668;C0444504;C2347634;C2348143;C3259781	\N	\N
519	ls mean ( $nmbr$ % ci )  %	C0008107;C0023668;C0444504;C2347634;C2348143;C3259781	\N	\N
519	ls mean ( $nmbr$ % ci )	C0008107;C0023668;C0444504;C2347634;C2348143;C3259781	\N	\N
519	ls - mean difference between treatment groups ( $nmbr$ % ci )	C0008107;C0023668;C0039798;C0087111;C0374505;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704	\N	\N
519	ls - mean change from baseline ( $nmbr$ % ci )	C0008107;C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952	\N	\N
519	ls - mean between - group difference ( $nmbr$ % ci )	C0008107;C0023668;C1705241;C1705242;C2347634;C3259781	\N	\N
519	least squares mean between - treatment difference ( $nmbr$ % ci )	C0008107;C0023189;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704	\N	\N
519	least - squares mean difference ( $nmbr$ % ci ) *	C0008107;C0023189;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781	\N	\N
519	hradjusted ( $nmbr$ % ci ) b	C0008107;C3259781	\N	\N
519	hradj ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	hr [ $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	hr ( $nmbr$ s % ci )	C0008107;C3259781	\N	\N
519	hr ( $nmbr$ % ci ) p   value	C0008107;C1709380;C3259781	\N	\N
519	hr ( $nmbr$ % ci ) p value for interaction *	C0008107;C1704675;C1709380;C3259781	\N	\N
519	hr  ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	heart failure  ci  confidence interval .	C0008107;C0009667;C0018801;C0018802;C3259781;C4554158	\N	\N
519	hazard ratio for cardiovascular death  stroke  or myocardial infarction ( $nmbr$ % ci )	C0008107;C0011065;C0027051;C0428953;C1306577;C2926063;C2985465;C3259781;C3810814;C4082313;C4552775;C4552959	\N	\N
519	hazard ratio * ( $nmbr$ % ci )	C0008107;C2985465;C3259781	\N	\N
519	hazard ratio ( $nmbr$ % ci ) $nmbr$ with vs . without psoriasis	C0008107;C0033860;C2985465;C3259781	\N	\N
519	hazard ratio ( $nmbr$ % ci )	C0008107;C2985465;C3259781	\N	\N
519	harzard ratio ( $nmbr$ % ci )	C0008107;C0456603;C1547037;C3259781	\N	\N
519	harzar ratio ( $nmbr$ % ci )	C0008107;C0456603;C1547037;C3259781	\N	\N
519	from baseline ( $nmbr$ % ci )	C0008107;C0168634;C1442488;C3259781	\N	\N
519	etr : $nmbr$ . $nmbr$ [ $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$	C0008107;C3259781	\N	\N
519	etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$	C0008107;C1180255;C3259781	\N	\N
519	etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$	C0008107;C1180255;C3259781	\N	\N
519	etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$	C0008107;C1180255;C3259781	\N	\N
519	etd ( % ) [ $nmbr$ % ci ]	C0008107;C1180255;C3259781	\N	\N
519	etd ( $nmbr$ % ci )	C0008107;C1180255;C3259781	\N	\N
519	estimated difference ( $nmbr$ % ci )	C0008107;C0750572;C1705241;C1705242;C3259781	\N	\N
519	estimate ( $nmbr$ % ci )	C0008107;C0750572;C3259781	\N	\N
519	difference in ls means ( $nmbr$ % ci ) versus placebo	C0008107;C0023668;C0032042;C1696465;C1704970;C1705241;C1705242;C1706408;C3259781	\N	\N
519	difference in ls means ( $nmbr$ % ci ) a	C0008107;C0023668;C1704970;C1705241;C1705242;C3259781	\N	\N
519	difference in ls means ( $nmbr$ % ci ) $nmbr$	C0008107;C0023668;C1704970;C1705241;C1705242;C3259781	\N	\N
519	difference in ls means ( $nmbr$ % ci )	C0008107;C0023668;C1704970;C1705241;C1705242;C3259781	\N	\N
519	difference in ls mean vs placebo ( $nmbr$ % ci )  mmol / mol	C0008107;C0023668;C0032042;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781;C3829066	\N	\N
519	difference in ls mean vs placebo ( $nmbr$ % ci )  %	C0008107;C0023668;C0032042;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781	\N	\N
519	difference ( $nmbr$ % ci ) *	C0008107;C1705241;C1705242;C3259781	\N	\N
519	difference ( $nmbr$ % ci  p value )	C0008107;C1705241;C1705242;C1709380;C3259781	\N	\N
519	d ( $nmbr$ % ci )	C0008107;C0073187;C0332173;C3259781;C4484261	\N	\N
519	coronary syndrome . ci = confidence interval  hr = hazard ratio .	C0008107;C0009667;C0018787;C0039082;C2985465;C3259781	\N	\N
519	cochranemantelehaenszel ( repeated $nmbr$ . $nmbr$ % ci ) c	C0008107;C0205341;C3259781	\N	\N
519	ci = confidence interval  na = not applicable or not analyzed .	C0008107;C0009667;C0597484;C0936012;C1272460;C1518422;C1546968;C1879645;C3259781;C4049872;C4552882	\N	\N
519	ci - aki risk score	C0008107;C0022660;C0035647;C0330978;C0449820;C3259781;C4050231;C4552904	\N	\N
519	atorvastatin ls means difference $nmbr$ mg ( $nmbr$ % ci ) a ( n = $nmbr$ )	C0008107;C0023668;C0024671;C0026410;C0286651;C0369718;C0439269;C0441922;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761	\N	\N
519	annt or bnnh ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	adjusted rate of pneumonia events ( per patient - year )  mean ( $nmbr$ % ci )	C0008107;C0030705;C0032285;C0439234;C0439508;C0441471;C0444504;C0456081;C0871208;C1521828;C2347634;C2348143;C3259781;C3541888	\N	\N
519	adjusted rate of hospitalized pneumonia events ( per patient - year )  mean ( $nmbr$ % ci )	C0008107;C0030705;C0032285;C0439234;C0439508;C0441471;C0444504;C0456081;C0701159;C0871208;C1521828;C2347634;C2348143;C3259781;C3541888	\N	\N
519	adjusted or ( $nmbr$ % ci ) c	C0008107;C0456081;C3259781	\N	\N
519	adjusted or ( $nmbr$ % ci ) b	C0008107;C0456081;C3259781	\N	\N
519	adjusted modelc hr  $nmbr$ % ci  p value	C0008107;C0456081;C1709380;C3259781	\N	\N
519	adjusted mean ± se ( $nmbr$ % ci )	C0008107;C0036919;C0444504;C0456081;C2347634;C2348143;C3259781	\N	\N
519	adjusted mean difference ( $nmbr$ % ci )	C0008107;C0444504;C0456081;C1705241;C1705242;C2347634;C2348143;C3259781	\N	\N
519	adjusted hr * ( $nmbr$ % ci )	C0008107;C0456081;C3259781	\N	\N
519	adjusted hr ( $nmbr$ % ci ) * comparing idm with bl	C0005918;C0006413;C0008107;C0270221;C0456081;C1552663;C1707455;C2827109;C3259781	\N	\N
519	adjusted hr ( $nmbr$ % ci ) * compared with no diabetes at bl or at year $nmbr$	C0005918;C0006413;C0008107;C0011847;C0011849;C0439234;C0439508;C0456081;C1552663;C1707455;C2827109;C3259781	\N	\N
519	adjusted hr ( $nmbr$ % ci )	C0008107;C0456081;C3259781	\N	\N
519	adjusted hr  $nmbr$ % ci	C0008107;C0456081;C3259781	\N	\N
519	adjusted * or ( $nmbr$ % ci ) p value	C0008107;C0456081;C1709380;C3259781	\N	\N
519	[ $nmbr$ % ci ] *	C0008107;C3259781	\N	\N
519	- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) a - $nmbr$ . $nmbr$ %  * p = $nmbr$ . $nmbr$	C0008107;C3259781	\N	\N
519	- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) * p = $nmbr$ . $nmbr$	C0008107;C3259781	\N	\N
519	- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ )	C0008107;C3259781	\N	\N
519	* ci denotes confidence interval .	C0008107;C0009667;C3259781	\N	\N
519	( mean difference  $nmbr$ % ci )	C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781	\N	\N
519	( mean change  $nmbr$ % ci )	C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952	\N	\N
519	( mean % difference  $nmbr$ % ci )	C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781	\N	\N
519	( mean % change  $nmbr$ % ci )	C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952	\N	\N
519	( ci ) b	C0008107;C3259781	\N	\N
519	( $nmbr$ % ci ] h	C0008107;C0033727;C0369286;C0441932;C0564385;C3259781;C4528284	\N	\N
519	( $nmbr$ % ci ] $nmbr$	C0008107;C3259781	\N	\N
519	( $nmbr$ % ci ) p value	C0008107;C1709380;C3259781	\N	\N
519	( $nmbr$ % ci ) c	C0008107;C3259781	\N	\N
519	( $nmbr$ % ci ) b	C0008107;C3259781	\N	\N
519	( $nmbr$ % ci ) a	C0008107;C3259781	\N	\N
519	( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	% difference  $nmbr$ % ci )	C0008107;C1705241;C1705242;C3259781	\N	\N
519	% change  $nmbr$ % ci )	C0008107;C0392747;C0443172;C1705241;C3259781;C4319952	\N	\N
519	% ( $nmbr$ % ci )	C0008107;C3259781	\N	\N
519	$nmbr$ . $nmbr$ ( $nmbr$ % ci : $nmbr$ . $nmbr$  $nmbr$ . $nmbr$  n = $nmbr$ )	C0008107;C3259781	\N	\N
519	$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$	C0008107;C3259781	\N	\N
519	$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ )	C0008107;C3259781	\N	\N
514	network	C0150775;C1513822;C1705739;C1882071	\N	\N
519	$nmbr$ . $nmbr$ $nmbr$ % ci : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ p = $nmbr$ . $nmbr$	C0008107;C3259781	\N	\N
519	$nmbr$ % ci $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$	C0008107;C3259781	\N	\N
519	$nmbr$ % ci $nmbr$	C0008107;C3259781	\N	\N
519	$nmbr$ % ci	C0008107;C3259781	\N	\N
518	mdi / hfa  n	C0015458;C0993596;C1839839;C4049613	\N	\N
518	mdi	C0993596;C1839839;C4049613	\N	\N
518	gp mdi	C0993596;C1705010;C1839839;C3811116;C4049613	\N	\N
518	gff mdi	C0993596;C1839839;C4049613	\N	\N
518	ff mdi	C0993596;C1839839;C4049613;C4554348	\N	\N
517	mri substudy ( n = $nmbr$ )	C0024485;C1824234;C3890166	\N	\N
517	criteria for subcortical vad ( by mri )  %	C0024485;C0077973;C0243161;C0815275;C1824234;C3890166	\N	\N
516	• ii : death from coronary heart disease  nonfatal mi  coronary revascularization > $nmbr$ days	C0011065;C0018799;C0439228;C0545743;C0581603;C1306577;C1710602;C3810814;C4082313;C4082587;C4552775	\N	\N
516	• any mi	C3810814	\N	\N
516	type of mi ( % )	C0332307;C1547052;C3810814	\N	\N
516	type of mi	C0332307;C1547052;C3810814	\N	\N
516	time from randomization to pci ( non - st - elevation mi )  h	C0033727;C0034656;C0040223;C0369286;C0441932;C0520886;C0564385;C1518422;C3541383;C3810814;C4049621;C4528284	\N	\N
516	second prior mi	C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814	\N	\N
516	qualifying mi type	C0332307;C1514624;C1547052;C3810814	\N	\N
516	qualifying mi < $nmbr$ yrs prior	C0332152;C1514624;C2826257;C3810814	\N	\N
516	qualifying mi $ $nmbr$ yrs prior	C0332152;C1514624;C2826257;C3810814	\N	\N
516	qmi	\N	\N	\N
516	pvaluefor any mi versus no mi	C3810814	\N	\N
516	prior mi within $nmbr$ y  no . ( % )	C0332152;C2826257;C3810814	\N	\N
516	prior mi n = $nmbr$	C0332152;C2826257;C3810814	\N	\N
516	prior mi diagnosis :	C0332132;C3810814	\N	\N
516	prior mi ( n = $nmbr$  $nmbr$ )	C0332152;C2826257;C3810814	\N	\N
516	prior mi ( n - $nmbr$  $nmbr$ )	C0332152;C2826257;C3810814	\N	\N
516	prior mi  n / n ( % )	C0332152;C2826257;C3810814	\N	\N
516	prior mi  %	C0332152;C2826257;C3810814	\N	\N
516	prior mi	C0332152;C2826257;C3810814	\N	\N
516	prior history of mi or ischaemic stroke	C0019664;C0019665;C0262512;C0262926;C0332152;C0948008;C1705255;C2004062;C2826257;C3810814	\N	\N
516	previous mi — no . ( % )	C0205156;C1552607;C3810814	\N	\N
516	previous mi ( % )	C0205156;C1552607;C3810814	\N	\N
516	previous mi  n ( % )	C0205156;C1552607;C3810814	\N	\N
516	previous mi  %	C0205156;C1552607;C3810814	\N	\N
516	previous mi	C0205156;C1552607;C3810814	\N	\N
516	nonfatal mi ( n = $nmbr$ )	C3810814	\N	\N
516	non - st — elevation mi	C0520886;C1518422;C3810814	\N	\N
516	non - st - elevation mi	C0520886;C1518422;C3810814	\N	\N
516	nocad / mi	C3810814	\N	\N
516	no prior mi n = $nmbr$	C0332152;C2826257;C3810814	\N	\N
516	no prior mi ( n = $nmbr$  $nmbr$ )	C0332152;C2826257;C3810814	\N	\N
516	no prior mi	C0332152;C2826257;C3810814	\N	\N
516	no mi ( n - $nmbr$  $nmbr$ )	C3810814	\N	\N
516	no mi	C3810814	\N	\N
516	mi — no . ( % )	C3810814	\N	\N
516	mi *	C3810814	\N	\N
516	mi  n ( % )	C3810814	\N	\N
516	mi	C3810814	\N	\N
516	mhi	\N	\N	\N
516	large mi	C0549177;C3810814	\N	\N
516	inferior mi *  %	C0340305;C3542426	\N	\N
516	history of second prior mi	C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814	\N	\N
516	fatal / nonfatal mi ( excluding silent mi )	C0332196;C0443304;C1302234;C1705232;C2828389;C3810814;C3816734	\N	\N
516	death  large mi	C0011065;C0549177;C1306577;C3810814;C4082313;C4552775	\N	\N
516	cvd or mi	C0007222;C3810814	\N	\N
516	cvd  mi  stroke  or recurrent ischemia - urgent revascularization	C0007222;C0022116;C0038454;C0439609;C0581603;C1455761;C2945760;C3272275;C3810814;C4321499;C4554100	\N	\N
516	cvd  mi  or stroke	C0007222;C0038454;C3810814;C4554100	\N	\N
516	cardiovascular death or nonfatal mi ( excluding silent mi )	C0007226;C0011065;C0332196;C0443304;C1306577;C2828389;C3810814;C3816734;C3887460;C4082313;C4552775	\N	\N
516	cardiovascular death  nonfatal mi ( excluding silent mi )  or stroke	C0007226;C0011065;C0038454;C0332196;C0443304;C1306577;C2828389;C3810814;C3816734;C3887460;C4082313;C4552775;C4554100	\N	\N
516	any mi ( n - $nmbr$  $nmbr$ )	C3810814	\N	\N
516	any mi	C3810814	\N	\N
516	anterior mi	C3536746	\N	\N
516	: mi  previous pci and chronic obstructive pulmonary disease .	C0024117;C0205156;C1552607;C3810814;C4049621	\N	\N
515	vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )	C0008107;C0205999;C3259781	\N	\N
515	vi - $nmbr$ % ( - $nmbr$ %  $nmbr$ % )	C0205999	\N	\N
515	vi $nmbr$   µ g	C0205999;C0439267	\N	\N
515	vi $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0205999;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
515	vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % )	C0205999	\N	\N
515	vi $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )	C0008107;C0205999;C3259781	\N	\N
515	vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % )	C0008107;C0205999;C3259781	\N	\N
515	umec / vi $nmbr$ . $nmbr$ / $nmbr$ ( n $nmbr$ $nmbr$ )	C0205999	\N	\N
515	umec / vi $nmbr$ . $nmbr$ / $nmbr$	C0205999	\N	\N
515	ff / vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % )	C0008107;C0205999;C3259781;C4554348	\N	\N
515	ff / vi ( n   =   $nmbr$ )	C0205999;C4554348	\N	\N
515	ff / vi $nmbr$ mg / $nmbr$ mg ( n = $nmbr$ )	C0205999;C1319635;C4554348	\N	\N
515	ff / vi $nmbr$ / $nmbr$   µ g	C0205999;C0439267;C4554348	\N	\N
515	ff / vi $nmbr$ / $nmbr$ pg od	C0030827;C0072225;C0205999;C0229089;C0439164;C1266240;C1512019;C3273373;C3665488;C4554348	\N	\N
515	ff / vi $nmbr$ . $nmbr$	C0205999;C4554348	\N	\N
515	ff / vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % )	C0205999;C4554348	\N	\N
515	ff / vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % )	C0008107;C0205999;C3259781;C4554348	\N	\N
515	favors ff / vi favors placebo	C0032042;C0205999;C0309049;C1696465;C1706408;C4554348	\N	\N
515	$nmbr$ . $nmbr$ % vi . $nmbr$ . $nmbr$ %	C0205999	\N	\N
515	$nmbr$ . $nmbr$ % vi  $nmbr$ . $nmbr$ %	C0205999	\N	\N
514	work and school	C0036375;C0043227	\N	\N
513	never took alendronate	C0102118;C1515187;C2003901	\N	\N
513	- $nmbr$ - $nmbr$ ( - $nmbr$ - $nmbr$ too $nmbr$ )	\N	\N	\N
512	transfemoral	\N	\N	\N
512	femoral neckc	C0015811	\N	\N
512	femoral access — no . / total no . ( % )	C0015811;C0439175;C0439810;C0444454;C1554204	\N	\N
512	femoral access	C0015811;C0444454;C1554204	\N	\N
512	femoral	C0015811	\N	\N
512	catheter site — femoral	C0015811;C0449652	\N	\N
511	t - score at femoral neck	C0015815;C3854607	\N	\N
511	mean femoral neck t score	C0015815;C3533236	\N	\N
511	femoral neck	C0015815	\N	\N
511	at femoral neck  mean ( sd )	C0015815;C0444504;C2347634;C2348143;C2699239	\N	\N
510	total study population ( n = $nmbr$ )	C0439175;C0439810;C0557651;C2348561;C2603343;C3258257	\N	\N
510	total study population ( n = $nmbr$  $nmbr$ )	C0439175;C0439810;C0557651;C2348561;C2603343;C3258257	\N	\N
510	total study population	C0439175;C0439810;C0557651;C2348561;C2603343;C3258257	\N	\N
510	total study itt population ( n = $nmbr$ )	C0439175;C0439810;C0557651;C2348561;C2603343;C3258257	\N	\N
510	total population n	C3258257	\N	\N
510	total population ( n = $nmbr$ )	C3258257	\N	\N
510	total population	C3258257	\N	\N
510	total ho population ( n = $nmbr$ )	C0019905;C1832110;C3258257;C3889614	\N	\N
510	total carmelina population	C3258257	\N	\N
509	total no . $nmbr$	C0439175;C0439810	\N	\N
509	total gadolinium - enhancing lesion count . no . ( % )	C0439175;C0439810;C0750480;C1333400;C1705566	\N	\N
509	total gadolinium - enhancing lesion count  no . ( % )	C0439175;C0439810;C0750480;C1333400;C1705566	\N	\N
509	no . ( % ) *	\N	\N	\N
509	no *	\N	\N	\N
509	cardiac - biomarker status 一 no . / total no . ( % ) $	C0005516;C0018787;C0439175;C0439810;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302	\N	\N
509	cardiac - biomarker status — no . / total no . ( % ) $	C0005516;C0018787;C0439175;C0439810;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302	\N	\N
509	$nmbr$ - $nmbr$  no . / totalno . ( % )	\N	\N	\N
508	v total ( n = $nmbr$ )	C0439175;C0439810	\N	\N
508	treated with pci — no . / total no . ( % )	C0332293;C0439175;C0439810;C4049621	\N	\N
508	total sgrq score	C0439175;C0439810;C0449820;C4050231	\N	\N
508	total resolution of nail psoriasisd	C0027342;C0439175;C0439810;C1432728;C1514893;C1706463;C2699488;C3538766	\N	\N
508	total resolution of enthesitisc	C0439175;C0439810;C1514893;C1706463;C2699488	\N	\N
508	total resolution of dactylitisb	C0439175;C0439810;C1514893;C1706463;C2699488	\N	\N
508	total randomized  n	C0034656;C0439175;C0439810;C3815594	\N	\N
508	total randomized	C0034656;C0439175;C0439810;C3815594	\N	\N
508	total randomised ( n )	C0439175;C0439810	\N	\N
508	total patients n = $nmbr$	C0030705;C0439175;C0439810	\N	\N
508	total patients  n	C0030705;C0439175;C0439810	\N	\N
508	total patients	C0030705;C0439175;C0439810	\N	\N
508	total number of patients	C0439175;C0439810;C2360800	\N	\N
508	total number of events / participants	C0439175;C0439810;C0679646;C4330837	\N	\N
508	total no . of patients	C0030705;C0439175;C0439810	\N	\N
508	total no .	C0439175;C0439810	\N	\N
508	total n   =   $nmbr$	C0439175;C0439810	\N	\N
508	total n = $nmbr$ n ( % )	C0439175;C0439810	\N	\N
508	total n = $nmbr$	C0439175;C0439810	\N	\N
508	total n $nmbr$	C0439175;C0439810	\N	\N
508	total n	C0439175;C0439810	\N	\N
508	total mortality all	C0026565;C0026566;C0439175;C0439810	\N	\N
508	total mortality	C0026565;C0026566;C0439175;C0439810	\N	\N
508	total invasive cancer	C0439175;C0439810;C0677898	\N	\N
508	total ige — lu / ml	C0439175;C0439810;C2697941	\N	\N
508	total ige  geometric	C0439175;C0439810;C0449829	\N	\N
508	total hipc	C0439175;C0439810	\N	\N
508	total hip bmd ( g / cm $nmbr$ )	C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725	\N	\N
508	total hip ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd )	C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C2699239;C3538851;C4284725	\N	\N
508	total hip	C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725	\N	\N
508	total haq  $nmbr$ - $nmbr$	C0102923;C0439175;C0439810;C0451208	\N	\N
508	total deaths  n	C0011065;C0439175;C0439810;C1306577	\N	\N
508	total deaths	C0011065;C0439175;C0439810;C1306577	\N	\N
508	total death	C0011065;C0439175;C0439810;C1306577;C4082313;C4552775	\N	\N
508	total c	C0439175;C0439810	\N	\N
508	total antihypertensive use	C0003364;C0042153;C0439175;C0439810;C0457083;C1947944	\N	\N
508	total > atients	C0439175;C0439810	\N	\N
508	total - c	C0439175;C0439810	\N	\N
508	total *	C0439175;C0439810	\N	\N
508	total ( v = $nmbr$  $nmbr$ )	C0439175;C0439810	\N	\N
508	total ( n   =   $nmbr$ )	C0439175;C0439810	\N	\N
508	total ( n   = $nmbr$ )	C0439175;C0439810	\N	\N
508	total ( n [ $nmbr$ )	C0439175;C0439810	\N	\N
508	total ( n = $nmbr$ )	C0439175;C0439810	\N	\N
508	total ( n = $nmbr$ $nmbr$ )	C0439175;C0439810	\N	\N
508	total ( n = $nmbr$  $nmbr$ ) - -	C0439175;C0439810	\N	\N
508	total ( n = $nmbr$  $nmbr$ )	C0439175;C0439810	\N	\N
508	total ( n )	C0439175;C0439810	\N	\N
508	total ( n $nmbr$ $nmbr$ )	C0439175;C0439810	\N	\N
508	total $nmbr$	C0439175;C0439810	\N	\N
508	total !	C0439175;C0439810	\N	\N
508	total  n = $nmbr$ $nmbr$	C0439175;C0439810	\N	\N
508	total  n = $nmbr$	C0439175;C0439810	\N	\N
508	total	C0439175;C0439810	\N	\N
508	totai mortaiity	\N	\N	\N
508	tiotropium salmeterol no . of patients / total no .	C0030705;C0073992;C0213771;C0439175;C0439810	\N	\N
508	statin — no . / total no . ( % )	C0360714;C0439175;C0439810	\N	\N
508	standardized total hip bmd ( g / cm $nmbr$ )	C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725	\N	\N
508	sgrq - c total scoreb	C0439175;C0439810;C3826872	\N	\N
508	previous cabg ( % total )	C0010055;C0205156;C0439175;C0439810;C1552607	\N	\N
509	antiplatelet — no . ( % )	\N	f	1191
508	patients total no .	C0030705;C0439175;C0439810	\N	\N
508	patients  no . / total no . ( % )	C0030705;C0439175;C0439810	\N	\N
508	oral study drug administered — no . / total no . ( % )	C0013175;C0439175;C0439810;C0442027;C1521801;C4521986	\N	\N
508	oral contraceptive pills — no . / total no . ( % )	C0009905;C0009906;C0029151;C0439175;C0439810	\N	\N
508	of patients meeting criterion / total no . of patients	C0030705;C0243161;C0439175;C0439810;C0556656	\N	\N
508	o total randomized	C0034656;C0439175;C0439810;C0483204;C3815594	\N	\N
508	nsaid use — no . / total no . ( % )	C0003211;C0042153;C0439175;C0439810;C0457083;C1947944;C3536840	\N	\N
508	normoalbuminuria — no . / total no . ( % )	C0439175;C0439810	\N	\N
508	no . of patients / total no . ( % )	C0030705;C0439175;C0439810	\N	\N
508	no . of panents . total no . $nmbr$ % )	C0439175;C0439810	\N	\N
508	no . / total no . ( % ) t	C0439175;C0439810;C2603360	\N	\N
508	no . / total no . ( % )	C0439175;C0439810	\N	\N
508	no . / total \t no . ( % )	C0439175;C0439810	\N	\N
508	no . / total	C0439175;C0439810	\N	\N
508	medications in use at baseline — no . / total no . ( % )	C0013227;C0042153;C0150312;C0168634;C0332285;C0439175;C0439810;C0457083;C0802604;C1442488;C1707101;C1947944;C2598133;C4284232	\N	\N
508	medications at study entry — no . / total no . ( % )	C0013175;C0439175;C0439810;C1705654	\N	\N
508	medical therapy before randomization — no . / total no . ( % )	C0034656;C0418981;C0439175;C0439810	\N	\N
508	managed medically — no . / total no . ( % )	C0439175;C0439810;C1273870	\N	\N
508	macroalbuminuria — no . / total no . ( % )	C0439175;C0439810	\N	\N
508	long - term treatment with aspirin — no . / total no . ( % )	C0004057;C0023977;C0439175;C0439810	\N	\N
508	infusion administered — no . / total no . ( % )	C0439175;C0439810;C0574032;C1521801;C1827465	\N	\N
508	history of gi bleeding or ulcer — no . / total no . ( % )	C0017181;C0019664;C0019665;C0041582;C0262512;C0262926;C0439175;C0439810;C1705255;C2004062;C3887532	\N	\N
508	gastrointestinal area involved — no . / total no . ( % )	C0017446;C0205146;C0439175;C0439810;C0521362;C1314939	\N	\N
7	interaction : treatment by psoriasis p value $nmbr$	C1704675;C1709380;C3258078	\N	\N
508	elevation of troponin levels — no . / total no . ( % )	C0041199;C0439175;C0439775;C0439810;C0441889;C0702240	\N	\N
508	diuretic — no . / total no . ( % )	C0012798;C0439175;C0439810	\N	\N
508	current alcohol use — no . / total no . ( % )	C0001962;C0001975;C0042153;C0439175;C0439810;C0457083;C0521116;C1705970;C1947944	\N	\N
508	colectomy ( partial or total )	C0009274;C0439175;C0439810;C0728938;C1550516	\N	\N
508	category — no . / total no . ( % )	C0439175;C0439810;C0683312;C3889287	\N	\N
508	between - treatment comparison of percentage change from baseline in total hip bmd	C0019552;C0022122;C0168634;C0439165;C0439175;C0439810;C1299575;C1442488;C1505163;C1549488;C1561533;C1707455;C3538851;C4284725	\N	\N
508	angiographic complications  site - reported — no . / total no . ( % )	C0002978;C0009566;C0205145;C0439175;C0439810;C0684224;C0700287;C1171258;C1515974;C2825164;C4319718	\N	\N
508	administration of study - drug bolus — no . / total no . ( % )	C0001554;C0013175;C0013227;C0150270;C0262754;C0439175;C0439810;C0557651;C1186706;C1254351;C1511237;C1533734;C1705509;C2603343;C3161471;C3469597;C3812160	\N	\N
508	$nmbr$ — no . / total no . ( % )	C0439175;C0439810	\N	\N
508	$nmbr$ or $nmbr$ — no . / total no . ( % )	C0439175;C0439810	\N	\N
508	$nmbr$ or $nmbr$  no . / total no . ( % )	C0439175;C0439810	\N	\N
508	$nmbr$ - $nmbr$ — no . / total no . ( % )	C0439175;C0439810	\N	\N
508	$nmbr$  no . / total no . ( % )	C0439175;C0439810	\N	\N
507	• death from cv causes  major coronary event  or nonfatal stroke	C0011065;C0015127;C0038454;C0205082;C0205164;C0741923;C1306577;C1314792;C1524003;C3538987;C4048877;C4082313;C4318503;C4318856;C4521762;C4552775;C4554100	\N	\N
507	stroke non - fatal	C0038454;C1302234;C1518422;C1705232;C4554100	\N	\N
507	stroke ( fatal / nonfatal )	C0038454;C1302234;C1705232;C4554100	\N	\N
507	stroke  fatal and nonfatal	C0038454;C1302234;C1705232;C4554100	\N	\N
507	nonfatal stroke ®	C0038454;C4554100	\N	\N
507	nonfatal stroke ( n = $nmbr$ )	C0038454;C4554100	\N	\N
507	nonfatal stroke	C0038454;C4554100	\N	\N
507	nonfatal	\N	\N	\N
507	nondisabling  nonfatal stroke	C0038454;C4554100	\N	\N
507	non - fatal stroke	C0038454;C1302234;C1518422;C1705232;C4554100	\N	\N
507	in - trial nonfatal or fatal stroke n = $nmbr$  $nmbr$	C0008976;C0038454;C0150312;C0332285;C1302234;C1705232;C1707101;C4554100	\N	\N
507	fatal stroke	C0038454;C1302234;C1705232;C4554100	\N	\N
507	fatal or nonlatal stroke	C0038454;C1302234;C1705232;C4554100	\N	\N
507	fatal or nonfatal stroke	C0038454;C1302234;C1705232;C4554100	\N	\N
507	fatal or non - fatal stroke	C0038454;C1302234;C1518422;C1705232;C4554100	\N	\N
507	fatal and nonfatal stroke	C0038454;C1302234;C1705232;C4554100	\N	\N
507	fatal / nonfatal stroke  n ( % )	C0038454;C1302234;C1705232;C4554100	\N	\N
507	fatal / nonfatal stroke	C0038454;C1302234;C1705232;C4554100	\N	\N
507	fatal & nonfatal hospitalized stroke	C0038454;C0701159;C1302234;C1705232;C4554100	\N	\N
506	role physical	C0031809;C0035820;C0205485;C1509143;C1705810;C3871154	\N	\N
506	role emotional	C0013987;C0035820;C0849912;C1705810;C3871154	\N	\N
506	physical role	C0031809;C0035820;C0205485;C1509143;C1705810;C3871154	\N	\N
506	emotional role	C0013987;C0035820;C0849912;C1705810;C3871154	\N	\N
505	neutropenia	C0023530;C0027947;C0853697	\N	\N
505	leukopenia	C0023530;C0750394	\N	\N
505	europa ( n = $nmbr$ l $nmbr$ )	C0242751	\N	\N
505	eastern and central europe	C0682369;C1707877	\N	\N
505	central europe	C0682369	\N	\N
505	central / eastern europe and russia hr ( $nmbr$ % cl )	C0015177;C0035970;C0205099;C0596019;C0682369;C1707877;C1879652	\N	\N
505	central / eastern europe / russia	C0015177;C0035970;C0205099;C0682369;C1707877;C1879652	\N	\N
504	white / european	C0007457;C0043157;C0220938;C0239307;C1535514	\N	\N
504	non - european trial	C0008976;C0239307;C1518422;C1535514	\N	\N
504	non - european	C0239307;C1518422;C1535514	\N	\N
504	european trial	C0008976;C0239307;C1535514	\N	\N
504	european subcategories	C0239307;C1515010;C1535514	\N	\N
504	european	C0239307;C1535514	\N	\N
503	prior pacemaker  n ( % )	C0030163;C0332152;C0810633;C1546728;C2826257;C3275122;C3853703	\N	\N
503	pacemaker — no . ( % )	C0030163;C0810633;C1546728;C3275122;C3853703	\N	\N
503	pacemaker  n ( % )	C0030163;C0810633;C1546728;C3275122;C3853703	\N	\N
503	pacemaker  ( % )	C0030163;C0810633;C1546728;C3275122;C3853703	\N	\N
503	pacemaker	C0030163;C0810633;C1546728;C3275122;C3853703	\N	\N
503	cardiac pacemaker — no . ( % )	C0030163;C0037189	\N	\N
503	biventricular pacemaker	C1719274	\N	\N
502	paracetamol	C0000970	\N	\N
502	acetaminophen	C0000970;C2917659	\N	\N
501	study drug loading days ( actual ) : $nmbr$ ( n = $nmbr$ )	C0013175;C0237400;C0439228;C1708715	\N	\N
501	actual ( l )	C0237400	\N	\N
500	paclitaxel - eluting stent use  n ( % )	C0038257;C0042153;C0144576;C0457083;C1947944	\N	\N
500	paclitaxel - eluting	C0144576	\N	\N
500	paclitaxel	C0144576	\N	\N
499	with long - acting j $nmbr$ - agonists	C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375	\N	\N
499	short - acting b $nmbr$ - agonists	C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375	\N	\N
499	short - acting	C0079613;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375	\N	\N
499	peak procedural act — sec	C0025664;C0079613;C0184661;C0444505;C0565930;C1704930;C1869853;C2700391;C3274430;C3538935;C3539779;C3890007;C4048375	\N	\N
499	long acting nitratef	C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375	\N	\N
499	long - acting or short - acting nitrates	C0028125;C0079613;C0205166;C1282927;C1704930;C1706317;C1806781;C1869853;C2350002;C3890007;C4048375	\N	\N
499	long - acting nitrates	C0028125;C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375	\N	\N
499	long - acting nitrate agents	C0028125;C0079613;C0205166;C0450442;C0699857;C1254351;C1521826;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375	\N	\N
499	long - acting nitrate	C0028125;C0079613;C0205166;C0699857;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375	\N	\N
7	heterogeneity p value	C0019409;C0242960;C1709380	\N	\N
499	long - acting bronchodilator use at screening	C0006280;C0042153;C0079613;C0205166;C0220908;C0220909;C0457083;C1698960;C1704930;C1706317;C1710031;C1710032;C1710477;C1869853;C1947944;C2348164;C3890007;C4048375	\N	\N
499	long - acting b $nmbr$ - agonists	C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375	\N	\N
499	long - acting ^	C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375	\N	\N
499	long - acting	C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375	\N	\N
499	b - agonists ( short - acting ) a	C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375	\N	\N
499	b - agonists ( long - acting ) a	C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375	\N	\N
499	anti - cholinergics ( short - acting ) a	C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375	\N	\N
499	anti - cholinergics ( long - acting )	C0079613;C0205166;C0242896;C1704930;C1706317;C1869853;C3890007;C4048375	\N	\N
499	act total score ≥   $nmbr$	C0079613;C1704930;C1869853;C2964552;C3890007;C4048375	\N	\N
499	act total score   ≥   $nmbr$ and / or improvement from baseline   ≥   $nmbr$	C0079613;C0168634;C1442488;C1704930;C1869853;C2964552;C2986411;C3890007;C4048375	\N	\N
499	act . $nmbr$	C0079613;C1704930;C1869853;C3890007;C4048375	\N	\N
499	act - $nmbr$	C0079613;C1704930;C1869853;C3890007;C4048375	\N	\N
-10	centrally acting sympathomimetics	C3653511	\N	\N
497	sexually active with female	C0043210;C0086287;C0241028;C1705497;C1705498	\N	\N
497	sexually active $nmbr$ ( % )	C0241028	\N	\N
497	sexually active	C0241028	\N	\N
496	reason for enrollment in active a — no . ( % )	C0150312;C0205177;C0332285;C0392360;C1516879;C1696073;C1707101;C3853793;C3888021;C3888249	\N	\N
496	reason for enrollment in active a	C0150312;C0205177;C0332285;C0392360;C1516879;C1696073;C1707101;C3853793;C3888021;C3888249	\N	\N
496	randomized to active yitamin e	C0034656;C0205177;C3815594;C3853793;C3888249	\N	\N
496	alive ( n = $nmbr$ )	C2584946;C4551704	\N	\N
496	active smoking	C0037369;C0205177;C0453996;C1881674;C3853793;C3888249	\N	\N
496	active pso wi $nmbr$ bsa > $nmbr$ %  n ( . % y	C0043193;C0205177;C1520135;C3853793;C3888249	\N	\N
496	active comparatorb	C0205177;C3853793;C3888249	\N	\N
496	active canakinumab ( n   =   $nmbr$  $nmbr$ )	C0205177;C2718773;C3853793;C3888249	\N	\N
496	active a	C0205177;C3853793;C3888249	\N	\N
496	active ( n = $nmbr$ )	C0205177;C3853793;C3888249	\N	\N
496	active	C0205177;C3853793;C3888249	\N	\N
-10	any acuity bleeding	C0333276	\N	\N
494	selena - sledai activity  n ( % )	C0205177;C0439167;C0441655;C0451528;C1561536;C3668946;C4049938;C4049939	\N	\N
494	activity limitation	C0205177;C0439167;C0441655;C0443288;C0449295;C1561536;C3668946;C4049938;C4049939	\N	\N
494	activity ( range $nmbr$ - $nmbr$ )  mean ± sd	C0205177;C0439167;C0441655;C0444504;C1514721;C1561536;C2347634;C2348143;C2348147;C2699239;C3542016;C3668946;C4049938;C4049939	\N	\N
494	activity	C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939	\N	\N
493	catheter access site	C0085590;C0444454;C0449652;C0589360;C1554204	\N	\N
493	arterial access site	C3272298	\N	\N
493	arterial access	C0003842;C0221464;C0444454;C1554204	\N	\N
493	arteriai access	C0444454;C1554204	\N	\N
493	access site	C0589360	\N	\N
492	randomised patients with dactylitis at baseline	C0030705;C0168634;C0239161;C1442488	\N	\N
492	patients with dactylitis at baseline  no .	C0030705;C0168634;C0239161;C1442488	\N	\N
492	patients with dactylitis  no . ( % )	C0030705;C0239161	\N	\N
492	patients with dactylitis	C0030705;C0239161	\N	\N
492	dactylitis severity score ) score > $nmbr$ — no . { % )	C0239161;C0449820;C0457451;C4050231	\N	\N
492	dactylitis score ( $nmbr$ – $nmbr$ scale )	C0175659;C0239161;C0349674;C0449820;C1947916;C4050231	\N	\N
492	dactylitis score ( $nmbr$ - $nmbr$ )  mean ( sd )	C0239161;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
492	dactylitis score ( $nmbr$ - $nmbr$ )	C0239161;C0449820;C4050231	\N	\N
492	dactylitis score	C0239161;C0449820;C4050231	\N	\N
492	dactylitis  n ( % )	C0239161	\N	\N
492	dactylitis  % #	C0239161	\N	\N
492	dactylitis	C0239161	\N	\N
492	% improvement in dactylitis score at week $nmbr$  n	C0239161;C0332174;C0439230;C0449820;C2986411;C4050231	\N	\N
491	patient global assessment of disease	C0012634;C4054229	\N	\N
491	patient assessment of pain ( $nmbr$ - $nmbr$ cm  vas )	C0042815;C0679830	\N	\N
491	patient assessment of disease activity  mm	C0679830;C1292728;C4330985;C4554674	\N	\N
491	patient assessment of arthritis pain  mm	C0679830;C4317006;C4330985;C4554674	\N	\N
491	patient ' s global assessment of response to therapy score	C0039798;C0087111;C0449820;C0871261;C1363945;C1704632;C1706817;C2911692;C4050231;C4054229	\N	\N
491	patient ' s global assessment of disease status score	C0449820;C3176928;C4050231;C4054229	\N	\N
491	patient ' s global assessment of disease	C0012634;C4054229	\N	\N
491	patient ' s global assessment of	C4054229	\N	\N
491	patient ' s global assessment !	C4054229	\N	\N
491	patient ' s global assessment	C4054229	\N	\N
491	patient ' s assessment of pain ( $nmbr$ - $nmbr$ vas )	C0042815;C0679830	\N	\N
490	patients with measurement	C0030705;C0242485	\N	\N
490	measurements	C0242485	\N	\N
490	* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^ consecutive defined as two or more measurements at least one week apart or one measurement < $nmbr$ days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal	C0010287;C0013175;C0015127;C0026845;C0030705;C0035173;C0040363;C0041260;C0074554;C0178602;C0205172;C0205448;C0242485;C0280604;C0332281;C0439849;C0445223;C0449438;C0521095;C0683368;C0750492;C0805162;C0869039;C0877248;C1114758;C1142985;C1266129;C1314792;C1415181;C1442452;C1457887;C1516048;C1519815;C1524003;C1704788;C1707491;C1883351;C2362652;C3242203;C3539106;C3542407;C3844320;C3887670;C3891303;C4083049;C4553172	\N	\N
489	preamendment	C1548596	\N	\N
489	postamendment	\N	\N	\N
489	before amendment ( % )	C0680532;C2346732	\N	\N
489	before amendment	C0680532;C2346732	\N	\N
489	after amendment ( % )	C0680532;C2346732	\N	\N
489	after amendment	C0680532;C2346732	\N	\N
488	temporal data and management strategy	C0001554;C0376636;C0442043;C0679199;C1273870;C1511726;C2362314;C3245479;C3273539;C3714741	\N	\N
488	primary management strategy	C0001554;C0205225;C0376636;C0439612;C0439631;C0679199;C1273870;C3273539	\N	\N
488	management distribution medical treatment	C0001554;C0030677;C0199168;C0205476;C0376636;C0520511;C0679624;C1273870;C1704711;C3273539	\N	\N
488	management distribution	C0001554;C0376636;C0520511;C1273870;C1704711;C3273539	\N	\N
488	acs management  no . ( % )	C0001554;C0376636;C0742343;C1273870;C3273539;C4318612	\N	\N
487	types of fibrinolytic agent	C0016018;C0332307	\N	\N
487	thrombolytic agents	C0016018	\N	\N
487	inotropic agent	C0304509	\N	\N
487	fibrinolytic agent given	C0016018;C1442162;C1550718;C1947971;C3244317	\N	\N
487	fibrinolytic agent before randomisation	C0016018;C0034656	\N	\N
486	use of antiarrhythmic agent	C0003195;C0301380;C1524063	\N	\N
486	class $nmbr$ antiarrhythmic agents	C0003195;C0301380;C0456387;C1518526;C1705943	\N	\N
486	antiarrhythmic agent	C0003195;C0301380	\N	\N
486	aget  y	\N	\N	\N
485	hypertension absent	C0020538;C0332197;C1963138;C4285062	\N	\N
485	factor absent	C0332197;C1521761;C2827422;C4285062	\N	\N
485	dm absent	C0011816;C0332197;C3250443;C4285062	\N	\N
485	absent ( < $nmbr$ mg / dl )	C0332197;C0439269;C4285062	\N	\N
485	absent	C0332197;C4285062	\N	\N
485	absence	C0332197;C1689985	\N	\N
484	three or more agents	C0205172;C0205449;C0450442;C1254351;C1521826	\N	\N
484	ras agents	C0034678;C0450442;C0525678;C1254351;C1521826	\N	\N
484	oral agents use	C0042153;C0442027;C0450442;C0457083;C1254351;C1521826;C1947944;C4521986	\N	\N
484	oral agents	C0442027;C0450442;C1254351;C1521826;C4521986	\N	\N
484	oral agent and / or insulin therapy	C0021641;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C1533581;C1579433;C3714501;C4521986	\N	\N
484	oral agent	C0442027;C0450442;C1254351;C1521826;C4521986	\N	\N
484	number of agents	C0237753;C0449788;C0450442;C1254351;C1521826	\N	\N
484	no . of agents	C0450442;C1254351;C1521826	\N	\N
484	ipah / fpah / drug and toxin	C0013227;C0040549;C0152171;C1254351;C1419079;C4522020	\N	\N
484	drug and insulint	C0013227;C1254351	\N	\N
484	conventional agents *	C0439858;C0450442;C1254351;C1521826	\N	\N
484	anyantianginal agent	C0450442;C1254351;C1521826	\N	\N
484	antialdosterone agents	C0450442;C1254351;C1521826	\N	\N
484	anti ‐ platelet agents  n ( % )	C0005821;C0432633;C0450442;C1254351;C1521826	\N	\N
484	> $nmbr$ oral agents	C0442027;C0450442;C1254351;C1521826;C4521986	\N	\N
484	> $nmbr$ and < $nmbr$	\N	\N	\N
483	age at diagnosis s $nmbr$ years	C0439234;C1828181;C3173302	\N	\N
483	age at diagnosis of sle  years	C0024141;C0439234;C1828181;C3173302	\N	\N
483	age at diagnosis of ln  years	C0439234;C0861352;C1428884;C1828181;C3173302;C3714709	\N	\N
483	age at diagnosis < $nmbr$ years	C0439234;C1828181;C3173302	\N	\N
483	age at diagnosis  y	C1828181;C3173302	\N	\N
482	p between age groups	C0001779;C0027362;C0369773;C0441849;C1959644;C2603361	\N	\N
482	age groups	C0027362	\N	\N
481	subjects $ $nmbr$ years of age  n ( % )	C0681850;C1510829;C1550501;C1706203;C2349001;C2697811	\N	\N
481	subjects  $nmbr$ years of age  n ( % )	C0681850;C1510829;C1550501;C1706203;C2349001;C2697811	\N	\N
479	$nmbr$ . $nmbr$  range $nmbr$ - $nmbr$	C1514721;C2348147;C3542016	\N	\N
484	antihyperglycemic oral agent therapy	C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986	f	33
484	oral diabetic agent	C0241863;C0442027;C0450442;C1254351;C1521826;C4521986	f	33
481	patients ' characteristics age ( years )  mean + sd	C0444504;C0815172;C1510829;C2347634;C2348143;C2699239	\N	\N
481	median age  years ( iqr )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
481	mean ± s . d . age  years	C0444504;C1510829;C2347634;C2348143	\N	\N
481	mean age ± sd ( years )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	mean age ± s . d .  years	C0444504;C1510829;C2347634;C2348143	\N	\N
481	mean age ( years ) race	C0034510;C0444504;C1510829;C1706779;C2347634;C2348143;C3853635	\N	\N
481	mean age ( years ) ( s . d . )	C0444504;C1510829;C2347634;C2348143	\N	\N
481	mean age ( years )	C0444504;C1510829;C2347634;C2348143	\N	\N
481	mean age ( years  sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	mean age ( sd )  years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	mean age  years ± sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	mean age  years ( range )	C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
481	mean age  years ( $nmbr$ % ci )	C0008107;C0444504;C1510829;C2347634;C2348143;C3259781	\N	\N
481	mean age  years	C0444504;C1510829;C2347634;C2348143	\N	\N
481	mean ( s . d . ) age  years	C0444504;C1510829;C2347634;C2348143	\N	\N
481	i $nmbr$ years of age	C0021966;C0221138;C1510829	\N	\N
481	age ≥ $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$	C0578022;C1510829;C1532718	\N	\N
481	age ≥ $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$	C0578022;C1510829;C1532718	\N	\N
481	age ≥ $nmbr$ years  n ( % )	C1510829	\N	\N
481	age ≥ $nmbr$ years	C1510829	\N	\N
481	age £ $nmbr$ years ( itt ) ( n = $nmbr$ )	C1510829	\N	\N
481	age years geographic region	C0017446;C1510829	\N	\N
481	age years	C1510829	\N	\N
481	age s $nmbr$ years ( n = $nmbr$  $nmbr$ )	C1510829	\N	\N
481	age range ( years )	C1510829;C1514721;C2348147;C3542016	\N	\N
481	age range  years	C1510829;C1514721;C2348147;C3542016	\N	\N
481	age mean age  years sex	C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143	\N	\N
481	age in years  mean ( sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age in years  mean	C0444504;C1510829;C2347634;C2348143	\N	\N
481	age in years	C1510829	\N	\N
481	age group ( ≥ $nmbr$ years ) — no . ( % )	C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001	\N	\N
481	age groiro : < $nmbr$ years	C1510829	\N	\N
481	age distribution  years  n ( % )	C0001782;C0439234;C0520511;C1510829;C1704711	\N	\N
481	age distribution  n ( % )	C0001782	\N	\N
481	age distribution	C0001782	\N	\N
481	age categories ( y )  n ( % )	C2916832	\N	\N
481	age categories  n ( % )	C2916832	\N	\N
481	age categories	C2916832	\N	\N
481	age at randomization ( years )	C0034656;C1510829	\N	\N
481	age at entry ( years )	C1510829;C1705654	\N	\N
481	age at enrolment  years	C1510829;C1516879;C1696073;C3888021	\N	\N
481	age at enrollment ( years )	C1510829;C1516879;C1696073;C3888021	\N	\N
481	age at baseline years	C0168634;C1442488;C1510829	\N	\N
481	age at baseline ( years )	C0168634;C1442488;C1510829	\N	\N
481	age [ years ] ( interaction : p = $nmbr$ . $nmbr$ )	C1510829;C1704675	\N	\N
481	age [ years ]  median ( range )	C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
481	age [ years ]	C1510829	\N	\N
481	age > = $nmbr$ years old	C0580836;C1510829	\N	\N
481	age > = $nmbr$ years	C1510829	\N	\N
481	age > $nmbr$ years ( n = $nmbr$ )	C1510829	\N	\N
481	age > $nmbr$ years ( median )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
481	age > $nmbr$ years ( itt ) ( n = $nmbr$ )	C1510829	\N	\N
481	age > $nmbr$ years $nmbr$	C1510829	\N	\N
481	age > $nmbr$ years  n ( % )	C1510829	\N	\N
481	age > $nmbr$ years  %	C1510829	\N	\N
481	age > $nmbr$ years	C1510829	\N	\N
481	age > $nmbr$ ( years ) t	C1510829	\N	\N
481	age < $nmbr$ years — no . ( % )	C1510829	\N	\N
481	age < $nmbr$ years old	C0580836;C1510829	\N	\N
481	age < $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$	C0578022;C1510829;C1532718	\N	\N
481	age < $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$	C0578022;C1510829;C1532718	\N	\N
481	age < $nmbr$ years ( n = $nmbr$ )	C1510829	\N	\N
481	age < $nmbr$ years ( n = $nmbr$  $nmbr$ )	C1510829	\N	\N
481	age < $nmbr$ years ( n =	C1510829	\N	\N
481	age < $nmbr$ years ( median )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
481	age < $nmbr$ years ( itt ) ( n = $nmbr$ )	C1510829	\N	\N
481	age < $nmbr$ years $nmbr$	C1510829	\N	\N
481	age < $nmbr$ years  n ( % )	C1510829	\N	\N
481	age < $nmbr$ years	C1510829	\N	\N
481	age : > $nmbr$ years	C1510829	\N	\N
481	age : < $nmbr$ years ( n = $nmbr$ )	C1510829	\N	\N
481	age : < $nmbr$ years	C1510829	\N	\N
481	age . years	C1510829	\N	\N
481	age - years	C1510829	\N	\N
481	age - mean ( sd ) years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years ) a	C1510829	\N	\N
481	age ( years ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ]	C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C1510829;C2347635;C2348144;C2939193;C4282123;C4285344	\N	\N
481	age ( years ) : mean ± sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years ) : > $nmbr$	C1510829	\N	\N
481	age ( years ) : < $nmbr$	C1510829	\N	\N
481	age ( years ) : $nmbr$ - < $nmbr$	C1510829	\N	\N
481	age ( years ) :	C1510829	\N	\N
481	age ( years ) - mean ± sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years ) - > = median ( n = $nmbr$  $nmbr$ )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
481	age ( years ) - < median ( n = $nmbr$  $nmbr$ )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
481	age ( years ) +	C1510829	\N	\N
481	age ( years ) *	C1510829	\N	\N
481	age ( years ) ( mean ± sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years ) ( mean  sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years )  median ( range )	C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
481	age ( years )  mean   ±   sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years )  mean ± sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years )  mean ± s . d .	C0444504;C1510829;C2347634;C2348143	\N	\N
481	age ( years )  mean _ sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years )  mean ( sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age ( years )  mean ( s . d . )	C0444504;C1510829;C2347634;C2348143	\N	\N
481	age ( years )	C1510829	\N	\N
481	age ( years ( s . d . ) )	C1510829	\N	\N
481	age ( years  sd )	C1510829;C2699239	\N	\N
481	age ( range ) ( years )	C1510829;C1514721;C2348147;C3542016	\N	\N
481	age ( per $nmbr$ years )	C1510829	\N	\N
481	age ( median  years )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
481	age $nmbr$ years or more	C0205172;C1510829	\N	\N
481	age $nmbr$ years ( n = $nmbr$ )	C1510829	\N	\N
481	age $nmbr$ years	C1510829	\N	\N
481	age $nmbr$ - $nmbr$ years ( n = $nmbr$ )	C1510829	\N	\N
481	age $nmbr$ - $nmbr$ years ( itt ) ( n = $nmbr$ )	C1510829	\N	\N
481	age $nmbr$ + years	C1510829	\N	\N
481	age $ $nmbr$ years § *	C1510829	\N	\N
481	age  years “	C1510829	\N	\N
481	age  years mean ± sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  years mean ( sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  years mean ( s . d . )	C0444504;C1510829;C2347634;C2348143	\N	\N
481	age  years geographical distribution of patients	C0030705;C0681686;C1510829	\N	\N
481	age  years ^	C1510829	\N	\N
481	age  years : median ( range )	C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
481	age  years *	C1510829	\N	\N
481	age  years ( sd )	C1510829;C2699239	\N	\N
481	age  years ( mean ± sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  years ( mean _ + sd ) sex  n ( % ) :	C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143;C2699239	\N	\N
481	age  years ( mean = sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  years ( mean $nmbr$ sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  years $nmbr$ '	C1510829	\N	\N
481	age  years  mean ± sd	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  years  mean ( sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  years  mean ( range )	C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
481	age  years	C1510829	\N	\N
481	age  median years	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	\N	\N
481	age  median ( range ) ( years )	C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
481	age  mean ± sd  years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  mean years ( sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  mean = sd  years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  mean ( sd ) years  n ( % )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  mean ( sd ) years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  mean ( sd ) ( years )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  mean ( sd )  years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  mean ( range ) years	C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
481	age  mean  years ( ± sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
481	age  ( years )	C1510829	\N	\N
481	age  $nmbr$ years	C1510829	\N	\N
481	> $nmbr$ years of age  n ( % )	C1510829	\N	\N
481	> $nmbr$ years of age	C1510829	\N	\N
481	< $nmbr$ years of age	C1510829	\N	\N
480	x cr $nmbr$ . $nmbr$ x age	C0001779;C0201975;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
480	unstable angina age	C0001779;C0002965	\N	\N
480	patients aged > $nmbr$ y  no  ( ss )	C0001779;C0001792;C0030705;C1999167;C2699257;C3891295;C4551874	\N	\N
480	p value for interaction ( age continuous )	C0001779;C0549178;C1704675;C1709380	\N	\N
480	min - max age	C0001779;C0702093;C1524029;C3813700	\N	\N
480	median age — yr §	C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
480	median age — yr	C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
480	median age [ interquartile range ] — yr	C0001779;C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193	\N	\N
480	median age ( $nmbr$ %  $nmbr$ % )  y	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
480	mean age 士 s . d .  year	C0001779;C0439234;C0439508;C0444504;C2347634;C2348143	\N	\N
480	mean age — yr ( range )	C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
480	mean age — yr	C0001779;C0439234;C0444504;C2347634;C2348143	\N	\N
480	mean age ± s . d .  year	C0001779;C0439234;C0439508;C0444504;C2347634;C2348143	\N	\N
480	mean age ( yrs )	C0001779;C0444504;C2347634;C2348143	\N	\N
480	mean age ( yr )	C0001779;C0439234;C0444504;C2347634;C2348143	\N	\N
480	mean age ( y )	C0001779;C0444504;C2347634;C2348143	\N	\N
480	mean age ( sd )  yr	C0001779;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
480	mean age ( sd )  y	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	mean age ( range ) — yr	C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
480	mean age  yrs	C0001779;C0444504;C2347634;C2348143	\N	\N
480	mean age  y : ( range )	C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
480	mean age  y ( range )	C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
480	mean age  y	C0001779;C0444504;C2347634;C2348143	\N	\N
480	mean ( sd ) age  yr	C0001779;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
480	mean ( sd ) age  y race  n ( % ) *	C0001779;C0034510;C0444504;C1706779;C2347634;C2348143;C2699239;C3853635	\N	\N
480	mean ( sd ) age  y	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	low - trauma fracture since age $nmbr$  n ( % )	C0001779;C0521170	\N	\N
480	infarction before age $nmbr$ ( a )	C0001779;C0021308	\N	\N
480	family history of myocardial infarction prior to age $nmbr$  %	C0001779;C0455406	\N	\N
480	established cvd / chronic kidney disease ( age > $nmbr$ ) ^ * ’	C0001779;C0007222;C0443211;C1272684;C1561643;C4553188	\N	\N
480	established cvd ( age > $nmbr$ )	C0001779;C0007222;C0443211;C1272684	\N	\N
480	cvd risk factors ( age > $nmbr$ ) ^ “ ^	C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904	\N	\N
480	cvd risk factors ( age > $nmbr$ )	C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904	\N	\N
480	baseline age	C0001779;C0168634;C1442488	\N	\N
480	average age ( year )	C0001779;C0439234;C0439508;C1510992;C2825518	\N	\N
480	aged $nmbr$ y or older  n ( % )	C0001779;C0001792;C0580836;C1999167	\N	\N
480	ageadj	\N	\N	\N
480	age\\\\yr	C0001779;C0439234	\N	\N
480	age — yrf	C0001779	\N	\N
480	age — yr race — no . ( % ) f	C0001779;C0016327;C0034510;C0439234;C1706779;C3853635	\N	\N
480	age — yr	C0001779;C0439234	\N	\N
480	age — year ( median )	C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
480	age — y £	C0001779	\N	\N
480	age — y  meantsd	C0001779	\N	\N
480	age   ≥ $nmbr$   y  n ( % )	C0001779	\N	\N
480	age £ $nmbr$	C0001779	\N	\N
480	age yrs	C0001779	\N	\N
480	age yr  range	C0001779;C0439234;C1514721;C2348147;C3542016	\N	\N
480	age y  median ( range )	C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
480	age subgroups	C0001779;C1079230	\N	\N
480	age subgroup  y	C0001779;C1079230;C1515021	\N	\N
480	age s * $nmbr$ yr	C0001779;C0439234	\N	\N
480	age s $nmbr$	C0001779	\N	\N
480	age range  y	C0001779;C1514721;C2348147;C3542016	\N	\N
480	age range	C0001779;C1514721;C2348147;C3542016	\N	\N
480	age mean ( yrs ± sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age groups  n ( % )	C0001779;C0441848	\N	\N
480	age group ( y )	C0001779;C0441858	\N	\N
480	age group  n ( % )	C0001779;C0441848	\N	\N
480	age b $nmbr$ y ( n = $nmbr$ )	C0001779	\N	\N
480	age at time of first seizure	C0001779;C0036572;C0040223;C0205435;C1279901;C1959629;C3541383;C4553401	\N	\N
480	age at screening	C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
480	age at randomization	C0001779;C0034656	\N	\N
480	age at randomisation	C0001779;C0034656	\N	\N
480	age at lipid randomization ( y )	C0001779;C0034656;C0065033	\N	\N
480	age at completion of highest level of	C0001779;C0205197;C1554962;C4321237	\N	\N
480	age a $nmbr$	C0001779	\N	\N
480	age ^ $nmbr$	C0001779	\N	\N
480	age [ year ]  mean ± sda	C0001779;C0276477;C0439234;C0439508;C0444504;C1428349;C1553165;C2347634;C2348143	\N	\N
480	age > = $nmbr$ yrs	C0001779	\N	\N
480	age > = $nmbr$	C0001779	\N	\N
480	age > : $nmbr$	C0001779	\N	\N
480	age > $nmbr$ yrs *	C0001779	\N	\N
480	age > $nmbr$ yrs  %	C0001779	\N	\N
480	age > $nmbr$ yrs	C0001779	\N	\N
480	age > $nmbr$ yr 十	C0001779;C0439234	\N	\N
480	age > $nmbr$ yr — no . ( % )	C0001779;C0439234	\N	\N
480	age > $nmbr$ yr and st - segment changes	C0001779;C0232326;C0439234	\N	\N
480	age > $nmbr$ yr and elevated biomarkers	C0001779;C0005516;C0205250;C0439234;C3163633	\N	\N
480	age > $nmbr$ yr ( % )	C0001779;C0439234	\N	\N
480	age > $nmbr$ yr  elevated biomarkers  and st - segment changes	C0001779;C0005516;C0205250;C0232326;C0439234;C3163633	\N	\N
480	age > $nmbr$ yr	C0001779;C0439234	\N	\N
480	age > $nmbr$ y * *	C0001779	\N	\N
480	age > $nmbr$ y *	C0001779	\N	\N
480	age > $nmbr$ y ( n = $nmbr$ )	C0001779	\N	\N
480	age > $nmbr$ y ( % )	C0001779	\N	\N
480	age > $nmbr$ y  n / n ( % )	C0001779	\N	\N
480	age > $nmbr$ y  n ( % )	C0001779	\N	\N
480	age > $nmbr$ y  %	C0001779	\N	\N
480	age > $nmbr$ y	C0001779	\N	\N
480	age > $nmbr$ vears n = $nmbr$	C0001779	\N	\N
480	age > $nmbr$  y	C0001779	\N	\N
480	age > $nmbr$  %	C0001779	\N	\N
480	age > $nmbr$	C0001779	\N	\N
480	age >	C0001779	\N	\N
480	age < $nmbr$ yrs	C0001779	\N	\N
480	age < $nmbr$ yr or > $nmbr$ yr	C0001779;C0439234	\N	\N
480	age < $nmbr$ yr	C0001779;C0439234	\N	\N
480	age < $nmbr$ y ( n = $nmbr$ )	C0001779	\N	\N
480	age < $nmbr$ y	C0001779	\N	\N
480	age < $nmbr$ vears n = $nmbr$	C0001779	\N	\N
480	age < $nmbr$	C0001779	\N	\N
480	age :	C0001779	\N	\N
480	age . y	C0001779	\N	\N
480	age . . . . . . . . y ( n = $nmbr$ )	C0001779	\N	\N
480	age - interaction	C0001779;C1704675	\N	\N
480	age *	C0001779	\N	\N
480	age ( yrs )  mean ± sd	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age ( yrs )  mean *	C0001779;C0444504;C2347634;C2348143	\N	\N
480	age ( yrs )	C0001779	\N	\N
480	age ( yr ) *	C0001779;C0439234	\N	\N
480	age ( yr )  mean ( sd ) bmd t - score  mean ( sd )	C0001779;C0439234;C2699239;C3533236	\N	\N
480	age ( yr )  mean ( sd )	C0001779;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age ( yr )	C0001779;C0439234	\N	\N
480	age ( yij	C0001779	\N	\N
480	age ( year )  mean ± sd	C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age ( year )	C0001779;C0439234;C0439508	\N	\N
480	age ( y ) ∗	C0001779	\N	\N
480	age ( y ) [ mean - sd ]	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age ( y )  median ( min  max }	C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
480	age ( y )  median ( min  max )	C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
480	age ( y )  median ( iqr )	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
480	age ( y )  mean ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age ( y )  mean ( range )	C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016	\N	\N
480	age ( y )	C0001779	\N	\N
480	age ( sd )  y	C0001779;C2699239	\N	\N
480	age ( p = o - $nmbr$ )	C0001779	\N	\N
480	age ' ^ $nmbr$ yrs	C0001779	\N	\N
480	age ' $nmbr$ y ( n $nmbr$ )	C0001779	\N	\N
480	age & $nmbr$	C0001779	\N	\N
480	age $nmbr$ y	C0001779	\N	\N
480	age $nmbr$ - $nmbr$ yr  elevated biomarkers  and previous vascular	C0001779;C0005516;C0005847;C0205156;C0205250;C0439234;C1552607;C1558950;C1801960;C3163633	\N	\N
480	age $nmbr$ - $nmbr$ y ( n = $nmbr$ )	C0001779	\N	\N
480	age $nmbr$ - $nmbr$	C0001779	\N	\N
480	age $nmbr$ + y	C0001779	\N	\N
480	age $nmbr$ +	C0001779	\N	\N
480	age $nmbr$ * $nmbr$ yr	C0001779;C0439234	\N	\N
480	age $nmbr$ $nmbr$ y	C0001779	\N	\N
480	age $nmbr$	C0001779	\N	\N
480	age $ $nmbr$ yrs	C0001779	\N	\N
480	age # $nmbr$ yrs	C0001779	\N	\N
480	age  yt	C0001779;C1412122	\N	\N
480	age  yrs *	C0001779	\N	\N
480	age  yrs ( mean ± sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  yrs  mean ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  yrs	C0001779	\N	\N
480	age  yr mean ( sd )	C0001779;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  yr  n ( % )	C0001779;C0439234	\N	\N
480	age  yr	C0001779;C0439234	\N	\N
480	age  yf $nmbr$ - $nmbr$	C0001779	\N	\N
480	age  year ( median )	C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
480	age  year	C0001779;C0439234;C0439508	\N	\N
480	age  ya	C0001779	\N	\N
480	age  y sex  no . ( % )	C0001779;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384	\N	\N
480	age  y gender  n ( % )	C0001779;C0079399;C1522384	\N	\N
480	age  y < $nmbr$	C0001779	\N	\N
480	age  y . o .	C0001779	\N	\N
480	age  y ( sd )	C0001779;C2699239	\N	\N
480	age  y ( mean ± s . d . )	C0001779;C0444504;C2347634;C2348143	\N	\N
480	age  y  median ( q $nmbr$ – q $nmbr$ )	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
480	age  y  mean ± sd	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  y	C0001779	\N	\N
480	age  x	C0001779	\N	\N
480	age  n ( % )	C0001779	\N	\N
480	age  median ( interquartile range )  y	C0001779;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193	\N	\N
480	age  mean ± sd ( year )	C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean ± sd  y	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean yr ( sd )	C0001779;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean yr	C0001779;C0439234;C0444504;C2347634;C2348143	\N	\N
480	age  mean ( sd ) [ range ]  y	C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016	\N	\N
480	age  mean ( sd )  yrs	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean ( sd )  yr	C0001779;C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean ( sd )  yearsa	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean ( sd )  y	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean ( s . e . )	C0001779;C0444504;C2347634;C2348143	\N	\N
480	age  mean ( min - max ) ( yrs )	C0001779;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700	\N	\N
480	age  mean  yrs ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
480	age  mean	C0001779;C0444504;C2347634;C2348143	\N	\N
480	age	C0001779	\N	\N
480	adults ( aged   ≥ $nmbr$ y )  no . ( % )	C0001675;C0001779;C0001792;C1999167	\N	\N
480	adolescents ( aged $nmbr$ - $nmbr$ y )  no . ( % )	C0001779;C0001792;C0205653;C1999167	\N	\N
480	> $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ )	C0001779	\N	\N
480	< $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ )	C0001779	\N	\N
480	( b ) age subgroups	C0001779;C1304659	\N	\N
479	§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv	C0007226;C0021966;C0022326;C0037455;C0175659;C0221138;C0238884;C0349674;C1514721;C1879987;C1947916;C2348147;C3542016;C3887460;C4265176	\N	\N
479	total updrs score ( range  $nmbr$ — $nmbr$ ) y	C0439175;C0439810;C0449820;C1514721;C2348147;C3542016;C3639721;C4050231	\N	\N
479	total updrs score ( range  $nmbr$ - $nmbr$ ) 卞	C0439175;C0439810;C0449820;C1514721;C2348147;C3542016;C3639721;C4050231	\N	\N
479	total scores ( total score range : $nmbr$ - $nmbr$ )	C1514721;C2348147;C2964552;C3542016	\N	\N
479	selena - sledai ( range u - $nmbr$ u $nmbr$ ) t	C0439148;C0451528;C1514721;C2348147;C3542016	\N	\N
479	seizure frequency during $nmbr$ ‐ week baseline  median ( range )	C0149775;C0168634;C0332174;C0439230;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
479	range race  n ( % )	C0034510;C1514721;C1706779;C2348147;C3542016;C3853635	\N	\N
479	range of sbp	C0085805;C1514721;C2348147;C3542016	\N	\N
479	range	C1514721;C2348147;C3542016	\N	\N
479	motor subscale ( range  $nmbr$ - $nmbr$ )	C1513492;C1514721;C1705994;C2348147;C3542016	\N	\N
479	median dose ( range ) b	C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
479	median dose ( range ) ' ’	C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
479	median ( range ) treatment duration  d	C0444921;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3259042;C3542016	\N	\N
479	median ( range ) duration of hospital stayi  d	C0019994;C0449238;C0549183;C0876920;C1510665;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016	\N	\N
479	il - $nmbr$ range  ng / l	C0020898;C0021764;C0022271;C0439297;C1514721;C2348147;C3542016	\N	\N
479	hscrp range  mg / l	C0439268;C1514721;C2348147;C3542016	\N	\N
479	health assessment questionnaire ( $nmbr$ - $nmbr$ range )	C0451208;C1514721;C2348147;C3542016	\N	\N
479	duration of current flare  median ( range ) months ( n = $nmbr$  $nmbr$  $nmbr$ )	C0439231;C0449238;C0521116;C0549183;C0876920;C1514721;C1517205;C1705970;C2347635;C2348144;C2348147;C2926735;C2939193;C3540542;C3542016	\N	\N
479	( range )	C1514721;C2348147;C3542016	\N	\N
479	$nmbr$ . $nmbr$ range $nmbr$ - $nmbr$	C1514721;C2348147;C3542016	\N	\N
478	repaired s - p shunts	C0205340;C0232180;C0542331;C1442858	\N	\N
478	repaired congenital shunts	C0009678;C0205340;C0232180;C0542331;C1442858;C1744681	\N	\N
478	repaired congenital shunt	C0009678;C0205340;C0232180;C0542331;C1442858;C1744681	\N	\N
478	pfo with large shunt without atrial septal aneurysm	C0232180;C0521533;C0542331;C0549177;C1442858	\N	\N
478	pfo with large shunt and atrial septal aneurysm	C0232180;C0521533;C0542331;C0549177;C1442858	\N	\N
478	large shunt	C0232180;C0542331;C0549177;C1442858	\N	\N
478	congenital shunts	C0009678;C0232180;C0542331;C1442858;C1744681	\N	\N
478	assoc  with corrected congenital shunts	C0009678;C0205202;C0232180;C0542331;C1442858;C1744681	\N	\N
477	residual perfusion defect > $nmbr$ % on lung scan  no . ( % )	C1457869;C1518040;C1609982	\N	\N
477	lung infection	C0876973;C4552950	\N	\N
477	lung	C0024109	\N	\N
477	lunchb	\N	\N	\N
477	high - probability ventilation / perfusion lung scanning	C0024109;C0560738;C4699572	\N	\N
476	lung neoplasm malignant	C0024121;C0205282	\N	\N
476	> $nmbr$ / $nmbr$ lung fields	C0225759	\N	\N
475	pool of long term ( hefh patients only ) and high fh	C0030705;C0205171;C0205250;C0337051;C0443252;C1299351;C1509144;C1720467;C2349200;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
475	hong kong	C0019907;C2987742	\N	\N
474	total occlusion  n ( % )	C0001168;C0011382;C0028778;C0439175;C0439810;C0441597;C1110554;C1947917	\N	\N
7	heterogeneity or trend p value	C0019409;C0242960;C1521798;C1709380;C4554533	\N	\N
473	cardiovascular inclusion criteriat	C0007226;C0007637;C1512693;C3887460	\N	\N
472	three or more lesions	C0205172;C0205449;C0221198;C1546698	\N	\N
472	t $nmbr$ lesion volume  mm '	C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674	\N	\N
472	t $nmbr$ lesion volume  mm $nmbr$	C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674	\N	\N
472	stents per lesion  n	C0038257;C0221198;C1546698	\N	\N
472	stented lesions	C0038257;C0221198	\N	\N
472	n ( stented lesions )	C0038257;C0221198;C0369718;C0441922	\N	\N
472	more than $nmbr$ lesions per vessel	C0005847;C0205172;C0221198;C1546698	\N	\N
472	mean stents per lesion ( sd ) ‡	C0038257;C0221198;C0444504;C1546698;C2347634;C2348143;C2699239	\N	\N
472	lesions b $nmbr$ / c	C0221198;C1546698	\N	\N
472	lesions	C0221198	\N	\N
472	lesion length ≥ $nmbr$ mm	C0221198;C1444754;C1546698;C1706316;C4330985;C4554674	\N	\N
472	lesion length > $nmbr$ mm	C0221198;C1444754;C1546698;C1706316;C4330985;C4554674	\N	\N
472	lesion length $ $nmbr$ mm	C0221198;C1444754;C1546698;C1706316;C4330985;C4554674	\N	\N
472	lesion length  mean ( sd )  mm	C0221198;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
472	lesion ( s )	C0221198;C1546698	\N	\N
472	intervention in complex lesions	C0221198;C1292781	\N	\N
472	direct stenting per lesion ‡	C0038257;C0221198;C0439851;C1546698;C1947931;C2348535	\N	\N
472	complex lesions ^	C0221198;C0439855;C1704241	\N	\N
472	age > $nmbr$ gd lesion > $nmbr$ n = $nmbr$	C0001779;C0221198;C1546698	\N	\N
472	age > $nmbr$ gd lesion = $nmbr$ n = $nmbr$	C0001779;C0221198;C1546698	\N	\N
472	age < $nmbr$ gd lesion > $nmbr$ n = $nmbr$	C0001779;C0221198;C1546698	\N	\N
472	age < $nmbr$ gd lesion = $nmbr$ n = $nmbr$	C0001779;C0221198;C1546698	\N	\N
472	age / gd lesion	C0001779;C0221198;C1546698	\N	\N
472	> $nmbr$ lesions per vessel	C0005847;C0221198	\N	\N
471	regadenoson ( n = $nmbr$ )	C1698215	\N	\N
471	regadenoson	C1698215	\N	\N
470	treatment before admission ( % )	C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
470	treatment after admission	C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
470	risk level at admission	C0184666;C0809949;C2923839	\N	\N
470	before admission )  %	C0184666;C0809949	\N	\N
469	no st depression or elevation	C0439775;C0520887;C0702240	\N	\N
469	no depression	C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827	\N	\N
469	depression ®	C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827	\N	\N
469	depression ^	C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827	\N	\N
469	depression	C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827	\N	\N
469	antidepressant	C0003289	\N	\N
468	linear regression	C0023733;C2346679	\N	\N
468	aggressive ( n = $nmbr$ )	C0001807;C0580822	\N	\N
468	aggressive ( $nmbr$ )	C0001807;C0580822	\N	\N
467	history of dyspepsia	C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968	\N	\N
467	dyspepsia	C0013395;C4552968	\N	\N
466	y es	C0013754;C0205944	f	-10
469	st depression > $nmbr$ mm	C0520887;C4330985;C4554674	f	1856
469	st - segment depression > $nmbr$ mm — no . ( % )	C0520887;C4330985;C4554674	f	1856
470	aspirin before admission	C0004057;C0184666;C0809949	f	1366
471	no readmission ( n = $nmbr$ )	C1548168;C4489276	f	1857
471	readmission ( n = $nmbr$ )	C1548168;C4489276	f	1857
475	long - term vitamin k antagonist	C0443252;C1096489;C2267235	f	858
475	long - term warfarin ( n = $nmbr$ )	C0043031;C0443252	f	858
475	long - term warfarin ( n - $nmbr$ )	C0043031;C0443252	f	858
475	long term *	C0443252	f	1858
475	long term ( n = $nmbr$ ) +	C0443252	f	1858
474	small - artery occlusion	C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917	f	1859
474	small - artery occlusion ( lacune )	C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917	f	1859
473	inclusion criteria	C1512693	f	1860
473	inclusion criteria — no . ( % )	C1512693	f	1860
465	with des	C0011702;C4551552	\N	\N
465	older des ( n = $nmbr$ )	C0011702;C0580836;C4551552	\N	\N
465	no des	C0011702;C4551552	\N	\N
465	des implantation for restenosis  n ( % )	C0011702;C0021107;C0029976;C0333186;C4551552	\N	\N
465	des ( % previous stenting )	C0011702;C0038257;C0205156;C1552607;C2348535;C4551552	\N	\N
465	des	C0011702;C4551552	\N	\N
464	yes  no	C1512698	\N	\N
464	non - metsyn	C1518422	\N	\N
464	metsyn	\N	\N	\N
464	ics use yes / no  %	C0042153;C0457083;C0815320;C1512698;C1947944;C4551720	\N	\N
464	ics use  yes / no %	C0042153;C0457083;C0815320;C1512698;C1947944;C4551720	\N	\N
464	ics use  yes / no  %	C0042153;C0457083;C0815320;C1512698;C1947944;C4551720	\N	\N
464	( yes / no )	C1512698	\N	\N
463	us	\N	\N	\N
463	non - us	C1518422	\N	\N
463	non - inhaled steroid use  n ( % )	C0586793;C1518422	\N	\N
463	non - black  us	C0005680;C0027567;C0085756;C0439541;C1518422	\N	\N
462	saphenous vein graft	C0729538	\N	\N
462	saphenous - vein graft	C0729538	\N	\N
462	graft occlusionsa	C0181074;C0332835;C1961139	\N	\N
462	graft  n ( % )	C0181074;C0332835;C1961139	\N	\N
462	graft	C0181074;C0332835;C1961139	\N	\N
462	gait	C0016928	\N	\N
462	all grafts	C0181074;C0332835;C1527362;C1961139	\N	\N
461	percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < $nmbr$ mg / dl . tbased on participant history or review of chart .	C0003211;C0007787;C0010055;C0013227;C0019664;C0019665;C0020443;C0023779;C0042373;C0085096;C0149721;C0168634;C0205100;C0205250;C0229671;C0262512;C0262926;C0439165;C0439269;C0441889;C0441994;C0455536;C0456079;C0521116;C0541653;C0600061;C0679646;C0700225;C0700287;C0802604;C0917805;C1054154;C1260596;C1442488;C1522133;C1524063;C1546774;C1547707;C1549488;C1550100;C1561533;C1705255;C2003888;C2004062;C2598133;C2698741;C2946261;C3163633;C3671888;C4284232;C4288581;C4521226;C4554048	\N	\N
461	granulating  n ( % ) a	\N	\N	\N
460	peak creatine kinase - mb  u / l	C0010290;C0439339;C0444505;C0523584	\N	\N
460	gamma glutamyltransferase  u / l	C0017040;C0439339	\N	\N
460	elevated creatine kinase mb ( > $nmbr$ u / l )	C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633	\N	\N
460	elevated creatine kinase - mb ( > $nmbr$ u / l )	C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633	\N	\N
460	alt ( units / l )	C0439339;C1266129;C4553172	\N	\N
460	alt  u / l	C0439339;C1266129;C4553172	\N	\N
459	idegasp – biasp $nmbr$	\N	\N	\N
459	biasp $nmbr$ bid	\N	\N	\N
459	biasp $nmbr$	\N	\N	\N
459	ast increased	C0205217;C0442805;C1415181;C3891303	\N	\N
459	ast  u / l	C0439339;C1415181;C3891303	\N	\N
459	asp	C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371	\N	\N
458	at	\N	\N	\N
457	within last $nmbr$ d	C1517741	\N	\N
457	mean arterial pressure  last	C0428886;C1517741	\N	\N
457	last infusion in the horizon - pft	C0024119;C0053122;C0279232;C0574032;C1517741;C1827465	\N	\N
438	no . ( % ) '	\N	\N	\N
461	coronary bypass graft	C1260596	f	1843
458	digoxin at last follow - up	C0012265;C0589120;C1522577;C1704685;C3274571	f	989
456	past or nonsmoker ( n = $nmbr$ )	C0337672;C0425293;C1444637;C4284302;C4554605	f	420
456	past smoking	C0037369;C0453996;C1444637;C1881674;C4284302	f	420
456	past smoker	C0337664;C1444637;C4284302	f	420
456	past smoker  n ( % )	C0337664;C1444637;C4284302	f	420
456	smoking in past yr	C0037369;C0439234;C0453996;C1444637;C1881674;C4284302	f	420
456	smoking past	C0037369;C0453996;C1444637;C1881674;C4284302	f	420
458	ace inhibitor or arb at last follow - up	C0003015;C0589120;C1522577;C1704685;C3274571;C3888198;C4541021	f	811
458	arb at last follow - up	C0589120;C1522577;C1704685;C3274571;C3888198	f	779
458	ace inhibitor at last follow - up	C0003015;C0589120;C1522577;C1704685;C3274571;C4541021	f	811
458	statin at last follow - up	C0360714;C0589120;C1522577;C1704685;C3274571	f	872
458	warfarin at last follow - up	C0043031;C0589120;C1522577;C1704685;C3274571	f	858
458	thiazide at last follow - up	C0541746;C0589120;C1522577;C1704685;C3274571	f	993
466	das $nmbr$ - esr remission	C0051767;C0057671;C0544452;C0687702;C3811131	f	298
466	das $nmbr$ - esr remission  %	C0051767;C0057671;C0544452;C0687702;C3811131	f	298
466	das $nmbr$ - $nmbr$ ( esr )	C0051767;C0057671;C3811131	f	298
466	das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ t	C0051767;C0057671;C3811131	f	298
461	bypass graft	C0185098	f	2032
461	arterial graft	C0450140	f	2032
461	bypass graft §	C0185098	f	2032
461	multivessel coronary - artery bypass grafting	C0010055	f	2032
466	das $nmbr$ - esr	C0051767;C0057671;C3811131	f	298
466	das $nmbr$ ( esr )	C0051767;C0057671;C3811131	f	298
466	das $nmbr$ - esr lda	C0051767;C0057671;C3811131;C4553195	f	298
466	das $nmbr$ - $nmbr$ ( esr ) $nmbr$	C0051767;C0057671;C3811131	f	298
466	das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ *	C0051767;C0057671;C3811131	f	298
461	prior bypass graft surgery	C0185098;C0455610	f	2032
461	need for urgent coronary - artery bypass grafting	C0010055;C0027552;C0439609;C0686904;C3272275	f	2032
462	graft  pci  percutaneous coronary intervention  tia  transient	C0007787;C0040704;C0181074;C0205374;C0332835;C0917805;C1054154;C1532338;C1961139	f	1661
456	past or never	C1444637;C2003901;C4284302	\N	\N
456	past or current angina pectoris	C0002962;C0521116;C1444637;C1705970;C4284302	\N	\N
456	past or current	C0521116;C1444637;C1705970;C4284302	\N	\N
456	past only	C0205171;C1444637;C1720467;C4284302	\N	\N
456	past cardiovascular history  no . ( % )	C0007226;C0332119;C1444637;C1880008;C3887460;C4284302	\N	\N
456	past	C1444637;C4284302	\N	\N
456	never or past	C1444637;C2003901;C4284302	\N	\N
456	intra - abdominal abscess ( past )	C0243001;C1444637;C4284302	\N	\N
456	current / past	C0521116;C1444637;C1705970;C4284302	\N	\N
456	bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .	C0005893;C0011847;C0011849;C0011900;C0012164;C0020538;C0031831;C0065058;C0085805;C0125953;C0332257;C0337664;C0444686;C0488055;C0489829;C0521116;C0536221;C0578022;C0804815;C0871470;C1096202;C1305855;C1306620;C1439335;C1441506;C1444637;C1527178;C1552866;C1704338;C1704656;C1705501;C1705938;C1705970;C1963138;C2700399;C3813197;C4281799;C4284302	\N	\N
455	killip ciass	\N	\N	\N
455	ciass i	C0021966;C0221138	\N	\N
455	ccs class §	C1879987	\N	\N
454	others  classes i and iiic	C0441885;C1319793;C1955473;C2698967;C3539125	\N	\N
454	class i	C0441885;C1319793;C2698967	\N	\N
453	nyha_class	C1882083	\N	\N
453	nyha class — no . ( % ) $	C1882083	\N	\N
453	nyha class — no . ( % )	C1882083	\N	\N
453	nyha class within past month — no . / total no . ( % )	C0439175;C0439810;C1882083;C4331910	\N	\N
453	nyha class not reported	C0684224;C0700287;C1518422;C1882083;C4319718	\N	\N
453	nyha class $nmbr$ or higher	C0205250;C1882083	\N	\N
453	nyha class $nmbr$ - $nmbr$ : no { n = llll )	C0369718;C0441922;C1882083	\N	\N
453	nyha class  n ( % ) i	C0021966;C0221138;C0369718;C0441922;C1882083	\N	\N
453	nyha class  n ( % )	C1882083	\N	\N
453	nyha class  ( % )	C1882083	\N	\N
453	nyha class	C1882083	\N	\N
453	nyha chf class	C0018802;C1882083	\N	\N
453	new york heart association congestive heart failure class	C0018802;C1882083	\N	\N
453	new york heart association class	C1882083	\N	\N
452	who functional class — no . ( % ) : c	C0205245;C0456387;C0542341;C1518526;C1705943;C2700217	\N	\N
452	who functional class	C0205245;C0456387;C0542341;C1518526;C1705943;C2700217	\N	\N
452	renal biopsy class	C0194073;C0456387;C1518526;C1705943	\N	\N
452	modified braunwald class	C0392747;C0456387;C1518526;C1705943;C3889737	\N	\N
452	modified acc or aha lesion class b $nmbr$ or c	C0050451;C0175754;C0221198;C0282160;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3541413;C3889737	\N	\N
452	modified acc / aha lesion class b $nmbr$ or cj	C0007481;C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694	\N	\N
452	modified acc / aha lesion class b $nmbr$ / c	C0050451;C0101856;C0221198;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3889737	\N	\N
452	modified acc - aha lesion class b $nmbr$ or c	C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694	\N	\N
452	kilip class	C0456387;C1518526;C1705943	\N	\N
452	heart failure ( class l - lll )	C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158	\N	\N
452	egfr in $nmbr$ classes	C0456387;C1518526;C1705943;C1739039;C3811844;C3812682;C4019422	\N	\N
452	class ic	C0020750;C0456387;C1518526;C1705943;C4554818	\N	\N
452	class ia	C0020980;C0456387;C0694634;C1518526;C1705943;C1947960	\N	\N
452	class > $nmbr$	C0456387;C1518526;C1705943	\N	\N
452	class $nmbr$	C0456387;C1518526;C1705943	\N	\N
452	calculated ldl - c in $nmbr$ classes	C0444686;C0456387;C1441506;C1518526;C1705943;C4019422	\N	\N
452	borg dyspnea score who functional class  n ( % )	C0013404;C0205245;C0449820;C0456387;C0542341;C1518526;C1705943;C1963100;C2700217;C4050231	\N	\N
452	baseline who functional class	C0168634;C0205245;C0456387;C0542341;C1442488;C1518526;C1705943;C2700217	\N	\N
452	baseline who function class	C0031843;C0168634;C0456387;C0542341;C0700205;C1442488;C1518526;C1705273;C1705943	\N	\N
452	baseline trl - c in $nmbr$ classes	C0168634;C0456387;C1442488;C1518526;C1705943;C4019422	\N	\N
452	baseline triglycerides in $nmbr$ classes	C0041004;C0168634;C0456387;C1442488;C1518526;C1705943;C4019422	\N	\N
452	baseline lp ( a ) in $nmbr$ classes	C0065058;C0168634;C0456387;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379	\N	\N
452	ara functional class — no . ( % )	C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455	\N	\N
452	ara functional class	C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455	\N	\N
452	angina class at baseline	C0002962;C0168634;C0456387;C1442488;C1518526;C1705943	\N	\N
452	age in $nmbr$ classes	C0001779;C0456387;C1518526;C1705943;C4019422	\N	\N
452	acc / aha lesion class b $nmbr$ or c  n ( % )	C0221198;C0456387;C1518526;C1546698;C1705943;C4072694	\N	\N
451	periprocedural anticoagulant	C0003280;C0848112;C3536711	\N	\N
438	no $nmbr$  $nmbr$	\N	\N	\N
438	no	\N	\N	\N
455	baseline heart failure severity nyha class i	C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158	f	453
455	nyha class iii / iv	C0278962	f	453
455	nyha class iii  % ( n )	C1882086	f	453
455	nyha class ii ( n = $nmbr$ )	C1882085	f	453
455	nyha class ii ( n = $nmbr$ l $nmbr$ )	C1882085	f	453
455	nyha class iv	C1882087	f	453
455	nyha class  n ( % ) ii	C1882085	f	453
455	tcomparison of proportion of patients with nyha class lll / iv heart failure .	C0018801;C0018802;C0030705;C1261077;C1709707;C1882087;C4554158	f	453
455	nyha functional class iii ( % )	C0205245;C0542341;C1882086;C2700217	f	453
455	nyha functional class iii	C0205245;C0542341;C1882086;C2700217	f	453
456	past or nonsmoker	C0337672;C0425293;C1444637;C4284302;C4554605	f	420
451	aspirin or other antiplatelet or anticoagulant agent	C0003280;C0004057	\N	\N
451	any anticoagulant	C0003280;C0848112;C3536711	\N	\N
451	antithrombotic and anticoagulant medications	C0003280	\N	\N
451	antiplatelets or anticoagulants	C0003280	\N	\N
451	antiplatelets	\N	\N	\N
451	antiplatelet or anticoagulant	C0003280;C0848112;C3536711	\N	\N
451	antiplatelet agent or anticoagulant	C0003280;C0085826;C0848112;C3536711	\N	\N
451	antiplatelet	\N	\N	\N
450	other anticoagulant	C0003280;C0848112;C3536711	\N	\N
450	concomitant anticoagulant  antithrombotic or nsaid  n ( % )	C0003211;C0003280;C0521115;C0848112;C3536711;C3536840	\N	\N
450	anticoagulant	C0003280;C0848112;C3536711	\N	\N
450	anti - coagulants - no . ( % )	C0848112	\N	\N
450	anti - coagulants	C0848112	\N	\N
449	piacebo ( n = $nmbr$ ) no . of participants with events ( % )	C0441471;C0679646;C3541888	\N	\N
449	piacebo	\N	\N	\N
449	nondiabetic participants !	C0679646	\N	\N
449	nondiabetic	\N	\N	\N
449	nondiabetes	\N	\N	\N
448	receiving concomitant nsaids and / or cox - $nmbr$ inhibitors	C0003211;C0085387;C0521115;C1514756	\N	\N
448	oads  n ( % )	\N	\N	\N
448	number of concomitant aeds  n ( % )	C0180309;C0237753;C0449788;C0521115	\N	\N
448	most common concomitant aeds  n ( % )	C0180309;C0205214;C0205393;C0521115;C1522138;C3245511	\N	\N
448	most common concomitant aeds  d n ( % )	C0180309;C0205214;C0205393;C0521115;C1522138;C3245511	\N	\N
448	concomitant oads  n ( % )	C0521115	\N	\N
448	concomitant aedsb    n   ( % )	C0521115	\N	\N
448	concomitant aedsb  n ( % )	C0521115	\N	\N
448	concomitant aedsa	C0521115	\N	\N
448	concomitant aeds  n ( % )	C0180309;C0521115	\N	\N
448	> - $nmbr$ . $nmbr$ and < - $nmbr$ . $nmbr$	\N	\N	\N
448	> $nmbr$ oads	\N	\N	\N
448	$nmbr$ oads	\N	\N	\N
447	no concomitant antiplatelet	C0521115	\N	\N
447	main concomitant treatments  no . ( % )	C0087111;C0205225;C0521115;C1542147	\N	\N
447	concomitant drugs  %	C0013227;C0521115;C3687832	\N	\N
447	concomitant drugs	C0013227;C0521115;C3687832	\N	\N
447	concomitant drug therapies  n ( % )	C0013216;C0521115	\N	\N
447	concomitant antiplatelet	C0521115	\N	\N
447	concomitant antihyperglycaemic drugs  n ( % )	C0013227;C0020616;C0521115;C3687832	\N	\N
447	concomitant	C0521115	\N	\N
446	use of concomitant lipid - modifying therapy	C0023779;C0392747;C1524063;C1707479	\N	\N
446	concomitant therapy  no . ( % )	C1707479	\N	\N
446	concomitant therapy  n [ % ]	C1707479	\N	\N
446	concomitant therapy	C1707479	\N	\N
446	concomitant therapies n ( % )	C1707479	\N	\N
446	concomitant therapies at hospital discharge	C0586003;C1707479	\N	\N
446	concomitant lipid - modifying therapy — no . { % )	C0023779;C0392747;C1707479	\N	\N
446	baseline / concomitant therapies	C0168634;C1442488;C1707479	\N	\N
445	tion — no . ( % )	\N	\N	\N
445	tics — no . ( % )	C0040188;C0278076;C2169806;C3889970	\N	\N
445	no . copies gly $nmbr$ - glu $nmbr$ - $nmbr$ c	C0068000;C1948062	\N	\N
445	no ( n = $nmbr$ )	C0369718;C0441922	\N	\N
445	no ( n = $nmbr$  $nmbr$ )	C0369718;C0441922	\N	\N
445	acecoumarol  no . ( % )	\N	\N	\N
445	$nmbr$ - $nmbr$ — no . ( % )	\N	\N	\N
444	inflotmas io mgluj versus piecew	C1046794;C3146236	\N	\N
444	$nmbr$ . $nmbr$ ( io . i )	C0021966;C0221138;C1046794;C3146236	\N	\N
444	$nmbr$ ( io - $nmbr$ % )	C1046794;C3146236	\N	\N
443	xho  p = o - $nmbr$	C4050013	\N	\N
443	ho active cancer	C0006826;C0019905;C0205177;C0998265;C1306459;C1832110;C3853793;C3888249;C3889614	\N	\N
443	ho	C0019905;C1832110;C3889614	\N	\N
442	glatiramer acetate  no . ( % )	C0289884	\N	\N
442	acarbose 一 no . ( % )	C0050393	\N	\N
442	> $nmbr$ — no . { % )	\N	\N	\N
441	study medication — no . ( % )	C0013227;C0557651;C2603343;C3244316;C4284232	\N	\N
441	other — no . ( % )	\N	\N	\N
441	other lipid - modifying drug 一 no . ( % )	C0013227;C0023779;C0392747;C1254351	\N	\N
441	no glucose lowering drugs	C0013227;C0017725;C0441994;C2003888;C3687832	\N	\N
441	no . a	\N	\N	\N
441	no ( % )	\N	\N	\N
441	medication use — no . { % )	C0013227;C0042153;C0457083;C1947944;C3244316;C4284232	\N	\N
441	medication use — no . ( % ) ^ |	C0013227;C0042153;C0457083;C1947944;C3244316;C4284232	\N	\N
441	medication use — no . ( % )	C0013227;C0042153;C0457083;C1947944;C3244316;C4284232	\N	\N
441	medication use  no . / total no . ( % )	C0013227;C0042153;C0439175;C0439810;C0457083;C1947944;C3244316;C4284232	\N	\N
440	£ $nmbr$ yo ( n = $nmbr$ )	C1413296	\N	\N
440	sso - $nmbr$	\N	\N	\N
440	< $nmbr$ yo ( n = $nmbr$ )	C1413296	\N	\N
440	- $nmbr$ . $nmbr$ ± lno ^	\N	\N	\N
439	no  no	\N	\N	\N
438	no ppi	C0358591;C0871125;C3811894	\N	\N
439	no antihypertensive medication	C0003364	f	1579
440	current smoking — no . ( % )	C0037369;C0453996;C0521116;C1705970;C1881674	f	420
440	current smoking — no . / total no . ( % )	C0037369;C0439175;C0439810;C0453996;C0521116;C1705970;C1881674	f	420
440	no smoking	C0037369;C0453996;C1881674	f	420
440	no smo king	C1311076;C1364142;C1423784	f	420
442	beta - blocker — no . ( % )	C0001645	f	959
442	no beta - blocker	C0001645	f	959
442	no beta - blocker use	C0001645;C0042153;C0457083;C1947944	f	959
451	anticoagulant group ( n = $nmbr$ )	C0003280;C0441848;C0848112;C3536711	f	450
451	anticoagulant — no . ( % )	C0003280;C0848112;C3536711	f	450
451	anticoagulants	C0003280	f	450
438	ppi but no aspirin	C0004057;C0358591;C0871125;C3811894	f	1366
437	pio $nmbr$	C0030800;C2347712	\N	\N
437	full po pulatio n	C0443225;C0946289	\N	\N
436	rro . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )	\N	\N	\N
436	rro $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )	\N	\N	\N
436	pro / pro homozygotes	C0019904;C1120626	\N	\N
435	type $nmbr$ diabetes pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )	C0031962;C1320657	\N	\N
435	score at week $nmbr$  mean ( se ) difference mepo - pbo ( $nmbr$ % ci )	C0008107;C0031962;C0036919;C0332174;C0439230;C1705241;C1705242;C3259781;C3533236	\N	\N
435	pbo to czp week $nmbr$ dose combined	C0031962;C0054841;C0178602;C0205195;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109	\N	\N
435	pbo n = $nmbr$	C0031962	\N	\N
435	pbo n ( % )	C0031962	\N	\N
435	pbo / simva - $nmbr$ yr km rale ( % )	C0031962;C0034642;C0439234;C3887676	\N	\N
435	pbo - sc every other week ( n = $nmbr$ )	C0031962;C0282380;C0332174;C0439230	\N	\N
435	pbo - adjusted ls mean change ( se )	C0023668;C0031962;C0036919;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952	\N	\N
435	pbo - adjusted ls mean change	C0023668;C0031962;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952	\N	\N
435	pbo + statin n = $nmbr$	C0031962;C0360714	\N	\N
435	pbo + statin $nmbr$	C0031962;C0360714	\N	\N
435	pbo + statin	C0031962;C0360714	\N	\N
435	pbo ( n   =   $nmbr$ )	C0031962	\N	\N
435	pbo ( n = $nmbr$ ) vs	C0031962	\N	\N
435	pbo ( n = $nmbr$ )	C0031962	\N	\N
435	pbo ( n - $nmbr$ )	C0031962	\N	\N
435	pbo ( n $nmbr$ )	C0031962	\N	\N
435	pbo ( n $nmbr$ $nmbr$ )	C0031962	\N	\N
435	pbo  no . ( o / o ) ^ ’	C0031962;C0483204	\N	\N
435	pbo  no . ( % ) ^	C0031962	\N	\N
435	pbo  n = $nmbr$	C0031962	\N	\N
435	pbo	C0031962	\N	\N
435	neither pbo + statin eze + statin	C0031962;C0360714	\N	\N
435	mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )	C0031962;C0812270;C1705694;C2939420	\N	\N
435	mepo ( n = $nmbr$ )	\N	\N	\N
435	insulin tx difference vs pbo  median change from baseline ( se ) $nmbr$	C0021641;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1533581;C1579433;C1705241;C1705242;C2347635;C2348144;C2939193;C3714501;C4319952	\N	\N
435	ind + pbo ( n = $nmbr$ )	C0031962;C4049864	\N	\N
435	ifg pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ )	C0031962;C1334085;C1708411	\N	\N
435	fpg tx difference vs pbo  median change from baseline ( se ) $nmbr$	C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952	\N	\N
435	flex pbo ®	C0031962	\N	\N
435	difference vs pbo	C0031962;C1705241;C1705242	\N	\N
435	difference mepo - pbo ( $nmbr$ % ci )	C0008107;C0031962;C1705241;C1705242;C3259781	\N	\N
435	blood pressure  pbo y patients with diabe teristics ( ncep atp i	C0005823;C0021966;C0030705;C0031962;C0221138;C1271104;C1272641;C2744579;C4552600	\N	\N
434	time from symptoms onset to $nmbr$ st balloon inflation ( h )	C0021398;C0033727;C0036056;C0336867;C0369286;C0441144;C0441932;C0449244;C0564385;C0683368;C1318493;C1457887;C3272372;C4528284	\N	\N
434	time from symptom onset to balloon inflation	C0021398;C0040223;C0336867;C0441144;C0449244;C1318493;C1457887;C3541383;C3854129;C4086878	\N	\N
434	time from randomisation to $nmbr$ st balloon inflation ( h )	C0021398;C0033727;C0034656;C0036056;C0040223;C0336867;C0369286;C0441144;C0441932;C0564385;C1318493;C3272372;C3541383;C4528284	\N	\N
434	time from qualifying ecg to balloon inflation	C0021398;C0040223;C0336867;C0441144;C1318493;C1514624;C1623258;C3541383	\N	\N
434	o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )	C0483204	\N	\N
434	o $nmbr$ o ( oo $nmbr$ - o - $nmbr$ o )	C0483204	\N	\N
434	antibodies to infliximab  n ( % ) * *	C3533054	\N	\N
434	- o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )	C0483204	\N	\N
434	$nmbr$ - $nmbr$ ( o - $nmbr$ - $nmbr$ - oo )	C0483204	\N	\N
434	$nmbr$ ( oo $nmbr$ - o . $nmbr$ )	\N	\N	\N
433	time to treatment  h	C0033727;C0369286;C0441932;C0564385;C3494202;C4528284	\N	\N
433	time to treatment	C3494202	\N	\N
433	time to angiography — hr	C0002978;C0040223;C3541383	\N	\N
433	mean time to first subcutaneous injectiong  h in relation to surgery  hr	C0033727;C0038894;C0038895;C0040223;C0205435;C0369286;C0441932;C0443315;C0444504;C0543467;C0564385;C1274039;C1279901;C2347634;C2348143;C3541383;C4528284	\N	\N
433	door - to - balloon time — hr	C4296144	\N	\N
432	unrelated to effectiveness	C0445356;C1280519;C1704623;C4553491	\N	\N
432	no . needed to treat ( $nmbr$ % cl ) *	C0027552;C0040363;C0041260;C0087111;C0596019;C0686904;C1292734;C1522326;C1883351	\N	\N
432	- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to - $nmbr$ - $nmbr$ )	C0596019	\N	\N
432	- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )	C0596019	\N	\N
432	$nmbr$ to < $nmbr$ — no . { % )	\N	\N	\N
432	$nmbr$ to < $nmbr$ cel	C0208736;C0346421;C0439237;C1413336	\N	\N
432	$nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$	C0596019	\N	\N
432	$nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ )	C0596019	\N	\N
432	$nmbr$ ( $nmbr$ % cl $nmbr$ to $nmbr$ )	C0596019	\N	\N
431	三 $nmbr$ to < $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	≥ $nmbr$ to < $nmbr$ %	C0040363;C0041260;C1883351	\N	\N
431	randomized to receive aspirin yes	C0004057;C0034656;C0040363;C0041260;C1514756;C1549445;C1705108;C1710701;C1883351;C3815594	\N	\N
431	randomization to end of study	C0034656;C0040363;C0041260;C0444930;C0557651;C1883351;C2603343;C2746065	\N	\N
431	randomised to canakinumab $nmbr$ mg	C0024671;C0026410;C0040363;C0041260;C0439269;C1883351;C1960952;C2346927;C2718773;C4321396;C4521761	\N	\N
431	patients meeting the criteria to receive $nmbr$ mg of	C0024671;C0026410;C0030705;C0040363;C0041260;C0243161;C0439269;C0556656;C1514756;C1883351;C1960952;C2346927;C4321396;C4521761	\N	\N
428	apob	C0003593;C3252643	f	426
433	$nmbr$ to < $nmbr$ hr	\N	f	-10
438	aspirin 一 no . ( % )	C0004057	f	1366
438	drug therapy at admission — no . ( % ) aspirin	C0004057;C0013216;C0013217;C0184666;C0809949	f	1366
431	patient ' s preference not to take vka  only reason	C0040363;C0041260;C0205171;C0376409;C0392360;C1515187;C1518422;C1720467;C1883351	\N	\N
431	patient ' s preference not to take	C0040363;C0041260;C0376409;C1515187;C1518422;C1883351	\N	\N
431	method used to diagnose the incident pulmonary embolism  no . ( % )	C0011900;C0025663;C0034065;C0040363;C0041260;C0449851;C0871511;C1273517;C1551358;C1883351	\N	\N
431	length of stay ( randomization to discharge  h )	C0012621;C0023303;C0030685;C0033727;C0034656;C0040363;C0041260;C0369286;C0441932;C0564385;C1883351;C2926602;C4528284	\N	\N
431	leading to study withdrawal	C0040363;C0041260;C0332152;C0557651;C1522538;C1710677;C1883351;C2349954;C2603343;C2825032;C3812880;C4049634	\N	\N
431	key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ $nmbr$ of the indicated char least - square means  except tc an note : all treatment by subgroup	C0015663;C0017725;C0023189;C0023823;C0036143;C0039411;C0039798;C0040363;C0040642;C0041004;C0041260;C0041405;C0041698;C0087111;C0327953;C0332257;C0683312;C1079230;C1316572;C1317574;C1436327;C1444656;C1515021;C1518422;C1522326;C1533734;C1552866;C1704970;C1705169;C1824670;C1883351;C2700399;C2744579;C2983605;C2986463;C3272447;C3538994;C3884535;C3887704;C3889287;C3890735;C4048285;C4521369;C4522122;C4552600	\N	\N
431	intention - to - treat without st - segment - elevation myocardial infarction	C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1536220;C1883351	\N	\N
431	intention - to - treat with st - segment - elevation myocardial infarction	C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1536220;C1883351	\N	\N
431	intention - to - treat	C0040363;C0041260;C0087111;C0162425;C1283828;C1292734;C1522326;C1883351	\N	\N
431	intent to use gp iib / iiia	C0016011;C0040363;C0041260;C0042153;C0162425;C0457083;C1283828;C1550453;C1883351;C1947944	\N	\N
431	intent to use glycoprotein iib / iiia inhibitor	C0016011;C0040363;C0041260;C0042153;C0162425;C0457083;C1283828;C1550453;C1883351;C1947944;C1999216	\N	\N
431	intent to use dti	C0040363;C0041260;C0042153;C0162425;C0457083;C1283828;C1537007;C1550453;C1883351;C1947944	\N	\N
431	intent to use direct thrombin	C0040018;C0040363;C0041260;C0042153;C0162425;C0439851;C0457083;C1283828;C1550453;C1883351;C1947931;C1947944	\N	\N
431	first disease - progression outcome to occur §	C0040363;C0041260;C0205435;C0242656;C0449258;C0679250;C1274040;C1279901;C1335499;C1709305;C1883351;C1947900;C2745955;C3542417;C4284875;C4552808	\N	\N
431	duration of total exposure to study treatment  weeks	C0039798;C0040363;C0041260;C0087111;C0439175;C0439230;C0439810;C0557651;C1522326;C1533734;C1705169;C1883351;C2603343;C2826870;C3538994;C3887704	\N	\N
431	cough ( leading to study drug discontinuation )	C0010200;C0013175;C0040363;C0041260;C0332152;C0457454;C1444662;C1522538;C1883351;C1961131;C3274924;C4084725;C4084726;C4084727;C4552847	\N	\N
431	adherence to study regimen — no . ( % ) ff	C0040363;C0040808;C0041260;C0557651;C1510802;C1883351;C2603343;C2945654;C4554348	\N	\N
431	adherence to study regimen — no . ( % )	C0040363;C0040808;C0041260;C0557651;C1510802;C1883351;C2603343;C2945654	\N	\N
431	> - $nmbr$ . $nmbr$ to < - $nmbr$ . $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	> $nmbr$ to s $nmbr$ yrs	C0040363;C0041260;C1883351	\N	\N
431	> $nmbr$ to < $nmbr$ uln	C0040363;C0041260;C1519815;C1883351	\N	\N
431	> $nmbr$ to < $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	> $nmbr$ to $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	> $nmbr$ . $nmbr$   vs . $nmbr$ . $nmbr$ to   ≤   $nmbr$ . $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ %	C0040363;C0041260;C1883351	\N	\N
431	> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )	C0040363;C0041260;C1883351;C3829066	\N	\N
431	> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to $nmbr$ mmol / mol )	C0040363;C0041260;C1883351;C3829066	\N	\N
431	> $nmbr$ % to < $nmbr$ %	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ to less than $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ to < $nmbr$ mumin	\N	\N	\N
431	$nmbr$ to < $nmbr$ bpm ( n = $nmbr$ )	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ to < $nmbr$ . $nmbr$ %	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ to < $nmbr$ ( % )	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ to < $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ to < $nmbr$ mmol / mol )	C0040363;C0041260;C1883351;C3829066	\N	\N
431	$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ( % )	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ %	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) ]	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ]	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ]	C0040363;C0041260;C1883351	\N	\N
431	$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ]	C0040363;C0041260;C1883351	\N	\N
-10	two - dimensional echocardiography	C0013524	\N	\N
429	two or more at baseline	C0168634;C0205172;C0205448;C1442488	\N	\N
429	two or more	C0205172;C0205448	\N	\N
429	two of the above	C0205448	\N	\N
429	two lesions	C0205448;C0221198	\N	\N
429	two agents	C0205448;C0450442;C1254351;C1521826	\N	\N
429	two - sided p - value for hetero - geneity	C0205448;C0441987;C1709380	\N	\N
428	apobe	\N	f	426
428	apob  g / l	C0003593;C0439294;C0456615;C3252643	f	426
428	apob $nmbr$	C0003593;C3252643	f	426
429	two or more antihypertensive medications	C0003364;C0205172;C0205448	f	1579
427	apob : apoa - l ratio	C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379	\N	\N
427	apob : apoa - $nmbr$ ratio	C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379	\N	\N
427	apob : apoa $nmbr$ ratio	C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379	\N	\N
427	apob : apoa $nmbr$	C0003592;C0003593;C0523508;C3252643;C4553344;C4553379	\N	\N
427	apoa - $nmbr$  g / l	C0003592;C0439294;C0456615;C0523508;C4553344;C4553379	\N	\N
427	apo b / apo a - l ratio ( mean )	C0003592;C0444504;C0456603;C0523508;C1447574;C1547037;C2347634;C2348143;C4521365;C4553344	\N	\N
427	apo b / apo a - l	C0003592;C0523508;C1447574;C4521365;C4553344	\N	\N
427	apo a $nmbr$ ( g / l )	C0003592;C0439294;C0456615;C0523508;C4553344;C4553379	\N	\N
427	apo a $nmbr$  mean ( sd )	C0003592;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379	\N	\N
427	< $nmbr$ . $nmbr$ mmol / liter apob : apoa - l ratio	C0003592;C0003593;C0456603;C0475211;C0523508;C1532563;C1547037;C3252643;C4553344;C4553379	\N	\N
426	apob : apoa - i ratio	C0003593;C0085201;C0456603;C1547037;C1677784;C3252643	\N	\N
426	apob : apoa - i	C0003593;C0085201;C1677784;C3252643	\N	\N
426	apo b : apo a - i ratio	C0003593;C0085201;C0456603;C1547037;C1677784;C3252643	\N	\N
425	week $nmbr$ mayo endoscopy subscorea	C0014245;C0332174;C0439230;C0454788;C1077578	\N	\N
425	total mayo score $ | |	C0454788;C1077578;C2964552	\N	\N
425	total mayo score	C0454788;C1077578;C2964552	\N	\N
425	partial mayo score $ | |	C0449820;C0454788;C0728938;C1077578;C1550516;C4050231	\N	\N
425	partial mayo score  mean ( sd )	C0444504;C0449820;C0454788;C0728938;C1077578;C1550516;C2347634;C2348143;C2699239;C4050231	\N	\N
425	partial mayo score	C0449820;C0454788;C0728938;C1077578;C1550516;C4050231	\N	\N
425	partial mayo clinic scored	C0002424;C0442592;C0449820;C0454788;C0728938;C1077578;C1550516	\N	\N
425	mean mayo score ( sd )	C0454788;C1077578;C2699239;C3533236	\N	\N
425	mayo score ( mean ± sd )	C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231	\N	\N
425	mayo score ( $nmbr$ - $nmbr$ )	C0449820;C0454788;C1077578;C4050231	\N	\N
425	mayo score  mean ( sd )	C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231	\N	\N
425	mayo clinic scoreb	C0002424;C0442592;C0454788;C1077578	\N	\N
425	mayo clinic score §	C0002424;C0442592;C0449820;C0454788;C1077578;C4050231	\N	\N
425	mayo clinic score  mean ± sd	C0002424;C0442592;C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231	\N	\N
425	mayo < $nmbr$  n	C0454788;C1077578	\N	\N
425	mayo $ $nmbr$  n	C0454788;C1077578	\N	\N
425	complete mayo clinic score  median ( min  max }	C0002424;C0205197;C0442592;C0449820;C0454788;C0549183;C0702093;C0725685;C0876920;C1077578;C1524029;C2347635;C2348144;C2939193;C3813700;C3853530;C4050231;C4283785	\N	\N
425	baseline mayo score	C0168634;C0449820;C0454788;C1077578;C1442488;C4050231	\N	\N
425	baseline composite mayo clinic score	C0002424;C0168634;C0442592;C0454788;C1077578;C1442488;C4055211	\N	\N
423	smokers	C0337664	f	420
423	smoker  n ( % )	C0337664	f	420
423	smoker  ! n ( % )	C0337664	f	420
423	smoker at baseline	C0168634;C0337664;C1442488	f	420
423	smoker ( % ) a	C0337664	f	420
423	smoker ( % )	C0337664	f	420
423	smoker  %	C0337664	f	420
423	smoker	C0337664	f	420
423	present smoker	C0150312;C0337664;C0449450	f	420
423	noncurrent smoker	C0337664	f	420
423	ever - smoker	C0337664;C3887636	f	420
423	currently smoker	C0337664;C0521116	f	420
423	active smokers	C0205177;C0337664;C3853793;C3888249	f	420
423	active smoker	C0205177;C0337664;C3853793;C3888249	f	420
424	b includes both ex - smokers and nonsmokers .	C0332257;C0337671;C0337672;C1552866;C2700399;C4554605;C4555205	f	420
424	current or former smoker	C0337671;C0521116;C1705970	f	420
424	exsmoker	C0337671;C4555205	f	420
424	ex - smoker	C0337671;C4555205	f	420
424	ex - smoker / current	C0337671;C0521116;C1705970;C4555205	f	420
424	ex - smoker ( n z $nmbr$ )	C0337671;C4555205	f	420
424	ex - smokers	C0337671;C4555205	f	420
424	ex - smokers ( itt ) ( n = $nmbr$ )	C0337671;C4555205	f	420
424	ex - smoker / smoker  %	C0337671;C4555205	f	420
424	ex - smokers $nmbr$	C0337671;C4555205	f	420
424	ex - smokers ( n = $nmbr$ )	C0337671;C4555205	f	420
424	ex - smokers : qvai $nmbr$ - sfc	C0337671;C4521536;C4555205	f	420
424	former smoker	C0337671	f	420
424	former smoker  n ( % )	C0337671	f	420
424	former smoker ( n = $nmbr$ )	C0337671	f	420
424	former smoker ( n = $nmbr$  $nmbr$ )	C0337671	f	420
424	former smoker — no . ( % )	C0337671	f	420
424	former smoker — no . { % )	C0337671	f	420
424	previous smoker	C0337671	f	420
424	previous smokers	C0337671	f	420
424	prior smoker	C0337671	f	420
424	smoker or ex - smoker  n ( % )	C0337664;C0337671;C4555205	f	420
426	apoa - i	C0085201;C1677784	f	1852
426	apo a - i	C0085201;C1677784	f	1852
426	apo a - i  mg / dl	C0085201;C0439269;C1677784	f	1852
428	apo b	C0003593;C3252643	f	426
428	apo - b	C0003593;C3252643	f	426
428	apo b ( g / l )	C0003593;C0439294;C0456615;C3252643	f	426
428	apo b  mean ( sd )  mg / dl	C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643	f	426
428	apo b  mg / dl	C0003593;C0439269;C3252643	f	426
428	apo b ( mg / dl )	C0003593;C0439269;C3252643	f	426
428	apo b ( mg / dl ) * *	C0003593;C0439269;C3252643	f	426
428	apo b ( mg / dl ) - mean ± sd	C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643	f	426
420	smoking pack year ( years ) fl	C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674	\N	\N
420	smoking pack year ( years ) ^	C0037369;C0439234;C0439508;C0453996;C1277691;C1881674	\N	\N
420	smoking pack - yearsb  n ( % )	C0037369;C0453996;C1881674;C1968515;C2825051;C2828395	\N	\N
420	smoking pack - yearsa	C0037369;C0453996;C1881674;C1968515;C2825051;C2828395	\N	\N
420	smoking pack - years	C0037369;C0453996;C1277691;C1881674	\N	\N
420	smoking in the past year	C0037369;C0453996;C1881674;C4086728	\N	\N
420	smoking classification  n ( % )	C0008902;C0008903;C0037369;C0453996;C0678229;C1881674	\N	\N
420	smoking * ( > $nmbr$ pack - years )	C0037369;C0453996;C1277691;C1881674	\N	\N
420	smoking *	C0037369;C0453996;C1881674	\N	\N
420	smoking ( a )	C0037369;C0453996;C1881674	\N	\N
420	smoking ( % ) laboratory parameters	C0022877;C0037369;C0449381;C0453996;C1881674;C3244292;C4283904	\N	\N
420	smoking ( % )	C0037369;C0453996;C1881674	\N	\N
420	smoking ' ! '	C0037369;C0453996;C1881674	\N	\N
420	smoking  n ( % )	C0037369;C0453996;C1881674	\N	\N
420	smoking  %	C0037369;C0453996;C1881674	\N	\N
420	smoking	C0037369;C0453996;C1881674	\N	\N
420	never smoked — no . ( % )	C0037366;C0439994;C1881674;C2003901	\N	\N
420	never smoked  n ( % )	C0037366;C0439994;C1881674;C2003901	\N	\N
420	never smoked	C0037366;C0439994;C1881674;C2003901	\N	\N
420	currently smokes	C0037366;C0037369;C0439994;C0521116;C1881674	\N	\N
419	tnfi - na ï ve  n ( % )	C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882	\N	\N
419	tnfi - na ï ve	C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882	\N	\N
419	tnf - na ï ve	C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882	\N	\N
419	rando . in na * *	C0597484;C1272460;C1546968;C1879645;C4049872;C4552882	\N	\N
419	not rando . in na *	C0597484;C1272460;C1518422;C1546968;C1879645;C4049872;C4552882	\N	\N
419	na ï ve	C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882	\N	\N
419	na ( mmol / l )	C0597484;C1272460;C1532563;C1546968;C1879645;C4049872;C4552882	\N	\N
419	na	C0597484;C1272460;C1546968;C1879645;C4049872;C4552882	\N	\N
419	n / a	C1272460	\N	\N
419	n . a .	C1272460	\N	\N
419	insulin - na ' ive	C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334	\N	\N
419	anti ‐ tnf ‐ na ï ve    n   ( % )	C0042469;C0432633;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882	\N	\N
419	a / v ( n = $nmbr$ ) v ( n = $nmbr$ )	C0560268;C1272460;C3887614	\N	\N
419	a / v ( n = $nmbr$ )	C1272460	\N	\N
419	a $nmbr$ c [ n ( % ) ]	C1272460	\N	\N
419	a $nmbr$ + e $nmbr$ ( n = $nmbr$ )	C1272460	\N	\N
418	neoplasia  n ( % )	C0027651;C1882062	\N	\N
418	neoplasia	C0027651;C1882062	\N	\N
418	detected during tumor evaluation	C0027651;C0220825;C0442726;C1261322;C1511790;C1578706;C3273930	\N	\N
417	tenecteplase	C0872913	\N	\N
417	symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !	C0003842;C0021107;C0035124;C0039798;C0040363;C0041260;C0087111;C0221464;C0227952;C0439659;C0441587;C0684253;C0872913;C1512796;C1522326;C1533734;C1705169;C1883351;C1883719;C3538994;C3887704;C4086878	\N	\N
416	pleased	C3829994;C4264468	\N	\N
415	elevated vs normalb	C0205250;C3163633	\N	\N
415	elevated vs . normalc	C0205250;C3163633	\N	\N
415	elevated vs . normalb	C0205250;C3163633	\N	\N
415	elevated cardiac markers — no . ( % ) : t	C0205250;C1271630;C2603360;C3163633	\N	\N
415	elevated cardiac markers	C0205250;C1271630;C3163633	\N	\N
415	elevated at wk $nmbr$ — no . ( % ) $nmbr$	C0205250;C0332174;C0439230;C3163633	\N	\N
415	elevated at wk $nmbr$ — no . ( % ) !	C0205250;C0332174;C0439230;C3163633	\N	\N
414	previous cardiovascular events	C0205156;C1320716;C1552607	\N	\N
414	previous cardiovascular event — no . ( % )	C0205156;C1320716;C1552607	\N	\N
414	previous cardiovascular event at randomization	C0034656;C0205156;C1320716;C1552607	\N	\N
414	previous cardiovascular event ( % )	C0205156;C1320716;C1552607	\N	\N
414	cardiovascular events	C1320716	\N	\N
413	recent	C0332185	\N	\N
412	with events ( % )	C0441471;C3541888	\N	\N
412	warfarin events / n ( % / y )	C0043031;C0441471;C3541888	\N	\N
412	use of aspirin at time of qualifying event ( % )	C0004057;C0040223;C0441471;C1514624;C1524063;C3541383;C4019010	\N	\N
413	recent cardiovascular eventf	C0007226;C0332185;C3887460	f	414
416	elevated high - sensitivity crp — no . { % ) * *	C0742906;C1441604	f	286
421	cigarette smoker	C0337667	f	420
421	cigarette smoker *	C0337667	f	420
421	passive smoker	C0425309	f	420
421	cigarette smoker  no . ( % )	C0337667	f	420
422	non - smoker ( n = $nmbr$  $nmbr$ )	C0337672;C0425293;C4554605	f	420
422	nonsmoker  n ( % )	C0337672;C0425293;C4554605	f	420
422	non - smoker	C0337672;C0425293;C4554605	f	420
422	$nmbr$ +  no . ( % )	\N	f	420
422	never smoker	C0425293	f	420
422	current smoker 一 no . ( % )	C3173209;C3241966	f	420
422	current smoker — no . / total no . ( % )	C0439175;C0439810;C3173209;C3241966	f	420
422	current smoker — no . of patients ( % )	C0030705;C3173209;C3241966	f	420
422	current smoker — no . ( % )	C3173209;C3241966	f	420
422	current smoker  no ( % )	C3173209;C3241966	f	420
422	current smoker  no . ( % )	C3173209;C3241966	f	420
422	current non - smoker	C0425311	f	420
422	current nonsmoker	C0337672;C0425293;C0521116;C1705970;C4554605	f	420
423	> $nmbr$ kg / m $nmbr$ smokers	C0337664;C1532718	f	420
414	adverse eventy	\N	f	47
412	total events  n	C0439175;C0439810;C0441471;C3541888	\N	\N
412	time since qualifying event	C0040223;C0441471;C1514624;C3541383;C4019010	\N	\N
412	qualifying symptomatic event  n ( % ) a	C0231220;C0441471;C1514624;C4019010	\N	\N
412	qualifying events	C0441471;C1514624;C3541888	\N	\N
412	qualifying event — no . ( % )	C0441471;C1514624;C4019010	\N	\N
412	qualifying event	C0441471;C1514624;C4019010	\N	\N
412	procedures for index event	C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010	\N	\N
412	probability  of event %	C0033204;C0441471;C4019010	\N	\N
412	prior to index event	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
412	previous cerebrovascular event	C0205156;C0441471;C1552607;C1880018;C4019010	\N	\N
412	presentation of index event	C0441471;C0449450;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
412	pneumonia events  n	C0032285;C0441471;C3541888	\N	\N
412	pervious cerebrovascular event	C0205326;C0441471;C1880018;C4019010	\N	\N
412	pciperformed for qualifying event	C0441471;C1514624;C4019010	\N	\N
412	pci postindex event	C0441471;C4019010;C4049621	\N	\N
412	pci or cabg surgery for index event	C0010055;C0038894;C0038895;C0441471;C0543467;C0600653;C0918012;C1274039;C1552854;C1637833;C2986546;C4019010;C4049621	\N	\N
412	pci for index event	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621	\N	\N
412	patients with pneumonia events  n ( % ) #	C0030705;C0032285;C0441471;C3541888	\N	\N
412	patients with hospitalized pneumonia events  n ( % )	C0032285;C0441471;C0870668;C3541888	\N	\N
412	patients with complicated events ( p = $nmbr$ - $nmbr$ 十 )	C0030705;C0231242;C0441471;C3541888	\N	\N
412	patients with complicated events	C0030705;C0231242;C0441471;C3541888	\N	\N
412	other antithrombotic medication for index event — no . ( % )	C0013227;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3244316;C4019010;C4284232	\N	\N
412	ophthalmologic events	C0029087;C0205481;C0441471;C3541888	\N	\N
412	number ( % ) of patients with event	C0441471;C2360800;C4019010	\N	\N
412	no revascularization for index acs event  no . ( % )	C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612	\N	\N
412	no revascularization for index acs event	C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612	\N	\N
412	no of events womenmen *	C0441471;C3541888	\N	\N
412	no of events / total n ( % )	C0439175;C0439810;C0441471;C3541888	\N	\N
412	no . with event / total no . { % )	C0439175;C0439810;C0441471;C4019010	\N	\N
412	no . of patients / no . of events ( % ) $nmbr$ / $nmbr$ ( $nmbr$ ) $nmbr$ / $nmbr$ ( $nmbr$ )	C0030705;C0441471;C3541888	\N	\N
412	no . of patients / no . of events	C0030705;C0441471;C3541888	\N	\N
412	no . of events / totol no . ( % )	C0441471;C3541888	\N	\N
412	no . of events / patients	C0030705;C0441471;C3541888	\N	\N
412	no . of events / no . of patients	C0030705;C0441471;C3541888	\N	\N
412	neurologicai events	C0441471;C3541888	\N	\N
412	n events ( % )	C0369718;C0441471;C0441922;C3541888	\N	\N
412	morphine use for index event / pci	C0242000;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621	\N	\N
412	km event ( % ) at $nmbr$ y	C0441471;C3887676;C4019010	\N	\N
412	index events : dvt n ( % )	C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3541888;C3899446	\N	\N
412	index events	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3541888	\N	\N
412	index event — no . ( % )	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
412	index event not confirmed	C0441471;C0521093;C0600653;C0750484;C0918012;C1518422;C1552854;C1637833;C2986546;C4019010	\N	\N
412	index event information	C0441471;C0600653;C0918012;C1533716;C1552854;C1637833;C2986546;C4019010	\N	\N
412	index event asymptomatic or unconfirmed	C0231221;C0441471;C0600653;C0918012;C1547326;C1552854;C1637833;C2986546;C4019010	\N	\N
412	index event  n / n ( % )	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
412	index event  n ( % )	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
412	index event	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
412	in - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk	C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0871208;C1264674;C1444641;C1521828;C1707101;C3541888;C4288115	\N	\N
412	icosapent ethyl ( events / n ( % ) )	C0058978;C0441471;C3541888	\N	\N
412	i no . of events	C0021966;C0221138;C0441471;C3541888	\N	\N
412	history of pci or cabg before index event	C0010055;C0019664;C0019665;C0262512;C0262926;C0441471;C0600653;C0918012;C1552854;C1637833;C1705255;C2004062;C2986546;C4019010;C4049621	\N	\N
412	history of ml before index event	C0019664;C0019665;C0262512;C0262926;C0439526;C0441471;C0600653;C0918012;C1552854;C1637833;C1705224;C1705255;C2004062;C2986546;C3887665;C4019010	\N	\N
412	history of chf before index event	C0018802;C0019664;C0019665;C0262512;C0262926;C0441471;C0600653;C0918012;C1552854;C1637833;C1705255;C2004062;C2986546;C4019010	\N	\N
412	heparin  ‘ ondaparinux or brvalirudin use between rxjex event	C0019134;C0042153;C0441471;C0457083;C0770546;C1947944;C4019010	\N	\N
412	gastrointestinal event	C0441471;C0521362;C4019010	\N	\N
412	frequency of events	C0376249;C0439603;C0441471;C0871396;C1561548;C1705502;C3541888;C3898838;C4321352	\N	\N
412	freqency of events	C0441471;C3541888	\N	\N
412	for treatment of index event	C0039798;C0087111;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C2986546;C3538994;C3887704;C4019010	\N	\N
412	fibrinolytic for qualifying event	C0040044;C0441471;C1514624;C4019010	\N	\N
412	events treatment ( $nmbr$ )	C0039798;C0087111;C0441471;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704	\N	\N
412	events consistent with volume depletion	C0332290;C0441471;C0546884;C3541888	\N	\N
412	events consistent with genital infection	C0332290;C0441471;C0729552;C3541888	\N	\N
412	events / statin group	C0360714;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888	\N	\N
412	events / patient - year ( n )	C0030705;C0439234;C0439508;C0441471;C3541888	\N	\N
412	events / n	C0441471;C3541888	\N	\N
412	events ( % )	C0441471;C3541888	\N	\N
412	events  no .	C0441471;C3541888	\N	\N
412	events  n ( % / y )	C0441471;C3541888	\N	\N
412	events  n ( % )	C0441471;C3541888	\N	\N
412	events	C0441471;C3541888	\N	\N
412	event { n ( % )	C0441471;C4019010	\N	\N
412	event number	C0237753;C0441471;C0449788;C4019010	\N	\N
412	event during overall	C0282416;C0441471;C1561607;C4019010	\N	\N
412	event during on -	C0441471;C4019010	\N	\N
412	event / total	C0439175;C0439810;C0441471;C4019010	\N	\N
412	event ( p = $nmbr$ . $nmbr$ o + )	C0441471;C4019010	\N	\N
412	event ( % )	C0441471;C4019010	\N	\N
412	event  n ( % )	C0441471;C4019010	\N	\N
412	event	C0441471;C4019010	\N	\N
412	cvd events	C0007222;C0441471;C3541888	\N	\N
412	cumulative events	C0441471;C1511559;C3541888	\N	\N
412	composite events	C0205199;C0441471;C1547335;C3541888	\N	\N
412	catheterization performed for qualifying event	C0007430;C0441471;C0884358;C1514624;C4019010	\N	\N
412	biochemical events	C0205474;C0441471;C3541888	\N	\N
412	atients with event	C0441471;C4019010	\N	\N
412	at qualifying event	C0441471;C1514624;C4019010	\N	\N
412	at index event : no . ( % )	C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010	\N	\N
412	any event	C0441471;C4019010	\N	\N
412	antithrombotic drug use at time of event	C0013227;C0040223;C0441471;C1254351;C1524063;C3541383;C4019010	\N	\N
412	anatomical extent of qualifying event — no . ( % ) : t	C0220784;C0439792;C0441471;C1514624;C2603360;C4019010	\N	\N
412	anatomic extent of qualifying event  n ( % . ) x	C0220784;C0439792;C0441471;C1514624;C4019010	\N	\N
412	$nmbr$ events [ $nmbr$ . $nmbr$ ]	C0441471;C3541888	\N	\N
412	$nmbr$ events	C0441471;C3541888	\N	\N
411	sd = standard deviation  bmi = body mass index  ed = erectile	C0030847;C0871420;C1305855;C2699239;C3538926	\N	\N
411	prior ed therapy	C1514463;C3538926	\N	\N
411	missing ed duration ( y )	C0449238;C1551393;C1705492;C2926735;C3272743;C3538926	\N	\N
411	educ ssy	\N	\N	\N
411	educ > $nmbr$ y	\N	\N	\N
411	educ $nmbr$ - $nmbr$ y	\N	\N	\N
411	edo	\N	\N	\N
411	eda  %	C0162359;C1539327;C3539920;C3887494	\N	\N
411	ed therapy	C0039798;C0087111;C1363945;C3538926	\N	\N
411	ed duration > $nmbr$ yr  n ( % )	C0439234;C0449238;C2926735;C3538926	\N	\N
411	ed duration	C0449238;C2926735;C3538926	\N	\N
411	ed characteristics	C1521970;C3538926	\N	\N
410	time to all - cause death up to end of the study	C0007465;C0015127;C0040223;C0444930;C0547043;C0557651;C1301931;C1524003;C2603343;C2746065;C3541383	\N	\N
410	study end concentration	C0086045;C0444930;C0557651;C1446561;C2603343;C2746065;C3827302	\N	\N
410	combined end poir	C0205195;C0444930;C2746065	\N	\N
409	era monotherapy	C1521863;C3495919	\N	\N
409	era and pde - $nmbr$ i	C0021966;C0221138;C1521863;C3495919	\N	\N
409	era	C1521863;C3495919	\N	\N
409	ebria	C1917247	\N	\N
408	no epa group no . of events ( % )	C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888	\N	\N
408	epa hr events ( % )	C0441471;C3541888	\N	\N
408	epa group no . of events ( % )	C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888	\N	\N
408	epa ( n = $nmbr$ )	\N	\N	\N
408	epa	\N	\N	\N
408	empa	C2699863	\N	\N
-10	entocort ec ( n = $nmbr$ )	C1170256	\N	\N
406	lvh on ecg	C0232306	\N	\N
406	lvh by echo or ecg	C0058928;C0149721;C1623258;C1655045	\N	\N
406	lvh by ecg or echocardiographyd	C0232306	\N	\N
406	lvh by ecg or echocardiography  no ( % )	C0013516;C0232306	\N	\N
406	lvh by ecg or echo . n ( % )	C0058928;C0232306;C1655045	\N	\N
406	lvh by ecg / echo	C0058928;C0232306;C1655045	\N	\N
406	lvh by ecg ( minnesota code )	C0009219;C0026183;C0232306;C0805701;C3889831	\N	\N
406	lvh by ecg	C0232306	\N	\N
406	lv hypertrophy per ecg	C0232306	\N	\N
406	ecg - lvh ( sokolow - lyon )	C0232306	\N	\N
406	ecg - lvh ( cornell )	C0232306	\N	\N
405	infrequent exacerbator	C0521114	\N	\N
405	influenza	C0021400;C0021403	\N	\N
404	frequent or continuous	C0332183;C0549178	\N	\N
404	frequent exacerbator	C0332183	\N	\N
403	insufficient	C0205412;C0231180;C0439856	\N	\N
403	inadequate response ( > $nmbr$ months mmf / ggs )	C0083765;C0205412;C0209368;C0439231;C0439856;C0871261;C1704632;C1706817;C2911692;C3848524	\N	\N
403	inadequate	C0205412;C0439856	\N	\N
402	treatment effect ( hr )	C1518681	\N	\N
402	main effect baseline hormone	C0019932;C0168634;C0205225;C1280500;C1442488;C1518681;C1542147;C2348382;C4521914	\N	\N
402	effect estimate	C0750572;C1280500;C1518681;C2348382	\N	\N
402	consistency of effect	C0332529;C1280500;C1518681;C1547017;C2348382	\N	\N
400	hemoglobin ale *	C0019046;C0678386;C2632076	\N	\N
400	hemoglobin ale  %  median ( iqr )	C0019046;C0549183;C0678386;C0876920;C2347635;C2348144;C2632076;C2939193	\N	\N
400	hale	\N	\N	\N
400	flex aln ^	C0729594;C2681220	\N	\N
400	ale < $nmbr$	C0678386;C2632076	\N	\N
400	ale	C0678386;C2632076	\N	\N
398	alpha glucosidase inhibitors	C1299007;C2756986;C3539108	\N	\N
398	alpha - glucosidase inhibitors	C1299007;C2756986;C3539108	\N	\N
397	all mis *	C0687670;C1333208;C1412384;C3538735	\N	\N
397	all mis	C0687670;C1333208;C1412384;C3538735	\N	\N
396	hba $nmbr$ c ( % ) all countries	C0019016;C0454664;C1825777;C3538758	\N	\N
396	all teaes *	\N	\N	\N
396	all teaes	\N	\N	\N
398	agi	C1299007	f	-10
399	laba '	\N	f	1508
399	laba alone	C0205171;C0439044;C0679994	f	1508
399	labd alone	C0205171;C0396059;C0439044;C0679994	f	1508
401	wafarin	\N	f	858
401	wafarin event incidence / n	C0021149;C0220856;C0441471;C4019010	f	858
412	aspirin alone group no of events / total n ( % )	C0004057;C0439175;C0439810;C0441471;C2826346;C3541888	f	1366
396	all participantst ( n = $nmbr$ / $nmbr$ )	\N	\N	\N
396	all participantsa	\N	\N	\N
396	all n = $nmbr$ $nmbr$	C0369718;C0441922	\N	\N
396	all n = $nmbr$  $nmbr$	C0369718;C0441922	\N	\N
396	all n = $nmbr$	C0369718;C0441922	\N	\N
396	all itt sutajects	\N	\N	\N
396	all diabetesd	\N	\N	\N
396	all countries	C0454664	\N	\N
396	all ( n = $nmbr$ f )	C0016327;C0369718;C0441922	\N	\N
396	all ( n = $nmbr$ * )	C0369718;C0441922	\N	\N
396	all ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0369718;C0441922	\N	\N
396	all ( n = $nmbr$ )	C0369718;C0441922	\N	\N
396	all ( n = $nmbr$  $nmbr$ )	C0369718;C0441922	\N	\N
395	mean alc  %	C0444504;C1424945;C2347634;C2348143;C3811058	\N	\N
395	baseline alc category	C0168634;C0683312;C1424945;C1442488;C3811058;C3889287	\N	\N
395	baseline alc < $nmbr$ . $nmbr$ %	C0168634;C1424945;C1442488;C3811058	\N	\N
395	alc group ( % )	C0441833;C0687744;C1257890;C1424945;C1519504;C1705428;C1705429;C3811058	\N	\N
395	alc at weeko ( % )	C1424945;C3811058	\N	\N
395	alc at week $nmbr$ ( % )	C0332174;C0439230;C1424945;C3811058	\N	\N
395	alc > = $nmbr$ . $nmbr$ %	C1424945;C3811058	\N	\N
395	alc > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %	C1424945;C3811058	\N	\N
395	alc < $nmbr$ . $nmbr$ % at baseline  n ( % )	C0168634;C1424945;C1442488;C3811058	\N	\N
395	alc < $nmbr$ . $nmbr$ %	C1424945;C3811058	\N	\N
395	alc ( % )	C1424945;C3811058	\N	\N
394	any	\N	\N	\N
394	> $nmbr$ and < $nmbr$ %	\N	\N	\N
393	aab $nmbr$ ( % )	\N	\N	\N
392	enrolled in the americas	C0002454;C0596070;C4684790	\N	\N
392	americas * *	C0002454;C0596070	\N	\N
392	americas ( n = $nmbr$ )	C0002454;C0596070	\N	\N
392	americas  excluding us	C0002454;C0332196;C0596070;C2828389	\N	\N
392	americas	C0002454;C0596070	\N	\N
391	p $nmbr$ vs usual care	C0369773;C1947933;C2603361;C3538928	\N	\N
391	care use	C0042153;C0457083;C1947933;C1947944	\N	\N
391	care	C1947933	\N	\N
391	cards	C2930619;C3275277	\N	\N
390	卞 at discharge .	C0012621;C0030685;C2926602	\N	\N
390	thienopyridine at discharge	C0012621;C0030685;C1120149;C2926602	\N	\N
390	therapy at discharge	C0012621;C0030685;C0039798;C0087111;C1363945;C2926602	\N	\N
390	medications during hospitalization or at discharge	C0012621;C0013227;C0019993;C0030685;C0802604;C2598133;C2926602;C4284232	\N	\N
390	discharge medication  n ( % )	C0012621;C0013227;C0030685;C2926602;C3244316;C4284232	\N	\N
390	concomitant drug therapy at discharge	C0012621;C0013216;C0013217;C0013227;C0030685;C0039798;C0087111;C0521115;C1254351;C1363945;C1707479;C2926602;C3850077	\N	\N
390	cardiac medications during indexhospitalization and / or discharge	C0012621;C0013227;C0018787;C0030685;C0802604;C1522601;C2598133;C2926602;C4284232	\N	\N
390	cardiac medications during index hospital stay and / or discharge	C0012621;C0013227;C0030685;C0428776;C0802604;C2598133;C2926602;C3489408;C4284232	\N	\N
390	and / or discharge	C0012621;C0030685;C2926602	\N	\N
389	treated with cabg — no . / total no . ( % )	C0010055;C0332293;C0439175;C0439810	\N	\N
389	prior coronary intervention or coronary artery bypass grafting	C0010055;C0018787;C0184661;C0332152;C0886296;C1273869;C2826257	\N	\N
389	prior coronary artery bypass surgery	C0010055;C0332152;C2826257	\N	\N
389	prior coronary artery bypass grafting	C0010055;C0332152;C2826257	\N	\N
389	prior coronary artery bypass graft surgery	C0010055;C0332152;C2826257	\N	\N
389	prior coronary artery bypass graft	C0010055;C0332152;C1260596;C2826257	\N	\N
389	prior cabg ( before index acs )	C0010055;C0332152;C0600653;C0742343;C0918012;C1552854;C1637833;C2826257;C2986546;C4318612	\N	\N
389	prior cabg  %	C0010055;C0332152;C2826257	\N	\N
389	prior cabg	C0010055;C0332152;C2826257	\N	\N
389	no prior cabg	C0010055;C0332152;C2826257	\N	\N
389	history of cabg surgery  n ( % )	C0010055;C0455610	\N	\N
389	history of cabg surgery	C0010055;C0455610	\N	\N
389	coronary bypass surgery	C0010055	\N	\N
389	coronary bypass  n ( % )	C0010055	\N	\N
389	coronary artery bypass surgery	C0010055	\N	\N
389	coronary artery bypass graft  n ( % )	C0010055;C1260596	\N	\N
389	coronary artery bypass graft	C0010055;C1260596	\N	\N
389	coronary artery bypass	C0010055	\N	\N
389	cabg — no . { % )	C0010055	\N	\N
389	cabg — no . ( % )	C0010055	\N	\N
391	usual care	C1947933;C3538928	f	1849
391	usual care ( n = $nmbr$ a )	C1947933;C3538928	f	1849
391	usual care ( n = $nmbr$ )	C1947933;C3538928	f	1849
391	usual care ( n = $nmbr$ la )	C0023031;C0023749;C0230347;C1947933;C2346906;C3538928;C4553351	f	1849
392	texcaps	\N	f	-10
393	european or arab	C0239307;C0282540;C1535514;C1561448	f	504
394	any oral hypoglycemic drug 一 no . ( % )	C0359086	f	33
394	insulin and oral hypoglycemic drugs	C0021641;C0359086;C1533581;C1579433;C3714501	f	33
389	percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % )	C0010055;C1532338	f	1524
392	afcaps /	\N	f	-10
293	pregnancy	C0032961	f	2370
389	cabg surgery by no . of vessels $nmbr$	C0010055;C0042381;C3714645	\N	\N
389	cabg or pci	C0010055;C4049621	\N	\N
389	cabg > $nmbr$ month ago	C0010055;C0332177;C0439231	\N	\N
389	cabg :	C0010055	\N	\N
389	cabg ( % )	C0010055	\N	\N
389	cabg  n ( % )	C0010055	\N	\N
389	cabg	C0010055	\N	\N
388	race and ss at baseline	C0034510;C0168634;C1442488;C1706779;C2699257;C3853635;C3891295;C4551874	\N	\N
388	> $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %	\N	\N	\N
387	avm ( n = $nmbr$ )	C0003857;C0279476	\N	\N
387	avm % △ ( se )	C0003857;C0036919;C0279476	\N	\N
386	s wave in v $nmbr$ ( mm )	C0456681;C4301968	\N	\N
385	q wave	C0429089;C1305738	\N	\N
385	non - q wave	C0429089;C1305738;C1518422	\N	\N
385	non - q - wave myocardial infarction	C0542269;C3537181	\N	\N
385	non - q - wave ml	C0429089;C0439526;C1305738;C1518422;C1705224;C3887665	\N	\N
384	intracranial hemorrhage †	C0151699;C4554169	\N	\N
384	intracranial hemorrhage  n ( % )	C0151699;C4554169	\N	\N
384	intracranial hemorrhage	C0151699;C4554169	\N	\N
384	intracranial bleeding	C0151699	\N	\N
384	intracranial bleed	C0151699	\N	\N
383	intrathoracic or intraperitoneal surgery	C0038894;C0038895;C0442120;C0543467;C0595836;C1274039	\N	\N
383	intraperitoneal	C0442120	\N	\N
382	no antianginal drug	C0013227;C1254351;C1874267;C3537168	\N	\N
382	new anti - anginal therapy	C1874267;C3242274;C3537168	\N	\N
382	intensification of antianginal therapy	C1511484;C1874267;C3537168	\N	\N
382	any antianginal drug !	C0013227;C1254351;C1874267;C3537168	\N	\N
382	$nmbr$ antianginal drug	C0013227;C1254351;C1874267;C3537168	\N	\N
381	tachyarrhythmias  n ( % )	C0080203	\N	\N
381	supraventricular tachyarrhythmias ( incl . atrial	C0018792;C1698480;C3853833	\N	\N
381	no . ( % ) of patients with atrial tachyarrhythmia	C0018792;C0030705;C0080203	\N	\N
380	prior arrhythmias  n ( % )	C0003811;C0332152;C2826257	\N	\N
380	cardiac arrhythmia  n ( % )	C0003811;C0264886;C1560249	\N	\N
380	cardiac arrhythmia	C0003811;C0264886;C1560249	\N	\N
380	arrhythmias	C0003811	\N	\N
380	arrhythmia !	C0003811	\N	\N
380	arrhythmia	C0003811	\N	\N
379	previous use of antiarrhythmic drugs	C0003195;C0205156;C1524063;C1552607	\N	\N
379	other antiarrhythmics ^	C0003195	\N	\N
379	any prerandomization failure of an antiarrhythmic drug — no . ( % )	C0003195;C0231174;C0301380;C0680095	\N	\N
379	antiarrhythmics	C0003195	\N	\N
379	antiarrhythmic therapy	C0003195;C0039798;C0087111;C1363945;C3537142	\N	\N
379	antiarrhythmic drugs    n   ( % )	C0003195	\N	\N
379	antiarrhythmic drug	C0003195;C0301380	\N	\N
379	antiarrhythmic	C0003195;C3537142	\N	\N
379	anti arrhythmic	C0003195;C3537142	\N	\N
378	arthralgia	C0003862;C4551938	\N	\N
376	patients with microalbuminuria at baseline	C0030705;C0168634;C0730345;C1442488	\N	\N
376	or no microalbuminuria or macroalbuminuria	C0730345	\N	\N
376	normoalbuminuria or microalbuminuria	C0730345	\N	\N
376	microalbuminuria — no . / total no . ( % )	C0439175;C0439810;C0730345	\N	\N
376	microalbuminuria — no . ( % )	C0730345	\N	\N
376	microalbuminuria or proteinuria	C0033687;C0730345;C1962972;C4554346	\N	\N
376	microalbuminuria or macroalbuminuria §	C0730345	\N	\N
376	microalbuminuria or macroalbuminuria	C0730345	\N	\N
376	microalbuminuria ( uacr $nmbr$ – $nmbr$ )	C0730345	\N	\N
376	microalbuminuria  n ( % )	C0730345	\N	\N
376	microalbuminuria	C0730345	\N	\N
376	macroalbuminuria ( uacr > $nmbr$ )	\N	\N	\N
376	and microalbuminuria or macroalbuminuria	C0730345	\N	\N
375	progression of albuminuria	C0001925;C0242656;C0449258	\N	\N
375	micro - albuminuria	C0001925;C0085672;C1553035;C3811161;C4049106	\N	\N
375	macro - albuminuria	C0001925;C2984010	\N	\N
375	any albuminuria — no . ( % )	C0001925	\N	\N
375	any albuminuria	C0001925	\N	\N
375	albuminuria_p_interaction	C0001925;C1704675	\N	\N
375	albuminuria progression	C0001925;C0242656;C0449258	\N	\N
375	albuminuria ( g / g )	C0001925;C1319635	\N	\N
375	albuminuria	C0001925	\N	\N
374	reteplase / abciximab - facilitated pci ( n = $nmbr$ )	C0256103;C0288672;C4049621	\N	\N
377	history of microalbuminuria — no . ( % )	C3532606	f	376
377	macroalbuminuriaf	\N	f	376
377	macroalbuminuria	\N	f	376
377	macroalbuminuria  n ( % )	\N	f	376
377	micro - or macroalbuminuria  n ( % ) §	C0085672;C1553035;C3811161;C4049106	f	376
377	micro - or macroalbuminuria  no . ( % )	C0085672;C1553035;C3811161;C4049106	f	376
377	normoalbuminuria	\N	f	376
377	normoalbuminuria  no . ( % )	\N	f	376
377	normoalbuminuria — no . ( % )	\N	f	376
378	duration of rheumatoid arthritis ( years )	C0003873;C0439234;C0449238;C2926735	f	1848
378	duration of rheumatoid arthritis — yr	C0003873;C0439234;C0449238;C2926735	f	1848
378	rheumatoid arthritis	C0003873	f	1848
378	arthritis mutilans	C0702102	f	-10
378	polyarticular arthritis  no rheumatoid nodules	C0035450;C0162323	f	-10
384	extracranial	C0580586	f	-10
384	transradial	\N	f	-10
384	intracranial	C0524466	f	-10
386	q wave mi	C0861151	f	385
386	q - wave mi	C0861151	f	385
386	death / q - wave mi / idr	C0011065;C0861151;C1306577;C4082313;C4552775	f	385
388	bdmard - naive	\N	f	231
388	cdmard	\N	f	231
388	none ( cdmard - naive or past use at baseline )	C0042153;C0168634;C0457083;C1442488;C1444637;C1947944;C4284302	f	231
374	abciximab vs . primary	C0205225;C0288672;C0439612;C0439631	\N	\N
374	abciximab no . / total ( % )	C0288672;C0439175;C0439810	\N	\N
374	abciximab - facilitated pci	C0288672;C4049621	\N	\N
374	abciximab ( n = $nmbr$ )	C0288672	\N	\N
374	abciximab	C0288672	\N	\N
374	$nmbr$ abciximab ( n = $nmbr$ )	C0288672	\N	\N
373	rate ratio ( lebrikizumab vs placebo  $nmbr$ % cl )	C0032042;C0456603;C0596019;C0871208;C1521828;C1547037;C1696465;C1706408;C2981360	\N	\N
373	rate difference ( lebrikizumab - placebo )	C0032042;C0871208;C1521828;C1696465;C1705241;C1705242;C1706408;C2981360	\N	\N
373	lebrikizumab ( n = $nmbr$ )	C2981360	\N	\N
372	canakinumab  il - $nmbr$ top tertilec	C0020898;C0021764;C0022271;C1704458;C2718773	\N	\N
372	canakinumab  il - $nmbr$ middle tertile	C0020898;C0021764;C0022271;C0444598;C0549183;C1552826;C2718773	\N	\N
372	canakinumab  il - $nmbr$ lowest tertile	C0020898;C0021764;C0022271;C1708760;C2718773	\N	\N
372	canakinumab  $nmbr$ - month on - treatment il - $nmbr$ below the median value ( < $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ )	C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704	\N	\N
372	canakinumab	C2718773	\N	\N
372	all canakinumab	C2718773	\N	\N
371	ustekinumab ® ( n = $nmbr$ )	C1608841	\N	\N
371	ustekinumab combined	C0205195;C1608841	\N	\N
371	ustekinumab ' ’ ( n = $nmbr$ )	C1608841	\N	\N
371	ustekinumab $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1608841;C1960952;C2346927;C4321396;C4521761	\N	\N
371	ustekinumab	C1608841	\N	\N
371	ustekinu	\N	\N	\N
371	usteki	\N	\N	\N
371	uistekinumab	\N	\N	\N
370	area of retinal thickening within the grid  mean ( sd )  dab	C0017446;C0086162;C0205146;C0444504;C1081457;C1302690;C1415284;C2347634;C2348143;C2348395;C2699239;C2825313;C4522144	\N	\N
370	area of retinal hemorrhage within the grid  mean ( sd )  dab	C0017446;C0035317;C0086162;C0205146;C0444504;C1081457;C1415284;C2347634;C2348143;C2348395;C2699239;C2825313;C4522144	\N	\N
370	area of fluorescein leakage within the grid  mean ( sd )  dab	C0017446;C0086162;C0205146;C0444504;C1081457;C1415284;C2347634;C2348143;C2348395;C2699239;C2825313;C4476700;C4522144	\N	\N
370	area	C0017446;C0205146	\N	\N
369	reqion	\N	\N	\N
369	regiont	\N	\N	\N
369	regions  n ( % )	C0017446;C0205147	\N	\N
369	region ofthe world	C0017446;C0205147;C2700280	\N	\N
369	region ofenrollment — %	C0017446;C0205147	\N	\N
369	region of world — no . ( % )	C0017446;C0205147;C2700280	\N	\N
369	region of the world	C0017446;C0205147;C2700280	\N	\N
369	region of residence ( p = $nmbr$ $nmbr$ )	C0017446;C0205147;C0237096	\N	\N
369	region of enrollment — no . ( % )	C0017446;C0205147;C1516879;C1696073;C3888021	\N	\N
369	region of enrollment  no . ( % )	C0017446;C0205147;C1516879;C1696073;C3888021	\N	\N
369	region of enrollment  n ( % ) +	C0017446;C0205147;C1516879;C1696073;C3888021	\N	\N
369	region of enrollment	C0017446;C0205147;C1516879;C1696073;C3888021	\N	\N
369	region n ( % )	C0017446;C0205147	\N	\N
369	region :	C0017446;C0205147	\N	\N
369	region - n ( % )	C0017446;C0205147	\N	\N
369	region *	C0017446;C0205147	\N	\N
369	region ( us )	C0017446;C0205147	\N	\N
369	region ( pooled )	C0017446;C0205147;C1709595;C2349200;C4522255	\N	\N
369	region ( % )	C0017446;C0205147	\N	\N
369	region    n   ( % )	C0017446;C0205147	\N	\N
369	region  n ( % ) a	C0017446;C0205147	\N	\N
369	region  n ( % )	C0017446;C0205147	\N	\N
369	region  latin america	C0017446;C0023122;C0205147	\N	\N
369	region  europe union	C0015179;C0017446;C0205147	\N	\N
369	region  %	C0017446;C0205147	\N	\N
369	region	C0017446;C0205147	\N	\N
369	p  treatment - by - region interaction	C0017446;C0039798;C0087111;C0205147;C0369773;C1522326;C1533734;C1704675;C1705169;C2603361;C3538994;C3887704	\N	\N
369	grouped region	C0017446;C0205147;C0439745;C4319846	\N	\N
369	geographical region ( % )	C0017446	\N	\N
369	geographical region  n ( % )	C0017446	\N	\N
369	geographical region	C0017446	\N	\N
369	geographic region ^	C0017446	\N	\N
369	geographic region - other	C0017446	\N	\N
369	geographic region  n ( % )	C0017446	\N	\N
369	geographic region  %	C0017446	\N	\N
368	± standard deviation . triglyceride	C0041004;C0871420	\N	\N
368	triglycerides — mmol / l	C0041004;C1532563	\N	\N
368	triglycerides — mg / dl | |	C0041004;C0439269	\N	\N
368	triglycerides — mg / dl ^	C0041004;C0439269	\N	\N
368	triglycerides — mg / dl	C0041004;C0439269	\N	\N
368	triglycerides > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l )	C0041004;C0439269;C1532563	\N	\N
368	triglycerides > $nmbr$ mg / dl	C0041004;C0439269	\N	\N
368	triglycerides > $nmbr$ - $nmbr$ mmol / l	C0041004;C1532563	\N	\N
368	triglycerides < $nmbr$ - $nmbr$ mmol / l	C0041004;C1532563	\N	\N
368	triglycerides - mg / dl * *	C0041004;C0439269	\N	\N
368	triglycerides * *	C0041004	\N	\N
368	triglycerides * ( mg / dl )	C0041004;C0439269	\N	\N
368	triglycerides *	C0041004	\N	\N
368	triglycerides ( week $nmbr$ ) a	C0041004;C0332174;C0439230	\N	\N
368	triglycerides ( mmol / l ) :	C0041004;C1532563	\N	\N
368	triglycerides ( mmol / l ) ( median  iqr )	C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	\N	\N
368	triglycerides ( mmol / l )  mean ( sd )	C0041004;C0444504;C1532563;C2347634;C2348143;C2699239	\N	\N
368	triglycerides ( mmol / l )	C0041004;C1532563	\N	\N
368	triglycerides ( mg / dl ) * *	C0041004;C0439269	\N	\N
368	triglycerides ( mg / dl )	C0041004;C0439269	\N	\N
368	triglycerides ( median  iqr )  mg / dl	C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
372	anakinra	C0245109	f	-10
368	triglycerides $nmbr$ nd third	C0041004;C0205437	\N	\N
368	triglycerides $nmbr$  d third	C0041004;C0205437	\N	\N
368	triglycerides $ $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l )	C0041004;C0439269;C1532563	\N	\N
368	triglycerides  mmol / l ®	C0041004;C1532563	\N	\N
368	triglycerides  mmol / l §	C0041004;C1532563	\N	\N
368	triglycerides  mmol / l  mean ± sd	C0041004;C0444504;C1532563;C2347634;C2348143;C2699239	\N	\N
368	triglycerides  mmol / l  mean ( sd )	C0041004;C0444504;C1532563;C2347634;C2348143;C2699239	\N	\N
368	triglycerides  mmol / l	C0041004;C1532563	\N	\N
368	triglycerides  mg / l	C0041004;C0439268	\N	\N
368	triglycerides  mg / dl ^	C0041004;C0439269	\N	\N
368	triglycerides  mg / dl  median ( q $nmbr$ : q $nmbr$ )	C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
368	triglycerides  median ( ql  q $nmbr$ )  mmol / l	C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	\N	\N
368	triglycerides  median ( qi  q $nmbr$ )  mmol / l	C0041004;C0376586;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193	\N	\N
368	triglycerides  median ( iqr )  mg / dl	C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
368	triglycerides  * mmol / l	C0041004;C1532563	\N	\N
368	triglycerides	C0041004	\N	\N
368	triglyceride a	C0041004	\N	\N
368	triglyceride ( mmol / l ) t	C0041004;C1532563	\N	\N
368	triglyceride ( mmol / l ) * blood pressure	C0005823;C0041004;C1271104;C1272641;C1532563	\N	\N
368	triglyceride ( mmol / l )	C0041004;C1532563	\N	\N
368	triglyceride ( mg / dl ) d	C0041004;C0439422;C3642216	\N	\N
368	triglyceride ( mg / dl ) $nmbr$	C0041004;C0439269	\N	\N
368	triglyceride ( median : mg / dl ) a [ $nmbr$ - $nmbr$ percentile ]	C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193	\N	\N
368	triglyceride ( median  mg / dl ) - $nmbr$ [ $nmbr$ - $nmbr$ percentile |	C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193	\N	\N
368	triglyceride  mmol / l	C0041004;C1532563	\N	\N
368	triglyceride	C0041004	\N	\N
368	tg  triglycerides . * median values ( standard deviation for medians ) .	C0041004;C0042295;C0399532;C0549183;C1442989;C2828392	\N	\N
368	pretreatment triglycerides	C0041004;C1550147;C2709094;C3539075;C3539076	\N	\N
368	median triglyceride ( mg / dl )	C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
368	fasting triglycerides — mg / dl	C0015663;C0041004;C0439269	\N	\N
368	fasting triglycerides > $nmbr$ mg / dl *	C0015663;C0041004;C0439269	\N	\N
368	fasting triglycerides  mg / dl	C0015663;C0041004;C0439269	\N	\N
368	fasting triglycerides  mean ( sd )  mg / dl	C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
368	fasting triglycerides	C0015663;C0041004	\N	\N
368	deviation  tg  triglyceride .	C0012727;C0041004;C0205419;C1705236	\N	\N
368	baseline triglycerides > $nmbr$ mg / dl and	C0041004;C0168634;C0439269;C1442488	\N	\N
368	baseline triglycerides < $nmbr$ mg / dl	C0041004;C0168634;C0439269;C1442488	\N	\N
368	- triglycerides	C0041004	\N	\N
368	$nmbr$ . $nmbr$ mg / dl triglycerides ^	C0041004;C0439269	\N	\N
367	no . of previous anti - tnf drugs — no . ( % )	C0013227;C0205156;C1448177;C1552607;C3687832	\N	\N
367	no . of drugs	C0013227;C3687832	\N	\N
367	lowering drugs	C0013227;C0441994;C2003888;C3687832	\N	\N
367	lipid - modulating drug	C0013227;C0023779;C0443264;C1254351	\N	\N
367	investigator - defined drug - related aes	C0013227;C0035173;C0439849;C0445223;C1254351;C1412268;C1704788;C2699274;C3539106	\N	\N
367	immunomodulatory drugs	C0013227;C3687832	\N	\N
367	glycemic drugs	C0005802;C0013227;C3687832	\N	\N
367	epilepsy drug	C0013227;C0014544;C1254351	\N	\N
367	drugs and toxins	C0013227;C0040549;C3687832	\N	\N
367	drug ‐ relateda	C0013227;C1254351	\N	\N
367	drug - relateda	C0013227;C1254351	\N	\N
367	blood glucose - lowering drugs  excluding insulin  n ( % )	C0005802;C0013227;C0017725;C0018938;C0021641;C0332196;C0441994;C1533581;C1579433;C2003888;C2828389;C3687832;C3714501	\N	\N
367	because of drug ‐ relateda   sae	C0013227;C1254351;C1519255;C1622657;C4553214	\N	\N
367	because of drug ‐ relateda   ae	C0013227;C1254351;C3887670	\N	\N
367	annanginal drugs ( $nmbr$ / l / s » $nmbr$ ) ^	C0013227;C3687832	\N	\N
367	> $nmbr$ drug - related aes *	C0013227;C0439849;C0445223;C1254351;C1412268;C2699274	\N	\N
367	> $nmbr$ drug - related	C0013227;C0439849;C0445223;C1254351	\N	\N
367	$nmbr$ antianginal drugs	C0013227;C1874267;C3537168;C3687832	\N	\N
366	use of medications for pah — no . ( % )	C0013227;C0030123;C0802604;C1524063;C2598133;C3203102;C4284232;C4284467	\N	\N
366	use of medication for pah	C0013227;C0030123;C1524063;C3203102;C3244316;C4284232;C4284467	\N	\N
366	use of medication at baseline — no . ( % )	C0013227;C0168634;C1442488;C1524063;C3244316;C4284232	\N	\N
366	use of cardiac medication *	C0013227;C0018787;C1522601;C1524063;C3244316;C4284232	\N	\N
366	systemic sle medications  n ( % )	C0013227;C0024141;C0205373;C0802604;C2598133;C4284232	\N	\N
366	selected medications — no . ( % )	C0013227;C0802604;C1707391;C2598133;C4284232	\N	\N
366	prior medications	C0013227;C0332152;C0802604;C2598133;C2826257;C4284232	\N	\N
366	previous medications  n ( % )	C0013227;C0205156;C0802604;C1552607;C2598133;C4284232	\N	\N
366	patients receiving any uc medication  n ( % )	C0013227;C0030705;C1514756;C3244316;C4284232	\N	\N
366	other medications	C0013227;C0802604;C2598133;C4284232	\N	\N
366	use of blood pressure lowering medication *	C0013227;C0020649;C1524063;C3244316;C4284232	f	1579
366	periprocedural medications	C0013227;C0802604;C2598133;C4284232	f	2267
366	periprocedural medications  n ( % )	C0013227;C0802604;C2598133;C4284232	f	2267
366	periprocedural medications — no . / total no .	C0013227;C0439175;C0439810;C0802604;C2598133;C4284232	f	2267
366	other lipid - lowering medication	C0013227;C0023779;C0441994;C2003888;C3244316;C4284232	\N	\N
366	op concomitant medications ( % )	C0013227;C0521115;C0802604;C2598133;C4284232	\N	\N
366	no . of previous ciu / csu medications  mean ( median )	C0013227;C0205156;C0444504;C0549183;C0578870;C0802604;C0876920;C1552607;C2347634;C2347635;C2348143;C2348144;C2598133;C2939193;C4284232	\N	\N
366	no . of previous ciu / csu medications	C0013227;C0205156;C0578870;C0802604;C1552607;C2598133;C4284232	\N	\N
366	medications for crohn ' s disease taken at baseline — no . ( % )	C0010346;C0013227;C0168634;C0802604;C1442488;C1883727;C2598133;C4284232	\N	\N
366	medication	C0013227;C3244316;C4284232	\N	\N
366	mean no . agents ( sd ) other medications	C0013227;C0444504;C0450442;C0802604;C1254351;C1521826;C2347634;C2348143;C2598133;C2699239;C4284232	\N	\N
366	iop - lowering medication	C0013227;C0441994;C0578862;C2003888;C3244316;C4284232	\N	\N
366	concurrent medications	C0013227;C0205420;C0802604;C2598133;C4284232	\N	\N
366	concurrent medication	C0013227;C0205420;C3244316;C4284232	\N	\N
366	concomitant pd medications at baseline  n ( % ) c  d	C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232;C4553228;C4553229	\N	\N
366	concomitant medication — no . ( % )	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medications	C0013227;C0521115;C0802604;C2598133;C4284232	f	1916
366	concomitant medications  %	C0013227;C0521115;C0802604;C2598133;C4284232	f	1916
366	concomitant medications ( % )	C0013227;C0521115;C0802604;C2598133;C4284232	f	1916
366	concomitant medications after randomization	C0013227;C0034656;C0521115;C0802604;C2598133;C4284232	f	1916
366	concomitant medications at baseline	C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232	f	1916
366	concomitant medications  * n ( % )	C0013227;C0521115;C0802604;C2598133;C4284232	f	1916
366	concomitant medications  n ( % )	C0013227;C0521115;C0802604;C2598133;C4284232	f	1916
366	concomitant medications  no . ( % )	C0013227;C0521115;C0802604;C2598133;C4284232	f	1916
366	concomitant medications — no . ( % )	C0013227;C0521115;C0802604;C2598133;C4284232	f	1916
366	medication at entry ( % )	C0013227;C1705654;C3244316;C4284232	f	2263
366	medication at randomization	C0013227;C0034656;C3244316;C4284232	f	2263
366	medication  n ( % )	C0013227;C3244316;C4284232	f	2263
366	medication $nmbr$ ( $nmbr$ . $nmbr$ )	C0013227;C3244316;C4284232	f	2263
366	medication continued into double - blind treatment period	C0013072;C0013227;C0039798;C0087111;C0439531;C0549178;C1522326;C1533734;C1705169;C1948053;C3244316;C3538994;C3887704;C4284232	f	2263
366	medication — no . ( % )	C0013227;C3244316;C4284232	f	2263
366	medications	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications ( % )	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications *	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications at baseline  n ( % )	C0013227;C0168634;C0802604;C1442488;C2598133;C4284232	f	2263
366	medications at baselinet	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications at coronary angiography	C0013227;C0085532;C0802604;C1548829;C2598133;C4284232	f	2263
366	medications at randomization	C0013227;C0034656;C0802604;C2598133;C4284232	f	2263
366	medications at the time of randomization — no . ( % )	C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232	f	2263
366	medications at time of randomization — no . ( % )	C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232	f	2263
366	medications before admission	C0013227;C0184666;C0802604;C0809949;C2598133;C4284232	f	2263
366	medications in use at baseline  n ( % )	C0013227;C0042153;C0150312;C0168634;C0332285;C0457083;C0802604;C1442488;C1707101;C1947944;C2598133;C4284232	f	2263
366	medications in use at baseline — no . ( % )	C0013227;C0042153;C0150312;C0168634;C0332285;C0457083;C0802604;C1442488;C1707101;C1947944;C2598133;C4284232	f	2263
366	medications  n	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications  n ( % )	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications  no . ( % )	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications . no . ( % )	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications — no . ( % )	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications — no . { % ) * *	C0013227;C0802604;C2598133;C4284232	f	2263
366	medications  n ( % of patients )	C0013227;C0030705;C0802604;C2598133;C4284232	f	2263
366	medications on admission  %	C0013227;C0457453;C0802604;C2598133;C4284232	f	2263
366	medications taken at time of randomization statins	C0013227;C0034656;C0040223;C0360714;C0802604;C1883727;C2598133;C3541383;C4284232	f	2263
366	medications through day $nmbr$	C0013227;C0332173;C0439228;C0439505;C0802604;C2598133;C4284232	f	2263
366	medication useb	C0013227;C3244316;C4284232	f	2263
366	glucose - lowering medication	C0013227;C0017725;C0441994;C2003888;C3244316;C4284232	f	33
366	glucose - lowering medications	C0013227;C0017725;C0441994;C0802604;C2003888;C2598133;C4284232	f	33
366	lipid - lowering medication	C0013227;C0023779;C0441994;C2003888;C3244316;C4284232	f	2265
366	lipid - lowering medication ( % )	C0013227;C0023779;C0441994;C2003888;C3244316;C4284232	f	2265
366	lipid - lowering medications ^	C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232	f	2265
366	cv medication	C0013227;C3244316;C3538987;C4048877;C4284232;C4318503	f	2266
366	cv medication  % of patients	C0013227;C0030705;C3244316;C3538987;C4048877;C4284232;C4318503	f	2266
366	diabetes medication	C0011847;C0011849;C0013227;C3244316;C4284232	f	33
366	concomitant asthma medications  n ( % )	C0004096;C0013227;C0521115;C0802604;C2598133;C2984299;C4284232	\N	\N
366	comorbidities and concomitant medications	C0009488;C0013227;C0521115;C0802604;C2598133;C4284232	\N	\N
366	comorbidities / concomitant medications	C0009488;C0013227;C0521115;C0802604;C2598133;C4284232	\N	\N
366	blood - pressure medications at randomization — no . / total no . ( % )	C0005823;C0013227;C0033095;C0034656;C0439175;C0439810;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232	\N	\N
366	baseline medications	C0013227;C0168634;C0802604;C1442488;C2598133;C4284232	\N	\N
366	baseline antihyperglycemic medications  n ( % )	C0013227;C0020616;C0168634;C0802604;C1442488;C2598133;C4284232	\N	\N
366	any medication	C0013227;C3244316;C4284232	\N	\N
366	antithrombotic medications  n ( % )	C0013227;C0802604;C2598133;C4284232	\N	\N
366	antianginal medications	C0013227;C0802604;C1874267;C2598133;C3537168;C4284232	\N	\N
366	anti - arthritic medications	C0013227;C0802604;C2598133;C4284232	\N	\N
366	acute medication intake ( days / month )	C0013227;C0205178;C0556971;C1512806;C3244316;C4284232	\N	\N
366	> $nmbr$ glucose - lowering medication . no . ( % )	C0013227;C0017725;C0441994;C2003888;C3244316;C4284232	\N	\N
365	type of drug - eluting stent  n ( % )	C0038257;C0332307;C0457591;C1322815;C1547052	\N	\N
365	received drug - eluting stent	C1322815;C1514756	\N	\N
365	non - drug - eluting stent	C1322815;C1518422	\N	\N
365	drug eluting stent	C1322815	\N	\N
365	drug - eluting stent — no . ( % )	C1322815	\N	\N
365	drug - eluting stent implanted — no . ( % )	C0021102;C1322815;C2828363	\N	\N
365	drug - eluting stent implanted ( at least one )	C0021102;C0205447;C1322815;C2828363	\N	\N
365	drug - eluting stent implanted	C0021102;C1322815;C2828363	\N	\N
365	drug - eluting stent  n ( % )	C1322815	\N	\N
365	drug - eluting stent	C1322815	\N	\N
365	at least one drug - eluting stent	C0205447;C1322815	\N	\N
364	stent placement	C0522776	\N	\N
364	stent implanted — no . ( % )	C0522776	\N	\N
364	stent implanted	C0522776	\N	\N
363	not hispanie / latino	C0086528;C1518422	\N	\N
363	latino	C0086528	\N	\N
363	hispanie / latino	C0086528	\N	\N
363	hispanic or latino ethnic groupf	C0015031;C0086409;C0086528;C0680174	\N	\N
363	hispanic or latino ethnic groupb	C0015031;C0086409;C0086528;C0680174	\N	\N
363	hispanic or latino ethnic group *	C0015031;C0086409;C0086528;C1879937	\N	\N
363	hispanic or latino ethnic group !	C0015031;C0086409;C0086528;C1879937	\N	\N
363	hispanic or latino ( n — $nmbr$ )	C0086409;C0086528	\N	\N
363	hispanic or latino ( n = $nmbr$ )	C0086409;C0086528	\N	\N
363	hispanic or latino	C0086409;C0086528	\N	\N
363	hispanic / latino ( n = $nmbr$ )	C0086409;C0086528	\N	\N
363	hispanic / latino	C0086409;C0086528	\N	\N
363	ethnicitya hispanic or latino	C0086409;C0086528	\N	\N
362	tnf inhibitor	C1448177;C1999216	\N	\N
362	tnf antagonist - naive ®	C0231491;C1448177	\N	\N
362	tnf antagonist - naive subgroup ( n - $nmbr$ )	C0231491;C1079230;C1448177;C1515021	\N	\N
362	tnf antagonist - naive ' ’	C0231491;C1448177	\N	\N
362	tnf - naivea	C1448177	\N	\N
362	tnf - naive patientsa	C1448177	\N	\N
362	tnf - failurea	C1448177	\N	\N
362	prior tnf inhibitor exposure  no . ( % )	C0274281;C0332152;C0332157;C1448177;C1999216;C2826257	\N	\N
362	prior tnf inhibitor exposure	C0274281;C0332152;C0332157;C1448177;C1999216;C2826257	\N	\N
362	prior biologic therapy ( including anti - tnfs )	C0278947;C0332257;C1448177	\N	\N
362	no prior tnf inhibitor exposure	C0274281;C0332152;C0332157;C1448177;C1999216;C2826257	\N	\N
362	history of tnf antagonist treatment failure — no . ( % ) * *	C0019664;C0019665;C0162643;C0231491;C0235828;C0262512;C0262926;C0521983;C1448177;C1547544;C1705255;C2004062	\N	\N
362	anti - tnf agent ( s )	C0221141;C0313162;C0450442;C1254351;C1448177;C1521826	\N	\N
362	anti - tnf - naive patients $nmbr$	C0030705;C1448177	\N	\N
362	anti - tnf - naive patients	C0030705;C1448177	\N	\N
362	anti - tnf - naive  n ( % )	C0432633;C1448177	\N	\N
362	anti - tnf - experienced patients	C0030705;C1448177	\N	\N
362	anti - tnf	C1448177	\N	\N
361	injectable anti ‐ hyperglycaemic  n ( % )	C0432633;C1272883	\N	\N
361	anti ‐ hyperglycaemic agent  n ( % )	C0432633;C1321567	\N	\N
360	anti - ccp antibody positive  n ( % )	C0432633;C0741132;C1525410;C1704514	\N	\N
360	anti - ccp antibody positive	C0741132;C4318437	\N	\N
360	anti - ccp antibody - positive  n ( % )	C0432633;C0741132;C1525410;C1704514	\N	\N
360	anti - ccp antibody ( u /	C0003241;C0003242;C0021027;C0439148;C1167408;C1525410;C1704514;C3665580;C4318437	\N	\N
360	anti - ccp antibodies *	C0003241;C1525410;C1624602;C1704514;C4318437	\N	\N
359	xanthinesg	\N	\N	\N
359	xanthines $nmbr$	C0043318;C3541955	\N	\N
359	xanthines  b   n ( % )	C0043318;C3541955	\N	\N
361	anti - anaemics	C0857322	f	-10
362	naive	\N	f	-10
366	concomitant medication	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medication  n ( % ) d	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medication ( > $nmbr$ % )	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medication  no . ( % )	C0013227;C0521115;C3244316;C4284232	f	1916
366	> $nmbr$ concomitant medication	C0013227;C0521115;C3244316;C4284232	f	2263
366	cardiac medications during index hospitalization	C0013227;C0019993;C0428776;C0802604;C2598133;C4284232	f	2266
366	cardiac medications during index hospitalization  %	C0013227;C0019993;C0428776;C0802604;C2598133;C4284232	f	2266
366	antihyperglycemic medications	C0013227;C0020616;C0802604;C2598133;C4284232	f	33
359	current xanthine derivative use	C0042153;C0043314;C0043318;C0457083;C0521116;C1527240;C1705970;C1947944	\N	\N
358	fasting indices	C0015663;C4033634	\N	\N
358	fasting	C0015663	\N	\N
358	fastest third	C0015663;C0205437;C0456962;C2985769	\N	\N
358	elevated fasting glucose	C0015663;C0017725;C0205250;C3163633	\N	\N
357	multi - racial	C0034510;C0439064;C1706779;C3266262;C3669213;C3853635	\N	\N
357	glacial $nmbr$	\N	\N	\N
357	brachial	C0445456	\N	\N
356	radial access — no . / total no . ( % )	C0439175;C0439810;C0442038;C0444454;C0920847;C1554204	\N	\N
356	radial access site	C0442038;C0589360;C0920847	\N	\N
356	radial access	C0442038;C0444454;C0920847;C1554204	\N	\N
354	placebo * ( add on to basal insulin )	C0032042;C0650607;C1696465;C1706408;C1883712	\N	\N
354	faster aspart   +   basal	C0015663;C0123677;C0205112;C0456962;C2985769	\N	\N
354	basal insulin doset	C0650607	\N	\N
354	basal insulin dose at run - in ( u / day )	C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438	\N	\N
354	basal insulin analogue dose * ( coefficient	C0178602;C0205112;C0243071;C0366513;C0650607;C0869039;C1114758;C1707429;C2825028	\N	\N
354	basal insulin analogue : insulin	C0205112;C0243071;C0650607;C2825028	\N	\N
354	basal insulin	C0650607	\N	\N
353	no nasal polyps	C0027430	\N	\N
353	nasal polyps at baseline : yes	C0027430;C0168634;C1442488;C1549445;C1705108;C1710701	\N	\N
353	nasal polyps  n ( % )	C0027430	\N	\N
353	nasal polyps	C0027430	\N	\N
353	nasal polyposis or chronic rhinosinusitis — no . { % )	C0027430;C0149516	\N	\N
353	either ocs use  nasal polyps  pre - bd fvc < $nmbr$ % of predicted or age at diagnosis sl $nmbr$ years	C0005126;C0027430;C0042153;C0332152;C0439234;C0457083;C0681842;C0740175;C1828181;C1882327;C1947944;C2257086;C2344255;C3173302;C3669034;C3714541;C3844638;C4050145	\N	\N
352	medial - distal - diag	C0205098;C0205108;C0348026;C4522154	\N	\N
352	distal	C0205108;C4522154	\N	\N
351	septal anomaly — no . ( % )	C0332447;C0442004;C1704258	\N	\N
351	e / e ' ( septal )	C0442004	\N	\N
350	mental status ( baseline spmsq scores )  n ( % )	C0168634;C0278060;C0369718;C0441922;C0449820;C1442488;C4050231	\N	\N
350	mental status	C0278060	\N	\N
350	mental component summary	C0229992;C0449432;C1552616;C1705248;C1706244	\N	\N
350	mental component score ( mcs )	C0229992;C0449432;C0449820;C1705248;C4050231	\N	\N
350	mental component	C0229992;C0449432;C1705248	\N	\N
350	mental	C0229992	\N	\N
350	mensa	\N	\N	\N
349	dermal	C0221928;C1522447	\N	\N
349	dental procedure	C0011331	\N	\N
348	bare metal stent  n ( % )	C2825200	\N	\N
348	bare metal stent	C2825200	\N	\N
348	bare metal	C0025552	\N	\N
348	bare - metal stent — no . ( % )	C2825200	\N	\N
348	bare - metal stent	C2825200	\N	\N
348	bare - metal	C0025552	\N	\N
348	all bare metal stents	C2825200	\N	\N
347	≥ $nmbr$ . $nmbr$ % and < $nmbr$ . $nmbr$ %	\N	\N	\N
347	seronegative ( rf - ve and acpa - ve ) subgroup	C0035448;C0042469;C0201660;C0521144;C0748398;C1079230;C1515021;C1525410;C1547111;C1706063;C3714652;C4321495	\N	\N
347	dopa and dopa derivativese	C0013023	\N	\N
346	propionic acid derivatives	C0033482;C0695274;C3540752	\N	\N
346	ethacrynic acid	C0014963	\N	\N
346	ampd $nmbr$	\N	\N	\N
346	acid	C0001128;C0202406	\N	\N
345	hazard ratiof ( $nmbr$ % ci )	C0008107;C0598697;C3259781	\N	\N
345	hazard ratiof	C0598697	\N	\N
345	hazard interaction	C0598697;C1704675	\N	\N
345	hazard inleraction	C0598697	\N	\N
345	hazard	C0598697	\N	\N
344	other ascvd  no . ( % )	C3665365	\N	\N
344	other ascvd	C3665365	\N	\N
344	oascvd	\N	\N	\N
344	no ascvd	C3665365	\N	\N
344	ascvd no prior ml	C0332152;C0439526;C1705224;C2826257;C3665365;C3887665	\N	\N
344	ascvd including tia	C0007787;C0332257;C0917805;C1054154;C3665365	\N	\N
344	ascvd as per protocol	C1698058;C3665365	\N	\N
344	ascvd * . n ( % )	C3665365	\N	\N
344	ascvd  n ( % )	C3665365	\N	\N
344	ascvd  b no . ( % )	C3665365	\N	\N
344	ascvd	C3665365	\N	\N
343	scd ( % )	\N	\N	\N
343	non - lad	C1518422	\N	\N
343	lad	\N	\N	\N
342	sustained esrd  death due to kidney failure  or sustained decrease of > $nmbr$ % in egfr from baseline	C0011065;C0022661;C0035078;C0168634;C0392756;C0443318;C0547047;C0678226;C1306577;C1442488;C1739039;C2316810;C3811844;C3812682;C4082313;C4552775	\N	\N
342	or esrd	C0022661;C0035078;C2316810	\N	\N
342	esrd or death	C0011065;C0022661;C0035078;C1306577;C2316810;C4082313;C4552775	\N	\N
342	esrd on losartan ( % )	C0022661;C0035078;C0126174;C2316810	\N	\N
342	esrd *	C0022661;C0035078;C2316810	\N	\N
342	esrd '	C0022661;C0035078;C2316810	\N	\N
352	distal anastomosis ( % )	C0448964	f	1845
354	basal	C0205112	f	-10
355	familial	C0015576;C0241888	f	-10
358	fasting glucose	C0015663;C0017725	f	1846
358	fasting glucose *	C0015663;C0017725	f	1846
358	impaired fasting glucosex	C0015663;C0221099	f	1846
358	normai fasting giucose levei ( n = $nmbr$ )	C0015663	f	1846
358	fasting lipid levels  mmol / l	C0015663;C0428460;C1532563	f	1847
358	fasting lipids ( mmol / $nmbr$ )	C0015663;C0023779;C0439190	f	1847
358	fasting plasma insulin — mu / liter	C0015663;C0028971;C0347978;C0475211;C0857690;C3714918	f	157
358	faster aspart	C0015663;C0123677;C0456962;C2985769	f	157
358	faster aspart ( mealtime )	C0015663;C0123677;C0456962;C0587119;C2985769	f	157
342	end - stage renal disease	C0022661;C2316810	\N	\N
342	composite of $nmbr$ % reduction in egfr  end - stage kidney disease  or death from renal causes	C0007465;C0022646;C0022661;C0205199;C0301630;C0392756;C1293152;C1547335;C1739039;C2316810;C3811844;C3812682;C4551656	\N	\N
341	gastroduodenum	C0391900	\N	\N
341	gastroduodenal	C0450199	\N	\N
340	women taking estrogen	C0014939;C0043210;C1515187;C2936882;C4542544	\N	\N
340	no estrogen	C0014939;C2936882;C4542544	\N	\N
340	estrogens	C0014939;C3537250;C3541386;C3714615	\N	\N
340	estrogen supplementation -	C0014939;C0242297;C2936882;C4542544	\N	\N
340	estrogen supplementation	C0014939;C0242297;C2936882;C4542544	\N	\N
340	estrogen ( ' % ? )	C0014939;C2936882;C4542544	\N	\N
340	estrogen	C0014939;C2936882;C4542544	\N	\N
339	us site of enrollment	C1516879;C1696073;C2945843;C3888021	\N	\N
339	time from symptom onset to enrollment	C0040223;C0449244;C1457887;C1516879;C1696073;C3541383;C3854129;C3888021;C4086878	\N	\N
339	time from hospital admission to enrollment	C0019994;C0040223;C1510665;C1516879;C1696073;C1959907;C3541383;C3888021	\N	\N
339	thienopyridine at enrollment	C1120149;C1516879;C1696073;C3888021	\N	\N
339	symptom onset to enrollment	C1516879;C1696073;C3888021;C4086878	\N	\N
339	primary enrollment diagnoses  n ( % )	C0332137;C0801658;C1516879;C1696073;C3888021	\N	\N
339	pre - enrollment antihyperglycemic therapy	C0020616;C1516879;C1696073;C1882440;C3888021	\N	\N
339	other medications at enrollment	C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232	\N	\N
339	medications at enrolment	C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232	\N	\N
339	medications at enrollment  n ( % ) :	C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232	\N	\N
339	medication at enrollment — no . ( % )	C0013227;C1516879;C1696073;C3244316;C3888021;C4284232	\N	\N
339	medication after enrolment	C0013227;C1516879;C1696073;C3244316;C3888021;C4284232	\N	\N
339	hospitalization to enrollment	C0019993;C1516879;C1696073;C3888021	\N	\N
339	enrollment to randomization	C0034656;C1516879;C1696073;C3888021	\N	\N
339	enrollment in lmwh substudy	C0019139;C1516879;C1696073;C3536766;C3888021	\N	\N
339	enrollment in lmwh	C0019139;C1516879;C1696073;C3536766;C3888021	\N	\N
339	ace inhibitor at enrollment	C0003015;C1516879;C1696073;C3888021;C4541021	\N	\N
338	naproxen	C0027396	\N	\N
337	western europe / australia / israel	C0004340;C0015176;C0022271;C0043128;C0043129	\N	\N
337	western europe / australia	C0004340;C0015176;C0043128;C0043129	\N	\N
337	western europe  israel  australia  or south africa	C0004340;C0015176;C0022271;C0037712;C0043128;C0043129	\N	\N
337	w europe	C0015176	\N	\N
337	w est europe	C0015176;C3811127;C3890902	\N	\N
337	w . europe	C0015176	\N	\N
337	region  europe	C0015176;C0017446;C0205147	\N	\N
337	non europe	C0015176;C1518422	\N	\N
337	geographic region - europe	C0015176;C0017446	\N	\N
337	europe n z $nmbr$	C0015176	\N	\N
337	europe i	C0015176;C0021966;C0221138	\N	\N
337	europe and canada	C0006823;C0015176	\N	\N
337	europe and australia	C0004340;C0015176	\N	\N
337	europe / lsrael	C0015176	\N	\N
337	europe ( zone $nmbr$ )	C0015176;C1710706	\N	\N
337	europe ( plus south africa )	C0015176;C0037712;C0332287	\N	\N
337	europe ( non - eu )	C0015176;C0015179;C1518422;C3665627	\N	\N
337	europe ( including south africa )	C0015176;C0037712;C0332257	\N	\N
337	europe ( eu )	C0015176;C0015179;C3665627	\N	\N
337	europe $nmbr$ ¶	C0015176	\N	\N
337	europe $nmbr$ +	C0015176	\N	\N
337	europe $nmbr$ ( n = $nmbr$ )	C0015176	\N	\N
337	europe $nmbr$ ( n = $nmbr$  $nmbr$ )	C0015176	\N	\N
337	europe $nmbr$	C0015176	\N	\N
337	europe  israel  or australia	C0004340;C0015176;C0022271	\N	\N
337	europe	C0015176	\N	\N
337	enrope + sonth afriea	\N	\N	\N
337	east europe	C0015176;C1707877	\N	\N
337	e europe	C0015176	\N	\N
337	e . europe	C0015176	\N	\N
336	stroke or see	C0038454;C0042789;C1947903;C4554100	\N	\N
336	stroke / see	C0038454;C0042789;C1947903;C4554100	\N	\N
336	stroke  see  or death	C0011065;C0038454;C0042789;C1306577;C1947903;C4082313;C4552775;C4554100	\N	\N
336	stroke  see  or cv death	C0011065;C0038454;C0042789;C1306577;C1947903;C3538987;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
336	old stroke *	C1536121	\N	\N
336	ischemic stroke or see	C0042789;C0948008;C1947903	\N	\N
336	cvd / stroke / see	C0007222;C0038454;C0042789;C1947903;C4554100	\N	\N
335	unprovoked	\N	\N	\N
335	provoked	C1444748	\N	\N
334	nt - probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum	C0042295;C0588446;C0669479;C0754710;C4684790	\N	\N
334	enrolled into osler	C4684790	\N	\N
334	> $nmbr$ enroll	\N	\N	\N
334	< $nmbr$ enroll	\N	\N	\N
333	diet controlled or no	C0743195	\N	\N
333	diet - controlled ( % )	C0743195	\N	\N
332	uncontrolled on oad ( s )	C0205318	\N	\N
332	uncontrolled on basal insulin	C0205318;C0650607	\N	\N
332	uncontrolled	C0205318	\N	\N
331	western europe  australia  new zealand  middle eai	C0043129;C0444598;C0549183;C1552826;C4289954	\N	\N
331	tertile $nmbr$ : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )	\N	\N	\N
331	tertile $nmbr$ ( n = $nmbr$ )	\N	\N	\N
331	middle third	C0442050	\N	\N
331	middle tertile : > $nmbr$ . $nmbr$ to b $nmbr$ . $nmbr$	C0444598;C0549183;C1552826	\N	\N
331	middle tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl )	C0024671;C0026410;C0439269;C0444504;C0444598;C0549183;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761	\N	\N
331	middle	C0444598;C0549183;C1552826	\N	\N
331	$nmbr$ mgrdl	\N	\N	\N
338	ibuprofen	C0020740	f	1844
339	statin at enrollment	C0360714;C1516879;C1696073;C3888021	f	872
339	loop at enrollment	C0445022;C1516879;C1696073;C3888021	f	991
335	unprovoked vte n ( % )	C0630906	f	2386
330	multiple tnfi and other bdmards §	C0439064	\N	\N
330	multiple tnfi *	C0439064	\N	\N
330	multiple diagnoses	C0011900;C0439064	\N	\N
330	multiple	C0439064	\N	\N
329	renal function  normal - mild	C0205307;C0231683;C0232804;C0439166;C2347086;C2945599;C4553972	\N	\N
329	normalfunction or mild impairment	C0221099;C0684336;C2945599	\N	\N
329	normal or mild ( iief - ef $nmbr$ - $nmbr$ )  n ( % )	C0205307;C0231683;C0439166;C2347086;C2945599;C3641331;C4553972	\N	\N
329	normal function or mild impairment	C0221099;C0684336;C2945599;C4296962	\N	\N
329	normal / mild ckd	C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972	\N	\N
329	mildly impaired	C0221099;C0750532;C2945599	\N	\N
329	mild teaes	C2945599	\N	\N
329	mild impairment ( £ $nmbr$ to	C0221099;C0684336;C2945599	\N	\N
329	mild impairment ( egfr $nmbr$ – $nmbr$ )  n ( % )	C0221099;C0684336;C1739039;C2945599;C3811844;C3812682	\N	\N
329	mild impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ )	C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C2945599;C3811844;C3812682	\N	\N
329	mild impairment ( egfr $nmbr$ - $nmbr$ )	C0221099;C0684336;C1739039;C2945599;C3811844;C3812682	\N	\N
329	mild impairment ( $nmbr$ to < $nmbr$ )	C0221099;C0684336;C2945599	\N	\N
329	mild impairment ( $nmbr$ to $nmbr$ ml / min )	C0221099;C0439445;C0684336;C2945599	\N	\N
329	mild impairment  < $nmbr$ to < $nmbr$	C0221099;C0684336;C2945599	\N	\N
329	mild impairment	C0221099;C0684336;C2945599	\N	\N
329	mild ed severe ed	C0205082;C2945599;C3538926;C4050465;C4050466	\N	\N
329	mild ed	C2945599;C3538926	\N	\N
329	mild ( n = $nmbr$ )	C2945599	\N	\N
329	mild ( n $nmbr$ = $nmbr$ ) $nmbr$	C2945599	\N	\N
329	mild ( iief - ef $nmbr$ - $nmbr$ )	C2945599;C3641331	\N	\N
329	mild ( gold $nmbr$ )	C0018026;C1304897;C2945599	\N	\N
329	mild ( > $nmbr$ to < $nmbr$ )	C2945599	\N	\N
329	mild ( < $nmbr$ )	C2945599	\N	\N
329	mild ( $nmbr$ - $nmbr$ )	C2945599	\N	\N
329	mild	C2945599	\N	\N
329	< mild	C2945599	\N	\N
329	$nmbr$ - $nmbr$ ( mild )	C2945599	\N	\N
328	sustained mucosal healingc n / n ( % )	C0026724;C0443318	\N	\N
328	sustained mucosal healingc	C0026724;C0443318	\N	\N
328	mucosal healingf	C0026724	\N	\N
328	mucosal healingc n / n ( % )	C0026724	\N	\N
327	complete ulcer healing at week $nmbr$	C0205197;C0332174;C0333293;C0439230;C0725685;C3853530;C4283785	\N	\N
327	complete healinga	C0205197;C0725685;C3853530;C4283785	\N	\N
326	health assessment questionnaire score	C2960025	\N	\N
325	self - rated health status	C0018759;C0036588;C0871208;C1551994	\N	\N
325	mental health	C0025353	\N	\N
325	health practices	C0018684;C0237607;C3245512	\N	\N
325	general health ( self - reported )	C0424575;C0681906;C2700446;C4018875	\N	\N
325	general health  self - reported	C0424575;C0681906;C2700446;C4018875	\N	\N
325	general health	C0424575;C4018875	\N	\N
325	$nmbr$ mentis	\N	\N	\N
324	early death	C1836407	\N	\N
323	vascular death	C0005847;C0011065;C1306577;C1558950;C1801960;C4082313;C4552775	\N	\N
323	stroke deaths	C0011065;C0038454;C1306577;C4554100	\N	\N
323	s / se  mb or death	C0011065;C0024853;C0036919;C0565930;C1306577;C2603362;C4082313;C4552775	\N	\N
323	patients with pneumonia resulting in death  n ( % )	C0011065;C0030705;C0032285;C0332294;C1306577;C4082313;C4552775	\N	\N
323	or death	C0011065;C1306577;C4082313;C4552775	\N	\N
323	noncardiac death	C0011065;C1306577;C4082313;C4552775	\N	\N
323	non - cvd deaths	C0007222;C0011065;C1306577;C1518422	\N	\N
323	no . of deaths	C0011065;C1306577	\N	\N
323	net clinical benefit : cv death  mi  stroke  gusto moderate / severe bleeding	C0011065;C0019080;C0038454;C0205081;C0205082;C1306577;C1456447;C1881878;C3538987;C3810814;C3853572;C3887809;C3890893;C4048877;C4049705;C4049706;C4050465;C4050466;C4082313;C4085643;C4318503;C4321335;C4552775;C4554100;C4684590	\N	\N
323	malignancy death	C0006826;C0011065;C1306459;C1306577;C4082313;C4282132;C4552775	\N	\N
323	macce ( death  mi  stroke )	C0011065;C0038454;C1306577;C3810814;C4082313;C4552775;C4554100	\N	\N
323	leading to death	C0011065;C0332152;C1306577;C1522538;C4082313;C4552775	\N	\N
323	hf hospitalization or cardiovascular death	C0007226;C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3887460;C4082313;C4552775	\N	\N
323	hazard ratio for cardiovascular death	C0007226;C0011065;C1306577;C2985465;C3887460;C4082313;C4552775	\N	\N
323	exploratory cardiovascular and death outcomes	C0007226;C0011065;C1274040;C1306577;C3887460;C4082313;C4552775	\N	\N
323	drug discontinuation not due to death	C0011065;C0013227;C0457454;C0678226;C1254351;C1306577;C1444662;C1518422;C4082313;C4552775;C4552847	\N	\N
323	death or myocardial infarction	C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959	\N	\N
323	death or mi at $nmbr$ days	C0011065;C0439228;C1306577;C3810814;C4082313;C4552775	\N	\N
323	death or ich	C0011065;C0019191;C1306577;C3272597;C3281105;C4082313;C4552775	\N	\N
323	death from	C0011065;C1306577;C4082313;C4552775	\N	\N
323	cvd deaths	C0007222;C0011065;C1306577	\N	\N
323	death	C0011065;C1306577;C4082313;C4552775	f	1855
323	death  n ( % )	C0011065;C1306577;C4082313;C4552775	f	1855
323	deaths  n ( % )	C0011065;C1306577	f	1855
324	sudden death	C0011071;C1964022;C4554103	f	2401
326	headache	C0018681;C4553197	f	2402
326	health habits	C0679786	f	2403
323	cvd death	C0007222;C0011065;C1306577;C4082313;C4552775	\N	\N
323	cv death or ml	C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death or hhf	C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death or hf hospitalization n	C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death or hf hosp .	C0011065;C0018488;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death n	C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death / mi / stroke	C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
323	cv death / hf hospitalization	C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death + hf hospitalization	C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death  myocardial infarction  stroke	C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4552959;C4554100	\N	\N
323	cv death  ml or ischemic stroke	C0011065;C0439526;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death  ml  or stroke	C0011065;C0038454;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
323	cv death  ml  ischemic stroke  hospitalization for unstable angina  revascularization or heart failure	C0002965;C0011065;C0018801;C0018802;C0019993;C0439526;C0581603;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775;C4554158	\N	\N
323	cv death  mi  stroke  recurrent ischemia	C0011065;C0022116;C0038454;C1306577;C1455761;C2945760;C3538987;C3810814;C4048877;C4082313;C4318503;C4321499;C4552775;C4554100	\N	\N
323	cv death  mi  stroke  or urgent coronary revascularization	C0011065;C0038454;C0439609;C0877341;C1306577;C3272275;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
323	cv death  mi  stroke	C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
323	cv death  mi  or stroke	C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
323	cv death  mi  or ischemic stroke	C0011065;C0948008;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death  mi  ischemic stroke  hospitalization for hf  coronary revascularization  ua	C0011065;C0018488;C0019993;C0041580;C0042014;C0376297;C0581603;C0877341;C0948008;C1306577;C1313497;C1538440;C3273279;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death  mi  ischemic stroke	C0011065;C0948008;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775	\N	\N
323	cv death	C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775	\N	\N
323	composite of death / mi / urg ent revasc	C0011065;C0205199;C0378365;C0919420;C1306577;C1367721;C1547335;C1705448;C3810814;C3889152;C4082313;C4552775	\N	\N
323	cardiovascular death ®	C0007226;C0011065;C1306577;C3887460;C4082313;C4552775	\N	\N
323	cardiovascular death or hospitalization for heart failure	C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775	\N	\N
323	cardiovascular death or heart failure hospitalization	C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775	\N	\N
323	cardiovascular death and hospital admission for heart failure	C0007226;C0011065;C0018801;C0018802;C0184666;C1306577;C3887460;C4082313;C4552775;C4554158	\N	\N
323	cardiovascular death / myocardial infarction / stroke	C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959	\N	\N
323	cardiovascular death *	C0007226;C0011065;C1306577;C3887460;C4082313;C4552775	\N	\N
323	cardiovascular death ( n = $nmbr$ )	C0007226;C0011065;C1306577;C3887460;C4082313;C4552775	\N	\N
323	cardiovascular death !	C0007226;C0011065;C1306577;C3887460;C4082313;C4552775	\N	\N
323	cardiovascular death  nonfatal myocardial infarction  or nonfatal stroke	C0007226;C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959;C4554100	\N	\N
323	cardiovascular death  myocardial infarction  or stroke	C0007226;C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959;C4554100	\N	\N
323	cardiovascular death  mi  or stroke	C0007226;C0011065;C0038454;C1306577;C3810814;C3887460;C4082313;C4552775;C4554100	\N	\N
323	cardiovascular death	C0007226;C0011065;C1306577;C3887460;C4082313;C4552775	\N	\N
323	a cardiovascular death or hospitalization for heart failure	C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775	\N	\N
322	severe / moderate	C1299393	\N	\N
322	pfo with mild - to - moderate shunt and atrial septal aneurysm	C0232180;C0521533;C0542331;C1299392;C1442858	\N	\N
322	moderate - to - severe copd exacerbation	C0740304;C1299393	\N	\N
322	mild to moderate	C1299392	\N	\N
322	mild - < moderate	C1299392	\N	\N
322	gusto severe / moderate	C1299393	\N	\N
321	severe or moderate	C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	renal function  moderate	C0205081;C0232804;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	pedal edema  slight / moderate / marked	C0205081;C0522501;C0574002;C1706089;C1881878;C2937276;C2945599;C4049705;C4049706;C4050469;C4085643;C4321335	\N	\N
321	patients with moderate - to - severe pain ( womac pain score  $nmbr$ - $nmbr$ )	C0030705;C0205081;C0205082;C0278140;C0449820;C0582148;C1881878;C4049705;C4049706;C4050231;C4050465;C4050466;C4085643;C4321335;C4521229	\N	\N
321	moderatez	\N	\N	\N
321	moderatey	\N	\N	\N
321	moderately impaired	C0205081;C0221099;C1881878;C4085643;C4321491	\N	\N
321	moderate ’	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ )	C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate teaes	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate severity	C0205081;C0439793;C0522510;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate severe ( n = $nmbr$ ) ( n = $nmbr$ )	C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	moderate risk ( $nmbr$ - $nmbr$ )	C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904	\N	\N
321	moderate risk	C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904	\N	\N
321	moderate or severe impairment	C0205081;C0205082;C0221099;C0684336;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	moderate or severe copd exacerbations	C0205081;C0205082;C0740304;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	moderate or less airflow limitation	C0205081;C0231999;C0439092;C0443288;C0449295;C0547044;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate n z $nmbr$	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate impairment ( $nmbr$ to < $nmbr$ )	C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate impairment ( $nmbr$ to $nmbr$ ml / min )	C0205081;C0221099;C0439445;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate impairment  < $nmbr$ to < $nmbr$	C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate impairment	C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate disease activity : > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$  n ( % )	C0012634;C0205081;C1292728;C1513375;C1881878;C3833417;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate disease	C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate copdb [ n z $nmbr$ ]	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate copd	C0024117;C0205081;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate chronic kidney disease	C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335;C4553188	\N	\N
321	moderate - to -	C0040363;C0041260;C0205081;C1881878;C1883351;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate - < severe	C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	moderate ( s $nmbr$ % . < $nmbr$ % )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( n = $nmbr$ )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( n $nmbr$ = $nmbr$ )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( iief - ef $nmbr$ - $nmbr$ )  n ( % )	C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( iief - ef $nmbr$ - $nmbr$ )	C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( > $nmbr$ to < $nmbr$ )	C0040363;C0041260;C0205081;C1881878;C1883351;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( > $nmbr$ and < $nmbr$ )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( > $nmbr$ % . < $nmbr$ % )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )	C0205081;C0369637;C0439445;C0441923;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( $nmbr$ risk factor )	C0035648;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( $nmbr$ - $nmbr$ )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( $nmbr$ % < fev  < $nmbr$ % predicted )	C0205081;C0681842;C1881878;C1882327;C3714541;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate ( $nmbr$ % . < $nmbr$ % )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate  n ( % ) a	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	moderate	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	mild or moderate copd	C0024117;C0205081;C1412502;C1881878;C2945599;C3714496;C4049705;C4049706;C4085643;C4321335	\N	\N
321	gusto moderate or severe bleeding	C0019080;C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	gusto moderate or severe	C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	gusto moderate	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	death  mi  idr  st  or gusto moderate / severe bleeding	C0011065;C0019080;C0036056;C0205081;C0205082;C1306577;C1881878;C3272372;C3810814;C4049705;C4049706;C4050465;C4050466;C4082313;C4085643;C4321335;C4552775	\N	\N
321	> $nmbr$ - $nmbr$ ( moderate risk )	C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904	\N	\N
321	< $nmbr$ and no moderate or severe deformity ( n = $nmbr$ )	C0000768;C0205081;C0205082;C0221430;C0302142;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
321	$nmbr$ - $nmbr$ ( moderate )	C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
321	$nmbr$ ( moderate disease )	C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
320	renal disease )	C0022658	\N	\N
320	renal disease	C0022658	\N	\N
320	previous renal disease  n ( % )	C0022658;C0205156;C1552607	\N	\N
320	nephropathy	C0022658	\N	\N
320	established renal disease *	C0022658;C0443211;C1272684	\N	\N
320	contrast nephropathy risk score	C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904	\N	\N
320	albuminuria and previous maerovaseular disease without established renal disease	C0001925;C0012634;C0022658;C0205156;C0443211;C1272684;C1552607	\N	\N
319	respiratory - related ^	C0439849;C0445223;C0521346;C1546767	\N	\N
319	ipf - related	C0034069;C0439849;C0445223;C1800706	\N	\N
319	infarct - related vessel ( % )	C0005847;C0021308;C0439849;C0445223	\N	\N
319	hospitalisation related to exacerbation  n ( % )	C0019993;C0439849;C0445223;C4086268	\N	\N
319	history of asthma - related intubation — no . ( % )	C0021925;C0439849;C0445223;C0455544	\N	\N
319	bph - related health status	C0005001;C0018759;C0439849;C0445223;C1704272	\N	\N
319	asthma - related health -	C0004096;C0018684;C0439849;C0445223;C2984299	\N	\N
318	vte / vte - related deathsb  n / n ( % )	C0439849;C0445223;C0630906	\N	\N
318	vte / vte - related deathsa  n / n ( % )	C0439849;C0445223;C0630906	\N	\N
318	any vte or vte - related death — no . ( % )	C0425043;C0630906	\N	\N
318	any vte - related death	C0425043;C0630906	\N	\N
317	delighted	C3830544	\N	\N
317	delayed reaction	C0205421;C0443286;C1545665;C3272602	\N	\N
317	delayed eptifibatide	C0205421;C0253563;C1545665;C3272602	\N	\N
300	fatal and nonfatal ml	C0439526;C1302234;C1705224;C1705232;C3887665	\N	\N
317	delayed - start group ( n = $nmbr$ )	C0205421;C0439659;C0441848;C1545665;C3272602	\N	\N
317	delayed - eptifibatide group ( n = $nmbr$ )	C0205421;C0253563;C0441848;C1545665;C3272602	\N	\N
317	delayed	C0205421;C1545665;C3272602	\N	\N
317	$nmbr$ mg / day early - start - delayed start	C0205421;C0439422;C0439659;C1279919;C1545665;C3272602	\N	\N
317	$nmbr$ mg / day early - start - delayed - start	C0205421;C0439422;C0439659;C1279919;C1545665;C3272602	\N	\N
317	$nmbr$ mg / day delayed - start	C0205421;C0439422;C0439659;C1545665;C3272602	\N	\N
316	smoking ( ever )	C0037369;C0453996;C1881674	\N	\N
316	never smoking	C0037369;C0453996;C1881674;C2003901	\N	\N
316	never drink	C0452428;C2003901	\N	\N
316	never	C2003901	\N	\N
316	ever	\N	\N	\N
315	vka naxve	\N	\N	\N
315	vka naive  n ( % )	\N	\N	\N
315	vka naive	\N	\N	\N
315	uncover - $nmbr$	\N	\N	\N
315	rarely / never	C4035880	\N	\N
315	never been on a vka	C2003901	\N	\N
315	ever been on a vka	\N	\N	\N
314	triglyceride level	C0428475	\N	\N
314	doubling of creatinine level	C0205173;C0428279;C1705764	\N	\N
314	creatinine level	C0428279	\N	\N
314	calcium level	C0201925;C0428302	\N	\N
313	severely impaired	C0205082;C0221099	\N	\N
313	severe to end - stage impairment ( $nmbr$ ml / min )	C0205082;C0205088;C0221099;C0439445;C0684336;C4050465;C4050466	\N	\N
313	severe teaes	C0205082;C4050465;C4050466	\N	\N
313	severe or worse airflow limitation	C0205082;C0231999;C0332271;C0443288;C0449295;C1279889;C1457868;C4050465;C4050466	\N	\N
313	severe oab subgroup	C0205082;C1079230;C1515021;C4050465;C4050466	\N	\N
313	severe n z $nmbr$	C0205082;C4050465;C4050466	\N	\N
313	severe impairment ( egfr < $nmbr$ ml / min / m ^ )	C0205082;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466	\N	\N
313	severe impairment ( egfr < $nmbr$ )  n ( % )	C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466	\N	\N
313	severe impairment ( egfr < $nmbr$ )	C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466	\N	\N
313	severe impairment ( < $nmbr$ )	C0205082;C0221099;C0684336;C4050465;C4050466	\N	\N
313	severe hypoglycemia	C0020615;C0205082;C4050465;C4050466;C4553659	\N	\N
313	severe hyperkalemiac	C0205082;C4050465;C4050466	\N	\N
313	severe hyperkalemia ‘ s	C0020461;C0205082;C4050465;C4050466;C4552983	\N	\N
313	severe hyperkalemia ' s	C0020461;C0205082;C4050465;C4050466;C4552983	\N	\N
313	severe exacerbations	C0205082;C4050465;C4050466;C4086268	\N	\N
313	severe ed	C0205082;C3538926;C4050465;C4050466	\N	\N
313	severe copdc [ n z $nmbr$ ]	C0205082;C4050465;C4050466	\N	\N
313	severe copd	C0024117;C0205082;C1412502;C3714496;C4050465;C4050466	\N	\N
313	severe aes	C0205082;C1412268;C2699274;C4050465;C4050466	\N	\N
313	severe / very severea	C0205082;C0442824;C2984081;C4050465;C4050466	\N	\N
313	severe / lite threatening	C0205082;C4050465;C4050466	\N	\N
313	severe / life ttireatening	C0205082;C0376558;C4050465;C4050466	\N	\N
313	severe / life threatening	C0205082;C1546953;C2826244;C3537125;C4050465;C4050466	\N	\N
313	severe - very severe	C0205082;C0442824;C2984081;C4050465;C4050466	\N	\N
313	severe ( n $nmbr$ = $nmbr$ )	C0205082;C4050465;C4050466	\N	\N
313	severe ( itt ) ( n = $nmbr$ )	C0205082;C4050465;C4050466	\N	\N
313	severe ( iief - ef < $nmbr$ )	C0205082;C3641331;C4050465;C4050466	\N	\N
313	severe ( iief - ef $nmbr$ - $nmbr$ )  n ( % )	C0205082;C3641331;C4050465;C4050466	\N	\N
313	severe ( > $nmbr$ )	C0205082;C4050465;C4050466	\N	\N
313	severe ( < $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )	C0205082;C0369637;C0439445;C0441923;C4050465;C4050466	\N	\N
313	severe  n ( % ) b	C0205082;C4050465;C4050466	\N	\N
313	severe	C0205082;C4050465;C4050466	\N	\N
313	risk of moderate / severe exacerbations	C0205082;C0332166;C4050465;C4050466;C4086268	\N	\N
313	renal function  severe	C0205082;C0232804;C4050465;C4050466	\N	\N
313	patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode of severe hypoglycemia *	C0017853;C0020615;C0030705;C0205082;C0332189;C4050465;C4050466;C4553659	\N	\N
313	patients with glycated hemoglobin < $nmbr$ . $nmbr$ % and no severe hypoglycemia or diabetic ketoacidosis	C0011880;C0017853;C0020615;C0030705;C0205082;C4050465;C4050466;C4553659	\N	\N
313	or severe	C0205082;C4050465;C4050466	\N	\N
313	no severe hypoglycemia	C0020615;C0205082;C4050465;C4050466;C4553659	\N	\N
313	no . of moderate or severe exacerbations in previous	C0205081;C0205082;C0205156;C1552607;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335	\N	\N
313	more severe ^	C0205082;C0205172;C4050465;C4050466	\N	\N
313	more severe	C0205082;C0205172;C4050465;C4050466	\N	\N
313	moderate or severe decrease in gfr { < $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ )	C0017654;C0205081;C0205082;C0369637;C0392756;C0439526;C0441923;C0547047;C1417190;C1424601;C1705224;C1881878;C3815103;C3887665;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
313	moderate / severe exacerbations  patient subgroups  n ( % )	C0030705;C0205081;C0205082;C1079230;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335	\N	\N
313	moderate / severe exacerbation	C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4086268;C4321335	\N	\N
313	less severe $nmbr$	C0205082;C0439092;C0547044;C4050465;C4050466	\N	\N
313	less severe	C0205082;C0439092;C0547044;C4050465;C4050466	\N	\N
313	gusto severe or	C0205082;C4050465;C4050466	\N	\N
313	gusto severe	C0205082;C4050465;C4050466	\N	\N
313	gusto moderate / severe bleeding	C0019080;C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
313	gusto moderate / severe	C0205081;C0205082;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
313	grade $nmbr$ ( severe copd )  n ( % )	C0024117;C0205082;C0441800;C0919553;C1412502;C3244287;C3714496;C4050465;C4050466	\N	\N
313	first severe asthma exacerbation	C0205082;C0205435;C0349790;C0581126;C1279901;C4050465;C4050466;C4086268	\N	\N
7	genotype - by - treatment interaction p values *	C0017431;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704	\N	\N
313	death / mi / idr / st / gusto - defined moderate or severe bleeding	C0011065;C0019080;C0036056;C0205081;C0205082;C1306577;C1704788;C1881878;C3272372;C3539106;C3810814;C4049705;C4049706;C4050465;C4050466;C4082313;C4085643;C4321335;C4552775	\N	\N
313	a severe hypoglycemia	C0020615;C0205082;C4050465;C4050466;C4553659	\N	\N
313	$nmbr$ - $nmbr$ ( severe )	C0205082;C4050465;C4050466	\N	\N
312	type of vessel involved	C1282017;C1314939	\N	\N
312	nail involvement  %	C0027342;C1314939;C1432728;C3538766	\N	\N
312	involved gastrointestinal	C0521362;C1314939	\N	\N
312	gastrointestinal area involved  n / total n ( % )	C0017446;C0205146;C0369718;C0439175;C0439810;C0441922;C0521362;C1314939	\N	\N
312	dip involvement  ! n ( % )	C1314939;C3539618	\N	\N
311	no . ( % ) of patients with ≥ $nmbr$ % bsa affected	C0030705;C0392760;C1314939	\N	\N
311	mean involved bsa  % ( $nmbr$ % ci )	C0008107;C0444504;C1314939;C2347634;C2348143;C3259781	\N	\N
311	bsa involved  % $nmbr$	C1314939	\N	\N
311	bsa affected  mean ± sd  %	C0392760;C0444504;C1314939;C2347634;C2348143;C2699239	\N	\N
311	bsa affected  %	C0392760;C1314939	\N	\N
-10	ttf - fv	C1332112;C1705840;C4087167	\N	\N
309	op  vfx	\N	\N	\N
309	op  no vfx	\N	\N	\N
309	no op  vfx	\N	\N	\N
309	no op  no vfx	\N	\N	\N
309	and vfx status	C0449438	\N	\N
309	> - $nmbr$ . $nmbr$ - vfx	\N	\N	\N
309	> - $nmbr$ . $nmbr$ + vfx	\N	\N	\N
309	< - $nmbr$ . $nmbr$ - vfx	\N	\N	\N
309	< - $nmbr$ . $nmbr$ + vfx	\N	\N	\N
308	— b - h —	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	within $nmbr$ h after	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	within $nmbr$ h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	use of h $nmbr$ bloekers  n ( % )	C0033727;C0369286;C0441932;C0564385;C1524063;C4528284	\N	\N
308	urgency episodes / $nmbr$ h	C0033727;C0332189;C0369286;C0439609;C0441932;C0564385;C4528284	\N	\N
308	time to randomization ( h )	C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284	\N	\N
308	time sample drawn ( h )	C0033727;C0040223;C0369286;C0370003;C0441932;C0564385;C2347026;C3541383;C4528284	\N	\N
308	time from symptoms to randomization  h	C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C0683368;C1457887;C3541383;C4528284	\N	\N
308	time from onset to randomization  h  mean ± sd	C0033727;C0034656;C0369286;C0441932;C0444504;C0449244;C0564385;C2347634;C2348143;C2699239;C4528284	\N	\N
308	time from onset to medication  h  mean ± sd	C0013227;C0033727;C0369286;C0441932;C0444504;C0449244;C0564385;C2347634;C2348143;C2699239;C3244316;C4284232;C4528284	\N	\N
308	symptom onset to pci  h	C0033727;C0369286;C0441932;C0564385;C4049621;C4086878;C4528284	\N	\N
308	ptca < $nmbr$ h	C0033727;C0369286;C0441932;C0564385;C2936173;C4528284	\N	\N
308	non - cabg related bleeding at $nmbr$ h	C0010055;C0019080;C0033727;C0369286;C0439849;C0441932;C0445223;C0564385;C1518422;C4528284	\N	\N
308	nocturia episodes / $nmbr$ h	C0028734;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284	\N	\N
308	migraine duration ( h )	C0033727;C0149931;C0369286;C0441932;C0449238;C0564385;C2926735;C4528284	\N	\N
308	micturitions / $nmbr$ h	C0033727;C0042034;C0369286;C0441932;C0564385;C4528284	\N	\N
308	incontinence episodes / $nmbr$ h	C0021167;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284	\N	\N
308	i - h	C0021966;C0033727;C0221138;C0369286;C0441932;C0564385;C4528284	\N	\N
308	h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	fev auc i $nmbr$ h	C0021966;C0033727;C0221138;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284	\N	\N
308	fev $nmbr$ auc $nmbr$ mine $nmbr$ h	C0033727;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284	\N	\N
308	duration of symptoms  h	C0033727;C0369286;C0436359;C0441932;C0564385;C4528284	\N	\N
308	b + h ( n = $nmbr$ )	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	> = $nmbr$ h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	> $nmbr$ to < $nmbr$ h  n ( % )	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	> $nmbr$ h  n ( % )	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	> $nmbr$ h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	< $nmbr$ h  n ( % )	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	< $nmbr$ h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	$nmbr$ — e - h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	$nmbr$ to < $nmbr$ h  n ( % )	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	$nmbr$ . $nmbr$ f $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ h	C0016327;C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
308	$nmbr$ - $nmbr$ h	C0033727;C0369286;C0441932;C0564385;C4528284	\N	\N
307	〉 $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0369637;C0439445;C0441923	\N	\N
307	≥ $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	≥ $nmbr$ ml / min	C0439445	\N	\N
307	• ? sd ml / min	C0439445;C2699239	\N	\N
307	£ $nmbr$ ml / min	C0439445	\N	\N
307	s $nmbr$ ml / min	C0439445;C0565930;C2603362	\N	\N
307	renal function ( ml / min )	C0232804;C0439445	f	592
307	renal function < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml / min ( n = $nmbr$ )	C0205390;C0439445;C1300072;C1306673;C1561643;C1739039;C3811844;C3812682	f	592
307	stage $nmbr$ : < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0439445;C0456533	f	592
307	stage $nmbr$ : > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0439445;C0456533	f	592
307	stage $nmbr$ : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0439445;C0456533	f	592
307	normal function ( crcl > $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] )	C0439445;C1846718;C4296962	\N	\N
307	moderate or severe decrease in gfr ( < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0017654;C0205081;C0205082;C0369637;C0392756;C0439445;C0441923;C0547047;C1424601;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	\N	\N
307	mildlydecreased baseline gfr ( $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488	\N	\N
307	mild or no dysfunction ( crcl > $nmbr$ ml / min  n = $nmbr$ $nmbr$  [ $nmbr$ . $nmbr$ % ] )	C0031847;C0277785;C0439445;C1846718;C2945599;C3887504;C3887505	\N	\N
307	mild dysfunction ( crcl > $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] )	C0439445;C1846718;C3274775	\N	\N
307	mild decrease ( $nmbr$ - < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0392756;C0439445;C0441923;C0547047;C2945599	\N	\N
307	mild ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % )	C0369637;C0439445;C0441923;C2945599	\N	\N
307	median — ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
307	median — ml / min	C0439445;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
307	median crcl — ml / min	C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193	\N	\N
307	mean ± sd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	\N	\N
307	interquartile range — ml / min	C0439445;C1711350	\N	\N
307	greater than or equal to $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0205163;C0369637;C0439093;C0439445;C0441923	\N	\N
307	estimated creatinine clearance — ml / min §	C0439445;C0750572;C0812399	\N	\N
307	estimated creatinine clearance — ml / min  i	C0021966;C0023806;C0221138;C0439445;C0702093;C0750572;C0812399;C1524029;C3813700	\N	\N
307	estimated creatinine clearance < $nmbr$ ml / min *	C0439445;C0750572;C0812399	\N	\N
307	estimated creatinine clearance ( ml / min )	C0439445;C0750572;C0812399	\N	\N
307	egfrmdrd ， ml - min - $nmbr$ - $nmbr$ . $nmbr$ m_ $nmbr$	C0369637;C0439445;C0441923	f	592
307	estimated gfr at baseline  ml • min $nmbr$	C0017654;C0168634;C0439445;C0750572;C1424601;C1442488	f	592
307	estimated gfr  ml / min	C0017654;C0439445;C0750572;C1424601	f	592
307	estimated gfr — ml / min / $nmbr$ . $nmbr$ m ^ |	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) ^ |	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	estimated gfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd )	C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239	f	592
307	estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$   of body - surface area	C0017446;C0017654;C0205146;C0369637;C0439445;C0441923;C0489451;C0750572;C1424601	f	592
307	estimated gfr  ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ ( sd ) a	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601;C2699239	f	592
307	estimated gfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd )	C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239	f	592
307	estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	estimated gfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	estimated gfr  < $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$  n ( % ) a	C0017654;C0369637;C0439445;C0441923;C0750572;C1424601	f	592
307	gfr ( mdrd ) ( ml / min / $nmbr$ - $nmbr$ m $nmbr$ )	C0017654;C0369637;C0439445;C0441923;C1424601;C3839656	f	592
307	gfr ( ml / min per $nmbr$ . $nmbr$ nr )	C0017654;C0027496;C0439445;C1424601;C3844738	f	592
307	gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0017654;C0369637;C0439445;C0441923;C1424601	f	592
307	mdrd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	mdrd - egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	mean ( s . d . ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C3811844;C3812682	f	592
307	normal or high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to low egfr ( < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0168634;C0205250;C0205251;C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1299351;C1442488;C1550472;C1739039;C2347086;C2700149;C3811844;C3812682;C3887512;C3889660;C3890211;C4048187;C4321237;C4321351;C4522209;C4522223;C4553972	f	592
307	outcome according to renal function level ( in ml / min )	C0022646;C0232804;C0439445;C0441889;C0456079;C0680240;C0935587;C1274040;C1547707;C2946261	f	592
307	patients with egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline	C0030705;C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	f	592
307	patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline	C0030705;C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	f	592
307	patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n	C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	patients with egfr $nmbr$ > $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n	C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  according to mdrd )  n ( % )	C0232804;C0369637;C0439445;C0441923;C0680240;C1739039;C3811844;C3812682;C3839656	f	592
7	chi - square p value	C1552646;C1709380	\N	\N
307	egfr ( ckd - epi  cystatinc )  ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0162734;C0369637;C0439445;C0441923;C1561643;C1739039;C3811844;C3812682;C4281721	f	592
307	egfr crcl ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$	C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682	f	592
307	egfr crcl < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682	f	592
307	egfr from the mdrd equation ( sd )  ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$	C0369637;C0439445;C0441923;C0552449;C1739039;C2699239;C3811844;C3812682;C3839656	f	592
307	egfr in ml / min / $nmbr$ . $nmbr$ m ^  median ( iqr )	C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682	f	592
307	egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m * *	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	egfr ( mdrd )  ml min − $nmbr$ $nmbr$ . $nmbr$   m − $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	egfr ( median  iqr )  ml / min / $nmbr$  $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682	f	592
307	egfr ( ml / min )	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr — ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr — ml / min / $nmbr$ . $nmbr$ m * *	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) §	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ [ mdrdequation ] )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd )	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
307	egfr +  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mean ± sd )	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
307	egfr ( ml / min / $nmbr$ - $nmbr$ mz )	C0026655;C0439445;C1705291;C1739039;C3811844;C3812682	f	592
307	egfr ( ml / min per $nmbr$ - $nmbr$ m ' )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ) t	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr > $nmbr$ ml / min	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$  ml / min / m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min  n ( % )	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr > $nmbr$ ml / min  n ( % )	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ §	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ *	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr > $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr > $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr £ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	egfr . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr > = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ mz	C0026655;C0439445;C1705291;C1739039;C3811844;C3812682	f	592
307	egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ mz	C0026655;C0439445;C1705291;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ – $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ’	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m *	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr via mdrd ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	ecrcl < $nmbr$ ml / min	C0439445	\N	\N
307	ecrcl  ml / min	C0439445	\N	\N
307	ecfr ( ml / min per $nmbr$ - $nmbr$ m ’ )	C0369637;C0439445;C0441923	\N	\N
307	ecfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	creatinine clearance — ml / min	C0439445;C0812399	\N	\N
307	creatinine clearance < $nmbr$ ml / min ( % )	C0439445;C0812399	\N	\N
307	creatinine clearance < $nmbr$ ml / min	C0439445;C0812399	\N	\N
307	creatinine clearance ( ml / min )  mean ± sd	C0439445;C0444504;C0812399;C2347634;C2348143;C2699239	\N	\N
307	creatinine clearance ( ml / min )	C0439445;C0812399	\N	\N
307	creatinine clearance  ml / min - $nmbr$ *	C0439445;C0812399	\N	\N
307	creatinine clearance  ml / min	C0439445;C0812399	\N	\N
307	creatine clearance  ml / min	C0373595;C0439445	\N	\N
307	creat clearance > $nmbr$ ml / min	C0201975;C0439445;C0449297;C1382187;C2825073;C4554548	\N	\N
307	creat clearance < $nmbr$ ml / min	C0201975;C0439445;C0449297;C1382187;C2825073;C4554548	\N	\N
307	crcl of $nmbr$ - $nmbr$ ml min '  n ( % )	C0439445;C1846718	\N	\N
307	crcl at randomization - ml / min	C0034656;C0439445;C1846718	\N	\N
307	crcl at randomization  ml / min	C0034656;C0439445;C1846718	\N	\N
307	crcl at baseline < $nmbr$ ml / min	C0168634;C0439445;C1442488;C1846718	\N	\N
307	crcl at baseline  ml / min	C0168634;C0439445;C1442488;C1846718	\N	\N
307	crcl > $nmbr$ ml / min	C0439445;C1846718	\N	\N
307	crcl > $nmbr$ - < $nmbr$ ml / min	C0439445;C1846718	\N	\N
307	crcl < $nmbr$ ml / min	C0439445;C1846718	\N	\N
307	crcl ( sd ) ml / min	C0439445;C1846718;C2699239	\N	\N
307	crcl ( ml / min ) at randomization	C0034656;C0439445;C1846718	\N	\N
307	crcl ( ml / min )	C0439445;C1846718	\N	\N
307	crcl  ml / min mean ( sd )	C0439445;C0444504;C1846718;C2347634;C2348143;C2699239	\N	\N
307	crcl  ml / min	C0439445;C1846718	\N	\N
307	crcl  median ( iqr )  ml / min	C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193	\N	\N
307	crcl  mean  ml / min ( ± sd )	C0439445;C0444504;C1846718;C2347634;C2348143;C2699239	\N	\N
307	chronic kidney disease stage : egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0007591;C0439445;C0456533;C1561643;C1739039;C3811844;C3812682;C4553188	\N	\N
307	cgfrby ckd - epi  ml / min / $nmbr$ . $nmbr$ m $nmbr$  median ( iqr )	C0162734;C0369637;C0439445;C0441923;C0549183;C0876920;C1561643;C2347635;C2348144;C2939193;C4281721	\N	\N
307	cgfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
7	bonferroni - adjusted p value  d vs a	C1709380;C1879894	\N	\N
307	baseline ecrq $nmbr$ $nmbr$ to < $nmbr$ ml / min	C0168634;C0439445;C1442488	\N	\N
307	baseline crcl  ml / min	C0168634;C0439445;C1442488;C1846718	\N	\N
307	egfr  mean ( sd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
307	egfr  median ( sd )  ml / min	C0439445;C0549183;C0876920;C1739039;C2347635;C2348144;C2699239;C2939193;C3811844;C3812682	f	592
307	egfr  ml / min	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr  ml / min / bsa	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr  ml / min / m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr  * ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656	f	592
307	egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )  mean ( sd )	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682;C3839656	f	592
307	egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd )	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
307	egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ± sd	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
307	egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( sd )	C0369637;C0439445;C0441923;C1739039;C2699239;C3811844;C3812682	f	592
307	egfr  ml min $nmbr$ $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ ml / min / $nmbr$ . $nmbr$	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ ( $nmbr$ . $nmbr$ % )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % )	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ to < $nmbr$ ml / min  n ( % )	C0439445;C1739039;C3811844;C3812682	f	592
307	egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$	C0439445;C1739039;C3811844;C3812682	f	592
307	baseline egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	f	592
306	men  no . ( % )	C0025266	f	1842
307	baseline ckd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682	\N	\N
307	^ $nmbr$ ml / min	C0439445	\N	\N
307	> l : $nmbr$ hrs : min ( n = $nmbr$ )	C0439393;C1568891	\N	\N
307	> = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	> = $nmbr$ l_ / min	C0439393	\N	\N
307	> = $nmbr$ l / min	C0439393	\N	\N
307	> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923	\N	\N
307	> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	> $nmbr$ to < $nmbr$ ml / min	C0439445	\N	\N
307	> $nmbr$ to < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a	C0040363;C0041260;C0369637;C0439445;C0441923;C1739039;C1883351;C3811844;C3812682	\N	\N
307	> $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	> $nmbr$ ml min ) $nmbr$	C0439445	\N	\N
307	> $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923	\N	\N
307	> $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	> $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923	\N	\N
307	> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	> $nmbr$ ml / min / $nmbr$ . $nmbr$	C0439445	\N	\N
307	> $nmbr$ ml / min ( n = $nmbr$ )	C0439445	\N	\N
307	> $nmbr$ ml / min	C0439445	\N	\N
307	< = $nmbr$ ml / min	C0439445	\N	\N
307	< $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m  $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	< $nmbr$ ml / min — %	C0439445	\N	\N
307	< $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0369637;C0439445;C0441923	\N	\N
307	< $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923	\N	\N
307	< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	< $nmbr$ ml / min / $nmbr$  $nmbr$ m ^	C0369637;C0439445;C0441923	\N	\N
307	< $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	< $nmbr$ ml / min ( n = $nmbr$ )	C0439445	\N	\N
307	< $nmbr$ ml / min	C0439445	\N	\N
307	< $nmbr$ l / min	C0439393	\N	\N
307	< $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	( $nmbr$ - $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923	\N	\N
307	( $ $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923	\N	\N
307	(  $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ – ≤ $nmbr$ ml / min	C0439445	\N	\N
307	$nmbr$ – < $nmbr$ ml / min	C0439445	\N	\N
307	$nmbr$ to o $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0483204	\N	\N
307	$nmbr$ to < $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ to < $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ to < $nmbr$ ml / min / $nmbr$ - $nmbr$	C0439445	\N	\N
307	$nmbr$ to < $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ to < $nmbr$ ml / min ( n = $nmbr$ $nmbr$ )	C0439445	\N	\N
307	$nmbr$ to < $nmbr$ ml / min	C0439445	\N	\N
307	$nmbr$ to $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ ml / min	C0439445	\N	\N
307	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ - < $nmbr$ ml / min	C0439445	\N	\N
307	$nmbr$ - $nmbr$ ml min ) $nmbr$	C0439445	\N	\N
307	$nmbr$ - $nmbr$ ml min  $nmbr$	C0439445	\N	\N
307	$nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923	\N	\N
307	$nmbr$ - $nmbr$ ml / min	C0439445	\N	\N
307	$nmbr$ - $nmbr$ ( < $nmbr$ ml / min )	C0439445	\N	\N
307	$nmbr$ ( $nmbr$ to < $nmbr$ ml / min )	C0439445	\N	\N
307	$nmbr$ ( $ $nmbr$ ml / min )	C0439445	\N	\N
306	women men	C0025266;C0043210	\N	\N
306	sex ( women  men )	C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384	\N	\N
306	sex ( men / women )	C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384	\N	\N
306	sex  men / women  %	C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384	\N	\N
306	ratio of women to men — %	C0025266;C0043210;C0456603;C1547037	\N	\N
306	p ( women vs men )	C0025266;C0043210;C0369773;C2603361	\N	\N
306	p $nmbr$ interaction women vs men	C0025266;C0043210;C0369773;C1704675;C2603361	\N	\N
306	no of events women men *	C0025266;C0043210;C0441471;C3541888	\N	\N
306	ment	C0084844;C1538994	\N	\N
307	> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
306	men ( % )	C0025266	f	1842
306	men ( n  % )	C0025266	f	1842
306	men ( n [ % ] )	C0025266	f	1842
306	men : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l )	C0025266;C0439269;C1532563	f	1842
306	men ( n = $nmbr$ )	C0025266	f	1842
306	men ( n = $nmbr$ vs $nmbr$ )	C0025266	f	1842
306	men ( n 二 $nmbr$ )	C0025266	f	1842
306	men  total ( n = $nmbr$ )	C0025266;C0439175;C0439810	f	1842
306	men  total ( n 二 $nmbr$ )	C0025266;C0439175;C0439810	f	1842
306	men with ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0025266;C3538926	f	1842
306	men : women ( % )	C0025266;C0043210	f	1842
306	men / women	C0025266;C0043210	f	1842
306	men    n   ( % )	C0025266	f	1842
306	no . men	C0025266	f	1842
306	sex  men ( % )	C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384	f	1842
306	low hdl - c ( for men < $nmbr$   mg / dl / for women < $nmbr$   mg / dl )	C0025266;C0043210;C0151691;C0439269	\N	\N
306	high hdl - c ( for men ≥ $nmbr$   mg / dl / for women ≥ $nmbr$   mg / dl )	C0025266;C0043210;C0205250;C0439269;C1299351;C2700149;C3715113;C3887512;C3889660;C4321237;C4522209	\N	\N
306	hemoglobin ( < $nmbr$ men  ， : : $nmbr$ women )	C0019046;C0025266;C0043210	\N	\N
306	hdl < $nmbr$ / $nmbr$ mg / dl ( $nmbr$ . $nmbr$ / $nmbr$ . $nmbr$ mmol / l ) for men / women	C0025266;C0043210;C3642216;C3715113;C3898312	\N	\N
306	gmi ( men )	C0025266	\N	\N
306	gender    n   ( % men )	C0025266;C0079399;C1522384	\N	\N
306	( _ > $nmbr$ . $nmbr$ mmol / l ) hdl - c women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ) men : < $nmbr$ mg / dl	C0025266;C0043210;C3539687;C3715113;C3898312	\N	\N
306	$nmbr$ - $nmbr$ ( men )	C0025266	\N	\N
305	smmse < $nmbr$	\N	\N	\N
305	smmse	\N	\N	\N
305	mmse score *	C0449820;C0451306;C4050231	\N	\N
305	mmse score	C0449820;C0451306;C4050231	\N	\N
305	mmse > $nmbr$	C0451306	\N	\N
305	mmse = mini - mental state examination  adas — cog = alzhei -	C0451306;C3539026	\N	\N
305	mmse < $nmbr$	C0451306	\N	\N
305	mmse ( points )	C0451306;C1552961;C2347617;C3714763	\N	\N
305	mmse $nmbr$ - $nmbr$	C0451306	\N	\N
305	mini - mental state examination  mean ( sd ) d	C0444504;C0451306;C2347634;C2348143;C2699239	\N	\N
305	mini - mental state examination	C0451306	\N	\N
305	mean mmse score	C0451306;C3533236	\N	\N
305	> < $nmbr$ . $nmbr$  < $nmbr$ . $nmbr$  r < mmse = mini - mental	C0205090;C0229992;C0445542;C0451306;C0684010;C2603358	\N	\N
304	recent treatment ( < $nmbr$ months mmf / ggs )	C0039798;C0083765;C0087111;C0209368;C0332185;C0439231;C1522326;C1533734;C1705169;C3538994;C3848524;C3887704	\N	\N
304	mycophenolate mofetil - cyclophosphamide	C0010583;C0209368	\N	\N
304	mycophenolate mofetil	C0209368	\N	\N
304	mmf ( n = $nmbr$ )	C0083765;C0209368;C3848524	\N	\N
303	mn population  n	C0026327;C0026405;C0032659;C1257890;C4285072	\N	\N
303	mn population	C0026327;C0026405;C0032659;C1257890;C4285072	\N	\N
303	mn - na ï ve population	C0026327;C0026405;C0032659;C0042469;C0597484;C1257890;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882	\N	\N
303	cardiac index  l • mn ' • m $nmbr$	C0026327;C0026405;C0369637;C0428776;C0441923;C4285072	\N	\N
303	all non - mn	C0026327;C0026405;C1518422;C4285072	\N	\N
302	mh + crpnorr	C0026514;C2930980	\N	\N
302	cr + mh	C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337	\N	\N
301	titre ( u / ml ) t	C0439340;C0475208;C1880521;C2945590	\N	\N
301	serum total ige  iu / ml	C0439458;C1441420	\N	\N
301	anti - dsdna ( > $nmbr$ iu / ml )  %	C0439458;C0741099	\N	\N
300	type of ml  no . ( % )	C0332307;C0439526;C1547052;C1705224;C3887665	\N	\N
300	treatment of the index ml	C0039798;C0087111;C0439526;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1705224;C2986546;C3538994;C3887665;C3887704	\N	\N
300	quartiles of fgf - $nmbr$ ( ru / ml )	C0016026;C0035970;C0439526;C0919505;C1425796;C1705224;C2828255;C3887665	\N	\N
300	pvr volume  ml  mean ( sd )	C0242852;C0439526;C0444504;C0449468;C0456261;C1419141;C1690016;C1705102;C1705224;C2347634;C2348143;C2699239;C2700258;C3887665	\N	\N
300	pvr  ml	C0242852;C0439526;C0456261;C1419141;C1705224;C3887665	\N	\N
300	pv  ml	C0030840;C0032463;C0439526;C1705224;C3887665	\N	\N
300	prior ml / stroke	C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100	\N	\N
300	prior ml	C0332152;C0439526;C1705224;C2826257;C3887665	\N	\N
300	prior history of ml or ischemic stroke	C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C0948008;C1705224;C1705255;C2004062;C2826257;C3887665	\N	\N
300	prior history ml or stroke	C0019664;C0019665;C0038454;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665;C4554100	\N	\N
300	previous ml ( interaction : p = $nmbr$ . $nmbr$ )	C0205156;C0439526;C1552607;C1704675;C1705224;C3887665	\N	\N
300	previous ml ( before index acs )	C0205156;C0439526;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C1705224;C2986546;C3887665;C4318612	\N	\N
300	previous ml	C0205156;C0439526;C1552607;C1705224;C3887665	\N	\N
300	placebo  $nmbr$ . $nmbr$ ml ( n = $nmbr$ )	C0032042;C0439526;C1696465;C1705224;C1706408;C3887665	\N	\N
300	patients with > $nmbr$ % ■ $nmbr$ ml increase in fev $nmbr$ post - bronchodilator ( % )	C0030705;C0439526;C0442805;C1705224;C2599594;C3714541;C3887665	\N	\N
300	normal or increased gfr ( > $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ )	C0017654;C0205217;C0205307;C0231683;C0369637;C0439166;C0439526;C0441923;C0442805;C1417190;C1424601;C1705224;C2347086;C3815103;C3887665;C4553972	\N	\N
300	nontatal ml	C0439526;C1705224;C3887665	\N	\N
300	nonfatal ml	C0439526;C1705224;C3887665	\N	\N
300	non - fatal ml	C0439526;C1302234;C1518422;C1705224;C1705232;C3887665	\N	\N
300	no prior ml or stroke	C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100	\N	\N
300	no prior ml	C0332152;C0439526;C1705224;C2826257;C3887665	\N	\N
300	ml c	C0439526;C1705224;C3887665	\N	\N
300	ml )	C0439526;C1705224;C3887665	\N	\N
300	ml	C0439526;C1705224;C3887665	\N	\N
7	bonferroni - adjusted p value  c vs a	C1709380;C1879894	\N	\N
300	mild decrease in gfr ( $nmbr$ - $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ )	C0017654;C0369637;C0392756;C0439526;C0441923;C0547047;C1417190;C1424601;C1705224;C2945599;C3815103;C3887665	\N	\N
300	lvesv ( ml )	C0439526;C1705224;C3887665	\N	\N
300	lvedv ( ml )	C0439526;C1705224;C3887665	\N	\N
300	lav ( ml )	C0019682;C0439526;C1705224;C3887665	\N	\N
300	history of ml at baseline	C0019664;C0019665;C0168634;C0262512;C0262926;C0439526;C1442488;C1705224;C1705255;C2004062;C3887665	\N	\N
300	history of ml	C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665	\N	\N
300	high eosinophil subgroup ( > $nmbr$ / ml ) ( n = $nmbr$ )	C0014457;C0439526;C1079230;C1515021;C1705224;C3887665	\N	\N
300	fvc  ml	C0439526;C1705224;C3714541;C3887665	\N	\N
300	fatal chd + nonfatal ml	C0280604;C0439526;C1302234;C1705224;C1705232;C3542407;C3887665	\N	\N
300	fatal / nonfatal ml	C0439526;C1302234;C1705224;C1705232;C3887665	\N	\N
300	decline #   ml · yr − $nmbr$	C0439234;C0439526;C1705224;C3887665	\N	\N
300	contrast used ( ml ) *	C0009924;C0439526;C1273517;C1705224;C1979874;C3887665	\N	\N
300	characteristics of the index ml	C0439526;C0600653;C0918012;C1521970;C1552854;C1637833;C1705224;C2986546;C3887665	\N	\N
300	alvesv ( per ml )	C0439526;C1705224;C3887665	\N	\N
300	alvedv ( per ml )	C0439526;C1705224;C3887665	\N	\N
300	alav ( per ml )	C0439526;C1705224;C3887665	\N	\N
300	adjusted rate of fev $nmbr$   decline ( se )  ml / yr	C0036919;C0439234;C0439526;C0456081;C0871208;C1521828;C1705224;C3714541;C3887665	\N	\N
300	> = $nmbr$ ml / mln	C0439526;C1417190;C1705224;C3815103;C3887665	\N	\N
300	> $nmbr$ ml	C0439526;C1705224;C3887665	\N	\N
300	< $nmbr$ ml	C0439526;C1705224;C3887665	\N	\N
300	* nonfatal ml	C0439526;C1705224;C3887665	\N	\N
300	$nmbr$ to < $nmbr$ ml per $nmbr$ - $nmbr$ m $nmbr$	C0369637;C0439526;C0441923;C1705224;C3887665	\N	\N
300	$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ) §	C0439526;C1705224;C3887665	\N	\N
300	$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ )	C0439526;C1705224;C3887665	\N	\N
300	$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n - $nmbr$ / $nmbr$ )	C0439526;C1705224;C3887665	\N	\N
300	$nmbr$ - $nmbr$ ml / rain	C0034640;C0439526;C1705224;C3887665	\N	\N
299	urine qmax  ml / s	C0042036;C0042037;C0439390;C2963137	\N	\N
299	qmax ( ml / s )	C0439390	\N	\N
299	qmax  ml / s  mean ( sd )	C0439390;C0444504;C2347634;C2348143;C2699239	\N	\N
299	qmax  ml / s	C0439390	\N	\N
299	> $nmbr$ ml / s	C0439390	\N	\N
299	< $nmbr$ ml / s	C0439390	\N	\N
298	mean ( sd ) esr  mm / h *	C0444504;C0456680;C2347634;C2348143;C2699239;C3811131	\N	\N
298	esr ( mm / h )  mean ( sd )	C0444504;C0456680;C2347634;C2348143;C2699239;C3811131	\N	\N
298	esr ( mm / h )	C0456680;C3811131	\N	\N
298	erythrocyte sedimentation rate ( mm / h )	C0456680;C1176468;C1619634	\N	\N
297	triglyceride ( mm	C0041004;C4330985;C4554674	\N	\N
297	total length of implanted stents  mm  mean ( sd )	C0021102;C0439175;C0439810;C0444504;C0449462;C2347634;C2348143;C2699239;C2828363;C4330985;C4554674	\N	\N
297	total back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd	C0004600;C0042815;C0205095;C0439175;C0439810;C0444504;C0460009;C1995000;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
297	subcortical wml load diameter  mm  mean ( sd )	C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674	\N	\N
297	subcortical wml load diameter  mm   mean ( sd )	C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674	\N	\N
297	stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ )	C0184666;C0809949;C4330985;C4554674	\N	\N
297	sokolow - lyon voltage  mm	C0598352;C4330985;C4554674	\N	\N
297	sokolow - lyon ( mm ) *	C4330985;C4554674	\N	\N
297	sokolow - lyon  mm	C4330985;C4554674	\N	\N
297	r wave in avl ( mm )	C0429091;C0449216;C4330985;C4554674	\N	\N
297	ptgada ( mm )	C4330985;C4554674	\N	\N
297	phgada ( mm )	C4330985;C4554674	\N	\N
297	patient global assessment of pain ( vas $nmbr$ - $nmbr$ mm )	C0042815;C4054229;C4330985;C4554674	\N	\N
297	pain vas  $nmbr$ - $nmbr$ mm	C0042815;C4330985;C4554674	\N	\N
297	pain ( $nmbr$ mm vas )	C0042815;C4330985;C4554674	\N	\N
297	pain ( $nmbr$ - $nmbr$ mm vas )	C0042815;C4330985;C4554674	\N	\N
297	pain  mm	C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674	\N	\N
297	pain  $nmbr$ - $nmbr$ mm vas	C0042815;C4330985;C4554674	\N	\N
297	nocturnal back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd	C0042815;C0444504;C1970122;C2347634;C2348143;C2699239;C3536884;C3827561;C4330985;C4554674	\N	\N
297	no stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ )	C0184666;C0809949;C4330985;C4554674	\N	\N
297	mssbp  mm hga	C4330985;C4554674	\N	\N
297	msdbp  mm hga	C4330985;C4554674	\N	\N
297	mean of mean cimt  mean ( sd )  mm	C0444504;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
297	mean of jsw ( mm )	C0444504;C2347634;C2348143;C4330985;C4554674	\N	\N
297	lvdd ( mm )	C4330985;C4554674	\N	\N
7	bonferroni - adjusted p value  b vs a	C1709380;C1879894	\N	\N
7	adjusted p - value for interaction	C0456081;C1704675;C1709380	\N	\N
297	elevation of cardiac biomarker levels or st - seg - ment deviation > $nmbr$ mm — no . / total no . ( % )	C0084844;C0439175;C0439775;C0439810;C0441889;C0702240;C1114722;C1116089;C1271630;C1519133;C1538994;C1705293;C4330985;C4554674	\N	\N
297	deviation  mm	C0012727;C0205419;C1705236;C4330985;C4554674	\N	\N
297	blood pressure  mean ( sd )  mm hgt	C0428886;C2699239;C4330985;C4554674	\N	\N
297	baseline £ std  mm	C0168634;C1442488;C4330985;C4554674	\N	\N
297	baseline ste in worst lead  mm	C0023175;C0168634;C0181586;C1420459;C1442488;C1442948;C1522166;C1522538;C2348269;C3275067;C3811127;C4330985;C4554674	\N	\N
297	baseline sbp ( mm )	C0085805;C0168634;C1442488;C4330985;C4554674	\N	\N
297	baseline ^ ste  mm	C0168634;C1420459;C1442488;C3811127;C4330985;C4554674	\N	\N
297	arterial area ( mm $nmbr$ )	C0003842;C0017446;C0205146;C0221464;C4330985;C4554674	\N	\N
297	> $nmbr$ mm ( n = $nmbr$ )	C4330985;C4554674	\N	\N
297	> $nmbr$ mm	C4330985;C4554674	\N	\N
297	> $nmbr$ . $nmbr$ mm	C4330985;C4554674	\N	\N
297	esr — mm / hr	C3811131;C4330985;C4554674	f	298
297	esr  $nmbr$ - $nmbr$ mm / hour	C0439227;C0564385;C3811131;C4330985;C4554674	f	298
297	platelet count  x $nmbr$ mm $nmbr$	C0032181;C1287267;C4330985;C4554674	f	2385
297	platelets xlooo / mm ^	C0005821;C0443116;C1963076;C4330985;C4554674	f	2385
297	< = $nmbr$ . $nmbr$ mm	C4330985;C4554674	\N	\N
297	< $nmbr$ mm	C4330985;C4554674	\N	\N
297	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mm	C4330985;C4554674	\N	\N
297	$nmbr$ - $nmbr$ mm	C4330985;C4554674	\N	\N
297	$nmbr$ - $nmbr$ . $nmbr$ mm	C4330985;C4554674	\N	\N
296	pre fvc % pred	C0032952;C0044955;C0332152;C0740175;C2257086;C3669034;C3714541	\N	\N
296	pre fev $nmbr$   % pred	C0032952;C0044955;C0332152;C0740175;C2257086;C3669034;C3714541	\N	\N
296	post fev $nmbr$   % pred	C0032952;C0044955;C0687676;C1704687;C3469826;C3714541	\N	\N
296	fev $nmbr$ % pred	C0032952;C0044955;C3714541	\N	\N
296	% pred	C0032952;C0044955	\N	\N
296	$nmbr$ ( fev $nmbr$ < $nmbr$ % pred )	C0032952;C0044955;C3714541	\N	\N
295	predose fvc ( l ) *	C0439565;C3714541;C3812758	\N	\N
295	predose fvc ( l )	C0439565;C3714541;C3812758	\N	\N
295	predose fev ^ at screening	C0220908;C0220909;C0439565;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541;C3812758	\N	\N
295	predose fev / fvc	C0439565;C3714541;C3812758	\N	\N
295	predose fev -  at randomization	C0034656;C0439565;C3714541;C3812758	\N	\N
295	predose fev $nmbr$ ( l ) *	C0439565;C3714541;C3812758	\N	\N
294	st ‐ str ≥ $nmbr$ % pre ‐ ci	C0008107;C0036056;C0332152;C0740175;C2257086;C3259781;C3272372;C3669034	\N	\N
294	received > $nmbr$ prior anti - tnf therapies  n	C0279936;C0332152;C0432633;C1514756;C2826257	\N	\N
294	received $nmbr$ prior anti - tnf therapy  n	C0279936;C0332152;C0432633;C1514756;C2826257	\N	\N
294	prior vka use for > $nmbr$ d  %	C0042153;C0332152;C0457083;C1947944;C2826257	\N	\N
294	prior use of systemic	C0205373;C0332152;C1524063;C2826257	\N	\N
294	prior use of conventional dmards only ( biologic - nai ' ve )  n ( % )	C0042469;C0205171;C0332152;C0439858;C1524063;C1720467;C2826257;C3537218;C3714652;C4055380;C4321495	\N	\N
294	prior use of $ $nmbr$ systemic therapies	C0205373;C0332152;C1514463;C1515119;C1524063;C2826257	\N	\N
294	prior upper gi clinical event	C0203057;C0205210;C0332152;C0441471;C2826257;C4019010	\N	\N
294	prior ugi event	C0332152;C0441471;C0560042;C2826257;C4019010	\N	\N
294	prior peripheralarterialdisease	C0332152;C2826257	\N	\N
294	prior pad	C0182158;C0332152;C0332568;C2826257;C3540603;C3669270;C3814046;C4319657	\N	\N
294	prior oma use ( n = $nmbr$ )	C0042153;C0332152;C0457083;C1947944;C2826257	\N	\N
294	prior oma use	C0042153;C0332152;C0457083;C1947944;C2826257	\N	\N
294	prior om	C0028971;C0332152;C1705272;C2826257	\N	\N
294	prior oad :	C0332152;C2826257	\N	\N
294	prior oac	C0332152;C2826257	\N	\N
294	prior non - cns se	C0036919;C0332152;C1518422;C2826257;C3714787	\N	\N
294	prior ml or stroke at baseline	C0038454;C0168634;C0332152;C0439526;C1442488;C1705224;C2826257;C3887665;C4554100	\N	\N
294	prior mi / stroke	C0038454;C0332152;C2826257;C3810814;C4554100	\N	\N
294	prior medication use  n ( % )	C0240320;C0332152;C2826257	\N	\N
294	prior lower gi clinical event	C0205210;C0332152;C0441471;C0441994;C1548802;C1708130;C2003888;C2826257;C3539617;C4019010;C4050121	\N	\N
294	prior llt	C0332152;C2347090;C2826257	\N	\N
294	prior lipid - lowering agent use	C0042153;C0086440;C0332152;C0457083;C1947944;C2826257	\N	\N
294	prior lgi event	C0332152;C0441471;C2826257;C4019010	\N	\N
294	prior lev use	C0023556;C0042153;C0332152;C0457083;C1947944;C2826257	\N	\N
294	prior lev	C0023556;C0332152;C2826257	\N	\N
294	prior implantable cardiodefibrillator  n ( % )	C0021102;C0332152;C2826257	\N	\N
294	prior immunosuppressive exposure  n ( % )	C0021081;C0274281;C0332152;C0332157;C2826257	\N	\N
294	prior immunosuppressant failurec	C0021081;C0332152;C2826257	\N	\N
294	prior tnfi  n ( % )	C0332152;C2826257	f	2375
294	prior therapy with tnf antagonist  n ( % )	C0231491;C0279936;C0332152;C1448177;C1514463;C2826257	f	2376
294	prior use of synthetic dmards	C0242708;C0332152;C1524063;C1883254;C2826257	f	2377
294	prior use of synthetic dmards  n ( % )	C0242708;C0332152;C1524063;C1883254;C2826257	f	2377
294	with prior mi / stroke ( n = $nmbr$ )	C0038454;C0332152;C2826257;C3810814;C4554100	f	2378
294	ticagrelor pre ‐ hosp ( n = $nmbr$ )	C0332152;C0740175;C1999375;C2257086;C3669034	f	2379
294	prior stroke	C0038454;C0332152;C2826257;C4554100	f	2380
294	prior stroke ( % )	C0038454;C0332152;C2826257;C4554100	f	2380
294	prior stroke ( before index event )	C0332152;C0441471;C0456712;C2826257;C4019010	f	2380
294	prior stroke / mi  n ( % )	C0038454;C0332152;C2826257;C3810814;C4554100	f	2380
294	prior stroke — no . ( % )	C0038454;C0332152;C2826257;C4554100	f	2380
294	prior stroke ( n = $nmbr$ )	C0038454;C0332152;C2826257;C4554100	f	2380
294	prior stroke or tia	C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100	f	2380
294	prior stroke or tia  %	C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100	f	2380
294	prior stroke or tza	C0038454;C0039298;C0332152;C2826257;C4554100	f	2380
294	prior stroke / tia	C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100	f	2380
294	prior tia	C0007787;C0332152;C0917805;C1054154;C2826257	f	2380
294	prior transient ischemic attack	C0007787;C0332152;C0917805;C2826257	f	2380
294	prior pci  %	C0332152;C2826257;C4049621	f	1661
294	prior pci	C0332152;C2826257;C4049621	f	1661
294	prior pci or cabg	C0010055;C0332152;C2826257;C4049621	f	1661
294	prior ptca or pci	C0332152;C2826257;C2936173;C4049621	f	1661
294	prior ptca / pci	C0332152;C2826257;C2936173;C4049621	f	1661
295	study medication  pre - dose	C0013227;C0439565;C0557651;C2603343;C3244316;C3812758;C4284232	f	2383
295	pre - dose	C0439565;C3812758	f	2383
296	prednisone	C0032952	f	2384
296	prednisone use  %	C0032952;C0042153;C0457083;C1947944	f	2384
294	prior immunosuppressant failure	C0021081;C0231174;C0332152;C0680095;C2826257	\N	\N
294	prior hospitalizations  n ( % )	C0019993;C0332152;C2826257	\N	\N
294	prior history of bleeding on oac	C0019080;C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257	\N	\N
294	prior failure of anti - tnf therapy — no . ( % )	C0231174;C0281481;C0332152;C0680095;C2826257	\N	\N
294	prior exposure to topiramate	C0076829;C0274281;C0332152;C0332157;C2826257	\N	\N
294	prior corticosteroid failure only	C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709	\N	\N
294	prior conventional synthetic dmards  n ( % )	C0242708;C0332152;C0439858;C1883254;C2826257	\N	\N
294	prior brachytherapy	C0006098;C0332152;C2826257	\N	\N
294	prior bp use	C0037623;C0042153;C0332152;C0457083;C1415692;C1708288;C1947944;C2826257;C4318478	\N	\N
294	prior bisphosphonate usage	C0012544;C0332152;C0457083;C2267018;C2826257	\N	\N
294	prior aeds  ≥ $nmbr$  n ( % )	C0180309;C0332152;C2826257	\N	\N
294	prior admb	C0332152;C2826257	\N	\N
294	prior	C0332152;C2826257	\N	\N
294	pre svc	C0231957;C0332152;C0740175;C2257086;C3669034	\N	\N
294	pre fvc	C0332152;C0740175;C2257086;C3669034;C3714541	\N	\N
294	pre - treatedforhypertension [ n ( % ) ]	C0332152;C0740175;C2257086;C3669034	\N	\N
294	pre - hospital	C0019994;C0332152;C0740175;C1510665;C2257086;C3669034	\N	\N
294	pre - h	C0033727;C0332152;C0369286;C0441932;C0564385;C0740175;C2257086;C3669034;C4528284	\N	\N
294	pre - bd fvc s $nmbr$ % of predicted	C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145	\N	\N
294	pre - bd fvc < $nmbr$ % of predicted	C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145	\N	\N
294	no prior ugi event	C0332152;C0441471;C0560042;C2826257;C4019010	\N	\N
294	no prior statin ( n = $nmbr$  $nmbr$ )	C0332152;C0360714;C2826257	\N	\N
294	no prior oma use ( n = $nmbr$ )	C0042153;C0332152;C0457083;C1947944;C2826257	\N	\N
294	no prior oma use	C0042153;C0332152;C0457083;C1947944;C2826257	\N	\N
294	no prior llt	C0332152;C2347090;C2826257	\N	\N
294	no prior lgi event	C0332152;C0441471;C2826257;C4019010	\N	\N
294	no prior admc	C0332152;C2826257	\N	\N
294	heparin pre - randomization	C0019134;C0034656;C0332152;C0740175;C0770546;C2257086;C3669034	\N	\N
294	enrollment strata : prior hospitalization	C0019993;C0332152;C1516879;C1696073;C2826257;C3888021	\N	\N
294	duration of prior statin therapy ^	C0332152;C0360714;C0444917;C2826257	\N	\N
294	duration of pre - randomization anticoagulant therapy	C0034656;C0332152;C0740175;C2257086;C2711563;C3669034	\N	\N
294	dissatisfied with / stopped $ $nmbr$ prior systemic therapy because of side effects	C0001688;C0205373;C0332152;C0870433;C0877248;C0879626;C1272691;C1514463;C1515119;C2826257;C4085546	\N	\N
294	dissatisfied with / stopped $ $nmbr$ prior systemic therapies because of side effects	C0001688;C0205373;C0332152;C0870433;C0877248;C0879626;C1272691;C1514463;C1515119;C2826257;C4085546	\N	\N
294	% predicted pre - bd	C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C4050145	\N	\N
293	presence of erosions  n ( % )	C0150312;C0333307;C0392148;C1959609;C3854307	\N	\N
293	presence of dactylitis	C0150312;C0239161;C0392148;C3854307	f	2365
293	presence of angioedema at baseline	C0002994;C0150312;C0168634;C0392148;C1442488;C3854307	f	2366
293	presence of enthesitis  n ( % )	C0150312;C0392148;C1282952;C3854307	f	2367
293	presence of tophi	C0150312;C0221248;C0392148;C3854307	f	2369
293	presence of tophi  n ( % )	C0150312;C0221248;C0392148;C3854307	f	2369
293	presence of honeycombing  $nmbr$ n ( % )	C0150312;C0332468;C0349384;C0392148;C3854307	f	2371
294	$nmbr$ prior tnf antagonist failure  n ( % ) b	C0231174;C0231491;C0332152;C0680095;C2826257;C3887647	f	2372
294	no . of prior tnfi	C0332152;C2826257	f	2373
294	no . of prior aeds  c n ( % )	C0180309;C0332152;C2826257	f	2374
294	no . of prior aedsd	C0332152;C2826257	f	2374
294	no . of prior aeds  n ( % )	C0180309;C0332152;C2826257	f	2374
294	prior anti - tnf exposure	C0274281;C0332152;C0332157;C1448177;C2826257	f	2375
294	prior anti - tnf therapy	C0281481;C0332152;C2826257	f	2375
294	prior anti - tnf therapy — no . ( % )	C0281481;C0332152;C2826257	f	2375
294	# of prior non - tnfi bdmards *	C0332152;C1518422;C2826257	f	2377
294	# of prior bdmards	C0332152;C2826257	f	2377
294	prior cardiovascular event	C0332152;C1320716;C2826257	f	2378
294	prior cardiovascular event  '	C0332152;C1320716;C2826257	f	2378
294	prior cardiovascular event — no . ( % )	C0332152;C1320716;C2826257	f	2378
294	prior cardiovascular history	C0332152;C1880008;C2826257	f	2378
294	patients with a prior mi or stroke at baseline	C0030705;C0038454;C0168634;C0332152;C1442488;C2826257;C3810814;C4554100	f	2378
294	patients without a prior mi or stroke at baseline	C0030705;C0038454;C0168634;C0332152;C1442488;C2826257;C3810814;C4554100	f	2378
294	pre hospital ticagrelor	C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034	f	2379
294	pre - hospital ticagrelor ( n = $nmbr$ )	C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034	f	2379
294	no prior stroke	C0038454;C0332152;C2826257;C4554100	f	2380
294	no prior stroke ( n = $nmbr$ )	C0038454;C0332152;C2826257;C4554100	f	2380
294	no prior stroke / tia	C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100	f	2380
294	prior biologic exposure	C0005515;C0205460;C0274281;C0332152;C0332157;C2826257	f	2381
294	prior biologic use	C0005515;C0042153;C0205460;C0332152;C0457083;C1947944;C2826257	f	2381
294	prior antiinflammatory / antirheumatic products  n ( % )	C0003191;C0003209;C0332152;C1514468;C1515999;C2826257	f	2382
294	prior aspirin	C0004057;C0332152;C2826257	f	1366
294	prior aspirin use	C0004057;C0042153;C0332152;C0457083;C1947944;C2826257	f	1366
292	prostate biopsy	C0194804	\N	\N
291	proportion of days without heartburn at week $nmbr$  percentage	C0018834;C0332174;C0439165;C0439228;C0439230;C1549488;C1561533;C1709707	\N	\N
291	percentages of patients with event	C0030705;C0439165;C0441471;C1549488;C1561533;C4019010	\N	\N
291	percentages	C0439165;C1549488;C1561533	\N	\N
291	percentage points	C0439165;C1549488;C1552961;C1561533;C2347617;C3714763	\N	\N
291	percentage of patients with event	C0030705;C0439165;C0441471;C1549488;C1561533;C4019010	\N	\N
291	percentage of p	C0439165;C1549488;C1561533	\N	\N
291	percentage of fevj reversibility	C0439165;C0449261;C1549488;C1561533	\N	\N
291	percentage of females	C0086287;C0439165;C1549488;C1561533	\N	\N
291	percentage of days without heartburn	C0018834;C0439165;C0439228;C1549488;C1561533	\N	\N
291	percentage of bsa involved	C0439165;C1314939;C1549488;C1561533	\N	\N
291	percentage	C0439165;C1549488;C1561533	\N	\N
291	mean percentage of nights without heartburn	C0018834;C0240526;C0439165;C0444504;C1549488;C1561533;C2347634;C2348143	\N	\N
290	within $nmbr$ h after first procedure	C0033727;C0184661;C0205435;C0369286;C0441932;C0564385;C1279901;C2700391;C3274430;C3539779;C4528284	\N	\N
290	with dm ( n proactive intervention ( n = $nmbr$ a )	C0011816;C0184661;C0886296;C1273869;C3250443	\N	\N
290	unsuccessful procedure	C0184661;C1272705;C2700391;C3274430;C3539779	\N	\N
290	time  mean ( sd )  min procedure	C0040223;C0184661;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C2700391;C3274430;C3539779;C3541383;C3813700	\N	\N
290	procedures in the hospital — no . ( % )	C0019994;C0025664;C0184661;C1510665;C2700391;C3538935	\N	\N
290	procedures after discharge — no . ( % )	C0012621;C0025664;C0030685;C0184661;C2700391;C2926602;C3538935	\N	\N
290	procedure * *	C0184661;C2700391;C3274430;C3539779	\N	\N
290	procedure	C0184661;C2700391;C3274430;C3539779	\N	\N
290	proactive intervention ( n = $nmbr$ a )	C0184661;C0886296;C1273869	\N	\N
290	pro - active intervention	C0033382;C0184661;C0205177;C0523852;C0886296;C1273869;C2987124;C3853793;C3888249	\N	\N
290	prior carotid intervention	C0184661;C0332152;C0741968;C0886296;C1273869;C2826257	\N	\N
290	previous intervention ( % )	C0184661;C0205156;C0886296;C1273869;C1552607	\N	\N
290	multivessel intervention  n ( % )	C0184661;C0886296;C1273869	\N	\N
290	intervention group ( n = $nmbr$ )	C0184661;C0441848;C0886296;C1273869	\N	\N
290	intervention .	C0184661;C0886296;C1273869	\N	\N
290	intervention ( n = $nmbr$ )	C0184661;C0886296;C1273869	\N	\N
290	intervention	C0184661;C0886296;C1273869	\N	\N
290	interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . lisinopril vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .	C0001779;C0008294;C0008976;C0011847;C0011849;C0015385;C0019664;C0019665;C0019993;C0034510;C0040363;C0041260;C0051696;C0065374;C0079399;C0085096;C0184661;C0205543;C0262512;C0262926;C0280604;C0332283;C0369773;C0441994;C0581603;C1522384;C1548802;C1704436;C1704675;C1705255;C1706779;C1709380;C1719822;C1883351;C2003888;C2004062;C2603361;C2700391;C3274430;C3539779;C3542407;C3853635;C4281991	\N	\N
290	first procedure	C0184661;C0205435;C1279901;C2700391;C3274430;C3539779	\N	\N
290	experimental intervention group ( n = $nmbr$ )	C0184661;C0441848;C0886296;C1273869;C1517586	\N	\N
290	cystoscopic procedure	C0184661;C0560573;C2700391;C3274430;C3539779	\N	\N
290	baseline procedure  n ( % )	C0168634;C0184661;C1442488;C2700391;C3274430;C3539779	\N	\N
-10	potential predictor	C2698872;C3245505	\N	\N
288	pulmonary function tests  % of predicted	C0024119;C0681842;C1882327;C2598152	\N	\N
288	predicted normal ) t	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972	\N	\N
288	predicted normal ( % )	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972	\N	\N
288	prebronchodilator fev $nmbr$ ( % predicted normal ) t	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C2599602;C3714541;C4553972	\N	\N
288	postbronchodilator fevj ( % predicted )	C0681842;C1882327;C2599594	\N	\N
288	pef  post - bronchodilator  % predicted normal	C0030771;C0205307;C0231683;C0439166;C0681842;C1518922;C1542834;C1882327;C2347086;C2599594;C4553972	\N	\N
288	mean ( sd ) % of predicted normal fev $nmbr$	C0444504;C0520835;C0681842;C1882327;C2347634;C2348143;C2699239	\N	\N
288	mean ( sd ) % of predicted normal eevi	C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C4553972	\N	\N
288	fevj % predicted !  t	C0681842;C1882327	\N	\N
288	fev $nmbr$   % of predicted normal post - bronchodilator	C0520835;C0681842;C1882327;C2599594	\N	\N
288	fev $nmbr$ ( % predicted normal )	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C3714541;C4553972	\N	\N
288	fev $nmbr$ % predicted normal	C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C3714541;C4553972	\N	\N
288	diffusion capacity of the lung for carbon monoxide  % predicted !	C0007018;C0231971;C0681842;C1882327;C4520712	\N	\N
288	b postbronchodilator fevl ( % predicted )	C0681842;C1882327;C2599594	\N	\N
288	> $nmbr$ % predicted to < $nmbr$ % predicted	C0681842;C1882327	\N	\N
288	> $nmbr$ % predicted	C0681842;C1882327	\N	\N
288	< $nmbr$ % predicted	C0681842;C1882327	\N	\N
77	mercaptopurine	C0000618	\N	\N
290	non pci procedure	C0184661;C1518422;C2700391;C3274430;C3539779;C4049621	f	1661
290	percutaneous intervention	C0184661;C0522523;C0886296;C1273869	f	1661
290	pci procedure	C0184661;C2700391;C3274430;C3539779;C4049621	f	1661
290	coronary intervention	C0018787;C0184661;C0886296;C1273869	f	1661
290	coronary angiography and intervention	C0085532;C0184661;C0886296;C1273869;C1548829	f	1661
293	baseline presence of nasal polyps	C0027430;C0150312;C0168634;C0392148;C1442488;C3854307	f	2368
293	history / presence of tophi	C0019664;C0019665;C0150312;C0221248;C0262512;C0262926;C0392148;C1705255;C2004062;C3854307	f	2369
288	% predicted value ( sd )	C0681842;C1522609;C1882327;C2699239	\N	\N
288	% predicted	C0681842;C1882327	\N	\N
288	% of predicted normal value *	C0086715;C0681842;C1882327	\N	\N
288	% of predicted	C0681842;C1882327	\N	\N
287	time from onset of symptoms to presentation — hr	C0449450;C1320528	\N	\N
287	syndesmophyte present  n ( % )	C0150312;C0221690;C0449450	\N	\N
287	presentation to tertiary care hospital — %	C0337954;C0449450	\N	\N
287	presentation *	C0449450	\N	\N
287	present smokerc	C0150312;C0449450	\N	\N
287	present at screening	C0150312;C0220908;C0220909;C0449450;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
287	present ( £ $nmbr$ mg / dl )	C0150312;C0439269;C0449450	\N	\N
287	present ( > $nmbr$ mg / dl )	C0150312;C0439269;C0449450	\N	\N
287	present	C0150312;C0449450	\N	\N
287	number ( s ) of features present	C0150312;C0237753;C0449450;C0449788;C1521970;C1706388;C2346469;C2348519	\N	\N
287	not present at screening  but within previous year	C0150312;C0205156;C0220908;C0220909;C0439234;C0439508;C0449450;C1518422;C1552607;C1698960;C1710031;C1710032;C1710477;C2348164	\N	\N
287	factor present	C0150312;C0449450;C1521761;C2827422	\N	\N
287	dx at presentation  n ( % )	C0449450;C3538936	\N	\N
286	high - sensitivityc - reactive protein  mg / l	C0033684;C0205250;C0205332;C0439268;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
286	high - sensitivity c - reactive protein — mg / liter |	C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761	\N	\N
286	high - sensitivity c - reactive protein stratification	C0006560;C1413716;C1441604;C1514983;C4048285	\N	\N
286	high - sensitivity c - reactive protein  mg / ltt	C0006560;C0024671;C0026410;C0439269;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761	\N	\N
286	das $nmbr$ ( c - reactive protein )	C0006560;C0051767;C0057671;C1413716;C4048285	\N	\N
286	c - reactive proteinc	C0205332	\N	\N
286	c - reactive protein — mg / literj	C0006560;C0024671;C0026410;C0439269;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761	\N	\N
286	c - reactive protein ( mg / dl_ )	C0006560;C0439269;C1413716;C4048285	\N	\N
286	c - reactive protein ( mg / dl )	C0006560;C0439269;C1413716;C4048285	\N	\N
286	c - reactive protein  u / l	C0006560;C0439339;C1413716;C4048285	\N	\N
286	c - reactive protein	C0006560;C1413716;C4048285	\N	\N
286	batellna c - reective protein	C0033684	\N	\N
285	proteinuria ( > $nmbr$ g / $nmbr$ h )  %	C0033687;C0560020;C1962972;C4554346	\N	\N
285	proteinuria $nmbr$ ( g / day )	C0033687;C0439417;C1962972;C4554346	\N	\N
285	protein in urine    ≥ $nmbr$ +	C0033687	\N	\N
284	oriental	C0078988;C0699027	\N	\N
284	oretal	\N	\N	\N
284	asian or oriental	C0078988;C0699027	\N	\N
284	asian / oriental	C0078988;C0699027	\N	\N
283	origin [ n ( % ) ]	C0079946;C0439659;C1550512	\N	\N
282	worsened	C1457868;C4084902	\N	\N
282	incident or worsening nephropathy	C0022658;C0332271;C1457868;C1546960;C1551358	\N	\N
282	hf symptom worsened	C0018488;C1313497;C1457868;C1457887;C1538440;C3273279;C3854129;C4084902	\N	\N
282	copd worsening	C0024117;C0332271;C1412502;C1457868;C1546960;C3714496	\N	\N
281	post - menopausal without hormone replacement	C0019930	\N	\N
281	post - menopausal with hormone replacement	C0019930	\N	\N
280	hormones	C0019932	\N	\N
280	estrogen - containing hormones	C0014939;C0019932;C0332256;C2700400;C2936882;C4542544	\N	\N
279	orthopnea  frequent / continuous	C0085619;C0332183;C0549178	\N	\N
279	orthopnea  ( % )	C0085619	\N	\N
279	orthopnea	C0085619	\N	\N
278	lipid trial participants - n ( % )	C0023779;C1997894;C2242969	\N	\N
278	lipid trial participants #	C0023779;C1997894;C2242969	\N	\N
278	lipid trial participants  no . ( % )	C0023779;C1997894;C2242969	\N	\N
278	lipid trial participants	C0023779;C1997894;C2242969	\N	\N
278	lioid trial participants	C1997894;C2242969	\N	\N
278	limited i -	C0021966;C0221138;C0439801;C2674459;C3542948;C4050251	\N	\N
278	limited	C0439801;C2674459;C3542948;C4050251	\N	\N
277	albiglutide events / patients ( %	C0030705;C0441471;C2607479;C3541888	\N	\N
277	albiglutide ( n = $nmbr$ )	C2607479	\N	\N
276	visits $nmbr$ e $nmbr$	C0545082;C1512346;C2826704	\N	\N
276	visit	C0545082;C1512346;C2826704	\N	\N
276	randomisation visit ( baseline )	C0034656;C0168634;C0545082;C1442488;C1512346;C2826704	\N	\N
276	number of er visits in last year prior to baseline	C0168634;C0237753;C0439234;C0439508;C0449788;C0545082;C1442488;C1512346;C2826704;C3810541;C3811131	\N	\N
276	no . with visit	C0545082;C1512346;C2826704	\N	\N
276	last study visit	C0545082;C0557651;C1512346;C1517741;C2603343;C2826704	\N	\N
276	er visit	C0545082;C1512346;C2826704;C3810541;C3811131	\N	\N
276	ed visit related to exacerbation  n ( % )	C0439849;C0445223;C0545082;C1512346;C2826704;C3538926;C4086268	\N	\N
276	ed severity  visit $nmbr$ * *	C0439793;C0522510;C0545082;C1512346;C2826704;C3538926	\N	\N
276	ed duration  visit $nmbr$ * *	C0449238;C0545082;C1512346;C2826704;C2926735;C3538926	\N	\N
274	dip joint arthritis	C0003864;C0932510;C4552845	\N	\N
279	orthopaedic	C0029355	f	-10
281	thyroid hormone	C0040135;C4522017	f	-10
286	probenecid	C0033209	f	-10
276	visit $nmbr$ blood pressures :	C0545082;C1272641;C1512346;C2826704	f	15
276	types of antihypertensive medications at last visit   §	C0003364;C0332307;C0545082;C1512346;C1517741;C2826704	f	1579
283	stroke of atherosclerotic origin	C0038454;C0079946;C0333482;C0439659;C1550512;C4554100	f	336
287	angioedema present  n ( % ) {	C0002994;C0150312;C0449450	f	2364
287	angioedema present  n ( % ) $nmbr$	C0002994;C0150312;C0449450	f	2364
287	dm present	C0011816;C0150312;C0449450;C3250443	f	909
274	arthritis type *	C0003864;C0332307;C1547052;C4552845	\N	\N
274	arthritis characteristics	C0003864;C1521970;C4552845	\N	\N
274	arthritis	C0003864;C4552845	\N	\N
273	pharyngitis	C0031350;C4553308	\N	\N
273	nasopharyngitis	C0027441	\N	\N
272	rhinitis	C0035455	\N	\N
272	allergic rhinitis — no . ( % )	C1334103;C2607914;C4552864	\N	\N
272	allergic rhinitis duration  mean ± sd  y *	C0444504;C0449238;C1334103;C2347634;C2348143;C2607914;C2699239;C2926735;C4552864	\N	\N
272	allergic rhinitis	C1334103;C2607914;C4552864	\N	\N
271	randomised patients with enthesitis at baselinet	C0030705;C1282952	\N	\N
271	patients with enthesitis at week $nmbr$  n ( % )	C0030705;C0332174;C0439230;C1282952	\N	\N
271	patients with enthesitis at baseline  no .	C0030705;C0168634;C1282952;C1442488	\N	\N
271	patients with enthesitis  no . ( % )	C0030705;C1282952	\N	\N
271	patients with enthesitis  n ( % )	C0030705;C1282952	\N	\N
271	patients with enthesitis	C0030705;C1282952	\N	\N
271	patients with $ $nmbr$ dactylitis digit at week $nmbr$ enthesitis	C0030705;C0332174;C0439230;C1282952;C3863761	\N	\N
271	enthesitis score at baseline  median ( iqr ) week $nmbr$	C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1282952;C1442488;C2347635;C2348144;C2939193;C4050231	\N	\N
271	enthesitis score *	C0449820;C1282952;C4050231	\N	\N
271	enthesitis  n ( % )	C1282952	\N	\N
271	enthesitis  % §	C1282952	\N	\N
271	enthesitis	C1282952	\N	\N
271	% improvement in enthesitis score at week $nmbr$  n	C0332174;C0439230;C0449820;C1282952;C2986411;C4050231	\N	\N
270	pancolitis	C0868908	\N	\N
270	extensive / pancolitis	C0205231;C0868908	\N	\N
269	spondylitis	C0038012	\N	\N
269	randomised patients with spondylitis at baseline  n	C0030705;C0038012;C0168634;C1442488	\N	\N
268	chronic bronchitis ( n = $nmbr$ )	C0008677	\N	\N
268	chronic bronchitis ( itt ) ( n = $nmbr$ )	C0008677	\N	\N
268	chronic bronchitis ( % )	C0008677	\N	\N
268	chronic bronchitis !	C0008677	\N	\N
268	chronic bronchitis	C0008677	\N	\N
268	bronchitis	C0006277	\N	\N
267	diagnostic catheterization	C0596429	\N	\N
267	cardiac catheterization	C0018795	\N	\N
266	ambition	C0870128	\N	\N
265	toast classification	C1710306;C4521230	\N	\N
265	patient classification	C0008902;C0008903;C0030705;C0678229	\N	\N
265	pah classification — no . ( % )	C0008902;C0008903;C0030123;C0678229;C3203102;C4284467	\N	\N
265	pah classification	C0008902;C0008903;C0030123;C0678229;C3203102;C4284467	\N	\N
265	classification of af  no . ( % )	C0008902;C0008903;C0344434;C0678229;C4049859	\N	\N
264	heavy calcification	C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558	\N	\N
264	calcification  n ( % )	C0006660;C0006663;C0175895;C1533591;C1879982;C2242558	\N	\N
263	intermittent claudication	C0021775	\N	\N
263	claudication only	C0021775;C0205171;C0311395;C1456822;C1720467	\N	\N
263	claudication ( fontaine class > $nmbr$ )	C0021775;C0311395;C0456387;C1456822;C1518526;C1705943	\N	\N
263	claudication	C0021775;C0311395;C1456822	\N	\N
262	dcct a $nmbr$ c	\N	\N	\N
262	ccv history / condition at baseline	C0168634;C0683519;C1442488	\N	\N
262	ccv history / condition	C0683519	\N	\N
261	medications in the hospital after randomization — no . ( % )	C0013227;C0019994;C0034656;C0802604;C1510665;C2598133;C4284232	\N	\N
261	in - hospital medication	C0013227;C0019994;C1510665;C3244316;C4284232	\N	\N
261	in - hospital	C0019994;C1510665	\N	\N
260	hospitalized pneumonia events  n	C0032285;C0441471;C0701159;C3541888	\N	\N
260	hospitalized angina	C0002962;C0701159	\N	\N
260	hospitalized !	C0701159	\N	\N
260	hospitalized	C0701159	\N	\N
258	time to death due to pah or hospitalization due to pah up to the end of the treatment periodd	C0019993;C0030123;C0039798;C0087111;C0444930;C0547043;C0678226;C1301931;C1522326;C1533734;C1705169;C2746065;C3203102;C3538994;C3887704;C4284467	\N	\N
268	sinusitis	C0037199;C4553555	f	1838
268	synovitis	C0039103	f	1839
270	tendonitis	C0039503	f	-10
271	uniti - $nmbr$	\N	f	-10
271	uveitis	C0042164;C1963266	f	-10
271	im - uniti	\N	f	-10
271	bursitis	C0006444	f	-10
272	cystitis	C0010692;C0600041;C1963088	f	-10
272	osteitis	C0029400	f	-10
259	hospitalisation for heart failure	C3898876	f	12
259	required hospitalization	C1708385	f	12
261	pci - hospital	C0019994;C1510665;C4049621	f	1661
261	community hospital	C0020003	f	2361
259	hospitalization for heart failure within previous $nmbr$ mo — no . ( % )	C0026544;C0205156;C0332177;C1552607;C3898876	f	824
259	previous hospitalization for heart failure	C0205156;C1552607;C3898876	f	824
259	cardiovascular death / hospitalization for heart failure	C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775	f	12
259	hospitalization for heart failure	C3898876	f	12
261	community hospital ( % )	C0020003	f	2361
261	community hospital  n ( % )	C0020003	f	2361
265	gold classification	C0008902;C0008903;C0018026;C0678229;C1304897	f	213
265	classification of epilepsy type  n ( % )	C0008902;C0008903;C0014544;C0332307;C0678229;C1547052	f	2362
265	diabetes mellitus classification	C0008902;C0008903;C0011849;C0678229	f	907
266	infliximab combination therapy	C0009429;C0205195;C0556895;C0666743;C1947911;C3811910;C4076075	f	154
266	combination therapy * *	C0009429;C0556895	f	2363
266	combination therapy  n = $nmbr$	C0009429;C0556895	f	2363
266	combination therapy ( n = $nmbr$ )	C0009429;C0556895	f	2363
267	cardiac catheterisation or pci for index event	C0018795;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621	f	1661
258	medical therapy during index hospitalization — %	C0019993;C0418981;C0600653;C0918012;C1552854;C1637833;C2986546	\N	\N
257	ct ratio > $nmbr$ . $nmbr$	C0007673;C0456603;C1547037;C3540513;C3813556;C3888140	\N	\N
257	ct ratio ( % )	C0007673;C0456603;C1547037;C3540513;C3813556;C3888140	\N	\N
257	ct + tt	C0007673;C1452561;C3540513;C3813556;C3888140;C4554543	\N	\N
257	ct	C0007673;C3540513;C3813556;C3888140	\N	\N
256	icd or crt - d	C0021122	\N	\N
256	icd / crt - d  n ( % )	C0021122	\N	\N
256	crt - p + d  n ( % )	\N	\N	\N
256	crt - p	\N	\N	\N
256	crt - d	\N	\N	\N
256	crt	\N	\N	\N
255	it $nmbr$ . $nmbr$	\N	\N	\N
255	copd assessment test ( cat ) score	C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282	\N	\N
255	comparison : cat . $nmbr$ vs . cat . $nmbr$	C0007450;C0325090;C0524517;C1443200;C1707455;C3665481;C4050461;C4284282	\N	\N
255	cat total score $nmbr$	C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282	\N	\N
255	cat total score	C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282	\N	\N
255	cat scoreff	C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282	\N	\N
255	cat score category	C0007450;C0325090;C0449820;C0524517;C0683312;C1443200;C3665481;C3889287;C4050231;C4050461;C4284282	\N	\N
255	cat score  mean ( sd )	C0007450;C0325090;C0444504;C0449820;C0524517;C1443200;C2347634;C2348143;C2699239;C3665481;C4050231;C4050461;C4284282	\N	\N
255	cat score	C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282	\N	\N
255	cat > = $nmbr$ ( n = $nmbr$  $nmbr$ )	C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282	\N	\N
255	cat > = $nmbr$	C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282	\N	\N
255	cat > $nmbr$	C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282	\N	\N
255	cat < $nmbr$	C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282	\N	\N
255	cat . $nmbr$ n / n ( % )	C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282	\N	\N
255	$nmbr$ % cit	C0008864;C0523573;C1427027;C4553421	\N	\N
254	p value ( on vs off omt )	C1709380	\N	\N
254	on omt ( n = $nmbr$ )	\N	\N	\N
254	on omt	\N	\N	\N
254	oma / oat ( n   =   $nmbr$ )	C0028753;C0331496;C0939905;C3539067;C3897364	\N	\N
254	oma / oat	C0028753;C0331496;C0939905;C3539067;C3897364	\N	\N
254	oat ( n   =   $nmbr$ )	C0028753;C0331496;C0939905;C3539067;C3897364	\N	\N
254	oat	C0028753;C0331496;C0939905;C3539067;C3897364	\N	\N
253	zt = $nmbr$	\N	\N	\N
253	ra ndosii zat ion	C0022023;C1700702;C3538806;C4048756	\N	\N
252	without dvt dvt alone	C0149871;C0205171;C0439044;C0679994;C2926618;C3899446	\N	\N
252	treatment period index dvt : event	C0039798;C0087111;C0149871;C0439531;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1948053;C2926618;C2986546;C3538994;C3887704;C3899446;C4019010	\N	\N
252	only dvt	C0149871;C0205171;C1720467;C2926618;C3899446	\N	\N
252	locafon of index dvt	C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446	\N	\N
252	kheeatne index dvt	C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446	\N	\N
252	dvt only	C0149871;C0205171;C1720467;C2926618;C3899446	\N	\N
252	dvt	C0149871;C2926618;C3899446	\N	\N
252	concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % )	C0149871;C0168634;C0521115;C0669479;C0754710;C1442488;C2926618;C3899446	\N	\N
252	concomitant dvt  n ( % )	C0149871;C0521115;C2926618;C3899446	\N	\N
252	acute dvt study	C0149871;C0205178;C0557651;C2603343;C2926618;C3899446	\N	\N
251	tt	C1452561;C4554543	\N	\N
251	tgt	C1421391;C1428265;C4321338	\N	\N
251	low tt < $nmbr$ . $nmbr$ ( n = $nmbr$ )	C0205251;C1452561;C1550472;C3890211;C4048187;C4321351;C4522223;C4554543	\N	\N
250	p value by gt	C1435727;C1704693;C1709380;C2697657	\N	\N
250	gt + tt	C1435727;C1452561;C1704693;C2697657;C4554543	\N	\N
250	gt	C1435727;C1704693;C2697657	\N	\N
249	psa ‐ modified shs of hands and feet	C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737	\N	\N
249	psa - modified shs of hands & feet $nmbr$ ( $nmbr$ - $nmbr$ )	C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737	\N	\N
257	ct findings	C0007673;C2607943;C2926606;C3539655;C3540513;C3813556;C3888140	f	2357
258	hospitalisation	C0019993	f	2358
258	hospitalization	C0019993	f	2358
258	hospitalization for	C0019993	f	2358
258	hospitalization for / due to	C0019993	f	2358
258	hospitalizations	C0019993	f	2358
258	hospitalization  n ( % )	C0019993	f	2358
258	hospitalizations  n	C0019993	f	2358
258	hospitalization stratum  n ( % )	C0019993	f	2358
258	hf hospitalization	C0018488;C0019993;C1313497;C1538440;C3273279	f	2359
258	hf hospitalizations  median ( iqr )	C0018488;C0019993;C0549183;C0876920;C1313497;C1538440;C2347635;C2348144;C2939193;C3273279	f	2359
258	hospitalization for hf	C0018488;C0019993;C1313497;C1538440;C3273279	f	2359
258	prior hf hospitalization	C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279	f	2359
258	prior hf hospitalization ( n = $nmbr$ )	C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279	f	2359
258	prior hospitalization for hf  %	C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279	f	2359
258	hospitalization for unstable ap	C0002680;C0019993;C0443343;C1883468;C3887950	f	2360
258	previous hospitalization for unstable angina	C0002965;C0019993;C0205156;C1552607	f	2360
258	pci during index hospitalization	C0019993;C0600653;C0918012;C1552854;C1637833;C2986546;C4049621	f	1661
249	msfc timed $nmbr$ - foot walk test .	C0016504;C0347981;C0392761;C2346504;C2348613;C2348704;C4277740	\N	\N
249	feet	C0016504;C0347981	\N	\N
248	patients ( ft )	C0030705;C1881534;C3890579	\N	\N
248	> $nmbr$ ft	C1881534;C3890579	\N	\N
248	< $nmbr$ ft	C1881534;C3890579	\N	\N
248	$nmbr$ - $nmbr$ ft	C1881534;C3890579	\N	\N
247	rest ofworld	C0035253;C1622890	\N	\N
247	rest ofthe world	C0035253;C1622890;C2700280	\N	\N
247	rest of world n z $nmbr$	C0035253;C1622890;C2700280	\N	\N
247	rest of world	C0035253;C1622890;C2700280	\N	\N
247	rest of the world	C0035253;C1622890;C2700280	\N	\N
247	rest - of - world ( n = $nmbr$ )	C0035253;C1622890;C2700280	\N	\N
246	st - $nmbr$ ( ng / ml )	C0036056;C0439275;C3272372	\N	\N
246	st -	C0036056;C3272372	\N	\N
246	st +	C0036056;C3272372	\N	\N
246	st ( arc definite only )	C0036056;C0205171;C0439544;C1704787;C1720467;C3272372	\N	\N
246	st	C0036056;C3272372	\N	\N
246	key secondary end point : st	C0036056;C3272372;C4528314	\N	\N
246	death / st	C0011065;C0036056;C1306577;C3272372;C4082313;C4552775	\N	\N
246	death / mi / idr / st	C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775	\N	\N
246	death  mi  idr  st  or gusto mod / sev bleeding	C0011065;C0011860;C0019080;C0036056;C0439793;C0458216;C1306577;C2983285;C3272372;C3810814;C4082313;C4552775	\N	\N
246	death  mi  idr  st  or any timi bleeding	C0011065;C0019080;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775	\N	\N
246	death  mi  idr  or st	C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775	\N	\N
246	copd medication taken for at least $nmbr$ months before st	C0013227;C0024117;C0036056;C0439231;C1412502;C1883727;C3244316;C3272372;C3714496;C4284232	\N	\N
246	> $nmbr$ st and < $nmbr$ nd quartile	C0036056;C2828255;C3272372	\N	\N
246	< $nmbr$ st quartile	C0036056;C2828255;C3272372	\N	\N
246	$nmbr$ st < $nmbr$ . $nmbr$	C0036056;C3272372	\N	\N
246	$nmbr$ st : $nmbr$ - $nmbr$ . $nmbr$ pmol / l	C0036056;C0439284;C3272372	\N	\N
246	$nmbr$ days definite st	C0036056;C0439228;C0439544;C1704787;C3272372	\N	\N
246	$nmbr$ days composite of death / new mi / urgent revascularization and definite st	C0011065;C0036056;C0205199;C0439544;C0439609;C0581603;C1306577;C1547335;C1704787;C3272275;C3272372;C3810814;C4082313;C4552775;C4689466	\N	\N
245	post svc	C0231957;C0687676;C1704687;C3469826	\N	\N
245	post hoc analysis	C0002778;C0687676;C0936012;C1524024;C1704687;C3469826	\N	\N
244	post - mi	C0856742	\N	\N
243	mostly satisfied	C0205393;C0242428;C0750554;C4049977;C4084799	\N	\N
242	trend / het . test	C0022885;C0039593;C0392366;C0456984;C0898753;C1335803;C1515976;C1521798;C1704827;C3831328;C4318744;C4554533	\N	\N
242	test for trend	C0022885;C0039593;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533	\N	\N
242	test for interaction between treatment and race	C0022885;C0034510;C0039593;C0039798;C0087111;C0392366;C0456984;C1515976;C1522326;C1533734;C1704675;C1705169;C1706779;C3538994;C3831328;C3853635;C3887704;C4318744	\N	\N
242	test for interaction	C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744	\N	\N
242	ppg post - meal test  mmol / l	C0022885;C0039593;C0376674;C0392366;C0456984;C1418888;C1515976;C1532563;C3831328;C4318744	\N	\N
242	positive orthostatic test }	C0022885;C0039593;C0231472;C0392366;C0439178;C0456984;C1446409;C1514241;C1515976;C2825490;C3812269;C3831328;C4318744	\N	\N
242	positive cu index test  z n ( % )	C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744	\N	\N
242	positive cu index test	C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744	\N	\N
242	orthostatic test *	C0022885;C0039593;C0231472;C0392366;C0456984;C1515976;C3831328;C4318744	\N	\N
242	likelihood test	C0022885;C0033204;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744	\N	\N
242	laboratory tests	C0022885	\N	\N
242	laboratory testing	C0022885	\N	\N
242	heterogeneity test	C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C3831328;C4318744	\N	\N
242	heterogeneity / trend test	C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533	\N	\N
243	most frequent infections	C0205393;C0239998	f	2353
243	mostly dissatisfied	C0205393;C0750554;C0870433;C4085546	f	2354
244	timi flow grade $nmbr$ of mi culprit vessel post ‐ pci	C0005847;C0441800;C0856742;C0919553;C3244287;C3272266;C4049621	f	2355
245	post fvc	C0687676;C1704687;C3469826;C3714541	f	680
245	fev $nmbr$ / fvc  post - albuterol  %	C0001927;C0687676;C1704687;C3469826;C3714541	f	680
245	post - cabg	C0010055;C0687676;C1704687;C3469826	f	389
246	st - t wavett	C0036056;C3272372	f	2356
246	st - t wave  n ( % )	C0036056;C0429103;C3272372	f	2356
246	st - t wave  no . ( % )	C0036056;C0429103;C3272372	f	2356
246	st - t waveft	C0036056;C3272372	f	2356
246	st - t wave changes	C0036056;C0392747;C0429103;C0443172;C1705241;C3272372;C4319952	f	2356
246	st / t wave	C0036056;C0429103;C3272372	f	2356
246	st - t wave abnormality d	C0036056;C1839341;C3272372	f	2356
246	st ‐ str ≥ $nmbr$ % post pci	C0036056;C0687676;C1704687;C3272372;C3469826;C4049621	f	2356
246	st change > $nmbr$ mm	C0036056;C0392747;C0443172;C1705241;C3272372;C4319952;C4330985;C4554674	f	2356
246	st - segment deviation > $nmbr$ mm — no . / total no . ( % )	C0012727;C0036056;C0205419;C0429029;C0429066;C0439175;C0439810;C0441635;C1114722;C1116089;C1705236;C3272372;C4330985;C4554674	f	2356
246	triglycerides $nmbr$ st third	C0036056;C0041004;C0205437;C3272372	f	209
247	aapo $nmbr$ at rest  mm hg	C0035253;C0439475;C1622890	f	-10
247	pao $nmbr$ at rest  mm hg	C0035253;C0232555;C0439475;C1423784;C1427155;C1622890;C4318615	f	-10
242	dfisher ' s exact test .	C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744	\N	\N
242	cu index test  n ( % ) $nmbr$	C0022885;C0039593;C0392366;C0456984;C0600653;C0918012;C1177210;C1515976;C1552854;C1637833;C2347872;C2986546;C3831328;C4318744	\N	\N
242	cfisher ' s exact test .	C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744	\N	\N
241	ratio to baseline in total ige at week $nmbr$  geometric mean ( se on loge scale ) u / ml	C0036919;C0168634;C0175659;C0332174;C0349674;C0439230;C0439340;C0456603;C0806481;C1442488;C1547037;C1880521;C1947916;C2697934;C2945590;C2986759	\N	\N
241	geometric mean uacr	C2986759	\N	\N
241	geometric mean of baseline	C0168634;C1442488;C2986759	\N	\N
241	geometric mean ige on loge scale — u / ml	C0175659;C0349674;C0439340;C1880521;C1947916;C2697934;C2945590;C2986759	\N	\N
241	geometric mean	C2986759	\N	\N
241	baseline geometric mean ( $nmbr$ ® / l )	C0168634;C1442488;C2986759	\N	\N
239	no mra at baseline	C0168634;C0243032;C1442488;C1609165;C3891069	\N	\N
239	mra use	C0042153;C0243032;C0457083;C1609165;C1947944;C3891069	\N	\N
239	mra regimen ( n - $nmbr$ )	C0040808;C0243032;C1609165;C2945654;C3891069	\N	\N
239	mra at baseline	C0168634;C0243032;C1442488;C1609165;C3891069	\N	\N
239	mra  ( % )	C0243032;C1609165;C3891069	\N	\N
239	mra	C0243032;C1609165;C3891069	\N	\N
238	cuban	C1553379	\N	\N
237	ua ( n = $nmbr$ )	C0041580;C0042014	\N	\N
237	ua	C0041580;C0042014	\N	\N
237	serum ua < $nmbr$ mg / dl by month $nmbr$	C0041580;C0042014;C0229671;C0332177;C0439231;C0439269;C1546774;C1550100	\N	\N
236	with treatment	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	vka therapy	C0039798;C0087111;C1363945	\N	\N
236	treatment   ×   lipid interaction	C0023779;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704	\N	\N
236	treatment with candesartan	C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment with anti - platelet drugs	C0039798;C0087111;C1522326;C1533734;C1705169;C2963157;C3538994;C3887704	\N	\N
236	treatment groups [ n / nb ( % ) ]	C0028101;C0039798;C0087111;C0441848;C0919442;C1522326;C1533734;C1705169;C1705347;C3538994;C3887704;C4553907	\N	\N
236	treatment groups  n ( % )	C0039798;C0087111;C0441848;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment group	C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704	\N	\N
236	treatment glargine	C0039798;C0087111;C0907402;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment for latent tuberculosis ^	C0039798;C0087111;C0205275;C0749724;C1522326;C1533734;C1609538;C1705169;C3538994;C3887704	\N	\N
236	treatment difference  ml	C0039798;C0087111;C0439526;C1522326;C1533734;C1705169;C1705224;C1705241;C1705242;C3538994;C3887665;C3887704	\N	\N
236	treatment difference	C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704	\N	\N
236	treatment characteristics	C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment by subgroup interaction	C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704	\N	\N
67	rolofylline	C0166128	\N	\N
236	with corticosteroid treatment > $nmbr$	C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704	f	1348
236	treatment with drugeluting stent	C0039798;C0087111;C1322815;C1522326;C1533734;C1705169;C3538994;C3887704	f	365
237	russia / ukraine / belarus	C0006539;C0035970;C0041580	f	2348
238	riva roxa ban n / n { % ) $nmbr$ ( $nmbr$ . $nmbr$ )	C0683610;C4553947	f	1792
237	ukraine	C0041580	f	2349
238	poba  n ( % )	\N	f	-10
239	magnetic resonance angiography	C0243032	f	2350
240	hbai	\N	f	820
240	hbaic ( % )	\N	f	820
240	hbaic — %	\N	f	820
240	hbaic ( % )  mean ± s . d .	C0444504;C2347634;C2348143	f	820
240	hbaie ( % )	\N	f	820
240	hbaie  %	\N	f	820
240	hbaie ( % ) mean ± sd	C0444504;C2347634;C2348143;C2699239	f	820
240	hbalc  %	\N	f	820
240	hbalc ( % )	\N	f	820
240	hbalc  %  mean ( sd )	C0444504;C2347634;C2348143;C2699239	f	820
240	hbalc  mean ( s . d . )	C0444504;C2347634;C2348143	f	820
240	hbalc ( % )  mean ( sd ) ^	C0444504;C2347634;C2348143;C2699239	f	820
240	hbalc > = $nmbr$ % ( n - $nmbr$ )	\N	f	820
240	mean hbaic = • = s . d .  %	C0444504;C2347634;C2348143	f	820
240	mean ( s . d . ) hbalc  %	C0444504;C2347634;C2348143	f	820
241	geometric mean blood eosinophil count on loge scale — cells / ^ ljj	C0175659;C0200638;C0349674;C1947916;C2697934;C2986759	f	849
241	geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mm $nmbr$	C0175659;C0200638;C0349674;C1947916;C2697934;C2699239;C2986759;C4330985;C4554674	f	849
242	atopic ( based on phadiatop test )	C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C1527178;C1705938;C3831328;C4318744	f	2351
242	atopy by phadiatop test  n ( % )	C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C3539705;C3831328;C4318744	f	2351
236	treatment before randomization  %	C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment before catheterization	C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment at baseline	C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment and parameter	C0039798;C0087111;C0549193;C1522326;C1533734;C1704769;C1705169;C2350001;C3538994;C3887704	\N	\N
236	treatment - by - subgroup interaction  p = $nmbr$ . $nmbr$	C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704	\N	\N
236	treatment - by - subgroup interaction	C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704	\N	\N
236	treatment  n ( % )	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	treatment	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	total by treatment	C0039798;C0087111;C0439175;C0439810;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	topical therapy	C0039798;C0087111;C0332237;C1363945	\N	\N
236	time since cessation of full - dose warfarin therapy	C0039798;C0040223;C0087111;C0178602;C0366686;C0443225;C0869039;C1114758;C1363945;C1880019;C3541383;C4303340	\N	\N
236	time from symptoms to treatment	C0039798;C0040223;C0087111;C0683368;C1457887;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704	\N	\N
236	time between cessation of full - dose warfarin therapy and enrollment ( mo )	C0026544;C0039798;C0087111;C0178602;C0332177;C0366686;C0682295;C0869039;C1114758;C1363945;C1516879;C1696073;C1880019;C3888021;C4303340	\N	\N
236	thrombolytic treatment before randomization	C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	therapy	C0039798;C0087111;C1363945	\N	\N
236	therapies	C0087111	\N	\N
236	table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela	C0039224;C0039601;C0039798;C0087111;C0168634;C0205363;C0370003;C0947343;C1315074;C1442488;C1516050;C1522326;C1533734;C1705169;C1706074;C2347026;C3538994;C3887704;C4684572	\N	\N
236	sulfasalazine treatment	C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	subgroup treatment	C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	refractory to such therapy — no . ( % )	C0039798;C0087111;C0205269;C1363945	\N	\N
236	receiving insulin therapy	C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501	\N	\N
236	randomized treatment  % ( n )	C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704	\N	\N
236	randomized treatment	C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704	\N	\N
236	randomised treatment	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	previous treatment with tnf antagonist — no . ( % ) §	C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
236	previous treatment ?	C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
236	previous treatment	C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
236	pretreatment / concomitant treatment	C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704	\N	\N
236	prestudy treatment ( % ) a	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	other treatment assignment	C0039798;C0087111;C1516050;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	oab therapy	C0039798;C0087111;C1363945	\N	\N
236	noninsulin therapy	C0039798;C0087111;C1363945	\N	\N
236	no pah therapy	C0030123;C0039798;C0087111;C1363945;C3203102;C4284467	\N	\N
236	no pah - specific therapy	C0030123;C0039798;C0087111;C0205369;C1363945;C1552740;C3203102;C4284467	\N	\N
236	no . of background glucose - lowering therapies  no . ( % )	C0017725;C0087111;C0441994;C1706907;C2003888	\N	\N
236	naive to antihyperglycemic agent therapy	C0020616;C0039798;C0087111;C0450442;C1254351;C1363945;C1521826	\N	\N
236	month $nmbr$ subgroup x treatment interaction p - value	C0039798;C0087111;C0332177;C0439231;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704	\N	\N
236	mean treatment exposure  wk	C0039798;C0087111;C0274281;C0332157;C0332174;C0439230;C0444504;C1522326;C1533734;C1705169;C2347634;C2348143;C3538994;C3887704	\N	\N
236	long term vka therapy	C0039798;C0087111;C0443252;C1363945	\N	\N
236	long - term vka therapy	C0039798;C0087111;C0443252;C1363945	\N	\N
236	initial treatment randomization	C0034656;C0039798;C0087111;C0205265;C1279901;C1522326;C1533734;C1555582;C1705169;C1705685;C3538994;C3887704	\N	\N
236	ineffective therapy	C0039798;C0087111;C1363945;C3242229	\N	\N
236	icd therapy vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl )	C0021122;C0032042;C0039798;C0087111;C0596019;C1363945;C1696465;C1706408;C2985465	\N	\N
236	icd therapy ( n =	C0021122;C0039798;C0087111;C1363945	\N	\N
236	h $nmbr$ blocker ( n  % ) long - term vka therapy	C0033727;C0039798;C0087111;C0369286;C0441932;C0443252;C0564385;C1363945;C4528284	\N	\N
236	epa treatment ( n = $nmbr$ )	C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
229	primary pci no .	C0205225;C0439612;C0439631;C4049621	f	2340
236	insulin therapy	C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501	f	2347
236	insulin therapy  n ( % )	C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501	f	2347
236	insulin therapy  n ( % ) 本	C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501	f	2347
236	ldl cholesterol - lowering therapy	C0023824;C0039798;C0087111;C0202117;C0441994;C1363945;C2003888	f	1773
236	ics / laba therapy  n ( % )	C0039798;C0087111;C0815320;C1363945;C4551720	f	2182
236	hypoglycaemic therapy	C0020616;C0039798;C0087111;C1363945	f	33
236	lipid treatment	C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704	f	1773
236	taking antihypertensive treatment at	C0003364;C0039798;C0087111;C1515187;C1522326;C1533734;C1705169;C3538994;C3887704	f	1579
236	currently on aha therapy	C0039798;C0050451;C0087111;C0521116;C0772110;C1363945	\N	\N
236	concomitant treatment 一 no . ( % )	C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	concomitant treatment	C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	characteristic and treatment	C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	background treatment  n ( % )	C0039798;C0087111;C1522326;C1533734;C1705169;C1706907;C3538994;C3887704	\N	\N
236	background therapy	C0039798;C0087111;C1363945;C1706907	\N	\N
236	background lipid therapy per acc / aha definition    n   ( % ) a	C0023767;C0039798;C0087111;C1363945;C1550452;C1704788;C1706907;C3539107;C3888054;C4072694	\N	\N
236	background aha therapy at screening  n ( % ) §	C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164	\N	\N
236	background aha therapy at screening  n ( % )	C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164	\N	\N
236	background aha therapy at screening  n	C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164	\N	\N
236	background aha therapy at screening  a   n ( % )	C0039798;C0050451;C0087111;C0220908;C0220909;C0369718;C0441922;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164	\N	\N
236	background aha therapy at screening  a	C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164	\N	\N
236	asian itt population by treatment group	C0032659;C0039798;C0078988;C0087111;C0374505;C1257890;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
236	any treatment - emergent ae	C0039798;C0087111;C0750573;C1522326;C1533734;C1705169;C3538994;C3887670;C3887704	\N	\N
236	any therapy — no . ( % )	C0039798;C0087111;C1363945	\N	\N
236	actual treatment strategy	C0039798;C0087111;C0237400;C0679199;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
235	tests for categoric	C0589061	\N	\N
235	pfor heterogeneity	C0019409;C0242960;C1151635	\N	\N
235	pfor	C1151635	\N	\N
234	poor	C0032854;C0542537;C2700379	\N	\N
234	fair or poor	C0032854;C0542537;C2700379;C2911689	\N	\N
234	fair / poor	C0032854;C0542537;C2700379;C2911689	\N	\N
233	pack - years ( iqr )	C1277691	\N	\N
233	over past $nmbr$ years  n ( % )	C4086728	\N	\N
233	( iqr )	\N	\N	\N
232	war	C0043027	\N	\N
232	mar imputation ( random . ) ( n = $nmbr$ )	C0034656;C0439605;C2699638;C3829202;C4255469	\N	\N
232	mar ( itt ) ( n = $nmbr$ )	C3829202;C4255469	\N	\N
231	previously taken any other dmards  n ( % )	C0242708;C1883727	\N	\N
231	other dmards	C0242708	\N	\N
231	other dmard use	C0042153;C0242708;C0457083;C1947944	\N	\N
231	dmard − ( n   =   $nmbr$ )	C0242708	\N	\N
231	dmard | |	C0242708	\N	\N
231	dmard + ( n   =   $nmbr$ )	C0242708	\N	\N
231	concomitant use of conventional synthetic dmard up to $nmbr$ mo — no . { % ) methotrexate	C0025677;C0026544;C0242708;C0332177;C0439858;C0521115;C1524063;C1883254	\N	\N
231	concomitant conventional dmard use	C0042153;C0242708;C0439858;C0457083;C0521115;C1947944	\N	\N
230	primary trial end point	C0008976;C2986535	\N	\N
230	primary safety end point : severe / life - threatening	C0036043;C0205082;C1546953;C1705187;C2826244;C2986535;C3537125;C4050465;C4050466	\N	\N
230	primary indication	C1549995	\N	\N
230	primary endpoint ’	C2986535	\N	\N
230	primary endpoint death / mi / idr / st	C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775	\N	\N
230	primary endpoint at $nmbr$ months	C0439231;C2986535	\N	\N
230	primary endpoint at $nmbr$ days	C0439228;C2986535	\N	\N
230	primary endpoint ^	C2986535	\N	\N
230	primary endpoint :	C2986535	\N	\N
230	primary endpoint $nmbr$	C2986535	\N	\N
230	primary endpoint	C2986535	\N	\N
230	primary end point |	C2986535	\N	\N
230	primary end point kaplan - meier rate  %	C0871208;C1521828;C2986535	\N	\N
230	primary end point : death / mi / idr / st	C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775	\N	\N
230	primary end point *	C2986535	\N	\N
230	primary end point	C2986535	\N	\N
230	primary end - point	C2986535	\N	\N
230	primary cv endpoint	C2986535;C3538987;C4048877;C4318503	\N	\N
230	nace ( primary endpoint )	C2986535	\N	\N
229	year of publication of primary results	C0034036;C0034037;C0205225;C0439234;C0439508;C0439612;C0439631;C1274040;C1546471;C1704324;C2825142	\N	\N
229	third primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ )	C0205225;C0205437;C0332174;C0392747;C0439230;C0439612;C0439631;C0443172;C0449820;C1705241;C3639721;C4050231;C4319952	\N	\N
229	primary target vessel ( % )	C0205225;C0439612;C0439631;C0449618	\N	\N
229	primary study joint  n ( % )	C0022417;C0205225;C0392905;C0439612;C0439631;C0557651;C1706309;C2603343	\N	\N
209	tg > $nmbr$ . $nmbr$	C0337445	\N	\N
229	primary pcit	C0205225;C0439612;C0439631	f	2340
229	second co - primary	C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1561503;C1705190;C3245499	f	2341
229	second primary composite outcome	C0205199;C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1547335;C1561503;C1705190	f	2342
233	exacerbations requiring hospitalisation ( past year ) ( % )	C0019993;C4086268;C4086728	f	2345
233	no . of exacerbations in past year	C4086268;C4086728	f	2345
233	pneumonia in past year	C0032285;C4086728	f	2346
236	anti - platelet therapy	C0005821;C0039798;C0087111;C1363945	f	1191
236	anti platelet therapy	C0005821;C0039798;C0087111;C1363945	f	1191
236	antithrombotic therapy	C0039798;C0087111;C1363945	f	1191
236	ace inhibitor treatment	C0003015;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C4541021	f	811
236	chronic treatment with aspirin	C0004057;C0039798;C0087111;C0205191;C1522326;C1533734;C1705169;C3538994;C3887704	f	1366
229	primary nonresponse	C0205225;C0439612;C0439631	\N	\N
229	primary analysis	C0002778;C0205225;C0439612;C0439631;C0936012;C1524024	\N	\N
229	primary *	C0205225;C0439612;C0439631	\N	\N
229	primary	C0205225;C0439612;C0439631	\N	\N
229	overall cohort ( primary analysis )	C0086027;C0205225;C0282416;C0439612;C0439631;C1561607	\N	\N
229	combo vs . primary	C0205225;C0439612;C0439631	\N	\N
229	accord primary  n ( % )	C0205225;C0439612;C0439631;C0680240	\N	\N
228	native coronary - artery lesions	C0205042;C0221198;C0302891	\N	\N
228	left main coronary artery bifurcation	C3898614	\N	\N
228	coronary artery stenosis > $nmbr$ %	C0242231	\N	\N
228	coronary artery osteochondrosis	C0029376;C0029429;C0205042;C0729346	\N	\N
228	coronary artery	C0205042	\N	\N
228	> $nmbr$ % coronary stenosis	C0242231	\N	\N
227	previous coronary artery bypass surgery  no . ( % )	C2144990	\N	\N
227	previous coronary artery bypass grafting	C2144990	\N	\N
227	previous coronary artery bypass graft	C2144990	\N	\N
227	previous coronary - artery bypass grafting	C2144990	\N	\N
226	• death from coronary heart disease	C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775	\N	\N
226	stable coronary artery disease	C0010054;C0010068;C0205360;C1547311;C1956346	\N	\N
226	prior coronary artery disease yes	C0010054;C0010068;C0332152;C1549445;C1705108;C1710701;C1956346;C2826257	\N	\N
226	previous coronary heart disease	C0010054;C0010068;C0205156;C1552607;C1956346	\N	\N
226	previous coronary artery disease  n ( % )	C0010054;C0010068;C0205156;C1552607;C1956346	\N	\N
226	only coronary artery disease	C0010054;C0010068;C0205171;C1720467;C1956346	\N	\N
226	multivessel coronary artery disease — no . / total no . ( % )	C0010054;C0010068;C0439175;C0439810;C1956346	\N	\N
226	multivessel coronary artery disease	C0010054;C0010068;C1956346	\N	\N
226	hope patients with coronary - artery disease ( n = $nmbr$ )	C0010054;C0010068;C0030705;C0392347;C1956346	\N	\N
226	documented coronary artery disease	C0010054;C0010068;C1301725;C1609436;C1956346	\N	\N
226	coronary heart disease — no . ( % )	C0010054;C0010068;C1956346	\N	\N
226	coronary heart disease death	C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775	\N	\N
226	coronary heart disease ( % )	C0010054;C0010068;C1956346	\N	\N
226	coronary heart disease  n ( % ) t	C0010054;C0010068;C1956346	\N	\N
226	coronary heart disease  n ( % ) b	C0010054;C0010068;C1956346	\N	\N
226	coronary heart disease	C0010054;C0010068;C1956346	\N	\N
226	coronary disease	C0010068;C1956346	\N	\N
226	coronary artery disease — no . / total no . ( % )	C0010054;C0010068;C0439175;C0439810;C1956346	\N	\N
226	coronary artery disease — no . ( % ) : c	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease — no . ( % ) : ! :	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease — no . ( % )	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease — %	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease §	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease history	C0010054;C0010068;C0019664;C0019665;C0262512;C0262926;C1705255;C1956346;C2004062	\N	\N
226	coronary artery disease ^	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease *	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease ( n = $nmbr$ $nmbr$ )	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease ( % )	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease    n   ( % )	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease  n ( % )	C0010054;C0010068;C1956346	\N	\N
226	coronary artery disease  %	C0010054;C0010068;C1956346	\N	\N
209	tg < = $nmbr$ . $nmbr$	C0337445	\N	\N
226	voluntary	C0439656;C3543419	f	-10
229	first primary composite outcome	C0205199;C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C1547335	f	2339
229	primary composite ^	C0205199;C0205225;C0439612;C0439631;C1547335	f	2339
229	primary composite end points	C0205199;C0205225;C0439612;C0439631;C1547335;C2349179	f	2339
229	primary composite outcome	C0205199;C0205225;C0439612;C0439631;C1274040;C1547335	f	2339
229	primary efficacy outcome	C0205225;C0439612;C0439631;C1274040;C1280519;C1707887	f	2339
229	primary end points	C0205225;C0439612;C0439631;C2349179	f	2339
229	primary outcome	C0205225;C0439612;C0439631;C1274040	f	2339
229	primary outcome !	C0205225;C0439612;C0439631;C1274040	f	2339
229	primary outcome : $nmbr$ % decrease in womac pain score	C0205225;C0392756;C0439612;C0439631;C0547047;C0582148;C1274040	f	2339
229	primary outcome ! ( n = $nmbr$ )	C0205225;C0439612;C0439631;C1274040	f	2339
229	primary outcome plus revascularization or nonfatal hf	C0018488;C0205225;C0332287;C0439612;C0439631;C0581603;C1274040;C1313497;C1538440;C3273279	f	2339
229	primary outcomes	C0205225;C0439612;C0439631;C1274040	f	2339
229	primary pci	C0205225;C0439612;C0439631;C4049621	f	2340
229	primary pci ( n = $nmbr$ )	C0205225;C0439612;C0439631;C4049621	f	2340
229	primary angioplasty ( n = $nmbr$ )	C0162577;C0205225;C0439612;C0439631;C1548817	f	2340
229	primary pci n = $nmbr$	C0205225;C0439612;C0439631;C4049621	f	2340
229	fibrinolysis primary pci ( n = $nmbr$ ) ( n = $nmbr$ ) no . of patients / total no . ( % )	C0016017;C0030705;C0205225;C0439175;C0439612;C0439631;C0439810;C1305868;C4049621	f	2340
229	primary cause of chf	C0015127;C0018802;C0205225;C0439612;C0439631;C1524003	f	2343
229	primary cause of heart failure	C0015127;C0018801;C0018802;C0205225;C0439612;C0439631;C1524003;C4554158	f	2343
229	primary ischemic stroke	C0205225;C0439612;C0439631;C0948008	f	2344
226	coronary artery disease	C0010054;C0010068;C1956346	\N	\N
226	any established coronary artery disease	C0010054;C0010068;C0443211;C1272684;C1956346	\N	\N
226	any coronary artery disease	C0010054;C0010068;C1956346	\N	\N
226	* atherosclerotic coronary heart disease  ischaemic stroke or peripheral arterial disease . † n / n = number of people in phase $nmbr$ studies only . ‡ high ‐ intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg  rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily .	C0003842;C0010054;C0010068;C0012634;C0018787;C0024671;C0026410;C0027361;C0074554;C0205100;C0205171;C0205390;C0221464;C0237753;C0286651;C0332173;C0333482;C0360714;C0439269;C0449788;C0557651;C0947630;C0948008;C0965129;C1704788;C1710475;C1720467;C1956346;C1960952;C2346927;C2603343;C3539106;C4081854;C4321396;C4521761	\N	\N
225	time from acute coronary syndrome to randomization ( days )	C0034656;C0040223;C0439228;C0948089;C3541383	\N	\N
225	median time from index acute coronary syndrome to randomization ( iqr ) — mo	C0026544;C0034656;C0040223;C0332177;C0549183;C0600653;C0876920;C0918012;C0948089;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C3541383	\N	\N
225	coronary events $nmbr$	C0741923	\N	\N
225	acute coronary syndrome $nmbr$	C0948089	\N	\N
225	acute coronary syndrome	C0948089	\N	\N
225	acute coronary event	C0205178;C0741923	\N	\N
224	right coronary artery  n ( % )	C1261316	\N	\N
224	right coronary artery	C1261316	\N	\N
224	right coronary	C0225808	\N	\N
223	prior coronary revascularization — no . { % )	C0332152;C0877341;C2826257	\N	\N
223	prior coronary revascularization ( pci or cabg )	C0010055;C0332152;C0877341;C2826257;C4049621	\N	\N
223	prior coronary revascularization  no . ( % )	C0332152;C0877341;C2826257	\N	\N
223	prior coronary revascularization  n / n ( % )	C0332152;C0877341;C2826257	\N	\N
223	prior coronary revascularization  n ( % )	C0332152;C0877341;C2826257	\N	\N
223	prior coronary revascularization	C0332152;C0877341;C2826257	\N	\N
223	previous coronary revascularization — no . ( % )	C0205156;C0877341;C1552607	\N	\N
223	previous coronary revascularization	C0205156;C0877341;C1552607	\N	\N
223	previous coronary revascularisation	C0205156;C0877341;C1552607	\N	\N
223	history ol coronary revascularization *	C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062	\N	\N
223	history of coronary revascularization  no . ( % )	C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062	\N	\N
223	coronary revascularization procedure	C0877341	\N	\N
223	coronary revascularization	C0877341	\N	\N
223	coronary revascularisation §	C0877341	\N	\N
223	coronary revascularisation	C0877341	\N	\N
223	any coronary revascularization	C0877341	\N	\N
222	rr *	\N	\N	\N
222	rr $nmbr$ . $nmbr$ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ )	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ }	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) * *	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$ . $nmbr$ . $nmbr$ ) *	\N	\N	\N
222	rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$  $nmbr$ . $nmbr$ )	\N	\N	\N
222	rr $nmbr$ . $nmbr$	\N	\N	\N
222	hr * or rr †	\N	\N	\N
222	aml / val  $nmbr$ / $nmbr$ mg rr = $nmbr$ *	C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761;C4554402	\N	\N
221	unadjusted irr	C1439367;C4082285	\N	\N
221	irr = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$	C4082285	\N	\N
220	death / udmi / idr	C0011065;C1306577;C4082313;C4552775	\N	\N
220	death / q - mi / idr	C0011065;C1306577;C3810814;C4082313;C4552775	\N	\N
220	death  mi  idr  st or gusto severe bleeding	C0011065;C0019080;C0036056;C0205082;C1306577;C3272372;C3810814;C4050465;C4050466;C4082313;C4552775	\N	\N
220	cv death / mi / stroke / ucr	C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100	\N	\N
219	prior oabg surgery	C0455610	\N	\N
219	prior cabg surgery	C0010055;C0455610	\N	\N
219	prior aortocoronary bypass surgery 一 no . ( % )	C0010055;C0455610	\N	\N
219	prior aortocoronary bypass surgery — no . ( % )	C0010055;C0455610	\N	\N
219	prior aortocoronary bypass surgery	C0010055;C0455610	\N	\N
218	cancer surgery	C0920424	\N	\N
217	use of clopidogrel	C0070166;C1524063	\N	\N
217	timing of clopidogrel loading dose	C0070166;C0449243;C1704250;C3714444	\N	\N
217	open - label clopidogrel after completion of study drug	C0013227;C0070166;C0205197;C1254351;C1554962;C1709323	\N	\N
217	interval from clopidogrel loading  h	C0033727;C0070166;C0369286;C0441932;C0564385;C1272706;C1552654;C1552713;C1708715;C4528284	\N	\N
217	interval clopidogrel to pci	C0070166;C1272706;C1552654;C1552713;C4049621	\N	\N
217	duration of clopidogrel pretreatment 一 hr median	C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076	\N	\N
217	clopiodogrel	\N	\N	\N
217	clopidogrel pretreatment duration	C0070166;C0449238;C1550147;C2709094;C2926735;C3539075;C3539076	\N	\N
217	clopidogrel plus aspirin ( n = $nmbr$ )	C0004057;C0070166;C0332287	\N	\N
217	clopidogrel plus aspirin % / yr	C0004057;C0070166;C0332287;C0439234	\N	\N
219	prior surgery : no	C0455610	f	2040
218	emergent / urgent surgery	C0750573;C2188405	f	2334
218	urgent surgery	C2188405	f	2334
218	major surgery	C0679637	f	2335
218	minor surgery	C0038904	f	2336
218	other cardiac surgery  n ( % )	C0018821;C0524727	f	2337
218	undergoing major vascular surgery	C0005847;C0042381;C0205082;C0205164;C0679637;C1558950;C1801960;C3714645;C4318856;C4521762	f	2338
218	otherb	\N	f	-10
220	idr	\N	f	-10
220	ucr	\N	f	-10
220	upcr  n ( % )	\N	f	-10
217	clopidogrel plus aspirin	C0004057;C0070166;C0332287	\N	\N
217	clopidogrel no . of patients % )	C0030705;C0070166	\N	\N
217	clopidogrel n / n { % )	C0070166	\N	\N
217	clopidogrel n / n ( % )	C0070166	\N	\N
217	clopidogrel given before procedure	C0070166;C0184661;C1442162;C1550718;C1947971;C2700391;C3244317;C3274430;C3539779	\N	\N
217	clopidogrel / total no . of patients % %	C0030705;C0070166;C0439175;C0439810	\N	\N
217	clopidogrel + aspirin ( n = $nmbr$ )	C0004057;C0070166	\N	\N
217	clopidogrel ( n = $nmbr$ ) n / n ( % )	C0070166	\N	\N
217	clopidogrel ( n = $nmbr$ )	C0070166	\N	\N
217	clopidogrel ( n = $nmbr$ $nmbr$ )	C0070166	\N	\N
217	clopidogrel ( n = $nmbr$  $nmbr$ )	C0070166	\N	\N
217	clopidogrel %	C0070166	\N	\N
217	clopidogrel  %	C0070166	\N	\N
217	clopidogrel	C0070166	\N	\N
217	aspirin plus clopidogrel ( n = $nmbr$ )	C0004057;C0070166;C0332287	\N	\N
217	aspirin i clopidogrel ( n = $nmbr$  $nmbr$ )	C0004057;C0021966;C0070166;C0221138	\N	\N
217	aspirin + clopidogrel ( n = $nmbr$ ) $nmbr$ . $nmbr$	C0004057;C0070166	\N	\N
217	aspirin $nmbr$ clopidogrel	C0004057;C0070166	\N	\N
216	loading dose of clopidogrel or ticlopidine	C0040207;C0070166;C3714444	\N	\N
216	clopidogrel or ticlopidine	C0040207;C0070166	\N	\N
216	clopidogrel / ticlopidine	C0040207;C0070166	\N	\N
216	clopidogrel  ticlopidine  or prasugrel	C0040207;C0070166;C1620287	\N	\N
215	piroxicam	C0031990	\N	\N
215	non - biological systemic	C0205373;C0445097	\N	\N
215	meloxicam	C0083381	\N	\N
215	biological	C0005532;C0205460	\N	\N
214	prior use of biologics  n ( % )	C0005515;C0005522;C0332152;C1524063;C2826257;C4553887	\N	\N
214	prior use of biologic agents	C0005515;C0332152;C1524063;C2826257	\N	\N
214	prior biologic therapeutic failures  n ( % )	C0005515;C0087111;C0205460;C0231174;C0302350;C0332152;C0680095;C2826257	\N	\N
214	other biologic agent	C0005515	\N	\N
214	biologic therapeutic failure	C0005515;C0087111;C0205460;C0231174;C0302350;C0680095	\N	\N
214	biologic naive	C0005515;C0205460	\N	\N
214	biologic agents	C0005515	\N	\N
214	biologic	C0005515;C0205460	\N	\N
213	severity ofcopd ( gold $nmbr$ )  n ( % )	C0018026;C0439793;C0522510;C1304897	\N	\N
213	severity of the disease ( gold $nmbr$ )  n ( % )	C0018026;C0521117;C1304897	\N	\N
213	severity of copd  n ( % ) ( gold $nmbr$ ) : moderate	C0018026;C0024117;C0205081;C0439793;C0522510;C1304897;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335	\N	\N
213	severity of airflow limitation ( gold $nmbr$ - $nmbr$ )  n ( % )	C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897	\N	\N
213	severe ( gold $nmbr$ )	C0018026;C0205082;C1304897;C4050465;C4050466	\N	\N
213	severe  gold $nmbr$	C0018026;C0205082;C1304897;C4050465;C4050466	\N	\N
213	moderate ( gold $nmbr$ )	C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
213	moderate  gold $nmbr$	C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335	\N	\N
213	gold stage ( % ) : c	C0018026;C0441785;C1304897	\N	\N
213	gold ii	C0018026;C1304897;C1710602;C4082587	\N	\N
213	gold groups a - d using mmrcb	C0018026;C0441833;C0687744;C0718133;C1257890;C1304897;C1519504;C1524063;C1552839;C1705428;C1705429	\N	\N
213	gold group d — no . ( % ) | |	C0018026;C0441838;C1304897	\N	\N
213	gold group d	C0018026;C0441838;C1304897	\N	\N
213	gold group b	C0018026;C1304897;C4522078	\N	\N
213	gold group  n ( % )	C0018026;C0441848;C1304897	\N	\N
213	gold group	C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1705428;C1705429	\N	\N
213	gold d	C0018026;C1304897	\N	\N
213	gold c	C0018026;C1304897	\N	\N
213	gold b	C0018026;C1304897	\N	\N
213	gold a	C0018026;C1304897	\N	\N
213	gold $nmbr$ groups  n ( % )	C0018026;C0369718;C0441833;C0441922;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429	\N	\N
213	gold $nmbr$ groups	C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429	\N	\N
213	gold $nmbr$ - $nmbr$ ( « = $nmbr$ )	C0018026;C1304897	\N	\N
213	gold $nmbr$ - $nmbr$ ( n = $nmbr$ )	C0018026;C1304897	\N	\N
213	gold $nmbr$ - $nmbr$	C0018026;C1304897	\N	\N
213	gold $nmbr$ ( « = $nmbr$ )	C0018026;C1304897	\N	\N
213	gold $nmbr$	C0018026;C1304897	\N	\N
213	gold  n ( % )	C0018026;C1304897	\N	\N
212	good / moderate response	C0205170;C4085643	\N	\N
212	good	C0205170	\N	\N
211	tnt and ideal ( pooled )	C1512612;C1709595;C2349200;C4522255	\N	\N
211	pooled itt	C1709595;C2349200;C4522255	\N	\N
211	pooled analysis sample	C0002778;C0936012;C1303103;C1524024;C1709595;C2349200;C4522255	\N	\N
211	pooled analysis of sustain $nmbr$ — $nmbr$ trials	C0002778;C0008976;C0443318;C0936012;C1524024;C1709595;C2349200;C2732140;C4522255	\N	\N
211	pooled analysis	C0002778;C0936012;C1524024;C1709595;C2349200;C4522255	\N	\N
211	pooled	C1709595;C2349200;C4522255	\N	\N
210	ltg subgroup  n = $nmbr$	C1079230;C1420817;C1515021;C4521367;C4521846	\N	\N
210	ltg - naive	C1420817;C4521367;C4521846	\N	\N
210	lrg	C1428862	\N	\N
209	tg ’	C0337445	\N	\N
209	tg §	C0337445	\N	\N
212	good  tried previous glucocorticoid	C0017710;C0205156;C0205170;C1552607	f	1348
212	good  tried previous glucocorticoid + laba	C0017710;C0205156;C0205170;C1552607	f	1348
211	empagliflozin pooled ( n = $nmbr$ )	C1709595;C2349200;C3490348;C4522255	f	2332
211	pooled empagliflozin ( n = $nmbr$ )	C1709595;C2349200;C3490348;C4522255	f	2332
211	pooled secukinumab	C1709595;C2349200;C3179547;C4522255	f	2333
211	secukinumab pooled †   ( n   = $nmbr$ )	C1709595;C2349200;C3179547;C4522255	f	2333
211	pooled eze / simva	C1709595;C2349200;C4522255	f	1840
211	pooled simva	C1709595;C2349200;C4522255	f	1840
213	severity of airflow limitation ( gold $nmbr$ )  n ( % )	C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897	f	213
209	tg < $nmbr$  hdl > $nmbr$ ( n = $nmbr$ )	C0337445;C3715113	\N	\N
209	tg +	C0337445	\N	\N
209	tg *	C0337445	\N	\N
209	tg ( mmol / l ) c	C0337445;C1532563	\N	\N
209	tg ( mmol / l )	C0337445;C1532563	\N	\N
209	tg  median ( min  max )	C0337445;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700	\N	\N
209	tg	C0337445	\N	\N
209	middle tg tertile	C0337445;C0444598;C0549183;C1552826	\N	\N
209	median ( q $nmbr$ : q $nmbr$ ) tg - rich lipoprotein cholesterol	C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193	\N	\N
209	lowest tg tertile	C0337445;C1708760	\N	\N
209	highest tg tertile	C0337445;C1522410	\N	\N
209	hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .	C0023822;C0337445;C0743559;C0858892;C1608199	\N	\N
209	elevated tg	C0205250;C0337445;C3163633	\N	\N
209	change in tg	C0337445;C0392747;C0443172;C1705241;C4319952	\N	\N
209	baseline tg level { n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl	C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261	\N	\N
209	baseline tg level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl	C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261	\N	\N
209	baseline tg level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl	C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261	\N	\N
209	baseline tg level ( n = $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl	C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261	\N	\N
209	baseline tg > $nmbr$ . $nmbr$ mmol / l	C0168634;C0337445;C1442488;C1532563	\N	\N
209	baseline tg < $nmbr$ . $nmbr$ mmol / l	C0168634;C0337445;C1442488;C1532563	\N	\N
209	baseline tg	C0168634;C0337445;C1442488	\N	\N
208	sfc $nmbr$ / $nmbr$ pg twice daily ( n = $nmbr$ )	C0030827;C0072225;C0585361;C1266240;C4521536	\N	\N
208	sfc $nmbr$ / $nmbr$ pg b . i . d . n = $nmbr$	C0021966;C0030827;C0072225;C0152277;C0221138;C1266240;C2827928;C4521536	\N	\N
208	qva $nmbr$ / $nmbr$ pg once daily ( n = $nmbr$ )	C0030827;C0072225;C0332173;C1266240	\N	\N
208	nt - probnp  pg / mlt	C0030827;C0072225;C0669479;C0754710;C1266240;C4553833	\N	\N
208	gly ( $nmbr$ . $nmbr$ pg b . i . d . ) n = $nmbr$	C0030827;C0072225;C0152277;C1266240;C1415124	\N	\N
208	ff $nmbr$ pg ( n = $nmbr$ )	C0030827;C0072225;C1266240;C4554348	\N	\N
208	fdc $nmbr$ / $nmbr$ pg vs placebo	C0030827;C0032042;C0072225;C0340427;C1266240;C1413520;C1696465;C1706408;C3539652	\N	\N
208	fdc $nmbr$ / $nmbr$ pg vs formoterol $nmbr$ pg	C0030827;C0060657;C0072225;C0340427;C1266240;C1413520;C3539652	\N	\N
208	fdc $nmbr$ / $nmbr$ pg vs aclidinium $nmbr$ pg	C0030827;C0072225;C0340427;C1266240;C1413520;C2699757;C3539652	\N	\N
208	fdc $nmbr$ / $nmbr$ pg	C0030827;C0072225;C0340427;C1266240;C1413520;C3539652	\N	\N
208	difference vs ff $nmbr$ pg ( $nmbr$ % ci )	C0008107;C0030827;C0072225;C1266240;C1705241;C1705242;C3259781;C4554348	\N	\N
208	ab / ff $nmbr$ / $nmbr$ pg ( n = $nmbr$ )	C0030827;C0072225;C1266240;C4554348	\N	\N
208	ab $nmbr$ pg ( n = $nmbr$ )	C0030827;C0072225;C1266240	\N	\N
208	$nmbr$ - h pg ( mmol / l )	C0030827;C0072225;C0439190;C1266240;C2827798;C2827804	\N	\N
207	≤ $nmbr$ ug / g	C0439272	\N	\N
207	≤ $nmbr$ u / kg / day	C1532634	\N	\N
207	£ l $nmbr$ kg	C1637390	\N	\N
207	tcz $nmbr$ mg / kg n = $nmbr$	C0439272	\N	\N
207	mean ( sd )  mg / kg $nmbr$	C0439272;C0444504;C2347634;C2348143;C2699239	\N	\N
207	> $nmbr$ ug / g	C0439272	\N	\N
207	> $nmbr$ u / kg / day	C1532634	\N	\N
207	$nmbr$ mg / kg ( n = $nmbr$ )	C0439272	\N	\N
207	$nmbr$ mg / kg	C0439272	\N	\N
206	≥ $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	≥ $nmbr$  kg / m $nmbr$	C1532718	\N	\N
206	£ $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	bmi  median ( iqr )  kg / m $nmbr$	C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193	\N	\N
206	bmi  mean ± sd kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  mean ± sd  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  mean ( sd ) kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  mean ( sd ) ( kg / m $nmbr$ )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  mean ( sd )  kg / m ^	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  mean ( sd )  kg / m $nmbr$ c	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  mean  kg / m $nmbr$ ( ± sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  kg / m ^ *	C0578022;C1532718	\N	\N
206	bmi  kg / m ^	C0578022;C1532718	\N	\N
207	infliximab ( combined $nmbr$ mg / kg and $nmbr$ mg / kg )  n ( % )	C0205195;C0439272;C0666743	f	2327
207	infliximab $nmbr$ mg / kg	C0439272;C0666743	f	2327
207	golimumab $nmbr$ mg / kg + mtx	C0025677;C0439272;C1417487;C2353893	f	2328
208	aclidinium / formoterol $nmbr$ / $nmbr$ pg twice daily	C0030827;C0060657;C0072225;C0585361;C1266240;C2699757	f	2329
208	aclidinium $nmbr$ pg	C0030827;C0072225;C1266240;C2699757	f	2329
208	aclidinium $nmbr$ pg vs placebo	C0030827;C0032042;C0072225;C1266240;C1696465;C1706408;C2699757	f	2329
208	formoterol $nmbr$ pg	C0030827;C0060657;C0072225;C1266240	f	2330
208	formoterol $nmbr$ pg vs placebo	C0030827;C0032042;C0060657;C0072225;C1266240;C1696465;C1706408	f	2330
208	indacaterol $nmbr$ pg	C0030827;C0072225;C1266240;C1722260	f	2331
206	s $nmbr$ kg / m ^	C0565930;C1532718;C2603362	\N	\N
206	s $nmbr$ kg / m $nmbr$	C0565930;C1532718;C2603362	\N	\N
206	patients with bw decrease of $ $nmbr$ % in patients with baseline bmi of $ $nmbr$ kg / m $nmbr$ +	C0005910;C0006041;C0030705;C0168634;C0392756;C0547047;C0578022;C1442488;C1532718;C2986891	\N	\N
206	obesity ( body mass index > $nmbr$ kg / m $nmbr$ )	C0005893;C0028754;C0578022;C1305855;C1532718;C1963185	\N	\N
206	obesity ( bmi £ $nmbr$ kg / m $nmbr$ )	C0028754;C0578022;C1532718;C1963185	\N	\N
206	obesity ( bmi > $nmbr$ kg / m $nmbr$ )  %	C0028754;C0578022;C1532718;C1963185	\N	\N
206	obese ( bmi > $nmbr$ kg / m $nmbr$ )	C0028754;C0578022;C1532718	\N	\N
206	obese ( > $nmbr$ kg / m ^ $nmbr$ )	C0028754;C1532718	\N	\N
206	mean total ipss mean ipss by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ )	C0439175;C0439810;C0444504;C0578022;C1019118;C1532718;C1998280;C2347634;C2348143;C2827405;C3811063	\N	\N
206	mean qmax score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ )	C0578022;C1532718;C3533236	\N	\N
206	mean iief ef score mean iief domain score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ )	C0578022;C1532718;C1880389;C1883221;C3533236;C3541951;C3641331	\N	\N
206	mean bmii 士 s . d .  kg / m $nmbr$	C0444504;C1532718;C2347634;C2348143	\N	\N
206	mean bmi ± sd ( kg / m $nmbr$ )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	mean bmi ± s . d .  kg / m ^	C0444504;C0578022;C1532718;C2347634;C2348143	\N	\N
206	mean bmi ± s . d .  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143	\N	\N
206	mean bmi ( sd )  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	mean bmi  kg / m $nmbr$ ± sd	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	mean ( sd ) bmi  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	low ( < $nmbr$ kg / m ^ ) baseline bmi	C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
206	low ( < $nmbr$ kg / m $nmbr$ ) baseline bmi	C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223	\N	\N
206	lean ( < $nmbr$ kg / m $nmbr$ )	C1532718	\N	\N
206	kg / m $nmbr$ )	C1532718	\N	\N
206	kg / m $nmbr$	C1532718	\N	\N
206	high ( i $nmbr$ kg / m $nmbr$ ) baseline bmi	C0021966;C0168634;C0205250;C0221138;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
206	high ( > $nmbr$ kg / m ^ ) baseline bmi	C0168634;C0205250;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209	\N	\N
206	egfr  ml / kg per $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439526;C0441923;C1300574;C1532718;C1705224;C1739039;C3811844;C3812682;C3887665	\N	\N
206	bodymass index ( kg / m $nmbr$ )	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body mass index group ( ≥ $nmbr$ kg / m $nmbr$ ) — no . ( % )	C0005893;C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1305855;C1519504;C1532718;C1705428;C1705429;C4054209	\N	\N
206	body mass index > $nmbr$ kg / m $nmbr$ *	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body mass index > $nmbr$ kg / m $nmbr$  n ( % )	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body mass index < $nmbr$ kg / m $nmbr$	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body mass index ( range ) ( kg / m $nmbr$ )	C0005893;C0578022;C1305855;C1514721;C1532718;C2348147;C3542016	\N	\N
206	body mass index ( kg / m ^ )	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body mass index ( kg / m $nmbr$ ) ∗	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body mass index  kg / m ^ ^	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body - mass index ( kg / m ’ )	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body - mass index ( kg / m - ) !	C0005893;C0578022;C1305855;C1532718	\N	\N
206	body - mass index  kg / m $nmbr$	C0005893;C0578022;C1305855;C1532718	\N	\N
206	bmp kg - m “ $nmbr$	C0053932;C0279266;C1532718;C4281808	\N	\N
206	bmi kg - m - $nmbr$	C0578022;C1532718	\N	\N
206	bmi group ( kg / m ^ )	C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1519504;C1532718;C1705428;C1705429;C4054209	\N	\N
206	bmi at baseline ( kg / m $nmbr$ )	C0168634;C0578022;C1442488;C1532718	\N	\N
206	bmi > = $nmbr$ kg / m $nmbr$ population ( n = $nmbr$ )	C0032659;C0578022;C1257890;C1532718	\N	\N
206	bmi > $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
206	bmi > $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ )	C0578022;C1532718	\N	\N
206	bmi > $nmbr$ kg / m $nmbr$ ( % )	C0578022;C1532718	\N	\N
206	bmi ( sd )  kg / m $nmbr$	C0578022;C1532718;C2699239	\N	\N
206	bmi ( kg / m $nmbr$ ) < $nmbr$	C0578022;C1532718	\N	\N
206	bmi ( kg / m $nmbr$ ) ( sd )	C0578022;C1532718;C2699239	\N	\N
206	bmi ( kg / m $nmbr$ )  median ( range )	C0549183;C0578022;C0876920;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016	\N	\N
206	bmi # kg - m “ $nmbr$	C0578022;C1532718	\N	\N
204	psap - b ( ng / ml )	C0439275;C1418975;C1420002;C1425004	\N	\N
206	bmi  kg / m $nmbr$ cholesterol  mg / dl	C0008377;C0439269;C0578022;C1532718	\N	\N
206	bmi  kg / m $nmbr$ ( sd )	C0578022;C1532718;C2699239	\N	\N
206	bmi  kg / m $nmbr$ ( mean $nmbr$ sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	\N	\N
206	bmi  kg / m $nmbr$  n ( % )	C0578022;C1532718	\N	\N
206	bmi  kg / m $nmbr$  mean	C0444504;C0578022;C1532718;C2347634;C2348143	\N	\N
206	bm $nmbr$ ( kg / m $nmbr$ )	C0006416;C1532718	\N	\N
206	bl bm $nmbr$ < $nmbr$ kg / m ^	C0005918;C0006413;C0006416;C1532718;C1552663;C2827109	\N	\N
206	baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks	C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952	\N	\N
206	baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$	C0168634;C0578022;C1442488;C1532718	\N	\N
206	baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$	C0168634;C0578022;C1442488;C1532718	\N	\N
206	baseline bmi > $nmbr$ kg / m $nmbr$	C0168634;C0578022;C1442488;C1532718	\N	\N
206	baseline bmi < $nmbr$ kg / m $nmbr$	C0168634;C0578022;C1442488;C1532718	\N	\N
206	baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks	C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952	\N	\N
206	baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks	C0168634;C0392747;C0439230;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952	\N	\N
206	baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$	C0168634;C0578022;C1442488;C1532718	\N	\N
206	baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$	C0168634;C0578022;C1442488;C1532718	\N	\N
206	a $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	[ kg / m ^ ]	C1532718	\N	\N
206	> = $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	> $nmbr$ kg / m ’	C1532718	\N	\N
206	> $nmbr$ kg / m ^ ( obesity )	C0028754;C1532718;C1963185	\N	\N
206	> $nmbr$ kg / m ^	C1532718	\N	\N
206	> $nmbr$ kg / m $nmbr$ ( n — $nmbr$ )	C1532718	\N	\N
206	> $nmbr$ kg / m $nmbr$ ( n = $nmbr$ )	C1532718	\N	\N
206	> $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	> $nmbr$ . $nmbr$ kg / m $nmbr$ hypertension :	C0020538;C1532718;C1963138	\N	\N
206	> $nmbr$ . $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	> $nmbr$ - s $nmbr$ kg / m ’	C0565930;C1532718;C2603362	\N	\N
206	> $nmbr$ - ^ $nmbr$ kg / m ’	C1532718	\N	\N
206	> $nmbr$ - < s $nmbr$ kg / m ’	C0565930;C1532718;C2603362	\N	\N
206	> $nmbr$ - < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ )	C1532718	\N	\N
206	< $nmbr$ kg / m ^	C1532718	\N	\N
206	< $nmbr$ kg / m $nmbr$ ( n — $nmbr$ )	C1532718	\N	\N
206	< $nmbr$ kg / m $nmbr$ ( n = $nmbr$ )	C1532718	\N	\N
206	< $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	< $nmbr$ . $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	< $nmbr$  kg / m $nmbr$	C1532718	\N	\N
206	$nmbr$ to < $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	$nmbr$ kg / m ’	C1532718	\N	\N
206	$nmbr$ kg / m $nmbr$ or more	C0205172;C1532718	\N	\N
206	$nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	$nmbr$ bmi  kg / m	C0578022;C1532718	\N	\N
206	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	$nmbr$ - < $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	$nmbr$ - $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	$nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$	C1532718	\N	\N
206	$nmbr$ $nmbr$ to < $nmbr$ kg / m $nmbr$	C1532718	\N	\N
205	« $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	£ $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	total daily insulin dose ( lu / kg )	C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209	\N	\N
205	q $nmbr$ : > $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ )	C0022718;C0439209;C4054209	\N	\N
66	theophyllines	C0039771	\N	\N
205	weight - kg	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight ( kg )	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight — kg	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight ( kg ) a	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight  kg ( mean $nmbr$ sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight  kg  mean ( sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight  kg  mean ± sd	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight  kg mean ( sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight ( kg )  mean ± sd	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight ( kg )  mean   ±   sd	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight ( kg ) ( mean ± sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight ( kg ) 十	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight  mean ( sd )  kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight  mean ± sd kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
205	weight  median ( sd )  kg	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2699239;C2939193;C4054209	f	2326
205	weight < $nmbr$ kg  n ( % )	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight > $nmbr$ kg  n ( % )	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight 一 kg	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	q $nmbr$ : < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ )	C0022718;C0439209;C4054209	\N	\N
205	o $nmbr$ kg  n ( % )	C0022718;C0439209;C0483204;C4054209	\N	\N
205	lu / kg	C0022718;C0024171;C0024176;C0439209;C2697939;C4054209	\N	\N
205	kg	C0022718;C0439209;C4054209	\N	\N
205	grip strength ( kg )	C0022718;C0429271;C0439209;C2598165;C4054209	\N	\N
205	dose adjustment reason < $nmbr$ kg	C0022718;C0439209;C2826286;C4054209	\N	\N
205	difference vs . placebo  kg ( $nmbr$ % cl )	C0022718;C0032042;C0439209;C0596019;C1696465;C1705241;C1705242;C1706408;C4054209	\N	\N
205	daily total dose of insulin — lu / kg	C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209	\N	\N
205	> = $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	> $nmbr$ kg — no . ( % )	C0022718;C0439209;C4054209	\N	\N
205	> $nmbr$ kg nr	C0022718;C0027496;C0439209;C3844738;C4054209	\N	\N
205	> $nmbr$ kg / nr	C0022718;C0027496;C0439209;C3844738;C4054209	\N	\N
205	> $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	> $nmbr$ . $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	> $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	> $nmbr$ - $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	< = € $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	< = $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	< $nmbr$ kg ' i '	C0021966;C0022718;C0221138;C0439209;C4054209	\N	\N
205	< $nmbr$ kg  n ( % )	C0022718;C0439209;C4054209	\N	\N
205	< $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	< $nmbr$ . $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	. $nmbr$ kg mtx use	C0022718;C0025677;C0042153;C0439209;C0457083;C1417487;C1947944;C4054209	\N	\N
205	. $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	$nmbr$ to < $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	$nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	$nmbr$ - < $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	$nmbr$ - $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
205	# $nmbr$ kg	C0022718;C0439209;C4054209	\N	\N
204	≥ $nmbr$ ng / ml	C0439275	\N	\N
204	wap $nmbr$ c ( ng / ml )	C0439275	\N	\N
204	vegfr ( ng / ml )	C0439275;C1568520	\N	\N
204	troy ( ng / ml )	C0439275;C1420811;C1883402	\N	\N
204	tnf - r $nmbr$ a ( ng / ml )	C0439275;C1363984;C1706001	\N	\N
204	tertile $nmbr$ ( < $nmbr$ . $nmbr$ ng / ml ) n - $nmbr$	C0439275	\N	\N
204	t $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml )	C0439275;C2603360	\N	\N
204	syndecan - $nmbr$ ( ng / ml )	C0075691;C0439275;C1419891	\N	\N
204	sdc ( ng / ml )	C0439275;C1419891;C3273112	\N	\N
204	sdc ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml )	C0439275;C1419891;C3273112	\N	\N
204	sdc $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml	C0439275;C1419891;C3273112	\N	\N
204	rage ( ng / ml )	C0034634;C0439275;C3539760;C3815186	\N	\N
204	ptx $nmbr$ ( ng / ml )	C0030899;C0439275	\N	\N
205	body - mass index ( kg / mq	C0005893;C0022718;C0024853;C0439209;C0578022;C1305855;C4054209	f	1734
205	body mass index ( kg / nr )	C0005893;C0022718;C0027496;C0439209;C0578022;C1305855;C3844738;C4054209	f	1734
205	body - mass index > $nmbr$ kg / nrn	C0005893;C0022718;C0439209;C0578022;C1305855;C1425210;C4054209	f	1734
205	body mass  kg	C0022718;C0439209;C0518010;C4054209	f	1734
205	body weight  kg	C0005910;C0022718;C0439209;C1305866;C4054209	f	1734
205	body weight  kg ^	C0005910;C0022718;C0439209;C1305866;C4054209	f	1734
205	body weight ( kg )	C0005910;C0022718;C0439209;C1305866;C4054209	f	1734
205	body weight ( kg ) *	C0005910;C0022718;C0439209;C1305866;C4054209	f	1734
205	mean body - mass index ( kg / mq	C0005893;C0022718;C0024853;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C4054209	f	1734
205	bw at $nmbr$ weeks  kg +	C0005910;C0006041;C0022718;C0439209;C0439230;C2986891;C4054209	f	2326
205	body weight  mean = sd  kg	C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209	f	2326
205	bw  kg	C0005910;C0006041;C0022718;C0439209;C2986891;C4054209	f	2326
205	body weight  kg ( sd )	C0005910;C0022718;C0439209;C1305866;C2699239;C4054209	f	2326
205	body weight ( kg )  n ( % )	C0005910;C0022718;C0439209;C1305866;C4054209	f	2326
205	bodyweight ( kg )	C0005910;C0022718;C0439209;C1305866;C4054209	f	2326
205	bodyweight  kg	C0005910;C0022718;C0439209;C1305866;C4054209	f	2326
205	adjusted mean change ( kg )	C0022718;C0392747;C0439209;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4054209;C4319952	f	2326
205	baseline weight  kg	C0022718;C0439209;C1303013;C4054209	f	2326
205	body weight — kg	C0005910;C0022718;C0439209;C1305866;C4054209	f	2326
205	actual or estimated weight  kg	C0022718;C0237400;C0439209;C4054209;C4329797	f	2326
205	low body weight ( < $nmbr$ kg )	C0022718;C0041667;C0439209;C4054209	f	2326
205	mean body weight  kg ( range )	C0005910;C0022718;C0439209;C0444504;C1305866;C1514721;C2347634;C2348143;C2348147;C3542016;C4054209	f	2326
205	mean body weight ( sd )  kg	C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209	f	2326
205	median body weight ( kg )	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209	f	2326
205	median body weight — kg	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209	f	2326
205	median m / kg $nmbr$ ( iqr )	C0022718;C0369637;C0439209;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209	f	2326
205	median weight  kg ( iqr )	C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209	f	2326
204	psa level  ng / ml	C0439275;C4086720	\N	\N
204	psa ( ng / ml )	C0439275;C3810537;C3813209	\N	\N
204	psa  ng / ml  mean ( sd )	C0439275;C0444504;C2347634;C2348143;C2699239;C3810537;C3813209	\N	\N
204	proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - > = median ( n = $nmbr$  $nmbr$ )	C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813	\N	\N
204	proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - < median ( n = $nmbr$  $nmbr$ )	C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813	\N	\N
204	procalcitonin ( ng / ml )	C0072027;C0439275	\N	\N
204	proadm ( ng / ml )	C0439275	\N	\N
204	pigr ( ng / ml )	C0439275;C1418569	\N	\N
204	pentraxin - $nmbr$ ( ng / ml )	C0439275	\N	\N
204	osteopontin ( ng / ml )	C0069676;C0439275;C1420369;C1505427;C4084879	\N	\N
204	opg  ( ng / ml )	C0439275;C1262886;C1336645;C1412836;C1710303	\N	\N
204	ntpro - cnp ( ng / ml )	C0439275;C3889729	\N	\N
204	nt probnp > $nmbr$ ng / ml n ( % ) §	C0439275;C1317554;C2825907;C4284038	\N	\N
204	ngal ( ng / ml )	C0215955;C0439275;C1416806;C2346625	\N	\N
204	neuropilin ( ng / ml )	C0287275;C0439275	\N	\N
204	mpo ( ng / ml )	C0439275	\N	\N
204	mmp - $nmbr$ ( ng / ml ) *	C0439275;C0623362;C0919336	\N	\N
204	mmp - $nmbr$ ( ng / ml )	C0439275;C0623362;C0919336	\N	\N
204	mesothelin ( ng / ml )	C0380162;C0439275;C1334533	\N	\N
204	ltbr ( ng / ml )	C0439275;C1416931	\N	\N
204	gdf - $nmbr$ ( ng / ml )	C0439275;C1418244	\N	\N
204	galectin - $nmbr$ ( ng / ml )	C0439275;C0607430	\N	\N
204	fasting c - peptide ( ng / ml )	C0006558;C0015663;C0439275	\N	\N
204	fasting c - peptide  ng / ml	C0006558;C0015663;C0439275	\N	\N
204	esam ( ng / ml )	C0439275;C1424976	\N	\N
204	ctn - l  ng / ml	C0439275;C0917591	\N	\N
204	ctn - i  ng / ml	C0021966;C0221138;C0439275;C0917591	\N	\N
204	crp ( ng / ml )	C0439275;C3890735;C4048285	\N	\N
204	ck - mb  ng / ml	C0010290;C0439275	\N	\N
204	cholesterol ( ng / ml )	C0008377;C0439275	\N	\N
204	biomarker low ( periostin < $nmbr$ ng / ml or blood eosinophils < $nmbr$ cells per pl )  na	C0005516;C0005773;C0007584;C0007634;C0014467;C0200638;C0205251;C0219433;C0439275;C0597484;C1272460;C1424662;C1546968;C1550472;C1879645;C3812270;C3890211;C3897966;C4048187;C4049765;C4049872;C4321351;C4522223;C4552882	\N	\N
204	angiogenin ( ng / ml )	C0051844;C0439275;C1367482	\N	\N
204	> $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ )	C0439275	\N	\N
204	> $nmbr$ . $nmbr$ ng / ml	C0439275	\N	\N
204	< $nmbr$ ng / ml	C0439275	\N	\N
204	< $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ )	C0439275	\N	\N
204	< $nmbr$ . $nmbr$ ng / ml	C0439275	\N	\N
203	ng ( n = $nmbr$  $nmbr$ )	C0017887;C0028074	\N	\N
203	ng	C0017887;C0028074	\N	\N
203	median serum periostin  ng / mla	C0017887;C0028074;C0219433;C0229671;C0549183;C0599973;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270	\N	\N
202	tnf - alpha ( pg / ml )	C0439297;C1448177;C1456820;C1522669	\N	\N
202	kim $nmbr$ ( pg / ml )	C0439297	\N	\N
202	avp pg / ml	C0439297;C1098706;C1568204;C1708407	\N	\N
202	> ulnand < $nmbr$ ng / l	C0439297	\N	\N
202	> = $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % )	C0439297	\N	\N
202	> = $nmbr$ ng / l ( n = $nmbr$ ) n ( % )	C0439297	\N	\N
202	> = $nmbr$ ng / l ( n = $nmbr$ )	C0439297	\N	\N
202	> = $nmbr$ . $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % )	C0439297	\N	\N
202	> $nmbr$ ng / l	C0439297	\N	\N
202	< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ) n ( % )	C0439297	\N	\N
202	< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ )	C0439297	\N	\N
202	% phg	\N	\N	\N
202	$nmbr$ . $nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ )	C0439297	\N	\N
202	$nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ )	C0439297	\N	\N
201	mmp - $nmbr$  median ( iqr )  gg / l	C0017454;C0018370;C0549183;C0623362;C0876920;C0919336;C2347635;C2348144;C2939193	\N	\N
201	ind $nmbr$ gg q . d . n / n ( % )	C0017454;C0018370;C4049864	\N	\N
201	gly $nmbr$ . $nmbr$ gg b . i . d n / n ( % )	C0017454;C0018370;C0152277;C1415124	\N	\N
201	gg	C0017454;C0018370	\N	\N
200	s $nmbr$ mg / mmol	C0565930;C0567349;C2348885;C2603362	\N	\N
200	s $nmbr$ . $nmbr$ mg / mmol	C0565930;C0567349;C2348885;C2603362	\N	\N
200	mg / mmol	C0567349;C2348885	\N	\N
200	median ( sd )  mg / mmol	C0549183;C0567349;C0876920;C2347635;C2348144;C2348885;C2699239;C2939193	\N	\N
200	mean a ± sd  mg / dl ( mmol / $nmbr$ )	C0439190;C0439269;C0444504;C0567349;C2347634;C2348143;C2348885;C2699239;C3642216	\N	\N
200	bl mean  mg / dl ( mmol / $nmbr$ )	C0005918;C0006413;C0439190;C0439269;C0444504;C0567349;C1552663;C2347634;C2348143;C2348885;C2827109;C3642216	\N	\N
200	> $nmbr$ . $nmbr$ mg / mmol	C0567349;C2348885	\N	\N
200	< $nmbr$ . $nmbr$ mg / mmol	C0567349;C2348885	\N	\N
200	. $nmbr$ . $nmbr$ mg / mmol	C0567349;C2348885	\N	\N
200	$nmbr$ . $nmbr$ to # $nmbr$ . $nmbr$ mg / mmol	C0567349;C2348885	\N	\N
200	$nmbr$ . $nmbr$ mg / mmol	C0567349;C2348885	\N	\N
202	troponin i ( pg / ml )	C0077401;C0439297	f	2322
202	troponin t ( pg / ml )	C0077404;C0439297;C1420827	f	2322
202	interleukin - $nmbr$ ( ng / l )	C0021764;C0439297;C1527200	f	2322
202	interleukin $nmbr$ ( pg / ml )	C0021764;C0439297;C1527200	f	2322
202	b - natriuretic peptide . pg / ml	C0070338;C0439297;C0597421	f	2323
202	n - terminal pro - brain natriuretic peptide  pg / ml	C0439297;C3272900	f	2323
202	endothelin $nmbr$ ( pg / ml )	C0079284;C0439297	f	2324
203	d - dimer level  mean ( sd )  ng / mld	C0017887;C0023522;C0028074;C0060323;C0441889;C0444504;C0456079;C1539265;C1547707;C2347634;C2348143;C2699239;C2946261;C3539688;C3539689	f	2325
200	$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ mg / mmol	C0567349;C2348885	\N	\N
199	umec $nmbr$ . $nmbr$ mcg ( n = $nmbr$ )	C0439211;C3463985	\N	\N
199	tio i $nmbr$ mcg ( n = $nmbr$ )	C0021966;C0221138;C0439211;C3463985	\N	\N
198	rsg $nmbr$ mg / day	C0439422	\N	\N
198	placebo + $nmbr$ mg / d of simvastatin ( n = $nmbr$ )	C0032042;C0074554;C0439422;C1696465;C1706408	\N	\N
198	no . of $nmbr$ - mg acetaminophen tablets / day	C0439422;C1243102	\N	\N
198	mg / day	C0439422	\N	\N
198	mean dose ( sd ) ( mg / day )	C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239	\N	\N
198	itca $nmbr$ $nmbr$ mg / day ( n = $nmbr$ )	C0165330;C0439422	\N	\N
198	ind $nmbr$ mg q . d . n = $nmbr$	C0439422;C4049864	\N	\N
198	dose ( mg / day )	C0178602;C0439422;C0869039;C1114758	\N	\N
198	dietary epa - dha intake ( mg / day ) *	C0142831;C0439422;C1286104;C2348308	\N	\N
198	dapagliflozin $nmbr$ mg / day ( n = $nmbr$ )	C0439422;C2353951	\N	\N
198	brv dosage  mg / d	C0155502;C0178602;C0439422;C2986497	\N	\N
198	brv > $nmbr$ mg / day	C0155502;C0439422	\N	\N
198	brv $nmbr$   mg / day	C0155502;C0439422	\N	\N
198	brv $nmbr$ mg / day ( n = $nmbr$ )	C0155502;C0439422	\N	\N
198	brv $nmbr$ mg / day ( n =	C0155502;C0439422	\N	\N
198	> $nmbr$ mg / day	C0439422	\N	\N
198	> $nmbr$ mg / d peq	C0439422	\N	\N
198	> $nmbr$ . $nmbr$ mg / day  %	C0439422	\N	\N
198	< $nmbr$ mg / day	C0439422	\N	\N
198	< $nmbr$ mg / d peq	C0439422	\N	\N
198	$nmbr$ mg / day	C0439422	\N	\N
198	$nmbr$ mg / d ( n = $nmbr$ )	C0439422	\N	\N
197	( pg / mg )	C1627892	\N	\N
196	≥ $nmbr$ to < $nmbr$ mg / g	C1300563	\N	\N
196	≥ $nmbr$ mg / g	C1300563	\N	\N
196	mg / g	C1300563	\N	\N
196	fcal  mg / g  mean ± sd	C0444504;C1300563;C2347634;C2348143;C2699239	\N	\N
196	^ $nmbr$ mg / g  n ( % )	C1300563	\N	\N
196	> = $nmbr$ mg / g	C1300563	\N	\N
196	> $nmbr$ to $nmbr$ mg / g	C1300563	\N	\N
196	> $nmbr$ mg / g	C1300563	\N	\N
196	< $nmbr$ mg / g  n ( % )	C1300563	\N	\N
196	< $nmbr$ mg / g	C1300563	\N	\N
196	$nmbr$ − $nmbr$ mg / g	C1300563	\N	\N
196	$nmbr$ to $nmbr$ mg / g	C1300563	\N	\N
196	$nmbr$ mg / g  n ( % )	C1300563	\N	\N
196	$nmbr$ mg / g	C1300563	\N	\N
196	$nmbr$ - $nmbr$ mg / g	C1300563	\N	\N
197	$nmbr$ baricitinib $nmbr$ mg ■ baricitinib $nmbr$ mg	C1319635;C4044947	f	1956
196	acr ( mg / g )  mean ( sd )	C0444504;C1300563;C1412134;C1515941;C2347634;C2348143;C2699239	f	2315
195	serum cholesterol  median ( iqr )  mg / dl	C0439269;C0549183;C0587184;C0876920;C2347635;C2348144;C2939193	f	1501
198	methotrexate dose on day $nmbr$ — mg per wl < $nmbr$	C0025677;C0178602;C0332173;C0439228;C0439422;C0439505;C0869039;C1114758;C4086581	f	1408
196	acr > $nmbr$ mg / g	C1300563;C1412134;C1515941	f	2315
196	baseline uacr < $nmbr$ mg / g	C0168634;C1300563;C1442488	f	2315
196	uac > $nmbr$ mg / g	C1300563	f	2315
196	uac $nmbr$ - $nmbr$ mg / g	C1300563	f	2315
196	uacra  mg / g  gmean = gcv	C0017066;C1300563	f	2315
196	uacra  mg / g  n ( % )	C1300563	f	2315
196	uacr  median ( iqr )  mg / g	C0549183;C0876920;C1300563;C2347635;C2348144;C2939193	f	2315
196	uacr ( mg / g )	C1300563	f	2315
196	uacr  mg / g  median ( iqr )	C0549183;C0876920;C1300563;C2347635;C2348144;C2939193	f	2315
196	uacr ( mg / g  median [ iqr ] )	C0549183;C0876920;C1300563;C2347635;C2348144;C2939193	f	2315
196	uacr — mg / g  median ( iqr )	C0549183;C0876920;C1300563;C2347635;C2348144;C2939193	f	2315
196	uacr *  mg / g ( q $nmbr$  q $nmbr$ )	C1300563	f	2315
196	urine acr geometric mean ( cv % )  a  b mg / g	C0042036;C0042037;C1300563;C1412134;C1515941;C2963137;C2986759;C3538987;C4048877;C4318503	f	2315
196	urine acr ( mg / g )	C0042036;C0042037;C1300563;C1412134;C1515941;C2963137	f	2315
196	prevalent kidney disease ( egfr < $nmbr$ ml / min / usm ^ or maeroalbuminuria uacr > $nmbr$ mg / g )	C0022658;C0033105;C0220900;C0439445;C1300563;C1739039;C3811844;C3812682	f	2315
196	normoalbuminuria ( uacr < $nmbr$ mg / g )	C1300563	f	2315
196	normal acr ( < $nmbr$ mg / mg ) at baseline to albuminuria ( acr > $nmbr$ mg / g )	C0001925;C0168634;C0205307;C0231683;C0439166;C1300563;C1319635;C1412134;C1442488;C1515941;C2347086;C4553972	f	2315
196	- median urine acr ( mg / g ) ( iqr )	C0042036;C0042037;C0549183;C0876920;C1300563;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137	f	2315
196	microalbuminuria  mg / g cr	C0201975;C0730345;C1300563;C3539604;C3711669;C4084730;C4553336;C4553337	f	2315
196	mean fecal calprotectin level  mg / g stool ( sd )	C0015733;C0183622;C0441889;C0444504;C0456079;C0950624;C1300563;C1335798;C1366582;C1547707;C2347634;C2348143;C2699239;C2946261	f	780
195	fg > $nmbr$	C0016703;C0439214;C2348814	f	21
195	serum fg  mg / dl	C0016703;C0229671;C0439214;C0439269;C1546774;C1550100;C1638318;C2348814;C3642216	f	21
197	uacr  pg / mg	C1627892	f	2318
197	urinary albumin : creatinine ratio ( pg / mg )  median ( iqr )	C0455271;C0549183;C0876920;C1318330;C1627892;C2347635;C2348144;C2939193	f	2318
197	urinary protein : creatinine ratioa ( mg / mg )	C0042027;C0369901;C0428627;C1319635;C1524119	f	2318
198	baseline corticosteroidst ( mean dose : $nmbr$ . $nmbr$ mg / day )  n ( % )	C0168634;C0178602;C0439422;C0444504;C0869039;C1114758;C1442488;C2347634;C2348143	f	1348
198	leflunomide ( mean dose : $nmbr$ . $nmbr$ mg / day )	C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143	f	2319
198	levodopa dose  mean ± sd  mg / day	C0023570;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239	f	2320
198	rasagiline  $nmbr$ mg / day	C0439422;C0525678	f	2321
198	steroid use at baseline ( mg / day )	C0168634;C0281991;C0439422;C1442488	f	1348
194	$nmbr$ mg / $nmbr$ wk ( n = $nmbr$ )	C1881833	\N	\N
193	≤ $nmbr$ mg / l	C0439268	\N	\N
193	final median  mg / l	C0205088;C0439268;C0549183;C0876920;C1546485;C2347635;C2348144;C2939193;C3853528	\N	\N
193	cld $nmbr$ mg ( n = l $nmbr$ )	C0439268	\N	\N
193	baseline serum mg > = $nmbr$ . $nmbr$ mmol / l	C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761	\N	\N
193	baseline serum mg < $nmbr$ . $nmbr$ mmol / l	C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761	\N	\N
193	baseline median  mg / l	C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193	\N	\N
193	about $nmbr$ mg / l or more	C0205172;C0439268	\N	\N
193	about $nmbr$ mg / l	C0439268	\N	\N
193	> $nmbr$ mg / l ( n = $nmbr$ )	C0439268	\N	\N
193	> $nmbr$ mg / l	C0439268	\N	\N
193	> $nmbr$ . $nmbr$ mg / l	C0439268	\N	\N
193	< $nmbr$ mg / l ( n = $nmbr$ )	C0439268	\N	\N
193	< $nmbr$ mg / l	C0439268	\N	\N
193	< $nmbr$ . $nmbr$ mg / l	C0439268	\N	\N
193	( ≥ $nmbr$ mg / l )	C0439268	\N	\N
193	( < $nmbr$ mg / l )	C0439268	\N	\N
193	$nmbr$ to $nmbr$ mg / l ( n = $nmbr$ )	C0439268	\N	\N
193	$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / l	C0439268	\N	\N
192	≥ $nmbr$ to < $nmbr$ mg / dl	C0439269	\N	\N
192	≥ $nmbr$ mg / dl	C0439269	\N	\N
192	£ $nmbr$ mg / dl	C0439269	\N	\N
192	with baseline crp level of > $nmbr$ mg / liter	C0024671;C0026410;C0168634;C0439269;C0441889;C0456079;C0475211;C1442488;C1547707;C1960952;C2346927;C2946261;C3890735;C4048285;C4321396;C4521761	\N	\N
192	week $nmbr$ ertugliflozin $nmbr$   mg vs . placebo	C0024671;C0026410;C0032042;C0332174;C0439230;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
192	week $nmbr$ ertugliflozin $nmbr$ mg vs placebo	C0024671;C0026410;C0032042;C0332174;C0439230;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
192	week $nmbr$ ertugliflozin $nmbr$ mg vs . placebo	C0024671;C0026410;C0032042;C0332174;C0439230;C0439269;C1696465;C1706408;C1960952;C2346927;C4079805;C4321396;C4521761	\N	\N
192	week $nmbr$ czp $nmbr$ mg q $nmbr$ w ( n = $nmbr$ )	C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	\N	\N
192	week $nmbr$ czp $nmbr$ mg q $nmbr$ w	C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	\N	\N
192	> $nmbr$ but < $nmbr$ mg / dl	C0439269	\N	\N
193	crp  mg / l *	C0439268;C3890735;C4048285	f	286
193	crp — mg / l	C0439268;C3890735;C4048285	f	286
193	crp ( mg / l )  mean ( sd )	C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	f	286
193	crp  mg / l : median ( range )	C0439268;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285	f	286
193	crp ( mg / l )  median ± sd	C0439268;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3890735;C4048285	f	286
193	crp ( mg / l )  n	C0439268;C3890735;C4048285	f	286
193	crp ( mg / l ) : < $nmbr$	C0439268;C3890735;C4048285	f	286
193	crp < $nmbr$ mg / l  n	C0439268;C3890735;C4048285	f	286
193	crp $ $nmbr$ mg / l  n	C0439268;C3890735;C4048285	f	286
193	baseline crp category ( mg / l )	C0168634;C0439268;C0683312;C1442488;C3889287;C3890735;C4048285	f	286
193	baseline crp levels < $nmbr$ mg / l	C0168634;C0439268;C0441889;C1442488;C3890735;C4048285	f	286
193	baseline crp levels ≥ $nmbr$ mg / l	C0168634;C0439268;C0441889;C1442488;C3890735;C4048285	f	286
193	high - sensitivity c - reactive protein  mg / l	C0006560;C0439268;C1413716;C1441604;C4048285	f	286
193	high - sensitivity c - reactive protein ( mg / l )	C0006560;C0439268;C1413716;C1441604;C4048285	f	286
193	high sensitivity c - reactive protein ( mg / l )	C0006560;C0439268;C1413716;C1441604;C4048285	f	286
193	hscrp > $nmbr$ to < $nmbr$ mg / l	C0439268	f	286
193	hscrp > $nmbr$ . $nmbr$ mg / l	C0439268	f	286
193	hscrp < $nmbr$ . $nmbr$ mg / l	C0439268	f	286
193	hscrp > $nmbr$ mg / l	C0439268	f	286
193	hscrp ( mg / l )  median ( minimum ‒ maximum )	C0439268;C0549183;C0806909;C0876920;C1524031;C1552614;C1552615;C2347635;C2348144;C2826545;C2826546;C2939193	f	286
193	hscrp ( mg / l )  median ( first  third quartiles )	C0205435;C0205437;C0439268;C0549183;C0876920;C1279901;C2347635;C2348144;C2828255;C2939193	f	286
193	hscrp ( mg / l ) c	C0439268	f	286
193	hscrp ( mg / l )	C0439268	f	286
193	hscrp  mg / l	C0439268	f	286
193	hscrp  median ( iqr )  mg / l	C0439268;C0549183;C0876920;C2347635;C2348144;C2939193	f	286
193	mean crp level  mg / l ( sd )	C0439268;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285	f	286
193	mean hscrp  mg / l ( sd )	C0439268;C0444504;C2347634;C2348143;C2699239	f	286
193	mean ( sd ) crp  mg / l *	C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	f	286
193	canakinumab  hscrp < $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ )	C0439231;C0439268;C2718773	f	372
193	canakinumab  hscrp > $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ )	C0439231;C0439268;C2718773	f	372
193	% change median baseline crp > $nmbr$ mg / l	C0168634;C0392747;C0439268;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C3890735;C4048285;C4319952	f	286
193	geometric mean crp concentration ( mg / l )	C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285	f	286
193	high - density lipoprotein cholesterol  mg / l	C0023822;C0439268	f	821
193	upadacitinib $nmbr$ mg ( n = l $nmbr$ )	C0439268	f	2314
193	mean baseline ibdq score ( sd ) § crp concentration  mg / l	C0086045;C0168634;C0439268;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285	f	2313
194	mtx ( mean dose : $nmbr$ . $nmbr$ mg / wk )	C0366550;C0444504;C1881833;C2347634;C2348143	f	716
192	vonoprazan $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C4080009;C4321396;C4521761	\N	\N
192	upa $nmbr$ mg qd	C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761	\N	\N
192	u » c » ( mg / g )	C0024671;C0026410;C0439148;C0439267;C0439269;C1300563;C1532633;C1638407;C1960952;C2346927;C2608091;C4321396;C4521761	\N	\N
192	t $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2603360;C4321396;C4521761	\N	\N
192	sita $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	silodosin $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1870115;C1960952;C2346927;C4321396;C4521761	\N	\N
192	> $nmbr$ and < $nmbr$ mg / dl	C0439269	\N	\N
192	ticagrelor $nmbr$ mg diabetes n = $nmbr$	C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761	f	2299
192	ticagrelor $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761	f	2299
192	tiotropium $nmbr$ mg	C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761	f	2300
192	tiotropium $nmbr$ mg ( n = $nmbr$	C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761	f	2300
192	tiotropium $nmbr$ mg respimat ® ( n = $nmbr$ )	C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761	f	2300
192	tiotropium $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761	f	2300
192	tiotropium $nmbr$ mg respimat ® ( n z $nmbr$ )	C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761	f	2300
192	tiotropium $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761	f	2300
192	tiotropium / olodaterol $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761	f	2301
192	tiotropium + olodaterol $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761	f	2301
192	tiotropium / olodaterol $nmbr$ / $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761	f	2301
192	tiotropium / olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761	f	2301
192	tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761	f	2301
192	tofacitinib  $nmbr$ mg twice daily	C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761	f	2302
192	tofacitinib $nmbr$ mg twice daily n = $nmbr$	C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761	f	2302
192	toricoxib $nmbr$ mg n = $nmbr$ ) ( % )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1130
192	serum glucose ( mg / dl )	C0202041;C0439269;C3534430	f	2305
192	serum triglycerides  mg / dle	C0024138;C0024671;C0026410;C0439269;C0542495;C1960952;C2346927;C3542918;C4321396;C4521761	f	2306
192	serum urea nitrogen  mg / dl	C0028158;C0229671;C0439269;C0600137;C0856666;C1291218;C1546774;C1550100;C1550581;C3683557	f	2271
192	serum urate ( mg / dl )	C0439269;C0455272	f	2308
192	serum urate ( mg / dl )  n ( % )	C0439269;C0455272	f	2308
192	serum uric acid ( mg / dl )	C0439269;C0455272;C0700634	f	2308
192	serum uric acid  mg / dl	C0439269;C0455272;C0700634	f	2308
192	tanezumab $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761	f	2309
192	tanezumab $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761	f	2309
192	tanezumab $nmbr$ mg + nsaid	C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761	f	2309
192	tanezumab $nmbr$ . $nmbr$ mg + nsaid	C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761	f	2309
192	tg ( mg / dl )	C0337445;C0439269	f	368
192	tg  mg / dl  mean ± sd	C0337445;C0439269;C0444504;C2347634;C2348143;C2699239	f	368
192	tg ( mg / dl )  median ± sd	C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193	f	368
192	tg mg / dl  median ( sd )	C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193	f	368
192	tg > $nmbr$ . hdl < $nmbr$ ( mg / dl ) ( / ? = $nmbr$ )	C0337445;C0439269;C3715113	f	368
192	tg > $nmbr$ mg / dl  n ( ° / o )	C0337445;C0439269	f	368
192	triglyceride ( mg / dl )	C0041004;C0439269	f	368
192	triglyceride  mg / dl  mean ( sd )	C0041004;C0439269;C0444504;C2347634;C2348143;C2699239	f	368
192	triglycerides level  mg / dl	C0428475;C0439269	f	368
192	triglycerides  mg / dl	C0041004;C0439269	f	368
192	triglycerides ( sd )  mg / dl	C0041004;C0439269;C2699239	f	368
192	uric acid fertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl )	C0015895;C0041980;C0439269	f	2310
192	uric acid tertile $nmbr$ ( < $nmbr$ . $nmbr$ mg / dl )	C0041980;C0439269	f	2310
192	uric acid ( mg / dl )	C0041980;C0439269	f	2310
192	uric acid ( mg / dl ) creatinine clearance ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )	C0024671;C0026410;C0041980;C0151280;C0369637;C0439269;C0441923;C1960952;C2346927;C3642208;C4321396;C4521761	f	2310
192	viidagliptin $nmbr$ mg daily + glimepiride	C0024671;C0026410;C0061323;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	f	2068
192	sirukumab $nmbr$ mg q $nmbr$ w	C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761	f	2311
192	total glucose mg / dl	C0017725;C0439175;C0439269;C0439810	f	2311
192	total intravenous loop diuretic ( mg ) median	C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C0549183;C0876920;C1960952;C2346927;C2347635;C2348144;C2939193;C3536704;C4321396;C4521761	f	991
192	sc belimumab $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761	\N	\N
192	saxa $nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	saxa $nmbr$ mg $nmbr$ metformin ( n $nmbr$ $nmbr$ )	C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	saxa $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	randomized to canakinumab $nmbr$ mg	C0024671;C0026410;C0034656;C0040363;C0041260;C0439269;C1883351;C1960952;C2346927;C2718773;C3815594;C4321396;C4521761	\N	\N
192	r $nmbr$ mg + fa ( « = $nmbr$ )	C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761	\N	\N
192	r $nmbr$ mg + fa	C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761	\N	\N
192	r $nmbr$ mg ( « = $nmbr$ )	C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761	\N	\N
192	r $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C0687673;C1960952;C2346927;C4321396;C4521761	\N	\N
192	r $nmbr$ mg	C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761	\N	\N
192	prednisone - equivalent dose — mg	C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761	\N	\N
192	ppg  mg / dl	C0439269;C1418888	\N	\N
192	plasma lipids ( mg / dl ) $nmbr$ total cholesterol mean	C0023779;C0439269;C0444504;C0858034;C2347634;C2348143	\N	\N
192	plasma cholesterol — mg / dl	C0439269;C0858034	\N	\N
192	placebofigolimumab $nmbr$ mg / $nmbr$ mgt	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	periprocedural medications  n ( % ) clopidogrel  $nmbr$ mg *	C0013227;C0024671;C0026410;C0070166;C0439269;C0802604;C1960952;C2346927;C2598133;C4284232;C4321396;C4521761	\N	\N
192	pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ ( n = $nmbr$ )	C0024671;C0026410;C0031962;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	\N	\N
192	patients receiving $nmbr$ mg of edoxaban at randomization — no . ( % ) f	C0016327;C0024671;C0026410;C0030705;C0034656;C0439269;C1514756;C1960952;C2346927;C2975435;C4321396;C4521761	\N	\N
192	p - value d $nmbr$ mg vs . warfarin	C0024671;C0026410;C0043031;C0439269;C1709380;C1960952;C2346927;C4321396;C4521761	\N	\N
192	on maximum tolerated medications ( % ) median ( $nmbr$ th to $nmbr$ th quartile ) sua ( mg / dl )	C0013227;C0039725;C0039738;C0439269;C0549183;C0802604;C0806909;C0876920;C1420718;C1552615;C2347635;C2348144;C2598133;C2826546;C2828255;C2939193;C4282123;C4284232;C4285344	\N	\N
192	mtx ≤ $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	f	716
192	mtx > $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	f	716
192	mtx > $nmbr$ – $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	f	716
192	elevated serum creatinine  > $nmbr$ . $nmbr$ mg / dl	C0439269;C0700225	f	952
192	non - hdl - c  mg / dl	C0439269;C1518422;C3715113	f	2291
192	non - hdl - c ( mg / dl )	C0439269;C1518422;C3715113	f	2291
192	non - hdl ( mg / dl ) < $nmbr$	C0439269;C1518422;C3715113	f	2291
192	non - hdl - c ( mg / dl ) * *	C0439269;C1518422;C3715113	f	2291
192	no . of $nmbr$ - mg tablets of acetaminophen	C0024671;C0026410;C0439269;C1243102;C1960952;C2346927;C4321396;C4521761	f	2292
192	olmesartan medoxomil $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0386393;C0439269;C1960952;C2346927;C4321396;C4521761	f	2293
192	olodaterol $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761	f	2294
192	olodaterol $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761	f	2294
192	omalizumab $nmbr$ mg ( n [ $nmbr$ )	C0024671;C0026410;C0439269;C0966225;C1960952;C2346927;C4321396;C4521761	f	940
192	pitavastatin $nmbr$ mg	C0024671;C0026410;C0439269;C1101838;C1960952;C2346927;C4321396;C4521761	f	2296
192	secukinumab intravenous $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0348016;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761	f	2297
192	secukinumab $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761	f	2297
192	secukinumab $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761	f	2297
192	secukinumab $nmbr$   mg	C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761	f	2297
192	rosiglitazone $nmbr$ mg daik	C0024671;C0026410;C0289313;C0439269;C1960952;C2346927;C4321396;C4521761	f	2298
192	rosiglitazone $nmbr$ mg daily	C0024671;C0026410;C0289313;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	f	2298
192	rosuva $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	886
192	rosuva $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	886
192	oral glucocorticoid dose  mg ( prednisone equivalent )	C0017710;C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0442027;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761;C4521986	f	1348
192	serum cholesterol  mean ( sd )  mg / dl	C0439269;C0444504;C0587184;C2347634;C2348143;C2699239	f	2303
192	serum cholesterol  mean ( sd ) mg / dl	C0439269;C0444504;C0587184;C2347634;C2348143;C2699239	f	2303
192	serum cholesterol  mg / dld	C0024671;C0026410;C0439269;C0587184;C1414063;C1960952;C2346927;C2826331;C4321396;C4521761	f	2303
192	serum creatinine level  mean ( sd )  mg / dl	C0439269;C0444504;C0600061;C2347634;C2348143;C2699239	f	2304
192	serum creatinine  mg / dlb	C0024671;C0026410;C0201976;C0439269;C0600061;C0752347;C1960952;C2346927;C3890365;C4321396;C4521761	f	2304
192	mg daily )	C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	mg / dl	C0439269	\N	\N
192	metsyn with ldl > $nmbr$ . $nmbr$ mg / dl	C0439269	\N	\N
192	metformin dose  mg	C0024671;C0025598;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761	\N	\N
192	median c - reactive protein — mg / liter	C0006560;C0024671;C0026410;C0439269;C0475211;C0549183;C0876920;C1413716;C1960952;C2346927;C2347635;C2348144;C2939193;C4048285;C4321396;C4521761	\N	\N
192	mean — mg / dl level — no . ( % )	C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261	\N	\N
192	mean — mg / dl	C0439269;C0444504;C2347634;C2348143	\N	\N
192	mean ± sd triglycerides  mg / dl	C0041004;C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
192	mean serum potassium  mg / dl	C0302353;C0439269;C0444504;C0543465;C2347634;C2348143	\N	\N
192	mean serum glucose  mg / dl  mean = sd	C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430	\N	\N
192	mean serum cholesterol  mg / dl	C0439269;C0444504;C0587184;C2347634;C2348143	\N	\N
192	mean sd ldl - c  mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
192	mean sd hdl - c  mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239;C3715113	\N	\N
192	mean sd fpg  mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
192	mean lipid difference ( mg / dl ) hdl - c	C0023779;C0439269;C0444504;C1705241;C1705242;C2347634;C2348143;C3715113	\N	\N
192	mean dose ( sd ) ( mg / week )	C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761	\N	\N
192	mean daily dose ( range ) — mg  i	C0021966;C0024671;C0026410;C0221138;C0439269;C0444504;C1514721;C1960952;C2346927;C2347634;C2348070;C2348143;C2348147;C3542016;C4321396;C4521761	\N	\N
192	mean change in dbp from baseline  mg / dl  mean ( sd )	C0168634;C0392747;C0439269;C0443172;C0444504;C0536221;C1442488;C1705241;C2347634;C2348143;C2699239;C3813197;C4281799;C4319952	\N	\N
192	mean ( sd ) mtx dose  mg / week	C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761	\N	\N
192	mean ( sd ) calcium intake in mg daily	C0024671;C0026410;C0332173;C0439269;C0444504;C0489458;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761	\N	\N
192	mean ( s . d . ) apoc - ll $nmbr$  mg / dl	C0003594;C0439269;C0444504;C2347634;C2348143	\N	\N
192	mean ( s . d . ) apob  mg / dl	C0003593;C0439269;C0444504;C2347634;C2348143;C3252643	\N	\N
192	mean ( median ) mtx dose  mg / week	C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C0549183;C0876920;C1960952;C2346927;C2347634;C2347635;C2348143;C2348144;C2939193;C4321396;C4521761	\N	\N
192	mean  mg / dl	C0439269;C0444504;C2347634;C2348143	\N	\N
192	male acr definition  ^ . g / mg	C0024671;C0026410;C0086582;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1706180;C1706428;C1706429;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761	\N	\N
192	lpa  mg / dl	C0439269;C1096202;C1439335;C3539666;C4049711;C4553379	\N	\N
192	ldl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients	C0023824;C0030705;C0202117;C0439269;C0444504;C0470187;C2347634;C2348143;C2699239	f	1963
192	ldl cholesterol ( sd )  mg / dl	C0023824;C0202117;C0439269;C2699239	f	1963
192	ldl cholesterol  mean ( sd )  mg / dl	C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239	f	1963
192	ldl - cholesterol ( mg / dl )	C0023824;C0202117;C0439269	f	1963
192	ldl cholesterol  mg / dl	C0023824;C0202117;C0439269	f	1963
192	ldl cholesterol — mg / dl | |	C0023824;C0202117;C0439269	f	1963
192	ldl cholesterol — mg / dl	C0023824;C0202117;C0439269	f	1963
192	ldl - cholesterol  mg / dl  mean ( sd )	C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239	f	1963
192	ldl cholesterol ( mg / dl )	C0023824;C0202117;C0439269	f	1963
192	mtx < $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	f	716
192	lipid levels — mg / dl	C0428460;C0439269	f	1967
192	methotrexate dose | |  mg	C0024671;C0025677;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761	f	1408
192	lipid difference ( mg / dl )	C0023779;C0439269;C1705241;C1705242	f	1967
192	lipid and lipoprotein values ( mg / dl )	C0023779;C0023820;C0042295;C0439269	f	1967
192	lipid parameters  mg / dl  mean ( sd )	C0023779;C0439269;C0444504;C0449381;C2347634;C2348143;C2699239	f	1967
192	lipid levels — mg / dlj total cholesterol	C0024671;C0026410;C0201950;C0428460;C0439269;C0543421;C1960952;C2346927;C4321396;C4521761	f	1967
192	lipid measures at baseline — mg / dl	C0023779;C0079809;C0168634;C0242485;C0439269;C1442488;C1879489	f	1967
192	lipids  mean ( sd )  mg / dlf	C0023779;C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761	f	1967
192	lipids  mean ( sd )  mg / dlt	C0023779;C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761	f	1967
192	lebrikizumab $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761	f	2287
192	lebrikizumab $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761	f	2287
192	lebrikizumab $nmbr$ - $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761	f	2287
192	lebrikizumab $nmbr$ - $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761	f	2287
192	llraglutide $nmbr$ - $nmbr$ mg mean ( n )	C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761	f	1566
192	lovastatin $nmbr$ mg	C0024027;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	2290
192	mepolizumab  $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761	f	2307
192	mepolizumab $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761	f	2307
192	iv - $nmbr$ mg	C0022326;C0024671;C0026410;C0439269;C1960952;C2346927;C4265176;C4321396;C4521761	\N	\N
192	initiation of dialysis  renal transplantation  or creatinine . $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mmol / l )	C0010294;C0011945;C0011946;C0019004;C0022671;C0040732;C0040733;C0439269;C0589507;C1059964;C1158830;C1532563;C1561535;C1704686;C4551529	\N	\N
192	ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$ )	C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761	\N	\N
192	ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$  $nmbr$ )	C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761	\N	\N
192	i - $nmbr$ mg / d ( n = $nmbr$ )	C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C4321396;C4521761	\N	\N
192	glycopyrronium $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3814772;C4321396;C4521761	\N	\N
192	gly $nmbr$ . $nmbr$ mg b . i . d . n = $nmbr$	C0024671;C0026410;C0152277;C0439269;C1415124;C1960952;C2346927;C4321396;C4521761	\N	\N
192	geometric mean ofcrp — mg / liter ( range )	C0024671;C0026410;C0439269;C0475211;C1514721;C1960952;C2346927;C2348147;C2986759;C3542016;C4321396;C4521761	\N	\N
192	fsg ( mg / dl )	C0439269	\N	\N
192	fsg  mg / dl ( mean ± sd )	C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
192	fpg month $nmbr$ ( mg / dl )	C0332177;C0439231;C0439269	\N	\N
192	fpg change ( mg / dl ) *	C0392747;C0439269;C0443172;C1705241;C4319952	\N	\N
192	fpg ( mg / dl ) x	C0439269	\N	\N
192	fpg ( mg / dl )	C0439269	\N	\N
192	fpg  mg / dl  mean ± sd	C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
192	fpg  mg / dl	C0439269	\N	\N
192	hscrp — mg / liter	C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	f	286
192	hdl - cholesterol  mg / dl  mean ( sd )	C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239	f	1962
192	hdl - c level  mean ( sd )  mg / dl	C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3715113	f	1962
192	hdl - c  mean ( sd )  mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239;C3715113	f	1962
192	hdl - c level  mg / dl	C0439269;C0441889;C0456079;C1547707;C2946261;C3715113	f	1962
192	hdl - c level  < $nmbr$ mg / dld	C0024671;C0026410;C0439269;C0441889;C0456079;C1414063;C1547707;C1960952;C2346927;C2826331;C2946261;C3715113;C4321396;C4521761	f	1962
192	hdl - c ( median  iqr )  mg / dl	C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3715113	f	1962
192	hdl - c  mg / dl	C0439269;C3715113	f	1962
192	hdl - c ( mg / dl )	C0439269;C3715113	f	1962
192	hdl - c ( mg / dl ) *	C0439269;C3715113	f	1962
192	hdl - c  mg / dl  mean + sd	C0439269;C0444504;C2347634;C2348143;C2699239;C3715113	f	1962
192	hdl - c ( mg / dl ) - mean ± sd	C0439269;C0444504;C2347634;C2348143;C2699239;C3715113	f	1962
192	hdl - c < $nmbr$ mg / dl_	C0439269;C3715113	f	1962
192	hdl - c < $nmbr$ mg / dl	C0439269;C3715113	f	1962
192	hdl - c < $nmbr$ mg / dl  no . ( % )	C0439269;C3715113	f	1962
192	hdl - c  $nmbr$ mg / dl  n ( % )	C0439269;C3715113	f	1962
192	hdl - c < $nmbr$ mg / dl . n ( % )	C0439269;C3715113	f	1962
192	hdl ( mg / dl )	C0439269;C3715113	f	1962
192	hdl < $nmbr$ mg / dl	C0439269;C3715113	f	1962
192	hdl cholesterol  mean ( sd )  mg / dl	C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239	f	1962
192	hdl - cholesterol  mean ( sd ) mg / dl	C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239	f	1962
192	ldl - c $nmbr$ - $nmbr$ mg / dl	C0439269	f	1963
192	ldl - c > $nmbr$ mg / dl	C0439269	f	1963
192	ldl - c < $nmbr$ mg / dl  no . ( % )	C0439269	f	1963
192	ldl - c < $nmbr$ mg / dl	C0439269	f	1963
192	ldl - c ( mg / dl ) < $nmbr$	C0439269	f	1963
192	ldl - c  mg / dl  mean + sd	C0439269;C0444504;C2347634;C2348143;C2699239	f	1963
192	ldl - c ( mg / dl ) * *	C0439269	f	1963
192	ldl - c  mg / dl	C0439269	f	1963
192	ldl - c  mg / dl *	C0439269	f	1963
192	ldl - c ( mg / dl )	C0439269	f	1963
192	ldl - c  mean ( sd )  mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239	f	1963
192	ldl - c level  mean ( sd )  mg / dl	C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261	f	1963
192	ldl - c level  mg / dl	C0439269;C0441889;C0456079;C1547707;C2946261	f	1963
192	ldl - c ( bq ) ( mg / dl ) - mean ± sd	C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216	f	1963
192	ldl - c ( calculated )  mg / dl  mean ( sd )	C0439269;C0444504;C0444686;C1441506;C2347634;C2348143;C2699239	f	1963
192	ldl - cholesterol  mean ( sd ) mg / dl	C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239	f	1963
192	ldl - c  mg / dl  mean ± sd	C0439269;C0444504;C2347634;C2348143;C2699239	f	1963
192	glucose ( mg / dl )	C0017725;C0439269	f	2283
192	glucose — mg / dl	C0017725;C0439269	f	2283
192	glucose  mg / dl  mean	C0017725;C0439269;C0444504;C2347634;C2348143	f	2283
192	glycemia  mg / dl	C0005802;C0439269	f	2283
192	increase creatinine  < $nmbr$ . $nmbr$ mg / dl	C0010294;C0439269;C0442805;C1561535	f	2284
192	increase creatinine  > $nmbr$ . $nmbr$ mg / dl	C0010294;C0439269;C0442805;C1561535	f	2284
192	i intensive  $nmbr$ mg of atorvastatin ( n = $nmbr$ )	C0021966;C0024671;C0026410;C0162425;C0221138;C0286651;C0439269;C0522510;C1283828;C1550453;C1960952;C2346927;C4321396;C4521761	f	885
192	indacaterol $nmbr$ mg	C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761	f	2285
192	indacaterol $nmbr$ mg [ n z $nmbr$ ]	C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761	f	2285
192	impaired fasting glucose ( > $nmbr$ mg / dl ) ( % )	C0439269;C1272092	f	2286
192	lansoprazole $nmbr$ mg qd	C0024671;C0026410;C0050940;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	f	2288
192	fpg  mean ( sd )  mg / dlt	C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761	\N	\N
192	fpg  mean ( sd )  mg / dlf	C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761	\N	\N
192	fpg  mean ( sd )  mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
192	fpg  ( mg / dl )	C0439269	\N	\N
192	female acr definition  ^ g / mg	C0024671;C0026410;C0043210;C0086287;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1705497;C1705498;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761	\N	\N
192	fbs > = $nmbr$ mg / dl	C0439269;C3812213	\N	\N
192	fbs < $nmbr$ mg / dl	C0439269;C3812213	\N	\N
192	fa $nmbr$ mg ( « = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	fa $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	eze = ezetimibe $nmbr$ mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .	C0003591;C0003594;C0008377;C0023821;C0023824;C0024671;C0026410;C0031529;C0033684;C0039225;C0041004;C0074554;C0178602;C0201950;C0242821;C0439267;C0439269;C0460148;C0543421;C0577559;C0577573;C0600653;C0674390;C0918012;C1096155;C1142985;C1268086;C1306372;C1532737;C1538326;C1552854;C1637833;C1705223;C1709595;C1960952;C2346927;C2349200;C2986546;C3152252;C3539882;C3541325;C3891451;C4054077;C4082212;C4283905;C4319774;C4321396;C4521761;C4522255	\N	\N
192	esrd saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0022661;C0024671;C0026410;C0035078;C0439269;C1960952;C2316810;C2346927;C4321396;C4521761	\N	\N
192	elevated symptomatic serum creatinine  hypotension > $nmbr$ . $nmbr$ mg / dl	C0020649;C0231220;C0439269;C0700225;C3163620	\N	\N
53	anesthesiad  n ( % )	\N	\N	\N
192	fasting cholesterol — mg / dl	C0008377;C0015663;C0439269	f	2000
192	elevated serum creatinine ( > $nmbr$ . $nmbr$ mg / dl_ )	C0439269;C0700225	f	952
192	fc - ldl - c  mg / dl	C0439269;C2983605	f	1963
192	empagiiflozin $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	2277
192	empaglifiozin $nmbr$ . $nmbr$ mg ( w = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	2277
192	empaglifiozin $nmbr$ mg ( w = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	2277
192	erlugliflozin $nmbr$ mg vs placebo / glimepiride	C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761	f	2278
192	ertuglifldzin $nmbr$ mg vs placebo / glinepiride	C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761	f	2278
192	esr  mean ± sd mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239;C3811131	f	298
192	famotidine $nmbr$ mg ( n = $nmbr$ )	C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	2279
192	fasting glucose level  mg / dl	C0202045;C0439269	f	2280
192	fasting glucose  mean ( sd )  mg / dl	C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239	f	2280
192	fasting glucose  mg / dl	C0015663;C0017725;C0439269	f	2280
192	fasting glucose ( mg / dl )	C0015663;C0017725;C0439269	f	2280
192	fasting glucose  mg / dl '	C0015663;C0017725;C0439269	f	2280
192	fasting glucose — mg / dl	C0015663;C0017725;C0439269	f	2280
192	fasting glucose mg / dl diabetes classification	C0008902;C0008903;C0011847;C0011849;C0015663;C0017725;C0439269;C0678229	f	2280
192	fasting glucose  mg / dl  mean ( sd ) §	C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239	f	2280
192	fasting glucose > $nmbr$ mg / dl *	C0015663;C0017725;C0439269	f	2280
192	fasting glucose > $nmbr$ mg / dl  n ( % )	C0015663;C0017725;C0439269	f	2280
192	fasting serum glucose level  mean ( sd )  mg / dl	C0015663;C0202045;C0229671;C0439269;C0444504;C0583332;C1546774;C1550100;C2347634;C2348143;C2699239	f	2280
192	fasting serum glucose  mean ( sd ) mg / dl	C0015663;C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430	f	2280
192	fasting serum glucose  median ( sd )  mg / dl	C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3534430	f	2280
192	fasting serum glucose  mg / dl	C0015663;C0202041;C0439269;C3534430	f	2280
192	fasting serum glucose ( mg / dl )	C0015663;C0202041;C0439269;C3534430	f	2280
192	fasting serum glucose — mg / dl * *	C0015663;C0202041;C0439269;C3534430	f	2280
192	fasting serum glucose ( mg / dl )  median ( iqr )	C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430	f	2280
192	fasting triglyceride level  mean ( sd )  mg / dl	C0015663;C0428475;C0439269;C0444504;C2347634;C2348143;C2699239	f	2281
192	fasting triglycerides  mean ( sd ) mg / dl	C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239	f	2281
192	fbg ( mg / dl )	C0439269	f	2280
192	febuxostat $nmbr$ mg	C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761	f	2282
192	febuxostat $nmbr$ mg daily n = $nmbr$	C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	f	2282
192	febuxostat $nmbr$ mg daily n = $nmbr$ n ( % )	C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	f	2282
192	feno  $nmbr$ mg dn = $nmbr$ )	C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761	f	803
192	feno $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	803
192	dupiiumab  $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	dose equivalent  mg ( sd ) )	C0024671;C0026410;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C2699239;C4321396;C4521761	\N	\N
192	dose ( mg / week )	C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761	\N	\N
192	dose  mg	C0024671;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761	\N	\N
192	dbp $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) baseline lipid profile  mg / dl  mean ( sd )	C0023779;C0168634;C0439269;C0444504;C0536221;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239;C3813197;C4281799	\N	\N
192	daily dose > $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761	\N	\N
192	daily dose $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761	\N	\N
192	daily dose $nmbr$ - $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761	\N	\N
192	d $nmbr$ mg vs . warfarin	C0024671;C0026410;C0043031;C0073187;C0332173;C0439269;C1960952;C2346927;C4321396;C4484261;C4521761	\N	\N
188	non - hispanic black	C0005680;C0027567;C0085756;C0439541;C1518424	\N	\N
192	crp  mg / dl	C0439269;C3890735;C4048285	f	286
192	crp ( mg / dl )	C0439269;C3890735;C4048285	f	286
192	crp ( mg / dl ) * *	C0439269;C3890735;C4048285	f	286
192	crp  mg / dl  mean ( sd )	C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	f	286
192	crp  mg / dl  median	C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285	f	286
192	crp ( mg / dl ) < $nmbr$ . $nmbr$	C0439269;C3890735;C4048285	f	286
192	crp ( mg / dl  per unit )	C0024671;C0026410;C0439148;C0439269;C0439453;C1509845;C1519795;C1532632;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C3890735;C4048285;C4321396;C4521761	f	286
192	crp — mg / liter ^	C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761	f	286
192	crp > $nmbr$ . $nmbr$ mg / dl  n ( % )	C0439269;C3890735;C4048285	f	286
192	crp > $nmbr$ mg / $nmbr$  n [ % ]	C0024671;C0026410;C0439269;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761	f	286
192	crp ( normal < $nmbr$ . $nmbr$ mg / dl )	C0205307;C0231683;C0439166;C0439269;C2347086;C3890735;C4048285;C4553972	f	286
192	crp ( normal range : $nmbr$ - $nmbr$ . $nmbr$ )  mg / dl  mean ( sd )	C0086715;C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	f	286
192	dabigatran $nmbr$ mg bid vs warfarin	C0024671;C0026410;C0043031;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$ mg ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$ mg versu swarfarin	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$ mg versus warfarin	C0024671;C0026410;C0043031;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran  $nmbr$ mg  vs . warfarin	C0024671;C0026410;C0043031;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$   mg b . i . d .	C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	czp $nmbr$ mg	C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	czp $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ )	C0024671;C0026410;C0054841;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	czp $nmbr$ mg ( n = lll )	C0024671;C0026410;C0054841;C0439269;C1261077;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	czp $nmbr$ mg  % ( n / n )	C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	dabigatran  $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran  $nmbr$ mg bid	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	dabigatran $nmbr$ mg bid	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
192	czp $nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	czp $nmbr$ mg q $nmbr$ w	C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	dapagliflozin $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761	f	2275
192	dapagliflozin $nmbr$ mg group ( n = $nmbr$ )	C0024671;C0026410;C0439269;C0441848;C1960952;C2346927;C2353951;C4321396;C4521761	f	2275
192	dapagliflozin $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761	f	2275
192	dulaglutide $nmbr$ . $nmbr$ mg *	C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761	f	2276
192	dulaglutide $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761	f	2276
192	dulaglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761	f	2276
192	dulaglutide $nmbr$ · $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761	f	2276
192	cld $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	change in fpg $nmbr$ to month $nmbr$ ( mg / dl )	C0332177;C0392747;C0439231;C0439269;C0443172;C1705241;C4319952	\N	\N
192	change from baseline to eos  mg / dl	C0168634;C0392747;C0439269;C0443172;C1442488;C1623465;C1705241;C1861303;C4319952	\N	\N
192	change from baseline  mg / dl  mean ( sd )	C0168634;C0392747;C0439269;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C4319952	\N	\N
192	cana $nmbr$ mg ( n = $nmbr$ ) *	C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761	\N	\N
192	cana $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761	\N	\N
192	cana $nmbr$ mg ( n - $nmbr$ )	C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761	\N	\N
192	cana $nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761	\N	\N
192	cana $nmbr$ mg	C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761	\N	\N
192	baseline sildenafil dose mg	C0024671;C0026410;C0168634;C0178602;C0439269;C0529793;C0869039;C1114758;C1442488;C1960952;C2346927;C4321396;C4521761	\N	\N
192	baseline serum urate ( mg / dl ) a	C0168634;C0439269;C0455272;C1442488	\N	\N
192	baseline mean ( mg / dl ]	C0168634;C0439269;C0444504;C1442488;C2347634;C2348143	\N	\N
192	baseline mean  mg / dl	C0168634;C0439269;C0444504;C1442488;C2347634;C2348143	\N	\N
192	baseline lp ( a )  mg / dl	C0065058;C0168634;C0439269;C1439335;C1442488;C4553379	\N	\N
192	baseline fpg  mg / dl	C0168634;C0439269;C1442488	\N	\N
192	baseline . mean _ sd . mg / dl	C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
192	baseline . mean _ sd  mg / dl	C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239	\N	\N
192	baseline  mg / dl ( mmol / l )	C0168634;C0439269;C1442488;C1532563	\N	\N
192	> $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	creatinine — mg / dl	C0010294;C0439269;C1561535	f	952
192	creatinine ( mg / dl )	C0010294;C0439269;C1561535	f	952
192	creatinine  mg / dl_	C0010294;C0439269;C1561535	f	952
192	creatinine  mg / dl	C0010294;C0439269;C1561535	f	952
192	creatinine  mean ( sd )  mg / dl	C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239	f	952
192	baseline crp ( mg / dl )	C0168634;C0439269;C1442488;C3890735;C4048285	f	286
192	c - reactive protein — mg / liter * *	C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761	f	286
192	clopidogrel loading dose $nmbr$ mg	C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C3714444;C4321396;C4521761	f	217
192	clopidogrel  $nmbr$ mg *	C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C4321396;C4521761	f	217
192	clopidogrel  $nmbr$ - mg loading dose	C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761	f	217
192	baseline aspirin dose < $nmbr$ mg	C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761;C4696290	f	1366
192	baseline hdl - c level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113	f	2001
192	blood urea nitrogen  mg / dl	C0005845;C0439269;C0600137	f	2271
192	blood urea nitrogen ( mg / dl )	C0005845;C0439269;C0600137	f	2271
192	bun ( mg / dl )	C0439269	f	2271
192	baseline ldlc level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261	f	1964
192	baseline ldlc level ( n = $nmbr$  $nmbr$ ) ^ $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261	f	1964
192	baseline ldl - c  mg / dl	C0168634;C0439269;C1442488	f	1964
192	baseline ldl - c > $nmbr$ mg / dl	C0168634;C0439269;C1442488	f	1964
192	baseline ldl ‐ c  mg / dl	C0168634;C0439269;C1442488	f	1964
192	baseline ldl ( mg % )	C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761	f	1964
192	baseline low - density lipoprotein cholesterol ( mg / dl )	C0023824;C0168634;C0439269;C1442488	f	1964
192	baseline ldlc level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261	f	1964
192	bun  mg / dl	C0439269	f	2271
192	baseline hdl ‐ c  mg / dl	C0168634;C0439269;C1442488;C3715113	f	2001
192	baseline hdl - c  mg / dl	C0168634;C0439269;C1442488;C3715113	f	2001
192	baseline hdl - c level ( n = s $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113	f	2001
192	cholesterol — mg / dl	C0008377;C0439269	f	2000
192	cholesterol ( mg / dl )	C0008377;C0439269	f	2000
192	cholesterol  mg / dl	C0008377;C0439269	f	2000
192	baseline hdl - c level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113	f	2001
192	belimumab $nmbr$ mg sc ( n $nmbr$ )	C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761	f	2272
192	body mass index ( mg / m $nmbr$ )	C0005893;C0024671;C0026410;C0369637;C0439269;C0441923;C0578022;C1305855;C1960952;C2346927;C4321396;C4521761	f	1734
192	canakinumab $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C2718773;C4321396;C4521761	f	372
192	carisbamate $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761	f	2273
192	carisbamate $nmbr$  $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761	f	2273
192	azl - m $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0369637;C0439269;C0441923;C1960952;C2346927;C4321396;C4521761	\N	\N
192	average dose ( mg / week )	C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761	\N	\N
192	asa > $nmbr$ mg	C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761	\N	\N
192	asa < $nmbr$ mg	C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761	\N	\N
192	ami $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761	\N	\N
192	ami $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761	\N	\N
192	> = $nmbr$ mg / dl	C0439269	\N	\N
192	> $nmbr$ to < $nmbr$ mg dl	C0439269	\N	\N
192	> $nmbr$ to < $nmbr$ mg / dl	C0439269	\N	\N
192	> $nmbr$ to < $nmbr$ - $nmbr$ mg / week	C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	> $nmbr$ mg dl	C0439269	\N	\N
192	> $nmbr$ mg / liter	C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	\N	\N
192	> $nmbr$ mg / dl — %	C0439269	\N	\N
192	> $nmbr$ mg / dl simva ( „ = $nmbr$ )	C0439269	\N	\N
192	> $nmbr$ mg / dl simva $nmbr$ = $nmbr$ ]	C0439269	\N	\N
192	> $nmbr$ mg / dl simva	C0439269	\N	\N
192	> $nmbr$ mg / dl eze / simva ( „ = $nmbr$ )	C0439269	\N	\N
192	> $nmbr$ mg / dl eze / simva $nmbr$ = $nmbr$ }	C0439269	\N	\N
192	> $nmbr$ mg / dl eze / simva	C0439269	\N	\N
192	> $nmbr$ mg / dl	C0439269	\N	\N
152	anemia	C0002871;C1000483;C4554633	\N	\N
192	aspirin $nmbr$ mg	C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1366
192	alogliptin $nmbr$ mg + pioglitazone ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761	f	1955
192	alogliptin $nmbr$ . $nmbr$ mg + pioglitazone ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761	f	1955
192	amlodipine / valsartan $nmbr$ to $nmbr$ / $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761	f	78
192	amlodipine / valsartan $nmbr$ / $nmbr$ vs $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761	f	78
192	amlodipine $nmbr$ to $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761	f	78
192	amlodipine $nmbr$ mg / v = $nmbr$	C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761	f	78
192	apixaban  $nmbr$ mg	C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761	f	1224
192	apixaban  $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761	f	1224
192	apixaban $nmbr$ mg bid	C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761	f	1224
192	apixaban  $nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761	f	1224
192	apixaban $nmbr$ . $nmbr$ mg bid	C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761	f	1224
192	apixaban  $nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761	f	1224
192	aplxaban $nmbr$ . $nmbr$ mg bid	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1224
192	apolipoprotein a $nmbr$ ( mg / dl )	C0003592;C0439269;C0523508	f	1028
192	apolipoprotein b ( mg / dl )	C0003593;C0439269	f	1028
192	apolipoprotein b $nmbr$  mg / dl	C0003593;C0439269	f	1028
192	apolipoprotein b  mg / dl	C0003593;C0439269	f	1028
192	baricitinib $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761	f	1956
192	baricitinib  $nmbr$ mg daily ( n = $nmbr$ )	C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761	f	1956
192	baricitinib $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761	f	1956
192	baricitinib $nmbr$ mg qd ( n = $nmbr$ )	C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761	f	1956
192	baricitinib $nmbr$ mg qd	C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761	f	1956
192	baricitinib $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761	f	1956
192	average weekly mtx dose ( mg / week )	C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761	f	716
192	average weekly mtx dose ( mg / week ) t	C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761	f	716
192	all dulaglutide $nmbr$ . $nmbr$ mg + insulin lispro / insulin glargine ( n = $nmbr$ )	C0024671;C0026410;C0293359;C0439269;C0907402;C1960952;C2346927;C3179549;C4321396;C4521761	f	2268
192	apoal  mg / dl	C0439269	f	2269
192	apoal ( mg / dl ) *	C0439269	f	2269
192	apo a $nmbr$ ( mg / dl )	C0003592;C0439269;C0523508;C4553344;C4553379	f	2269
192	apoa $nmbr$  mg / dl	C0003592;C0439269;C0523508;C4553344;C4553379	f	2269
192	apob  mg / dl	C0003593;C0439269;C3252643	f	2269
192	apob ( mg / dl )	C0003593;C0439269;C3252643	f	2269
192	apremilast $nmbr$ mg bid n = $nmbr$	C0024671;C0026410;C0439269;C1678805;C1960952;C2346927;C4321396;C4521761	f	2270
192	ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1420068;C1960952;C2346927;C4321396;C4521761	f	1840
192	ato $nmbr$ mg and sim $nmbr$ - $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1420068;C1960952;C2346927;C4321396;C4521761	f	1840
192	ato $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	885
192	> $nmbr$ . $nmbr$ mg / liter	C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	\N	\N
192	> $nmbr$ . $nmbr$ mg / dl	C0439269	\N	\N
192	> $nmbr$ & < $nmbr$ mg / dl	C0439269	\N	\N
192	> $nmbr$  < $nmbr$ mg / dl	C0439269	\N	\N
192	< $nmbr$ mg / liter	C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	\N	\N
192	< $nmbr$ mg / dl simva ( n = $nmbr$ ]	C0439269	\N	\N
192	< $nmbr$ mg / dl simva ( n = $nmbr$ )	C0439269	\N	\N
192	< $nmbr$ mg / dl simva	C0439269	\N	\N
192	< $nmbr$ mg / dl eze / simva ( n = $nmbr$ }	C0439269	\N	\N
192	< $nmbr$ mg / dl eze / simva ( n = $nmbr$ )	C0439269	\N	\N
192	< $nmbr$ mg / dl eze / simva	C0439269	\N	\N
192	< $nmbr$ mg / dl *	C0439269	\N	\N
192	< $nmbr$ mg / dl	C0439269	\N	\N
192	< $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	< $nmbr$ / $nmbr$ mmhg  ldl - c < $nmbr$ mg / dl	C0439269;C0439475	\N	\N
192	< $nmbr$ . $nmbr$ mg / liter	C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761	\N	\N
192	< $nmbr$ . $nmbr$ mg / dl	C0439269	\N	\N
192	- median fasting serum glucose ( mg / dl ) ( iqr )	C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430	\N	\N
192	( sd )  mg / dl	C0439269;C2699239	\N	\N
192	( mg / dl ± sd )	C0439269;C2699239	\N	\N
192	( mg / dl )	C0439269	\N	\N
192	$nmbr$   mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ to < $nmbr$ mg / dl	C0439269	\N	\N
192	$nmbr$ mg vs placebo	C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg twice daily n = $nmbr$	C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg sirukumab every $nmbr$ weeks ( n = $nmbr$ )	C0024671;C0026410;C0439230;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761	\N	\N
192	$nmbr$ mg qw $nmbr$ . $nmbr$ pt yrs	C0024671;C0026410;C0032743;C0043011;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg qd ( n = $nmbr$ )	C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg q $nmbr$ w	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg ew n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg eow n = $nmbr$	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg cohort	C0009247;C0024671;C0026410;C0439269;C0599755;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg clopidogrel load	C0024671;C0026410;C0070166;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg biw $nmbr$ . $nmbr$ pt yrs	C0024671;C0026410;C0032743;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg bid	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg a	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg / kgf ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg / dl ldl cholesterol | |	C0023824;C0202117;C0439269	\N	\N
192	$nmbr$ mg / dl	C0439269	\N	\N
192	$nmbr$ mg / $nmbr$ mgc	C0024671;C0026410;C0439269;C1960952;C2346927;C3888239;C4321396;C4521761	\N	\N
192	$nmbr$ mg / $nmbr$ mgb	C0024671;C0026410;C0373680;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg + mtx	C0024671;C0025677;C0026410;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg ( n $nmbr$ $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg ( $nmbr$  $nmbr$ . $nmbr$ % )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ / $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ . $nmbr$ mg bid	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ . $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ . $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
192	$nmbr$ - h pmg ( mg / dl )	C0033727;C0369286;C0439269;C0441932;C0564385;C4528284	\N	\N
192	$nmbr$ - $nmbr$ mg / dl *	C0439269	\N	\N
192	$nmbr$ - $nmbr$ mg / dl	C0439269	\N	\N
192	$nmbr$ $nmbr$ mg / dl	C0439269	\N	\N
191	symptom onset to first medical contact : ambulance or emergency department	C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C0562508;C1279901;C1705415;C3812666;C3846685;C4086878	\N	\N
191	non - pci hospital / ambulance	C0002422;C0019994;C1510665;C1518422;C3846685;C4049621	\N	\N
191	in emergency department before ambulance transfer	C0002422;C0040671;C0562508;C1705822;C3846685;C4319192	\N	\N
191	in ambulance	C0002422;C3846685	\N	\N
191	first medical contact in ambulance	C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685	\N	\N
191	ambulance ( % )	C0002422;C3846685	\N	\N
191	ambulance  n ( % )	C0002422;C3846685	\N	\N
191	ambulance	C0002422;C3846685	\N	\N
190	locally advanced	C0205179;C1517927	\N	\N
190	advanced  n ( % )	C0205179	\N	\N
190	advanced	C0205179	\N	\N
189	north america plus australia and new zealand	C0004340;C0027978;C0028405;C0324547;C0332287	\N	\N
189	north america ( plus australia and new zealand )	C0004340;C0027978;C0028405;C0324547;C0332287	\N	\N
189	new zealand	C0027978;C0324547	\N	\N
189	australia and new zealand	C0004340;C0027978;C0324547	\N	\N
189	austrafca and new zealand	C0027978;C0324547	\N	\N
188	worldwide non - black patients	C0005680;C0027567;C0085756;C0439541;C1829939	\N	\N
188	u . s . non - black patients	C0005680;C0027567;C0041703;C0085756;C0439541;C1829939	\N	\N
188	race  black or african - american  n ( % )	C0005680;C0027567;C0034510;C0085756;C0439541;C1706779;C3853635	\N	\N
188	non - hispanic black or african - american	C0005680;C0027567;C0085756;C0439541;C1518424	\N	\N
189	poland	C0032356	f	-10
188	non - black participants	C0005680;C0027567;C0085756;C0439541;C0679646;C1518422	\N	\N
188	non - black ( n = $nmbr$ )	C0005680;C0027567;C0085756;C0439541;C1518422	\N	\N
188	non - black  worldwide	C0005680;C0027567;C0085756;C0439541;C1518422	\N	\N
188	hispanic black	C0005680;C0027567;C0085756;C0086409;C0439541	\N	\N
188	black participants	C0005680;C0027567;C0085756;C0439541;C0679646	\N	\N
188	black or african ‐ american	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black or african heritage	C0005680;C0027567;C0085756;C0439541;C2986513	\N	\N
188	black or african american	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black or african america	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black or african - american	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black or african	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black non - hispanic - n ( % )	C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018	\N	\N
188	black non - hispanic	C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018	\N	\N
188	black / non - black	C0005680;C0027567;C0085756;C0439541;C1518422	\N	\N
188	black / african american *	C0085756	\N	\N
188	black / african american	C0085756	\N	\N
188	black / african - american ( $nmbr$ . $nmbr$ % )	C0085756	\N	\N
188	black / african - american	C0085756	\N	\N
188	black *	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black ( n — $nmbr$ )	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black ( n   = $nmbr$ )	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black  worldwide	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black  us	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black  no . ( % )	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black  n ( % )	C0005680;C0027567;C0085756;C0439541	\N	\N
188	black	C0005680;C0027567;C0085756;C0439541	\N	\N
188	b : u . s . black and non - black patients	C0005680;C0027567;C0041703;C0085756;C0439541;C1829939	\N	\N
188	african americans	C0085756	\N	\N
188	african american n = $nmbr$	C0085756	\N	\N
188	african american / black	C0005680;C0027567;C0085756;C0439541	\N	\N
188	african american  n ( % )	C0085756	\N	\N
188	african american	C0085756	\N	\N
188	african america	C0085756	\N	\N
188	african - latin american	C0085756	\N	\N
188	african - american / african heritage ( n = $nmbr$ )	C0085756;C2986513	\N	\N
188	african - american	C0085756	\N	\N
188	african	C0027567	\N	\N
188	a : worldwide black and non - black patients	C0005680;C0027567;C0085756;C0439541;C1829939	\N	\N
188	* non - black *	C0005680;C0027567;C0085756;C0439541;C1518422	\N	\N
187	uacr ( mgg - $nmbr$ )	\N	\N	\N
187	uacr  n ( % ) †	\N	\N	\N
187	uacr  mgg $nmbr$ ( gm )	C0017480;C3854019	\N	\N
187	uacr  mg / mmol ( interquartile range ) b	C0567349;C1711350;C2348885	\N	\N
187	uacr	\N	\N	\N
187	scr  gmol / l	C1539487;C4050416	\N	\N
186	om $nmbr$ mg / aml $nmbr$ mg / hctz $nmbr$ mg	C0020261;C0023465;C0023467;C0028971;C1319635;C1705272	\N	\N
186	om $nmbr$ mg / aml $nmbr$ mg ( n = $nmbr$ )	C0023465;C0023467;C0028971;C1319635;C1705272	\N	\N
186	om $nmbr$ mg / aml $nmbr$ mg	C0023465;C0023467;C0028971;C1319635;C1705272	\N	\N
186	om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ )	C0020261;C0023465;C0023467;C0028971;C1319635;C1705272	\N	\N
186	om $nmbr$ / aml $nmbr$ /	C0023465;C0023467;C0028971;C1705272	\N	\N
186	aml / val $nmbr$ / $nmbr$ mg	C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761	\N	\N
186	aml ( n = $nmbr$ )	C0023465;C0023467	\N	\N
186	aml $nmbr$ /	C0023465;C0023467	\N	\N
186	aml	C0023465;C0023467	\N	\N
186	a / aml ( n = $nmbr$ )	C0023465;C0023467	\N	\N
185	ppi or h $nmbr$ receptor antagonist  n ( % )	C0033727;C0358591;C0369286;C0441932;C0564385;C0871125;C3811894;C4528284;C4543207	\N	\N
185	mineralocorticoid receptor antagonists	C1373021;C1579268	\N	\N
185	mineralocorticoid receptor antagonist n ( % )	C1579268	\N	\N
185	mineralocorticoid receptor antagonist	C1579268	\N	\N
185	mineralcorticoid receptor antagonist	C4543207	\N	\N
185	leukotriene receptor antagonists	C0595726;C2757015;C3542962	\N	\N
185	leukotriene - receptor antagonist	C0595726;C3537183;C4521995	\N	\N
185	h $nmbr$ receptor antagonist	C0033727;C0369286;C0441932;C0564385;C4528284;C4543207	\N	\N
185	h $nmbr$ - receptor antagonist	C0033727;C0369286;C0441932;C0564385;C4528284;C4543207	\N	\N
185	endothelin - receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors	C0031638;C0332307;C1134681;C1547052;C1656262;C2266875;C3539996	\N	\N
185	endothelin - receptor antagonists	C1134681;C2266875	\N	\N
185	aldosterone receptor antagonists	C1579268	\N	\N
184	tnf antagonist	C0231491;C1448177	\N	\N
184	ras antagonist  %	C0034678;C0231491;C0525678	\N	\N
184	no history of tnf antagonist treatment — no . ( % )	C0019664;C0019665;C0039798;C0087111;C0231491;C0262512;C0262926;C1448177;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704	\N	\N
184	miami k antagonist received	C0231491;C0597277;C1514756;C1551421;C1708601	\N	\N
184	history of disease refractory to treatment with tnf antagonist — no . ( % )	C0039798;C0087111;C0205269;C0231491;C0683519;C0730226;C0850708;C0944983;C1448177;C1522326;C1533734;C1705169;C3538994;C3887704	\N	\N
184	antagonist	C0231491	\N	\N
184	adp antagonist	C0231491;C0523452	\N	\N
183	total included in combined analysis	C0002778;C0205195;C0332257;C0439175;C0439810;C0936012;C1524024	\N	\N
183	stratified analyses	C0002778;C0205363;C0936012;C1524024	\N	\N
183	sensitivity analyses	C0002778;C0020517;C0036667;C0312418;C0427965;C0936012;C1511883;C1522640;C1524024;C2346484;C2349185	\N	\N
183	responder analyses ( achieving alc < $nmbr$ . $nmbr$ % )	C0002778;C0936012;C1424945;C1524024;C3811058	\N	\N
183	prespecified analysis	C0002778;C0936012;C1524024	\N	\N
183	patients included in analysis	C0002778;C0030705;C0332257;C0936012;C1524024	\N	\N
183	patients in analysis  n	C0002778;C0030705;C0936012;C1524024	\N	\N
183	patients ( full analysis sety )  n	C0002778;C0030705;C0443225;C0936012;C1524024	\N	\N
183	overall analysis	C0002778;C0282416;C0936012;C1524024;C1561607	\N	\N
183	integrated analysis set ( n = $nmbr$ )	C0002778;C0036849;C0369718;C0441922;C0936012;C1158478;C1442518;C1524024;C1705195;C1705422	\N	\N
183	included in analysis	C0002778;C0332257;C0936012;C1524024	\N	\N
183	full analysis set  n	C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195	\N	\N
183	full analysis set	C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195	\N	\N
183	final analysis ( all patients )	C0002778;C0030705;C0205088;C0936012;C1524024;C1546485;C3853528	\N	\N
183	analysis	C0002778;C0936012;C1524024	\N	\N
183	$nmbr$ days until end of study ( landmark analysis )	C0002778;C0444930;C0936012;C1524024;C2746065;C2826182	\N	\N
182	interim analysis ( all patients )	C0030705;C4684691	\N	\N
182	interim analysis	C4684691	\N	\N
181	subgroup statistics	C0038215;C0600673;C1079230;C1515021	\N	\N
181	statistics	C0038215;C0600673	\N	\N
181	statisticd	\N	\N	\N
181	statistic * *	C2348149;C2828391	\N	\N
181	sample statistics	C2348149	\N	\N
181	parameter statistics	C0681933	\N	\N
180	ugt induction status : as randomizeda  n ( % )	C0205263;C0449438;C0857127;C1420188;C4284131	\N	\N
180	ish status  n ( % )	C0449438	\N	\N
180	ish	\N	\N	\N
180	as	\N	\N	\N
179	established maerovaseular disease and albuminuria	C0001925;C0012634;C0443211;C1272684	\N	\N
179	established disease	C0012634;C0443211;C1272684	\N	\N
179	established ( n = $nmbr$ )	C0443211;C1272684	\N	\N
179	established	C0443211;C1272684	\N	\N
178	drinker ( $nmbr$ to $nmbr$ drinks / week )	C0332174;C0439230;C0452428;C0556338	\N	\N
178	drinker ( $nmbr$ - $nmbr$ drinks / week )	C0332174;C0439230;C0452428;C0556338	\N	\N
178	alcohol use  drinks / wk *	C0001948;C0332174;C0439230;C0452428	\N	\N
178	alcohol use  drinks / wk	C0001948;C0332174;C0439230;C0452428	\N	\N
178	> $nmbr$ drinks / wk	C0332174;C0439230;C0452428	\N	\N
178	> $nmbr$ drinks / week	C0332174;C0439230;C0452428	\N	\N
178	> $nmbr$ drinks / dav	C0452428	\N	\N
178	> $nmbr$ drinks	C0452428	\N	\N
178	> $nmbr$ ( $nmbr$ ) drinks / day if male ( female )	C0043210;C0086287;C0086582;C0332173;C0439228;C0439505;C0452428;C1705497;C1705498;C1706180;C1706428;C1706429	\N	\N
178	$nmbr$ drinks / wk	C0332174;C0439230;C0452428	\N	\N
178	$nmbr$ drinks	C0452428	\N	\N
178	$nmbr$ - $nmbr$ drinks / wk	C0332174;C0439230;C0452428	\N	\N
178	$nmbr$ - $nmbr$ drinks / dav	C0452428	\N	\N
178	$nmbr$ - $nmbr$ drinks	C0452428	\N	\N
178	$nmbr$ + drinks / wk	C0332174;C0439230;C0452428	\N	\N
177	handihaler and diskus  n	C1553480	\N	\N
177	diskus only  n	C0205171;C1553480;C1720467	\N	\N
176	non - / ex - drinker	C0457801	\N	\N
176	former / non - drinker	C0205156;C0457801;C0750523	\N	\N
176	ex - drinker	C0337679	\N	\N
176	drinker ( % ) a	C0556338	\N	\N
176	drinker ( % )	C0556338	\N	\N
176	drinker  n ( % )	C0556338	\N	\N
176	alcohol drinker  n ( % )	C0001962;C0001975;C0556338	\N	\N
176	alcohol drinker	C0001962;C0001975;C0556338	\N	\N
175	three of seven risk factors	C0035648;C0205449;C0205453;C1553898	\N	\N
175	temporary risk factor	C0035648;C0205374;C1548539;C3245481	\N	\N
175	risk factors — no . ( % )	C0035648;C1553898	\N	\N
175	risk factors specified as inclusion criteria — no . ( % ) f	C0016327;C0035648;C0205369;C1512693;C1553898	\N	\N
175	risk factors only	C0035648;C0205171;C1553898;C1720467	\N	\N
175	risk factors for stroke  no . ( % )	C0035648;C0038454;C1553898;C4554100	\N	\N
175	risk factors for stroke	C0035648;C0038454;C1553898;C4554100	\N	\N
175	risk factors for recurrent vte — no . ( % ) f	C0016327;C0035648;C0630906;C1455761;C1553898;C2945760	\N	\N
175	risk factors ( % )	C0035648;C1553898	\N	\N
175	risk factors  no . ( % )	C0035648;C1553898	\N	\N
175	risk factors  %	C0035648;C1553898	\N	\N
175	risk factors	C0035648;C1553898	\N	\N
175	risk factor profile index event	C0035648;C0441471;C0600653;C0918012;C1552854;C1637833;C1979963;C2003903;C2986546;C4019010	\N	\N
175	risk factor	C0035648	\N	\N
175	qualifying risk factors — no . ( % )	C0035648;C1514624;C1553898	\N	\N
175	qualifying risk factor — no . ( % )	C0035648;C1514624	\N	\N
175	qualifying risk factor  n ( % )	C0035648;C1514624	\N	\N
175	qualifying risk factor	C0035648;C1514624	\N	\N
175	psychosocial risk factors	C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904	\N	\N
175	other risk factors	C0035648;C1553898	\N	\N
175	other major risk factors	C0035648;C0205082;C0205164;C1553898;C4318856;C4521762	\N	\N
175	non - transient risk factors for recurrent vte  n ( % )	C0035648;C0040704;C0205374;C0439597;C0630906;C1553898	\N	\N
175	no . of risk factors for venous thromboembolism  no . ( % )	C0035648;C1553898;C1861172	\N	\N
175	no . of risk factors ( % ) | |	C0035648;C1553898	\N	\N
175	multiple risk factors	C0035648;C0439064;C1553898	\N	\N
175	multiple ( > $nmbr$ ) chd risk factors that confer a $nmbr$ - year risk of chd > $nmbr$ %	C0035648;C0280604;C0439064;C0439234;C0439508;C1282512;C1553898;C3542407	\N	\N
175	male sex — no . ( % ) risk factors	C0035648;C0086582;C1553898	\N	\N
175	history of cvd and of cv risk factors - no . ( % )	C0007222;C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503	\N	\N
179	> $nmbr$ cv risk factors 咐 or established atherosclerotic cv disease	C0007222;C0035648;C0333482;C0443211;C1272684;C1553898;C3538987;C4048877;C4318503	f	1698
179	established renal disease ( egfr $nmbr$ - < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ with any uacr mg / g or egfr > $nmbr$ - $nmbr$ ml / inin / l $nmbr$ m $nmbr$ with an uacr > $nmbr$ mg / g ) without previous maerovaseular and albuminuria disease	C0001925;C0012634;C0022658;C0205156;C0369637;C0439445;C0439526;C0441923;C0443211;C0456616;C1272684;C1300563;C1552607;C1705224;C1739039;C3811844;C3812682;C3887665	f	967
175	diagnoses / risk factors  n ( % ]	C0011900;C0035648;C1553898	\N	\N
175	diagnoses / risk factors  n ( % )	C0011900;C0035648;C1553898	\N	\N
175	cv risk factors  % of patients	C0030705;C0035648;C1553898;C3538987;C4048877;C4318503	\N	\N
175	chd risk factors #	C0035648;C0280604;C1553898;C3542407	\N	\N
175	baseline risk factors	C0035648;C0168634;C1442488;C1553898	\N	\N
175	any risk factor for stent thrombosis	C0035648;C3897493	\N	\N
175	> $nmbr$ chd risk factors	C0035648;C0280604;C1553898;C3542407	\N	\N
174	pci delay due to low risk	C0205421;C0678226;C3272281;C3538919;C4049621	\N	\N
174	lower risk ( n = $nmbr$ )	C3272281;C3538919	\N	\N
174	lower risk	C3272281;C3538919	\N	\N
174	low risk and fewer symptoms ( group a )	C0205388;C0441835;C0683368;C1457887;C3272281;C3538919;C4522145	\N	\N
174	low risk ( ri = $nmbr$ - $nmbr$ )	C0035487;C1826843;C3272281;C3538919	\N	\N
174	low risk ( n $nmbr$ $nmbr$ )	C3272281;C3538919	\N	\N
174	low risk ( ? ics )	C0815320;C3272281;C3538919;C4551720	\N	\N
174	low risk ( - ics )	C0815320;C3272281;C3538919;C4551720	\N	\N
174	low risk ( $nmbr$ - $nmbr$ )	C3272281;C3538919	\N	\N
174	low risk	C3272281;C3538919	\N	\N
174	group b ( low risk  more symptoms )  n ( % )	C0441848;C0683368;C1457887;C3272281;C3538919	\N	\N
174	$nmbr$ - $nmbr$ ( low risk )	C3272281;C3538919	\N	\N
173	shock risk indext	C0035647;C0036974;C4552904	\N	\N
173	risk stratum	C0035647;C4552904	\N	\N
173	risk score category ( points )	C0035647;C0449820;C0683312;C1552961;C2347617;C3714763;C3889287;C4050231;C4552904	\N	\N
173	risk category ( points )	C0035647;C0683312;C1552961;C2347617;C3714763;C3889287;C4552904	\N	\N
173	risk categories	C0035647;C0683312;C4552904	\N	\N
173	risk at	C0035647;C4552904	\N	\N
173	risk *	C0035647;C4552904	\N	\N
173	risk	C0035647;C4552904	\N	\N
173	no increased risk for falls	C0000921;C0035647;C0085639;C1849142;C4552904;C4699158	\N	\N
173	ncep risk category at study entry  n ( % )	C0035647;C1705654;C2983287;C2983669;C4552904	\N	\N
173	moderate risk ( > $nmbr$ - $nmbr$ )	C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904	\N	\N
173	increased risk for falls	C0000921;C0035647;C0085639;C1849142;C4552904;C4699158	\N	\N
173	cardio - renal risk	C0018787;C0022646;C0035647;C4552904	\N	\N
173	cardiac risk	C0018787;C0035647;C1522601;C4552904	\N	\N
173	> $nmbr$ ( moderate or high bleeding risk )  no . / total ( % )	C0019080;C0035647;C0205081;C0205250;C0439175;C0439810;C1299351;C1881878;C2700149;C3887512;C3889660;C4049705;C4049706;C4085643;C4321237;C4321335;C4522209;C4552904	\N	\N
172	unadjusted $nmbr$ - y risk per $nmbr$ population = se ( adjusted rate )	C0036919;C0242444;C0456081;C0871208;C1439367;C1521828;C2987720	\N	\N
172	risk group	C0242444	\N	\N
172	intermediate risk ( ri = $nmbr$ )	C0035487;C1826843;C3640764	\N	\N
172	intermediate risk	C3640764	\N	\N
171	risk reduction ( %  $nmbr$ % ci )	C0008107;C1137094;C3259781	\N	\N
171	risk reduction  %	C1137094	\N	\N
171	reduction in risk ( $nmbr$ % ci ) %	C0008107;C0035647;C0520870;C1137094;C3259781;C4552904	\N	\N
171	reduction in risk % ( $nmbr$ % ci )	C0008107;C0035647;C0520870;C1137094;C3259781;C4552904	\N	\N
171	absolute risk reductions	C3179139	\N	\N
171	absolute risk reduction ( $nmbr$ % cl ) *	C0596019;C3179139	\N	\N
171	absolute risk reduction ( $nmbr$ % ci )  % / y	C0008107;C3179139;C3259781	\N	\N
171	* risk reduction  $nmbr$ percent confidence interval ( ci )  and p value are derived from cox models . for risk reductions  negative numbers indicate an increase in risk . † diabetes and hypertension were defined by clinical history . ‡ a family history was defined as having one or more first - degree relatives with either myocardial infarction or sudden death before the age of $nmbr$ . § hdl cholesterol levels are shown according to the median value ( $nmbr$ . $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¶ triglyceride levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¿ ldl cholesterol levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) and according to the values that divide the subjects into three equal groups ( < $nmbr$  $nmbr$ to $nmbr$  and > $nmbr$ mg per deciliter [ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$  and > $nmbr$ . $nmbr$ mmol per liter ] ) .	C0008107;C0009667;C0010234;C0019664;C0019665;C0020538;C0023824;C0024671;C0026410;C0027051;C0042295;C0202069;C0202117;C0205163;C0205172;C0205210;C0205447;C0205449;C0241889;C0262512;C0262926;C0332849;C0392885;C0428475;C0428953;C0439165;C0439190;C0439241;C0439269;C0441833;C0441889;C0442805;C0475211;C0549183;C0567349;C0680240;C0681850;C0687744;C0876920;C1137094;C1171304;C1257890;C1276802;C1441547;C1518469;C1519504;C1522609;C1546180;C1547282;C1549782;C1550501;C1552839;C1704788;C1705255;C1705428;C1705429;C1706203;C1709380;C1960952;C1963138;C2004062;C2346927;C2347285;C2347635;C2348144;C2348885;C2349001;C2697811;C2825415;C2926063;C2939193;C3245521;C3259781;C3539106;C3810814;C4321396;C4521761;C4552959	\N	\N
171	% risk reduction ( $nmbr$ % ci )	C0008107;C1137094;C3259781	\N	\N
170	sk . $nmbr$	\N	\N	\N
170	rash	C0015230	\N	\N
170	heart disease risk factors	C0741920	\N	\N
170	coronary heart disease risk equivalents  n ( % ) c	C0439185;C1277690;C4049980	\N	\N
173	vascular risk score |	C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904	f	1953
173	vascular risk score *	C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904	f	1953
173	vascular risk score — no . { % ) ^	C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904	f	1953
173	timi risk score category — no . ( % )	C0035647;C0449820;C0683312;C3889287;C4050231;C4552904	f	1954
173	timi risk score > $nmbr$  n ( % )	C0035647;C0449820;C4050231;C4552904	f	1954
173	timi risk score $nmbr$ - $nmbr$	C0035647;C0449820;C4050231;C4552904	f	1954
173	timi risk score  n / n ( % )	C0035647;C0449820;C4050231;C4552904	f	1954
170	$nmbr$ - yr risk of coronary heart disease ( % ) ^ |	C0439234;C1277690	\N	\N
169	nih stroke scale	C1697238;C3484372	\N	\N
169	$nmbr$ nil	C0442734	\N	\N
168	india	C0021201;C2700456	\N	\N
168	* other - europe ( n = $nmbr$ )  australia ( n = $nmbr$ ) and india ( n = $nmbr$ ) - the data from these regions were collapsed due to the small numbers	C0004340;C0015176;C0017446;C0021201;C0205147;C0237753;C0344329;C0392748;C0449788;C0678226;C0700321;C1511726;C2700456;C3245479;C3714741	\N	\N
167	laba ( inhaled )  d   n ( % )	C0004048;C0073187;C0332173;C4484261	\N	\N
167	inhaledb	\N	\N	\N
167	inhaled §	C0004048	\N	\N
167	inhaled j $nmbr$ - agonist §	C0004048;C2987634	\N	\N
167	inhaled anticholinergic §	C0004048;C0242896;C3537004	\N	\N
167	inhaled ^	C0004048	\N	\N
167	a ) those receiving no inhaled pre - treatment maintenance medication	C0004048;C0013227;C0021459;C0024501;C0039798;C0087111;C0332152;C0740175;C1514756;C1522326;C1533734;C1705169;C2257086;C2347660;C3244316;C3469597;C3538994;C3669034;C3887704;C4284232	\N	\N
-10	unhappy	C1688635	\N	\N
-10	nap	C0870935;C1423800;C4283878	\N	\N
164	enalapril lcz $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ )	C0014025	\N	\N
164	enalapril dm = $nmbr$ non - dm = $nmbr$	C0011816;C0014025;C1518422;C3250443	\N	\N
164	enalapril + aliskiren ( n = $nmbr$ )	C0014025;C1120110	\N	\N
164	enalapril ( n = $nmbr$ )	C0014025	\N	\N
164	enalapril	C0014025	\N	\N
163	insulin detemir	C0537270	\N	\N
163	insulin aspart ( mealtime )	C0123677;C0587119;C1708521	\N	\N
163	insulin aspart	C0123677;C1708521	\N	\N
163	detemir / insulin glargine  %	C0537270;C0907402	\N	\N
162	type of insulin therapy — no . ( % ) $nmbr$	C0039798;C0087111;C0457592;C1363945	\N	\N
162	type of insulin	C0457592	\N	\N
162	type of basal insulin  n ( % )	C0205112;C0332307;C0457592;C0650607;C1547052	\N	\N
162	method of insulin administration	C0025663;C0199782;C0449851;C0871511	\N	\N
162	insulin type  n ( % )	C0457592	\N	\N
162	insulin administration	C0199782	\N	\N
161	insulins and analogs	C0021641;C0243071;C3537244;C4049919	\N	\N
161	insulins	C0021641;C3537244;C4049919	\N	\N
161	insulin sensitivity — % §	C0920563;C4049919	\N	\N
161	composite index of insulin sensitivity ( isi )	C0205199;C0600653;C0918012;C0920563;C1547335;C1552854;C1637833;C2986546;C4049919	\N	\N
160	insulin - dependent diabetes mellitus	C0011854	\N	\N
160	insulin - dependent diabetes	C0011854	\N	\N
159	oral antidiabetes combination therapy without insulina  n ( % )	C0009429;C0442027;C0556895;C4521986	\N	\N
159	insulina  n ( % )	\N	\N	\N
159	insulina	\N	\N	\N
158	octave induction $nmbr$ and $nmbr$	C0205263;C0857127	\N	\N
158	octave induction $nmbr$	C0205263;C0857127	\N	\N
158	noninducing	\N	\N	\N
158	non - enzyme inducing	C0014442;C0205263;C1518422;C4521602	\N	\N
158	induction - trial group assignment — no . ( % )	C0205263;C0857127;C1320290;C1516050	\N	\N
158	inducing	C0205263	\N	\N
158	enzyme inducing	C0014442;C0205263;C4521602	\N	\N
157	yes  non - insulin - treated	C0021641;C1518422;C1522326;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501	\N	\N
157	yes  insulin - treated	C0021641;C1522326;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501	\N	\N
157	without insulin or insulin - modifying therapy	C0021641;C0039798;C0087111;C0392747;C1363945;C1533581;C1579433;C3714501	\N	\N
157	treated with insulin	C0021641;C0332293;C1533581;C1579433;C3714501	\N	\N
157	total daily insulin dose ( u / day )	C0021641;C0456683;C1533581;C1579433;C2348070;C3714501	\N	\N
157	total daily insulin dose  units / kgt	C0021641;C0439148;C1519795;C1533581;C1579433;C2348070;C3714501;C3853603	\N	\N
157	total daily insulin dose  u	C0021641;C0439148;C1533581;C1579433;C2348070;C3714501	\N	\N
157	total baseline insulin dose	C0021641;C0168634;C0366513;C0439175;C0439810;C1442488;C1533581;C1579433;C2986497;C3714501	\N	\N
157	sustain $nmbr$ : semaglutide add ‐ on to insulin vs . placebo	C0021641;C0032042;C0443318;C1533581;C1579433;C1696465;C1706408;C1883712;C2732140;C3714501;C3885068	\N	\N
157	premixed insulin with oads ( % )	C0021641;C1533581;C1579433;C3714501	\N	\N
157	premixed insulin only ( % )	C0021641;C0205171;C1533581;C1579433;C1720467;C3714501	\N	\N
157	pre - mixed insulin	C0021641;C0205430;C0332152;C0740175;C1533581;C1579433;C2257086;C3160715;C3669034;C3714501	\N	\N
157	placebo + insulin ( n   = $nmbr$ )	C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501	\N	\N
157	placebo + insulin ( n = $nmbr$ )	C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501	\N	\N
157	patients treated with insulin	C0021641;C0030705;C0332293;C1533581;C1579433;C3714501	\N	\N
157	participants taking insulin	C0021641;C0679646;C1515187;C1533581;C1579433;C3714501	\N	\N
157	oad plus insulin	C0021641;C1533581;C1579433;C3714501	\N	\N
157	median fasting insulin ( iqr ) — pu per milliliter	C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501	\N	\N
157	mean ± sd fasting insulin  uu / ml	C0015663;C0021641;C0439342;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501	\N	\N
157	insulin 一 no . ( % )	C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin — iu	C0021641;C0049272;C0439453;C0694756;C1533581;C1579433;C3714501	\N	\N
157	insulin — / tu / ml	C0021641;C0041400;C0439526;C1532464;C1533581;C1579433;C1705224;C2700314;C3714501;C3811255;C3887665	\N	\N
157	insulin yes	C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501	\N	\N
157	insulin treated	C0021641;C1522326;C1533581;C1579433;C3714501	\N	\N
157	insulin secretagogue	C0021641;C1533581;C1579433;C3714501;C4704833	\N	\N
157	insulin plus oral	C0021641;C0442027;C1533581;C1579433;C3714501;C4521986	\N	\N
157	insulin plus > $nmbr$ oral agent	C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986	\N	\N
157	insulin plus $nmbr$ oral agent	C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986	\N	\N
157	insulin only	C0021641;C0205171;C1533581;C1579433;C1720467;C3714501	\N	\N
151	nyhaii	\N	\N	\N
157	insulin glargin arm	C0021641;C0446516;C1533581;C1579433;C3714501;C3715044;C4553528	\N	\N
157	insulin dependentc	C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin based	C0021641;C1527178;C1533581;C1579433;C1705938;C3714501	\N	\N
157	insulin at baseline	C0021641;C0168634;C1442488;C1533581;C1579433;C3714501	\N	\N
157	insulin alone	C0021641;C0205171;C0439044;C0679994;C1533581;C1579433;C3714501	\N	\N
157	insulin : glucose ratio	C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501	\N	\N
157	insulin - treated dm	C0011816;C0021641;C1522326;C1533581;C1579433;C3250443;C3714501	\N	\N
157	insulin - treated diabetes  %	C0011847;C0011849;C0021641;C1522326;C1533581;C1579433;C3714501	\N	\N
157	insulin - treated diabetes	C0011847;C0011849;C0021641;C1522326;C1533581;C1579433;C3714501	\N	\N
157	insulin - treated	C0021641;C1522326;C1533581;C1579433;C3714501	\N	\N
157	insulin - requiring diabetes	C0011847;C0011849;C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin - requiring	C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin - naive  n ( % )	C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin - dependent	C0021641;C0429964;C0429986;C0851827;C1533581;C1579433;C1701901;C3244310;C3714501;C4321395	\N	\N
157	insulin + oad	C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin + metformin	C0021641;C0025598;C1533581;C1579433;C3714501	\N	\N
157	insulin ( pmol / l ) t vital signs	C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501	\N	\N
157	insulin ( pmol / l )	C0021641;C0439284;C1533581;C1579433;C3714501	\N	\N
157	insulin ( mu / ml )	C0021641;C0439339;C1533581;C1579433;C3714501	\N	\N
157	insulin ( % )	C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin  pmol / l	C0021641;C0439284;C1533581;C1579433;C3714501	\N	\N
157	insulin  n ( % )	C0021641;C1533581;C1579433;C3714501	\N	\N
157	insulin  iu / ml  median ( q $nmbr$  q $nmbr$ )	C0021641;C0439458;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501	\N	\N
157	insulin	C0021641;C1533581;C1579433;C3714501	\N	\N
157	initiation of insulin	C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501	\N	\N
157	fasting insulin — pmol / liter	C0015663;C0021641;C0439192;C0475211;C1533581;C1579433;C3714501	\N	\N
157	fasting insulin — / tiu / ml §	C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665	\N	\N
157	fasting insulin ( pmol / l )	C0015663;C0021641;C0439284;C1533581;C1579433;C3714501	\N	\N
157	fasting insulin ( miu / ml )	C0015663;C0021641;C0439457;C1533581;C1579433;C3714501	\N	\N
157	fasting insulin ( giu / ml )	C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665	\N	\N
157	fasting insulin  pmol / l ( mean ± sd )	C0015663;C0021641;C0439284;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501	\N	\N
157	fasting insulin  iiiu / ml  mean ± sd	C0015663;C0021641;C0439526;C0444504;C1533581;C1579433;C1705224;C2347634;C2348143;C2699239;C3714501;C3887665	\N	\N
157	fasting insulin  * median ( iqr )  gu / ml	C0015663;C0021641;C0120446;C0439526;C0549183;C0876920;C1533581;C1579433;C1705224;C2347635;C2348144;C2939193;C3714501;C3887515;C3887665	\N	\N
157	fasting insulin	C0015663;C0021641;C1533581;C1579433;C3714501	\N	\N
157	daily insulin dose  mean ( sd )  iu	C0021641;C0049272;C0332173;C0366513;C0439453;C0444504;C0694756;C1533581;C1579433;C2347634;C2348070;C2348143;C2699239;C3714501	\N	\N
157	bolus insulin doseh	C0021641;C1186706;C1511237;C1533581;C1579433;C1705509;C3714501;C3812160	\N	\N
157	baseline insulin	C0021641;C0168634;C1442488;C1533581;C1579433;C3714501	\N	\N
157	$nmbr$ - h postprandial insulin ( miu / ml )	C0021641;C0033727;C0369286;C0376674;C0439457;C0441932;C0564385;C1533581;C1579433;C3714501;C4528284	\N	\N
156	values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .	C0003209;C0003211;C0010055;C0012000;C0013227;C0019664;C0019665;C0023779;C0042295;C0085805;C0242821;C0262512;C0262926;C0439165;C0441994;C0460148;C0521116;C0536221;C0577559;C0577573;C0578022;C0600653;C0745413;C0802604;C0871470;C0918012;C0935929;C1096155;C1268086;C1306372;C1444656;C1515187;C1549488;C1552854;C1561533;C1637833;C1705255;C2003888;C2004062;C2598133;C2986546;C3152252;C3539882;C3813197;C4082212;C4281799;C4283905;C4284232	\N	\N
156	previous anti - inflammatory / antirheumatic products n ( % )	C0003191;C0205156;C0333348;C0432633;C1514468;C1552607	\N	\N
156	inflammatory	C0333348	\N	\N
156	anti - inflammatory drugs	C0003209	\N	\N
155	inflammation	C0021368	\N	\N
155	baseline inflammation markers	C0005516;C0021368;C0168634;C1442488	\N	\N
154	previous treatment with infliximab	C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
154	no previous treatment with infliximab	C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704	\N	\N
154	infliximab monotherapy	C0666743	\N	\N
154	infliximab - naive ( n = $nmbr$ )	C0666743	\N	\N
154	infliximab - experienced ( n = $nmbr$ )	C0666743	\N	\N
154	infliximab ( n = $nmbr$ )	C0666743	\N	\N
154	infliximab	C0666743	\N	\N
154	inflix  yes	C0666743;C1549445;C1705108;C1710701	\N	\N
154	inflix  no	C0666743	\N	\N
154	combined infliximab	C0205195;C0666743	\N	\N
153	npi	C1412208;C1549728;C3539727	\N	\N
153	ni	C0028075;C2348274;C3869926;C3869927	\N	\N
153	> $nmbr$ ml / niin / l $nmbr$ ni -	C0028075;C1635169;C2348274;C3869926;C3869927	\N	\N
153	< $nmbr$ ml / min / $nmbr$ . $nmbr$ ni -	C0028075;C0439445;C2348274;C3869926;C3869927	\N	\N
152	no anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$	C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633	\N	\N
152	new anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i - $nmbr$	C0002871;C0019046;C0021966;C0205314;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633	\N	\N
152	improving anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$	C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1272745;C1319635;C1549954;C4554633	\N	\N
152	anemia — no . ( % ) | |	C0002871;C1000483;C4554633	\N	\N
152	anemia ( % )	C0002871;C1000483;C4554633	\N	\N
152	anemia  no . / total ( % ) ”	C0002871;C0439175;C0439810;C1000483;C4554633	\N	\N
152	anemia  %	C0002871;C1000483;C4554633	\N	\N
151	nyha iv  n ( % )	C0022326;C1275491;C4265176	\N	\N
151	nyha iv  %	C0022326;C1275491;C4265176	\N	\N
151	nyha iii or iv § ( n = $nmbr$ $nmbr$ )	C0022326;C0439070;C1275491;C1705160;C4265176	\N	\N
151	nyha iii or iv	C0022326;C0439070;C1275491;C1705160;C4265176	\N	\N
151	nyha iii  n ( % )	C0439070;C1275491;C1705160	\N	\N
151	nyha ii  n ( % )	C1275491;C1710602;C4082587	\N	\N
151	nyha ii	C1275491;C1710602;C4082587	\N	\N
151	nyha	C1275491	\N	\N
151	nph	C0020258;C0027442	\N	\N
151	heart failure nyha ii - iii	C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158	\N	\N
151	heart failure ( nyha ii ‐ iii )  n ( % )	C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158	\N	\N
151	dyspnea at rest ( nyha iv )  ( % )	C0022326;C0743330;C1275491;C4265176	\N	\N
151	( nyha grade iii or iv )	C0022326;C0205617;C0450094;C0475271;C0687697;C1275491;C3889290;C4050000;C4265176;C4283820;C4283821;C4283822	\N	\N
-10	has - bledo	C1019275	\N	\N
149	less than $nmbr$ y ears	C0013443;C0439092;C0521421	\N	\N
149	< $nmbr$ y ears	C0013443;C0521421	\N	\N
148	≥ $nmbr$ yearsa	\N	\N	\N
148	£ $nmbr$ . $nmbr$ yrs	\N	\N	\N
148	younger subjects ( aged < $nmbr$ years )	C0001779;C0001792;C0332239;C0439234;C0681850;C1550501;C1706203;C1999167;C2349001;C2697811	\N	\N
148	younger patients ( aged $nmbr$ years )	C0001779;C0001792;C0030705;C0332239;C0439234;C1999167	\N	\N
148	older subjects ( aged > $nmbr$ years '	C0001779;C0001792;C0439234;C0580836;C0681850;C1550501;C1706203;C1999167;C2349001;C2697811	\N	\N
148	older patients ( aged > $nmbr$ years )	C0001779;C0001792;C0030705;C0439234;C0580836;C1999167	\N	\N
148	aged ≥ $nmbr$ years	C0001779;C0001792;C0439234;C1999167	\N	\N
148	aged a $nmbr$ years	C0001779;C0001792;C0439234;C1999167	\N	\N
148	aged ^ $nmbr$ years	C0001779;C0001792;C0439234;C1999167	\N	\N
148	aged < $nmbr$ years	C0001779;C0001792;C0439234;C1999167	\N	\N
148	age ≥ $nmbr$ yearsa	C0001779	\N	\N
148	age ± sd ( yrs )	C0001779;C2699239	\N	\N
148	age ^ $nmbr$ yrs  n ( % )	C0001779	\N	\N
148	age > $nmbr$ yrs  n ( % )	C0001779	\N	\N
148	age ( yrs ) < $nmbr$	C0001779	\N	\N
148	age ( yrs ) $nmbr$ - $nmbr$	C0001779	\N	\N
148	age $nmbr$ + yrs	C0001779	\N	\N
148	age  yrs  median ( iqr )	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	\N	\N
148	age  yrs  median ( $nmbr$ th  $nmbr$ th )	C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	\N	\N
148	< $nmbr$ yrs	\N	\N	\N
148	< $nmbr$ . $nmbr$ yrs	\N	\N	\N
147	yes vs . no	C1549445;C1705108;C1710701	\N	\N
147	yes *	C1549445;C1705108;C1710701	\N	\N
147	yes ( stopped for trial )	C0008976;C1272691;C1549445;C1705108;C1710701	\N	\N
147	yes ( n = $nmbr$ )	C1549445;C1705108;C1710701	\N	\N
147	yes ( n  % )	C1549445;C1705108;C1710701	\N	\N
147	yes ( any )	C1549445;C1705108;C1710701	\N	\N
147	yes ( % )	C1549445;C1705108;C1710701	\N	\N
147	yes '	C1549445;C1705108;C1710701	\N	\N
147	yes  z $nmbr$ cm	C1549445;C1705108;C1710701	\N	\N
147	yes  yes	C1549445;C1705108;C1710701	\N	\N
147	yes  unknown	C0439673;C1549445;C1705108;C1710701;C3541433;C4050014	\N	\N
147	yes  r $nmbr$ y	C0205090;C0684010;C1549445;C1705108;C1710701;C2603358	\N	\N
147	yes  proliferative	C0334094;C1549445;C1705108;C1710701	\N	\N
147	yes  o $nmbr$ cm	C1549445;C1705108;C1710701	\N	\N
147	yes  non - proliferative	C0334094;C1518422;C1549445;C1705108;C1710701	\N	\N
147	yes  n ( % )	C1549445;C1705108;C1710701	\N	\N
147	yes  $nmbr$ $nmbr$ y	C1549445;C1705108;C1710701	\N	\N
147	yes	C1549445;C1705108;C1710701	\N	\N
147	use of cgm ( yes )	C1524063;C1549445;C1705108;C1710701	\N	\N
147	thiazolidinedione yes	C0289779;C1257987;C1549445;C1705108;C1710701;C3537039	\N	\N
147	prior tnf antagonist treatment - yes	C0231491;C1448177;C1514463;C1549445;C1705108;C1710701	\N	\N
147	prior hypertensiona yes	C0332152;C1549445;C1705108;C1710701;C2826257	\N	\N
147	partner  n ( % yes )	C0682323;C1549445;C1705108;C1710701;C3887537	\N	\N
147	parental history of ml before age $nmbr$ y yes	C0001779;C0019664;C0019665;C0030551;C0262512;C0262926;C0439526;C1549445;C1705108;C1705224;C1705255;C1710701;C2004062;C3887665	\N	\N
147	no  yes	C1549445;C1705108;C1710701	\N	\N
147	naive : yes	C1549445;C1705108;C1710701	\N	\N
147	metformin : no / yes  %	C0025598;C1549445;C1705108;C1710701	\N	\N
147	long ( > $nmbr$ mm ) stenting yes ( n = $nmbr$ )	C0038257;C0205166;C1549445;C1705108;C1706317;C1710701;C2348535;C4330985;C4554674	\N	\N
147	ics use yes	C0042153;C0457083;C0815320;C1549445;C1705108;C1710701;C1947944;C4551720	\N	\N
147	ics : yes	C0815320;C1549445;C1705108;C1710701;C4551720	\N	\N
147	etn  yes	C0014758;C0717758;C1549445;C1705108;C1710701	\N	\N
147	ed history  n ( % yes )	C0019664;C0019665;C0262512;C0262926;C1549445;C1705108;C1705255;C1710701;C2004062;C3538926	\N	\N
147	diabetics - yes ( n = $nmbr$  $nmbr$ )	C0241863;C1549445;C1705108;C1710701	\N	\N
147	diabetic yes	C0241863;C1549445;C1705108;C1710701	\N	\N
147	diabetic ( yes )	C0241863;C1549445;C1705108;C1710701	\N	\N
147	diabetesh yes	C1549445;C1705108;C1710701	\N	\N
147	diabetes | | yes	C0011847;C0011849;C1549445;C1705108;C1710701	\N	\N
147	diabetes mellitus yes ( n  % ) hypertension	C0011849;C0020538;C1549445;C1705108;C1710701;C1963138	\N	\N
147	diabetes mellitus  n ( % ) yes	C0011849;C1549445;C1705108;C1710701	\N	\N
147	current smoker yes	C1549445;C1705108;C1710701;C3173209;C3241966	\N	\N
147	corticosteroid use at baseline - yes	C0168634;C0239126;C1442488;C1549445;C1705108;C1710701	\N	\N
147	copd exacerbation : yes	C0740304;C1549445;C1705108;C1710701	\N	\N
147	concomitant medications ( yes )  n ( % }	C0013227;C0521115;C0802604;C1549445;C1705108;C1710701;C2598133;C4284232	\N	\N
147	cardiac rhythm disorder at baseline yes	C0168634;C0264886;C1442488;C1549445;C1705108;C1710701	\N	\N
147	baseline sulfonylurea yes	C0038766;C0168634;C1442488;C1549445;C1705108;C1710701;C3536898	\N	\N
147	baseline ocs use : yes	C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944	\N	\N
135	a vs . c	\N	\N	\N
147	baseline ics use : yes	C0042153;C0168634;C0457083;C0815320;C1442488;C1549445;C1705108;C1710701;C1947944;C4551720	\N	\N
147	baseline calcium yes	C0006675;C0006726;C0168634;C1442488;C1549445;C1705108;C1710701;C2936886;C3540037;C3714611	\N	\N
147	amiodarone use at baseline yes $nmbr$  $nmbr$	C0002598;C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944	\N	\N
147	ace inhibitor yes	C0003015;C1549445;C1705108;C1710701;C4541021	\N	\N
147	[ no / yes ] ( % )	C1549445;C1705108;C1710701	\N	\N
146	tass ’	C0559483	\N	\N
146	mean body - mass indexj	C0444504;C0518010;C2347634;C2348143	\N	\N
146	lv mass index ( mg / m $nmbr$ )	C0024671;C0026410;C0369637;C0439269;C0441923;C0455825;C0600653;C0918012;C1552854;C1637833;C1960952;C2346927;C2986546;C4321396;C4521761	\N	\N
146	lv mass	C0455825	\N	\N
145	vdhmtss	\N	\N	\N
145	mtss cfb mean ± sd	C0009002;C0444504;C1824728;C2347634;C2348143;C2699239	\N	\N
145	mtss cfb	C0009002;C1824728	\N	\N
-10	( fxs )	C0016667	\N	\N
143	mean score on das $nmbr$ - $nmbr$ ( crp ) ^	C0051767;C0057671;C3533236;C3890735;C4048285	\N	\N
143	das - $nmbr$ ( crp ) < $nmbr$ . $nmbr$  n ( % )	C0051767;C0057671;C3890735;C4048285	\N	\N
143	das - $nmbr$ ( crp )  mean ( sd )	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	\N	\N
143	das $nmbr$ ‐ crp	C0051767;C0057671;C3890735;C4048285	\N	\N
143	das $nmbr$ score	C0051767;C0057671;C0449820;C4050231	\N	\N
143	das $nmbr$ - hscrp	C0051767;C0057671	\N	\N
143	das $nmbr$ - crp §	C0051767;C0057671;C3890735;C4048285	\N	\N
143	das $nmbr$ - crp  ls mean change from baseline ( se ) ¥	C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952	\N	\N
143	das $nmbr$ - crp	C0051767;C0057671;C3890735;C4048285	\N	\N
143	das $nmbr$ ( crp )  mean ( sd )	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	\N	\N
143	das $nmbr$ ( crp )	C0051767;C0057671;C3890735;C4048285	\N	\N
143	das $nmbr$	C0051767;C0057671	\N	\N
143	c . das $nmbr$ - crp < $nmbr$ . $nmbr$	C0051767;C0057671;C3890735;C4048285	\N	\N
142	time of symptom onset to randomization ( hrs )	C0034656;C1320528;C1568891	\N	\N
142	time of symptom onset to balloon inflation ( hrs )	C0021398;C0336867;C0441144;C1318493;C1320528;C1568891	\N	\N
142	time of qualifying ecg to balloon inflation ( hrs )	C0021398;C0040223;C0336867;C0441144;C1318493;C1514624;C1568891;C1623258;C3541383	\N	\N
142	hps	C0242994	\N	\N
142	^ $nmbr$ hrs	C1568891	\N	\N
142	> $nmbr$ hrs	C1568891	\N	\N
142	< $nmbr$ hrs	C1568891	\N	\N
141	qrs interval > $nmbr$ msec — no . ( % )	C0439223;C0520880	\N	\N
141	qrs < $nmbr$ msec	C0439223	\N	\N
140	time since first af diagnosis  yrs	C0011900;C0040223;C0205435;C0344434;C1279901;C1704338;C1704656;C3541383;C4049859	\N	\N
140	time since copd diagnosis ( yrs )	C0011900;C0024117;C0040223;C1412502;C1704338;C1704656;C3541383;C3714496	\N	\N
140	mras	C1335594;C1367476	\N	\N
140	> $nmbr$ . $nmbr$ yrs	\N	\N	\N
140	$nmbr$ yrs l	\N	\N	\N
139	total pack - yrs	C0439175;C0439810;C1968515;C2825051;C2828395	\N	\N
139	grs	C1412761;C3539564	\N	\N
139	$nmbr$ yrs	\N	\N	\N
138	psoriasis duration  yrs *	C0033860;C0449238;C2926735	\N	\N
138	duration of ra  mean ( min - max ) ( yrs )	C0444504;C0449238;C0702093;C1524029;C2347634;C2348143;C2926735;C3538806;C3813700;C4048756	\N	\N
138	duration of crohn ’ s disease ( yrs )	C0010346;C0449238;C2926735	\N	\N
138	duration of crohn ' s disease ( yrs )	C0010346;C0449238;C2926735	\N	\N
138	disease duration  yrs  mean ( sd )	C0444504;C0872146;C2347634;C2348143;C2699239	\N	\N
138	> $nmbr$ yrs	\N	\N	\N
138	$nmbr$ . $nmbr$ yrs	\N	\N	\N
138	$nmbr$ - < $nmbr$ yrs	\N	\N	\N
138	$nmbr$ - $nmbr$ yrs	\N	\N	\N
137	previous ics only	C0205156;C0205171;C0815320;C1552607;C1720467;C4551720	\N	\N
137	is only	C0205171;C1720467	\N	\N
137	ics only	C0205171;C0815320;C1720467;C4551720	\N	\N
137	ibs ( $nmbr$ . $nmbr$ )	C0022104;C0432306	\N	\N
137	$nmbr$ is ( $nmbr$ . $nmbr$ )	\N	\N	\N
136	previous or current use of im or cs : no	C0010182;C0205156;C0271160;C0521116;C1524063;C1552607;C1705970;C3540510;C4085345	\N	\N
136	previous or current use of im and cs : no	C0010182;C0205156;C0271160;C0521116;C1524063;C1552607;C1705970;C3540510;C4085345	\N	\N
136	previous or current cs use : no	C0010182;C0042153;C0205156;C0271160;C0457083;C0521116;C1552607;C1705970;C1947944;C3540510;C4085345	\N	\N
136	no cs and is	C0010182;C0271160;C3540510;C4085345	\N	\N
136	no cs and imm	C0010182;C0205470;C0271160;C3540510;C4085345	\N	\N
136	neither cs nor imm	C0010182;C0205470;C0271160;C3540510;C4085345	\N	\N
136	im or cs use : no	C0010182;C0042153;C0271160;C0457083;C1947944;C3540510;C4085345	\N	\N
136	im and cs use : no	C0010182;C0042153;C0271160;C0457083;C1947944;C3540510;C4085345	\N	\N
136	glycopyrrolate / glycopyrrolate / eflow cs $nmbr$ meg eflow cs $nmbr$ meg ( n = $nmbr$ ) ( n = $nmbr$ )	C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345	\N	\N
136	glycopyrrolate / eflow cs $nmbr$ meg ( n = $nmbr$ )	C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345	\N	\N
136	cs use : no	C0010182;C0042153;C0271160;C0457083;C1947944;C3540510;C4085345	\N	\N
136	cs only	C0010182;C0205171;C0271160;C1720467;C3540510;C4085345	\N	\N
136	cs and is	C0010182;C0271160;C3540510;C4085345	\N	\N
136	cs and imm	C0010182;C0205470;C0271160;C3540510;C4085345	\N	\N
136	cs and im	C0010182;C0271160;C3540510;C4085345	\N	\N
136	cs	C0010182;C0271160;C3540510;C4085345	\N	\N
135	p $nmbr$ vs no treatment $nmbr$	C0039798;C0087111;C0369773;C1522326;C1533734;C1705169;C2603361;C3538994;C3887704	\N	\N
135	p  all vs all	C0369773;C2603361	\N	\N
146	body mass indexb	C0518010	f	1734
146	body mass indexa < median	C0518010;C0549183;C0876920;C2347635;C2348144;C2939193	f	1734
146	body mass indexa	C0518010	f	1734
132	tp vs no tp	C0036183;C3541334	\N	\N
132	q $nmbr$ : $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ )	C0022718;C0439209;C4054209	\N	\N
132	ith vs . without )	\N	\N	\N
132	e $nmbr$ / s $nmbr$ vs s $nmbr$	C0565930;C2603362;C3846405	\N	\N
132	e $nmbr$ / s $nmbr$ vs e $nmbr$	C3846405	\N	\N
132	> $nmbr$ to   ≤   $nmbr$   vs .   ≤   $nmbr$	\N	\N	\N
132	> $nmbr$ and   ≤   $nmbr$   vs   ≤   $nmbr$	\N	\N	\N
132	> $nmbr$ and   ≤   $nmbr$   vs .   ≤   $nmbr$	\N	\N	\N
132	> $nmbr$ . $nmbr$   vs .   >   $nmbr$ . $nmbr$ and   ≤   $nmbr$ . $nmbr$	\N	\N	\N
131	notes :	C1317574	\N	\N
131	nos $nmbr$ glu $nmbr$ asp g . t  n ( % )	C0125690;C0326287;C0439267;C1518425;C2986835	\N	\N
131	nos $nmbr$ $nmbr$ c . t  n ( % )	C0326287;C1518425	\N	\N
131	nos $nmbr$ $nmbr$ a . g  n ( % )	C0326287;C0439267;C1518425	\N	\N
130	tion  os = overall satisfaction  qmax = maximal urinary flow rate .	C0229090;C0230028;C0262950;C0393706;C0429784;C1561953;C4086680	\N	\N
130	os domain	C0229090;C0230028;C0262950;C0393706;C1561953;C1880389;C1883221;C3541951	\N	\N
130	ocs  n ( % )	\N	\N	\N
130	no ocs	\N	\N	\N
130	- o . os	C2673162	\N	\N
130	$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . os )	C0229090;C0230028;C0262950;C0393706;C1561953	\N	\N
129	sys : ns dia : < $nmbr$ . $nmbr$	C0038944;C1112705;C1425041;C1705982;C1706546	\N	\N
129	ns cardiac cisease	C0018787;C0038944;C1112705;C1522601;C1705982	\N	\N
129	ns	C0038944;C1112705;C1705982	\N	\N
128	tgs ( mg / dl )	C0439269;C1156212;C1537574	\N	\N
128	fasting tgs §	C0015663;C1156212;C1537574	\N	\N
128	baseline fasting tgs  mg / dl	C0015663;C0168634;C0439269;C1156212;C1442488;C1537574	\N	\N
127	ssed as ls means	C0023668;C1704970	\N	\N
127	ls / ul $nmbr$ $nmbr$	C0023668;C1300557	\N	\N
127	lis	C2247545	\N	\N
127	lips	C0023759	\N	\N
127	aml vs . lis	C0023465;C0023467;C2247545	\N	\N
126	qrs width  ms	C0487742;C2349943;C3539704;C3713294	\N	\N
126	qrs duration > $nmbr$ ms  n ( % )	C0429025;C0488377;C2349943;C3539704;C3713294	\N	\N
126	qrs duration  ms	C0429025;C0488377;C2349943;C3539704;C3713294	\N	\N
126	qrs > $nmbr$ ms *	C2349943;C3539704;C3713294	\N	\N
126	qrs > $nmbr$ ms  n ( % )  available for $nmbr$ patients	C0030705;C0470187;C2349943;C3539704;C3713294	\N	\N
126	qrs > $nmbr$ ms  % ( n )	C2349943;C3539704;C3713294	\N	\N
126	qrs < $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$  $nmbr$ )	C0596019;C2349943;C3539704;C3713294	\N	\N
126	qrs $ $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$ )	C0596019;C2349943;C3539704;C3713294	\N	\N
126	ms < $nmbr$  n [ % ]	C2349943;C3539704;C3713294	\N	\N
126	ms & ng	C0017887;C0028074;C2349943;C3539704;C3713294	\N	\N
126	ms $nmbr$ - $nmbr$  n [ % ]	C2349943;C3539704;C3713294	\N	\N
126	ms  mean [ sd ]	C0444504;C2347634;C2348143;C2349943;C2699239;C3539704;C3713294	\N	\N
126	cornell voltage x duration product  mm x ms	C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674	\N	\N
126	cornell voltage - duration product  mm × ms	C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674	\N	\N
126	cornell voltage - duration product  mm x ms	C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674	\N	\N
126	corneii product  mm - ms	C1514468;C1704444;C2349943;C3539704;C3713294;C4330985;C4554674	\N	\N
126	( n = ms )	C0369718;C0441922;C2349943;C3539704;C3713294	\N	\N
126	$nmbr$ ms score †	C0449820;C2349943;C3539704;C3713294;C4050231	\N	\N
125	psa ‐ modified mases score ( $nmbr$ – $nmbr$ scale )	C0175659;C0349674;C0392747;C0449820;C1947916;C3810537;C3813209;C3889737;C4050231	\N	\N
125	psa subtypes  n ( % )	C0449560;C3810537;C3813209	\N	\N
125	psa reported  n ( % )	C0369718;C0441922;C0684224;C0700287;C3810537;C3813209;C4319718	\N	\N
125	psa pain ( vas )	C0042815;C3810537;C3813209	\N	\N
125	psa - modified total shs	C0392747;C0439175;C0439810;C3810537;C3813209;C3889737	\N	\N
125	psa - modified shs ( $nmbr$ - $nmbr$ )	C0392747;C3810537;C3813209;C3889737	\N	\N
125	psa - modified mases score ( $nmbr$ - $nmbr$ )	C0392747;C0449820;C3810537;C3813209;C3889737;C4050231	\N	\N
125	psa ( n = $nmbr$ )	C3810537;C3813209	\N	\N
125	psa	C3810537;C3813209	\N	\N
125	patients with change from baseline in psa - modified total shs score # $nmbr$	C0030705;C0168634;C0392747;C0439175;C0439810;C0443172;C0449820;C1442488;C1705241;C3810537;C3813209;C3889737;C4050231;C4319952	\N	\N
125	no psa ( n = $nmbr$ )	C3810537;C3813209	\N	\N
125	no psa	C3810537;C3813209	\N	\N
125	no . of patients with psa	C0030705;C3810537;C3813209	\N	\N
124	total ipss	C0439175;C0439810;C1019118;C1998280;C2827405;C3811063	\N	\N
124	severe ( ipss > $nmbr$ ) age group	C0027362;C0205082;C1019118;C1998280;C2348001;C2827405;C3811063;C4050465;C4050466	\N	\N
124	severe ( ipss > $nmbr$ ) ( n = $nmbr$ )	C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466	\N	\N
124	severe ( ipss > $nmbr$ )	C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466	\N	\N
124	moderate ( ipss < $nmbr$ ) ( n = $nmbr$ )	C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335	\N	\N
124	moderate ( $nmbr$ < ipss < $nmbr$ )	C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335	\N	\N
124	mild / moderate ( ipss < $nmbr$ )	C1019118;C1299392;C1998280;C2827405;C3811063	\N	\N
124	mild - to - moderate ( ipss < $nmbr$ )	C1019118;C1299392;C1998280;C2827405;C3811063	\N	\N
124	mild ( ipss < $nmbr$ )	C1019118;C1998280;C2827405;C2945599;C3811063	\N	\N
124	ipss total score	C1019118;C1998280;C2827405;C2964552;C3811063	\N	\N
124	ipss hrql	C1019118;C1998280;C2827405;C3811063	\N	\N
124	ipss categories	C0683312;C1019118;C1998280;C2827405;C3811063	\N	\N
124	ipss - v	C1019118;C1998280;C2827405;C3811063	\N	\N
133	chlorthalidone vs lisinopril	C0008294;C0065374	f	70
134	male vs . female	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	f	1970
134	women ( n = $nmbr$ vs $nmbr$ )	C0043210	f	1970
124	ipss - s	C1019118;C1998280;C2827405;C3811063	\N	\N
124	ipss ( unit )	C0439148;C0439453;C1019118;C1509845;C1519795;C1704753;C1880519;C1998280;C2827405;C3811063;C3853603	\N	\N
124	ipss  “ / o	C1019118;C1998280;C2827405;C3811063	\N	\N
124	ipss	C1019118;C1998280;C2827405;C3811063	\N	\N
124	erectile function  ipss	C0030847;C0031843;C0542341;C0700205;C1019118;C1705273;C1998280;C2827405;C3811063	\N	\N
124	baseline total ipss	C0168634;C0439175;C0439810;C1019118;C1442488;C1998280;C2827405;C3811063	\N	\N
124	= international prostate symptom score	C1998280	\N	\N
124	( ngml ' ' ) total mean ipss score	C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C2964552;C3533236;C3811063	\N	\N
123	russia and georgia	C0017452;C0017454;C0035970	\N	\N
123	russia / georgia ( n = $nmbr$ )	C0017452;C0017454;C0035970	\N	\N
123	russia / georgia	C0017452;C0017454;C0035970	\N	\N
123	russia	C0035970	\N	\N
123	europe and russia	C0015176;C0035970	\N	\N
123	enrolled in russia or georgia	C0017452;C0017454;C0035970;C4684790	\N	\N
122	prior insulin use ( years )	C0240016;C0332152;C0439234;C2826257	\N	\N
123	rs - chest symptomsd	C0035970;C0817096;C1527391;C3714753;C3813325	f	-10
123	rs - totala	C0035970;C3714753;C3813325	f	-10
122	insulin use at baseline	C0168634;C0240016;C1442488	\N	\N
122	insulin use    n   ( % )	C0240016	\N	\N
122	insulin use	C0240016	\N	\N
122	heparin use	C0239945	\N	\N
121	us w = $nmbr$	\N	\N	\N
121	us resident	C1320928;C1549439;C2347958;C3835651	\N	\N
120	systemic corticosteroid use	C0042153;C0205373;C0239126;C0457083;C1947944;C4053960	\N	\N
120	steroid use at baseline  n ( % )	C0168634;C0281991;C1442488	\N	\N
120	steroid use at baseline	C0168634;C0281991;C1442488	\N	\N
120	steroid use  %	C0281991	\N	\N
120	no steroid use at baseline ( ref )	C0168634;C0281991;C1425988;C1442488	\N	\N
120	corticosteroid use at randomization    n   ( % )	C0034656;C0239126	\N	\N
120	corticosteroid use at randomization	C0034656;C0239126	\N	\N
120	corticosteroid use at baseline - no	C0168634;C0239126;C1442488	\N	\N
120	corticosteroid use at baseline	C0168634;C0239126;C1442488	\N	\N
120	corticosteroid use  n ( % )	C0239126	\N	\N
120	corticosteroid use  %	C0239126	\N	\N
120	corticosteroid use  $nmbr$ n ( % )	C0239126	\N	\N
120	corticosteroid use	C0239126	\N	\N
120	concomitant corticosteroid use  n ( % )	C0239126;C0521115	\N	\N
120	concomitant corticosteroid use	C0239126;C0521115	\N	\N
120	baseline corticosteroid use ( mg )	C0024671;C0026410;C0168634;C0239126;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761	\N	\N
119	use of rescue medication	C0240320	\N	\N
119	rescue medication use  inh / d {	C0022209;C0240320	\N	\N
119	no use ofdiabetes drugs — no . ( % )	C0240320	\N	\N
119	medication use before enrollment  no . ( % )	C0240320;C1516879;C1696073;C3888021	\N	\N
119	medication use at entry ( % )	C0240320;C1705654	\N	\N
119	medication use ( % ) aspirin	C0004057;C0240320	\N	\N
119	medication use ( % )	C0240320	\N	\N
119	medication use  n ( % )	C0240320	\N	\N
119	medication use	C0240320	\N	\N
119	current medication use	C0042153;C0240320;C0457083;C0521116;C0746467;C1705970;C1947944	\N	\N
119	concomitant medication use	C0240320;C0521115	\N	\N
119	blood pressure lowering medication use	C0005823;C0240320;C0441994;C1271104;C1272641;C2003888	\N	\N
118	use oforal glucose - lowering agent — no . ( % )	C0017725;C0042153;C0441994;C0450442;C0457083;C1254351;C1521826;C1947944;C2003888	\N	\N
118	use ( % )	C0042153;C0457083;C1947944	\N	\N
118	use	C0042153;C0457083;C1947944	\N	\N
118	triple therapy use at screening  n ( % )	C0039798;C0042153;C0087111;C0457083;C1363945;C1947944;C2121434	\N	\N
118	therapy use	C0039798;C0042153;C0087111;C0457083;C1363945;C1947944	\N	\N
118	rotablator use  n ( % )	C0042153;C0457083;C1260867;C1947944	\N	\N
118	regular aspirin use	C0004057;C0042153;C0205272;C0457083;C1947944	\N	\N
118	recurrent vte ( statin use vs non - use )	C0042153;C0360714;C0457083;C0630906;C1455761;C1518422;C1947944;C2945760	\N	\N
118	prior mesalazine use *	C0042153;C0127615;C0332152;C0457083;C1947944;C2826257	\N	\N
118	previous or current im use : no	C0042153;C0205156;C0457083;C0521116;C1552607;C1705970;C1947944	\N	\N
118	p - gp use	C0042153;C0369773;C0457083;C1705010;C1947944;C2603361;C3811116	\N	\N
118	no use	C0042153;C0457083;C1947944	\N	\N
118	no regular aspirin use	C0004057;C0042153;C0205272;C0457083;C1947944	\N	\N
118	no prior statin use	C0042153;C0332152;C0360714;C0457083;C1947944;C2826257	\N	\N
118	no concomitant cortcosteroid use	C0042153;C0457083;C0521115;C1947944	\N	\N
118	mesalamine use  n ( % ) a	C0042153;C0127615;C0457083;C1947944	\N	\N
118	major bleeding ( statin use vs non - use )	C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1518422;C1947944;C4318856;C4521762	\N	\N
118	maintenance use — no . ( % )	C0024501;C0042153;C0457083;C1947944	\N	\N
118	no statin use	C0042153;C0360714;C0457083;C1947944	f	872
118	methotrexate use	C0025677;C0042153;C0457083;C1947944	f	716
118	methotrexate use at randomisation	C0025677;C0034656;C0042153;C0457083;C1947944	f	716
118	sulfasalazine use at randomization	C0034656;C0036078;C0042153;C0457083;C1947944	f	2184
118	sulfasalazine use at randomization    n   ( % )	C0034656;C0036078;C0042153;C0457083;C1947944	f	2184
118	saba use in past $nmbr$ days	C0042153;C0439228;C0457083;C1444637;C1947944;C4284302	f	2185
118	saba use  occasions / weekt	C0042153;C0457083;C1947944	f	2185
118	prior statin use	C0042153;C0332152;C0360714;C0457083;C1947944;C2826257	f	2186
118	prior statin use ( n = $nmbr$ )	C0042153;C0332152;C0360714;C0457083;C1947944;C2826257	f	2186
118	laba use at enrolment	C0042153;C0457083;C1516879;C1696073;C1947944;C3888021	\N	\N
118	initiated use during double - blind treatment period	C0013072;C0039798;C0042153;C0087111;C0439531;C0457083;C1522326;C1533734;C1548602;C1704686;C1705169;C1947944;C1948053;C3538994;C3887704	\N	\N
118	im use : no	C0042153;C0457083;C1947944	\N	\N
118	ezetimibe use	C0042153;C0457083;C1142985;C1947944	\N	\N
118	dopamine agonist use  no . ( % )	C0042153;C0178601;C0457083;C1947944;C3536925	\N	\N
118	days without albuterol use  * %	C0001927;C0042153;C0439228;C0457083;C1947944	\N	\N
118	current lra use	C0042153;C0457083;C0521116;C1705970;C1947944	\N	\N
118	current laba use	C0042153;C0457083;C0521116;C1705970;C1947944	\N	\N
118	cse ] +	\N	\N	\N
118	concomitant mao - b inhibitor use	C0042153;C0457083;C0521115;C0595265;C1947944;C2917433	\N	\N
118	concomitant aspirin use	C0004057;C0042153;C0457083;C0521115;C1947944	\N	\N
118	concomitant antibiotic use  n [ % ]	C0003232;C0042153;C0457083;C0521115;C1947944	\N	\N
118	cholinesterase inhibitor use at baseline  no . ( % )	C0008425;C0042153;C0168634;C0457083;C1442488;C1947944;C3536756;C4521309	\N	\N
118	cholinesterase inhibitor use	C0008425;C0042153;C0457083;C1947944;C3536756;C4521309	\N	\N
118	cgm use	C0042153;C0457083;C1947944	\N	\N
118	before bronchodilator use	C0006280;C0042153;C0457083;C1947944	\N	\N
118	baseline aspirin use strata	C0004057;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
118	baseline aspirin use	C0004057;C0042153;C0168634;C0457083;C1442488;C1947944	\N	\N
118	background laba use - yes  n ( % )	C0042153;C0457083;C1549445;C1705108;C1706907;C1710701;C1947944	\N	\N
118	background laba use	C0042153;C0457083;C1706907;C1947944	\N	\N
118	any use	C0042153;C0457083;C1947944	\N	\N
118	any glycoprotein iib / iiia inhibitor use	C0016011;C0042153;C0457083;C1947944;C1999216	\N	\N
118	antithrombotic use before enrollment  no . ( % )	C0042153;C0457083;C1516879;C1696073;C1947944;C3888021	\N	\N
118	antithrombotic use	C0042153;C0457083;C1947944	\N	\N
118	anorexigen use	C0042153;C0457083;C1947944	\N	\N
118	aldosterone use	C0002006;C0042153;C0457083;C1947944	\N	\N
118	albuterol use	C0001927;C0042153;C0457083;C1947944	\N	\N
118	after bronchodilator use	C0006280;C0042153;C0457083;C1947944	\N	\N
117	ssi - $nmbr$	\N	\N	\N
117	ss at baseline	C0168634;C1442488;C2699257;C3891295;C4551874	\N	\N
117	ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ )	C2699257;C3891295;C4551874	\N	\N
117	ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ )	C2699257;C3891295;C4551874	\N	\N
116	js $nmbr$ - agonists	C0243192;C1552154;C2987634	\N	\N
116	$nmbr$ [ $nmbr$ - $nmbr$ js	C1552154	\N	\N
115	observed case	C0868928;C1441672;C1706255;C1706256	\N	\N
115	observed	C1441672	\N	\N
115	mbesc  n / n ( % )	\N	\N	\N
115	mbesb  n / n ( % )	\N	\N	\N
115	mbes / crbesc	\N	\N	\N
115	mbes / crbesb  n / n ( % )	\N	\N	\N
115	$nmbr$ - $nmbr$ . $nmbr$ : obese class i	C3853264	\N	\N
114	teaes  cases per $nmbr$ - patient years ( ci )	C0008107;C0030705;C0439234;C0868928;C1533148;C3259781	\N	\N
114	no cases	C0868928;C1533148	\N	\N
114	mtss at baseline observed case	C0168634;C0868928;C1441672;C1442488;C1706255;C1706256	\N	\N
114	mtss at	\N	\N	\N
114	mtss ( $nmbr$ - $nmbr$ )	\N	\N	\N
114	mtss	\N	\N	\N
114	cases	C0868928;C1533148	\N	\N
113	post - dose	C0439568	\N	\N
113	percentage of patients receiving dose adjustment	C0030705;C0439165;C1514756;C1549488;C1561533;C2826232	\N	\N
113	first dose admin . $nmbr$ - $nmbr$ h / $nmbr$ - $nmbr$ h post onset of symptoms	C0033727;C0205435;C0369286;C0439568;C0441932;C0564385;C1279901;C4084955;C4086878;C4528284	\N	\N
113	dose adjustment n ( % )	C2826232	\N	\N
112	lower dose	C0445550;C1708745	\N	\N
112	lower - dose	C0445550;C1708745	\N	\N
112	low dose combination therapy	C0009429;C0445550;C0556895;C1708745	\N	\N
112	low dose	C0445550;C1708745	\N	\N
112	low - dose statin	C0360714;C0445550;C1708745	\N	\N
112	fenofibric acid - i - low - dose statin	C0021966;C0060179;C0221138;C0360714;C0445550;C1708745	\N	\N
112	fenofibric acid - $nmbr$ - low - dose statin	C0060179;C0360714;C0445550;C1708745	\N	\N
112	fenofibric acid + low - dose statin	C0060179;C0360714;C0445550;C1708745	\N	\N
112	edoxaban lower dose vs warfarin	C0043031;C0445550;C1708745;C2975435	\N	\N
111	higher dose	C0444956	\N	\N
111	higher - dose edoxaban vs warfarin	C0043031;C0444956;C2975435	\N	\N
111	higher - dose edoxaban ( n = $nmbr$ )  n ( % / y )	C0444956;C2975435	\N	\N
111	higher - dose	C0444956	\N	\N
111	high dose statin ( n = $nmbr$  $nmbr$ )	C0360714;C0444956	\N	\N
111	high dose	C0444956	\N	\N
111	high - dose statin use at screening *	C0042153;C0220908;C0220909;C0360714;C0444956;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	\N	\N
53	anaesthesia / analgesia	C0002905	\N	\N
118	aspirin use	C0004057;C0042153;C0457083;C1947944	f	1366
118	aspirin use ( % )	C0004057;C0042153;C0457083;C1947944	f	1366
118	aspirin use ( p = $nmbr$ . $nmbr$ t )	C0004057;C0042153;C0457083;C1947944	f	1366
118	aspirin use ( p = $nmbr$ - $nmbr$ 十 )	C0004057;C0042153;C0457083;C1947944	f	1366
118	concomitant methotrexate use  n ( % )	C0025677;C0042153;C0457083;C0521115;C1947944	f	716
118	low - dose aspirin use	C0042153;C0457083;C1947944;C2608320	f	2183
118	low - dose aspirin use at baseline	C0042153;C0168634;C0457083;C1442488;C1947944;C2608320	f	2183
118	low - dose aspirin use . strata *  n ( % )	C0042153;C0457083;C1947944;C2608320	f	2183
118	low - dose aspirin use strata * n ( % )	C0042153;C0457083;C1947944;C2608320	f	2183
118	cox - $nmbr$ selective inhibitor use	C0036576;C0042153;C0085387;C0457083;C1707391;C1947944	f	2123
111	high - dose statin use  n ( % ) e	C0042153;C0360714;C0444956;C0457083;C1947944	\N	\N
111	high - dose statin	C0360714;C0444956	\N	\N
111	high - dose edoxaban vs warfarin	C0043031;C0444956;C2975435	\N	\N
111	high - dose edoxaban ( n = $nmbr$ )	C0444956;C2975435	\N	\N
111	high - dose edoxaban	C0444956;C2975435	\N	\N
111	high - dose arb ( n = $nmbr$ )	C0444956;C3888198	\N	\N
111	edoxaban higher dose vs warfarin	C0043031;C0444956;C2975435	\N	\N
110	tanezumab ( all doses combined ) + nsaida	C0178602;C0205195;C2346819	\N	\N
110	tanezumab ( all doses combined )	C0178602;C0205195;C2346819	\N	\N
110	smedian prednisone dose  n ( % )	C0032952;C0178602;C0869039;C1114758	\N	\N
110	ras % target dose	C0034678;C0178602;C0525678;C0869039;C1114758;C1521840;C2986546	\N	\N
110	ptrend across doses	C0178602	\N	\N
110	prednisone or equivalent dose ( mg / day )	C0032952;C0178602;C0205163;C0439185;C0439422;C0869039;C1114758	\N	\N
110	prednisone - equivalent dose  mg	C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761	\N	\N
110	patients with supplemental vitamin d dose of $nmbr$ iu / day starting at screeningc    n   ( % )	C0030705;C0178602;C0420176;C0439465;C0439659;C0869039;C1114758;C3541352	\N	\N
110	oral corticosteroid dose ( mg / day )	C0001617;C0178602;C0439422;C0442027;C0869039;C1114758;C3536709;C4521986	\N	\N
110	need for $nmbr$ ng edoxaban dose at	C0017887;C0027552;C0028074;C0178602;C0686904;C0869039;C1114758;C2975435	\N	\N
110	metformin dose	C0025598;C0178602;C0869039;C1114758	\N	\N
110	metformin - dose	C0025598;C0178602;C0869039;C1114758	\N	\N
110	mean ( s . d . ) metformin dose †  mg / day	C0025598;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143	\N	\N
110	intended clopidogrel dose $nmbr$ mg	C0024671;C0026410;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1551357;C1960952;C2346927;C4321396;C4521761	\N	\N
110	edoxaban dose adjusted at randomisation  n ( % ) *	C0034656;C0178602;C0456081;C0869039;C1114758;C2975435	\N	\N
110	doubling statin dose	C0178602;C0205173;C0360714;C0869039;C1114758;C1705764	\N	\N
110	dose reduction at randomization — no . ( % )  i	C0021966;C0034656;C0178602;C0221138;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656	\N	\N
110	dose reduction at randomization  %	C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656	\N	\N
110	dose reduction at randomization	C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656	\N	\N
110	dose reduction  n ( % )	C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656	\N	\N
110	dose reduced at randomization *	C0034656;C0178602;C0392756;C0869039;C1114758	\N	\N
110	dose adjusted	C0178602;C0456081;C0869039;C1114758	\N	\N
110	dose ( n )	C0178602;C0869039;C1114758	\N	\N
110	corticosteroid dose ( prednisone	C0001617;C0032952;C0178602;C0869039;C1114758;C3536709	\N	\N
110	clopidogrel dose	C0070166;C0178602;C0869039;C1114758	\N	\N
110	canakinumab dose ( per month )	C0178602;C0332177;C0439231;C0869039;C1114758;C2718773	\N	\N
110	canakinumab dose ( per mo )	C0026544;C0178602;C0332177;C0869039;C1114758;C2718773	\N	\N
110	canakinumab dose	C0178602;C0869039;C1114758;C2718773	\N	\N
110	any dose reduction	C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656	\N	\N
110	all doses ( n = $nmbr$ )	C0178602	\N	\N
110	all doses	C0178602	\N	\N
110	< median prednisone dose  n ( % )	C0032952;C0178602;C0549183;C0869039;C0876920;C1114758;C2347635;C2348144;C2939193	\N	\N
110	( phase $nmbr$ dose - finding trial )	C0008976;C0037088;C0178602;C0205390;C0243095;C0869039;C1114758;C1710475;C2825141	\N	\N
-10	decreased appetite	C0232462	\N	\N
108	connective tissue disease	C0009782	\N	\N
108	connective - tissue disease	C0009782	\N	\N
108	associated with connective tissue disease	C0009782;C0332281	\N	\N
108	assoc  with connective tissue disease	C0009782	\N	\N
107	inflammatory disease	C1290884	\N	\N
107	inflammatory bowel disease	C0021390	\N	\N
107	chronic inflammatory disease	C1290886	\N	\N
107	active inflammatory bowel disease	C0021390;C0205177;C3853793;C3888249	\N	\N
106	pulmonary disease — no . ( % )	C0024115	\N	\N
106	pulmonary disease	C0024115	\N	\N
106	chronic pulmonary disease	C0746102	\N	\N
105	thyroid disease	C0040128	\N	\N
105	patient history of disease n ( % )	C0030705;C0683519;C0730226;C0850708;C0944983	\N	\N
105	patient history of disease	C0030705;C0683519;C0730226;C0850708;C0944983	\N	\N
105	microvascular disease history  no . ( % )	C0443258;C0683519	\N	\N
105	microvascular disease history  n ( % )	C0443258;C0683519	\N	\N
105	microvascular disease history	C0443258;C0683519	\N	\N
105	history of thyroid disease  n ( % )	C0040132;C0683519;C0730226;C0850708;C0944983;C3540038	\N	\N
105	history of peripheral arterial disease ( % )	C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of peripheral arterial disease	C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of microvascular eye disease 本  n ( % )	C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062	\N	\N
105	history of microvascular disease — no . ( % )	C0443258;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of microvascular disease ( % )	C0443258;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of microvascular disease	C0443258;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of major microvascular disease — no . ( % )	C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762	\N	\N
105	history of major microvascular disease  n ( % )	C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762	\N	\N
360	anti - p $nmbr$	\N	f	-10
105	history of major macrovascular disease — no . ( % )	C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762	f	1698
105	history of macrovascular disease ( % )	C0683519;C0730226;C0850708;C0944983	f	1698
105	history of ischemic heart disease — no . ( % )	C0018787;C0475224;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of fistullzing disease  n ( % )	C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of fistulizing disease  n ( % )	C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of fistulising disease  n [ % ]	C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of cv disease	C0683519;C0730226;C0850708;C0944983;C3538987;C4048877;C4318503	\N	\N
105	history of crohn ' s disease surgery  n ( % )	C0010346;C0455610	\N	\N
105	history of coronary heart disease at	C0018787;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of coronary heart disease  no . ( % )	C0018787;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of coronary arteiy disease	C0018787;C0683519;C0730226;C0850708;C0944983	\N	\N
105	history of bone disease ( predefined )  n ( % )	C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0369718;C0441922;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062	\N	\N
105	disease history	C0683519	\N	\N
105	crohn ' s disease	C0010346	\N	\N
105	concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff	C0010346;C0030705;C0039798;C0087111;C0205420;C0557651;C1522326;C1533734;C1705169;C1705654;C2603343;C3538994;C3887704;C4554348	\N	\N
105	baseline history of vascular disease ( % )	C0005847;C0168634;C0683519;C0730226;C0850708;C0944983;C1442488;C1558950;C1801960	\N	\N
104	kidney disease ( usrds )	C0022658	\N	\N
104	duration of chronic kidney disease * ( years )	C0022658;C0205191;C0439234;C0449238;C2926735	\N	\N
104	diabetic kidney disease	C0011881	\N	\N
104	chronic kidney diseased	C2364010	\N	\N
103	valvular heart disease — no . ( % )	C0018824;C1963123	\N	\N
103	valvular heart disease  n ( % )	C0018824;C1963123	\N	\N
103	valvular heart disease	C0018824;C1963123	\N	\N
103	valvular disease ( % )	C3258293	\N	\N
103	valvular disease  mitral	C0746591;C3258293	\N	\N
103	valvular disease	C3258293	\N	\N
103	mitral valve disease ( n = $nmbr$ $nmbr$ )	C0026265;C4553832	\N	\N
103	cardiac valvular disease	C0018824	\N	\N
102	vessel disease	C0042373	\N	\N
102	vascular disease indicator no ( n = $nmbr$ )	C0021212;C0042373;C0369718;C0441922;C1235732;C1522602	\N	\N
102	vascular disease	C0042373	\N	\N
102	single vessel disease	C0037179;C0042373;C0087136;C0205171	\N	\N
102	single - vessel disease  n ( % )	C0037179;C0042373;C0087136;C0205171	\N	\N
102	single - vessel disease	C0037179;C0042373;C0087136;C0205171	\N	\N
102	other vascular disease — no . ( % )	C0042373	\N	\N
102	double - vessel disease  n ( % )	C0042373;C0205173;C1705764;C1705765	\N	\N
102	any vascular disease	C0042373	\N	\N
101	simplified disease activity index score ( $nmbr$ - $nmbr$ )	C0449820;C3869582;C4050231	\N	\N
101	simplified disease activity index score	C0449820;C3869582;C4050231	\N	\N
101	simplified disease activity index	C3869582	\N	\N
101	ptga of disease activity ( $nmbr$ ‒ $nmbr$ mm )  mean ( sd ) †	C0444504;C1292728;C2347634;C2348143;C2699239;C4330985;C4554674	\N	\N
101	high disease activity : > $nmbr$ . $nmbr$  n ( % )	C0012634;C0205250;C1292728;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C4699623	\N	\N
101	disease activity ]	C1292728	\N	\N
101	disease activity ( n ( % ) )	C1292728	\N	\N
101	disease activity	C1292728	\N	\N
101	clinical disease activity index score ( $nmbr$ - $nmbr$ )	C0449820;C3869583;C4050231	\N	\N
101	clinical disease activity index	C3869583	\N	\N
100	ease activity ]	C0205177;C0439167;C0441655;C1331418;C1561536;C3668946;C4049938;C4049939	\N	\N
100	ease - $nmbr$	C1331418	\N	\N
100	base	C0002055;C0178499;C1880279	\N	\N
99	type of reflux disease	C0232483;C0457464;C1882919;C4317146	\N	\N
99	gastrooesophageal reflux disease	C0017168;C4553201	\N	\N
99	gastroesophageal reflux disease	C0017168;C4553201	\N	\N
99	erosive reflux disease	C0012634;C0232483;C0439679;C1882919;C4317146	\N	\N
98	polyvascular disease * status	C3176928	\N	\N
98	physician ' s global assessment of disease status score	C0449820;C3176928;C4050231;C4050369	\N	\N
98	global assessment of disease status score	C0281858;C0449820;C3176928;C4050231	\N	\N
98	disease stage	C0699749	\N	\N
97	severe disease	C1836348	\N	\N
97	self - reported disease severity  $nmbr$ - $nmbr$ scale *	C0175659;C0349674;C0521117;C0681906;C1947916;C2700446	\N	\N
97	rheumatic heart disease	C0035439	\N	\N
97	endoscopic disease severity	C0014245;C0442418;C0521117	\N	\N
97	disease severity	C0521117	\N	\N
97	congenital heart disease	C0152021	\N	\N
97	$nmbr$ ( severe disease )	C1836348	\N	\N
96	cigarettesmoking  %	\N	\N	\N
96	cigarette users	C0677453;C1704760;C1706077;C3890423	\N	\N
95	unspecified	C0205370;C1549663;C2983689;C4048188	\N	\N
95	unified parkinson disease	C0030567;C1521736;C1548174;C1706076	\N	\N
95	unclassified	C0205426;C1546437;C2347854;C4085229	\N	\N
94	or per unit for continuous variables	C0439148;C0439453;C0439828;C0549178;C1509845;C1519795;C1704753;C1880519;C3853603	\N	\N
94	mtss units	C0439148;C1519795;C3853603	\N	\N
94	insulin dose ( u )	C0366513;C0439148	\N	\N
94	insulin dose  u	C0366513;C0439148	\N	\N
94	ae / e ' ratio ( per $nmbr$ unit )	C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670	\N	\N
90	( ne  ne )	C0027608;C0028219;C3538705	f	-10
105	history of macrovascular disease	C0683519;C0730226;C0850708;C0944983	f	1698
97	moderate or severe renal disease  b   n ( % )	C0022646;C0022658;C0205081;C0205082;C1836348;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	f	937
105	history of carotid artery disease	C0007273;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	2195
105	history of carotid disease - n ( % )	C0683519;C0730226;C0741968;C0850708;C0944983	f	2195
105	carotid artery disease	C0007273	f	2195
94	ae / a ratio ( per $nmbr$ . $nmbr$ unit )	C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670	\N	\N
93	unknown — no . { % )	C0439673;C3541433;C4050014	\N	\N
93	unknown type	C0332307;C0439673;C1547052;C3541433;C4050014	\N	\N
93	unknown ( none of the above )	C0439673;C1282910;C1552828;C3541433;C4050014	\N	\N
93	unknown ( % )	C0439673;C3541433;C4050014	\N	\N
93	unknown	C0439673;C3541433;C4050014	\N	\N
93	non - detectable / unknown  n ( % )	C0439673;C1518422;C3541433;C3830527;C4050014	\N	\N
93	non - detectable / unknown	C0439673;C1518422;C3541433;C3830527;C4050014	\N	\N
93	no or unknown	C0439673;C3541433;C4050014	\N	\N
93	no / unknown	C0439673;C3541433;C4050014	\N	\N
93	mi type unknown ( % )	C0332307;C0439673;C1547052;C3541433;C3810814;C4050014	\N	\N
93	ischaemic or unknown stroke	C0038454;C0439673;C0475224;C3541433;C4050014;C4554100	\N	\N
93	indeterminate or unknown	C0205258;C0439673;C3541433;C4050014	\N	\N
93	a excludes two randomized patients with unknown diabetes status at baseline .	C0034656;C0168634;C0205448;C0332196;C0439673;C1315719;C1442488;C2828389;C3541433;C3815594;C4050014	\N	\N
92	uacr not available	C0686905	f	80
92	not severe	C4316743	\N	\N
92	not available	C0686905	\N	\N
92	not assessable	C1883425	\N	\N
92	nnt	C1417750	\N	\N
90	ne	C0027608;C0028219;C3538705	f	-10
91	p - value ( ■ nt )	C0332126;C1449832;C1709380;C3889152;C4050156;C4283901;C4284038	\N	\N
91	nt estimated	C0332126;C0750572;C1449832;C3889152;C4050156;C4283901;C4284038	\N	\N
91	n nt	C0332126;C0369718;C0441922;C1449832;C3889152;C4050156;C4283901;C4284038	\N	\N
90	new - onset atrial fibrillation	C0741281	\N	\N
90	lone atrial fibrillation — no . ( % ) §	C0340489	\N	\N
90	duration of qualifying atrial fibrillation » $nmbr$ days — no . ( % )	C0004238;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735	\N	\N
90	atrial fibrillation  duration — no . ( % )	C0004238;C0344434;C0449238;C1963067;C2926735	\N	\N
89	nx *	C0445085	\N	\N
89	no . ( % ) $nmbr$ ( $nmbr$ )	\N	\N	\N
89	modified rankin scale — no . ( % ) |	C2984908;C3854213	\N	\N
88	traditional chinese medicine for respiratory disease — no . ( % )	C0025124;C0035204;C0035242;C1515884	\N	\N
88	no po	C0032729;C0442027	\N	\N
88	fluindione  no . ( % )	C0117899	\N	\N
88	chronic cardiovascular disease  no . ( % )	C1290380	\N	\N
88	associatedproximaldeep - veinthrombosisatdiagnosis  no . ( % )	\N	\N	\N
87	onsetofaf  no . ( % )	\N	\N	\N
87	nonsustained ventricular tachycardia — no . ( % ) - j -	C0750194;C2919575	\N	\N
87	enox	C3147679	\N	\N
86	no ( $nmbr$ . $nmbr$ )	\N	\N	\N
86	family history of cad ( diagnosed at < $nmbr$ yr of age ) — no . ( % ) cigarette smoker — no . ( % )	C0001779;C0011900;C0241889;C0337667;C0439234;C1504769;C2239547;C3813548;C4284121	\N	\N
86	diagnosis at study entry — no . ( % )	C1704656;C1705654;C4068481	\N	\N
86	age > $nmbr$ yr  no . ( % )	C0001779;C0439234	\N	\N
86	> $nmbr$  no . ( % )	\N	\N	\N
86	< $nmbr$ yr — no . { % )	C0439234	\N	\N
86	< $nmbr$ vr — no . ( % )	C3476815	\N	\N
86	$nmbr$ - $nmbr$ vr — no . ( % )	C3476815	\N	\N
85	on non ‐ metformin aha	C0025598;C0050451;C0772110;C1518422	\N	\N
85	not tested	C0392366;C1518422	\N	\N
85	not reported / unknown	C0439673;C0684224;C0700287;C1518422;C3541433;C4050014;C4319718	\N	\N
85	not reported	C0684224;C0700287;C1518422;C4319718	\N	\N
85	not provided	C1518422;C1999230	\N	\N
85	not perfused	C1518422;C1549542	\N	\N
85	not on metformin	C0025598;C1518422	\N	\N
85	not on an aha	C0050451;C0772110;C1518422	\N	\N
85	not localized	C0392752;C1518422	\N	\N
85	not estimable	C1518422	\N	\N
85	not collected ^	C1516695;C1516698;C1518422	\N	\N
85	non diuretics	C0012798;C1518422	\N	\N
85	non - united states	C0041703;C1518422	\N	\N
85	non - u . s .	C0041703;C1518422	\N	\N
85	non - spondylitis	C0038012;C1518422	\N	\N
85	non - severe hypoglycaemia	C0020615;C0205082;C1518422;C4050465;C4050466;C4553659	\N	\N
85	non - rollover	C0517067;C0543436;C1518422	\N	\N
85	non - hispanicwhite	C1518422	\N	\N
85	non - hishnic	C1518422	\N	\N
85	non - epa number of <	C0237753;C0449788;C1518422	\N	\N
85	non - epa ( n = $nmbr$ )	C1518422	\N	\N
85	non - cabg or combined	C0010055;C0205195;C1518422	\N	\N
85	non - c	C1518422	\N	\N
85	no . of tnfi among non - tnfi naive	C1518422	\N	\N
85	no . of non - tnfi	C1518422	\N	\N
85	nct $nmbr$	\N	\N	\N
85	major or clinically relevant non - major bleeding	C0019080;C0205082;C0205164;C1518422;C2347946;C4318856;C4521762	\N	\N
85	major or clinically relevant non - major bleed	C0019080;C0205082;C0205164;C1518422;C2347946;C4318856;C4521762	\N	\N
85	infarction  date not reported	C0011008;C0021308;C0684224;C0700287;C1518422;C2348077;C4319718	\N	\N
85	did not enrol into osler	C1518422	\N	\N
85	clinically relevant non	C1518422;C2347946	\N	\N
84	white tcz + mtx ( n )	C0007457;C0025677;C0043157;C0220938;C1417487	\N	\N
84	tx $nmbr$	C0041403	\N	\N
84	tx	C0041403	\N	\N
84	tcz + mtx ( n )	C0025677;C1417487	\N	\N
82	creatinine ciearance	C0010294;C1561535	f	79
82	creatinine clearanceb  ml / min	C0010294;C0439445;C1561535	f	79
82	estimated creatinine clearancet	C0010294;C0750572;C1561535	f	79
82	ratio of urinary albumin ( mg ) to creatinine ( g )	C0010294;C0024671;C0026410;C0439267;C0439269;C0456603;C1547037;C1561535;C1960952;C2346927;C2362049;C4321396;C4521761	f	80
82	ratio of urinary albumin ( mg ) to creatinine ( g ) median	C0010294;C0024671;C0026410;C0439267;C0439269;C0456603;C0549183;C0876920;C1547037;C1561535;C1960952;C2346927;C2347635;C2348144;C2362049;C2939193;C4321396;C4521761	f	80
90	$nmbr$ . $nmbr$ ( ne  ne )	C0027608;C0028219;C3538705	f	-10
90	< $nmbr$ no . ( % )	\N	f	-10
85	non - rheumatic valvular heart disease	C0264757;C1518422	f	103
84	$nmbr$ tcz + mtx mtx	C0025677;C1417487	\N	\N
84	$nmbr$ tcz + mtx	C0025677;C1417487	\N	\N
84	$nmbr$ tcz	\N	\N	\N
83	qtc > $nmbr$ n = $nmbr$	\N	\N	\N
83	qtc < $nmbr$ n = $nmbr$	\N	\N	\N
83	freedom from gtc seizures  n ( % )	C1299590	\N	\N
80	mean ( sd ) values are presented for all variables  except medical history  race or ethnic group  and sex ( n  % ) and urinary albumin / creatinine ratio ( median ( range ) ) . abody mass index is the weight in kilograms divided by the square of the height in meters . bto convert values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . estimated using the modified equation from the modification of diet in renal disease study . dto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . eto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ^ to convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ .	C0005910;C0009253;C0015031;C0019664;C0019665;C0034510;C0036864;C0040363;C0041260;C0042027;C0042295;C0043100;C0079399;C0199168;C0205120;C0205476;C0262512;C0262926;C0332849;C0392747;C0439190;C0439194;C0439209;C0439828;C0441074;C0444504;C0449450;C0457987;C0475211;C0486293;C0489786;C0549183;C0552449;C0557651;C0577559;C0577573;C0600653;C0724655;C0750572;C0804628;C0876920;C0918012;C1096155;C1305866;C1306372;C1314687;C1318293;C1514721;C1522384;C1524063;C1524119;C1552595;C1552854;C1554963;C1637833;C1705104;C1705255;C1706779;C1719797;C1879937;C1883351;C2004062;C2347634;C2347635;C2348143;C2348144;C2348147;C2603343;C2699239;C2911648;C2939193;C2986546;C3152252;C3539882;C3542016;C3840684;C3853635;C3889737;C4283905	f	-10
81	no colchicine ( n = $nmbr$ )	C0009262	\N	\N
81	colchicine ( n = $nmbr$ )	C0009262	\N	\N
80	urine albumin / creatinine ratio ( mg / g )	C0455271;C1300563;C1318330	\N	\N
80	urine albumin / creatinine ratio  mg / mmol	C0455271;C0567349;C1318330;C2348885	\N	\N
80	urine albumin / creatinine ( mg / mmol )	C0455271;C0567349;C1318330;C2348885	\N	\N
80	urine albumin - to - ereatinine ratio	C0001924;C0042038;C0456603;C0587185;C1273442;C1547037;C2362049	\N	\N
80	urine albumin - to - creatinine ratio - no . ( % ) § §	C0455271;C1318330	\N	\N
80	urine albumin - to - creatinine ratio	C0455271;C1318330	\N	\N
80	urinary protein - to - creatinine ratio | |	C1096054	\N	\N
80	urinary albumin : creatinine ratioa ( mg / g )	C0455271;C1300563;C1318330	\N	\N
80	urinary albumin : creatinine ratio ^	C0455271;C1318330	\N	\N
80	urinary albumin : creatinine ratio *	C0455271;C1318330	\N	\N
80	urinary albumin : creatinine ratio ( mg / g )	C0455271;C1300563;C1318330	\N	\N
80	urinary albumin - to - creatinine ratio — no . ( % ) §	C0455271;C1318330	\N	\N
80	urinary albumin - to - creatinine ratio §	C0455271;C1318330	\N	\N
80	urinary albumin - to - creatinine ratio ^	C0455271;C1318330	\N	\N
80	urinary albumimcreatinine ratio	C1273442	\N	\N
80	median albumin - to - creatinine ratio ( interquartile range )	C0486293;C0549183;C0876920;C1318293;C1711350;C2347635;C2348144;C2939193	\N	\N
80	baseline albumin / creatinine ratio in $nmbr$ classes	C0168634;C0456387;C0486293;C1318293;C1442488;C1518526;C1705943;C4019422	\N	\N
80	albumin creatinine ratio	C0486293;C1318293	\N	\N
80	albumin / creatinine ratio  n ( % )	C0486293;C1318293	\N	\N
80	albumin - to - creatinine ratio ( acr )	C0486293;C1318293;C1412134;C1515941	\N	\N
80	albumin - to - creatinine ratio	C0486293;C1318293	\N	\N
79	renal fmclicn : creatntoe clearance	C0232813;C0699829	\N	\N
79	estimated creatinine clearance < $nmbr$ rmb ' mint	C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C3890003	\N	\N
79	estimated creatinine clearance < $nmbr$ ml / mint	C0439526;C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C1705224;C3887665;C3890003	\N	\N
79	estimated creatinine clearance  !	C0750572;C0812399	\N	\N
79	estimated * creatinine clearance < $nmbr$ mlvmin  %	C0750572;C0812399	\N	\N
79	creatinine clearance ， : : $nmbr$ ml / min  %	C0439445;C0812399	\N	\N
79	creatinine clearance — no . ( % )	C0812399	\N	\N
79	creatinine clearance category [ ml / min ]	C0439445;C0683312;C0812399;C3889287	\N	\N
79	creatinine clearance category  ml / min  no . ( % ) b	C0439445;C0683312;C0812399;C3889287	\N	\N
79	creatinine clearance at randomization ( ixrs )	C0034656;C0812399	\N	\N
79	creatinine clearance at randomization	C0034656;C0812399	\N	\N
79	creatinine clearance < $nmbr$ ml / min — no . ( % ) weight < $nmbr$ kg — no . ( % )	C0005910;C0022718;C0043100;C0439209;C0439445;C0812399;C1305866;C1705104;C4054209	\N	\N
79	creatinine clearance < $nmbr$ ml / min  no . / total ( % )	C0439175;C0439445;C0439810;C0812399	\N	\N
79	creatinine clearance  no . ( % )	C0812399	\N	\N
79	creatinine clearance  n ( % )	C0812399	\N	\N
79	creatinine clearance  an   ( % )	C0812399	\N	\N
79	creatinine clearance	C0812399	\N	\N
78	chlorthalidone vs amlodipine	C0008294;C0051696	\N	\N
78	chlorthalidone - amlodipine - lisinopril	C0008294;C0051696;C0065374	\N	\N
78	benazepril / hydrochlorothiazide - benazepril / amlodipine	C0051696;C0717481	\N	\N
78	amlodipine vs chlorthalidone overweight	C0008294;C0051696;C0497406	\N	\N
78	amlodipine vs chlorthalidone obese	C0008294;C0028754;C0051696	\N	\N
78	amlodipine / wlsartan i $nmbr$ / $nmbr$ mg	C0021966;C0024671;C0026410;C0051696;C0221138;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
78	amlodipine / vaisartan ( n = $nmbr$ )	C0051696	\N	\N
78	amlodipine / lisinopril $nmbr$	C0051696;C0065374	\N	\N
78	amlodipine - amlodipine / valsartan	C1962523	\N	\N
78	amlodipine ( n = $nmbr$ )	C0051696	\N	\N
78	amlodipine	C0051696	\N	\N
78	! amlodipine	C0051696	\N	\N
82	creatinine ratio	C0010294;C0456603;C1547037;C1561535	f	952
82	creatinine ratio $nmbr$ - $nmbr$	C0010294;C0456603;C1547037;C1561535	f	952
82	doubling of creatinine	C0010294;C0205173;C1561535;C1705764	f	952
82	doubling of creatinine †	C0010294;C0205173;C1561535;C1705764	f	952
78	nilvadipine	C0132512	f	-10
77	corticosteroid - azathioprine / $nmbr$ - mercaptopurine	C0000618;C0001617;C0004482;C3536709	\N	\N
77	$nmbr$ - mercaptopurine / azathioprine	C0000618;C0004482	\N	\N
77	$nmbr$ - mercaptopurine	C0000618	\N	\N
-10	leukotriene modifier	C0023545;C0205349;C1514623;C1516451;C3542952	\N	\N
75	prior exposure to lamotrigine	C0064636;C0274281;C0332152;C0332157;C0524166;C2826257	\N	\N
75	lamotrigine	C0064636;C0524166	\N	\N
74	placebo - famotidine $nmbr$ - famotidine $nmbr$	C0015620;C0032042;C1696465;C1706408	\N	\N
74	placebo - famotidine $nmbr$	C0015620;C0032042;C1696465;C1706408	\N	\N
74	famotidine $nmbr$ - famotidine $nmbr$	C0015620	\N	\N
73	thienopyridine use	C0042153;C0457083;C1120149;C1947944	\N	\N
73	thienopyridine type	C0332307;C1120149;C1547052	\N	\N
73	thienopyridine n = $nmbr$	C1120149	\N	\N
73	thienopyridine + dipyridamole	C0012582;C1120149	\N	\N
73	thienopyridine ( n = $nmbr$ )	C1120149	\N	\N
73	thienopyridine	C1120149	\N	\N
73	prior thienopyridine ( - )	C0332152;C1120149;C2826257	\N	\N
73	prior thienopyridine ( + )	C0332152;C1120149;C2826257	\N	\N
73	planned thienopyridine at enrollment	C1120149;C1709561	\N	\N
73	no thienopyridine	C1120149	\N	\N
73	aspirin and thienopyridine therapy	C0004057;C0039798;C0087111;C1120149;C1363945	\N	\N
73	aspirin + thienopyridine	C0004057;C1120149	\N	\N
73	- thienopyridine	C1120149	\N	\N
73	+ thienopyridine	C1120149	\N	\N
72	thiazolidinedionesc	\N	\N	\N
72	thiazolidinediones *	C1257987;C3541957	\N	\N
72	thiazolidinediones	C1257987;C3541957	\N	\N
72	thiazolidinedioneb	\N	\N	\N
72	thiazolidinedione 一 no . ( % )	C0289779;C1257987;C3537039	\N	\N
72	thiazolidinedione use at baseline	C0042153;C0168634;C0289779;C0457083;C1257987;C1442488;C1947944;C3537039	\N	\N
72	thiazolidinedione no	C0289779;C1257987;C3537039	\N	\N
72	thiazolidinedione based	C0289779;C1257987;C1527178;C1705938;C3537039	\N	\N
72	thiazolidinedione ( includes pioglitazone )	C0071097;C0289779;C0332257;C1257987;C1552866;C2700399;C3537039	\N	\N
72	thiazolidinedione	C0289779;C1257987;C3537039	\N	\N
72	any thiazolidinedione	C0289779;C1257987;C3537039	\N	\N
71	sulfasalazine	C0036078	\N	\N
71	ranozaline	\N	\N	\N
71	ranolazine n = $nmbr$	C0073633	\N	\N
71	ranolazine ( n = $nmbr$ )	C0073633	\N	\N
71	ranolazine ( n = $nmbr$  $nmbr$ )	C0073633	\N	\N
71	ranolazine ( n $nmbr$ $nmbr$ )	C0073633	\N	\N
71	ranolazine  n   =   $nmbr$	C0073633	\N	\N
71	ranolazine  n = i $nmbr$ i $nmbr$	C0021966;C0073633;C0221138	\N	\N
71	ranolazine	C0073633	\N	\N
71	prior sulfasalazine use *	C0036078;C0042153;C0332152;C0457083;C1947944;C2826257	\N	\N
71	hydralazine	C0020223	\N	\N
70	lisinopril vs chlorthalidone normal	C0008294;C0065374;C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
70	lisinopril vs chlorthalidone	C0008294;C0065374	\N	\N
70	lisinopril / chlorthalidone	C0008294;C0065374	\N	\N
70	lisinopril - chlorthalidone	C0008294;C0065374	\N	\N
70	favors lisinopril favors chlorthalidone	C0008294;C0065374;C0309049	\N	\N
70	favors favors lisinopril chlorthalidone	C0008294;C0065374;C0309049	\N	\N
70	favors favors amlodipine chlorthalidone	C0008294;C0051696;C0309049	\N	\N
70	favors amlodipine favors chlorthalidone	C0008294;C0051696;C0309049	\N	\N
70	chlorthalidone vs doxazosin	C0008294;C0114873	\N	\N
70	chlorthalidone group	C0008294;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
70	chlorthalidone ( n = $nmbr$ )	C0008294	\N	\N
70	chlorthalidone $nmbr$	C0008294	\N	\N
70	chlorthalidone	C0008294	\N	\N
70	amlodipione - chlorthalidone	C0008294	\N	\N
70	amlodipine vs chlorthalidone normal	C0008294;C0051696;C0205307;C0231683;C0439166;C2347086;C4553972	\N	\N
70	amlodipine / lisinopril / chlorthalidone comparison	C0008294;C0051696;C0065374;C1707455	\N	\N
70	amlodipine / chlorthalidone	C0008294;C0051696	\N	\N
70	$nmbr$ lisinopril - chlorthalidone	C0008294;C0065374	\N	\N
70	$nmbr$ chlorthalidone amlodipine	C0008294;C0051696	\N	\N
70	$nmbr$ chlorthalidone ( n = $nmbr$ )	C0008294	\N	\N
70	$nmbr$ chlorthalidone	C0008294	\N	\N
70	$nmbr$ amlodipine - chlorthalidone	C0008294;C0051696	\N	\N
69	placebo + insulin glargine ( award - $nmbr$  n = $nmbr$ )	C0004446;C0032042;C0907402;C1696465;C1706408	\N	\N
69	insulin glargine   ±   oad   +   od prandial	C0229089;C0439164;C0907402;C1512019;C1998602;C3273373;C3665488;C4553624	\N	\N
69	insulin glargine   ±   oad   +   bd prandial	C0005126;C0907402;C1998602;C2344255;C4050145;C4553624	\N	\N
69	insulin glargine   ±   oad   +   > bd prandial	C0005126;C0907402;C1998602;C2344255;C4050145;C4553624	\N	\N
69	insulin glargine   ±   oad	C0907402	\N	\N
69	insulin glargine n ( x )	C0907402	\N	\N
69	insulin glargine allocation	C0907402;C1706778	\N	\N
69	insulin glargine + insulin lispro ( award - $nmbr$  n = $nmbr$ )	C0004446;C0293359;C0907402	\N	\N
69	insulin glargine ( n = $nmbr$ )	C0907402	\N	\N
69	insulin glargine	C0907402	\N	\N
69	insuiin giargine ± oad	\N	\N	\N
69	iglar ( n   =   $nmbr$ )	\N	\N	\N
69	iglar ( insulin glargine l $nmbr$ u )	C0439148;C0907402	\N	\N
69	glargine allocation	C0907402;C1706778	\N	\N
69	glargine $nmbr$	C0907402	\N	\N
69	glargine	C0907402	\N	\N
69	giargine	\N	\N	\N
68	ivabradine group ( n = $nmbr$ )	C0257190;C0441848	\N	\N
68	ivabradine group	C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	\N	\N
68	ivabradine ( n = $nmbr$ )	C0257190	\N	\N
68	ivabradine	C0257190	\N	\N
67	rolofylline rx	C0166128;C1425688;C1521941;C2709207	\N	\N
67	rolofylline n	C0166128	\N	\N
67	rolofylline dose	C0166128;C0178602;C0869039;C1114758	\N	\N
67	rolofylline ( n = $nmbr$ )	C0166128	\N	\N
67	rolofylline ( n = $nmbr$  $nmbr$ )	C0166128	\N	\N
67	rolofylline $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0166128;C0439269;C1960952;C2346927;C4321396;C4521761	\N	\N
66	theophylline compound	C0039771;C0205198;C1706082	\N	\N
65	prior angina pectoris — no . / total no . ( % )	C0002962;C0332152;C0439175;C0439810;C2826257	\N	\N
65	prior angina pectoris	C0002962;C0332152;C2826257	\N	\N
65	prior angina ( n = $nmbr$  $nmbr$ )	C0002962;C0332152;C2826257	\N	\N
65	prior angina  n / n ( % )	C0002962;C0332152;C2826257	\N	\N
65	prior angina	C0002962;C0332152;C2826257	\N	\N
65	previous angina pectoris	C0002962;C0205156;C1552607	\N	\N
65	previous angina  n ( % )	C0002962;C0205156;C1552607	\N	\N
65	no prior angina ( n = $nmbr$  $nmbr$ )	C0002962;C0332152;C2826257	\N	\N
65	myocardial infarction or angina	C0002962;C0027051;C0428953;C2926063;C3810814;C4552959	\N	\N
65	hospitaiization for angina	C0002962	\N	\N
65	angina symptoms ^	C0858277	\N	\N
65	angina pectorisf	C0002962	\N	\N
65	angina pectoris 本	C0002962	\N	\N
65	angina pectoris — no . ( % )	C0002962	\N	\N
65	angina pectoris *	C0002962	\N	\N
65	angina pectoris  ( % )	C0002962	\N	\N
65	angina pectoris	C0002962	\N	\N
65	angina or acute mi	C0002962;C0155626	\N	\N
65	angina .	C0002962	\N	\N
65	angina  n ( % )	C0002962	\N	\N
65	angina	C0002962	\N	\N
63	aii patients ( n = $nmbr$ )	C0030705;C1424250;C2698414	\N	\N
63	aii participants ( n = $nmbr$ )	C0679646;C1424250;C2698414	\N	\N
63	ai $nmbr$	C0003504;C4551710	\N	\N
63	$nmbr$ i - $nmbr$ - $nmbr$ ai	C0003504;C0021966;C0221138;C4551710	\N	\N
62	flex ain ' ’	C0347129	\N	\N
62	ain  no . ( % ) “ *	C0347129	\N	\N
62	ain  no . ( % ) * *	C0347129	\N	\N
61	insulin glargine - air insulin / insulin glargine	C0001861;C0907402;C3536832	\N	\N
61	air insulin - insulin glargine - air insulin / insulin glargine	C0001861;C0907402;C3536832	\N	\N
61	air insulin - air insulin / insulin glargine	C0001861;C0907402;C3536832	\N	\N
61	air ( n = $nmbr$ )	C0001861;C3536832	\N	\N
60	s - asa compounds at baseline	C0004057;C0010139;C0043474;C0168634;C1442488;C3853627	\N	\N
60	prior asa use	C0004057;C0042153;C0332152;C0457083;C1947944;C2826257;C3853627	\N	\N
60	pfo + asa	C0004057;C3853627	\N	\N
60	no asa use at baseline	C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627	\N	\N
60	no asa	C0004057;C3853627	\N	\N
64	due worsening angina	C0002965;C0678226;C3146286	f	65
60	baseline $nmbr$ - asa	C0004057;C0168634;C1442488;C3853627	\N	\N
64	rest angina	C0002965;C0152172	f	65
64	rest angina but not past $nmbr$ h	C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C1518422;C4284302;C4528284	f	65
64	unstable angina	C0002965	f	65
64	unstable angina ( n = $nmbr$  $nmbr$ )	C0002965	f	65
64	unstable angina — no . ( % )	C0002965	f	65
64	unstable but no rest angina	C0002965;C0152172;C0443343;C1883468	f	65
64	worsening angina	C0002965	f	65
60	asas partial remission    n   ( % )	C0004057;C1521726;C3853627;C4552913;C4552914	\N	\N
60	asas partial remission  %	C0004057;C1521726;C3853627;C4552913;C4552914	\N	\N
60	asas $nmbr$ / $nmbr$    n   ( % )	C0004057;C3853627	\N	\N
60	asas $nmbr$ / $nmbr$    %	C0004057;C3853627	\N	\N
60	asas $nmbr$    %	C0004057;C3853627	\N	\N
60	asas $nmbr$  %	C0004057;C3853627	\N	\N
60	asas $nmbr$	C0004057;C3853627	\N	\N
60	asa use at baseline  n ( % )	C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627	\N	\N
60	asa use at baseline	C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627	\N	\N
60	asa  n ( % )	C0004057;C3853627	\N	\N
60	asa	C0004057;C3853627	\N	\N
59	myalgia	C0231528;C4552646	\N	\N
59	malaysia	C0024552	\N	\N
58	prior analgesic products  n ( % )	C0002771;C0332152;C2826257	\N	\N
58	analgesic medication  n ( % )	C0002771	\N	\N
57	alpha reductase inhibitors	C0439095;C0597153;C1655741;C2003941;C2350010	\N	\N
56	corticosteroid or azathioprine / $nmbr$ - mercaptopurine	C0000618;C0001617;C0004482;C3536709	\N	\N
56	azathioprine monotherapy	C0004482	\N	\N
56	azathioprine / $nmbr$ - mercaptopurine	C0000618;C0004482	\N	\N
56	azathioprine ( n = $nmbr$ )	C0004482	\N	\N
56	azathioprine	C0004482	\N	\N
56	aza ( n = $nmbr$ )	C0004482	\N	\N
56	and / or aza at baseline	C0004482;C0168634;C1442488	\N	\N
56	$nmbr$ - up and / or aza at baseline	C0004482;C0168634;C1442488	\N	\N
55	the netherlands  australia  new zealand  and south africa	C0027778;C0037712;C4289954	\N	\N
55	austria	C0004348	\N	\N
55	australia / new zealand / south africa	C0037712;C4289954	\N	\N
55	australia / new zealand	C4289954	\N	\N
55	asia / australia / new zealand	C0003980;C4289954	\N	\N
54	western european includinq australia  israel  and south africa	C0004340;C0022271;C0037712;C0043128;C0239307;C0239312;C1535514	\N	\N
54	western europe and australia	C0004340;C0043129	\N	\N
54	australia / nz	C0004340;C0027978	\N	\N
54	australia	C0004340	\N	\N
54	australasia	C0282279;C1257882	\N	\N
53	regional anaesthesia	C0002911	\N	\N
53	paresthesia	C0030554;C4553220	\N	\N
53	general anaesthesia	C0002915;C2930406	\N	\N
60	aspirin at last follow - up	C0004057;C0589120;C1522577;C1704685;C3274571	f	1366
60	aspirin group	C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429	f	1366
60	aspirin group ( n = $nmbr$ )	C0004057;C0441848	f	1366
60	aspirin $nmbr$	C0004057	f	1366
60	aspirin $nmbr$  $nmbr$	C0004057	f	1366
60	aspirin ( n = $nmbr$ )	C0004057	f	1366
60	baseiine aspirin	C0004057	f	1366
60	high - dose aspirin	C0004057;C0444956	f	1366
57	alpha receptor antagonist	C0439095;C2003941;C2350010;C4543207	f	961
52	urinary acr	C0042027;C1412134;C1515941;C1524119	\N	\N
52	sprint acr > $nmbr$ - $nmbr$	C1412134;C1515941	\N	\N
52	sprint acr < $nmbr$ - $nmbr$	C1412134;C1515941	\N	\N
52	categories of urinary acr  ^ g / mg	C0042027;C0683312;C1300563;C1412134;C1515941;C1524119	\N	\N
52	b . acr $nmbr$	C1412134;C1515941	\N	\N
52	albuminuria ( acr > $nmbr$ m . g / g ) at baseline to normoalbuminuria	C0001925;C0168634;C0369637;C0441923;C1319635;C1412134;C1442488;C1515941	\N	\N
52	acr response by baseline weight	C0871261;C1303013;C1412134;C1515941;C1704632;C1706817;C2911692	\N	\N
52	acr response by baseline mtx use  no . / total no . ( % ) acr $nmbr$	C0025677;C0042153;C0168634;C0439175;C0439810;C0457083;C0871261;C1412134;C1417487;C1442488;C1515941;C1704632;C1706817;C1947944;C2911692	\N	\N
52	acr response  % acr $nmbr$	C0871261;C1412134;C1515941;C1704632;C1706817;C2911692	\N	\N
52	acr response  %	C0871261;C1412134;C1515941;C1704632;C1706817;C2911692	\N	\N
52	acr functional class  n ( % )	C0205245;C0456387;C0542341;C1412134;C1515941;C1518526;C1705943;C2700217	\N	\N
52	acr deciles	C1412134;C1515941	\N	\N
52	acr $nmbr$ response at week $nmbr$  n ( % )	C0332174;C0439230;C0871261;C1412134;C1515941;C1704632;C1706817;C2911692	\N	\N
52	acr $nmbr$ response  n / n ( % )	C0871261;C1412134;C1515941;C1704632;C1706817;C2911692	\N	\N
52	acr $nmbr$ response	C0871261;C1412134;C1515941;C1704632;C1706817;C2911692	\N	\N
52	acr $nmbr$	C1412134;C1515941	\N	\N
52	acr	C1412134;C1515941	\N	\N
52	accord acr > $nmbr$ - $nmbr$	C0680240;C1412134;C1515941	\N	\N
52	accord acr < $nmbr$ - $nmbr$	C0680240;C1412134;C1515941	\N	\N
52	a . acr $nmbr$	C1412134;C1515941	\N	\N
51	arr ( % )	C2170357;C4084934	\N	\N
51	arr ( $nmbr$ % cl )	C0596019;C2170357;C4084934	\N	\N
51	arr ( $nmbr$ % ci )	C0008107;C2170357;C3259781;C4084934	\N	\N
51	arr	C2170357;C4084934	\N	\N
51	> $nmbr$ % predicted arr ( n = $nmbr$ )	C0681842;C1882327;C2170357;C4084934	\N	\N
51	> $nmbr$ % and < $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ )	C0681842;C1882327;C2170357;C4084934	\N	\N
51	< $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ )	C0681842;C1882327;C2170357;C4084934	\N	\N
50	diarrhoea	C0011991;C1963091;C3641756;C4084784;C4084802;C4085317	\N	\N
50	diarrhea	C0011991;C1963091;C3641756;C4084784;C4084802;C4085317	\N	\N
49	married	C0024841;C0555047	\N	\N
49	marital status  married	C0024819;C0024841;C0555047;C1716536;C3172566	\N	\N
48	middle east  africa  or asia - pacific	C0001737;C0001741;C0003980;C0026068;C0444598;C0549183;C1552826	\N	\N
48	asia pacific and africa	C0001737;C0003980	\N	\N
48	africa or near east	C0001737;C0205674	\N	\N
48	africa *	C0001737	\N	\N
48	africa ! near east	C0001737;C1707877	\N	\N
48	africa  asia  or the middle east	C0001737;C0003980;C0026068	\N	\N
48	africa	C0001737	\N	\N
47	≥ $nmbr$ ae	C3887670	\N	\N
47	laboratory ae  n ( % }	C0022877;C3244292;C3887670;C4283904	\N	\N
47	drug - related ae *	C0013227;C0439849;C0445223;C1254351;C3887670	\N	\N
47	clinical ae  n ( % }	C0205210;C3887670	\N	\N
47	because of ae	C3887670	\N	\N
47	any drug - related ae  n ( % )	C0013227;C0439849;C0445223;C1254351;C3887670	\N	\N
47	any clinical ae	C0205210;C3887670	\N	\N
47	any ae  n ( % ) ‡	C3887670	\N	\N
47	any ae	C3887670	\N	\N
47	any adverse event ( ae )	C0877248;C3887670	\N	\N
46	randomly assigned to ace	C1452534;C1516050;C1552601;C4284014	\N	\N
46	no ace - i / arb	C0021966;C0221138;C1452534;C3888198;C4284014	\N	\N
46	neither ace - i nor arb use	C0021966;C0042153;C0221138;C0457083;C1452534;C1947944;C3888198;C4284014	\N	\N
46	arb / ace	C1452534;C3888198;C4284014	\N	\N
46	ace ‐ i or arb	C0021966;C0221138;C1452534;C3888198;C4284014	\N	\N
46	ace or arb	C1452534;C3888198;C4284014	\N	\N
46	ace / arb users	C1452534;C1706077;C3888198;C4284014	\N	\N
46	ace / arb medication ( % )	C0013227;C1452534;C3244316;C3888198;C4284014;C4284232	\N	\N
46	ace / arb	C1452534;C3888198;C4284014	\N	\N
46	ace - lorarb	C1452534;C4284014	\N	\N
46	ace - l / arbs	C1452534;C3888198;C4284014	\N	\N
46	ace - i or arb use at baseline	C0021966;C0042153;C0168634;C0221138;C0457083;C1442488;C1452534;C1947944;C3888198;C4284014	\N	\N
46	ace - i or arb use	C0021966;C0042153;C0221138;C0457083;C1452534;C1947944;C3888198;C4284014	\N	\N
46	ace - i or arb  % ( n )	C0021966;C0221138;C1452534;C3888198;C4284014	\N	\N
46	ace - i or arb	C0021966;C0221138;C1452534;C3888198;C4284014	\N	\N
46	ace - i / arb  ( % )	C0021966;C0221138;C1452534;C3888198;C4284014	\N	\N
46	ace - i / arb	C0021966;C0221138;C1452534;C3888198;C4284014	\N	\N
46	ace - i ( n  % )	C0021966;C0221138;C1452534;C4284014	\N	\N
46	ace	C1452534;C4284014	\N	\N
45	age — yr age group — no . ( % )	C0027362;C0439234;C2348001	\N	\N
45	age group 一 ％	C0027362;C2348001	\N	\N
45	age group — no . ( % )	C0027362;C2348001	\N	\N
45	age group ( ≥ $nmbr$ ) — no . ( % )	C0027362;C2348001	\N	\N
45	age group ( years )	C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001	\N	\N
45	age group $nmbr$	C0027362;C2348001	\N	\N
45	age group  no . ( % )  y	C0027362;C2348001	\N	\N
45	age group  no . ( % )	C0027362;C2348001	\N	\N
45	age group	C0027362;C2348001	\N	\N
45	age cohort  no . ( % )	C2348001	\N	\N
44	without acei / arb	C3888198	\N	\N
44	with acei / arb	C3888198	\N	\N
44	use of ace inhibitors / arbs  n ( % )	C0003015;C1524063;C3888198	\N	\N
44	use of ace inhibitor  arb  or both — no . ( % )	C0003015;C1524063;C3888198;C4541021	\N	\N
44	prior bb plus acbi plus arb use	C0004739;C0042153;C0332152;C0332287;C0332297;C0457083;C1947944;C2826257;C3888198	\N	\N
44	prior acbi or arb use	C0042153;C0332152;C0457083;C1947944;C2826257;C3888198	\N	\N
44	previously on acei + arb	C3888198	\N	\N
44	peri - op ace - inhibitors / arbs : no ( n = $nmbr$ )	C0003015;C0347985;C0369718;C0441922;C3888198	\N	\N
44	no ace inhibitor / arb	C0003015;C3888198;C4541021	\N	\N
367	drug eluting	C0013227;C1254351	f	365
44	neither ace inhibitor nor arb	C0003015;C3888198;C4541021	\N	\N
44	both ace inhibitor and arb	C0003015;C3888198;C4541021	\N	\N
44	baseiine acei / arb	C3888198	\N	\N
44	arbs or ace inhibitors	C0003015;C3888198	\N	\N
44	arbs	C3888198	\N	\N
44	arb or ace inhibitor  n ( % )	C0003015;C3888198;C4541021	\N	\N
44	arb or ace inhibitor	C0003015;C3888198;C4541021	\N	\N
44	arb monotherapy	C3888198	\N	\N
44	arb at enrollment	C1516879;C1696073;C3888021;C3888198	\N	\N
44	arb ( n  % )	C3888198	\N	\N
44	arb  n ( % )	C3888198	\N	\N
44	arb  %	C3888198	\N	\N
44	arb	C3888198	\N	\N
44	aceis / arbs	C3888198	\N	\N
44	aceis  n ( % )	\N	\N	\N
44	aceis	\N	\N	\N
44	acei or arb pre - randomisation	C0034656;C0332152;C0740175;C2257086;C3669034;C3888198	\N	\N
44	acei or arb post - randomisation	C0034656;C0687676;C1704687;C3469826;C3888198	\N	\N
44	acei or arb	C3888198	\N	\N
44	acei and / or arb	C3888198	\N	\N
44	acei / arb therapy  n ( % )	C0039798;C0087111;C1363945;C3888198	\N	\N
44	acei / arb	C3888198	\N	\N
44	ace inhibitors or arbs	C0003015;C3888198	\N	\N
44	ace inhibitors or arb	C0003015;C3888198	\N	\N
44	ace inhibitors and arb	C0003015;C3888198	\N	\N
44	ace inhibitors / arbs  n ( % )	C0003015;C3888198	\N	\N
44	ace inhibitors / arbs	C0003015;C3888198	\N	\N
44	ace inhibitors / arb	C0003015;C3888198	\N	\N
44	ace inhibitor or arb at enrollment	C0003015;C1516879;C1696073;C3888021;C3888198;C4541021	\N	\N
44	ace inhibitor or arb	C0003015;C3888198;C4541021	\N	\N
44	ace inhibitor and / or arb	C0003015;C3888198;C4541021	\N	\N
44	ace inhibitor / arb therapy	C1444755;C3888198	\N	\N
44	ace inhibitor / arb  %	C0003015;C3888198;C4541021	\N	\N
44	ace inhibitor / arb	C0003015;C3888198;C4541021	\N	\N
44	ace inhibitor  arb  or both	C0003015;C3888198;C4541021	\N	\N
44	ace / arb use	C0042153;C0457083;C1452534;C1947944;C3888198;C4284014	\N	\N
44	ace - inhibitors / arbs  n ( % )	C0003015;C3888198	\N	\N
44	ace - inhibitor or arb ( % )	C0003015;C3888198;C4541021	\N	\N
43	limited to left side of colon	C0227388;C0439801;C2674459;C3542948;C4050251	\N	\N
43	left sided colitis	C2887821	\N	\N
43	left side only	C3842976	\N	\N
43	left side of colon	C0227388	\N	\N
43	left shoulder	C0524469	\N	\N
43	left - sided disease only	C0012634;C3842976	\N	\N
43	left - sided colitis	C2887821	\N	\N
42	unprotected left main stented	C0038257;C0205091;C0205225;C0443246;C1542147;C1552822	\N	\N
42	multivessel ( two vessel  three vessel  or left main )	C0205091;C0205225;C0205449;C0443246;C1542147;C1552822;C4012475;C4037954	\N	\N
42	left side  n ( % )	C0205091	\N	\N
42	left main treated	C0205091;C0205225;C0443246;C1522326;C1542147;C1552822	\N	\N
42	left main disease  n ( % )	C0012634;C0205091;C0205225;C0443246;C1542147;C1552822	\N	\N
42	left main disease	C0012634;C0205091;C0205225;C0443246;C1542147;C1552822	\N	\N
42	left main artery	C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822	\N	\N
42	left main	C0205091;C0205225;C0443246;C1542147;C1552822	\N	\N
42	left - sided colitisz	C0205091;C0443246	\N	\N
42	left	C0205091;C0443246;C1552822	\N	\N
41	left atrial dimension  cm	C0018792;C0439534;C2950135	\N	\N
41	alert	C0239110;C2004580;C3665546;C3669039;C4084853;C4553014	\N	\N
40	left ventricular systolic or diastolic dysfunction	C0039155;C0225897;C0520863	\N	\N
40	left ventricular systolic dysfunction  n ( % )	C1277187;C1963159;C4553199	\N	\N
40	left ventricular ejection	C2733342	\N	\N
40	left ventricular dysfunction	C0242698	\N	\N
40	ecg left ventricular	C0225897;C1623258	\N	\N
40	af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme  hf heart failure  and lvd left ventricular dysfunction .	C0003018;C0007226;C0012634;C0014442;C0018792;C0018801;C0205171;C0205543;C0242698;C0344434;C0344720;C0348080;C0387288;C0439044;C0679994;C1452534;C1705253;C3864998;C3887460;C4049859;C4050619;C4284014;C4521302;C4521602	\N	\N
39	saxa + met n = $nmbr$	C0369718;C0428210;C0441922;C1550543;C4317104	\N	\N
39	saxa + dapa + met n = $nmbr$	C0369718;C0428210;C0441922;C1550543;C4317104	\N	\N
39	no longer met study criteria	C0205166;C0243161;C0428210;C0557651;C1550543;C1706317;C2603343;C4317104	\N	\N
39	met criterion at finalt	C0243161;C0428210;C1550543;C4317104	\N	\N
39	met criterion at final ( n [ % ] )	C0205088;C0243161;C0428210;C1546485;C1550543;C3853528;C4317104	\N	\N
39	met criterion at blt ( n [ % ] )	C0243161;C0428210;C1550543;C1563149;C1708627;C4317104	\N	\N
39	met criterion at bl ( n [ % ] )	C0005918;C0006413;C0243161;C0428210;C1550543;C1552663;C2827109;C4317104	\N	\N
39	met ( n = $nmbr$ )	C0428210;C1550543;C4317104	\N	\N
39	met % △ ( se )	C0036919;C0428210;C1550543;C4317104	\N	\N
39	mean ( $nmbr$ % ci ) difference vs saxa + dapa + met	C0008107;C0428210;C0444504;C1550543;C1705241;C1705242;C2347634;C2348143;C3259781;C4317104	\N	\N
39	dapa + met n = $nmbr$	C0369718;C0428210;C0441922;C1550543;C4317104	\N	\N
39	cana $nmbr$ / met ( n = $nmbr$ )	C0369718;C0428210;C0441922;C1418845;C1550543;C4317104	\N	\N
39	add - on to met + su $nmbr$	C0038642;C0428210;C1550543;C1705534;C1883712;C4317104	\N	\N
39	add - on to met + su	C0038642;C0428210;C1550543;C1705534;C1883712;C4317104	\N	\N
39	add - on to met $nmbr$	C0428210;C1550543;C1883712;C4317104	\N	\N
39	add - on to met	C0428210;C1550543;C1883712;C4317104	\N	\N
38	placeboa	\N	\N	\N
38	mean_delta	C0439097;C0444504;C1705241;C2347634;C2348143;C3146239;C3538806;C3540585;C3815527	\N	\N
38	difference from placeboa	C1705241;C1705242	\N	\N
38	am_delta	C0439097;C1705241;C3146239;C3538806;C3540585;C3815527	\N	\N
38	am_ % delta	C0439097;C1705241;C3146239;C3538806;C3540585;C3815527	\N	\N
37	★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .	C0031831;C0237753;C0444504;C0449788;C0549183;C0876920;C1444656;C1511726;C1709908;C2347634;C2347635;C2348143;C2348144;C2699239;C2939193;C3245479;C3714741	\N	\N
37	years ( mean ± sd )	C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
37	years  mean ( sd )	C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
37	week $nmbr$ fpg  mean ( s . e . )	C0332174;C0439230;C0444504;C2347634;C2348143	\N	\N
37	van der heijde mtss  mean ( sd )	C0444504;C0557775;C1511780;C2347634;C2348143;C2699239	\N	\N
37	ups score  mean ( sd )	C0334463;C0444504;C0449820;C2347634;C2348143;C2699239;C3542434;C4050231	\N	\N
37	units per week  mean ( sd )	C0444504;C0560588;C2347634;C2348143;C2699239	\N	\N
37	type $nmbr$ collagen  mean ( sd )  ng / ml £	C0009325;C0332307;C0439275;C0444504;C1547052;C2347634;C2348143;C2699239	\N	\N
37	treatment duration mean ( sd )	C0444504;C0444921;C2347634;C2348143;C2699239;C3259042	\N	\N
37	total updrs score ( baseline )  mean ( sd )	C0168634;C0439175;C0439810;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C3639721;C4050231	\N	\N
37	total pack - years mean ( sd )	C0439175;C0439810;C0444504;C1277691;C2347634;C2348143;C2699239	\N	\N
37	total daily dose of ics  mean  μ gc	C0444504;C0815320;C2347634;C2348070;C2348143;C3537453;C4281799;C4551720	\N	\N
37	total cigarette pack - years  mean ( sd )	C0439175;C0439810;C0444504;C1303175;C2347634;C2348143;C2699239	\N	\N
37	total basdai score  mean   ±   sd	C0439175;C0439810;C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231	\N	\N
37	time since start of fit  mean ( sd )  y	C0036572;C0040223;C0439659;C0444504;C1711239;C2347634;C2348143;C2349186;C2699239;C3541383;C4048158;C4553125	\N	\N
37	time since pd diagnosis  mean ± sd	C0011900;C0040223;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383;C4553228;C4553229	\N	\N
37	time since first psoriasis diagnosis ( y )  mean ( sd )	C0011900;C0033860;C0040223;C0205435;C0444504;C1279901;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383	\N	\N
37	time since end of fit  mean ( sd )  y	C0036572;C0040223;C0444504;C0444930;C1711239;C2347634;C2348143;C2349186;C2699239;C2746065;C3541383;C4048158;C4553125	\N	\N
37	time since diagnosis of diabetes  mean ( sd )	C0011847;C0011849;C0011900;C0040223;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383	\N	\N
37	time since as diagnosis ( years )  mean ( sd )	C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383	\N	\N
37	time since as diagnosis  mean ( sd ) years	C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383	\N	\N
37	tchdl - c  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	tc level  mean ( sd ) mg / dl	C0039411;C0040642;C0041405;C0041698;C0439269;C0441889;C0444504;C0456079;C1547707;C1824670;C2347634;C2348143;C2699239;C2946261;C3272447;C4522122	\N	\N
37	tc  mg / dl  mean ± sd	C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122	\N	\N
37	tc  mg / dl  mean + sd	C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122	\N	\N
37	tc  mean ( sd )  rrig / dl	C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C3642216;C4522122	\N	\N
37	tc  mean ( sd )	C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122	\N	\N
37	symptoms mean ( sd )	C0444504;C0683368;C1457887;C2347634;C2348143;C2699239	\N	\N
37	sulfasalazine ( mean dose : $nmbr$ . $nmbr$ g / day )	C0036078;C0178602;C0439417;C0444504;C0869039;C1114758;C2347634;C2348143	\N	\N
37	standardized mean difference	C0444504;C1705241;C1705242;C2347634;C2348143	\N	\N
37	smoking history  pack - years  mean ( sd )	C0444504;C1277691;C1519384;C2347634;C2348143;C2699239	\N	\N
37	smoking  mean	C0037369;C0444504;C0453996;C1881674;C2347634;C2348143	\N	\N
37	shs  mean ± sd	C0444504;C2347634;C2348143;C2699239	\N	\N
37	shs  mean $nmbr$ sd	C0444504;C2347634;C2348143;C2699239	\N	\N
37	sgrq scores  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
37	weight ( kg )  mean ( s . e . )	C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143	f	1915
37	weight  mean $nmbr$ sd kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	1915
37	weight  mean ( sd ) kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	1915
37	weight  mean ± sd ( kg )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	1915
37	triglycerides mean	C0041004;C0444504;C2347634;C2348143	f	368
37	triglycerides mean ( mg / dl ± sd )	C0041004;C0439269;C0444504;C2347634;C2348143;C2699239	f	368
37	triglycerides ( mg / dl )  mean + sd  available for $nmbr$ patients	C0030705;C0041004;C0439269;C0444504;C0470187;C2347634;C2348143;C2699239	f	368
37	sgrq score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
37	ses - cd  mean ( sd )	C0007928;C0034283;C0444504;C2347634;C2348143;C2699239;C4552032	\N	\N
37	serum $nmbr$ ( oh ) d concentrations  ng / ml  mean ( sd )	C0220853;C0439275;C0444504;C0683149;C2347634;C2348143;C2699239	\N	\N
37	sbp  mm hg ( mean $nmbr$ h )  mean ( sd )	C0025424;C0085805;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239	\N	\N
37	sbp  mm hg  mean ± sdc	C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112	\N	\N
37	sbp  mm hg  mean + sdc	C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112	\N	\N
37	rescue use : mean no . of inhalations / d	C0004048;C0042153;C0354922;C0444504;C0457083;C1947944;C2347634;C2348143	\N	\N
37	rescue medication use  mean inhalations / previous $nmbr$ d	C0004048;C0205156;C0240320;C0354922;C0444504;C1552607;C2347634;C2348143	\N	\N
37	pulse in beats / minute  mean ( sd )	C0232117;C0391850;C0439385;C0444504;C1947910;C2347634;C2348143;C2699239	\N	\N
37	previous dmards  mean ± sd	C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239	\N	\N
37	plp - c  mean ( sd )  mg / dl	C0034266;C0439269;C0444504;C1175541;C1257874;C1705623;C2347634;C2348143;C2699239	\N	\N
37	placebo estimated mean	C0032042;C0444504;C0750572;C1696465;C1706408;C2347634;C2348143	\N	\N
37	phosphatase  mean ( sd )  ng / ' mlf	C0017887;C0028074;C0031678;C0066495;C0444504;C1149880;C2347634;C2348143;C2699239;C4522024	\N	\N
37	pasi score ( $nmbr$ - $nmbr$ ) t  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685	\N	\N
37	pasi score ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685	\N	\N
37	pasi score  mean ± sd	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685	\N	\N
37	pasi score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685	\N	\N
37	pasi  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C4528685	\N	\N
37	pain vas ( range $nmbr$ - $nmbr$ )  mean ± sd	C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016	\N	\N
37	pain vas  range $nmbr$ - $nmbr$ mm  mean ( sd )	C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C4330985;C4554674	\N	\N
37	pack - years  mean ( sd )	C0444504;C1277691;C2347634;C2348143;C2699239	\N	\N
37	ocs dose *  mean ( sd )	C0178602;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239	\N	\N
37	number of visits  mean ± sd	C0444504;C1549755;C2347634;C2348143;C2699239	\N	\N
37	number of implanted stents  n  mean ( sd )	C0237753;C0444504;C0449788;C0522776;C2347634;C2348143;C2699239	\N	\N
37	number of exacerbations in previous year  mean ( sd )	C0205156;C0237753;C0439234;C0439508;C0444504;C0449788;C1552607;C2347634;C2348143;C2699239;C4086268	\N	\N
37	non - hdl - c ( mg / dl ) - mean ± sd	C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113	\N	\N
37	non - hdl - c  mg / dl  mean ( sd )	C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113	\N	\N
37	no . previous dmard  mean ( sd )	C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239	\N	\N
37	mtss  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	msasss  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	months since first ra symptom  mean ( sd ) f	C0016327;C0205435;C0439231;C0444504;C1279901;C1457887;C2347634;C2348143;C2699239;C3538806;C3854129;C4048756	\N	\N
37	modified hachinski ischemia scale  mean ( sd ) c	C0022116;C0175659;C0349674;C0392747;C0444504;C1947916;C2347634;C2348143;C2699239;C3889737;C4321499	\N	\N
37	mg / dl  mean ± sd	C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean — ml / min / $nmbr$ . $nmbr$ m ^	C0369637;C0439445;C0441923;C0444504;C2347634;C2348143	\N	\N
37	mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area	C0017446;C0205146;C0369637;C0439445;C0441923;C0444504;C0489451;C2347634;C2348143	\N	\N
37	mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0444504;C2347634;C2348143	\N	\N
37	mean — ml / min	C0439445;C0444504;C2347634;C2348143	\N	\N
37	mean — kg	C0022718;C0439209;C0444504;C2347634;C2348143;C4054209	\N	\N
37	mean — g / dl	C0439267;C0444504;C2347634;C2348143	\N	\N
37	mean — %	C0444504;C2347634;C2348143	\N	\N
37	mean ±   sd	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ± sd unless otherwise indicated	C0444504;C1444656;C2347634;C2348143;C2699239	\N	\N
37	mean ± sd mg ( n = $nmbr$  $nmbr$  $nmbr$ )	C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761	\N	\N
37	mean ± sd ( n )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ± sd  n	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ± sd	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ± s . d . weight  kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209	\N	\N
37	mean ± s . d . fpg	C0444504;C2347634;C2348143	\N	\N
37	mean ± s . d .	C0444504;C2347634;C2348143	\N	\N
37	mean yearly decline	C0332181;C0439508;C0444504;C2347634;C2348143	\N	\N
37	mean weight ( sd )  kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	\N	\N
37	mean weight  kg ( sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	\N	\N
37	mean weight  kg  mean = sd	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	\N	\N
37	mean time since diagnosis  y	C0011900;C0040223;C0444504;C1704338;C1704656;C2347634;C2348143;C3541383	\N	\N
37	mean time since as diagnosis  years  mean ± sd	C0011900;C0040223;C0439234;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239;C3541383	\N	\N
37	mean sitting systolic blood pressure	C0277814;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2584297;C4050224	\N	\N
37	mean sitting diastolic blood pressure	C0444504;C1319894;C2347634;C2348143	\N	\N
37	mean score	C3533236	\N	\N
37	mean prebronchodilation ( l )	C0444504;C2347634;C2348143	\N	\N
37	mean or n	C0369718;C0441922;C0444504;C2347634;C2348143	\N	\N
37	mean number of puffs per day	C0237753;C0332173;C0439228;C0439505;C0444504;C0449788;C1533107;C2347634;C2348143	\N	\N
37	mean number of exacerbations in previous y ( sd )	C0205156;C0237753;C0444504;C0449788;C1552607;C2347634;C2348143;C2699239;C4086268	\N	\N
37	mean $nmbr$ mwd *  m ( sd )	C0369637;C0441923;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean number of exacerbations in previous $nmbr$ months ( sd )	C0205156;C0237753;C0439231;C0444504;C0449788;C1552607;C2347634;C2348143;C2699239;C4086268	\N	\N
37	mean number of combined visits / hospitalizations †	C0205195;C0444504;C0545082;C1512346;C2347634;C2348143;C4086639	\N	\N
37	mean number of caes in past $nmbr$ months ( number per patient ) ] |	C0030705;C0237753;C0444504;C0449788;C2347634;C2348143;C4331910	\N	\N
37	mean iglar dose ± sd ( u / day )	C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239	\N	\N
37	mean ics ( fluticasone propionate dpi or equivalent  pg per day )	C0117996;C0205163;C0439185;C0444504;C0815320;C2347634;C2348143;C2827928;C4551720	\N	\N
37	mean eosinophil count  per ml	C0200638;C0439526;C0444504;C0750879;C1705224;C2347634;C2348143;C3887665	\N	\N
37	mean doseb	C0444504;C2347634;C2348143	\N	\N
37	mean dose ' ’	C0178602;C0444504;C0869039;C1114758;C2347634;C2348143	\N	\N
37	mean dlco ± sd	C0444504;C1516251;C2347634;C2348143;C2699239	\N	\N
37	mean difference = seb	C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268	\N	\N
37	mean change in total updrs scores adjusted according to baseline updrs	C0168634;C0392747;C0439175;C0439810;C0443172;C0444504;C0456081;C0680240;C1442488;C1705241;C2347634;C2348143;C2964552;C3533236;C3639721;C4319952	\N	\N
37	mean change in radiographic end points shs  mean ± sd	C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C2699239;C4319952	\N	\N
37	mean bm $nmbr$ ± s . d .  kg / m $nmbr$	C0006416;C0444504;C1532718;C2347634;C2348143	\N	\N
37	mean blood eosinophil count ( cells per pl )	C0200638;C0444504;C2347634;C2348143;C3897966;C4049765	\N	\N
37	mean asui scored	C0444504;C0449820;C2347634;C2348143	\N	\N
37	mean annualized exacerbation rate	C0444504;C0871208;C1521828;C2347634;C2348143;C4086268	\N	\N
37	mean age ( y ) ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean age ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean age  years ( sd )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
37	mean age  y ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean age  y  mean = sd	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean acrn	C0444504;C2347634;C2348143	\N	\N
37	mean acq - $nmbr$ scores	C0444504;C0449820;C2347634;C2348143;C2919686;C4050231	\N	\N
37	mean acq - $nmbr$ score at randomization  !	C0034656;C0444504;C0449820;C2347634;C2348143;C2919686;C4050231	\N	\N
37	mean a ± sdt	C0444504;C2347634;C2348143	\N	\N
37	mean = sd	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean *	C0444504;C2347634;C2348143	\N	\N
37	mean ( ± s . d . )	C0444504;C2347634;C2348143	\N	\N
37	mean ( sd on loge scale ) u / ml	C0175659;C0349674;C0439340;C0444504;C1880521;C1947916;C2347634;C2348143;C2697934;C2699239;C2945590	\N	\N
37	mean ( sd ) years daily ocs use  n ( % )	C0042153;C0332173;C0369718;C0439234;C0441922;C0444504;C0457083;C1947944;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) weight  kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	\N	\N
37	mean ( sd ) total asthma symptom scores	C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163	\N	\N
37	mean ( sd ) periostin  ng / ml	C0219433;C0439275;C0444504;C1424662;C2347634;C2348143;C2699239;C3812270	\N	\N
37	mean ( sd ) number of exacerbations *	C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268	\N	\N
37	mean ( sd ) number of albuterol per day  puff	C0001927;C0237753;C0332173;C0439228;C0439505;C0444504;C0449788;C1533107;C1882376;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) hba $nmbr$ c  %	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758	\N	\N
37	mean ( sd ) duration of smoking  pack years	C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735	\N	\N
37	mean ( sd ) duration of smoking  pack - years	C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735	\N	\N
37	mean ( sd ) das $nmbr$ - $nmbr$ ( esr ) *	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131	\N	\N
37	mean ( sd ) d	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) anthropometry	C0003188;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) age in years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) age ( years )	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) age  years	C0444504;C1510829;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) age	C0001779;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) [ range ]	C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016	\N	\N
37	mean ( sd ) ( years )	C0439234;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd ) % of predicted normal fevi	C0205307;C0231683;C0429706;C0439166;C0444504;C0681842;C0849974;C1561566;C1882327;C2347086;C2347634;C2348143;C2699239;C4528367;C4553972	\N	\N
37	mean ( sd ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd )  ng / ml £	C0439275;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean ( s . e . ) t	C0444504;C2347634;C2348143	\N	\N
37	mean ( s . e . )	C0444504;C2347634;C2348143	\N	\N
37	mean ( s . d . ) weight  kg	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209	\N	\N
37	mean ( s . d . ) total pcsk $nmbr$  ng / ml	C0439175;C0439275;C0439810;C0444504;C2347634;C2348143	\N	\N
37	mean ( s . d . ) non - hdl cholesterol	C0444504;C0729627;C1535899;C2347634;C2348143	\N	\N
37	mean ( s . d . ) ldl particle number  nmol / l	C0237753;C0439282;C0444504;C0449788;C2347634;C2348143;C2612459	\N	\N
37	mean ( s . d . ) hdl cholesterol	C0023822;C0392885;C0444504;C2347634;C2348143	\N	\N
37	mean ( s . d . ) free pcsk $nmbr$  ng / ml	C0332296;C0439275;C0444504;C1880497;C1996904;C2347634;C2348143	\N	\N
37	mean ( s . d . ) fpg	C0444504;C2347634;C2348143	\N	\N
37	mean ( s . d . )	C0444504;C2347634;C2348143	\N	\N
37	mean ( = sd ) days since	C0439228;C0444504;C2347634;C2348143;C2699239	\N	\N
37	mean % predicted value prebronchodilation	C0444504;C0681842;C1522609;C1882327;C2347634;C2348143	\N	\N
37	mean % predicted dlco * ( sd )	C0444504;C0681842;C1516251;C1882327;C2347634;C2348143;C2699239	\N	\N
37	mean $nmbr$ sd	C0444504;C2347634;C2348143;C2699239	\N	\N
370	geographic region	C0017446	f	369
37	mean $nmbr$ - h sbp *	C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284	\N	\N
37	mean  ml ( sd )	C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665	\N	\N
37	mean	C0444504;C2347634;C2348143	\N	\N
37	mases ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	lv ejection fraction  mean ( sd ) [ range ]  %	C0023128;C0444504;C0489482;C0731033;C1514721;C1881413;C2347634;C2348143;C2348147;C2699239;C2700378;C3542016	\N	\N
37	lung function  mean	C0035245;C0444504;C2347634;C2348143	\N	\N
37	ls mean difference ± seb	C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268	\N	\N
37	ls mean change ± sea	C0023668;C0036493;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
37	ls mean change	C0023668;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952	\N	\N
37	ls mean ( s . e . ) primary endpoint : % change from baseline to week $nmbr$	C0023668;C0168634;C0332174;C0392747;C0439230;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952	\N	\N
37	ls mean	C0023668;C0444504;C2347634;C2348143	\N	\N
37	lp ( a )  nmol / l  mean ( sd )	C0065058;C0439282;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379	\N	\N
37	lp ( a )  mean ( sd )	C0065058;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379	\N	\N
37	lowest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl )	C0024671;C0026410;C0439269;C0444504;C1514721;C1708760;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761	\N	\N
37	leeds enthesitis index  mean ( sd ) ’ ’ * ’	C0444504;C0451148;C2347634;C2348143;C2699239	\N	\N
37	leeds dactylitis index - basic  mean ( sd ) ’ ' ^	C0239161;C0444504;C0600653;C0918012;C1527178;C1552854;C1637833;C2347634;C2348143;C2699239;C2986546	\N	\N
37	least square mean ( se )	C0023189;C0036919;C0444504;C2347634;C2348143	\N	\N
37	ldl cholesterol mean ( mg / dl ± sd )	C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239	\N	\N
37	ldl - cihdl - c  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	ldl - c ( calculated )  mean ( sd )	C0444504;C0444686;C1441506;C2347634;C2348143;C2699239	\N	\N
37	ldl - c  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	insulin glargine vs standard care least - squares mean ( $nmbr$ % cl )	C0023189;C0444504;C0596019;C0907402;C1442989;C1947933;C2347634;C2348143;C2828392	\N	\N
37	in previous year  mean ( sd )	C0205156;C0439234;C0439508;C0444504;C1552607;C2347634;C2348143;C2699239	\N	\N
37	imaging data  mean ( sd )	C0011923;C0079595;C0444504;C1511726;C2347634;C2348143;C2699239;C3245479;C3714741	\N	\N
37	ileum ses - cd score  mean ( sd )	C0007928;C0020885;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4552032	\N	\N
37	ics use at enrollment  mean  mg / d	C0042153;C0439422;C0444504;C0457083;C0815320;C1516879;C1696073;C1947944;C2347634;C2348143;C3888021;C4551720	\N	\N
37	hscrp  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	highest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl )	C0024671;C0026410;C0439269;C0444504;C1514721;C1522410;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761	\N	\N
37	hemoglobin a $nmbr$ c  mean ( sd )  % b	C0062248;C0444504;C2347634;C2348143;C2699239	\N	\N
37	hemoglobin a $nmbr$ c  mean ( sd )  %	C0019020;C0444504;C2347634;C2348143;C2699239;C3889898	\N	\N
37	hdl cholesterol mean	C0023822;C0392885;C0444504;C2347634;C2348143	\N	\N
37	hdl cholesterol  mmol / l  women  mean ± sd	C0023822;C0043210;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239	\N	\N
37	hdl - c  mg / dl  mean ± sd	C0439269;C0444504;C2347634;C2348143;C2699239;C3715113	\N	\N
37	hdl - c  mg / dl  mean ( sd )	C0439269;C0444504;C2347634;C2348143;C2699239;C3715113	\N	\N
37	hdl - c  mean ( sd )	C0444504;C2347634;C2348143;C2699239;C3715113	\N	\N
37	hdl  mean ( sd )  mg / dl	C0439269;C0444504;C2347634;C2348143;C2699239;C3715113	\N	\N
37	hba $nmbr$ ca  %  mean ± sd	C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3887642	\N	\N
37	haq pain scale  mean	C0102923;C0444504;C0451208;C1504479;C2347634;C2348143	\N	\N
37	haemoglobin ( g / dl )  mean + sd  available for $nmbr$ patients	C0019046;C0030705;C0439267;C0444504;C0470187;C1319312;C2347634;C2348143;C2699239;C3642216	\N	\N
37	glycated hemoglobin  mean ( sd )  %	C0017853;C0444504;C2347634;C2348143;C2699239	\N	\N
37	fpg ( mmol / l )  mean ± s . d .	C0439433;C0444504;C2347634;C2348143	\N	\N
37	fevi  l  mean ( sd ) $nmbr$	C0429706;C0444504;C0849974;C1561566;C2347634;C2348143;C2699239;C4528367	\N	\N
37	fevi  % predicted  mean ( sd ) $nmbr$	C0444504;C0681842;C0849974;C1561566;C1882327;C2347634;C2348143;C2699239;C4528367	\N	\N
37	fas  range $nmbr$ - $nmbr$  mean ( sd )	C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016	\N	\N
37	estimated mean	C0444504;C0750572;C2347634;C2348143	\N	\N
37	enthesitis score ( mases  $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C0449820;C1282952;C2347634;C2348143;C2699239;C4050231	\N	\N
37	ejection fraction ( mean )	C0444504;C0489482;C2347634;C2348143;C2700378	\N	\N
37	egfr — mean ( sd  n )	C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	\N	\N
37	egfr  mean ± sd	C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	\N	\N
37	duration of alendronate use  mean ( sd )  y	C0102118;C0444504;C1881378;C2347634;C2348143;C2699239;C2826775	\N	\N
37	duration  mean ( sd )  years	C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
37	diagnosis ( y )  mean ( sd )	C0011900;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239	\N	\N
37	diabetesduration  mean ( sd )  y	C0444504;C2347634;C2348143;C2699239	\N	\N
37	daily “ off ” time  mean ± sd  h / dayf	C0033727;C0040223;C0332173;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C3541383;C4528284	\N	\N
28	statin + placebo ( n = $nmbr$ )	C0032042;C0360714;C1696465;C1706408	\N	\N
37	crcb - ( ml / min )  mean ( s . e . )	C0439390;C0439445;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700	\N	\N
37	colon ' ses - cd score  mean ( sd )	C0007928;C0009368;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C3888384;C4050231;C4552032	\N	\N
37	cognitive subscale on alzheimer ' s disease assessment scale  mean ( sd ) e	C0444504;C0450989;C1516691;C2347634;C2348143;C2699239	\N	\N
37	clinical dementia rating sum of boxes  mean ( sd ) f	C0444504;C0451074;C1515051;C1517104;C2347634;C2348143;C2699239	\N	\N
37	clean  n ( % ) a	C1947930	\N	\N
37	cigarette smoking  mean pack - years ( sd )	C0037369;C0444504;C0453996;C1303175;C1881674;C2347634;C2348143;C2699239	\N	\N
37	change from baseline in das $nmbr$ - esr  mean $nmbr$ sd	C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C3811131;C4319952	\N	\N
37	cclear < $nmbr$	\N	\N	\N
37	cclear $nmbr$ - $nmbr$	\N	\N	\N
37	cclear $nmbr$ +	\N	\N	\N
37	calculated annual decline  mean ± se	C0036919;C0332181;C0444504;C0444686;C1441506;C2347634;C2348143	\N	\N
37	bm $nmbr$  kg / m $nmbr$ ( mean ± s . d . )	C0006416;C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C1275571;C1513009;C2347634;C2348143;C4054209	\N	\N
37	blood eosinophils  mean ( range )  cells / ml	C0014467;C0444504;C1514721;C2347634;C2348143;C2348147;C2699156;C3542016	\N	\N
37	biochemical parameters at randomization  mean	C0034656;C0205474;C0444504;C0449381;C2347634;C2348143	\N	\N
37	beam values ( mg / dl )  mean ( sd )	C0042295;C0338248;C0439269;C0444504;C2347634;C2347880;C2348143;C2699239;C4521565	\N	\N
37	baseline haq mean ( s . e . )	C0102923;C0168634;C0444504;C0451208;C1442488;C2347634;C2348143	\N	\N
37	baseline dyspnea index  mean total score	C0439175;C0439810;C0444504;C1511069;C2347634;C2348143;C2964552;C3533236	\N	\N
37	baseline daytime nasal symptoms score  mean ± sd	C0168634;C0231918;C0332169;C0444504;C0449820;C1442488;C2347634;C2348143;C2699239;C4050231	\N	\N
37	basdai score ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231	\N	\N
37	basdai score  mean ( sd )	C0444504;C0449820;C1998004;C2347634;C2348143;C2699239;C4050231	\N	\N
37	basdai question $nmbr$ score ( $nmbr$ - $nmbr$ )  mean ( sd )	C0444504;C0449820;C1522634;C1998004;C2347634;C2348143;C2699239;C4050231	\N	\N
37	basdai  total  mean ± sd	C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239	\N	\N
37	asui score  mean ( sd )	C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	\N	\N
37	asui score  mean	C0444504;C0449820;C2347634;C2348143;C4050231	\N	\N
37	as duration  y  mean ( sd )	C0444504;C0449238;C2347634;C2348143;C2699239;C2926735	\N	\N
37	apob  g / l  mean ( sd )	C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239;C3252643	\N	\N
37	adjusted ∗   mean of difference ( se ) ( ml )	C0036919;C0439526;C0444504;C0456081;C1705224;C1705241;C1705242;C2347634;C2348143;C3887665	\N	\N
37	adjusted mean ± se change from baseline	C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952	\N	\N
37	adjusted mean change	C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952	\N	\N
37	adjusted mean ( se )	C0036919;C0444504;C0456081;C2347634;C2348143	\N	\N
37	> mean	C0444504;C2347634;C2348143	\N	\N
37	> $nmbr$ months  mean ( sd )	C0439231;C0444504;C2347634;C2348143;C2699239	\N	\N
37	< mean	C0444504;C2347634;C2348143	\N	\N
37	< $nmbr$ months  mean ( sd )	C0439231;C0444504;C2347634;C2348143;C2699239	\N	\N
28	serum uric acid  difference vs placebo ( $nmbr$ % cl )	C0032042;C0455272;C0596019;C0700634;C1696465;C1705241;C1705242;C1706408	\N	\N
37	age  mean ± sd years	C0444504;C1510829;C2347634;C2348143;C2699239	f	1907
37	age — mean ( sd ) ( years )	C0444504;C1510829;C2347634;C2348143;C2699239	f	1907
37	age  mean years  [ sd ]	C0444504;C1510829;C2347634;C2348143;C2699239	f	1907
37	age  mean years ( sd ) ’ gender  n ( % )	C0079399;C0444504;C1510829;C1522384;C2347634;C2348143;C2699239	f	1907
37	age when diabetes first diagnosed ( years )  mean ( sd )	C0001779;C0011847;C0011849;C0011900;C0205435;C0439234;C0444504;C1279901;C2347634;C2348143;C2699239	f	1907
37	age  years  mean + sd	C0444504;C1510829;C2347634;C2348143;C2699239	f	1907
37	age ( years ) mean ( sd )	C0444504;C1510829;C2347634;C2348143;C2699239	f	1907
37	age ( years ) mean ± sd	C0444504;C1510829;C2347634;C2348143;C2699239	f	1907
37	age  y  mean ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	f	1907
37	age  y ( mean ± sd )	C0001779;C0444504;C2347634;C2348143;C2699239	f	1907
37	age  y mean ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	f	1907
37	anthropometrics  mean ( sd )	C0444504;C2347634;C2348143;C2699239	f	1908
37	anthropometry : mean ( sd )	C0003188;C0444504;C2347634;C2348143;C2699239	f	1908
37	apo a - l ( mg / dl ) - mean ± sd	C0439269;C0444504;C1447574;C2347634;C2348143;C2699239;C4521365	f	1909
37	apo a - $nmbr$  mean ( sd )  mg / dl	C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379	f	1909
37	apo a $nmbr$  mg / dl  mean ( sd )	C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379	f	1909
37	apo b  mean ( sd )	C0003593;C0444504;C2347634;C2348143;C2699239;C3252643	f	1910
37	apo b  mg / dl  mean ( sd )	C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643	f	1910
37	body massindex  mean ( sd ) a	C0242821;C0444504;C0460148;C1268086;C2347634;C2348143;C2699239;C4082212	f	1911
37	body weight  kg ( mean ± sd )	C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209	f	1912
37	body weight ( kg )  mean ± sd	C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209	f	1912
37	cholesterol  mg / dl  mean ( sd ) §	C0008377;C0439269;C0444504;C2347634;C2348143;C2699239	f	1501
37	cholesterol - mean ( sd  n )	C0008377;C0444504;C2347634;C2348143;C2699239	f	1501
37	* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .	C0031831;C0237753;C0444504;C0449788;C0549183;C0876920;C1444656;C1511726;C1709908;C2347634;C2347635;C2348143;C2348144;C2699239;C2939193;C3245479;C3714741	\N	\N
37	( % )  $nmbr$ mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
37	% \\mean ± sd	C0444504;C2347634;C2348143;C2699239	\N	\N
36	weeko mean + sem	C0444504;C2347634;C2348143	\N	\N
36	week $nmbr$ mean ± sem	C0332174;C0439230;C0444504;C2347634;C2348143	\N	\N
36	week $nmbr$ mean + sem	C0332174;C0439230;C0444504;C2347634;C2348143	\N	\N
36	percent change from baseline to week $nmbr$ in auc ( mean  sem )	C0332174;C0376690;C0439230;C0444504;C2347634;C2348143;C3272907	\N	\N
36	mean a ± sem ( % )	C0444504;C2347634;C2348143	\N	\N
36	left ventricular ef  mean ( sd )  %	C0225897;C0444504;C2347634;C2348143;C2699239	\N	\N
36	hab $nmbr$ c ( mean ± sem )  %	C0444504;C2347634;C2348143	\N	\N
36	ef > $nmbr$ % n = $nmbr$	\N	\N	\N
36	ef < $nmbr$ %	\N	\N	\N
36	ef ( % )  mean ( sd )	C0444504;C2347634;C2348143;C2699239	\N	\N
36	( sem )	\N	\N	\N
35	nonsevere hypoglycemia	C0020615;C4553659	\N	\N
35	no nonsevere hypoglycemia	C0020615;C4553659	\N	\N
35	major hypoglycemia	C0020615;C0205082;C0205164;C4318856;C4521762;C4553659	\N	\N
35	investigator - reported hypoglycaemia *	C0020615;C0035173;C0684224;C0700287;C4319718;C4553659	\N	\N
35	investigator - reported hypoglycaemia	C0020615;C0035173;C0684224;C0700287;C4319718;C4553659	\N	\N
35	hypoglycemiat	\N	\N	\N
35	hypoglycemia ^	C0020615;C4553659	\N	\N
35	hypoglycemia	C0020615;C4553659	\N	\N
35	hosji fcrhypoglycemia	\N	\N	\N
35	b nonsevere hypoglycemia	C0020615;C4553659	\N	\N
34	normoglycemic {	C0580545	\N	\N
34	normoglycemic ^	C0580545	\N	\N
34	normoglycemic $nmbr$	C0580545	\N	\N
34	normoglycemic	C0580545	\N	\N
34	normoglycemia ^	C0580545	\N	\N
34	normoglycemia	C0580545	\N	\N
34	baseline normoglycemia	C0168634;C0580545;C1442488	\N	\N
33	took prior antihyperglycemic agent ( any )	C0020616;C0332152;C0450442;C1254351;C1515187;C1521826;C2826257	\N	\N
33	other hypoglycemic agent  n ( % )	C0020616	\N	\N
33	hypoglycemic agent	C0020616	\N	\N
33	hypoglycaemic agents	C0020616	\N	\N
33	antihyperglycemictherapies  %	\N	\N	\N
33	antihyperglycemic medication usage	C0013227;C0020616;C0457083;C3244316;C4284232	\N	\N
33	antihyperglycemic	C0020616	\N	\N
32	hypokalemia ‡   ( potassium < $nmbr$ . $nmbr$ mmol / l )	C0020621;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4553966	\N	\N
32	hypokalemia	C0020621;C4553966	\N	\N
32	hypokalaemia	C0020621;C4553966	\N	\N
32	hvookalemia	\N	\N	\N
32	olaemia  n ( % )	\N	f	-10
32	hypovolaemia	C0546884	f	-10
31	hyponatremia	C0020625;C4553967	\N	\N
30	hyperkalemiab	\N	\N	\N
30	hyperkalemia * ’	C0020461;C4552983	\N	\N
30	hyperkalemia ( > $nmbr$ . $nmbr$ meq / l )	C0020461;C0439375;C4552983	\N	\N
30	hyperkalemia  n ( % )	C0020461;C4552983	\N	\N
30	hyperkalaemia ( investigator reported )	C0020461;C0035173;C0684224;C0700287;C4319718;C4552983	\N	\N
30	hyperkalaemia	C0020461;C4552983	\N	\N
29	hyperlipidemia — no . / total no . ( % )	C0020473;C0428465;C0439175;C0439810;C4555212	\N	\N
29	hyperlipidemia — no . ( % )	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia § yes	C0020473;C0428465;C1549445;C1705108;C1710701;C4555212	\N	\N
29	hyperlipidemia §	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia | | yes	C0020473;C0428465;C1549445;C1705108;C1710701;C4555212	\N	\N
29	hyperlipidemia | |	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia ^	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia ( % ) §	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia ( % )	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia  n / n ( % )	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia  n ( % )	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia  %	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidemia	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidaemia ( % )	C0020473;C0428465;C4555212	\N	\N
29	hyperlipidaemia  n ( % ) yes	C0020473;C0428465;C1549445;C1705108;C1710701;C4555212	\N	\N
29	hyperlipidaemia	C0020473;C0428465;C4555212	\N	\N
28	with placebo ( n $nmbr$ $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	with placebo	C0032042;C1696465;C1706408	\N	\N
28	we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * $nmbr$ % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .	C0004083;C0018623;C0018787;C0027976;C0030705;C0032042;C0032615;C0034869;C0042508;C0201950;C0205091;C0205351;C0237688;C0237881;C0428772;C0439849;C0443246;C0444686;C0470187;C0488728;C0543421;C0596019;C0596306;C0699792;C0750502;C1079230;C1275491;C1441506;C1515021;C1546944;C1552822;C1565830;C1696465;C1704610;C1704675;C1706408;C2986480;C3853788	\N	\N
28	we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' $nmbr$ % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .	C0004083;C0018787;C0027976;C0030705;C0032042;C0033489;C0034869;C0201950;C0237688;C0237881;C0428772;C0439849;C0444686;C0470187;C0543421;C0596019;C0596306;C0699792;C0750502;C0965129;C1079230;C1275491;C1441506;C1515021;C1546944;C1565830;C1696465;C1704610;C1704675;C1706408;C2986480;C3853788	\N	\N
28	vs . placebo	C0032042;C1696465;C1706408	\N	\N
28	vorapaxar placebo $nmbr$ - yr . km %	C0032042;C0439234;C1696465;C1706408;C2974521;C3887676	\N	\N
28	tiotropium + placebo ( n [ $nmbr$ )	C0032042;C0213771;C1696465;C1706408	\N	\N
28	therapy ( asa $nmbr$ / placebo $nmbr$ )	C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627	\N	\N
28	therapy ( asa $nmbr$  $nmbr$ / placebo $nmbr$ )	C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627	\N	\N
370	geographic site  %	C0017446	f	369
28	sbp  difference vs placebo ( $nmbr$ % cl )	C0032042;C0085805;C0596019;C1696465;C1705241;C1705242;C1706408	\N	\N
28	s $nmbr$ vs placebo	C0032042;C0565930;C1696465;C1706408;C2603362	\N	\N
28	s $nmbr$ - $nmbr$ vs placebo	C0032042;C0565930;C1696465;C1706408;C2603362	\N	\N
28	rerandomization to placebo ( n = $nmbr$ ) f	C0016327;C0032042;C1696465;C1706408	\N	\N
28	rate ratio vs placebo ( $nmbr$ % ci )	C0008107;C0032042;C0456603;C0871208;C1521828;C1547037;C1696465;C1706408;C3259781	\N	\N
28	ranolazine vs . placebo km failure rate	C0032042;C0073633;C0231174;C0680095;C0871208;C1521828;C1696465;C1706408;C3887676	\N	\N
28	ranolazine ( n = $nmbr$ ) placebo ( n = $nmbr$ )	C0032042;C0073633;C1696465;C1706408	\N	\N
28	proportion ( % ) of individuals a alirocumab • placebo	C0027361;C0032042;C0237401;C1696465;C1706408;C1709707;C3491162	\N	\N
28	pooled placebo	C0032042;C1696465;C1706408;C1709595;C2349200;C4522255	\N	\N
28	plaeebo	\N	\N	\N
28	placebo §	C0032042;C1696465;C1706408	\N	\N
28	placebo |	C0032042;C1696465;C1706408	\N	\N
28	placebo to ustekinumab $nmbr$ mgt	C0032042;C1608841;C1696465;C1706408	\N	\N
28	placebo tiotropium n = $nmbr$ non - tiotropium n = $nmbr$	C0032042;C0213771;C1518422;C1696465;C1706408	\N	\N
28	placebo slope lsm ± se ( mm / year )	C0032042;C0036919;C0439234;C0439508;C0807955;C1696465;C1706408;C4330985;C4554674	\N	\N
28	placebo secukinumab pooled	C0032042;C1696465;C1706408;C1709595;C2349200;C3179547;C4522255	\N	\N
28	placebo r %	C0032042;C0205090;C0684010;C1696465;C1706408;C2603358	\N	\N
28	placebo plus statin ( n = $nmbr$ )	C0032042;C0332287;C0360714;C1696465;C1706408	\N	\N
28	placebo plus aspirin	C0004057;C0032042;C0332287;C1696465;C1706408	\N	\N
28	placebo patients with events / total	C0030705;C0032042;C0439175;C0439810;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo patients with events	C0030705;C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo patients / events n	C0030705;C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo no diabetes n = $nmbr$	C0011847;C0011849;C0032042;C1696465;C1706408	\N	\N
28	placebo no . of events / total no . ( % )	C0032042;C0439175;C0439810;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo no . of events / no .	C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo no . / total no .	C0032042;C0439175;C0439810;C1696465;C1706408	\N	\N
28	placebo no . / total ( % )	C0032042;C0439175;C0439810;C1696465;C1706408	\N	\N
28	placebo no . ( $nmbr$ - y km % )	C0032042;C1696465;C1706408;C3887676	\N	\N
28	placebo n [ $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo n = $nmbr$ subjects	C0032042;C0681850;C1550501;C1696465;C1706203;C1706408;C2349001;C2697811	\N	\N
28	placebo n = $nmbr$ n ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo n = $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo n / n ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo n / n	C0032042;C1696465;C1706408	\N	\N
28	placebo n ( rate ) *	C0032042;C0871208;C1521828;C1696465;C1706408	\N	\N
28	placebo n ( rate ) $nmbr$	C0032042;C0871208;C1521828;C1696465;C1706408	\N	\N
28	placebo n ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo n	C0032042;C1696465;C1706408	\N	\N
28	placebo mortality rate  events per $nmbr$ person - y	C0026565;C0027361;C0032042;C0205848;C0441471;C1696465;C1706408;C2347489;C3541888	\N	\N
28	placebo mean change ( sd )	C0032042;C0392747;C0443172;C0444504;C1696465;C1705241;C1706408;C2347634;C2348143;C2699239;C4319952	\N	\N
28	placebo mean ( n )	C0032042;C0444504;C1696465;C1706408;C2347634;C2348143	\N	\N
28	placebo mean	C0032042;C0444504;C1696465;C1706408;C2347634;C2348143	\N	\N
28	placebo mdi	C0032042;C0993596;C1696465;C1706408;C1839839;C4049613	\N	\N
28	placebo ls means ( n )	C0023668;C0032042;C1696465;C1704970;C1706408	\N	\N
28	placebo km %	C0032042;C1696465;C1706408;C3887676	\N	\N
28	placebo group ( n = $nmbr$ ) ’ j '	C0032042;C0441844;C1696465;C1706408	\N	\N
28	placebo group ( n = $nmbr$ ) f	C0016327;C0032042;C0441848;C1696465;C1706408	\N	\N
28	placebo group ( n = $nmbr$ )	C0032042;C0441848;C1696465;C1706408	\N	\N
28	placebo group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years )	C0027361;C0032042;C0439234;C0441848;C1696465;C1706408;C2347489	\N	\N
28	placebo group	C0032042;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408	\N	\N
28	placebo every $nmbr$ weeks ( n = $nmbr$ )	C0032042;C0439230;C1696465;C1706408	\N	\N
28	placebo events / patients ( % )	C0030705;C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo events / patients (	C0030705;C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo events / n ( % )	C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo event rate ( n = $nmbr$ )  %	C0032042;C0441471;C0871208;C1521828;C1696465;C1706408;C4019010	\N	\N
28	placebo dr = $nmbr$ )	C0013014;C0031831;C0032042;C1696465;C1706408;C1707664;C2348314;C3540849	\N	\N
28	placebo dn = $nmbr$ )	C0032042;C1333964;C1696465;C1706408;C1707618	\N	\N
28	placebo diabetes n = $nmbr$	C0011847;C0011849;C0032042;C1696465;C1706408	\N	\N
28	placebo croup  n / n ( % )	C0010380;C0032042;C1696465;C1706408	\N	\N
28	placebo arm	C0032042;C0446516;C1696465;C1706408;C3715044;C4553528	\N	\N
28	placebo analysed ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo allocation	C0032042;C1696465;C1706408;C1706778	\N	\N
28	placebo [ n z $nmbr$ ]	C0032042;C1696465;C1706408	\N	\N
28	placebo [ n = $nmbr$ |	C0032042;C1696465;C1706408	\N	\N
28	placebo [ n = $nmbr$ ]	C0032042;C1696465;C1706408	\N	\N
28	placebo / simva	C0032042;C1696465;C1706408	\N	\N
28	placebo /	C0032042;C1696465;C1706408	\N	\N
28	placebo - vonoprazan $nmbr$ - vonoprazan $nmbr$	C0032042;C1696465;C1706408;C4080009	\N	\N
28	placebo - vonoprazan $nmbr$	C0032042;C1696465;C1706408;C4080009	\N	\N
28	placebo - dexlansoprazole	C0032042;C1696465;C1706408;C2348248	\N	\N
28	placebo - carisbamate $nmbr$ mg - carisbamate $nmbr$ mg	C0032042;C1319635;C1696465;C1706408;C1871983	\N	\N
28	placebo + statin ( n = $nmbr$  $nmbr$ )	C0032042;C0360714;C1696465;C1706408	\N	\N
28	placebo + statin	C0032042;C0360714;C1696465;C1706408	\N	\N
219	hungary	C0020174	f	2040
28	placebo + pioglitazone ( n = $nmbr$ )	C0032042;C0071097;C1696465;C1706408	\N	\N
28	placebo + mtx ( n = $nmbr$ )	C0025677;C0032042;C1417487;C1696465;C1706408	\N	\N
28	placebo + mtx	C0025677;C0032042;C1417487;C1696465;C1706408	\N	\N
28	placebo ( » = $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( « = $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( w = $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n — $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n   =   $nmbr$ ) b	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n   =   $nmbr$ ) a	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n   =   $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n   =   $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n   =   $nmbr$  $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n   = $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n   = $nmbr$  $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n z $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n [ $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = l $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ o )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ l )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ i $nmbr$ )	C0021966;C0032042;C0221138;C0369718;C0441922;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ * )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ ) †	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ ) n ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ ) i -	C0021966;C0032042;C0221138;C0369718;C0441922;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ ) '	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ )  n ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$ $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$  $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n = $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n : $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n - $nmbr$ . $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n - $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n $nmbr$ $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( n $nmbr$ $nmbr$  $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( lsm )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( events / n ( % ) )	C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo ( dm - vs . dm + )	C0011816;C0032042;C1696465;C1706408;C3250443	\N	\N
28	placebo ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( $nmbr$ = $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo ( $nmbr$  $nmbr$ . $nmbr$ % )	C0032042;C1696465;C1706408	\N	\N
28	placebo %	C0032042;C1696465;C1706408	\N	\N
28	placebo $nmbr$ yr km %	C0032042;C0439234;C1696465;C1706408;C3887676	\N	\N
28	placebo $nmbr$ year km ( % )	C0032042;C0439234;C0439508;C1696465;C1706408;C3887676	\N	\N
28	placebo $nmbr$ o $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo $nmbr$ / $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo $nmbr$ . $nmbr$ pt yrs	C0032042;C0032743;C0699718;C1696465;C1706408	\N	\N
28	placebo $nmbr$ . $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo $nmbr$  $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo  n   =   $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo  n = l $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo  n = i $nmbr$	C0021966;C0032042;C0221138;C0369718;C0441922;C1696465;C1706408	\N	\N
28	placebo  n = $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	placebo  n / n ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo  n *	C0032042;C1696465;C1706408	\N	\N
28	placebo  n ( rate )	C0032042;C0871208;C1521828;C1696465;C1706408	\N	\N
28	placebo  n ( % )	C0032042;C1696465;C1706408	\N	\N
28	placebo  n	C0032042;C1696465;C1706408	\N	\N
28	placebo  events / patients ( % )	C0030705;C0032042;C0441471;C1696465;C1706408;C3541888	\N	\N
28	placebo  ( n = $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	placebo  % > ( n / n )	C0032042;C1696465;C1706408	\N	\N
28	placebo  % ( n / n )	C0032042;C1696465;C1706408	\N	\N
28	placebo	C0032042;C1696465;C1706408	\N	\N
28	patients in the placebo group  nt - probnp values were reported for $nmbr$ patients	C0030705;C0032042;C0042295;C0441833;C0588446;C0669479;C0687744;C0754710;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408	\N	\N
28	p   vs . placebo	C0032042;C0369773;C1696465;C1706408;C2603361	\N	\N
28	p vs placebo	C0032042;C0369773;C1696465;C1706408;C2603361	\N	\N
28	p value versus placebo	C0032042;C1696465;C1706408;C1709380	\N	\N
28	p $nmbr$ vs placebo	C0032042;C0369773;C1696465;C1706408;C2603361	\N	\N
28	or placebo treatment	C0032042;C0039798;C0087111;C1522326;C1533734;C1696465;C1705169;C1706408;C3538994;C3887704	\N	\N
28	omega - $nmbr$ fatty acid vs placebo least - squares mean ( $nmbr$ % cl )	C0015684;C0023189;C0032042;C0444504;C0596019;C1696465;C1706408;C1719844;C2347634;C2348143	\N	\N
28	nominal p vs placebo	C0032042;C1696465;C1706408	\N	\N
28	no laba  no ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ )	C0032042;C0213771;C0815320;C1696465;C1706408;C4551720	\N	\N
28	no . of patients ( indacaterol / placebo )	C0030705;C0032042;C1696465;C1706408;C1722260	\N	\N
28	n ( indacaterol $nmbr$ ug / indacaterol $nmbr$ ug / placebo )	C0032042;C0369718;C0441922;C1319635;C1696465;C1706408;C1722260	\N	\N
28	mtx plus placebo	C0025677;C0032042;C0332287;C1417487;C1696465;C1706408	\N	\N
28	ls mean difference vs placebo ( $nmbr$ % ci )	C0008107;C0023668;C0032042;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781	\N	\N
28	ls mean difference ( se ) vs placebo	C0023668;C0032042;C0036919;C0444504;C1696465;C1705241;C1705242;C1706408;C2347634;C2348143	\N	\N
27	previous tnf antagonist exposure  n ( % )	C0205156;C0231491;C0274281;C0332157;C1448177;C1552607	\N	\N
28	ls mean [ $nmbr$ % ci ] treatment difference vs placebo	C0008107;C0023668;C0032042;C0039798;C0087111;C0444504;C1522326;C1533734;C1696465;C1705169;C1705241;C1705242;C1706408;C2347634;C2348143;C3259781;C3538994;C3887704	\N	\N
28	laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ )	C0032042;C0213771;C1696465;C1706408	\N	\N
28	ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ )	C0032042;C0213771;C0815320;C1696465;C1706408;C4551720	\N	\N
28	i placebo ( n = $nmbr$ )	C0021966;C0032042;C0221138;C1696465;C1706408	\N	\N
28	i placebo	C0021966;C0032042;C0221138;C1696465;C1706408	\N	\N
28	hba $nmbr$ c  difference vs placebo ( $nmbr$ % cl )	C0019016;C0032042;C0596019;C1696465;C1705241;C1705242;C1706408;C1825777;C3538758	\N	\N
28	figure $nmbr$ least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fev $nmbr$ in the itt population and subpopulations . copd  chronic obstructive pulmonary disease  fev $nmbr$  forced expiratory volume in $nmbr$ s  ics  inhaled corticosteroid  itt  intent to treat  laba  long - acting b $nmbr$ - agonist .	C0001617;C0004048;C0016529;C0023189;C0023668;C0024117;C0032042;C0032659;C0035826;C0040363;C0041260;C0079613;C0087111;C0162425;C0205166;C0332152;C0444504;C0740175;C0815320;C1257890;C1283828;C1292734;C1306036;C1413096;C1522326;C1550453;C1696465;C1704930;C1705241;C1705242;C1706317;C1706408;C1869853;C1883351;C2257086;C2347634;C2348143;C2599594;C2987048;C2987634;C3536709;C3669034;C3714541;C3890007;C4048375;C4551720	\N	\N
28	feno placebo ( lsm )	C0032042;C1696465;C1706408	\N	\N
28	feno	\N	\N	\N
28	favors ffa / i favors placebo	C0015688;C0021966;C0032042;C0221138;C0309049;C1696465;C1706408	\N	\N
28	f $nmbr$ vs placebo	C0016327;C0032042;C1696465;C1706408	\N	\N
28	esrd on placebo ( % )	C0022661;C0032042;C0035078;C1696465;C1706408;C2316810	\N	\N
28	duration from clopidogrel / placebo to pci  min ( median  iqr )	C0032042;C0070166;C0449238;C0549183;C0702093;C0876920;C1524029;C1696465;C1706408;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621	\N	\N
28	dm - ( aliskiren vs . placebo )	C0011816;C0032042;C1120110;C1696465;C1706408;C3250443	\N	\N
28	dm + ( aliskiren vs . placebo )	C0011816;C0032042;C1120110;C1696465;C1706408;C3250443	\N	\N
28	differences between indacaterol + tiotropium versus tiotropium + placebo	C0032042;C0213771;C1696465;C1705241;C1705242;C1706408;C1722260	\N	\N
28	difference vs placebo * *	C0032042;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference vs placebo ( $nmbr$ % ci )	C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781	\N	\N
28	difference vs placebo '	C0032042;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference vs placebo  % [ $nmbr$ % cl ]  p	C0032042;C0596019;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference vs placebo	C0032042;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference vs . placebo  % ( $nmbr$ % cl )	C0032042;C0596019;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference vs . placebo	C0032042;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference from placebo ¥	C0032042;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference from placebo * ( $nmbr$ % ci )	C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781	\N	\N
28	difference from placebo ( $nmbr$ % cl )	C0032042;C0596019;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference from placebo ( $nmbr$ % ci )	C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781	\N	\N
28	difference from placebo	C0032042;C1696465;C1705241;C1705242;C1706408	\N	\N
28	difference ( n - $nmbr$ fa - placebo ) lsm ± se ( mm / year )	C0032042;C0036919;C0439234;C0439508;C1696465;C1705241;C1705242;C1706408;C4330985;C4554674	\N	\N
28	difference ( a ) vs placebo ( $nmbr$ % cl )	C0032042;C0596019;C1696465;C1705241;C1705242;C1706408	\N	\N
28	dapagliflozin placebo no . of events / no . of patients	C0030705;C0032042;C0441471;C1696465;C1706408;C2353951;C3541888	\N	\N
28	copd - placebo ( n = $nmbr$ )	C0024117;C0032042;C1412502;C1696465;C1706408;C3714496	\N	\N
28	copd - placebo ( $nmbr$ pt ) n . ( % )	C0024117;C0032042;C0032743;C0699718;C1412502;C1696465;C1706408;C3714496	\N	\N
28	comparison with placebo ( mean	C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143	\N	\N
28	comparison with placebo	C0032042;C1696465;C1706408;C1707455	\N	\N
28	chf on placebo ( % )	C0018802;C0032042;C1696465;C1706408	\N	\N
28	baseline to eom placebo ( n = $nmbr$ )	C0032042;C0168634;C0241886;C1442488;C1696465;C1706408	\N	\N
28	b digit symbol substitution  omega - $nmbr$ fatty acids vs placebo	C0015684;C0032042;C0582802;C0679214;C1555721;C1696465;C1698987;C1706204;C1706408;C1719844;C3241971	\N	\N
28	assigned to placebo	C0032042;C1516050;C1552601;C1696465;C1706408	\N	\N
28	any placebo	C0032042;C1696465;C1706408	\N	\N
28	ambulatory sbp  difference vs placebo ( $nmbr$ % cl )	C0032042;C0085805;C0439841;C0596019;C1696465;C1705241;C1705242;C1706408	\N	\N
28	active   versus   placebo	C0032042;C0205177;C1696465;C1706408;C3853793;C3888249	\N	\N
28	active vs placebo	C0032042;C0205177;C1696465;C1706408;C3853793;C3888249	\N	\N
28	absolutedifferenceestimate vs placebo ( $nmbr$ % ci )	C0008107;C0032042;C1696465;C1706408;C3259781	\N	\N
28	absolute difference estimate vs placebo ( $nmbr$ % ci )	C0008107;C0032042;C0750572;C1549031;C1696465;C1706408;C3259781	\N	\N
28	a $nmbr$ vs placebo	C0032042;C1696465;C1706408	\N	\N
28	[ } ifrerence vs . placebo  % ( $nmbr$ % cl )	C0032042;C0596019;C1696465;C1706408	\N	\N
28	= placebo  eze : tes ( fc j > $nmbr$ rr $nmbr$ definition ) .	C0032042;C0076172;C1422793;C1550452;C1696465;C1704788;C1706408;C2983605;C3539107;C3888054;C4554402	\N	\N
28	- $nmbr$ placebo	C0032042;C1696465;C1706408	\N	\N
28	( tiotropium n = $nmbr$  placebo n =	C0032042;C0213771;C1696465;C1706408	\N	\N
28	( tiotropium n = $nmbr$  placebo n	C0032042;C0213771;C1696465;C1706408	\N	\N
28	$nmbr$ placebo n = $nmbr$	C0032042;C1696465;C1706408	\N	\N
28	$nmbr$ placebo ( n = $nmbr$ $nmbr$ )	C0032042;C1696465;C1706408	\N	\N
28	$nmbr$ placebo	C0032042;C1696465;C1706408	\N	\N
28	$nmbr$ mg / day - placebo	C0032042;C0439422;C1696465;C1706408	\N	\N
28	$nmbr$ - year rates in placebo groups	C0032042;C0439234;C0439508;C0441833;C0687744;C0871208;C1257890;C1519504;C1521828;C1552839;C1696465;C1705428;C1705429;C1706408	\N	\N
27	tnfi exposed	C0332157	\N	\N
27	tnfi - exposed †	C0332157	\N	\N
27	tnf antagonist - exposed	C0231491;C0332157;C1448177	\N	\N
27	ltg - exposed	C0332157;C1420817;C4521367;C4521846	\N	\N
27	exposure	C0274281;C0332157	\N	\N
27	exposed ( n = $nmbr$ )	C0332157	\N	\N
27	exposed	C0332157	\N	\N
26	participated in a previous febuxostat studyb  n ( % )	C0205156;C0249529;C1552607	\N	\N
26	febuxostat - febuxostat / lesinurad $nmbr$ - febuxostat / lesinurad $nmbr$	C0249529;C3886073	\N	\N
26	febuxostat - febuxostat / lesinurad $nmbr$	C0249529;C3886073	\N	\N
26	febuxostat	C0249529	\N	\N
26	completed prior febuxostat studya	C0205197;C0249529;C0332152;C2826257;C3854010	\N	\N
26	completed previous febuxostat study	C0205156;C0249529;C1552607;C2348557	\N	\N
25	use of ticagrelor	C1524063;C1999375	\N	\N
25	use of proton inhibitors  n ( % )	C0033727;C0243077;C1524063	\N	\N
25	use of parenteral antithrombotic	C0030547;C1524063;C4522267	\N	\N
25	use of diuretics  n ( % )	C0012798;C1524063	\N	\N
25	postoperative use of p - blocker	C0032790;C1524063	\N	\N
25	new use of gpa	C0205314;C1524063;C3495801;C4553145	\N	\N
25	menopausal status and use of ht	C0018510;C0677607;C1513126;C1524063	\N	\N
25	menopausal status and use of hrt ( % ) y	C0282402;C1513126;C1524063	\N	\N
25	diabetes with use of oral diabetes drugs	C0011847;C0011849;C0020616;C0029167;C0175795;C0304289;C0442027;C1524063;C4521986	\N	\N
25	diabetes with no use of diabetes drugs	C0020616;C1524063	\N	\N
25	continued use of gpa	C0549178;C1524063;C3495801;C4553145	\N	\N
24	ocs use	C0042153;C0457083;C1947944	\N	\N
24	ocs	\N	\N	\N
24	oam use [ n ( % ) ]	C0042153;C0457083;C1947944	\N	\N
24	oad use  n ( % )	C0042153;C0457083;C1947944	\N	\N
24	maintenance ocs use  n ( % )	C0024501;C0042153;C0369718;C0441922;C0457083;C1947944	\N	\N
24	$nmbr$ oam	\N	\N	\N
24	$nmbr$ oad	\N	\N	\N
23	tobacco user	C3853727	\N	\N
23	tobacco use — no . ( % )	C0040335;C0543414;C0841002;C3853727	\N	\N
23	tobacco use ( % )	C0040335;C0543414;C0841002;C3853727	\N	\N
23	tobacco use  yes  n ( % )	C0040335;C0543414;C0841002;C1549445;C1705108;C1710701;C3853727	\N	\N
23	tobacco use  n ( % )	C0040335;C0543414;C0841002;C3853727	\N	\N
23	tobacco use	C0040335;C0543414;C0841002;C3853727	\N	\N
23	tobacco abuse	C0040336	\N	\N
23	prior tobacco use  n ( % )	C0040335;C0332152;C0543414;C0841002;C2826257;C3853727	\N	\N
23	non - / ex - tobacco user	C1518422;C3853727	\N	\N
23	no current tobacco use	C0040335;C0521116;C0543414;C0841002;C1705970;C3853727	\N	\N
23	current tobacco use	C0040335;C0521116;C0543414;C0841002;C1705970;C3853727	\N	\N
23	baseline tobacco use	C0040335;C0168634;C0543414;C0841002;C1442488;C3853727	\N	\N
22	glucose in urine    ≥ $nmbr$ +	C0004076	\N	\N
22	dosing	\N	\N	\N
22	$nmbr$ - h plasma glucose during ogtt ( mmol / l )	C0029161;C0202042;C0455280;C2827804	\N	\N
21	fasting plasma glucose — mg / dl	C0015663;C0202042;C0439269;C0455280	\N	\N
21	fasting plasma glucose categories  n ( % )	C0015663;C0202042;C0455280;C0683312	\N	\N
21	fasting plasma glucose *	C0015663;C0202042;C0455280	\N	\N
21	fasting plasma glucose ( mg / dl ) $nmbr$	C0015663;C0202042;C0439269;C0455280	\N	\N
21	fasting plasma glucose ( mg / dl )	C0015663;C0202042;C0439269;C0455280	\N	\N
21	fasting plasma glucose $nmbr$ medan	C0015663;C0202042;C0455280	\N	\N
21	fasting plasma glucose  mg / dl  mean ( sd ) b	C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239	\N	\N
21	fasting plasma glucose  mg / dl  mean ( sd )	C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239	\N	\N
21	fasting plasma glucose  mg / dl	C0015663;C0202042;C0439269;C0455280	\N	\N
21	fasting plasma glucose	C0015663;C0202042;C0455280	\N	\N
21	fascng plasma glucose a medan	C0202042;C0455280	\N	\N
21	casual plasma glucose ( mg / dl )	C0202042;C0439269;C0455280	\N	\N
21	baseline fasting plasma glucose	C0015663;C0168634;C0202042;C0455280;C1442488	\N	\N
21	$nmbr$ - hr plasma glucose — mg / dl	C0202042;C0439269;C0455280	\N	\N
20	who / idf impaired fasting glucose	C1272092	\N	\N
20	impaired glucose tolerance or impaired fasting glucose — no . ( % )	C0271650;C1272092	\N	\N
20	impaired glucose tolerance or impaired fasting glucose	C0271650;C1272092	\N	\N
20	impaired fasting glucose §	C1272092	\N	\N
20	impaired fasting glucose level ( n = $nmbr$ )	C0202045;C0221099;C0441889;C0456079;C1272092;C1547707;C2946261	\N	\N
20	impaired fasting glucose	C1272092	\N	\N
20	both impaired glucose tolerance and impaired fasting glucose tolerance — no .	C0013220;C0015663;C0020963;C0220929;C0231197;C0271650;C1272092;C1704410	\N	\N
19	salmeterol / fluticasone $nmbr$ / $nmbr$   μ g b . i . d .	C0086706;C0939232	\N	\N
19	salmeterol / fluticasone $nmbr$ / $nmbr$ pg twice daily	C0030827;C0072225;C0585361;C0939232;C1266240	\N	\N
19	salmeterol - fluticasone group ( n = $nmbr$ )	C0441848;C0939232	\N	\N
19	fluticasone furoate  n = $nmbr$	C1948374	\N	\N
19	fluticasone - salmeterol ( n = $nmbr$ )	C0939232	\N	\N
19	fluticasone - fluticasone / salmeterol	C0939232	\N	\N
17	red blood cell counting  $nmbr$ / l	C0005767;C0005768;C0022827;C0229664;C0332575;C0750480;C1260956;C1705566;C4049926	\N	\N
25	use of low - dose aspirin ( < $nmbr$	C1524063;C2608320	f	1366
25	use of systemic glucocorticoid at random -	C0017710;C0034656;C0205373;C0439605;C1524063	f	1348
25	use of methotrexate at randomization —	C0025677;C0034656;C1524063	f	1408
20	glucose test	C0337438;C0595310	f	2317
18	fasting blood glucose	C0428568;C1261430	f	2280
18	fasting blood glucose ( mg / dl )	C0428568;C0439269;C1261430	f	2280
17	any blood	C0005767;C0005768;C0229664	\N	\N
15	weight  kg blood pressure  mm hg	C0005823;C0005910;C0022718;C0043100;C0439209;C0439475;C1271104;C1272641;C1305866;C1705104;C4054209	\N	\N
15	treatment with any blood - pressure -	C0005823;C0033095;C0039798;C0087111;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C3538994;C3887704;C4284008	\N	\N
15	preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria	C0005823;C0030705;C0439475;C0445204;C1271104;C1272641;C1512693;C1550543	\N	\N
15	lvh by ecgt blood pressure  mm hg	C0005823;C0149721;C0439475;C1271104;C1272641	\N	\N
15	body - mass index : ! : blood pressure — mm hg	C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855	\N	\N
15	blood pressure — mmhg	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure — mm hg	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure while seated — mm hg	C0005823;C0277814;C0439475;C1271104;C1272641;C1283233	\N	\N
15	blood pressure eontrolt	C0005823;C1271104;C1272641	\N	\N
15	blood pressure at target level ( % ) §	C0005823;C0441889;C0456079;C1271104;C1272641;C1521840;C1547707;C2946261;C2986546	\N	\N
15	blood pressure at entry ( mm   hg )	C0005823;C0439475;C1271104;C1272641;C1705654	\N	\N
15	blood pressure > $nmbr$ mm hg	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure < $nmbr$ mm hg	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure < $nmbr$ / $nmbr$ mmhg  n ( % )	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure - lowering treatment	C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008	\N	\N
15	blood pressure ( mmhg )	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure ( mm hg ) *	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure ( mm hg )	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure ( % )	C0005823;C1271104;C1272641	\N	\N
15	blood pressure  mmhg systolic	C0005823;C0039155;C0439475;C1271104;C1272641	\N	\N
15	blood pressure  mmhg	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure  mm hg	C0005823;C0439475;C1271104;C1272641	\N	\N
15	blood pressure  mm	C0005823;C1271104;C1272641;C4330985;C4554674	\N	\N
15	blood pressure	C0005823;C1271104;C1272641	\N	\N
15	arterial blood pressure  mm hg	C0439475;C1272641	\N	\N
14	rosigiitazone ± oad	\N	\N	\N
14	previous oral glucose - lowering agents  % of patients	C0205156;C0441994;C0600419;C1552607;C1955477;C2003888	\N	\N
14	previous oad ( % )	C0205156;C1552607	\N	\N
14	previous limb or foot amputation	C0015385;C0188605;C0205156;C1552607	\N	\N
14	previous aorta - femoral or lower extremity bypass surgery  pta of iliac  or infrainguinal artery	C0003483;C0003842;C0015811;C0020889;C0187763;C0205156;C0226004;C0741847;C1552607;C3274435	\N	\N
14	oralb	\N	\N	\N
14	or $nmbr$	\N	\N	\N
14	oad	\N	\N	\N
14	glulisine + oad	\N	\N	\N
14	giimepiride ± oad	\N	\N	\N
13	smoking status  n ( % ) former	C0205156;C0750523;C1519386	\N	\N
13	smoker ( current / former )	C0205156;C0337664;C0521116;C0750523;C1705970	\N	\N
13	previous exposure to a vitamin k antagonist — no . ( % ) current or former never	C0042839;C0087161;C0205156;C0231491;C0332157;C0521116;C0597277;C0750523;C1552607;C1705970;C1708601;C2003901;C2825076;C3714656	\N	\N
13	previous a - blocker use	C0042153;C0205156;C0457083;C1552607;C1947944	\N	\N
13	previous a - blocker	C0205156;C1552607	\N	\N
13	former smoking	C0037369;C0205156;C0453996;C0750523;C1881674	\N	\N
13	former or never diabetes	C0011847;C0011849;C0205156;C0750523;C2003901	\N	\N
13	former or never	C0205156;C0750523;C2003901	\N	\N
13	former n z $nmbr$	C0205156;C0750523	\N	\N
13	former / current smoker ( n = $nmbr$ $nmbr$ )	C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966	\N	\N
13	former / current smoker  n ( % )	C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966	\N	\N
13	former ( n   = $nmbr$  $nmbr$ )	C0205156;C0750523	\N	\N
13	former  n ( % )	C0205156;C0750523	\N	\N
13	former	C0205156;C0750523	\N	\N
13	ever smoked ( current / former )	C0037366;C0205156;C0439994;C0521116;C0750523;C1705970;C1881674	\N	\N
13	b - blocker	\N	\N	\N
13	a - blocker	\N	\N	\N
12	worsening heart failure	C0018801;C0018802;C0332271;C1457868;C1546960;C4554158	\N	\N
12	time since diagnosis of heart failure	C0011900;C0018801;C0018802;C0040223;C1704338;C1704656;C3541383;C4554158	\N	\N
12	score on the minnesota living with heart failure scaled	C0018801;C0018802;C0026183;C0175659;C0349674;C0449820;C0595998;C1947916;C4050231;C4520849;C4551704;C4554158	\N	\N
12	recurrent heart failure	C0018801;C0018802;C1455761;C2945760;C4554158	\N	\N
12	priorheartfailure  %	\N	\N	\N
12	prior heart failure — no . { % )	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	prior heart failure yes	C0018801;C0018802;C0332152;C1549445;C1705108;C1710701;C2826257;C4554158	\N	\N
12	prior heart failure ( n = $nmbr$  $nmbr$ )	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	prior heart failure  n / n ( % )	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	prior heart failure  n ( % )	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	prior heart failure  %	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	prior heart failure	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	previous hospital admission for heart failure	C0018801;C0018802;C0184666;C0205156;C1552607;C4554158	\N	\N
12	participants without heart failure	C0018801;C0018802;C0679646;C4554158	\N	\N
12	participants with heart failure	C0018801;C0018802;C0679646;C4554158	\N	\N
307	> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
17	baseline diastolic blood	C0005767;C0005768;C0012000;C0168634;C0229664;C1442488	f	1469
17	blood pressure at baseline :	C0005767;C0005768;C0005823;C0168634;C0229664;C0443150;C1271104;C1272641;C1442488	f	1469
17	blood bilirubin increased	C0005437;C0005767;C0005768;C0205217;C0229664;C0442805	f	1684
12	not hospitalized for heart failure in the year prior to study enrollment	C0018801;C0018802;C0332152;C0701159;C1516879;C1518422;C1696073;C3258203;C3888021;C4554158	\N	\N
12	no prior heart failure ( n = $nmbr$  $nmbr$ )	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	no prior heart failure	C0018801;C0018802;C0332152;C2826257;C4554158	\N	\N
12	no heart failure	C0018801;C0018802;C4554158	\N	\N
12	mortality  shock or congestive heart failure within $nmbr$ days	C0018802;C0026565;C0026566;C0036974;C0439228	\N	\N
12	medical history of cv disease or heart failure  n ( % )	C0007222;C0018801;C0018802;C0262926;C4554158	\N	\N
12	hospitalized heart failure	C0018801;C0018802;C0701159;C4554158	\N	\N
12	hospitalized for heart failure during that time period	C0018801;C0018802;C0701159;C1948053;C4554158	\N	\N
12	hospitalized / fatal heart failure	C0018801;C0018802;C0701159;C1302234;C1705232;C4554158	\N	\N
12	hospital admission for heart failure	C0018801;C0018802;C0184666;C4554158	\N	\N
12	histor y of heart failure	C0018801;C0018802;C4554158	\N	\N
12	histor y of congestive heart failure — no . ( % )	C0018802	\N	\N
12	heart failure ‡	C0018801;C0018802;C4554158	\N	\N
12	heart failure — no . / total no . ( % )	C0018801;C0018802;C0439175;C0439810;C4554158	\N	\N
12	heart failure — no . ( % )	C0018801;C0018802;C4554158	\N	\N
12	heart failure history	C0018801;C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4554158	\N	\N
12	heart failure criteria met	C0018801;C0018802;C0243161;C0428210;C1550543;C4317104;C4554158	\N	\N
12	heart failure cause	C0015127;C0018801;C0018802;C1524003;C4554158	\N	\N
12	heart failure at entry  no . ( % )	C0018801;C0018802;C1705654;C4554158	\N	\N
12	heart failure *	C0018801;C0018802;C4554158	\N	\N
12	heart failure ( treated / hospitalized / fatal )	C0018801;C0018802;C0701159;C1302234;C1522326;C1705232;C4554158	\N	\N
12	heart failure  no . / total no . ( % )	C0018801;C0018802;C0439175;C0439810;C4554158	\N	\N
12	heart failure  n ( % )	C0018801;C0018802;C4554158	\N	\N
12	heart failure  hospitalized or fatal	C0018801;C0018802;C0701159;C1302234;C1705232;C4554158	\N	\N
12	heart failure	C0018801;C0018802;C4554158	\N	\N
12	fatal & nonfatal hospitalized heart failure	C0018801;C0018802;C0701159;C1302234;C1705232;C4554158	\N	\N
12	congestive heart failure †	C0018802	\N	\N
12	congestive heart failure — no . ( % ) | |	C0018802	\N	\N
12	congestive heart failure — no . ( % ) |	C0018802	\N	\N
12	congestive heart failure — no . ( % )	C0018802	\N	\N
12	congestive heart failure — %	C0018802	\N	\N
12	congestive heart failure §	C0018802	\N	\N
12	congestive heart failure at randomisation	C0018802;C0034656	\N	\N
12	congestive heart failure ( definite )	C0018802;C0439544;C1704787	\N	\N
12	congestive heart failure ( chf ) ( in past $nmbr$ weeks )	C0018802;C2987125	\N	\N
12	congestive heart failure ( < $nmbr$ wk )	C0018802;C0332174;C0439230	\N	\N
12	congestive heart failure  n ( % )	C0018802	\N	\N
12	congestive heart failure	C0018802	\N	\N
12	combined cardiac failure  cardiomyopathy or other cardiac disorder  n ( % ) luts severity  n ( % )	C0018787;C0018799;C0018801;C0018802;C0205195;C0439793;C0521117;C0522510;C0574785;C0878544;C1292730;C1522601	\N	\N
12	chronic heart failure class ii - iii	C0018802;C0264716;C0439070;C0441886;C0441887;C1705160;C1710602;C2698968;C2698969;C4082587	\N	\N
12	chronic heart failure	C0018802;C0264716	\N	\N
12	cause of heart failure — no . ( % )	C0015127;C0018801;C0018802;C1524003;C4554158	\N	\N
12	cause of heart failure	C0015127;C0018801;C0018802;C1524003;C4554158	\N	\N
12	cardiac failure —	C0018801;C0018802	\N	\N
12	cardiac failure §	C0018801;C0018802	\N	\N
12	cardiac failure *	C0018801;C0018802	\N	\N
12	cardiac failure  n ( % )	C0018801;C0018802	\N	\N
12	cardiac failure	C0018801;C0018802	\N	\N
12	baseline heart failure severity amongthose with priorheartfailure  %	C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C4554158	\N	\N
11	type of tnf failure  n ( % ) b	C0231174;C0332307;C0680095;C1547052;C3887647	\N	\N
11	type of tnf antagonist failure  n ( “ / o ) ”	C0231174;C0231491;C0332307;C0680095;C1448177;C1547052	\N	\N
11	type of tnf antagonist failure  n ( % ) ' ’	C0231174;C0231491;C0332307;C0680095;C1448177;C1547052	\N	\N
11	tnf antagonist - failure population ( n - $nmbr$ )	C0032659;C0231174;C0231491;C0680095;C1257890;C1448177	\N	\N
11	tnf - failure patientsa	C0231174;C0680095;C1448177	\N	\N
11	prior immunnosupressive failure but no anti - tnf failure	C0231174;C0332152;C0680095;C1448177;C2826257	\N	\N
11	prior anti - tnf failure	C0231174;C0332152;C0680095;C1448177;C2826257	\N	\N
11	any prior anti - tnf treatment failure	C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257	\N	\N
10	question $nmbr$ ( fatigue / tiredness )	C0015672;C1522634;C3463815;C4050243;C4553152;C4554645	\N	\N
10	fatigue ( range $nmbr$ - $nmbr$ )	C0015672;C1514721;C2348147;C3463815;C3542016;C4050243;C4554645	\N	\N
10	fatigue	C0015672;C3463815;C4050243;C4554645	\N	\N
10	facit - fatigue . mean $nmbr$ sd ( range $nmbr$ - $nmbr$ )	C0015672;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3463815;C3476791;C3542016;C4050243;C4554645	\N	\N
10	energy / fatigue	C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645	\N	\N
9	value for nteraction	C1522609	\N	\N
9	value *	C1522609	\N	\N
9	value	C1522609	\N	\N
9	troponin or ckmb value	C0010290;C0041199;C0523584;C1522609	\N	\N
9	proportion of predicted normal fev $nmbr$ value   §	C0086715;C0520835;C0681842;C1522609;C1709707;C1882327;C3714541	f	1197
11	heat failure	C0018837;C0231174;C0680095	f	-10
11	> $nmbr$ failure	C0231174;C0680095	f	1969
11	failure	C0231174;C0680095	f	1969
9	or_value	C1522609	\N	\N
9	or $nmbr$ _value	C1522609	\N	\N
9	l ’ - value ’	C0439394;C1522609;C1706495;C3642217	\N	\N
9	d - value	C1522609	\N	\N
9	baseline value	C0168634;C1442488;C1522609	\N	\N
9	/ ’ - value $nmbr$ ’	C1522609	\N	\N
9	/ ’ - value	C1522609	\N	\N
8	valve replacement / repair with or without cabg	C0010055;C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149	\N	\N
7	* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .	C0011847;C0011849;C0039593;C0237913;C0374505;C0392366;C0441833;C0687744;C1257890;C1519504;C1704675;C1705428;C1705429;C1709380	\N	\N
7	* p value	C1709380	\N	\N
7	$nmbr$ p value	C1709380	\N	\N
6	plaque score ( $nmbr$ - $nmbr$ )	C0429153	\N	\N
6	plaque ( n  % )	C0011389;C0241148;C0332461;C0333463;C4316797	\N	\N
6	percent of predicted value before bronchodilation ^	C1371299;C1882327;C3537072	\N	\N
6	/ j - valuc ! l	\N	\N	\N
5	pvalue ∗	\N	\N	\N
5	pvalue for heterogeneity	C0019409;C0242960	\N	\N
5	pvalue	\N	\N	\N
5	p value for heterogeneity （ rosiglitazone versus metformin ）	C0019409;C0025598;C0242960;C0289313;C1709380	\N	\N
5	p value for heterogeneity	C0019409;C0242960;C1709380	\N	\N
4	prasugrel or ticagrelor	C1620287;C1999375	\N	\N
4	prasugrel	C1620287	\N	\N
3	outcome measure	C0086749	\N	\N
3	leisure	C0086542	\N	\N
2	physiological measures	C0079809;C0205463;C1879489	\N	\N
2	measures of lung function	C0035245;C0079809;C1879489	\N	\N
2	measures ( mmol / l )	C0079809;C0242485;C1532563;C1879489	\N	\N
2	measures ( % )	C0079809;C1879489	\N	\N
2	measures	C0079809;C1879489	\N	\N
2	measure	C0079809;C0242485	\N	\N
2	lipid measure *	C0023779;C0079809;C0242485	\N	\N
2	efficacy measures	C0079809;C0242485;C1280519;C1707887;C1879489	\N	\N
2	diff_measure	C0079809;C0242485	\N	\N
2	biochemical measures  mean ( sd )	C0079809;C0205474;C0444504;C1879489;C2347634;C2348143;C2699239	\N	\N
1	weeks_measured	C0439230;C0444706;C3541902	\N	\N
358	fasting glucose ( mmol / l )	C0015663;C0017725;C1532563	f	1846
367	drug - eluting	C0013227;C1254351	f	365
18	blood - glucose control	C3267174	f	18
909	apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol	C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C3715113;C4522122	f	-10
913	extreme tortuosity	C0205403;C0333076;C3641272;C4085555	f	-10
913	severe or very severe copd	C0024117;C0205082;C1412502;C3641272;C3714496;C4050419;C4050465;C4050466	f	1836
913	very severe  gold $nmbr$	C0018026;C1304897;C3641272;C4050419	f	1836
913	very severe ( gold $nmbr$ )	C0018026;C1304897;C3641272;C4050419	f	1836
216	ticlopidin	\N	f	1837
216	ticlopidine	C0040207	f	1837
216	ticlopidine after completion of study drug	C0013175;C0013227;C0040207;C0205197;C1254351;C1554962;C2348557	f	1837
216	ticlopidine ( n = $nmbr$ )	C0040207	f	1837
224	coronary risk factors — no . ( % )	C2024776	f	-10
227	previous coronary angioplasty  n ( % )	C2114427	f	1722
264	calcitonin	C0006668;C0770558;C1704385;C2825090;C4520796	f	-10
268	chronic sinusitis + nasal polypsd  n ( % )	C0028429;C0149516;C4520890	f	1838
271	uniti - $nmbr$ and uniti - $nmbr$ im - uniti	\N	f	-10
275	asymmetric peripheral arthritis	C0238694;C0332514	f	274
275	spondylitis with peripheral arthritis	C0038012;C0238694	f	274
307	egfr at baseline  $nmbr$ ml / min ( % ) b	C0168634;C0439445;C1442488;C1739039;C3811844;C3812682	f	592
307	egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ )	C0010294;C0369637;C0439445;C0441923;C1561535;C1739039;C3811844;C3812682	f	592
307	egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] )	C0010294;C0036919;C0369637;C0439445;C0441923;C1561535;C1739039;C2986759;C3811844;C3812682	f	592
307	egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] )	C0036919;C0071744;C0369637;C0439445;C0441923;C1413772;C1739039;C2986759;C3811844;C3812682	f	592
307	egfr ( ckd - epi  cystatin c )  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0071744;C0162734;C0369637;C0439445;C0441923;C1413772;C1561643;C1739039;C3811844;C3812682;C4281721	f	592
307	egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  mean [ se ] )	C0036919;C0071744;C0369637;C0439445;C0441923;C0444504;C1413772;C1739039;C2347634;C2348143;C3811844;C3812682	f	592
307	egfrmdrd  ml / min / $nmbr$ . $nmbr$ m $nmbr$ bsa	C0369637;C0439445;C0441923	f	592
307	egfrmdrd  ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$	C0369637;C0439445;C0441923	f	592
307	egfrmdrd < $nmbr$ ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$  n ( % )	C0369637;C0439445;C0441923	f	592
307	egfr  mean = sd  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
307	egfr  ml / min ( mdrd )	C0439445;C1739039;C3811844;C3812682;C3839656	f	592
307	egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$  mean ( sd )	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
307	estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) lipid baseline lipid profile	C0017654;C0023779;C0168634;C0369637;C0439445;C0441923;C0750572;C1424601;C1442488;C1979963;C2003903	f	592
307	mean ( sd ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682	f	592
370	geographic region — number ( % )	C0017446;C0237753;C0449788	f	369
1	ldl - c ( measured ) *	C0444706;C3541902	f	1068
1	ldl - c ( measured )  mean ( sd )	C0444504;C0444706;C2347634;C2348143;C2699239;C3541902	f	1068
307	normal or increased baseline gfr ( > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0017654;C0168634;C0205217;C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C0442805;C1424601;C1442488;C2347086;C4553972	f	592
307	renal impairment ( crcl < $nmbr$ ml / min )	C0439445;C1565489;C1846718	f	592
307	stage i ( gfr > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) and stage v ( gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) were not considered because they included only $nmbr$ and $nmbr$ patient  respectively . chf  congestive	C0007591;C0017654;C0018802;C0021966;C0023806;C0030705;C0205171;C0221138;C0332257;C0369637;C0439445;C0441766;C0441777;C0441923;C0456533;C0702093;C0742742;C0750591;C1424601;C1518422;C1524029;C1720467;C3813700	f	592
307	renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ )	C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682	f	592
307	baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	f	592
307	baseline egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	f	592
307	baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ c	C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682	f	592
307	baseline gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488	f	592
307	baseline gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % )	C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488	f	592
338	improved	C0184511;C0332272;C1561611;C4084203	f	-10
873	simvastatin	C0074554	f	1840
873	simvastatin  n ( % )	C0074554	f	1840
873	simvastatin $nmbr$ mg ( n = $nmbr$ ) *	C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761	f	1840
873	simvastatin monotherapy ( n = $nmbr$  $nmbr$ * )	C0074554	f	1840
873	simvastatin $nmbr$ mg	C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761	f	1840
873	simvastatin $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761	f	1840
882	pravastatin	C0085542	f	1841
882	pravastatin $nmbr$ mg	C0024671;C0026410;C0085542;C0439269;C1960952;C2346927;C4321396;C4521761	f	1841
882	pravastatin ( n = $nmbr$ >	C0085542	f	1841
882	pravastatin ( n = $nmbr$ )	C0085542	f	1841
882	pravastatin n = $nmbr$	C0085542	f	1841
882	pravastatin vs usual care	C0085542;C1947933;C3538928	f	1841
1763	any llt other than statins  n ( % ) b	C0360714;C2347090	f	872
1763	no statin vs statin alone vs any statin plus other llt	C0205171;C0360714;C0439044;C0679994;C2347090	f	872
1763	any statin + other llt	C0360714;C2347090	f	872
1763	statin + fibrate or niacin	C0027996;C0360714;C1142562	f	872
1763	other statin	C0360714	f	872
1763	statin + fibrate or	C0360714	f	872
836	high - intensity statin	C0360714;C4081854	f	872
836	high ‐ intensity statins ‡	C0360714;C4081854	f	872
836	high - intensity statin *	C0360714;C4081854	f	872
836	high - intensity statin vs medium - or low - intensity statin at randomization	C0009458;C0034656;C0360714;C0439536;C0596836;C1705217;C3244283;C4081854;C4085196;C4522282;C4522283	f	872
836	no high - intensity statin	C0360714;C4081854	f	872
836	high - intensity statin use	C0042153;C0360714;C0457083;C1947944;C4081854	f	872
1166	placebo - ezetimibe $nmbr$ / simvastatin $nmbr$ - fenofibrate $nmbr$ - ezetimibe $nmbr$ / simvastatin $nmbr$ / ezetimibe $nmbr$	C0032042;C0033228;C1532737;C1696465;C1706408	f	1840
1166	ezetimibe / simvastatin - double dose statin - rosuvastatin	C0178602;C0205173;C0360714;C0869039;C0965129;C1114758;C1532737;C1705764;C1705765	f	1840
1166	ezetimibe + simvastatin ( n = $nmbr$ * )	C1532737	f	1840
1166	ezetimibe + simvastatin ( n = $nmbr$  $nmbr$ * )	C1532737	f	1840
1166	ezetimibe / simvastatin	C1532737	f	1840
1166	chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease	C0010068;C0015663;C0039225;C0074554;C0085096;C0202042;C0455280;C1532737;C1705223;C4319774	f	-10
198	simvastatin ( $nmbr$ / $nmbr$ mg / d )	C0074554;C0439422	f	1840
198	simvastatin ( $nmbr$ / $nmbr$ mg / d ) ( n = $nmbr$ )	C0074554;C0439422	f	1840
589	estonia	C0014908	f	-10
599	southern europe	C0037724	f	-10
306	all men	C0025266	f	1842
306	chd + cerebrovascular disease men $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ )	C0007820;C0025266;C0280604;C3542407	f	1842
306	chd men	C0025266;C0280604;C3542407	f	1842
306	men	C0025266	f	1842
306	men  %	C0025266	f	1842
306	men  n ( % )	C0025266	f	1842
306	men  < $nmbr$ cm	C0025266	f	1842
306	men  > $nmbr$ cm	C0025266	f	1842
306	men ( n = $nmbr$ $nmbr$ )	C0025266	f	1842
306	men ( n = $nmbr$ )  n / n ( % )	C0025266	f	1842
306	men without ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$	C0025266;C3538926	f	1842
1323	hdl cholesterol < $nmbr$ ( men ) or < $nmbr$ mg / dl ( women )	C0023822;C0025266;C0043210;C0392885;C0439269	f	-10
1323	history of gestational diabetes mellitus — no . ( % of women )	C0043210;C2183115	f	-10
1323	p value ( men versus women )	C0025266;C0043210;C1709380	f	-10
975	tio ( n $nmbr$ $nmbr$ )	\N	f	-10
975	tio	\N	f	-10
975	primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  $nmbr$ % cl  $nmbr$ % confidence interval  tia  transient ischemic attack .	C0007787;C0011849;C0020538;C0037369;C0079399;C0205225;C0237529;C0439612;C0439631;C0453996;C0596019;C0679699;C1079230;C1272706;C1522384;C1552654;C1552713;C1704725;C1704726;C1881674;C1963138;C2985465;C4300468	f	-10
355	diagnosis of heterozygous familial hypercholester	C0011900;C0015576;C0019425;C0241888;C1704338;C1704656	f	-10
358	fasting glucose  mmol / l  mean ± sd	C0015663;C0017725;C0444504;C1532563;C2347634;C2348143;C2699239	f	1846
358	impaired fasting giucose levei ( n = $nmbr$ )	C0015663;C0221099	f	1846
358	glucose  non - fasting or random ( nmol / l )	C0015663;C0017725;C0034656;C0439282;C0439605;C1518422	f	1846
370	geographic location	C0017446	f	369
370	geographic region ?	C0017446	f	369
377	micro / macroalbuminuria	C0085672;C1553035;C3811161;C4049106	f	376
377	micro / macroaibuminuria	C0085672;C1553035;C3811161;C4049106	f	376
903	prothrombin mutation ( % )	C1610621	f	-10
386	death  q wave mi or ischemia - driven revasc	C0011065;C0022116;C0378365;C0861151;C1306577;C4082313;C4321499;C4552775;C4683688	f	385
397	at increased fall risk ( n - $nmbr$ )	C0085639;C0205217;C0238715;C0442805;C1268740;C4553726;C4699158	f	1850
397	notatincreased fall risk ( n - $nmbr$  $nmbr$ )	C1268740	f	1850
399	previous labd alone	C0205156;C0205171;C0396059;C0439044;C0679994;C1552607	f	1508
975	bp : blood pressure  ci : confidence interval  esrd : end - stage renal disease  hr  hazard ratio . all patients ( except patients with other race ) were included with missing covariates imputed . event : no . of patients with esrd  rate : event rate per $nmbr$ years of follow - up  pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or x $nmbr$ g / g ) as strata  adjusted : a multivariate cox model with treatment group  time - varying systolic and diastolic bp as covariates . pre - specified analysis and adjusted for time - varying bp	C0002778;C0005823;C0008107;C0009667;C0012634;C0017446;C0022646;C0022661;C0030705;C0033687;C0034510;C0035078;C0037623;C0039155;C0039798;C0040223;C0087111;C0168634;C0205088;C0205147;C0332257;C0332283;C0428883;C0439234;C0441471;C0441833;C0441835;C0441889;C0456079;C0456081;C0679845;C0687744;C0871208;C0936012;C1257890;C1319635;C1415692;C1442488;C1519504;C1521828;C1522326;C1524024;C1533734;C1547707;C1551393;C1565830;C1705169;C1705428;C1705429;C1705492;C1706779;C1708288;C1719822;C1962972;C2316810;C2699638;C2826245;C2946261;C2985465;C3161035;C3259781;C3272743;C3274659;C3538994;C3541383;C3714583;C3853635;C3853906;C3887704;C4019010;C4281991;C4318478;C4522145;C4554346	f	-10
192	creatinine $nmbr$ . $nmbr$ mg / dl medications	C0010294;C0013227;C0439269;C0802604;C1561535;C2598133;C4284232	f	952
192	creatinine — mg / dl urinary albumin - to - creatinine ratio §	C0010294;C0439269;C0456603;C1547037;C1561535;C2362049	f	952
192	creatinine ≥ $nmbr$ . $nmbr$ mg / dl	C0010294;C0439269;C1561535	f	952
192	creatinine  mg / dl ( sd )	C0010294;C0439269;C1561535;C2699239	f	952
192	creatinine ( mg / dl )  mean ( sd )	C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239	f	952
192	creatinine  mg / dl  mean	C0010294;C0439269;C0444504;C1561535;C2347634;C2348143	f	952
82	creatinine	C0010294;C1561535	f	952
82	creatinine  mmol 八	C0010294;C0439190;C1561535	f	952
82	creatinine ( µ mol / l )	C0010294;C0347982;C1561535	f	952
82	creatinine ( p  mol / l )	C0010294;C0347982;C1561535	f	952
82	creatinine  pmol / l	C0010294;C0439284;C1561535	f	952
82	creatinine ( ^ mol / l ) ( median  iqr )	C0010294;C0347982;C0549183;C0876920;C1561535;C2347635;C2348144;C2939193	f	952
200	acr  mg / mmol	C0567349;C1412134;C1515941;C2348885	f	80
200	albumin / creatinine ratio - mg / mmol  median ( iqr )	C0486293;C0549183;C0567349;C0876920;C1318293;C2347635;C2348144;C2348885;C2939193	f	80
200	uacr   < $nmbr$   mg / mmol ∗	C0567349;C2348885	f	80
200	urine acr ( mg / mmol )	C0042036;C0042037;C0567349;C1412134;C1515941;C2348885;C2963137	f	80
200	uacr   ≥ $nmbr$   mg / mmol ∗	C0567349;C2348885	f	80
200	urinary acr ( mg / mmol )	C0042027;C0567349;C1412134;C1515941;C1524119;C2348885	f	80
389	ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary	C0010055;C0022709;C0027051;C0189695;C0545743;C3640258	f	-10
389	data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation  † at discharge . ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .	C0007226;C0007447;C0010055;C0012621;C0018787;C0022709;C0027051;C0030685;C0037455;C0040363;C0041260;C0184661;C0238884;C0439175;C0439453;C0439526;C0439810;C0439836;C0522523;C0552449;C0565930;C0750572;C0812399;C0886296;C1273869;C1511726;C1516705;C1705224;C1719797;C1883351;C2603362;C2911648;C2926602;C3245479;C3538926;C3714741;C3887460;C3887665;C4049621	f	-10
389	pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > $nmbr$ mg / l  for europa > $nmbr$ mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .	C0010055;C0023779;C0039798;C0087111;C0184661;C0189695;C0242751;C0392347;C0441994;C0444504;C0522523;C0545743;C0680443;C0886296;C1273869;C1444656;C1511726;C1522326;C1533734;C1705169;C2003888;C2347634;C2348143;C2699239;C2827881;C3245479;C3538994;C3714741;C3887704;C4049621	f	-10
432	creatinine clearance > $nmbr$ to < $nmbr$ ml / min — no . ( % ) f	C0016327;C0151280	f	79
461	coronary - artery bypass grafting	C0010055	f	1843
461	coronar y - artery bypass grafting	C0450140;C0741847	f	1843
461	coronary artery bypass grafting	C0010055	f	1843
461	coronary artery bypass grafting n ( % )	C0010055	f	1843
461	coronary - artery bypass grafting §	C0010055	f	1843
461	coronary artery bypass graft — no . ( % )	C0010055;C1260596	f	1843
470	creatinine clearance at admission ( ml / min )	C0151280;C0184666;C0809949	f	79
666	elevated creatinine ( > $nmbr$ pmol / l )	C0151578;C0439284;C0700225	f	952
1036	normoalbuminuria §	\N	f	80
1036	patients with macroalbuminuria at baseline	C0030705;C0168634;C1442488	f	80
1036	patients with normoalbuminuria at baseline	C0030705;C0168634;C1442488	f	80
1579	“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age  reciprocal of serum creatinine  sbp  up excretion  treatment assignment and terms for studies $nmbr$  $nmbr$ $nmbr$ and $nmbr$ ( see footnotes of table $nmbr$ ) . other baseline variables considered for analysis ( p < $nmbr$ . $nmbr$ in univariate analysis ) included dp mean arterial pressure  type of antihypertensive regimen in the control group  planned duration of follow - up  whether or not the investigators were blinded  whether or not dietary advice was given and the year of publication .	C0001779;C0002778;C0003364;C0009932;C0034036;C0034037;C0035173;C0039224;C0039798;C0040808;C0042789;C0085805;C0087111;C0150108;C0168634;C0201976;C0204932;C0221102;C0232108;C0233324;C0242492;C0243148;C0332257;C0332307;C0439234;C0439508;C0439828;C0441833;C0444504;C0504085;C0600061;C0683962;C0687744;C0750591;C0936012;C0947630;C1257890;C1272641;C1274040;C1442162;C1442488;C1515273;C1516050;C1518422;C1519504;C1522326;C1524024;C1531217;C1533734;C1547052;C1550141;C1550718;C1704324;C1705169;C1705313;C1705428;C1705429;C1706074;C1882911;C1882979;C1947903;C1947971;C2347634;C2348143;C2587213;C2699704;C2825232;C2826302;C2945654;C2986775;C3161035;C3244317;C3274648;C3538994;C3887704;C4288391;C4553389	f	-10
343	digoxin scd  no . ( % / y )	C0012265	f	989
990	digitalis	C0012252;C0304520	f	989
990	digitalis glycoside	C0012253	f	989
990	digoxin / digitalis glycoside	C0012253;C0012265	f	989
990	digitalis  n ( % )	C0012252;C0304520	f	989
990	digoxin or digitalis glycoside	C0012253;C0012265	f	989
356	radial	C0442038;C0920847	f	-10
414	serious adverse events	C1519255	f	1851
416	elevated crp  n ( % )	C0742906	f	286
416	elevated crp ( > ulnt )  n ( % )	C0742906	f	286
416	elevated baseline crp	C0168634;C0742906;C1442488	f	286
422	nonsmoker	C0337672;C0425293;C4554605	f	420
422	current smoker — no . ( % ) blood pressure — mm hg	C0005823;C0439475;C1271104;C1272641;C3173209;C3241966	f	420
423	smoking history : ex - smoker	C0337664;C1519384	f	420
423	smokers : qva $nmbr$ - $nmbr$ fc	C0337664;C2983605	f	420
423	smokers  no . ( % )	C0337664	f	420
423	smokers  n ( % )	C0337664	f	420
423	smokers ( at baseline )	C0168634;C0337664;C1442488	f	420
423	smokers  %	C0337664	f	420
424	former smokers	C0337671	f	420
424	smoking : ex - smoker	C0037369;C0337671;C0453996;C1881674;C4555205	f	420
426	apo a - i ( mg / dl ) *	C0085201;C0439269;C1677784	f	1852
426	apo a - l ( g / l )	C0628062	f	1852
428	apoal	\N	f	427
428	apob : apoal	C0003593;C3252643	f	426
428	apo b *	C0003593;C3252643	f	426
428	apob : apoal ratio	C0003593;C0456603;C1547037;C3252643	f	426
428	apo bt	\N	f	426
438	no aspirin or ppi	C0004057;C0358591;C0871125;C3811894	f	1366
438	aspirin — no . ( % )	C0004057	f	1366
439	antihypertensive medication  open - label  no . ( % )	C0003364;C1709323	f	1579
439	antihypertensive randomization  no . ( % ) a	C0003364;C0034656	f	1579
439	any blood - pressure - lowering drug 一 no . ( % )	C0003364	f	1579
439	> $nmbr$ antihypertensive medication  no . ( % )	C0003364	f	1579
440	no current smoking	C0037369;C0453996;C0521116;C1705970;C1881674	f	420
959	j $nmbr$ - blocker	\N	f	-10
959	( $nmbr$ blocker	\N	f	-10
959	/ $nmbr$ - blockers	\N	f	-10
959	$nmbr$ - blocker	\N	f	-10
454	heart failure ( class i — iii )	C0018801;C0018802;C0021966;C0221138;C0439070;C0441885;C0441887;C1319793;C1705160;C2698967;C2698969;C4554158	f	453
455	nyha classes iii - iv	C0278962	f	453
455	nyha class ii	C1882085	f	453
455	nyha class i	C1882084	f	453
455	nyha class > ii	C1882085	f	453
455	nyha class iii	C1882086	f	453
811	dipeptidyl peptidase - $nmbr$ inhibitor	C0003015;C2757044;C3536837	f	1854
811	dipeptidyl peptidase $nmbr$ inhibitor	C0003015;C2757044;C3536837	f	1854
811	dipeptidyl peptidase $nmbr$ inhibitors	C0003015	f	1854
779	ace inhibitor or angiotensin ii receptor blocker	C0003015;C0521942;C3536793;C4541021	f	811
779	ace inhibitor or angiotensin receptor blocker	C0003015;C0034787;C1622222;C4541021	f	811
779	ace inhibitors or angiotensin - receptor blockers	C0003015;C0521942;C0815017	f	811
779	ace inhibitors or angiotensin - receptor blockers ^	C0003015;C0521942;C0815017	f	811
1396	denotes angiotensin - converting enzyme .	C0022709;C1452534	f	811
1396	converting enzyme inhibitor	C0014432;C0919438;C4521603	f	811
1396	angiotension converting enzyme - inhibitor	C0014432;C0919438;C4521603	f	811
1396	angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers	C0003018;C0014432;C1152555;C2756995;C4521302	f	811
1396	ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .	C0022709;C0597357;C3888198	f	811
1396	angiotensin - eonverting enzyme inhibitors	C0003018;C0014432;C1152555;C2756995;C4521302	f	811
522	ace inhibitors or angiotensin ii	C0003009;C0003015;C1366631;C3714928	f	811
522	ace inhibitors or angiotensin ii blockers	C0003009;C0003015;C1366631;C3714928	f	811
522	angiotensin ii antagonists	C0003009;C0243076;C1366631;C3714928	f	811
12	data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme  arb = angiotensin - receptor blocker . chf = congestive heart failure . * any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery .	C0004057;C0018802;C0022709;C0033727;C0034787;C0038894;C0038895;C0042153;C0205171;C0369286;C0369718;C0439228;C0441922;C0441932;C0444504;C0457083;C0543467;C0564385;C1274039;C1511726;C1514873;C1622222;C1720467;C1947944;C2347634;C2348143;C2699239;C3245479;C3714741;C3888198;C4528284	f	-10
758	thiazide	C0541746	f	993
758	thiazide at enrollment	C0541746;C1516879;C1696073;C3888021	f	993
758	thiazides	C0541746	f	993
758	thiazide users	C0541746;C1706077	f	993
1638	antiplatelet - onl group ( n = $nmbr$ )	C0441848	f	1191
1638	antiplatelet - only group ( n = $nmbr$ )	C0205171;C0441848;C1720467	f	1191
1192	other antiplatelet agents  n ( % )	C0085826	f	1191
1192	other antiplatelet agents	C0085826	f	1191
1192	other anti - platelet agents	C0005821;C0040616	f	1191
1192	other antiplatelet	\N	f	1191
1192	aspirin or other antiplatelet agents	C0004057;C0085826	f	1191
1192	aspirin / other antiplatelet agents  n ( % )	C0004057;C0085826	f	1191
555	antiplatelet or anticoagulant therapy	C0150457	f	1191
555	antiplatelet therapy	C1096021	f	1191
555	antiplatelet therapy §	C1096021	f	1191
555	antiplatelet therapy dual	C0205173;C1096021;C1554184	f	1191
555	no antiplatelet therapy	C1096021	f	1191
555	long - term antiplatelet therapy	C0443252;C1096021	f	1191
509	antiplatelet — no . / total no . ( % )	C0439175;C0439810	f	1191
861	nonaspirin antiplatelet	C0722138	f	1191
861	nonaspirin antiplatelet agent	C0085826;C0722138	f	1191
1624	dual antiplatelet therapy	C0205173;C1096021;C1554184	f	1191
1624	dual therapy	C0039798;C0087111;C0205173;C1363945;C1554184	f	1191
1624	dual antiplatelet	C0205173;C1554184	f	1191
1773	^ - blockers	\N	f	-10
118	antiplatelet use	C0042153;C0457083;C1947944	f	1191
692	antiplatelet at randomization	C0034656	f	1191
156	antiplatelet or anti - inflammatory drugs	C0003209	f	1191
366	aspirin / antiplatelet medication	C0004057;C0013227;C0085826;C3244316;C4284232	f	1191
1476	antiplatelet within $nmbr$ mo before randomization	C0026544;C0034656;C0332177	f	1191
1020	non - trial antiplatelet	C0008976;C1518422	f	1191
1730	duration antiplatelet use as % of study duration ( sd )	C0557651;C1881378;C2603343;C2699239;C2826775	f	1191
118	statin use	C0042153;C0360714;C0457083;C1947944	f	872
118	statin use ( % )	C0042153;C0360714;C0457083;C1947944	f	872
118	statin use — no . { % )	C0042153;C0360714;C0457083;C1947944	f	872
118	concomitant statin use	C0042153;C0360714;C0457083;C0521115;C1947944	f	872
534	statin non - users ( n = $nmbr$ )	C0360714;C1518422;C1706077	f	872
534	statin users	C0360714;C1706077	f	872
534	statin users ( n = $nmbr$ )	C0360714;C1706077	f	872
625	baseline statin	C0168634;C0360714;C1442488	f	872
625	baseline statin usec	C0168634;C0360714;C0439224;C1442488	f	872
625	statin use at baseline :	C0042153;C0168634;C0360714;C0457083;C1442488;C1947944	f	872
294	prior statin ( n = $nmbr$  $nmbr$ )	C0332152;C0360714;C2826257	f	872
545	fenofibric acid - i - moderate - dose statin	C0021966;C0060179;C0221138;C0360714;C1709056	f	872
545	moderate - dose statin	C0360714;C1709056	f	872
545	statin with fibrate	C0360714	f	872
603	type of concomitant statin	C0332307;C0360714;C0521115;C1547052	f	872
1832	atorvastatin $nmbr$ mg ( zi = $nmbr$ )	C0024671;C0026410;C0043476;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761	f	885
41	$nmbr$ s = scandinavian simvastatin survival study . $nmbr$ woscops = west of scotland coronary prevention study . $nmbr$ care = cholesterol and recurrent events . $nmbr$ post - cabg = post - coronary artery bypass graft . $nmbr$ afcaps / texcaps = air force / texas coronary atherosclerosis prevention study . $nmbr$ lipid = long - term intervention with pravastatin in ischaemic disease . $nmbr$ gissi prevention = gruppo italiano per lo studio della sopravvivenza nell ’ infarto miocardico . $nmbr$ lips = lescol intervention prevention study . $nmbr$ hps = heart protection study . $nmbr$ prosper = prospective study of pravastatin in the elderly at risk . $nmbr$ allhat - llt = antihypertensive and lipid - lowering treatment to prevent heart attack trial . $nmbr$ ascot - lla = anglo - scandinavian cardiac outcomes trial - lipid lowering arm . $nmbr$ alert = assessment of lescol in renal transplantation . $nmbr$ cards = collaborative atorvastatin diabetes study . $nmbr$ s = simvastatin . l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  $nmbr$ s  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step $nmbr$ diet and care intensi ﬁ ed to step $nmbr$ diet if ldl cholesterol $nmbr$ · $nmbr$ mmol / l ( $nmbr$ mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease	C0001792;C0002458;C0003364;C0005847;C0005910;C0008377;C0008976;C0010054;C0010055;C0011847;C0011849;C0012155;C0012159;C0012171;C0016327;C0018787;C0019664;C0019665;C0022671;C0023759;C0023779;C0023824;C0023981;C0024027;C0027051;C0027361;C0030705;C0033522;C0035647;C0036453;C0038454;C0038952;C0039711;C0039798;C0040363;C0040704;C0041260;C0043100;C0050451;C0074554;C0085542;C0085565;C0086153;C0087111;C0150158;C0184661;C0199176;C0202117;C0204932;C0205082;C0205164;C0205374;C0206579;C0220921;C0231220;C0237401;C0239110;C0240951;C0242994;C0262512;C0262926;C0277793;C0280604;C0282416;C0286651;C0309872;C0332196;C0332257;C0420180;C0439394;C0439673;C0441471;C0441994;C0444504;C0446516;C0449238;C0455536;C0475224;C0489835;C0557651;C0565930;C0589120;C0591720;C0679698;C0680782;C0681804;C0687676;C0718674;C0745413;C0750480;C0772110;C0870136;C0886296;C0948008;C1096775;C1185738;C1232424;C1260596;C1261512;C1261552;C1273517;C1273869;C1304680;C1305866;C1455761;C1519433;C1522326;C1522577;C1522601;C1527178;C1533734;C1545588;C1552866;C1558950;C1561607;C1704379;C1704436;C1704685;C1704687;C1705117;C1705169;C1705255;C1705493;C1705566;C1705938;C1706132;C1706420;C1706495;C1709709;C1711260;C1736144;C1801960;C1883351;C1947933;C1999167;C1999230;C2003888;C2004062;C2004580;C2347090;C2347634;C2348143;C2348152;C2603343;C2603362;C2700399;C2700409;C2825408;C2828389;C2919552;C2926735;C2930619;C2937358;C2945760;C2983588;C3274571;C3275277;C3469826;C3538926;C3538994;C3541433;C3541888;C3542407;C3642216;C3642217;C3665546;C3668949;C3669039;C3715044;C3810814;C3814463;C3887704;C3889123;C3898312;C4025272;C4050014;C4084853;C4318856;C4521762;C4552904;C4553014;C4553528;C4554100	f	-10
1494	history of heart failure	C0455531	f	12
1494	history of heart failure at baseline	C0168634;C0455531;C1442488	f	12
1494	history of heart failure  n ( % )	C0455531	f	12
1494	history of heart failure — no . ( % )	C0455531	f	12
1494	history of heart failure — no . { % )	C0455531	f	12
1494	history of heart failure  no . ( % )	C0455531	f	12
1044	previous congestive heart failure	C0018802;C0205156;C1552607	f	12
1044	previous congestive heart failure — no . ( % )	C0018802;C0205156;C1552607	f	12
1044	previous congestive heart failure ( % )	C0018802;C0205156;C1552607	f	12
1475	baseline heart rate ( beat / min )	C0168634;C0425583;C0702093;C0871208;C1442488;C1521828;C1524029;C3813700	f	1105
1475	heart rate at rest — beats / min	C0018810;C0035253;C0702093;C1524029;C1622890;C3813700	f	1105
1475	heart rate  beats / min	C0018810;C0702093;C1524029;C3813700	f	1105
1475	heart rate ( beats / min )	C0018810;C0702093;C1524029;C3813700	f	1105
1475	heart rate — beats / min	C0018810;C0702093;C1524029;C3813700	f	1105
1475	heart rate at rest in the supine position ( beats / min )	C0018810;C0035253;C0038846;C0702093;C1524029;C1622890;C3813700	f	1105
323	all - cause death n	C0011065;C0015127;C1306577;C1524003;C4082313;C4552775	f	1855
323	all - cause death	C0011065;C0015127;C1306577;C1524003;C4082313;C4552775	f	1855
323	all - cause death / stroke / see	C0011065;C0015127;C0038454;C0042789;C1306577;C1524003;C1947903;C4082313;C4552775;C4554100	f	1855
323	all death	C0011065;C1306577;C4082313;C4552775	f	1855
323	any death	C0011065;C1306577;C4082313;C4552775	f	1855
323	dead ( n = $nmbr$ )	C0011065	f	1855
323	death *	C0011065;C1306577;C4082313;C4552775	f	1855
323	death ( all - cause )	C0011065;C0015127;C1306577;C1524003;C4082313;C4552775	f	1855
323	death ( all cause )	C0011065;C0015127;C1306577;C1524003;C4082313;C4552775	f	1855
323	deaths	C0011065;C1306577	f	1855
323	data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at $nmbr$ year . * cardiovascular ( cv ) death  myocardial infarction ( mi )  or recurrent ischemia . † cv death  mi  or severe recurrent ischemia	C0007226;C0011065;C0022116;C0027051;C0205082;C0428953;C0439234;C0439508;C0441471;C0684224;C0700287;C0871208;C1306577;C1455761;C1511726;C1521828;C1720943;C2926063;C2945760;C3245479;C3538987;C3714741;C3810814;C3887460;C4019010;C4048877;C4050465;C4050466;C4082313;C4318503;C4319718;C4321499;C4552775;C4552959	f	-10
712	heart rate at baseline  bpm	C0018810;C0168634;C1442488	f	1105
712	heart rate at baseline ( bpm	C0018810;C0168634;C1442488	f	1105
712	heart rate  bpm	C0018810	f	1105
712	heart rate  bpm  mean ( sd )	C0018810;C0444504;C2347634;C2348143;C2699239	f	1105
712	heart rate  mean ( sd )  bpm ( n = $nmbr$ $nmbr$ )	C0018810;C0444504;C2347634;C2348143;C2699239	f	1105
712	heart rate < $nmbr$ bpm	C0018810	f	1105
1287	heart rate  beats / min  mean ± sd	C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C3813700	f	1105
1287	heart rate  b . p . m . mean ± sd	C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239	f	1105
1287	heart rate  mean ( sd )	C0018810;C0444504;C2347634;C2348143;C2699239	f	1105
1287	heart rate ( b . p . m . )  mean ± sd	C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239	f	1105
1287	heart rate  mean ( sd )  beats / min	C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C3813700	f	1105
1287	heart rate  mean ± sd ( b . p . m . )	C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239	f	1105
1564	any history of congestive heart failure	C0455531;C0742742	f	12
1564	congestive heart	C0018787;C0742742	f	12
1564	history of congestive heart failure	C0455531;C0742742	f	12
1564	infarction ( yr ) history of congestive heart failure ( % )	C0021308;C0439234;C0455531;C0742742	f	12
1747	oral medications	C0304289	f	1921
1481	cardiac failurec	C0018787;C1522601	f	12
1481	heart failurea	C0018787	f	12
1476	heart failure $nmbr$ month before admission	C0018801;C0018802;C0184666;C0332177;C0439231;C0809949;C4554158	f	12
561	statin intensity $nmbr$ * $nmbr$	C0360714;C0522510	f	872
561	statin intensity per acc / ahac	C0175754;C0282160;C0360714;C0522510;C3541413	f	872
297	esr  median ( range ) mm / hour	C0439227;C0549183;C0564385;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3811131;C4330985;C4554674	f	298
297	esr  mm / hour	C0439227;C0564385;C3811131;C4330985;C4554674	f	298
297	erythrocyte sedimentation rate  mm / hour	C0439227;C0564385;C1176468;C1619634;C4330985;C4554674	f	298
297	esr ( mm / hour )	C0439227;C0564385;C3811131;C4330985;C4554674	f	298
297	esr ( mm / hour ) git config - - global user . name  your name	C0027365;C0205246;C0439227;C0564385;C1418224;C1547383;C1548600;C1706077;C2348867;C2827597;C3811131;C4330985;C4522128;C4554674	f	298
297	esr ( mm / hour  per unit )	C0456685;C3811131;C4330985;C4554674	f	298
466	das $nmbr$ - esr  mean ( sd )	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131	f	298
466	das $nmbr$ - esr  mean ± sd das $nmbr$ - esr remission  %	C0051767;C0057671;C0444504;C0544452;C0687702;C2347634;C2348143;C2699239;C3811131	f	298
826	erythrocyte sedimentation rate — mm / hr | |	C1176468;C1619634;C4330985;C4554674	f	298
466	esr	C3811131	f	298
469	st depression or elevation	C0439775;C0520887;C0702240	f	1856
469	st depression ( without st elevation )	C0011570;C0011581;C0344315;C0439775;C0460137;C0520886;C0520887;C0702240;C4049644;C4084909;C4085311;C4553827	f	1856
469	st segment depression	C0520887	f	1856
469	st - segment depression	C0520887	f	1856
469	st - segment depression > $nmbr$ mm	C0520887;C4330985;C4554674	f	1856
118	aspirin use at randomization	C0004057;C0034656;C0042153;C0457083;C1947944	f	1366
118	aspirin use n ( % )	C0004057;C0042153;C0457083;C1947944	f	1366
118	aspirin use at randomization - n ( % )	C0004057;C0034656;C0042153;C0457083;C1947944	f	1366
118	aspirin use ( p = $nmbr$ - $nmbr$ t )	C0004057;C0042153;C0457083;C1947944	f	1366
60	acetyl - salicylic acid	C0004057	f	1366
60	acetylsalicylic acid	C0004057	f	1366
60	aspirin ( asa ) ( » = $nmbr$ $nmbr$ )	C0004057;C3853627	f	1366
60	aspirin at enrollment	C0004057;C1516879;C1696073;C3888021	f	1366
1367	aspirin at any dose	C4696290	f	1366
1367	aspirin dose	C4696290	f	1366
1367	aspirin + dipyridamole ( n = $nmbr$ )	C0732279	f	1366
1367	aspirin + dipyridamole	C0732279	f	1366
1367	aspirin dose  mg / d	C0439422;C4696290	f	1366
1367	dose of aspirin	C4696290	f	1366
192	aspirin dose at baseline  mg	C0004057;C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4086581;C4321396;C4521761;C4696290	f	1366
192	aspirin $nmbr$ mg ( n = $nmbr$ )	C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1366
192	aspirin use ( > $nmbr$ mg )	C0004057;C0024671;C0026410;C0042153;C0439269;C0457083;C1947944;C1960952;C2346927;C4321396;C4521761	f	1366
625	aspirin at baseline	C0004057;C0168634;C1442488	f	1366
625	aspirin use at baseline	C0004057;C0042153;C0168634;C0457083;C1442488;C1947944	f	1366
294	no prior aspirin	C0004057;C0332152;C2826257	f	1366
438	drug therapy at admission 一 no . ( % ) aspirin	C0004057;C0013216;C0013217;C0184666;C0809949	f	1366
25	use of low - dose aspirin ( < $nmbr$ mg daily )	C0024671;C0026410;C0332173;C0439269;C1524063;C1960952;C2346927;C2608320;C4321396;C4521761	f	1366
28	aspirin plus placebo ( n = $nmbr$ )	C0004057;C0032042;C0332287;C1696465;C1706408	f	1366
925	aspirin only	C0004057;C0205171;C1720467	f	1366
925	aspirin only ( n = $nmbr$  $nmbr$ )	C0004057;C0205171;C1720467	f	1366
110	aspirin ( any dose )	C0004057;C0178602;C0869039;C1114758	f	1366
483	aqc < $nmbr$	\N	f	-10
483	aqe i $nmbr$	C0021966;C0221138	f	-10
483	aqe ^ $nmbr$	\N	f	-10
483	aqe < $nmbr$	\N	f	-10
483	no ocs use  no nasal polyps  pre - bd fvc s $nmbr$ % of predicted and age at diagnosis < $nmbr$ years	C0005126;C0027430;C0042153;C0332152;C0439234;C0457083;C0681842;C0740175;C1828181;C1882327;C1947944;C2257086;C2344255;C3173302;C3669034;C3714541;C4050145	f	-10
480	goncomitant treatment with age inhibitors / angiotensin	C0001779;C0003018;C0039798;C0087111;C0243077;C1522326;C1533734;C1705169;C3538994;C3887704;C4521302	f	-10
1826	l compared wit	C0043197;C0439394;C1706495;C1707455;C3642217	f	-10
1826	l $nmbr$	C0439394;C1706495;C3642217	f	-10
1826	l ( % )	C0439394;C1706495;C3642217	f	-10
1826	l . i ( $nmbr$ . $nmbr$ )	C0021966;C0221138;C0439394;C1706495;C3642217	f	-10
1827	$nmbr$ . l ( $nmbr$ . l )	C3539687	f	-10
1828	gfr $nmbr$ - $nmbr$	C0017654;C1424601	f	592
1828	estimated gfr  mean ( sd )  mlvmin per $nmbr$ . $nmbr$ m ^ *	C0017654;C0369637;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239	f	592
1828	estimated gfr ^	C0017654;C0750572;C1424601	f	592
1829	other glp - $nmbr$ receptor agonist	C0018301;C1422069;C1425391;C1539338;C2350813;C4543206	f	1153
1831	eze / simva  $nmbr$ / $nmbr$ mg dn = $nmbr$ c $nmbr$ )	C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761	f	1862
1165	ezetimibe $nmbr$ mg + statin ( n = $nmbr$  $nmbr$ )	C0024671;C0026410;C0360714;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761	f	1862
1165	statin and / or ezetimibe	C0360714;C1142985	f	1862
1165	statin + ezetimibe	C0360714;C1142985	f	1862
1165	statin + ezetimibe  n ( % )	C0360714;C1142985	f	1862
1165	statin + ezetimibe ( n = $nmbr$ . $nmbr$ )	C0360714;C1142985	f	1862
1806	< $nmbr$ cells / pl	C0007584;C0007634;C3897966;C4049765	f	-10
1806	> $nmbr$ cells / pl	C0007584;C0007634;C3897966;C4049765	f	-10
1806	/ pl $nmbr$ $nmbr$	C3897966;C4049765	f	-10
1815	asia ( excluding japan )	C0003980;C0022341;C0332196;C2828389	f	1864
1814	japanese subpopulation	C0376247;C1257890;C1556094	f	1815
1814	japanese subgroup ( n = $nmbr$ )	C0376247;C1079230;C1515021;C1556094	f	1815
1814	no . japanese	C0376247;C1556094	f	1815
1749	tah ( n = $nmbr$ )	C0404079	f	-10
1819	pancreatic cancer	C0235974;C0346647;C2984259	f	1865
1697	atherosclerotic cvd	C0007222;C0333482	f	1698
1697	atherosclerotic cvd §	C0007222;C0333482	f	1698
1697	other atherosclerotic	C0333482	f	1698
1697	other atherosclerotic cvd	C0007222;C0333482	f	1698
1697	atherosclerotic cvdj	C0333482	f	1698
1697	other atherosclerotic cvd * *	C0007222;C0333482	f	1698
1279	atherosclerotic disease ( % )	C0012634;C0333482	f	1698
179	established ascvd	C0443211;C1272684;C3665365	f	1698
1279	atherosclerotic disease *	C0012634;C0333482	f	1698
179	established atherosclerotic disease  n ( % )	C0012634;C0333482;C0443211;C1272684	f	1698
179	established ascvd or > $nmbr$ cv risk factors	C0035648;C0443211;C1272684;C1553898;C3538987;C3665365;C4048877;C4318503	f	1698
179	established atherosclerotic	C0333482;C0443211;C1272684	f	1698
832	atherosclerotic vascular disease history  no . ( % ) ‡	C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	1698
1790	established atherosclerotic cv disease §	C0007222;C0333482;C0443211;C1272684	f	1698
105	history of atherosclerotic vascular disease — no . ( % ) §	C0005847;C0333482;C0683519;C0730226;C0850708;C0944983;C1558950;C1801960	f	1698
105	history of major macrovascular disease  n ( % )	C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762	f	1698
105	history of macrovascular disease at baseline  n ( % )	C0168634;C0683519;C0730226;C0850708;C0944983;C1442488	f	1698
747	large vessel atherosclerosis	C0003850;C0004153;C0225990	f	1698
933	values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index . † other forms of atherosclerosis are peripheral arterial disease  abdom - inal aortic aneurysm  symptomatic carotid artery disease  transient isch - emic attack  and stroke . ‡ family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged $nmbr$ years or female ﬁ rst - degree relative $nmbr$ years . § blood pressure $nmbr$ / $nmbr$ mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .	C0001675;C0001779;C0001792;C0003364;C0003486;C0003850;C0004153;C0005823;C0005893;C0007273;C0008377;C0011198;C0011900;C0015576;C0017480;C0019664;C0019665;C0020538;C0030688;C0030705;C0038454;C0040704;C0042295;C0043210;C0080103;C0085096;C0086287;C0086582;C0151526;C0205252;C0205345;C0205374;C0205448;C0231220;C0237753;C0262512;C0262926;C0277793;C0280604;C0340629;C0348078;C0376315;C0439165;C0439234;C0439475;C0441833;C0441889;C0444504;C0449286;C0449788;C0542560;C0578022;C0679841;C1261512;C1271104;C1272641;C1304680;C1305855;C1425219;C1516050;C1518340;C1527178;C1547039;C1551393;C1552601;C1704338;C1704436;C1704656;C1704727;C1705255;C1705492;C1705497;C1705498;C1705938;C1706180;C1706365;C1706428;C1706429;C1706450;C1963138;C1999167;C1999270;C2004062;C2347634;C2348088;C2348143;C2699239;C2744579;C3245503;C3272743;C3541240;C3542407;C4018905;C4552600;C4554100	f	-10
1790	> $nmbr$ cv risk factors ^ or established atherosclerotic cv disease	C0007222;C0035648;C0333482;C0443211;C1272684;C1553898;C3538987;C4048877;C4318503	f	1698
1279	multivessel disease 一 no . ( % )	C0012634	f	1867
1279	multivessel disease — no . ( % )	C0012634	f	1867
1279	multivessel disease  n ( % )	C0012634	f	1867
1279	polyvascular disease and type $nmbr$ diabetes ( n = $nmbr$ )	C0012634;C1320657	f	1868
1279	polyvascular disease ( n = $nmbr$ )	C0012634	f	1868
1279	polyvascular disease * ( n = $nmbr$ )	C0012634	f	1868
1810	number of lesions  n ( % ) a	C0449791	f	1870
1823	p - val . ( $nmbr$ )	C0042285;C0369773;C0523975;C2603361	f	1872
1823	p - valuea	C0369773;C2603361	f	1872
1823	p valuea	C0369773;C2603361	f	1872
1823	p valueb	C0369773;C2603361	f	1872
1823	p - valueb	C0369773;C2603361	f	1872
1823	p inleraclion	C0369773;C2603361	f	1874
1824	$nmbr$ - $nmbr$ ( o - $nmbr$ i - o - $nmbr$ )	C0021966;C0221138;C0483204	f	-10
1824	$nmbr$ $nmbr$ ( o - $nmbr$ - i - o $nmbr$ )	C0021966;C0221138;C0483204	f	-10
1824	$nmbr$ - $nmbr$ { o - $nmbr$ - $nmbr$ - o $nmbr$ )	C0483204	f	-10
1509	indacaterol group ( n = $nmbr$ )	C0441848;C1722260	f	1875
1509	indacaterol $nmbr$ ug ( n = $nmbr$ )	C0041573;C0439211;C1722260	f	1875
1509	indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug	C0041573;C0439211;C1722260	f	1875
1509	indacaterol $nmbr$ ug versus placebo	C0032042;C0041573;C0439211;C1696465;C1706408;C1722260	f	1875
1509	indacaterol n = $nmbr$	C1722260	f	1875
1509	indacaterol + tiotropium ( n [ $nmbr$ )	C0213771;C1722260	f	1875
1785	$nmbr$ < $nmbr$ s ) n $nmbr$ ( $nmbr$ . $nmbr$ )	C2986823	f	-10
1785	s $nmbr$ gallop  n ( % )	C2986823	f	-10
1785	s $nmbr$ ( n = $nmbr$ )	C2986823	f	-10
1795	( e ) aza treatment ( ref )	C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704	f	1881
1795	( a ) aza treatment ( ref )	C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704	f	1881
1795	( c ) ' ' kza treatment ( ref )	C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704	f	1881
1795	( b ) aza treatment ( ref )	C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704	f	1881
1273	values are mean ± sd  median [ quartile range ]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .	C0005823;C0022709;C0033382;C0042295;C0054015;C0205088;C0332307;C0428772;C0444504;C0488728;C0523852;C0549183;C0597357;C0600137;C0876920;C1095989;C1144709;C1291218;C1317554;C1417808;C1452534;C1514721;C1547052;C1705314;C1705315;C2347634;C2347635;C2348143;C2348144;C2348147;C2699239;C2709270;C2825907;C2828255;C2939193;C2982014;C2987124;C3537020;C3542016;C3683557;C3888198;C4284014;C4284038	f	-10
1536	right ventricular dysfunction  n / n ( % ) j	C0242707;C1556315	f	1882
1536	right ventricular dysfunction — no . / total no . ( % ) §	C0242707;C0439175;C0439810;C1556315	f	1882
1801	hbalc	\N	f	1176
1801	hbalc < $nmbr$ %	\N	f	1176
1801	hbalc ( mmol / mol )	C3829066	f	1176
1801	hbalc £ $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ )	C3829066	f	1176
1801	hbalc < $nmbr$ % ( $nmbr$ mmol / mol )	C3829066	f	1176
960	calcium channel blocker	C0006684;C3536851;C4521885	f	1884
960	= calcium channel blocker  bmi = body	C0006684;C0242821;C0460148;C0578022;C1268086;C3536851;C4082212;C4521885	f	1884
960	calcium channel blocker ( % )	C0006684;C3536851;C4521885	f	1884
960	ca - channel blockers  n ( % )	C0870261;C3887642	f	1884
644	cardiac glycosides	C0007158	f	989
644	cardiac resynchronization therapy n ( % )	C1167956	f	1885
644	cardiac resynchronization therapy	C1167956	f	1885
644	prior cardiac resynchronization therapy  n ( % )	C0332152;C1167956;C2826257	f	1885
644	d includes cardiac glycosides  antiarrhythmics classes i and iii  vasodilators used in cardiac disease and other cardiac preparations .	C0003195;C0007158;C0018787;C0018799;C0042402;C0073187;C0332173;C0332257;C0439070;C0441885;C1273517;C1319793;C1521827;C1522601;C1552866;C1705160;C2698967;C2700399;C3812761;C4484261	f	-10
1492	history of atrial fibrillation	C0729790	f	1009
1492	history of atrial fibrillation and / or flutter	C0016385;C0729790;C2242390	f	1009
1492	history of atrial fibrillation  n ( % )	C0729790	f	1009
1492	history of atrial fibrillation  type 一 no . ( % )	C0332307;C0729790;C1547052	f	1009
1492	history of atrial fibrillation or flutter	C0016385;C0729790;C2242390	f	1009
1492	history of atrial fibrillation or flutter treatment at randomisation	C0016385;C0034656;C0039798;C0087111;C0729790;C1522326;C1533734;C1705169;C2242390;C3538994;C3887704	f	1009
1446	paroxysmal  n ( % )	C0205311	f	1886
1446	paroxysmal ( n  % )	C0205311	f	1886
1446	paroxysmal	C0205311	f	1886
1446	paroxysmal !	C0205311	f	1886
1530	symptoms of atrial fibrillation in the $nmbr$ months before randomization — no . ( % )	C0004238;C0034656;C0344434;C0439231;C0683368;C1457887;C1963067	f	90
1500	data are presented as mean sd . * n $nmbr$ for ldl cholesterol . † n $nmbr$ for ldl cholesterol . ‡ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . § signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . ¶ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ .	C0002778;C0002780;C0023824;C0042295;C0168634;C0202117;C0369718;C0441922;C0444504;C0449450;C0565965;C0871881;C0936012;C1442488;C1511726;C1524024;C1705242;C1711260;C2347634;C2348143;C2348152;C2699239;C3245479;C3714741	f	-10
1500	* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert triglycerides to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpg to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpi to picomoles per liter  multiply by $nmbr$ . $nmbr$ .	C0003842;C0005910;C0008377;C0010055;C0015663;C0022709;C0023821;C0023824;C0040363;C0041004;C0041061;C0041260;C0042295;C0043100;C0185098;C0202042;C0205120;C0205369;C0226004;C0332849;C0439165;C0439192;C0439194;C0439209;C0441074;C0444686;C0455280;C0475211;C0489786;C0681850;C0857690;C1305855;C1305866;C1441506;C1442162;C1511726;C1549488;C1550501;C1550718;C1552595;C1561533;C1705104;C1706203;C1719797;C1883351;C1947971;C2349001;C2697811;C2911648;C2936173;C3244317;C3245479;C3714741	f	-10
1500	* the $nmbr$ substrata with baseline ( bl ) ldl cholesterol $nmbr$ to $nmbr$ mg / dl and $nmbr$ to $nmbr$ mg / dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg / dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg / dl . † bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg / dl for men and $nmbr$ or $nmbr$ mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe $nmbr$ mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides	C0005918;C0006413;C0023822;C0023824;C0024671;C0025266;C0026410;C0036919;C0040363;C0041260;C0043210;C0168634;C0202117;C0205195;C0332257;C0337445;C0368910;C0392885;C0439269;C0441833;C0687744;C0687760;C0700321;C1142985;C1257890;C1305855;C1442160;C1442488;C1519504;C1552663;C1704759;C1705428;C1705429;C1707156;C1881534;C1883351;C1960952;C2346927;C2360800;C2827109;C3274014;C3541345;C3642216;C3715113;C3889135;C4321396;C4521761	f	-10
1469	iop  mm hg	C0439475;C0578862	f	1887
1469	< $nmbr$ mm hg	C0439475	f	1888
1469	> $nmbr$ mmhg	C0439475	f	1888
1469	> = $nmbr$ mmhg	C0439475	f	1888
1469	> $nmbr$ mm hg	C0439475	f	1888
1469	< $nmbr$ mm hg — no . ( % )	C0439475	f	1888
1469	< $nmbr$ / < $nmbr$ mm hg	C0439475	f	1888
1469	$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mm hg	C0439475	f	1888
1469	$nmbr$ to < $nmbr$ mm hg — no . { % )	C0439475	f	1888
635	age in years  median ( iqr )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	f	1890
635	age < median	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	f	1890
635	age  median ( iqr )	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	f	1890
635	age ( median  iqr )  y	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	f	1890
635	age  median ( iqr )  y	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	f	1890
635	age > - median	C0001779;C0549183;C0876920;C2347635;C2348144;C2939193	f	1890
635	body mass index ( median	C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193	f	1891
635	body mass index  median ( iqr ) b	C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193	f	1891
635	body mass index  median ( iqr )	C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193	f	1891
635	duration of pci ( min )  median n ( iqr )	C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621	f	1895
635	fasting plasma glucose < median	C0015663;C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193	f	1896
635	fastng plasma glucose < median	C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193	f	1896
635	hba $nmbr$ c  %  median ( q $nmbr$  q $nmbr$ )	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758	f	1897
635	hba $nmbr$ c  median ( q $nmbr$  q $nmbr$ )  %	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758	f	1897
1749	ta ( n = $nmbr$ )	C0039297;C1506978;C1705538;C3272501;C4553364	f	-10
926	methotrexate alone ^	C0025677;C0205171;C0439044;C0679994	f	716
1115	clinical fracture	C0016658;C0205210	f	2026
635	hba $nmbr$ c tx difference vs pbo  median change from baseline ( se ) $nmbr$	C0019016;C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C1825777;C2347635;C2348144;C2939193;C3538758;C4319952	f	1897
635	hba $nmbr$ c  median ( q $nmbr$ – q $nmbr$ )	C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758	f	1897
635	median age ( iqr  years )	C0549183;C0876920;C1510829;C2347635;C2348144;C2939193	f	1901
635	median age  y ( range )	C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016	f	1901
635	median cardiac troponin t ( iqr ) 一 pg / ml	C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889	f	1903
1118	pollen exposure	C0032385;C0274281;C0332157;C0795585;C1320238	f	1905
1118	pollent s $nmbr$	\N	f	1906
16	baseline systolic blood pressure	C4274438	f	1469
16	pulsed blood pressure	C0232108	f	1469
16	systolic blood pressure ( change from baseline )	C0392747;C0443172;C1705241;C4274438;C4319952	f	1469
37	age at baseline in years  mean ( sd )	C0001779;C0168634;C0439234;C0444504;C1442488;C2347634;C2348143;C2699239	f	1907
37	age at enrollment ( years )  mean ( sd )	C0444504;C1510829;C1516879;C1696073;C2347634;C2348143;C2699239;C3888021	f	1907
37	age at first seizure  years  mean ( sd )	C0036572;C0205435;C0444504;C1279901;C1510829;C1959629;C2347634;C2348143;C2699239;C4553401	f	1907
37	age  mean $nmbr$ sd years	C0444504;C1510829;C2347634;C2348143;C2699239	f	1907
37	age  mean ( sd )	C0001779;C0444504;C2347634;C2348143;C2699239	f	1907
37	age  mean ± sd	C0001779;C0444504;C2347634;C2348143;C2699239	f	1907
37	das $nmbr$  range $nmbr$ - $nmbr$  mean ( sd )	C0051767;C0057671;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016	f	1914
37	das $nmbr$  mean ± sd	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239	f	1914
37	das $nmbr$  mean ( sd )	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239	f	1914
37	das $nmbr$ - hscrp  mean ( sd )	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239	f	1914
37	das $nmbr$ ( esr )  mean ( sd )	C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131	f	1914
37	weight in kg ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] )	C0022718;C0036919;C0332174;C0392747;C0439209;C0439230;C0443172;C0444504;C1303013;C1705241;C2347634;C2348143;C2699239;C4054209;C4319952	f	1915
37	weight in kg  mean ( sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	1915
37	weight ( kg )  mean ( s . d . )	C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143	f	1915
37	weight  kg : mean ( sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	1915
37	weight ( kg )  mean ( sd )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	1915
37	weight  kg ( mean ± s . d . )	C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143	f	1915
366	concomitant medication | |	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medication ( % )	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medication after randomisation	C0013227;C0034656;C0521115;C3244316;C4284232	f	1916
366	concomitant medication  n ( % )	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medication  n [ % ]	C0013227;C0521115;C3244316;C4284232	f	1916
366	concomitant medication — no . { % ) | ace inhibitor	C0003015;C0013227;C0521115;C3244316;C4284232;C4541021	f	1916
614	systolic	C0039155	f	1917
635	crp  median ( range ) mg / literl	C0024671;C0026410;C0439269;C0549183;C0876920;C1514721;C1960952;C2346927;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285;C4321396;C4521761	f	286
193	c - reactive protein concentration ( mg / l )	C0006560;C0086045;C0439268;C1413716;C1446561;C3827302;C4048285	f	286
193	c - reactive protein  * mg / l	C0006560;C0439268;C1413716;C4048285	f	286
193	c - reactive protein  mg / l	C0006560;C0439268;C1413716;C4048285	f	286
193	c - reactive protein ( mg / l )	C0006560;C0439268;C1413716;C4048285	f	286
193	crp  mean mg / l ( sd )	C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	f	286
193	crp  mg / l	C0439268;C3890735;C4048285	f	286
625	c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < $nmbr$ . $nmbr$  § p = $nmbr$ . $nmbr$  * p = $nmbr$ . $nmbr$ . nteractions were not statistically significant ( p > $nmbr$ . $nmbr$ ) .	C0001675;C0005507;C0006560;C0009667;C0011847;C0011849;C0023822;C0025663;C0025664;C0030705;C0031962;C0040363;C0041260;C0042295;C0065055;C0087111;C0150375;C0162425;C0168634;C0178587;C0205250;C0243073;C0369773;C0392747;C0439070;C0449450;C0449851;C0549183;C0596019;C0679841;C1273937;C1283828;C1292734;C1299351;C1413716;C1441604;C1442488;C1510438;C1522326;C1550452;C1550453;C1552738;C1704788;C1705160;C1706450;C1883351;C2603361;C2700149;C2744579;C2983605;C3245503;C3539107;C3642216;C3887512;C3888054;C3889660;C3889737;C3898312;C4048285;C4321237;C4522209;C4552600;C4554402	f	-10
192	crp level  mean ± sd mg / dl	C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285	f	286
192	crp mean ( mg / dl ± sd )	C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285	f	286
192	crp  median  mg / dl	C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285	f	286
192	crp  mean [ sd ] mg / $nmbr$	C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C3890735;C4048285;C4321396;C4521761	f	286
192	hscrp  mg / dl	C0439269	f	286
192	high - sensitivity crp — mg / liter | |	C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761	f	286
1776	st - segment depression > $nmbr$ . $nmbr$ mv	C0520887;C1454484;C1705503;C4281602	f	1920
1776	st - segment depression < $nmbr$ . $nmbr$ mv  %	C0520887;C1454484;C1705503;C4281602	f	1920
1776	st - segment depression > $nmbr$ . $nmbr$ mv on admission  %	C0457453;C0520887;C1454484;C1705503;C4281602	f	1920
1747	oral contraceptives	C0009905	f	1921
1757	* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter ( $nmbr$ . $nmbr$ mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute . ‡ to convert weight to kilograms  divide by $nmbr$ . $nmbr$ . § to convert values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ¶ data for follow - up medication were available for $nmbr$ patients ( amiodarone  $nmbr$  placebo  $nmbr$  and icd  $nmbr$ ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < $nmbr$ . $nmbr$ for the comparison among the groups	C0002598;C0005910;C0010294;C0011198;C0013227;C0015663;C0017480;C0018827;C0020443;C0021122;C0022709;C0023824;C0030705;C0032042;C0040363;C0041260;C0042295;C0043100;C0205172;C0332849;C0369773;C0425583;C0439209;C0439241;C0439300;C0439385;C0439583;C0441833;C0441889;C0456079;C0456962;C0470187;C0475211;C0521942;C0567349;C0589120;C0687744;C0750194;C0871208;C1257890;C1305866;C1316572;C1317574;C1452534;C1511726;C1516879;C1519504;C1521828;C1522133;C1522565;C1522577;C1547707;C1552839;C1561535;C1696073;C1696465;C1704685;C1704788;C1705104;C1705428;C1705429;C1706408;C1707455;C1707491;C1719797;C1883351;C2347285;C2348885;C2603361;C2911648;C2919575;C2946261;C2985769;C3244316;C3245479;C3274571;C3536793;C3539106;C3541240;C3714741;C3888021;C3888198;C4284014;C4284232	f	-10
1734	the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .	C0005893;C0005910;C0019409;C0022885;C0025663;C0039593;C0039798;C0043100;C0087111;C0205120;C0205448;C0242960;C0332849;C0392366;C0439209;C0441074;C0441833;C0449851;C0456984;C0489786;C0542339;C0578022;C0687744;C0871511;C1257890;C1264637;C1305855;C1305866;C1515976;C1518681;C1519504;C1522326;C1533734;C1552595;C1552839;C1704675;C1705104;C1705169;C1705428;C1705429;C1707455;C3538994;C3831328;C3887704;C4048755;C4318744	f	-10
205	bmi ( kg / rrr )	C0022718;C0439209;C0578022;C4054209	f	1734
205	bmi $nmbr$ - < $nmbr$ kg / ni - ( n = $nmbr$ / $nmbr$ )	C0022718;C0028075;C0439209;C0578022;C2348274;C3869926;C3869927;C4054209	f	1734
205	body - mass index ( kg / mj ) previous diagnosis	C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025	f	1734
205	bmi : < $nmbr$ kg / nr	C0022718;C0027496;C0439209;C0578022;C3844738;C4054209	f	1734
205	bmi  mean ( sd )  kg / rn $nmbr$	C0022718;C0439209;C0444504;C0578022;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819	f	1734
205	body mass index ( bmi  kg / m $nmbr$ )  n ( % ) < $nmbr$ kg / m $nmbr$	C0005893;C0022718;C0439209;C0578022;C1305855;C1709500;C4054209	f	1734
1250	data are number of patients ( % ) or hazard ratio ( $nmbr$ % cl )  p values are forthe test of heterogeneity . cad = coronary artery disease . bmi = body - mass index  which is weight in kg divided by the square of height in metres . ldl = low - density lipoprotein . hdl = high - density lipoprotein . there is a deficit of clinical data in some patients with the events .	C0005910;C0018787;C0019409;C0022718;C0022885;C0023820;C0023821;C0030705;C0039593;C0042295;C0043100;C0162429;C0178587;C0205120;C0205251;C0242960;C0332849;C0392366;C0439209;C0441471;C0456984;C0475209;C0489786;C0596019;C0852949;C1305855;C1305866;C1504769;C1511726;C1515976;C1516606;C1550472;C1552595;C1705104;C2239547;C2360800;C2985465;C2987487;C3245479;C3541888;C3714741;C3813548;C3831328;C3890211;C4048187;C4054209;C4284121;C4318744;C4321351;C4522223	f	-10
146	body mass indext	C0518010	f	1734
146	body mass indexf  < $nmbr$	C0518010	f	1734
146	body mass indexf	C0518010	f	1734
146	body - mass indexj	C0518010	f	1734
146	body - mass indexf	C0518010	f	1734
146	body mass indexc	C0518010	f	1734
817	alpha - blocker / other vasodilator	C0001641;C0042402;C3537240	f	961
961	^ - blocker	\N	f	1926
961	$nmbr$ blocker	\N	f	1926
961	p - blocker use	C0042153;C0369773;C0457083;C1947944;C2603361	f	1926
961	preoperative p - blocker use yes	C0042153;C0445204;C0457083;C1549445;C1705108;C1710701;C1947944	f	1926
961	preoperative use p - blocker	C0042153;C0445204;C0457083;C1947944	f	1926
961	prior a - blocker use	C0042153;C0332152;C0457083;C1947944;C2826257	f	1926
820	hbau  %	\N	f	1928
820	patients with possible new dm at randomization ( hba $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ % )	C0011816;C0019016;C0030705;C0034656;C0205314;C0332149;C1705910;C1825777;C2362652;C3250443;C3538758	f	1928
820	pen - label empagliflozin $nmbr$ mg ( baseline hba $nmbr$ c > $nmbr$ % )	C0019016;C0024671;C0026410;C0168634;C0181496;C0439269;C1424886;C1442488;C1825777;C1960952;C2346927;C2827499;C3273588;C3490348;C3538758;C4319659;C4321396;C4521761;C4522130;C4551445	f	1928
822	ldlc : hdlc	C1416822;C1704429	f	821
822	non - hdlc	C1518422;C1704429	f	821
822	non - hdlc concentration	C0086045;C1446561;C1518422;C1704429;C3827302	f	821
823	low hdl cholesterol	C0151691	f	821
823	non ‐ hdl cholesterol	C0729627;C1535899	f	821
823	non - hdl cholesterol	C0729627;C1535899	f	821
847	losartan + lisinopril	C0065374;C0126174	f	1930
847	losartan plus lisinopril ( n = $nmbr$ )	C0065374;C0126174;C0332287	f	1930
133	$nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$	\N	f	-10
133	lisinopril vs amlodipineb	C0065374	f	1931
133	lisinopril vs chlorthalidone obese	C0008294;C0028754;C0065374	f	70
852	low - density lipoprotein	C0023823	f	1932
852	low - density lipoprotein ^	C0023823	f	1932
852	low - density lipoprotein choles -	C0023823	f	1932
852	low - density lipoprotein  mg / dl	C0023823;C0439269	f	1932
192	low density lipoprotein cholesterol - mg / dltt	C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1963
192	low - density lipoprotein cholesterol  mg / dl	C0023824;C0439269	f	1963
192	eze $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1165
192	eze $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1165
192	ezetimibe $nmbr$ mg ( n — $nmbr$ )	C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761	f	1165
192	mtx > $nmbr$ and si $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	f	716
192	mtx dose > $nmbr$ mg / week  %	C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761	f	716
219	bypass surgery	C1536078	f	2040
1144	* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$  to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » $nmbr$ . $nmbr$ ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .	C0001779;C0008107;C0008377;C0009667;C0019409;C0022885;C0023820;C0023821;C0030705;C0032042;C0034656;C0039593;C0039798;C0040363;C0041004;C0041260;C0042295;C0084844;C0085542;C0087111;C0168634;C0178587;C0205251;C0205447;C0205448;C0205449;C0205450;C0231290;C0237881;C0242960;C0332282;C0332287;C0392366;C0428460;C0428475;C0439175;C0439190;C0439230;C0439810;C0439828;C0441833;C0444706;C0456984;C0475211;C0549178;C0687744;C0750502;C0884358;C1079230;C1257890;C1280500;C1292734;C1442488;C1510992;C1511726;C1515021;C1515976;C1516048;C1518681;C1519504;C1522326;C1527178;C1532563;C1533734;C1538994;C1546944;C1550472;C1551393;C1696465;C1704675;C1704788;C1705169;C1705428;C1705429;C1705492;C1706408;C1719797;C1874451;C1882932;C1883351;C1883712;C2348382;C2825518;C2911648;C3245479;C3259781;C3272743;C3538994;C3539106;C3541902;C3714741;C3715113;C3831328;C3887511;C3887704;C3890211;C4048187;C4318744;C4321351;C4522223	f	-10
292	scarring on renal biopsy	C0005558;C0008767;C0194073;C0220797;C1700247;C2004491	f	1943
894	st elevation	C0520886	f	1944
894	st - segment elevation	C0520886	f	1944
894	st - elevation mi	C0520886;C3810814	f	1944
894	st segment elevation	C0520886	f	1944
906	anterior infarct location	C0340293;C0450429;C1515974;C2349195;C4284930;C4284931	f	1948
906	infarct location ( interactsn $ : p = $nmbr$ . $nmbr$ )	C0021308;C0450429;C1515974;C4284930;C4284931	f	1948
906	infarct location — no . / total no . ( % )	C0021308;C0439175;C0439810;C0450429;C1515974;C4284930;C4284931	f	1948
906	infarct related artery location	C0003842;C0021308;C0226004;C0439849;C0445223;C0450429;C1515974;C4284930;C4284931	f	1948
906	location of infarction	C0021308;C0450429;C1515974;C4284930;C4284931	f	1948
1611	acute rheumatic disorders	C0001314	f	1950
97	moderate or severe renal disease  n ( % )	C0022646;C0022658;C0205081;C0205082;C1836348;C1881878;C4049705;C4049706;C4050465;C4050466;C4085643;C4321335	f	937
173	framingham risk score	C0035647;C0449820;C3166866;C4050231;C4552904	f	1952
173	framingham risk score ( % )	C0035647;C0449820;C3166866;C4050231;C4552904	f	1952
173	framingham risk score *	C0035647;C0449820;C3166866;C4050231;C4552904	f	1952
173	framingham risk score  arbitrary units	C0035647;C0439183;C0449820;C3166866;C4050231;C4552904	f	1952
173	timi risk scoret	C0035647;C4552904	f	1954
173	timi risk score — no . / total no . ( % ) : c	C0035647;C0439175;C0439810;C0449820;C4050231;C4552904	f	1954
192	amlodipine / valsartan $nmbr$ / $nmbr$ mg / v = $nmbr$	C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761	f	78
192	amlodipine / valsartan $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761	f	78
192	amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ i )	C0021966;C0024671;C0026410;C0221138;C0369718;C0439269;C0441922;C1960952;C1962523;C2346927;C4321396;C4521761	f	78
192	amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761	f	78
192	clopidogrel  $nmbr$ mg loading dose !	C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761	f	217
192	clopidogrel  $nmbr$ mg loading doset	C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C4321396;C4521761	f	217
192	dabigatran $nmbr$ mg bid events / n ( % / y )	C0024671;C0026410;C0439269;C0441471;C1960952;C2346927;C2348066;C3541888;C4321396;C4521761	f	775
192	dabigatran $nmbr$ mg bid ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761	f	775
678	amended dabigatran protocol	C0442711;C1507394;C1522729;C1691222;C2348066;C2348563;C2599718;C3715209;C4282383	f	775
1096	dabigatran $nmbr$ vs . warfarin p ( inter )	C0043031;C0205103;C1548610;C2348066	f	775
1099	dabigatran $nmbr$ mg $nmbr$ mg % per yr	C0439234;C1319635;C2348066	f	775
9	fev $nmbr$ ( % of predicted value )	C0681842;C1522609;C1882327;C3714541	f	1197
9	fev $nmbr$ — % of predicted value	C0681842;C1522609;C1882327;C3714541	f	1197
9	post - bronchodilator fev $nmbr$  reversibility percentage of baseline value	C0168634;C0439165;C0449261;C1442488;C1522609;C1549488;C1561533;C2599594;C3714541	f	1197
681	spirometry after bronchodilation §	C0037981;C1371299;C3537072	f	1197
192	low - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl	C0023824;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	f	1963
192	low - density lipoprotein cholesterol — mg / dlf	C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761	f	1963
192	ezetimibe $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761	f	1165
192	ezetimibe / simvastatin $nmbr$ / $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1532737;C1960952;C2346927;C4321396;C4521761	f	1165
192	ezetimibe $nmbr$ mg ( n = $nmbr$ * )	C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761	f	1165
192	mtx > $nmbr$ and £ $nmbr$ mg / week	C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761	f	716
192	mtx average weekly dose  mg / week  mean ( sd )	C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1510992;C1960952;C2346927;C2347634;C2348143;C2699239;C2825518;C4321396;C4521761	f	716
1332	previously taken methotrexate  %	C0025677;C1883727	f	716
118	methotrexate use at randomization	C0025677;C0034656;C0042153;C0457083;C1947944	f	716
118	methotrexate use at randomization    n   ( % )	C0025677;C0034656;C0042153;C0457083;C1947944	f	716
1408	nonbiologic disease - modifying drug other than methotrexate : :	C0025677;C0392747;C4036059	f	231
1501	abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^ defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . $nmbr$ for major cardiovascular event . no other interactions are significant . ^ calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl_ ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . ^ diabetes defined by self - report . # calculated using the framingham risk score among $nmbr$ $nmbr$ women who provided a blood sample at baseline .	C0000723;C0005767;C0005768;C0005910;C0007226;C0008377;C0009667;C0010068;C0011065;C0011847;C0011849;C0011900;C0020473;C0020538;C0021308;C0027061;C0031831;C0033095;C0035647;C0036183;C0038454;C0039155;C0043100;C0043210;C0168634;C0178913;C0201950;C0205082;C0205120;C0205164;C0205199;C0205250;C0205435;C0229664;C0237881;C0242492;C0332849;C0428465;C0428883;C0439209;C0439269;C0439475;C0439526;C0441074;C0441471;C0444686;C0444930;C0449820;C0460139;C0475209;C0489786;C0543421;C0596019;C0681906;C0750502;C0804815;C1279901;C1299351;C1305849;C1305866;C1306345;C1306577;C1320716;C1441506;C1442488;C1522564;C1522609;C1524063;C1532563;C1546944;C1547335;C1552595;C1704675;C1704788;C1705104;C1705224;C1706378;C1963138;C1999230;C2700149;C2700400;C2700446;C2746065;C2924612;C3166866;C3539106;C3541334;C3541888;C3887460;C3887512;C3887665;C3889660;C4050231;C4082313;C4284008;C4318856;C4321237;C4521762;C4522209;C4552775;C4552904;C4554100;C4554402;C4555212	f	-10
670	total c ( mmol / l  mean )	C0439175;C0439810;C0444504;C1532563;C2347634;C2348143	f	1504
670	serum total cholesterol  mmol / l ( sd )	C0587184;C1287371;C1532563;C2699239	f	1504
1012	hdl cholesterol ( week $nmbr$ ) a	C0023822;C0332174;C0392885;C0439230	f	821
1012	ldl particle numbers ( week $nmbr$ )	C0237753;C0332174;C0439230;C0449788;C2612459	f	1068
195	serum cholesterol ( mg / l ) *	C0439268;C0587184	f	1501
195	serum cholesterol  mg / dl	C0439269;C0587184	f	1501
209	* p < $nmbr$ . $nmbr$ for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein	C0003591;C0008377;C0009247;C0023189;C0023821;C0023822;C0036919;C0039411;C0040642;C0041004;C0041405;C0041698;C0062152;C0065055;C0074554;C0178587;C0178602;C0201950;C0205250;C0337445;C0369773;C0439175;C0439751;C0439810;C0444504;C0444667;C0449450;C0543421;C0549183;C0599755;C0729627;C0876920;C1079230;C1142985;C1299351;C1511726;C1515021;C1518422;C1707391;C1708438;C1709595;C1710181;C1824670;C2347634;C2347635;C2348143;C2348144;C2349200;C2603361;C2700149;C2939193;C3245479;C3272447;C3714741;C3715113;C3887512;C3889660;C4321237;C4522122;C4522209;C4522255	f	-10
670	fasting plasma glucose ( mmol / l ) $nmbr$	C0015663;C0202042;C0455280;C1532563	f	1960
670	fpg  mean ( sd )  mg / dl [ mmol / l ]	C0439269;C0444504;C1532563;C2347634;C2348143;C2699239	f	1960
670	fbg ( mmol / l )	C1532563	f	1960
670	serum potassium ( mmol / l )	C0302353;C0543465;C1532563	f	1959
1501	hdl cholesterol ^ :	C0023822;C0392885	f	821
1501	hdl cholesterol §	C0023822;C0392885	f	821
1501	hdl cholesterol *	C0023822;C0392885	f	821
1501	hdl cholesterol ( mmol / l )  mean ( sd )	C0023822;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239	f	821
1501	high - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl	C0023822;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	f	821
1390	acholesterol ( % )	\N	f	1957
670	ldl - cholesterol ( mmol / l )	C0023824;C0202117;C1532563	f	1068
670	ldl cholesterol  mmol / l	C0023824;C0202117;C1532563	f	1068
670	ldl - cholesterol  mmol / l	C0023824;C0202117;C1532563	f	1068
670	ldl cholesterol  mmol / l *	C0023824;C0202117;C1532563	f	1068
670	ldl cholesterol ( mmol / l ) :	C0023824;C0202117;C1532563	f	1068
670	ldl cholesterol ( mmol / l )	C0023824;C0202117;C1532563	f	1068
670	low - density lipoprotein cholesterol  mean ( sd )  mmol / l	C0023824;C0444504;C1532563;C2347634;C2348143;C2699239	f	1068
987	glucose — mmol / liter	C0017725;C0439190;C0475211	f	1958
987	plasma glucose $nmbr$ hr after glucose load — mmol / liter	C0202042;C0439190;C0455280;C0475211;C1550025;C1704782;C1708715	f	1958
987	plasma glucose — mmol per liter	C0202042;C0439190;C0455280;C0475211	f	1958
1066	ldl  - c	\N	f	1068
1066	ldl	\N	f	1068
1066	ldl choleslerol	\N	f	1068
1066	ldl cholesterohhdl cholesterol ratio	C0023824;C0202117;C0456603;C1547037	f	1068
1066	ldl cholesterolt	\N	f	1068
1678	total cholesterol > $nmbr$ ' $nmbr$ mmol / lt	C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399	f	1504
1678	total cholesterol  mmol / lt	C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399	f	1504
1678	total cholesterol > $nmbr$ - $nmbr$ mmol / lt	C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399	f	1504
1678	total cholesterol < $nmbr$ - $nmbr$ mmol / lt	C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399	f	1504
1678	total cholesterol < $nmbr$ $nmbr$ mmol / lt	C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399	f	1504
192	hdl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients	C0023822;C0030705;C0392885;C0439269;C0444504;C0470187;C2347634;C2348143;C2699239	f	1962
192	hdl cholesterol — mg / dl triglycerides — mg / dl	C0023822;C0024671;C0026410;C0041004;C0392885;C0439269;C1960952;C2346927;C3539687;C4321396;C4521761	f	1962
192	h dl cholesterol < $nmbr$ mg / dl	C0008377;C0024671;C0026410;C0033727;C0369286;C0439269;C0441932;C0564385;C1960952;C2346927;C3539687;C4321396;C4521761;C4528284	f	1962
192	low density lipoprotein cholesterol  mg / dl * *	C0023824;C0439269	f	1963
987	triglycerides — mmol / liter	C0041004;C0439190;C0475211	f	368
987	serum triglycerides — mmol / liter	C0439190;C0475211;C0542495	f	368
1408	concomitant csdmards other than methotrexate  n ( % )	C0025677;C0521115	f	231
625	median ( iqr ) mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use : weight	C0005910;C0025677;C0042153;C0043100;C0168634;C0332174;C0439230;C0441833;C0444504;C0457083;C0549183;C0687744;C0876920;C1257890;C1305866;C1417487;C1442488;C1519504;C1705104;C1705428;C1705429;C1947944;C2347634;C2347635;C2348143;C2348144;C2939193	f	1408
1584	potassium - sparing at last follow - up	C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637	f	1966
192	toial cholcsierol ( mg / dl )	C0439269	f	1968
192	total cholesterol level  mg / dl	C0439269;C0878805;C1445957	f	1968
192	total chol  mg / dl	C0201950;C0439175;C0439269;C0439810	f	1968
192	total c ( mg / dl ) *	C0439175;C0439269;C0439810	f	1968
824	all cause mortality or hosp . for worsening hf hs - crp < $nmbr$ . $nmbr$ mg / l	C0015127;C0018488;C0026565;C0026566;C0332271;C0439268;C0444868;C1313497;C1457868;C1524003;C1538440;C1546960;C3273279;C3539085;C3890735;C4048285	f	12
824	congestive hf	C0018488;C0742742;C1313497;C1538440;C3273279	f	12
259	heart failure hospitalizations	C3898876	f	12
259	hospitalization for heart failure n ( % )	C3898876	f	12
259	hospitalization for heart failure within $nmbr$ mo	C0026544;C0332177;C3898876	f	12
1379	pravastatin sodium	C0700474	f	1841
1028	= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are	C0003591;C0030705;C0032042;C0392747;C0439165;C0443172;C0524620;C1142985;C1549488;C1561533;C1696465;C1706408	f	-10
1033	by gfr stratum tor all participants  ml / min per $nmbr$ . $nmbr$ m ^ !	C0017654;C0076836;C0369637;C0439445;C0441923;C0679646;C1199517;C1419603;C1424601;C3539732	f	592
1033	by gfr stratum for all participants  ml / min per $nmbr$ . $nmbr$ m ’ !	C0017654;C0369637;C0439445;C0441923;C0679646;C1424601	f	592
1037	female patients  n ( % )	C0150905	f	1970
1036	supplementary table $nmbr$ . change from baseline in urine albumin - to - creatinine ratio by hba $nmbr$ c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .	C0019016;C0030705;C0039224;C0168634;C0392747;C0443172;C0455271;C0730345;C1318330;C1442488;C1705241;C1706074;C1825777;C3538758;C4319952	f	-10
1050	dyslipidaemia and hypertensiont	C0242339	f	1364
1052	alcohol users  n ( % )	C0556297	f	1053
1054	colon only  ' n ( % )	C0009368;C0205171;C1720467;C3888384	f	1971
1054	colon only	C0009368;C0205171;C1720467;C3888384	f	1971
1054	colon or rectum	C0009368;C0034896;C3888384	f	1971
1054	colon	C0009368;C3888384	f	1971
1054	colon only  n ( % )	C0009368;C0205171;C1720467;C3888384	f	1971
1055	bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < $nmbr$ . $nmbr$ for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than $nmbr$ mg / dl . dblood pressure control defined as < $nmbr$ / $nmbr$ or < $nmbr$ / $nmbr$ in patients with diabetes or a history of renal insufficiency .	C0003211;C0004147;C0007787;C0011847;C0011849;C0012634;C0019664;C0019665;C0023779;C0030685;C0030705;C0033095;C0035078;C0037623;C0042523;C0085096;C0149721;C0150936;C0201976;C0205091;C0205250;C0243148;C0262512;C0262926;C0282402;C0340279;C0391871;C0439092;C0439180;C0439269;C0441994;C0443246;C0443318;C0460139;C0521116;C0600061;C0680255;C0753208;C0935929;C0947487;C1283071;C1305855;C1306345;C1415692;C1515187;C1550141;C1552822;C1565489;C1704788;C1705255;C1708288;C1709991;C1882979;C1963578;C2003888;C2004062;C2587213;C3163633;C3274648;C3539106;C3813610;C3890900;C3891546;C4284008;C4318478;C4521226;C4553389	f	-10
1524	history of pci / ptca	C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C2936173;C4049621	f	1661
1063	any ae leading to discontinuation  n ( % )	C0332152;C0457454;C1444662;C1522538;C3887670;C4552847	f	1974
1063	aes leading to discontinuation of study drugb	C0332152;C0457454;C0557651;C1412268;C1444662;C1522538;C2603343;C2699274;C4552847	f	1974
1113	vertebral fracture and / or t score s - $nmbr$ . $nmbr$	C0080179;C0449820;C0718146;C4050231	f	2023
1115	fracture history  n ( % )	C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	2026
1115	fracture history	C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	2026
1119	contrast volume ( ml )	C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665	f	2030
1119	contrast volume	C0009924;C0449468;C1690016;C1705102;C1979874;C2700258	f	2030
1119	contrast volume  ml	C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665	f	2030
1125	nitrate ( oral or topical )	C0028125;C0332237;C0442027;C0699857;C3848573;C4521986	f	2031
1129	history of lvh on electrocardiogram	C0013798;C0019664;C0019665;C0149721;C0262512;C0262926;C1547122;C1623258;C1705255;C2004062	f	1496
1129	lvh by electrocardiogram  n ( % )	C0013798;C0149721;C1547122;C1623258	f	1496
1129	lvh ( from electrocardiogram )	C0013798;C0149721;C1547122;C1623258	f	1496
1389	dactylitis count ( $nmbr$ - $nmbr$ )  mean ( sd )	C0239161;C0444504;C0750480;C1705566;C2347634;C2348143;C2699239	f	492
1417	current dactylitis  n	C0239161;C0521116;C1705970	f	492
219	lower - limb angioplasty or bypass surgery	C0745788;C1536078	f	2040
219	previous bypass surgery  n ( % )	C0205156;C1536078;C1552607	f	2040
832	cabg history	C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	389
832	history of cabg	C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	389
832	participants with a history of cabg	C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062	f	389
832	history of cabg  n ( % )	C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062	f	389
832	participants without a history of cabg	C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062	f	389
258	cabg during index hospitalization	C0010055;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546	f	389
1069	ap = $nmbr$ . $nmbr$  bp $nmbr$ . $nmbr$  cp = $nmbr$ . $nmbr$ . * the study - speci ﬁ c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg ( or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm ) . the ldl - c target was $nmbr$ mg / dl or $nmbr$ mg / dl  depending on risk factor status at baseline in accordance with ncep atp iii guidelines . odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site . an interaction between treatment effect and dm status was observed for bp goal attainment ( p = $nmbr$ . $nmbr$ ) and dual bp / ldl - c goal attainment ( p = $nmbr$ . $nmbr$ ) among patients with or without dm calculated based on a mixed - effects linear model ( not adjusted for differences in baseline values ) . abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure	C0000723;C0001675;C0002680;C0005767;C0005768;C0005823;C0006938;C0011816;C0011849;C0023732;C0025424;C0025663;C0028873;C0030705;C0033095;C0035648;C0037623;C0039155;C0039798;C0042295;C0065055;C0085805;C0086858;C0087111;C0162791;C0168634;C0178587;C0205145;C0205173;C0205198;C0205246;C0205251;C0205430;C0220845;C0229664;C0282423;C0332257;C0332516;C0428257;C0428883;C0439070;C0439269;C0439475;C0441833;C0444686;C0445247;C0449438;C0449851;C0456081;C0460139;C0536221;C0552449;C0557651;C0680230;C0681850;C0725813;C0750572;C0871511;C1280500;C1306345;C1415692;C1441506;C1441672;C1442488;C1515974;C1518422;C1518681;C1521840;C1522326;C1527178;C1533734;C1550472;C1550501;C1552866;C1554184;C1704640;C1704675;C1705160;C1705169;C1705241;C1705242;C1705938;C1706082;C1706203;C1706365;C1706450;C1706515;C1708288;C1709380;C1999270;C2347108;C2347109;C2348272;C2349001;C2603343;C2697811;C2700399;C2744579;C2825164;C2825575;C2946465;C2986546;C3160715;C3245503;C3250443;C3538994;C3813197;C3887704;C3887950;C3890211;C4048187;C4050020;C4050026;C4068104;C4281799;C4284008;C4318478;C4319583;C4321351;C4330985;C4522223;C4552600;C4553629;C4554674	f	-10
1078	dd	C3538867;C3814791	f	-10
1078	dd ( n = $nmbr$ )	C3538867;C3814791	f	-10
1077	budesonide / formoterol fdc	C0340427;C1276807;C1413520;C3539652	f	1978
1080	below - knee popliteal crural	C0022742;C0022745;C0023216;C0442037;C0542339;C1140621;C1552829;C1963703	f	1979
1093	potential injection site reactions	C0151735;C3245505	f	1983
1094	intolerance '	C0231199;C1744706;C2355652	f	1984
1094	intolerance ®	C0231199;C1744706;C2355652	f	1984
1096	p ( inter )	C0205103;C0369773;C1548610;C2603361	f	1986
1096	p ( inter - action )	C0205103;C0369773;C0441472;C1548610;C2603361;C3266814	f	1986
1096	inter . p - value	C0205103;C1548610;C1709380	f	1986
1099	admission for hf in previous year	C0018488;C0184666;C0205156;C0439234;C0439508;C0809949;C1313497;C1538440;C1552607;C3273279	f	12
1099	admission for hf in previous year  n ( % )	C0018488;C0184666;C0205156;C0439234;C0439508;C0809949;C1313497;C1538440;C1552607;C3273279	f	12
1099	copd exacerbation history in the previous year  n ( % )	C0019664;C0019665;C0205156;C0262512;C0262926;C0439234;C0439508;C0740304;C1552607;C1705255;C2004062	f	1987
1099	duration of diabetes in years  median ( iqr )	C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193	f	1988
1099	duration diabetes ( years )	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	duration dm in dm ( years )	C0011816;C0439234;C0449238;C2926735;C3250443	f	1988
1099	diabetes duration ( years ) *	C0011847;C0011849;C0439234;C0449238;C2926735	f	1988
1099	disease duration ( years )  mean ± s . d .	C0439234;C0444504;C0872146;C2347634;C2348143	f	1989
1099	education < $nmbr$ years	C0013621;C0013622;C0013658;C0039401;C0439234	f	1990
1099	exacerbations in previous year	C0205156;C0439234;C0439508;C1552607;C4086268	f	1991
1099	exacerbations in previous year requiring hospitalization  n ( % )	C0019993;C0205156;C0439234;C0439508;C1552607;C4086268	f	1991
1099	exacerbations in previous year requiring hospitalization and / or ed visit  n ( % )	C0019993;C0205156;C0439234;C0439508;C0545082;C1512346;C1552607;C2826704;C3538926;C4086268	f	1991
1099	exacerbations in the year before study	C0439234;C0439508;C0557651;C2603343;C4086268	f	1991
1099	exacerbations in the prev . year : $nmbr$	C0439234;C0439508;C1552852;C4086268	f	1991
192	baseline hdl - c level ( n = $nmbr$ �� $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113	f	2001
192	baseline hdl - c level ( n = $nmbr$ » $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl	C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113	f	2001
614	systolic  total	C0039155;C0439175;C0439810	f	1917
1100	white race	C0007457;C0043157	f	2003
1100	white race ( n = $nmbr$ $nmbr$ )	C0007457;C0043157	f	2003
1100	white race — number ( % )	C0007457;C0043157;C0237753;C0449788	f	2003
1103	adjusted exacerbation rate { per patient peryear )	C0030705;C0456081;C0871208;C1521828;C4086268	f	2005
1103	annual exacerbation rate	C0332181;C0871208;C1521828;C4086268	f	2005
1103	annual asthma exacerbation rates	C0332181;C0349790;C0871208;C1521828	f	2005
1103	event rate ( per $nmbr$ person - years )	C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010	f	2007
1103	event rate ( per $nmbr$ person years )	C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010	f	2007
1103	rate †	C0871208;C1521828	f	2009
1103	rate ‡	C0871208;C1521828	f	2009
1103	rate per $nmbr$ - patient - years ( control vs alirocumab ) *	C0030705;C0243148;C0439234;C0871208;C1521828;C1550141;C1882979;C2587213;C3274648;C3491162;C4553389	f	2009
1103	rate per $nmbr$ - patient - years ( control vs alirocumab ) i	C0021966;C0030705;C0221138;C0243148;C0439234;C0871208;C1521828;C1550141;C1882979;C2587213;C3274648;C3491162;C4553389	f	2009
1107	female race white	C0007457;C0034510;C0043157;C0043210;C0086287;C0220938;C1705497;C1705498;C1706779;C3853635	f	2014
1107	female sex — no . ( % ) race — no . ( % ) f	C0016327;C0034510;C0086287;C1706779;C3853635	f	2014
1107	female sex  n ( % ) race  n ( % )	C0034510;C0086287;C1706779;C3853635	f	2014
1109	adjudicated mace $nmbr$	C0349381;C0949745;C1445339	f	414
1109	b mace	C0349381;C0949745;C1445339	f	414
1109	expanded mace	C0205229;C0349381;C0949745;C1445339	f	414
1109	hard mace	C0018599;C0349381;C0949745;C1445339	f	414
1109	first mace	C0205435;C0349381;C0949745;C1279901;C1445339	f	414
1109	mace	C0349381;C0949745;C1445339	f	414
1109	$nmbr$ - point mace ( $nmbr$ - point mace plus hospitalization for unstable angina )	C0002965;C0019993;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763	f	414
1113	vertebral fracture	C0080179	f	2023
258	cabg performed during index hospitalization	C0010055;C0019993;C0600653;C0884358;C0918012;C1552854;C1637833;C2986546	f	389
1145	wssng	\N	f	-10
1148	morning peak expiratory flow — liters / min	C0332170;C0475211;C0702093;C1518922;C1524029;C3813700	f	2042
1151	hbalc tx difference vs pbo  median change from baseline ( se ) $nmbr$	C0031962;C0036919;C0041403;C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C1705242;C2347635;C2348144;C2939193;C4319952	f	1176
1155	ertuglrflozin $nmbr$ mg vs placebo / glimepiride	C0024671;C0026410;C0032042;C0061323;C0439269;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761	f	2045
1163	acpa positive ( > $nmbr$ iu / ml )  n ( % )	C0439178;C0439458;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269	f	2051
1163	acpa positive  no . ( % )	C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269	f	2051
748	timi risk score	C0035647;C0449820;C4050231;C4552904	f	2052
748	timi risk score  %	C0035647;C0449820;C4050231;C4552904	f	2052
748	timi risk score !	C0035647;C0449820;C4050231;C4552904	f	2052
748	timi risk score *	C0035647;C0449820;C4050231;C4552904	f	2052
748	timi risk score — %	C0035647;C0449820;C4050231;C4552904	f	2052
748	timi risk score ( interaction : p = $nmbr$ . $nmbr$ )	C0035647;C0449820;C1704675;C4050231;C4552904	f	2052
748	jsn score ( $nmbr$ - $nmbr$ )	C0449820;C4050231	f	2055
748	crusade bleeding score  mean ( sd ) ^	C0019080;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231	f	2056
748	crusade score	C0449820;C4050231	f	2056
748	aqlq ( s ) + $nmbr$ score : §	C0449820;C4050231;C4055434	f	2057
748	aqlq ( s ) + $nmbr$ scored	C0449820;C4055434	f	2057
748	aqlq ( s ) score	C0449820;C4050231;C4055434	f	2057
94	% anti - ccp + ( > $nmbr$ units )	C0439148;C1519795;C3853603;C4318437	f	360
1179	hemoglobin a ^ c  %	C0019020;C3889898	f	1176
1179	serum haemoglobin a $nmbr$ c concentration ( % )  mean ( sd )	C0019020;C0444504;C0683149;C2347634;C2348143;C2699239;C3889898	f	1176
1180	dapagliflozin $nmbr$ mg + insulin ( n   = $nmbr$ )	C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761	f	2066
1180	dapagliflozin $nmbr$ mg + insulin ( n = $nmbr$ )	C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761	f	2066
1180	dapagliflozin	C2353951	f	2066
1183	vildagliptin $nmbr$ mg daily + glimepiride	C0024671;C0026410;C0061323;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761	f	2068
1183	vildagliptin $nmbr$ mg bid n = $nmbr$	C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761	f	2068
1188	teaes	\N	f	47
1456	adverse event	C0877248	f	47
1456	any early adverse event	C0877248;C1279919	f	47
1456	unacceptable adverse events	C0877248;C1705413;C1883420	f	47
1456	unacceptable side effects	C0001688;C0877248;C0879626;C1883420	f	47
724	insulin treatment	C0745343	f	2075
724	insulin treatment  n ( % )	C0745343	f	2075
1472	gastrointestinal major bleed	C0017181;C0205082;C0205164;C4318856;C4521762	f	2076
1472	gi major bleeding	C0017181;C0205082;C0205164;C4318856;C4521762	f	2076
1472	- major bleed	C0019080;C0205082;C0205164;C4318856;C4521762	f	2076
1472	major bleed	C0019080;C0205082;C0205164;C4318856;C4521762	f	2076
1472	major bleeding events *	C0019080;C0205082;C0205164;C0441471;C3541888;C4318856;C4521762	f	2076
1472	major bleeding	C0019080;C0205082;C0205164;C4318856;C4521762	f	2076
1472	major coronary disease event ( fatal / non - fatal mi )	C0010068;C0012634;C0205082;C0205164;C0441471;C0741923;C1302234;C1518422;C1705232;C1956346;C3810814;C4019010;C4318856;C4521762	f	2077
1194	effect size ^	C0814843	f	2080
1194	effect size !	C0814843	f	2080
1195	type ii diabetes	C0011860	f	2081
1206	sacubitril / valsartan ( n = $nmbr$ )	C4033631	f	2084
1207	serum creatinine concentration and randomization to losartan	C0010294;C0034656;C0086045;C0126174;C0201976;C0600061;C0683149;C1446561;C1561535;C3827302	f	952
1208	aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .	C0003015;C0011702;C0013227;C0017654;C0023821;C0023823;C0027964;C0028407;C0038257;C0067895;C0265987;C0717550;C0750572;C1254351;C1518422;C1561549;C1739039;C2757044;C3811844;C3812682;C4551552	f	-10
1210	intestinal area involved — no . ( % )	C0017446;C0021853;C0205146;C1314939	f	2088
1215	estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$	C0369637;C0439445;C0441923;C3811844	f	592
1215	estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area §	C0017446;C0205146;C0369637;C0439445;C0441923;C0489451;C3811844	f	592
1220	low - dose edoxaban	C0445550;C1708745;C2975435	f	2091
1220	low - dose edoxaban ( n = $nmbr$ )	C0445550;C1708745;C2975435	f	2091
1220	lower dose edoxaban regimen	C0441994;C1548802;C2003888;C2348331;C2975435	f	2091
1235	taci ( n = $nmbr$ )	C0666480;C1425349;C4284230	f	2094
1237	number omega - $nmbr$ number placeb fatty acid	C0015684;C0237753;C0449788;C1719844	f	1236
1237	fatty acid profile	C0015684;C1979963;C2003903	f	1236
1237	omega - $nmbr$ fatty acid	C0015684;C1719844	f	1236
1237	omega - $nmbr$ fatty acid ( n = $nmbr$ )	C0015684;C1719844	f	1236
1237	omega - $nmbr$ fatty acids	C0015684;C1719844	f	1236
1243	left anterior descending coronary artery	C0226032	f	2098
1243	left anterior descending artery  n ( % )	C0226032	f	2098
1243	l eft anterior descending coronary artery	C0226032;C0439394;C0451214;C1706495;C3642217	f	2098
1256	combination treatment ifx + aza	C0004482;C0020823;C0039798;C0087111;C0205195;C1522326;C1533734;C1705169;C1947911;C3538994;C3811910;C3887704	f	2099
1256	ifx + aza ( n = $nmbr$ )	C0004482;C0020823	f	2099
1266	glycoprotein llb / llla inhibitors	C0017968;C0243077	f	2104
1253	insulin glargine dose at screening visit  iu	C0049272;C0178602;C0220908;C0220909;C0366513;C0439453;C0545082;C0694756;C0869039;C0907402;C1114758;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704	f	2100
1276	[ cm { female ) / cm { male ) ]	C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429	f	2109
1276	caleitonin  ng / l  males mean ± sd	C0086582;C0439297;C0444504;C2347634;C2348143;C2699239	f	2109
1279	priorvascular disease  %	C0012634	f	2113
1279	previous disease — no . ( % ) f	C0012634;C0016327;C0205156;C1552607	f	2120
1279	previous disease and drug use	C0012634;C0205156;C0242510;C1552607	f	2120
1280	prior nsaid use	C0003211;C0042153;C0332152;C0457083;C1947944;C2826257;C3536840	f	2121
1280	prior nsaid  n ( % ) a	C0003211;C0332152;C2826257;C3536840	f	2121
1280	nsaid   at   least   once	C0003211;C3536840	f	2121
1280	traditional nsaid	C0003211;C0443324;C1548559;C3536840	f	2121
1280	traditional nsaid use	C0003211;C3536840;C3897349	f	2121
1280	abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal $nmbr$ due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^ history of or currently have elevated serum creatinine level but less than $nmbr$ mg / dl_ ( < $nmbr$ pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = $nmbr$ for calcium antagonist strategy and n = $nmbr$ for non - calcium antagonist strategy ) .	C0000723;C0003211;C0006684;C0006826;C0010055;C0023779;C0033572;C0038952;C0042295;C0043210;C0205163;C0205166;C0205171;C0205250;C0220921;C0237753;C0332196;C0332490;C0359086;C0369718;C0439092;C0439165;C0441922;C0441994;C0444099;C0449788;C0521116;C0600061;C0678226;C0679138;C0679199;C0679831;C0935929;C0998265;C1123023;C1305855;C1306459;C1444656;C1515187;C1518422;C1532338;C1549488;C1553893;C1554077;C1561533;C1706317;C1720467;C2003888;C2828389;C3146286;C3163633;C3642216;C3898174;C4520765	f	-10
1287	bmi in kg / m $nmbr$  mean ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	bmi  kg / m ^  mean ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	bmi  kg / m $nmbr$  mean ± sd	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	bmi ( kg / m $nmbr$ ) ( mean ± sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	bmi  kg / m $nmbr$  mean + sd	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	bmi ( kg / m ^ )  mean ( sd )	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2125
1287	sbp  mean ( sd )  mmhg	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sbp ( mmhg )  mean ( sd )	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sbp  mean = sd  mmhg	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sbp ( mmhg )  mean ± sd	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sbp ( mmghg )  mean ( sd )	C0085805;C0444504;C2347634;C2348143;C2699239	f	2127
1287	sbp  mean ± sd ( mmhg )	C0085805;C0439475;C0444504;C2347634;C2348143;C2699239	f	2127
1287	hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % ( > $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se )	C0008107;C0019016;C0023031;C0023749;C0027960;C0030705;C0032042;C0036919;C0168634;C0230347;C0324740;C0392747;C0439189;C0443172;C0444504;C0456081;C1442488;C1456781;C1696465;C1705241;C1706408;C1719767;C1824986;C1825777;C1960955;C2346906;C2347634;C2348143;C2348589;C2699239;C3259781;C3538758;C3665593;C4319952;C4553351	f	2139
1287	mean ± sd bmi  kg / m $nmbr$	C0444504;C0578022;C1532718;C2347634;C2348143;C2699239	f	2141
1287	post - bronchodilator reversibility fev $nmbr$ ( % ) mean ( sd )	C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541	f	2142
1287	pulmonary function tests ( post - bronchodilator )  mean ( sd )	C0024119;C0444504;C2347634;C2348143;C2598152;C2599594;C2699239	f	2142
1294	acs ( n = $nmbr$  $nmbr$ )	C0742343;C4318612	f	2147
1294	acs event	C0441471;C0742343;C4019010;C4318612	f	2147
1294	acs treatment	C0039798;C0087111;C0742343;C1522326;C1533734;C1705169;C3538994;C3887704;C4318612	f	2147
1294	acs presentation	C0449450;C0742343;C4318612	f	2147
1294	acs ( n - $nmbr$  $nmbr$ )	C0742343;C4318612	f	2147
1294	index acs — no . ( % )	C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612	f	2147
1304	univariable or ( $nmbr$ % ci )  p value *	C0008107;C1709380;C3259781	f	2154
1304	multivariable adjusted model hr ( $nmbr$ % ci )	C0008107;C0456081;C3161035;C3259781;C3274659;C3714583;C3853906	f	975
1305	ics ? laba ( free or fdc )	C0332296;C0340427;C0815320;C1413520;C1880497;C1996904;C3539652;C4551720	f	1650
1305	+ ics / + laba n z $nmbr$	C0815320;C4551720	f	1650
1305	ics / labd	C0396059;C0815320;C4551720	f	1650
699	chad $nmbr$ > $nmbr$	C0007928;C1413373	f	2128
699	chadsj < $nmbr$	\N	f	2128
699	chadsa < $nmbr$	\N	f	2128
699	chads $nmbr$	C0007928;C1413373	f	2128
699	chadsj > $nmbr$	\N	f	2128
699	chads $nmbr$ ^	C0007928;C1413373	f	2128
699	chads $nmbr$ scoreb	C0007928;C1413373	f	2128
699	chads $nmbr$ score per outcome stroke or systemic embolism	C0007928;C0013922;C0038454;C0205373;C0449820;C1274040;C1413373;C1704212;C4050231;C4554100	f	2128
1312	cardiovascular mortality ( per $nmbr$ person - years )	C0007226;C0026565;C0026566;C0027361;C0439234;C2347489;C3887460	f	2157
1312	cvd mortality	C0007222;C0026565;C0026566	f	2157
1315	reversibility s $nmbr$ % ( itt ) ( n = $nmbr$ )	C0449261	f	2160
1315	reversibility > $nmbr$ % ( n = $nmbr$ )	C0449261	f	2160
1325	omega - $nmbr$ fa intake $nmbr$  d third	C0205437;C1512806;C1719844	f	1236
1325	omega - $nmbr$ fa intake $nmbr$ st third	C0036056;C0205437;C1512806;C1719844;C3272372	f	1236
1325	omega - $nmbr$ fa ( n = $nmbr$ )	C1719844	f	1236
1325	phospholipid omega - $nmbr$ levels : < $nmbr$ % ( n = $nmbr$ )	C0031676;C0202177;C0441889;C1719844	f	1236
1338	time from onset of pain to randomization — hr	C0030193;C0034656;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132	f	2169
1338	time from onset of pain to randomization  median ( iqr )  h	C0030193;C0033727;C0034656;C0369286;C0441932;C0449244;C0518090;C0549183;C0564385;C0876920;C1962977;C2347635;C2348144;C2939193;C2984058;C4085210;C4085211;C4085212;C4528284;C4553004;C4554132	f	2169
1339	sf - $nmbr$ bodily pain  mean change from baselineb	C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952	f	1338
1351	glycemic status	C1320980	f	2174
1351	glycemic status f	C0016327;C1320980	f	2174
1353	previous vka use ( stratified randomization )	C0042153;C0205156;C0457083;C1552607;C1947944;C4687737	f	1352
1355	selena - sledai > $nmbr$  %	C0451528	f	2175
1357	psoriatic arthropathy	C0003872	f	2176
1357	time from psoriatic arthritis diagnosis [ a ]  years	C0003872;C0011900;C0040223;C0439234;C1704338;C1704656;C3541383	f	2176
1358	£ $nmbr$ % bsa psoriasis  no . ( % )	C0033860	f	2177
1358	previous exposure to systemic psoriasis therapyb ( yes )  n ( % )	C0033860;C0205156;C0205373;C0332157;C1549445;C1552607;C1705108;C1710701	f	2181
1359	baseline ics	C0168634;C0815320;C1442488;C4551720	f	2182
1359	baseline ics use  n ( % )	C0042153;C0168634;C0369718;C0441922;C0457083;C0815320;C1442488;C1947944;C4551720	f	2182
1359	baseline ics > $nmbr$ pg per day ( fluticasone propionate dpi or equivalent ) and laba	C0117996;C0168634;C0205163;C0439185;C0815320;C1442488;C2827928;C4551720	f	2182
1359	baseline ics use : no	C0042153;C0168634;C0457083;C0815320;C1442488;C1947944;C4551720	f	2182
1359	baseline ics dose  n ( % )	C0168634;C0178602;C0815320;C0869039;C1114758;C1442488;C4551720	f	2182
1370	east asian	C0078988;C1707877	f	1369
1373	calcium channelantagonist	C0006675;C0006726;C2936886;C3540037;C3714611	f	1884
1373	taking calcium supplements at baseline  n ( % )	C0006675;C0006726;C0168634;C0242295;C1442488;C1515187;C1947943;C2348609;C2936886;C3540037;C3714611	f	2187
1374	calcium antagonist strategy ( cas ) ( events / n )	C0006684;C0441471;C0679199;C3541888	f	1884
1374	calcium antagonists	C0006684	f	1884
1374	calcium antagonists  n ( % )	C0006684	f	1884
625	baseline hbalc ’	C0168634;C1442488	f	2188
625	baseline hbalc < $nmbr$ %	C0168634;C1442488	f	2188
625	baseline hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % )	C0168634;C1442488;C3829066	f	2188
625	baseline hbalc > $nmbr$ %	C0168634;C1442488	f	2188
625	baseline lipids	C0023779;C0168634;C1442488	f	2190
625	baseline lipid / lipoprotem values	C0023779;C0042295;C0168634;C1442488	f	2190
625	baseline lipids  mean ± sd ( mmol / $nmbr$ )	C0023779;C0168634;C0439190;C0444504;C1442488;C2347634;C2348143;C2699239	f	2190
1359	laba / ics use at screening  n ( % )	C0042153;C0220908;C0220909;C0457083;C0815320;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164;C4551720	f	2193
1376	average maximum common and bifurcation cimt ( mm )	C0184906;C0205214;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3146289;C3245511;C4330985;C4554674	f	1262
1376	maximum cimt a med an	C0806909;C1552615;C2826546;C4321267	f	1262
1376	mean of maximum cimt  mean ( sd )  mm	C0444504;C0806909;C1552615;C2347634;C2348143;C2699239;C2826546;C4330985;C4554674	f	1262
1547	carotid endarterectomy	C0014099	f	2194
290	carotid artery intervention *	C0007272;C0162859;C0184661;C0397581;C0741968;C0886296;C1273869	f	2197
1381	sa acs	C0036243;C0038702;C0742343;C1539696;C1825840;C3539736;C4318612;C4521691	f	-10
1383	whole cohort	C0009247;C0444667;C0599755	f	2208
1383	cohort $nmbr$ ( n = $nmbr$ ) f	C0009247;C0016327;C0599755	f	2208
1383	entire cohort	C0009247;C0439751;C0444667;C0599755	f	2208
1387	use $nmbr$ - asa compounds	C0004057;C0042153;C0205198;C0457083;C1706082;C1947944;C3853627	f	1691
1406	czp + mtx n = $nmbr$	C0025677;C0054841;C1417487;C1861828;C1872109	f	2217
1406	czp + mtx to mtx	C0025677;C0054841;C1417487;C1861828;C1872109	f	2217
1407	ez / simva $nmbr$ / $nmbr$ mg	C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761	f	1862
1409	* $nmbr$ to < $nmbr$ y	\N	f	-10
1417	current alcohol drinking  n ( % )	C0001948;C0521116;C0556297;C1705970	f	2219
1417	current smoking *	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	current smoking  n ( % )	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	current tobacco abuse  n ( % )	C0040336;C0521116;C1705970	f	2224
1417	smoking — current	C0037369;C0453996;C0521116;C1705970;C1881674	f	2224
1417	smoking status current	C0521116;C1519386;C1705970	f	2224
1421	transaminases increased	C0002594;C0205217;C0442805;C0919834	f	2227
1423	time to first cv hospitalization or death from any cause	C0007465;C0019993;C0040223;C0205435;C1279901;C3538987;C3541383;C4048877;C4318503	f	323
1426	acenocoumaroi	\N	f	-10
1427	angiographic data	C0002978;C1511726;C3245479;C3714741	f	2231
1427	angiographic data and treatment :	C0002978;C0039798;C0087111;C1511726;C1522326;C1533734;C1705169;C3245479;C3538994;C3714741;C3887704	f	2231
1429	randomized to receive beta carotene	C0034656;C0040363;C0041260;C0053396;C0696105;C1514756;C1883351;C3815594	f	2233
1063	aes leading to	C0332152;C1412268;C1522538;C2699274	f	47
431	any adverse event leading to study drug discontinuation  n ( % )	C0013175;C0040363;C0041260;C0332152;C0457454;C0877248;C1444662;C1522538;C1883351;C4552847	f	1974
1433	age  median ( $nmbr$ th — $nmbr$ th percentiles )  y	C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	f	2234
1433	age ( y )  median ( $nmbr$ th to $nmbr$ th percentiles )	C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	f	2234
1433	age  median ( $nmbr$ th  $nmbr$ th )  y	C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344	f	2234
1434	tc / hdl - c	C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122	f	2236
1434	tc / hdl - c ratio	C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122	f	2236
1453	aes leading to dose reduction of study drugb	C0178602;C0557651;C0861063;C0869039;C1114758;C1412268;C2603343;C2699274	f	47
1453	aes related to	C0040363;C0041260;C0439849;C0445223;C1412268;C1883351;C2699274	f	47
1453	any aes  n ( % )	C1412268;C2699274	f	47
1453	any aes	C1412268;C2699274	f	47
1466	absolute risk difference ( $nmbr$ % cl )	C0035647;C0596019;C1519101;C1549031;C1705241;C1705242;C4552904	f	2259
1417	current cigarette use	C0521116;C0694535;C1705970	f	420
625	baseline anti - hyperglycemic medications  n ( % )	C0013227;C0168634;C0432633;C0802604;C1442488;C2598133;C4284232	f	33
294	no . of prior aeds  n ( % ) $nmbr$ - $nmbr$	C0180309;C0332152;C2826257	f	2374
1082	number of tender joints ( $nmbr$ - $nmbr$ )  mean ( sd )	C0234234;C0444504;C0449813;C2347634;C2348143;C2699239	f	1139
1417	current cigarette use  n ( % )	C0521116;C0694535;C1705970	f	420
557	antihypertensive therapy — no . ( % )	C0585941	f	1579
557	anti - hypertensive therapy - no . ( % )	C0585941	f	1579
731	receiving antihypertensive treatment -	C0003364;C0039798;C0087111;C1514756;C1522326;C1533734;C1705169;C3538994;C3887704	f	1579
731	receiving antihypertensive	C0003364;C1514756	f	1579
366	medication at randomization  %	C0013227;C0034656;C3244316;C4284232	f	2263
366	medication at randomization  n ( % )	C0013227;C0034656;C3244316;C4284232	f	2263
366	medication at time of randomization	C0013227;C0034656;C0040223;C3244316;C3541383;C4284232	f	2263
366	medication at time of randomization — no . ( % )	C0013227;C0034656;C0040223;C3244316;C3541383;C4284232	f	2263
366	prior use of osteoporosis medications	C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622	f	2264
366	prior use of osteoporosis medications  n ( % )	C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622	f	2264
366	lipid - lowering medications	C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232	f	2265
366	lipids medications	C0013227;C0023779;C0802604;C2598133;C4284232	f	2265
366	lipid medication  n ( % )	C0013227;C0023779;C3244316;C4284232	f	2265
366	cardiac medications during index hospitalization — no . ( % )	C0013227;C0019993;C0428776;C0802604;C2598133;C4284232	f	2266
366	periprocedural medications — no . / total no . ( % )	C0013227;C0439175;C0439810;C0802604;C2598133;C4284232	f	2267
192	czp $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	czp $nmbr$ mg ( n $nmbr$ )	C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761	f	2274
192	febuxostat $nmbr$ mg n = $nmbr$	C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761	f	2282
192	febuxostat $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761	f	2282
192	febuxostat $nmbr$ mg daily n = $nmbr$ % ( n / n )	C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761	f	2282
832	history of omalizumab treatment :	C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704	f	940
192	secukinumab $nmbr$   mg no load ( n   =   $nmbr$ )	C0024671;C0026410;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C3179547;C4321396;C4521761	f	2297
28	placebo / rosu vastatin	C0032042;C1099881;C1696465;C1706408	f	886
396	all rosuva	\N	f	886
798	inhaled glucocorticoid use at screening	C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164	f	2182
798	use of inhaled glucocorticoids at screening — no . ( % )	C0004048;C0017710;C0220908;C0220909;C1524063;C1698960;C1710031;C1710032;C1710477;C2348164;C3540777;C3540778	f	2182
167	daily dose of inhaled glucocorticoid — no . ( % ) §	C0004048;C0017710;C2348070	f	2182
167	use of high - dose inhaled glucocorticoid — no . { % )	C0004048;C0017710;C0444956;C1524063	f	2182
234	poor  tried previous glucocorticoid + laba	C0017710;C0032854;C0205156;C0542537;C1552607;C2700379	f	2182
234	poor  tried previous glucocorticoid / non - laba	C0017710;C0032854;C0205156;C0542537;C1518422;C1552607;C2700379	f	2182
192	ticagrelor $nmbr$ mg km %	C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761	f	2299
192	ticagrelor  $nmbr$ mg ( n = $nmbr$ )	C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761	f	2299
192	ticagrelor $nmbr$ mg $nmbr$ year km ( % )	C0024671;C0026410;C0439234;C0439269;C0439508;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761	f	2299
192	ticagrelor $nmbr$ mg no diabetes n = $nmbr$	C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761	f	2299
236	glucose - lowering therapies	C0017725;C0087111;C0441994;C2003888	f	33
236	glucose - lowering therapy	C0017725;C0039798;C0087111;C0441994;C1363945;C2003888	f	33
236	glucose - lowering therapies — no . { % )	C0017725;C0087111;C0441994;C2003888	f	33
236	glucose - lowering therapy  n ( % )	C0017725;C0039798;C0087111;C0441994;C1363945;C2003888	f	33
236	glucose - lowering therapy - no . ( % )	C0017725;C0039798;C0087111;C0441994;C1363945;C2003888	f	33
987	serum triglycerides — pmol / liter	C0439192;C0475211;C0542495	f	368
192	uric acid tertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl )	C0041980;C0439269	f	2310
192	uric acid tertile $nmbr$ ( $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mg / dl )	C0041980;C0439269	f	2310
540	ibdq total score  mean [ sd ]	C0444504;C2347634;C2348143;C2699239;C2964552	f	2313
196	cohort $nmbr$ ( uacr > $nmbr$ . $nmbr$ mg / g )	C0009247;C0599755;C1300563	f	2315
196	baseline uacr > $nmbr$ mg / g	C0168634;C1300563;C1442488	f	2315
196	cohort $nmbr$ ( uacr < $nmbr$ . $nmbr$ mg / g )	C0009247;C0599755;C1300563	f	2315
18	fasting blood glucose  mean ( sd )  mg / dlt	C0024671;C0026410;C0428568;C0439269;C0444504;C1261430;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761	f	2280
18	fasting blood glucose > $nmbr$ mg / dl	C0428568;C0439269;C1261430	f	2280
18	fasting blood glucose > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l )	C0428568;C0439269;C1261430;C1532563	f	2280
205	weight at randomization ( kg )	C0022718;C0439209;C2985844;C4054209	f	2326
205	weight  kg	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight  kg *	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight [ kg ]	C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209	f	2326
205	weight  mean ( sd ) ( kg )	C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209	f	2326
294	prior tnf antagonist failure  n ( % ) b	C0231174;C0231491;C0332152;C0680095;C2826257;C3887647	f	2375
294	prior tnf antagonist failure - no	C0231174;C0231491;C0332152;C0680095;C1448177;C2826257	f	2375
294	prior tnf antagonist  n [ % ] ‘ *	C0231491;C0332152;C1448177;C2826257	f	2375
294	prior tnf antagonist failure  n [ % ]	C0231174;C0231491;C0332152;C0680095;C1448177;C2826257	f	2375
206	values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group . † obesity was defined as body mass index $nmbr$ kg / m $nmbr$ . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criteria $nmbr$ as any $nmbr$ of the following : waist circumference $nmbr$ cm for men or $nmbr$ cm for women  triglycerides $nmbr$ mg / dl  high - density lipoprotein cholesterol $nmbr$ mg / dl for men or $nmbr$ mg / dl for women  mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg  fasting glucose $nmbr$ mg / dl . § by medical history . aliskiren  n $nmbr$  hydrochlorothiazide  n $nmbr$ .	C0001675;C0005893;C0008377;C0015663;C0017725;C0020261;C0023822;C0024671;C0025266;C0026410;C0028754;C0030705;C0032659;C0034656;C0039798;C0041004;C0042295;C0043210;C0086858;C0087111;C0150375;C0205437;C0220825;C0231290;C0243161;C0262926;C0332282;C0376691;C0439070;C0439269;C0439475;C0441833;C0444504;C0449450;C0455829;C0518010;C0524620;C0578022;C0600653;C0680240;C0684224;C0687744;C0700287;C0918012;C1120110;C1257890;C1261322;C1301808;C1305855;C1442792;C1511726;C1511790;C1519504;C1522326;C1532718;C1533734;C1547282;C1551393;C1552854;C1637833;C1704706;C1704788;C1705160;C1705169;C1705428;C1705429;C1705492;C1706365;C1709697;C1960952;C1963185;C1999270;C2241628;C2346927;C2347634;C2348143;C2699239;C2728259;C2986546;C3245479;C3245503;C3272743;C3273238;C3484370;C3538994;C3539106;C3539687;C3714741;C3815594;C3842522;C3887704;C4068104;C4255046;C4321396;C4521761	f	-10
229	a . primary composite outcome	C0205199;C0205225;C0439612;C0439631;C1274040;C1547335	f	2339
229	first co - primary outcome	C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C3245499	f	2339
229	first co - primary	C0205225;C0205435;C0439612;C0439631;C1279901;C3245499	f	2339
229	chd ( primary outcome )	C0205225;C0280604;C0439612;C0439631;C1274040;C3542407	f	2339
229	or primary outcome	C0205225;C0439612;C0439631;C1274040	f	2339
229	second co - primary outcome	C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1561503;C1705190;C3245499	f	2341
229	medical history duration of heart failure ( years ) primary cause of heart failure	C0015127;C0199168;C0205225;C0205476;C0439234;C0439612;C0439631;C0449238;C0455531;C1524003;C2926735	f	2343
236	with corticosteroid treatment < $nmbr$	C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704	f	1348
236	treatment with sulphonylurea + biguanide  n ( % )	C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165	f	752
236	treatment with sulphonylurea + biguanide  n { % )	C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165	f	752
236	treatment with sulphonylurea  n ( % )	C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3538994;C3887704	f	752
668	baseline hba $nmbr$ c ≤ median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )	C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066	f	820
668	baseline hba $nmbr$ c > median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )	C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066	f	820
668	baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )	C0019016;C0168634;C1442488;C1825777;C3538758;C3829066	f	820
668	baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % to < $nmbr$ . $nmbr$ % ( $nmbr$ – $nmbr$ mmol / mol )	C0019016;C0168634;C1442488;C1825777;C3538758;C3829066	f	820
668	baseline hba $nmbr$ c < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol )	C0019016;C0168634;C1442488;C1825777;C3538758;C3829066	f	820
668	baseline hba $nmbr$ c ≥ $nmbr$ mmol / mol ( ≥ $nmbr$ . $nmbr$ % )  n ( % )	C0019016;C0168634;C1442488;C1825777;C3538758;C3829066	f	820
241	gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : $nmbr$ x ( $nmbr$ — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .	C0006938;C0017480;C0032042;C0039798;C0042295;C0087111;C0126174;C0168634;C0301630;C0392747;C0392756;C0441833;C0443172;C0444686;C0444706;C0456603;C0679646;C0687744;C1257890;C1273442;C1293152;C1441506;C1442103;C1442488;C1444656;C1519504;C1522326;C1522544;C1533734;C1547037;C1547049;C1552839;C1696465;C1704695;C1705169;C1705241;C1705242;C1705428;C1705429;C1706408;C1707455;C2698741;C2986759;C3538994;C3541902;C3854019;C3887704;C4050020;C4319952;C4551656;C4554048	f	-10
243	most frequent aesa	C0205393;C0332183	f	2352
243	most frequent non - infectious teaesb	C0205393;C0239998;C1518422	f	2352
243	most frequent serious teaes	C0205393;C0205404;C0332183	f	2352
245	fev $nmbr$ / fvc ( post - albuterol )	C0001927;C0687676;C1704687;C3469826;C3714541	f	680
245	post fvc % pred	C0032952;C0044955;C0687676;C1704687;C3469826;C3714541	f	680
246	st - t wave	C0036056;C0429103;C3272372	f	2356
257	ct or mr scan of the brain *	C0007673;C0024485;C0034606;C0441633;C0596217;C0881827;C1417249;C2347167;C2826292;C3254418;C3540513;C3813556;C3888140;C4050513	f	2357
258	no prior hf hospitalization	C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279	f	2359
258	hospitalisation for chf within $nmbr$ years of randomisation	C0018802;C0019993;C0034656;C0439234	f	2359
258	no prior hf hospitalization ( n = $nmbr$  $nmbr$ )	C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279	f	2359
734	percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % )	C0010055;C0600653;C0918012;C0948089;C1532338;C1552854;C1637833;C2986546	f	1661
290	previous coronary intervention	C0018787;C0184661;C0205156;C0886296;C1273869;C1552607	f	1661
1524	percutaneous transluminal coronary angioplasty	C2936173	f	1661
1524	previous ptca	C0205156;C1552607;C2936173	f	1661
1524	ptca	C2936173	f	1661
276	dbp at visit $nmbr$	C0536221;C0545082;C1512346;C2826704;C3813197;C4281799	f	15
276	sbp at visit $nmbr$	C0085805;C0545082;C1512346;C2826704	f	15
276	mean number of antihypertensive medication at last visit   ‡	C0003364;C0237753;C0444504;C0449788;C0545082;C1512346;C1517741;C2347634;C2348143;C2826704	f	1579
293	presence of dactylitis  n ( % )	C0150312;C0239161;C0392148;C3854307	f	2365
293	presence of enthesitis	C0150312;C0392148;C1282952;C3854307	f	2367
294	$nmbr$ prior tnf antagonist failures  n ( % ) b	C0231174;C0231491;C0332152;C0680095;C2826257;C3887647	f	2372
294	prior tnf antagonist failure - yes	C0231174;C0231491;C0332152;C0680095;C1448177;C1549445;C1705108;C1710701;C2826257	f	2375
294	prior cardiovascular event — no . ( % ) - j -	C0332152;C1320716;C2826257	f	2378
1044	previous infliximab therapy — no . of patients ( % ) * *	C0030705;C0205156;C1552607;C4076075	f	2387
1044	previous cvd ^	C0007222;C0205156;C1552607	f	2390
1044	previous infarction	C0021308;C0205156;C1552607	f	2390
1044	previous use of biologic systemic therapy  n ( % )	C0005515;C0005527;C0205156;C0205373;C0205460;C1515119;C1524063;C1552607	f	2391
1044	previous use of nonbiologic systemic therapy  n ( % )	C0205156;C1515119;C1524063;C1552607	f	2391
1044	previous use of other biologic agents in addition to tne	C0005515;C0205156;C1524063;C1552607;C3896585	f	2391
628	thromboembolism	C0040038	f	2399
1044	previous pci ( % total )	C0205156;C0439175;C0439810;C1552607;C4049621	f	1661
318	deathsb	\N	f	2400
\.


--
-- TOC entry 2934 (class 0 OID 0)
-- Dependencies: 197
-- Name: annotations_N_seq; Type: SEQUENCE SET; Schema: public; Owner: postgres
--

SELECT pg_catalog.setval('public."annotations_N_seq"', 2029, true);


--
-- TOC entry 2797 (class 2606 OID 24597)
-- Name: annotations pkey; Type: CONSTRAINT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY public.annotations
    ADD CONSTRAINT pkey PRIMARY KEY (docid, page, "user");


--
-- TOC entry 2799 (class 2606 OID 24619)
-- Name: clusterdata ppkey; Type: CONSTRAINT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY public.clusterdata
    ADD CONSTRAINT ppkey PRIMARY KEY (cn);


--
-- TOC entry 2801 (class 2606 OID 24623)
-- Name: clusters unique_concepts; Type: CONSTRAINT; Schema: public; Owner: postgres
--

ALTER TABLE ONLY public.clusters
    ADD CONSTRAINT unique_concepts PRIMARY KEY (concept);


-- Completed on 2019-10-29 14:44:33 GMT

--
-- PostgreSQL database dump complete
--

